<SEC-DOCUMENT>0001802768-22-000011.txt : 20220215
<SEC-HEADER>0001802768-22-000011.hdr.sgml : 20220215
<ACCEPTANCE-DATETIME>20220215090334
ACCESSION NUMBER:		0001802768-22-000011
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		91
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220215
DATE AS OF CHANGE:		20220215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Royalty Pharma plc
		CENTRAL INDEX KEY:			0001802768
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39329
		FILM NUMBER:		22637203

	BUSINESS ADDRESS:	
		STREET 1:		110 EAST 59TH STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		(212) 883-0200

	MAIL ADDRESS:	
		STREET 1:		110 EAST 59TH STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>rprx-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:ca5bf1b5-7b51-40b4-bf4b-78f0f34b00d0,g:ba501133-7b9f-46c5-b0d4-2c55034547ac,d:15fafc99ab5c41deb08ee816ca47172c--><html xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:rprx="http://royaltypharma.com/20211231" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>rprx-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY180L2ZyYWc6ZTcwNjE0ZGNjNDA5NGJmMTlmOTk3YjdiYTEzNTc2MDgvdGFibGU6N2Y2NTBlMjg3NWJjNDA1NmIxMDMxMGYwNjMyY2U1NTAvdGFibGVyYW5nZTo3ZjY1MGUyODc1YmM0MDU2YjEwMzEwZjA2MzJjZTU1MF8xLTEtMS0xLTA_576ec597-64ae-4b0d-8d2e-1d051c529ec6">0001802768</ix:nonNumeric><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY180L2ZyYWc6ZTcwNjE0ZGNjNDA5NGJmMTlmOTk3YjdiYTEzNTc2MDgvdGFibGU6N2Y2NTBlMjg3NWJjNDA1NmIxMDMxMGYwNjMyY2U1NTAvdGFibGVyYW5nZTo3ZjY1MGUyODc1YmM0MDU2YjEwMzEwZjA2MzJjZTU1MF8yLTEtMS0xLTA_bf13abf0-a769-42d9-8a3c-234984d864de">2021</ix:nonNumeric><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY180L2ZyYWc6ZTcwNjE0ZGNjNDA5NGJmMTlmOTk3YjdiYTEzNTc2MDgvdGFibGU6N2Y2NTBlMjg3NWJjNDA1NmIxMDMxMGYwNjMyY2U1NTAvdGFibGVyYW5nZTo3ZjY1MGUyODc1YmM0MDU2YjEwMzEwZjA2MzJjZTU1MF8zLTEtMS0xLTA_9ffaeb2c-6668-4cf6-a2ed-c1d47c48bbd9">FY</ix:nonNumeric><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY180L2ZyYWc6ZTcwNjE0ZGNjNDA5NGJmMTlmOTk3YjdiYTEzNTc2MDgvdGFibGU6N2Y2NTBlMjg3NWJjNDA1NmIxMDMxMGYwNjMyY2U1NTAvdGFibGVyYW5nZTo3ZjY1MGUyODc1YmM0MDU2YjEwMzEwZjA2MzJjZTU1MF80LTEtMS0xLTA_c76ea528-6827-48c7-b93e-5c81d9dc9041">FALSE</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i4719611fdef547db987f7d2d30dadbc7_I20211231" decimals="-5" name="rprx:LongTermPurchaseCommitmentAmountOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY183Ni9mcmFnOjk4MzM2MDdhZWI5NTQxMmE5NDNjZmUyZDcyMTllZjBhL3RleHRyZWdpb246OTgzMzYwN2FlYjk1NDEyYTk0M2NmZTJkNzIxOWVmMGFfMTA5OTUxMTYzMzI0Mw_0666d905-8be3-4416-a66f-8e0d671d65c8">129.6</ix:nonFraction><ix:nonNumeric contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzExLTAtMS0xLTA_7826f12a-67da-4efa-9c4b-296fe436efc8">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i3468b5dba8434479a8f400dd5c49c174_D20190405-20190405" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzAvZnJhZzpiNmUzOGVmYzdkMmI0NmUzYjkxMDM2OTJhZWM4YmZmNy90ZXh0cmVnaW9uOmI2ZTM4ZWZjN2QyYjQ2ZTNiOTEwMzY5MmFlYzhiZmY3XzM5OQ_0ca1c62c-91b5-4d27-a427-11caf92896c8">200</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i0cc5aaad296f4b2ebbafb25210d95261_D20190405-20190405" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzAvZnJhZzpiNmUzOGVmYzdkMmI0NmUzYjkxMDM2OTJhZWM4YmZmNy90ZXh0cmVnaW9uOmI2ZTM4ZWZjN2QyYjQ2ZTNiOTEwMzY5MmFlYzhiZmY3Xzc1MA_9078991a-5a7b-43d2-8a39-380179363f48">200</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ie7ffbb1b682a454ea429c1fb003ce9d8_D20190405-20190405" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzAvZnJhZzpiNmUzOGVmYzdkMmI0NmUzYjkxMDM2OTJhZWM4YmZmNy90ZXh0cmVnaW9uOmI2ZTM4ZWZjN2QyYjQ2ZTNiOTEwMzY5MmFlYzhiZmY3Xzk0MA_df2aa2cb-44a6-492b-99fe-9fa44c1ffcec">200</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="if92704d2e5e74022812f0c24cecf4b2e_D20200807-20200807" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzAvZnJhZzpiNmUzOGVmYzdkMmI0NmUzYjkxMDM2OTJhZWM4YmZmNy90ZXh0cmVnaW9uOmI2ZTM4ZWZjN2QyYjQ2ZTNiOTEwMzY5MmFlYzhiZmY3XzIzNDM_5caaa24c-f201-42b4-bee7-4bb4207c53ba">180</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="if1ba671053ae4c678a08effbbc36a0d6_D20200807-20200807" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzAvZnJhZzpiNmUzOGVmYzdkMmI0NmUzYjkxMDM2OTJhZWM4YmZmNy90ZXh0cmVnaW9uOmI2ZTM4ZWZjN2QyYjQ2ZTNiOTEwMzY5MmFlYzhiZmY3XzI2Nzg_fc37ef66-812b-4b22-964a-36995b3b5c77">180</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="if1ba671053ae4c678a08effbbc36a0d6_D20200807-20200807" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzAvZnJhZzpiNmUzOGVmYzdkMmI0NmUzYjkxMDM2OTJhZWM4YmZmNy90ZXh0cmVnaW9uOmI2ZTM4ZWZjN2QyYjQ2ZTNiOTEwMzY5MmFlYzhiZmY3XzI4NjE_f41984c4-4a58-4fdc-8e63-f40161319793">180</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i563d98aa4d6540f88726ebcbf9a18b2f_D20190405-20190405" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjEvZnJhZzo4OThjZTk0NTliYzE0NWZhODNhMjk0NDI3NjdjY2VjNy90ZXh0cmVnaW9uOjg5OGNlOTQ1OWJjMTQ1ZmE4M2EyOTQ0Mjc2N2NjZWM3XzQ_939beab6-52db-48eb-a722-f9f0de90dab5">200</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i0c20ae236c2f417082e6a9e92e6d43b8_D20210101-20211231" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjEvZnJhZzo4OThjZTk0NTliYzE0NWZhODNhMjk0NDI3NjdjY2VjNy90ZXh0cmVnaW9uOjg5OGNlOTQ1OWJjMTQ1ZmE4M2EyOTQ0Mjc2N2NjZWM3XzE2OA_2df5abe5-efc2-461b-98d8-a8b84e82d7e8">180</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="id0938578b1c44708b42aae9c1e2c0857_I20210602" decimals="INF" name="rprx:CollaborativeArrangementRightsAndObligationsExpectedReturn" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185MzQvZnJhZzplYWZjMmRjOGVmZDI0NWNjYjVjN2U3NGE2ZTBlMzY5MC90ZXh0cmVnaW9uOmVhZmMyZGM4ZWZkMjQ1Y2NiNWM3ZTc0YTZlMGUzNjkwXzI5Njg2ODEzOTQ5OTYw_e189498c-fefc-444d-a932-0e375c1d198f">220</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="rprx-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58e8c79f7b7640d089df3eefd8c4584f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i1bcce023e17042be90c95db2fc81e685_I20220211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ia539779374e8435abf5929170c65ac83_I20220211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4719611fdef547db987f7d2d30dadbc7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">rprx:LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i355f63584077498c9358681b1f440182_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52867fbe6d2d4e9f9ef1cc8a39a6730d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i7048c06f34e64e98a9f8db168c52ecf6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46e28e4cc5cc4a16bbb2deb97423b415_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic092b803ad4d4d1bb1fc65733358f33f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i953778adf0344a989190761672294312_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbpPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="icd2e4870b58b4b92961362030330fa39_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1bd23e9eb02461c8e78d787a6ed33aa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:FinancialRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25b8e421f3694fbcaafdb0d3eaa6b71f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:FinancialRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22755b6a900743c384bc4e39a0795f90_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:FinancialRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1452e9acf8c84b5fa30c3213757d431e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0297e01d516f433c9c55632b22b93b76_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16e458adecdb45bfbf9b94d5656d1d13_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8996266cd2b47c186f6cb14ad934f59_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:RoyaltyIncomeOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2caa252cd23b45869207612ea8852d80_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:RoyaltyIncomeOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20e6b58350b843a5b8d17f5da029afa2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:RoyaltyIncomeOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf79e602f6744689882e0662af486960_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7242e01e0d3e49c99430b9b17185b69d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21cc13814c2346169554442b708375ad_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4278e9fc64b540edb08bf8d281986583_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc6628a62f9e40b48736982ad0adfbee_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb893068fb11474089dc46eccc39ab67_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibab3544b72654443a832b73062c67deb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:UnitHoldersAndShareholdersContributionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d606c35a9d1498aa2be490653c9ef76_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83390defcd6345cb9ec5d13109b97307_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia43c5365c0cb479391cb94db6dca5463_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd82d6eb2e3a47a7b8091e80bc813a3b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa26755fbc5e413fbf3122ec0db17370_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb8081ea351a4070b344194caa18eee3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id719b4a4fe4147c580198f101363e139_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aba922b7da5469cb7d51eeaebbde78c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82e5c0912520456188cd5703e13cd8ec_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a4cf2dc46aa4a0b98fcc0c810dc8893_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i580d0bd186a14217bc04733016854e77_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19b48e73113548da88d30125b457bca0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e3a705f76b44890a7020ab2ae505a43_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i315143a2dcd345708f419d259a93d568_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3ecbb7d51644c5aad611d5a9b22c148_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:UnitHoldersAndShareholdersContributionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i830800ad2baf473c9739d42417c534c6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i602e6cc9310d4444b6d71a94d4089ae5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66a738c1e19d441f908f46dd78470217_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ff6f34aeece4e29977f6ac850691398_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id30f26bcb6cd4b64982e6cd53528c44e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94ea8958cd1e4ee696d732dd9a041dca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:UnitHoldersAndShareholdersContributionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib04d3453e6dc4ca3a0b79e01ab3fe12a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7ab9fefed164e08ac6ad01d99d06780_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e6f9f489a134c76840c0b3b1b1954e4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b0efd440f45499a9d75e2fbc4ff25a1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3422c7350bb14d2d869ff498fa12e855_D20200101-20200617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76f06ecc81464fc3ba1731d5296c531a_D20200101-20200617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7594b0b1464b4340a377c43cf71ef3c9_D20200101-20200617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d52a6096c48447f93a4da355c6da2e3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f4f3dd76bcf49369de9f193a116d553_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a9ba8c328db404aa63b9d27dabe97d3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia045aaf00ae04e51a9df144d9df23caf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic835f9f0906c4a4cb5e88b614197540b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2120ee6be2e44acca10b4f204c1cddf2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief437e0dfe9a4e449e52e28b7c5f4b71_D20200618-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id19e65b6c08c41b59cd152b688647d77_D20200618-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1399e8120f4459da1c98eaec460657b_D20200618-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i026910ef30a142baa787995540a3555f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00c7c0edff0e4ac2a68115eef01ff73d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd3e01d69d404333b2e0170fe5853c55_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief96e993bf2a4bad8348a1f2176e9808_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68fb25a3dc3e456893c7bc42ba425cbd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if26943d0c125428899ab95101e2214b9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:UnitHoldersAndShareholdersContributionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cb528cec9b5436688d56f37b5a8fdb8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i857c20e661b346998fb3a0f68c1afaf2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a4c8ddad1f14b6b87799e8a6512c515_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66335cce09fd4d5aa1361b620f554b05_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bdb46f25b6846f5b9310b232d39718a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f493fdc35c04ea9b3f1ab89b24ba7be_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8df459188f6346b8b8d77947f07ece9e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c91bc2a7dfa43c18d941b318eb6c1a1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20b582d2d470476abea2f967a5ff5d4d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie00bc8af28a248a3bab0ff42f302d437_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ideedfd0352184c20a5b0ac18ede8b733_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec5b04d241a742c1bf88cb734be536cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i237eac50dc20448f9dc9e9bc7dce35cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i831945c7a36b4b9a9c9ce724bfbde784_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cf16ec8ae244acb94018fe5616afde0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf5276dc05624d1c9f3c9eb9743788dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cf92db35b544207b1e43d9e1641760f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:UnitHoldersAndShareholdersContributionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe420d445c0a4fd99c2d658b9393d0ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9443f77254524e56b4e02c6d9e30af84_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03b5b882444a44ad9e231eaa7b05228b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i568f4691ddec40e6848d6b317d8a5792_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cb0ee2d2cce4d55b7e14f29d979d9bc_D20200211-20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:ExchangeOfferTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="idb95cff49c3e4b6483e5a57868295bb3_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaInvestmentsOldRPIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:ExchangeOfferTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41e5a726a82b47548d1f945e92636296_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaCollectionTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb7af162272940eead234259d17da45b_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaCollectionTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74a3535e1f304c089ec2b07d0bdc6f52_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i196399f1da794ae7a1ec4de607513d77_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RPI2019IntermediateFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibabbf759907e4aee8080ea0173539d93_D20200211-20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OldCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70f4f8cb8c6d440883d5034075ba2017_D20200211-20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIFTSeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RPI2019IntermediateFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f263e6903ec49b1bb03a648b164d00e_D20200618-20200618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0861ac581a4a474c88d227f3b54a6874_I20200618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff33cf273b964edf907891fec81037d3_D20200618-20200618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:IPOSharesFromCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia342308de5774def81f37403f622bd7b_D20200618-20200618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:IPOSharesFromSellingShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i414a5cb6c59c4311a4ff39f341e18444_D20200618-20200618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i586b66d2b65b47dfaf4325e8b30978d9_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:IPOContinuingInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c1e7922bf5d4fb7a873526ac9e2acd2_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaInvestmentsOldRPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb99eff80794423ca92bd7db72623f54_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="partnership"><xbrli:measure>rprx:partnership</xbrli:measure></xbrli:unit><xbrli:context id="i6e7e9177eb1b4c9da6650b9f74990c36_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RPHoldingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89b6773bde7741e89cfa1ba14576b98f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f493e893d9e41c9836fd0b92cee6bf2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0a851bce2a945d59b0ed1c24aa99168_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:VertexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b0975d860cd4ef59dd25d4eb5f1f7a6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:VertexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>rprx:segment</xbrli:measure></xbrli:unit><xbrli:context id="ie7ffbb1b682a454ea429c1fb003ce9d8_D20190405-20190405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-05</xbrli:startDate><xbrli:endDate>2019-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia849c0d494314af388e9fb0fc01f197d_D20190405-20190405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-05</xbrli:startDate><xbrli:endDate>2019-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f03e1e1f0254cb1bffbcef4de9ba54d_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82b90b8f41a142668c8944a95809becc_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c9ec20561ed410bb20159b77b9b7247_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aa7200994f445fd859a024412126926_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdc9b73456ed4691907032f9740bfd6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60d163174d8f44a18183225e8dcce57d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98c2c17dcf19455ebbe7cea65ea027d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rprx:DevelopmentFundingBondForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfc7e15ceae44635ac92046eaa0b27e9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfad0763e8bb4821b3d973d0d57f0477_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3468b5dba8434479a8f400dd5c49c174_D20190405-20190405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodAxis">rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-05</xbrli:startDate><xbrli:endDate>2019-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cc5aaad296f4b2ebbafb25210d95261_D20190405-20190405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodAxis">rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-05</xbrli:startDate><xbrli:endDate>2019-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if92704d2e5e74022812f0c24cecf4b2e_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodAxis">rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1ba671053ae4c678a08effbbc36a0d6_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodAxis">rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i625666873b2d4977bdc6062d4f56c5df_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rprx:TreasuryRateLockContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4106b129e51b45058ce78e36709ad420_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25065e59308648fd8df2e62e3adccc34_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3d1194dc3e540d18ba20eae1762f548_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:EpizymeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dfa9c83d55a4cd497bbc3d7fa0263f5_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:EpizymeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iede0453e00c74915afde71174a783562_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rprx:EpizymeCommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cb61b17854748238238595ab84bc83d_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:EpizymeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rprx:EpizymeCommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8411dbd9065417ea1c3895bc9dcf30d_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:EpizymeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:PutOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if08b51e367da4f1b95ea56119a60ebc2_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:EpizymeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:PutOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b2fd60a894245f5a07e1097cd77b5a5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:EpizymeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3144c1b6231e4ae3b4870c4b3899f3bc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8655b88be914b679ef264228d3e1920_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa98c432df2e41d197b0bbeeda56b8f3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2307a5ce88e48c2a06297ee38c8ff92_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1e2a2af5b8c4eae95b037e3cda81bcf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00b63eb6a93e410fa76fd2e629ddcb94_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i763fc198266c47f18427206c9825f562_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia35d113ea7024ba6950f218601bacf6d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifef0f1d7958a463da43eae42d4bfdcda_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14182ec6f41e44f390626af261a6307c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50aadab619674413a318d22a3934817f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28aa4e83beed49649514ca87068e5ff6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b1e737cb86341c5927dafb07d9750e7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51d19c62ebf442779da8aeb40a4ab214_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib358915627fb4011bf72f88cea09f234_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11eaf253ae3b4547aad0185800a4c0d2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89b8a39a63294eebab3e3f0053f1e384_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i005aac99b4434d53866b784c5d193d69_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaef13cf1a72b4d638ba70defd6ec0717_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17ed9cdd951d4b46941b7212a8ac2d44_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8604b93633cf417e954376d722a8dadd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcf29dd183834411bbff2b3741c8ce8e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72d6d03d3001450dae8929c471f09b33_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie89c03cbaa3a415f8d13313d6d33a664_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rprx:TreasuryRateLockContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3c1f334b1114d27b5ab4a6b83b6d95b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rprx:TreasuryRateLockContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cb8fcdaa4e94b9bb101f554c36c0944_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rprx:TreasuryRateLockContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i766dfe5e45ea4f72a26e59216bb302d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia020dbee158643459651f9ece93d0d05_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75566fc435584c81949dbaf5d363ad0a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie446f1fa1f9b4244a2ca74087c37da2e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dcc53a90d444210880be69baae720a5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia44ca4ca5b24467685453ef798071b9c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88285f19e15c4b32ad8309928003f3bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib075989af1f74896bccaba43480cd27b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3416e4f9b18349ecad1f073e06dec3f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a89ba14dcfe4b38bdf299da4317bd92_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9e6b9ca88f64d7a856e5091b1586275_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9922aa0da964460ac7f278f5e9ce3bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd56db919beb4b91b95510f88bc8e307_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55d925c488be4a8f8163990bbb352b7e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e3aa405803e46c2ae8f0944494d7a94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc0c4c7c6cdc45479c7eb9dc86d86a1d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30d5c89a92a5482d9d74e4bb2241752e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53c4649842db44e4a15eb412da6b88a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c9704b6d9d7401fab5346287e978380_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49b4a4e11f71489ab6998095636e4351_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i077a711c86ba4484a165902a8b44eeb1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib89be7641277478e8f7b293085ccc5d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia66c162bc44045988727b18f854dba73_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d769bb3068b491086f572bdae712fb8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04f203e10aa24bcfa8ec0905052a2b27_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d667d912c354a0c9c379aefc62e6fa7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie404feec194c4015ae7728b646421169_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic527ce521bf44f7fb2922ba14cf8f680_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i088b28295ac64e85ab5dfa6a843058cf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19d9bd3151754f33acff24aea97d4f03_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7fb8fef2b7f4c048ec7656d0e9bd6fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a7676bf6609461692e1aa4be16e7345_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfafac4f4f2a4e088f1da17e816e5e52_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id085ae202d524bdb9d5d849459675315_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48b720aa212947f48ab2d55101f95e2b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28195bb07d164725b7b634f4d19d0532_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i809b4052446c46388345163c43a4aa56_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb619f9a9745447ca9b38d75ccc38904_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i796b378a6f1c40c48579f653afadb541_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f327e7169c8452880bd81a8f13ed03b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i248b66c121454f309190c31387007f6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bb92f2605164dc8b141abf08c6f5b56_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i022c0d8159864ed7a2a1944cc714c2cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id26c9a8cd8884671b2c7a640a4b6d7df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ac959fb66e143fcaddb2cb43efeae1a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee8b694599fb4dd39b9e68aadeed7ed0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie51f46e72bfd4d7e834c4fdb560fbee4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7ec150c06fd4f4e91c18c223d223ea5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1a1aa3351a743f085a5b2c2f8f8be34_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19a72b318bc84259bb294a3c971a4b85_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04227885885f4891916e264c27f329ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fb80ebaf7cf4a41b7bb7ee7eecd1a0c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd91a77eb7224e71a43cdcab940fb6bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad06d81ace0f4a3fbccf1299e4f6f414_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee5dd61b76084db79478047617833a62_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96f3647beb944cfb9113b173115bb16f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b086c90802248e181f4562a5f891cef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fd0b4b6026a47dfa690bc790142dc6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e710c51efc64f67a80cd232937add07_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc65e75ec15e4a8d9dae69a3405cb50d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c452309c9434a04aed49ed1b90eadaf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7ab09bfb5bd4da3a4014bc287abc1b4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23b9ee584ca349bfb13948d7e36428be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7b300d23f844817bdcfa222399539cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa7fcc31f05a4cd38338bef84fd13226_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3b3d077c01141fabeaf491e1ebfa108_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5aeecb6ade049569e8f33d8ba05292c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94e2f508014f476987e71ff61fb7acc0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4190ee3791704e3cb28414c2e7b90290_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib55e7cd67be640bcbc6bf9021cbd80ab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i011c26d52667488b9a934f794e0b528f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25d1766cd2c74c1d9a6e6b47a1ff4db5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ccc4c3e02d8454db2beb623053c69a4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i361e783ed15347028eee1b52d6e057f6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if100f3b0b4694f76acfbd85a49861791_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23115a36ef69401581d68e8923fad129_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id424947d5ae8418b9adaf58a03fddf26_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98c2487e5b2648e7b109d6723b860233_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77465b4fae3745838d33803f0ec0bbc7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6228c34e36964903b7d23917ea68a634_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia90e169e7f6c423bb0c4f735d01ae17b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib39b424185204ed8abf5c36761702ce7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cc4a0220a37443eb7239af4691991c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5879c529f1044590b63a67bad0d16f8d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3565d1e114564c88a5bdaaff4011b9bd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7177d9153404fb68d339079a331543f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4e245eba01b40829373277b36665d51_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae02917f54274b579c2894c8155d9e11_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0e7d3e451a44f16bafd403564c15c33_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib406cf1143e641fd8a07fb8084d1848a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae1bbd4d1fb242f38ccaf2f15e20b521_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa9f1ac8ede24d5ea9cae25ddd1c125f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6de6823bdc2b4ac98c04ae502140745a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c7c87185ab54de39f17a1a1526628ab_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81dbcb5a23f349fe855015cfdaaa1937_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c970570f47a4749aeb33f585934e58f_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BioCrystPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81db589362444c02b90538016ac19ba1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0f6dd75074a4324b2b360f729714ac3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id95940867f7f46d1832cf3e16823033c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9de83b17a2d84f7081715a46a48bb989_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i563d98aa4d6540f88726ebcbf9a18b2f_D20190405-20190405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodAxis">rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-05</xbrli:startDate><xbrli:endDate>2019-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c20ae236c2f417082e6a9e92e6d43b8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodAxis">rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35db462f272349c080f522a5c4e7f55a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:CysticFibrosisFranchiseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i910a6938c4b04c46b87813b7b69e8dce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:TysabriMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide9c8ac9b7834772b270536662c1c607_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:ImbruvicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d275aee32304e029188d994792d2f92_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:XtandiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dea9589e6e74a59a7d713e718e4a80d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65da27051b834e589474daa7e00772a9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:EvrysdiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98a31ea009fd41ae9b93b9a0ba894b4b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:OtherFinancialRoyaltyAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i548f6928715a4fd7ad65b15d47cba2a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:CysticFibrosisFranchiseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bf9a6954f4b4608ac3db7c1a9515015_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:TysabriMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60ad6794898d4cdc903f9017ab626e3f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:ImbruvicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ee684b3e062472b855ba68705d802d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:XtandiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6afe0a950f444f6986eed827af96e29_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:PromactaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i653d2d4470454f40b058b645513ec385_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:EvrysdiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd8901ad6baa4fe485e98132407e4d74_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:OtherFinancialRoyaltyAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6a50a564e8b4b0b934ac4b3000f4c8a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rprx:DPPIVPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc0fb3b2f3e24224b3fb2f9cc5ef7df9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rprx:DPPIVPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d7161b299de4f37949a7b5dcce2e1f7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rprx:DPPIVPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i874783a606094b5b9faa8d9db9749829_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">rprx:IndividualLicenseesConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id875c4379b7740e39a9bb8d8d1ddfe28_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">rprx:IndividualLicenseesConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6fb304c08604399aba5e92d08d1d6b7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">rprx:IndividualLicenseesConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05361955890f48e2a999133572daa6a8_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fbdc80a9a134e2b9b74bd14842984f8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f98a06986334cf4ac1ea37c17735d57_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i795acc0e43ad49819be20554560459e9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff8840832b23407c89930ca87f5e3a14_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28b1ff263ad7477ba427e73b282c6efc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e5a064854514c4e9d147a383d33e903_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f295d9e2c304799a502469a6920f5c2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48ff7ddf47f44c04b36ecf13d3a578f4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia502c1c929d940d39390b7214482871a_I20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">rprx:MerckAssetPhaseIIClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecadc5607804420f9e9904632d1e8a25_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3c9990279364489bd57aa8cf39a801b_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">rprx:MerckAssetPhaseIIClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfbcd815ad3241e08b3899f248245e53_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">rprx:MerckAssetPhaseIIClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cde2b63bf59491b8925224bea22907a_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">rprx:AZAssetPhaseIIAndPhaseIIIClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47df9f0f55ed4282855d6acd42a023ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib68731c3079e4d3ca394ac6b77b028f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i286e267288774fbe92ab611abb8069de_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:FundingAgreementsWithSanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40bac185075247a39792ae4ffa91c2ce_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if273f44aa1484854b5d3ea003908542c_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rprx:BioCrystPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i479dbbd40a7348a1919d32453a73a811_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:FundingAgreementsWithSanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9150e6c7578b456aad25125ca3f4404d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:FundingAgreementWithBioCrystMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i170879596f064c7ea75b778e24446320_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:FundingAgreementsWithSanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie35632bef26942e9a813a4eb6a249893_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:FundingAgreementsWithPfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4861f1f472c3491ba7a17eb5040be7f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:FundingAgreementsWithSanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9796b650407b44c3957bc1e7ffbd1229_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:PointSevenFivePercentSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dc45b08ebac451f91ea39248eeab27b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:PointSevenFivePercentSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2c6ec4ac80d4a6ba66238bf0a9eb4cb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:PointSevenFivePercentSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2fafea4522943eca815863b7d3d8349_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b0aacd47d5b4487854882d7e7b776da_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia43476884d9241af8b829c570791446c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43310a7b9e4c4cbb9b03ef370bd43b77_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointSevenFivePercentSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifee8d1bb44854cc4a3188d158569c76c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointSevenFivePercentSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d33126321d44b4aabd868a581153c4b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointSevenFivePercentSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12aa5c25ace14515980e127e89b84e78_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4e846ac7a044335959896d695fb4eb6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdaffc234a45408a8a359e973745feb8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c4c0408ec6340e9bdb1a602e36ce18b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointOneFivePercentSeniorNotesDue2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd6ff013438940249c31fcaec596a041_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointOneFivePercentSeniorNotesDue2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafcd19db0e464d11b58358856023c8b3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointOneFivePercentSeniorNotesDue2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i214ee7900f3d49228322f94559a11682_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd0fbf3fb9684880981bb0db110314f6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i273747e9c3c9428a95fbb9a2dc8580ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b8870452b5a460ba6814149888615ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35930b3c5c694b58bdad83cb5488ec9f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf88d4d19d624f61acc05f3da6e97e88_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4daec00bc1054f378d9fa9e9841e7e3b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeFivePercentSeniorNotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0162f5b487c74cacb76db77bc7f972bc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeFivePercentSeniorNotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03b010a1e0b24651a9e2d279ef1f4a19_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeFivePercentSeniorNotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie681b3df9681426ba637a173be7ba1dc_I20210726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68470da82fa849aabc13b3b1753af6d4_I20210726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d77b9cf09984cf791139a8ba06caf1e_I20210726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorNotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ce08489650c4f10a179aeb963c83319_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorNotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36b01c03000b44fbbe2d2aa0ad142157_I20200902"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida43ed4cd5d84bc4bfff97ddd4ade4dd_I20200902"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RPI2019IntermediateFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2faebe6b2bb249f9bacffbdee1da7d22_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i761809a342d742f8846055709c5f4ea7_D20200902-20200902"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-02</xbrli:startDate><xbrli:endDate>2020-09-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02f715ec0012457ca0402d8dc7e85a1b_D20200902-20200902"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-02</xbrli:startDate><xbrli:endDate>2020-09-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06737af3814f449197ef9f5868fd6001_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32d8e5ca0cdc4cdcbf57357cd3014fc4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4141d72c0fa3426ea79348fd59066693_D20200918-20200918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-18</xbrli:startDate><xbrli:endDate>2020-09-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dc7c9c8b8c844b59270fcb640d8fbde_I20200918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibecbcfc3dadd481d9155173824469951_D20200918-20200918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">rprx:OvernightBankFundingRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-18</xbrli:startDate><xbrli:endDate>2020-09-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief16c63a8fed4314b8dbf9cd08433170_D20200918-20200918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsPurchasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-18</xbrli:startDate><xbrli:endDate>2020-09-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8563b235bf8f445ab53d170d2ea1cc7d_D20200918-20200918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-18</xbrli:startDate><xbrli:endDate>2020-09-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb917668901f4fa88d71cb0dad938ffc_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fd1d6e21848456dba10bcb5be7800b7_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fa1890df4f64955a27b5a2e7f1eb6f4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib99e303d9a2649bba418d9bec8ce14f3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="class"><xbrli:measure>rprx:class</xbrli:measure></xbrli:unit><xbrli:context id="i466cdba264f14dbba8111c43a48fa933_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="noncontrolling_interest"><xbrli:measure>rprx:noncontrolling_interest</xbrli:measure></xbrli:unit><xbrli:context id="i7d508394642a4a0ab6e3a02929fd6dd4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e834532d49b48d183dee4dfa980b04c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b032830d76c44b9a92d95e245ce0a21_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a47bfd8cfda47409c0410907da54f68_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if27b249e1d7e4d108a2f24ec3c67006f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc89c3a01e3b4ee9876dc2317f1f1faa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78eee2afc7d1460ab607760dbad7a025_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a4eb1b3391f4185a844dba1b8ad1349_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if61940f2e40d400ead5fbf3844bb3dc0_D20200101-20200617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3642192137f47c8a326c30a5d6bbb91_D20200101-20200617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i737c7ca0fc4741d4908eb966f08f3fa9_D20200101-20200617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i882f3c7d9ced490c80ad72c747e61ae9_D20200101-20200617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c5760f9e15d4ad292c0f7ae423767a7_D20200618-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc1471d809d64fbb9f020dbcf89a38cc_D20200618-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f82fba017484ebc85a41aa90b9dc063_D20200618-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2d9b4e5e10d4c36a707ba0f30bd0fc7_D20200618-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie11ab38cff9248ce8459b4a78a07f67c_D20200618-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdbce45f889b42cb99f32b9a959ebb1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0317f1e1eed4aecbd740d3419ac7fd7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie11804f07d7c4f1ebc7cfa8b439e5803_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbe6045b78dd46d38b235d59ba1967c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3fe08cf37364580ab8e966ac247b010_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RPHoldingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88b0d9786c874e6f8a16be78aef6d637_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RPHoldingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8496598191ee444d9545f8252ee00014_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d8ada1253ef445f9cf1d4b92a7a6385_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if195a301ef504b6faade4870a19f4275_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bac599d33534baa86881a2afa9afcc0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79703258b5994db9b9b004b77c7e1c58_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b9c1b4135444d46968e0d3445750ae7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3166f885d1dd43e7ad16fe6b65c05bc0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90964cc296394e8cbcf965379f0538cd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbdd368fbe3941059a474c997b396f0a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RPHoldingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie53671576bce41518be8f910184feaec_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cc52872c2794894927c82c640746a99_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08c8a6f2c3554638b8b9e8e94b41d3ab_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3af896a7f0c42529577ce561a976e90_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib32135ef98664a82a742199b45769f54_I20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rprx:A2020EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9506994fe6124fe08c513652cc6fdd3c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rprx:A2020EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i941486f8afa342d49e11f69d4af24754_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadabb8c442dd4ffcbc66a71a0fe7341b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9eca6903b754336ab978b1c6859dbee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1da7232b999b4b67b6bf844dd97d818a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i850c4112163e4a4da3d1fd1aa181af6c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:ClassBHoldersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63532b6df7f947d8b3cff39df953d6f5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:LegacyInvestorsPartnershipsAndRPSFTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a17c53123fa4e12b0b8749ed24171a4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:ClassBHoldersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07a6da6cb1b14ad78d9d0a893435f6a3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:LegacyInvestorsPartnershipsAndRPSFTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a4d899516f7416083d6a452d72dff94_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16167be66e5642fa8c58da773ea9dd57_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c98f12437f9466181a216b35a41b08f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i197418bb01ba4a16bc643f9b8299428a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0c9719a7e4c49a6888e5a5a55e6a756_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b15a91be9e9493798198e66a8d123b0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc74be5e7f2b4443888aa58295087c78_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69d044ffec6446e0896ba4f3dde2181c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ef6d97fcbd2450783139f7b7ee49dc4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29031751451245b7b580c18872827fbb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4f46b5e4015492f9d8f108c0637d93f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85fa20a518334b9fa7796f9712ef4b1d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1006e57c6def4fd5ae9330e75305eda2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16fdeeb9bb4649b8bb751998b5e4aa0d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea955efbad0b414690fc8195ca1de338_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54dfb90328614a55aba5dfd030436f8a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7ee447648cf4185a3ad39d6a4c5b190_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie65b03ddad0a41228c36c13d797b9715_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56d5126b8d034d6caef67a58b8e9b69e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedeb31da272b4fc68f60ac39c1f3cf68_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dc56eeaf4e74cf0a58f82575803d294_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe95870b105d4aadbf0f7ea315240ffe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:OperatingAndPersonnelPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68845df194e84a7d80a8bd8a4940e91d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:OperatingAndPersonnelPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97ca2cea9f6f43ddaa7f3e5b85bf3ea6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:FormerOperatingAndPersonnelPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8e86ed407fe484e8200e769e2f1bb39_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:FormerOperatingAndPersonnelPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i645cb20517d04607a53311447c97b49a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:FormerOperatingAndPersonnelPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e60ab1409db4a2697d00163b861a712_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70b38d22ad90490ba1b7d51417e278e8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7b7fdb0deff479196b3afda650a0570_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie31b0e40de594cdd9c6ae104e8a737c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb1bbffa95a546f8bb9ed80b3df9b06b_D20171208-20171208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementBenefitOfPaymentStreamMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-08</xbrli:startDate><xbrli:endDate>2017-12-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61362e5f58b24b40a91040ec047f877f_D20171208-20171208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementFundingObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-08</xbrli:startDate><xbrli:endDate>2017-12-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i892f2facb5f94c52a537787b30d9bedb_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementFundingObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67eff68d96604fa8be650fb4b9c29499_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementFundingObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i476f13cf218b4efabc6d088270acc46d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementFundingObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e9cfc8aaf7e4e8694cd83fe4460da68_D20210416-20210416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AgreementWithMSCIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-16</xbrli:startDate><xbrli:endDate>2021-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2947dd542964da4bc1a05e210e2204b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AgreementWithMSCIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9edec4e140234b36b02f7525c49128f0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rprx:PabloLegorretaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:PurchasingAndDonatingVentilatorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i577a0329d95541e3802de867916ac6d6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cc96b6d6e9e4707b52d5a0f86086779_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id61bed594e7b481cb6b9d98f501ad606_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb00ed73f9984375a78b3989a66be135_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib03c23cba7a244bb9c45ccd577d4c56b_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">rprx:LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id128cc5ba3f14e5e9d39b99e553584ce_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">rprx:LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i745d2f50fe8b4f46a787612b29f6bed4_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">rprx:LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0a161191b444d5bac5c44aa63d77be4_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">rprx:LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1895cd7ab821494986c2e4e15419aa87_D20211104-20211104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">rprx:LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-04</xbrli:startDate><xbrli:endDate>2021-11-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0938578b1c44708b42aae9c1e2c0857_I20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if022a6e3714949948eb2520d7c7ab729_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001802768</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="payment"><xbrli:measure>rprx:payment</xbrli:measure></xbrli:unit><xbrli:unit id="tranche"><xbrli:measure>rprx:tranche</xbrli:measure></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUzLTMtMS0xLTA_a435e31d-dffb-4b96-ba18-64e6deef6779 id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzU2LTMtMS0xLTM3MDAx_e03bcac5-4b4c-4b66-a2e9-e6f0e4129fe4 id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUyLTMtMS0xLTA_76e4811f-8f61-4261-8b05-1bb3b6605340 id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUzLTEtMS0xLTA_c5f85727-ab8f-46b3-91e4-92ac158a0433 id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzU1LTMtMS0xLTM3MDAx_492268b9-a345-4c82-840d-920ff3e1f7c8 id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzU1LTEtMS0xLTM3MDIx_4990eee5-dee5-4619-8a5d-ff70d21298b6 id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzU2LTEtMS0xLTM3MDIx_5072f657-16e7-4822-913b-4fa5624a9150 id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUyLTEtMS0xLTA_4ebc0264-fc9b-41e8-bd70-756d832684b4" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90ZXh0cmVnaW9uOmE0MTg4YTgxMGFkNTQ0OGY4ZWFhM2I1MTIzNWFiZjQ0XzQwMw_44e224c8-6066-4813-9082-30da4843a311" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i15fafc99ab5c41deb08ee816ca47172c_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:144%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:144%">FORM <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8zODY2_c63764f2-c2d1-4025-9678-22e323b99e1f">10-K</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:144%">(Mark One)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.327%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6MGEwNTZlNDk5YTkxNDVkMzliMjkyZjYwNjFmNjFhYjMvdGFibGVyYW5nZTowYTA1NmU0OTlhOTE0NWQzOWIyOTJmNjA2MWY2MWFiM18wLTAtMS0xLTA_d9132102-c8b6-4aa4-ac2e-e0f57badb1e0">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">For the fiscal year ended <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8xNDI5MzY1MTE2NTc1OQ_07669eac-a7a8-4f76-80b3-a1f86553dde3"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8xNDI5MzY1MTE2NTc1OQ_6e0da946-3b66-4e84-99e4-56bf1d812df8">December 31</ix:nonNumeric>, 2021</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:144%">OR</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.327%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6OGRmNTkwMzgyN2RhNGY2OTk4YThlNzllZjY3NDliODcvdGFibGVyYW5nZTo4ZGY1OTAzODI3ZGE0ZjY5OThhOGU3OWVmNjc0OWI4N18wLTAtMS0xLTA_d03ed7ca-c75e-4d89-b961-ef32d7c406d6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">For the transition period from                                    to                                  </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:144%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:144%">Commission file number </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8zODcx_edaade14-a9a6-4a5a-b061-010277797bef">001-39329</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:144%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8zODc1_cc2c4eec-af4c-4d1b-9c6f-725204800df6">Royalty Pharma plc</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"></td><td style="width:178.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:199.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6MGY3MDhjYzQ1MTU3NDY4YWJhOWYxYjZmYmIxNTEyMjUvdGFibGVyYW5nZTowZjcwOGNjNDUxNTc0NjhhYmE5ZjFiNmZiYjE1MTIyNV8wLTAtMS0xLTA_eb4af650-310f-41d3-9706-40070bf7d0b9">England and Wales</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6MGY3MDhjYzQ1MTU3NDY4YWJhOWYxYjZmYmIxNTEyMjUvdGFibGVyYW5nZTowZjcwOGNjNDUxNTc0NjhhYmE5ZjFiNmZiYjE1MTIyNV8wLTMtMS0xLTA_0f6218b3-c142-460f-a5f1-a1f62594ae64">98-1535773</ix:nonNumeric></span></div></td></tr><tr style="height:12pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6MGY3MDhjYzQ1MTU3NDY4YWJhOWYxYjZmYmIxNTEyMjUvdGFibGVyYW5nZTowZjcwOGNjNDUxNTc0NjhhYmE5ZjFiNmZiYjE1MTIyNV8zLTAtMS0xLTA_bae8dff2-83aa-4484-9a5f-738b2e454dcb"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">110 East 59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> Street</span></ix:nonNumeric></div></td></tr><tr style="height:12pt"><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6MGY3MDhjYzQ1MTU3NDY4YWJhOWYxYjZmYmIxNTEyMjUvdGFibGVyYW5nZTowZjcwOGNjNDUxNTc0NjhhYmE5ZjFiNmZiYjE1MTIyNV80LTAtMS0xLTAvdGV4dHJlZ2lvbjplNDBkMmJmNzQ2ZDE0MDAyYmE3N2FmODZiN2JkZWRmOF80_784c3c88-38a9-44a4-8ed8-be0cecb5a4e3">New York</ix:nonNumeric>, <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6MGY3MDhjYzQ1MTU3NDY4YWJhOWYxYjZmYmIxNTEyMjUvdGFibGVyYW5nZTowZjcwOGNjNDUxNTc0NjhhYmE5ZjFiNmZiYjE1MTIyNV80LTAtMS0xLTAvdGV4dHJlZ2lvbjplNDBkMmJmNzQ2ZDE0MDAyYmE3N2FmODZiN2JkZWRmOF84_55d6f06d-82bf-4bec-8994-72e1993f23f6">New York</ix:nonNumeric> <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6MGY3MDhjYzQ1MTU3NDY4YWJhOWYxYjZmYmIxNTEyMjUvdGFibGVyYW5nZTowZjcwOGNjNDUxNTc0NjhhYmE5ZjFiNmZiYjE1MTIyNV80LTAtMS0xLTAvdGV4dHJlZ2lvbjplNDBkMmJmNzQ2ZDE0MDAyYmE3N2FmODZiN2JkZWRmOF8xMQ_d18081b1-3cb1-4d24-ad8f-1b0e3be1b0eb">10022</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(Address of principal executive offices and Zip Code)</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:144%">(<ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8zODc2_330e9477-7568-4f50-9750-be2417b7e8a1">212</ix:nonNumeric>) <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8zODcz_3dc02531-ae1f-4569-a8ad-e3f699143e36">883-0200</ix:nonNumeric> </span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">(Registrant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:110%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.468%"><tr><td style="width:1.0%"></td><td style="width:38.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6NGEyMzJmMjZhNjY2NDY2NjhiOTU1NDMzNWQ3ODZjMDYvdGFibGVyYW5nZTo0YTIzMmYyNmE2NjY0NjY2OGI5NTU0MzM1ZDc4NmMwNl8xLTAtMS0xLTA_832912c6-2ee8-4355-8722-b6704a2e32eb"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Class A ordinary shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">, par value $0.0001</span></ix:nonNumeric></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6NGEyMzJmMjZhNjY2NDY2NjhiOTU1NDMzNWQ3ODZjMDYvdGFibGVyYW5nZTo0YTIzMmYyNmE2NjY0NjY2OGI5NTU0MzM1ZDc4NmMwNl8xLTEtMS0xLTA_f2c51e36-ccb6-4dd8-8563-7415cfeb8225">RPRX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6NGEyMzJmMjZhNjY2NDY2NjhiOTU1NDMzNWQ3ODZjMDYvdGFibGVyYW5nZTo0YTIzMmYyNmE2NjY0NjY2OGI5NTU0MzM1ZDc4NmMwNl8xLTItMS0xLTA_0a0060fd-471c-4d33-8e7d-6538c31e9a5e">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:144%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. &#160;<ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8xNDI5MzY1MTE2NTc3MQ_4a001fa1-3ec5-4804-b27f-f30976a37f22">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:144%">&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:144%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8zODY5_d55ed5f6-1e03-46f2-9469-7904675ddef5">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:144%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8zODc0_6d76f63a-2a28-4f94-80cc-013d6b217839">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:144%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8zODY3_f6a70e36-bb4b-4993-9297-9d495a22265b">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9744;</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.553%"><tr><td style="width:1.0%"></td><td style="width:31.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6YzhiM2QzMjE1YTQxNGI0NjgzMzcwZDdhZDUxOWZmZGQvdGFibGVyYW5nZTpjOGIzZDMyMTVhNDE0YjQ2ODMzNzBkN2FkNTE5ZmZkZF8wLTAtMS0xLTE4_db3cf2d6-d9a2-42e8-9859-358f8985b207">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6YzhiM2QzMjE1YTQxNGI0NjgzMzcwZDdhZDUxOWZmZGQvdGFibGVyYW5nZTpjOGIzZDMyMTVhNDE0YjQ2ODMzNzBkN2FkNTE5ZmZkZF8xLTMtMS0xLTA_e17276b4-2a86-4177-b33e-f80a7be1aef9">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6YzhiM2QzMjE1YTQxNGI0NjgzMzcwZDdhZDUxOWZmZGQvdGFibGVyYW5nZTpjOGIzZDMyMTVhNDE0YjQ2ODMzNzBkN2FkNTE5ZmZkZF8yLTMtMS0xLTA_8b255111-19c7-40a0-af42-2f231ba3187b">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:144%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8xNDI5MzY1MTE2NTc3Mg_de433ebb-7ac2-4a7e-a49d-d54824fc2e96">&#9746;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). &#160;&#160;&#160;&#160;Yes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#160;&#160;<ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8zODcw_d31c613b-a43c-49c5-a147-a3fbf929f740">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:110%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#9746;</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The aggregate market value of the voting and non-voting ordinary shares held by non-affiliates of t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">he registrant as of June 30, 2021, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="usd" contextRef="i58e8c79f7b7640d089df3eefd8c4584f_I20210630" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8xNDI5MzY1MTE2NjIyNg_85ef1864-7abe-4043-950c-14edd217a9e0">16.6</ix:nonFraction>&#160;billion based upon the closing price reported for such date on the Nasdaq Stock Market LLC. This determination of affiliate status is not necessarily a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">conclusive determination for any other purposes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of February&#160;11, 2022, Royalty Pharma plc had <ix:nonFraction unitRef="shares" contextRef="i1bcce023e17042be90c95db2fc81e685_I20220211" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8zMTgw_58cb1cc5-4304-4fb4-9c87-7cacaebd5d65">432,963,472</ix:nonFraction> Class A ordinary shares outstanding and <ix:nonFraction unitRef="shares" contextRef="ia539779374e8435abf5929170c65ac83_I20220211" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8zMjIz_03c27806-674b-4d1b-8114-30b9474dd1da">174,212,681</ix:nonFraction> Class B ordinary shares outstanding.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:144%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8zODY1_01ce440a-1b20-45a7-b05a-c3c714cbc1bd" escape="true">Portions of the registrant&#8217;s definitive proxy statement for the 2022 Annual General Meeting of Shareholders, or Proxy Statement, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant&#8217;s fiscal year ended December 31, 2021. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, the Proxy Statement shall not be deemed to be filed as part hereof.</ix:nonNumeric></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.610%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i15fafc99ab5c41deb08ee816ca47172c_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-indent:4.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_16">1</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_19">20</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_22">47</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_25">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_25">47</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_28">47</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_31">47</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_37">Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_37">47</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_40">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_40">49</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_43">Management</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_43">s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_43">49</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_85">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_85">84</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_88">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_88">86</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_175">Changes in and Disagreements with Accountants on Accounting and Financial Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_175">129</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_178">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_178">129</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_181">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_181">129</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART III</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_187">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_187">129</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_190">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_190">130</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_193">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_193">130</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_196">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_196">130</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_199">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_199">130</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART IV</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_205">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_205">131</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_208">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_208">132</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_211">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_211">133</a></span></div></td></tr></table></div><div id="i15fafc99ab5c41deb08ee816ca47172c_10"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-indent:4.5pt"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Special Note Regarding Forward-Looking Statements</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Annual Report on Form 10-K contains statements reflecting our views about our future performance that constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; the negative of these terms and other comparable terminology. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about us, our current and prospective assets, our industry, our beliefs and our assumptions. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. You should evaluate all forward-looking statements made in this Annual Report on Form 10-K in the context of the numerous risks outlined in Part I under Item 1A. under &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">These risks and uncertainties include factors related to:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">sales risks of biopharmaceutical products on which we receive royalties;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ability of RP Management, LLC (the &#8220;Manager&#8221;) to locate suitable assets for us to acquire;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">uncertainties related to the acquisition of interests in development-stage biopharmaceutical product candidates and our strategy to add development-stage product candidates to our product portfolio;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the assumptions underlying our business model;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to successfully execute our royalty acquisition strategy;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to leverage our competitive strengths;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">actual and potential conflicts of interest with the Manager and its affiliates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ability of the Manager or its affiliates to attract and retain highly talented professionals;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the effect of changes to tax legislation and our tax position; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the risks, uncertainties and other factors we identify elsewhere in this Annual Report on Form 10-K and in our other filings with the U.S. Securities and Exchange Commission.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Although we believe the expectations reflected in the forward-looking statements are reasonable, any of those expectations could prove to be inaccurate, and as a result, the forward-looking statements based on those expectations also could be inaccurate. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this Annual Report on Form 10-K should not be regarded as a representation by us that our plans and business objectives will be achieved. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. We are under no duty to update any of these forward-looking statements after the date of this Annual Report on Form 10-K to conform our prior statements to actual results or revised expectations.</span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_13"></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-indent:4.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I &#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_16"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;BUSINESS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Overview </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry&#8217;s leading therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson &amp; Johnson&#8217;s Imbruvica, Astellas and Pfizer&#8217;s Xtandi, Biogen&#8217;s Tysabri, Johnson &amp; Johnson&#8217;s Tremfya, Gilead&#8217;s Trodelvy, Merck&#8217;s Januvia, Novartis&#8217; Promacta, Vertex&#8217;s Kalydeco, Orkambi, Symdeko and Trikafta, and ten</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">development-stage product candidates. We fund innovation in the biopharmaceutical industry both directly and indirectly - directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our capital-efficient business model enables us to benefit from many of the most attractive characteristics of the biopharmaceutical industry, including long product life cycles, significant barriers to entry and noncyclical revenues, but with substantially reduced exposure to many common industry challenges such as early stage development risk, therapeutic area constraints, high research and development costs, and high fixed manufacturing and marketing costs. We have a highly flexible approach that is agnostic to both therapeutic area and treatment modality, allowing us to acquire royalties on the most attractive therapies across the biopharmaceutical industry. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The success of our business has been the result of a focused strategy of actively identifying and tracking the development and commercialization of key new therapies, allowing us to move quickly to make acquisitions when opportunities arise. We acquire royalties on approved products, often in the early stages of their commercial launches, and development-stage product candidates with strong proof of concept data, mitigating development risk and expanding our opportunity set. From 1996 through 2021, we have deployed more than $22 billion of cash to acquire biopharmaceutical royalties, representing more than 50% of all royalty transactions during this period. From 2012, when we began acquiring royalties on development-stage product candidates, through 2021, we have deployed more than $17 billion of cash to acquire biopharmaceutical royalties, representing approximately 60% of all royalty transactions during this period.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2021, we generated cash from operating activities of $2.0&#160;billion, Adjusted Cash Receipts (as defined in &#8220;&#8212;Non-GAAP Financial Results&#8221;) of $2.1 billion and Adjusted Cash Flow (as defined in &#8220;&#8212;Non-GAAP Financial Results&#8221;) of $1.8 billion. We deployed $2.7&#160;billion of cash in 2021 for royalties and related securities.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Portfolio Overview</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our portfolio consists of royalties on more than 35 commercial products and ten development-stage product candidates. We believe that end market sales of the therapies in our portfolio are important drivers of our financial performance as a substantial portion of our royalties are based on end market sales. In addition, end market sales are a strong indicator of the importance of the therapies to both patients and the marketers. The following table provides an overview of our current portfolio of royalties: </span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product(s)</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketer(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product Detail </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 Royalty Receipts <br/>(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 End Market Sales (in millions) (1)</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Approved Products</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cystic fibrosis franchise (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cystic fibrosis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$702</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$7,573</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relapsing forms of multiple sclerosis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">369</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,063</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AbbVie, Johnson &amp; Johnson</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hematological malignancies and chronic graft versus host disease</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,943</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chronic immune thrombocytopenic purpura and aplastic anemia </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,016</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pfizer, Astellas</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prostate cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,582</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Januvia, Janumet, Other DPP-IVs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Merck &amp; Co., others</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,288</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HIV franchise (3)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gilead, others</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Human immunodeficiency virus (HIV)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,315</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nurtec ODT/Biohaven payment (4)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biohaven, Pfizer</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Migraine</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">455</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Merck &amp; Co.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prophylaxis of CMV in adult recipients of stem cell transplant</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Farxiga/Onglyza</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,365</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Johnson &amp; Johnson</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plaque psoriasis and psoriatic arthritis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,127</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cabometyx/Cometriq</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exelixis, Ipsen, Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Kidney, liver and thyroid cancers</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,590</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Crysvita</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ultragenyx, Kyowa Kirin</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X-linked hypophoshatemia</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Roche</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal muscular atrophy</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">659</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emgality</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lilly</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Migraine prevention &amp; episodic cluster headache</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">577</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Erleada</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Johnson &amp; Johnson</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prostate cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,291</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Metastatic triple-negative breast cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IDHIFA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bristol Myers Squibb</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relapsed/refractory AML with an IDH2 mutation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not disclosed</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Orladeyo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BioCryst</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hereditary angioedema prophylaxis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tazverik</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Epizyme</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Epithelioid sarcoma and follicular lymphoma</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oxlumo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alnylam</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Primary hyperoxaluria type 1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other products (5)(6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total royalty receipts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$2,609</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Development Stage Product Candidates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aficamten (7)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cytokinetics</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Obstructive hypertrophic cardiomyopathy (Phase 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BCX9930</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BioCryst</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Paroxysmal nocturnal hemoglobinuria (Phase 3) </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CPI-0209</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MorphoSys</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hematological malignancies and solid tumors (Phase 2)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gantenerumab</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Roche</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alzheimer&#8217;s disease (Phase 3)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Omecamtiv mecarbil (8)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cytokinetics</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Heart failure (Phase 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Otilimab</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GlaxoSmithKline</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rheumatoid arthritis (Phase 3)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pelabresib</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MorphoSys</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Myelofibrosis (Phase 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PT027</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asthma (Phase 3) </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Seltorexant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Johnson &amp; Johnson</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MDD with insomnia symptoms (Phase 3) </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Zavegepant</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biohaven</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Migraine (Phase 3) </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">CMV is Cytomegalovirus, AML is Acute Myelogenous Leukemia, IDH2 is isocitrate dehydrogenase-2 and MDD is Major Depressive Disorder.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Amounts shown in the table may not add due to rounding.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Notes: </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(1) &#160;&#160;&#160;&#160;Represents end market sales for the year ended December 31, 2021 as reported by respective product marketers or based on Visible Alpha projections as of February 9, 2022 where marketers have not reported end market sales. Sales shown for Crysvita represent Europe, the Middle East and Africa only. For the majority of our royalties, royalty receipts lag product performance by one quarter and can generally be estimated by applying our publicly disclosed royalty rate to the preceding quarter&#8217;s marketer-announced net revenues on a product-by-product basis.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(2) &#160;&#160;&#160;&#160;The cystic fibrosis franchise includes the following approved products: Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio.  </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(3) &#160;&#160;&#160;&#160;The HIV franchise includes the following approved products: Atripla, Truvada, Emtriva, Complera, Stribild, Genvoya, Descovy, Odefsey, Symtuza and Biktarvy. Royalties are received on the emtricitabine portion of sales only. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(4) &#160;&#160;&#160;&#160;Includes royalty receipts for Nurtec ODT of $7.7 million and quarterly redemptions of $15.6 million of the Series A Biohaven Preferred Shares (presented as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:115%">Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> on the Statement of Cash Flows).</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(5) &#160;&#160;&#160;&#160;Excludes duplicate end-market sales where we have multiple royalties on the same product: Kombiglyze, Nesina, Onglyza and Soliqua. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(6) &#160;&#160;&#160;&#160;Other products primarily include royalties on the following products: Bosulif (a product co-developed by our joint venture investee, Avillion, for which receipts are presented as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:115%">Distributions from non-consolidated affiliates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> on the Statement of Cash Flows), Lexiscan, Soliqua, Nesina, Cimzia, Letairis, Entyvio, Myozyme and Mircera. Other products includes a one-time $45.0 million milestone payment that we received on Soliqua and contributions from the Legacy SLP Interest (defined below).</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(7) &#160;&#160;&#160;&#160;Royalty was acquired in January 2022.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(8) &#160;&#160;&#160;&#160;The financial royalty asset associated with omecamtiv mecarbil was written off in the year ended December 31, 2020 given the uncertainty around the future of omecamtiv mecarbil at the time.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Biopharmaceutical Industry and the Role of Royalties</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business is supported by significant growth and unprecedented innovation within the biopharmaceutical industry. Global prescription pharmaceutical sales are projected to grow from approximately $0.9 trillion in 2021 to approximately $1.3 trillion in 2026, representing a CAGR of 7% according to EvaluatePharma despite more than $130 billion in cumulative sales being lost to expected patent expiries during the same period. The growth of the biopharmaceutical industry is driven by global secular trends, including population growth, increasing life expectancy and growth of the middle classes in emerging markets. In addition, a dramatic acceleration of medical research in recent years has led to a better understanding of the molecular origins of disease and identification of potential targets for therapeutic intervention. This has created research and development opportunities for new drugs. The significant pace of biopharmaceutical innovation coupled with the proliferation of new biotechnology companies and the increasing cost of drug development has created a significant capital need over recent years that we believe will provide a sustainable tailwind for our business.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Royalties play a fundamental and growing role in the biopharmaceutical industry. As a result of the increasing cost and complexity of drug development, the creation of a new drug today typically involves a number of industry participants. Academia and other research institutions conduct basic research and license new technologies to industry for further development. Biotechnology companies typically in-license these new technologies, add value through applied research and early-stage clinical development, and then either out-license the resulting development-stage product candidates to large biopharmaceutical companies for late-stage clinical development and commercialization, or commercialize the products themselves. As new drugs are transferred along this value chain, royalties are created as compensation for the licensing or selling institutions. Biotechnology companies are also increasingly creating royalties on existing products within their portfolios, known as synthetic royalties, in order to provide a source of non-dilutive capital to fund their businesses. As a result of this industry paradigm, the development of a single new drug can lead to the creation of multiple royalties. Given our leadership position within the biopharmaceutical royalty sector, we are able to capitalize on the growing volumes of royalties that are created as new therapies are developed to address unmet medical needs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Business Model</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that the following elements of our business and product portfolio provide a unique and compelling proposition to investors seeking exposure to the biopharmaceutical sector. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our portfolio provides direct exposure to a broad array of blockbuster therapies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2021, our portfolio included royalties on 14 therapies that each generated end-market sales of more than $1 billion, including five therapies that each generated end-market sales of more than $3 billion. The therapies within our royalty portfolio are marketed by leading global biopharmaceutical companies for whom these products are important sources of revenue. Given the marketers&#8217; significant focus on and investment in these products, they are motivated to invest substantial resources in driving continued sales growth. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our portfolio is highly diversified across products, therapeutic areas and marketers. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our portfolio consists of royalties on more than 35 marketed biopharmaceutical therapies which address a wide range of therapeutic areas, including rare diseases, cancer, neurology, immunology, hematology and diabetes. In the year ended December 31, 2021, no individual therapy accounted for more than 19% of our royalty receipts, no therapeutic area accounted for more than 29% of our royalty receipts and no marketer represented more than 27% of our royalty receipts. The royalties in our portfolio entitle us to payments based directly on the top-line sales of the associated therapies, rather than the profits of these therapies. As such, the diversification of our profits directly reflects the diversification of our royalty receipts, rather than varying levels of product-level profitability, as would typically be expected within a biopharmaceutical company. The graphic below shows the diversification within our 2021 royalty receipts by product, therapeutic area and marketer.</span></div><div style="text-align:center;text-indent:24.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:24.5pt"><img src="rprx-20211231_g1.jpg" alt="rprx-20211231_g1.jpg" style="height:226px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="text-align:center;text-indent:24.5pt"><span><br/></span></div><div style="text-align:center;text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Note:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> Only categories of at least 5% are separately presented in the charts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"> </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(1)&#160;&#160;&#160;&#160;Comprised of royalty receipts from Januvia, Janumet and other DPP-IVs</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The key growth-driving royalties in our portfolio are protected by long patent lives. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The estimated weighted average royalty duration of our portfolio is approximately 13 years based on projected cumulative cash royalty receipts. Our largest marketed royalty in 2021 was on Vertex&#8217;s cystic fibrosis franchise, and existing patent applications covering Trikafta, the most significant product in that franchise, are expected to provide exclusivity through 2037. Our right to receive royalties is perpetual, but we expect that the 2037 patent expiration for Trikafta may result in potential sales declines based on potential generic entry. Several of our marketed royalties have unlimited durations and could provide cash flows for many years after key patents have expired. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Simple and efficient operating model generates substantial cash flow for reinvestment in new biopharmaceutical royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Our capital-efficient operating model requires limited operating expenses and no material capital investment in fixed assets or infrastructure in order to support the ongoing growth of our business. As a result, we generate high Adjusted Cash Flow relative to our Adjusted Cash Receipts and we convert the vast majority of our Adjusted Cash Flow into operating cash flow. In 2021, we generated cash from operating activities of $2.0&#160;billion, Adjusted Cash Receipts of $2.1&#160;billion and Adjusted Cash Flow of $1.8&#160;billion. We deployed $2.7&#160;billion of cash in 2021 for royalties and related securities. Our high cash flow conversion provides us with significant capital that we can deploy for new royalty acquisitions and also use to grow our dividend to shareholders. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business model captures many of the most attractive aspects of the biopharmaceutical industry, but with reduced exposure to many common industry challenges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The biopharmaceutical industry benefits from a number of highly attractive characteristics, including long product life cycles, significant barriers to entry and non-cyclical revenues. We have a highly flexible approach that is agnostic to both therapeutic area and treatment modality, allowing us to acquire royalties on the most attractive therapies from across the biopharmaceutical industry. We focus on the acquisition of royalties on approved products or development-stage product candidates that have generated strong proof of concept data, avoiding the risks associated with early stage research and development. By acquiring royalties, we are able to realize payments based directly on the top-line sales of leading biopharmaceutical therapies, without the costs associated with fixed research and development, manufacturing and commercial infrastructure. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our unique role in the biopharmaceutical ecosystem positions us to benefit from multiple compounding growth drivers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. As a result of our significant scale and highly flexible business model, we believe that we are uniquely positioned to capitalize on multiple compounding growth drivers: an accelerating understanding of the molecular origins of disease, technological innovation leading to the creation of new treatment modalities, an increasing number of biopharmaceutical industry participants with significant capital needs, competitive industry dynamics which reward companies that can rapidly execute broad clinical development programs, increasing U.S. Food and Drug Administration (&#8220;FDA&#8221;) drug approvals which reached an all-time high in 2018 and the potential for multiple royalties to be created from each new drug that reaches the market.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have the ability to access innovation from across the biopharmaceutical ecosystem. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our approach is to first assess innovative science in areas of significant unmet medical need and then evaluate how to acquire royalties on therapies that we believe are attractive. We closely follow a broad range of therapeutic areas and treatment modalities and are therefore able to move quickly when we identify compelling opportunities to acquire new royalties.</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have deep access to attractively priced investment grade debt that provides a significant cost of capital advantage. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that we have an attractive cost of capital that enables us to acquire high-quality biopharmaceutical royalties at competitive prices while still creating value for our shareholders. As of December 31, 2021, we had an aggregate principal amount of $7.3 billion of senior unsecured notes outstanding with a weighted average coupon of 2.24% and a weighted-average maturity of approximately 13 years. In addition, we have an undrawn $1.5 billion senior unsecured revolving credit facility. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have a talented, long-tenured team with extensive experience and deep industry relationships. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our team has significant experience identifying, evaluating and acquiring royalties on biopharmaceutical therapies. Together they have been responsible for more than $22 billion of acquisitions of biopharmaceutical royalties and related assets. Our acquisitions have included many of the industry&#8217;s leading therapies across the past three decades, such as Humira, Imbruvica, Trikafta, Lyrica, Tecfidera, Truvada, Xtandi, Neupogen, Remicade and Rituxan, among others. Our long history of collaboration has resulted in deep relationships with a broad range of participants across the biopharmaceutical industry.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are the leader in acquiring biopharmaceutical royalties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We are the leader within the space, having executed transactions with an aggregate announced transaction value of more than $17 billion from 2012 through December 31, 2021. We estimate this to represent an estimated market share of approximately 60% by value. This compares to our next nearest competitor, which we believe has executed $2.8 billion of transactions, which we estimate to represent market share of 9%. Given the scale of our business relative to our competitors, we have a particularly strong leadership position within large royalty transactions. Since 2012, there have been 11 transactions with an aggregate value of more than $500 million each. We executed 9 of these 11 royalty transactions, for a total aggregate transaction value of $11.6 billion of cash and estimated market share of more than 80%, in this transaction size range. The charts below show our market share since 2012 across all transaction sizes and in royalty transactions with an aggregate value of more than $500 million. </span></div><div style="text-align:center;text-indent:24.5pt"><span><br/></span></div><div style="text-align:center;text-indent:24.5pt"><img src="rprx-20211231_g2.jpg" alt="rprx-20211231_g2.jpg" style="height:347px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Note:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> Graphs above include transactions through December 31, 2021 and exclude royalty debt transactions from market share calculations.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Strategic Plan to Grow the Portfolio </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We intend to grow our business by continuing to partner with constituents across the biopharmaceutical value chain to fund innovation. The three key pillars of our growth strategy are summarized below.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Acquisition of royalties on approved products which provide dependable cash flows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We intend to continue capturing a leading share of royalties on approved products, particularly those that are early in their life cycles, so that we can participate in the growth that is generated as they penetrate their markets, and enter new indications or geographies.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Acquisition of royalties on attractive development-stage product candidates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We intend to supplement our diverse portfolio of royalties on approved products with acquisitions of royalties on development-stage product candidates that have generated strong clinical proof of concept data to minimize risk and provide attractive upside potential.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Acquisition of royalties in connection with merger and acquisition (&#8220;M&amp;A&#8221;) transactions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We acquire royalties in connection with M&amp;A transactions in a number of ways: by purchasing non-strategic assets following the closing of acquisitions, by partnering with biopharmaceutical companies to acquire other biopharmaceutical companies that own significant royalties, or in select circumstances, by seeking to acquire biopharmaceutical companies on our own that have significant royalties or products that could be out-licensed to create royalties.</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We acquire royalties in a number of ways including by acquiring existing royalties, acquiring new synthetic royalties and by funding R&amp;D in exchange for future royalties and/or milestones. During the early years of our business, we focused our acquisitions on royalties on approved biopharmaceutical products. However, as we grew and diversified our business, we began acquiring royalties on development-stage product candidates that had demonstrated strong clinical proof of concept. These development-stage transactions have broadened our landscape of potential opportunities where we are able to leverage our scientific expertise and financial strength. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From 2012 through 2021, we deployed $7.8 billion of cash to acquire royalties and milestones on development-stage product candidates. Products underlying $6.3 billion of these acquisitions have already been approved, representing a success rate to date of 81%, while products underlying $0.3 billion were not approved and products underlying $1.1 billion are still in development.</span></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><img src="rprx-20211231_g3.jpg" alt="rprx-20211231_g3.jpg" style="height:297px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Notes: </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(1) &#160;&#160;&#160;&#160;Reflects cash deployed for royalty acquisitions from 2012 through 2021.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(2) &#160;&#160;&#160;&#160;Not approved includes investments in vosaroxin, palbociclib, and Merck KgaA&#8217;s anti-IL17 nanobody M1095.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In recent years, we have increased the scope of our investments beyond royalties to include additional assets such as equity investments and the acquisition of businesses with significant royalty assets. Our broad scope maximizes our total addressable market and has allowed us to provide a broad range of solutions to our partners across the biopharmaceutical ecosystem.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our approach is to first assess innovative science in areas of significant unmet medical need and then evaluate how to acquire royalties on therapies that we believe are attractive. We have a strong base of institutional knowledge of important therapeutic areas and key industry trends. Our team of scientific experts actively monitors the evolving treatment landscape across many therapeutic areas and treatment modalities in order to identify new opportunities. We analyze a wide range of scientific data and stay in constant communication with leading physicians, scientists, biopharmaceutical executives and venture capital firms. This allows us to quickly assess and gain conviction in the value of assets when acquisition opportunities arise.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We take a disciplined approach in assessing opportunities and seek to acquire exposure to therapies based on the following key product characteristics: </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Clinically validated:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> therapies that have received regulatory approval or have strong clinical proof-of-concept data that gives us confidence in the clinical and commercial profile. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">High unmet need:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">therapies that address areas of significant unmet medical need that also represent large commercial opportunities. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Significant benefits to patients:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> therapies that have potential to disrupt or significantly enhance the treatment paradigm for patients and physicians based on compelling clinical data. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Unique competitive positioning:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> therapies that are well-positioned to be leaders in their respective categories and are expected to maintain a competitive advantage in the long-term. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Growth potential:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> therapies where we see strong long-term potential, based on our in-depth evaluation and in-house expertise. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Strong marketer:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> therapies marketed by biopharmaceutical companies that have the resources, capabilities and commitment to successfully develop them and maximize their commercial potential. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Intellectual Property:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> therapies that have strong patent portfolios and offer durable, long-term cash flows. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Attractive value proposition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> therapies that we believe provide value-add to the healthcare system. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our focus is to create significant long-term value for our shareholders by acquiring both approved and development-stage product candidates through a variety of structures. In evaluating these acquisition opportunities, we focus on the following financial characteristics: </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Long duration cash flows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> we prioritize long-duration assets over short-duration assets that may boost near-term financial performance. The durability of our cash flows also allows us to add leverage to our portfolio, enhancing returns and providing capital that we can use to acquire additional assets. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Attractive risk-adjusted returns:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> we focus on generating attractive returns on our investments on a risk-adjusted basis. We do not target the same return for all assets and evaluate opportunities across the risk spectrum. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Growth and scale:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> we seek assets that are accretive to our long-term growth profile and additive to our overall scale. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conduct extensive due diligence when evaluating potential new opportunities. We have end-to-end capabilities that span clinical and commercial analysis, valuation and transaction structuring. We have a highly focused and experienced team that conducts proprietary primary market research, forms its own views on the clinical and commercial outlook for the product, and builds its own financial models, allowing us to generate direct insights and allowing us to take significant accountability and ownership for our investments. We invest significant time and resources across all levels of the organization, including senior leadership, in the evaluation of potential opportunities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Portfolio</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Commercial Products </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The key royalties in our marketed portfolio related to approved products include the ones listed below. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Descriptions of estimated royalty expiration dates are based on our estimates of patent expiry dates (which may include estimated patent term extensions) or estimates of the dates on which the royalties otherwise expire and are based on each product&#8217;s key geographies; duration may differ in other geographies. Royalty expiration dates can change due to patent, regulatory, commercial or other developments. In addition, the royalties in our portfolio are subject to the underlying contractual agreements from which they arise and may be subject to reductions or other adjustments in accordance with the terms of such agreements.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cystic fibrosis franchise </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our cystic fibrosis franchise consists of our right to receive royalty payments on the sale of various products marketed by Vertex for use in the treatment of cystic fibrosis, including Kalydeco (ivacaftor), Orkambi (lumacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor and ivacaftor) and Trikafta/Kaftrio (elexacaftor, tezacaftor and ivacaftor). Vertex&#8217;s cystic fibrosis franchise represents the leading treatments for cystic fibrosis, providing treatment options for approximately 90% of cystic fibrosis patients.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added the cystic fibrosis franchise to our portfolio in November 2014 and purchased an additional residual royalty interest in November 2020. Our right to receive royalties is perpetual, but we expect that the 2037 patent expiration for Trikafta may result in potential sales declines based on potential generic entry. Total global end market sales for the cystic fibrosis franchise during 2021 were approximately $7.6&#160;billion and we collected $702&#160;million in related royalty receipts over the same period. Global end market sales of the cystic fibrosis franchise are projected to grow to approximately $10.4&#160;billion in 2026, according to Visible Alpha. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Tysabri </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tysabri (natalizumab) is a monoclonal antibody marketed by Biogen for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. Tysabri competes in the high efficacy segment of the multiple sclerosis market, often reserved for patients with aggressive disease at onset and patients who have failed front-line therapies. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Tysabri to our portfolio in February 2017. Our right to receive royalties is perpetual. Total global end market sales for Tysabri during 2021 were approximately $2.1&#160;billion and we collected $369&#160;million in related royalty receipts over the same period. Global end market sales of Tysabri are projected to be approximately $1.7&#160;billion in 2026, according to Visible Alpha. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Imbruvica </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Imbruvica (ibrutinib) is a first-in-class small molecule Bruton&#8217;s tyrosine kinase inhibitor that is the leading therapy in chronic lymphocytic leukemia, relapsed/refractory mantle cell lymphoma and other blood cancers. Imbruvica is marketed by AbbVie and Janssen, a subsidiary of Johnson &amp; Johnson. A robust clinical program supports Imbruvica&#8217;s use across a wide range of patient populations and cancer types, including 11 FDA approvals in six distinct indications.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Imbruvica to our portfolio in July 2013. We estimate that our royalties will substantially end between 2027 and 2032. Total global end market sales for Imbruvica during 2021 were approximately $6.9&#160;billion and we collected $353&#160;million in related royalty receipts over the same period. Global end market sales of Imbruvica are projected to grow to approximately $7.9&#160;billion in 2026, according to Visible Alpha. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Promacta </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Promacta (eltrombopag) is an oral, small molecule activator of the thrombopoietin receptor used to increase the number of platelets in the blood, marketed by Novartis for the treatment of chronic immune thrombocytopenia and aplastic anemia. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Promacta to our portfolio in March 2019. We estimate that our royalties will substantially end between 2025 and 2028. Total global end market sales for Promacta during 2021 were approximately $2.0&#160;billion and we collected $174&#160;million in related royalty receipts over the same period. Global end market sales of Promacta are projected to be approximately $600&#160;million in 2026, according to Visible Alpha. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Xtandi </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Xtandi (enzalutamide) is an oral, small molecule androgen receptor inhibitor marketed by Pfizer and Astellas for the treatment of non-metastatic and metastatic castration-resistant prostate cancer as well as metastatic castration sensitive prostate cancer.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Xtandi to our portfolio in March 2016. We estimate that our royalties will substantially end between 2027 and 2028. Total global end market sales for Xtandi during 2021 were approximately $4.6&#160;billion and we collected $158&#160;million in related royalty receipts over the same period. Global end market sales of Xtandi are projected to grow to approximately $6.3&#160;billion in 2026, according to Visible Alpha. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Januvia, Janumet, other DPP-IVs</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We hold patents covering the DPP-IV inhibitors which entitle us to royalty payments on the sale of various products, including Januvia (sitagliptin)/Janumet (sitagliptin and metformin) marketed by Merck &amp; Co.; Tradjenta (linagliptin)/Jentadueto (linagliptin and metformin) marketed by Boehringer Ingelheim and Lilly; and Nesina (alogliptin) marketed by Takeda and Teijin Pharma, which have been approved for the treatment of type 2 diabetics in substitution of, or in addition to, insulin therapy. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added the DPP-IV inhibitors to our portfolio in June 2011. Our royalties on Januvia and Janumet will expire in 2022 and royalties on the other DPP-IVs have substantially ended. Total global end market sales for the DPP-IV inhibitors during 2021 were approximately $5.3&#160;billion and we collected $151&#160;million in related royalty receipts over the same period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">HIV franchise </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our HIV franchise consists of our right to receive royalty payments on the sale of various products, including Atripla, Biktarvy, Complera, Descovy, Emtriva, Genvoya, Odefsey, Stribild, Symtuza and Truvada, which have been approved for the treatment and prevention of HIV and acquired immune deficiency syndrome. Gilead is the primary marketer for the products in our HIV franchise. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added the HIV franchise to our portfolio starting in July 2005. Our royalties substantially ended in 2021. Total global end market sales for the products in the HIV franchise during 2021 were approximately $16.3&#160;billion and we collected $78&#160;million in related royalty receipts over the same period. </span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Nurtec ODT/Biohaven fixed payments</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Nurtec ODT (rimegepant) is an oral, small molecule calcitonin gene-related peptide receptor antagonist marketed by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biohaven and Pfizer for the acute treatment and prevention of migraine. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Nurtec ODT to our portfolio in June 2018 and purchased an additional interest in Nurtec ODT as part of our expanded funding agreement with Biohaven in August 2020. We estimate that our royalties will substantially end between 2034 and 2036. Total global end market sales for Nurtec ODT during 2021 were estimated to be approximately $455&#160;million and we collected $8&#160;million in related royalty receipts over the same period. In addition, as a result of the approval of Nurtec ODT in February 2020, we received $63&#160;million in fixed payments from Biohaven during the year ended December 31, 2021, which represent the first four of 16 consecutive quarterly payments to be received from Biohaven relating to the Series A Biohaven Preferred Shares. Global end market sales of Nurtec ODT are projected to grow to approximately $2.4&#160;billion in 2026, according to Visible Alpha. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Prevymis</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prevymis (letermovir) is a first-in-class prophylactic marketed by Merck &amp; Co. for the prophylaxis of cytomegalovirus infection and disease in adults who have received an allogeneic hematopoietic stem cell transplant.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Prevymis to our portfolio in June 2020. We estimate that our royalties will substantially end in 2029. Total global end market sales for Prevymis during 2021 were approximately $370&#160;million and we collected $38&#160;million in related royalty receipts over the same period. Global end market sales of Prevymis are projected to grow to approximately $450&#160;million in 2026, according to Visible Alpha. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Farxiga/Onglyza</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Farxiga (dapagliflozin) is a first-in-class selective inhibitor of human sodium-glucose co-transporter 2 indicated as both monotherapy and as part of combination therapy with Onglyza, a dipeptidyl peptidase-4 inhibitor, to improve glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes. Farxiga received FDA approval in May 2020 for the treatment of patients with heart failure with reduced ejection fraction in both patients with and without type 2 diabetes. Farxiga and Onglyza are both marketed by AstraZeneca.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Farxiga/Onglyza to our portfolio in November 2017. We estimate that our royalties will substantially end in 2025. Total global end market sales for Farxiga/Onglyza during 2021 were approximately $3.4&#160;billion and we collected $36&#160;million in related royalty receipts over the same period. Global end market sales of Farxiga/Onglyza are projected to grow to approximately $4.2&#160;billion in 2026, according to Visible Alpha.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Tremfya</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tremfya (guselkumab) is an anti-interleukin 23 marketed by Johnson &amp; Johnson for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis. Tremfya is also in clinical development for ulcerative colitis and Crohn&#8217;s disease.</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Tremfya to our portfolio in July 2021. We estimate that our royalties will substantially end between 2031 and 2032. Total global end market sales for Tremfya during 2021 were approximately $2.1&#160;billion and we collected $36 million in related royalty receipts for the partial period subsequent to acquisition in July 2021. Global end market sales of Tremfya are projected to grow to approximately $5.4 billion in 2026, according to Visible Alpha.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cabometyx/Cometriq</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cabometyx (cabozantinib) is a multi-tyrosine kinase inhibitor approved for the treatment of patients with advanced renal cell carcinoma (RCC) both as monotherapy and in combination with Bristol Myers Squibb&#8217;s Opdivo (nivolumab) as a first line treatment. Cabometyx is also approved for hepatocellular carcinoma in patients previously treated with sorafenib. Cometriq is approved for progressive, metastatic medullary thyroid cancer. Cabometyx and Cometriq are marketed by Exelixis in the United States and by Ipsen in regions outside the United States and Japan. Cabometyx is marketed in Japan by Takeda.</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Cabometyx/Cometriq to our portfolio in March 2021. We estimate that our royalties will substantially end between 2026 and 2029. Total global end market sales for Cabometyx/Cometriq during 2021 were estimated to be approximately $1.6&#160;billion and we collected $34&#160;million in related royalty receipts for the partial period subsequent to acquisition in March 2021. Global end market sales of Cabometyx/Cometriq are projected to grow to approximately $3.4&#160;billion in 2026, according to Visible Alpha.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Crysvita </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Crysvita (burosumab) is a monoclonal antibody against fibroblast growth factor 23 marketed by Ultragenyx and Kyowa Kirin that has received European Commission (&#8220;EC&#8221;) conditional marketing authorization for the treatment of X-linked hypophosphatemia with radiographic evidence of bone disease in children one year of age and older and adolescents with growing skeletons. In October 2020, this authorization was expanded to include older adolescents and adults.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added a royalty on Crysvita sales in Europe to our portfolio in December 2019. Our royalties expire when we receive aggregate royalties equal to $608 million if that happens prior to December 31, 2030, and otherwise when we receive aggregate royalties of $800 million. We estimate that our royalties will substantially end between 2033 and 2038. End market sales for Crysvita in Europe during 2021 were $179&#160;million and we collected approximately $17&#160;million in related royalty receipts over the same period. End market sales of Crysvita in Europe are projected to grow to approximately $400&#160;million in 2026, according to Visible Alpha.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Evrysdi </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Evrysdi (risdiplam) is a survival motor neuron 2 splicing modifier marketed by Roche, and is the first oral treatment approved for infants, children and adults with all types of spinal muscular atrophy. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Evrysdi to our portfolio in July 2020. Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion. Total global end market sales for Evrysdi during 2021 were approximately $659&#160;million and we collected $16&#160;million in related royalty receipts over the same period. Global end market sales of Evrysdi are projected to grow to approximately $2.9&#160;billion in 2026, according to Visible Alpha. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Emgality</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Emgality (galcanezumab-gnlm) is a monoclonal antibody calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine and for the treatment of episodic cluster headache marketed by Lilly.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Emgality to our portfolio in March 2019. We estimate that our royalties will substantially end in 2033. Total global end market sales for Emgality during 2021 were approximately $577&#160;million and we collected $15&#160;million in related royalty receipts over the same period. Global end market sales of Emgality are projected to grow to approximately $1.4&#160;billion in 2026, according to Visible Alpha. </span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Erleada</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Erleada (apalutamide) is an oral, small molecule androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer and for the treatment of patients with metastatic castration sensitive prostate cancer. It is marketed by Johnson &amp; Johnson.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Erleada to our portfolio in February 2019. We estimate that our royalties will substantially end in 2032. Total global end market sales for Erleada during 2021 were approximately $1.3&#160;billion and we collected $14&#160;million in related royalty receipts over the same period. Global end market sales of Erleada are projected to grow to approximately $4.0&#160;billion in 2026, according to Visible Alpha. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Trodelvy </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate for the treatment of adult patients with metastatic triple-negative breast cancer. Trodelvy was initially developed by Immunomedics and is now marketed by Gilead following the acquisition of Immunomedics in 2020. Gilead is exploring monotherapy and combinations of Trodelvy across numerous cancer indications and lines of therapy. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Trodelvy to our portfolio in January 2018. Our right to receive royalties is perpetual. Total global end market sales for Trodelvy during 2021 were approximately $380&#160;million and we collected $13&#160;million in related royalty receipts over the same period. Global end market sales of Trodelvy are projected to grow to approximately $2.3&#160;billion in 2026, according to Visible Alpha. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">IDHIFA</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">IDHIFA (enasidenib) is an oral, targeted therapy approved by the FDA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation. It is marketed by Bristol Myers Squibb.</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added IDHIFA to our portfolio in June 2020. We estimate that our royalties will substantially end in the U.S. in 2033. End market sales for IDHIFA are not disclosed by Bristol Myers Squibb. We collected $12&#160;million in related royalty receipts in 2021. We also hold rights to receive up to $55 million in outstanding regulatory milestone payments from Bristol Myers Squibb. Visible Alpha does not currently have estimates available for global end market sales of IDHIFA in 2026. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Orladeyo</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Orladeyo (berotralstat) is a first-in-class oral inhibitor of plasma kallikrein marketed by BioCryst for the prevention of hereditary angioedema attacks.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Orladeyo to our portfolio in December 2020 and purchased an additional interest as part of our expanded funding agreement with BioCryst in November 2021. Our right to receive royalties is perpetual, but we expect that the 2036-2039 patent expirations for Orladeyo may result in potential sales declines based on potential generic entry. Total global end market sales for Orladeyo during 2021 were estimated to be approximately $117&#160;million and we collected $7&#160;million in related royalty receipts over the same period. Global end market sales of Orladeyo are projected to grow to approximately $600&#160;million in 2026, according to Visible Alpha. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Tazverik </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tazverik (tazemetostat) is a first-in-class, oral EZH2 inhibitor marketed by Epizyme that was granted accelerated approval for the treatment of epithelioid sarcoma and follicular lymphoma. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Tazverik to our portfolio in November 2019. We estimate that our royalties will substantially end in 2034. Total global end market sales for Tazverik during 2021 were estimated to be approximately $32&#160;million and we collected $3&#160;million in related royalty receipts over the same period. Global end market sales of Tazverik are projected to grow to approximately $400&#160;million in 2026, according to Visible Alpha. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Oxlumo</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Oxlumo (lumasiran) is a small interfering ribonucleic acid therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1 marketed by Alnylam. Oxlumo was approved by the FDA in November 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added Oxlumo to our portfolio in April 2021. We estimate that our royalties will substantially end between 2034 and 2035. Total global end market sales for Oxlumo during 2021 were approximately $60 million and we collected $1 million in related royalty receipts over the same period. Global end market sales of Oxlumo are projected to grow to approximately $350&#160;million in 2026, according to Visible Alpha.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Development-Stage Product Candidates </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our current portfolio includes ten development-stage product candidates. These development-stage product candidates have not yet been approved, and therefore have not generated any royalties (and we have not collected any related royalty receipts) to date. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Aficamten </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Aficamten is a small molecule cardiac myosin inhibitor, in Phase 3 development by Cytokinetics for obstructive hypertrophic cardiomyopathy (oHCM). We added aficamten to our portfolio in January 2022. If approved, global end market sales of aficamten are projected to grow to approximately $400&#160;million&#160;in 2026, according to Visible Alpha.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BCX9930</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">BCX9930 is an oral Factor D inhibitor in Phase 3 clinical development by BioCryst as monotherapy for paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases. We added BCX9930 to our portfolio in December 2020 and purchased an additional interest as part of our expanded funding agreement with BioCryst in November 2021. If approved, global end market sales of BCX9930 are projected to grow to approximately $200 million&#160;in 2026, according to Visible Alpha.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">CPI-0209 </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CPI-0209 is a second-generation enhancer of zeste homolog 2 inhibitor, in Phase 2 development by MorphoSys for hematological malignancies and solid tumors. We added CPI-0209 to our portfolio in July 2021. Visible Alpha does not currently have estimates available for global end market sales of CPI-0209 in 2026.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Gantenerumab </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gantenerumab is an anti-amyloid-beta monoclonal antibody, in Phase 3 development by Roche for Alzheimer&#8217;s disease. We added gantenerumab to our portfolio in July 2021. If approved, global end market sales of gantenerumab are projected to grow to approximately $1.9&#160;billion in 2026, according to Visible Alpha.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Omecamtiv mecarbil </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Omecamtiv mecarbil is an oral, small molecule cardiac myosin activator in Phase 3 clinical development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">by Cytokinetics for the treatment of heart failure with reduced ejection fraction. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added omecamtiv</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">mecarbil to our portfolio in 2017. In November 2020, results from the Phase 3 GALACTIC-HF trial of omecamtiv mecarbil in patients with heart failure were presented at the American Hearth Association Scientific Sessions which showed that the trial met the primary composite endpoint of reduction in cardiovascular death or heart failure events, but did not meet the secondary endpoint of reduction in cardiovascular death. Cytokinetics subsequently regained global rights to develop and commercialize omecamtiv mecarbil when Amgen and Servier elected to terminate their collaboration agreement. Following the Phase 3 results and termination of the collaboration announced in 2020, given the uncertainty around the future of omecamtiv mecarbil at the time, we recognized an impairment charge of $65 million related to the write-off of the associated financial royalty asset of $90 million and its associated provision of $25 million in the year ended December 31, 2020. If approved, global end market sales of omecamtiv mecarbil are projected to grow to approximately $200&#160;million in 2026, according to Visible Alpha. </span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Otilimab </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Otilimab is a fully human monoclonal antibody that inhibits granulocyte-macrophage colony-stimulating factor, in Phase 3 development by GlaxoSmithKline for rheumatoid arthritis. We added otilimab to our portfolio in July 2021. We are also entitled to 100% of future regulatory and success-based milestone payments on otilimab. If approved, global end market sales of otilimab are projected to grow to approximately $250&#160;million in 2026, according to Visible Alpha.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Pelabresib </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pelabresib is a bromodomain and extra-terminal inhibitor, in Phase 3 development by MorphoSys for myelofibrosis. We added pelabresib to our portfolio in July 2021. If approved, global end market sales of pelabresib are projected to grow to approximately $200&#160;million in 2026, according to Visible Alpha.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">PT027 </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PT027 is an investigational fixed dose combination of the inhaled corticosteroid, budesonide and albuterol, a short-acting beta-2 agonist for the treatment of asthma in Phase 3 development. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2018, we entered into an agreement with Avillion II, which was amended in July 2021, to fund up to approximately $122.5 million over multiple years to fund a portion of the costs for Phase 2 and 3 clinical trials of Avillion II, which is a party to a co-development agreement with AstraZeneca to advance PT027 through a global clinical development program for the treatment of asthma in exchange for royalties, a series of success-based milestones, and other potential payments. We estimate that our royalties will substantially end in 2030, but AstraZeneca is entitled to certain buyout rights which, if exercised, would result in earlier expiration. If approved, global end market sales of PT027 are projected to grow to approximately $500&#160;million in 2026, according to Visible Alpha.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Seltorexant</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Seltorexant is a selective orexin 2 receptor antagonist currently in Phase 3 development for the treatment of major depressive disorder with insomnia symptoms by Johnson &amp; Johnson. We added seltorexant to our portfolio in January 2021. Visible Alpha does not currently have estimates available for global end market sales of seltorexant in 2026.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Zavegepant </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Zavegepant is a small molecule calcitonin gene-related peptide receptor antagonist in clinical development by Biohaven for the acute treatment and prevention of migraines in Phase 3 development. In November 2021, Biohaven and Pfizer announced a strategic commercialization arrangement for Pfizer to commercialize zavegepant in markets outside of the United States upon approval.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We added zavegepant to our portfolio in June 2018 and purchased an additional interest as part of our expanded funding agreement with Biohaven in August 2020. We estimate that our royalties will substantially end between 2034 and 2036. As a result of an additional transaction in 2020, we are also entitled to success-based milestone payments. If approved, global end market sales of zavegepant are projected to grow to approximately $650&#160;million in 2026, according to Visible Alpha.</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Royalty Portfolio Summary</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below provides a summary of the estimated royalty expiration and the royalty rates for our portfolio: </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Therapeutic Area</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated&#160;Royalty&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expiration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Approved Products</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2037</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For combination therapies, sales are allocated equally to each of the active pharmaceutical ingredients; tiered royalties ranging from single digit to subteen percentages on annual worldwide net sales of ivacaftor, lumacaftor and tezacaftor, and mid-single digit percentages on annual worldwide net sales of elexacaftor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Perpetual</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent payments of 18% on annual worldwide net sales up to $2.0 billion and 25% on annual worldwide net sales above $2.0 billion</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tiered royalty in the mid-single digits on annual worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hematology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025-2028</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tiered royalty ranging from 4.7% to 9.4% on annual worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty slightly less than 4% on annual worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Januvia and Janumet</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Low-single digit royalty on annual worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nurtec ODT</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2034-2036</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1% royalty on annual combined worldwide net sales of Nurtec ODT and zavegepant up to $1.5 billion and 1.5% on annual combined worldwide net sales above $1.5 billion. 0.4% incremental royalty on all Nurtec ODT worldwide net sales.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prevymis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Infectious disease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Low-double digit royalty on annual worldwide net sales up to $300 million</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Farxiga/Onglyza</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments to Royalty Pharma equivalent to low-single digit downward tiered royalty on annual worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mid-single digit, tiered royalty on annual worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cabometyx/Cometriq</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026-2029</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3% royalty on annual worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Crysvita</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2033-2038</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10% royalty on annual EU, U.K. and Switzerland net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2030-2035</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total royalties are tiered at 8% on worldwide annual net sales up to $500 million, 11% on net sales between $500 million and $1 billion, 14% on net sales between $1 billion and $2 billion, 16% on net sales over $2 billion; Royalty Pharma is entitled to approximately 43% of total royalties</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Emgality</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2033</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Low-single digit royalties on annual worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Erleada</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Low-single digit royalties on annual worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Perpetual</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.15% royalty on annual worldwide net sales up to $2 billion, declining stepwise based on sales tiers to 1.75% on annual worldwide net sales above $6 billion</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">IDHIFA </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2033</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tiered royalty in the low-double digits to mid-teens based on annual worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Orladeyo</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2036-2039</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.50% royalty on direct annual net sales of up to $350 million, 4.50% on sales between $350 million and $550 million, no royalty on sales over $550 million; tiered percentage of sublicense revenue in certain territories</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tazverik</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2034</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties in the mid-teens percentages on annual worldwide net sales, stepping down on annual worldwide net sales above certain sales thresholds</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Oxlumo</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2034-2035</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties in the mid- to high-single digits based on annual worldwide net sales</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Development Stage Product Candidates</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aficamten</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardiology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5% royalty on annual worldwide net sales up to $1 billion and 3.5% on net sales above $1 billion, subject to certain potential step-downs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BCX9930</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0% royalty on annual worldwide net sales up to $1.5 billion, 3.0% royalty on annual worldwide net sales between $1.5 billion and $3.0 billion, and 1.0% royalty on annual worldwide net sales above $3.0 billion</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CPI-0209</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0% royalty on annual worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gantenerumab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total royalties tiered between 5.5% and 7.0% on annual worldwide net sales; Royalty Pharma is entitled to 60% of total royalties</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Omecamtiv mecarbil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardiology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2032-2033</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mid-single digit royalty on worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Otilimab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tiered double-digit total royalties on annual worldwide net sales; Royalty Pharma is entitled to 80% of total royalties</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pelabresib</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0% royalty on annual worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PT027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Respiratory</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2030</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tiered royalties in the low-single digits on annual worldwide net sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(11)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Seltorexant </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mid-single digit royalty on worldwide net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Zavegepant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2034-2036</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1% royalty on annual combined worldwide net sales of Nurtec ODT and zavegepant up to $1.5 billion and 1.5% on annual combined worldwide net sales above $1.5 billion. Up to a 3.0% incremental royalty on zavegepant worldwide net sales up to $1.5 billion and up to 2.0% incremental royalty on zavegepant worldwide net sales above $1.5 billion.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Notes:</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(1) &#160;&#160;&#160;&#160;Dates shown represent our estimates as of current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(2) &#160;&#160;&#160;&#160;The royalties in our portfolio are subject to the underlying contractual agreements from which they arise and may be subject to reductions or other adjustments in accordance with the terms of such agreements. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(3) &#160;&#160;&#160;&#160;Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(4) &#160;&#160;&#160;&#160;Royalties on net sales of cabozantinib products in the United States through September 2026 and non-U.S. markets through the full term of the royalty. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(5) &#160;&#160;&#160;&#160;Royalties expire when we receive aggregate royalties equal to $608 million if that happens prior to December 31, 2030, and otherwise when we receive aggregate royalties of $800 million.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(6) &#160;&#160;&#160;&#160;Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(7) &#160;&#160;&#160;&#160;Royalty is perpetual; years shown represent estimated United States patent expiration for Orladeyo and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(8) &#160;&#160;&#160;&#160;Represents the estimated patent expiration date in the United States.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(9) &#160;&#160;&#160;&#160;Royalty was acquired in January 2022.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(10) &#160;&#160;&#160;&#160;AstraZeneca is entitled to certain buyout rights which, if exercised, would result in earlier expiration. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(11) &#160;&#160;&#160;&#160;Represents the portion of the royalties owed to Avillion II attributable to our minority ownership stake in Avillion II. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There can be no assurance that our royalties will expire when expected. Any reductions in the durations of royalties relative to our estimates may adversely affect our financial condition and results of operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Risk Factors&#8221; in Item 1A, Risk Factors for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">further information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Fixed Payment Arrangements </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below provides a summary of our fixed payment arrangements: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:62.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funding Arrangement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Therapeutic Area</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Key Terms</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biohaven Series A<br/>Preferred Shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">16 consecutive quarterly payments of $15.6 million to Royalty Pharma from the three months ended March 31, 2021 through the three months ended December 31, 2024 totaling $250.0 million (2.0 times the $125.0 million total purchase price of Series A Biohaven Preferred Shares that Royalty Pharma acquired in 2019).</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biohaven Series B<br/>Preferred Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">24 consecutive quarterly payments of $14.8 million to Royalty Pharma from the three months ended March 31, 2025 through the three months ended December 31, 2030 totaling $354.5 million (approximately 1.8 times the $200.0 million total purchase price of Series B Biohaven Preferred Shares that Royalty Pharma has agreed to acquire between the three months ended March 31, 2021 and the three months ended December 31, 2024).</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Zavegepant Success-Based Milestones</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Success-based milestone payments to Royalty Pharma ranging from 1.9 to 2.95 times the funded amount of $250.0 million, depending on achievement of specific regulatory approvals for zavegepant. 40 consecutive quarterly payments commencing on the first day of the second calendar quarter following a milestone event. If zavegepant&#8217;s first regulatory approval in migraine is achieved, Royalty Pharma will receive total success-based milestone payments of $475.0 million, or 1.9 times the funded amount, related to this specific approval. Incremental payments of up to 1.05 times the funded amount could be triggered by certain additional regulatory approvals. </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">MorphoSys Development Funding Bonds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Not applicable</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Payments to Royalty Pharma totaling approximately 2.2 times the amount drawn by MorphoSys. Up to $350.0 million in potential funding is available to be drawn through July 15, 2022, with a minimum draw of $150.0 million. 36 consecutive quarterly payments to Royalty Pharma commencing in the ninth quarter following the quarter of the applicable funding date. As of February 15, 2022, the Development Funding Bonds remain undrawn.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Cytokinetics Commercial Launch Funding</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cardiology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Payments to Royalty Pharma totaling 1.9 times the amount drawn for up to five tranches totaling $300.0 million in potential funding to Cytokinetics, including an initial $50.0 million tranche that was funded in the three months ended March 31, 2022. Each subsequent tranche has a 12-month draw period following achievement of certain clinical and regulatory milestones. 34 consecutive quarterly payments to Royalty Pharma commencing on the last business day of the seventh quarter following the quarter of the applicable funding date for each tranche. </span></div></td></tr></table></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(1) &#160;&#160;&#160;&#160;Our fixed payment arrangements are subject to the underlying contractual agreements and legal instruments from which they arise and may be subject to reduction, accelerations, and other adjustments in accordance with the respective terms of such agreements and instruments.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Competition </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We face competition from other entities that acquire biopharmaceutical royalties, including competitors to the Manager that are in the similar business of acquiring biopharmaceutical royalties. There are a limited number of suitable and attractive acquisition opportunities available in the market. Therefore, competition to acquire such assets is intense. The Manager is subject to competition from other potential royalty buyers, including from the companies that market the products on which royalties are paid, financial institutions and other entities. These potential royalty buyers may be larger and better capitalized than us. The Manager may not be able to identify and obtain a sufficient number of asset acquisition opportunities to invest the full amount of capital that may be available to us. There can be no assurance that we will continue to acquire biopharmaceutical products and companies that hold biopharmaceutical royalties that are acceptable to us. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The products that provide the basis for the cash flows of the biopharmaceutical products in which we invest are also subject to intense competition. The biopharmaceutical industry is a highly competitive and rapidly evolving industry. The length of any product&#8217;s commercial life cannot be predicted. There can be no assurance that one or more products will not be rendered obsolete or non-competitive by new products or improvements made to existing products, either by the current marketer of such products or by another marketer. Adverse competition, obsolescence or governmental and regulatory action or healthcare policy changes could significantly affect the revenues, including royalty-related revenues, of the products which serve as the security or other support for the payments due under the biopharmaceutical products that we hold. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Competitive factors affecting the market position and success of each product include: </span></div><div style="text-indent:55.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">effectiveness; </span></div><div style="text-indent:55.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">safety and side effect profile; </span></div><div style="text-indent:55.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">price, including third-party insurance reimbursement policies; </span></div><div style="text-indent:55.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">timing and introduction of the product; </span></div><div style="text-indent:55.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">efficacy of marketing strategy; </span></div><div style="text-indent:55.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">governmental regulation; </span></div><div style="text-indent:55.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">availability of lower-cost generics and/or biosimilars; </span></div><div style="text-indent:55.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">treatment innovations that eliminate or minimize the need for a product; and </span></div><div style="text-indent:55.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">product liability claims. </span></div><div style="text-indent:55.05pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If a product for which we have a royalty receivable or other interest is rendered obsolete or non-competitive by new products, including generics and/or biosimilars, or improvements on existing therapies or governmental or regulatory action, such developments could have a material adverse effect on the ability of the payor with respect to a biopharmaceutical asset to make payments to us, and consequently could materially adversely affect our business, financial condition and results of operations. If additional side effects or complications are discovered with respect to a product, and such product&#8217;s market acceptance is impaired or it is withdrawn from the market, continuing payments with respect to biopharmaceutical products, including royalty payments and payments of interest on and repayment of the principal, relating to such product may not be made on time or at all. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Corporate Responsibility </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharma industry. We play an important role in providing capital to the biopharma ecosystem and thereby positively impact human health. Our responsibility to stakeholders is based around three key areas: integrity (maintaining the highest ethical standards), culture (promoting an inclusive and diverse workforce) and taking responsibility (being a responsible citizen). We do not directly conduct biopharmaceutical research and development or manufacture or market the biopharmaceutical assets in which we participate. We strive to invest in novel therapies that address unmet patient needs and to support ethical business practices that drive innovation, competition and patient choice.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Integrity</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We maintain the highest standards of integrity and trust in our role as investors and partners to the biopharma industry. This is recognized in our market-leading position and the high esteem with which we believe we are held in the industry. We conduct thorough diligence and monitoring with all of our investment positions. The biopharmaceutical companies and academic and non-profit institutions with which we work typically have well-developed and transparent environmental, social and governance (ESG) policies, which seek to benefit wider society through sustainable and ethical business practices.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Culture</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A diverse, talented and motivated workforce is essential to maintain our competitive advantages and to successfully execute our business strategy. We consider it highly important to strive for an appropriate gender balance: currently approximately 50% of the workforce of our Manager are women. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Responsibility</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are committed to good corporate citizenship and actively support the work of a number of patient advocacy groups and medical research foundations, including the American Heart Association, the Alliance for Lupus Research, Children of Bellevue, the Melanoma Research Alliance, the National Multiple Sclerosis Society and the Prostate Cancer Foundation. Over one-third (by value) of the transactions we have completed since our founding have been with leading academic and non-profit institutions. By partnering with these institutions, we have provided capital which has been used to further scientific research (for example, the Cystic Fibrosis Foundation) or to help fund capital projects. These diverse organizations are united in their quest to advance science, the careers of scientists and human health around the globe.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Employees </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our directors and executive officers manage our operations and activities. However, we do not currently have any employees or any officers other than our executive officers. Pursuant to the management agreement entered into in connection with our initial public offering (the &#8220;Management Agreement&#8221;) with the Manager, the Manager performs corporate and administration services for us. </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2021, the Manager had 66 employees. None of these employees are represented by labor unions or covered by any collective bargaining agreement. We believe that the Manager&#8217;s relations with its employees are satisfactory. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Human Capital Resources</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because we are &#8220;externally managed,&#8221; we do not employ our own personnel, but instead depend upon the Manager and its executive officers and employees for all of the services we require. Under the Management Agreement, the Manager manages the assets of our business and sources and evaluates royalty acquisitions. Accordingly, our success is dependent upon the expertise and services of the executive officers and other personnel provided to us through the Manager. The Manager is responsible for the selection of these executive officers and other personnel, and our Board of Directors reviews personnel with the Manager with the objective of evaluating the Manager&#8217;s internal capabilities. The Management Agreement requires the Manager&#8217;s executives to devote substantially all of their time to managing us, Royalty Pharma Investments 2019 ICAV (&#8220;RPI&#8221; or &#8220;RPI 2019 ICAV&#8221;) and any legacy vehicles related to Royalty Pharma Investments, an Irish unit trust (&#8220;Old RPI&#8221;) unless otherwise approved by our Board of Directors. The Management Agreement also provides for the development of succession plans for the senior management of the Manager by the Management Development and Compensation Committee of our Board of Directors in consultation with the Manager. </span></div><div style="text-indent:55.05pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Governmental Regulation and Environmental Matters</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business has been and will continue to be subject to numerous laws and regulations. Failure to comply with these laws and regulations could subject us to administrative and legal proceedings and actions by various governmental bodies. See &#8220;Risk Factors&#8221; in Item 1A, Risk Factors for further information. Our compliance with these laws and regulations has not had a material impact on our capital expenditures, earnings, financial condition or competitive position in excess of those affecting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">others in our industry.</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that there are no compliance issues with laws and regulations that have been enacted or adopted regulating the discharge of materials into the environment, or otherwise relating to the protection of the environment, that have adversely affected, or are reasonably expected to adversely affect, our business, financial condition and results of operations, and we do not currently anticipate material capital expenditures arising from environmental regulation. We believe that climate change could present risks to our business. Some of the potential impacts of climate change to our business include increased operating costs due to additional regulatory requirements and the risk of disruptions to our business. We do not believe these risks are material to our business at this time.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">U.S. Investment Company Act Status </span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We intend to conduct our business so as not to become regulated as an investment company under the U.S. Investment Company Act. An entity generally will be determined to be an investment company for purposes of the U.S. Investment Company Act if, absent an applicable exemption, (i) it is or holds itself out as being engaged primarily, or proposes to engage primarily, in the business of investing, reinvesting or trading in securities or (ii) it owns or proposes to acquire investment securities having a value exceeding 40% of the value of its total assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis, which we refer to as the ICA 40% Test. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not hold ourselves out as being engaged primarily, or propose to engage primarily, in the business of investing, reinvesting or trading in securities, and believe that we are not engaged primarily in the business of investing, reinvesting or trading in securities. We believe that, for U.S. Investment Company Act purposes, we are engaged primarily, through one or more of our subsidiaries, in the business of purchasing or otherwise acquiring certain obligations that represent part or all of the sales price of merchandise. Our subsidiaries that are so engaged rely on Section 3(c)(5)(A) of the U.S. Investment Company Act, which, according to certain SEC staff interpretations, generally may be available to an issuer that invests at least 55% of its assets in &#8220;notes, drafts, acceptances, open accounts receivable, and other obligations representing part or all of the sales price of merchandise, insurance, and services,&#8221; which we refer to as ICA Exception Qualifying Assets and that does not issue any redeemable securities, face-amount certificates of the installment type or periodic payment plan certificates. </span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In a no-action letter, dated August 13, 2010, to our predecessor, the SEC staff promulgated an interpretation that royalties that entitle an issuer to collect royalty receivables that are directly based on the sales price of specific biopharmaceutical assets that use intellectual property covered by specific license agreements are ICA Exception Qualifying Assets under Section 3(c)(5)(A). We rely on this no-action letter for the position that royalty receivables relating to biopharmaceutical assets that we hold are ICA Exception Qualifying Assets under Section 3(c)(5)(A) and Section 3(c)(6), which is described below.  </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As the parent of one or more subsidiaries that rely on Section 3(c)(5)(A), we currently are excepted from registration as an investment company based on Section 3(a)(1)(C) and/or Section 3(c)(6) of the U.S. Investment Company Act. To ensure that we are not obligated to register as an investment company, we must not exceed the thresholds provided by the ICA 40% Test. For purposes of the ICA 40% Test, the term &#8220;investment securities&#8221; does not include U.S. government securities or securities issued by majority-owned subsidiaries that are not themselves investment companies and are not relying on Section 3(c)(1) or Section 3(c)(7) of the U.S. Investment Company Act, such as majority-owned subsidiaries that rely on Section 3(c)(5)(A). We also may rely on Section 3(c)(6), which, based on SEC staff interpretations, requires us to invest, either directly or through majority-owned subsidiaries, at least 55% of our assets in, as relevant here, businesses relying on Section 3(c)(5)(A). For a subsidiary to be &#8220;majority-owned,&#8221; a parent entity must own a majority of the voting securities of the applicable security. Therefore, the assets that we and our subsidiaries hold and acquire are limited by the provisions of the U.S. Investment Company Act and the rules and regulations promulgated thereunder. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the SEC or its staff in the future adopts a contrary interpretation to that provided in the no-action letter to Royalty Pharma or otherwise restricts the conclusions in the SEC staff&#8217;s no-action letter such that royalties are no longer treated as ICA Exception Qualifying Assets for purposes of Section 3(c)(5)(A) and Section 3(c)(6), or the SEC or its staff in the future determines that the no-action letter does not apply to some or all types of royalty receivables relating to biopharmaceutical assets, our business will be materially and adversely affected. In particular, we would be required either to convert to a corporation formed under the laws of the United States or a state thereof (which would likely result in our being subject to U.S. federal corporate income taxation) and to register as an investment company, or to stop all business activities in the United States until such time as the SEC grants an application to register us as an investment company formed under non-U.S. law. It is unlikely that such an application would be granted and, even if it were, requirements imposed by the Investment Company Act, including limitations on our capital structure, our ability to transact business with affiliates and our ability to compensate key employees, could make it impractical for us to continue our business as currently conducted. Our no longer qualifying for an exemption from registration as an investment company would materially and adversely affect the value of your Class A ordinary shares and our ability to pay dividends in respect of our Class A ordinary shares. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Corporate Information</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our predecessor was founded in 1996 and we were incorporated under the laws of England and Wales on February 6, 2020. We are a holding company, and our principal asset is a controlling equity interest in Royalty Pharma Holdings Ltd. (&#8220;RP Holdings&#8221;). Our principal executive offices are located at 110 East 59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Street, New York, NY 10022, and our telephone number is (212) 883-0200. Our Internet site is www.royaltypharma.com. Our website and the information contained therein or connected thereto is not incorporated into this Annual Report on Form 10-K. Our agent for service in the United States is CSC North America located at 251 Little Falls Drive, Wilmington, Delaware, 19808.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Available Information</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our reports filed with or furnished to the SEC pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, are available, free of charge, on the Investors section of our website at https://royaltypharma.com as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SEC maintains a website at http://www.sec.gov that contains reports, and other information regarding us and other companies that file materials with the SEC electronically. We use the Investor section of our website as a means of disclosing material information. Accordingly, investors should monitor our website, in addition to following our press releases, SEC filings, and public conference calls and webcasts.</span></div><div><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_19"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Described below are certain risks that we believe apply to our business. You should carefully consider the following information about these risks, together with the other information contained in this Annual Report on Form 10-K, including the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our consolidated financial statements and related notes</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Summary of Risk Factors</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business is subject to a number of risks, including risks that may adversely affect our business, financial condition and results of operations. These risks are discussed more fully below and include, but are not limited to, risks related to:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Relating to Our Business </span></div><div><span><br/></span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">sales risks of biopharmaceutical products on which we receive royalties;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the growth of the royalty market;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ability of the Manager to identify suitable assets for us to acquire;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">uncertainties related to the acquisition of interests in development-stage biopharmaceutical product candidates and our strategy to add development-stage product candidates to our product portfolio;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">potential strategic acquisitions of biopharmaceutical companies;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our use of leverage in connection with our capital deployment; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our reliance on the Manager for all services we require;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our reliance on key members of the Manager</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8217;s senior advisory team; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to successfully execute our royalty acquisition strategy;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to leverage our competitive strengths;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">actual and potential conflicts of interest with the Manager and its affiliates;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">interest rate and foreign exchange fluctuations;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the assumptions underlying our business model;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our reliance on a limited number of products;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ability of the Manager or its affiliates to attract and retain highly talented professionals;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the competitive nature of the biopharmaceutical industry; </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Relating to Our Organization and Structure </span></div><div><span><br/></span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our organizational structure, including our status as a holding company;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Relating to Our Class A Ordinary Shares </span></div><div><span><br/></span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">volatility of the market price of our Class A ordinary shares;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our incorporation under English law;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Relating to Taxation </span></div><div><span><br/></span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the effect of changes to tax legislation and our tax position; and</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">General Risk Factors </span></div><div><span><br/></span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the impact of COVID-19, or the future outbreak of any other infectious or contagious diseases, on our operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Relating to Our Business </span></div><div><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Biopharmaceutical products are subject to sales risks. </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biopharmaceutical product sales may be lower than expected due to a number of reasons, including pricing pressures, insufficient demand, product competition, failure of clinical trials, lack of market acceptance, obsolescence, lack of acceptance by government healthcare programs and private insurance plans, loss of patent protection, the impact of the COVID-19 global pandemic or other factors and development-stage product candidates may fail to reach the market. Unexpected side effects, safety or efficacy concerns can arise with respect to a product, leading to product recalls, withdrawals or declining sales. As a result, payments of our royalties may be reduced or cease. In addition, these payments may be delayed, causing our near-term financial performance to be weaker than expected. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The royalty market may not grow at the same rate as it has in the past, or at all, and we may not be able to acquire sufficient royalties to sustain the growth of our business. </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have been able to grow our business over time by primarily acquiring royalties. However, we may not be able to identify and acquire a sufficient number of royalties, or royalties of sufficient scale, to invest the full amount of capital that may be available to us in the future, or at our targeted amount and rate of deployment, which could prevent us from executing our growth strategy and negatively impact our results of operations. Changes in the royalty market, including its structure and participants, or a reduction in the growth of the biopharmaceutical industry, could lead to diminished opportunities for us to acquire royalties, fewer royalties (or royalties of significant scale) being available, or increased competition for royalties. Even if we continue to acquire royalties, they may not generate a meaningful return for a period of several years, if at all, due to the price we pay for such royalties or other factors relating to the underlying products. As a result, we may not be able to continue to grow as we have in the past, or at all. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Acquisitions of royalties from development-stage biopharmaceutical product candidates are subject to a number of uncertainties. </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may acquire more royalties on development-stage product candidates that have not yet received marketing approval by any regulatory authority. There can be no assurance that the FDA, the European Medicines Agency (&#8220;EMA&#8221;) or other regulatory authorities will approve such products or that such products will be brought to market timely or at all, or that the market will be receptive to such products. For example, in January 2016, we partnered with Pfizer to provide up to $300 million in funding for Pfizer&#8217;s ongoing Phase 3 clinical trials, the PALLAS and PENELOPE-B trials, of Ibrance (palbociclib) for the adjuvant treatment of breast cancer. On May 29, 2020, Pfizer reported that the independent data monitoring committee for the PALLAS trial had concluded after the recent interim analysis that the PALLAS trial is &#8220;unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival.&#8221; Subsequently on October 9, 2020, Pfizer announced that the Phase 3 PENELOPE-B trial did not meet the primary endpoint of improved invasive disease-free survival in women with hormone receptor-positive (HR+), human epidermal growth factor-negative early breast cancer who have residual invasive disease after completing neoadjuvant chemotherapy. If the FDA, the EMA or other regulatory authority approves a development-stage product candidate that generates our royalties, the labeling, packaging, manufacturing, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. The subsequent discovery of previously unknown problems with the product, including adverse events of unanticipated severity or frequency, may result in restrictions on the marketing of the product, and could include withdrawal of the product from the market. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the developers of these development-stage product candidates may not be able to raise additional capital to continue their discovery, development and commercialization activities, which may cause them to delay, reduce the scope of, or eliminate one or more of their clinical trials or research and development programs. If other product developers introduce and market products that are more effective, safer or less expensive than the relevant products that generate our royalties, or if such developers introduce their products prior to the competing products underlying our royalties, such products may not achieve commercial success and thereby result in a loss for us. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, the developers of such products may not have sales, marketing or distribution capabilities. If no sales, marketing or distribution arrangements can be made on acceptable terms or at all, the affected product may not be able to be successfully commercialized, which will result in a loss for us. Losses from such assets could adversely affect our business, financial condition and results of operations. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While we believe that we can evaluate the likelihood of a development-stage product candidate&#8217;s approval and achieving significant sales, there can be no assurance that our assumptions will prove correct, that regulatory authorities will approve such development-stage product candidates, that such development-stage product candidates will be brought to market timely or at all, or that such products will achieve commercial success. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our strategy of acquiring royalty interests in development-stage product candidates, including by co-funding clinical development and acquiring securities of biopharmaceutical companies, is subject to risks and uncertainties. </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We intend to continue to provide capital to innovators to co-fund clinical development of a product candidate in exchange for a share of the future revenues of that asset and when we do so, we do not control its clinical development. In these situations, the innovators may not complete activities on schedule or in accordance with our expectations or in compliance with applicable laws and regulations. Failure by one or more of these third parties to meet their obligations, comply with applicable laws or regulations or any disruption in the relationships between us and these third parties, could delay or prevent the development, approval, manufacturing or commercialization of the development-stage product candidate for which we have provided funding. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We seek to further expand our market opportunity by acquiring securities issued by biopharmaceutical companies. Where we may acquire equity securities as all or part of the consideration for business development activities, the value of those securities will fluctuate, and may depreciate in value. We will likely not control the company in which we acquire securities, and as a result, we may have limited ability to determine its management, operational decisions and policies. Further, while we may seek to mitigate the risks and liabilities of such transactions through, among other things, due diligence, there may be risks and liabilities that such due diligence efforts fail to discover, that are not disclosed to us, or that we inadequately assess. In addition, as a result of our activities we receive material non-public information about other companies from time to time. Where such information relates to a company whose equity securities we hold, we may be delayed or prevented from selling such securities when we would otherwise choose to do so, and such delay or prohibition may result in a loss or reduced gain on such securities. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may undertake strategic acquisitions of biopharmaceutical companies with significant royalty assets. Our failure to realize expected benefits of such acquisitions or our incurrence of unanticipated liabilities, could adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may acquire companies with significant royalty assets or where we believe we could create significant synthetic royalties. These acquired or created royalty assets may not perform as we project. Moreover, the acquisition of operating biopharmaceutical companies will result in the assumption of, or exposure to, liabilities of the acquired business that are not inherent in our other royalty acquisitions, such as direct exposure to product liability claims, high fixed costs and an expansion of our operations and expense structure, thereby potentially decreasing our profitability. The diversion of our management&#8217;s attention and any delay or difficulties encountered in connection with any future acquisitions we may consummate could result in the disruption of our on-going business operations. Despite our business, financial and legal due diligence efforts, we have limited experience in assessing acquisition opportunities, and we ultimately may be unsuccessful in ascertaining or evaluating all risks associated with such acquisitions. Moreover, we may need to raise additional funds through public or private debt or equity financing to acquire any businesses or products, which may result in dilution for shareholders or the incurrence of indebtedness. As a result, our acquisition of biopharmaceutical companies could adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We use leverage in connection with our capital deployment, which magnifies the potential for loss if the royalties acquired do not generate sufficient income to us. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We use borrowed funds to finance a significant portion of our deployed capital. The use of leverage creates an opportunity for an increased return but also increases the risk of loss if our assets do not generate sufficient income to us. The interest expense and other costs incurred in connection with such borrowings may not be covered by our cash flow. In addition, leverage may inhibit our operating flexibility and reduce cash flow available for dividends to our shareholders. The level of our indebtedness could limit our ability to respond to changing business conditions. The various agreements relating to our borrowings may impose operating and financial restrictions on us which could affect the number and size of the royalties that we may pursue. Therefore, no assurance can be given that we will be able to take advantage of favorable conditions or opportunities as a result of any restrictive covenants under our indebtedness. There can also be no assurance that additional debt financing, either to replace or increase existing debt financing, will be available when needed or, if available, will be obtainable on terms that are commercially reasonable. Additional risks related to our leverage include: </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">our royalties may be used as collateral for our borrowings; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">in the event of a default under secured borrowings, if any, one or more of our creditors or their assignees could obtain control of our royalties and, in the event of a distressed sale, these creditors could dispose of these royalties for significantly less value than we could realize for them; </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">we have to comply with various financial covenants in the agreements that govern our debt, including requirements to maintain certain leverage ratios and coverage ratios, which may affect our ability to achieve our business objectives; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">our ability to pay dividends to our shareholders may be restricted; and</span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to the extent that interest rates at which we borrow increase, our borrowing costs will increase and our leveraging strategy will become more costly, which could lead to diminished net profits. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We do not employ our own personnel and are entirely dependent upon the Manager for all the services we require. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because we are &#8220;externally managed,&#8221; we do not employ our own personnel but instead depend upon the Manager, its executive officers and its employees for all of the services we require. The Manager selects and manages the acquisition of royalties and similar payment streams that meet our investment criteria and provides all of our other administrative services. Accordingly, our success is dependent upon the expertise and services of the executive officers and other personnel provided to us through the Manager. The Management Agreement has an initial term of ten years, after which it can be renewed for an additional term of three years, unless either we or the Manager provide notice of non-renewal 180 days prior the expiration of the initial term or renewal term. The Manager may not be removed during the initial or any renewal term without cause. While our agreement with the Manager requires its executives to devote substantially all of their time to managing us and any legacy vehicles related to Old RPI or RPI unless otherwise approved by the board of directors, such resources may prove to be inadequate to meet our needs. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The success of our business depends upon key members of the Manager&#8217;s senior advisory team who may not continue to work for the Manager. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We depend on the expertise, skill and network of business contacts of the advisory professionals of the Manager, who evaluate, negotiate, structure, execute, monitor and service our assets in accordance with the terms of the Management Agreement between us and the Manager. Our future success depends to a significant extent on the continued service and coordination of the senior advisory professionals of the Manager, particularly Mr. Legorreta. Pursuant to the Management Agreement, executives of the Manager must devote substantially all of their business time to managing us, unless otherwise approved by the board of directors. Despite this, Mr. Legorreta and other key advisory professionals may have other demands on their time now and in the future, and we cannot assure you that they will continue to be actively involved in our business. Each of these individuals is an employee of the Manager and is not subject to an employment contract with us. The departure of any of these individuals or competing demands on their time in the future could impact our ability to achieve our business objectives. This could adversely affect our financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The senior advisory professionals of the Manager have relationships with participants in the biopharmaceutical industry, financial institutions and other advisory professionals, which we rely upon to source potential asset acquisition opportunities. If the senior advisory professionals of the Manager fail to maintain such relationships, or to develop new relationships with other sources, we will not be able to grow our current asset portfolio. In addition, we can offer no assurance that these relationships, even if maintained, will generate asset acquisition opportunities for us in the future. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">There can be no assurance that the policies and procedures we have established to mitigate conflicts of interest will be effective in doing so. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the Management Agreement, the Manager cannot manage another entity that invests in or acquires royalties other than any legacy vehicle related to Old RPI or RPI. Every executive of our Manager is subject to a non-compete agreement that is effective for 18 months following termination of their employment with the Manager for any reason. We are a beneficiary of this agreement. In addition, executives of the Manager must devote substantially all of their business time to managing us and any legacy vehicle related to Old RPI or RPI, unless otherwise approved by the board of directors. Despite this, the ability of our Manager and its officers and employees to engage in other business activities, subject to the terms of our Management Agreement, may reduce the amount of time our Manager, its officers or other employees spend managing us. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, there could be conflicts of interest between us and our senior advisory personnel. For instance, Mr. Legorreta, our Chief Executive Officer, is also a co-founder of and has significant influence over Pharmakon Advisors, which shares physical premises with the Manager. Pharmakon manages BioPharma Credit PLC (LSE: BPCR) and other investment vehicles that collectively are leading providers of debt capital to the biopharmaceutical industry. Mr. Legorreta has a substantial investment in BioPharma Credit. Even though he has the involvement with Pharmakon and BioPharma Credit PLC described above, Mr. Legorreta does not have any material constraints on the time he has available to devote to us and the Manager. From time to time, the Manager and Pharmakon may pursue similar investment opportunities for their respective clients, although we believe that actual conflicts of interest are rare due to the differing investment strategies of Pharmakon and us, and the fact that royalty holders, rather than Pharmakon and us, determine the type of transaction they seek. Under arrangements with Pharmakon, the Manager subleases office space to Pharmakon, and the parties may provide research, business development, legal, compliance, financial and administrative services to one another. The Manager and Pharmakon reimburse each other to the extent that one of them provides materially more services to the other than they receive in return. In consideration of the support provided to Pharmakon by the Manager, certain employees of the Manager receive compensation from Pharmakon. In addition, Mr. Legorreta has founded and participates in two foundations that provide medical research funding. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the structure of our Manager&#8217;s compensation arrangements may have unintended consequences for us. We have agreed to pay our Manager or its affiliates quarterly operating and personnel expenses (the &#8220;Operating and Personnel Payments&#8221;), a portion of which is based on the mark-to-market value of security investments, including equity securities and derivative financial instruments, at the end of each quarter and is payable to the Manager regardless of whether we realize any gain on the security investments when sold. Consequently, the Manager may be incentivized to have us make security investments regardless of our expected gain on such investments, which may not align with our or our shareholders&#8217; long-term interests. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">To service our indebtedness and meet our other ongoing liquidity needs, we will require a significant amount of cash. Our ability to generate cash depends on many factors beyond our control. If we cannot generate the required cash, we may not be able to make the required payments under our indebtedness.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2021, our total principal amount of Notes outstanding was $7.3&#160;billion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In addition, we have up to $1.5&#160;billion of available revolving commitments under our unsecured revolving credit facility (the &#8220;Revolving Credit Facility&#8221;). Except for RP Holdings, our subsidiaries that do not guarantee the Notes will have no obligation, contingent or otherwise, to pay amounts due under the Notes or to make any funds available to pay those amounts, whether by dividend, distribution, loan or other payment. We cannot assure you that our business will generate sufficient cash flow from operations to enable us to pay our indebtedness or to fund our other liquidity needs. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Absent sufficient cash flow and the ability to refinance, we could also be forced to sell assets to make up for any shortfall in our payment obligations. However, the terms of the agreements that govern our existing outstanding debt limit, our and our subsidiaries&#8217; ability to sell assets and also restrict the use of proceeds from such a sale. Accordingly, we may not be able to sell assets quickly enough or for sufficient amounts to enable us to meet our obligations on our indebtedness.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business is subject to interest rate and foreign exchange risk. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to interest rate fluctuation exposure through any borrowings under our Revolving Credit Facility and our investments in money market accounts and marketable securities, the majority of which bear a variable interest rate. To the extent that interest rates generally increase, our borrowing costs will increase and our leveraging strategy will become more costly, leading to diminished net profits. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain products pay royalties in currencies other than U.S. dollars, which creates foreign currency risk primarily with respect to the Euro, Canadian Dollar, Swiss Franc and Japanese Yen, as our functional and reporting currency is the U.S. dollar. In addition, our results of operations are subject to foreign currency exchange risk through transactional exposure resulting from movements in exchange rates between the time we recognize royalty income or royalty revenue and the time at which the transaction settles, or we receive the royalty payment. Because we are entitled to royalties on worldwide sales for various products, there is an underlying exposure to foreign currency as the marketer converts payment amounts from local currencies to U.S. dollars using a quarterly average exchange rate. Therefore, cash received may differ from the estimated receivable based on fluctuations in currency. As a result, significant changes in foreign exchange rates can impact our results. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Information about the biopharmaceutical products underlying the royalties we buy available to us may be limited and therefore our ability to analyze each product and its potential future cash flow may be similarly limited. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may have limited information concerning the products generating the royalties we are evaluating for acquisition. Often, the information we have regarding products following our acquisition of a royalty may be limited to the information that is available in the public domain. Therefore, there may be material information that relates to such products that we would like to know but do not have and may not be able to obtain. For example, we do not always know the results of studies conducted by marketers of the products or others or the nature or amount of any complaints from doctors or users of such products. In addition, the market data that we obtain independently may also prove to be incomplete or incorrect. Due to these and other factors, the actual cash flow from a royalty may be significantly lower than our estimates. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our future income is dependent upon numerous royalty-specific assumptions and, if these assumptions prove not to be accurate, we may not achieve our expected rates of returns. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business model is based on multiple-year internal and external forecasts regarding product sales and numerous product-specific assumptions in connection with each royalty acquisition, including where we have limited information regarding the product. There can be no assurance that the assumptions underlying our financial models, including those regarding product sales or competition, patent expirations or license terminations for the products underlying our portfolio, are accurate. These assumptions involve a significant element of subjective judgment and may be and in the past have been adversely affected by post-acquisition changes in market conditions and other factors affecting the underlying product. Our assumptions regarding the financial stability or operational or marketing capabilities of the partner obligated to pay us royalties may also prove and in the past have proven to be incorrect. Due to these and other factors, the assets in our current portfolio or future assets may not generate expected returns or returns in line with our historical financial performance or in the time periods we expect. This could negatively impact our results of operation for a given period. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We make assumptions regarding the royalty duration for terms that are not contractually fixed, and a shortened royalty term could result in a reduction in the effective interest rate, a decline in income from royalties, significant reductions in royalty payments compared to expectations, or a permanent impairment. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with generally accepted accounting principles in the United States GAAP, we classify most royalty assets that we acquire as financial assets that are measured at amortized cost using the prospective effective interest method described in ASC 835-30. The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount, net of any purchased receivables. A critical component of such forecast is our assumptions regarding duration of the royalty. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The royalty duration is important for purposes of accurately measuring interest income over the life of a royalty. In making assumptions around the royalty duration for terms that are not contractually fixed, we consider the strength of existing patent protection, expected entry of generics, geographical exclusivity periods and potential patent term extensions tied to the underlying product. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The duration of a royalty usually varies on a country-by-country basis and can be based on a number of factors, such as patent expiration dates, regulatory exclusivity, years from first commercial sale of the patent-protected product, the entry of competing generic or biosimilar products, or other terms set out in the contracts governing the royalty. It is common for royalty durations to expire earlier or later than anticipated due to unforeseen positive or negative developments over time, including with respect to the granting of patents and patent term extensions, the invalidation of patents, litigation between the party controlling the patents and third party challengers of the patents, the ability of third parties to design around or circumvent valid patents, the granting of regulatory exclusivity periods or extensions, timing for the arrival of generic or biosimilar competitor products, changes to legal or regulatory regimes affecting intellectual property rights or the regulation of pharmaceutical products, product life cycles, and industry consolidations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If an unexpected shortening of a royalty term were to occur, it could result in a reduction in the effective interest rate, a decline in income from royalties, a significant reduction in royalty payments compared to expectations, or a permanent impairment. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our reliance on a limited number of products may adversely affect our business, financial condition and results of operation. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While our current asset portfolio includes royalties relating to over 35 marketed products and ten development-stage product candidates, the top five product franchises accounted for 67% of our royalty receipts in the year ended December 31,<br/>2021. In addition, our asset portfolio may not be fully diversified by geographic region or other criteria. Any significant deterioration in the cash flows from the top products in our asset portfolio could adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We face competition in acquiring assets and locating suitable assets to acquire. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There are a limited number of suitable and attractive opportunities to acquire high-quality royalties available in the market. Therefore, competition to acquire such royalties is intense and may increase. We compete with other potential acquirers for these opportunities, including companies that market the products on which royalties are paid, financial institutions and others. These competitors may be able to access lower cost capital, may be larger than us, may have relationships that provide them access to opportunities before us, or may be willing to acquire royalties for lower projected returns than we are. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Biopharmaceutical products are subject to substantial competition. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The biopharmaceutical industry is a highly competitive and rapidly evolving industry. The length of any product&#8217;s commercial life cannot be predicted with certainty. There can be no assurance that one or more products on which we are entitled to a royalty will not be rendered obsolete or non-competitive by new products or improvements on which we are not entitled to a royalty made to existing products, either by the current marketer of such products or by another marketer. Current marketers of products may undertake these development efforts in order to improve their products or to avoid paying our royalty. Adverse competition, obsolescence or governmental and regulatory action or healthcare policy changes could significantly affect the revenues, including royalty-related revenues, of the products which generate our royalties. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Competitive factors affecting the market position and success of each product include: </span></div><div style="margin-bottom:8pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">effectiveness; </span></div><div style="margin-bottom:8pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">safety and side effect profile; </span></div><div style="margin-bottom:8pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">price, including third-party insurance reimbursement policies; </span></div><div style="margin-bottom:8pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">timing and introduction of the product; </span></div><div style="margin-bottom:8pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">effectiveness of marketing strategy and execution; </span></div><div style="margin-bottom:8pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">governmental regulation; </span></div><div style="margin-bottom:8pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">availability of lower-cost generics and/or biosimilars; </span></div><div style="margin-bottom:8pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">treatment innovations that eliminate or minimize the need for a product; and </span></div><div style="margin-bottom:8pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">product liability claims. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Products on which we have a royalty may be rendered obsolete or non-competitive by new products, including generics and/or biosimilars, improvements on existing products or governmental or regulatory action. In addition, as biopharmaceutical companies increasingly devote significant resources to innovate next-generation products and therapies using gene editing and new curative modalities, such as cell and gene therapy, products on which we have a royalty may become obsolete. These developments could adversely affect the sales of the biopharmaceutical products that generate our royalties, and consequently could adversely affect our business, financial condition and results of operations. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Marketers of products that generate our royalties are outside of our control. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the case of our royalty receivables, our cash flow consists primarily of payments supported by royalties paid by marketers. These marketers may have interests that are different from our interests. For example, these marketers may be motivated to maximize income by allocating resources to other products and, in the future, may decide to focus less attention on the products generating our royalties or by allocating resources to develop products that do not generate royalties to us. There can be no assurance that any marketer or person with whom the marketer has a working relationship has adequate resources and motivation to continue to produce, market and sell the products generating our royalties. Aside from any limited audit rights relating to the activities of the marketers that we may have in certain circumstances pursuant to the terms of our arrangements with the licensor, we do not have oversight rights with respect to the marketers&#8217; operations and do not have rights allowing us to direct their operations or strategy nor do our agreements contain performance standards for their operations. We also have limited information on the marketers&#8217; operations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In these circumstances, while we may be able to receive certain information relating to sales of products through the exercise of audit rights and review of royalty reports we receive from the licensor, we will not have the right to review or receive certain information relating to products that the marketers may have, including the results of any studies conducted by the marketers or others, or complaints from doctors or users of products. The market performance of the products generating our royalties may therefore be diminished by any number of factors relating to the marketers that are outside of our control. </span></div><div style="margin-bottom:9pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The marketers of biopharmaceutical products are, generally, entirely responsible for the ongoing regulatory approval, commercialization, manufacturing and marketing of products. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Generally, the holders of royalties on products have granted exclusive regulatory approval, commercialization, manufacturing and marketing rights to the marketers of such products. The marketers have full control over those efforts and sole discretion to determine the extent and priority of the resources they will commit to their program for a product. Accordingly, the successful commercialization of a product depends on the marketer&#8217;s efforts and is beyond our control. If a marketer does not devote adequate resources to the ongoing regulatory approval, commercialization and manufacture of a product, or if a marketer engages in illegal or otherwise unauthorized practices, the product&#8217;s sales may not generate sufficient royalties, or the product&#8217;s sales may be suspended, and consequently, could adversely affect our business. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">License agreements relating to products may, in some instances, be unilaterally terminated or disputes may arise which may affect our royalties. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">License agreements relating to the products generating our royalties may be terminated, which may adversely affect sales of such products and therefore the payments we receive. For example, under certain license agreements, marketers retain the right to unilaterally terminate the agreements with the licensors. When the last patent covering a product expires or is otherwise invalidated in a country, a marketer may be economically motivated to terminate its license agreement, either in whole or with respect to such country, in order to terminate its payment and other obligations. In the event of such a termination, a licensor may no longer receive all of the payments it expected to receive from the licensee and may also be unable to find another company to continue developing and commercializing the product on the same or similar terms as those under the license agreement that has been terminated. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, license agreements may fail to provide significant protection for the licensor in case of the licensee&#8217;s failure to perform or in the event of disputes. License agreements which relate to the products underlying our royalties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what the licensor believes to be the scope of its rights to the relevant intellectual property or technology, or decrease the licensee&#8217;s financial or other obligations under the relevant agreement, any of which could in turn impact the value of our royalties and adversely affect our business, financial condition and results of operations. If a marketer were to default on its obligations under a license agreement, the licensor&#8217;s remedy may be limited either to terminating certain licenses related to certain countries or to generally terminate the license agreement with respect to such country. In such cases, we may not have the right to seek to enforce the rights of the licensor and we may be required to rely on the resources and willingness of the licensor to enforce its rights against the licensee. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In any of these situations, if the expected payments under the license agreements do not materialize, this could result in a significant loss to us and adversely affect our business, financial condition and results of operations. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The insolvency of a marketer could adversely affect our receipt of cash flows on the related royalties that we hold. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If a marketer were to become insolvent and seek to reorganize under Chapter 11 of Title 11 of the U.S. Code, as amended, or the Bankruptcy Code, or liquidate under Chapter 7 of the Bankruptcy Code (or foreign equivalent), such event could delay or impede the payment of the amounts due under a license agreement, pending a resolution of the insolvency proceeding. Any unpaid royalty payments due for the period prior to the filing of the bankruptcy proceeding would be unsecured claims against the marketer, which might not be paid in full or at all. While royalty payments due for periods after the filing may qualify as administrative expenses entitled to a higher priority, the actual payment of such post-filing royalty payments could be delayed for a substantial period of time and might not be in the full amount due under the license agreement. The licensor would be prevented by the automatic stay from taking any action to enforce its rights without the permission of the bankruptcy court. In addition, the marketer could elect to reject the license agreement, which would require the licensor to undertake a new effort to market the applicable product with another distributor. Such proceedings could adversely affect the ability of a payor to make payments with respect to a royalty, and could consequently adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Unsuccessful attempts to acquire new royalties could result in significant costs and negatively impact subsequent attempts to locate and acquire other assets. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The investigation of each specific target royalty and the negotiation, drafting and execution of relevant agreements, disclosure and other documents requires substantial management time and attention and results in substantial costs for accountants, attorneys and others. If a decision is made not to complete a specific acquisition, the costs incurred for the proposed transaction would not be recoverable from a third party. Furthermore, even if an agreement is reached relating to a specific target asset, we may fail to consummate the acquisition for any number of reasons, including, in the case of an acquisition of a royalty through a business combination with a public company, approval by the target company&#8217;s public shareholders. Multiple unsuccessful attempts to acquire new royalties could hurt our reputation, result in significant costs and waste the Manager&#8217;s time. The opportunity cost of diverting management and financial resources could negatively impact our ability to locate and acquire other assets. </span></div><div style="margin-bottom:9pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Most of our royalties are classified as financial assets that are measured at amortized cost using the effective interest method as a result of which our GAAP results of operations can be volatile and unpredictable. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with GAAP, most of the royalty assets we acquire are treated as investments in cash flow streams and are thus classified as financial assets. Under this classification, our financial royalty assets are treated as having a yield component that resembles loans measured at amortized cost under the effective interest accounting methodology. Under this accounting methodology, we calculate the effective interest rate on each financial royalty asset using a forecast of the expected cash flows to be received over the life of the financial royalty asset relative to the initial acquisition price. The yield, which is calculated at the end of each reporting period and applied prospectively, is then recognized via accretion into our income at the effective rate of return over the expected life of the financial royalty asset. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of the non-cash charges associated with the application of the effective interest method accounting methodology, our income statement activity in respect of many of our royalties can be volatile and unpredictable. Small declines in sell-side equity research analysts&#8217; consensus sales forecasts over a long time horizon can result in an immediate non-cash income statement expense recognition, even though the applicable cash inflows will not be realized for many years into the future. For example, in late 2014 we acquired the cystic fibrosis franchise royalty, which is classified as a financial royalty asset. Beginning in the second quarter of 2015, declines in near-term sales forecasts of sell-side equity research analysts caused us to recognize non-cash provision expenses to the income statement and build up a corresponding cumulative allowance which reduced the gross balance for this financial royalty asset. Over the course of 10 quarters, we recognized non-cash provision expenses as a result of these changes in forecasts, including a non-cash expense of $743.2 million in 2016, ultimately reaching a peak cumulative allowance of $1.30 billion by September 30, 2017 related to this financial royalty asset. With the approval of the Vertex triple combination therapy, Trikafta, in October 2019, sell-side equity research analysts&#8217; consensus sales forecasts increased to reflect the larger addressable market and the extension of the expected duration of the Trikafta royalty. While small reductions in the cumulative allowance for the cystic fibrosis franchise were recognized as provision income in 2017 and 2018, there remained a $1.10 billion cumulative allowance that was fully reduced by $1.10 billion in 2019 as a result of an increase in sell-side equity research analysts&#8217; consensus sales forecasts associated with the Trikafta approval. The financial statement impact caused by the application of the effective interest accounting methodology could result in a negative perception of our results in a given period. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sales of the products that generate our royalties are subject to uncertainty related to healthcare reimbursement policies, managed care considerations and pricing pressures. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In both the U.S. and non-U.S. markets, sales of biopharmaceutical products, and the success of such products, depends in part on the availability and extent of coverage and reimbursement from third-party payors, including government healthcare programs and private insurance plans. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the United States, pharmaceutical product pricing is subject to enhanced government regulation, public scrutiny and calls for reforms. Some states have implemented, and other states are considering, pharmaceutical price controls or patient access constraints under their Medicaid program. There have also been recent state legislative efforts that have generally focused on increasing transparency around drug costs or limiting drug prices. In addition, the growth of large managed care organizations and prescription benefit managers, as well as the prevalence of generic substitution, has hindered price increases for prescription drugs. Continued intense public scrutiny of the price of drugs, together with government and payor dynamics, may limit the ability of producers and marketers to set or adjust the price of products based on their value. There can be no assurance that new or proposed products will be considered cost-effective or that adequate third-party reimbursement will be available to enable the producer or marketer of such product to maintain price levels sufficient to realize an appropriate return. Outside the United States, numerous major markets, including the EU, Japan and China, have pervasive government involvement in funding healthcare, and, in that regard, fix the pricing and reimbursement of pharmaceutical products. Consequently, in those markets, the products generating our royalties are subject to government decision-making and budgetary actions. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These pricing pressures may adversely affect our current royalties and the attractiveness of future acquisitions of royalties. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The products that generate our royalties are subject to uncertainty related to the regulation of the healthcare industry. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The U.S. healthcare industry is highly regulated and subject to frequent and substantial changes. For example, the U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (the &#8220;ACA&#8221;) was enacted by Congress in March 2010 and established a major expansion of healthcare coverage, financed in part by a number of new rebates, discounts, and taxes that had a significant effect on the expenses and profitability on the companies that manufacture the products that generate our royalties. These companies and their products face uncertainty due to federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the ACA. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other U.S. federal or state legislative or regulatory action and/or policy efforts could adversely affect the healthcare industry, including, among others, general budget control actions, changes in patent laws, the importation of prescription drugs from outside the United States at prices that are regulated by governments of various foreign countries, revisions to reimbursement of biopharmaceutical products under government programs, restrictions on U.S. direct-to-consumer advertising or limitations on interactions with healthcare professionals. No assurances can be provided that these laws and regulations will not adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, many of the products in our portfolio benefit from regulatory exclusivity. If, in an effort to regulate pricing, regulatory exclusivity is not maintained, our business, financial condition and results of operations may be adversely impacted. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The biopharmaceutical industry may be negatively affected by federal government deficit reduction policies, which could reduce the value of the royalties that we hold. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In an effort to contain the U.S. federal deficit, the pharmaceutical industry could be considered a potential source of savings via legislative proposals. Government action to reduce federal spending on entitlement programs, including Medicare, Medicaid or other publicly funded or subsidized health programs, or to lower drug spending, may affect payment for the products that generate our royalties. These and any other cost controls and/or any significant additional taxes or fees that may be imposed on the biopharmaceutical industry as part of deficit reduction efforts could reduce cash flows from our royalties and therefore adversely affect our business, financial condition and results of operations. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sales of products that generate our royalties are subject to regulatory approvals and actions in the United States and foreign jurisdictions that could harm our business. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The procedures to approve biopharmaceutical products for commercialization vary among countries and can involve additional testing and time. Such procedures may include on-site inspections by regulatory authorities at clinical trial sites or manufacturing facilities, which inspections may be delayed by travel restrictions imposed in response to the COVID-19 pandemic or other pandemics. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval and many include additional risks, such as pricing approval. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There can be no assurance that any of these regulatory approvals will be granted or not be revoked or restricted in a manner that would adversely affect the sales of such products and on the ability of payors to make payments with respect to such royalties to us. </span></div><div style="margin-bottom:9pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The manufacture and distribution of a biopharmaceutical product may be interrupted by regulatory agencies or supplier deficiencies. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The manufacture of products generating our royalties is typically complex and is highly regulated. In particular, biopharmaceutical products are manufactured in specialized facilities that require the approval of, and ongoing regulation by, the FDA in the United States and, if manufactured outside of the United States, both the FDA and non-U.S. regulatory agencies, such as the EMA. With respect to a product, to the extent that operational standards set by such agencies are not adhered to, manufacturing facilities may be closed or production interrupted until such time as any deficiencies noted by such agencies are remedied. Any such closure or interruption may interrupt, for an indefinite period of time, the manufacture and distribution of a product and therefore the cash flows from the related biopharmaceutical asset may be significantly less than expected. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, manufacturers of a product may rely on third parties for selected aspects of product development, such as packaging or to supply bulk raw material used in the manufacture of such product. In the United States, the FDA requires that all suppliers of pharmaceutical bulk materials and all manufacturers of pharmaceuticals for sale in or from the United States adhere to the FDA&#8217;s current &#8220;Good Manufacturing Practice&#8221; regulations and guidelines and similar requirements that exist in jurisdictions outside the United States. Licensees generally rely on a small number of key, highly specialized suppliers, manufacturers and packagers. Any interruptions, however minimal, in the operation of these manufacturing and packaging facilities could adversely affect production and product sales and therefore adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Product liability claims may diminish the returns on biopharmaceutical products. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The developer, manufacturer or marketer of a product could become subject to product liability claims. A product liability claim, regardless of its merits, could adversely affect the sales of the product and the amount of any related royalty payments, and consequently, could adversely affect the ability of a payor to make payments with respect to a royalty. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we believe that we will not bear responsibility in the event of a product liability claim against the developer, manufacturer, marketer or other seller of the product that generates our royalty, such claims could adversely affect our business, financial condition and results of operations due to the lower than expected cash flows from the royalty. </span></div><div style="margin-bottom:9pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are typically not involved in maintaining, enforcing and defending patent rights on products that generate our royalties. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our right to receive royalties generally depends on the existence of valid and enforceable claims of registered and/or issued patents in the United States and elsewhere in the world. The products on which we receive payments are dependent on patent protection and on the fact that the manufacturing, marketing and selling of such products do not infringe, misappropriate or otherwise violate intellectual property rights of third parties. Typically, we have no ability to control the prosecution, maintenance, enforcement or defense of patent rights, but must rely on the willingness and ability of our partners or their marketers to do so. There can be no assurance that these third parties will vigorously prosecute, maintain, enforce or defend such rights. Even if such third parties seek to prosecute, maintain, enforce or defend such rights, they may not be successful. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has been the subject of much litigation. Furthermore, changes in patent laws or interpretation of patent laws in the United States and in other jurisdictions could increase the uncertainties surrounding the successful prosecution of patent applications and the successful enforcement or defense of issued patents by our partners, all of which could diminish the value of patent protection relating to the biopharmaceutical assets. As a result, the issuance, scope, validity, enforceability and commercial value of the patent rights of our partners and their marketers are highly uncertain. In addition, such third parties&#8217; pending and future patent applications may not result in patents being issued which protect their products, development-stage product candidates and technologies or which effectively prevent others from commercializing competitive products, development-stage product candidates and technologies. Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even if the patent applications our partners and their marketers license or own do issue as patents, they may not issue in a form that will provide them with any meaningful protection, prevent competitors or other third parties from competing with them or otherwise provide them with any competitive advantage. Competitors or other third parties may be able to circumvent patents of our partners and their marketers by developing similar or alternative products in a non-infringing manner. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit the ability of our partners and their marketers from preventing others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of their products, development-stage product candidates and technologies. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any loss or reduction in the scope or duration of patent protection for any product that generates our royalties, or any failure to successfully prosecute, maintain, enforce or defend any patents that protect any such product may result in a decrease in the sales of such product and any associated royalties payable to us. Any such event would adversely affect the ability of the payor to make payments of royalties to us or may otherwise reduce the value of our royalty interest, and could consequently adversely affect our business, financial condition and results of operations. In cases where our contractual arrangements with our partner permit us to do so, we could participate in patent suits brought by third parties but this could result in substantial litigation costs, divert management&#8217;s attention from our core business and there can be no assurance that such suits would be successful. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The existence of third-party patents in relation to products may result in additional costs for the marketer and reduce the amount of royalties paid to us. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The commercial success of a product depends, in part, on avoiding infringement, misappropriation or other violations of the intellectual property rights and proprietary technologies of others. Third-party issued patents or patent applications claiming subject matter necessary to manufacture and market a product could exist or issue in the future. Such third-party patents or patent applications may include claims directed to the mechanism of action of a product. There can be no assurance that a license would be available to marketers for such subject matter if such infringement were to exist or, if offered, would be offered on reasonable and/or commercially feasible terms. Without such a license, it may be possible for third parties to assert infringement or other intellectual property claims against the marketer of such product based on such patents or other intellectual property rights. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even if the marketer was able to obtain a license, it could be non-exclusive, thereby giving its competitors and other third parties access to the same technologies. In addition, if a marketer of a product that generates our royalties is required to obtain a license from a third party, the marketer may, in some instances, have the right to offset the licensing and royalty payments to such third party against royalties that would be owed to our partner, which may ultimately reduce the value of our royalty interest. An adverse outcome in infringement or other intellectual property-related proceedings could subject a marketer to significant liabilities to third parties, require disputed rights to be licensed from third parties or require the marketer to cease or modify its manufacturing, marketing and distribution of any affected product, any of which could reduce the amount of cash flow generated by the affected products and any associated royalties payable to us and therefore adversely affect our business, financial condition and results of operations. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Disclosure of trade secrets of marketers of products could negatively affect the competitive position of the products underlying our biopharmaceutical assets. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The marketers of the products that generate our royalties depend, in part, on trade secrets, know-how and technology, which are not protected by patents, to maintain the products&#8217; competitive position. This information is typically protected through confidentiality agreements with parties that have access to such information, such as collaborative partners, licensors, employees and consultants. Any of these parties may breach the agreements and disclose the confidential information or competitors might independently develop or learn of the information in some other way, which could harm the competitive position of the products and therefore reduce the amount of cash flow generated by our royalty interest. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The internal computer systems of our counterparties may fail or suffer security breaches, which could result in a significant disruption of their ability to operate their business effectively, adversely affect the cash flow generated by the related biopharmaceutical products, and adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The internal computer systems and cloud-based computing services of our counterparties and those of their current and any future collaborators and other contractors or consultants are vulnerable to damage or interruption from computer viruses, data corruption, cyber-based attacks, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. We have been subject to cyber-based attacks and unauthorized access in the past. If such an event were to occur in the future and cause interruptions in their operations, it could result in a disruption of their development and commercialization programs and business operations, whether due to a loss of trade secrets or other proprietary information or other similar disruptions. To the extent that any disruption or security breach were to result in a loss of, or damage to, a counterparties&#8217; data or applications, or inappropriate disclosure of confidential or proprietary information, our partners&#8217; operations may be harmed and the development and commercialization of their products, development-stage product candidates and technologies could be delayed. Such an event may reduce the amount of cash flow generated by the related biopharmaceutical products and therefore adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our ability to pay periodic dividends to our shareholders or make share repurchases may be limited by applicable provisions of English law and contractual restrictions and obligations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under English law, we will only be able to declare dividends, make distributions or repurchase shares (other than out of the proceeds of a new issuance of shares for that purpose) out of profits available for distribution. Profits available for distribution are accumulated, realized profits, to the extent that they have not been previously utilized by distribution or capitalization, less its accumulated, realized losses, to the extent that they have not been previously written off in a reduction or reorganization of capital duly made. The amount of our distributable reserves is a cumulative calculation. We may be profitable in a single financial year but unable to pay a dividend or make share repurchases if our accumulated, realized profits do not offset all previous years&#8217; accumulated, realized losses. Additionally, we may only make a distribution if our net assets are not less than the amount of our aggregate called-up share capital and distributable reserves, and if, and to the extent that, the distribution does not reduce the amount of those assets to less than that aggregate. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to the terms of our indebtedness or other contractual obligations, the approval and payment of any interim dividends are at the sole discretion of our board of directors, which may change our dividend policy at any time and the payment of any final dividends will be subject to majority approval by holders of Class A ordinary and Class B ordinary shares and in each case will be paid out of profits available for that purpose under English law. Our Articles of Association authorize the board of directors to approve interim dividends without shareholder approval to the extent that such dividends appear justified by profits available for such purpose. The board of directors may also recommend final dividends be approved and declared by shareholders at an annual general meeting. No such dividend may exceed the amount recommended by the board of directors. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There can be no assurance that any dividends, whether quarterly or otherwise, will or can be paid or that any shares will or can be repurchased. Our ability to pay dividends to our shareholders or make share repurchases depends on a number of factors, including among other things, general economic and business conditions, our strategic plans and prospects, our business and acquisition opportunities, our financial condition and results of operations, working capital requirements and anticipated cash needs, contractual restrictions and obligations, including fulfilling our current and future capital commitments, legal, tax and regulatory restrictions, restrictions and other implications on the payment of dividends by us to our shareholders or make any share repurchases and such other factors as our board of directors may deem relevant. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A shareholder who receives a distribution under circumstances where he or she knows or has reasonable grounds for believing that the distribution is unlawful in the circumstances is obliged to repay such distribution (or that part of it, as the case may be) to us. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we were determined to be an investment company under the U.S. Investment Company Act of 1940, applicable restrictions could make it impractical for us to continue our business as contemplated and could</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We intend to conduct our business so as not to become regulated as an investment company under the U.S. Investment Company Act. An entity generally will be determined to be an investment company for purposes of the U.S. Investment Company Act if, absent an applicable exemption, (i) it is or holds itself out as being engaged primarily, or proposes to engage primarily, in the business of investing, reinvesting or trading in securities; or (ii) it owns or proposes to acquire investment securities having a value exceeding 40% of the value of its total assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis, which we refer to as the ICA 40% Test. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not hold ourselves out as being engaged primarily, or propose to engage primarily, in the business of investing, reinvesting or trading in securities, and believe that we are not engaged primarily in the business of investing, reinvesting or trading in securities. We believe that, for U.S. Investment Company Act purposes, we are engaged primarily, through one or more of our subsidiaries, in the business of purchasing or otherwise acquiring certain obligations that represent part or all of the sales price of merchandise. Our subsidiaries that are so engaged rely on Section 3(c)(5)(A) of the U.S. Investment Company Act, which, as interpreted by the SEC staff, requires each such subsidiary to invest at least 55% of its assets in &#8220;notes, drafts, acceptances, open accounts receivable, and other obligations representing part or all of the sales price of merchandise, insurance, and services,&#8221; which we refer to as the ICA Exception Qualifying Assets. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In a no-action letter, dated August 13, 2010, to our predecessor, the SEC staff promulgated an interpretation that royalty interests that entitle an issuer to collect royalty receivables that are directly based on the sales price of specific biopharmaceutical assets that use intellectual property covered by specific license agreements are ICA Exception Qualifying Assets under Section 3(c)(5)(A). We rely on this no-action letter for the position that royalty receivables relating to biopharmaceutical assets that we hold are ICA Exception Qualifying Assets under Section 3(c)(5)(A) and Section 3(c)(6), which is described below. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To ensure that we are not obligated to register as an investment company, we must not exceed the thresholds provided by the ICA 40% Test. For purposes of the ICA 40% Test, the term investment securities does not include U.S. government securities or securities issued by majority-owned subsidiaries that are not themselves investment companies and are not relying on Section 3(c)(1) or Section 3(c)(7) of the U.S. Investment Company Act, such as majority-owned subsidiaries that rely on Section 3(c)(5)(A). We also may rely on Section 3(c)(6), which, based on SEC staff interpretations, requires us to invest, either directly or through majority-owned subsidiaries, at least 55% of our assets in, as relevant here, businesses relying on Section 3(c)(5)(A). Therefore, the assets that we and our subsidiaries hold and acquire are limited by the provisions of the U.S. Investment Company Act and the rules and regulations promulgated thereunder. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the SEC or its staff in the future adopts a contrary interpretation to that provided in the no-action letter to Royalty Pharma or otherwise restricts the conclusions in the SEC staff&#8217;s no-action letter such that royalty interests are no longer treated as ICA Exception Qualifying Assets for purposes of Section 3(c)(5)(A) and Section 3(c)(6), or the SEC or its staff in the future determines that the no-action letter does not apply to some or all types of royalty receivables relating to biopharmaceutical assets, our business will be materially and adversely affected. In particular, we would be required either to convert to a corporation formed under the laws of the United States or a state thereof (which would likely result in our being subject to U.S. federal corporate income taxation) and to register as an investment company, or to stop all business activities in the United States until such time as the SEC grants an application to register us as an investment company formed under non-U.S. law. It is unlikely that such an application would be granted and, even if it were, requirements imposed by the Investment Company Act, including limitations on our capital structure, our ability to transact business with affiliates and our ability to compensate key employees, could make it impractical for us to continue our business as currently conducted. Our ceasing to qualify for an exemption from registration as an investment company could materially and adversely affect the value of our Class A ordinary shares and our ability to pay dividends in respect of our Class A ordinary shares. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The equity performance awards payable to an affiliate of the Manager may create incentives that are not fully aligned with the interests of our shareholders. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to certain conditions, at the end of each fiscal quarter, an affiliate of the Manager is entitled to a distribution in the form of equity from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the &#8220;Equity Performance Awards&#8221;). The right to Equity Performance Awards may create an incentive for the Manager to make riskier or more speculative asset acquisitions than would be the case absent such Equity Performance Awards. In addition, the Manager may cause us to incur more debt or otherwise use more leverage in connection with asset acquisitions, as generally the use of leverage can increase the rate of return on an investment and therefore our profits. This Equity Performance Awards structure may encourage the Manager to cause us to borrow money to finance additional asset acquisitions or to maintain leverage which poses higher risks for our business when it would otherwise be appropriate to not use such leverage. Under certain circumstances, the use of borrowed money may increase the likelihood of default, which would disfavor our shareholders. In addition, there is no correlation between our profits and the obligation of our board of directors to pay dividends to shareholders. Consequently, you may receive limited or no dividends while an affiliate of the Manager remains entitled to Equity Performance Awards based on our Net Economic Profit. In addition, even though Equity Performance Awards are payable on a portfolio-by-portfolio basis (with portfolios comprised of investments made during sequential two-year periods) in order to reduce the risks that affiliates of the Manager will be paid Equity Performance Awards on individual investments even though our overall portfolio of investments is not performing well, Equity Performance Awards may nevertheless be payable to affiliates of the Manager when our overall portfolio of investments is not performing as well as the individual portfolios that are used as the basis for measuring the Equity Performance Awards. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our board of directors may make decisions with respect to the cash generated from our operations that may result in no dividends paid to our shareholders or no repurchases made of our ordinary shares. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our board of directors is under no obligation to pay dividends, make distributions or repurchase our ordinary shares and it may decide to use cash to fund asset acquisitions or operations in lieu of paying dividends, making distributions or repurchasing our ordinary shares. We will pay Equity Performance Awards to an affiliate of the Manager based on our Net Economic Profit regardless of whether any dividends are paid to our shareholders or any ordinary shares are repurchased. Our board of directors&#8217; decisions with respect to our cash may result in no dividends to our shareholders and no ordinary shares repurchased. Furthermore, our board of directors&#8217; decisions with respect to dividends or repurchases of ordinary shares may adversely affect the market price of our Class A ordinary shares. In the event that we generate positive income, but pay limited or no dividends, holders of Class A ordinary shares may, if they have made certain elections for U.S. federal income tax purposes with respect to their Class A ordinary shares, have a tax liability on our income in excess of the actual cash dividends received by such holders. If our board of directors decides to approve limited or no dividends or repurchases of ordinary shares, the primary remedy for holders of Class A ordinary shares will be to sell their shares at prevailing market prices, including at a loss, which prices may be low due to unfavorable or inconsistent dividends or repurchases of our ordinary shares. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The royalties that we acquire may fall outside the biopharmaceutical industry, and any such assets, and the cash flows therefrom, may not resemble the assets in our current portfolio. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have discretion as to the types of healthcare assets that we may acquire. While we expect the Manager to acquire assets that primarily fall within the biopharmaceutical industry, we are not obligated to do so and may acquire other types of healthcare assets that are peripheral to or outside of the biopharmaceutical industry. Consequently, our asset acquisitions in the future, and the cash flows from such assets, may not resemble those of the assets in our current portfolio. There can be no assurance that assets acquired in the future will have returns similar to the returns expected of the assets in our current portfolio or be profitable at all. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The Manager may be the subject of a change of control resulting in a disruption in our operations that could adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There could be a change of control of the Manager and, in such a case, the new controlling party may have a different philosophy, employ advisory professionals who are less experienced, be unsuccessful in identifying asset acquisition opportunities or have a track record that is not as successful as that of the Manager prior to such a change of control. If the foregoing were to occur, we could experience difficulty in making new asset acquisitions, and the value of our existing assets, our business, financial condition and results of operations could materially suffer. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The Manager&#8217;s liability is limited under the Management Agreement, and we have agreed to indemnify the Manager against certain liabilities. As a result, we could experience unfavorable operating results or incur losses for which the Manager would not be liable. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the Management Agreement, the Manager does not assume any responsibility other than to render the services called for thereunder. Under the terms of the Management Agreement, the Manager and its affiliates (including RPI EPA Holdings, LP (&#8220;EPA Holdings&#8221;)) and their respective officers, directors, stockholders, members, employees, agents and partners, and any other person who is entitled to indemnification (each, an &#8220;Indemnitee&#8221;) is not liable to us, any subsidiary of ours, our directors, our stockholders or any subsidiary&#8217;s stockholders or partners for acts or omissions performed in accordance with and pursuant to the Management Agreement, except those resulting from acts constituting fraud, bad faith, willful misconduct, gross negligence (as such concept is interpreted under the laws of the State of New York) and a material breach of the Management Agreement that is not cured in accordance with its terms or a violation of applicable securities laws. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, to the fullest extent permitted by law, we have agreed to indemnify the Indemnitees from and against any and all claims, liabilities, damages, losses, penalties, actions, judgments, costs and expenses (including amounts paid in satisfaction of judgments, in compromises and settlements, as fines and penalties and legal or other costs and reasonable expenses of investigating or defending against any claim or alleged claim) of any nature whatsoever, known or unknown, liquidated or unliquidated that are incurred by any Indemnitee or to which such Indemnitee may be subject by reason of its activities on behalf of us or any of our subsidiaries to the extent that such Indemnitee&#8217;s conduct did not constitute fraud, bad faith, willful misconduct, gross negligence (as such concept is interpreted under the laws of the State of New York), material breach of the Management Agreement that is not cured in accordance with the terms of the Management Agreement or a violation of applicable securities laws. As a result, we could experience unfavorable operating results or incur losses for which the Manager would not be liable. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operational risks may disrupt our businesses, result in losses or limit our growth. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We and the Manager rely heavily on our respective financial, accounting, information and other data processing systems and cloud computing services, as well as those of our current and future collaborators, contractors or consultants. Such systems are vulnerable to damage or interruption from computer viruses, data corruption, cyber-based attacks, unauthorized access, natural disasters, pandemics, such as the current COVID-19 pandemic, terrorism, war and telecommunication and electrical failures. If any of these events occur and such systems do not operate properly or are disabled or if there is any unauthorized disclosure of data, whether as a result of tampering, a breach of network security systems, a cyber-incident or attack or otherwise, we could suffer substantial financial loss, increased costs, a disruption of our business, loss of trade secrets or other proprietary information, liability to us, regulatory intervention or reputational damage. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, federal, state and international laws and regulations relating to data privacy and protection, such as the European Union&#8217;s General Data Protection Regulation, which took effect in May 2018, and the California Consumer Privacy Act, which took effect in January 2020, can expose us to enforcement actions and investigations by regulatory authorities, and potentially result in regulatory penalties and significant legal liability, if our information technology security efforts or data privacy and protection compliance efforts fail. In addition, we operate a business that is highly dependent on information systems and technology. Our information systems and technology and that of the Manager may not continue to be able to accommodate our growth, and the cost of maintaining such systems may increase from its current level. Such a failure to accommodate growth, or an increase in costs related to such information systems, could adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A disaster or a disruption in the public infrastructure that supports our business, including a disruption involving electronic communications or other services used by us or third parties with whom we conduct business, could adversely affect our ability to continue to operate our business without interruption. Our disaster recovery programs and those of the Manager may not be sufficient to mitigate the harm that may result from such a disaster or disruption. In addition, insurance and other safeguards might only partially reimburse us for our losses, if at all. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, sustaining our growth may require us or the Manager to commit additional management, operational and financial resources to identify new professionals to join the team and to maintain appropriate operational and financial systems to adequately support expansion. Due to the fact that the market for hiring talented professionals is competitive, we may not be able to grow at the pace we desire. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are subject to the U.K. Bribery Act, the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, import and customs laws, trade and economic sanctions laws and other laws governing our operations. </span></div><div style="margin-bottom:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operations are subject to anti-corruption laws, including the U.K. Bribery Act 2010 (&#8220;Bribery Act&#8221;), the U.S. Foreign Corrupt Practices Act of 1977, as amended the (&#8220;FCPA&#8221;), the U.S. domestic bribery statute contained in 18 U.S.C. &#167;201, the U.S. Travel Act, and other anti-corruption laws that apply in countries where we do business. The Bribery Act, the FCPA and these other laws generally prohibit us and our employees and intermediaries from authorizing, promising, offering, or providing, directly or indirectly, improper or prohibited payments, or anything else of value, to government officials or other persons to obtain or retain business or gain some other business advantage. Under the Bribery Act, we may also be liable for failing to prevent a person associated with us from committing a bribery offense. We and the marketers of products that generate our royalties operate in a number of jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we participate in collaborations and relationships with third parties whose corrupt or illegal activities could potentially subject us to liability under the Bribery Act, FCPA or local anti-corruption laws, even if we do not explicitly authorize or have actual knowledge of such activities. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United Kingdom and the United States, and authorities in the European Union, including applicable export control regulations, economic sanctions and embargoes on certain countries and persons, anti-money laundering laws, import and customs requirements and currency exchange regulations, collectively referred to as the Trade Control laws. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the Bribery Act, the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control laws by the United Kingdom, United States or other authorities could also have an adverse impact on our reputation, our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities or our business arrangements with third parties could be subject to challenge under one or more of such laws. It is possible that governmental authorities will conclude that our business practices or the business practices of the marketers of products that generate our royalties may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations or the operations of the marketers of products that generate are royalties are found to be in violation of any of these laws or any other governmental regulations, we or marketers of products that generate our royalties may be subject to significant criminal, civil and administrative sanctions, including monetary penalties, damages, fines, disgorgement, individual imprisonment and exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we or marketers of products that generate our royalties become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm, and we or marketers of products that generate our royalties may be required to curtail or restructure operations, any of which could adversely affect our ability to operate our business and our results of operations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The EU directive on alternative investment fund managers (the &#8220;AIFM Directive&#8221;) may significantly increase our compliance costs. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The AIFM Directive has been implemented into the national law of the majority of member states of the European Economic Area and the United Kingdom (each an &#8220;AIFM state&#8221;). The AIFM Directive sets out minimum conditions related to the marketing of interests in alternative investment funds (such as our Class A ordinary shares) in the AIFM states and may impact our ability to attract investors in the AIFM states and may significantly increase our and the Manager&#8217;s compliance costs. Such conditions include requirements for us to register with the competent authority in the relevant AIFM in order to market the Class A ordinary shares to investors, state requirements to file periodic reports with the competent authority in the relevant AIFM state and requirements to comply with disclosure and reporting obligations in respect of investors in the relevant AIFM state. Such reports and disclosures may become publicly available. While such conditions are met in relation to the AIFM states where our Class A ordinary shares will be marketed, there can be no guarantee that this will continue to be the case. The AIFM Directive does not, however, prohibit an investor in such AIFM state from subscribing for our Class A ordinary shares at their own initiative in circumstances where such Class A ordinary shares have not been marketed in such AIFM state and we may issue our Class A ordinary shares to such investors, as long as they have provided us and the Manager with representations that they have done so at their own initiative. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In each AIFM state, our Class A ordinary shares may only be offered to investors in accordance with local measures implementing the AIFM Directive. Investors, together with any person making or assisting in the decision to invest in us, who are situated, domiciled or who have a registered office, in an AIFM state where our Class A ordinary shares are not being offered pursuant to private placement rules implementing the AIFM Directive may invest, or effect an investment in our Class A ordinary shares, but only in circumstances where they do so at their own initiative. Any investor acquiring our Class A ordinary shares at their own initiative in such AIFM state should note that as we have not been registered for marketing in that AIFM state, no reports will be filed with the competent authority in the relevant AIFM state by or in respect of us and no investor shall be entitled to receive any disclosure or report that is mandated in respect of an alternative investment fund being marketed pursuant to the AIFM Directive. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Relating to Our Organization and Structure </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are a holding company with no operations and rely on our subsidiaries to provide us with funds necessary to meet our financial obligations and to pay dividends. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a holding company with no material direct operations. Our principal asset is our controlling equity interest in RP Holdings. As a result, we are dependent on loans, dividends and other payments from our subsidiaries to generate the funds necessary to meet our financial obligations and to pay dividends on our Class A ordinary shares. Our subsidiaries are legally distinct from us and may be prohibited or restricted from paying dividends or otherwise making funds available to us under certain conditions. If the cash we receive from our subsidiaries pursuant to dividend payments is insufficient for us to fund our obligations, or if a subsidiary is unable to pay dividends to us, provided that we have sufficient distributable profits, our net assets exceed the total of our called-up share capital and distributable reserves and any dividend would not reduce our net assets to less than such total, we may be required to raise cash through the incurrence of debt, the issuance of equity or the sale of assets to fund the payment of the dividends. However, there is no assurance that we would be able to raise cash by these means. If the ability of any of our subsidiaries to pay dividends or make other distributions or payments to us is materially restricted by regulatory or legal requirements, bankruptcy or insolvency, or our need to maintain our financial strength ratings, or is limited due to operating results or other factors, it could adversely affect our ability to pay our operating costs and other corporate expenses and we may be unable to, or our board may exercise its discretion not to, pay dividends. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our structure will result in tax distributions to the owner of the RP Holdings Class C Special Interest. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RP Holdings is treated as a partnership for U.S. federal income tax purposes and has owners that are subject to U.S. federal income taxation. To the extent permitted by applicable law, RP Holdings is required to make cash distributions, or tax distributions, to the owner of the RP Holdings Class C Special Interest, calculated using an assumed tax rate that is generally uniform for all recipients regardless of their tax status. Funds used by RP Holdings to satisfy its tax distribution obligations will not be available for reinvestment in our business. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Relating to Our Class A Ordinary Shares </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The market price of our Class A ordinary shares may be volatile, which could cause the value of your investment to decline. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The market price of our Class A ordinary shares may be highly volatile and could be subject to wide fluctuations. Securities markets worldwide experience significant price and volume fluctuations. This market volatility, as well as general economic, market or political conditions, could reduce the market price of Class A ordinary shares in spite of our operating performance. In addition to the factors discussed in this Annual Report on Form 10-K, our operating results could be below the expectations of public market analysts and investors due to a number of potential factors, including: </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">market conditions in the broader stock market in general, or in our industry in particular; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">variations in our quarterly operating results or dividends to shareholders; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">additions or departures of key management personnel at the Manager; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">timing and rate of capital deployment, including relative to estimates;</span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">changes in our portfolio mix or acquisition strategy;</span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">failure to meet analysts&#8217; earnings estimates; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">publication of research reports about our industry; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">third-party healthcare reimbursement policies and practices; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">litigation and government investigations; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">changes or proposed changes in laws or regulations or differing interpretations or enforcement thereof affecting our business; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">no results, or projected results, from marketers of products that generate our royalties; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">results from, and any delays to, the clinical trial programs of development-stage product candidates underlying our biopharmaceutical assets or other issues relating to such products, including regulatory approval or commercialization; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">adverse market reaction to any indebtedness that we may incur or securities we may issue in the future; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">changes in market valuations of similar companies or speculation in the press or investment community; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">announcements by our competitors of significant contracts, acquisitions, dispositions, strategic partnerships, joint ventures or capital commitments; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">litigation; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">economic and political conditions or events; and </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">adverse publicity about us or the industries in which we participate or individual scandals. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These and other factors may cause the market price of and demand for our Class A ordinary shares to fluctuate significantly, which may limit or prevent our existing shareholders from reselling their Class A ordinary shares at or above the purchase price. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The stock market in general has from time to time experienced extreme price and volume fluctuations, including in recent months. In addition, in the past, following periods of volatility in the overall market and the market price of a company&#8217;s securities, securities class action litigation has often been instituted against public companies. This type of litigation, if instituted against us, could result in substantial costs and a diversion of our management&#8217;s attention and resources. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our Articles of Association provide that the courts of England and Wales will be the exclusive forum for the resolution of all shareholder complaints other than complaints asserting a cause of action arising under the Securities Act and the Exchange Act, and that the U.S. federal district courts will be the exclusive forum for the resolution of any shareholder complaint asserting a cause of action arising under the Securities Act and the Exchange Act. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Articles of Association provide that the courts of England and Wales will be the exclusive forum for resolving all shareholder complaints other than shareholder complaints asserting a cause of action arising under the Securities Act and the Exchange Act, and that the U.S. federal district courts will be the exclusive forum for resolving any shareholder complaint asserting a cause of action arising under the Securities Act and the Exchange Act. This choice of forum provision may limit a shareholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits. If a court were to find either choice of forum provision contained in our Articles of Association to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our results of operations and financial condition. </span></div><div style="margin-bottom:9pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">U.S. investors may have difficulty enforcing civil liabilities against our company, our directors or members of senior management and the experts named herein. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a public limited company with our registered office in England and our subsidiaries are incorporated in various jurisdictions, including jurisdictions outside the United States. One of our directors is not a resident of the United States, and a substantial portion of our assets and the assets of this director are located outside the United States. As a result, it may be difficult for investors to effect service of process on this director in the United States or to enforce in the United States judgments obtained in U.S. courts against us or this director based on the civil liability provisions of the U.S. securities laws or otherwise. Even if you are successful in bringing an action of this kind, the laws of England may render you unable to enforce a judgment against our assets or the assets of our directors and executive officers. In addition, it is doubtful whether English courts would enforce certain civil liabilities under U.S. securities laws in original actions or judgments of U.S. courts based upon these civil liability provisions. In addition, awards of punitive damages in actions brought in the United States or elsewhere may be unenforceable in the United Kingdom. An award for monetary damages under the U.S. securities laws would likely be considered punitive if it does not seek to compensate the claimant for loss or damage suffered and is intended to punish the defendant. The enforceability of any judgment in the United Kingdom will depend on the particular facts of the case as well as the laws and treaties in effect at the time. The United States and the United Kingdom do not currently have a treaty providing for recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters. As a result of the above, public holders of our Class A ordinary shares may have more difficulty in protecting their interest through actions against our management, directors or major shareholders than they would as shareholders of a U.S. public company. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation and these differences may make our Class A ordinary shares less attractive to investors. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are incorporated under English law. The rights of holders of our Class A ordinary shares are governed by English law, including the provisions of the Companies Act 2006 (the &#8220;U.K. Companies Act&#8221;), and by our Articles of Association. These rights differ in certain respects from the rights of shareholders in typical U.S. corporations and these differences may make our Class A ordinary shares less attractive to investors. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The City Code on Takeovers and Mergers (the &#8220;Takeover Code&#8221;) applies, among other things, to an offer for a public company whose registered office is in the United Kingdom (or the Channel Islands or the Isle of Man) and whose securities are not admitted to trading on a regulated market in the United Kingdom (or the Channel Islands or the Isle of Man) if the company is considered by the Panel on Takeovers and Mergers (the &#8220;Takeover Panel&#8221;) to have its place of central management and control in the United Kingdom (or the Channel Islands or the Isle of Man). This is known as the &#8220;residency test.&#8221; The test for central management and control under the Takeover Code is different from that used by the U.K. tax authorities. Under the Takeover Code, the Takeover Panel will determine whether we have our place of central management and control in the United Kingdom by looking at various factors, including the structure of our board of directors, the functions of the directors and where they are resident. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If at the time of a takeover offer the Takeover Panel determines that we have our place of central management and control in the United Kingdom, we would be subject to a number of rules and restrictions, including but not limited to the following: (i) our ability to enter into deal protection arrangements with a bidder would be extremely limited; (ii) we might not, without the approval of our shareholders, be able to perform certain actions that could have the effect of frustrating an offer, such as issuing shares or carrying out acquisitions or disposals; and (iii) we would be obliged to provide equality of information to all bona fide competing bidders. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Given that our central management and control is currently not situated within, and our current intention is not to have it in the future situated within the United Kingdom (or the Channel Islands or the Isle of Man), but to have such management and control situated within the United States, we do not currently envisage that the Takeover Code will apply to an offer for us. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under English law, and whether or not we are subject to the Takeover Code, an offeror for us that has acquired (i) 90% in value of; and (ii) 90% of the voting rights carried by the shares to which the offer relates may exercise statutory squeeze-out rights to compulsorily acquire the shares of the non-assenting minority. However, if an offer for us is conducted by way of a scheme of arrangement the threshold for the offeror obtaining 100% of Company shares comprises two components (i) approval by a majority in number of each class of Company shareholders present and voting at the shareholder meeting; and (ii) approval of Company shareholders representing 75% or more in value of each class of Company shareholders present and voting at that meeting. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">As an English public limited company, certain capital structure decisions will require shareholder approval, which may limit our flexibility to manage our capital structure. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a public limited company incorporated under the laws of England and Wales. English law provides that a board of directors may only allot shares (or rights to subscribe for or convert into shares) with the prior authorization of shareholders, such authorization stating the aggregate nominal amount of shares that it covers and valid for a maximum period of five years, each as specified in the articles of association or relevant shareholder resolution. We have obtained authority from our shareholders to allot additional shares for a period expiring on May 31, 2025, which authorization will need to be renewed upon expiration (i.e., at least every five years) but may be sought more frequently for additional five-year terms (or any shorter period). </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">English law also generally provides shareholders with preemptive rights when new shares are issued for cash. However, it is possible for the articles of association, or for shareholders to pass a special resolution at a general meeting, being a resolution passed by at least 75% of the votes cast, to disapply preemptive rights. Such a disapplication of preemptive rights may be for a maximum period of up to five years from the date of adoption of the articles of association, if the disapplication is contained in the articles of association, or from the date of the shareholder special resolution, if the disapplication is by shareholder special resolution. In either case, this disapplication would need to be renewed by our shareholders upon its expiration (i.e., at least every five years). We have obtained authority from our shareholders to disapply preemptive rights for a period expiring on May 31, 2025, which disapplication will need to be renewed upon expiration (i.e., at least every five years) to remain effective, but may be sought more frequently for additional five-year terms (or any shorter period). </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">English law also generally prohibits a public company from repurchasing its own shares by way of &#8220;off market purchases&#8221; without the prior approval of shareholders by ordinary resolution, being a resolution passed by a simple majority of votes cast, and other formalities. Such approval may be for a maximum period of up to five years but may be sought more frequently. English law prohibits us from conducting &#8220;on market purchases&#8221; as our shares are listed on the NASDAQ  and will not be traded on a recognized investment exchange in the United Kingdom.</span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The United Kingdom&#8217;s vote in favor of withdrawing from the European Union may have a negative effect on global economic conditions, financial markets and our business, which could reduce the market price of our Class A ordinary shares.</span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The withdrawal of the United Kingdom from the European Union (commonly referred to as &#8220;Brexit&#8221;) took effect on January 31, 2020. On December 30, 2020, the United Kingdom passed legislation giving effect to a trade and cooperation agreement, with the EU, which became effective on May 1, 2021. The trade and cooperation agreement covers the general objectives and framework of the relationship between the United Kingdom and the European Union, including as it related to trade, transport, visas, judicial, law enforcement and security matters, and provides for continued participation in community programs and mechanisms for dispute resolution. Notably, under the trade and cooperation agreement, U.K. service suppliers no longer benefit from automatic access to the entire EU single market, U.K. goods no longer benefit from the free movement of goods and there is no longer the free movement of people between the United Kingdom and the European Union. Since a significant proportion of the regulatory framework in the United Kingdom is derived from European Union directives and regulations, the impact on the regulatory regime with respect to obtaining marketing approval of our development-stage product candidates in the United Kingdom remains unclear. The United Kingdom will no longer be covered by the centralized procedures for obtaining European Union-wide marketing authorization from the EMA and, unless a specific agreement is entered into, a separate process for authorization of drug products will be required in the United Kingdom. Depending on the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">outcome of these developments, we could face new regulatory costs and challenges that could adversely affect our operations and the market price of our Class A ordinary shares. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If our Class A ordinary shares are not eligible for deposit and clearing within the facilities of DTC, then transactions in our securities may be disrupted. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The facilities of The Depository Trust Company (&#8220;DTC&#8221;) are a widely-used mechanism that allow for rapid electronic transfers of securities between the participants in the DTC system, which include many large banks and brokerage firms. While our Class A ordinary shares are eligible for deposit and clearing within the DTC system and DTC has agreed to accept our Class A ordinary shares for deposit and clearing within its facilities in certain specified circumstances, DTC will generally have discretion to cease to act as a depository and clearing agency for the Class A ordinary shares, including to the extent that any changes in U.K. law change the stamp duty or stamp duty reserve tax (&#8220;SDRT&#8221;) position in relation to the Class A ordinary shares. If DTC determined at any time that the shares were not eligible for continued deposit and clearance within its facilities, then we believe the shares would not be eligible for continued listing on a U.S. securities exchange and trading in the shares would be disrupted. While we would pursue alternative arrangements to preserve our listing and maintain trading, any such disruption could adversely affect the market price of our Class A ordinary shares. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The requirements of being a public company may strain our resources, divert management&#8217;s attention and affect our ability to attract and retain qualified board members. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a public company, we are subject to the reporting requirements of the Exchange Act, the requirements of the U.S. Sarbanes-Oxley Act of 2002 (&#8220;Sarbanes-Oxley Act&#8221;), and the requirements of the U.K. Companies Act and, if applicable, the Takeover Code. The requirements of these rules and regulations increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and increase demand on our systems and resources. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are obligated to file with the SEC annual and quarterly information and other reports that are specified in the Exchange Act, and therefore will need to have the ability to prepare financial statements that are compliant with all SEC reporting requirements on a timely basis. In addition, we are subject to other reporting and corporate governance requirements, including certain requirements of Nasdaq and certain provisions of the Sarbanes-Oxley Act and the regulations promulgated thereunder, which will impose significant compliance obligations upon us. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are required to comply with Section 404 of the Sarbanes-Oxley Act, which requires management assessments of the effectiveness of internal control over financial reporting and disclosure controls and procedures. If we are unable to maintain effective internal control over financial reporting or disclosure controls and procedures, our ability to record, process and report financial information accurately and to prepare financial statements within required time periods could be adversely affected, which could subject us to regulatory consequences, including sanctions by the SEC, negatively affect investor confidence in our financial statements, restrict access to capital markets and adversely impact the market price of our Class A ordinary shares.</span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our compliance with the requirements under the Exchange Act, the Sarbanes-Oxley Act, the U.K. Companies Act and, if applicable, the Takeover Code and the rules and regulations thereunder increases our legal and financial compliance costs and makes some activities more time consuming and costly. These rules and regulations have made it more difficult and more expensive for us to obtain directors&#8217; and officers&#8217; liability insurance, and we may in the future be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as executive officers. We may not be able to predict or estimate accurately the amount of additional costs we may incur or the timing of such costs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Relating to Taxation </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our structure involves complex provisions of tax law for which no clear precedent or authority may be available. Our structure also is subject to potential legislative, judicial or administrative change and differing interpretations, possibly on a retroactive basis. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our tax treatment, including Irish, U.K. and U.S. federal income tax treatment, depends in some instances on determinations of fact and interpretations of complex provisions of applicable tax law for which no clear precedent or authority may be available. You should be aware that our tax position is not free from doubt, and that applicable tax rules are generally subject to ongoing review by legislative and administrative bodies and relevant tax authorities, as well as by the Organization for Economic Co-operation and Development (&#8220;OECD&#8221;), which is continuously considering recommendations for changes to existing tax rules. These review processes could result in revised interpretations of established concepts, statutory changes, revisions to regulations and other modifications and interpretations. No ruling will be sought from the relevant tax authority regarding any of the tax issues discussed herein, and no assurance can be given that the relevant tax authorities will not challenge any of our tax positions and that such challenge would not succeed. If any such position is successfully challenged, our tax liabilities could materially increase, which would have an adverse effect on our profitability and cash flows. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There have been significant changes both made and proposed to international tax laws that increase the complexity, burden and cost of tax compliance for all multinational groups. We expect to continue to monitor these and other developments in international tax law. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We could be liable for significant taxes due to changes in our eligibility for certain income tax treaty benefits or challenges to our tax positions with respect to the application of income tax treaties. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our subsidiaries expect to receive revenue from both U.S. and non-U.S. sources. We expect that our subsidiaries generally will be eligible for benefits under the applicable income tax treaties between Ireland and the jurisdictions where income is sourced. However, no assurances can be provided in this regard, and it is possible that a taxing authority could successfully assert that any of our subsidiaries does not qualify for treaty benefits as a result of its failure to satisfy the applicable requirements to be eligible to claim treaty benefits. If a taxing authority were to challenge our position regarding the application of an applicable income tax treaty, we could become subject to increased withholding taxes, and such taxes could be significant. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Specifically, with respect to certain U.S.-source income, we expect that our subsidiaries will be eligible for benefits under the U.S.-Ireland income tax treaty (the &#8220;Treaty&#8221;), and, under that Treaty, will not be subject to any U.S. withholding taxes on such U.S.-source payments. Our current treaty position with respect to U.S.-source payments relies in part on U.S. citizens or tax residents (as defined for purposes of the Treaty) owning, directly or indirectly, at least 50% of the beneficial interest in, or at least 50% of the aggregate vote and value of, each of our subsidiaries that earns U.S.-source income. Our treaty position is based on the current U.S. status of the majority of the existing indirect investors in RP Holdings and Old RPI. Subject to certain exceptions, the existing indirect U.S. investors in RP Holdings have the right to exchange their interests for our publicly traded Class A ordinary shares. Such publicly traded Class A ordinary shares could be further transferred on the public market to other persons. Therefore, it is possible that over time U.S. persons will own indirectly in the aggregate less than 50% of the interests in our subsidiaries. We currently expect that our Class A ordinary shares and other existing indirect interests in RP Holdings and Old RPI in the aggregate will continue to be owned in sufficient amount by U.S. citizens or tax residents, and that we will be able to establish such ownership, for purposes of satisfying the 50% ownership requirement under the Treaty. However, there is no assurance that RP Holdings and Old RPI will continue to be owned directly or indirectly by sufficient U.S. citizens or residents or that we will be able to establish to the IRS&#8217; satisfaction such ownership for purposes of satisfying the 50% U.S. ownership requirement under the Treaty. It is possible that if the indirect U.S. ownership in our subsidiaries becomes lower than 50% (or we cannot establish such ownership) we may in the future be able to qualify for another applicable exemption from U.S. withholding under the Treaty, but there can be no assurance in this regard. A substantial portion of our revenue is, and is expected to continue to be, derived from U.S.-source royalties. Therefore, if our subsidiaries failed to qualify for an exemption from U.S. withholding tax under the Treaty (by satisfying either the 50% U.S. ownership requirement or an alternative Treaty exemption) and such royalties were subject to a 30% U.S. withholding tax, our financial position, profitability and cash flows could be adversely affected. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, on August 25, 2016, the Irish Department of Finance announced that, in the context of the publication by the United States Treasury Department of a revised U.S. Model Income Tax Convention in February 2016, discussions have begun with the United States Treasury on updating certain elements of the Treaty. It is at this time not clear what elements of the Treaty may be updated, or when any such updates would go into effect. However, certain elements of the revised U.S. Model Income Tax Convention could, if included in an update to the Treaty, result in our subsidiaries being unable to qualify for the benefits of the Treaty or eliminate or reduce the benefits of the Treaty that otherwise would have been available to us. If our subsidiaries are unable to qualify for the benefits of the Treaty, or if any benefits of the Treaty that otherwise would have been available to us are eliminated or reduced, then all or a portion of our income may become subject to increased withholding taxes, and such taxes could be very significant and materially and adversely affect our financial position, profitability and cash flows. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If our subsidiaries are considered to be engaged in a U.S. trade or business, we could be liable for significant U.S. taxation. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In general, if a foreign corporation, such as Royalty Pharma plc, is considered to be engaged in a U.S. trade or business, such corporation&#8217;s share of any income that is effectively connected with such U.S. trade or business will be subject to regular U.S. federal income taxation (currently imposed at a maximum rate of 21%) on a net basis and, potentially, an additional 30% U.S. &#8220;branch profits&#8221; tax on distributions attributable to income that is effectively connected with such U.S. trade or business. In addition, it is possible that such corporation could be subject to taxation on a net basis by state or local jurisdictions within the United States. We intend to conduct our activities, through our subsidiaries, such that no income realized by us will be effectively connected with the conduct of a U.S. trade or business or otherwise subject to regular U.S. federal income taxation on a net basis. If we are able to conduct our activities in this way, income or gains realized by us will not be subject to U.S. net </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">federal income taxation. However, no assurance can be provided in this regard. The proper characterization of our income and gains for U.S. tax purposes is not certain, and it is possible that all or a portion of our income and gains could be characterized as income that is &#8220;effectively connected&#8221; with the conduct of a U.S. trade or business. If our income and gains were characterized as effectively connected with a U.S. trade or business, we would be subject to significant U.S. taxes plus interest and possible penalties, and our financial position, cash flows and profitability could be materially and adversely affected. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We expect to operate, and expect that RP Holdings will operate, so as to be treated solely as a resident of the U.K. for tax purposes, but changes to our management and organizational structure and/or to the tax residency laws of other jurisdictions where we operate may cause the relevant tax authorities to treat us or RP Holdings as also being a resident of another jurisdiction for tax purposes. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under current U.K. tax law, a company that is incorporated in the U.K. is regarded as resident for tax purposes in the U.K. unless (i) it is concurrently treated as resident for tax purposes in another jurisdiction (applying the rules of that other jurisdiction for determining tax residency) that has a double tax treaty with the U.K. and (ii) there is a residency tie-breaker provision in that tax treaty which allocates tax residence to that other jurisdiction. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based upon our anticipated management and organizational structure, we believe that we and RP Holdings should be regarded as tax resident solely in the U.K. However, because this analysis is highly factual and may depend on future changes in our management and organizational structure, as well as future changes in the tax residency laws of other jurisdictions where we operate, there can be no assurance regarding the determination of our tax residence in the future. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As U.K. tax resident companies, we and RP Holdings will be subject to U.K. corporation tax on our worldwide taxable profits and gains. Should we (or RP Holdings) be treated as resident in a jurisdiction other than the U.K., we (or RP Holdings, as applicable) could be subject to taxation in that jurisdiction and may be required to comply with a number of material and formal tax obligations, including withholding tax and/or reporting obligations provided under the relevant tax law, which could result in additional costs and expenses. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We believe that we should not be subject to material U.K. corporation tax in respect of certain profits of our non-U.K. tax resident subsidiaries as a result of the U.K.&#8217;s &#8220;controlled foreign companies&#8221; rules but it cannot be guaranteed that this will continue to be the case. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As U.K. tax resident companies, we and RP Holdings will be subject to the U.K.&#8217;s &#8220;controlled foreign companies&#8221; rules (the &#8220;U.K. CFC Rules&#8221;). The U.K. CFC Rules, broadly, can impose a charge to U.K. tax on U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the &#8220;Controlled Foreign Company&#8221;) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. The types of profits of a Controlled Foreign Company that can potentially be subject to a U.K. corporation tax charge under the U.K. CFC Rules include business profits of the Controlled Foreign Company that are attributable to assets or risks that are managed by activities in the U.K., or certain finance profits of the Controlled Foreign Company that arise from capital or other assets contributed, directly or indirectly, to the Controlled Foreign Company from a connected U.K. tax resident company. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI (which is Irish tax resident) and Old RPI (which is Irish tax resident and which is held indirectly by us through our participation in RP Holdings), will be Controlled Foreign Companies for U.K. tax purposes. We and RP Holdings will therefore be required to apply the CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis. We do not expect material U.K. corporation tax charges to arise under the U.K. CFC Rules in respect of our royalty assets or our financing arrangements, however no assurances can be given that this will continue to be the case. The U.K. CFC Rules are highly complex and fact-dependent, and changes to, or adverse interpretations of, these rules, or changes in the future activities of RPI or other non-U.K. companies in which we hold an interest, directly or indirectly, may alter this position and could impact our group&#8217;s effective tax rate. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We believe that dividends received by us and RP Holdings should be exempt from U.K. corporation tax, but it cannot be guaranteed that this will continue to be the case. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. However, a number of conditions must be met in order for such dividends to qualify for this tax exemption, including (in respect of dividends paid by RPI, which are tax resident in Ireland) conditions relating to the application of Irish tax law. As such, it cannot be guaranteed that these conditions for the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.K. tax exemption in respect of distributions will continue at all times to be satisfied. If distributions received by us or by RP Holdings were not to fall within an exempt class, such distributions would likely be subject to U.K. corporation tax at the then prevailing corporation tax rate. </span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even where distributions fall within an exempt class, certain anti-avoidance and recharacterization rules may also apply. For instance, if RPI were to constitute an &#8220;offshore fund&#8221; for U.K. tax purposes that has at any time in an accounting period more than 60% by market value of its investments in debt securities, money placed at interest (other than cash awaiting investment), certain contracts for differences, or in holdings in other offshore funds with, broadly, more than 60% of their investments similarly invested, RP Holdings&#8217; shareholding in RPI may be subject to U.K. corporation tax as a deemed &#8220;loan relationship&#8221;, with the result that dividends received by RP Holdings from RPI could be subject to U.K. tax as deemed interest and RP Holdings may be subject to U.K. corporation tax on increases in the fair market value of its shareholding in RPI. The term &#8220;offshore fund&#8221; is defined for U.K. tax purposes through a characteristics-based approach and, broadly, can include arrangements constituted by a non-U.K. resident body corporate in which a reasonable investor would expect to be able to realize their investment entirely, or almost entirely, by reference to net asset value. We believe and have been advised that RP Holdings&#8217; shareholding in RPI should not fall within these rules, however no guarantee can be offered that this will continue to be the case. Changes to, or adverse interpretations of, the offshore funds rules, or changes in the nature of our investments, may alter this position and could impact our group&#8217;s effective rate. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Distributions that we pay to individual and other non-corporate U.S. Holders will not be eligible for taxation at reduced rates, which could potentially adversely affect the value of our Class A ordinary shares.</span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Distributions made to non-corporate U.S. Holders will not be eligible for taxation at reduced tax rates generally applicable to dividends paid by certain U.S. corporations and &#8220;qualified foreign corporations&#8221; because of our status as a passive foreign investment company (&#8220;PFIC&#8221;). The more favorable rates applicable to qualifying corporate dividends could cause individuals to perceive investment in our Class A ordinary shares to be less attractive than investment in the shares of other corporations because of our PFIC status, and this perception could adversely affect the value of our Class A ordinary shares.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">General Risk Factors</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cyber-attacks or other failures in telecommunications or information technology systems could result in information theft, data corruption and significant disruption of our business operations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We utilize information technology systems and networks to process, transmit and store electronic information in connection with our business activities. As use of digital technologies has increased, cyber incidents, including deliberate attacks and attempts to gain unauthorized access to computer systems and networks, have increased in frequency and sophistication. These threats pose a risk to the security of our systems and networks and the confidentiality, availability and integrity of our data. We have been subject to these attacks in the past and expect to be subject to them in the future. There can be no assurance that we will be successful in preventing cyber-attacks or mitigating their effects. Any cyber-attack or destruction or loss of data could adversely affect our business. In addition, we may suffer reputational harm or face litigation as a result of cyber-attacks or other data security breaches and may incur significant additional expense to implement further data protection measures. </span></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in the application of accounting standards issued by the U.S. Financial Accounting Standards Board or other standard-setting bodies may adversely affect our financial statements. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our financial statements are prepared in accordance with GAAP, which are periodically revised, interpreted and/or expanded. From time to time, we are required to adopt new or revised accounting standards issued by recognized authoritative bodies. It is possible that future accounting standards we are required to adopt may require changes to the current accounting treatment that we apply to our consolidated financial statements and may require us to make significant changes to our systems. Such changes could adversely affect our financial condition and results of operations. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The current outbreak of the novel coronavirus, or COVID-19, or the future outbreak of any other infectious or contagious diseases, could materially and adversely affect our results of operations, financial condition and cash flows. Further, the spread of the COVID-19 outbreak has caused severe disruptions in the U.S. and global economy and financial markets and could potentially create widespread business continuity issues of an as yet unknown magnitude and duration. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, a novel strain of coronavirus (COVID-19) was reported to have surfaced in Wuhan, China. COVID-19 has since spread to over 100 countries, including every state in the United States. On March 11, 2020, the World Health Organization declared COVID-19 a pandemic, and on March 13, 2020 the United States declared a national emergency with respect to COVID-19. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The outbreak of COVID-19 has severely impacted global economic activity and caused significant volatility and negative pressure in financial markets. The global impact of the outbreak has been rapidly evolving and many countries, including the United States, have reacted by instituting quarantines, mandating business and school closures and restricting travel. Many experts predict that the outbreak will trigger a period of global economic slowdown or a global recession. COVID-19 or another pandemic could have material and adverse effects on us due to, among other factors: </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a general decline in business activity; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the destabilization of the markets could negatively impact our partners in the biopharmaceutical industry and the sales of products generating our royalties; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">difficulty accessing the capital and credit markets on favorable terms, or at all, and a severe disruption and instability in the global financial markets, or deteriorations in credit and financing conditions which could affect our access to capital necessary to fund business operations or address maturing liabilities on a timely basis; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the potential negative impact on the health of our Manager&#8217;s highly qualified personnel, especially if a significant number of them are impacted; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a deterioration in our ability to ensure business continuity during a disruption; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">interruptions, shortages, delivery delays and potential discontinuation of supply to our partners, which could (i) delay the clinical trials of the development-stage product candidates underlying our assets and result in a loss of our market share for products generating our royalties or development-stage product candidates underlying our assets, if approved, and (ii) hinder our partners&#8217; ability to timely distribute products generating our royalties and satisfy customer demand; </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">travel restrictions, shelter-in-place policies or restrictions and other disruptions, which could cause or continue to cause delays and other direct impacts at our partners&#8217; manufacturing sites, which could impact the ability of our partners to manufacture development-stage product candidates underlying our biopharmaceutical assets and products generating our royalties; and </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">potential interruptions to our partners&#8217; clinical trial programs of development-stage product candidates underlying our biopharmaceutical assets, including: (i) the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns; (ii) changes in hospital or research institution policies or government regulations, which could delay or adversely impact our partners&#8217; ability to conduct their clinical trials; and (iii) pauses to or delays of trial procedures (particularly any procedures that may be deemed non-essential), patient dosing, shipment of our partners&#8217; development-stage product candidates, distribution of clinical trial materials, study monitoring, site inspections and data analysis due to reasons related to the pandemic, each of which could cause or continue to cause a disruption or delay to the development or the approval of development-stage product candidates underlying our biopharmaceutical assets. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To date, certain marketers of some of our portfolio products have commented that the performance of these products have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not resulted in a material effect to our results of operations and liquidity and we do not believe it is reasonably likely to in the future. Nevertheless, COVID-19 presents material uncertainty which could adversely affect our results of operations, financial condition and cash flows. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Legal claims and proceedings could adversely affect our business. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may be subject to a wide variety of legal claims and proceedings. Regardless of their merit, these claims can require significant time and expense to investigate and defend. Since litigation is inherently uncertain, there is no guarantee that we will be successful in defending ourselves against such claims or proceedings, or that our assessment of the materiality of these matters, including any reserves taken in connection therewith, will be consistent with the ultimate outcome of such matters. The resolution of, or increase in the reserves taken in connection with, one or more of these matters could adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:24.5pt"><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_22"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_25"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;PROPERTIES</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive offices are located at 110 East 59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Street, New York, NY 10022, and are provided by the Manager. We believe that our office facilities are suitable and adequate for our business as it is contemplated to be conducted.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_28"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, we may be a party to various claims, charges and litigation matters arising in the ordinary course of business. Management and legal counsel regularly review the probable outcome of such proceedings. While we cannot feasibly predict the outcome of these matters with certainty, we believe, based on examination of these matters, experience to date and discussions with counsel, that the ultimate liability, individually or in the aggregate, will not adversely affect our business, financial condition or results of operations.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_31"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_34"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. &#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;MARKET FOR THE REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Class A ordinary shares are traded in the Nasdaq Global Select Market under the symbol &#8220;RPRX&#8221;. Our Class B ordinary shares are not listed on any stock exchange nor traded on any public market. As of February 11, 2022, there were 2 shareholders of record of our Class A ordinary shares and 2 shareholders of record of our Class B ordinary shares. The number of record holders does not include persons who held our Class A ordinary shares in nominee or &#8220;street name&#8221; accounts through brokers or other institutions on behalf of shareholders. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Use of Proceeds</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Dividends</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the year ended December 31, 2021, we declared and paid four quarterly cash dividends of $0.17 per Class A ordinary share for an aggregate amount of $285.2 million to holders of our Class A ordinary shares. Future dividends are subject to declaration by the board of directors. To the extent approved and payable, we intend to pay dividends on or about March 15, June 15, September 15 and December 15 to holders of record on or about the twentieth day of each such prior month.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Item 12, &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; for information regarding securities authorized for issuance.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Stock Performance Graph</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph below compares the cumulative total stockholder return, calculated on a dividend-reinvested basis, on our Class A ordinary shares, the Standard &amp; Poor&#8217;s 500 Index (&#8220;S&amp;P 500&#8221;) and the Nasdaq Composite Index (&#8220;Nasdaq Composite&#8221;). The graph assumes an initial investment of $100 in our Class A ordinary shares at the market close on June 16, 2020, which was our initial trading day and its relative performance is tracked through December 31, 2021. The comparisons in the graph below are based upon historical data and are not indicative of, nor intended to forecast, future performance of our Class A ordinary shares.</span></div><div style="text-align:center"><img src="rprx-20211231_g4.jpg" alt="rprx-20211231_g4.jpg" style="height:350px;margin-bottom:5pt;vertical-align:text-bottom;width:780px"/></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above performance graph shall not be deemed soliciting material or to be filed with the SEC for purposes of Section 18 of the Exchange Act, nor shall such information be incorporated by reference into any of our other filings under the Exchange Act or the Securities Act.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Sales of Unregistered Securities</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no unregistered sales of equity securities in the year ended December 31, 2021.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Issuer Purchases of Equity Securities</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i15fafc99ab5c41deb08ee816ca47172c_40"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Reserved</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-27pt"><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_43"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;MANAGEMENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) is intended to help the reader understand our results of operations and financial condition, cash flows and other changes in financial condition. MD&amp;A is provided as a supplement to, and should be read in conjunction with, our audited consolidated financial statements and the accompanying notes to our consolidated financial statements included in our Annual Report on Form 10-K. This discussion may contain forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in Special Note Regarding Forward-Looking Statements and the section titled &#8220;Risk Factors&#8221; in Part I, Item 1A.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Royalty Pharma plc is an English public limited company incorporated under the laws of England and Wales that was created for the purpose of consolidating our predecessor entities and facilitating the initial public offering (&#8220;IPO&#8221;) of our Class A ordinary shares that was completed in June 2020. &#8220;Royalty Pharma,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Royalty Pharma plc and its subsidiaries on a consolidated basis. After the consummation of the Exchange Offer Transactions (as defined below) and execution of the Management Agreement (collectively, the &#8220;Reorganization Transactions&#8221;) in February 2020 and before the consummation of the IPO, &#8220;Royalty Pharma,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Royalty Pharma Investments 2019 ICAV (&#8220;RPI 2019 ICAV&#8221;). Prior to the Reorganization Transactions, &#8220;Royalty Pharma,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Royalty Pharma Investments, an Irish unit trust (&#8220;Old RPI&#8221;). </span></div><div><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Business Overview </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry&#8217;s leading therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson &amp; Johnson&#8217;s Imbruvica, Astellas and Pfizer&#8217;s Xtandi, Biogen&#8217;s Tysabri, Johnson &amp; Johnson&#8217;s Tremfya, Gilead&#8217;s Trodelvy, Merck&#8217;s Januvia, Novartis&#8217; Promacta, Vertex&#8217;s Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates. We fund innovation in the biopharmaceutical industry both directly and indirectly - directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our capital-efficient business model enables us to benefit from many of the most attractive characteristics of the biopharmaceutical industry, including long product life cycles, significant barriers to entry and noncyclical revenues, but with substantially reduced exposure to many common industry challenges such as early stage development risk, therapeutic area constraints, high research and development costs, and high fixed manufacturing and marketing costs. We have a highly flexible approach that is agnostic to both therapeutic area and treatment modality, allowing us to acquire royalties on the most attractive therapies across the biopharmaceutical industry.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We classify our royalty acquisitions by the approval status of the therapy at the time of acquisition: </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Approved Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; We acquire royalties in approved products that generate predictable cash flows and may offer upside potential from unapproved indications. Since inception in 1996 through 2021, we have deployed $15.0 billion of cash to acquire royalties on approved products. From 2012 through 2021, we have acquired $10.2 billion of royalties on approved products. </span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Development-Stage Product Candidates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; We acquire royalties on development-stage product candidates that have demonstrated strong clinical proof of concept. From 2012, when we began acquiring royalties on development-stage product candidates, through 2021, we have deployed $7.8 billion to acquire royalties on development-stage product candidates. </span></div><div style="text-indent:55.05pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While we classify our acquisitions in these two broad categories, several of our acquisitions of royalties on approved products were driven by the long-term potential of these products in other, unapproved indications. Similarly, some of our royalty acquisitions in development-stage product candidates are for products that are approved in other indications. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We acquire product royalties in a variety of ways that can be tailored to the needs of our partners. We classify our product royalty acquisitions according to the following structures: </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Third-party Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; A royalty is the contractual right to a percentage of top-line sales from a licensee&#8217;s use of a product, technology or intellectual property. The majority of our current portfolio consists of third-party royalties. </span></div><div style="padding-left:67.5pt;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Synthetic/Hybrid Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; A synthetic royalty is the contractual right to a percentage of top-line sales created by the developer and/or marketer of a therapy in exchange for funding. A synthetic royalty may also include contingent milestone payments, or be structured as a long-term stream of fixed-payments with a predetermined schedule. In many of our synthetic royalties, we may also make investments in the public equity of the company, where the main value driver of the company is the product on which we concurrently acquired a royalty. </span></div><div style="padding-left:67.5pt;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Research &amp; Development (&#8220;R&amp;D&#8221;) Funding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; We have historically funded ongoing R&amp;D, typically for large biopharmaceutical companies, in exchange for future royalties and/or milestones if the product or indication we are funding is approved. We have also made upfront R&amp;D payments to biotechnology companies to acquire royalties and/or milestones on development-stage product candidates.</span></div><div style="padding-left:31.5pt;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">M&amp;A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; We acquire royalties in connection with M&amp;A transactions, often from the buyers of biopharmaceutical companies when they dispose of the non-strategic assets of the target company following the closing of the acquisition. We also seek to partner with companies to acquire other biopharmaceutical companies that own significant royalties. We may also seek to acquire biopharmaceutical companies that have significant royalties or where we can create royalties in subsequent transactions.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Background and Format of Presentation </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with our IPO, we consummated an exchange offer on February 11, 2020 (the &#8220;Exchange Date&#8221;). Through the exchange offer, investors representing 82% of the aggregate limited partnership in the various partnerships owned by Old RPI (the &#8220;Legacy Investors Partnerships&#8221;), exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in RPI US Partners 2019, LP, a Delaware limited partnership or RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the &#8220;Continuing Investors Partnerships&#8221;). The exchange offer transaction together with (i) the concurrent incurrence of indebtedness under a new credit facility and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the &#8220;Exchange Offer Transactions.&#8221; </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following our IPO, we operate and control the business affairs of Royalty Pharma Holdings Ltd, (&#8220;RP Holdings&#8221;) through our controlling ownership of RP Holdings&#8217; Class A ordinary shares (the &#8220;RP Holdings Class A Interests&#8221;) and RP Holdings&#8217; Class B ordinary shares (the &#8220;RP Holdings Class B Interests&#8221;). We include RP Holdings and its subsidiaries in our consolidated financial statements. RP Holdings is the sole owner of RPI 2019 ICAV, which is an Irish collective asset management entity formed to facilitate our Exchange Offer Transactions. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of the Exchange Offer Transactions, we own, through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (&#8220;RPI Intermediate FT&#8221;), an 82% economic interest in Old RPI. Through our 82% indirect ownership of Old RPI, we are legally entitled to 82% of the economics of Old RPI&#8217;s wholly-owned subsidiaries, RPI Finance Trust, a Delaware statutory trust (&#8220;RPIFT&#8221;) and RPI Acquisitions (Ireland), Limited (&#8220;RPI Acquisitions&#8221;), an Irish private limited company, and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (&#8220;RPCT&#8221;). </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (&#8220;RPSFT&#8221;), which is wholly owned by Royalty Pharma Select, an Irish unit trust. From the Exchange Date until the expiration of the Legacy Investors Partnerships&#8217; investment period on June 30, 2020 (the &#8220;Legacy Date&#8221;), the Legacy Investors Partnerships had the option to participate proportionately in any investment made by Old RPI. Following the Legacy Date, Old RPI ceased making new investments and each of Old RPI and the Legacy Investors Partnerships became legacy entities. Following the Legacy Date, we have made and plan to make new investments solely through our subsidiaries. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following management&#8217;s determination that a high degree of common ownership exists in Royalty Pharma both before and after the Exchange Date, Royalty Pharma recognized Old RPI&#8217;s assets and liabilities at the carrying value reflected on Old RPI&#8217;s balance sheet as of the Exchange Date. Old RPI is our predecessor for financial reporting purposes. The results of operations in the following discussion is comprised of the financial results of Old RPI prior to the Reorganization Transactions, RPI 2019 ICAV subsequent to the Reorganization Transactions and before the consummation of the IPO, and Royalty Pharma plc subsequent to the consummation of the IPO. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Understanding Our Financial Reporting </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with U.S. GAAP, most of the royalties we acquire are treated as investments in cash flow streams and are thus classified as financial assets. These investments have yield components that most closely resemble loans measured at amortized cost under the effective interest accounting methodology. Under this accounting methodology, we calculate the effective interest rate on each financial royalty asset using a forecast of the expected cash flows to be received over the life of the financial royalty asset relative to the initial acquisition price. The yield, which is calculated at the end of each reporting period and applied prospectively, is then recognized via accretion into our income at the effective rate of return over the expected life of the financial royalty asset. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of our financial statements in this manner requires the use of estimates, judgments and assumptions that affect both our reported assets and liabilities and our income and revenue and expenses. The most significant judgments and estimates applied by management are associated with the measurement of income derived from our financial royalty assets, including management&#8217;s judgment in forecasting the expected future cash flows of the underlying royalties and the expected duration of the financial royalty asset. Our cash flow forecasts are generated and updated each reporting period by manually compiling sell-side equity research analysts&#8217; consensus sales estimates for each of the products in which we own royalties. We then calculate our expected royalty cash flows using these consensus sales forecasts. In any given reporting period, any decline or increase in the expected future cash flows associated with a financial royalty asset is recognized in our income statement as non-cash provision expense or provision income, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of the non-cash charges associated with applying the effective interest method accounting methodology, our income statement activity in respect of many of our royalties can be volatile and unpredictable. Small declines in sell-side equity research analysts&#8217; consensus sales forecasts over a long time horizon can result in an immediate non-cash income statement expense recognition, even though the applicable cash inflows will not be realized for many years into the future. For example, in late 2014 we acquired the cystic fibrosis franchise royalty, which is classified as a financial royalty asset. Beginning in the second quarter of 2015, declines in near-term sales forecasts of sell-side equity research analysts caused us to recognize non-cash provision expenses to the income statement and build up a corresponding cumulative allowance which reduced the gross balance for this financial royalty asset. Over the course of 10 quarters, we recognized non-cash provision expenses as a result of these changes in forecasts including non-cash provision expense of $743.2 million in 2016, ultimately reaching a peak cumulative allowance of $1.30 billion by September 30, 2017 related to this financial royalty asset. With the approval of the Vertex triple combination therapy, Trikafta, in October 2019, sell-side equity research analysts&#8217; consensus sales forecasts increased to reflect the larger addressable market and the extension of the expected duration of the Trikafta royalty. While small reductions in the cumulative allowance for the cystic fibrosis franchise were recognized as provision income in 2017 and 2018, there remained a $1.10 billion cumulative allowance that was fully reduced by $1.10 billion recognized in 2019 as a result of an increase in sell-side equity research analysts&#8217; consensus sales forecasts associated with the Trikafta approval. This example illustrates the volatility caused by our accounting model. Therefore, management believes investors should not look to income from royalties and the associated provision for changes in future cash flows as a measure of our near-term financial performance or as a source for predicting future income or growth trends. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operations have historically been financed primarily with cash flows generated by our royalties. Due to the nature of our accounting methodology for our financial royalty assets, there is no direct correlation between our income from royalties and our royalty receipts. As noted above, income from such royalties is measured at amortized cost under the effective interest method accounting methodology. Given the importance of cash flows and their predictability to management&#8217;s operation of the business, management uses royalty receipts as the primary measure of our operating performance. Royalty receipts refer to the summation of the following line items from our GAAP Statement of Cash Flows: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cash collections from financial royalty assets, Cash collections from intangible royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other royalty cash collections, Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Distributions from non-consolidated affiliates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to analyzing our results on a GAAP basis, management also reviews our results on a non-GAAP basis. The closest comparable GAAP measure to each of the non-GAAP measures that management review is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The key non-GAAP metrics we focus on are Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow, each of which is further discussed in the section titled &#8220;Non-GAAP Financial Results.&#8221; </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjusted Cash Receipts and Adjusted Cash Flow are used by management as key liquidity measures in the evaluation of our ability to generate cash from operations. Both measures are an indication of the strength of the Company and the performance of the business. Management uses Adjusted Cash Flow to compare its performance against non-GAAP adjusted net income used by companies in the biopharmaceutical industry. Adjusted EBITDA, which is derived from Adjusted Cash Receipts, is used by our lenders to assess our ability to meet our financial covenants. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Refer to the section titled &#8220;Non-GAAP Reconciliations&#8221; for additional discussion of management&#8217;s use of non-GAAP measures as supplemental financial measures.</span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_55"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Portfolio Overview </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our portfolio consists of royalties on more than 35 marketed therapies and ten development-stage product candidates. The therapies in our portfolio address therapeutic areas such as rare disease, cancer, neurology, infectious disease, hematology and diabetes, and are delivered to patients across both primary and specialty care settings. The&#160;&#160;&#160;&#160; table below includes royalty receipts for the years ended December 31, 2021 and 2020 in order of contributions to royalty receipts for the year ended December 31, 2021.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty Receipts</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketer(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Therapeutic Area</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Products</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">702,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biogen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345,845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AbbVie, Johnson &amp; Johnson</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">322,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hematology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pfizer, Astellas</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Januvia, Janumet, Other DPP-IVs (2)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merck &amp; Co., others</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HIV franchise (3)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gilead, others</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Infectious disease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nurtec ODT/Biohaven payment (4)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biohaven, Pfizer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merck &amp; Co.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Infectious disease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Farxiga/Onglyza </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &amp; Johnson</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cabometyx/Cometriq</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exelixis, Ipsen, Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Crysvita</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ultragenyx, Kyowa Kirin</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Roche</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emgality</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lilly</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Erleada</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &amp; Johnson</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IDHIFA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bristol Myers Squibb</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orladeyo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BioCryst</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tazverik</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Epizyme</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Oxlumo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alnylam</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rare disease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other products (5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total royalty receipts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,608,542</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,344,399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(1) The cystic fibrosis franchise includes the following approved products: Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(2) Januvia, Janumet, Other DPP-IVs include the following approved products: Tradjenta, Onglyza, Kombiglyze, Galvus, Eucreas and Nesina. The Other DPP-IVs are marketed by Boehringer Ingelheim, AstraZeneca, Novartis and Takeda.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(3) The HIV franchise includes the following approved products: Atripla, Truvada, Emtriva, Complera, Stribild, Genvoya, Descovy, Odefsey, Symtuza and Biktarvy. Royalties are received on the emtricitabine portion of sales only.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(4) Includes royalty receipts for Nurtec ODT of $7.7&#160;million for the year ended December 31, 2021 and quarterly redemptions of $15.6 million of the Series A Biohaven Preferred Shares (presented as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> on the Statement of Cash Flows) in 2021. For the year ended December 31, 2020, the amount also includes a payment from Biohaven in respect of an expired option to exercise additional funding of the Biohaven Series A Preferred Shares which is presented as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> on the Statement of Cash Flows in 2020.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(5) Other products primarily include royalties on the following products: Bosulif (a product co-developed by our joint venture investee, Avillion, for which receipts are presented as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Distributions from non-consolidated affiliates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> on the Statement of Cash Flows), Lexiscan, Soliqua, Nesina, Cimzia, Letairis, Entyvio, Myozyme, Mircera and Lyrica. Other products for the year ended December 31, 2021 includes a one-time milestone payment of $45.0 million that we received on Soliqua. Other products for the year ended December 31, 2020 includes a one-time $21.3 million distribution from Avillion in respect of the Merck KGaA Asset (defined below) for which the receipt is presented as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Distributions from non-consolidated affiliates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> in both the operating and investing section of the Statement of Cash Flows. Subsequent to the Exchange Offer Transactions, other products also includes contributions from the Legacy SLP Interest (defined below).</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Financial highlights </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18.3pt">Net cash provided by operating activities totaled $2.0 billion, $2.0 billion and $1.7 billion for the years ended December 31, 2021, 2020 and 2019, respectively. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> is the closest comparable GAAP financial measure to the supplemental non-GAAP liquidity measures that follow. </span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">Adjusted Cash Receipts (a non-GAAP metric) totaled $2.1&#160;billion, $1.8&#160;billion and $2.1&#160;billion for the years ended December 31, 2021, 2020 and 2019, respectively.  </span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18.3pt">Adjusted EBITDA (a non-GAAP metric) totaled $1.9&#160;billion, $1.6&#160;billion and $2.0&#160;billion for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18.3pt">Adjusted Cash Flow (a non-GAAP metric) totaled $1.8&#160;billion, $1.5&#160;billion and $1.6&#160;billion for the years ended December 31, 2021, 2020 and 2019, respectively.  </span></div><div><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Understanding Our Results of Operations </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with our IPO, Royalty Pharma plc became a holding company whose principal asset is a controlling equity interest in RP Holdings, which is the sole equity owner of RPI 2019 ICAV, an entity that is included in our consolidated financial statements. We report non-controlling interest related to four minority interests in our subsidiaries held by third parties. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1. &#160;&#160;&#160;&#160;The first minority interest is attributable to the Legacy Investors Partnerships&#8217; 18% ownership interest in Old RPI. The value of this non-controlling interest will decline over time as the assets in Old RPI expire. </span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2. &#160;&#160;&#160;&#160;The second minority interest is attributable to the RP Holdings Class C ordinary share (the &#8220;RP Holdings Class C Special Interest&#8221;) held by RPI EPA Holdings, LP  (&#8220;EPA Holdings&#8221;), an affiliate of the Manager. Income will not be allocated to this non-controlling interest until certain conditions are met. </span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3. &#160;&#160;&#160;&#160;The third minority interest is attributable to the RP Holdings Class B Interests held indirectly by the Continuing Investors Partnerships, which represent an approximate 29% ownership interest in RP Holdings as of December 31, 2021 and are exchangeable for our Class A ordinary shares. The value of this non-controlling interest will decline over time if the investors who indirectly own the RP Holdings Class B Interests conduct exchanges for our Class A ordinary shares. During the year ended December 31, 2021, 44,763&#160;thousand RP Holdings Class B Interests were exchanged for our Class A ordinary shares.</span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4. &#160;&#160;&#160;&#160;The fourth minority interest is attributable to a de minimis interest in RPCT held by RPSFT as a result of a 2011 reorganization transaction. The value of this non-controlling interest will decline over time as the royalty assets owned by RPCT expire and is expected to be substantially eliminated by the end of 2022. </span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fourth non-controlling interest related to ownership in RPCT held by RPSFT, is the only non-controlling interest that existed prior to the Exchange Offer Transactions and is reflected in our financial statements through December 31, 2019. The non-controlling interest related to the Legacy Investors Partnerships&#8217; 18% ownership interest in Old RPI is reflected in our financial statements from and after the Exchange Date. The other two non-controlling interests are reflected in our financial statements from and after the date of our IPO. All of the results of operations of RP Holdings, Old RPI and RPCT are consolidated into our financial statements. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following the IPO, EPA Holdings is entitled to receive Equity Performance Awards through its RP Holdings Class C Special Interest. Equity Performance Awards owed to EPA Holdings will be recognized as an equity transaction when the obligation becomes due and will impact the income allocated to non-controlling interest related to the RP Holdings Class C Special Interest at that time. We do not currently expect any material Equity Performance Awards to be payable until certain performance conditions are met, which we do not expect to occur until the mid-2020s. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Total income and other revenues </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total income and other revenues is primarily comprised of income from our financial royalty assets, royalty revenue from our intangible royalty assets, and royalty income arising from successful commercialization of products developed through joint R&amp;D funding arrangements. Most of our royalties on both approved products and development-stage product candidates that are not accounted for as R&amp;D funding expense are classified as financial assets as our ownership rights are generally passive in nature. In instances in which we acquire a royalty  that does include more substantial rights or ownership of the underlying intellectual property, we classify such royalties as intangible assets. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognize interest income related to our financial royalty assets. Royalty revenue relates solely to revenue from our DPP-IV patent estate for which the patent rights have been licensed to various counterparties. For the years ended December 31, 2021 and 2020, the royalty payors accounting for greater than 10% of our total income and other revenues in any one year are shown in the table below: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.461%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.938%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty Payor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AbbVie</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HIV franchise, Letairis, Lexiscan, Trodelvy (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biogen</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(1) We began recognizing income related to Trodelvy in the three months ended June 30, 2020. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">*Represents less than 10%.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">     Income from financial royalty assets </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our financial royalty assets represent investments in cash flow streams with yield components that most closely resemble loans measured at amortized cost under the effective interest method. We calculate the effective interest rate using forecasted expected cash flows to be received over the life of the royalty asset relative to the initial acquisition price. Interest income is recognized at the effective rate of return over the expected life of the asset, which is calculated at the end of each reporting period and applied prospectively. As changes in sell-side equity research analysts&#8217; consensus sales estimates are updated on a quarterly basis, the effective rate of return changes. For example, if sell-side equity research analysts&#8217; consensus sales forecasts increase, the yield to derive income on a financial royalty asset will increase and result in higher income for subsequent periods.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Variables affecting the recognition of interest income from financial royalty assets on individual products under the prospective effective interest method include any one of the following: (1) additional acquisitions, (2) changes in expected cash flows of the underlying pharmaceutical products, derived primarily from sell-side equity research analysts&#8217; consensus sales forecasts, (3) regulatory approval of additional indications which leads to new cash flow streams, (4) changes to the estimated duration of the royalty (i.e., patent expiration date) and (5) changes in amounts and timing of projected royalty receipts and milestone payments. Our financial royalty assets are directly linked to sales of underlying pharmaceutical products whose life cycle typically peaks at a point in time, followed frequently by declining sales trends due to the entry of generic competition, resulting in natural declines in the asset balance and periodic interest income over the life of our royalties. The recognition of interest income from royalties requires management to make estimates and assumptions around many factors, including those impacting the variables noted above. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">     Revenue from intangible royalty assets </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from intangible royalty assets is derived from sales of Januvia, Janumet and other DPP-IV products by our licensees.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">     Other royalty income </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other royalty income includes primarily income from financial royalty assets that have been fully amortized by the expected expiry date and royalty income from synthetic royalties arising out of R&amp;D funding arrangements. Occasionally, a royalty asset may be amortized on an accelerated basis due to collectability concerns, which, if resolved, may result in future cash collections when no financial royalty asset remains. Similarly, we may continue to collect royalties on a financial royalty asset beyond the estimated patent expiration date by which the financial asset was amortized in full. In each scenario where a financial royalty asset has been fully amortized, income from such royalty is recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other royalty income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Provision for changes in expected cash flows from financial royalty assets </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The provision for changes in expected future cash flows from financial royalty assets includes the following: </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">the movement in the cumulative allowance for changes in expected future cash flows; and </span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">expense or income related to the provision for current expected credit losses subsequent to adoption of ASU 2016-13 on January 1, 2020. </span></div><div style="text-indent:55.05pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The provision for changes in expected cash flows is the current period activity resulting from adjustments to the cumulative allowance for changes in expected cash flows, which is netted against the non-current portion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">balance on the consolidated balance sheets. As discussed above, income is accreted on our financial royalty assets using the effective interest method. As we update our forecasted cash flows on a periodic basis and recalculate the present value of the remaining future cash flows, any shortfall when compared to the carrying value of the financial royalty asset is recorded directly to the income statement through the line item </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Provision for changes in expected cash flows from financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. If, in a subsequent period, there is an increase in expected cash flows or if actual cash flows are greater than cash flows previously expected, we reduce the cumulative allowance previously established for a financial royalty asset for the incremental increase in the present value of cash flows expected to be collected. This results in provision income (i.e., a credit to the provision). </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Most of the same variables and management&#8217;s estimates affecting the recognition of interest income on our financial royalty assets also impact the provision. In any period, we will recognize provision income or expense as a result of the following factors: (1) changes in expected cash flows of the underlying pharmaceutical products, derived primarily from sell-side equity research analysts&#8217; consensus sales forecasts, (2) regulatory approval of additional indications which leads to new cash flow streams, (3) changes to the estimated duration of the royalty (i.e., patent expiration date) and (4) changes in amounts and timing of projected royalty receipts and milestone payments. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon the adoption on January 1, 2020 of ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;ASU 2016-13&#8221;), we recorded a cumulative adjustment to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Retained earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of $192.7 million to recognize an allowance for current expected credit losses on our portfolio of financial royalty assets. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Provision for changes in expected cash flows from financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> reflects the activity for the period, primarily new financial royalty assets with limited protective rights and changes in the underlying cash flow forecasts used in the effective interest model to measure income from our financial royalty assets. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">R&amp;D funding expense </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">R&amp;D funding expense consists of upfront and ongoing R&amp;D payments we have made to counterparties to acquire royalties and/or milestones on development-stage product candidates. Ongoing R&amp;D payments are made as the related development-stage product candidates undergo clinical trials with our counterparties. These expenditures relate to the activities performed by our counterparties to develop and test new products, to test existing products for treatment in new indications, and to ensure product efficacy and regulatory compliance prior to launch. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">General and administrative expenses </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative (&#8220;G&amp;A&#8221;) expenses include primarily Operating and Personnel Payments, legal expenses, other expenses for professional services and share-based compensation. The expenses incurred in respect of Operating and Personnel Payments are expected to comprise the most significant component of G&amp;A expenses on an ongoing basis. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Management Agreement, we pay Operating and Personnel Payments equal to 6.5% of the Adjusted Cash Receipts for each quarter and 0.25% of the value of our security investments under GAAP as of the end of each quarter. The operating and personnel payments for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected in our consolidated net income, are payable in equal quarterly installments and calculated as the greater of $1 million per quarter and 0.3125% of royalties from Royalty Investments (as defined in the limited partnership agreements of the Legacy Investors Partnerships) during the previous twelve calendar months. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prior to the Exchange Date, operating and personnel payments were fixed and grew at 5% annually and were not linked to any financial line item. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Equity in losses/(earnings) of non-consolidated affiliates </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Legacy SLP Interest </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Exchange Offer Transactions, we acquired an equity method investment from the Continuing Investors Partnerships in the form of a special limited partnership interest in the Legacy Investors Partnerships (the &#8220;Legacy SLP Interest&#8221;) in exchange for issuing shares in our subsidiary. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and a performance income allocation on a similar basis. The performance income allocation attributable to us is equal to the general partner&#8217;s former contractual rights to the income of the Legacy Investors Partnerships. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As the Legacy Investors Partnerships no longer participate in investment opportunities, the value of the Legacy SLP Interest is expected to decline over time. Our equity method investee, the Legacy Investors Partnerships, also owns a non-controlling interest in Old RPI. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The Avillion Entities</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Avillion entities (as defined below) partner with global biopharmaceutical companies to perform R&amp;D in exchange for success-based milestones and/or royalties once products are commercialized. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2017, our equity method investee Avillion Financing I, LP (&#8220;Avillion I&#8221;) received U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of a supplemental New Drug Application for Pfizer&#8217;s Bosulif to expand its label into front-line chronic myeloid leukemia, which triggered a series of contractual fixed payments from Pfizer to Avillion I over a 10-year period, which we recognize through receipt of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Distributions from non-consolidated affiliates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the Statement of Cash Flows. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2019, we entered into an amended agreement with BAv Financing II, LP (&#8220;Avillion II&#8221;, or, together with Avillion I, the &#8220;Avillion Entities&#8221;), to invest $19.0&#160;million to fund approximately 50% of the costs of a Phase 2 clinical trial for the use of Merck KGaA&#8217;s anti-IL 17 nanobody M1095 (the &#8220;Merck KGaA Asset&#8221;) for the treatment of psoriasis in exchange for certain milestone and royalty payments. During 2020, our involvement in the development for the Merck KGaA Asset ceased. We do not expect to record significant earnings or losses in the future related to this investment.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2021, we entered into an amended agreement with Avillion II to increase our investment from $105.0 million to $122.5 million over multiple years to fund a portion of the costs for Phase 2 and 3 clinical trials of Avillion II, which is a party to a co-development agreement with AstraZeneca to advance PT027 through a global clinical development program for the treatment of asthma in exchange for royalties, a series of success-based milestones, and other potential payments. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other expense/(income), net </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other expense/(income), net primarily includes the change in fair market value of our equity securities and the unrealized (gains)/losses on our available for sale debt securities, including related forwards and derivatives. Other expense/(income), net also includes losses on extinguishment of debt and interest income. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:12.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net income attributable to non-controlling interest </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subsequent to our IPO, net income attributable to non-controlling interest includes the RP Holdings Class B Interests held by the Continuing Investors Partnerships and will include net income attributable to the Class C Special Interest held by EPA Holdings once certain conditions have been met. Future net income attributable to the non-controlling interest related to the RP Holdings Class B Interests held by the Continuing Investors Partnerships will decline over time if the investors who indirectly own the RP Holdings Class B Interests conduct exchanges for our Class A ordinary shares. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of and following the Exchange Date, the net income attributable to non-controlling interest also includes the Legacy Investors Partnerships</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> approximately 18% share of earnings in Old RPI. As the Legacy Investors Partnerships no longer participate in investment opportunities, the related net income attributable to this non-controlling interest is expected to decline over time. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net income attributable to non-controlling interest also includes RPSFT&#8217;s 20% share of earnings in RPCT, which is a consolidated subsidiary of Old RPI. We expect net income attributable to this non-controlling interest to decline over time as the royalty assets owned by RPCT expire and to be substantially eliminated by the end of 2022.  </span></div><div><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In this section, we discuss the results of our operations for the year ended December 31, 2021 compared to the year ended December 31, 2020. For a discussion of the year ended December 31, 2020 compared to the year ended December 31, 2019, please refer to Part II, Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The comparison of our historical results of operations for the years ended December 31, 2021 and 2020 is as follows: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 vs. 2020 Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income and other revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from financial royalty assets </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,065,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,959,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from intangible royalty assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total income and other revenues </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,289,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,122,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167,110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for changes in expected cash flows from financial royalty assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">222,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development funding expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">661.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(65,053)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">858,748&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">526,954&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">331,794&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,430,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,595,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(164,684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other expense/(income)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in losses/(earnings) of non-consolidated affiliates </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44,459)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(143.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other expense/(income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(219,155)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">223,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(101.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other expense/(income), net </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">189,514&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(106,555)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296,069&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(277.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consolidated net income </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,241,201&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,701,954&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(460,753)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interest </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621,473&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">726,914&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(105,441)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to controlling interest </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">619,728&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">975,040&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(355,312)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Total income and revenues </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income from financial royalty assets </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income from financial royalty assets by product for our top products for the years ended December 31, 2021 and 2020 is as follows, in order of contribution to income for the year ended December 31, 2021. </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 vs. 2020 Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">762,885&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">611,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,937&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,935)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,948)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tazverik</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">453,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">520,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66,908)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total income from financial royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,065,083&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,959,975&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,108&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income from financial royalty assets increased by $105.1&#160;million, or 5.4%, in the year ended December 31, 2021 compared to the year ended December 31, 2020, primarily driven by the performance of the cystic fibrosis franchise, including additional interest income attributable to the residual royalty interest that we acquired in the three months ended December 31, 2020. We also recorded $57.0&#160;million in income in the year ended December 31, 2021 related to newly acquired assets in 2021, primarily Cabometyx/Cometriq, Tremfya and Oxlumo. The increase in income was partially offset by declines from the maturity of our royalties from the HIV franchise. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue from intangible royalty assets </span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from intangible royalty interests increased by $27.9&#160;million, or 19.4%, in the year ended December 31, 2021 compared to the year ended December 31, 2020, primarily related to the expected recovery of underpaid royalties on Tradjenta of approximately $16.5 million based on a legal judgment received in a litigation with Boehringer Ingelheim. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other royalty income </span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other royalty income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">increased</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> by $34.1&#160;million, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">179.7%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the year ended December 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the year ended December 31, 2020,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> driven primarily by increased income from Nurtec ODT and Trodelvy that arose from our R&amp;D funding agreements with Biohaven and Immunomedics, respectively. Other royalty income in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">year ended December 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> also includes income from the HIV franchise, a fully amortized financial royalty asset, and Letairis, which was also fully amortized, but for which we expect minimal residual royalty income. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Provision for changes in expected cash flows from financial royalty assets </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The breakdown of our provision for changes in expected future cash flows includes the following: </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">movement in the cumulative allowance for changes in expected future cash flows; and </span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:19pt">expense or income related to the provision for current expected credit losses subsequent to adoption of ASU 2016-13 on January 1, 2020. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As the former activity is a combination of income and expense items, the provision breakdown by product, exclusive of the provision for current expected credit losses, is as follows, based on the largest contributors to each year&#8217;s provision income or expense: </span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:38.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.756%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tazverik</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IDHIFA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emgality</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Soliqua</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96,103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(187,059)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total provision, exclusive of provision for credit losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">465,755</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total provision, exclusive of provision for credit losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">74,653</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for current expected credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,913)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for current expected credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total provision expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">452,842</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total provision expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">230,839</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the year ended December 31, 2021, we recorded total provision expense of $452.8&#160;million, of which $465.8&#160;million and $12.9&#160;million related to provision expense for changes in expected cash flows and provision income for current expected credit losses, respectively. We recorded provision expense for Tazverik, Imbruvica, Emgality and the cystic fibrosis franchise, primarily due to significant declines in sell-side research analysts&#8217; consensus sales forecasts. The provision expense was partially offset by provision income from a significant increase in sell-side equity research analysts&#8217; consensus sales forecasts for Tysabri. The current expected credit loss activity in the year ended December 31, 2021 resulted in provision income that was primarily driven by a significant decrease in current expected credit losses related to Tazverik as a result of the corresponding significant decline in the financial asset value. This was partially offset by provision expense for credit losses recognized as a result of the increases to our portfolio of financial royalty assets with limited protective rights, primarily related to zavegepant from a $100.0 million funding payment we made to Biohaven upon the start of the oral zavegepant Phase 3 program and a new royalty interest in Cabometyx/Cometriq. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the year ended December 31, 2020, we recorded total provision expense of $230.8&#160;million, of which $74.7&#160;million and $156.2&#160;million related to provision expense for changes in expected cash flows and provision expense for current expected credit losses, respectively. We recorded provision expense for IDHIFA, which was acquired in the year ended December 31, 2020, and for Imbruvica and Tysabri due to declines in sell-side research analysts&#8217; consensus sales forecasts. The provision expense was partially offset by provision income from a significant increase in sell-side equity research analysts&#8217; consensus sales forecasts for Xtandi. We recognized provision expense for current expected credit losses as a result of our adoption of the new accounting standard in the year ended December 31, 2020. The provision expense for current expected credit losses in the year ended December 31, 2020 was driven primarily by certain additions to our portfolio of financial royalty assets, including the additional tranche of Tazverik and our acquisition of the zavegepant royalty. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">R&amp;D funding expense </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">R&amp;D funding expense incurred in the year ended December 31, 2021 was comprised of $193.2&#160;million in upfront R&amp;D funding and $6.9&#160;million in ongoing R&amp;D expenses, primarily under our co-funding agreement with Sanofi. The increase of R&amp;D funding expense of $173.8&#160;million, or 661.1%, in the year ended December 31, 2021 as compared to the year ended December 31, 2020 was primarily driven by upfront R&amp;D funding of $103.2&#160;million related to an additional royalty on a development-stage product that we acquired from BioCryst in November 2021 and $90.0 million related to royalties on two development-stage products acquired from MorphoSys in July 2021. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">R&amp;D funding expense incurred in the year ended December 31, 2020 was comprised of $20.5 million in ongoing development-stage funding payments, primarily under our co-funding agreement with Sanofi, and $5.8 million in upfront funding related to a royalty on a development-stage product that we acquired from BioCryst. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">G&amp;A expenses </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">G&amp;A expenses were relatively flat in the year ended December 31, 2021 compared to the year ended December 31, 2020. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other operating expenses </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other operating expenses were $65.1&#160;million in the year ended December 31, 2020 due to the recognition of a non-cash impairment charge related to the write-off of our omecamtiv mecarbil financial royalty asset balance of $90.2 million, net of cumulative allowance of $25.2 million. During the three months ended December 31, 2020, it was announced that omecamtiv mecarbil, a development stage product, did not meet the clinical trial objectives. There was no comparable activity in the year ended December 31, 2021.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Equity in losses/(earnings) of non-consolidated affiliates </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recorded equity in losses of non-consolidated affiliates of $19.5&#160;million for the year ended December 31, 2021 compared to equity in earnings of non-consolidated affiliates of 44.5 million for the year ended December 31, 2020. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equity in earnings of the Legacy SLP Interest was $8.9&#160;million and $62.0&#160;million during the years ended December 31, 2021 and 2020, respectively. Equity in losses of the Avillion Entities was $28.4&#160;million and $17.6&#160;million during the years ended December 31, 2021 and 2020, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest expense </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest expense increased by $9.1&#160;million, or 5.8%, in the year ended December 31, 2021 as compared to the year ended December 31, 2020, primarily driven by interest expense related to the $1.3 billion senior unsecured notes issued in July 2021 (&#8220;2021 Notes&#8221;) offset by the lower interest expense related to the $6.0 billion senior unsecured notes issued in September 2020 (the &#8220;2020 Notes&#8221;), which had a lower weighted average interest rate compared to the senior secured credit facilities that were in place during the year ended December 31, 2020. We refer to the 2020 Notes and 2021 Notes, collectively, as the &#8220;Notes&#8221;.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Refer to the &#8220;Liquidity and Capital Resources&#8221; section for additional discussion of the Notes and our debt refinancings in 2020. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other expense/(income), net </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other expense, net of $3.9&#160;million in the year ended December 31, 2021 was primarily comprised of net losses on equity securities of $48.1&#160;million, including losses on MorphoSys ordinary shares and Epizyme common stock, partially offset by a gain on Biohaven common shares; and losses of $21.5 million on our derivative financial instruments related to our treasury rate lock contracts that were unwound and settled in connection with the issuance of the 2021 Notes. The losses were partially offset by interest income of $50.9 million related to our Series A Biohaven Preferred Shares and a gain of $17.9&#160;million on the unrealized change in fair value of our available for sale debt securities. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other income, net of $219.2&#160;million in the year ended December 31, 2020 was primarily comprised of net gains on equity securities of $247.1 million, of which $292.3 million was driven by the redemption of our investment in Immunomedics common stock upon Gilead&#8217;s acquisition of Immunomedics in October 2020 and $66.0 million was related to an increase in share price of our investment in Biohaven common shares. These gains were partially offset by a loss of $120.1 million related to a decrease in share price of our investment in Epizyme common stock. In the year ended December 31, 2020, we also recognized $42.1 million in losses on our derivative financial instruments, primarily related to Epizyme warrants as a result of the decrease in Epizyme common stock price. Additionally, we recognized a loss on debt extinguishment of $30.5 million related to the debt refinancings completed in the year ended December 31, 2020.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net income attributable to non-controlling interest </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net income attributable to the Continuing Investors Partnerships was $297.3&#160;million and $317.0&#160;million in the years ended December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and 2020, respectively. The net income attributable to the Continuing Investors Partnerships reflects a partial period of net income subsequent to the IPO in the year ended December 31, 2020 compared to the full period of net income in the year ended December 31, 2021. The decrease in net income attributable to Continuing Investors Partnerships was primarily driven by lower net income attributable to RP Holdings in the year ended December 31, 2021. The decrease was further driven by the ongoing exchanges in 2021 by investors in the Continuing Investors Partnerships who indirectly own the RP Holdings Class B Interests for our Class A ordinary shares, resulting in a decline in the Continuing Investors Partnerships&#8217; ownership of RP Holdings.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net income attributable to the Legacy Investors Partnerships, which arose in February 2020 in connection with the Exchange Offer Transactions, was $266.6&#160;million and $321.0&#160;million in the years ended December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and 2020, respectively. The net income attributable to the Legacy Investors Partnerships reflects a partial period of net income subsequent to the Exchange Date in the year ended December 31, 2020. The decrease in net income attributable to the Legacy Investors Partnerships was primarily driven by lower net income attributable to Old RPI in 2021. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net income attributable to RPSFT was $57.6&#160;million and $88.9&#160;million in the years ended December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and 2020, respectively. We expect net income attributable to RPSFT to continue to decline as the royalty assets owned by RPCT mature. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Key developments and upcoming events relating to our portfolio</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The key developments impacting our cash receipts and income and revenue from our royalty interests are discussed below: </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Commercial Products </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Cystic fibrosis franchise.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In October 2019, Vertex received approval from the FDA for Trikafta for the treatment of patients with cystic fibrosis ages 12 years and older who have at least one copy of the F508del mutation. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, Vertex announced that the EC had granted marketing authorization of Kaftrio in combination with ivacaftor for the treatment of patients with cystic fibrosis ages 12 years and older with one</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F508del</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">mutation and one minimal function mutation, or two F508del</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">mutations in the cystic fibrosis transmembrane conductance regulator gene.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2020, the FDA expanded the eligibility for Trikafta to include people with cystic fibrosis ages 12 and older with certain mutations that are responsive to Trikafta based on in vitro data.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, Vertex announced EC approval for Kaftrio in combination with ivacaftor for the treatment of patients with cystic fibrosis ages 12 and older who have at least one F508del mutation.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2021, Vertex announced that FDA approved Trikafta for the treatment of children with cystic fibrosis ages 6 through 11 who have at least one F508del</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">mutation or have certain mutations that are responsive to Trikafta based on in vitro data. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2022, Vertex announced that the EC granted approval for the label expansion of Kaftrio in combination with ivacaftor for the treatment of cystic fibrosis in patients ages 6 through 11 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Tysabri. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, Biogen announced that the EC granted marketing authorization for a subcutaneous injection of Tysabri to treat relapsing-remitting multiple sclerosis. Biogen also announced that it had received a Complete Response Letter from the FDA for its sBLA for subcutaneous Tysabri. The Complete Response Letter indicates that the FDA is unable to approve Biogen&#8217;s filing as submitted. Biogen announced that it is evaluating the Complete Response Letter and will determine next steps in the United States.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2021, Biogen announced results from Phase 3b NOVA study evaluation every six-week dosing with Tysabri intravenous administration in relapsing-remitting multiple sclerosis. Results show that every six-week Tysabri intravenous administration provides a high level of efficacy in controlling multiple sclerosis disease activity in patients who switched from the approved every four-week dosing regimen. </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Imbruvica. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, Imbruvica received FDA approval for use in combination with rituximab for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). </span></div><div><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, the EC granted marketing authorization for Imbruvica in combination with rituximab for the treatment of adult patients with previously untreated CLL. This milestone marked the 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> FDA approval for Imbruvica since it was first approved in 2013 and sixth in CLL.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2021, Phase 3 GLOW study results for Imbruvica in combination with Venetoclax for the treatment of first-line CLL and SLL demonstrated superior progression-free survival versus chlorambucil plus obinutuzumab as a first-line treatment of CLL. The study also showed improved duration of remission and significantly improved depth of remission. AbbVie has indicated that approval could occur in 2022. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2021, AbbVie announced that the U.S. District Court for the District of Delaware had issued a decision holding patent rights relating to Imbruvica were valid and infringed by a generic product from Alvogen and Natco. The decision, which is subject to appeal, prohibits regulatory approval of that generic product until the last AbbVie patent expires. Previously, AbbVie entered into several settlement and license agreements with other generic companies. Consequently, AbbVie does not expect any generic product entry prior to March 30, 2032, assuming pediatric exclusivity is granted. </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:18.3pt">Xtandi. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, Astellas and Pfizer announced that the FDA approved Xtandi for the treatment of patients with metastatic castration sensitive prostate cancer.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, Astellas and Pfizer announced that the EC approved Xtandi for the treatment of patients with metastatic hormone-sensitive prostate cancer. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2021, Astellas Pharma and Pfizer announced that Xtandi plus androgen deprivation therapy (ADT) reduced the risk of death by 34% compared to placebo plus ADT in the Phase 3 ARCHES study in men with metastatic hormone-sensitive prostate cancer. The primary results from the ARCHES trial were published in 2019.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Astellas and Pfizer have indicated that there could be a potential readout of the Phase 3 EMBARK trial for high-risk non-metastatic prostate cancer in the second half of 2022.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Nurtec ODT. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In February 2020, Biohaven announced that the FDA approved Nurtec ODT for the acute treatment of migraine in adults. The FDA approval of Nurtec ODT triggered a redemption provision related to our investment in the Series A Biohaven Preferred Shares, which entitles us to receive a fixed payment amount of $250.0&#160;million payable in equal quarterly payments from March 31, 2021 through December 31, 2024. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, Biohaven announced that the FDA approved Nurtec ODT for the preventative treatment of migraine, indicated for adult patients with episodic migraine who experience less than 15 headache days per month.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2021, Biohaven announced a strategic collaboration with Pfizer for the commercialization of rimegepant outside the United States. Pfizer also gains rights outside the U.S. to zavegepant, which is being studied in an intranasal delivery and an oral formulation in Phase 3 clinical trials for migraine indications.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biohaven has indicated it expects an EMA decision on Vydura (rimegepant) in the first half of 2022.</span></div><div style="padding-left:45pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Trodelvy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, Immunomedics announced that the FDA granted accelerated approval of Trodelvy for the treatment of patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2020, Gilead and Immunomedics announced that Gilead would acquire Immunomedics for approximately $21 billion in cash. In 2018, we entered into a partnership with Immunomedics whereby we acquired a tiered sales-based royalty on Trodelvy for $175.0 million and acquired 4,373,178 shares of Immunomedics common stock for $75.0 million. Gilead&#8217;s acquisition of Immunomedics closed in October 2020, resulting in gross cash proceeds upon redemption of our Immunomedics common stock of approximately $385 million.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, Gilead announced the FDA granted full approval to Trodelvy for adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. The approval is supported by data from the Phase 3 ASCENT study. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, Gilead announced that the FDA granted an accelerated approval of Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and either a programmed death receptor-1 or a programmed death-ligand 1 inhibitor. The accelerated approval was based on data from the international Phase 2, single-arm TROPHY study. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2021, Gilead announced superior outcomes to standard of care in second-line treatment of metastatic TNBC in the Phase 3 ASCENT study. Trodelvy more than doubled overall survival as a second-line treatment in the new ASCENT subgroup analysis. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, Gilead announced a collaboration with Merck &amp; Co. to investigate Trodelvy in combination with Keytruda as a first-line treatment for people with locally advanced or metastatic TNBC.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2021, Gilead announced that the EC granted marketing authorization for Trodelvy as a monotherapy indicated for the treatment of adult patients with unresectable or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for advanced disease. The EC&#8217;s decision is supported by results from the Phase 3 ASCENT study, where Trodelvy reduced the risk of death by 49% and improved median overall survival to 11.8 months versus 6.9 months with physician&#8217;s choice of chemotherapy.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2022, Gilead announced it has entered into two clinical trial collaboration and supply agreements with Merck &amp; Co. to evaluate the combination of Trodelvy and Merck&#8217;s anti-PD-1 therapy Keytruda in first-line metastatic non-small cell lung cancer (NSCLC). As part of the collaboration, Merck will sponsor a global Phase 3 clinical trial of Trodelvy in combination with Keytruda as a first-line treatment of patients with metastatic NSCLC. Additionally, the companies recently established an agreement whereby Gilead will sponsor a Phase 2 signal-seeking study evaluating combinations that include pembrolizumab in first-line NSCLC.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gilead has indicated that it expects progression-free survival data as well as the first planned interim analysis of overall survival data from the Phase 3 TROPiCS-02 trial in hormone receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer in March 2022.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Cabometyx. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, Exelixis announced that the FDA approved Cabometyx for patients with advanced renal cell carcinoma (RCC) as a first-line treatment in combination with Bristol Myers Squibb&#8217;s Opdivo. The approval was based on the Phase 3 CheckMate -9ER trial, in which the combination of Cabometyx and Opdivo significantly improved overall survival while doubling progression-free survival and objective response rate versus sunitinib as a first-line treatment for patients with advanced RCC.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021, Ipsen announced that the EC approved the combination of Cabometyx and Opdivo for the first-line treatment of advanced RCC.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, Exelixis announced results from cohort six of COSMIC-021, a Phase 1b trial evaluating Cabometyx in combination with atezolizumab in patients with locally advanced or metastatic solid tumors, including patients with metastatic castration-resistant prostate cancer (CRPC). In high-risk patients, the combination of Cabometyx and atezolizumab resulted in objective response rates of 27% and 18% per investigator assessment and Blinded Independent Radiology Committee, respectively.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2021, Exelixis and Ipsen announced that COSMIC-312, a Phase 3 trial evaluating Cabometyx in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma. The trial met one of its primary endpoints by demonstrating significant improvement in progression-free survival at the planned primary analysis. However, a prespecified interim analysis was not statistically significant for the second primary endpoint of overall survival. Based on the preliminary overall survival data, Exelixis anticipates that the probability of reaching statistical significance at the time of the final analysis is low.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2021, Exelixis announced that their partners Takeda and Ono received approval in Japan for Cabometyx in combination with Opdivo for the treatment of unresectable or metastatic RCC. Approval is based on the CheckMate -9ER trial of Cabometyx in combination with Opdivo, which demonstrated superior overall survival and doubled mean progression-free survival and objective response rate versus sunitinib, with a favorable safety profile.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2021, Exelixis announced detailed results from the expanded Cohort 6 of the Phase 1b COSMIC-021 trial of Cabometyx in combination with atezolizumab in patients with metastatic CRPC, which included patients with metastatic CRPC who had been previously treated with novel hormone therapies enzalutamide and/or abiraterone acetate used along with prednisone. Following discussions with FDA, Exelixis will not pursue a regulatory submission for the combination regimen based on cohort 6 of COSMIC-021. CONTACT-02, a global Phase 3 pivotal trial that initiated enrollment in June 2020 may serve as a basis for future regulatory applications. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2021, Exelixis announced FDA approved Cabometyx for patients with previously treated radioactive iodine-refractory differentiated thyroid cancer. The approval was based on the Phase 3 COSMIC-311 pivotal trial.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exelixis has indicated it expects Phase 3 data from the COSMIC-313 trial in 1L RCC in the first half of 2022 and initial Phase 3 data in the second half of 2022 from CONTACT-01 in metastatic NSCLC and CONTACT-03 in advanced or metastatic RCC.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Evrysdi. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, the FDA approved Evrysdi, the first at-home, orally administered treatment for spinal muscular atrophy (SMA) in adults and children ages 2 months and older.  </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021, Roche announced that the EC approved Evrysdi for the treatment of SMA in patients two months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four splicing modifier of motor neuron 2 copies. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2021, Evrysdi was approved in Japan for the treatment of SMA. </span></div><div style="padding-left:45pt"><span><br/></span></div><div><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Orladeyo. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2020, BioCryst announced that Orladeyo was approved by the FDA for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ages 12 years and older.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, Orladeyo was approved in Japan, becoming the first and only prophylactic HAE medication approved in the region.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, BioCryst announced that the EC approved Orladeyo for the prevention of recurrent HAE attacks in patients 12 years and older. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, BioCryst announced approval of Japanese National Health Insurance System price listing of Orladeyo for prophylactic treatment of HAE.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Oxlumo. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2021, Alnylam announced results from ILLUMINATE-C, a Phase 3 open-label study of lumasiran in patients of all ages with advanced primary hyperoxaluria type 1 associated with progressive decline in renal function. Results from the primary analysis at six months demonstrated a substantial reduction in plasma oxalate from baseline in patients with advanced disease, including those on hemodialysis. The safety and tolerability profile of lumasiran following six months of treatment was encouraging across all ages, with no drug related serious adverse events and injection site reactions as the most common adverse event.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, Alnylam submitted a supplemental New Drug Application for lumasiran to the FDA and a Type II Variation with the EMA for the reduction of plasma oxalate in the treatment of patients with advanced primary hyperoxaluria type 1.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Development-Stage Product Candidates </span></div><div style="padding-left:9pt"><span><br/></span></div><div><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Aficamten.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In February 2022, Cytokinetics announced positive topline results from Cohort 3 of the REDWOOD-HCM Phase 2 trial. Results from Cohort 3 showed that substantial reductions in the average resting LVOT-G as well as the post-Valsalva LVOT-G were achieved for patients with oHCM and a resting or post-Valsalva LVOT-G of &#8805;50 mmHg whose background therapy included disopyramide and in the majority a beta-adrenergic blocker. The safety and tolerability of aficamten were consistent with prior experience in REDWOOD-HCM with no treatment interruptions and no serious adverse events attributed to treatment reported by the investigators.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, Cytokinetics announced the FDA granted Breakthrough Therapy Designation for aficamten for the treatment of symptomatic oHCM based on results from REDWOOD-HCM. Cytokinetics has indicated it plans to initiate a pivotal study of aficamten in oHCM in the first quarter of 2022.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Gantenerumab. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, Roche announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the FDA for the treatment of people living with Alzheimer&#8217;s disease. This designation is based on data showing that gantenerumab significantly reduced brain amyloid plaque, a pathological hallmark of Alzheimer&#8217;s disease, in the ongoing SCarlet RoAD and Marguerite RoAD open-label extension trials, as well as other studies. Roche has indicated it expects Phase 3 data from the GRADUATE 1/2 trial in Alzheimer&#8217;s disease in the fourth quarter of 2022.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Omecamtiv mecarbil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In November 2020, Amgen, Cytokinetics and Servier presented the results of GALACTIC-HF study, a Phase 3 trial of omecamtiv mecarbil in patients with heart failure, at the American Heart Association Scientific Sessions. The trial met the primary composite endpoint of reduction in cardiovascular death or heart failure events, but did not meet the secondary endpoint of reduction in cardiovascular death. Cytokinetics subsequently regained global rights to develop and commercialize omecamtiv mecarbil when Amgen and Servier elected to terminate their collaboration agreement effective, May 2021. Following the Phase 3 results and termination of the collaboration, we wrote off the full value of our financial royalty asset given the uncertainty around the future of omecamtiv mecarbil.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2022, Cytokinetics announced that FDA has accepted and filed the company&#8217;s New Drug Application (NDA) for omecamtiv mecarbil. The FDA assigned the NDA a standard review with a PDUFA target action date of November 30, 2022. The FDA also indicated that it is currently not planning to hold an advisory committee meeting to discuss the application. The submission is supported by GALACTIC-HF, which demonstrated a positive effect on the primary composite endpoint of cardiovascular death or heart failure events in patients with heart failure and reduced ejection fraction who were receiving standard of care plus omecamtiv mecarbil.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Otilimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. GlaxoSmithKline has indicated it expects Phase 3 data from the contRast trials in rheumatoid arthritis in the second half of 2022.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Pelabresib:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In December 2021, MorphoSys presented the latest data from the Phase 2 MANIFEST study evaluating pelabresib in the treatment of myelofibrosis. As of September 10, 2021, the data cut-off, a total of 84 JAK inhibtor-naive patients were enrolled and received the first-line combination of pelabresib and ruxolitinib. The data showed 68% (n=57) of patients treated with the combination achieved a greater than or equal to 35% reduction in spleen volume (SVR35) from baseline at week 24 and 60% (n=47) maintained SVR35 at week 48. Most patients also saw their symptoms reduced, with 56% (n=46) achieving greater than or equal to 50% reduction in total symptom score from baseline at week 24. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">PT027. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2021, AstraZeneca and Avillion announced positive results from MANDALA and DENALI, two Phase 3 trials evaluating PT027 (albuterol/budesonide) in patients with asthma. PT027 is a potential first-in-class inhaled, fixed-dose combination of albuterol, a short-acting beta2-agonist, and budesonide, an inhaled corticosteroid. In MANDALA, PT027 demonstrated a statistically significant and clinically meaningful reduction in the risk of severe exacerbations compared to albuterol, when used as a rescue medicine in response to symptoms. In DENALI, PT027 showed a statistically significant improvement in lung function measured by forced expiratory volume in one second, compared to the individual components albuterol and budesonide, and compared to placebo. The safety and tolerability of PT027 in both trials was consistent with the known profiles of the components. AstraZeneca has indicated PT027 regulatory submissions will occur in the first half of 2022.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Zavegepant. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, Biohaven announced positive topline results from the Phase 2/3 trial of intranasal zavegepant for the acute treatment of migraine.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021, Biohaven announced that it enrolled the first patient in a Phase 2/3 clinical trial of oral zavegepant for the preventive treatment of migraine. Accordingly, per the agreement with Biohaven announced in August 2020, Royalty Pharma paid $100 million to Biohaven for the achievement of this milestone, bringing the total zavegepant funding to $250 million.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, Biohaven announced positive topline results from the second pivotal clinical trial evaluating the safety and efficacy of intranasal zavegepant for the acute treatment of migraine in adults. The Phase 3 study achieved its co-primary regulatory endpoints of pain freedom and freedom of most bothersome symptom at 2 hours and showed broad efficacy by demonstrating statistically significant superiority to placebo across a total of 15 prespecified primary and secondary outcome measures. Biohaven plans to file an NDA for zavegepant with the FDA in the first quarter of 2022 and other countries thereafter.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_67"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Non-GAAP Financial Results </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to analyzing our results on a GAAP basis, management also reviews our results on a non-GAAP basis. There is no direct correlation between income from financial royalty assets and royalty receipts due to the nature of the accounting methodology applied for financial royalty assets. Further, income from financial royalty assets and the provision for changes in expected cash flows related to these financial royalty assets can be volatile and unpredictable. As a result, management places importance on royalty receipts as they are predictable and we use them as a measure of our operating performance. Refer to section titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Non-GAAP Reconciliations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; for additional discussion of management&#8217;s use of non-GAAP measures as supplemental financial measures and reconciliations from the most directly GAAP comparable measures of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjusted Cash Receipts is a measure calculated with inputs directly from the Statement of Cash Flows and includes (1) royalty receipts by product: (i) Cash collections from royalty assets (financial assets and intangible assets), (ii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other royalty cash collections</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, (iii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Distributions from non-consolidated affiliates,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> plus (2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Proceeds from available for sale debt securities; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">less</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Distributions to non-controlling interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which represents contractual distributions of royalty receipts and proceeds from available for sale debt securities to our historical non-controlling interest attributable to a de minimis interest in RPCT held by certain legacy investors and to the non-controlling interest that was created as a result of the Exchange Offer Transactions in February 2020 related to the Legacy Investors Partnerships&#8217; ownership of approximately 18% in Old RPI. Adjusted Cash Receipts is most directly comparable to the GAAP measure of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjusted EBITDA and Adjusted Cash Flow are similar non-GAAP liquidity measures that are both most closely comparable to the GAAP measure, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Adjusted EBITDA is important to our lenders and is defined under the Credit Agreement as Adjusted Cash Receipts less Payments for operating and professional costs. Payments for operating and professional costs are comprised of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Payments for operating and professional costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Payments for rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from the Statement of Cash Flows. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjusted Cash Flow is defined as Adjusted EBITDA less (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Ongoing development-stage funding payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, (2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interest paid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, net of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interest received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, (3) Other (including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Derivative collateral posted,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> net of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Derivative collateral received,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Termination payments on derivative instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) and (4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investments in non-consolidated affiliates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, plus (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Contributions from non-controlling interest- R&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, all directly reconcilable to the Statement of Cash Flows. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjusted Cash Receipts and Adjusted Cash Flow are used by management as key liquidity measures in the evaluation of our ability to generate cash from operations. Both measures are an indication of the strength of the Company and the performance of the business. Management also uses Adjusted Cash Flow to compare its performance against non-GAAP adjusted net income used by companies in the biopharmaceutical industry. Adjusted EBITDA, as derived from Adjusted Cash Receipts, is used by our lenders to assess our ability to meet our financial covenants. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following is a discussion of our results on a non-GAAP basis for the years ended December 31, 2021 and 2020. For a discussion comparing our results on a non-GAAP basis for the years ended December 31, 2020 and 2019, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below includes the royalty receipts and non-GAAP financial results for the years ended December 31, 2021 and 2020 by product in order of contribution to royalty receipts for the year ended December 31, 2021. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 vs. 2020 Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Products</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">702,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345,845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">322,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Januvia, Janumet, Other DPP-IVs (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HIV franchise (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(215,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nurtec ODT/Biohaven payment (4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Farxiga/Onglyza </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cabometyx/Cometriq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Crysvita</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emgality</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Erleada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trodelvy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IDHIFA</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orladeyo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tazverik</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Oxlumo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other products (5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total royalty receipts</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,608,542</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,344,399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">264,143</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(479,604)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(543,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted Cash Receipts (non-GAAP)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,128,938</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,800,447</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">328,491</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for operating and professional costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(184,511)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(179,709)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,802)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted EBITDA (non-GAAP)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,944,427</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,620,738</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">323,689</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(127,295)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95,492)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,803)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in non-consolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34,855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40,155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ongoing development-stage funding payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,876)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,479)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,093)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25,897)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(264.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions from non-controlling interest- R&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted Cash Flow (non-GAAP)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,766,647</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,482,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">283,749</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fully diluted Class A ordinary shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">607,176</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">607,111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">*Percentage change is not meaningful. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(1) The cystic fibrosis franchise includes the following approved products: Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(2) Januvia, Janumet, Other DPP-IVs include the following approved products: Tradjenta, Onglyza, Kombiglyze, Galvus, Eucreas and Nesina. The Other DPP-IVs are marketed by Boehringer Ingelheim, AstraZeneca, Novartis and Takeda.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(3) The HIV franchise includes the following approved products: Atripla, Truvada, Emtriva, Complera, Stribild, Genvoya, Descovy, Odefsey, Symtuza and Biktarvy. Royalties are received on the emtricitabine portion of sales only.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(4) Includes royalty receipts for Nurtec ODT of $7.7&#160;million and quarterly redemptions of $15.6 million of the Series A Biohaven Preferred Shares (presented as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> on the Statement of Cash Flows) for the year ended December 31, 2021. For the year ended December 31, 2020, the amount also includes a payment from Biohaven in respect of an expired option to exercise additional funding of the Biohaven Series A Preferred Shares which is presented as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> on the Statement of Cash Flows.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(5) Other products primarily include royalties on the following products: Bosulif (a product co-developed by our joint venture investee, Avillion, for which receipts are presented as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Distributions from non-consolidated affiliates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> on the Statement of Cash Flows), Lexiscan, Soliqua, Nesina, Cimzia, Letairis, Entyvio, Myozyme, Mircera and Lyrica. Other products for the year ended December 31, 2021 includes a one-time milestone payment of $45.0 million that we received on Soliqua. Other products for the year ended December 31, 2020 includes a one-time $21.3 million distribution from Avillion in respect of the Merck KGaA Asset for which the receipt is presented as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Distributions from non-consolidated affiliates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> in both the operating and investing section of the Statement of Cash Flows. Subsequent to the Exchange Offer Date, other products also includes contributions from the Legacy SLP Interest.</span></div><div><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Adjusted Cash Receipts (non-GAAP) </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjusted Cash Receipts increased by $328.5&#160;million to $2.1&#160;billion in the year ended December 31, 2021 compared to the year ended December 31, 2020, primarily driven by an increase in royalty receipts from the cystic fibrosis franchise, including royalty receipts related to the residual interest in the cystic fibrosis franchise that we acquired in October 2020, fixed payments from Biohaven on the Series A Biohaven Preferred Shares and new assets acquired subsequent to the year ended December 31, 2020. Offsetting the increase in royalty receipts was a decline in royalty receipts from maturing assets, primarily the HIV franchise, Lyrica and Letairis. Additionally, we received one-time payments of $45.0 million related to a commercial milestone for Soliqua and $21.3 million from Avillion II in connection with the cessation of our involvement in the Merck KGaA Asset development in the years ended December 31, 2021 and 2020, respectively. The increase in Adjusted Cash Receipts was further driven by a decrease in distributions to non-controlling interest, primarily due to a decline in royalty receipts from maturing assets in the year ended December 31, 2021 and a non-recurring distribution to the Legacy Investors Partnerships made in connection with the Exchange Offer Transactions that occurred in the three months ended March 31, 2020.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Below we discuss the key drivers of royalty receipts. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Royalty Receipts</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Cystic fibrosis franchise</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; Royalty receipts from the cystic fibrosis franchise, which includes Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio, which are marketed by Vertex for patients with certain mutations causing cystic fibrosis, increased by $150.8&#160;million in the year ended December 31, 2021 compared to the year ended December 31, 2020. The increase was primarily driven by the performance of Trikafta in the United States, including its rapid uptake in children 6 through 11 years old and the launch of Kaftrio in Europe. The year ended December 31, 2021 also benefited from a clawback adjustment related to Vertex&#8217;s agreement with French authorities around reimbursement </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">for Orkambi, which had reduced royalty receipts in the three months ended March 31, 2020 by approximately $41 million (to reflect a true-up in prior periods where we collected royalties on sales in France at a higher selling price). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following our acquisition of the residual interest in the cystic fibrosis franchise from the Cystic Fibrosis Foundation in the three months ended December 31, 2020, we are entitled to all royalty receipts on annual worldwide net sales above $5.8 billion. We received royalty receipts related to the residual interest in the cystic fibrosis franchise in the year ended December 31, 2021.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Tysabri</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; Royalty receipts from Tysabri, which is marketed by Biogen for the treatment of multiple sclerosis, increased by $23.3&#160;million in the year ended December 31, 2021 compared to the year ended December 31, 2020, primarily driven by continued patient growth.</span></div><div style="text-indent:55.05pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Imbruvica</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; Royalty receipts from Imbruvica, which is marketed by AbbVie and Johnson &amp; Johnson for the treatment of blood cancers and chronic graft versus host disease, increased by $30.8&#160;million in the year ended December 31, 2021 compared to the year ended December 31, 2020, primarily driven by continued global penetration in patients with chronic lymphocytic leukemia and favorable pricing. This increase was partially offset by modest market share losses in the United States, lower new patient starts due to the COVID-19 pandemic as well as the impact of COVID-19 inventory stocking. </span></div><div style="text-indent:55.05pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Promacta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; Royalty receipts from Promacta, which is marketed by Novartis for the treatment of chronic immune thrombocytopenia and aplastic anemia, increased by $29.9&#160;million in the year ended December 31, 2021 compared to the year ended December 31, 2020. This growth was primarily driven by increased use in chronic immune thrombocytopenia and as first-line treatment for severe aplastic anemia in the United States.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Xtandi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; Royalty receipts from Xtandi, which is marketed by Pfizer and Astellas for the treatment of prostate cancer, increased by $11.7&#160;million in the year ended December 31, 2021 compared to the year ended December 31, 2020, primarily driven by demand across various prostate cancer indications.</span></div><div style="text-indent:55.05pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Januvia, Janumet, Other DPP-IVs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; Royalty receipts from the DPP-IVs for type 2 diabetes, which includes Januvia and Janumet, both marketed by Merck &amp; Co., increased $7.4&#160;million in the year ended December 31, 2021 compared to the year ended December 31, 2020.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:19pt">Nurtec ODT </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211; Royalty receipts from Nurtec ODT, marketed by Biohaven and Pfizer for the acute treatment of migraine, were $7.7&#160;million in the year ended December 31, 2021. In addition, as a result of the approval of Nurtec ODT in February 2020, we received $62.5&#160;million in fixed payments from Biohaven in the year ended December 31, 2021, which represent the first four of 16 consecutive quarterly payments to be received from Biohaven relating to the Series A Biohaven Preferred Shares.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:19pt">Tremfya</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#8211; Royalty receipts from Tremfya, which is marketed by Johnson &amp; Johnson, were $35.7&#160;million in the year ended December 31, 2021. We acquired the Tremfya royalty in July 2021.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:19pt">Cabometyx/Cometriq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#8211; Royalty receipts from Cabometyx/Cometriq, which is marketed by Exelixis, Ipsen and Takeda, were $33.7&#160;million in the year ended December 31, 2021. We acquired the Cabometyx/Cometriq royalty in March 2021.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:19pt">HIV franchise</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#8211; Royalty receipts from the HIV franchise, which is based on products marketed by Gilead that contain emtricitabine, including Biktarvy, Genvoya and Truvada, among others, decreased by $215.8&#160;million in the year ended December 31, 2021 compared to the year ended December 31, 2020. This decrease was driven by the maturity of our royalties from the HIV franchise in 2021.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Distributions to Non-Controlling Interest</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Distributions to non-controlling interest decreased by $64.3&#160;million to $479.6&#160;million in the year ended December 31, 2021 compared to the year ended December 31, 2020, which positively impacted Adjusted Cash Receipts. The decrease in distributions to non-controlling interest is primarily due to a decline in royalty receipts from maturing assets, primarily the HIV franchise, and a non-recurring distribution to the Legacy Investors Partnerships made in connection with the Exchange Offer Transactions that occurred in the three months ended March 31, 2020. Partially offsetting these decreases was a distribution to non-controlling interest related to the one-time milestone payment we received on Soliqua in the year ended December 31, 2021. </span></div><div><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Adjusted EBITDA (non-GAAP)</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjusted EBITDA increased by $323.7&#160;million to $1.9&#160;billion in the year ended December 31, 2021 compared to the year ended December 31, 2020 as a result of the factors noted above in &#8220;Adjusted Cash Receipts (Non-GAAP).&#8221; Payments for operating and professional costs, the only adjustment between Adjusted Cash Receipts and Adjusted EBITDA, increased slightly in the year ended December 31, 2021 as a result of higher Operating and Personnel Payments under the terms of our Management Agreement offset by a decrease in non-recurring professional services fees, restructuring fees and refinancing fees incurred in the year ended December 31, 2020 in connection with the Exchange Offer Transactions and the IPO.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Adjusted Cash Flow (non-GAAP)</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Years ended December 31, 2021 and 2020</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjusted Cash Flow increased by $283.7&#160;million to $1.8&#160;billion in the year ended December 31, 2021 compared to the year ended December 31, 2020 primarily for the same reasons noted above in &#8220;Adjusted Cash Receipts (Non-GAAP)&#8221; and &#8220;Adjusted EBITDA (non-GAAP).&#8221; The adjustments between &#8220;Adjusted EBITDA (non-GAAP)&#8221; and &#8220;Adjusted Cash Flow (non-GAAP)&#8221; increased by $39.9 million in the year ended December 31, 2021 compared to the year ended December 30, 2020. The increase was driven by a $31.8&#160;million increase in net interest paid in the year ended December 31, 2021 due to a shift to semi-annual interest payments on the 2020 Notes and a $16.1&#160;million one-time payment related to the settlement of treasury rate lock contracts in connection with the 2021 Notes issuance. This increase was partially offset by lower ongoing development-stage funding requirements under our co-funding agreement with Sanofi and lower funding requirements by the Avillion entities in 2021 following the cessation of our involvement in the Merck KGaA Asset development in 2020.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Non-GAAP Reconciliations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">          Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow are non-GAAP measures presented as supplemental measures to our GAAP financial performance. These non-GAAP financial measures exclude the impact of certain items and therefore have not been calculated in accordance with GAAP. In each case, because our operating performance is a function of our liquidity, the non-GAAP measures used by management are presented and defined as supplemental liquidity measures. We caution readers that amounts presented in accordance with our definitions of Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow may not be the same as similar measures used by other companies. Not all companies and analysts calculate the non-GAAP measures we use in the same manner. We compensate for these limitations by using non-GAAP financial measures as supplements to GAAP financial measures and by presenting the reconciliations of the non-GAAP financial measures to their most comparable GAAP financial measures, in each case being </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that Adjusted Cash Receipts and Adjusted Cash Flow provide meaningful information about our operating performance because the business is heavily reliant on its ability to generate consistent cash flows and these measures reflect the core cash collections and cash charges comprising our operating results. Management strongly believes that our significant operating cash flow is one of the attributes that attracts potential investors to our business. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we believe that Adjusted Cash Receipts and Adjusted Cash Flow help identify underlying trends in the business and permit investors to more fully understand how management assesses the performance of the Company, including planning and forecasting for future periods. Adjusted Cash Receipts and Adjusted Cash Flow are used by management as key liquidity measures in the evaluation of the Company&#8217;s ability to generate cash from operations. Both measures are an indication of the strength of the Company and the performance of the business. Management uses Adjusted Cash Receipts and Adjusted Cash Flow when considering available cash, including for decision-making purposes related to funding of acquisitions, voluntary debt repayments, dividends and other discretionary investments. Further, these non-GAAP financial measures help management, the audit committee and investors evaluate our ability to generate liquidity from operating activities. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management believes that Adjusted EBITDA is an important non-GAAP measure in analyzing our liquidity and is a key component of certain material covenants contained within the Company&#8217;s credit agreement. Noncompliance with the interest coverage ratio and leverage ratio covenants under the credit agreement could result in our lenders requiring the Company to immediately repay all amounts borrowed. If we cannot satisfy these financial covenants, we would be prohibited under our credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to the assessment of our liquidity.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management uses Adjusted Cash Flow to evaluate its ability to generate cash and performance of the business and to evaluate the Company&#8217;s performance as compared to its peer group. Management also uses Adjusted Cash Flow to compare its performance against non-GAAP adjusted net income measures used by many companies in the biopharmaceutical industry, even though each company may customize its own calculation and therefore one company&#8217;s metric may not be directly comparable to another&#8217;s. We believe that non-GAAP financial measures, including Adjusted Cash Flow, are frequently used by securities analysts, investors and other interested parties to evaluate companies in our industry.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The non-GAAP financial measures used in this Annual Report on Form 10-K have limitations as analytical tools, and you should not consider them in isolation or as a substitute for the analysis of our results as reported under GAAP. We have provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure, in each case being</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> below.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To arrive at Adjusted Cash Receipts, we start with the GAAP line item, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and adjust for the following items from the Statement of Cash Flows: to add back (1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (primarily the redemption of Biohaven Preferred Shares), which are cash inflows that management believes are derived from royalties and form part of our core business strategy, (2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Distributions from non-consolidated affiliates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> which are cash inflows from investing activities, (3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interest paid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, net of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Interest received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, (4) Development-stage funding payments, (5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Payments for operating and professional costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, (6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Payments for rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and (7) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Termination payments on derivative instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and to deduct (1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Distributions to non-controlling interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which represents distributions to our historical non-controlling interest attributable to a de minimis interest in RPCT held by certain legacy investors and to a new non-controlling interest that was created as a result of the Exchange Offer Transactions in February 2020 related to the Legacy Investors Partnerships&#8217; ownership of approximately 18% in Old RPI and (2) Derivative collateral posted or (received), net, both of which are excluded when management assesses its operating performance through cash collections, or, Adjusted Cash Receipts.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To arrive at Adjusted EBITDA, we start with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and adjust for the following items from the Statement of Cash Flows: to add back (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (primarily redemption of Biohaven Preferred Shares), (2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Distributions from non-consolidated affiliates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> which are cash inflows from investing activities, (3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Interest paid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, net of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interest received,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (4) Development-stage funding payments and (5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Termination payments on derivative instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and to deduct (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Distributions to non-controlling interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and (2) Derivative collateral posted or (received), net.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To arrive at Adjusted Cash Flow, we start with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and adjust for the following items from the Statement of Cash Flows: to add back (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (primarily redemption of Biohaven Preferred Shares), (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Distributions from non-consolidated affiliates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> classified as Cash used in investing activities, (3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Upfront development-stage funding payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and (4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Contributions from non-controlling interest- R&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and to deduct (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Distributions to non-controlling interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Investments in non-consolidated affiliates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. This is intended to present an Adjusted Cash Flow measure that is representative of cash generated from the broader business strategy of acquiring royalty-generating assets that are available for reinvestment and for discretionary purposes.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities (GAAP)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,017,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,034,629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from available for sale debt securities (1), (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions from non-consolidated affiliates &#8211; investing (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid, net (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ongoing development-stage funding payments (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Upfront development-stage funding payments (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for operating and professional costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Termination payments on derivative instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to non-controlling interest (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(479,604)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(543,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative collateral received, net (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45,252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted Cash Receipts (non-GAAP)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,128,938</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,800,447</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities (GAAP)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,017,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,034,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from available for sale debt securities (1), (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions from non-consolidated affiliates &#8211; investing (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid, net (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ongoing development-stage funding payments (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Upfront development-stage funding payments (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Termination payments on derivative instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to non-controlling interest (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(479,604)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(543,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative collateral received, net (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45,252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted EBITDA (non-GAAP)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,944,427</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,620,738</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities (GAAP)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,017,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,034,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from available for sale debt securities (1), (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions from non-consolidated affiliates &#8211; investing (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Upfront development-stage funding payments (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to non-controlling interest (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(479,604)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(543,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in non-consolidated affiliates (2), (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34,855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40,155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions from non-controlling interests-R&amp;D (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted Cash Flow (non-GAAP)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,766,647</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,482,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:40.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)&#160;Receipts from the quarterly redemption of the Series A Biohaven Preferred Shares are presented as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> on the Statement of Cash Flows for the year ended December 31, 2021. A</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> payment from Biohaven in respect of an expired option to exercise additional funding of the Biohaven Series A Preferred Shares is</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> presented as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Proceeds from available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> on the Statement of Cash Flows for the year ended December 31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)&#160;The table below shows the line item for each adjustment and the direct location for such line item on the Statement of Cash Flows.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reconciling Adjustment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Statement of Cash Flows Classification</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Proceeds from available for sale debt securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Investments in non-consolidated affiliates</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Distributions to non-controlling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Interest paid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> less </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Interest received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative collateral (received)/posted, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Derivative collateral received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> less </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Derivative collateral posted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Contributions from non-controlling interest- R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions from non-consolidated affiliates - investing</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)&#160;Our lenders consider all payments made to support R&amp;D activities for products undergoing late-stage development similar to asset acquisitions as these funds are expected to generate operational returns in the future. All ongoing and upfront development-stage funding payments are reported in R&amp;D funding expense in net income and are added back in aggregate to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> to arrive at Adjusted EBITDA. As a result, Adjusted EBITDA captures the full add-back for R&amp;D funding payments while Adjusted Cash Flow only reflects the add-back for the upfront portion of development-stage funding payments due to the fact that ongoing development-stage funding payments are considered an ongoing business expense.</span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)&#160;We consider all payments to fund our operating joint ventures that are performing R&amp;D activities for products undergoing late stage development similar to asset acquisitions as these funds are expected to generate operational returns in the future. As a result, amounts funded through capital calls by our equity method investees, the Avillion Entities, are deducted to arrive at Adjusted Cash Flow, but are not deducted in Adjusted EBITDA.</span></td></tr></table></div><div><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_70"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Investments Overview </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ongoing investment in new royalties is fundamental to the long-term prospects of our business. New investments provide a source of growth for our royalty receipts, supplementing growth within our existing portfolio and offsetting declines for products in our portfolio that have lost market exclusivity. We evaluate an array of royalty acquisition opportunities on a continuous basis and expect to continue to make acquisitions in the ordinary course of our business. Our team has established a strong track record of identifying, evaluating and investing in royalties tied to leading products across therapeutic areas and treatment modalities. We invest in approved products and development-stage product candidates that have generated robust proof of concept data. We invest in these therapies through the purchase of royalties, by making hybrid investments and by acquiring businesses with significant existing royalty assets or the potential for the creation of such assets. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December 31, 2021, we invested $2.7&#160;billion in royalties and related assets across five separate transactions. While volatility exists in the quantum of our new acquisitions on a year-to-year basis due to the unpredictable timing of new investment opportunities, we have consistently deployed significant amounts of cash when measured over multi-year periods. Our approach is rooted in a highly disciplined evaluation process that is not dictated by a minimum annual investment threshold. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Included below is a table of investment activity over each of the last ten years based on the type of investment at the acquisition date. Amounts presented in the table below reflect cash paid at the acquisition date; any associated contractual payments are reflected in the period in which cash was paid.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.812%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">2013</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">2012</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Approved / marketed royalties</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,018,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,819,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,404,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,848,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">269,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,200,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,197,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">337,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">468,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">510,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">124,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Development-stage royalties (1) (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">778,633</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">830,713</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">894,469</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">445,699</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">569,592</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220,093</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99,242</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120,285</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,428,530</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">391,287</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">786,417</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Totals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,796,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,650,616&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,298,690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,294,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">839,146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,420,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,296,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">458,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,896,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">901,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">910,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(1) Development stage royalties include: direct R&amp;D funding arrangements and funding arrangements executed through our joint venture partnership with the Avillion Entities, investments in development-stage product candidates, and investments in securities primarily made in connection with acquisitions of royalties on development stage products from the seller. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(2) In 2014, acquisitions of development-stage royalties included $3.3 billion for the acquisition of royalties on the cystic fibrosis franchise. At the time of the investment, Kalydeco was the only approved product in the franchise, while the vast majority of the value of our investment was tied to development-stage product candidates.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Summary of royalty acquisition activity </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In January 2022, we acquired a royalty interest in aficamten from Cytokinetics, Incorporated (&#8220;Cytokinetics&#8221;) for $150.0 million comprised of an upfront payment of $50&#160;million and two additional $50&#160;million payments, conditional upon the initiation of potential pivotal clinical trials for oHCM and nonobstructive hypertrophic cardiomyopathy, respectively. Additionally, we will provide Cytokinetics long-term capital of up to $300&#160;million (&#8220;Cytokinetics Commercial Launch Funding&#8221;) to support potential commercialization of omecamtiv mecarbil and further development of aficamten. The Cytokinetics Commercial Launch Funding is available in five tranches, including an initial tranche of $50&#160;million funded upon closing and four additional tranches in the aggregate amount of $250&#160;million to be funded upon the occurrence of certain regulatory and clinical development milestones.  </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In November 2021, we acquired incremental royalty interests in BCX9930 and Orladeyo (berotralstat) from BioCryst for an upfront cash payment of $150 million. Additionally, we paid $50 million to purchase 3,846&#160;thousand shares of common stock in BioCryst, which was calculated based on the volume-weighted average price of BioCryst common stock over a period preceding the closing of the transaction. The funds from this transaction will enable further advancement of BCX9930 and support additional investment in the global launch of Orladeyo (berotralstat). </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In June 2021, we announced a long-term strategic funding partnership with MorphoSys AG (&#8220;MorphoSys&#8221;) to support MorphoSys&#8217; acquisition of Constellation Pharmaceuticals, Inc. (&#8220;Constellation&#8221;), which closed on July 15, 2021. We agreed to provide up to $2.025&#160;billion of funding to MorphoSys, comprised of an upfront payment of $1.425&#160;billion, additional milestone payments of up to $150&#160;million, up to $350&#160;million of capital (&#8220;Development Funding Bonds&#8221;), which MorphoSys may draw over a one-year period from the close of its acquisition of Constellation. MorphoSys is required to draw a minimum of $150&#160;million of Development Funding Bonds. In connection with the closing of MorphoSys&#8217; acquisition of Constellation, we purchased 1,337,552 ordinary shares of MorphoSys for $100 million at a price of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8364;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.35 per ordinary share, based on the average trading price of the ordinary shares over a period preceding the closing of the acquisition. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In April 2021, we acquired a royalty interest in Oxlumo from Dicerna Pharmaceuticals, Inc. for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments. Oxlumo, which has been approved by the FDA and EMA for the treatment of primary hyperoxaluria (PH) type 1, is marketed by Alnylam.  </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In March 2021, we acquired a royalty interest in the cabozantinib products Cabometyx and Cometriq from GSK for an upfront payment of $342 million and up to $50 million in additional payments contingent on the achievement of regulatory approvals of cabozantinib for prostate cancer and lung cancer in the United States and Europe.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In January 2021, we acquired a royalty interest in seltorexant from Minerva Neurosciences, Inc. for an upfront payment of $60 million and up to $95 million in additional milestone payments, contingent on the achievement of certain clinical, regulatory and commercialization milestones. Seltorexant is currently in Phase 3 development for the treatment of major depressive disorder (MDD) with insomnia symptoms by Johnson &amp; Johnson. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In December 2020, we acquired royalty interests from BioCryst on (1) Orladeyo (berotralstat) to support the launch of the product in hereditary angioedema (HAE) and (2) its development stage Factor D inhibitor BCX9930 in exchange for an upfront cash payment of $125 million. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In October 2020, we acquired the residual royalty interest in Vertex&#8217;s cystic fibrosis franchise owned by the Cystic Fibrosis Foundation. The agreement includes an upfront payment of $575 million and a potential milestone payment of $75 million.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In August 2020, we entered into an expanded agreement with Biohaven for up to $450 million to fund the development of zavegepant and the commercialization of Nurtec ODT. Biohaven received an upfront payment of $150 million at closing and received an additional $100 million payment in March 2021 upon the start of the oral zavegepant Phase 3 program. We will receive a royalty on Nurtec ODT and zavegepant and success-based milestone payments based on zavegepant regulatory approvals. We are also committed to provide further support for the ongoing launch of Nurtec ODT through the purchase of committed, non-contingent Commercial Launch Preferred Equity (defined below) for a total of $200 million payable on a quarterly basis from the three months ended March 31, 2021 through the three months ended December 31, 2024. In return, Biohaven will pay a series of equal fixed payments from the three months ended March 31, 2025 through the three months ended December 31, 2030.</span></div><div style="padding-left:18pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In July 2020, we acquired a royalty on risdiplam, a development-stage product for the treatment of Types 1, 2 and 3 spinal muscular atrophy (SMA) from PTC Therapeutics, Inc. in exchange for an upfront payment of $650 million. Evrysdi (risdiplam) was subsequently approved by the FDA in August 2020, representing the first, oral treatment approved for infants, children and adults with all SMA types.</span></div><div style="padding-left:18pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In June 2020, we acquired a royalty on (1) Prevymis, an approved product to prevent cytomegalovirus infection in stem cell transplants, from AiCuris Anti-infective Cures GmbH in exchange for an upfront payment of $220 million and (2) IDHIFA, an approved product for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 mutation, from Agios Pharmaceuticals, Inc. in exchange for an upfront payment of $255 million. </span></div><div style="text-indent:55.05pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In March 2020, we acquired a royalty on Entyvio, an approved product for the treatment of ulcerative colitis and Crohn&#8217;s disease, from The General Hospital Corporation in exchange for an upfront payment of $86.6 million. </span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In the fourth quarter of 2019, we agreed to pay $320 million to acquire from Ultragenyx Pharmaceutical, Inc. a royalty on the European sales of Crysvita, an approved product for the treatment of x-linked hypophosphatemia, a rare genetic orphan disease that has a profound impact on bone development in adults and children, subject to certain caps. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In the fourth quarter of 2019, we agreed to pay up to $330 million to purchase a royalty owned by Eisai, on future worldwide sales outside Japan of Tazverik (tazemetostat), a novel targeted therapy in late-stage clinical development with the potential to be approved in several cancer indications. We acquired a portion Eisai&#8217;s future worldwide royalties on net sales by Epizyme of Tazverik outside Japan, for an upfront payment of $110 million plus up to an additional $220 million for the remainder of the royalty upon FDA approval of Tazverik for certain indications. The FDA approved Tazverik in January 2020 for epithelioid sarcoma which triggered our obligation to fund the second $110 million tranche in November 2020. In June 2020, the FDA approval of additional indications triggered our recognition of a liability for the final tranche of $110.0&#160;million, which was paid in November 2021.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In the fourth quarter of 2019, we made a $100 million investment in Epizyme. In exchange for an upfront payment of $100 million, we received (1) shares of Epizyme common stock, (2) a warrant to purchase an additional 2.5 million shares of Epizyme common stock at $20 per share over a three-year term and (3) Epizyme&#8217;s royalty on sales of Tazverik in Japan payable by Eisai. We also lowered Epizyme&#8217;s royalty on Tazverik above certain sales thresholds and granted Epizyme an 18-month put option to sell an additional $50 million of its common stock to RPIFT at then-prevailing prices, not to exceed $20 per share. Epizyme exercised its put option on December 30, 2019, which resulted in Epizyme issuing RPIFT 2.5 million shares on settlement in February 2020. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In the first quarter of 2019, we entered into a preferred share purchase agreement with Biohaven through which we purchased $125 million in Series A Preferred Shares, providing us with a fixed return on redemption of two times our investment on FDA approval of Biohaven&#8217;s pipeline product, Nurtec ODT, for migraine treatment. The FDA approved Nurtec ODT for the acute treatment of migraine in adults in February 2020. </span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In the first quarter of 2019, we acquired the following: (1) a royalty on Promacta, an approved product for the treatment of chronic immune thrombocytopenia and aplastic anemia, from Ligand Pharmaceuticals in exchange for an upfront payment of $827 million, (2) a royalty on Lilly&#8217;s Emgality, an approved product for the treatment of migraine, from Atlas Ventures and Orbimed for $260 million and (3) a royalty on Johnson &amp; Johnson&#8217;s Erleada, an approved product for the treatment of prostate cancer, from the Regents of the University of California for $105.4 million and potential future milestones.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in April 2021, we entered into an agreement with MSCI Inc. (&#8220;MSCI&#8221;), a leading provider of critical decision support tools and services where we will assist MSCI to design a classification framework and index methodologies which will expand MSCI&#8217;s thematic index suite with the launch of new indexes. In return, we will receive a portion of MSCI&#8217;s revenues from those indexes. The financial statement impact associated with this transaction was not material for the year ended December 31, 2021.</span></div><div><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_73"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Liquidity and Capital Resources </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Overview </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our primary source of liquidity is cash provided by operations. For the years ended December 31, 2021, 2020 and 2019, we generated $2.0&#160;billion, $2.0&#160;billion and $1.7&#160;billion, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We believe that our existing capital resources, cash provided by operating activities and our Revolving Credit Facility will continue to allow us to meet our operating and working capital requirements, to fund planned strategic acquisitions and R&amp;D funding arrangements, and to meet our debt service obligations for the foreseeable future. We have historically operated at a low level of fixed operating costs. Our primary cash operating expenses, other than R&amp;D funding commitments, include interest expense, our Operating and Personnel Payments, and legal and professional fees. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have access to substantial sources of funds in the capital markets and we may, from time to time, seek additional capital through a combination of additional debt or equity financings. In June 2020, we completed our IPO and received net proceeds of approximately $1.9&#160;billion from the IPO after deducting underwriting discounts and commissions of approximately $86.3&#160;million. In February 2020, in connection with the Exchange Offer Transactions, we repaid outstanding debt held by RPIFT in full and issued new long-term debt at RPI Intermediate FT. In September 2020, we repaid in full our senior secured credit facilities entered into in February 2020 using the proceeds of the 2020 Notes in addition to cash on hand. In July 2021, we issued an additional $1.3 billion of senior unsecured notes. Additionally, we have a Revolving Credit Facility which provides for borrowing capacity of up to $1.5 billion that remains undrawn and available to us as of December 31, 2021. As of December 31, 2021 and 2020, we had total long-term debt outstanding of $7.1&#160;billion and $5.8&#160;billion, respectively.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have historically funded our acquisition program through free cash flow, equity contributions and debt. Our low operating costs coupled with a lack of capital expenditures and low taxes have contributed to our strong financial profile, resulting in high operating leverage and high conversion of our Adjusted Cash Receipts to Adjusted Cash Flow. We expect to continue funding our current and planned operating costs (excluding acquisitions) principally through our cash flow from operations and our acquisition program through cash flow and issuances of equity and debt. In the past, we have supplemented our available cash and cash equivalents on hand with attractive debt capital to fund certain strategic acquisitions.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to satisfy our working capital needs, debt service and other obligations, and to comply with the financial covenants under our financing agreements depends on our future operating performance and cash flow, which are in turn subject to prevailing economic conditions and other factors, many of which are beyond our control. </span></div><div><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash flows </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">following table and analysis of cash flow changes presents a summary of our cash flow activity for the year ended December 31, 2021 compared to the year ended December 31, 2020. For a discussion of the year ended December 31, 2020 compared to the year ended December 31, 2019, please refer to Part II, Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 vs 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,017,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,034,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,093)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Investing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,870,280)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,759,320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">889,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Financing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,487,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,102,060)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Analysis of Cash Flow Changes</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Years ended December 31, 2021 and 2020</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities decreased by $17.1&#160;million in the year ended December 31, 2021 compared to the year ended December 31, 2020, primarily driven by an increase of $187.4&#160;million in upfront R&amp;D funding and an increase of $27.2&#160;million in interest paid. The increase was driven by upfront R&amp;D funding payments of $103.2 million related to an additional royalty on a development-stage product acquired in connection with our expanded funding agreement with BioCryst and $90.0 million related royalties on two development-stage products acquired from MorphoSys. The increase in interest paid was primarily due to the shift from quarterly to semi-annual interest payments with the issuance of the 2020 Notes, for which we did not make any interest payments on the 2020 Notes in the year ended December 31, 2020. The higher uses of cash were partially offset by an increase in cash collections from financial royalty assets of $193.9 million.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Investing activities</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Years ended December 31, 2021 and 2020</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities decreased by $889.0&#160;million in the year ended December 31, 2021 compared to the year ended December 31, 2020, primarily driven by a $1.3&#160;billion increase in the overall net cash provided by marketable securities which was partially offset by a decrease of $268.9&#160;million in proceeds from equity securities. We received $116.0 million related to the sale of our Cytokinetics common stock and a portion of our Biohaven common shares in the year ended December 31, 2021, as compared to $384.8&#160;million received from the full redemption of our investment in Immunomedics common stock upon its acquisition by Gilead in the fourth quarter of 2020. The decrease in cash used in investing activities was further offset by an increase of $85.1&#160;million in purchases of equity securities. We purchased $135.1 million of equity securities in Morphosys and BioCryst in the year ended December 31, 2021, compared to purchases of equity securities of $50.0 million related to the exercise of the Epizyme put option in the year ended December 31, 2020.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Financing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Years ended December 31, 2021 and 2020</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash provided by financing activities decreased by $1.1&#160;billion in the year ended December 31, 2021 compared to the year ended December 31, 2020, primarily driven by the $1.9 billion net proceeds received from our IPO in June 2020. Offsetting the decreases in cash provided by financing activities were net proceeds of $1.3 billion from issuance of 2021 Notes in the year ended December 31, 2021 compared to the net proceeds of $727.9 million related to the debt refinancings in the year ended December 31, 2020. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Sources of Capital </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2021, our cash and cash equivalents and marketable securities totaled $1.5&#160;billion and $581.9 million, respectively. As of December 31, 2020, our cash and cash equivalents and marketable securities totaled $1.0&#160;billion and $983.3 million, respectively. We intend to fund short-term and long-term financial obligations as they mature through cash and cash equivalents, sales of marketable securities, future cash flows from operations or the issuance of additional debt. Our ability to generate cash flows from operations, issue debt or enter into financing arrangements on acceptable terms could be adversely affected if there is a material decline in the sales of the underlying pharmaceutical products in which we hold royalties, deterioration in our key financial ratios or credit ratings, or other material unfavorable changes in business conditions. Currently, we believe that we have sufficient financial flexibility to issue debt, enter into other financing arrangements and attract long-term capital on acceptable terms to support our growth objectives. </span></div><div><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Borrowings </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our borrowings at </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2021 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2020 consisted of the following (in thousands):</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:37.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 0.75% (issued at 99.322% of par)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.20% (issued at 98.875% of par)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.75% (issued at 98.284% of par)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 2.20% (issued at 97.760% of par)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$600,000, 2.15% (issued at 98.263% of par)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2031</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.30% (issued at 95.556% of par)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2040</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.55% (issued at 95.306% of par)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2050</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$700,000, 3.35% (issued at 97.565% of par)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2051</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total senior unsecured debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,000,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(203,930)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(183,416)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,096,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,816,584</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">Senior Unsecured Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 26, 2021, we issued $1.3 billion of the 2021 Notes with a weighted average coupon rate of 2.80% and requiring annual interest payments of approximately $36.4 million, paid semi-annually. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 2, 2020, we issued $6.0 billion of the 2020 Notes with a weighted average coupon rate of 2.125% and requiring annual interest payments of approximately $127.5 million, paid semi-annually. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We used the net proceeds from the 2020 Notes offering, together with available cash on hand, to repay in full the senior secured credit facilities. Indentures governing the Notes contain certain covenants, which w</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e were in compliance with as of December 31, 2021.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Senior Unsecured Revolving Credit Facility</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 15, 2021, we entered into an amended and restated revolving credit agreement (the &#8220;Credit Agreement&#8221;). The Credit Agreement amends and restates the credit agreement that our subsidiary, RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured Revolving Credit Facility with borrowing capacity of up to $1.5 billion for general corporate purposes. The Credit Agreement extends the maturity of the Revolving Credit Facility to September 15, 2026. The Credit Agreement contains certain customary covenants, which we were in compliance as of December 31, 2021. The Revolving Credit Facility remains undrawn and available to us as of December 31, 2021.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Senior Secured Credit Facilities </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 11, 2020, in connection with the Exchange Offer Transactions and using funds contributed by RPI Intermediate FT and the Legacy Investors Partnerships, RPIFT repaid its outstanding debt and accrued interest, and terminated all outstanding interest rate swaps. RPI Intermediate FT, as borrower, entered into a term loan credit agreement with Bank of America, N.A., as administrative agent, the lenders party thereto from time to time and the other parties thereto. In September 2020, we repaid in full the outstanding principal amounts of term loans under the senior secured credit facilities with the net proceeds from the 2020 Notes and available cash on hand.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">RPIFT Senior Secured Credit Facilities</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The RPIFT Senior Secured Credit Facilities were repaid in full in February 2020 and new senior secured credit facilities were issued by RPI Intermediate FT in connection with the Exchange Offer Transactions.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Uses of Capital </span></div><div><span><br/></span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Acquisitions of royalties </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We acquire product royalties in a variety of ways that can be tailored to the needs of our partners. We classify our product royalty acquisitions by the following structures: </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Third-party Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; A royalty is the contractual right to a percentage of top-line sales from a licensee&#8217;s use of a product, technology or intellectual property. The majority of our current portfolio consists of third-party royalties. </span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Synthetic / Hybrid Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; A synthetic royalty is the contractual right to a percentage of top-line sales created by the developer and/or marketer of a therapy in exchange for funding. A synthetic royalty may also include contingent milestone payments, or be structured as a long-term stream of fixed-payments with a predetermined schedule. In many of our synthetic royalties, we also make investments in the public equity of the company, where the main value driver of the company is the product for which we concurrently acquired a royalty. </span></div><div style="text-indent:55.05pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:18.3pt">R&amp;D Funding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#8211; We have historically funded ongoing R&amp;D, typically for large biopharmaceutical companies, in exchange for future royalties and/or milestones if the product or indication we are funding is approved. We have also made upfront R&amp;D payments to biotechnology companies to acquire royalties and/or milestones on development-stage product candidates. </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">M&amp;A </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We acquire royalties in connection with M&amp;A transactions, often from the buyers of biopharmaceutical companies when they dispose of the non-strategic assets of the target company following the closing of the acquisition. We also seek to partner with companies to acquire other biopharmaceutical companies that own significant royalties. We may also seek to acquire biopharmaceutical companies that have significant royalties or where we can create royalties in subsequent transactions. </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Distributions to Shareholders/Unitholders </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We paid dividends to holders of our Class A ordinary shares of $285.2&#160;million in the year ended </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We do not have a legal obligation to pay a quarterly dividend or dividends at any specified rate or at all. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We made distributions of $285.4&#160;million to shareholders/unitholders prior to the IPO in June 2020. We paid dividends to holders of our Class A ordinary shares of $112.5&#160;million in the year ended December 31, 2020 subsequent to the IPO. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We made distributions of $739.3&#160;million to unitholders in the year ended December 31, 2019. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Funding Arrangements</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2021, we announced a long-term strategic funding partnership with MorphoSys to support MorphoSys&#8217; acquisition of Constellation, which closed on July 15, 2021. As part of the partnership, we agreed to provide MorphoSys up to $350 million of Development Funding Bonds, which MorphoSys may draw over a one-year period from the close of its acquisition of Constellation. MorphoSys is required to draw a minimum of $150 million of Development Funding Bonds. In return, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years, with the first payment beginning two years after the funding. As of December 31, 2021, MorphoSys has not drawn any amount under the Development Funding Bonds.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 7, 2020, we entered into the Series B Biohaven Preferred Share Purchase Agreement (&#8220;Series B Biohaven Preferred Share Agreement&#8221;) with Biohaven where we committed to acquire 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share (the &#8220;Commercial Launch Preferred Equity&#8221;), for a total of $200.0&#160;million payable on a quarterly basis from the three months ended March 31, 2021 through the three months ended December 31, 2024. In the three months ended March 31, 2021, we began purchasing the Series B Biohaven Preferred Shares </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and have a remaining commitment of $129.6&#160;million under our Commercial Launch Preferred Equity as of December 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have other funding arrangements where we are contractually obligated to fund R&amp;D activities performed by our development partners and to provide additional capital related to our equity method investment in the Avillion entities. As our committed capital requirements are based on phases of development, the completion of which is highly uncertain, only the capital required to fund the current stage of development under such funding arrangements is considered committed capital requirements which approximate $41.0&#160;million as of December 31, 2021. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We also have certain milestone payments that are contingent on the successful achievement of certain development, regulatory approval or commercial milestones. As such, these contingent milestone payments are not considered contractual obligations. In the year ended December 31, 2021, we made a $100.0 million payment to Biohaven related to a development milestone that was achieved upon the start of the oral zavegepant Phase 3 program. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Debt service </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">As of December 31, 2021, the future principal and interest payments under our Notes over the next five years and thereafter are as follows: </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Interest Payments</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,384&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,300,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,070,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,858,534&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1) Excludes unamortized debt discount and issuance costs of $203.9&#160;million as of December 31, 2021, which are amortized through interest expense over the remaining life of the underlying debt obligations. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating and Personnel Payments</span></div><div style="padding-left:13.5pt;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Under the Management Agreement, we pay quarterly Operating and Personnel Payments equal to 6.5% of the Adjusted Cash Receipts for such quarter and 0.25% of our security investments under GAAP as of the end of each quarter. Because the Operating and Personnel Payments is determined based on Adjusted Cash Receipts, the amounts are fixed. The expenses incurred in respect of Operating and Personnel Payments are expected to comprise the most significant component of G&amp;A expenses on an ongoing basis.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Guarantor Financial Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary (the &#8220;Guarantor Subsidiary&#8221;). Our remaining subsidiaries (the &#8220;Non-Guarantor Subsidiaries&#8221;) do not guarantee the Notes. Under the terms of the indenture governing the Notes, Royalty Pharma plc and the Guarantor Subsidiary each fully and unconditionally, jointly and severally, guarantee the payment of interest, principal and premium, if any, on the Notes. As of December 31, 2021, the par value and carrying value of the total outstanding and guaranteed Notes was $7.3&#160;billion and $7.1 billion, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following financial information presents summarized combined balance sheet financial information as of December 31, 2021, and summarized combined statement of operations information for the year ended December 31, 2021 for Royalty Pharma plc and RP Holdings. All intercompany balances and transactions between Royalty Pharma plc and RP Holdings are eliminated in the presentation of the combined financial statements. RP Holdings&#8217; most significant asset is its investment in operating subsidiaries, which has been eliminated in the table below to exclude investments in Non-Guarantor Subsidiaries. Our operating subsidiaries hold the majority of our cash and cash equivalents, marketable securities and financial royalty assets. As a result, our ability to make required payments on the Notes depends on the performance of our operating subsidiaries and their ability to distribute funds to us. There are no material restrictions on distributions from the operating subsidiaries. Amounts presented below do not represent our total consolidated amounts as of December 31, 2021 or for the year ended December 31, 2021.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.194%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Summarized Combined Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Current interest receivable on intercompany notes due from Non-Guarantor Subsidiaries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">16,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Non-current assets </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">4,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Non-current intercompany notes receivable due from Non-Guarantor Subsidiaries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2,039,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">59,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Current interest payable on intercompany notes due to Non-Guarantor Subsidiaries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">16,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">7,095,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current intercompany notes payable due to Non-Guarantor Subsidiaries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2,039,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.778%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Summarized Combined Statement of Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Interest income on intercompany notes receivable from Non-Guarantor Subsidiaries</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">187,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Interest expense on intercompany notes payable with Non-Guarantor Subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">50,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">11,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net loss </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">199,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="i15fafc99ab5c41deb08ee816ca47172c_82"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Critical Accounting Policies and Use of Estimates</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenue and expenses. Certain of these policies are considered critical as they have the most significant impact on our financial condition and results of operations and require the most difficult, subjective, or complex judgments, often because of the need to make estimates about the effect of matters that are inherently uncertain. On an ongoing basis, we evaluate our estimates that are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. The result of these evaluations forms the basis for making judgments about the carrying values of assets and liabilities and the reported amount of income and expenses that are not readily apparent from other sources. Because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our most critical accounting policies relate to our financial royalty assets and the full descriptions can be found in Note 2&#8211;Summary of Significant Accounting Policies to our consolidated financial statements. Similarly, the most significant judgments and estimates applied by management are associated with the measurement of our financial royalty assets at amortized cost using the prospective effective interest method. The application of the prospective approach to calculate interest income from our financial royalty assets requires management&#8217;s judgment in forecasting the expected future cash flows of the underlying royalties. These estimates and judgments arise because of the inherent uncertainty in predicting future events.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We evaluate financial royalty assets for impairment on an individual basis by comparing the effective interest rate at each reporting date to that of the prior period. If the effective interest rate for the current period is lower than the prior period, and if the gross cash flows have declined (expected and collected), management records a provision for the change in expected cash flows. The provision is measured as the difference between the financial royalty asset&#8217;s amortized cost basis and the net present value of the expected future cash flows, calculated based on the prior period&#8217;s effective interest rate. The amount recognized as provision expense increases the financial royalty asset&#8217;s cumulative allowance, which reduces the net carrying value of the financial royalty asset. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Factors Impacting Expected Future Cash Flows</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amounts and timing of forecasted expected future cash flows are largely influenced by sell-side equity research analyst coverage, commercial performance of the product and the royalty duration.</span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19pt">Analyst coverage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Forecasts of expected future cash flows are developed from sales projections of the underlying biopharmaceutical products as published in sell-side equity research analyst reports. In projecting future cash flows, our policy is to rely on sell-side research analysts&#8217; consensus sales forecasts for a product to derive annual sales projections for each financial royalty asset over the periods for which we are entitled to royalties or milestones. When royalty-bearing biopharmaceutical products have no coverage, limited sell-side equity research analyst coverage or where sell-side equity research analyst estimates are not available for the full term of the royalty, particularly for the later years in a product&#8217;s life, management uses reasonable judgment to make assumptions about the growth or decline in the sales of these products based on historical data, market trends and management&#8217;s own expertise.</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19pt">Commercial performance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The approval of a product for use in new indications can extend the date through which we are entitled to royalties or milestones on that product. For certain financial royalty assets, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and whose sales were previously not reflected in expected future cash flows. We generally do not recognize income from, or forecast sales for, unapproved products or indications. If a product is removed from all or a portion of a market, subsequent sell-side equity research analysts&#8217; forecasts will reflect the expected drop in sales. Both the new cash flow streams and the cessation of cash flow streams related to a product&#8217;s performance in the market over the royalty term can materially affect our forecast of expected future cash flows. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19pt">Royalty duration. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The duration of a financial royalty asset can be based on a number of factors, such as regulatory and marketing approval dates, patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, strength of patent protection, the entry of generics or a contractual date arising from litigation, which are all impacted by the time in the product&#8217;s life cycle at which we acquire the financial royalty asset. Royalty duration varies by geography as United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms. Products may be covered by a number of patents and, for products whose royalty term is linked to the existence of valid patents, management is required to make judgments about the patent providing the strongest patent protection to align the period over which management forecasts expected future cash flows to the royalty term. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Significant Assumptions Applied in Developing Forecasted Expected Future Cash Flows</span></div><div style="padding-left:9pt;text-indent:-4.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant assumptions used in forecasting the expected future cash flows for our royalties and requiring management&#8217;s judgement include (1) estimates of the duration of the royalty</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which includes consideration of the strength of patent protection and anticipated entry of generics,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and (2) sales trends and product growth rates in outer years of the royalty term, which are primarily based on statistical models. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalty duration is important for purposes of accurately measuring interest income over the life of a financial royalty asset. In making assumptions around the royalty duration for terms that are not contractually fixed, management considers the strength of existing patent protection, expected entry of generics, geographical exclusivity periods and potential patent term extensions tied to the underlying product. It is common for royalty durations to expire earlier or later than anticipated due to unforeseen developments over time, including with respect to the granting of patents and patent term extensions, the invalidation of patents, litigation between the party controlling the patents and third party challengers of the patents, the ability of third parties to design around or circumvent valid patents, the granting of regulatory exclusivity periods or extensions, timing for the arrival of generic or biosimilar competitor products, changes to legal or regulatory regimes affecting intellectual property rights or the regulation of pharmaceutical products, product life cycles, and industry consolidations.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When royalty-bearing pharmaceutical products have limited or no coverage by sell-side equity research analysts, or where sell-side equity research analyst estimates are not available for the full term of our royalty, particularly for the later years in a product&#8217;s life, we generally incorporate a statistical curve developed using historical sales data and available consensus sales projections to forecast product sales over the remaining life of the product. In cases where the statistical curve is not used, we use reasonable judgment to make assumptions about the growth or decline in the sales of these products based on historical data, publicly available information for the marketer, industry data and market trends and our own expertise. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even though we believe interest income from financial royalty assets and the associated non-cash provision for changes in future cash flows are not indicative of our near-term financial performance and should not be used as a source for predicting future income or growth trends, changes in the aforementioned assumptions could result in a material impact to our financial statements. A shortened royalty term can result in a reduction in interest income, significant reductions in total royalty payments over time compared to expectations or a permanent impairment. If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected) this would result in the immediate recognition of non-cash provision expense even though the applicable cash inflows will not be realized for many years into the future. Changes in sell-side equity research analyst consensus sales forecasts directly impact future interest income and recognition of any provision income or expense in a similar manner.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Below is a summary of the sensitivity of our current year results in relation to the royalty duration for our top three financial royalty assets based on net carrying value as of December 31, 2021. Because these are long-dated financial royalty assets, we have assumed a change of two years in the estimated duration to sensitize the financial statement impact. The effect of a change in estimated duration is the factor that would have the most significant impact on our consolidated statement of operations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">There have not been any significant changes to the estimated duration of expected future cash flows for our top three financial royalty assets during the years ended December 31, 2021, 2020 and 2019, with the exception of the cystic fibrosis franchise due to the FDA approval of Trikafta in 2019, which extended the expected duration at that time. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the duration of these financial royalty assets were extended by two years by assuming the statistically projected growth trends continue and all other royalty terms and assumptions remain unchanged, any impact to interest income would not be reflected until the subsequent period and is therefore not disclosed below. However, an extended duration for a financial royalty asset could result in the reduction of any cumulative allowance for changes in expected future cash flows, which would be recognized in the current period as provision income and is reflected in the table below for these top three financial royalty assets. If the duration for these financial royalty assets were shortened by two years by eliminating the estimated expected future cash flows for the final two years while keeping all other royalty terms and assumptions unchanged, we would recognize immediate incremental provision expense in the current period as a result of applying the prospective method of the effective interest rate methodology. The disclosure of the duration sensitivity below does not include any consideration of the related allowance for current expected credit losses. The impact of these sensitivity assumptions is summarized as follows (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:20.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.839%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Duration Assumption Applied </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Provision (Income)/Expense for Changes in Expected Cash Flows</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;+/- 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;+/- 2 years  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;+/- 2 years </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(99,398)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt">Dates shown represent our estimates as of the date of this Annual Report on Form 10-K of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, our estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of generic entry. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt">Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Accounting Pronouncements </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Note 2&#8211;Summary of Significant Accounting Policies to our consolidated financial statements for additional information on recently issued accounting standards. </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_85"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. &#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Market Risk </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to certain risks which may affect our results of operations, cash flows and fair values of assets and liabilities, including volatility in foreign currency exchange rates and interest rates. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because the nature of the marketable securities we hold. In order to manage our exposures, we follow established risk management policies and procedures, including the use of derivative financial instruments, such as swaps, rate locks and forwards. We do not enter into derivative instruments for trading or speculative purposes. The counterparties to these contracts are all major financial institutions. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Foreign Currency Exchange Risk </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our results of operations are subject to foreign currency exchange risk through transactional exposure resulting from movements in exchange rates between the time we recognize royalty income or royalty revenue and the time at which the transaction settles, or we receive the royalty payment. The current portion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial royalty assets, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accrued royalty receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> account for the most common types of transactional exposure. Because we are entitled to royalties on worldwide sales for various products, there is an underlying exposure to foreign currency as the marketer converts payment amounts from local currencies to U.S. dollars using a quarterly average exchange rate. Therefore, cash received may differ from the estimated receivable based on fluctuations in currency. In addition, certain products pay royalties in currencies other than U.S. dollars, which also creates foreign currency risk primarily with respect to the Euro, Canadian Dollar, Swiss Franc and Japanese Yen, as our functional and reporting currency is the U.S. dollar. To manage foreign currency exchange risk, we may periodically utilize non-deliverable forward exchange contracts. We do not currently have any foreign exchange contracts in place. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest Rate Risk </span></div><div style="text-indent:12.2pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to interest rate fluctuation exposure through our investments in money market accounts and marketable securities, the majority of which bear a variable interest rate. As of December 31, 2021, we held cash and cash equivalents of $1.5 billion, of which $887.8&#160;million was cash, $598.3&#160;million was invested in interest-bearing money market funds and $55.0&#160;million was invested in commercial paper and certificates of deposit. We also held $581.9 million in marketable securities at December 31, 2021 which was invested in commercial paper and certificates of deposit. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2020, we had cash and cash equivalents of $1.0 billion, of which $832.7 million was cash, $151.7 million was invested in commercial paper and certificates of deposit and $24.3&#160;million was invested in interest-bearing money market funds. In addition, as of December 31, 2020, we had $983.3 million in marketable securities which was invested in corporate debt securities, commercial paper and certificates of deposit. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The objectives of our investment policy are the preservation of capital and fulfillment of liquidity needs. In order to maximize income without assuming significant market risk, we maintain our excess cash and cash equivalents in money market funds and marketable securities, largely composed of investment grade, short to intermediate term fixed income and debt securities. Because of the short term maturities of our cash equivalents and the short term nature of our marketable securities, we do not believe that a decrease in interest rates would have any material negative impact on the fair value of our cash equivalents or marketable securities. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our debt portfolio is managed on a consolidated basis and management makes financing decisions to achieve the lowest cost of debt capital and to maximize portfolio objectives. As of December 31, 2021, 100% of our outstanding debt has fixed interest rates. We have a $1.5 billion Revolving Credit Facility with a variable interest rate that remained undrawn as of December 31, 2021. We are subject to interest rate fluctuation exposure related to the Revolving Credit Facility, if drawn. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may manage our exposure to interest rate volatility on future debt issuances by entering into treasury rate lock contracts to lock in the rate on the interest payments related to anticipated debt issuances. In June 2021, we executed treasury rate lock contracts with notional amounts totaling $600.0 million to fix the interest rate on a portion of the principal related to our 2021 Notes issued in July 2021. The treasury lock contracts were terminated in July 2021.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Credit and Counterparty Risk </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are exposed to credit risk related to the counterparties with which we do business. We are subject to credit risk from our royalty assets, our receivables and our derivative financial instruments. The majority of our royalty assets and receivables arise from contractual royalty agreements that pay royalties on the sales of underlying pharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading biopharmaceutical industry participants, including, among others, AbbVie, Amgen, Bristol Myers Squibb, Gilead, Johnson &amp; Johnson, Lilly, Merck, Pfizer, Novartis, Biogen, Roche/Genentech and Vertex. For the years ended December 31, 2021 and 2020, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32% and 27% of our current portion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial royalty assets, net, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">respectively, representing the largest individual marketer and payor of our royalties. Refer to &#8220;&#8212;Understanding Our Results of Operations&#8221; within this MD&amp;A for a discussion of the marketers or royalty payors accounting for 10% or more of our total income and other revenues for the years ended December 31, 2021 and 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements and to our derivative financial instruments so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets or on the settlement of our derivative financial instruments. If a counterparty becomes bankrupt, or otherwise fails to perform its obligations under a derivative financial instruments due to financial difficulties, we may experience significant delays in obtaining any recovery under the derivative financial instruments in a bankruptcy or other reorganization proceeding. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i15fafc99ab5c41deb08ee816ca47172c_88"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data</span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_91"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Index to Audited Consolidated Financial Statements</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_94">Report</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_94">s</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_94"> of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID: <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185MS9mcmFnOjVkYWM2ZDg3N2NlYTRiMDViMTA3MDIyN2IzYTVlNmE1L3RhYmxlOmNmMmEyYTcyODcxZjQ4NzZiODJmODkyZTA0ZmNhNGVmL3RhYmxlcmFuZ2U6Y2YyYTJhNzI4NzFmNDg3NmI4MmY4OTJlMDRmY2E0ZWZfMC0wLTEtMS03Mzk5My90ZXh0cmVnaW9uOmUxODk3NDA5OTE1ODQ1OGJiMzk3N2Q0MTA5MmU0Yzk5XzE0MjkzNjUxMTYxMTg5_4afbef89-8e7a-4391-b235-4e03c96580b9">1411</ix:nonNumeric>)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_94">87</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_97">Consolidated Balance Sheets at December 31, 2021 and 2020</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_97">90</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_100">Consolidated Statements of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_100">Operations </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_100">for the Years Ended December 31, 2021, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_100">91</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_942">Consolidated Statements of Comprehensive Income </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_942">for the Years Ended December 31, 2021, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_942">92</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_103">Consolidated Statements of Shareholders&#8217; Equity for the Years Ended December 31, 2021, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_103">93</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_106">Consolidated Statements of Cash Flows for the Years Ended December 31, 2021, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_106">95</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_109">Notes to Consolidated Financial Statements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i15fafc99ab5c41deb08ee816ca47172c_109">96</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i15fafc99ab5c41deb08ee816ca47172c_94"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the Shareholders and the Board of Directors of Royalty Pharma plc </span></div><div><span><br/></span></div><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Opinion on the Financial Statements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited the accompanying consolidated balance sheets of Royalty Pharma plc (the &#8220;Company&#8221;) as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive income, shareholders' equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control &#8212; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 15, 2022 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Basis for Opinion</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Critical Audit Matter</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.316%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation of Financial Royalty Assets and related Interest Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As disclosed in Note 6 to the consolidated financial statements, the Company&#8217;s total financial royalty assets, net, were carried at $14,332,596 thousand as of December 31, 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">For the year ended December 31, 2021, the Company recognized income from financial royalty assets of $2,065,083 thousand. As explained in Note 2 to the consolidated financial statements, the Company&#8217;s financial royalty assets are measured at amortized cost using the prospective effective interest rate method.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Auditing the valuation of the financial royalty assets and related interest income involved complex auditor judgment, because the assumptions used by management to forecast the expected cash flows from the underlying royalties are forward-looking and are therefore affected by future economic and market conditions, such as the impact of the entry of competing or generic products to the market, among other uncertainties. The key assumptions used in the valuation of the financial royalty assets and related interest income are product growth rates applied to forecasted sales in the later years in the royalty life and the royalty duration.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">To test the valuation of the financial royalty assets and related interest income, our audit procedures included, among others, evaluating the methodology and completeness and accuracy of the data used to develop the key assumptions identified above. For example, with the support of statistical modelling specialists, we evaluated management&#8217;s statistical methodology for sales growth forecasts and performed sensitivity analysis over the resulting forecasted product sales. We also tested the inputs to the model, principally comprising historic product sales and third-party analyst estimates of nearer-term sales amounts, by comparing to analyst reports or published sales information. For royalty duration, among other procedures, we compared management&#8217;s assessment of the likely date of expiry of the Company&#8217;s cash flows against original purchase agreements, as well as independently assessing the royalty duration against available published information sources, such as those from regulatory bodies, counterparties, and product marketers.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We assessed the historical accuracy of management&#8217;s estimates by comparing expected cash flows to actual cash receipts. We also evaluated the related disclosures in the consolidated financial statements.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">/s/ <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NC9mcmFnOmExMjk4N2Q3NmIxYzRhY2I4MmZhZjM0YWVlYmU5ZTNkL3RleHRyZWdpb246YTEyOTg3ZDc2YjFjNGFjYjgyZmFmMzRhZWViZTllM2RfMTQyOTM2NTExNjgyNDE_fec55b1e-4930-474b-99ef-61741186cefa">Ernst &amp; Young</ix:nonNumeric> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We have served as the Company&#8217;s auditor since 2003.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NC9mcmFnOmExMjk4N2Q3NmIxYzRhY2I4MmZhZjM0YWVlYmU5ZTNkL3RleHRyZWdpb246YTEyOTg3ZDc2YjFjNGFjYjgyZmFmMzRhZWViZTllM2RfMTQyOTM2NTExNjgyNDI_235f928f-c5e2-499b-a5e9-194ec506fd03">Dublin, Ireland</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">February 15, 2022</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Report of Independent Registered Public Accounting Firm </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">To the Shareholders and the Board of Directors of Royalty Pharma plc  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Opinion on Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited Royalty Pharma plc&#8217;s (the Company) internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control &#8212; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, the Company  maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive income, shareholders' equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes and our report dated February 15, 2022 expressed an unqualified opinion thereon.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Basis for Opinion</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">/s/ <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NC9mcmFnOmExMjk4N2Q3NmIxYzRhY2I4MmZhZjM0YWVlYmU5ZTNkL3RleHRyZWdpb246YTEyOTg3ZDc2YjFjNGFjYjgyZmFmMzRhZWViZTllM2RfMTY0OTI2NzQ1NzE3MA_d632d262-3987-49af-869b-010e7e0fd204">Ernst &amp; Young</ix:nonNumeric> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NC9mcmFnOmExMjk4N2Q3NmIxYzRhY2I4MmZhZjM0YWVlYmU5ZTNkL3RleHRyZWdpb246YTEyOTg3ZDc2YjFjNGFjYjgyZmFmMzRhZWViZTllM2RfMTY0OTI2NzQ1NzE3MQ_cb3da1e1-781a-40e7-8923-e8a67ec2c830">Dublin, Ireland</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">February 15, 2022</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="i15fafc99ab5c41deb08ee816ca47172c_97"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"> CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">(In thousands, except par value)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNC0xLTEtMS0w_9d694a30-03a6-478a-9c3a-5077ea099a85">1,541,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNC0zLTEtMS0w_4c1fe4f2-d03b-44f4-9967-9870b4623fc2">1,008,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNi0xLTEtMS0w_0425e8d9-cb79-4949-ab6d-c8a17dea9d43">581,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNi0zLTEtMS0w_90fcc6df-354a-4acf-842a-af536eb56846">983,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNy0xLTEtMS0w_ac5237d5-df16-4044-8671-e55bafa1afad">614,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNy0zLTEtMS0w_d10243fa-c441-4a0d-9a2b-b7d393b61848">587,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accrued royalty receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="rprx:AccruedRoyaltyReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfOC0xLTEtMS0w_a9b0fa66-1075-4dc5-acec-4e4bd26b9cba">53,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="rprx:AccruedRoyaltyReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfOC0zLTEtMS0w_e0998049-6652-43ae-995a-bd2891237666">33,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTAtMS0xLTEtMA_83f81064-7ded-427a-9c2e-f4dedd940207">66,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTAtMy0xLTEtMA_76b2b3b7-b0ec-4892-b929-41ff35836d4c">69,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other royalty income receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="rprx:OtherRoyaltyIncomeReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTItMS0xLTEtMA_b3b311ac-bf0a-4157-8cab-3b99059ec921">15,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="rprx:OtherRoyaltyIncomeReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTItMy0xLTEtMA_f3a17d5d-0d92-4adc-8bcc-522610dd4865">6,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTMtMS0xLTEtMA_d3001db9-0723-4c21-a128-2a504550efbd">6,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTMtMy0xLTEtMA_d6007bd6-ace6-40a4-861d-820e2b31e5fb">8,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTQtMS0xLTEtMA_604e4198-9522-4b7c-9a0f-c9818507cfca">2,878,211</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTQtMy0xLTEtMA_33a24a65-4f5a-4726-b609-9a4b497e4528">2,696,898</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial royalty assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTYtMS0xLTEtMA_eee8ee1e-cb1e-40f0-a108-f36749f05f69">13,718,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTYtMy0xLTEtMA_6149af87-156a-4795-92a9-1c3e58529156">12,368,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Intangible royalty assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTctMS0xLTEtMA_760a89d7-6534-44ab-8a70-c6ef91eaf0d9">5,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTctMy0xLTEtMA_6694b9da-70c5-43ae-8e08-b85f61400601">28,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTgtMS0xLTEtMA_8ee46d5b-fdbb-4a45-9a3a-0a795d816b8a">269,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTgtMy0xLTEtMA_5bbd0296-2443-4631-905f-83ac511ea7bc">298,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTktMS0xLTEtMA_136eb21e-fc69-499e-ad4a-3cc1524da508">204,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTktMy0xLTEtMA_525204f1-929a-48f4-b946-d6b07885fc75">163,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments in non-consolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMjEtMS0xLTEtMA_b4ec4da8-6822-48bd-82da-fd539f16741e">435,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMjEtMy0xLTEtMA_f1d073ae-2495-49e3-b62c-5271363f4452">454,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMjItMS0xLTEtMA_7d331f1e-3a51-4676-a4da-9b4f4270e44a">4,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMjItMy0xLTEtMA_e2ec82c4-4582-479d-9a53-a54eb0a067bc">9,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMjQtMS0xLTEtMA_e8fc0ec8-fb60-4542-bc61-b04be12b6170">17,515,865</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMjQtMy0xLTEtMA_819f1491-9316-46b7-910b-9f661b07f6ba">16,020,286</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Liabilities and equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Distribution payable to non-controlling interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMjgtMS0xLTEtMA_ec232924-de0d-477e-ac80-133cd3b5f4be">107,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMjgtMy0xLTEtMA_f060a860-22c5-43c4-bb86-6a25c5cc3e85">126,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMjktMS0xLTEtMA_80671de2-69cd-44ca-b2fa-689eebffac9d">5,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMjktMy0xLTEtMA_304ddeb7-cdde-445c-9463-6cfbc8407aa2">10,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMzAtMS0xLTEtMA_2755bf03-7f4c-4099-89ad-6109aa4d4b23">57,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMzAtMy0xLTEtMA_fb49c03d-1f13-4530-8539-a1ed1361425a">42,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accrued purchase obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="rprx:AccruedPurchaseObligationCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMzEtMS0xLTEtMA_3376cf94-64a0-4137-bc51-00b630db14ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="rprx:AccruedPurchaseObligationCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMzEtMy0xLTEtMA_4b862bdb-2022-41b8-94dd-f3a55fcaa1cb">110,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMzUtMS0xLTEtMA_173b5a2d-ac7d-4f02-a87f-0384219f67b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMzUtMy0xLTEtMA_075d39a0-445f-4fc9-8e36-2b8d360f608f">18,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMzYtMS0xLTEtMA_bb81736d-5f08-4666-9d98-fc48b1d0a345">171,250</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMzYtMy0xLTEtMA_5236e29d-1f0b-4988-9019-473dfc2aa024">307,887</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMzgtMS0xLTEtMA_9af5b3cf-4cba-4059-be75-bbfab14475f1">7,096,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMzgtMy0xLTEtMA_79019cf9-dcce-4fda-82ea-427dd0ea3d3f">5,816,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDItMS0xLTEtMA_17901fff-bcb6-4467-8397-d47963eacdbf">7,267,320</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDItMy0xLTEtMA_924b1404-85d9-4a0f-941c-ff0ef2813e2d">6,124,471</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDQtMS0xLTEtMA_b11cd1cc-b5c3-443d-ab65-250a6bd10b1c"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDQtMy0xLTEtMA_73baac1e-ca80-4a9c-8d74-a250abfd3470"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Class&#160;A ordinary shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="i52867fbe6d2d4e9f9ef1cc8a39a6730d_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDctMC0xLTEtMC90ZXh0cmVnaW9uOmRhMjFhMzBiMWU1NjQ4YzM4YTJjOGQxNmE3MTkzMTk5XzI5_2603d842-4287-4df5-8826-e47e63411cd8"><ix:nonFraction unitRef="usdPerShare" contextRef="i7048c06f34e64e98a9f8db168c52ecf6_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDctMC0xLTEtMC90ZXh0cmVnaW9uOmRhMjFhMzBiMWU1NjQ4YzM4YTJjOGQxNmE3MTkzMTk5XzI5_c5f5ee44-c395-4dfa-ac6f-df3b7cb5367c">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i7048c06f34e64e98a9f8db168c52ecf6_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDctMC0xLTEtMC90ZXh0cmVnaW9uOmRhMjFhMzBiMWU1NjQ4YzM4YTJjOGQxNmE3MTkzMTk5XzQz_174256d9-40e1-419a-9999-06861313b2f4"><ix:nonFraction unitRef="shares" contextRef="i7048c06f34e64e98a9f8db168c52ecf6_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDctMC0xLTEtMC90ZXh0cmVnaW9uOmRhMjFhMzBiMWU1NjQ4YzM4YTJjOGQxNmE3MTkzMTk5XzQz_89e0a581-128b-4e60-a782-3b64a40c15af">432,963</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i52867fbe6d2d4e9f9ef1cc8a39a6730d_I20201231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDctMC0xLTEtMC90ZXh0cmVnaW9uOmRhMjFhMzBiMWU1NjQ4YzM4YTJjOGQxNmE3MTkzMTk5XzUw_5100cda5-b7a0-480c-a30d-5601b373bd0e"><ix:nonFraction unitRef="shares" contextRef="i52867fbe6d2d4e9f9ef1cc8a39a6730d_I20201231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDctMC0xLTEtMC90ZXh0cmVnaW9uOmRhMjFhMzBiMWU1NjQ4YzM4YTJjOGQxNmE3MTkzMTk5XzUw_c4f4588f-9940-4b28-b570-4d5fce9f410e">388,135</ix:nonFraction></ix:nonFraction> issued and outstanding, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7048c06f34e64e98a9f8db168c52ecf6_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDctMS0xLTEtMA_d2b6b39e-a6f4-4dcc-afdc-7488a5dc2fce">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52867fbe6d2d4e9f9ef1cc8a39a6730d_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDctMy0xLTEtMA_e2a8c5ce-5d4c-4553-85f4-34865bf3d234">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Class&#160;B ordinary shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="i46e28e4cc5cc4a16bbb2deb97423b415_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDgtMC0xLTEtMC90ZXh0cmVnaW9uOjg4MGZiZDhjY2RkMDQwMDBiMDQyZDc4ZTY1MGQ3ZjRhXzIw_87a24fc4-06e3-49ab-a260-3da3c1874611"><ix:nonFraction unitRef="usdPerShare" contextRef="ic092b803ad4d4d1bb1fc65733358f33f_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDgtMC0xLTEtMC90ZXh0cmVnaW9uOjg4MGZiZDhjY2RkMDQwMDBiMDQyZDc4ZTY1MGQ3ZjRhXzIw_feb12a08-d348-4a87-883c-a2191a1e4cdc">0.000001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ic092b803ad4d4d1bb1fc65733358f33f_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDgtMC0xLTEtMC90ZXh0cmVnaW9uOjg4MGZiZDhjY2RkMDQwMDBiMDQyZDc4ZTY1MGQ3ZjRhXzM0_a62c3fb5-69d8-499c-8e27-19b2342b76f7"><ix:nonFraction unitRef="shares" contextRef="ic092b803ad4d4d1bb1fc65733358f33f_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDgtMC0xLTEtMC90ZXh0cmVnaW9uOjg4MGZiZDhjY2RkMDQwMDBiMDQyZDc4ZTY1MGQ3ZjRhXzM0_fd8e2379-3270-4d45-a1a6-6a87d7e3b03c">174,213</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i46e28e4cc5cc4a16bbb2deb97423b415_I20201231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDgtMC0xLTEtMC90ZXh0cmVnaW9uOjg4MGZiZDhjY2RkMDQwMDBiMDQyZDc4ZTY1MGQ3ZjRhXzQx_2203e53f-6bb0-478e-955d-d68ba4379cb4"><ix:nonFraction unitRef="shares" contextRef="i46e28e4cc5cc4a16bbb2deb97423b415_I20201231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDgtMC0xLTEtMC90ZXh0cmVnaW9uOjg4MGZiZDhjY2RkMDQwMDBiMDQyZDc4ZTY1MGQ3ZjRhXzQx_7146b2da-8763-4fda-9037-ec662e5bc938">218,976</ix:nonFraction></ix:nonFraction> issued and outstanding, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic092b803ad4d4d1bb1fc65733358f33f_I20211231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDgtMS0xLTEtMA_4adf4eeb-782f-4469-b840-04cd32c7291e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46e28e4cc5cc4a16bbb2deb97423b415_I20201231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDgtMy0xLTEtMA_d1e3f447-fc88-4660-b8b2-b4a7b9e1d175">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Class R redeemable shares, &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="i953778adf0344a989190761672294312_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDktMC0xLTEtMC90ZXh0cmVnaW9uOjNjODNjNjllYTU2MDQ0OGFiN2I0NDY1YWI3ZjZjZmQxXzMx_55616155-3ec7-421a-ac0a-b478ed7b291e"><ix:nonFraction unitRef="gbpPerShare" contextRef="icd2e4870b58b4b92961362030330fa39_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDktMC0xLTEtMC90ZXh0cmVnaW9uOjNjODNjNjllYTU2MDQ0OGFiN2I0NDY1YWI3ZjZjZmQxXzMx_9a17a844-2d80-4ee1-a7f3-3ed3a983fec9">1</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="icd2e4870b58b4b92961362030330fa39_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDktMC0xLTEtMC90ZXh0cmVnaW9uOjNjODNjNjllYTU2MDQ0OGFiN2I0NDY1YWI3ZjZjZmQxXzQ1_2977bcf2-d1ce-4f10-882a-c5ab1c392980"><ix:nonFraction unitRef="shares" contextRef="icd2e4870b58b4b92961362030330fa39_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDktMC0xLTEtMC90ZXh0cmVnaW9uOjNjODNjNjllYTU2MDQ0OGFiN2I0NDY1YWI3ZjZjZmQxXzQ1_85d512d3-8fa2-47d0-bf5c-f73ef1190ea0">50</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i953778adf0344a989190761672294312_I20201231" decimals="-3" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDktMC0xLTEtMC90ZXh0cmVnaW9uOjNjODNjNjllYTU2MDQ0OGFiN2I0NDY1YWI3ZjZjZmQxXzUy_1e13a1a8-2be4-4388-865b-7f809676d1d2"><ix:nonFraction unitRef="shares" contextRef="i953778adf0344a989190761672294312_I20201231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDktMC0xLTEtMC90ZXh0cmVnaW9uOjNjODNjNjllYTU2MDQ0OGFiN2I0NDY1YWI3ZjZjZmQxXzUy_cd8d5069-d352-4e4c-9b80-2098c0920c9e">50</ix:nonFraction></ix:nonFraction> issued and outstanding, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd2e4870b58b4b92961362030330fa39_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDktMS0xLTEtMA_282ef2b1-82d7-49a1-8898-11f71c35ed1c">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953778adf0344a989190761672294312_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDktMy0xLTEtMA_87d9439a-8232-49a3-ba35-6878c769116e">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="INF" name="rprx:DeferredSharesParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyYmJkZWQ2ZGY4NTRhYTdiNTI2YzRiZmUyYzNmNTIzXzIx_55cdc29a-54b7-4ba6-b4a1-2e62b90da757"><ix:nonFraction unitRef="usdPerShare" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="INF" name="rprx:DeferredSharesParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyYmJkZWQ2ZGY4NTRhYTdiNTI2YzRiZmUyYzNmNTIzXzIx_c3f69ace-07ab-48ba-a9be-11d349ede039">0.000001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="rprx:DeferredSharesSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyYmJkZWQ2ZGY4NTRhYTdiNTI2YzRiZmUyYzNmNTIzXzM1_288614be-6041-44b2-9193-a54ad3886f54"><ix:nonFraction unitRef="shares" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="rprx:DeferredSharesSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyYmJkZWQ2ZGY4NTRhYTdiNTI2YzRiZmUyYzNmNTIzXzM1_da84e14c-2d6a-4459-875d-19e4afe52d5d">361,170</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="rprx:DeferredSharesSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyYmJkZWQ2ZGY4NTRhYTdiNTI2YzRiZmUyYzNmNTIzXzQy_1b63c73a-0b65-4a49-b491-a794ff401547"><ix:nonFraction unitRef="shares" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="rprx:DeferredSharesSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyYmJkZWQ2ZGY4NTRhYTdiNTI2YzRiZmUyYzNmNTIzXzQy_96b97851-ae58-4833-99ce-2c2f5695021c">316,407</ix:nonFraction></ix:nonFraction> issued and outstanding, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="rprx:DeferredSharesValueIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTAtMS0xLTEtMA_ed119ae8-f4b0-42e3-a9ce-46e157db1e7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="rprx:DeferredSharesValueIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTAtMy0xLTEtMA_d376ecda-f8bc-453b-83d6-c69b13dc289e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTEtMS0xLTEtMA_7ede3a2c-5f6d-4bf9-86ae-51888d4eb8c0">3,507,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTEtMy0xLTEtMA_4ca8eaf5-4ab2-4700-adf1-3531b1eb6d41">2,865,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTItMS0xLTEtMA_e0e84c37-733d-4f9e-95c8-124ed9e1aa85">2,255,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTItMy0xLTEtMA_b0e75f42-ad42-4971-88a7-1200e79c2a3a">1,920,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTMtMS0xLTEtMA_c741fbd8-fa6c-4980-a467-5e685175fce0">4,471,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTMtMy0xLTEtMA_d92de564-bda0-41c9-b80c-b637488e9edd">5,077,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTQtMS0xLTEtMA_79cab78f-96a8-4186-9599-4e263805b2fb">16,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTQtMy0xLTEtMA_3e139f17-0ccd-4900-9bee-94fee032c699">34,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Treasury interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTUtMS0xLTEtMA_8f809412-6531-4ae3-a18d-6fcb2ad00039">2,715</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTUtMy0xLTEtMA_d49e1472-574a-4c85-bdee-61a0667b9e13">2,317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTctMS0xLTEtMA_2bcadd78-7797-44e8-bc48-84e456012c24">10,248,545</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTctMy0xLTEtMA_05cf52c1-ccbf-4a89-97d1-58f5a617e90c">9,895,815</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total liabilities and shareholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTktMS0xLTEtMA_668d0321-bffe-4c4f-bdc7-34b12f566098">17,515,865</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTktMy0xLTEtMA_1d929fac-64c6-4c29-968e-1d211ebd2f48">16,020,286</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.  </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="i15fafc99ab5c41deb08ee816ca47172c_100"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"> CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">(In thousands, except per share amounts)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total income and revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1bd23e9eb02461c8e78d787a6ed33aa_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUtMS0xLTEtMA_d7f9d108-995d-4f5a-9de1-6f98862350d4">2,065,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25b8e421f3694fbcaafdb0d3eaa6b71f_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUtMy0xLTEtMA_bb496438-2e56-41df-9520-9ba9c556408a">1,959,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22755b6a900743c384bc4e39a0795f90_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUtNS0xLTEtMA_9c95793b-1c6f-4051-8e9f-bb148583deb9">1,648,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue from intangible royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1452e9acf8c84b5fa30c3213757d431e_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzYtMS0xLTEtMA_6f369ba2-dadf-41a5-82f5-d11644e5343b">171,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0297e01d516f433c9c55632b22b93b76_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzYtMy0xLTEtMA_382de8f3-23d1-4466-9273-de041fd4cbbe">143,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16e458adecdb45bfbf9b94d5656d1d13_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzYtNS0xLTEtMA_32060125-99d9-4d7f-9830-e1f1c1821d5d">145,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other royalty income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8996266cd2b47c186f6cb14ad934f59_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzctMS0xLTEtMzY4MzM_fb443aa6-7582-4c99-a35d-6d79135e4777">53,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2caa252cd23b45869207612ea8852d80_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzctMy0xLTEtMzcwMDE_879623a2-345f-4bd4-b3e9-e53b0972930c">18,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e6b58350b843a5b8d17f5da029afa2_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzctNS0xLTEtMA_5f9e3718-913c-4e77-a42b-23c936c4f297">19,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total income and other revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzgtMi0xLTEtMzY4MDQ_5441155e-13ee-463e-a6f6-6aecfbe883d1">2,289,463</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzgtMy0xLTEtMzcwMDE_6c397d08-0b1a-4740-bfd3-aac48fa112ac">2,122,353</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzgtNS0xLTEtMA_2a49f9d1-0c49-4993-88b8-c744a7f34869">1,814,254</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provision for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:ProvisionForLoanAndLeaseLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzExLTEtMS0xLTM3MDIx_682ff3e7-dcb3-4367-a9b9-835f0b2b9c51">452,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:ProvisionForLoanAndLeaseLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzExLTMtMS0xLTM3MDAx_3d2df153-0789-4b59-a2d8-b0ee0139331b">230,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ProvisionForLoanAndLeaseLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzExLTUtMS0xLTM2OTI4_c2664419-f1a9-49df-8b03-920d58c64efe">1,019,321</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development funding expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzExLTEtMS0xLTA_c562cbc5-52f0-4cf0-83be-bfeecdbc6cb9">200,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzExLTMtMS0xLTA_6f001109-e874-420c-9a35-8b29a07cc5a9">26,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzExLTUtMS0xLTA_8713a984-c233-4006-bb62-2065edc4f60d">83,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzEzLTEtMS0xLTA_60d65e7b-8449-4427-b051-6ee2e0810e76">22,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzEzLTMtMS0xLTA_e5861b70-80d6-4377-bb62-31ca3387259e">23,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzEzLTUtMS0xLTA_7aba3d47-ec0e-47a5-859b-edb28b8aa726">23,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzE0LTEtMS0xLTA_93c7767e-a445-4abc-ba3e-abca276dabdf">182,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzE0LTMtMS0xLTA_179abb64-ff15-4d2d-9b4e-825ec7e88f50">181,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzE0LTUtMS0xLTA_fe8189ef-485f-48af-b3e2-d46d0053665f">103,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:OtherCostAndExpenseOperating" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzE1LTEtMS0xLTM3MDIx_04e243ba-1c06-4b59-800c-c39dfde5602d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:OtherCostAndExpenseOperating" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzE1LTMtMS0xLTM3MDAx_20ac799a-1363-4761-9b17-6eeb54c7e1cc">65,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:OtherCostAndExpenseOperating" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzE1LTUtMS0xLTA_269145df-bd27-4f6d-aa27-f11710a812eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total operating expenses/(income), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzE2LTEtMS0xLTA_bf05ff64-b96d-432a-9f8f-699f955c4aaa">858,748</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzE2LTMtMS0xLTA_bdbbf7e8-d78f-41a7-8bc5-0be6c0dcd283">526,954</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzE2LTUtMS0xLTA_10d1698c-0260-489a-b1c6-05f3bbcce481">808,922</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzE4LTItMS0xLTM2ODA0_69aa1202-fb9a-4524-9246-2aeb2235097b">1,430,715</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzE4LTMtMS0xLTM3MDAx_7cb4b9e4-45cf-46f0-be34-a54247c4b682">1,595,399</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzE4LTUtMS0xLTA_c74cb7c4-8f30-4922-af0d-78911dacb4c1">2,623,176</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other expense/(income)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity in losses/(earnings) of non-consolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzIxLTEtMS0xLTA_78caa8fe-0a11-41fc-8486-e5487af73e5e">19,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzIxLTMtMS0xLTA_19e7a566-d9aa-426a-b5ac-954e7f58a523">44,459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzIxLTUtMS0xLTA_f576a628-b5ed-4aa4-bd8c-e714ca8ca692">32,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzIyLTEtMS0xLTA_f68662f9-5956-4a1d-8cc7-962fa28dd265">166,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzIyLTMtMS0xLTA_89542fc8-086b-46d7-8da3-503a6282f3c9">157,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzIyLTUtMS0xLTA_f5a52cfd-99e2-4b51-90b0-70abf2cae4f5">268,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI0LTEtMS0xLTA_9e6b24fb-041d-4658-82eb-af4b190702fe">21,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI0LTMtMS0xLTA_2060d33c-4858-4ebc-8c43-f652741e2a44">42,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI0LTUtMS0xLTA_7d37cf5d-f803-459d-bb83-365dcc08d2bc">39,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses/(gains) on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI1LTEtMS0xLTA_746543ba-69a9-4e9a-aeee-5aa3a9247ffc">48,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI1LTMtMS0xLTA_1c84e893-651f-48ac-82d1-655cdf511651">247,073</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI1LTUtMS0xLTA_16b18594-ad04-4e7f-ab4c-d555bb850fe4">155,749</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI3LTEtMS0xLTA_633d886b-58ad-4f6f-a9a7-461ab31ca16e">17,859</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI3LTMtMS0xLTA_3b93c519-f4f9-42b2-a325-9941bbeee720">18,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI3LTUtMS0xLTA_b8c1255a-4e11-49f4-adf3-54445946121f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI4LTEtMS0xLTA_19a68bce-149f-4916-8790-fc8746bb5b12">53,535</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI4LTMtMS0xLTA_1a7acb1c-568b-4c6d-9d69-e84e68635eab">28,379</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI4LTUtMS0xLTA_c93a5dd9-3e16-4d0d-bf0f-d00552861dbd">22,329</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other non-operating expense/(income), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI5LTEtMS0xLTA_51b75f31-6849-4c43-b682-71e82c46a14b">5,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI5LTMtMS0xLTA_739bfb87-690c-4e23-bbb8-fc1b15165d9e">32,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI5LTUtMS0xLTA_4a0da83d-0c9b-44cb-a473-4763b371b309">393</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total other expense/(income), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzMwLTEtMS0xLTA_c106593c-8118-42fa-a654-3214f40ea1b4">189,514</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzMwLTMtMS0xLTA_9dc9ea89-5f24-4563-9ec4-d655690aa987">106,555</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzMwLTUtMS0xLTA_20751982-e1c6-4099-b5ce-65fd83146a37">161,757</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Consolidated net income before tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzMxLTEtMS0xLTA_ed3a0269-fa84-477f-a0a1-959f29dd499c">1,241,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzMxLTMtMS0xLTA_161535f8-40d6-4ece-8a24-adde66b17e28">1,701,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzMxLTUtMS0xLTA_7de9195b-8f31-4fa3-92db-65845245c683">2,461,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzMyLTEtMS0xLTM3MDIx_94b6e703-c2ae-40f8-913c-7bd7d6732d6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzMyLTMtMS0xLTM3MDAx_53670c97-2362-45d9-ad22-1ed8afc89ba9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzMyLTUtMS0xLTA_0a797dd6-aa8b-41d6-8984-219ecc269171">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzMzLTEtMS0xLTA_e566b9a8-907e-4b0a-80b9-20f3ab3d3028">1,241,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzMzLTMtMS0xLTA_dfb93ba0-8888-43dd-83d7-e7bf59953ef5">1,701,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzMzLTUtMS0xLTA_e29ceb65-973c-4f1e-b5f2-911a115b0028">2,461,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzM1LTEtMS0xLTA_afad235f-8878-44a6-b7b3-1f495e57b92a">621,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzM1LTMtMS0xLTA_dc657c8d-3e09-42bb-95c6-e25de3034299">726,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzM1LTUtMS0xLTA_2b5d0d32-e586-4a76-ade9-9b7a3ffc3073">112,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income attributable to controlling interest</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzM3LTItMS0xLTM2ODA0_fe0ef37d-eef5-481b-abfb-3a53cf1bf7bd">619,728</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzM3LTMtMS0xLTM3MDAx_fa77b827-7d41-4e73-9512-41a488ab71dc">975,040</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzM3LTUtMS0xLTA_2cdc224f-9de0-448e-b5a1-23e990b1057d">2,348,535</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Earnings per Class A ordinary share (1):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUyLTEtMS0xLTA_4ebc0264-fc9b-41e8-bd70-756d832684b4">1.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUyLTMtMS0xLTA_76e4811f-8f61-4261-8b05-1bb3b6605340">1.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUzLTEtMS0xLTA_c5f85727-ab8f-46b3-91e4-92ac158a0433">1.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUzLTMtMS0xLTA_a435e31d-dffb-4b96-ba18-64e6deef6779">1.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average Class A ordinary shares outstanding (1):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzU1LTEtMS0xLTM3MDIx_4990eee5-dee5-4619-8a5d-ff70d21298b6">414,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzU1LTMtMS0xLTM3MDAx_492268b9-a345-4c82-840d-920ff3e1f7c8">375,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzU2LTEtMS0xLTM3MDIx_5072f657-16e7-4822-913b-4fa5624a9150">414,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzU2LTMtMS0xLTM3MDAx_e03bcac5-4b4c-4b66-a2e9-e6f0e4129fe4">375,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1) <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90ZXh0cmVnaW9uOmE0MTg4YTgxMGFkNTQ0OGY4ZWFhM2I1MTIzNWFiZjQ0XzQwMw_44e224c8-6066-4813-9082-30da4843a311" footnoteRole="http://www.xbrl.org/2003/role/footnote">Represents earnings per Class A ordinary share and weighted average Class A ordinary shares outstanding for the period from June 16, 2020 through December 31, 2020 following our initial public offering (&#8220;IPO&#8221;) in the year ended December 31, 2020. See Note 13&#8211;Earnings per Share.</ix:footnote></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="i15fafc99ab5c41deb08ee816ca47172c_942"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"> CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">(In thousands)</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzItMS0xLTEtNjY1Nzg_e566b9a8-907e-4b0a-80b9-20f3ab3d3028">1,241,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzItMy0xLTEtNjY1Nzg_dfb93ba0-8888-43dd-83d7-e7bf59953ef5">1,701,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzItNS0xLTEtNjY1Nzg_e29ceb65-973c-4f1e-b5f2-911a115b0028">2,461,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reclassification of loss on interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzMtMS0xLTEtNjY1NTE_28c266ab-8903-484d-8f86-9982dec4d103">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzMtMy0xLTEtNjY1NTE_3deaf153-afdd-4fc9-8879-3a2273a9b319">4,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzMtNS0xLTEtNjY1NTE_755a87b9-b311-4660-b7ae-7f736f860286">6,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzUtMS0xLTEtNjY1NTE_269b8b48-1935-42c5-aae3-9ce0ba57bed0">11,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzUtMy0xLTEtNjY1NTE_c43871a4-faa8-4c45-81e5-23715ff2302a">83,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzUtNS0xLTEtNjY1NTE_6824b867-8ddf-4a36-b3ee-707f31bba080">6,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzYtMS0xLTEtNjY1NTE_f0dfd6aa-c820-4aee-a675-aad79beb01e2">50,896</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzYtMy0xLTEtNjY1NTE_4d73328a-f720-41e9-925c-2c6a42318b1d">20,551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzYtNS0xLTEtNjY1NTE_5ab54148-8dd1-418d-b990-c80b5dd16e82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total other comprehensive (loss)/income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzctMS0xLTEtNjY1NTE_a15b5631-bf4e-4310-8479-b111e695d943">39,296</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzctMy0xLTEtNjY1NTE_6447e9d7-a39c-4b18-a309-d65f1a6e751f">66,635</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzctNS0xLTEtNjY1NTE_257c08de-2f2b-4db7-acdb-7d24965ea219">12,348</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzgtMS0xLTEtNjY1NTE_00e38a34-63c2-4691-a5e0-052128e4bc2c">1,201,905</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzgtMy0xLTEtNjY1NTE_54838f41-7469-4a6d-b34c-41409ca2de79">1,768,589</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzgtNS0xLTEtNjY1NTE_310a6987-8494-457d-84a0-c5fd9acbc52d">2,473,767</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Comprehensive income attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzEwLTEtMS0xLTY2NTUx_a14dea50-ef52-4b29-acd2-4db581ba9a19">604,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzEwLTMtMS0xLTY2NTUx_aa6135af-6a9e-438e-a6e7-731055529071">739,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzEwLTUtMS0xLTY2NTUx_c912c2fc-2830-4c7b-b066-76d61447b480">112,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comprehensive income attributable to controlling interest</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzEzLTEtMS0xLTY2NTUx_d0e04871-444a-4e17-b1a6-c57f5a0ed7b0">597,582</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzEzLTMtMS0xLTY2NTUx_01dac687-1458-4f65-aff1-25d02f2deea6">1,028,802</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzEzLTUtMS0xLTY2NTUx_f3307db6-38a2-42e8-bbe1-5926f4337bad">2,360,883</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="i15fafc99ab5c41deb08ee816ca47172c_103"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"> CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">In thousands</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.311%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.644%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class A <br/>Ordinary Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class B <br/>Ordinary Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class R <br/>Redeemable Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Deferred Shares</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unitholders&#8217;/ Shareholders&#8217; Contributions</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive  Income/(Loss)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-Controlling Interest</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury Interests</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7242e01e0d3e49c99430b9b17185b69d_I20181231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEtMS0xLTEtMA_b1791aee-9e18-4402-98cc-c6aca61ab7cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7242e01e0d3e49c99430b9b17185b69d_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEtMi0xLTEtMA_7bb659f7-d8ae-4b00-aa4d-836ba7e48294">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21cc13814c2346169554442b708375ad_I20181231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEtMy0xLTEtMA_486c8af2-d86c-4810-936a-2918869b6331">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21cc13814c2346169554442b708375ad_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEtNC0xLTEtMA_84c99cd7-497c-445d-86f9-acaa6d3a13f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4278e9fc64b540edb08bf8d281986583_I20181231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEtNS0xLTEtMA_94702175-822b-4e75-81a8-b02ce601ea8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4278e9fc64b540edb08bf8d281986583_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEtNi0xLTEtMA_50116f3d-edfd-4414-922d-09ad20213be1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc6628a62f9e40b48736982ad0adfbee_I20181231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzItNy0xLTEtMzcyNzA_bc490fb3-37ef-4cc6-be0b-4fdc1819004f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc6628a62f9e40b48736982ad0adfbee_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzItOC0xLTEtMzcyNzA_40db2132-3e48-4680-96e8-8545592544f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb893068fb11474089dc46eccc39ab67_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzItOS0xLTEtMzcyNzA_c6175435-89da-4853-8cb9-aeb0dd8750ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibab3544b72654443a832b73062c67deb_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzItMTAtMS0xLTM3Mjcw_b22a4497-3bf6-4a2c-9c46-09442b088d8a">3,282,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d606c35a9d1498aa2be490653c9ef76_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzItMTEtMS0xLTM3Mjcw_ba513724-8eea-421f-9936-03bd285a0670">1,215,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83390defcd6345cb9ec5d13109b97307_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzItMTItMS0xLTM3Mjcw_c6ba3841-ffa9-4215-8cbb-e71ef42fc368">10,255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia43c5365c0cb479391cb94db6dca5463_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzItMTMtMS0xLTM3Mjcw_3f47f019-dfdf-4409-9d42-8fcf36b7313d">63,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd82d6eb2e3a47a7b8091e80bc813a3b_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzItMTQtMS0xLTM3Mjcw_f2895f21-6a61-40a9-aae2-34f5a3814661">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26755fbc5e413fbf3122ec0db17370_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzItMTUtMS0xLTM3Mjcw_b275cdce-e3ff-4b00-9cd5-25a36a5918af">4,552,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb8081ea351a4070b344194caa18eee3_D20190101-20191231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzMtMTEtMS0xLTM3Mjcw_19c533c4-0f6a-47a0-81d7-ee2f0105d040">739,276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id719b4a4fe4147c580198f101363e139_D20190101-20191231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzMtMTMtMS0xLTM3Mjcw_d7b4ec79-eb49-4d65-bf65-a8cd141e856c">140,866</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzMtMTUtMS0xLTM3Mjcw_0436376c-5416-4165-b2c7-2e7687dfb163">880,142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb8081ea351a4070b344194caa18eee3_D20190101-20191231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzQtMTEtMS0xLTM3Mjcw_b6e4436b-8c4f-4e06-9cad-fad2a657ab1a">2,348,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id719b4a4fe4147c580198f101363e139_D20190101-20191231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzQtMTMtMS0xLTM3Mjcw_eb23b964-11fe-49c7-8891-9f1d3bc7f284">112,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzQtMTUtMS0xLTM3Mjcw_32a0882d-a2d0-4103-8d13-a0f8e049b7d2">2,461,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aba922b7da5469cb7d51eeaebbde78c_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzYtMTItMS0xLTM3Mjcw_426e79ad-7558-4e15-8457-66b817e40a20">6,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzYtMTUtMS0xLTM3Mjcw_af4b81d9-573a-40fd-99c8-8b062fc63e9e">6,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reclassification of loss on interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aba922b7da5469cb7d51eeaebbde78c_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzctMTItMS0xLTM3Mjcw_ca8a5044-7c24-4e7c-8415-87c13fbddf8a">6,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzctMTUtMS0xLTM3Mjcw_28acc450-cb1c-4bad-a7c0-6266482d4aab">6,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of treasury interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82e5c0912520456188cd5703e13cd8ec_D20190101-20191231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzgtMTQtMS0xLTM3Mjcw_84de8752-d2fb-4b40-9ad5-e800050905bf">4,266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzgtMTUtMS0xLTM3Mjcw_ddcd294f-07e9-4485-8a02-b00daf39d0a8">4,266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a4cf2dc46aa4a0b98fcc0c810dc8893_I20191231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzgtMS0xLTEtMA_626b2d1b-bc49-4b76-bc2b-1d73902a0906">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a4cf2dc46aa4a0b98fcc0c810dc8893_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzgtMi0xLTEtMA_b8bf4fcb-b24b-434e-bd3a-02933ab3c07b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i580d0bd186a14217bc04733016854e77_I20191231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzgtMy0xLTEtMA_721ada7a-05d4-4c39-8efc-1fac7a7d9332">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i580d0bd186a14217bc04733016854e77_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzgtNC0xLTEtMA_b53106f2-5a39-42b3-a928-75877ec28fc0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19b48e73113548da88d30125b457bca0_I20191231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzgtNS0xLTEtMA_4312ab99-42e3-45f1-8243-d6e95e7b4796">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19b48e73113548da88d30125b457bca0_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzgtNi0xLTEtMA_69b6dbe4-fec3-4181-9b3b-b9bc885062cb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e3a705f76b44890a7020ab2ae505a43_I20191231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzktNy0xLTEtMzcyNzA_d6b2546c-3612-4d9b-826d-95e861681bcc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e3a705f76b44890a7020ab2ae505a43_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzktOC0xLTEtMzcyNzA_bb5066df-a8a6-48bf-850d-0484ff255a91">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i315143a2dcd345708f419d259a93d568_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzktOS0xLTEtMzcyNzA_dcab93fc-f4d3-4839-ac22-3b0b33a3d581">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3ecbb7d51644c5aad611d5a9b22c148_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzktMTAtMS0xLTM3Mjcw_9435a66a-f2bc-40c4-8df2-b5bdfd5699c5">3,282,516</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830800ad2baf473c9739d42417c534c6_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzktMTEtMS0xLTM3Mjcw_e2babe8d-fe04-4605-80e6-90d2db2d65ab">2,825,212</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602e6cc9310d4444b6d71a94d4089ae5_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzktMTItMS0xLTM3Mjcw_7bc81f7f-4e34-41cb-bd2b-51f9f697827e">2,093</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66a738c1e19d441f908f46dd78470217_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzktMTMtMS0xLTM3Mjcw_83beea66-1344-4401-ac48-8d9e1c6491e6">35,883</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ff6f34aeece4e29977f6ac850691398_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzktMTQtMS0xLTM3Mjcw_24a2e5a4-9842-435c-ad56-54299ba7dd8b">4,266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id30f26bcb6cd4b64982e6cd53528c44e_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzktMTUtMS0xLTM3Mjcw_e3485d66-1a3a-4ce5-bf7c-4e5071053ef4">6,141,438</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94ea8958cd1e4ee696d732dd9a041dca_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEwLTEwLTEtMS0zNzI3MA_bcd99630-6c96-4dac-94fa-a7b3d824158c">307,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEwLTEzLTEtMS0zNzI3MA_12afbf5f-2235-4080-8738-093790ce8bde">1,174,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEwLTE1LTEtMS0zNzI3MA_ccd1a049-fee3-428f-8b26-67632c7500d9">1,482,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfer of interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94ea8958cd1e4ee696d732dd9a041dca_D20200101-20201231" decimals="-3" sign="-" name="rprx:NoncontrollingInterestTransfersOfInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzExLTEwLTEtMS0zNzI3MA_c3b840de-13cc-423d-b99e-556da9def24e">1,037,161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestTransfersOfInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzExLTEzLTEtMS0zNzI3MA_846577ff-caad-433a-a76c-1445626ee5a1">1,037,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestTransfersOfInterests" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzExLTE1LTEtMS0zNzI3MA_a41146f0-8d78-4835-87ee-5fff6fc1cdd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzExLTAtMS0xLTA_7826f12a-67da-4efa-9c4b-296fe436efc8">Cumulative adjustment for adoption of ASU 2016-13</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib04d3453e6dc4ca3a0b79e01ab3fe12a_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEyLTExLTEtMS0zNzI3MA_c11a1dc1-0340-4e47-bf51-3b9879ef58a3">192,705</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7ab9fefed164e08ac6ad01d99d06780_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEyLTE1LTEtMS0zNzI3MA_87f3d236-8056-4bc6-96ca-35331a36f003">192,705</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e6f9f489a134c76840c0b3b1b1954e4_D20200101-20201231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEzLTExLTEtMS0zNzI3MA_47b83a4c-46fb-4fd4-9442-7fc80a3bed18">313,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEzLTEzLTEtMS0zNzI3MA_d9c78a6b-65f0-4986-9105-0d13862780bb">792,357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEzLTE1LTEtMS0zNzI3MA_d4a88cc2-e9a5-4cea-b14c-f3ed99649f62">1,105,765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Initial share issuance upon registration of Royalty Pharma plc</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b0efd440f45499a9d75e2fbc4ff25a1_D20200101-20201231" decimals="-3" name="rprx:StockIssuedDuringPeriodSharesIssuedForRegistration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEzLTUtMS0xLTA_7980ea38-0cc5-44f5-9c0d-d7f313e671d1">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0efd440f45499a9d75e2fbc4ff25a1_D20200101-20201231" decimals="-3" name="rprx:StockIssuedDuringPeriodValueIssuedForRegistration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEzLTYtMS0xLTA_f61f20bb-f51c-42ac-bfbd-be6534fd3901">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:StockIssuedDuringPeriodValueIssuedForRegistration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE0LTE1LTEtMS0zNzI3MA_27aad126-a66e-4f14-81d0-fd46f7a2b54a">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income prior to IPO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3422c7350bb14d2d869ff498fa12e855_D20200101-20200617" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE1LTExLTEtMS0zNzI3MA_0aaaac18-a545-4571-8710-4a2dfd238f08">479,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f06ecc81464fc3ba1731d5296c531a_D20200101-20200617" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE1LTEzLTEtMS0zNzI3MA_e7b60033-26c3-447c-998a-adab0bc57230">145,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7594b0b1464b4340a377c43cf71ef3c9_D20200101-20200617" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE1LTE1LTEtMS0zNzI3MA_1ac45b32-c644-472e-ae8a-e48cdd8b9125">624,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Class B ordinary shares to Continuing Investors Partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d52a6096c48447f93a4da355c6da2e3_D20200101-20201231" decimals="-3" name="rprx:StockIssuedDuringPeriodSharesIssuedToPartnerships" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE1LTMtMS0xLTA_57da9f03-e093-43ce-866c-bccfce8a2579">535,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d52a6096c48447f93a4da355c6da2e3_D20200101-20201231" decimals="-3" name="rprx:StockIssuedDuringPeriodValueIssuedToPartnerships" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE1LTQtMS0xLTA_eb41c81a-b3ae-4ad1-9f30-d3e1f0702e78">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:StockIssuedDuringPeriodValueIssuedToPartnerships" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE2LTE1LTEtMS0zNzI3MA_0077ff86-44e7-4bec-8b1c-5aeb5748a1a1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f4f3dd76bcf49369de9f193a116d553_D20200101-20201231" decimals="-3" name="rprx:StockholdersEquitySharesEffectOfExchangeAndReallocation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE3LTEtMS0xLTM3Mjcw_27a51168-4d70-4cec-bbf0-78567762c41b">294,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f4f3dd76bcf49369de9f193a116d553_D20200101-20201231" decimals="-3" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE3LTItMS0xLTM3Mjcw_2cfd4ddc-613a-48cc-94e4-9147624bdaae">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7d52a6096c48447f93a4da355c6da2e3_D20200101-20201231" decimals="-3" sign="-" name="rprx:StockholdersEquitySharesEffectOfExchangeAndReallocation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE3LTMtMS0xLTM3Mjcw_745d180f-f119-49ec-905a-6245dabadfdf">294,176</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d52a6096c48447f93a4da355c6da2e3_D20200101-20201231" decimals="-3" sign="-" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE3LTQtMS0xLTM3Mjcw_5d9ca4d7-6ea4-4fe5-8a56-d07bb7b913a4">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a9ba8c328db404aa63b9d27dabe97d3_D20200101-20201231" decimals="-3" name="rprx:StockholdersEquitySharesEffectOfExchangeAndReallocation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE3LTctMS0xLTM3Mjcw_73dd1f9e-7b98-4dda-a2a5-43a22639e1ba">294,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia045aaf00ae04e51a9df144d9df23caf_D20200101-20201231" decimals="-3" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE3LTktMS0xLTM3Mjcw_e9b0ad63-c013-4075-a502-6fb144017776">1,402,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94ea8958cd1e4ee696d732dd9a041dca_D20200101-20201231" decimals="-3" sign="-" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE3LTEwLTEtMS0zNzI3MA_9ccc0d96-9348-40dc-934c-271fdafacbfd">2,553,001</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e6f9f489a134c76840c0b3b1b1954e4_D20200101-20201231" decimals="-3" sign="-" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE3LTExLTEtMS0zNzI3MA_35ec0a3a-845a-4070-bcbe-5c6f1ff47d37">1,261,014</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic835f9f0906c4a4cb5e88b614197540b_D20200101-20201231" decimals="-3" sign="-" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE3LTEyLTEtMS0zNzI3MA_cdeb575d-f2c6-47d0-b319-8ee0293b36a6">24,022</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231" decimals="-3" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE3LTEzLTEtMS0zNzI3MA_678c483c-fce2-4122-af58-b1d15b2bbf34">2,433,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2120ee6be2e44acca10b4f204c1cddf2_D20200101-20201231" decimals="-3" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE3LTE0LTEtMS0zNzI3MA_ff8a9362-499c-4270-acad-0a16cbb0be4c">2,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" sign="-" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE3LTE1LTEtMS0zNzI3MA_12e46f7e-a0d8-4148-be04-d519ef6c05c2">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Class A ordinary shares sold in IPO, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f4f3dd76bcf49369de9f193a116d553_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE4LTEtMS0xLTM3Mjcw_cc810a82-5d5b-44e3-9fa5-5f11af9316d6">71,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f4f3dd76bcf49369de9f193a116d553_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE4LTItMS0xLTM3Mjcw_14dfdbd7-65df-47ae-a1c0-51a664dd57d9">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia045aaf00ae04e51a9df144d9df23caf_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE4LTktMS0xLTM3Mjcw_42d53772-7b41-4aeb-a503-5a82c987701f">1,150,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE4LTEzLTEtMS0zNzI3MA_61154fbd-3b53-4eb3-a154-d3c43ac07961">758,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE4LTE1LTEtMS0zNzI3MA_d5358dd6-3e7c-4527-9c40-2753c6468415">1,908,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based compensation and related issuances of Class A ordinary shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f4f3dd76bcf49369de9f193a116d553_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIwLTEtMS0xLTM3Mjcw_30bb0aa6-82c3-41ff-a7f1-2b67c2bf5101">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia045aaf00ae04e51a9df144d9df23caf_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIwLTktMS0xLTM3Mjcw_e5833cd0-37db-4ea3-98d4-65fb35ae96f5">5,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIwLTE1LTEtMS0zNzI3MA_9b3ae0a2-a30f-493c-9e57-13bcd9f7281d">5,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f4f3dd76bcf49369de9f193a116d553_D20200101-20201231" decimals="-3" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIxLTEtMS0xLTM3Mjcw_16109214-55f9-4270-a8b6-2c13a6c606a4">22,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f4f3dd76bcf49369de9f193a116d553_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIxLTItMS0xLTM3Mjcw_b64671e4-9b53-42a6-b670-5118c6f27d47">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7d52a6096c48447f93a4da355c6da2e3_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIxLTMtMS0xLTM3Mjcw_02f8ad61-bbac-4d6a-b60d-9a79efc653bc">22,231</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a9ba8c328db404aa63b9d27dabe97d3_D20200101-20201231" decimals="-3" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIxLTctMS0xLTM3Mjcw_f49f0e23-6326-4f55-a1d7-3292a2a7f00d">22,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia045aaf00ae04e51a9df144d9df23caf_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIxLTktMS0xLTM3Mjcw_04493c88-d7c2-4f34-b38e-abb92545ea3f">307,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic835f9f0906c4a4cb5e88b614197540b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIxLTEyLTEtMS0zNzI3MA_c4e57dd6-8918-4e0c-9820-55265ca77375">2,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIxLTEzLTEtMS0zNzI3MA_e7836cf6-c64b-41fe-96ed-856deb365e5f">309,566</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2120ee6be2e44acca10b4f204c1cddf2_D20200101-20201231" decimals="-3" name="us-gaap:StockholdersEquityOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIxLTE0LTEtMS0zNzI3MA_06f6d96a-158f-497a-953c-eac2773a145d">198</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIxLTE1LTEtMS0zNzI3MA_8940947d-c6fc-4968-ac4e-93a86d9b8d06">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividends ($<ix:nonFraction unitRef="usdPerShare" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIxLTAtMS0xLTM3MTQ4L3RleHRyZWdpb246YWJiNWMxZGQxZTcxNGE5MzgxZjhmNjM2ZTIxZDQ3ZTVfMjc0ODc3OTA2OTUyMg_2681dd54-02b9-434f-bf43-46f8804f9d01">0.30</ix:nonFraction> per Class A ordinary share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e6f9f489a134c76840c0b3b1b1954e4_D20200101-20201231" decimals="-3" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIyLTExLTEtMS0zNzI3MA_d7ee22c1-2302-4204-a9f0-bc2b5c068941">112,490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIyLTE1LTEtMS0zNzI3MA_d1620864-6ca3-48c3-9a34-b340c746da96">112,490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income subsequent to IPO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief437e0dfe9a4e449e52e28b7c5f4b71_D20200618-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIzLTExLTEtMS0zNzI3MA_3d2217ac-c80f-4fc2-9a87-b94c37db4793">495,198</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id19e65b6c08c41b59cd152b688647d77_D20200618-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIzLTEzLTEtMS0zNzI3MA_63855a8e-0d72-4b24-87c0-f4f1c1782e2b">581,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1399e8120f4459da1c98eaec460657b_D20200618-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIzLTE1LTEtMS0zNzI3MA_afbceb8b-2ed7-46df-8e42-bbcb6d6f7557">1,077,069</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reclassification of loss on interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic835f9f0906c4a4cb5e88b614197540b_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI1LTEyLTEtMS0zNzI3MA_13d627a3-789c-4174-bd80-feae5b994cbf">4,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI1LTE1LTEtMS0zNzI3MA_5d031770-4e5d-4f78-bd1e-fd9e59de2d26">4,066</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic835f9f0906c4a4cb5e88b614197540b_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI2LTEyLTEtMS0zNzI3MA_fa3f8d01-15bc-4f00-9192-e6d491cf57f4">60,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI2LTEzLTEtMS0zNzI3MA_df065952-eb40-41a4-bf18-7dce290de353">22,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI2LTE1LTEtMS0zNzI3MA_ec92eb58-dc4f-4e8b-babf-ae4587f0977d">83,120</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic835f9f0906c4a4cb5e88b614197540b_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI3LTEyLTEtMS0zNzI3MA_d2d88965-731e-4230-bd65-9d881a01a71a">10,921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI3LTEzLTEtMS0zNzI3MA_1834ea4a-715d-40da-aa75-b6de201415be">9,630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI3LTE1LTEtMS0zNzI3MA_8d331261-6824-455c-9401-89dd32c24949">20,551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i026910ef30a142baa787995540a3555f_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTEtMS0xLTM3Mjcw_536762ff-e6d8-49ff-8f8c-e33b46093578">388,135</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i026910ef30a142baa787995540a3555f_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTItMS0xLTM3Mjcw_1abdb801-be92-4d0d-89b9-f7fd9dbb2636">39</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00c7c0edff0e4ac2a68115eef01ff73d_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTMtMS0xLTM3Mjcw_83b8cf42-3dff-48f7-9ec6-8dafa9bc3621">218,976</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00c7c0edff0e4ac2a68115eef01ff73d_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTQtMS0xLTM3Mjcw_ecbb24c1-bd28-4328-ad04-5d1d51398482">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd3e01d69d404333b2e0170fe5853c55_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTUtMS0xLTM3Mjcw_4585dd25-1e8d-4bf7-b6bf-8ac7d6724b7e">50</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd3e01d69d404333b2e0170fe5853c55_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTYtMS0xLTM3Mjcw_92638ac5-10c7-4813-91f4-2c285a8720c3">63</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief96e993bf2a4bad8348a1f2176e9808_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTctMS0xLTM3Mjcw_e6f1ffb0-2753-4837-8799-a1a088cfffd2">316,407</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief96e993bf2a4bad8348a1f2176e9808_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTgtMS0xLTM3Mjcw_927a4f29-a64d-4151-892b-e41eebdfcc8e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68fb25a3dc3e456893c7bc42ba425cbd_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTktMS0xLTM3Mjcw_e8099f4b-8e57-4020-8895-c95891fe30bc">2,865,964</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if26943d0c125428899ab95101e2214b9_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTEwLTEtMS0zNzI3MA_fabd0c37-c7f5-4c42-8514-4be4e95060cf">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cb528cec9b5436688d56f37b5a8fdb8_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTExLTEtMS0zNzI3MA_f867290a-2dca-4e7b-8de5-8b15bb33e099">1,920,635</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857c20e661b346998fb3a0f68c1afaf2_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTEyLTEtMS0zNzI3MA_bfc25c98-c127-4195-94de-08b4df7824d1">34,395</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a4c8ddad1f14b6b87799e8a6512c515_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTEzLTEtMS0zNzI3MA_7a73bef9-fa1f-4c7b-9642-d9201969e656">5,077,036</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66335cce09fd4d5aa1361b620f554b05_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTE0LTEtMS0zNzI3MA_5978d368-f296-4c13-8b89-92a74ba1546a">2,317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTE1LTEtMS0zNzI3MA_cd58b250-e681-408b-9268-6da2a5daa82d">9,895,815</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"> CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">(In thousands)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.641%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class A <br/>Ordinary Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class B <br/>Ordinary Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class R <br/>Redeemable Shares</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Deferred Shares</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shareholders&#8217; Contributions</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive  Income/(Loss)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-Controlling Interest</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury Interests</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Equity</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i026910ef30a142baa787995540a3555f_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItMS0xLTEtMA_536762ff-e6d8-49ff-8f8c-e33b46093578">388,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i026910ef30a142baa787995540a3555f_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItMi0xLTEtMA_1abdb801-be92-4d0d-89b9-f7fd9dbb2636">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00c7c0edff0e4ac2a68115eef01ff73d_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItMy0xLTEtMA_83b8cf42-3dff-48f7-9ec6-8dafa9bc3621">218,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00c7c0edff0e4ac2a68115eef01ff73d_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItNC0xLTEtMA_ecbb24c1-bd28-4328-ad04-5d1d51398482">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd3e01d69d404333b2e0170fe5853c55_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItNS0xLTEtMA_4585dd25-1e8d-4bf7-b6bf-8ac7d6724b7e">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd3e01d69d404333b2e0170fe5853c55_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItNi0xLTEtMA_92638ac5-10c7-4813-91f4-2c285a8720c3">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief96e993bf2a4bad8348a1f2176e9808_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItNy0xLTEtMA_e6f1ffb0-2753-4837-8799-a1a088cfffd2">316,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief96e993bf2a4bad8348a1f2176e9808_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItOC0xLTEtMA_927a4f29-a64d-4151-892b-e41eebdfcc8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68fb25a3dc3e456893c7bc42ba425cbd_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItOS0xLTEtMA_e8099f4b-8e57-4020-8895-c95891fe30bc">2,865,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if26943d0c125428899ab95101e2214b9_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItMTAtMS0xLTA_fabd0c37-c7f5-4c42-8514-4be4e95060cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cb528cec9b5436688d56f37b5a8fdb8_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItMTEtMS0xLTA_f867290a-2dca-4e7b-8de5-8b15bb33e099">1,920,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857c20e661b346998fb3a0f68c1afaf2_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItMTItMS0xLTA_bfc25c98-c127-4195-94de-08b4df7824d1">34,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a4c8ddad1f14b6b87799e8a6512c515_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItMTMtMS0xLTA_7a73bef9-fa1f-4c7b-9642-d9201969e656">5,077,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66335cce09fd4d5aa1361b620f554b05_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItMTQtMS0xLTA_5978d368-f296-4c13-8b89-92a74ba1546a">2,317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItMTUtMS0xLTA_cd58b250-e681-408b-9268-6da2a5daa82d">9,895,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzMtMTMtMS0xLTA_c8ff36be-ad83-4855-8a3e-d657c8fc98af">48,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzMtMTUtMS0xLTA_7aaa559a-f8e0-4bac-a1d7-4287c0b6e05a">48,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzQtMTMtMS0xLTA_2a5c8ee5-ba23-422e-83d1-86bff6bff896">614,973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzQtMTUtMS0xLTA_73ff2e61-f4d6-4dd9-908f-d7fe7f859b33">614,973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividends ($<ix:nonFraction unitRef="usdPerShare" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzUtMC0xLTEtMC90ZXh0cmVnaW9uOjljZWRmYzQ1MWQ2YzRiZmFhOTVjNjg3MDg0Zjg4NWNlXzI3NDg3NzkwNjk1MTY_bebd342e-61b4-4f83-8948-df69341f863e">0.68</ix:nonFraction> per Class A ordinary share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bdb46f25b6846f5b9310b232d39718a_D20210101-20211231" decimals="-3" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzUtMTEtMS0xLTA_e352b650-7053-43f4-8609-e912af7f2095">285,184</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzUtMTUtMS0xLTA_5b1dd3e2-bc61-4edb-8674-7a4bcf4edb14">285,184</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f493fdc35c04ea9b3f1ab89b24ba7be_D20210101-20211231" decimals="-3" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzYtMS0xLTEtMA_054497a3-98c3-477a-839e-2a2c1104789f">44,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f493fdc35c04ea9b3f1ab89b24ba7be_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzYtMi0xLTEtMA_555c85b6-268c-402b-b8f9-e50f6de2b81f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8df459188f6346b8b8d77947f07ece9e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzYtMy0xLTEtMA_e45a9d34-b14b-4df4-b277-ba7629d03a7d">44,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c91bc2a7dfa43c18d941b318eb6c1a1_D20210101-20211231" decimals="-3" name="us-gaap:StockholdersEquityOtherShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzYtNy0xLTEtMA_235791b2-9963-4032-9ddd-f46d5fddfeda">44,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b582d2d470476abea2f967a5ff5d4d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzYtOS0xLTEtMA_5bdb0d80-38b0-4334-97a2-cca4372ef938">639,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie00bc8af28a248a3bab0ff42f302d437_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzYtMTItMS0xLTA_f94d6c84-7129-4af8-a3c6-9a8f967e9153">4,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzYtMTMtMS0xLTA_1715bfc1-c6bc-497a-8cdf-d1b3ae9afe47">642,974</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ideedfd0352184c20a5b0ac18ede8b733_D20210101-20211231" decimals="-3" name="us-gaap:StockholdersEquityOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzYtMTQtMS0xLTA_cbd70200-cf08-48ff-bded-dfaff02c3946">398</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzYtMTUtMS0xLTA_423decf8-745e-44bc-b350-b166cdaf1bcf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based compensation and related issuances of Class A ordinary shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f493fdc35c04ea9b3f1ab89b24ba7be_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzctMS0xLTEtMA_bba100df-1b23-4834-b1f0-256bac6108c9">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b582d2d470476abea2f967a5ff5d4d_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzctOS0xLTEtMA_4e15c644-e204-4ebe-8063-c732e660c093">2,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzctMTUtMS0xLTA_a056e5ab-36fa-43a3-99b3-03055f61aaec">2,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bdb46f25b6846f5b9310b232d39718a_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzEwLTExLTEtMS0w_fed22120-cfde-4cec-b017-1351ef1c3f50">619,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzEwLTEzLTEtMS0w_abba22b9-d841-499a-87de-405954396de8">621,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzEwLTE1LTEtMS0w_3161fa09-94b6-4313-9378-6c17876bb618">1,241,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie00bc8af28a248a3bab0ff42f302d437_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzEyLTEyLTEtMS0w_c5fb911d-d32d-499f-865b-0674309f4cbc">6,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzEyLTEzLTEtMS0w_196d9538-5804-48ae-8617-30d28e2024df">5,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzEyLTE1LTEtMS0w_a3434b82-86a8-48e4-b5e0-4ab558c3e3d2">11,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie00bc8af28a248a3bab0ff42f302d437_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzEzLTEyLTEtMS0w_ca0dcbc2-f673-478d-bd4f-8b51efecae20">28,481</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzEzLTEzLTEtMS0w_d3e6b907-0fa0-4f3d-82b7-a73f3ff35a14">22,415</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzEzLTE1LTEtMS0w_8f8166ea-daed-4cca-b894-deaad879d8d7">50,896</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec5b04d241a742c1bf88cb734be536cb_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTEtMS0xLTA_08e2bf4f-3a43-4b36-b475-522b2040ac10">432,963</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec5b04d241a742c1bf88cb734be536cb_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTItMS0xLTA_5571e687-07f8-48d4-a005-6e5ee5ce7c1b">43</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i237eac50dc20448f9dc9e9bc7dce35cf_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTMtMS0xLTA_ca3714a5-f17f-4abb-bcbf-d8f24242630a">174,213</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i237eac50dc20448f9dc9e9bc7dce35cf_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTQtMS0xLTA_5de63771-07ac-46a6-b877-35d709b7ee13">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i831945c7a36b4b9a9c9ce724bfbde784_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTUtMS0xLTA_7bd486e3-5881-42e9-875d-babf7ce67cbb">50</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i831945c7a36b4b9a9c9ce724bfbde784_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTYtMS0xLTA_15205949-b838-4946-b663-9bad83f11fc0">63</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9cf16ec8ae244acb94018fe5616afde0_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTctMS0xLTA_6c3a09b1-58c0-41df-bfcb-0b6589f75502">361,170</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cf16ec8ae244acb94018fe5616afde0_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTgtMS0xLTA_fb5820ef-7a1d-46ef-880c-fd6c083d1fc3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf5276dc05624d1c9f3c9eb9743788dd_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTktMS0xLTA_9fc11a22-9062-48aa-8e95-a41b2f89a1c3">3,507,533</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf92db35b544207b1e43d9e1641760f_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTEwLTEtMS0w_0d0c90e8-ba2c-452a-8838-f32f75f0faf0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe420d445c0a4fd99c2d658b9393d0ef_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTExLTEtMS0w_1e43a4ec-9feb-4bb5-9765-ff32232cfbab">2,255,179</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9443f77254524e56b4e02c6d9e30af84_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTEyLTEtMS0w_b2b6e4e6-639a-4373-b6ea-d39a81a8a689">16,491</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03b5b882444a44ad9e231eaa7b05228b_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTEzLTEtMS0w_73d7b960-be4e-4033-b821-44a010be0593">4,471,951</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i568f4691ddec40e6848d6b317d8a5792_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTE0LTEtMS0w_f66b73ec-002a-4936-939f-620a43450972">2,715</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTE1LTEtMS0w_515c9dc9-95db-4999-b2d9-8f55f35e0777">10,248,545</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="i15fafc99ab5c41deb08ee816ca47172c_106"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"> CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">(In thousands)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collections from financial royalty assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzMtMS0xLTEtMA_7f725826-cd24-48d1-8b3f-9260456fc14a">2,315,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzMtMy0xLTEtMA_d2bdcb6b-f3af-4aed-bc19-58556c6c1627">2,121,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzMtNS0xLTEtMA_c6777b08-5e6d-42bc-91dc-2744ce5a59e8">1,934,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collections from intangible royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQtMS0xLTEtMA_3749f652-4232-47f9-bfd4-083b3bb96b2e">151,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQtMy0xLTEtMA_c462588b-7b9b-4dc0-aecf-57c8beed9801">143,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQtNS0xLTEtMA_a7687d34-ac77-49de-909e-f6240fbbc24f">143,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty cash collections</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzUtMS0xLTEtMA_5ab94e47-fe8a-4a3b-be60-be1bbf6ec7de">44,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzUtMy0xLTEtMA_58617e16-ab8e-4088-a65d-a233c62f7077">18,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzUtNS0xLTEtMA_1aa1ad9e-fc96-4a07-9840-30054e1eb731">27,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions from non-consolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzYtMS0xLTEtMA_c849c70b-c3f3-4f02-ba8a-c7634473cc1c">34,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzYtMy0xLTEtMA_e1df10db-3168-4818-a63e-d7950ee44fb4">42,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzYtNS0xLTEtMA_00de7e39-0f46-4216-bfaa-3dca470ef1c6">14,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromInterestReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzctMS0xLTEtMA_311826a9-3527-4ee3-88a4-74f4fd42ef94">3,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromInterestReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzctMy0xLTEtMA_43fa87c6-4db6-4045-85da-5b0bdc5b90d9">7,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromInterestReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzctNS0xLTEtMA_f24f440e-9d45-4956-a391-d7ab39a39dd4">20,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative collateral received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzgtMS0xLTEtMA_1adf9fc5-6d80-4beb-8b49-f87aa1c71644">34,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzgtMy0xLTEtMA_ef786605-f2d5-4f08-a5df-2e1229ab92d3">45,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzgtNS0xLTEtMA_53c539f1-f54f-45b5-ac80-f95e41145ae9">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative collateral posted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:PaymentsForCollateralPostedOnDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzktMS0xLTEtMA_4fef99f1-8216-4f90-97c6-3e4f53f7aa03">34,660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:PaymentsForCollateralPostedOnDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzktMy0xLTEtMA_5880bbd4-91b1-45dd-b969-649cb040e413">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:PaymentsForCollateralPostedOnDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzktNS0xLTEtMA_cebf7f62-1d52-4e65-9fbd-55fa0fa2430c">45,630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination payments on derivative instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:PaymentsToTerminateDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzEwLTEtMS0xLTA_638a0019-590d-47e3-be3c-40103003b126">16,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:PaymentsToTerminateDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzEwLTMtMS0xLTA_1ffea484-b69e-4bd6-a535-8790857894dd">35,448</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:PaymentsToTerminateDerivativeInstruments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzEwLTUtMS0xLTA_a72c517b-cacc-49b3-9e4b-09952d5b8dda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ongoing development-stage funding payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:PaymentsForOngoingDevelopmentStageFunding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzExLTEtMS0xLTA_3fe72aed-3cfd-4231-bd6e-1e600ed9a358">6,876</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:PaymentsForOngoingDevelopmentStageFunding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzExLTMtMS0xLTA_0d43c84e-dc4f-4dab-baa2-3e7803376468">20,479</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:PaymentsForOngoingDevelopmentStageFunding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzExLTUtMS0xLTA_bb6cfc60-19e8-4916-ad61-55bc4097f019">83,036</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Upfront development-stage funding payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:PaymentsForUpfrontDevelopmentStageFunding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzEyLTEtMS0xLTA_3792d5d1-6001-454b-8fc9-b81a27058b64">193,208</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:PaymentsForUpfrontDevelopmentStageFunding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzEyLTMtMS0xLTA_0bf655f4-875d-48a6-bfab-d3c2582bfbf8">5,810</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:PaymentsForUpfrontDevelopmentStageFunding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzEyLTUtMS0xLTA_2c37a9c6-7c31-4d9f-a438-c04cc7c2cec9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments for operating and professional costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:PaymentsForOperatingCostsAndProfessionalServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzEzLTEtMS0xLTA_66e2a405-ffa2-4844-9974-a6c05c2aca3b">184,511</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:PaymentsForOperatingCostsAndProfessionalServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzEzLTMtMS0xLTA_24e05c43-8c2e-4c9d-90b7-debcd660a7a7">179,709</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:PaymentsForOperatingCostsAndProfessionalServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzEzLTUtMS0xLTA_91a6e829-4317-4567-a6d7-204eeb4889fe">88,524</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzE1LTEtMS0xLTA_44fb3c97-f998-4021-a4c0-17d1424565fe">130,430</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzE1LTMtMS0xLTA_cb926753-7ea6-472a-8dad-fb73e95dc2b1">103,196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzE1LTUtMS0xLTA_9a89a0b8-f6cf-4097-9f9a-195cdc3326e1">254,964</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzE3LTEtMS0xLTA_0cab8fe7-4fac-45a8-8425-7636a6ebc4be">2,017,536</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzE3LTMtMS0xLTA_0e043c75-dbc7-4ab6-a101-e7795962781d">2,034,629</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzE3LTUtMS0xLTA_ef41dfd2-f00b-407f-82e7-55a79b3a36d4">1,667,239</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions from non-consolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIwLTEtMS0xLTQzNzI0_5133144d-dcfe-480b-8f77-07241da08da0">523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIwLTMtMS0xLTQzNzI0_f4d17bec-8910-4be1-b67d-5e60d277f70f">15,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIwLTUtMS0xLTQzNzI0_d392f5db-920a-4a31-9f11-2d052bb263bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments in non-consolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIwLTEtMS0xLTA_02f7994f-848b-40a3-a9e0-da029f06d4b4">34,855</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIwLTMtMS0xLTA_5fe59b3b-cb2d-4789-8081-e759e13bf85b">40,155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIwLTUtMS0xLTA_da18cf1b-d04a-4f34-aa47-adac49b05535">27,042</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:PaymentsToAcquireEquitySecuritiesFNNI" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIyLTEtMS0xLTA_e3c036a5-f773-4699-93c3-b83744773417">135,134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:PaymentsToAcquireEquitySecuritiesFNNI" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIyLTMtMS0xLTA_1e9ee606-a450-4a70-9569-38cc2ab90b6b">50,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:PaymentsToAcquireEquitySecuritiesFNNI" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIyLTUtMS0xLTA_3f4fbe63-9d79-4aa4-8ea3-14f8e9d6ed3a">78,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:ProceedsFromIssuanceOfEquitySecuritiesFNNI" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIzLTEtMS0xLTQzNzQ2_97f9eab5-d775-429b-b3d1-21c72b1ba2a1">115,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:ProceedsFromIssuanceOfEquitySecuritiesFNNI" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIzLTMtMS0xLTQzNzQ2_8125bfaa-577c-471f-8f31-ab3a7fd53228">384,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:ProceedsFromIssuanceOfEquitySecuritiesFNNI" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIzLTUtMS0xLTQzNzQ2_265e1ef4-94d0-4916-a24b-b84a62228d0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIzLTEtMS0xLTI1NjYy_1a015c40-815d-4644-86b4-b690314abba7">70,441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIzLTMtMS0xLTI1NjYy_584b75ab-dbb3-4969-94ec-51b3494d0742">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIzLTUtMS0xLTI1NjYy_a665d066-97ec-4c44-8997-6f68d5921caf">125,121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIzLTEtMS0xLTA_75d3abce-3527-476b-8090-ea98bfb44cd5">62,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIzLTMtMS0xLTA_ac8a2266-ce59-4622-8d4f-7b8cac2ed301">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIzLTUtMS0xLTA_d2429b60-09db-49f7-9483-0e82b2264f7f">150,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzI0LTEtMS0xLTA_67d702d8-c681-44b8-b8cf-7318af8f3998">1,196,579</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzI0LTMtMS0xLTA_647ecdb8-78a1-433e-be32-3bf6c1601745">1,705,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzI0LTUtMS0xLTA_60ff4185-836d-4897-8b31-05fd11bf5024">817,402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzI1LTEtMS0xLTA_e0048a31-d574-40ca-ab7e-74bebe9743e5">1,597,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzI1LTMtMS0xLTA_d57e4872-0037-42bf-a717-2068f785be1d">815,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzI1LTUtMS0xLTA_a3ee2c4e-88e6-4c81-a4bb-1a5d475542ff">725,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:PaymentsToAcquireWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzI4LTEtMS0xLTA_c1478bcd-3068-4e97-a1df-5e4a6b037185">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:PaymentsToAcquireWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzI4LTMtMS0xLTA_889c4d9f-40a7-4e16-b01e-e879eddfd22b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:PaymentsToAcquireWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzI4LTUtMS0xLTA_1bb64627-52bf-4631-ae0c-e67f31015419">8,840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions of financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireFinanceReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzI5LTEtMS0xLTA_21732f16-c0d4-4a43-9ea5-8d55c06d2749">2,191,502</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireFinanceReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzI5LTMtMS0xLTA_db92e458-191d-41df-8c78-682e2e1e776f">2,182,246</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireFinanceReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzI5LTUtMS0xLTA_617b9499-c7b0-4232-8850-55e901475f82">1,721,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Milestone payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:PaymentsForMilestones" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzMwLTEtMS0xLTA_464f4237-f96e-4631-8da7-c72d19b8fa0f">18,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:PaymentsForMilestones" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzMwLTMtMS0xLTA_e36e26ae-f294-443c-835a-446c8d9daa45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:PaymentsForMilestones" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzMwLTUtMS0xLTA_a836bf33-c5dc-4542-9b4c-54ed3af2a02e">250,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzMxLTEtMS0xLTA_dc2a676b-10ac-4646-abf5-a6943289b121">1,870,280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzMxLTMtMS0xLTA_c4d858ae-14c3-40e7-a519-9d4e8bcdca22">2,759,320</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzMxLTUtMS0xLTA_2f23c045-3ed5-40e6-96dd-d1a514fb0eeb">2,153,625</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions to shareholders/unitholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:PaymentsForDistributionsToShareholdersAndUnitholders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM0LTEtMS0xLTA_4546ff2a-2ccf-4c82-9dde-a31a91a7e894">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:PaymentsForDistributionsToShareholdersAndUnitholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM0LTMtMS0xLTA_09b8d334-1a38-4e9d-bf51-e0b6fc9cc121">285,353</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:PaymentsForDistributionsToShareholdersAndUnitholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM0LTUtMS0xLTA_15b5fd34-32da-41c4-b017-a9ce10b6e0c4">739,276</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM1LTEtMS0xLTA_9772da4f-f8bc-4e86-8094-4809988c026f">479,604</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM1LTMtMS0xLTA_7066c4b7-c58c-46ba-8d2a-638f80e913f7">543,952</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM1LTUtMS0xLTA_2efe94c0-bce7-4540-bb54-568b417d4978">154,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions to non-controlling interest- other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:PaymentsToNoncontrollingInterestsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM2LTEtMS0xLTA_663e2415-c941-49c6-8a04-f40e9d4c80b0">153,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:PaymentsToNoncontrollingInterestsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM2LTMtMS0xLTA_9fb48a61-37c0-4b7c-a7c7-968e85422272">181,135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:PaymentsToNoncontrollingInterestsOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM2LTUtMS0xLTA_e1ac0988-de90-48e2-a3b9-f18930048c52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends to shareholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:PaymentOfDividendsToShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM3LTEtMS0xLTA_ca24b22c-e201-4a17-a6fd-997c76303adc">285,184</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:PaymentOfDividendsToShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM3LTMtMS0xLTA_c3db5074-756e-4053-810e-6d1c183be262">112,490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:PaymentOfDividendsToShareholders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM3LTUtMS0xLTA_209ced3c-38ad-40eb-9a1d-7dc2f7fe788f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contributions from non-controlling interest- R&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:ProceedsFromNoncontrollingInterestsResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM5LTEtMS0xLTA_97d31d87-2aaf-4a3f-839f-991a77ba5cf3">7,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:ProceedsFromNoncontrollingInterestsResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM5LTMtMS0xLTA_ab763700-e327-46f9-baa3-4d24b1adebfb">8,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:ProceedsFromNoncontrollingInterestsResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM5LTUtMS0xLTA_1e2eb6c5-e8d9-4e1b-a0bd-811f80b977d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contributions from non-controlling interest- other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:ProceedsFromNoncontrollingInterestsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQwLTEtMS0xLTA_616135f9-fd6e-4b61-8ea2-adeb76932795">36,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:ProceedsFromNoncontrollingInterestsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQwLTMtMS0xLTA_aadf01b2-8c84-4375-a0aa-e1b1038d3a2f">58,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:ProceedsFromNoncontrollingInterestsOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQwLTUtMS0xLTA_c7f2a44c-eb2c-4338-b771-36f21aafe2bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Scheduled repayments of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:RepaymentsOfLongTermDebtScheduledPayments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQxLTEtMS0xLTA_8ce2f01c-9eaf-423b-af80-dad3b38a1cd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:RepaymentsOfLongTermDebtScheduledPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQxLTMtMS0xLTA_86c53e74-c4b2-4897-80a0-9c354126ad52">94,200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:RepaymentsOfLongTermDebtScheduledPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQxLTUtMS0xLTA_afd2a6e3-168c-4200-8ed7-2ec3ef095e0b">294,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQyLTEtMS0xLTA_f0a817af-69ec-4d46-b1d6-77d9ddd7ea36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQyLTMtMS0xLTA_2d33c9b8-f30d-4589-b27f-082952930edb">11,116,196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQyLTUtMS0xLTA_2bce69ab-39db-4b64-be5a-6e21d4f026d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt, net of discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQzLTEtMS0xLTA_54dc386c-1ec7-410f-abe0-a474f4135e12">1,272,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQzLTMtMS0xLTA_b563b76e-bb5f-442e-b29a-68bbac9530dc">11,891,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQzLTUtMS0xLTA_608b44ab-3434-4be8-84e0-f5bad850d7e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt issuance costs and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ0LTEtMS0xLTA_41f889ec-afb9-41d9-9e5a-a1256da1d917">13,046</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ0LTMtMS0xLTA_d4df1eab-1536-4343-b04a-9047539a5924">46,715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ0LTUtMS0xLTA_659125d1-b8ae-4ccb-8307-797a04c3aa16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of treasury interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ1LTEtMS0xLTA_0383f8f7-c12f-4a43-a0ec-8fa54af590f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ1LTMtMS0xLTA_b144e9be-5edf-4381-8a71-ffa7d990619b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ1LTUtMS0xLTA_85310abe-d85d-4931-af40-09e901404286">4,266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of Class A ordinary shares upon IPO, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ2LTEtMS0xLTA_978c0adf-b896-43ea-a261-d7b3420d0213">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ2LTMtMS0xLTA_aa772a64-581a-4329-963c-34165e51784b">1,908,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ2LTUtMS0xLTA_68e56d7b-4b17-40d7-8611-11824083917a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by/(used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ4LTEtMS0xLTA_3698356d-138d-4de9-9a16-7896f68c7346">385,112</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ4LTMtMS0xLTA_9f3944ec-3d24-4c51-a04d-eaa6f2e3705a">1,487,172</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ4LTUtMS0xLTA_b301421d-064c-4b99-a163-6bf9f53aa6c2">1,191,626</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ5LTEtMS0xLTA_13683180-007e-4c5a-9881-1f836df8cd47">532,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ5LTMtMS0xLTA_9046bfb6-73b6-425d-abe1-716bf1f92099">762,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ5LTUtMS0xLTA_6d26ff06-4c9b-4ed5-a671-40ab5c1de544">1,678,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzUwLTEtMS0xLTA_15df8d23-7b04-40b3-ae4d-e2a0499e13cc">1,008,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id30f26bcb6cd4b64982e6cd53528c44e_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzUwLTMtMS0xLTA_d15819c9-5187-46ea-8397-1ef8aa7d43b1">246,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26755fbc5e413fbf3122ec0db17370_I20181231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzUwLTUtMS0xLTA_e2bfcc4e-eb0d-4ed4-9ff9-9d3edc9b9973">1,924,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzUxLTEtMS0xLTA_6f659d37-2434-41bc-8ab5-49725eac9125">1,541,048</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzUxLTMtMS0xLTA_16a53f7d-7112-464a-a497-4879fb584362">1,008,680</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id30f26bcb6cd4b64982e6cd53528c44e_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzUxLTUtMS0xLTA_7b7cacfc-461c-46d2-b5d7-c2fb31250d89">246,199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="i15fafc99ab5c41deb08ee816ca47172c_109"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">                                                                                                                                                                                       </span></div><div><span><br/></span></div></div><div><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_112"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3Xzg4MDk_72cf4147-37f5-4184-8c04-05539d1c460b" continuedAt="i7281dc19a34d4676b8e461e6ea34939b" escape="true">Organization and Purpose </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i7281dc19a34d4676b8e461e6ea34939b" continuedAt="icf0d3235858a4d5bb072151c247c8649"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Royalty Pharma plc is an English public limited company incorporated under the laws of England and Wales that was created for the purpose of consolidating our predecessor entities and facilitating the IPO of our Class A ordinary shares that was completed in June 2020. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following our IPO, we control Royalty Pharma Holdings Ltd. (&#8220;RP Holdings&#8221;), a private limited company incorporated under the laws of England and Wales and U.K. tax resident through our ownership of RP Holdings&#8217; Class A ordinary shares (the &#8220;RP Holdings Class A Interests&#8221;) and RP Holdings&#8217; Class B ordinary shares (the &#8220;RP Holdings Class B Interests&#8221;). We conduct our business through RP Holdings and its subsidiaries and include RP Holdings and its subsidiaries in our consolidated financial statements. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV (&#8220;RPI 2019 ICAV&#8221;), which is an Irish collective asset management entity formed to facilitate our Exchange Offer Transactions (defined below), and is the successor to Royalty Pharma Investments, an Irish unit trust (&#8220;Old RPI&#8221;), for accounting and financial reporting purposes. RP Holdings is owned by RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the &#8220;Continuing Investors Partnerships&#8221;), and Royalty Pharma plc. Old RPI is a unit trust established in August 2011 under the laws of Ireland and authorized by the Central Bank of Ireland pursuant to the Unit Trusts Act, 1990. Prior to the Exchange Offer Transactions, Old RPI was owned by various partnerships (the &#8220;Legacy Investors Partnerships&#8221;).  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RP Management, LLC (the &#8220;Manager&#8221;), a Delaware limited liability company, is an external adviser which is responsible for our management. RP Management (Ireland) Ltd. (&#8220;RP Ireland&#8221;), is the manager of Old RPI and equivalent to the board of directors of a company or general partner of a partnership and is responsible for the day to day operations of Old RPI. Its functions can be delegated to third parties. RP Ireland delegated responsibility for investment management of Old RPI to its parent company, the Manager, in accordance with the investment objectives and policies of Old RPI. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Royalty Pharma,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Royalty Pharma plc and its subsidiaries on a consolidated basis. After the consummation of the Reorganization Transactions (defined below) and before the consummation of the IPO, &#8220;Royalty Pharma,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to RPI 2019 ICAV. Prior to the Reorganization Transactions, &#8220;Royalty Pharma,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Old RPI.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. We fund innovation in the biopharmaceutical industry both directly and indirectly&#8212;directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reorganization Transactions </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our IPO, we consummated an exchange offer on February 11, 2020 (the &#8220;Exchange Date&#8221;). Through the exchange offer, investors representing <ix:nonFraction unitRef="number" contextRef="i2cb0ee2d2cce4d55b7e14f29d979d9bc_D20200211-20200211" decimals="2" name="us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzMzNjc_6103663d-f887-4dd9-a91b-b7afbd536ddb">82</ix:nonFraction>% of the aggregate limited partnership in the Legacy Investors Partnerships, exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in the Continuing Investors Partnerships. The exchange offer transaction together with (i) the concurrent incurrence of indebtedness under our new credit facility and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the &#8220;Exchange Offer Transactions.&#8221;</span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="icf0d3235858a4d5bb072151c247c8649"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Exchange Offer Transactions, we own, through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (&#8220;RPI Intermediate FT&#8221;), an <ix:nonFraction unitRef="number" contextRef="idb95cff49c3e4b6483e5a57868295bb3_I20200211" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzQxNDQ_fd411d82-8b52-4a73-a3d0-6d19edf0c677">82</ix:nonFraction>% economic interest in Old RPI. Through our <ix:nonFraction unitRef="number" contextRef="idb95cff49c3e4b6483e5a57868295bb3_I20200211" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzQxODk_042ce3b4-1b4f-4ca9-b064-f163259a7acd">82</ix:nonFraction>% indirect ownership of Old RPI, we are legally entitled to <ix:nonFraction unitRef="number" contextRef="idb95cff49c3e4b6483e5a57868295bb3_I20200211" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzQyNTA_afd7ca14-ef5e-41c5-b9eb-6bff1babff1a">82</ix:nonFraction>% of the economics of Old RPI&#8217;s wholly-owned subsidiaries, RPI Finance Trust, a Delaware statutory trust (&#8220;RPIFT&#8221;) and RPI Acquisitions (Ireland), Limited (&#8220;RPI Acquisitions&#8221;), an Irish private limited company, and <ix:nonFraction unitRef="number" contextRef="i41e5a726a82b47548d1f945e92636296_I20200211" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzQ0NjY_dbd775a5-2b60-40a4-bc8b-eea3d6e66872">66</ix:nonFraction>% of Royalty Pharma Collection Trust, a Delaware statutory trust (&#8220;RPCT&#8221;). The remaining <ix:nonFraction unitRef="number" contextRef="idb7af162272940eead234259d17da45b_I20200211" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzQ1NTY_c830d717-7225-4854-964c-cc2abbdbff98">34</ix:nonFraction>% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (&#8220;RPSFT&#8221;), which is wholly owned by Royalty Pharma Select, an Irish unit trust. From the Exchange Date until the expiration of the Legacy Investors Partnerships&#8217; investment period on June 30, 2020 (the &#8220;Legacy Date&#8221;), the Legacy Investors Partnerships were offered to participate proportionately in any investment made by Old RPI. Following the Legacy Date, Old RPI ceased making new investments and each of Old RPI and the Legacy Investors Partnerships became legacy entities. Since the Legacy Date, we have made and plan to make new investments through our subsidiaries, including RPI Intermediate FT. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Exchange Offer Transactions, the Legacy Investors Partnerships and RPI Intermediate FT entered into new credit facilities in the amount of $<ix:nonFraction unitRef="usd" contextRef="i74a3535e1f304c089ec2b07d0bdc6f52_I20200211" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzE2NDkyNjc0NTE4MDQ_7ab38ef3-4419-46c8-a420-441d46326656">1.3</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i196399f1da794ae7a1ec4de607513d77_I20200211" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzE2NDkyNjc0NTE3NDQ_6224d0f8-314e-4bda-9e2e-60eb4af62eaa">6.0</ix:nonFraction>&#160;billion, respectively, the proceeds of which were used to repay the $<ix:nonFraction unitRef="usd" contextRef="ibabbf759907e4aee8080ea0173539d93_D20200211-20200211" decimals="-8" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzE2NDkyNjc0NTE4MTI_adc48e5f-2caf-4655-80df-b2999dfd7439">6.3</ix:nonFraction>&#160;billion outstanding debt of RPIFT and, in the case of RPI Intermediate FT, were also available to be used to fund investments. As part of the new credit facilities, RPI Intermediate FT repaid $<ix:nonFraction unitRef="usd" contextRef="i70f4f8cb8c6d440883d5034075ba2017_D20200211-20200211" decimals="-8" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzE2NDkyNjc0NTE4MjA_fa9379e1-91fb-470d-a7cb-190d7f392dd0">5.2</ix:nonFraction>&#160;billion, its pro rata portion of RPIFT&#8217;s outstanding debt and accrued interest. RPIFT also terminated all outstanding interest rate swaps in connection with the debt refinancing. </span></div><div style="margin-bottom:1pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to, and as a condition precedent to the closing of the IPO, various reorganization transactions became effective, including the following:</span></div><div style="margin-bottom:1pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Exchange Offer Transactions (as described above); and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the execution of a new management agreement with the Manager (the &#8220;Management Agreement&#8221;).</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We refer to these transactions collectively as the &#8220;Reorganization Transactions.&#8221;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As Old RPI is our predecessor for financial reporting purposes, we have recorded Old RPI&#8217;s assets and liabilities at the carrying value reflected on Old RPI&#8217;s balance sheet as of the Exchange Date. The references in the following notes for the periods prior to the Exchange Date refer to the financial results of Old RPI for the same periods. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IPO</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2020, we completed our IPO on the Nasdaq Global Select Market under the ticker symbol &#8220;RPRX&#8221;, in which we issued <ix:nonFraction unitRef="shares" contextRef="i8f263e6903ec49b1bb03a648b164d00e_D20200618-20200618" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzY3MDk_eace8314-b480-4565-9532-7c34063aa0d4">89,334</ix:nonFraction>&#160;thousand Class A ordinary shares at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0861ac581a4a474c88d227f3b54a6874_I20200618" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzY3NzQ_cae7c48c-d7cd-4f26-b12c-ae0459db5b65">28.00</ix:nonFraction> per Class A ordinary share, of which <ix:nonFraction unitRef="shares" contextRef="iff33cf273b964edf907891fec81037d3_D20200618-20200618" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzY3OTc_764eed00-8018-4fe7-aa5f-94753f3f0b47">71,652</ix:nonFraction>&#160;thousand Class A ordinary shares and <ix:nonFraction unitRef="shares" contextRef="ia342308de5774def81f37403f622bd7b_D20200618-20200618" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzY4MDQ_9b733fc5-b9da-4617-916c-93054e8c10cb">17,682</ix:nonFraction>&#160;thousand Class A ordinary shares were offered by the Company and selling shareholders, respectively. We used the net proceeds from the IPO to acquire RP Holdings Class A Interests and, as a result, we own <ix:nonFraction unitRef="number" contextRef="i414a5cb6c59c4311a4ff39f341e18444_D20200618-20200618" decimals="INF" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzcyNzE_ddfa7d33-d46c-48a1-b337-baa31701789b">100</ix:nonFraction>% of RP Holdings Class A Interests.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon consummation of the IPO, certain of the Continuing Investors agreed to exchange, pursuant to the Exchange Offer Transactions, interests in the Continuing Investors Partnerships represented by their ownership of <ix:nonFraction unitRef="shares" contextRef="i586b66d2b65b47dfaf4325e8b30978d9_D20200601-20200630" decimals="INF" name="rprx:SaleOfStockNumberOfSharesAvailableToConvert" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3Xzc1NjU_1473b47f-7ea5-419f-9d19-fe56caacd2ff">294,176</ix:nonFraction>&#160;thousand RP Holdings Class B Interests into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i586b66d2b65b47dfaf4325e8b30978d9_D20200601-20200630" decimals="INF" name="rprx:SaleOfStockNumberOfSharesAvailableToConvert" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3Xzc2MTk_1473b47f-7ea5-419f-9d19-fe56caacd2ff">294,176</ix:nonFraction>&#160;thousand Class A ordinary shares of Royalty Pharma plc. Upon completion of the exchange, Royalty Pharma plc indirectly owned <ix:nonFraction unitRef="shares" contextRef="i586b66d2b65b47dfaf4325e8b30978d9_D20200601-20200630" decimals="INF" name="rprx:SaleOfStockNumberOfSharesAvailableToConvert" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3Xzc3MzE_1473b47f-7ea5-419f-9d19-fe56caacd2ff">294,176</ix:nonFraction>&#160;thousand RP Holdings Class B Interests. The remaining investors in the Continuing Investors Partnerships who did not elect to exchange into Class A ordinary shares held <ix:nonFraction unitRef="shares" contextRef="i586b66d2b65b47dfaf4325e8b30978d9_D20200601-20200630" decimals="INF" name="rprx:SaleOfStockNumberOfSharesNotConverted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3Xzc4OTQ_91d9d7c7-428e-46bf-bd5e-bfdd4d0bc02d">241,207</ix:nonFraction>&#160;thousand newly issued Class B ordinary shares of Royalty Pharma plc. As a result, the Continuing Investors Partnerships held a number of our Class B ordinary shares equal to the number of RP Holdings Class B Interests indirectly held by them at such time which are exchangeable on a one-for-one basis for Class A ordinary shares of Royalty Pharma plc.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_115"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDIx_6d988321-3307-432d-9e9f-927ca259118a" continuedAt="i10ba2d36aff34ef4b11b0f01ff6dcc70" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i10ba2d36aff34ef4b11b0f01ff6dcc70" continuedAt="i4dd34284e06e40b99f885288f3126d2b"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of preparation and use of estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDI2_ac55ca6b-485e-4af4-aab0-4ddda317ebc4" escape="true">The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</ix:nonNumeric></span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i4dd34284e06e40b99f885288f3126d2b" continuedAt="i7e17a6e5ed1d44c8b9db57bde34e5442"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDM5_44bd19fa-a67d-41da-8862-7a07f13b8da9" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The precise extent to which the COVID-19 pandemic will impact our operational and financial performance will depend on various factors. To date, certain marketers of some of our portfolio products have commented that the performance of these products have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not resulted in a material effect to our results of operations and liquidity and we do not believe it is reasonably likely to in the future. Due to the nature of our business, the effect of the COVID-19 pandemic may not be fully reflected in certain of our results of operations until future periods.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of consolidation</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDI3_eec9304b-ade4-47d1-be67-602bef45da50" continuedAt="i1f13fe3da593423c890376775a0f0b62" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity&#8217;s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net income attributable to non-controlling interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in our consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following management&#8217;s determination that a high degree of common ownership existed in Royalty Pharma both before and after the Exchange Date, Royalty Pharma recognized Old RPI&#8217;s assets and liabilities at the carrying value reflected on Old RPI&#8217;s balance sheet as of the Exchange Date. </span></div></ix:nonNumeric><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Exchange Offer Transactions, our only historical non-controlling interest was attributable to a de minimis interest in RPCT held by RPSFT. As a result of the Exchange Offer Transactions in February 2020, a new non-controlling interest was created related to the Legacy Investors Partnerships&#8217; ownership of approximately <ix:nonFraction unitRef="number" contextRef="i4c1e7922bf5d4fb7a873526ac9e2acd2_I20200229" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzI0OTg_677f4cdb-6c80-4697-b4f5-1b7c13c3bc20">18</ix:nonFraction>% in Old RPI. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following the consummation of our IPO in June 2020, <ix:nonFraction unitRef="partnership" contextRef="ifb99eff80794423ca92bd7db72623f54_I20200630" decimals="INF" name="rprx:NumberOfNoncontrollingInterestsCreated" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzI1Njc_69e6027f-b93f-42ff-932b-4bc4a88575e7">two</ix:nonFraction> new non-controlling interests were created: (1) a non-controlling interest related to the Continuing Investors Partnerships&#8217; ownership in RP Holdings through their ownership of the RP Holdings Class B Interests, which amounted to approximately <ix:nonFraction unitRef="number" contextRef="i6e7e9177eb1b4c9da6650b9f74990c36_I20211231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQ5NDc4MDIzODE0MzE_ee2974d8-b42d-456b-8354-7c56154c6cc2">29</ix:nonFraction>% as of December 31, 2021, and (2) a non-controlling interest related to RPI EPA Holdings, LP (&#8220;EPA Holdings&#8221;), an affiliate of the Manager through its ownership of the  RP Holdings&#8217; Class C ordinary share (the &#8220;RP Holdings Class C Special Interest&#8221;). Income will not be allocated to the latter non-controlling interest until certain conditions are met.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1f13fe3da593423c890376775a0f0b62">All intercompany transactions and balances have been eliminated in consolidation.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adjustment to prior period presentation </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the preparation of our condensed consolidated interim financial statements for the three months ended September 30, 2020, we identified an adjustment to the classification of our short-term investments on our consolidated balance sheets, as of December 31, 2019, based on the original maturity dates of the investments. The adjustment resulted in an increase of $<ix:nonFraction unitRef="usd" contextRef="i89b6773bde7741e89cfa1ba14576b98f_I20191231" decimals="-5" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzE2NDkyNjc0OTExNjQ_1c2c8a6e-b797-4c49-bb1e-a345c47c1254"><ix:nonFraction unitRef="usd" contextRef="i89b6773bde7741e89cfa1ba14576b98f_I20191231" decimals="-5" sign="-" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzE2NDkyNjc0OTExNjQ_a73842b3-66de-46b3-ac35-d9eeb2dae3ea">37.5</ix:nonFraction></ix:nonFraction> million to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Marketable securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and a corresponding decrease to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on the consolidated balance sheet as of December 31, 2019. In addition, the adjustment resulted in an increase of $<ix:nonFraction unitRef="usd" contextRef="i9f493e893d9e41c9836fd0b92cee6bf2_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzE2NDkyNjc0OTExNjg_3522fa8c-91c3-4e81-954f-7c55eadcbf61">388.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9f493e893d9e41c9836fd0b92cee6bf2_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzE2NDkyNjc0OTExNzI_c8bff732-ccc3-4d78-a5a5-2241915a6ad5">350.5</ix:nonFraction> million in cash activity related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Purchases of marketable securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Proceeds from sales and maturities of marketable securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, respectively, within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash used in investing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for the year ended December 31, 2019, with a net impact on net cash flow from investing of $<ix:nonFraction unitRef="usd" contextRef="i9f493e893d9e41c9836fd0b92cee6bf2_D20190101-20191231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzE2NDkyNjc0OTExNzY_9302671e-09d4-46f8-b295-dbc307a15692">37.5</ix:nonFraction> million. The adjustment had no effect on our reported total income and revenues, consolidated net income, total assets, or shareholders&#8217; equity for any period. In addition, the adjustment does not impact net cash provided by operating activities in any period. We evaluated the adjustment and determined that, based on quantitative and qualitative analysis, it was not material to the consolidated financial statements as of and for the year ended December 31, 2019.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzE0MjkzNjUxMjQ2NDcz_35cdb14b-6a78-4d04-8cba-b52824da5aa5" escape="true">Certain prior period amounts have been reclassified to conform to the current period presentation.</ix:nonNumeric></span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i7e17a6e5ed1d44c8b9db57bde34e5442" continuedAt="i9b7e78e6071c49b8af707556ab0452cb"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDMy_0b8c6c51-2e05-4420-a5ee-dbaa67e51aab" continuedAt="i05ec2b8c963e495b8f3a87630c793086" escape="true">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, financial royalty assets and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances at December 31, 2021 and 2020 were held with State Street and Bank of America. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.</ix:nonNumeric></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i05ec2b8c963e495b8f3a87630c793086">The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, AbbVie, Bristol Myers Squibb, Gilead, Johnson &amp; Johnson, Lilly, Merck, Pfizer, Novartis, Biogen, Roche and Vertex.</ix:continuation> For the years ended December 31, 2021 and 2020, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for <ix:nonFraction unitRef="number" contextRef="id0a851bce2a945d59b0ed1c24aa99168_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzIxNDQwNDc2ODI1NDUy_ae9ed150-7afb-4461-809c-79098ccc4158">32</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i5b0975d860cd4ef59dd25d4eb5f1f7a6_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzIxNDQwNDc2ODI1NDYw_a08f9099-0f49-4acb-bc57-eaaccb071a3e">27</ix:nonFraction>% of our current portion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, representing the largest individual receivable balance in both years.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment information</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDQx_ca4d46bc-9e7d-4fb5-ab47-758225f7f147" escape="true">Our chief operating decision maker is our Chief Executive Officer who reviews financial information presented on a consolidated basis to allocate resources, evaluates financial performance and makes overall operating decisions. As such, we concluded that we operate as <ix:nonFraction unitRef="segment" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzY3MDM_511541fc-9a50-4a95-8e7f-ae288df27d78">one</ix:nonFraction> single reportable segment, which is primarily focused on acquiring biopharmaceutical royalties.</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty assets</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="rprx:RoyaltyAssetsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDIz_d31e77b9-6d39-42ab-84a2-2881b68c94db" escape="true"><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An acquisition of a royalty asset provides the buyer with contractual rights to cash flows relating to royalties from the sales of patent-protected biopharmaceutical products. These acquisitions entitle us to receive a portion of income from the sale of patent-protected biopharmaceutical products by unrelated biopharmaceutical companies. For the majority of our royalties, our rights are protective in nature. In other words, we do not own the intellectual property and we do not have the right to commercialize the underlying products. These contractual cash flow rights have yield components that most closely resemble loans and are classified as financial royalty assets.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the limited instances where we possess rights to exploit the underlying patents, rights to the intellectual property related to the biopharmaceutical products, or the ability to influence the amount or duration of future royalty payments, these royalties are classified as intangible assets.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial royalty assets, net</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:FinanceLoansAndLeasesReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDMx_e2f8865a-7d7a-4bf4-9bc0-a2b3b992f4dd" continuedAt="i5f4f20e0e6794ca790b248594987107c" escape="true"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we analogize to the accounting guidance within Accounting Standards Codification 310 (&#8220;ASC&#8221;), Receivables, as it most closely aligns with the underlying economics of our financial royalty assets. Therefore, such financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Imputation of Interest</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i9b7e78e6071c49b8af707556ab0452cb" continuedAt="id62bb283ea0b41d8affd8e6b4acec642"><ix:continuation id="i5f4f20e0e6794ca790b248594987107c" continuedAt="i8bb86a54db264024b270ca9e8db9e955"><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is reviewed and adjusted each reporting period as differences between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows. Income is calculated by multiplying the carrying value of the financial royalty asset by the effective interest rate. The carrying value of a financial royalty asset is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by the interest income accrual and decreased by cash receipts in the period to arrive at the ending balance. If the ending balance is greater than the net present value of the expected future cash flows, a provision is recorded to reduce the asset balance to the net present value. The provision is recorded through the income statement as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected cash flows from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the carrying value of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is presented net of the cumulative allowance for changes in expected future cash flows.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The application of the prospective approach to measure financial royalty assets requires management&#8217;s judgment in forecasting the expected future cash flows of the underlying royalties. The amounts and duration of forecasted expected future cash flows used to calculate and measure interest income are largely impacted by sell-side equity research analyst coverage, commercial performance of the product, and royalty duration, each discussed in further detail below.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Analyst coverage.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Forecasts of expected future cash flows are developed from sales projections of the underlying biopharmaceutical products as published in sell-side equity research analyst reports. In projecting future cash flows, our policy is to rely on sell-side research analysts&#8217; consensus sales forecasts for a product to derive annual sales projections for each financial royalty asset over the periods for which we are entitled to royalties or milestones. These forecasts are based on input from internal and external market research that analyzes factors such as growth in global economies, industry trends and product life cycles. When royalty-bearing biopharmaceutical products have no coverage, limited sell-side equity research analyst coverage or where sell-side equity research analyst consensus sales estimates are not available for the full term of the royalty, particularly for the later years in a product&#8217;s life, management uses reasonable judgment to make assumptions about the growth or decline in the sales of these products based on historical data, market trends and management&#8217;s own expertise. For the majority of the portfolio of financial royalty assets, management utilizes statistical curves based on historical trends to project future sales when sell-side equity research analyst consensus sales estimates end or are not available for the full term of the royalty. In other cases, management may develop and apply growth rate estimates from existing sell-side equity research analysts&#8217; consensus sales forecasts to project future sales for products that cannot be modeled through the statistical curves, such as those where the entrance of a biosimilar is expected to impact future sales. Based on the level of detail in sell-side equity research analyst models, management can also be required to apply assumptions to the sales forecasts to estimate the quarterly and geographical allocation from annual sales projections and, for franchised products, to estimate the product mix and pricing mix, or to exclude from projections sales forecasts for unapproved products or indications. Our contractual royalty terms, rates, and any milestones are then applied to the adjusted sales projections to calculate the expected royalty or milestone payments over the term of the financial royalty asset&#8217;s life, forming the basis for our forecast of expected future cash flows used to calculate and measure interest income.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Commercial performance.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The approval of a product for use in new indications can extend the date through which we are entitled to royalties or milestones on that product. For certain financial royalty assets, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and whose sales were previously not reflected in expected future cash flows. We generally do not recognize income from, or forecast sales for, unapproved products or indications. If a product is removed from all or a portion of a market, subsequent sell-side equity research analysts&#8217; consensus sales forecasts will reflect the expected drop in sales. Both the new cash flow streams and the cessation of cash flow streams related to a product&#8217;s performance in the market over the royalty term can materially affect our forecast of expected future cash flows.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="id62bb283ea0b41d8affd8e6b4acec642" continuedAt="i186968807b3846998243a0362cef12a2"><ix:continuation id="i8bb86a54db264024b270ca9e8db9e955" continuedAt="ib9cec17ab56a4660a0bd2515132caa7f"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Royalty duration. </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The duration of a royalty can be based on a number of factors, such as regulatory and marketing approval dates, patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, the entry of generics or a contractual date arising from litigation, which are all impacted by the time in the product&#8217;s life cycle at which we acquire the royalty. Royalty duration varies by geography as United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms. Products may be covered by a number of patents and, for products whose royalty term is linked to the existence of valid patents, management is required to make judgments about the patent providing the strongest patent protection to align the period over which management forecasts expected future cash flows to the royalty term. It is common for the latest expiring patent in effect at the date we acquire a financial royalty asset to be extended, adjusted or replaced with newer dated patents subsequent to our acquisition of a royalty due to new information, resulting in changes to the royalty duration in later periods. Patents may expire earlier than expected at the time of the acquisition due to the loss of patent protection, loss of data exclusivity on intellectual property, contractual licensing terms limiting royalty payments based on time from product launch, due to recent legal developments or litigation. Macroeconomic factors, such as changes in economies or the competitive landscape, including the unexpected loss of exclusivity to the products underlying our portfolio of royalties, changes in government legislation, product life cycles, industry consolidations and other changes beyond our control could result in a positive or negative impact on our forecast of expected future cash flows.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the preparation of the forecasted expected future cash flows, which relies on the sources and variables discussed above, management is required to make assumptions around the following forecast inputs: (1) estimates of the duration of the royalty, which includes consideration of the strength of patent protection and anticipated entry of generics, (2) product growth rates and sales trends in outer years, (3) the product and pricing mix for franchised products, and (4) the geographical allocation of annual sales data from sell-side equity research analysts&#8217; models. The most sensitive of these assumptions relates to management&#8217;s estimate of the royalty duration in the final years of an asset&#8217;s life. In some cases, patent protection may extend to a later period than the expiration date management has estimated. Management may apply a shorter royalty term in this situation if, based on its experience and expertise, management believes that it is more likely that the associated patents are subject to opposition or infringement, that the market for a particular product may shift based on pipeline approvals and products, or that product sales may be harmed by competition from generics. For products providing perpetual royalties, management applies judgment in establishing the duration over which it forecasts expected future cash flows. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A shortened royalty term can result in a reduction in the effective interest rate, a decline in the carrying value of the financial royalty asset, a decline in income from financial royalty assets, significant reductions in royalty payments compared to expectations, or a permanent impairment. Additionally, royalty payments may occasionally continue beyond the estimated royalty expiration date for such reasons we cannot foresee such as excess inventory in the channel or additional scope of patent protection identified after expiry, including royalties we may become entitled to from new indications, new compounds, or for new regulatory jurisdictional approvals.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter and for which the estimates are derived from the latest external publicly available sell-side equity research analyst reports, reported in arrears. </span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cumulative allowance and Provision for changes in expected cash flows from financial royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate financial royalty assets for impairment on an individual basis by comparing the effective interest rate at each reporting date to that of the prior period. If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected), we record a provision for the change in expected cash flows. The provision is measured as the difference between the financial royalty asset&#8217;s amortized cost basis and the net present value of the expected future cash flows, calculated based on the prior period&#8217;s effective interest rate. The amount recognized as provision expense increases the financial royalty asset&#8217;s cumulative allowance, which reduces the net carrying value of the financial royalty asset.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i186968807b3846998243a0362cef12a2" continuedAt="i1a73c64288a94f289964615b214c0b09"><ix:continuation id="ib9cec17ab56a4660a0bd2515132caa7f"><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance for the increase in the present value of cash flows expected to be collected, resulting in a non-cash credit to the provision line on the income statement. We also recalculate the amount of accretable yield to be received based on the revised remaining future cash flows. The adjustment to the accretable yield is treated as a change in estimate and is recognized prospectively over the remaining life of the financial royalty asset by adjusting the effective interest rate used to calculate income.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Movements in the cumulative allowance for changes in expected future cash flows, which forms part of the </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line item on the consolidated balance sheet, are accompanied by corresponding changes to the provision. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. Recoveries of previously written-off amounts are credited to the allowance. In some cases, when a financial royalty asset&#8217;s contractual cash flows expire, the final royalty payment may differ from the remaining net carrying value. We account for this non-cash true-up at the end of the royalty term as either </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected cash flows from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of operations.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income from financial royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. The accretable yield is recognized as income at the effective rate of return over the expected life of financial royalty assets. After acquisition of a financial royalty asset, if we are not able to reliably estimate expected cash flows for a product or if we have not completed the required funding obligations payable over time for an approved product, a financial royalty asset is placed in non-accrual status (e.g., for royalties from products that have not yet received FDA approval or for accelerated royalties). Such financial royalty assets are held at cost and no income is recognized until the reasonable expectation of the timing of the future cash flows to be collected is available or until funding obligations payable over time for an approved product are complete. We evaluate such financial royalty assets held at cost for impairment based on, among other factors, a review of development progress, clinical trial results, and publicly available information around regulatory discussions and approval status. An impairment loss is recognized if, based on current information and events, it is probable that we will be unable to collect amounts due according to the contractual terms of the financial royalty asset, and the amount of loss can be reasonably estimated.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When royalties are received for financial royalty assets that have been fully amortized, such income is recognized as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income.</span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for current expected credit losses</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:CreditLossFinancialInstrumentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDM1_88471635-714e-4134-b992-2b6bc34e2824" escape="true"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 1, 2020, we adopted ASU 2016-13, </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(&#8220;ASU 2016-13&#8221;) which requires earlier recognition of credit losses. We now recognize an allowance for current expected credit losses on our portfolio of financial royalty assets with limited protective rights. The credit loss allowance is estimated using the probability of default and loss given default method. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the probability of default of the marketers responsible for paying our royalties and the resulting loss given default. The allowance for current expected credit losses is presented net within the non-current portion of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated balance sheets. Any subsequent movement in the allowance for credit losses is recorded as part of the </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Provision for changes in expected future cash flows from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated statements of operations.</span></ix:nonNumeric></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Refer to Note 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">for further information.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible royalty assets, net</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDI5_4e23b787-a260-4257-9679-d9d4269ced8a" continuedAt="ibe53e98e7ea44614b65cc4effac91389" escape="true">Currently, our only intangible royalty assets are the Januvia and Janumet (&#8220;DPP-IV&#8221;) patents. The DPP-IV patents are finite-life intangible royalty assets whose cost is amortized using the straight-line method over the expected lives of the patents, the majority of which terminate at various dates through 2022. The amortization period commenced concurrent with the sale of the product underlying the royalty asset.</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i1a73c64288a94f289964615b214c0b09" continuedAt="i94062fb006d34b70b43346aec8edec88"><div style="text-indent:22.5pt"><ix:continuation id="ibe53e98e7ea44614b65cc4effac91389"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management reviews the performance of intangible royalty assets periodically for impairment as required by ASC 360-10,</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Property, Plant, and Equipment - Overall</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The test for recoverability is performed by comparing the carrying value of the intangible royalty asset with the estimated future undiscounted cash flows generated through royalty payments from sales of the underlying DPP-IV products. When evaluating indicators of impairment, we consider factors such as competitive environment and the product&#8217;s life cycle stage, recent and prospective sales trends, collectability concerns, and any potential rebate chargebacks that may occur at the end of a royalty&#8217;s term. An impairment loss is recognized if the carrying value of the intangible royalty asset is not recoverable and its carrying amount exceeds its fair value.</span></ix:continuation></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from intangible royalty assets and Accrued royalty receivable</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDQz_44342ddb-8291-48fa-87f8-70d3409a9f46" escape="true"><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We earn royalties on sales by our licensees of DPP-IV products covered under patents that we own. We do not have future performance obligations under these license arrangements. Royalty revenue from sales of DPP-IV products is recognized in the period the product is sold. However, under the license agreements, licensees generally provide royalty reports and payments on a one quarter lag. Thus, the accrued royalty receivable is based on an analysis of historical royalties received and sell-side equity research analysts&#8217; projected sales, adjusted for any changes in estimates. Royalty-bearing sales are net of certain rebates and other discounts, as permitted under the terms of the license agreements. Because rebates are generally invoiced and paid in arrears by the marketer, royalty reports often reflect deductions in current periods for rebates related to prior periods which we do not have the ability to estimate.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical estimates that could cause a change in estimated future cash flows include changes in product demand and market growth assumptions, a change in the pricing strategy of the marketer or reimbursement coverage, and changes in country-specific contractual or patent expiry dates. Actual royalty receipts may differ from estimates and any differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically on the basis of royalty receipts.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestone payments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain acquisition agreements provide for future incoming or outgoing contingent payments based on the commercial, regulatory or clinical performance of the related biopharmaceutical product generally over a multi-year period. For purposes of measuring income from financial royalty assets, commercial milestones payable or receivable are reflected in the cash flows used to forecast expected future cash flows in the period in which the milestone criteria is projected to be satisfied based on sell-side equity research analysts&#8217; consensus sales forecasts. Milestones based on regulatory approval or clinical criteria are generally not reflected in the expected future cash flows until such approval is achieved.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts related to outgoing contingent milestone payments are not considered contractual obligations as they are contingent on the successful completion of the defined milestones. Payments under these agreements generally become due and payable upon achievement of certain commercial milestones, and when the contingency is resolved.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial instruments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDM4_dc148f29-a086-432c-a52a-2ae26f4d9de1" escape="true"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain financial instruments reflected in the consolidated balance sheets, (e.g., cash and cash equivalents, certain other assets, accounts payable and certain other liabilities) are recorded at cost, which approximates fair value due to their short-term nature. The fair values of financial instruments other than </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are determined through a combination of management estimates and information obtained from third parties using the latest market data. The fair value of financial instruments is determined utilizing the valuation techniques appropriate to the type of instrument as discussed in Note 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair Value Measurements and Financial Instruments.</span></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and cash equivalents and Marketable securities</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDQ1_e0101476-d76e-4c6c-8f9b-330e10b3ffb2" escape="true">Cash and cash equivalents include cash held at banks and all highly liquid financial instruments with original maturities of 90 days or less. We invest excess cash in marketable debt securities that are classified as trading securities and reported at fair value.</ix:nonNumeric> </span></div></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i94062fb006d34b70b43346aec8edec88" continuedAt="ib9f5c73289f14796908b0ed2fd67e32c"><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity securities and Available for sale debt securities</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="rprx:DebtSecuritiesAvailableForSalePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDM2_69081e90-88ca-4254-97eb-fc897a5e38c5" escape="true"><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our equity securities are measured and recorded at fair value with unrealized gains and losses recorded in earnings. Our equity securities represent investments in publicly traded equity securities. Available for sale debt securities are measured at fair value. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The unrealized change in fair value of available for sale debt securities for which we elected the fair value option is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on the consolidated statements of operations. The </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">unrealized change in fair value for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biohaven Series A Preferred Share is</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> included in </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accumulated other comprehensive income </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(&#8220;AOCI&#8221;) and are reclassified to earnings as interest income is recognized. Interest income is recognized when we can reliably estimate forecasted cash flows. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decline in the market value of any available for sale debt security below its cost that is deemed to have resulted from a credit loss results in a reduction in carrying amount to fair value and is recognized in earnings. The determination of whether a decline in fair value below the amortized cost basis for an available for sale debt security has resulted from a credit loss requires significant judgment and requires consolidation of available quantitative and qualitative evidence in evaluating the potential impairment. Factors evaluated to determine whether a decline in the fair value below the amortized cost basis has resulted from a credit loss include: the extent to which fair value is less than the amortized cost basis, adverse conditions related to the security, an industry, or geographic area, the payment structure of the security, failure of the issuer to make scheduled payments, any changes to the rating of the security by a rating agency, the remaining payment terms of the security, prepayment speeds, the financial condition of the issuer expected defaults, our intent not to sell, and an evaluation as to whether it is more likely than not that we will have to sell before recovery of the cost basis. Assumptions associated with these factors are subject to future market and economic conditions, which could differ from management&#8217;s assessment.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may elect to apply the fair value option for certain investments in debt securities where the fair value option better aligns with the economics of such investment. Upon such election, the entire investment is measured at fair value on a recurring basis, with movements in fair value recognized in earnings.</span></div></ix:nonNumeric><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDM3_436a26d5-499f-4b71-a197-0512b8dd0062" continuedAt="i7726c5f8d5b2473d8adc31b175e62fb2" escape="true">All derivatives are measured at fair value on the consolidated balance sheets with movements in fair value recognized in earnings. Prior to 2017, RPIFT applied hedge accounting to its interest rate swap agreements. </ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><ix:continuation id="i7726c5f8d5b2473d8adc31b175e62fb2" continuedAt="i52b2d4914fac42c0bd9ea0a3a6701510"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the discontinuation of hedge accounting, the AOCI previously recorded on the cash flow hedges was reversed out of other comprehensive income in line with terms of the associated swap contract until the termination of all of our interest rate swaps in February 2020. This reclassification adjustment is shown on the consolidated statements of operations as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Losses on derivative financial instruments</span></ix:continuation><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i52b2d4914fac42c0bd9ea0a3a6701510">.</ix:continuation> </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment in non-consolidated affiliates</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDMw_78d2b340-8ae3-4908-bf0d-93ee96876d7c" continuedAt="if736e26aaece45de9de1f9704afa78e3" escape="true"><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Investments in entities that provide us with the ability to exercise significant influence, but not a controlling financial interest, and where we are not the primary beneficiary are accounted for under the equity method. Investments accounted for under the equity method are initially recorded at fair value. If there is a difference between the fair value and the carrying amount of the equity method investment at inception, we quantify the basis difference and amortize it in a rational manner over the life of the investment. Subsequently, we recognize through earnings our proportionate share of the investee&#8217;s net income or loss, net of any adjustment to reflect the amortization of basis differences. We generally record our share of the results of our investees one quarter in arrears within </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Equity in losses/(earnings) of non-consolidated affiliates</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in the consolidated statements of operations. The investment is reflected as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investments in non-consolidated affiliates</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated balance sheet.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have variable interests in entities formed for the purposes of entering into co-development arrangements for potential biopharmaceutical products (the &#8220;Avillion entities&#8221;). The Avillion entities are variable interest entities for which we are not the primary beneficiary as we do not have the power to direct the activities that most significantly influence the economic performance of the entity. In determining whether we are the primary beneficiary of an entity, management applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant. Management continuously assesses whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of one or more of its investees.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ib9f5c73289f14796908b0ed2fd67e32c" continuedAt="if7bc96b2e1084207b4fddd4a5d9cb11c"><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="if736e26aaece45de9de1f9704afa78e3">When we have committed to provide further support to the investee through capital call commitments and the investment has been reduced to zero, we provide for additional losses, resulting in a negative equity method investment, which is presented as a liability on the consolidated balance sheets.</ix:continuation></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development funding expense</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDMz_39eafcfa-ebaf-470a-81b5-3fafed6acfc2" escape="true"><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We enter into transactions where we agree to fund a portion of the research and development (&#8220;R&amp;D&#8221;) performed by our partners for products undergoing late-stage clinical trials in exchange for future royalties or milestones if the products are successfully developed and commercialized. In accordance with ASC 730, </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and Development</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we account for the funded amounts as R&amp;D expense when we have the ability to obtain the results of the R&amp;D, the transfer of financial risk is genuine and substantive and, at the time of entering into the transaction, it is not yet probable that the product will receive regulatory approval. We may pay funded amounts upfront or over time as the underlying products undergo clinical trials.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty payments owed to the Company on successfully commercialized products generated from R&amp;D arrangements are recognized as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the same period in which the sale of the product occurs. Fixed or milestone payments receivable based on the achievement of contractual criteria for products arising out of our R&amp;D arrangements are also recognized as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the period that the milestone threshold is met. Milestone thresholds are typically not triggered until after all funding obligations have been completed.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDI0_2bf26074-3925-4bb4-9285-7e923e90f5bb" continuedAt="ic58deeff48184e10a68a47fcc8ad4e37" escape="true"><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically assess if our activities, as conducted through our subsidiaries, and as currently contemplated, constitute being engaged in the conduct of a trade or business within the United States. Neither the U.S. Internal Revenue Code (&#8220;the Code&#8221;) nor the applicable Treasury regulations provide a general definition of what constitutes being engaged in the conduct of a trade or business within the United States, and the limited case law on the subject does not provide definitive guidance. Based on our periodic assessment, we believe that we are not engaged in the conduct of a trade or business within the United States, and as such, we do not record a provision for U. S. federal income tax for the years presented in the consolidated financial statements.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe we are not engaged in the conduct of a trade or business within the United States or subject to U.S. taxation in that regard, we are subject to U. S. federal withholding tax on certain fixed or determinable annual or periodical gains, profits and income, such as royalties from sources within the United States, unless reduced or eliminated under an applicable tax treaty or provision of the Code. Generally, this tax is imposed by withholding 30% of the payments, or deemed payments, that are subject to this tax. We believe our subsidiaries are eligible for benefits under the U.S.-Ireland income tax treaty, and, under that treaty, are not be subject to any U.S. withholding taxes on U.S.-source royalty payments. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, because we believe that we are not engaged in the conduct of a trade or business within the United States and our subsidiaries are eligible for benefits under the U.S.-Ireland tax treaty, we do not record a provision for income taxes. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While we do not currently record a provision for income taxes, we are party to certain arrangements that will give rise to a tax provision in the future. We currently have funding arrangements in place that allow our counterparties to draw on capital over a prescribed period of time. When such funding arrangements are drawn and we begin to recognize income from these funding arrangements, such activities will be subject to U.S. taxation and we will record a provision for income taxes in accordance with ASC 740, </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. We also entered into an arrangement with MSCI during 2021 as discussed in Note 16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Related Party Transactions that will become subject to U.S. taxation when we begin to recognize revenue from this transaction.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate so as to be treated solely as resident in the U.K. for tax purposes. As a U.K. tax resident company, we are subject to U.K. corporation tax on our worldwide taxable profits and gains. U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. As such, we do not record a provision for U.K. income taxes with respect to the dividends received from RP Holdings or with respect to the dividends received by RP Holdings from RPI. </span></div></ix:nonNumeric></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="if7bc96b2e1084207b4fddd4a5d9cb11c"><div style="text-indent:22.5pt"><ix:continuation id="ic58deeff48184e10a68a47fcc8ad4e37" continuedAt="icabe34d3461c447dbd584353bb5732d0"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the U.K.&#8217;s &#8220;controlled foreign companies&#8221; rules (the &#8220;U.K. CFC Rules&#8221;). The U.K. CFC Rules, broadly, can impose a charge to U.K. tax on U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the &#8220;Controlled Foreign Company&#8221;) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI (which is Irish tax resident) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Old RPI (which is Irish tax resident and which is held indirectly by us through our participation in RP Holdings)</span></ix:continuation><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icabe34d3461c447dbd584353bb5732d0">, will be Controlled Foreign Companies for U.K. tax purposes. We are therefore required to apply the CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis.  We do not expect material U.K. corporation tax charges to arise under the U.K. CFC Rules in respect of our royalty assets and we therefore do not record a provision for U.K. income taxes.</ix:continuation>  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings per share</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDI1_ea6095b0-5223-4669-9c9f-da5fe8db94a3" escape="true">Basic earnings per share (&#8220;EPS&#8221;) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include the outstanding Class B ordinary shares, Class B ordinary shares contingently issuable to RPI EPA Holdings, LP (&#8220;EPA Holdings&#8221;) related to Equity Performance Awards and unvested restricted share units (&#8220;RSUs&#8221;) issued under our 2020 Independent Director Equity Incentive Plan (&#8220;Equity Incentive Plan&#8221;). We include potentially dilutive shares in the denominator to compute diluted EPS if (i) the inclusion of the ordinary shares is dilutive for the respective reporting periods, and (ii) contingencies are satisfied as of the end of the reporting period for ordinary shares that are contingently issuable.  We use the &#8220;if-converted&#8221; method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs.</ix:nonNumeric></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no Class A ordinary shares or Class B ordinary shares outstanding prior to June 16, 2020; therefore, no earnings per share information has been presented for any period prior to that date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting standards</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDQ0_50f53c24-45d2-4144-9ca8-15077b1b4463" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model (ASU 2016-13). Accordingly, these financial assets are presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model.  With certain exceptions, adjustments are applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retained earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $<ix:nonFraction unitRef="usd" contextRef="ib04d3453e6dc4ca3a0b79e01ab3fe12a_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzE2NDkyNjc0OTA5MTk_aa4f397a-6877-45c0-b096-fe40ac0a87f1">192.7</ix:nonFraction>&#160;million to recognize an allowance for current expected credit losses on our financial royalty assets. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued a new accounting standard that eliminates, adds and modified certain disclosures requirements for fair value measurements under Topic 820 (ASU 2018-13). The ASU modifies the disclosures by removing the requirement to disclose the amount and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers. The ASU expands the disclosure requirements for Level 3 fair value measurements, primarily focused on changes in unrealized gains and losses included in other comprehensive income/(loss). We adopted this standard as of January 1, 2020 with no material impact on our consolidated financial statements and accompanying notes.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><div id="i15fafc99ab5c41deb08ee816ca47172c_127"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzU2ODE_b27eb228-5bbf-4d3a-bcbb-7aac26143546" continuedAt="i08812ffb915b4571a2712ef7b08754b1" escape="true">Available for Sale Debt Securities </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i08812ffb915b4571a2712ef7b08754b1" continuedAt="i3b1883bdfd644239bab821949f8e81f7"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series A Biohaven Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 5, 2019, RPIFT funded the purchase of <ix:nonFraction unitRef="shares" contextRef="ie7ffbb1b682a454ea429c1fb003ce9d8_D20190405-20190405" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzUyOA_678205c2-cfb1-4aa7-a2a4-e2dfbe01991a">2,495</ix:nonFraction> Series A Biohaven Preferred Shares from Biohaven Pharmaceutical Holding Company Ltd. (&#8220;Biohaven&#8221;) at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie7ffbb1b682a454ea429c1fb003ce9d8_D20190405-20190405" decimals="INF" name="rprx:DebtSecuritiesAvailableForSalePricePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzU5NA_a5b32a54-282d-4a4b-b919-375a675350f3">50,100.00</ix:nonFraction> per preferred share, for a total of $<ix:nonFraction unitRef="usd" contextRef="ia849c0d494314af388e9fb0fc01f197d_D20190405-20190405" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzYzMw_62a3c5e1-4474-4e79-ae4c-ca8c59935f03">125.0</ix:nonFraction>&#160;million (the &#8220;First Tranche&#8221;). The approval of Nurtec ODT by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in February 2020 results in a payment due to us of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments beginning in the three months ended March 31, 2021 through the three months ended December 31, 2024. In the three months ended March 31, 2021, we began receiving payments from the quarterly redemption of the Series A Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to redeem, in a single payment, any outstanding Series A Biohaven Preferred Shares at a price equal to two times the original purchase price of the Series A Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series A Biohaven Preferred Shares, in a single payment, at a price equal to two times the original purchase price. In the event that Biohaven defaults on any obligation to redeem Series A Biohaven Preferred Shares when required, the redemption amount shall accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="ie7ffbb1b682a454ea429c1fb003ce9d8_D20190405-20190405" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzE0OTE_7a6a0db2-0f09-4539-a09d-e23f29624b96">18</ix:nonFraction>% annually until the redemption price for such unredeemed Series A Biohaven Preferred Shares is paid in full, subject to applicable law. If any such default continues for at least <ix:nonNumeric contextRef="ie7ffbb1b682a454ea429c1fb003ce9d8_D20190405-20190405" name="rprx:DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzEwOTk1MTE2MzYzODY_7b432db8-89c6-471e-b424-a09d317bbe49">one year</ix:nonNumeric>, we will be entitled to convert all unredeemed Series A Biohaven Preferred Shares into common shares equal to the redemption price, plus accrued interest, divided by the five-day volume-weighted trading price immediately preceding the conversion date. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Series A Biohaven Preferred Shares are classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in our consolidated balance sheets. The unrealized change in the fair value of the Series A Biohaven Preferred Shares is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on the consolidated statements of comprehensive income.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series B Biohaven Preferred Shares </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 7, 2020 we entered into a Series B Biohaven Preferred Share Purchase Agreement (&#8220;Series B Biohaven Preferred Share Agreement&#8221;) with Biohaven where we committed to acquire <ix:nonFraction unitRef="shares" contextRef="i3f03e1e1f0254cb1bffbcef4de9ba54d_D20200807-20200807" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzIxNDE_ab8b1d02-3c2f-405e-9930-4ac6131b2a06">3,992</ix:nonFraction> shares of Series B Biohaven Preferred Shares at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3f03e1e1f0254cb1bffbcef4de9ba54d_D20200807-20200807" decimals="INF" name="rprx:DebtSecuritiesAvailableForSalePricePerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzIyMDM_0425640d-f1ad-424e-9c41-ebbeca43fa32">50,100</ix:nonFraction> per preferred share (the &#8220;Commercial Launch Preferred Equity&#8221;), for a total of $<ix:nonFraction unitRef="usd" contextRef="i82b90b8f41a142668c8944a95809becc_D20200807-20200807" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzIyODU_57be69e1-5029-4042-aed0-e37267451466">200.0</ix:nonFraction>&#160;million payable on a quarterly basis between the three months ended March 31, 2021 and the three months ended December 31, 2024. Our commitment to purchase the Series B Biohaven Preferred Shares is recognized as the Series B Forwards. In return, Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between March 31, 2025 and December 31, 2030 at a price equal to approximately 1.8 times the original purchase price of the Series B Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to issue to us all unissued Series B Biohaven Preferred Shares and to redeem, in a single payment, any outstanding Series B Biohaven Preferred Shares at a price equal to approximately 1.8 times the Series B original issue price per share. Biohaven may redeem at their election, any outstanding Series B Biohaven Preferred Shares, in a single payment, at a price equal to approximately 1.8 times the original issue price for the Series B Biohaven Preferred Shares. In the event that Biohaven defaults on any obligation to redeem Series B Biohaven Preferred Shares, the redemption amount shall accrue interest on the applicable original issue price at the rate of <ix:nonFraction unitRef="number" contextRef="i3f03e1e1f0254cb1bffbcef4de9ba54d_D20200807-20200807" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzM1MDc_ebedde15-60d0-492f-9697-8fec95b6f14f">18</ix:nonFraction>% annually until the redemption price for such unredeemed Series B Biohaven Preferred Shares is paid in full, subject to applicable law. If any such default continues for at least <ix:nonNumeric contextRef="i3f03e1e1f0254cb1bffbcef4de9ba54d_D20200807-20200807" name="rprx:DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzM2ODg_4973b2e2-1a23-467e-954c-38d5ce76fdda">one year</ix:nonNumeric>, we will be entitled to convert any or all unredeemed Series B Biohaven Preferred Shares into common shares equal to the redemption price, plus accrued interest, divided by the five-day volume-weighted trading price immediately preceding the conversion date. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended March 31, 2021, we began purchasing the Series B Biohaven Preferred Shares. As of December 31, 2021, we have acquired <ix:nonFraction unitRef="shares" contextRef="i1c9ec20561ed410bb20159b77b9b7247_D20210101-20211231" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzEwOTk1MTE2NDEwMzQ_e7dd1a1f-23a0-4f13-be3f-e7512d1ac8b7">1,406</ix:nonFraction> shares of Series B Biohaven Preferred Shares. We have elected the fair value option to account for the Series B Forwards and the Series B Biohaven Preferred Shares, which are recorded in aggregate on the consolidated balance sheets as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe the fair value option most accurately reflects the nature of these instruments. The unrealized change in fair value of the Series B Biohaven Preferred Shares and Series B Forwards is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statements of operations.</span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i3b1883bdfd644239bab821949f8e81f7" continuedAt="i7ea69b285c24480da37765b8deb465c7"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MorphoSys Development Funding Bonds</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys AG (&#8220;MorphoSys&#8221;) to support MorphoSys&#8217; acquisition of Constellation Pharmaceuticals, Inc. (&#8220;Constellation&#8221;), which closed on July 15, 2021. As part of the funding agreement, we agreed to provide MorphoSys up to $<ix:nonFraction unitRef="usd" contextRef="ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602" decimals="INF" name="rprx:CollaborativeArrangementRightsAndObligationsPaymentOfCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzEwOTk1MTE2NDEwOTc_0132b80f-f7f5-41af-afdb-0c37a4e94ddb">350</ix:nonFraction>&#160;million of capital (the &#8220;Development Funding Bonds&#8221;), which MorphoSys may draw over a one-year period from the close of its acquisition of Constellation. MorphoSys is required to draw a minimum of $<ix:nonFraction unitRef="usd" contextRef="ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602" decimals="INF" name="rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzEwOTk1MTE2NDExMTI_1ad35bfd-d202-48ee-bc20-0a93c18bc695">150</ix:nonFraction>&#160;million. As of December 31, 2021, MorphoSys has not drawn any amount under the Development Funding Bonds. Our commitment to fund at least $<ix:nonFraction unitRef="usd" contextRef="ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602" decimals="INF" name="rprx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzEwOTk1MTE2NDExMjc_b052fc2c-eabb-49e0-86c7-2a5de9b45af5">150</ix:nonFraction>&#160;million of the Development Funding Bonds is recognized as the Development Funding Bond Forward. Once drawn, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over <ix:nonNumeric contextRef="ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602" name="rprx:CollaborativeArrangementRightsAndObligationsPeriodOfReturn" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzE0MjkzNjUxMTc1NTM1_d73e5ad8-bd48-4b3c-9686-ea24b9976a9c">nine years</ix:nonNumeric>, with the first payment beginning <ix:nonNumeric contextRef="ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602" name="rprx:CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzE0MjkzNjUxMTc1NTE2_33575444-a817-4161-9828-11358e1160d3">two years</ix:nonNumeric> after the funding. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have elected the fair value option to account for the Development Funding Bond Forward as it most accurately reflects the nature of the instrument. The Development Funding Bond Forward is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in our consolidated balance sheet. The unrealized change in fair value of the Development Funding Bond Forward is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Unrealized gains on available for sale debt securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on the consolidated statements of operations.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzE0MjkzNjUxMTc0Nzkx_abc284c7-f051-40b7-902a-9ab30ded2bb8" continuedAt="i52242fe3c84a4b1dbb810325d026cc4a" escape="true"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below summarizes our available for sale debt securities recorded at fair value as of December 31, 2021 and 2020 (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.287%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Biohaven Preferred Shares</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aa7200994f445fd859a024412126926_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzItMS0xLTEtMjU3NjQ_437c07d9-2935-4d61-90a7-3b4fe97ce247">134,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aa7200994f445fd859a024412126926_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzItMy0xLTEtMjU3NjQ_125c70fb-f235-42d5-8e3e-2f087df4caba">29,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aa7200994f445fd859a024412126926_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzItNS0xLTEtMjU3NjQ_0564482c-300f-4879-b5ef-b545e78b7cc0">163,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aa7200994f445fd859a024412126926_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzItNy0xLTEtMzc5MzY_5ec675ac-49e6-4d66-99a2-3f5f34bd6083">66,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aa7200994f445fd859a024412126926_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzItOS0xLTEtMzc5NDM_d818c753-713d-4638-878b-229e846d777e">97,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aa7200994f445fd859a024412126926_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzItMTEtMS0xLTM3OTUw_e81431a5-4057-487f-935c-9db388420a6c">163,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series B Biohaven Preferred Shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdc9b73456ed4691907032f9740bfd6a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzMtMS0xLTEtMjU3NjQ_ca3e8e7d-0cf7-4d48-9c1f-e5afdab77577">70,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdc9b73456ed4691907032f9740bfd6a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzMtMy0xLTEtMjU3NjQ_a4443233-6235-42a4-8391-c03176a7718f">19,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdc9b73456ed4691907032f9740bfd6a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzMtNS0xLTEtMjU3NjQ_5311b02b-5f54-4fa8-b76d-e5571c6785a9">90,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdc9b73456ed4691907032f9740bfd6a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzMtNy0xLTEtMzc5MzY_1e5bc225-8880-436c-8b7c-0f6f247cba25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdc9b73456ed4691907032f9740bfd6a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzMtOS0xLTEtMzc5NDM_8a38e2e8-d5c0-41eb-a7bc-47110f04cf3c">90,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdc9b73456ed4691907032f9740bfd6a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzMtMTEtMS0xLTM3OTUw_725e9965-340b-4684-9d19-800571f74762">90,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series B Forwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60d163174d8f44a18183225e8dcce57d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzQtMS0xLTEtMjU3NjQ_60d90203-6887-4a95-998a-4ddfe2186cce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60d163174d8f44a18183225e8dcce57d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzQtMy0xLTEtMjU3NjQ_956cf625-8a0c-4431-8200-24d53bd38428">12,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60d163174d8f44a18183225e8dcce57d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzQtNS0xLTEtMjU3NjQ_f1817faf-28ab-47b2-8d55-e23fe159a5b4">12,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60d163174d8f44a18183225e8dcce57d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzQtNy0xLTEtMzc5MzY_d75d699a-cf66-4e2f-b205-9134aeed9ad7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60d163174d8f44a18183225e8dcce57d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzQtOS0xLTEtMzc5NDM_931c7c3e-6737-4357-9ca1-c6457e5f5a4d">12,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60d163174d8f44a18183225e8dcce57d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzQtMTEtMS0xLTM3OTUw_c71bb9bf-5feb-4d26-bc72-62f9948dd8ea">12,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development Funding Bond Forward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98c2c17dcf19455ebbe7cea65ea027d8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzUtMS0xLTEtMjU3NjQ_eed23ded-dea9-4525-9945-1b010c1d07f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98c2c17dcf19455ebbe7cea65ea027d8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzUtMy0xLTEtMjU3NjQ_8653994e-c799-41c1-b5e7-4b2dd5738238">4,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98c2c17dcf19455ebbe7cea65ea027d8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzUtNS0xLTEtMjU3NjQ_4f49bb2f-3806-4281-aa85-7233af1d71f3">4,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98c2c17dcf19455ebbe7cea65ea027d8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzUtNy0xLTEtMzc5MzY_d0235dfb-5f5d-4c45-9217-ae9fc379d527">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98c2c17dcf19455ebbe7cea65ea027d8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzUtOS0xLTEtMzc5NDM_806d19a6-23da-4a51-bb43-20fe2d12d15b">4,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98c2c17dcf19455ebbe7cea65ea027d8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzUtMTEtMS0xLTM3OTUw_eb7aaf34-f403-4031-a7f4-b1463e4282de">4,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzYtMS0xLTEtMjU3NjQ_232a647d-30e7-47ca-a21f-8f449a857575">204,509</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzYtMy0xLTEtMjU3NjQ_c0b61da7-51eb-425b-a434-138701137916">65,891</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzYtNS0xLTEtMjU3NjQ_6a15ad7f-9944-4242-b278-230214f72606">270,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzYtNy0xLTEtMzc5MzY_a4fca268-17e2-44f7-8a94-9e0fb0db19ff">66,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzYtOS0xLTEtMzc5NDM_d8ba2f87-f681-4096-b207-087e1026effc">204,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzYtMTEtMS0xLTM3OTUw_a25921ee-a114-4491-8679-6372d00f4825">270,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Biohaven Preferred Shares</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc7e15ceae44635ac92046eaa0b27e9_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzktMS0xLTEtMzc4NzY_868b333a-d674-4e7c-92e8-e76399e326c3">145,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc7e15ceae44635ac92046eaa0b27e9_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzktMy0xLTEtMzc5MDE_0312d0da-20c2-4d56-88ef-31f32d9cac87">68,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc7e15ceae44635ac92046eaa0b27e9_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzktNS0xLTEtMzc5MjY_e3a4df15-dc26-49f9-b062-b6c18fb79043">214,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc7e15ceae44635ac92046eaa0b27e9_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzktNy0xLTEtMzc5MzY_6e1b6f6a-a2a3-47e3-92b5-d75011043391">69,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc7e15ceae44635ac92046eaa0b27e9_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzktOS0xLTEtMzc5NDM_2075e2df-c840-4018-81ed-2578104c5c19">144,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc7e15ceae44635ac92046eaa0b27e9_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzktMTEtMS0xLTM3OTUw_41e6109b-f1b6-4de1-8d8b-4b36850e41b1">214,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series B Forwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad0763e8bb4821b3d973d0d57f0477_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzEwLTEtMS0xLTM3ODc2_b6ba909e-99d6-497c-ada0-75f32146d92e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad0763e8bb4821b3d973d0d57f0477_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzEwLTMtMS0xLTM3OTAx_2eded706-26a6-4bc3-864f-2531d1adc682">18,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad0763e8bb4821b3d973d0d57f0477_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzEwLTUtMS0xLTM3OTI2_0ab7aedf-66ac-4b16-b3cf-c235a8b45c21">18,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad0763e8bb4821b3d973d0d57f0477_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzEwLTctMS0xLTM3OTM2_4293011f-7d59-4cba-8a01-20df01cec7e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad0763e8bb4821b3d973d0d57f0477_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzEwLTktMS0xLTM3OTQz_0dba668a-e217-4e2e-af28-3878d1405742">18,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad0763e8bb4821b3d973d0d57f0477_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzEwLTExLTEtMS0zNzk1MA_0c899c82-a91b-477b-998f-ab0d63f97106">18,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzExLTEtMS0xLTM3ODc2_6b7c823d-b99a-4b2b-b8c9-6cdd3614be9c">145,647</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzExLTMtMS0xLTM3OTAx_8f435ca1-13f7-4f06-be3e-9751ecab4c03">87,353</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzExLTUtMS0xLTM3OTI2_7f175058-c15a-4744-8f00-00a0634e32bd">233,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzExLTctMS0xLTM3OTM2_343126d9-4e67-4467-a658-bddbbb580ae8">69,984</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzExLTktMS0xLTM3OTQz_a3eca214-9c72-4d5f-a3d4-4b0336304664">163,016</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzExLTExLTEtMS0zNzk1MA_b20fd613-82e3-461e-94be-c6e0fe2f891c">233,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:continuation id="i7ea69b285c24480da37765b8deb465c7" continuedAt="if96764ead6db4b218a147983905b7d6c"><ix:continuation id="i52242fe3c84a4b1dbb810325d026cc4a" continuedAt="i100f201de621404eabef7e98c88d878e">(1)</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt"><ix:continuation id="if96764ead6db4b218a147983905b7d6c"><ix:continuation id="i100f201de621404eabef7e98c88d878e">Cost for Series A Biohaven Preferred Shares represents amortized cost. Cost for Series B Biohaven Preferred Shares represents the amounts paid to purchase the instruments. There were no costs associated with the Series B Forwards and Development Funding Bond Forward.</ix:continuation></ix:continuation> </span></div><div><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_124"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzY4Nzk_958ab400-ba28-4009-823b-db7f9f482be7" continuedAt="i467dd73d85c04b4c85b8314b6ab6940f" escape="true">Derivative Instruments</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i467dd73d85c04b4c85b8314b6ab6940f" continuedAt="i3f8d10220ba74fadbb7372c2922ff756"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically managed the impact of foreign currency exchange rate and interest rate risk through various financial instruments, including derivative instruments such as treasury rate lock contracts, interest rate swap contracts and foreign currency forward contracts. Our policy is to use derivatives strategically to hedge existing and future interest rate exposure and to minimize volatility in cash flow arising from our exposure to interest rate risk and foreign currency risk. We may also acquire other financial instruments that are classified as derivatives. We do not enter into derivative instruments for trading or speculative purposes. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury rate lock contracts</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2021, we entered into treasury rate lock contracts with notional amounts totaling $<ix:nonFraction unitRef="usd" contextRef="i58e8c79f7b7640d089df3eefd8c4584f_I20210630" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzEwOTk1MTE2MzQ4MDg_bcc8873d-bf70-49cb-b2c8-0aac65d1c888">600.0</ix:nonFraction>&#160;million to manage the impact of fluctuations in the underlying benchmark interest rate associated with the 2021 Notes (as further discussed and defined in Note 11&#8211;Borrowings). The treasury rate lock contracts were not designated as hedge instruments. All of the treasury rate lock contracts had collateral requirements. The treasury rate lock contracts were unwound and settled in connection with the issuance of the 2021 Notes and the resulting net loss was recognized in earnings in the year ended December 31, 2021. We paid $<ix:nonFraction unitRef="usd" contextRef="i625666873b2d4977bdc6062d4f56c5df_D20210701-20210731" decimals="-5" name="rprx:PaymentsToTerminateDerivativeInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzEwOTk1MTE2MzU0OTM_e0c40cc6-b1be-4a2b-a338-65d77853d6fa">16.1</ix:nonFraction>&#160;million in July 2021 to terminate our treasury rate lock contracts.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i3f8d10220ba74fadbb7372c2922ff756" continuedAt="ied2f1248c3ad41958de5f546324ecde9"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate swaps</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2020, RPIFT terminated all outstanding interest rate swaps in connection with the Exchange Offer Transactions. We paid $<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-5" name="rprx:PaymentsToTerminateDerivativeInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzEwOTk1MTE2NDM0OTI_f3e86e39-5e13-4d67-bf6f-a6d5fb015091">35.4</ix:nonFraction>&#160;million to terminate these swaps and reclaimed $<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-5" name="rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzEwOTk1MTE2NDM0OTk_e34e5b3b-7c04-420c-8ed6-9b1f1af2099c">45.3</ix:nonFraction>&#160;million of collateral that was held by the respective counterparties. During the years ended December 31, 2020 and 2019, we recorded unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="i4106b129e51b45058ce78e36709ad420_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzEwOTk1MTE2NDMxNzc_bf7ec6a0-6c32-4943-bf66-e48b6ca7011c">10.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i25065e59308648fd8df2e62e3adccc34_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzEwOTk1MTE2NDMzMDY_83aba55e-0ffa-4e13-bb17-1b05d78b93ac">72.6</ix:nonFraction>&#160;million, respectively, on interest rate swaps in the consolidated statements of operations. We did not enter into any interest rate swaps subsequent to the February 2020 termination discussed above and as of December 31, 2021, we do not hold any interest rate swap contracts. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Epizyme put option and warrant</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, RPIFT made an equity investment in Epizyme, Inc. (&#8220;Epizyme&#8221;) of $<ix:nonFraction unitRef="usd" contextRef="id3d1194dc3e540d18ba20eae1762f548_I20191130" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzM3MTA_b73b3258-0877-4215-ade7-e50b7ad592b5">100.0</ix:nonFraction>&#160;million. Under the terms of the agreement with Epizyme, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i7dfa9c83d55a4cd497bbc3d7fa0263f5_D20191101-20191130" decimals="-5" name="rprx:PaymentsToAcquireEquityInvestmentsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzM3OTQ_497c31ab-e93c-4a1c-811d-5d248a0d5cb3">100.0</ix:nonFraction>&#160;million for (1) shares of Epizyme common stock, (2) a warrant to purchase an additional <ix:nonFraction unitRef="shares" contextRef="iede0453e00c74915afde71174a783562_I20191130" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzM4Nzc_9a1bcd92-ab44-4e70-acbc-768bd848e25d">2.5</ix:nonFraction>&#160;million shares of Epizyme common stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="i7cb61b17854748238238595ab84bc83d_I20191130" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzM5MTQ_0a0531c3-d7e1-45b1-bcdf-3dab414eaeb9">20</ix:nonFraction> per share over a <ix:nonNumeric contextRef="i7cb61b17854748238238595ab84bc83d_I20191130" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzY4ODA_5fbaf9c0-1a39-49dc-82a8-44fa124ba30b">three-year</ix:nonNumeric> term and (3) Epizyme&#8217;s royalty on sales of Tazverik in Japan payable by Eisai Co., Ltd (&#8220;Eisai&#8221;). In addition, Epizyme had an <ix:nonNumeric contextRef="ia8411dbd9065417ea1c3895bc9dcf30d_D20191101-20191130" name="rprx:OptionIndexedToIssuersEquityTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzQwNzI_84dafe77-7dee-4af8-a358-25ed5cbbf715">18</ix:nonNumeric> month put option to sell an additional $<ix:nonFraction unitRef="usd" contextRef="if08b51e367da4f1b95ea56119a60ebc2_I20191130" decimals="-5" name="rprx:OptionIndexedToIssuersEquityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzQxMTQ_f229a025-4a66-4769-9268-598d8c627b44">50.0</ix:nonFraction>&#160;million of its common stock to RPIFT at then prevailing prices, not to exceed $<ix:nonFraction unitRef="usdPerShare" contextRef="ia8411dbd9065417ea1c3895bc9dcf30d_D20191101-20191130" decimals="INF" name="us-gaap:OptionIndexedToIssuersEquityStrikePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzQxODc_e2819a8c-f263-452b-bf15-174f32d8116f">20</ix:nonFraction> per share. On December 31, 2019, Epizyme notified RPIFT of its intention to exercise the put option. As a result, we recorded a forward purchase contract equal to the difference between the market value and exercise price of $<ix:nonFraction unitRef="usd" contextRef="i3b2fd60a894245f5a07e1097cd77b5a5_I20191231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzE0MjkzNjUxMTgzMjcy_db869675-790b-4571-9a7b-09520dc748c1">11.5</ix:nonFraction>&#160;million within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets at December 31, 2019. The exercise of the put option was settled in February 2020.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrant was recognized at fair value of $<ix:nonFraction unitRef="usd" contextRef="i3144c1b6231e4ae3b4870c4b3899f3bc_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzEwOTk1MTE2NDMwNTI_b893d8d5-be1c-4cd6-89e2-b1188ed2ef43">5.4</ix:nonFraction>&#160;million within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets at December 31, 2020. The fair value of the warrant was <ix:nonFraction unitRef="usd" contextRef="id8655b88be914b679ef264228d3e1920_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzE0MjkzNjUxMTgzNjk2_5094e637-4e36-4b9b-b69d-776769d75f44">no</ix:nonFraction>t material as of December 31, 2021. We recorded an unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="iaa98c432df2e41d197b0bbeeda56b8f3_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzEwOTk1MTE2NDMxNTY_44be00aa-b200-43c0-9e84-2fd642881235">5.4</ix:nonFraction>&#160;million, an unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="ia2307a5ce88e48c2a06297ee38c8ff92_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzEwOTk1MTE2NDMxNjA_2fbd1ce0-3cce-499c-a4af-d6cfa93bbd56">25.4</ix:nonFraction>&#160;million and an unrealized gain of $<ix:nonFraction unitRef="usd" contextRef="if1e2a2af5b8c4eae95b037e3cda81bcf_D20190101-20191231" decimals="-5" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzE2NDkyNjc0NTk1MDQ_2b063e10-74d7-4f58-98e6-198952890818">22.0</ix:nonFraction>&#160;million on derivative contracts related to the change in fair value of the warrant on the consolidated statements of operations for the years ended December 31, 2021, 2020 and 2019, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of derivatives and reclassifications</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzY4ODE_66c6c0be-8981-418a-89cd-6318316f6681" continuedAt="i2188062587e64991a68c36079fc5f3e2" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below summarize the change in fair value of the derivatives for the years ended December 31, 2021, 2020 and 2019 and the line items within the consolidated statements of operations where the gains or losses on these derivatives are recorded (in thousands). </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.190%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location on Consolidated Statements of Operations</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Derivatives in hedging relationships (1)</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest Rate Swaps:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount of loss reclassified from accumulated other comprehensive income into income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b63eb6a93e410fa76fd2e629ddcb94_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzQtMS0xLTEtMA_f70bf3b8-3237-4a97-85bc-64d63f28ebda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i763fc198266c47f18427206c9825f562_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzQtMy0xLTEtMA_c07749be-1e5c-4266-ba23-7d2a1ef5d071">4,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia35d113ea7024ba6950f218601bacf6d_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzQtNS0xLTEtMA_457195bd-248b-4826-8b00-ec0e0c496bcd">6,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b63eb6a93e410fa76fd2e629ddcb94_D20210101-20211231" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzUtMS0xLTEtMA_ffdeb4e4-04bb-4f69-b7b6-f1526dfa19d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i763fc198266c47f18427206c9825f562_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzUtMy0xLTEtMA_44275470-37bb-4469-869f-9ff4e9de7c2a">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia35d113ea7024ba6950f218601bacf6d_D20190101-20191231" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzUtNS0xLTEtMA_4c0b5961-0c6f-4b7f-9038-b8b749dbd4c9">16,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense/(income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifef0f1d7958a463da43eae42d4bfdcda_D20210101-20211231" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzYtMS0xLTEtMA_09468c42-725a-46f3-8890-1c7fb1d32a87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14182ec6f41e44f390626af261a6307c_D20200101-20201231" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzYtMy0xLTEtMA_6f938239-4e2f-4dae-b96f-3cb4089b90e0">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50aadab619674413a318d22a3934817f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzYtNS0xLTEtMA_7d06d218-a1a6-4979-a984-b4bc8d90e048">9,565</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest Rate Swaps:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28aa4e83beed49649514ca87068e5ff6_D20210101-20211231" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzEwLTEtMS0xLTA_af5104ee-0346-464e-bb68-2320283d05ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1e737cb86341c5927dafb07d9750e7_D20200101-20201231" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzEwLTMtMS0xLTA_dc852eed-3319-4357-b000-d0ef4eb14aeb">6,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51d19c62ebf442779da8aeb40a4ab214_D20190101-20191231" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzEwLTUtMS0xLTA_fb94fa63-034f-4fc7-af58-a1f6a6ca2b96">49,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense/(income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib358915627fb4011bf72f88cea09f234_D20210101-20211231" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzExLTEtMS0xLTA_d8eac28a-38e0-48a0-9f3a-38805683916b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11eaf253ae3b4547aad0185800a4c0d2_D20200101-20201231" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzExLTMtMS0xLTA_3ef3df3b-00fe-41fa-a417-dc82006c28b7">408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b8a39a63294eebab3e3f0053f1e384_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzExLTUtMS0xLTA_1ee9a856-519d-4649-8c0f-467e2736bf44">2,681</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i005aac99b4434d53866b784c5d193d69_D20210101-20211231" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzE0LTEtMS0xLTA_c94f2452-5921-46ab-9d80-086192f22c3e">5,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaef13cf1a72b4d638ba70defd6ec0717_D20200101-20201231" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzE0LTMtMS0xLTA_5a50b7ca-8889-4ec8-a03d-b7ad6e437c27">25,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17ed9cdd951d4b46941b7212a8ac2d44_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzE0LTUtMS0xLTA_538e6d08-e13e-403b-8325-101d6e0efe21">21,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward purchase contract:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of forward purchase contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8604b93633cf417e954376d722a8dadd_D20210101-20211231" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzE3LTEtMS0xLTA_be26ec36-e741-415c-8f0e-8d9d47363930">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcf29dd183834411bbff2b3741c8ce8e_D20200101-20201231" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzE3LTMtMS0xLTA_03fba435-52df-4399-b82b-1fb8516cc98d">5,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72d6d03d3001450dae8929c471f09b33_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzE3LTUtMS0xLTA_0926e983-1921-4e3e-aef6-58d56611f2d0">11,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury rate lock contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of treasury rate lock contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89c03cbaa3a415f8d13313d6d33a664_D20210101-20211231" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzE5LTEtMS0xLTM4MTc4_5c44f876-825d-4a9c-900c-03d6bbabf31a">16,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3c1f334b1114d27b5ab4a6b83b6d95b_D20200101-20201231" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzE5LTMtMS0xLTM4MTg1_961a1b84-e019-498f-984b-53fc81fad476">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cb8fcdaa4e94b9bb101f554c36c0944_D20190101-20191231" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzE5LTUtMS0xLTM4MTky_037d82aa-23c2-40d0-8c88-0e2ce5805b72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:18pt;text-indent:-18pt"><ix:continuation id="ied2f1248c3ad41958de5f546324ecde9" continuedAt="ia3c5705f858d47e6ad550cd2f6d96708"><ix:continuation id="i2188062587e64991a68c36079fc5f3e2" continuedAt="id88b53ac1c2f4b4199fb8085a7421452"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;Certain interest rate swaps were previously designated as cash flow hedges. These swaps became ineffective as debt refinancings occurred between 2013 and 2016. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="ia3c5705f858d47e6ad550cd2f6d96708"><ix:continuation id="id88b53ac1c2f4b4199fb8085a7421452"> were released into earnings.</ix:continuation></ix:continuation> </span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><div id="i15fafc99ab5c41deb08ee816ca47172c_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzExMjM0_faf90485-a6ca-44b8-8bb7-b73f3f1331ee" continuedAt="i02e01aecb974495d84a3100ccd88b269" escape="true">Fair Value Measurements and Financial Instruments </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i02e01aecb974495d84a3100ccd88b269" continuedAt="ice21c5227fc7413fa777d66c00d56d5c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair value hierarchy</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzExMjMy_d0925be1-5ba8-4d09-98a7-7e43aa45afe8" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives and available for sale debt securities are reported at their respective fair values in our consolidated balance sheets. For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. Long-term debt and financial royalty assets are reported at their amortized costs in our consolidated balance sheets but for which fair values are disclosed. The remaining financial instruments are reported in our consolidated balance sheets at amounts that approximate current fair values.</span></div></ix:nonNumeric><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and liabilities measured at fair value on a recurring basis</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzExMjMz_adfbebda-36ff-4364-9f5f-792cdbb962f0" continuedAt="ic67449f4de06453bb202a41acc623796" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes financial assets and financial liabilities that we measured at fair value on a recurring basis at the dates indicated, classified in accordance with the fair value hierarchy described above (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i766dfe5e45ea4f72a26e59216bb302d3_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzYtMS0xLTEtMA_6a03bc5a-08fa-4d77-b50a-eed9ff9fa510">598,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia020dbee158643459651f9ece93d0d05_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzYtMy0xLTEtMA_1522f75d-7e23-4dbd-a50c-5d19df1de279">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75566fc435584c81949dbaf5d363ad0a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzYtNS0xLTEtMA_89660903-333d-44f3-a997-5bb2b6af7958">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie446f1fa1f9b4244a2ca74087c37da2e_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzYtNy0xLTEtMA_ce8efa50-1f21-414a-b0d4-df48cc71870a">598,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dcc53a90d444210880be69baae720a5_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzYtOS0xLTEtNjE3MjM_dae06fb1-b238-46b6-ab03-e73758e26ef3">24,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44ca4ca5b24467685453ef798071b9c_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzYtMTEtMS0xLTYxNzY0_5c5884d8-97be-4ef6-a1ba-e33518e588d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88285f19e15c4b32ad8309928003f3bb_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzYtMTMtMS0xLTYxNzgx_d02a0f87-9a60-4ac1-b38c-cc3842a37590">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib075989af1f74896bccaba43480cd27b_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzYtMTUtMS0xLTYxNzkx_68bf7d34-1fcc-4541-8369-b69143d52a5a">24,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3416e4f9b18349ecad1f073e06dec3f6_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzctMS0xLTEtMA_2db918a0-87dd-4fad-a19d-9b1c52a594c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a89ba14dcfe4b38bdf299da4317bd92_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzctMy0xLTEtMA_095e8dfd-1880-47d6-bc1c-c1f0ab01e438">13,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9e6b9ca88f64d7a856e5091b1586275_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzctNS0xLTEtMA_64c24be5-7aa2-473d-a1cc-6d1ba4702247">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9922aa0da964460ac7f278f5e9ce3bb_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzctNy0xLTEtMA_fbe2d5d9-3d7d-4fd3-bf13-cf9585b3b3f9">13,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd56db919beb4b91b95510f88bc8e307_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzctOS0xLTEtNjE3MjM_797aec94-e43d-4d49-8f9a-56e3a85187c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55d925c488be4a8f8163990bbb352b7e_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzctMTEtMS0xLTYxNzY0_ef35a323-dec0-4325-8019-cfdfeec9f9c7">77,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e3aa405803e46c2ae8f0944494d7a94_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzctMTMtMS0xLTYxNzgx_994bb394-126c-43fd-bf02-6bcd5b58e9af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c4c7c6cdc45479c7eb9dc86d86a1d_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzctMTUtMS0xLTYxNzkx_6f70bdb8-c5e2-44b4-8cc4-b3e0b882c678">77,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30d5c89a92a5482d9d74e4bb2241752e_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzgtMS0xLTEtMA_ddffe92b-2135-47a9-abbc-daf2cfc0b50c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53c4649842db44e4a15eb412da6b88a6_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzgtMy0xLTEtMA_7f73b767-0013-40fd-9895-2d265524e8f0">40,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c9704b6d9d7401fab5346287e978380_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzgtNS0xLTEtMA_08ca5235-20dd-4c3b-bd64-a21472177332">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49b4a4e11f71489ab6998095636e4351_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzgtNy0xLTEtMA_7fa6b749-9043-4fc8-9053-8f5557e561bb">40,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i077a711c86ba4484a165902a8b44eeb1_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzgtOS0xLTEtNjE3MjM_dfab6ec4-9e11-4317-8810-fdcad3b23c79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib89be7641277478e8f7b293085ccc5d1_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzgtMTEtMS0xLTYxNzY0_3a9d764a-e225-4f4d-9297-dd90110a3e9e">74,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia66c162bc44045988727b18f854dba73_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzgtMTMtMS0xLTYxNzgx_ebb63e13-dfeb-458e-a070-c866759dc9c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d769bb3068b491086f572bdae712fb8_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzgtMTUtMS0xLTYxNzkx_39a49d88-a210-4b77-b68a-2a8a46ebb340">74,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04f203e10aa24bcfa8ec0905052a2b27_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEwLTEtMS0xLTA_5a094617-e494-40a4-a5f2-f40035b8b890">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d667d912c354a0c9c379aefc62e6fa7_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEwLTMtMS0xLTA_297f3eb0-7eb4-4d9e-81a1-38246531d309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie404feec194c4015ae7728b646421169_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEwLTUtMS0xLTA_ec8390f0-a478-4a68-9094-cd2793bab03d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic527ce521bf44f7fb2922ba14cf8f680_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEwLTctMS0xLTA_d5b98dd5-6fd0-4aed-9873-eee6c3c4f072">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088b28295ac64e85ab5dfa6a843058cf_I20201231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEwLTktMS0xLTYxNzIz_615c2918-f810-485b-bc8a-bfdf06991024">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19d9bd3151754f33acff24aea97d4f03_I20201231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEwLTExLTEtMS02MTc2NA_8b15d809-a295-48b2-b6ad-a4db59d0a4a8">32,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fb8fef2b7f4c048ec7656d0e9bd6fe_I20201231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEwLTEzLTEtMS02MTc4MQ_6529948e-4261-435e-b0a7-a2f62ddc6365">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7676bf6609461692e1aa4be16e7345_I20201231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEwLTE1LTEtMS02MTc5MQ_b0fe7945-4ea0-4ec3-9d43-94282b02edf3">32,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfafac4f4f2a4e088f1da17e816e5e52_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzExLTEtMS0xLTA_a1d6e701-5ef3-4f9f-a233-d4297bab0e54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id085ae202d524bdb9d5d849459675315_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzExLTMtMS0xLTA_ffa06773-f8a4-46d1-b2f3-4a7b560828be">207,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48b720aa212947f48ab2d55101f95e2b_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzExLTUtMS0xLTA_0cbac99f-67d7-40ef-90af-60d9ba6637fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28195bb07d164725b7b634f4d19d0532_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzExLTctMS0xLTA_e88388c6-17bd-48b7-a2e7-9cbb1b70002a">207,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i809b4052446c46388345163c43a4aa56_I20201231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzExLTktMS0xLTYxNzIz_c39cce23-3703-47ef-b487-3ba53878a18d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb619f9a9745447ca9b38d75ccc38904_I20201231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzExLTExLTEtMS02MTc2NA_c78d7506-88d7-4c7f-b63c-a860489ed6cb">444,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i796b378a6f1c40c48579f653afadb541_I20201231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzExLTEzLTEtMS02MTc4MQ_b1392efb-7962-4a2c-96ee-6ab433aff064">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f327e7169c8452880bd81a8f13ed03b_I20201231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzExLTE1LTEtMS02MTc5MQ_6bdbd125-7d8d-48aa-b80a-495979dfcd6a">444,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i248b66c121454f309190c31387007f6a_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEyLTEtMS0xLTA_d5a27131-8152-4661-85ba-5615f42f8324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bb92f2605164dc8b141abf08c6f5b56_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEyLTMtMS0xLTA_21aad242-9496-4c20-a98e-7160417d62eb">374,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i022c0d8159864ed7a2a1944cc714c2cf_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEyLTUtMS0xLTA_a9fee7c9-5d5e-4121-aca0-7d5417c5ea4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id26c9a8cd8884671b2c7a640a4b6d7df_I20211231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEyLTctMS0xLTA_787f9619-dfe6-468e-b429-f7616885d427">374,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac959fb66e143fcaddb2cb43efeae1a_I20201231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEyLTktMS0xLTYxNzIz_ba0ca090-3c41-4571-b723-62b2a9478f3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee8b694599fb4dd39b9e68aadeed7ed0_I20201231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEyLTExLTEtMS02MTc2NA_5a52d759-1b62-4f5c-9bd0-417b63cebbf6">505,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie51f46e72bfd4d7e834c4fdb560fbee4_I20201231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEyLTEzLTEtMS02MTc4MQ_992d5126-b2ae-451b-899c-0dca028f5011">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ec150c06fd4f4e91c18c223d223ea5_I20201231" decimals="-3" name="us-gaap:TradingSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEyLTE1LTEtMS02MTc5MQ_c8a761d2-9487-4843-ba8b-8978895d851d">505,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1a1aa3351a743f085a5b2c2f8f8be34_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEzLTEtMS0xLTA_8b335c8b-7321-4294-8309-fa7946b4aee7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a72b318bc84259bb294a3c971a4b85_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEzLTMtMS0xLTA_ea7089ad-3ad2-48b1-9bae-ac3d18f1f763">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04227885885f4891916e264c27f329ce_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEzLTUtMS0xLTA_d562e010-86f2-4b37-9d98-4ccd2e7074a8">66,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb80ebaf7cf4a41b7bb7ee7eecd1a0c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEzLTctMS0xLTA_baa77c7b-332d-4782-b99f-e0476d28032d">66,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd91a77eb7224e71a43cdcab940fb6bd_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEzLTktMS0xLTYxNzIz_0f4b9b67-15b8-4329-8aec-d8473c81b759">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad06d81ace0f4a3fbccf1299e4f6f414_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEzLTExLTEtMS02MTc2NA_f3d2c8d2-9e98-49cd-9c0b-33e1efac32e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee5dd61b76084db79478047617833a62_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEzLTEzLTEtMS02MTc4MQ_ca8b8822-c4ec-43ee-8891-066574b95cf1">69,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96f3647beb944cfb9113b173115bb16f_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEzLTE1LTEtMS02MTc5MQ_8f677231-cfd8-4188-a285-ac2d19850b7a">69,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1a1aa3351a743f085a5b2c2f8f8be34_I20211231" decimals="-3" name="rprx:AssetsFairValueDisclosureCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE1LTEtMS0xLTA_85f33d93-5355-4f90-b0bd-b3cba3589373">598,253</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a72b318bc84259bb294a3c971a4b85_I20211231" decimals="-3" name="rprx:AssetsFairValueDisclosureCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE1LTMtMS0xLTA_fc503033-5aec-4d81-84ad-09f938d208cc">636,823</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04227885885f4891916e264c27f329ce_I20211231" decimals="-3" name="rprx:AssetsFairValueDisclosureCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE1LTUtMS0xLTA_97609ec0-c045-45d4-afce-c670de376e24">66,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb80ebaf7cf4a41b7bb7ee7eecd1a0c_I20211231" decimals="-3" name="rprx:AssetsFairValueDisclosureCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE1LTctMS0xLTA_8a2423ef-4cc0-439a-afde-adef613461df">1,301,076</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd91a77eb7224e71a43cdcab940fb6bd_I20201231" decimals="-3" name="rprx:AssetsFairValueDisclosureCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE1LTktMS0xLTYxNzIz_f7cd1dc8-9f6d-426c-99cf-40aa4e8c1ef9">24,302</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad06d81ace0f4a3fbccf1299e4f6f414_I20201231" decimals="-3" name="rprx:AssetsFairValueDisclosureCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE1LTExLTEtMS02MTc2OQ_3d25193d-2076-45dd-a544-096e04ba0218">1,134,957</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee5dd61b76084db79478047617833a62_I20201231" decimals="-3" name="rprx:AssetsFairValueDisclosureCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE1LTEzLTEtMS02MTc4NA_066eebbc-1efe-4e55-948c-83a758dfb580">69,984</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96f3647beb944cfb9113b173115bb16f_I20201231" decimals="-3" name="rprx:AssetsFairValueDisclosureCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE1LTE1LTEtMS02MTc5NA_0c8052fa-9eed-4d62-b0ec-d5ce348821f2">1,229,243</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1a1aa3351a743f085a5b2c2f8f8be34_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE3LTEtMS0xLTA_fd78744d-6d92-491f-8669-e262346e8a5d">226,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a72b318bc84259bb294a3c971a4b85_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE3LTMtMS0xLTA_cf5ebd76-2303-467d-8dcd-34711c45c968">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04227885885f4891916e264c27f329ce_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE3LTUtMS0xLTA_442f4ff4-25cc-4ed2-ab16-904800f4d511">43,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb80ebaf7cf4a41b7bb7ee7eecd1a0c_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE3LTctMS0xLTA_2efb0cbb-06ab-4713-bb48-4247aba42c23">269,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd91a77eb7224e71a43cdcab940fb6bd_I20201231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE3LTktMS0xLTYxNzIz_f1b27294-0298-4a01-bf0d-e21e5eda30b5">298,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad06d81ace0f4a3fbccf1299e4f6f414_I20201231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE3LTExLTEtMS02MTc3NA_11d54d60-ef8a-4ef7-8072-efc547cb2b2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee5dd61b76084db79478047617833a62_I20201231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE3LTEzLTEtMS02MTc4Nw_be9d6290-b111-4849-b363-9c0ab015f5fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96f3647beb944cfb9113b173115bb16f_I20201231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE3LTE1LTEtMS02MTc5Nw_0dec620d-ae8a-4254-9be6-5b9cd2ef1d4d">298,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1a1aa3351a743f085a5b2c2f8f8be34_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE4LTEtMS0xLTA_265a3824-e665-40b5-980b-97b2f80499d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a72b318bc84259bb294a3c971a4b85_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE4LTMtMS0xLTA_0e6542df-7b3b-45b7-a59d-97854e787221">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04227885885f4891916e264c27f329ce_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE4LTUtMS0xLTA_5dea1655-9486-4aba-8f36-960b4e796e26">187,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb80ebaf7cf4a41b7bb7ee7eecd1a0c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE4LTctMS0xLTA_5c656878-7966-40dd-818b-8ffa3a98dc4a">187,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd91a77eb7224e71a43cdcab940fb6bd_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE4LTktMS0xLTYxNzIz_7a95afad-7b3f-4727-9df3-3279563b7705">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad06d81ace0f4a3fbccf1299e4f6f414_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE4LTExLTEtMS02MTc3NA_618f39c6-7c47-4c21-a7d0-b7a905aef5a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee5dd61b76084db79478047617833a62_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE4LTEzLTEtMS02MTc4Nw_a8c3dbd2-17e2-4527-be3e-65c506a1d577">144,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96f3647beb944cfb9113b173115bb16f_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE4LTE1LTEtMS02MTc5Nw_1fe070b6-d922-45e7-b58c-da9388d53d51">144,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b086c90802248e181f4562a5f891cef_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE5LTEtMS0xLTA_be3fb8d9-f76a-4c28-8d3a-e85462775ca4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd0b4b6026a47dfa690bc790142dc6a_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE5LTMtMS0xLTA_6314a15a-7e1c-42f0-8d97-de2b9216e819">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e710c51efc64f67a80cd232937add07_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE5LTUtMS0xLTA_a30d639d-4df4-4b59-8b28-4d96d2796f5c">16,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc65e75ec15e4a8d9dae69a3405cb50d_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE5LTctMS0xLTA_3e2231be-48ec-4d8b-b4eb-a99dbb5a8150">16,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c452309c9434a04aed49ed1b90eadaf_I20201231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE5LTktMS0xLTYxNzIz_83a64225-8491-47b7-929d-1d9af09abf5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7ab09bfb5bd4da3a4014bc287abc1b4_I20201231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE5LTExLTEtMS02MTc3NA_196cf890-5396-4513-b11a-d965fbdea556">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23b9ee584ca349bfb13948d7e36428be_I20201231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE5LTEzLTEtMS02MTc4Nw_fc5f3b42-0ea9-4342-8005-81a816ed21b1">18,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b300d23f844817bdcfa222399539cd_I20201231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE5LTE1LTEtMS02MTc5Nw_47de3cd3-91e7-4e9f-91cc-c20335648bf1">18,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7fcc31f05a4cd38338bef84fd13226_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIwLTEtMS0xLTA_1b8c9b7b-fd2c-4e5c-8747-91fe7a83965e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3b3d077c01141fabeaf491e1ebfa108_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIwLTMtMS0xLTA_d32ec10e-68eb-4507-a469-c5a26846250c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5aeecb6ade049569e8f33d8ba05292c_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIwLTUtMS0xLTA_882f9631-1ecd-46bb-b5d9-799fbdbe97d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e2f508014f476987e71ff61fb7acc0_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIwLTctMS0xLTA_c6289ad2-f475-4728-94ec-f86dc2cdb7ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4190ee3791704e3cb28414c2e7b90290_I20201231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIwLTktMS0xLTYxNzIz_f66d937a-d826-4c67-95fb-4f5e82a5dfb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib55e7cd67be640bcbc6bf9021cbd80ab_I20201231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIwLTExLTEtMS02MTc3NA_6c6e49c1-314c-40e5-8a7c-d4a52d86dae9">5,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i011c26d52667488b9a934f794e0b528f_I20201231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIwLTEzLTEtMS02MTc4Nw_5d9135a0-90b7-4fc2-b645-833530e7721c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25d1766cd2c74c1d9a6e6b47a1ff4db5_I20201231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIwLTE1LTEtMS02MTc5Nw_90dc41f9-f204-4da7-8c89-9bb62d12d82a">5,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current assets</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1a1aa3351a743f085a5b2c2f8f8be34_I20211231" decimals="-3" name="rprx:AssetsFairValueDisclosureNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIxLTEtMS0xLTM4MjIx_f1a79a89-d45f-47a4-a6a0-763efa110c65">226,787</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a72b318bc84259bb294a3c971a4b85_I20211231" decimals="-3" name="rprx:AssetsFairValueDisclosureNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIxLTMtMS0xLTM4MjI4_4cbab1bc-cb91-442a-91d1-8f0c59c01250">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04227885885f4891916e264c27f329ce_I20211231" decimals="-3" name="rprx:AssetsFairValueDisclosureNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIxLTUtMS0xLTM4MjM1_386532cd-b270-401d-bade-2d7faf0d7a3c">247,413</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb80ebaf7cf4a41b7bb7ee7eecd1a0c_I20211231" decimals="-3" name="rprx:AssetsFairValueDisclosureNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIxLTctMS0xLTM4MjQy_45edbe5c-9842-4c09-a31a-37b6e451c2c3">474,200</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd91a77eb7224e71a43cdcab940fb6bd_I20201231" decimals="-3" name="rprx:AssetsFairValueDisclosureNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIxLTktMS0xLTYxNzU4_9bbc062c-77a1-4641-ac4b-b55f85b704b8">298,689</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad06d81ace0f4a3fbccf1299e4f6f414_I20201231" decimals="-3" name="rprx:AssetsFairValueDisclosureNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIxLTExLTEtMS02MTc3NA_a0f57172-5e77-481e-8313-cdbccd65ada9">5,439</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee5dd61b76084db79478047617833a62_I20201231" decimals="-3" name="rprx:AssetsFairValueDisclosureNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIxLTEzLTEtMS02MTc4Nw_8494a329-9d13-44e2-a66b-16fd75686df7">163,016</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96f3647beb944cfb9113b173115bb16f_I20201231" decimals="-3" name="rprx:AssetsFairValueDisclosureNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIxLTE1LTEtMS02MTc5Nw_b768be5a-5144-49a6-85c0-b60aeb719b71">467,144</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The balance as of December 31, 2021 includes Series B Forwards and the Development Funding Bond Forward, recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the consolidated balance sheet, related to our obligations to fund acquisitions of the Series B Biohaven Preferred Shares and $<ix:nonFraction unitRef="usd" contextRef="i5ccc4c3e02d8454db2beb623053c69a4_D20210101-20211231" decimals="INF" name="rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzE0MjkzNjUxMjA1NDA0_0381931c-255d-488c-9127-96c9a37d1c0b">150</ix:nonFraction>&#160;million of the Development Funding Bonds, respectively. The balance as of December 31, 2020 relates to Series B Forwards, recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the consolidated balance sheet. See Note 3&#8211;Available for Sale Debt Securities for additional discussion. </span></div></ix:nonNumeric><div style="padding-left:18pt;text-indent:-18pt"><ix:continuation id="ic67449f4de06453bb202a41acc623796" continuedAt="i7ba2c03ce3fc4214ad31accd9db84375"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the Epizyme transaction as described in Note 4&#8211;Derivative Instruments and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i7ba2c03ce3fc4214ad31accd9db84375"> in the consolidated balance sheets as of December 31, 2021 and 2020. The fair value of the warrant was <ix:nonFraction unitRef="usd" contextRef="id8655b88be914b679ef264228d3e1920_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzM4NDgyOTA3NDA3MjY_5094e637-4e36-4b9b-b69d-776769d75f44">no</ix:nonFraction>t material as of December 31, 2021.</ix:continuation> </span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ice21c5227fc7413fa777d66c00d56d5c" continuedAt="ie3678fea67354abcb716cf876c267526"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021, 2020 and 2019, we recognized a loss of $<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzU0OTc1NTgxNzM5NDc_e8c2dfa3-4ead-4de5-a6ec-8eacf9c9da7f">60.1</ix:nonFraction>&#160;million, a loss of $<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzU0OTc1NTgxNzM5NTY_81dd249b-f4e8-4502-b172-564be2f0f4fe">85.4</ix:nonFraction>&#160;million and a gain of $<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-5" name="us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzU0OTc1NTgxNzM5NjU_cc92f326-d84f-4118-a92f-0e3e1d35e5cd">104.4</ix:nonFraction>&#160;million, on equity securities still held as of December 31, 2021, respectively.  </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzExMjM2_57a683c2-e873-4013-8614-35e0f7714e70" continuedAt="i8ee8d1b89ac043ac945509af69853ea2" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables presented below summarize the change in the combined fair value (current and non-current) of Level 3 financial instruments, which relate to equity securities and available for sale debt securities, including the underlying debt securities and related forwards (in thousands). </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Equity Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at the beginning of the year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361e783ed15347028eee1b52d6e057f6_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZGM4MThiMjViN2U0NTEyYjdkNGI4YTgwYTVlNDZiYy90YWJsZXJhbmdlOjJkYzgxOGIyNWI3ZTQ1MTJiN2Q0YjhhODBhNWU0NmJjXzMtMS0xLTEtNjIxMDU_962df46f-d15a-434f-a8f9-b22970eec783">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if100f3b0b4694f76acfbd85a49861791_I20191231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZGM4MThiMjViN2U0NTEyYjdkNGI4YTgwYTVlNDZiYy90YWJsZXJhbmdlOjJkYzgxOGIyNWI3ZTQ1MTJiN2Q0YjhhODBhNWU0NmJjXzMtMy0xLTEtNjIxMjA_8c698458-b834-4de5-9d4c-3283ffe60343">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23115a36ef69401581d68e8923fad129_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZGM4MThiMjViN2U0NTEyYjdkNGI4YTgwYTVlNDZiYy90YWJsZXJhbmdlOjJkYzgxOGIyNWI3ZTQ1MTJiN2Q0YjhhODBhNWU0NmJjXzQtMS0xLTEtNjIxMDU_6d153577-caf7-4a40-81ac-ef879e4e033a">35,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id424947d5ae8418b9adaf58a03fddf26_D20200101-20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZGM4MThiMjViN2U0NTEyYjdkNGI4YTgwYTVlNDZiYy90YWJsZXJhbmdlOjJkYzgxOGIyNWI3ZTQ1MTJiN2Q0YjhhODBhNWU0NmJjXzQtMy0xLTEtNjIxMjA_0f777713-135d-42bb-bc9e-e9da09b3a28f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23115a36ef69401581d68e8923fad129_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZGM4MThiMjViN2U0NTEyYjdkNGI4YTgwYTVlNDZiYy90YWJsZXJhbmdlOjJkYzgxOGIyNWI3ZTQ1MTJiN2Q0YjhhODBhNWU0NmJjXzUtMS0xLTEtNjIxMDU_352d6358-c387-42bf-95bb-fbe98f357d91">7,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id424947d5ae8418b9adaf58a03fddf26_D20200101-20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZGM4MThiMjViN2U0NTEyYjdkNGI4YTgwYTVlNDZiYy90YWJsZXJhbmdlOjJkYzgxOGIyNWI3ZTQ1MTJiN2Q0YjhhODBhNWU0NmJjXzUtMy0xLTEtNjIxMjA_8d8bf8e0-a246-4f5c-a217-1f64b1f59402">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the year</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98c2487e5b2648e7b109d6723b860233_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZGM4MThiMjViN2U0NTEyYjdkNGI4YTgwYTVlNDZiYy90YWJsZXJhbmdlOjJkYzgxOGIyNWI3ZTQ1MTJiN2Q0YjhhODBhNWU0NmJjXzctMS0xLTEtNjIxMTU_257e655d-b6d3-46c4-902c-9f72460e102f">43,013</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361e783ed15347028eee1b52d6e057f6_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZGM4MThiMjViN2U0NTEyYjdkNGI4YTgwYTVlNDZiYy90YWJsZXJhbmdlOjJkYzgxOGIyNWI3ZTQ1MTJiN2Q0YjhhODBhNWU0NmJjXzctMy0xLTEtNjIxMjA_d51ac099-6ccf-4d86-bd81-abd11ca078de">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Debt Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at the beginning of the year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77465b4fae3745838d33803f0ec0bbc7_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzQtMS0xLTEtMA_976dc7cf-0ce5-486f-b47e-c42a091208e1">214,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6228c34e36964903b7d23917ea68a634_I20191231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzQtMy0xLTEtMA_a9b62986-446d-4f56-9b7c-0de60babf100">131,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90e169e7f6c423bb0c4f735d01ae17b_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzUtMS0xLTEtMA_d258a6e3-e6a5-4a9e-9043-672d36f789a1">70,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib39b424185204ed8abf5c36761702ce7_D20200101-20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzUtMy0xLTEtMA_e21bd8c6-e164-4a1d-b378-39357fd33acf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90e169e7f6c423bb0c4f735d01ae17b_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzYtMS0xLTEtMA_2d462d6d-fe3a-4709-b110-1e10a69cc9af">12,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib39b424185204ed8abf5c36761702ce7_D20200101-20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzYtMy0xLTEtMA_14e964c3-0fdd-41d1-9d4f-05d406d4c4ea">52,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement of forwards (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90e169e7f6c423bb0c4f735d01ae17b_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzctMS0xLTEtMzg0Mjg_b334f44d-81a8-4a81-a3c4-92f1503f83fb">18,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib39b424185204ed8abf5c36761702ce7_D20200101-20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzctMy0xLTEtMzg0Mzg_58dce253-1542-4009-ba27-fe953c22f42d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer to Level 2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90e169e7f6c423bb0c4f735d01ae17b_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzctMS0xLTEtMA_74603564-9950-458b-95b1-9de3619f920e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib39b424185204ed8abf5c36761702ce7_D20200101-20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzctMy0xLTEtMA_81c4c397-829b-4a91-98c7-ff5dbc3c4666">184,005</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer from Level 2 (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90e169e7f6c423bb0c4f735d01ae17b_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzgtMS0xLTEtMA_ab2c5566-9090-464c-ba65-f9bfe544d83c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib39b424185204ed8abf5c36761702ce7_D20200101-20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzgtMy0xLTEtMA_3cc258df-9ae8-4ba2-9c46-99949c231744">198,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90e169e7f6c423bb0c4f735d01ae17b_D20210101-20211231" decimals="-3" name="rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzEwLTEtMS0xLTY4ODMx_b2e6dfd2-a627-4869-ba59-64e91821d50c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib39b424185204ed8abf5c36761702ce7_D20200101-20201231" decimals="-3" name="rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzEwLTMtMS0xLTY4ODM4_4e34238a-8272-45f8-9163-7764afaa5a29">15,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Redemption</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia90e169e7f6c423bb0c4f735d01ae17b_D20210101-20211231" decimals="-3" sign="-" name="rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzktMS0xLTEtMA_5ee97081-d6bd-4f89-9f93-1e4fc4164faf">62,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib39b424185204ed8abf5c36761702ce7_D20200101-20201231" decimals="-3" name="rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzktMy0xLTEtMA_25c2c7cb-37ec-4b64-b273-04f68fc41477">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the year</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cc4a0220a37443eb7239af4691991c1_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzEwLTEtMS0xLTA_1a7b771c-5d56-45d9-8621-cf4d8cabf9f8">253,700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77465b4fae3745838d33803f0ec0bbc7_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzEwLTMtMS0xLTA_b5ee9b66-e692-4934-8cfc-7f5a5a3e02db">214,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Forwards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at the beginning of the year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5879c529f1044590b63a67bad0d16f8d_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZTBkNWIzNWY0Y2Q0YWMwYjY1ODRlYzk2MWZmYzY1NS90YWJsZXJhbmdlOjJlMGQ1YjM1ZjRjZDRhYzBiNjU4NGVjOTYxZmZjNjU1XzMtMS0xLTEtMzg0NzY_ff3de0fd-a124-496a-9430-1fe28c4c0c8c">18,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3565d1e114564c88a5bdaaff4011b9bd_I20191231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZTBkNWIzNWY0Y2Q0YWMwYjY1ODRlYzk2MWZmYzY1NS90YWJsZXJhbmdlOjJlMGQ1YjM1ZjRjZDRhYzBiNjU4NGVjOTYxZmZjNjU1XzMtMS0xLTEtMA_1064480f-246c-41e6-beb2-8b64300eb030">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7177d9153404fb68d339079a331543f_D20210101-20211231" decimals="-3" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZTBkNWIzNWY0Y2Q0YWMwYjY1ODRlYzk2MWZmYzY1NS90YWJsZXJhbmdlOjJlMGQ1YjM1ZjRjZDRhYzBiNjU4NGVjOTYxZmZjNjU1XzUtMS0xLTEtMzg0NzY_958cb4bd-9cd7-462b-ae8f-5d7cfc42f6bc">16,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4e245eba01b40829373277b36665d51_D20200101-20201231" decimals="-3" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZTBkNWIzNWY0Y2Q0YWMwYjY1ODRlYzk2MWZmYzY1NS90YWJsZXJhbmdlOjJlMGQ1YjM1ZjRjZDRhYzBiNjU4NGVjOTYxZmZjNjU1XzUtMS0xLTEtMA_72a1dfc4-c438-48bf-a35d-eb05b135f150">18,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement of forwards (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7177d9153404fb68d339079a331543f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZTBkNWIzNWY0Y2Q0YWMwYjY1ODRlYzk2MWZmYzY1NS90YWJsZXJhbmdlOjJlMGQ1YjM1ZjRjZDRhYzBiNjU4NGVjOTYxZmZjNjU1XzYtMS0xLTEtMzg0NzY_442c469e-7b65-4d4f-af79-346ced92420d">18,459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4e245eba01b40829373277b36665d51_D20200101-20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZTBkNWIzNWY0Y2Q0YWMwYjY1ODRlYzk2MWZmYzY1NS90YWJsZXJhbmdlOjJlMGQ1YjM1ZjRjZDRhYzBiNjU4NGVjOTYxZmZjNjU1XzYtMS0xLTEtMA_2ef4727c-68b4-4b76-97eb-c55750a1933a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the year</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae02917f54274b579c2894c8155d9e11_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZTBkNWIzNWY0Y2Q0YWMwYjY1ODRlYzk2MWZmYzY1NS90YWJsZXJhbmdlOjJlMGQ1YjM1ZjRjZDRhYzBiNjU4NGVjOTYxZmZjNjU1XzctMS0xLTEtMzg0NzY_1bcf3ebb-3d87-41c5-a3cd-231a851a03ef">16,700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5879c529f1044590b63a67bad0d16f8d_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZTBkNWIzNWY0Y2Q0YWMwYjY1ODRlYzk2MWZmYzY1NS90YWJsZXJhbmdlOjJlMGQ1YjM1ZjRjZDRhYzBiNjU4NGVjOTYxZmZjNjU1XzctMS0xLTEtMA_2eb3fa92-5f99-4bde-a155-4ce6d1c5e6b3">18,600</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">For the year ended December 31, 2021, the unrealized gains on available for sale debt securities is comprised of $<ix:nonFraction unitRef="usd" contextRef="ia0e7d3e451a44f16bafd403564c15c33_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzcxNDY4MjU2MTc1MTY_b7cdb581-aef5-4e93-bdb5-123538e82ea8">11.6</ix:nonFraction>&#160;million related to Series A Biohaven Preferred Shares as recorded on the consolidated statements of comprehensive income and $<ix:nonFraction unitRef="usd" contextRef="ib406cf1143e641fd8a07fb8084d1848a_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzcxNDY4MjU2MTc1MzU_28c41f7b-a0f5-40e7-8016-1b5c49769222">1.3</ix:nonFraction>&#160;million related to the Series B Biohaven Preferred Shares as recorded on the consolidated statements of operations. For the year ended December 31, 2020, the unrealized gains on available for sale debt securities related to the Series A Biohaven Preferred Shares as recorded on the consolidated statements of comprehensive income, including $<ix:nonFraction unitRef="usd" contextRef="iae1bbd4d1fb242f38ccaf2f15e20b521_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzE0MjkzNjUxMjA1NDMz_f4209b50-1de9-4121-a3c2-2dfb6d7f3e3f">52.7</ix:nonFraction>&#160;million prior to transferring out of Level 3 and then $<ix:nonFraction unitRef="usd" contextRef="ifa9f1ac8ede24d5ea9cae25ddd1c125f_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzE0MjkzNjUxMjA1NDE4_bc93b9d3-72bb-474c-aee7-d3cb189257c4">15.9</ix:nonFraction>&#160;million after transferring back to Level 3. &#160;&#160;&#160;&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value attributed to the Series B Forwards that were settled in the period as the Series B Biohaven Preferred Shares were acquired, which is included in the fair value of the Series B Biohaven Preferred Shares. See Note 3&#8211;Available for Sale Debt Securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes $<ix:nonFraction unitRef="usd" contextRef="i6de6823bdc2b4ac98c04ae502140745a_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzE2NDkyNjc0NjYzODk_c6bd6420-97c4-451b-a339-755990a19bbd">14.5</ix:nonFraction>&#160;million of unrealized gains on available for sale debt securities included in other comprehensive income while the Series A Biohaven Preferred Shares was classified as a Level 2 asset.</span></div></ix:nonNumeric><div style="padding-left:18pt;text-indent:-18pt"><ix:continuation id="i8ee8d1b89ac043ac945509af69853ea2" continuedAt="if6045c9e32414cb292889b52f077ddf1"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="if6045c9e32414cb292889b52f077ddf1">on the consolidated statements of operations.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation inputs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a discussion of the valuation inputs used for financial instruments classified as Level 2 and Level 3 measurements in the fair value hierarchy.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ie3678fea67354abcb716cf876c267526" continuedAt="i07fb8116e29941e49ee38f394a38ae97"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Series A Biohaven Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the Series A Biohaven Preferred Shares as of December 31, 2021 and 2020 was based on the cash flows due to us from Biohaven of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments of $<ix:nonFraction unitRef="usd" contextRef="i8c7c87185ab54de39f17a1a1526628ab_D20210101-20211231" decimals="-5" name="rprx:DebtSecuritiesAvailableForSaleQuarterlyPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzM3NjI_4487b9b3-7b80-4000-82f7-746e8e289b2a">15.6</ix:nonFraction>&#160;million following the FDA approval and starting one-year after FDA approval, through December 31, 2024. The FDA approved Nurtec ODT in February 2020, at which point we became entitled to receive a fixed payment amount of $<ix:nonFraction unitRef="usd" contextRef="i8c7c87185ab54de39f17a1a1526628ab_D20210101-20211231" decimals="-5" name="rprx:DebtSecuritiesAvailableForSaleFixedPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzQwMjQ_531f2c50-13ca-43d5-9c66-a385be2193ae">250.0</ix:nonFraction>&#160;million payable in equal quarterly payments from March 31, 2021 through December 31, 2024. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Series A Biohaven Preferred Shares as of December 31, 2021 and 2020 was calculated using probability-adjusted discounted cash flow calculations incorporating Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability of a change of control event occurring during the investment term, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over a <ix:nonNumeric contextRef="i8c7c87185ab54de39f17a1a1526628ab_D20210101-20211231" name="rprx:DebtSecuritiesAvailableForSaleChangeInControlEventPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzE0MjkzNjUxMjEyNDAy_cecb7457-e8ae-49cb-97cc-7cd10091fe5d">four-year</ix:nonNumeric> time period and developing a risk-adjusted discount rate requires significant judgement. Our estimate of a risk adjusted discount rate of <ix:nonFraction unitRef="number" contextRef="i8c7c87185ab54de39f17a1a1526628ab_D20210101-20211231" decimals="3" name="rprx:DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzEwOTk1MTE2NTExMzU_18e500e3-e692-47aa-8fb2-162b3b9adb7b">9.5</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i81dbcb5a23f349fe855015cfdaaa1937_D20200101-20201231" decimals="3" name="rprx:DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzEwOTk1MTE2NTE2Nzk_1de21661-553a-44e7-a2d0-c986d99abf42">8.3</ix:nonFraction>% as of December 31, 2021 and 2020, respectively, could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series A Biohaven Preferred Shares, which would mean that the estimated fair value could be significantly higher or lower.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to February 2020, we measured our investment in the Series A Biohaven Preferred Shares using a Black-Derman- Toy lattice model, which included the use of Level 3 fair value measurements and inputs. In February 2020, when Nurtec ODT received FDA approval, we began measuring the fair value of the Series A Biohaven Preferred Shares using a discounted cash flow analysis that relied on observable inputs, and therefore, we transferred the Series A Biohaven Preferred Shares from a Level 3 to a Level 2 asset. During the three months ended December 31, 2020, information pertaining to Biohaven&#8217;s issuance of debt and its effective interest rate became available and we refined our valuation of the Series A Biohaven Preferred shares as of December 31, 2020 to incorporate this significant unobservable input. As a result, we reclassified the investment from a Level 2 to a Level 3 asset during the three months ended December 31, 2020.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i07fb8116e29941e49ee38f394a38ae97" continuedAt="i41dde07dc4d6404fa2eeee4b7db36b20"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Series B Biohaven Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the Series B Biohaven Preferred Shares and Series B Forwards as of December 31, 2021 and the fair value of the Series B Forwards as of December 31, 2020 were based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability that there will be a change of control event in different periods of time, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over the duration of the Series B Biohaven Preferred Shares and developing a risk-adjusted discount rate requires significant judgement. Our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than the timing of an actual change of control event, and if so, would mean that the estimated fair value could be significantly higher or lower than the fair value determined by management at any particular date. Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series B Biohaven Preferred Shares or the Series B Forwards, which would mean that the estimated fair value could be significantly higher or lower.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">MorphoSys Development Funding Bonds</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the Development Funding Bond Forward as of December 31, 2021 was based on a discounted cash flow calculation using an estimated risk-adjusted discount rate, which is a Level 3 fair value input. Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower. We have elected the fair value option to account for the Development Funding Bond Forward as it most accurately reflects the nature of the instrument. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BioCryst Equity Securities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2021, we purchased <ix:nonFraction unitRef="shares" contextRef="i1c970570f47a4749aeb33f585934e58f_D20211101-20211130" decimals="INF" name="rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzEwOTk1MTE2NjI5Mzg_6c91bcc5-536a-4f79-b1d4-dd9c1705887f">3,846</ix:nonFraction>&#160;thousand shares of common stock in BioCryst Pharmaceuticals, Inc.(&#8220;BioCryst&#8221;), which was calculated based on the volume-weighted average price of BioCryst common stock over a period preceding the closing of the transaction. As part of the transaction, we are restricted from selling the common stock for <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="rprx:DebtSecuritiesAvailableForSaleRestrictionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzE0MjkzNjUxMjEyMzg0_1abf02e9-c426-44ff-91b7-e19cb6cac6a9">six months</ix:nonNumeric> following the close of the transaction. The fair value of the BioCryst common stock as of December 31, 2021 was based on the closing stock price and adjusted for the transfer restriction, which was determined by calculating the value of a put option over the common stock to match the duration of the transfer restriction. This methodology includes the use of Level 3 inputs, including the estimated volatility of the BioCryst common stock, which requires the use of significant judgement. Our estimated volatility could be reasonably different than the actual volatility for the common stock which would mean that the estimated fair value for the common stock could be significantly higher or lower than the fair value determined by management at any particular date.    </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other financial instruments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use third party pricing services for Level 2 inputs used to value cash equivalents, marketable securities, derivative instruments and borrowings, which provide documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. Warrants are valued using a Black-Scholes option pricing model which considers observable and unobservable inputs. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial assets not measured at fair value</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial royalty assets are measured and carried on the consolidated balance sheets at amortized cost using the effective interest method. The fair value of financial royalty assets is calculated by management using the forecasted royalty payments we expect to receive based on the projected product sales for all royalty bearing products as estimated by sell-side equity research analysts&#8217; consensus sales forecasts or, where such consensus sales forecasts are not available, management uses reasonable judgment to make assumptions about the projected product sales. These projected future royalty payments by asset along with any projected incoming or outgoing milestone payments are then discounted to a present value using appropriate individual discount rates. The fair value of our financial royalty assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzExMjM1_3717424b-0101-4cfb-b1be-ed67cd8d68c7" continuedAt="i9a409279dca94fcd95ac3b4332f20707" escape="true">Estimated fair values based on Level 3 inputs and related carrying values for our financial royalty assets as of December 31, 2021 and 2020 are presented below (in thousands).</ix:nonNumeric></span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><ix:continuation id="i41dde07dc4d6404fa2eeee4b7db36b20"><ix:continuation id="i9a409279dca94fcd95ac3b4332f20707"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial royalty assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81db589362444c02b90538016ac19ba1_I20211231" decimals="-3" name="rprx:FinancingReceivablesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTozYjI2ZGZjYTliZjk0YWI1YTMwZGYyMTVhZjZmNTE2MS90YWJsZXJhbmdlOjNiMjZkZmNhOWJmOTRhYjVhMzBkZjIxNWFmNmY1MTYxXzItMS0xLTEtMA_9f4cdb84-9a5b-4b8c-8a5d-fb0a9f863e3b">19,047,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f6dd75074a4324b2b360f729714ac3_I20211231" decimals="-3" name="rprx:FinancingReceivablesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTozYjI2ZGZjYTliZjk0YWI1YTMwZGYyMTVhZjZmNTE2MS90YWJsZXJhbmdlOjNiMjZkZmNhOWJmOTRhYjVhMzBkZjIxNWFmNmY1MTYxXzItMy0xLTEtMA_91dbe1d7-a330-4d33-8bf5-7c17f18550c6">14,332,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id95940867f7f46d1832cf3e16823033c_I20201231" decimals="-3" name="rprx:FinancingReceivablesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTozYjI2ZGZjYTliZjk0YWI1YTMwZGYyMTVhZjZmNTE2MS90YWJsZXJhbmdlOjNiMjZkZmNhOWJmOTRhYjVhMzBkZjIxNWFmNmY1MTYxXzItNS0xLTEtMA_2afadd6a-a30f-4c57-acbc-abbd68ce4cc9">18,718,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9de83b17a2d84f7081715a46a48bb989_I20201231" decimals="-3" name="rprx:FinancingReceivablesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTozYjI2ZGZjYTliZjk0YWI1YTMwZGYyMTVhZjZmNTE2MS90YWJsZXJhbmdlOjNiMjZkZmNhOWJmOTRhYjVhMzBkZjIxNWFmNmY1MTYxXzItNy0xLTEtMA_6b28e39b-d4f7-4b42-8739-8a1950e2930a">12,955,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_133"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:FinancingReceivablesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90ZXh0cmVnaW9uOmI1NDJkNjUwZjU0NTQ0MDRhNGU4YzgwNTE3OTQ0ODUxXzM2ODQ_bd5e340a-e16f-4c5f-b9d1-c2e44b44b3b5" continuedAt="ib02f12370515400cbaf61f340aa72250" escape="true">Financial Royalty Assets, Net</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ib02f12370515400cbaf61f340aa72250" continuedAt="ie2881b72e6374fcca5dcf4ad23d7d0c3"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consist of contractual rights to cash flows relating to royalty payments derived from the expected sales of patent-protected biopharmaceutical products that entitle us and our subsidiaries to receive a portion of income from the sale of such products by third parties.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90ZXh0cmVnaW9uOmI1NDJkNjUwZjU0NTQ0MDRhNGU4YzgwNTE3OTQ0ODUxXzM2ODU_045c3ddd-5018-441c-9817-05af149f4f37" continuedAt="i63e00c9103454ac0b19a80ebcedf9818" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets at December 31, 2021 and 2020 are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 7)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value (e)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35db462f272349c080f522a5c4e7f55a_I20211231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzEtNC0xLTEtMA_fb263ec1-f98f-4e6e-8cce-3c0b24adf0cd">5,335,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35db462f272349c080f522a5c4e7f55a_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzItNi0xLTEtMzg3NTI_f5e607c2-9572-4a11-b55e-5f1da95ba8a5">48,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35db462f272349c080f522a5c4e7f55a_I20211231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzItOC0xLTEtMzg3NzA_d6ae959b-985f-4bb5-842b-ded499b68b81">5,287,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i910a6938c4b04c46b87813b7b69e8dce_I20211231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzItNC0xLTEtMA_674a12cf-8fb5-4780-b19b-45e6a2bb365e">1,846,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i910a6938c4b04c46b87813b7b69e8dce_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzItNi0xLTEtMA_100b5a91-4e4c-4251-b5ce-b51ed48994aa">16,617</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i910a6938c4b04c46b87813b7b69e8dce_I20211231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzItOC0xLTEtMA_4634bdc2-0473-4690-aa8d-0294930e21de">1,829,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9c8ac9b7834772b270536662c1c607_I20211231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzMtNC0xLTEtMA_d462cbdd-1d41-42d0-8086-5ce7d4b21086">1,438,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide9c8ac9b7834772b270536662c1c607_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzMtNi0xLTEtMA_f86a503e-5169-44c0-94ee-1b9b2bf1177a">236,871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9c8ac9b7834772b270536662c1c607_I20211231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzMtOC0xLTEtMA_f3f0969c-865b-498a-84ee-8c34febfbab6">1,201,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d275aee32304e029188d994792d2f92_I20211231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzQtNC0xLTEtMA_81bc5b0f-1379-4668-9cdc-df6e77a03284">1,100,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d275aee32304e029188d994792d2f92_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzQtNi0xLTEtMA_043f328b-6256-42ea-a590-60f0327a16c2">172,101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d275aee32304e029188d994792d2f92_I20211231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzQtOC0xLTEtMA_56e4253e-5e38-4093-a024-22127092352b">927,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dea9589e6e74a59a7d713e718e4a80d_I20211231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzUtNC0xLTEtMA_d4d91d25-4af0-47cd-a9f9-35957a200082">881,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dea9589e6e74a59a7d713e718e4a80d_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzUtNi0xLTEtMA_16c8688e-5dbc-4886-986a-d0a09bc6a599">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dea9589e6e74a59a7d713e718e4a80d_I20211231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzUtOC0xLTEtMA_13a098f2-9d44-4198-8f6b-d090440ac1a5">881,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 (d)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65da27051b834e589474daa7e00772a9_I20211231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzYtNC0xLTEtMA_0a1a4af8-45ad-4576-b459-bd438979ef00">727,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65da27051b834e589474daa7e00772a9_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzYtNi0xLTEtMA_6e62208c-6193-406e-b8b3-b7c4347ced8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65da27051b834e589474daa7e00772a9_I20211231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzYtOC0xLTEtMA_ae3d3b9c-3a91-40db-b3a9-4cfd21b198cc">727,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020-2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a31ea009fd41ae9b93b9a0ba894b4b_I20211231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzctNC0xLTEtMA_58923d57-51ca-4c92-97aa-08995528091a">4,697,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a31ea009fd41ae9b93b9a0ba894b4b_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzctNi0xLTEtMA_aae74695-231c-4653-b87a-c0cc89f4ebf8">909,916</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a31ea009fd41ae9b93b9a0ba894b4b_I20211231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzctOC0xLTEtMA_67b3c7d8-5b5d-4000-95b8-82755636be90">3,787,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzgtNC0xLTEtMA_41819eda-cee6-4635-bf2f-81f84e199505">16,027,541</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzgtNi0xLTEtMA_ecb3bce2-fba2-4fe2-9361-fca178a0a464">1,384,141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzgtOC0xLTEtMA_1e09f9d4-8495-4e05-9902-4c280e392fc3">14,643,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less: Cumulative allowance for credit losses (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzktOC0xLTEtMA_a12ae4aa-93d1-4dde-9a04-240c5c0a8245">310,804</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzEwLTgtMS0xLTA_3032fe5c-79e6-4418-8aed-4ee9826c4901">14,332,596</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt">Dates shown represent our estimates as of current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt">Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $<ix:nonFraction unitRef="usd" contextRef="i65da27051b834e589474daa7e00772a9_I20211231" decimals="-8" name="rprx:FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90ZXh0cmVnaW9uOmI1NDJkNjUwZjU0NTQ0MDRhNGU4YzgwNTE3OTQ0ODUxXzEwOTk1MTE2MzE3MzQ_3ef68589-cd64-45c8-9c5f-6e51080af306">1.3</ix:nonFraction>&#160;billion. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:9.13pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7&#8211;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 7)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value (e) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i548f6928715a4fd7ad65b15d47cba2a8_I20201231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzEtNC0xLTEtMA_001bb0de-3d25-4f4d-9117-5a0b56a7e3d3">5,274,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i548f6928715a4fd7ad65b15d47cba2a8_I20201231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzItNi0xLTEtMzg4NTI_7a7fb145-5bc7-4ea6-9830-5d0471bc9463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i548f6928715a4fd7ad65b15d47cba2a8_I20201231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzItOC0xLTEtMzg4Njg_5edd8294-22f3-43b5-858e-69e98e798989">5,274,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bf9a6954f4b4608ac3db7c1a9515015_I20201231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzItNC0xLTEtMA_b57a090d-90f4-43ae-aff1-49ca76dbbcd9">2,003,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bf9a6954f4b4608ac3db7c1a9515015_I20201231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzItNi0xLTEtMA_b38780b8-655d-40e8-8480-acc2e7fb399c">112,720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bf9a6954f4b4608ac3db7c1a9515015_I20201231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzItOC0xLTEtMA_e53221d3-f743-4305-8245-6828a208f3f1">1,891,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60ad6794898d4cdc903f9017ab626e3f_I20201231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzMtNC0xLTEtMA_d5a0c77c-9221-4990-84ee-40e49a6921a2">1,406,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60ad6794898d4cdc903f9017ab626e3f_I20201231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzMtNi0xLTEtMA_e633ee62-1373-486e-a836-e084a5cc4f83">46,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60ad6794898d4cdc903f9017ab626e3f_I20201231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzMtOC0xLTEtMA_a869bd2b-017d-4266-b401-1f74c92a34d3">1,359,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ee684b3e062472b855ba68705d802d1_I20201231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzQtNC0xLTEtMA_ed2be63c-af01-4a7f-9e1a-9a7fd0c519bc">1,150,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ee684b3e062472b855ba68705d802d1_I20201231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzQtNi0xLTEtMA_b267ab62-0ef0-4d90-9d81-c4d35e4f69ee">145,565</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ee684b3e062472b855ba68705d802d1_I20201231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzQtOC0xLTEtMA_78f8635b-7ffe-4447-a5e2-b6b47d1f80b2">1,004,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025-2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6afe0a950f444f6986eed827af96e29_I20201231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzUtNC0xLTEtMA_63ed81a6-00d0-4947-805b-6ed60bfea6ae">686,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6afe0a950f444f6986eed827af96e29_I20201231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzUtNi0xLTEtMA_be4b64cd-6669-418f-9da5-9bbd7dd3c754">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6afe0a950f444f6986eed827af96e29_I20201231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzUtOC0xLTEtMA_845c02ab-1530-410a-b4d2-4bbd79994cd2">686,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 (d)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i653d2d4470454f40b058b645513ec385_I20201231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzYtNC0xLTEtMA_973eb871-f7e8-43b4-bdae-d44e2926176a">675,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i653d2d4470454f40b058b645513ec385_I20201231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzYtNi0xLTEtMA_56b5e710-6757-49a5-90b2-b028585b4d9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i653d2d4470454f40b058b645513ec385_I20201231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzYtOC0xLTEtMA_19e374f9-fa4e-4bb3-9ae9-0b1366609799">675,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020-2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd8901ad6baa4fe485e98132407e4d74_I20201231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzctNC0xLTEtMA_0fc96462-ba4b-4444-a1f8-a65c3ec7409d">3,022,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd8901ad6baa4fe485e98132407e4d74_I20201231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzctNi0xLTEtMA_37dad9dc-36b7-4110-9e1a-3574604a7679">634,950</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd8901ad6baa4fe485e98132407e4d74_I20201231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzctOC0xLTEtMA_c048a54f-2569-4f48-abe3-ea04ded2f270">2,387,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzgtNC0xLTEtMA_4e58c861-d033-4908-bddd-ab1503e97ad5">14,219,101</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzgtNi0xLTEtMA_d331ef12-5bbb-4dc4-b51b-11685b7308e6">940,107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzgtOC0xLTEtMA_5b33d43e-136f-4ce2-9cbb-6ae5d95e5b95">13,278,994</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less: Cumulative allowance for credit losses (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="rprx:FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzktOC0xLTEtMA_3a1343d3-4f2a-46c1-8adc-f1ca6537bba1">323,717</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzExLTgtMS0xLTM4ODY4_8b708ddf-8931-484b-806d-8701a5b302e0">12,955,277</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:9.13pt">Dates shown represent our estimates as of current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ie2881b72e6374fcca5dcf4ad23d7d0c3"><ix:continuation id="i63e00c9103454ac0b19a80ebcedf9818"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt">Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $<ix:nonFraction unitRef="usd" contextRef="i653d2d4470454f40b058b645513ec385_I20201231" decimals="-8" name="rprx:FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90ZXh0cmVnaW9uOmI1NDJkNjUwZjU0NTQ0MDRhNGU4YzgwNTE3OTQ0ODUxXzEwOTk1MTE2MzI0OTU_d0e5639f-89ae-4358-bdbb-5ef129dc5cd0">1.3</ix:nonFraction>&#160;billion.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7&#8211;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_136"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:CreditLossFinancialInstrumentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90ZXh0cmVnaW9uOjUwNGJmMGZmZDIwYjRjMWE5Y2NiNDc4NzJkOWE0N2EwXzI1ODk_b09c7423-bbd2-4863-88c7-9bbfc57c362c" continuedAt="i69048794e4694e3cad47a4ccf11025da" escape="true">Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i69048794e4694e3cad47a4ccf11025da"><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative allowance for changes in expected future cash flows from financial royalty assets is presented net within the non-current portion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated balance sheets and includes the following activities:</span></div><div style="margin-top:3pt;text-indent:22.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the movement in the cumulative allowance related to changes in forecasted royalty payments we expect to receive based on projected product sales for royalty bearing products as estimated by sell-side equity research analysts&#8217; </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">consensus sales forecasts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the movement in the cumulative allowance for current expected credit losses.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The periodic movement in the cumulative allowance is presented on the consolidated statements of operations as the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected cash flows from financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Retained earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of $<ix:nonFraction unitRef="usd" contextRef="ib04d3453e6dc4ca3a0b79e01ab3fe12a_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90ZXh0cmVnaW9uOjUwNGJmMGZmZDIwYjRjMWE5Y2NiNDc4NzJkOWE0N2EwXzEwOTk1MTE2MzEyMDc_aa4f397a-6877-45c0-b096-fe40ac0a87f1">192.7</ix:nonFraction>&#160;million to recognize an allowance for current expected credit losses on our portfolio of financial royalty assets with limited protective rights. The current period provision for changes in expected cash flows from financial royalty assets reflects the activity for the period primarily new financial royalty assets and changes in the underlying cash flow forecasts used in the effective interest model to measure income from our financial royalty assets. </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Refer to Note 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Summary of Significant Accounting Policies for further information.</span></div><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90ZXh0cmVnaW9uOjUwNGJmMGZmZDIwYjRjMWE5Y2NiNDc4NzJkOWE0N2EwXzI1OTE_dd15c2a6-3cb1-43b2-a3ec-1ab3c4dc115a" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:78.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Activity for the Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa26755fbc5e413fbf3122ec0db17370_I20181231" decimals="-3" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzEtMS0xLTEtMA_2834455a-0d32-4ecb-8321-9f48cb6f4352">1,982,897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzItMS0xLTEtMA_e0b96a8b-f368-448f-909c-3a2db4c489be">322,717</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzMtMS0xLTEtMA_82efe01c-3bb7-4aec-b7ea-d91370b68322">1,342,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:FinancingReceivableChangeInPresentValueExpenseReversal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzQtMS0xLTEtMA_d557c6fb-4ffd-4da5-b023-a6a7a64e994f">95,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id30f26bcb6cd4b64982e6cd53528c44e_I20191231" decimals="-3" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzUtMS0xLTEtMA_83e20585-e484-494f-9710-a21949a64fac">868,418</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative adjustment for adoption of ASU 2016-13</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7ab9fefed164e08ac6ad01d99d06780_I20191231" decimals="-3" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzYtMS0xLTEtMA_0cc1ddee-1aa9-4b90-ad8a-c72c3e23dd1d">192,705</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzctMS0xLTEtMA_13b9111b-bf82-4c56-8117-7811d0104d5e">645,612</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzgtMS0xLTEtMA_31304a4d-15e8-494a-b8cb-c8bff3b0b48b">570,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:FinancingReceivableChangeInPresentValueExpenseReversal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzktMS0xLTEtMA_71625750-b684-42ac-b0bc-edcc0480825c">2,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of credit loss allowance (b)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:FinancingReceivableAllowanceForCreditLossesWriteOffs" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzEwLTEtMS0xLTA_288605bf-f766-497b-9b72-1077e5bb8c01">25,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision expense for credit losses, net (c)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:ProvisionForLoanLossesExpensed" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzExLTEtMS0xLTA_38b0220c-0a6d-4391-8314-378952ae413f">156,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzEyLTEtMS0xLTA_fd1874a9-5ee4-4b67-ab2c-6678ad61162f">1,263,824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzE0LTEtMS0xLTA_aef2d718-ad6a-4d88-852e-541145913387">912,710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzE1LTEtMS0xLTA_6e74c88c-d64d-4841-b35a-54242d2ca5cb">446,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:FinancingReceivableChangeInPresentValueExpenseReversal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzE2LTEtMS0xLTA_0e9fa3f4-5d84-4ea0-837c-0fb07ea33e4d">21,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision income for credit losses, net (c)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProvisionForLoanLossesExpensed" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzE4LTEtMS0xLTM4OTQ4_cb41fccc-659c-405d-94c1-2f59b8d72f1d">12,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzE5LTEtMS0xLTM4OTQ4_0ed210da-3d30-469c-9f82-774e426276bf">1,694,945</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;Relates to amounts removed from the allowance at the end of a royalty asset&#8217;s life to bring the account balance to zero. Write-offs solely impact the asset account and allowance account; there is no impact on the consolidated statements of operations.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;Relates to amounts reversed out of the credit loss allowance associated with omecamtiv mecarbil as a result of the write-off of the related financial royalty asset balance of $<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-5" name="rprx:FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90ZXh0cmVnaW9uOjUwNGJmMGZmZDIwYjRjMWE5Y2NiNDc4NzJkOWE0N2EwXzE2NDkyNjc0NDUxNjE_a5eb2a80-35d0-4bbe-a4e3-f57c3572856a">90.2</ix:nonFraction>&#160;million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%">(c) &#160;&#160;&#160;&#160;In the year ended December 31, 2020, the provision for credit losses was primarily related to certain additions to our portfolio of financial royalty assets with limited protective rights in 2020, mainly the final tranche of Tazverik. In the year ended December 31, 2021,the provision income for credit losses was primarily related to a significant decline in the financial asset value for Tazverik, which was offset by increases in our portfolio of financial royalty assets with limited protective rights in 2021, primarily related to zavegepant.</span></div></ix:nonNumeric></ix:continuation><div id="i15fafc99ab5c41deb08ee816ca47172c_139"></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90ZXh0cmVnaW9uOjk3NTY4NTM0ZDNmMjQ4MGE4YTVjYzc1NDhkYTk2YmI1XzEyNzc_cfef2b15-557b-4b1c-98ec-be8a834ee236" continuedAt="i53cd0bae2d0045e8aed7d743b703a632" escape="true">Intangible Royalty Assets, Net</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i53cd0bae2d0045e8aed7d743b703a632" continuedAt="ia79f06b249084b28a01bb1a55e83cd25"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90ZXh0cmVnaW9uOjk3NTY4NTM0ZDNmMjQ4MGE4YTVjYzc1NDhkYTk2YmI1XzEyNzk_327a188b-e67c-400f-bd5d-6c9deea7372c" escape="true"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following schedules of the intangible royalty assets present the cost, accumulated amortization and net carrying value as of December 31, 2021 and 2020 (in thousands).</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a50a564e8b4b0b934ac4b3000f4c8a_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90YWJsZTpiZGM1OWJkYzRlZTM0ZmRkYTc1ZDkwMWQ1OWM4Nzg1NC90YWJsZXJhbmdlOmJkYzU5YmRjNGVlMzRmZGRhNzVkOTAxZDU5Yzg3ODU0XzItMS0xLTEtMA_c9a489a0-49f9-4259-8d66-461141688dc2">606,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a50a564e8b4b0b934ac4b3000f4c8a_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90YWJsZTpiZGM1OWJkYzRlZTM0ZmRkYTc1ZDkwMWQ1OWM4Nzg1NC90YWJsZXJhbmdlOmJkYzU5YmRjNGVlMzRmZGRhNzVkOTAxZDU5Yzg3ODU0XzItMy0xLTEtMA_9f213e79-286d-49be-a33f-37ffbc8b0638">600,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a50a564e8b4b0b934ac4b3000f4c8a_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90YWJsZTpiZGM1OWJkYzRlZTM0ZmRkYTc1ZDkwMWQ1OWM4Nzg1NC90YWJsZXJhbmdlOmJkYzU5YmRjNGVlMzRmZGRhNzVkOTAxZDU5Yzg3ODU0XzItNS0xLTEtMA_b7b55a54-ef8f-499a-9e8b-408f1c8c3456">5,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90YWJsZTpiZGM1OWJkYzRlZTM0ZmRkYTc1ZDkwMWQ1OWM4Nzg1NC90YWJsZXJhbmdlOmJkYzU5YmRjNGVlMzRmZGRhNzVkOTAxZDU5Yzg3ODU0XzQtMS0xLTEtMA_d203cb23-b2a9-45f7-b6da-94f81036520e">606,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90YWJsZTpiZGM1OWJkYzRlZTM0ZmRkYTc1ZDkwMWQ1OWM4Nzg1NC90YWJsZXJhbmdlOmJkYzU5YmRjNGVlMzRmZGRhNzVkOTAxZDU5Yzg3ODU0XzQtMy0xLTEtMA_27899c46-62a2-4ac8-807a-60f8b50ae120">600,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90YWJsZTpiZGM1OWJkYzRlZTM0ZmRkYTc1ZDkwMWQ1OWM4Nzg1NC90YWJsZXJhbmdlOmJkYzU5YmRjNGVlMzRmZGRhNzVkOTAxZDU5Yzg3ODU0XzQtNS0xLTEtMA_b4f5e599-73ca-48c1-b388-52b835d25b0e">5,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc0fb3b2f3e24224b3fb2f9cc5ef7df9_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90YWJsZTozNmE3YzM1YTcwNDU0ZGIwYmE4MjMyMzU2MzA5N2U5Yi90YWJsZXJhbmdlOjM2YTdjMzVhNzA0NTRkYjBiYTgyMzIzNTYzMDk3ZTliXzItMS0xLTEtMA_1c7d5f7b-b881-46f3-820c-06525e6caf7e">606,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc0fb3b2f3e24224b3fb2f9cc5ef7df9_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90YWJsZTozNmE3YzM1YTcwNDU0ZGIwYmE4MjMyMzU2MzA5N2U5Yi90YWJsZXJhbmdlOjM2YTdjMzVhNzA0NTRkYjBiYTgyMzIzNTYzMDk3ZTliXzItMy0xLTEtMA_a1df0701-6540-45f5-81cb-036b02a95914">577,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc0fb3b2f3e24224b3fb2f9cc5ef7df9_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90YWJsZTozNmE3YzM1YTcwNDU0ZGIwYmE4MjMyMzU2MzA5N2U5Yi90YWJsZXJhbmdlOjM2YTdjMzVhNzA0NTRkYjBiYTgyMzIzNTYzMDk3ZTliXzItNS0xLTEtMA_a9b1ed13-4741-4235-ac92-2bb71dee11bf">28,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90YWJsZTozNmE3YzM1YTcwNDU0ZGIwYmE4MjMyMzU2MzA5N2U5Yi90YWJsZXJhbmdlOjM2YTdjMzVhNzA0NTRkYjBiYTgyMzIzNTYzMDk3ZTliXzQtMS0xLTEtMA_209c9272-cbce-4b56-94a3-282a57fbbaf2">606,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90YWJsZTozNmE3YzM1YTcwNDU0ZGIwYmE4MjMyMzU2MzA5N2U5Yi90YWJsZXJhbmdlOjM2YTdjMzVhNzA0NTRkYjBiYTgyMzIzNTYzMDk3ZTliXzQtMy0xLTEtMA_c5ce198f-2757-4b4a-93ed-d73a96027a39">577,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90YWJsZTozNmE3YzM1YTcwNDU0ZGIwYmE4MjMyMzU2MzA5N2U5Yi90YWJsZXJhbmdlOjM2YTdjMzVhNzA0NTRkYjBiYTgyMzIzNTYzMDk3ZTliXzQtNS0xLTEtMA_d7db19bb-7804-471a-95d3-de4495275bcb">28,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our DPP-IV patents associated with the intangible royalty assets terminate at various dates through 2022. The weighted average remaining life of the intangible royalty assets is less than <ix:nonNumeric contextRef="i7d7161b299de4f37949a7b5dcce2e1f7_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90ZXh0cmVnaW9uOjk3NTY4NTM0ZDNmMjQ4MGE4YTVjYzc1NDhkYTk2YmI1XzE0MjkzNjUxMTYyNTg2_c03e2e8b-44bd-44de-ab2a-b2a077fc846c">one year</ix:nonNumeric>. We project amortization expense will be $<ix:nonFraction unitRef="usd" contextRef="ib6a50a564e8b4b0b934ac4b3000f4c8a_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90ZXh0cmVnaW9uOjk3NTY4NTM0ZDNmMjQ4MGE4YTVjYzc1NDhkYTk2YmI1XzQzNg_f47b1760-4e7f-4c3f-a534-9396da7ddd30">5.7</ix:nonFraction>&#160;million in 2022.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia79f06b249084b28a01bb1a55e83cd25">Our revenue is tied to underlying patent protected sales of DPP-IV products of various licensees. Such revenue from royalty assets is earned from sales occurring primarily in the United States and Europe; however, we do not have the ability to disaggregate our royalty revenue from licensees based on the geography of the underlying sales, as this level of information is not always included in royalty reports provided to us. The marketers paying us royalties on these products do not always provide, and are not necessarily required to provide, the breakdown of product sales by geography. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for <ix:nonFraction unitRef="number" contextRef="i874783a606094b5b9faa8d9db9749829_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90ZXh0cmVnaW9uOjk3NTY4NTM0ZDNmMjQ4MGE4YTVjYzc1NDhkYTk2YmI1XzExNzc_52fc7cdc-98c4-4244-8e8c-94ccdb83ee86">86</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="id875c4379b7740e39a9bb8d8d1ddfe28_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90ZXh0cmVnaW9uOjk3NTY4NTM0ZDNmMjQ4MGE4YTVjYzc1NDhkYTk2YmI1XzExODI_dfae3ecf-8fc2-406f-b71b-f2668c552706">97</ix:nonFraction>%  and <ix:nonFraction unitRef="number" contextRef="id6fb304c08604399aba5e92d08d1d6b7_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90ZXh0cmVnaW9uOjk3NTY4NTM0ZDNmMjQ4MGE4YTVjYzc1NDhkYTk2YmI1XzExOTA_9fbd0129-b6a0-495c-b77c-bc1428ccb233">91</ix:nonFraction>% of our revenues from intangible royalty assets in the years ended December 31, 2021,  2020 and 2019, respectively.</ix:continuation> </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_142"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzQwOTU_249f20bd-ca2a-482b-9155-f202f64b81b7" continuedAt="ide5248bec0c6469b942b1f4e25b616c4" escape="true">Non-Consolidated Affiliates</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ide5248bec0c6469b942b1f4e25b616c4" continuedAt="iaaee9f378ba943c697c41973e5428bad"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Legacy SLP Interest</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Exchange Offer Transactions, we acquired a special limited partnership interest in the Legacy Investors Partnerships (the &#8220;Legacy SLP Interest&#8221;) from the Continuing Investors Partnerships for $<ix:nonFraction unitRef="usd" contextRef="i05361955890f48e2a999133572daa6a8_I20200211" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzI3Nw_4496cba5-42f0-49de-a2cd-86006e60f574">303.7</ix:nonFraction>&#160;million in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and an income allocation on a similar basis. Our income allocation is equal to the general partner&#8217;s former contractual rights to the income of the Legacy Investors Partnerships, net of amortization of the basis difference. The Legacy SLP Interest is treated as an equity method investment as our Manager is also the Manager of the Legacy Investors Partnerships and has the ability to exercise significant influence. The Legacy Investors Partnerships no longer participate in investment opportunities from June 30, 2020 and, as such, the value of the Legacy SLP Interest is expected to decline over time. The Legacy Investors Partnerships also own a non-controlling interest in Old RPI. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income allocation from the Legacy SLP Interest is based on an estimate, as the Legacy Investors Partnerships are private partnerships that are expected to report on a lag subsequent to the date of this annual report. Management&#8217;s estimate of equity in earnings from the Legacy SLP Interest for the current period will be updated for historical results in the subsequent period. During the years ended December 31, 2021 and 2020, we recorded an income allocation of $<ix:nonFraction unitRef="usd" contextRef="i2fbdc80a9a134e2b9b74bd14842984f8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDY2MTI_aa0bcdde-5d48-461e-8df0-5767485a44d6">8.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1f98a06986334cf4ac1ea37c17735d57_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDY2MTY_6ecae9fb-5d5b-4744-b140-c7c07891729b">62.0</ix:nonFraction>&#160;million, respectively, within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity in losses/(earnings) of non-consolidated affiliates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We received cash distributions from the Legacy SLP Interest of $<ix:nonFraction unitRef="usd" contextRef="i2fbdc80a9a134e2b9b74bd14842984f8_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDY2OTA_a25b89ea-c7c9-4bbb-b4f0-59096e71be80">21.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1f98a06986334cf4ac1ea37c17735d57_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDY2OTQ_e4a88a7d-9d34-4a32-864e-a388c90cca3e">22.7</ix:nonFraction>&#160;million during the years ended December 31, 2021 and 2020, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="iaaee9f378ba943c697c41973e5428bad"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Avillion Entities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our partnership interests in Avillion Financing I, LP (&#8220;Avillion I&#8221;) and BAv Financing II, LP (&#8220;Avillion II&#8221;, or, together, the &#8220;Avillion Entities&#8221;) as equity method investments because RPIFT has the ability to exercise significant influence over the entities. We recorded a loss allocation from the Avillion Entities of $<ix:nonFraction unitRef="usd" contextRef="i795acc0e43ad49819be20554560459e9_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDY3MDc_d8b9002e-f179-4eb2-9af7-fd70f083ae54">28.4</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="iff8840832b23407c89930ca87f5e3a14_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDY3MTE_d3323422-77bd-4f59-a227-bb916cd80159">17.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i28b1ff263ad7477ba427e73b282c6efc_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDY3MTU_0e0fc332-a01c-47e0-a11a-5b78c95e6617">32.5</ix:nonFraction>&#160;million within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Equity in losses/(earnings) of non-consolidated affiliates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the years ended December 31, 2021, 2020 and 2019, respectively. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 19, 2017, the FDA approved a supplemental New Drug Application for Pfizer&#8217;s Bosulif. Avillion I is eligible to receive fixed payments from Pfizer based on this approval. Subsequent to the asset sale, the only operations of Avillion I are the collection of cash and unwinding of discount on the series of fixed annual payments due from Pfizer. We received distributions from Avillion I of $<ix:nonFraction unitRef="usd" contextRef="i1e5a064854514c4e9d147a383d33e903_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDY3MzM_4f4a9aa7-711c-4faf-b16a-e0a57cb84c35"><ix:nonFraction unitRef="usd" contextRef="i4f295d9e2c304799a502469a6920f5c2_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDY3MzM_dc00c8bb-303d-4bfe-94cb-14fe0272749d">13.4</ix:nonFraction></ix:nonFraction>&#160;million during each of the years ended December 31, 2021 and 2020, and $<ix:nonFraction unitRef="usd" contextRef="i48ff7ddf47f44c04b36ecf13d3a578f4_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDc1NTA_338eedd1-460a-4d22-ac3b-bdd96d4d3f69">14.1</ix:nonFraction>&#160;million in the year ended December 31, 2019 in connection with Avillion I&#8217;s receipt of the fixed annual payments due under its co-development agreement with Pfizer. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, RPIFT entered into an agreement with Avillion II, which was amended in 2019, to invest approximately $<ix:nonFraction unitRef="usd" contextRef="ia502c1c929d940d39390b7214482871a_I20170331" decimals="-5" name="us-gaap:OtherCommitment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzMwMjk_87c520a3-81d3-4dfd-8d36-12549003fd63">19.0</ix:nonFraction>&#160;million to fund approximately <ix:nonFraction unitRef="number" contextRef="ia502c1c929d940d39390b7214482871a_I20170331" decimals="2" name="rprx:OtherCommitmentsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzMwNTQ_637fc969-c6e4-4018-8a01-24919e779633">50</ix:nonFraction>% of the costs of a Phase 2 clinical trial for the use of Merck KGaA&#8217;s anti-IL 17 nanobody M1095 (the &#8220;Merck KGaA Asset&#8221;) for the treatment of psoriasis in exchange for certain milestone and royalty payments. Our involvement in the development for the Merck KGaA Asset ceased in the year ended December 31, 2020, for which we received a distribution of $<ix:nonFraction unitRef="usd" contextRef="iecadc5607804420f9e9904632d1e8a25_D20200101-20201231" decimals="-5" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDY3NzI_7ce64dff-6da8-4344-95a3-abd2500ee3bc">21.3</ix:nonFraction>&#160;million from Avillion II. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, RPIFT entered into an additional agreement, which was amended in July 2021, to increase our investment up to $<ix:nonFraction unitRef="usd" contextRef="ie3c9990279364489bd57aa8cf39a801b_I20210731" decimals="-5" name="us-gaap:OtherCommitment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzEwOTk1MTE2MzI2MTg_139526c9-0202-4c99-b8e0-c1b74e7881e4">122.5</ix:nonFraction>&#160;million from $<ix:nonFraction unitRef="usd" contextRef="idfbcd815ad3241e08b3899f248245e53_I20180531" decimals="-5" name="us-gaap:OtherCommitment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE0MjkzNjUxMTY5NzIy_8a62e657-fe60-4b48-afc5-046a6a1e3047">105.0</ix:nonFraction>&#160;million in Avillion II over multiple years to fund approximately <ix:nonFraction unitRef="number" contextRef="i3cde2b63bf59491b8925224bea22907a_I20180531" decimals="2" name="rprx:OtherCommitmentsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzM1NDc_f723cb89-93ec-48f6-b351-5846a41ec74a">44</ix:nonFraction>% of the costs of Phase 2 and 3 clinical trials to advance PT027 through a global clinical development program for the treatment of asthma in exchange for royalties, a series of success-based milestones and other potential payments.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, RPIFT had $<ix:nonFraction unitRef="usd" contextRef="i47df9f0f55ed4282855d6acd42a023ca_I20211231" decimals="-5" sign="-" name="rprx:EquityMethodInvestmentsUnfundedCommitments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDY3NDk_f2fb803d-2117-42ea-892d-7db250f72090">11.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib68731c3079e4d3ca394ac6b77b028f7_I20201231" decimals="-5" name="rprx:EquityMethodInvestmentsUnfundedCommitments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDY3NTM_1987163c-f2fb-4d25-a582-23d0795902b4">28.6</ix:nonFraction>&#160;million respectively, of unfunded commitments related to the Avillion Entities. Our maximum exposure to loss at any particular reporting date is limited to the current carrying value of the investment plus the unfunded commitments.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_145"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzE1NDA_aa947181-8f1f-40f3-932c-fce7f06343ad" continuedAt="ic96ac8f9c90b4a7285282f0aaea3efac" escape="true">Research &amp; Development (&#8220;R&amp;D&#8221;) Funding Expense </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic96ac8f9c90b4a7285282f0aaea3efac"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D funding expense consists of upfront and ongoing R&amp;D payments we have made to counterparties to acquire royalties and/or milestones on development-stage product candidates. Ongoing R&amp;D payments are made as the related development-stage product candidates undergo clinical trials with our counterparties. During the year ended December 31, 2021, 2020, and 2019 we did not enter into any new ongoing R&amp;D funding arrangements. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognized R&amp;D funding expense of $<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzIxOTkwMjMyNjcyNjg_1dd265f3-801a-47f1-86f1-a1c68def86fa">200.1</ix:nonFraction>&#160;million during the year ended December 31, 2021, comprised of $<ix:nonFraction unitRef="usd" contextRef="i286e267288774fbe92ab611abb8069de_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzIxOTkwMjMyNjY2NjE_974050aa-2735-471b-a24d-fbe219f6f373">6.9</ix:nonFraction>&#160;million in ongoing R&amp;D expenses, primarily under our co-funding agreement with Sanofi, and $<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzIxOTkwMjMyNjY3NDg_51661818-8b0b-4a49-972a-04388d6e3e1e">193.2</ix:nonFraction>&#160;million in upfront R&amp;D funding. As part of a long-term strategic funding partnership with MorphoSys, which closed on July 15, 2021 (as further discussed in Note 17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commitments and Contingencies), we allocated $<ix:nonFraction unitRef="usd" contextRef="i40bac185075247a39792ae4ffa91c2ce_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzEwOTk1MTE2MzgyOTE_1069bed6-2ff8-4d4f-9e56-d68794d62341">90.0</ix:nonFraction>&#160;million of the upfront payment to R&amp;D funding expense, representing two development-stage products acquired in exchange for future royalties. Additionally, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="if273f44aa1484854b5d3ea003908542c_D20211101-20211130" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzEwOTk1MTE2MzgzMDk_1c158e57-08b4-4e8e-b50f-a7399a32b995">103.2</ix:nonFraction>&#160;million to BioCryst to acquire a royalty on a development-stage product in November 2021. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized R&amp;D funding expense of $<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzE2NDkyNjc0NDQzMDc_98088dcd-97a2-4ae6-b0d7-a179ddaf30e4">26.3</ix:nonFraction>&#160;million during the year ended December 31, 2020, of which $<ix:nonFraction unitRef="usd" contextRef="i479dbbd40a7348a1919d32453a73a811_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzQ5NDc4MDIzMzgwMTc_1b331233-ebf9-4aaa-b90f-f20d08cd4ed3">20.5</ix:nonFraction>&#160;million related to ongoing development-stage funding payments, primarily under our co-funding agreement with Sanofi and $<ix:nonFraction unitRef="usd" contextRef="i9150e6c7578b456aad25125ca3f4404d_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzE0MjkzNjUxMTcxMTM5_ec1aac3f-f6b0-42c6-8aaa-408a5c345ad7">5.8</ix:nonFraction>&#160;million related to upfront funding for a royalty on a development-stage product that we acquired from BioCryst. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzE2NDkyNjc0NDYwNzM_1559dd5e-b1bb-42ff-b0e4-88adffca9da8">83.0</ix:nonFraction>&#160;million of R&amp;D funding expense during the year ended December 31, 2019, of which $<ix:nonFraction unitRef="usd" contextRef="i170879596f064c7ea75b778e24446320_D20190101-20191231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzE2NDkyNjc0NDYwOTQ_b442362e-27cf-44d7-8850-d85d59f9e260">18.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie35632bef26942e9a813a4eb6a249893_D20190101-20191231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzE2NDkyNjc0NDYxMTQ_05870d11-ebcf-46d1-a0b4-7c5f87932036">62.8</ix:nonFraction>&#160;million related to our funding agreements with both Sanofi and Pfizer, respectively. We completed our funding commitments in the fourth quarter of 2019 under our agreement with Pfizer. We did not have upfront development-stage R&amp;D funding expense in 2019.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we have a remaining commitment of $<ix:nonFraction unitRef="usd" contextRef="i4861f1f472c3491ba7a17eb5040be7f6_I20211231" decimals="-5" name="rprx:ResearchAndDevelopmentRemainingFundingCommitment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzE2NDkyNjc0NDM5NDk_bdf8e7ea-0134-414f-9808-6f1d0f059600">10.7</ix:nonFraction>&#160;million related to our R&amp;D funding agreement with Sanofi.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_148"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzgyMjU_7d2fe44a-48ed-4adc-b739-83e15fc63107" continuedAt="ie568c18f04ec414f9575a5e7921b935a" escape="true">Borrowings</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ie568c18f04ec414f9575a5e7921b935a" continuedAt="i5770b7b8280a474aaa5e83fa962b2d81"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzgyMjI_88ca1aaf-6718-4679-90b8-16fdce3fe973" escape="true"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Our borrowings at December 31, 2021 and 2020 consisted of the following (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Issuance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i9796b650407b44c3957bc1e7ffbd1229_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzItMC0xLTEtMC90ZXh0cmVnaW9uOjhhNDMyZWJlNjM0MTRiMzBhNDQzMzZmYTM0M2Y5MTI2XzE2NDkyNjc0NDE3NTI_7c9b3782-be5b-4250-b5e3-6891590553af">1,000,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="i9796b650407b44c3957bc1e7ffbd1229_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzItMC0xLTEtMC90ZXh0cmVnaW9uOjhhNDMyZWJlNjM0MTRiMzBhNDQzMzZmYTM0M2Y5MTI2XzEwOTk1MTE2Mjc4NTE_0f0ad6cd-a7e5-458b-9904-41226e119004">0.75</ix:nonFraction>% (issued at <ix:nonFraction unitRef="number" contextRef="i7dc45b08ebac451f91ea39248eeab27b_D20210101-20211231" decimals="INF" name="rprx:DebtInstrumentIssuanceAsAPercentOfPar" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzItMC0xLTEtMC90ZXh0cmVnaW9uOjhhNDMyZWJlNjM0MTRiMzBhNDQzMzZmYTM0M2Y5MTI2XzEwOTk1MTE2Mjc4NDM_b49f6492-b0ba-4959-b1cd-617d758b8c81">99.322</ix:nonFraction>% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9796b650407b44c3957bc1e7ffbd1229_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzItNi0xLTEtMA_bb1c3d81-86fd-4cf8-80cf-7fa7466758ea">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2c6ec4ac80d4a6ba66238bf0a9eb4cb_I20201231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzItOC0xLTEtMA_b804331c-349c-4a30-be79-3e5a60361975">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ia2fafea4522943eca815863b7d3d8349_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzMtMC0xLTEtMC90ZXh0cmVnaW9uOjJkNTllMDExN2M4MTQ4NGQ4ODU1ZGRmODM4YzgxMjEyXzE2NDkyNjc0NDE3NTI_c810144c-910c-41ba-a8da-2f8b5d054e50">1,000,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="ia2fafea4522943eca815863b7d3d8349_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzMtMC0xLTEtMC90ZXh0cmVnaW9uOjJkNTllMDExN2M4MTQ4NGQ4ODU1ZGRmODM4YzgxMjEyXzEwOTk1MTE2Mjc4NTE_1350f426-c9e8-4313-8c5e-9df955114cc4">1.20</ix:nonFraction>% (issued at <ix:nonFraction unitRef="number" contextRef="i5b0aacd47d5b4487854882d7e7b776da_D20210101-20211231" decimals="INF" name="rprx:DebtInstrumentIssuanceAsAPercentOfPar" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzMtMC0xLTEtMC90ZXh0cmVnaW9uOjJkNTllMDExN2M4MTQ4NGQ4ODU1ZGRmODM4YzgxMjEyXzEwOTk1MTE2Mjc4NDM_a98a3b73-a68a-4b97-a89e-8d53295305cd">98.875</ix:nonFraction>% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2fafea4522943eca815863b7d3d8349_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzMtNi0xLTEtMA_f9426238-6f06-4f25-9286-02514eb608a1">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia43476884d9241af8b829c570791446c_I20201231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzMtOC0xLTEtMA_9edcf1a4-88fc-4f3e-b3ea-452a399d4c25">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i43310a7b9e4c4cbb9b03ef370bd43b77_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzQtMC0xLTEtMC90ZXh0cmVnaW9uOjBjYzNjMmQ4NmE2YzQxNWE5ZTgzZmM4YTc5MTZiMjJiXzE2NDkyNjc0NDE3NTI_61fd2c11-8d91-4a5b-b962-0d6ba4bbfb84">1,000,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="i43310a7b9e4c4cbb9b03ef370bd43b77_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzQtMC0xLTEtMC90ZXh0cmVnaW9uOjBjYzNjMmQ4NmE2YzQxNWE5ZTgzZmM4YTc5MTZiMjJiXzEwOTk1MTE2Mjc4NTE_b1a6c48b-cb5b-4c4c-84ce-483f9e17ae1c">1.75</ix:nonFraction>% (issued at <ix:nonFraction unitRef="number" contextRef="ifee8d1bb44854cc4a3188d158569c76c_D20210101-20211231" decimals="INF" name="rprx:DebtInstrumentIssuanceAsAPercentOfPar" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzQtMC0xLTEtMC90ZXh0cmVnaW9uOjBjYzNjMmQ4NmE2YzQxNWE5ZTgzZmM4YTc5MTZiMjJiXzEwOTk1MTE2Mjc4NDM_f83e35fc-8177-4eda-9936-5e49860cc6cf">98.284</ix:nonFraction>% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43310a7b9e4c4cbb9b03ef370bd43b77_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzQtNi0xLTEtMA_2580df51-f3c8-4463-970a-74982c98190c">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d33126321d44b4aabd868a581153c4b_I20201231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzQtOC0xLTEtMA_0b709ecc-10ce-4007-ad76-d79579caf1b7">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i12aa5c25ace14515980e127e89b84e78_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzUtMC0xLTEtMC90ZXh0cmVnaW9uOmE0YTk3NGVhZmIzMzQ1OTA5NmNlMmI2Y2M0YzkwZDA1XzE2NDkyNjc0NDE3NDA_d294f6b3-77ca-4060-a48b-a1f69a12b6bf">1,000,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="i12aa5c25ace14515980e127e89b84e78_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzUtMC0xLTEtMC90ZXh0cmVnaW9uOmE0YTk3NGVhZmIzMzQ1OTA5NmNlMmI2Y2M0YzkwZDA1XzEwOTk1MTE2Mjc4Mzk_8eaccde8-9b56-4559-8bf6-ecbcc8c2a197">2.20</ix:nonFraction>% (issued at <ix:nonFraction unitRef="number" contextRef="ia4e846ac7a044335959896d695fb4eb6_D20210101-20211231" decimals="INF" name="rprx:DebtInstrumentIssuanceAsAPercentOfPar" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzUtMC0xLTEtMC90ZXh0cmVnaW9uOmE0YTk3NGVhZmIzMzQ1OTA5NmNlMmI2Y2M0YzkwZDA1XzEwOTk1MTE2Mjc4MzE_6f46f7c8-6779-49ad-8ccf-6a08fc712e07">97.760</ix:nonFraction>% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12aa5c25ace14515980e127e89b84e78_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzUtNi0xLTEtMA_47e34677-84e3-4f97-9b24-94661535755e">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdaffc234a45408a8a359e973745feb8_I20201231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzUtOC0xLTEtMA_ff0d93b1-ec8c-4e48-b469-63837416ac04">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i4c4c0408ec6340e9bdb1a602e36ce18b_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzYtMC0xLTEtMjY5NjkvdGV4dHJlZ2lvbjplNjkxZmJlNjczYmE0NTg4YjZjZTJhMTExYTM5MGU3MF8xNjQ5MjY3NDQxNzYy_7eb47c78-5dcc-4316-9671-fa19aef9d3fa">600,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="i4c4c0408ec6340e9bdb1a602e36ce18b_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzYtMC0xLTEtMjY5NjkvdGV4dHJlZ2lvbjplNjkxZmJlNjczYmE0NTg4YjZjZTJhMTExYTM5MGU3MF8xMDk5NTExNjI3ODYz_2cd566d3-7b00-44f5-801e-9488727ef5f5">2.15</ix:nonFraction>% (issued at <ix:nonFraction unitRef="number" contextRef="ibd6ff013438940249c31fcaec596a041_D20210101-20211231" decimals="INF" name="rprx:DebtInstrumentIssuanceAsAPercentOfPar" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzYtMC0xLTEtMjY5NjkvdGV4dHJlZ2lvbjplNjkxZmJlNjczYmE0NTg4YjZjZTJhMTExYTM5MGU3MF8xMDk5NTExNjI3ODU1_ecaa9c97-490a-412a-aef0-0ad2365f4a4b">98.263</ix:nonFraction>% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c4c0408ec6340e9bdb1a602e36ce18b_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzYtNi0xLTEtNDA4OTQ_db6dba16-1e45-4c48-a239-1ea172a47358">600,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafcd19db0e464d11b58358856023c8b3_I20201231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzYtOC0xLTEtNDA4OTk_7c88d99c-b1a8-4de0-9d52-a117578c864f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i214ee7900f3d49228322f94559a11682_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzYtMC0xLTEtMC90ZXh0cmVnaW9uOjM2MTM5YzJlY2E1YTQ3Yzg4YjdkZmVkMjYxZjkwMGJjXzE2NDkyNjc0NDE3NDA_3c5e24d5-9262-443c-b94a-de00accd33bb">1,000,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="i214ee7900f3d49228322f94559a11682_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzYtMC0xLTEtMC90ZXh0cmVnaW9uOjM2MTM5YzJlY2E1YTQ3Yzg4YjdkZmVkMjYxZjkwMGJjXzEwOTk1MTE2Mjc4Mzk_70c23006-ddf4-45ca-ae9c-14125445c2e1">3.30</ix:nonFraction>% (issued at <ix:nonFraction unitRef="number" contextRef="icd0fbf3fb9684880981bb0db110314f6_D20210101-20211231" decimals="INF" name="rprx:DebtInstrumentIssuanceAsAPercentOfPar" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzYtMC0xLTEtMC90ZXh0cmVnaW9uOjM2MTM5YzJlY2E1YTQ3Yzg4YjdkZmVkMjYxZjkwMGJjXzEwOTk1MTE2Mjc4MzE_224504ce-a484-4784-b865-c650c39a8905">95.556</ix:nonFraction>% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214ee7900f3d49228322f94559a11682_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzYtNi0xLTEtMA_7e611256-d6e9-437a-8cc8-8eb3c0a99924">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i273747e9c3c9428a95fbb9a2dc8580ff_I20201231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzYtOC0xLTEtMA_57afcf8d-7ca9-49f3-9aee-4f9ed232f602">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i7b8870452b5a460ba6814149888615ae_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzctMC0xLTEtMC90ZXh0cmVnaW9uOjAzNTQ2ZjFkZWU4ZjQyNmY5YjMzNDQyNDI2Y2ZiNGEzXzE2NDkyNjc0NDE3NTI_7c0fb961-4cfa-46f0-b658-d984321be464">1,000,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="i7b8870452b5a460ba6814149888615ae_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzctMC0xLTEtMC90ZXh0cmVnaW9uOjAzNTQ2ZjFkZWU4ZjQyNmY5YjMzNDQyNDI2Y2ZiNGEzXzEwOTk1MTE2Mjc4NTE_a07073f5-04ba-4c83-b50e-bc5406731c70">3.55</ix:nonFraction>% (issued at <ix:nonFraction unitRef="number" contextRef="i35930b3c5c694b58bdad83cb5488ec9f_D20210101-20211231" decimals="INF" name="rprx:DebtInstrumentIssuanceAsAPercentOfPar" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzctMC0xLTEtMC90ZXh0cmVnaW9uOjAzNTQ2ZjFkZWU4ZjQyNmY5YjMzNDQyNDI2Y2ZiNGEzXzEwOTk1MTE2Mjc4NDM_f3dff801-64b3-41b2-b76e-1a14f8d5068a">95.306</ix:nonFraction>% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8870452b5a460ba6814149888615ae_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzctNi0xLTEtMA_6997ab9e-648f-4533-98f1-3610ba6f1b1d">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf88d4d19d624f61acc05f3da6e97e88_I20201231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzctOC0xLTEtMA_c259f7dc-2307-41b6-bdd6-bc6c0d01b0c4">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i4daec00bc1054f378d9fa9e9841e7e3b_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzktMC0xLTEtNDA4NzUvdGV4dHJlZ2lvbjpkOTEyMDNjZWY5YmY0NzQ0ODA5NjZmMDhhMjNmMmJkNF8xNjQ5MjY3NDQxNzQ4_afb42656-54b0-4912-95a2-264595743f5e">700,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="i4daec00bc1054f378d9fa9e9841e7e3b_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzktMC0xLTEtNDA4NzUvdGV4dHJlZ2lvbjpkOTEyMDNjZWY5YmY0NzQ0ODA5NjZmMDhhMjNmMmJkNF8xMDk5NTExNjI3ODQ5_0c86b3bc-1480-4113-b674-3345433a3b86">3.35</ix:nonFraction>% (issued at <ix:nonFraction unitRef="number" contextRef="i0162f5b487c74cacb76db77bc7f972bc_D20210101-20211231" decimals="INF" name="rprx:DebtInstrumentIssuanceAsAPercentOfPar" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzktMC0xLTEtNDA4NzUvdGV4dHJlZ2lvbjpkOTEyMDNjZWY5YmY0NzQ0ODA5NjZmMDhhMjNmMmJkNF8xMDk5NTExNjI3ODQx_39cb350a-da01-41d5-9384-4ea0958473c0">97.565</ix:nonFraction>% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4daec00bc1054f378d9fa9e9841e7e3b_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzktNi0xLTEtNDA4OTQ_ba153801-dde3-474b-8f39-3414351db05c">700,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03b010a1e0b24651a9e2d279ef1f4a19_I20201231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzktOC0xLTEtNDA4OTk_7a56acc0-dd0b-4596-9085-5c45ad9ec604">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzExLTYtMS0xLTQwODk0_76dfc7c9-6618-4607-9cad-1296d026a2d4">203,930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzExLTgtMS0xLTQwODk5_2c685e95-9df2-4ae3-8a28-935fcdd8b956">183,416</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt carrying value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzEwLTYtMS0xLTA_5e525e03-219e-4f6a-a331-48c5f5d55b77">7,096,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzEwLTgtMS0xLTA_be42f7e7-caae-43c7-83e3-8f475abdaff4">5,816,584</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzEzLTYtMS0xLTA_a35a3201-2135-43dc-9ea0-dcac8a216735">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzEzLTgtMS0xLTA_463b9df8-2dbd-48b2-82bf-e35b9eb26aed">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzE0LTYtMS0xLTA_33bc0422-b9a1-4b38-b188-cb698756addc">7,096,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzE0LTgtMS0xLTA_c759c250-a88e-4157-bcf7-f7ff0822f396">5,816,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Senior Unsecured Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 26, 2021, we issued $<ix:nonFraction unitRef="usd" contextRef="ie681b3df9681426ba637a173be7ba1dc_I20210726" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2MzY2MzE_ffcdb4ca-28f0-4276-980a-a6a183c28408">1.3</ix:nonFraction>&#160;billion of senior unsecured notes (the &#8220;2021 Notes&#8221;) comprised of $<ix:nonFraction unitRef="usd" contextRef="i68470da82fa849aabc13b3b1753af6d4_I20210726" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2NDE0Nzk_a506a3d9-6634-4009-94b0-cddce2318b87">600.0</ix:nonFraction>&#160;million principal amount of notes due September 2031 and $<ix:nonFraction unitRef="usd" contextRef="i4d77b9cf09984cf791139a8ba06caf1e_I20210726" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2NDE1MDE_0121aacd-9380-4de8-a7ad-cbfb999d94b8">700.0</ix:nonFraction>&#160;million principal amount of notes due September 2051. Interest on each series of the 2021 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year, beginning on March 2, 2022. The 2021 Notes were issued at a total discount of $<ix:nonFraction unitRef="usd" contextRef="ie681b3df9681426ba637a173be7ba1dc_I20210726" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2NDE1MjE_53a99e6d-7993-4fd9-a6ba-597273779d6b">27.5</ix:nonFraction>&#160;million and we capitalized approximately $<ix:nonFraction unitRef="usd" contextRef="i4d77b9cf09984cf791139a8ba06caf1e_I20210726" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2NDE1NDA_04d4af42-753a-4da7-828a-5adf76fd296a">12.3</ix:nonFraction>&#160;million in debt issuance costs primarily composed of underwriting fees. The 2021 Notes have a weighted average coupon rate and a weighted average effective interest rate of <ix:nonFraction unitRef="number" contextRef="i4ce08489650c4f10a179aeb963c83319_I20211231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2NDE1NTI_c6451057-7501-48bc-98ef-2e1378209c82">2.80</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i4ce08489650c4f10a179aeb963c83319_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2NDE1NTg_bb4d6570-0653-4da4-9daa-253952e2f6af">3.06</ix:nonFraction>%, respectively.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 2, 2020, we issued $<ix:nonFraction unitRef="usd" contextRef="i36b01c03000b44fbbe2d2aa0ad142157_I20200902" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2NDMyOTY_ebfb3a19-f49d-467c-be77-6420be9f2e85">6.0</ix:nonFraction>&#160;billion of senior unsecured notes (the &#8220;2020 Notes&#8221; and, together with the 2021 Notes, the &#8220;Notes&#8221;). We used the net proceeds from the 2020 Notes offering, together with available cash on hand, to repay in full the senior secured credit facilities. Interest on each series of the 2020 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year. The 2020 Notes were issued at a total discount of $<ix:nonFraction unitRef="usd" contextRef="ida43ed4cd5d84bc4bfff97ddd4ade4dd_I20200902" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2NDE1NjQ_ef4f2fdf-a22c-409d-8bd9-7b6301e76c9d">149.0</ix:nonFraction>&#160;million and we capitalized approximately $<ix:nonFraction unitRef="usd" contextRef="i36b01c03000b44fbbe2d2aa0ad142157_I20200902" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2NDE1NzI_91926044-c61c-44a4-90b9-faf67de0969e">40.4</ix:nonFraction>&#160;million in debt issuance costs primarily comprised of underwriting fees. The 2020 Notes have a weighted average coupon rate and a weighted average effective interest rate of <ix:nonFraction unitRef="number" contextRef="i2faebe6b2bb249f9bacffbdee1da7d22_I20211231" decimals="INF" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2Mzg2Njc_856b2e0c-af9f-43fd-8243-e466fd1bafed">2.125</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i2faebe6b2bb249f9bacffbdee1da7d22_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2Mzg2NzU_5b469b9b-dfaf-468b-aa3e-1d08fec65fd8">2.50</ix:nonFraction>%, respectively.&#160;&#160;&#160;&#160;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 3, 2021, we completed an exchange offer for the 2020 Notes where certain holders elected to tender their unregistered outstanding notes for freely tradable exchange notes that were registered under the Securities Act of 1933. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Notes may be redeemed at our option at a redemption price equal to the greater of (i) <ix:nonFraction unitRef="number" contextRef="i761809a342d742f8846055709c5f4ea7_D20200902-20200902" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzQ5NDc4MDIzNDA4NTI_0896c520-881a-492d-8ec0-748d77d14db3">100</ix:nonFraction>% of the principal amount of the Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the treasury rate, plus a make-whole premium as defined in the indenture. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon the occurrence of a change of control triggering event and downgrade in the rating of our Notes by two of three credit agencies, the holders may require us to repurchase all or part of their Notes at a price equal to <ix:nonFraction unitRef="number" contextRef="i02f715ec0012457ca0402d8dc7e85a1b_D20200902-20200902" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzQ5NDc4MDIzNDA4NTY_aa11583e-1cf0-4194-b06d-b462579ecbaa">101</ix:nonFraction>% of the aggregate principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.  </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i5770b7b8280a474aaa5e83fa962b2d81" continuedAt="i08e851af8e174785a4d72ed1f449d450"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary. We are required to comply with certain covenants under our Notes and, </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">as of December 31, 2021, we were in compliance with all applicable covenants.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2021 and 2020, the estimated fair value of our outstanding Notes using Level 2 inputs was approximately $<ix:nonFraction unitRef="usd" contextRef="i06737af3814f449197ef9f5868fd6001_I20211231" decimals="-8" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzIxOTkwMjMyNzQ4MDc_f8404337-a04c-4b5e-8bbf-a43f50662ee9">7.2</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i32d8e5ca0cdc4cdcbf57357cd3014fc4_I20201231" decimals="-8" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzE0MjkzNjUxMTgwOTU3_cc64d752-8b0e-4f98-8942-e65373fd9696">6.2</ix:nonFraction>&#160;billion, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Senior Unsecured Revolving Credit Facility</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 15, 2021, we entered into an amended and restated revolving credit agreement (the &#8220;Credit Agreement&#8221;). The Credit Agreement amends and restates the existing credit agreement that our subsidiary, RP Holdings, as borrower, entered into on September 18, 2020, which provided for a <ix:nonNumeric contextRef="i4141d72c0fa3426ea79348fd59066693_D20200918-20200918" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzE0MjkzNjUxMTgwOTg0_d9da4419-e4a5-471d-b548-4d7b809b41d5">five-year</ix:nonNumeric> unsecured revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) with borrowing capacity of up to $<ix:nonFraction unitRef="usd" contextRef="i8dc7c9c8b8c844b59270fcb640d8fbde_I20200918" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzE2NDkyNjc0NTc1NDM_45543491-0832-4cb5-920c-0cbeabd93167">1.5</ix:nonFraction>&#160;billion for general corporate purposes. The Credit Agreement extends the maturity of the Revolving Credit Facility to September 15, 2026. As of </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2021 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2020, there were no outstanding borrowings under the Revolving Credit Facility.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Revolving Credit Facility is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent&#8217;s prime rate, (2) the federal funds effective rate and the overnight bank funding rate, plus <ix:nonFraction unitRef="number" contextRef="ibecbcfc3dadd481d9155173824469951_D20200918-20200918" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzM4ODk_5183cbe4-253f-4016-8c1a-bf8683c832c8"><ix:nonFraction unitRef="number" contextRef="ief16c63a8fed4314b8dbf9cd08433170_D20200918-20200918" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzM4ODk_5f03c6d2-4741-4567-9aaa-40e82d9e08a4">0.5</ix:nonFraction></ix:nonFraction>% and (3) the one month adjusted LIBOR, plus <ix:nonFraction unitRef="number" contextRef="i8563b235bf8f445ab53d170d2ea1cc7d_D20200918-20200918" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzM5MzU_d0afe17c-0892-4022-ac85-aaf12b3f0391">1</ix:nonFraction>% or (b) the Eurocurrency Rate or the Alternative Currency Daily Rate (each as defined in the Credit Agreement), plus in each case, the applicable margin. The applicable margin for the Revolving Credit Facility varies based on our public debt rating. Accordingly, the interest rates for the Revolving Credit Facility fluctuates during the term of the facility based on changes in the applicable interest rate and future changes in our public debt rating.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Credit Agreement that governs the Revolving Credit Facility contains certain customary covenants, that among other things, require us to maintain (i) a consolidated leverage ratio at or below <ix:nonFraction unitRef="number" contextRef="i8dc7c9c8b8c844b59270fcb640d8fbde_I20200918" decimals="INF" name="rprx:DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzQ1NTc_45b45f2e-0419-4366-a3bc-cc9a46406a6e">4.00</ix:nonFraction> to 1.00 (or at or below <ix:nonFraction unitRef="number" contextRef="i8dc7c9c8b8c844b59270fcb640d8fbde_I20200918" decimals="INF" name="rprx:DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzQ1ODQ_bf3de77d-251b-46ff-92a4-2a7f928070b9">4.50</ix:nonFraction> to 1.00 following a qualifying material acquisition) of consolidated funded debt to consolidated EBITDA, each as defined and calculated with the ratio level calculated with further adjustments as set forth in the Credit Agreement and (ii) a consolidated coverage ratio at or above <ix:nonFraction unitRef="number" contextRef="i8dc7c9c8b8c844b59270fcb640d8fbde_I20200918" decimals="INF" name="rprx:DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzQ4Njg_36698647-a593-422d-a0a8-36eae51cfa3b">2.50</ix:nonFraction> to 1.00 of consolidated EBITDA to consolidated interest expense, each as defined and calculated with further adjustments as set forth in the Credit Agreement. All obligations under the Revolving Credit Facility are unconditionally guaranteed by us. As of </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, RP Holdings was in compliance with these covenants. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Secured Credit Facilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 11, 2020, in connection with the Exchange Offer Transactions (as discussed in Note 1&#8211;Organization and Purpose) and using funds contributed by RPI Intermediate FT and the Legacy Investors Partnerships, RPIFT repaid its outstanding debt and accrued interest, and terminated all outstanding interest rate swaps. RPI Intermediate FT, as borrower, entered into a term loan credit agreement with Bank of America, N.A., as administrative agent, the lenders party thereto from time to time and the other parties thereto. The senior secured credit facilities consisted of a term loan A and term loan B in the amounts of $<ix:nonFraction unitRef="usd" contextRef="ieb917668901f4fa88d71cb0dad938ffc_I20200211" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzU5NTM_20968115-7fd7-4d59-9211-0828c08900af">3.20</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i9fd1d6e21848456dba10bcb5be7800b7_I20200211" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzU5NjA_8ebc6700-1ab1-4496-8a99-9ed71889d919">2.84</ix:nonFraction>&#160;billion, respectively. In September 2020, we repaid in full the outstanding principal amounts of term loans under the senior secured credit facilities with net proceeds from the 2020 Notes and available cash on hand. Upon refinancing our senior secured credit facilities in September 2020, we recorded a loss on debt extinguishment of $<ix:nonFraction unitRef="usd" contextRef="i7fa1890df4f64955a27b5a2e7f1eb6f4_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2NDI1NjU_36225710-aa35-45b7-b83a-9d9212cdf803">25.1</ix:nonFraction>&#160;million as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other non-operating expense/(income), net,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> which primarily consisted of unamortized loan issuance costs and original issue discount related to our senior secured credit facilities.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RPIFT Senior Secured Credit Facilities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The RPIFT Senior Secured Credit Facilities were repaid in full in February 2020 in connection with the Exchange Offer Transactions. We recorded a loss on debt extinguishment of $<ix:nonFraction unitRef="usd" contextRef="ib99e303d9a2649bba418d9bec8ce14f3_D20200101-20201231" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2NDMyNjU_9c99ec76-575d-4765-bf07-9faa2752b11a">5.4</ix:nonFraction>&#160;million as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other non-operating expense/(income), net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">during the year ended December 31, 2020. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Principal Payments on the Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzgyMjQ_984ccaee-447a-4414-a5aa-4fa4c69ed2dc" continuedAt="i7d26bb459700419fbbce5d410ed44272" escape="true">The future principal payments for our borrowings as of December 31, 2021 over the next five years and thereafter are as follows (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><ix:continuation id="i08e851af8e174785a4d72ed1f449d450" continuedAt="ib6139169a771433baf9ca81672476a2b"><ix:continuation id="i7d26bb459700419fbbce5d410ed44272" continuedAt="ibeae00777a574fa0b5843cbc1c293e5e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2faebe6b2bb249f9bacffbdee1da7d22_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTphOTY5MGIyMDg0YjY0MzM2ODVhOTIxMzNhNDU2OTllZi90YWJsZXJhbmdlOmE5NjkwYjIwODRiNjQzMzY4NWE5MjEzM2E0NTY5OWVmXzMtMi0xLTEtMA_6daf9956-5c9a-4371-bdb8-0e2513fdc434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2faebe6b2bb249f9bacffbdee1da7d22_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTphOTY5MGIyMDg0YjY0MzM2ODVhOTIxMzNhNDU2OTllZi90YWJsZXJhbmdlOmE5NjkwYjIwODRiNjQzMzY4NWE5MjEzM2E0NTY5OWVmXzQtMi0xLTEtMA_10e34750-b080-40f6-9a31-758820e28152">1,000,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2faebe6b2bb249f9bacffbdee1da7d22_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTphOTY5MGIyMDg0YjY0MzM2ODVhOTIxMzNhNDU2OTllZi90YWJsZXJhbmdlOmE5NjkwYjIwODRiNjQzMzY4NWE5MjEzM2E0NTY5OWVmXzUtMi0xLTEtMA_b343844e-3a1e-4cd4-8f96-f63f23aee99c">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2faebe6b2bb249f9bacffbdee1da7d22_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTphOTY5MGIyMDg0YjY0MzM2ODVhOTIxMzNhNDU2OTllZi90YWJsZXJhbmdlOmE5NjkwYjIwODRiNjQzMzY4NWE5MjEzM2E0NTY5OWVmXzYtMi0xLTEtMA_e721e5ab-fc03-4956-9988-83f915f194fb">1,000,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2faebe6b2bb249f9bacffbdee1da7d22_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTphOTY5MGIyMDg0YjY0MzM2ODVhOTIxMzNhNDU2OTllZi90YWJsZXJhbmdlOmE5NjkwYjIwODRiNjQzMzY4NWE5MjEzM2E0NTY5OWVmXzctMi0xLTEtMA_410cbec0-0a0a-40c0-8f42-061db67e2b28">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2faebe6b2bb249f9bacffbdee1da7d22_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTphOTY5MGIyMDg0YjY0MzM2ODVhOTIxMzNhNDU2OTllZi90YWJsZXJhbmdlOmE5NjkwYjIwODRiNjQzMzY4NWE5MjEzM2E0NTY5OWVmXzgtMi0xLTEtMA_9a1215d4-25d5-457e-a819-4659b220e420">5,300,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2faebe6b2bb249f9bacffbdee1da7d22_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTphOTY5MGIyMDg0YjY0MzM2ODVhOTIxMzNhNDU2OTllZi90YWJsZXJhbmdlOmE5NjkwYjIwODRiNjQzMzY4NWE5MjEzM2E0NTY5OWVmXzktMy0xLTEtNDEyNjg_a661c006-d744-483f-8310-275d3ee6a7a8">7,300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="ib6139169a771433baf9ca81672476a2b"><ix:continuation id="ibeae00777a574fa0b5843cbc1c293e5e">(1)  &#160;&#160;&#160;&#160;Excludes unamortized debt discount and issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzE0MjkzNjUxMTgxMzg0_07636a9b-8ea0-458f-9c36-18e085b75b3c">203.9</ix:nonFraction> million as of December 31, 2021, which are amortized through interest expense over the remaining life of the underlying debt obligations.</ix:continuation></ix:continuation> </span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_151"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzU5ODg_942dc10d-4b80-486f-a79e-72e26864a6e5" continuedAt="i80d657d0d59e4799b6c1ed7cc3adebcf" escape="true">Shareholders&#8217; Equity</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i80d657d0d59e4799b6c1ed7cc3adebcf" continuedAt="ie27c9a80e98b4388a7c0e17446865c24"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital structure</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following the completion of our IPO as discussed in Note 1&#8211;Organization and Purpose, we have <ix:nonFraction unitRef="class" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="INF" name="rprx:NumberOfClassesOfVotingStock" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzE0MjkzNjUxMTc3OTg4_f8a0c3ff-522f-4f18-8f91-79f37506a5f4">two</ix:nonFraction> classes of voting shares: Class A ordinary shares and Class B ordinary shares, each of which has one vote per ordinary share. The Class A ordinary shares and Class B ordinary shares vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law. Our Class B ordinary shares are not publicly traded and holders of Class B ordinary shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up of the Company. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An exchange agreement entered into by us, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP and EPA Holdings (the &#8220;Exchange Agreement&#8221;) governs the exchange of RP Holdings Class B Interests held by the Continuing Investors Partnerships for Class A ordinary shares. Pursuant to the Exchange Agreement, RP Holdings Class B interests are exchangeable on a one-for-one basis for Class A ordinary shares on a quarterly basis. As of December 31, 2021, we have outstanding <ix:nonFraction unitRef="shares" contextRef="i7048c06f34e64e98a9f8db168c52ecf6_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzEwOTk1MTE2MzkwMzg_2fcde39a-b3bc-40cc-b7c4-820db8ee7a9d">432,963</ix:nonFraction>&#160;thousand Class A ordinary shares and <ix:nonFraction unitRef="shares" contextRef="ic092b803ad4d4d1bb1fc65733358f33f_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzEwOTk1MTE2MzkwNzQ_31a3d211-0af5-4b8d-b16b-ea7250bd682f">174,213</ix:nonFraction>&#160;thousand Class B ordinary shares. Each such exchange also results in the re-designation of the same number of our Class B ordinary shares as deferred shares. As of December 31, 2021, we have outstanding deferred shares of <ix:nonFraction unitRef="shares" contextRef="i9cf16ec8ae244acb94018fe5616afde0_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzEwOTk1MTE2MzY1ODQ_fd403936-c09e-433e-bfd7-f48cb3cf85c6">361,170</ix:nonFraction> thousand. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have in issue <ix:nonFraction unitRef="shares" contextRef="icd2e4870b58b4b92961362030330fa39_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzEwNDY_02b3b614-6969-4275-9fdf-5b38846e6916">50</ix:nonFraction> thousand Class R redeemable shares, which do not entitle the holder to voting or dividend rights. The purpose of the Class R redeemable shares was to ensure Royalty Pharma Limited had sufficient sterling denominated share capital at the time it was re-registered as a public limited company to Royalty Pharma plc, as required by the U.K. Companies Act. The Class R redeemable shares may be redeemed at our option in the future. Any such redemption would be at the nominal value of &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="i466cdba264f14dbba8111c43a48fa933_D20210101-20211231" decimals="2" name="rprx:RedeemableStockRedemptionPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzE1MzE_73d2e95c-5416-44ad-a18e-7fa9bc3b17ff">1</ix:nonFraction> each.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ie27c9a80e98b4388a7c0e17446865c24" continuedAt="i44f260189be1411caad63adfe06d6636"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-controlling interests</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The only non-controlling interest in the year ended December 31, 2019 related to RPSFT, for which the net change in the related balance is as presented in the statements of shareholders&#8217; equity. <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzU5OTA_96963cc4-5de9-4fb7-842a-7bf0ad7cfc52" continuedAt="ic0530f42f9d84171801f55147501ed6b" escape="true">The net change in the balance of our <ix:nonFraction unitRef="noncontrolling_interest" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="INF" name="rprx:NumberOfNoncontrollingInterests" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzIzOTQ_d407c5af-3e15-4090-817e-4dce460efaa3">four</ix:nonFraction> non-controlling interests for the years ended December 31, 2021 and 2020 is as follows (in thousands): </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic0530f42f9d84171801f55147501ed6b"><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.334%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d508394642a4a0ab6e3a02929fd6dd4_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEtMS0xLTEtNzc2ODU_3788234a-f443-491a-8b9c-3c969769ada8">35,883</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e834532d49b48d183dee4dfa980b04c_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEtMy0xLTEtNzc2ODU_0a813caf-17b5-40c8-ace0-b1f8fb98b218">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b032830d76c44b9a92d95e245ce0a21_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEtNS0xLTEtNzc2ODU_9bd2564d-9556-42b7-9ddd-c7e411324660">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a47bfd8cfda47409c0410907da54f68_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEtNy0xLTEtNzc2ODU_cc6d8788-0ef3-409e-81ad-5f01ae2c601e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66a738c1e19d441f908f46dd78470217_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEtOS0xLTEtNzc2ODU_22c3d4de-ad57-4014-bc02-98e5149a29c8">35,883</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if27b249e1d7e4d108a2f24ec3c67006f_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzItMS0xLTEtNzc2ODU_0f86f5d8-f580-4489-b375-868c02b59221">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc89c3a01e3b4ee9876dc2317f1f1faa_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzItMy0xLTEtNzc2ODU_ff616618-c42d-4519-85a8-5f6812e76b37">1,165,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78eee2afc7d1460ab607760dbad7a025_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzItNS0xLTEtNzc2ODU_3afe44ea-ddcc-4b88-8400-4b27cd43269d">9,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a4eb1b3391f4185a844dba1b8ad1349_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzItNy0xLTEtNzc2ODU_c3583c4d-0ff5-4d26-883c-61fe23e5aeda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzItOS0xLTEtNzc2ODU_a79a132f-623a-4373-8f19-ca44e1a435c1">1,174,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer of interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if27b249e1d7e4d108a2f24ec3c67006f_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestTransfersOfInterests" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzMtMS0xLTEtNzc2ODU_b7384b45-acd8-49ac-bdc0-b0601c514711">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc89c3a01e3b4ee9876dc2317f1f1faa_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestTransfersOfInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzMtMy0xLTEtNzc2ODU_798c4205-35fc-4462-b997-d4553864ab12">1,037,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78eee2afc7d1460ab607760dbad7a025_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestTransfersOfInterests" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzMtNS0xLTEtNzc2ODU_4e54e878-640b-48d8-a50b-89ad90940b41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a4eb1b3391f4185a844dba1b8ad1349_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestTransfersOfInterests" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzMtNy0xLTEtNzc2ODU_7a972a2a-8647-4966-b832-e00b3c68c56d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231" decimals="-3" name="rprx:NoncontrollingInterestTransfersOfInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzMtOS0xLTEtNzc2ODU_f3fe537f-82fa-407f-b855-f1a7eef57e0e">1,037,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if27b249e1d7e4d108a2f24ec3c67006f_D20200101-20201231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzQtMS0xLTEtNzc2ODU_144b5ea1-30cd-43e4-a048-3a2dab28a36d">112,339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc89c3a01e3b4ee9876dc2317f1f1faa_D20200101-20201231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzQtMy0xLTEtNzc2ODU_8cc0d5dd-1cc1-423d-9e2e-3729d22cfdde">594,592</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78eee2afc7d1460ab607760dbad7a025_D20200101-20201231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzQtNS0xLTEtNzc2ODU_54df474d-0548-4a0f-9be4-6c2dca627fb5">85,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a4eb1b3391f4185a844dba1b8ad1349_D20200101-20201231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzQtNy0xLTEtNzc2ODU_1f005d68-8180-4b7f-8192-323719395320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzQtOS0xLTEtNzc2ODU_b76d7bb4-96e2-44b8-8abb-a20ca3006df9">792,357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income prior to IPO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if61940f2e40d400ead5fbf3844bb3dc0_D20200101-20200617" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzUtMS0xLTEtNzc2ODU_406c212d-5519-4584-8904-b1e3b31e525b">42,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3642192137f47c8a326c30a5d6bbb91_D20200101-20200617" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzUtMy0xLTEtNzc2ODU_1a64ebbc-d0eb-4a42-be68-3f581875a327">102,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i737c7ca0fc4741d4908eb966f08f3fa9_D20200101-20200617" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzUtNS0xLTEtNzc2ODU_080cee13-93b3-4213-8262-5b64c45f596f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i882f3c7d9ced490c80ad72c747e61ae9_D20200101-20200617" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzUtNy0xLTEtNzc2ODU_175246a4-5f4f-428a-bcb7-1cf4a6340e66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f06ecc81464fc3ba1731d5296c531a_D20200101-20200617" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzUtOS0xLTEtNzc2ODU_767a728a-08c9-451b-a3bf-d19e221db6ab">145,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if27b249e1d7e4d108a2f24ec3c67006f_D20200101-20201231" decimals="-3" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzYtMS0xLTEtNzc2ODU_1bc1544f-4de3-4746-8c5a-3854c863667e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc89c3a01e3b4ee9876dc2317f1f1faa_D20200101-20201231" decimals="-3" sign="-" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzYtMy0xLTEtNzc2ODU_319d68b0-70f7-4060-8914-b7e861cd2fcc">750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78eee2afc7d1460ab607760dbad7a025_D20200101-20201231" decimals="-3" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzYtNS0xLTEtNzc2ODU_6621da9e-33e7-4fdb-b49a-ea5148183758">2,433,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a4eb1b3391f4185a844dba1b8ad1349_D20200101-20201231" decimals="-3" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzYtNy0xLTEtNzc2ODU_fb7efa72-e9d0-40ef-9efb-7dab99bbcf76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231" decimals="-3" name="rprx:StockholdersEquityValueEffectOfExchangeAndReallocation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzYtOS0xLTEtNzc2ODU_bcfe5adf-a142-42da-85a9-5bffbe73c633">2,433,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Class A ordinary shares sold in IPO, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if27b249e1d7e4d108a2f24ec3c67006f_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzctMS0xLTEtNzc2ODU_38a26238-cf45-465f-a241-c6d73526669b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc89c3a01e3b4ee9876dc2317f1f1faa_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzctMy0xLTEtNzc2ODU_a9ebedd4-d890-4401-ad68-a7d0ca7ac256">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78eee2afc7d1460ab607760dbad7a025_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzctNS0xLTEtNzc2ODU_f6b123d9-33e8-4dcd-8600-a6c599abd435">758,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a4eb1b3391f4185a844dba1b8ad1349_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzctNy0xLTEtNzc2ODU_c6638122-dd9f-4654-a2b6-99704b609a42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzctOS0xLTEtNzc2ODU_a599ba89-87af-48d3-a95e-63bf368298e5">758,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if27b249e1d7e4d108a2f24ec3c67006f_D20200101-20201231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzgtMS0xLTEtNzc2ODU_febaf2f5-fb38-472b-a01e-8005becffb3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc89c3a01e3b4ee9876dc2317f1f1faa_D20200101-20201231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzgtMy0xLTEtNzc2ODU_4d6871ce-2902-4413-935b-e494d68a7be5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78eee2afc7d1460ab607760dbad7a025_D20200101-20201231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzgtNS0xLTEtNzc2ODU_cec25680-beeb-4ed0-8b30-7c2c25639986">309,566</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a4eb1b3391f4185a844dba1b8ad1349_D20200101-20201231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzgtNy0xLTEtNzc2ODU_65fe8ca3-1ed6-4b4a-ab3b-32949094c97b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzgtOS0xLTEtNzc2ODU_1eb3ddf9-7b3f-4c00-a808-06a37e1146e9">309,566</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income subsequent to IPO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c5760f9e15d4ad292c0f7ae423767a7_D20200618-20200930" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzktMS0xLTEtNzc2ODU_ad928195-3c59-4db0-a1b7-3a8383a3aaad">46,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc1471d809d64fbb9f020dbcf89a38cc_D20200618-20200930" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzktMy0xLTEtNzc2ODU_84d0d71c-ae06-4dcf-bae9-c703135646ad">218,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f82fba017484ebc85a41aa90b9dc063_D20200618-20200930" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzktNS0xLTEtNzc2ODU_f3c5dc20-fcc7-44c1-b01c-29bcdf390bca">316,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2d9b4e5e10d4c36a707ba0f30bd0fc7_D20200618-20200930" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzktNy0xLTEtNzc2ODU_f0850633-6243-422c-be06-cbab30826fa5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie11ab38cff9248ce8459b4a78a07f67c_D20200618-20200930" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzktOS0xLTEtNzc2ODU_035e3e51-084d-42d3-9cb5-00b41f867aaf">581,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if27b249e1d7e4d108a2f24ec3c67006f_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzExLTEtMS0xLTc3Njg1_a33085b3-40bd-487c-a34b-83ed71cf7a3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc89c3a01e3b4ee9876dc2317f1f1faa_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzExLTMtMS0xLTc3Njg1_b927edd6-f72f-4e8f-867f-66999966ff1b">15,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78eee2afc7d1460ab607760dbad7a025_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzExLTUtMS0xLTc3Njg1_863b5985-57f7-455d-8535-507c62beea62">7,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a4eb1b3391f4185a844dba1b8ad1349_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzExLTctMS0xLTc3Njg1_57c84c6f-e91f-4ef2-b19e-97bbc6ac1e70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzExLTktMS0xLTc3Njg1_618f21f2-c3c2-4341-9805-08d517a107d4">22,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized losses on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if27b249e1d7e4d108a2f24ec3c67006f_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEyLTEtMS0xLTc3Njg1_723865fa-368d-4381-b8d8-1e6327bf00f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc89c3a01e3b4ee9876dc2317f1f1faa_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEyLTMtMS0xLTc3Njg1_6e2679b3-b95e-459d-b79d-848e05d5354d">3,612</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78eee2afc7d1460ab607760dbad7a025_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEyLTUtMS0xLTc3Njg1_e8eebffa-35cb-4198-91e7-690e54970244">6,018</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a4eb1b3391f4185a844dba1b8ad1349_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEyLTctMS0xLTc3Njg1_b85b4d02-3e37-4449-b0c3-c9664f42ec8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEyLTktMS0xLTc3Njg1_039fd8e6-067a-4607-a810-2042d5c0b738">9,630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdbce45f889b42cb99f32b9a959ebb1b_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEzLTEtMS0xLTc3Njg1_dbfec274-3956-41bb-b331-dd8ed6c46fa1">12,436</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0317f1e1eed4aecbd740d3419ac7fd7_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEzLTMtMS0xLTc3Njg1_670c4652-ed1b-48ee-9e0c-b37927e13cb2">1,939,509</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie11804f07d7c4f1ebc7cfa8b439e5803_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEzLTUtMS0xLTc3Njg1_4ff59354-ca60-4b7f-855c-01adaa7bf8a2">3,125,091</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbe6045b78dd46d38b235d59ba1967c1_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEzLTctMS0xLTc3Njg1_ec4c889e-b640-4a36-9030-7457e899bb51">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a4c8ddad1f14b6b87799e8a6512c515_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEzLTktMS0xLTc3Njg1_13144793-3743-43d3-812a-c9b4e6e20987">5,077,036</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;Related to the Continuing Investors Partnerships&#8217; ownership of approximately <ix:nonFraction unitRef="number" contextRef="ie3fe08cf37364580ab8e966ac247b010_I20201231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzU0OTc1NTgxNTQ1Njk_a52c6a37-288a-4fdd-9b49-d2dd3697691b">36</ix:nonFraction>% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2020. Royalty Pharma plc owns the remaining <ix:nonFraction unitRef="number" contextRef="i88b0d9786c874e6f8a16be78aef6d637_I20201231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzU0OTc1NTgxNTQ2OTg_99adeca7-45e0-40df-abec-09b49f5753d7">64</ix:nonFraction>% of RP Holdings through its ownership of RP Holdings Class A Interests and Class B Interests as of December 31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:32.479%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.481%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdbce45f889b42cb99f32b9a959ebb1b_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzEtMS0xLTEtMA_c762c1b6-1bae-4b88-bd69-b5034dcf3d66">12,436</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0317f1e1eed4aecbd740d3419ac7fd7_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzEtMy0xLTEtMA_5f843c0c-529f-4f4b-a868-6e42922350cb">1,939,509</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie11804f07d7c4f1ebc7cfa8b439e5803_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzEtNS0xLTEtMA_3b3bb020-d872-4a31-b884-b0ae8608ed01">3,125,091</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbe6045b78dd46d38b235d59ba1967c1_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzEtNy0xLTEtMA_01689969-88f3-4f74-a162-fe3e195cc935">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a4c8ddad1f14b6b87799e8a6512c515_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzEtOS0xLTEtMA_5936fa1d-e5ef-4777-9e32-532fa303d1e9">5,077,036</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8496598191ee444d9545f8252ee00014_D20210101-20211231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzItMS0xLTEtMA_0bf19dbd-b99d-40f4-9249-16bddc15c923">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8ada1253ef445f9cf1d4b92a7a6385_D20210101-20211231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzItMy0xLTEtMA_904a363f-e3ae-4a79-8883-33ac14ed396c">35,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if195a301ef504b6faade4870a19f4275_D20210101-20211231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzItNS0xLTEtMA_6ccec034-07c4-4f95-b05d-f21e9acc9ba1">13,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bac599d33534baa86881a2afa9afcc0_D20210101-20211231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzItNy0xLTEtMA_4b216385-f45b-414e-bad6-ff44de2e5a5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231" decimals="-3" name="rprx:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzItOS0xLTEtMA_f7a33a57-1fc1-4b2c-b713-559cf213a198">48,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8496598191ee444d9545f8252ee00014_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzMtMS0xLTEtMA_a1034c1f-44be-4169-bce0-146dd964c0fd">56,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d8ada1253ef445f9cf1d4b92a7a6385_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzMtMy0xLTEtMA_19c7c040-d972-40de-9f2e-e0f988dddeda">425,050</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if195a301ef504b6faade4870a19f4275_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzMtNS0xLTEtMA_f696be64-eb7d-43a8-9e0d-6f9197f8fccc">133,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bac599d33534baa86881a2afa9afcc0_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzMtNy0xLTEtMA_7370c769-2230-4be5-93a6-64951cad479a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzMtOS0xLTEtMA_2f8a3537-3fab-47c1-a369-3de350335cf9">614,973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8496598191ee444d9545f8252ee00014_D20210101-20211231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzQtMS0xLTEtMA_c82ac8e2-0482-4032-aa39-e1659cc11ca3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8ada1253ef445f9cf1d4b92a7a6385_D20210101-20211231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzQtMy0xLTEtMA_545d89bd-2a30-4409-aed7-20c74cfef9ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if195a301ef504b6faade4870a19f4275_D20210101-20211231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzQtNS0xLTEtMA_7f9c09dd-ed85-4563-88cc-1a63b50a9934">642,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bac599d33534baa86881a2afa9afcc0_D20210101-20211231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzQtNy0xLTEtMA_40a54fa7-c56e-430d-b98b-4b98416e2640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231" decimals="-3" name="us-gaap:StockholdersEquityOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzQtOS0xLTEtMA_aa3e5bbf-5065-4e2c-bf03-e116670b7352">642,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8496598191ee444d9545f8252ee00014_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzUtMS0xLTEtMA_b989f3ad-627d-44bd-826a-3e045cc3ac77">57,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8ada1253ef445f9cf1d4b92a7a6385_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzUtMy0xLTEtMA_53a4d704-3ea0-412d-92bf-6109e3d1e4d7">266,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if195a301ef504b6faade4870a19f4275_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzUtNS0xLTEtMA_01391fc4-e347-4766-ae44-280408103474">297,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bac599d33534baa86881a2afa9afcc0_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzUtNy0xLTEtMA_8987d8b4-76fa-4898-83fd-86d30b754248">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzUtOS0xLTEtMA_8b92aebe-a36e-4705-af54-dbfb836b615d">621,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8496598191ee444d9545f8252ee00014_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzctMS0xLTEtMA_bc878abf-d321-42ad-9c60-8666f9ee4c65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8ada1253ef445f9cf1d4b92a7a6385_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzctMy0xLTEtMA_8ec380f8-7b30-4794-8e74-d71cc1fdf714">2,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if195a301ef504b6faade4870a19f4275_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzctNS0xLTEtMA_1c461458-9779-49d7-b6dc-b3100d91fe4d">3,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bac599d33534baa86881a2afa9afcc0_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzctNy0xLTEtMA_a4eaa0a3-64e7-472f-a9df-fde102123b04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzctOS0xLTEtMA_4e9b1ea0-de7f-49e9-a34c-8186ebdb7419">5,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized losses on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8496598191ee444d9545f8252ee00014_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzgtMS0xLTEtMA_bce73554-2bcc-4607-a0a9-bad2f081ab1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d8ada1253ef445f9cf1d4b92a7a6385_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzgtMy0xLTEtMA_8dce52e0-46c6-4c29-9c55-e6dce512b625">8,946</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if195a301ef504b6faade4870a19f4275_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzgtNS0xLTEtMA_bfa2eeb1-4f45-43d9-abb4-adeb6b8a0eb3">13,469</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bac599d33534baa86881a2afa9afcc0_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzgtNy0xLTEtMA_ce3de4b7-edd7-41d0-bdf6-7ce9555ce88e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzgtOS0xLTEtMA_638ab67e-dfe0-4f5a-85e4-4f4548cd7863">22,415</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79703258b5994db9b9b004b77c7e1c58_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzEzLTEtMS0xLTA_bdbb04db-3cb7-4748-b0bc-f03507c57de3">13,528</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b9c1b4135444d46968e0d3445750ae7_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzEzLTMtMS0xLTA_96b1fb46-ffd7-40a6-a565-c47bbf2a3f46">1,809,269</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3166f885d1dd43e7ad16fe6b65c05bc0_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzEzLTUtMS0xLTA_fa19dd72-bab9-4d41-a35f-c7e4546160f4">2,649,154</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90964cc296394e8cbcf965379f0538cd_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzEzLTctMS0xLTA_b4090aa5-e0f3-4b8b-8cce-0db21af079ee">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03b5b882444a44ad9e231eaa7b05228b_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzEzLTktMS0xLTA_c7ee470c-d0f4-4626-b7d4-03d10a643625">4,471,951</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;Related to the Continuing Investors Partnerships&#8217; ownership of approximately <ix:nonFraction unitRef="number" contextRef="i6e7e9177eb1b4c9da6650b9f74990c36_I20211231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzQ5NDc4MDIzMzY5ODQ_ee2974d8-b42d-456b-8354-7c56154c6cc2">29</ix:nonFraction>% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2021. Royalty Pharma plc owns the remaining <ix:nonFraction unitRef="number" contextRef="ifbdd368fbe3941059a474c997b396f0a_I20211231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzQ5NDc4MDIzMzY5ODk_8e853ac0-8b32-4277-86be-f9c890a8b9fa">71</ix:nonFraction>% of RP Holdings through its ownership of RP Holdings Class A Interests  and Class B Interests as of December 31, 2021.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i44f260189be1411caad63adfe06d6636" continuedAt="ibd08643e55364e3b8b0f6a982ec0f3dd"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">RP Holdings Class C Special Interest held by EPA Holdings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EPA Holdings is entitled to Equity Performance Awards (as defined below) through its RP Holdings Class C Special Interest based on our performance, as determined on a portfolio-by-portfolio basis. Investments made during each two-year period will be grouped together as separate portfolios (each, a &#8220;Portfolio&#8221;). Subject to certain conditions, at the end of each fiscal quarter, EPA Holdings is entitled to a distribution from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the &#8220;Equity Performance Awards&#8221;). The Equity Performance Awards will be allocated and paid by RP Holdings to EPA Holdings as the holder of the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests for which we will issue the same number of Class B ordinary shares, which may be subsequently exchanged for our Class A ordinary shares. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently expect any material Equity Performance Awards to be payable until the performance conditions discussed above are met.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of Class A ordinary shares are entitled to receive dividends subject to approval by the board of directors. The holders of Class B ordinary shares do not have any rights to receive dividends; however the RP Holdings Class B Interests are entitled to dividends and distributions from RP Holdings, our consolidated subsidiary. In the year ended December 31, 2021, we declared and paid four quarterly cash dividends of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie53671576bce41518be8f910184feaec_D20210101-20210331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzEwOTk1MTE2MzgwMzM_8269d8c2-c9a4-4d1c-8375-acfe4263f3f8"><ix:nonFraction unitRef="usdPerShare" contextRef="i4cc52872c2794894927c82c640746a99_D20210401-20210630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzEwOTk1MTE2MzgwMzM_ab034488-ef0c-4828-b5b6-bd751540a147"><ix:nonFraction unitRef="usdPerShare" contextRef="i08c8a6f2c3554638b8b9e8e94b41d3ab_D20211001-20211231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzEwOTk1MTE2MzgwMzM_c96b7b62-e67d-4d5f-b282-f59b92505497"><ix:nonFraction unitRef="usdPerShare" contextRef="ic3af896a7f0c42529577ce561a976e90_D20210701-20210930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzEwOTk1MTE2MzgwMzM_d45971ea-f861-45da-84c0-ac6f1e4b8690">0.17</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> per Class A ordinary share for an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-5" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzEwOTk1MTE2MzgxNDQ_f424c00a-a56a-42a6-a1d9-4ad9077cae99">285.2</ix:nonFraction>&#160;million to holders</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our Class A ordinary shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Independent Directors Equity Incentive Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2020, our 2020 Independent Director Equity Incentive Plan was approved and became effective, whereby <ix:nonFraction unitRef="shares" contextRef="ib32135ef98664a82a742199b45769f54_I20200615" decimals="INF" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzQ3MTk_1b3c6976-8946-4846-b7af-25a43833af64">800</ix:nonFraction> thousand Class A ordinary shares have been reserved for future issuance to our independent directors. As of December 31, 2021, approximately <ix:nonFraction unitRef="shares" contextRef="i9506994fe6124fe08c513652cc6fdd3c_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzYwNDczMTM5Njk2NTA_c0064f57-68ad-4678-b163-cdb4c9147bd2">620</ix:nonFraction>&#160;thousand shares remain reserved for future issuance under the Equity Incentive Plan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSU activity and share-based compensation</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant RSUs to our independent directors under the 2020 Independent Director Equity Incentive Plan. Share-based compensation expense is recognized based on estimated fair value of the award on the grant date and amortized on a straight-line basis over the requisite service period of generally <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzI5Njg2ODEzOTYzOTMw_78330c70-e106-4321-9dbb-676730393dbd">one year</ix:nonNumeric> as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statement of comprehensive income. The estimated fair value of RSUs is based on the closing price of our Class A ordinary shares on the grant date.</span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><ix:continuation id="ibd08643e55364e3b8b0f6a982ec0f3dd" continuedAt="i99d5b3ada2994bdebcf36358b5241861"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized share-based compensation of approximately $<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzEwOTk1MTE2MzgxNTM_4231a368-2f66-4dd4-80f9-6288be7fba16">3.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzEwOTk1MTE2NDIzNDc_cecada3b-7d14-493e-904c-6d2d1f701c1c">5.7</ix:nonFraction>&#160;million for the years ended December 31, 2021 and 2020, which is recorded as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i99d5b3ada2994bdebcf36358b5241861"> in the consolidated statement of operations. There were <ix:nonFraction unitRef="usd" contextRef="i7594b0b1464b4340a377c43cf71ef3c9_D20200101-20200617" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzEwOTk1MTE2Mzc2NjQ_ec5a2813-4fe8-4532-a224-eae596f9ab23">no</ix:nonFraction> share-based awards or related expenses in periods prior to the IPO. As of December 31, 2021, the total unrecognized share-based compensation expense related to total outstanding RSUs was less than $<ix:nonFraction unitRef="usd" contextRef="i941486f8afa342d49e11f69d4af24754_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzU4MzY_c3bbdb47-bc46-422e-a4d1-bb0bd14aa736">1.0</ix:nonFraction>&#160;million, which we expect to recognize in the next <ix:nonNumeric contextRef="iadabb8c442dd4ffcbc66a71a0fe7341b_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzU4ODE_84757fa1-1d8f-4873-ad14-e4ee6a896be4">six months</ix:nonNumeric>.</ix:continuation> </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_154"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90ZXh0cmVnaW9uOjZmYTQ4Y2ViYjhkYTRkZTU4OGJiNzIyYzI1ODFhMzJmXzI4NzM_33347339-8e19-44cd-b249-95fea340f755" continuedAt="i34a9f066dfbb4f45b37384142615a1eb" escape="true">Earnings per Share</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i34a9f066dfbb4f45b37384142615a1eb" continuedAt="i35db3355c4c84b52b2481c735e7dacdb">Basic earnings per share (&#8220;EPS&#8221;) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to us, including the impact of potentially dilutive securities, by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include the outstanding Class B ordinary shares, Class B ordinary shares contingently issuable to EPA Holdings related to Equity Performance Awards, and unvested RSUs issued under our Equity Incentive Plan. We use the &#8220;if-converted&#8221; method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs.</ix:continuation></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i35db3355c4c84b52b2481c735e7dacdb"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Class B ordinary shares, Class R redeemable shares, and deferred shares do not share in the earnings or losses attributable to us and are therefore not participating securities. As such, separate presentation of basic and diluted earnings per share for Class B ordinary shares, Class R redeemable shares, and deferred shares under the two-class method has not been presented. Our Class B ordinary shares are, however, considered potentially dilutive shares of Class A ordinary shares because shares of Class B ordinary shares, together with the related RP Holdings Class B Interests, are exchangeable into Class A ordinary shares on a <ix:nonFraction unitRef="number" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="INF" name="rprx:CommonStockExchangeRatio" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90ZXh0cmVnaW9uOjZmYTQ4Y2ViYjhkYTRkZTU4OGJiNzIyYzI1ODFhMzJmXzE0MjkzNjUxMTc2MDY4_ac188599-83a4-44a6-b8ab-8bb5cfd7703f">one</ix:nonFraction>-for-one basis. For the years ended December 31, 2021 and 2020, Class B ordinary shares contingently issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact. Additionally, Class B ordinary shares in issue were evaluated under the if-converted method for potential dilutive effects and were determined to be anti-dilutive for the years ended December 31, 2021 and 2020, and therefore were excluded from the computation of diluted earnings per shares of Class A ordinary share. As of December 31, 2021 and 2020, we had <ix:nonFraction unitRef="shares" contextRef="ia9eca6903b754336ab978b1c6859dbee_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90ZXh0cmVnaW9uOjZmYTQ4Y2ViYjhkYTRkZTU4OGJiNzIyYzI1ODFhMzJmXzQ5NDc4MDIzMzk5NTI_000bd3c3-f874-4ee8-b99b-1f43565b43f5">607,176</ix:nonFraction>&#160;thousand and <ix:nonFraction unitRef="shares" contextRef="i1da7232b999b4b67b6bf844dd97d818a_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90ZXh0cmVnaW9uOjZmYTQ4Y2ViYjhkYTRkZTU4OGJiNzIyYzI1ODFhMzJmXzIxOTkwMjMyNzAzODI_739c7f25-5327-4fd9-8e4b-e1bb831d6669">607,111</ix:nonFraction>&#160;thousand fully diluted Class A ordinary shares outstanding, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90ZXh0cmVnaW9uOjZmYTQ4Y2ViYjhkYTRkZTU4OGJiNzIyYzI1ODFhMzJmXzI4NzE_cee13f84-2e9e-46df-9112-d56b3847c5e8" continuedAt="i19297ce96a5e41b18dd2a341df0a78ad" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings per Class A ordinary share for the year ended December 31, 2021 (in thousands, except per share amounts).</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.870%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZTo2MWJmOTNiNTM0ZGY0NjNhYTMyMzVmNTE0ZjFlYTYwZC90YWJsZXJhbmdlOjYxYmY5M2I1MzRkZjQ2M2FhMzIzNWY1MTRmMWVhNjBkXzItMi0xLTEtMA_edef1784-677f-47f2-b8b5-cbed3d009267">1,241,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i850c4112163e4a4da3d1fd1aa181af6c_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZTo2MWJmOTNiNTM0ZGY0NjNhYTMyMzVmNTE0ZjFlYTYwZC90YWJsZXJhbmdlOjYxYmY5M2I1MzRkZjQ2M2FhMzIzNWY1MTRmMWVhNjBkXzMtMi0xLTEtMA_3268093f-dc8e-4395-83db-17de43964739">297,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Legacy Investors Partnerships and RPSFT</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63532b6df7f947d8b3cff39df953d6f5_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZTo2MWJmOTNiNTM0ZGY0NjNhYTMyMzVmNTE0ZjFlYTYwZC90YWJsZXJhbmdlOjYxYmY5M2I1MzRkZjQ2M2FhMzIzNWY1MTRmMWVhNjBkXzQtMi0xLTEtMA_6a090e72-b05b-41e4-97d5-8cbe52953b01">324,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZTo2MWJmOTNiNTM0ZGY0NjNhYTMyMzVmNTE0ZjFlYTYwZC90YWJsZXJhbmdlOjYxYmY5M2I1MzRkZjQ2M2FhMzIzNWY1MTRmMWVhNjBkXzUtMi0xLTEtMA_1e93aada-34c2-49a1-ad68-2c2367ed328d"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZTo2MWJmOTNiNTM0ZGY0NjNhYTMyMzVmNTE0ZjFlYTYwZC90YWJsZXJhbmdlOjYxYmY5M2I1MzRkZjQ2M2FhMzIzNWY1MTRmMWVhNjBkXzUtMi0xLTEtMA_b2803f86-019f-464f-81c6-6a60d2fc7b60">619,728</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZTo2MWJmOTNiNTM0ZGY0NjNhYTMyMzVmNTE0ZjFlYTYwZC90YWJsZXJhbmdlOjYxYmY5M2I1MzRkZjQ2M2FhMzIzNWY1MTRmMWVhNjBkXzEwLTItMS0xLTA_731a78b7-15f6-4103-a6ce-d066890d40fa">414,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Dilutive effect&#160;of unvested RSUs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZTo2MWJmOTNiNTM0ZGY0NjNhYTMyMzVmNTE0ZjFlYTYwZC90YWJsZXJhbmdlOjYxYmY5M2I1MzRkZjQ2M2FhMzIzNWY1MTRmMWVhNjBkXzEzLTItMS0xLTA_064311b4-b7e7-458e-ab94-f0f8e60d75ca">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZTo2MWJmOTNiNTM0ZGY0NjNhYTMyMzVmNTE0ZjFlYTYwZC90YWJsZXJhbmdlOjYxYmY5M2I1MzRkZjQ2M2FhMzIzNWY1MTRmMWVhNjBkXzE0LTItMS0xLTA_fa042ef0-64ed-45f2-8a5d-30b611768540">414,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZTo2MWJmOTNiNTM0ZGY0NjNhYTMyMzVmNTE0ZjFlYTYwZC90YWJsZXJhbmdlOjYxYmY5M2I1MzRkZjQ2M2FhMzIzNWY1MTRmMWVhNjBkXzE2LTItMS0xLTA_f4bd3222-4655-426d-819d-d2e0288ec686">1.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZTo2MWJmOTNiNTM0ZGY0NjNhYTMyMzVmNTE0ZjFlYTYwZC90YWJsZXJhbmdlOjYxYmY5M2I1MzRkZjQ2M2FhMzIzNWY1MTRmMWVhNjBkXzE3LTItMS0xLTA_d14127d7-0451-46d8-b1dc-c59fb1a14dc7">1.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prior to the IPO, our capital structure mainly included unitholder interests. We analyzed the calculation of earnings per interest for periods prior to the IPO and determined that the resultant values would not be meaningful to the users of these consolidated financial statements. Therefore, the basic and diluted earnings per share for the year ended December 31, 2020 are only applicable for the period from June 16, 2020 to December 31, 2020, which represents the period in which we had outstanding Class A ordinary shares. <ix:continuation id="i19297ce96a5e41b18dd2a341df0a78ad" continuedAt="ifeac4081161c4a04ad26d033646bea4a">The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings per Class A ordinary share for the year ended December 31, 2020 (in thousands, except per share amounts).</ix:continuation></span></div><div><ix:continuation id="ifeac4081161c4a04ad26d033646bea4a" continuedAt="i6145e87e1c0f4153ade169c4e85995f3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZToyOGZjNGIxYWRkZDg0OTZkYWNlMDZhZjYwNjEyNzI0NC90YWJsZXJhbmdlOjI4ZmM0YjFhZGRkODQ5NmRhY2UwNmFmNjA2MTI3MjQ0XzEtMi0xLTEtNDQ4MzE_626a1599-1421-4450-a762-9e05b12efb84">1,701,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships prior to the IPO (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:NetIncomeLossAttributableToParentPriorToOffering" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZToyOGZjNGIxYWRkZDg0OTZkYWNlMDZhZjYwNjEyNzI0NC90YWJsZXJhbmdlOjI4ZmM0YjFhZGRkODQ5NmRhY2UwNmFmNjA2MTI3MjQ0XzItMi0xLTEtNDQ4MzE_be13cda0-1e8f-4a37-9059-4354a81107ec">479,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships subsequent to the IPO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a17c53123fa4e12b0b8749ed24171a4_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZToyOGZjNGIxYWRkZDg0OTZkYWNlMDZhZjYwNjEyNzI0NC90YWJsZXJhbmdlOjI4ZmM0YjFhZGRkODQ5NmRhY2UwNmFmNjA2MTI3MjQ0XzMtMi0xLTEtNDQ4MzE_dae5aee9-49d1-4b08-9519-9003faf6dd14">316,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Legacy Investors Partnerships and RPSFT</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07a6da6cb1b14ad78d9d0a893435f6a3_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZToyOGZjNGIxYWRkZDg0OTZkYWNlMDZhZjYwNjEyNzI0NC90YWJsZXJhbmdlOjI4ZmM0YjFhZGRkODQ5NmRhY2UwNmFmNjA2MTI3MjQ0XzQtMi0xLTEtNDQ4MzE_62192ea0-5678-4235-b944-faabc7607ca8">409,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZToyOGZjNGIxYWRkZDg0OTZkYWNlMDZhZjYwNjEyNzI0NC90YWJsZXJhbmdlOjI4ZmM0YjFhZGRkODQ5NmRhY2UwNmFmNjA2MTI3MjQ0XzUtMi0xLTEtNDQ4MzE_1698c43b-ee07-43cb-8cb5-2ad5e932a053"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZToyOGZjNGIxYWRkZDg0OTZkYWNlMDZhZjYwNjEyNzI0NC90YWJsZXJhbmdlOjI4ZmM0YjFhZGRkODQ5NmRhY2UwNmFmNjA2MTI3MjQ0XzUtMi0xLTEtNDQ4MzE_2572e0ae-328b-43c1-b005-f76ab5ffa008">495,198</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZToyOGZjNGIxYWRkZDg0OTZkYWNlMDZhZjYwNjEyNzI0NC90YWJsZXJhbmdlOjI4ZmM0YjFhZGRkODQ5NmRhY2UwNmFmNjA2MTI3MjQ0XzgtMi0xLTEtNDQ4MzE_fd5ae259-b910-447a-97ea-47d2dd7dfd2d">375,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Dilutive effect&#160;of unvested RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZToyOGZjNGIxYWRkZDg0OTZkYWNlMDZhZjYwNjEyNzI0NC90YWJsZXJhbmdlOjI4ZmM0YjFhZGRkODQ5NmRhY2UwNmFmNjA2MTI3MjQ0XzktMi0xLTEtNDQ4MzE_a150c3c9-9067-4dba-9780-58dfe9ebead8">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares&#160;outstanding - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZToyOGZjNGIxYWRkZDg0OTZkYWNlMDZhZjYwNjEyNzI0NC90YWJsZXJhbmdlOjI4ZmM0YjFhZGRkODQ5NmRhY2UwNmFmNjA2MTI3MjQ0XzEwLTItMS0xLTQ0ODMx_69cd6970-d2e8-4341-ae53-4eea353cb7a3">375,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZToyOGZjNGIxYWRkZDg0OTZkYWNlMDZhZjYwNjEyNzI0NC90YWJsZXJhbmdlOjI4ZmM0YjFhZGRkODQ5NmRhY2UwNmFmNjA2MTI3MjQ0XzEyLTItMS0xLTQ0ODMx_b88fed70-d894-49be-a12e-524b51b55087">1.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZToyOGZjNGIxYWRkZDg0OTZkYWNlMDZhZjYwNjEyNzI0NC90YWJsZXJhbmdlOjI4ZmM0YjFhZGRkODQ5NmRhY2UwNmFmNjA2MTI3MjQ0XzEzLTItMS0xLTQ0ODM5_bc409532-25c1-4d2d-b336-95f371bd5cd1">1.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><ix:continuation id="i6145e87e1c0f4153ade169c4e85995f3" continuedAt="i9fc3ba773e9148c3a8188901aee67283"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1) &#160;&#160;&#160;&#160;Reflected as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Net income attributable to controlling interest </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:continuation id="i9fc3ba773e9148c3a8188901aee67283">on the consolidated statements of operations</ix:continuation>.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><div id="i15fafc99ab5c41deb08ee816ca47172c_157"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90ZXh0cmVnaW9uOjljNzMyNjk0NTVkMTQ3OWNiN2Q5NGE0YWQ2MDI3YTNiXzI0Nw_6c34cd4f-b421-49bd-a066-e5ab81a46434" continuedAt="i6e17e844b9ff4cef8d5e1ff77d1bf848" escape="true">Indirect Cash Flow</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i6e17e844b9ff4cef8d5e1ff77d1bf848"><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90ZXh0cmVnaW9uOjljNzMyNjk0NTVkMTQ3OWNiN2Q5NGE0YWQ2MDI3YTNiXzI0OQ_3a298950-4a9f-4b86-b757-34e7ca4b49d2" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzMtMS0xLTEtMA_126930c5-7db9-492a-ad2f-24b6b9344f2c">1,241,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzMtMy0xLTEtMA_07e8ea0e-810e-49ef-a20d-5ff1b828e219">1,701,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzMtNS0xLTEtMA_704d4874-f6d1-412d-b686-ff2c4d1db9be">2,461,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile consolidated net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:IncreaseDecreaseInFinancialRoyaltyAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzUtMS0xLTEtMA_df8bf917-55d5-4c3b-8884-ce4b4e49c7bf">2,065,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:IncreaseDecreaseInFinancialRoyaltyAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzUtMy0xLTEtMA_bdacf592-a349-4e23-8a9f-5b1bc95c533a">1,959,975</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:IncreaseDecreaseInFinancialRoyaltyAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzUtNS0xLTEtMA_7c4be487-2529-4fcd-9081-36214a826db6">1,648,837</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:ProvisionForLoanAndLeaseLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzYtMS0xLTEtMA_37b46cc9-f4d2-4e3c-86c3-7d9b6c361464">452,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:ProvisionForLoanAndLeaseLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzYtMy0xLTEtMA_46767c4a-4471-463a-b08d-21a78c67a422">230,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ProvisionForLoanAndLeaseLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzYtNS0xLTEtMA_43851c5d-a905-4312-a9e9-1d82efc3db81">1,019,321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzctMS0xLTEtMA_c95c7686-8043-4252-9d37-836045d3d68b">22,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzctMy0xLTEtMA_e9d31102-d9e2-445c-9b71-f0fb408c90c0">23,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzctNS0xLTEtMA_15b7c81c-5069-40c5-b39a-e226a5ad8384">23,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzgtMS0xLTEtMA_c18e867f-3e82-448a-8020-eaeeffc61644">20,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzgtMy0xLTEtMA_592646f6-79b3-4ed7-9b06-f5bb3468ee9f">11,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzgtNS0xLTEtMA_4fd654a4-b4ed-4d07-8952-63f0111780ca">12,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzEwLTEtMS0xLTA_1759edbd-5e1c-4938-b421-790942095583">21,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzEwLTMtMS0xLTA_a15d1ba5-6393-4971-9bc2-5ade65360aa4">42,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzEwLTUtMS0xLTA_04eaa998-53c8-4602-a61a-7baf142cb81c">39,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses/(gains) on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzExLTEtMS0xLTA_cafaec6f-1648-486f-b2e3-f52a716fd071">48,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzExLTMtMS0xLTA_e21a8288-67a9-4dd7-aad7-215d360de070">247,073</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzExLTUtMS0xLTA_42963be8-5a11-4727-a9d0-5806e640b757">155,749</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in losses/(earnings) of non-consolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzEyLTEtMS0xLTA_4e8d8a4d-c8e4-46e6-835e-76f47de42e97">19,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzEyLTMtMS0xLTA_14e13a41-f311-47e1-8c51-87574fcdcb9f">44,459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzEyLTUtMS0xLTA_eea9446b-2dc3-49e8-9b5f-2542761a9188">32,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions from non-consolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzE1LTEtMS0xLTA_c3f72659-78e7-4437-965e-c30f9fb573d2">34,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzE1LTMtMS0xLTA_b7920a1b-9f73-4cfa-89f3-c7952e31c15d">42,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzE1LTUtMS0xLTA_77d3d4a4-efd0-474c-8454-489eb7e5e041">14,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzE3LTEtMS0xLTA_8faffe66-e374-4203-8562-f79a5ffadfec">358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzE3LTMtMS0xLTA_4f939659-68b6-40df-b458-75363c32a806">30,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzE3LTUtMS0xLTA_948d539d-1f45-48d0-b89d-4dc143bfc6b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzE5LTEtMS0xLTA_e1027d9f-418a-424f-bd89-f0dae8a01b84">2,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzE5LTMtMS0xLTA_848b6b05-a6ea-4588-9bf8-1bab5d5c19f8">5,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzE5LTUtMS0xLTA_020c26c7-733f-4582-a3da-fdd8cf2bd0b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzIwLTEtMS0xLTA_6c8c7c28-f4e6-4dd0-bc10-45def8e2c02e">50,896</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzIwLTMtMS0xLTA_03a9359e-a980-40a1-90dd-6c2e90859b2b">20,551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzIwLTUtMS0xLTA_27838375-21b1-492a-9bbb-a90dc2379426">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzIxLTEtMS0xLTA_553d5d22-6bcb-429d-839f-dd7b76a16e54">17,859</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzIxLTMtMS0xLTA_68d1f2d7-bdaf-427a-b38a-eaa13555563e">18,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzIxLTUtMS0xLTA_e13aa453-bd5b-464d-895c-e338726688d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzIyLTEtMS0xLTA_af5d0067-ca98-42a3-ab57-d8ec4e2f395b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzIyLTMtMS0xLTA_1bd4c6be-0b5c-453b-941a-8c117d081b9c">65,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzIyLTUtMS0xLTA_c934cdbc-549b-4648-85e8-9dd49486d424">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination of derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:GainLossOnDerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzIzLTEtMS0xLTA_c5ef718e-3ba8-479b-9edb-6824412a58cc">16,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:GainLossOnDerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzIzLTMtMS0xLTA_df334dfd-d8e0-4d8a-a0c0-c796d9e07d78">34,952</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:GainLossOnDerivativeFinancialInstruments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzIzLTUtMS0xLTA_3495faf4-68e6-4ecf-9936-6ef03fc7aa51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI0LTEtMS0xLTA_4f653c3a-2c73-49a2-a097-257ff217ff71">4,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI0LTMtMS0xLTA_652657ee-8fc9-4f77-b44a-3d0f46f0b08f">9,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI0LTUtMS0xLTA_c8e243fc-12a6-43c1-abe1-b4d45d3593ee">2,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Decrease/(increase) in operating assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collected on financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:IncreaseDecreaseInCashCollectionsOnFinancingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI3LTEtMS0xLTQyMDc1_b5c18e8c-3bb2-40c6-bbae-174d139026ad">2,315,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:IncreaseDecreaseInCashCollectionsOnFinancingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI3LTMtMS0xLTQyMDc1_3bb29d79-a53f-476c-88e2-6f34fbcb1fb0">2,121,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:IncreaseDecreaseInCashCollectionsOnFinancingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI3LTUtMS0xLTQyMDc1_bbe0a444-9fbf-4394-a60d-674adbab4438">1,934,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:IncreaseDecreaseInDebtSecuritiesAvailableForSale" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI3LTEtMS0xLTA_ef32ae62-fbb6-4b36-a45d-c89cf440a121">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:IncreaseDecreaseInDebtSecuritiesAvailableForSale" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI3LTMtMS0xLTA_8ad3c6a3-2e75-4440-8dff-57daa5e910fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:IncreaseDecreaseInDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI3LTUtMS0xLTA_c5e47cff-15e1-4245-8a59-bf60c8a84bb7">150,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued royalty receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:IncreaseDecreaseInAccruedRoyaltyReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI4LTEtMS0xLTA_6fe4381b-45df-45b1-a977-a22b8c0ef002">20,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" sign="-" name="rprx:IncreaseDecreaseInAccruedRoyaltyReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI4LTMtMS0xLTA_62307666-9529-4374-bd8c-bee37af69587">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" sign="-" name="rprx:IncreaseDecreaseInAccruedRoyaltyReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI4LTUtMS0xLTA_559e5db7-34f1-4e61-bede-564bedd76a62">2,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI5LTEtMS0xLTA_508774a3-0028-42d2-935c-4e8d9884df9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI5LTMtMS0xLTA_740e1066-a310-4f2a-b7b2-7942d9d1eac8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI5LTUtMS0xLTA_edffde6b-afdb-4e6b-af1b-91629ed6a453">150,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty income receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:IncreaseDecreaseInOtherRoyaltyIncomeReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzMwLTEtMS0xLTA_dacc2c34-ed13-4c3e-9af0-787513f029be">9,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:IncreaseDecreaseInOtherRoyaltyIncomeReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzMwLTMtMS0xLTA_3cb8915d-88a3-4a3e-b3a7-a07b6ab74800">770</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" sign="-" name="rprx:IncreaseDecreaseInOtherRoyaltyIncomeReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzMwLTUtMS0xLTA_e55aa2db-5a5f-4d89-80a4-230bcd978e3d">7,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzMxLTEtMS0xLTA_8e93fc07-e438-453d-87bc-eccef2c5de9a">1,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzMxLTMtMS0xLTA_961e16d8-e753-4054-ac5e-3c85e2857f55">34,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzMxLTUtMS0xLTA_5171855f-d88e-45b3-889e-f06013343756">41,028</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Decrease)/increase in operating liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzMzLTEtMS0xLTA_616f3a89-11f8-484f-8104-008ff7184a96">4,586</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzMzLTMtMS0xLTA_879186b9-9230-442b-9b46-b4b53fd8e7b6">766</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzMzLTUtMS0xLTA_c07d07d4-bdd0-4b4b-b8c3-6621ade9a775">6,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInInterestPayableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzM0LTEtMS0xLTA_f610ec5e-58f8-485f-9508-557fe80df4f8">15,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInInterestPayableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzM0LTMtMS0xLTA_b106acce-c078-4863-a7e8-66619d429be0">42,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInInterestPayableNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzM0LTUtMS0xLTA_7eb8a64c-02f7-44dd-a9e7-4371f83192cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzM3LTEtMS0xLTA_b3e67197-0cd7-4f8e-aeb7-d1dff4fd31ab">2,017,536</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzM3LTMtMS0xLTA_f25383bc-def2-48bb-9b41-be4d21eaa4c5">2,034,629</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzM3LTUtMS0xLTA_89b07614-5080-4223-b823-4e4d8256d311">1,667,239</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash investing and financing activities are summarized below (in thousands).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.377%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental Schedule of Non-cash Investing/Financing Activities:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receipt of contribution of investment in Legacy Investors Partnerships (Note 9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzItMS0xLTEtMA_bf20635c-f2ad-4b20-bd5e-a285bce703a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzItMy0xLTEtMA_4c63919c-5420-4258-8d21-a902a2116028">303,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzItNS0xLTEtMA_a6707b85-1e24-40d5-af0f-c7fa9d1cb6a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement of Epizyme forward purchase contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:SettlementsWithEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzMtMS0xLTEtMA_e067a322-7312-43da-8c91-0c2b4c64f376">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:SettlementsWithEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzMtMy0xLTEtMA_da38fe85-7b17-4546-849c-3991fde454ce">5,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:SettlementsWithEquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzMtNS0xLTEtMA_875dbd07-dcb1-4c65-860c-d84cb952ea29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued purchase obligation - Tazverik (Note 17)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:AccruedPurchaseObligationEquityInvestment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzQtMS0xLTEtMA_52e7fd93-3ceb-4f59-b9b9-e3d5ee302a78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:AccruedPurchaseObligationEquityInvestment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzQtMy0xLTEtMA_e0e27e17-1c3a-4790-ba95-7b1bfaa1f4d3">110,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:AccruedPurchaseObligationEquityInvestment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzQtNS0xLTEtMA_e2f83106-72e8-4ea3-af6e-8faaaf922066">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayments of long-term debt by contributions from non-controlling interest (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzUtMS0xLTEtMA_7b950188-fb90-4b9c-a304-e9f221700082">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzUtMy0xLTEtMA_8882389d-4fba-466a-815b-dd76939cfaa9">1,103,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzUtNS0xLTEtMA_79c4074e-5f19-4beb-943a-9f81dd634560">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Milestone payable - Erleada (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="rprx:MilestonePaymentAccruedButNotPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzctMS0xLTEtMA_852ad4c2-f8cb-404f-9952-125635724e7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:MilestonePaymentAccruedButNotPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzctMy0xLTEtMA_a1c0be9c-6932-4b4b-8143-64077ed47899">18,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231" decimals="-3" name="rprx:MilestonePaymentAccruedButNotPaid" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzctNS0xLTEtMA_43dfcb0f-30ce-4a3e-9626-c0b0304bb0e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1) Related to the pro rata portion of RPIFT&#8217;s outstanding debt repaid by the Legacy Investors Partnerships.</span></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2) Related to the achievement of a sales-based milestone that was not paid as of December 31, 2020 as recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> on the consolidated balance sheet.</span></div></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><div id="i15fafc99ab5c41deb08ee816ca47172c_163"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90ZXh0cmVnaW9uOjU4ZDlkNjYxYWEzYzQyY2NiZWVlNDYwMThhMjRkOTk3XzEwNDk_3c489225-16f5-4972-a535-6f9afbb2b058" continuedAt="i0e0b11acdfb64ca38d7837e22a22e4c4" escape="true">Accumulated Other Comprehensive Income</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i0e0b11acdfb64ca38d7837e22a22e4c4"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, the only component of accumulated other comprehensive income related to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gains on available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the Series A Biohaven Preferred Shares. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were released into earnings. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90ZXh0cmVnaW9uOjU4ZDlkNjYxYWEzYzQyY2NiZWVlNDYwMThhMjRkOTk3XzEwNDg_32b0ec71-570c-424d-8936-47ac9a96736a" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive income as of December 31, 2021 and 2020 are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.215%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.547%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains on Available for Sale Debt Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Losses on Interest Rate Swaps</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a4d899516f7416083d6a452d72dff94_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzQtMy0xLTEtMA_400a762c-22df-4bc3-a260-b74b31e6dc77">6,159</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16167be66e5642fa8c58da773ea9dd57_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzQtNS0xLTEtMA_9a951075-ccf6-487e-a2a4-74c3574ce630">4,066</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c98f12437f9466181a216b35a41b08f_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzQtNy0xLTEtMA_14a5250f-c031-439d-a070-a069b724a027">2,093</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification to net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i197418bb01ba4a16bc643f9b8299428a_D20200101-20201231" decimals="-3" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzUtMy0xLTEtMA_4656c297-0547-4aeb-ab57-e67d3e5ff100">10,921</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c9719a7e4c49a6888e5a5a55e6a756_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzUtNS0xLTEtMA_29f66461-19e8-43f8-acd7-bf1ad7e446dd">4,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzUtNy0xLTEtMA_1c65948b-6279-4248-a033-8f227baf2a7a">6,855</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Activity for the year</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i197418bb01ba4a16bc643f9b8299428a_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzYtMy0xLTEtMA_9a8f27fa-e6ee-4bcc-86a2-48df46fffa5a">60,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c9719a7e4c49a6888e5a5a55e6a756_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzYtNS0xLTEtMA_c0157ff8-fbd8-4716-ad28-d5677f10a15d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzYtNy0xLTEtMA_3e5d0afa-32c6-47e6-b0b0-a20fc8c63404">60,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification to non-controlling interest</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i197418bb01ba4a16bc643f9b8299428a_D20200101-20201231" decimals="-3" name="rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzctMy0xLTEtMA_601d8b0e-15a2-4ec1-b61e-923ea230daba">24,022</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c9719a7e4c49a6888e5a5a55e6a756_D20200101-20201231" decimals="-3" name="rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzctNS0xLTEtMA_0a35bc1d-4810-4772-bc61-be7198f8e2b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b15a91be9e9493798198e66a8d123b0_D20200101-20201231" decimals="-3" name="rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzctNy0xLTEtMA_aedfb88f-35df-47cf-b331-d91ee076cb2b">24,022</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification from non-controlling interest</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i197418bb01ba4a16bc643f9b8299428a_D20200101-20201231" decimals="-3" name="rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzgtMy0xLTEtMA_727dfc34-6033-468b-a6cc-55706c0aa0ca">2,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c9719a7e4c49a6888e5a5a55e6a756_D20200101-20201231" decimals="-3" name="rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzgtNS0xLTEtMA_c987dd59-feed-41c0-96c4-e47251a6c1c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231" decimals="-3" name="rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzgtNy0xLTEtMA_50a47990-3fdd-44e1-ab9d-68d7523428e1">2,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc74be5e7f2b4443888aa58295087c78_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzktMy0xLTEtMA_6f016819-f88c-4731-9040-42e58bd2741f">34,395</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69d044ffec6446e0896ba4f3dde2181c_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzktNS0xLTEtMA_045c51c9-7aa2-417b-a05f-883575623428">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef6d97fcbd2450783139f7b7ee49dc4_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzktNy0xLTEtMA_cf775fec-de79-4105-941f-6dc4172c0400">34,395</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification to net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29031751451245b7b580c18872827fbb_D20210101-20211231" decimals="-3" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzEwLTMtMS0xLTA_38ce0f91-f849-47cc-b6d3-3fa05d182c7d">28,481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4f46b5e4015492f9d8f108c0637d93f_D20210101-20211231" decimals="-3" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzEwLTUtMS0xLTA_cf402c4a-6241-4ff6-989b-1294c29cb96d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzEwLTctMS0xLTA_08d8ad92-9480-4e0d-be0e-6ccaba86b410">28,481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Activity for the year</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29031751451245b7b580c18872827fbb_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzExLTMtMS0xLTA_5dc8ada9-68ac-4d3d-b3b3-6f41130d73bc">6,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4f46b5e4015492f9d8f108c0637d93f_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzExLTUtMS0xLTA_eafdf055-a0d2-4c67-92d5-e5849acb1d73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzExLTctMS0xLTA_9ba05e38-7e0f-40d9-a048-583bd56b95db">6,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification from non-controlling interest</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29031751451245b7b580c18872827fbb_D20210101-20211231" decimals="-3" name="rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzEzLTMtMS0xLTA_1c887b1f-6b72-43c5-89df-256620f6d7eb">4,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4f46b5e4015492f9d8f108c0637d93f_D20210101-20211231" decimals="-3" name="rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzEzLTUtMS0xLTA_bf7415e1-792d-4ff5-8c45-69c3eda01668">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85fa20a518334b9fa7796f9712ef4b1d_D20210101-20211231" decimals="-3" name="rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzEzLTctMS0xLTA_83be7181-15b2-4995-a128-99f7a5e86671">4,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1006e57c6def4fd5ae9330e75305eda2_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzE0LTMtMS0xLTA_cf8d85ad-c0b8-43c4-92c4-e48dfa04d575">16,491</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16fdeeb9bb4649b8bb751998b5e4aa0d_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzE0LTUtMS0xLTA_30421c6f-4519-4666-b64b-55af7d1ce40d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea955efbad0b414690fc8195ca1de338_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzE0LTctMS0xLTA_94476786-a8f7-4a17-905b-712538bc9028">16,491</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reclassification of unrealized gains on available for sale debt securities of $<ix:nonFraction unitRef="usd" contextRef="i54dfb90328614a55aba5dfd030436f8a_D20210101-20211231" decimals="-5" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90ZXh0cmVnaW9uOjU4ZDlkNjYxYWEzYzQyY2NiZWVlNDYwMThhMjRkOTk3Xzg1OQ_d70e60ac-eeb1-428e-accf-d0b6871b147c">50.9</ix:nonFraction>&#160;million in the year ended December 31, 2021 is presented within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest incom</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e on the consolidated statements of operations, including $<ix:nonFraction unitRef="usd" contextRef="if7ee447648cf4185a3ad39d6a4c5b190_D20210101-20211231" decimals="-5" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90ZXh0cmVnaW9uOjU4ZDlkNjYxYWEzYzQyY2NiZWVlNDYwMThhMjRkOTk3XzQ5NDc4MDIzMzE1ODE_2fae5112-1537-4b97-8e08-7bcc2b97e7b4">28.5</ix:nonFraction>&#160;million attributable to controlling interest noted in the table above and $<ix:nonFraction unitRef="usd" contextRef="ie65b03ddad0a41228c36c13d797b9715_D20210101-20211231" decimals="-5" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90ZXh0cmVnaW9uOjU4ZDlkNjYxYWEzYzQyY2NiZWVlNDYwMThhMjRkOTk3XzQ5NDc4MDIzMzE1ODk_2c2737aa-3a67-443f-9f55-c350d9855bf3">22.4</ix:nonFraction>&#160;million attributable to the non-controlling interest. The total reclassification of unrealized gains on available for sale debt securities of $<ix:nonFraction unitRef="usd" contextRef="i56d5126b8d034d6caef67a58b8e9b69e_D20200101-20201231" decimals="-5" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90ZXh0cmVnaW9uOjU4ZDlkNjYxYWEzYzQyY2NiZWVlNDYwMThhMjRkOTk3XzQ5NDc4MDIzMzE1OTc_ec0d8843-68d1-433b-b6b7-3f0320b5aa13">20.6</ix:nonFraction>&#160;million in the year ended December 31, 2020 is presented within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest incom</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e on the consolidated statements of operations, including $<ix:nonFraction unitRef="usd" contextRef="iedeb31da272b4fc68f60ac39c1f3cf68_D20200101-20201231" decimals="-5" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90ZXh0cmVnaW9uOjU4ZDlkNjYxYWEzYzQyY2NiZWVlNDYwMThhMjRkOTk3XzQ5NDc4MDIzMzE2MDU_3d402e86-3689-4eba-a8f9-91c73d0e891f">10.9</ix:nonFraction>&#160;million attributable to controlling interest noted in the table above and $<ix:nonFraction unitRef="usd" contextRef="i9dc56eeaf4e74cf0a58f82575803d294_D20200101-20201231" decimals="-5" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90ZXh0cmVnaW9uOjU4ZDlkNjYxYWEzYzQyY2NiZWVlNDYwMThhMjRkOTk3XzQ5NDc4MDIzMzE2MTM_8685aa1b-b490-4a47-8e9d-8edfa1569619">9.6</ix:nonFraction>&#160;million attributable to the non-controlling interest.</span></div></ix:continuation><div><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_166"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzc0NTE_f21d891a-bcf9-4b33-962d-9b16c20720ba" continuedAt="i83be4d56a3e2401d9d00bbe12f46c835" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i83be4d56a3e2401d9d00bbe12f46c835" continuedAt="i99be5d2fd16e46f5aeb653f36cc969c0"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Manager</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Manager is the investment manager of Royalty Pharma and its subsidiaries. The Manager is an affiliate of RP Ireland, the administrator of RPIFT, RPI Intermediate FT and RPSFT. The sole member of the Manager, Pablo Legorreta, holds an interest in us and serves as our Chief Executive Officer and Chairman of the board of directors, and as a director on the board of directors of RP Holdings.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Exchange Offer Transactions (discussed in Note 1&#8211;Organization and Purpose), the Manager entered into Management Agreements with us and our subsidiaries, the Continuing Investors Partnerships, and with the Legacy Investors Partnerships. Pursuant to the Management Agreements, we pay quarterly operating and personnel expenses to the Manager or its affiliates (&#8220;Operating and Personnel Payments&#8221;) equal to <ix:nonFraction unitRef="number" contextRef="ibe95870b105d4aadbf0f7ea315240ffe_I20211231" decimals="INF" name="rprx:RelatedPartyTransactionRateAdjustedCashReceipts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzg2NA_69073312-2238-4146-ae1a-cd337e6236a1">6.5</ix:nonFraction>% of the Adjusted Cash Receipts (both, as defined in the Management Agreement) for such quarter and <ix:nonFraction unitRef="number" contextRef="ibe95870b105d4aadbf0f7ea315240ffe_I20211231" decimals="INF" name="rprx:RelatedPartyTransactionRateValueOfSecurityInvestments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzk2OQ_ab3f4add-ed85-47f3-a485-403a50415fbd">0.25</ix:nonFraction>% of the value of our security investments under GAAP as of the end of such quarter. The operating and personnel payments for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected in our consolidated net income, is calculated as the greater of $<ix:nonFraction unitRef="usd" contextRef="i68845df194e84a7d80a8bd8a4940e91d_D20210101-20211231" decimals="-6" name="rprx:RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzEyODY_217d5aae-37b6-4084-b54e-3967dfa36f65">1</ix:nonFraction>&#160;million per quarter and <ix:nonFraction unitRef="number" contextRef="i68845df194e84a7d80a8bd8a4940e91d_D20210101-20211231" decimals="INF" name="rprx:RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzEzMDU_60b127e2-a9dc-4916-a6e7-7a6fc2ef93c3">0.3125</ix:nonFraction>% of Royalty Investments (as defined in the limited partnership agreements of the Legacy Investor Partnerships) during the previous twelve calendar months. </span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i99be5d2fd16e46f5aeb653f36cc969c0" continuedAt="ie6cceb2052194b998ea3a0571a36184f"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Exchange Date, the Manager received operating and personnel payments payable in equal quarterly installments that increased by <ix:nonFraction unitRef="number" contextRef="i97ca2cea9f6f43ddaa7f3e5b85bf3ea6_D20210101-20211231" decimals="INF" name="rprx:RelatedPartyTransactionAnnualIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzE2MTU_b9ad86a9-d5c8-4e86-9cda-d556fb52e62f">5</ix:nonFraction>% annually on a compounded basis under the terms of its management agreement with Old RPI and the Legacy Investors Partnerships. RP Ireland receives an annual management fee payable in advance by Old RPI in equal quarterly installments under terms of the limited partnership agreements of the Legacy Investors Partnerships. After the Exchange Date, operating and personnel payments were calculated in accordance with the methodology discussed in the paragraph above. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021, 2020 and 2019, total operating and personnel payments incurred were $<ix:nonFraction unitRef="usd" contextRef="i97ca2cea9f6f43ddaa7f3e5b85bf3ea6_D20210101-20211231" decimals="-5" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzEwOTk1MTE2NDE4MjA_354a756a-7c84-4482-8a9a-824b0d311cb5">145.2</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ie8e86ed407fe484e8200e769e2f1bb39_D20200101-20201231" decimals="-5" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzEwOTk1MTE2NDE4MzM_d17983e0-d7b4-4272-ba62-bf9615bd9f0d">112.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i645cb20517d04607a53311447c97b49a_D20190101-20191231" decimals="-5" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzEwOTk1MTE2NDE4NDE_bdd4d930-a54c-45f3-a160-5d407d9c3061">60.0</ix:nonFraction>&#160;million, respectively, including the amounts attributable to Old RPI, and were recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution Payable to Non-Controlling Interest</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution payable to non-controlling interest represents the contractual cash flows required to be distributed based on the Legacy Investors Partnerships&#8217; non-controlling interest in Old RPI and RPSFT&#8217;s non-controlling interest in RPCT. <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzI5Njg2ODEzOTY1ODA3_9049bdcf-4018-4ccf-bc80-7312ebd250e0" continuedAt="ib84abdbff094447495030e3340914bc8" escape="true">The distribution payable to non-controlling interest as of December 31, 2021 and 2020 included the following (in thousands). </ix:nonNumeric></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><ix:continuation id="ib84abdbff094447495030e3340914bc8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to Legacy Investors Partnerships</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e60ab1409db4a2697d00163b861a712_I20211231" decimals="-3" name="us-gaap:DueToRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90YWJsZTphOThlYWU5ZTI0NjE0MTY5OTEwMTJmOTlhZDJkNDdmOC90YWJsZXJhbmdlOmE5OGVhZTllMjQ2MTQxNjk5MTAxMmY5OWFkMmQ0N2Y4XzEtMS0xLTEtNDI4MDA_ccb70191-539c-416c-a25e-2a84bede4f85">92,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70b38d22ad90490ba1b7d51417e278e8_I20201231" decimals="-3" name="us-gaap:DueToRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90YWJsZTphOThlYWU5ZTI0NjE0MTY5OTEwMTJmOTlhZDJkNDdmOC90YWJsZXJhbmdlOmE5OGVhZTllMjQ2MTQxNjk5MTAxMmY5OWFkMmQ0N2Y4XzEtMi0xLTEtNDI4MDA_4f1f52a2-546f-44f4-8b9f-bf428a75201d">100,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to RPSFT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7b7fdb0deff479196b3afda650a0570_I20211231" decimals="-3" name="us-gaap:DueToRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90YWJsZTphOThlYWU5ZTI0NjE0MTY5OTEwMTJmOTlhZDJkNDdmOC90YWJsZXJhbmdlOmE5OGVhZTllMjQ2MTQxNjk5MTAxMmY5OWFkMmQ0N2Y4XzItMS0xLTEtNDI4MDA_6dfc87bd-9a34-438f-b3fd-548f9a22e63d">15,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie31b0e40de594cdd9c6ae104e8a737c1_I20201231" decimals="-3" name="us-gaap:DueToRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90YWJsZTphOThlYWU5ZTI0NjE0MTY5OTEwMTJmOTlhZDJkNDdmOC90YWJsZXJhbmdlOmE5OGVhZTllMjQ2MTQxNjk5MTAxMmY5OWFkMmQ0N2Y4XzItMi0xLTEtNDI4MDA_2e165f79-2e65-4d88-bf9a-73a090e5dafb">26,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total distribution payable to non-controlling interest</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355f63584077498c9358681b1f440182_I20211231" decimals="-3" name="us-gaap:DueToRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90YWJsZTphOThlYWU5ZTI0NjE0MTY5OTEwMTJmOTlhZDJkNDdmOC90YWJsZXJhbmdlOmE5OGVhZTllMjQ2MTQxNjk5MTAxMmY5OWFkMmQ0N2Y4XzMtMS0xLTEtNDI4MDA_4a08c123-fe5a-4fb3-8186-fc284ee45b53">107,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231" decimals="-3" name="us-gaap:DueToRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90YWJsZTphOThlYWU5ZTI0NjE0MTY5OTEwMTJmOTlhZDJkNDdmOC90YWJsZXJhbmdlOmE5OGVhZTllMjQ2MTQxNjk5MTAxMmY5OWFkMmQ0N2Y4XzMtMi0xLTEtNDI4MDA_70ab311f-66f9-45ab-b8d0-a162195388b2">126,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition from Epizyme </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, in connection with a royalty acquisition and an equity investment in Epizyme made by RPIFT, Pablo Legorreta, our Chief Executive Officer, was appointed as a director of Epizyme, for which he received, and continues to receive, compensation in cash and shares of Epizyme, all of which are and will continue to be contributed to the Manager and used to reduce costs and expenses which would otherwise be billed to us or our affiliates. We continue to hold Epizyme common stock as of December 31, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition from Bristol Myers Squibb</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2017, RPI Acquisitions, a consolidated subsidiary, entered into a purchase agreement with Bristol Myers Squibb (&#8220;BMS&#8221;) to acquire from BMS a percentage of its future royalties on worldwide sales of Onglyza, Farxiga and related diabetes products marketed by AstraZeneca (the &#8220;Purchase Agreement&#8221;). We agreed to make payments to BMS based on sales of the products over eight quarters beginning with the first quarter of 2018 in exchange for a high single-digit royalty on worldwide sales of the products from 2020 through 2025. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 8, 2017, RPI Acquisitions entered into a purchase, sale and assignment agreement (&#8220;Assignment Agreement&#8221;) with a wholly owned subsidiary of BioPharma Credit PLC (&#8220;BPCR&#8221;), an affiliate of us. We considered BPCR as a related party due to the sole member of the Manager having significant influence over BPCR&#8217;s investment manager. Under the terms of the Assignment Agreement, RPI Acquisitions assigned the benefit of <ix:nonFraction unitRef="number" contextRef="ibb1bbffa95a546f8bb9ed80b3df9b06b_D20171208-20171208" decimals="INF" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzQ0NDI_a1725dd1-de53-4b80-95be-7efa574d9de3">50</ix:nonFraction>% of the payment stream acquired from BMS to BPCR in consideration for BPCR meeting <ix:nonFraction unitRef="number" contextRef="i61362e5f58b24b40a91040ec047f877f_D20171208-20171208" decimals="INF" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzQ1Mjc_91079010-89f4-4eea-828a-11ad47bb15a6">50</ix:nonFraction>% of the funding obligations owed to BMS under the Purchase Agreement. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began making installment payments to BMS in 2018 and completed our funding requirement, net of the assigned funding obligations, totaling $<ix:nonFraction unitRef="usd" contextRef="i892f2facb5f94c52a537787b30d9bedb_I20200331" decimals="-5" name="rprx:RelatedPartyTransactionCumulativeFundingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzEwOTk1MTE2NDA0NTY_8073fa6b-5c02-4960-be02-552ae4eccff1">162.4</ix:nonFraction>&#160;million in the three months ended March 31, 2020. We began to measure this financial royalty asset using the effective interest method once our installment funding obligation was completed and we received our first royalty payment in the three months ended June 30, 2020. As of December 31, 2021 and 2020, the financial royalty asset of $<ix:nonFraction unitRef="usd" contextRef="i67eff68d96604fa8be650fb4b9c29499_I20211231" decimals="-5" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzEwOTk1MTE2NDA0NzA_85a85013-75ba-44d4-bc28-22b5367063db">130.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i476f13cf218b4efabc6d088270acc46d_I20201231" decimals="-5" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzEwOTk1MTE2Mzc4MDI_882f6a66-52ca-4a32-888a-a194d33ff924">150.6</ix:nonFraction>&#160;million, respectively, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets represents only our right to the future payment streams acquired from BMS. </span></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ie6cceb2052194b998ea3a0571a36184f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other transactions</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Henry Fernandez, the lead independent director of our board of directors, serves as the chairman and chief executive officer of MSCI, Inc (&#8220;MSCI&#8221;). On April 16, 2021, we entered into an agreement with MSCI with an initial term of <ix:nonNumeric contextRef="i5e9cfc8aaf7e4e8694cd83fe4460da68_D20210416-20210416" name="rprx:RelatedPartyTransactionInitialTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzI5Njg2ODEzOTY1ODIz_ad4cc868-d4ba-419c-bac1-fbd8d0e8bc59">seven years</ix:nonNumeric> to assist MSCI in the design of a classification framework and index methodologies in order to expand MSCI&#8217;s thematic index suite with the launch of new indexes. In return, we will receive a percentage of MSCI&#8217;s revenues from those indexes. <ix:nonFraction unitRef="usd" contextRef="ib2947dd542964da4bc1a05e210e2204b_I20211231" decimals="INF" name="us-gaap:DueFromRelatedParties" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzE0MjkzNjUxMTc4MDUw_a4067fb3-3952-454f-b77c-91d0dbd86598">No</ix:nonFraction> amounts were due from MSCI as of December 31, 2021. The financial statement impact associated with this transaction was not material for the year ended December 31, 2021.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the year ended December 31, 2020, we reimbursed Pablo Legorreta approximately $<ix:nonFraction unitRef="usd" contextRef="i9edec4e140234b36b02f7525c49128f0_D20200101-20201231" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzE2NDkyNjc0NTQ5NDc_439b8d5f-98c2-4fa5-8f6c-69252f72b1a8">1.0</ix:nonFraction>&#160;million for the cost of purchasing and donating ventilators to hospitals on behalf of Royalty Pharma. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Exchange Offer Transactions, we acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy Investors Partnerships own a non-controlling interest in Old RPI. Refer to Note 9&#8211;Non-Consolidated Affiliates for additional discussion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RPIFT owns <ix:nonFraction unitRef="shares" contextRef="i577a0329d95541e3802de867916ac6d6_D20210101-20211231" decimals="INF" name="rprx:RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzY0MTM_7c40141c-971d-4cf8-823f-739f06107d6c">27,210</ix:nonFraction> limited partnership interests in the Continuing Investors Partnership whose only substantive operations are their investment in our subsidiaries. The total investment of $<ix:nonFraction unitRef="usd" contextRef="i8cc96b6d6e9e4707b52d5a0f86086779_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzE2NDkyNjc0NTU5NzE_432e8d93-1977-4b23-a2ec-284f6d8883d7">4.3</ix:nonFraction>&#160;million is recorded as treasury interests, of which $<ix:nonFraction unitRef="usd" contextRef="id61bed594e7b481cb6b9d98f501ad606_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzQ5NDc4MDIzNDE1ODc_8121da68-92fb-4b3c-9369-36d6422ff7c5">1.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="icb00ed73f9984375a78b3989a66be135_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzQ5NDc4MDIzNDE1Nzg_e20a1b52-44f1-425a-bf74-fbb56ccf451e">1.9</ix:nonFraction>&#160;million are held by non-controlling interest as of December 31, 2021 and 2020, respectively.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its ownership percentage of RP Holdings relative to the Company, each Continuing Investor Partnership pays a pro rata portion of any costs and expenses in connection with the contemplation of, formation of, listing and ongoing operation of us and any of our subsidiaries, including any third-party expenses of managing us and any of our subsidiaries, such as accounting, audit, legal, reporting, compliance, administration (including directors&#8217; fees), financial advisory, consulting, investor relations and insurance expenses relating to our affairs and those of any subsidiary.</span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_169"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzM3Mjc_bb6fda8a-bab0-4de0-8bb9-a3c064692197" continuedAt="i874a62b3d77c4ce58422dbf71e13cfed" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i874a62b3d77c4ce58422dbf71e13cfed" continuedAt="ib30cb13c525b4815b1eee634f53591e0"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of its business, we may enter into contracts or agreements that contain customary indemnifications relating to such things as confidentiality agreements and representations as to corporate existence and authority to enter into contracts. The maximum exposure under such agreements is indeterminable until a claim, if any, is made. However, no such claims have been made against us to date and we believe that the likelihood of such proceedings taking place in the future is remote.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys to support MorphoSys&#8217; acquisition of Constellation, which closed on July 15, 2021. As part of the funding agreement, we agreed to make additional milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602" decimals="INF" name="rprx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzEwOTk1MTE2MzIyNDk_b052fc2c-eabb-49e0-86c7-2a5de9b45af5">150.0</ix:nonFraction>&#160;million and provide up to $<ix:nonFraction unitRef="usd" contextRef="ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602" decimals="INF" name="rprx:CollaborativeArrangementRightsAndObligationsPaymentOfCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzEwOTk1MTE2MzIzNTQ_0132b80f-f7f5-41af-afdb-0c37a4e94ddb">350.0</ix:nonFraction>&#160;million of Development Funding Bonds, which MorphoSys may draw over a <ix:nonNumeric contextRef="ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602" name="rprx:CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzI5Njg2ODEzOTYwOTk3_57ddf6a6-b286-401f-9aba-ea8c38a0288a">one-year</ix:nonNumeric> period from the close of its acquisition of Constellation. MorphoSys is required to draw a minimum of $<ix:nonFraction unitRef="usd" contextRef="ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602" decimals="INF" name="rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzEwOTk1MTE2MzI3NzQ_1ad35bfd-d202-48ee-bc20-0a93c18bc695">150.0</ix:nonFraction>&#160;million, for which we have recognized the Development Funding Bond Forward within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> on the consolidated balance sheet as of December 31, 2021 (See Note 3&#8211;Available for Sale Debt Securities for additional discussion). Once drawn, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over <ix:nonNumeric contextRef="ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602" name="rprx:CollaborativeArrangementRightsAndObligationsPeriodOfReturn" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzEwOTk1MTE2MzMyODA_c9eedcf2-2de5-438c-b09e-1e6d4ba0b6f3">nine years</ix:nonNumeric>, with the first payment beginning <ix:nonNumeric contextRef="ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602" name="rprx:CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzEwOTk1MTE2MzMzNDM_1915f658-bf28-4176-87d2-002faa6a07ed">two years</ix:nonNumeric> after the funding. As of December 31, 2021, MorphoSys has not drawn any amount under the Development Funding Bonds.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 7, 2020, we entered into a funding agreement with Biohaven, including the Series B Biohaven Preferred Share Agreement, to fund the development of zavegepant and the commercialization of Nurtec ODT in exchange for royalties and success-based milestones. Pursuant to the Series B Biohaven Preferred Share Agreement, we agreed to provide further support for the ongoing launch of Nurtec ODT with the purchase of committed, non-contingent Commercial Launch Preferred Equity for a total of $<ix:nonFraction unitRef="usd" contextRef="ib03c23cba7a244bb9c45ccd577d4c56b_D20200807-20200807" decimals="-5" name="rprx:PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzExNjU_7c76953f-efe1-4850-9b7f-fbf447afd948">200.0</ix:nonFraction>&#160;million payable on a quarterly basis between March 31, 2021 and December 31, 2024. In return, Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between March 31, 2025 and December 31, 2030. During the three months ended March 30, 2021, we began purchasing the Series B Biohaven Preferred Shares. We have a remaining commitment of $<ix:nonFraction unitRef="usd" contextRef="i4719611fdef547db987f7d2d30dadbc7_I20211231" decimals="-5" name="rprx:LongTermPurchaseCommitmentAmountOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzEwOTk1MTE2MzUwMTU_0666d905-8be3-4416-a66f-8e0d671d65c8">129.6</ix:nonFraction>&#160;million under the Commercial Launch Preferred Equity, for which we have recognized the Series B Forwards within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated balance sheet as of December 31, 2021. See Note 3&#8211;Available for Sale Debt Securities for additional discussion.</span></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                       </span></div><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ib30cb13c525b4815b1eee634f53591e0"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, RPIFT agreed to pay $<ix:nonFraction unitRef="usd" contextRef="id128cc5ba3f14e5e9d39b99e553584ce_D20191101-20191130" decimals="-5" name="us-gaap:LongTermPurchaseCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzE0NjE_ef1091f3-b433-4c90-ae2e-3a03bbccbb3b">330.0</ix:nonFraction>&#160;million to purchase Eisai&#8217;s royalties on future worldwide sales of Tazverik, a novel targeted therapy in late-stage clinical development that was approved by the FDA in January 2020 for epithelioid sarcoma, and with the potential to be approved in several cancer indications. Under the terms of our agreement with Eisai, we acquired Eisai&#8217;s future worldwide royalties on net sales by Epizyme of Tazverik outside of Japan, for an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i745d2f50fe8b4f46a787612b29f6bed4_D20200101-20200131" decimals="-5" name="rprx:PurchaseCommitmentUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzE5MjI_3a482612-662f-4f59-865f-6017a60ee627">110.0</ix:nonFraction>&#160;million plus up to an additional $<ix:nonFraction unitRef="usd" contextRef="i745d2f50fe8b4f46a787612b29f6bed4_D20200101-20200131" decimals="-5" name="rprx:PurchaseCommitmentAdditionalPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzE5NTA_4ee2fb7b-cc89-4ebc-945b-6beec4218c77">220.0</ix:nonFraction>&#160;million for the remainder of the royalty upon FDA approval of Tazverik for certain indications. The FDA approval of Tazverik in January 2020 triggered our obligation to fund the second $<ix:nonFraction unitRef="usd" contextRef="id0a161191b444d5bac5c44aa63d77be4_D20201101-20201130" decimals="-5" name="rprx:PurchaseCommitmentAdditionalPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzIxMzA_966f5993-7c39-42de-9e1c-4b71021402ca">110.0</ix:nonFraction>&#160;million tranche in November 2020. On November 4, 2021, we funded the final $<ix:nonFraction unitRef="usd" contextRef="i1895cd7ab821494986c2e4e15419aa87_D20211104-20211104" decimals="-5" name="rprx:PurchaseCommitmentAdditionalPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzEwOTk1MTE2MzUzMTM_c10eac7b-51f8-405c-9ff4-24d37c6788f2">110.0</ix:nonFraction>&#160;million tranche. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have commitments to advance funds to counterparties through our investment in the Avillion Entities and R&amp;D arrangements. Please refer to Note 9&#8211;Non-Consolidated Affiliates and Note 10&#8211;Research &amp; Development (&#8220;R&amp;D&#8221;) Funding Expense, respectively, for details of these arrangements. We also have requirements to make Operating and Personnel Payments over the life of the management agreement as described in Note 16&#8211;Related Party Transactions, which are variable and primarily based on cash receipts.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to legal actions with respect to a variety of matters in the ordinary course of business. Some of these proceedings may be based on complex claims involving substantial uncertainties and unascertainable damages. Unless otherwise noted, it is not possible to determine the probability of loss or estimate damages, and therefore we have not established accruals for any of these proceedings in our consolidated balance sheets as of December 31, 2021 and 2020. When we determine that a loss is both probable and reasonably estimable, we record a liability, and, if the liability is material, we disclose the amount of the liability reserved. We do not believe the outcome of any existing legal proceedings to which we are a party, either individually or in the aggregate, will adversely affect our business, financial condition or results of operations.</span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_172"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNzIvZnJhZzozYzFjYjRjMWU4NWI0YmU0YmUxMzk3YjIwZGJiNGVlZS90ZXh0cmVnaW9uOjNjMWNiNGMxZTg1YjRiZTRiZTEzOTdiMjBkYmI0ZWVlXzQ5Mw_fd9e9b18-af91-4c3d-a59c-00a896754984" continuedAt="i28ad5692f0a1487781fd44b9928d41fb" escape="true">Subsequent Events</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i28ad5692f0a1487781fd44b9928d41fb">In January 2022, we acquired a royalty interest in aficamten from Cytokinetics, Incorporated (&#8220;Cytokinetics&#8221;) for $<ix:nonFraction unitRef="usd" contextRef="if022a6e3714949948eb2520d7c7ab729_D20220101-20220131" decimals="-5" name="rprx:PaymentsToAcquireRoyaltyInterestsAggregateAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNzIvZnJhZzozYzFjYjRjMWU4NWI0YmU0YmUxMzk3YjIwZGJiNGVlZS90ZXh0cmVnaW9uOjNjMWNiNGMxZTg1YjRiZTRiZTEzOTdiMjBkYmI0ZWVlXzE0MjkzNjUxMTcyNTEy_c6f8c5eb-c67a-4358-ba84-5649416665f5">150.0</ix:nonFraction>&#160;million, comprised of an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="if022a6e3714949948eb2520d7c7ab729_D20220101-20220131" decimals="-6" name="rprx:PaymentsToAcquireRoyaltyInterestsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNzIvZnJhZzozYzFjYjRjMWU4NWI0YmU0YmUxMzk3YjIwZGJiNGVlZS90ZXh0cmVnaW9uOjNjMWNiNGMxZTg1YjRiZTRiZTEzOTdiMjBkYmI0ZWVlXzM4NDgyOTA3MDY2NzY_2a42658a-730a-40a0-bd37-60ffc132485f">50</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="payment" contextRef="if022a6e3714949948eb2520d7c7ab729_D20220101-20220131" decimals="INF" name="rprx:PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNzIvZnJhZzozYzFjYjRjMWU4NWI0YmU0YmUxMzk3YjIwZGJiNGVlZS90ZXh0cmVnaW9uOjNjMWNiNGMxZTg1YjRiZTRiZTEzOTdiMjBkYmI0ZWVlXzM4NDgyOTA3MDY2ODQ_6998f0a0-1618-4ce5-9be5-3b3778fe23f4">two</ix:nonFraction> additional $<ix:nonFraction unitRef="usd" contextRef="if022a6e3714949948eb2520d7c7ab729_D20220101-20220131" decimals="-6" name="rprx:PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNzIvZnJhZzozYzFjYjRjMWU4NWI0YmU0YmUxMzk3YjIwZGJiNGVlZS90ZXh0cmVnaW9uOjNjMWNiNGMxZTg1YjRiZTRiZTEzOTdiMjBkYmI0ZWVlXzM4NDgyOTA3MDY2OTk_41b48c5b-53ff-4d09-b2b1-3ea3d96f5b8b">50</ix:nonFraction>&#160;million payments which are conditional upon the initiation of potential pivotal clinical trials for obstructive hypertrophic cardiomyopathy and nonobstructive hypertrophic cardiomyopathy, respectively. Additionally, we will provide Cytokinetics long-term capital of up to $<ix:nonFraction unitRef="usd" contextRef="if022a6e3714949948eb2520d7c7ab729_D20220101-20220131" decimals="-6" name="rprx:LongTermFundingPartnershipAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNzIvZnJhZzozYzFjYjRjMWU4NWI0YmU0YmUxMzk3YjIwZGJiNGVlZS90ZXh0cmVnaW9uOjNjMWNiNGMxZTg1YjRiZTRiZTEzOTdiMjBkYmI0ZWVlXzE0MjkzNjUxMTY5NDQx_13581f6a-8932-40e7-8577-d1b6b342f466">300</ix:nonFraction>&#160;million (&#8220;Cytokinetics Commercial Launch Funding&#8221;) to support further development of aficamten and potential commercialization of omecamtiv mecarbil. The Cytokinetics Commercial Launch Funding is available in <ix:nonFraction unitRef="tranche" contextRef="if022a6e3714949948eb2520d7c7ab729_D20220101-20220131" decimals="INF" name="rprx:LongTermFundingPartnershipNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNzIvZnJhZzozYzFjYjRjMWU4NWI0YmU0YmUxMzk3YjIwZGJiNGVlZS90ZXh0cmVnaW9uOjNjMWNiNGMxZTg1YjRiZTRiZTEzOTdiMjBkYmI0ZWVlXzE0MjkzNjUxMTY5NTEz_0bf9cc78-8c70-4858-a430-58ae015ac5ba">five</ix:nonFraction> tranches, including an initial tranche of $<ix:nonFraction unitRef="usd" contextRef="if022a6e3714949948eb2520d7c7ab729_D20220101-20220131" decimals="-6" name="rprx:LongTermFundingPartnershipInitialPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNzIvZnJhZzozYzFjYjRjMWU4NWI0YmU0YmUxMzk3YjIwZGJiNGVlZS90ZXh0cmVnaW9uOjNjMWNiNGMxZTg1YjRiZTRiZTEzOTdiMjBkYmI0ZWVlXzE0MjkzNjUxMTY5NDY5_9b372ac6-9ac1-412f-ab53-db99edd654fc">50</ix:nonFraction>&#160;million funded upon closing and <ix:nonFraction unitRef="tranche" contextRef="if022a6e3714949948eb2520d7c7ab729_D20220101-20220131" decimals="INF" name="rprx:LongTermFundingPartnershipNumberOfAdditionalPayments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNzIvZnJhZzozYzFjYjRjMWU4NWI0YmU0YmUxMzk3YjIwZGJiNGVlZS90ZXh0cmVnaW9uOjNjMWNiNGMxZTg1YjRiZTRiZTEzOTdiMjBkYmI0ZWVlXzE0MjkzNjUxMTY5NTMw_75c4e0ad-1ca3-4e61-95af-589bae8f97f5">four</ix:nonFraction> additional tranches in the aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="if022a6e3714949948eb2520d7c7ab729_D20220101-20220131" decimals="-6" name="rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNzIvZnJhZzozYzFjYjRjMWU4NWI0YmU0YmUxMzk3YjIwZGJiNGVlZS90ZXh0cmVnaW9uOjNjMWNiNGMxZTg1YjRiZTRiZTEzOTdiMjBkYmI0ZWVlXzE0MjkzNjUxMTY5NDU1_ff5ddd00-6daa-419a-a0eb-6307ac9e6733">250</ix:nonFraction>&#160;million upon the occurrence of certain regulatory and clinical development milestones.</ix:continuation> </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_175"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_178"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. &#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) prior to the filing of this Annual Report on Form 10-K. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Annual Report on Form 10-K, our disclosure controls and procedures were, in design and operation, effective to the reasonable assurance level.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">s Report on Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management is responsible </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of 1934, as amended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">). Our management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria established by the Committee of Sponsoring Organizations of the Treadway Commission in its 2013 Internal Control-Integrated Framework. Based on this assessment, our management has concluded that our internal control over financial reporting was effective as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Our</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> independent registered public accounting firm, Ernst &amp; Young, has issued an audit report on our internal control over financial reporting as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Their report is included in Item 8 of this Annual Report on Form 10-K.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no changes in our internal controls over financial reporting </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">identified in management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">during the three months ended December 31, 2021 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our Chief Executive Officer and Chief Financial Officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</span></div><div><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_181"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. &#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_184"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_187"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. &#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item will be presented in our Proxy Statement to be filed not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and is incorporated herein by reference.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><div id="i15fafc99ab5c41deb08ee816ca47172c_190"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. &#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item will be presented in our Proxy Statement, to be filed not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and is incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_193"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. &#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item will be presented in our Proxy Statement, to be filed not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and is incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_196"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN RELATIONSHIPS AND RELATED</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSACTIONS, AND DIRECTORS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEPENDENCE</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item will be presented in our Proxy Statement, to be filed not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and is incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_199"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item will be presented in our Proxy Statement, to be filed not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and is incorporated herein by reference.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><div id="i15fafc99ab5c41deb08ee816ca47172c_202"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_205"></div><div style="text-indent:36pt"><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. &#160;&#160;&#160;&#160;EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The following exhibits are filed as a part of this Annual Report on Form 10-K:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:7.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%;text-decoration:underline">Incorporated by Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Exhibit Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Exhibit Description</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Form</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Filing Date/<br/>Period End Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%;text-decoration:underline">Filed or Furnished Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520174109/d907102dex31.htm">Articles of Association of Royalty Pharma plc</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">6/19/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520174109/d907102dex32.htm">Articles of Association of Royalty Pharma Holdings Ltd</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">6/19/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520166398/d862976dex41.htm">Form of Class A Ordinary Share Certificate</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">6/11/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="rprx-20211231ex42.htm">Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520174109/d907102dex102.htm">Management and Services Agreement dated June 15, 2020, among the Company and RP Management, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">6/19/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520174109/d907102dex101.htm">Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Ltd, RPI  US Partners 2019, LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">6/19/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520174109/d907102dex104.htm">Registration Rights Agreement dated June 18, 2020, among the Company and the Persons listed on Schedule A and Schedule B theret</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520174109/d907102dex104.htm">o</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">6/19/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.4&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520158651/d862976dex105.htm">Form of Deed of Indemnity</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">6/2/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.5&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520166398/d862976dex106.htm">Director Appointment Agreement, dated June 9, 2020, between the Company and Mr. Germano Giuliani</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">6/11/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.6#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520158651/d862976dex107.htm">Amended and Restated Purchase and Sale Agreement, dated November 14, 2014, with the Cystic Fibrosis Foundation Therapeutics Incorporated</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">6/2/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.7#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520158651/d862976dex108.htm">Amendment No. 1 to the Amended and Restated Purchase and Sale Agreement, dated October 13, 2016 with the Cystic Fibrosis Foundation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">6/2/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.8#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520150246/d862976dex109.htm">Research, Development and Commercialization Agreement, dated May 24, 2004, between the Cystic Fibrosis Foundation Therapeutics Incorporated and Vertex Pharmaceuticals Inc., as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">5/22/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.9#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520150246/d862976dex1010.htm">Amendment No. 1 to Research, Development and Commercialization Agreement, dated January 6, 2006 by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics Incorporated</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">5/22/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520150246/d862976dex1011.htm">Amendment No. 2 to Research, Development and Commercialization Agreement, dated January 1, 2006, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics Incorporated</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">5/22/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.11#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520150246/d862976dex1012.htm">Amendment No. 5 to Research, Development and Commercialization Agreement, dated April 1, 2011, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics Incorporated</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">5/22/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.12#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520150246/d862976dex1013.htm">Amendment No. 7 to Research, Development and Commercialization Agreement, dated September  1, 2016, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics Incorporated</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">5/22/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:7.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520174109/d907102dex103.htm">Amended and Restated Management and Services Agreement dated June 11, 2020, among Royalty Pharma Investments 2019 ICAV and RP Management, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">6/19/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.14&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520166398/d862976dex1015.htm">Form of Independent Director Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">6/11/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000095010320017365/dp135934_ex0401.htm">Indenture, dated as of September 2, 2020, among Royalty Pharma plc, Royalty Pharma Holdings Ltd and Wilmington Trust, National Association, as Trustee</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">9/2/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000095010320017365/dp135934_ex0402.htm">First Supplemental Indenture, dated as of September 2, 2020, among Royalty Pharma plc, Royalty Pharma Holdings Ltd. and Wilmington Trust, National Association, as Trustee</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">9/2/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000095010320017365/dp135934_ex0409.htm">Registration Rights Agreement, dated as of September 2, 2020, among Royalty Pharma plc, Royalty Pharma Holdings Ltd, BofA Securities, Inc., Citigroup Global Markets Inc., Goldman Sachs  &amp; Co LLC, J.P. Morgan Securities LLC and Morgan Stanley &amp; Co. LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">9/2/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.18#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520286894/d66211dex101.htm">Amendment No. 2 to the Amended and Restated Purchase and Sale Agreement, dated October 30, 2020, by and among RPI Finance Trust, RPI 2019 Intermediate Finance Trust and Cystic Fibrosis Foundation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">11/5/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001802768/000119312521224416/d61746dex42.htm">Second Supplemental Indenture, dated as of July 26, 2021, Royalty Pharma plc, Royalty Pharma Holdings Ltd. and Wilmington Trust, National Association, as Trustee.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">7/26/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1802768/000119312520150246/d862976dex211.htm">List of subsidiaries</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">5/22/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="rprx-20211231ex231.htm">Consent of Ernst &amp; Young, Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">24.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Power of Attorney (reference is made to the signature page hereto)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="rprx-20211231ex311.htm">Certification of </a></span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="rprx-20211231ex311.htm">Chief Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="rprx-20211231ex311.htm"> </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="rprx-20211231ex312.htm">Certification of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="rprx-20211231ex312.htm"> Chief Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">32*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="rprx-20211231ex32.htm">Certifications of Chief Executive Office and Chief Financial Officer </a></span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="rprx-20211231ex32.htm">pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">101.INS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Taxonomy Extension </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Instance Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">101.SCH</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Taxonomy Extension </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Schema Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">101.CAL</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Taxonomy Extension </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Calculation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">101.DEF</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Taxonomy Extension </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Definition Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">101.LAB</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Taxonomy Extension </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Label Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">101.PRE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Taxonomy Extension </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Presentation Linkbase</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cover Page Interactive Data File (formatted in iXBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">x</span></td></tr></table></div><div><span><br/></span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8224; &#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"># &#160;&#160;&#160;&#160;Certain information has been excluded from the exhibit because it both (i) is not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">* &#160;&#160;&#160;&#160;The certifications furnished in Exhibit 32 hereto are deemed to accompany this Annual Report on Form 10-K and are not deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act of the Exchange Act.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div id="i15fafc99ab5c41deb08ee816ca47172c_208"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. &#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><div id="i15fafc99ab5c41deb08ee816ca47172c_211"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span><br/></span></div><div style="padding-left:252pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROYALTY PHARMA PLC</span></div><div style="padding-left:252pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant)</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:   </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Pablo Legorreta</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pablo Legorreta</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:  </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Terrance Coyne</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Terrance Coyne</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">POWER OF ATTORNEY</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Terrance Coyne and George Lloyd, and each of them,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Pablo Legorreta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Chairman of the Board, Director &amp; Chief Executive Officer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Principal Executive Officer and Royalty Pharma plc&#8217;s authorized representative in the United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pablo Legorreta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Terrance Coyne</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President &amp; Chief Financial Officer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Principal Financial Officer and Principal Accounting Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Terrance Coyne</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Bonnie Bassler</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonnie Bassler</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Errol De Souza</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Errol De Souza</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Catherine Engelbert</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Catherine Engelbert</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Henry Fernandez</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Henry Fernandez</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ William Ford</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William Ford</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ M. Germano Giuliani</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M. Germano Giuliani</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Ted Love</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ted Love</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Gregory Norden</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gregory Norden</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Rory Riggs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rory Riggs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>rprx-20211231ex42.htm
<DESCRIPTION>EX-4.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if82b1a2781dc4350abd5ec9b5a0f4df7_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.2</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF SECURITIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGISTERED UNDER SECTION 12 OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, Royalty Pharma plc (&#8220;Royalty Pharma&#8221; or the &#8220;Company&#8221;) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934&#58; our Class&#160;A ordinary shares,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">par value $0.0001 per share, which are listed on the Nasdaq Global Select Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;RPRX.&#8221; </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following description is a summary of our share capital as specified in our Articles of Association. This summary does not purport to be complete and the statements in this summary are qualified in their entirety by reference to, and are subject to, the detailed provisions of our Articles of Association and the U.K. Companies Act. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Structure </font></div><div style="margin-top:6pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issued Share Capital </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two classes of voting shares&#58; Class&#160;A and Class&#160;B, each of which has one vote per share. The Class&#160;A ordinary shares and Class&#160;B shares vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law. We also have in issue 50,000 Class&#160;R redeemable shares, which do not entitle the holder to voting or dividend rights, and deferred shares, which do not entitle the holder to voting or dividend rights. The purpose of the Class&#160;R redeemable shares was to ensure we had sufficient sterling denominated share capital at the time we re-registered as a public limited company, as required by the U.K. Companies Act. The Class&#160;R redeemable shares may be redeemed at some future point in order to leave the Company with only U.S. dollar denominated share capital. Any such redemption would be at nominal value. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The board of directors has been granted authority from our shareholders to allot and issue new Class&#160;A ordinary shares and other shares, and to grant rights to subscribe for or to convert any security into new Class&#160;A ordinary shares or other shares, up to a maximum aggregate nominal amount (i.e., par value) of $300,000, for a period expiring (unless previously renewed, varied or revoked by the Company in general meeting) on May&#160;31, 2025. Renewal of such authorization is expected to be sought at least once every five years, and possibly more frequently. This authority is in addition to authorities to allot and issue new Class&#160;A ordinary shares in exchange for Royalty Pharma Holdings Ltd Class&#160;B ordinary shares or the depositary receipts that represent them. The rights and restrictions to which the Class&#160;A ordinary shares are subject are prescribed by our Articles of Association. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class&#160;A Ordinary Shares </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting rights. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of Class&#160;A ordinary shares are entitled to one vote per share on all matters to be voted upon by the shareholders other than with respect to matters that require a separate class vote in accordance with applicable law. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend rights. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to preferences that may be applicable, the holders of Class&#160;A ordinary shares are entitled to receive ratably such dividends, if any, as may be approved from time to time by the board of directors out of funds legally available therefor. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rights upon liquidation. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of liquidation, dissolution or winding up of Royalty Pharma the holders of Class&#160;A ordinary shares are entitled to share ratably in all assets remaining after payment of liabilities. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class&#160;B Shares </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting rights. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of Class&#160;B shares are entitled to one vote per share on all matters to be voted upon by the shareholders other than with respect to matters that require a separate class vote in accordance with applicable law. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend rights. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of Class&#160;B shares do not have any rights to receive dividends. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rights upon liquidation. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of Class&#160;B shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up of Royalty Pharma, following the prior payment of the nominal capital paid up or credited as paid up on each Class&#160;A ordinary share as well as an amount of $10,000,000 on each Class&#160;A ordinary share upon such liquidation, dissolution or winding up. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under English law, the Company may only pay dividends out of profits available for that purpose. The Company&#8217;s profits available for distribution are its accumulated, realized profits, to the extent that they have not been previously utilized by distribution or capitalization, less its accumulated, realized losses, to the extent that they have not been previously written off in a reduction or reorganization of capital duly made. The amount of the Company&#8217;s distributable reserves is a cumulative calculation. The Company may be profitable in a single financial year but unable to pay a dividend if our accumulated, realized profits of that year do not offset all previous years&#8217; accumulated, realized losses. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company may only make a distribution if the amount of its net assets is not less than the aggregate of its called-up share capital and undistributable reserves, and if, and to the extent that, the distribution does not reduce the amount of those assets to less than that aggregate. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Articles of Association authorize our board of directors to approve interim dividends without shareholder approval to the extent that the approval of such dividends appears justified by profits. Our board of directors may also recommend a final dividend to be approved and declared by the shareholders at an annual general meeting and may direct that the payment be made by distribution of assets, shares or cash. No dividend may exceed the amount recommended by the board of directors. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Articles of Association also permit a scrip dividend scheme under which the board of directors may offer any holders of Class&#160;A ordinary shares the right to elect to receive Class&#160;A ordinary shares, credited as fully paid, instead of cash in respect of the whole (or some part determined by the board of directors) of all or any dividend subject to certain terms and conditions set out in our Articles of Association. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entitlement to a dividend lapses if unclaimed for 12 years. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Voting Rights </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Articles of Association, each holder of Class&#160;A ordinary shares or Class&#160;B shares is entitled to one vote for each share that he or she holds as of the record date for the meeting. Neither English law nor any of our constituent documents places limitations on the right of nonresident or foreign owners to vote or hold ordinary shares. The voting at a general meeting must be taken by poll. Subject to any relevant special rights or restrictions attached to any shares, on a poll taken at a general meeting, each qualifying shareholder present in person or by proxy (or, in the case of a corporation, a corporate representative) and entitled to vote on the resolution has one vote for every Class&#160;A ordinary share or Class&#160;B share held by such shareholder. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An ordinary resolution must be approved by a simple majority, and a special resolution approved by at least 75%, of shareholders attending and voting, whether in person or by proxy. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amendment to our Articles of Association </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under English law, shareholders may amend the articles of association of a company by special resolution. However, certain provisions of our Articles of Association require a higher threshold of shareholder approval or satisfaction of other procedures before such provision or provisions can be varied. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The article in our Articles of Association which requires voting at a general meeting to be taken on a poll may only be removed, amended or varied by resolution of the shareholders passed unanimously. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Winding Up </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a voluntary winding up of the Company, the liquidator may, with the sanction of a special resolution of the Company and any other sanction required by law, subject to the U.K. Insolvency Act of 1986, after effectively applying the Company&#8217;s property to satisfy the Company&#8217;s liabilities, divide among the holders of Class&#160;A ordinary shares of the Company the whole or any part of the assets of the Company, whether they consist of property of the same kind or not, and vest the whole or any part of the assets in trustees upon such trusts for the benefit of the holders of Class&#160;A ordinary shares of the Company as the liquidator, with such sanction, may determine. No shareholder of the Company shall be compelled to accept any assets upon which there is a liability. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a return of capital on a liquidation, reduction of capital or otherwise, the surplus assets of the Company available for distribution among the holders of Class&#160;A ordinary shares shall be applied pro rata (rounded to the nearest whole number). </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rights of Pre-Emption on New Issues of Shares </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the U.K. Companies Act, the allotment of &#8220;equity securities&#8221; (except pursuant to an employees&#8217; share scheme and as bonus shares) that are to be paid for wholly in cash must be offered first to the existing holders of ordinary shares in proportion to the respective nominal amounts (i.e., par values) of their holdings on the same or more favorable terms, unless a special resolution to the contrary has been passed or the articles of association otherwise provide disapplication from this requirement (which disapplication can be for a maximum of five years after which shareholders&#8217; approval would be required to renew the disapplication). &#8220;Equity securities&#8221; means ordinary shares or rights to subscribe for, or convert securities into, ordinary shares where ordinary shares means shares other than shares that, with respect to dividends and capital, carry a right to participate only up to a specified amount in a distribution. In relation to the Company, &#8220;equity securities&#8221; will therefore include the Class&#160;A ordinary shares, and all rights to subscribe for or convert securities into such shares. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The board of directors has been granted authority from our shareholders to allot and issue new Class&#160;A ordinary shares and other shares and to grant rights to subscribe for or to convert any security into new Class&#160;A ordinary shares or other shares, up to a maximum aggregate nominal amount (i.e., par value) of $300,000 for a period expiring (unless previously renewed, varied or revoked by the Company in general meeting) on May&#160;31, 2025. Renewal of such authorization is expected to be sought at least once every five years, and possibly more frequently. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure of Ownership Interests in Shares </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section&#160;793 of the U.K. Companies Act gives us the power to require persons whom we know have, or whom we have reasonable cause to believe have, or within the previous three years have had, an interest in any shares of the Company to disclose specified information regarding those shares. Failure to provide the information requested within the prescribed period (or knowingly or recklessly providing false information after the date the notice is sent) can result in criminal or civil sanctions being imposed against the person in default. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Articles of Association, if any of our shareholders, or any other person appearing to be interested in the shares of the Company held by such shareholder, has been duly served with a notice under section 793 and fails to give us the information required by such notice or has made a statement which is false or inadequate in a material particular, then our board of directors may, in its absolute discretion at any time by notice, withdraw voting rights and place restrictions on the rights to receive dividends and refuse to register a transfer of such shares. </font></div><div style="margin-top:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Alteration of Share Capital&#47;Share Repurchases </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the provisions of the U.K. Companies Act, and without prejudice to any relevant special rights attached to any class of shares, we may, from time to time, among other things&#58; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;increase our share capital by allotting and issuing new shares in accordance with our Articles of Association and any relevant shareholder resolution&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;consolidate all or any of our share capital into shares of a larger nominal amount (i.e., par value) than the existing shares&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;subdivide any of our shares into shares of a smaller nominal amount (i.e., par value) than the existing shares&#59; or </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;redenominate our share capital or any class of share capital </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not consolidate, divide, subdivide or redenominate any class of voting shares without consolidating, dividing, subdividing or redenominating (as the case may be) the other classes of voting shares. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">English law prohibits us from purchasing our own shares unless such purchase has been approved by our shareholders. Shareholders may approve two different types of such share purchases&#58; &#8220;on-market&#8221; share purchases or &#8220;off-market&#8221; share purchases. &#8220;On-market&#8221; purchases may only be made on a &#8220;recognised investment exchange,&#8221; which does not include Nasdaq, which is the only exchange on which the Company&#8217;s shares are traded. In order to purchase our own shares, as a Company listed on Nasdaq, we must therefore obtain the approval of our shareholders for an &#8220;off-market purchase&#8221; (on the basis of a specific purchase agreement with a financial intermediary) to acquire shares that are traded on Nasdaq. This requires our shareholders to pass an ordinary resolution approving an &#8220;off-market purchase,&#8221; where such approval may be for a maximum period of five years. In relation to an &#8220;off-market purchase,&#8221; we may not acquire our own shares until the terms of the contract pursuant to which the purchase(s) are to be made have been authorized by our shareholders. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transfer and Registration of Shares </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Articles of Association allow shareholders to transfer all or any of their shares by instrument of transfer in writing in any usual form or in any other form which our board of directors may approve. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The instrument of transfer must be executed by or on behalf of the transferor and (in the case of a transfer of a share that is not fully paid) by or on behalf of the transferee. Our Articles of Association also permit transfer of shares in uncertificated form by means of a relevant electronic system. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not charge a fee for registering the transfer of a share. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors may, in its absolute discretion, refuse to register a transfer of shares in certificated form if it is not fully paid (provided that the refusal does not prevent dealings in the shares from taking place on an open and proper basis) or is with respect to a share on which we have a lien and sums in respect of which the lien exists are payable and are not paid within 14 clear days after due notice has been sent. If our board of directors refuses to register a transfer of a share, it shall notify the transferor of the refusal and the reasons for it as soon as practicable and in any event within two months after the date on which the instrument of transfer was lodged with us (in the case of a transfer of a share in certificated form) or the instructions to the relevant system received. Any instrument of transfer which our board of directors refuses to register shall (except in the case of fraud) be returned to the person lodging it when notice of the refusal is sent. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computershare Trust Company, N.A. acts as our transfer agent and registrar. The share register reflects only registered owners of our Class&#160;A ordinary shares, Class&#160;B shares, Class&#160;R redeemable shares and deferred shares. Registration in the Company&#8217;s share register is determinative of ownership of shares of the Company. A shareholder who holds shares beneficially is not the holder of record of such shares. Instead, the clearance service or depositary (for example, Cede&#160;&#38; Co, as nominee for the Depository Trust Company, or DTC, or GTU Ops, Inc., as nominee for Computershare Trust Company, N.A.) or other nominee is the holder of record of those shares. Accordingly, a transfer of shares from a person who holds such shares beneficially to a person who holds such shares beneficially through a clearance service or depositary or other nominee will not be registered in the Company&#8217;s official share register, as the depositary or other nominee will remain the record holder of any such shares. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that the Company notifies one or both of the parties to a share transfer that it believes stamp duty or stamp duty reserve tax is required to be paid in connection with a transfer of shares of the Company, if the parties </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the transfer have an instrument of transfer duly stamped to the extent required and then provide such instrument of transfer to the Company&#8217;s share registrar, the buyer will be registered as the legal owner of the relevant shares on the official share register, subject to our rights with respect to the disclosure of interests in our shares. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Takeover Provisions </font></div><div style="margin-top:6pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation of Takeover Bids </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given that our central management and control is currently not situated within, and our current intention is not to have it in the future situated within the United Kingdom (or the Channel Islands or the Isle of Man), we do not currently envisage that the City Code on Takeovers and Mergers (the &#8220;Takeover Code&#8221;) will apply to an offer for the Company. It is possible that in the future circumstances could change that may cause the Takeover Code to apply to us. The Takeover Code provides a framework within which takeovers of companies subject to it are conducted. In particular, the Takeover Code contains certain rules in respect of mandatory offers. Under Rule 9 of the Takeover Code, if a person&#58; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;acquires an interest in shares that, when taken together with shares in which such person is already interested and in which persons acting in concert with such person are interested, carries 30% or more of the voting rights of shares&#59; or </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;who, together with persons acting in concert with such person, is interested in shares that in the aggregate carry not less than 30% of the voting rights but is not interested in shares carrying more than 50% of such voting rights and such person, or any person acting in concert with such person, acquires an additional interest in shares that increases the percentage of shares carrying voting rights in which that person is interested, </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the acquirer, and, depending on the circumstances, its concert parties, would be required (except with the consent of the Takeover Panel) to make a cash offer for the outstanding shares at a price not less than the highest price paid for any interests in the shares by the acquirer or its concert parties during the previous 12 months. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under English law, an offeror for the Company that has acquired (i)&#160;not less than 90% in value of&#59; and (ii)&#160;not less than 90% of the voting rights carried by the shares to which the offer relates may exercise statutory squeeze-out rights to compulsorily acquire the shares of the non-assenting minority. However, if an offer for the Company is conducted by way of a scheme of arrangement the threshold for the offeror obtaining 100% of Company shares comprises two components (i)&#160;approval by a majority in number of each class of Company shareholders present and voting at the shareholder meeting&#59; and (ii)&#160;approval of Company shareholders representing 75% or more in value of each class of Company shareholders present and voting at that meeting. </font></div><div style="margin-top:18pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Issues in the Context of an Acquisition </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Articles of Association provide the board of directors with the power to establish a rights plan and to grant rights to subscribe for our shares pursuant to a rights plan where, in the opinion of the board of directors, acting in good faith, in the context of an acquisition or potential acquisition of 15% or more of our issued voting shares, to do so would improve the likelihood that&#58; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;an acquisition process is conducted in an orderly manner&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;all our shareholders are treated equally and fairly and in a similar manner&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;an optimum price is achieved for our Class&#160;A ordinary shares&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the board of directors would have time to gather relevant information and pursue appropriate strategies&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the success of Royalty Pharma would be promoted for the benefit of our shareholders as a whole&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the long term interests of Royalty Pharma, our shareholders and business would be safeguarded&#59; and&#47;or </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Royalty Pharma would not suffer serious economic harm. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Articles of Association further provide that the board of directors may, in accordance with the terms of a rights plan, determine to (i)&#160;allot shares pursuant to the exercise of rights or (ii)&#160;exchange rights for our shares, where in the opinion of the board of directors acting in good faith, in the context of an acquisition or potential acquisition of 15% or more of our issued voting shares, to do so is necessary in order to prevent&#58; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the use of abusive tactics by any person in connection with such acquisition&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;unequal treatment of shareholders&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;an acquisition which would undervalue Royalty Pharma&#59; </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;harm to the prospects of the success of Royalty Pharma for the benefit of its shareholder as a whole&#59; and&#47;or </font></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;serious economic harm to the prospects of Royalty Pharma, </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or where to do so is otherwise necessary to safeguard the long term interests of Royalty Pharma, our shareholders and our business. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Takeover Code, the board of a public company incorporated under the laws of England and Wales is constrained from implementing such defensive measures. However, as discussed above, these measures are included in our Articles of Association as the Takeover Code is not expected to apply to us and these measures are included commonly in the constitution of U.S. companies. </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions will apply for so long as we are not subject to the Takeover Code. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>rprx-20211231ex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icab9d329f019482d9452297becc261f6_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Consent&#160;of Independent Registered Public Accounting Firm</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">We&#160;consent&#160;to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="margin-bottom:0.08pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:9.75pt">Registration Statement (Form S-8 No. 333-239193) pertaining to the Royalty Pharma plc 2020 Independent Director Equity Incentive Plan&#59; and</font></div><div style="margin-bottom:0.08pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:9.66pt">Registration Statement (Form S-4 No. 333-257188) of Royalty Pharma plc&#59; and </font></div><div style="margin-bottom:0.08pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:9.66pt">Registration Statement (Form S-3ASR No. 333-257883) of Royalty Pharma plc&#59; </font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">of our report dated February 15, 2022, with respect to the consolidated financial statements of Royalty Pharma plc and the effectiveness of internal control over financial reporting of Royalty Pharma plc, included in this Annual Report (Form 10-K) of Royalty Pharma plc for the year ended December 31, 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#47;s&#47; Ernst &#38; Young </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Dublin, Ireland</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">February 15, 2022</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>rprx-20211231ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2d68bf7df5454f9dbf267b00327fd14e_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULE 13A-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, Pablo Legorreta, certify that&#58; </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of Royalty Pharma plc&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d) &#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;All significant deficiencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and material weaknesses in the design or operation of internal control over financial reporting which</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58; February 15, 2022</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.545%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Pablo Legorreta</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pablo Legorreta</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>rprx-20211231ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i5009ffdf069a4ea0b428adf6f3d3092d_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Exhibit 31.2</font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULE 13A-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, Terrance Coyne, certify that&#58; </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of Royalty Pharma plc&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d) &#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;All significant deficiencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and material weaknesses in the design or operation of internal control over financial reporting which</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58; February 15, 2022</font></div><div><font><br></font></div><div style="padding-left:216pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.545%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Terrance Coyne</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Terrance Coyne</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Financial Officer</font></td></tr></table></div><div style="padding-left:216pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>rprx-20211231ex32.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if9f175683f8b4c44b637348b8660259c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 32</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AS ADOPTED PURSUANT TO SECTION 906 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Royalty Pharma plc (the &#8220;Company&#8221;) for the fiscal year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the Company certifies pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58;&#160;February 15, 2022</font></div><div style="margin-bottom:1pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.295%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Pablo Legorreta</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Pablo Legorreta</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Executive Officer</font></td></tr></table></div><div style="margin-bottom:1pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.295%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Terrance Coyne</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Terrance Coyne</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Financial Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>rprx-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:ca5bf1b5-7b51-40b4-bf4b-78f0f34b00d0,g:ba501133-7b9f-46c5-b0d4-2c55034547ac-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rprx="http://royaltypharma.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://royaltypharma.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rprx-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rprx-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rprx-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rprx-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://royaltypharma.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://royaltypharma.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://royaltypharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofOperations">
        <link:definition>1003005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>1004006 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquity" roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity">
        <link:definition>1005007 - Statement - Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquityParenthetical" roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical">
        <link:definition>1006008 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1007009 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandPurpose" roleURI="http://royaltypharma.com/role/OrganizationandPurpose">
        <link:definition>2101101 - Disclosure - Organization and Purpose</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandPurposeDetails" roleURI="http://royaltypharma.com/role/OrganizationandPurposeDetails">
        <link:definition>2402401 - Disclosure - Organization and Purpose (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2405402 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecurities" roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecurities">
        <link:definition>2106103 - Disclosure - Available for Sale Debt Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecuritiesTables" roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables">
        <link:definition>2307301 - Disclosure - Available for Sale Debt Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecuritiesNarrativeDetails" roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails">
        <link:definition>2408403 - Disclosure - Available for Sale Debt Securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails">
        <link:definition>2409404 - Disclosure - Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://royaltypharma.com/role/DerivativeInstruments">
        <link:definition>2110104 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://royaltypharma.com/role/DerivativeInstrumentsTables">
        <link:definition>2311302 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsNarrativeDetails" roleURI="http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails">
        <link:definition>2412405 - Disclosure - Derivative Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" roleURI="http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails">
        <link:definition>2413406 - Disclosure - Derivative Instruments - Summary of Derivatives and Reclassifications (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFinancialInstruments" roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments">
        <link:definition>2114105 - Disclosure - Fair Value Measurements and Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFinancialInstrumentsTables" roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables">
        <link:definition>2315303 - Disclosure - Fair Value Measurements and Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails">
        <link:definition>2416407 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails">
        <link:definition>2417408 - Disclosure - Fair Value Measurements and Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails">
        <link:definition>2418409 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails">
        <link:definition>2419410 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialRoyaltyAssetsNet" roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssetsNet">
        <link:definition>2120106 - Disclosure - Financial Royalty Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialRoyaltyAssetsNetTables" roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssetsNetTables">
        <link:definition>2321304 - Disclosure - Financial Royalty Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails">
        <link:definition>2422411 - Disclosure - Financial Royalty Assets, Net - Summary of Financial Royalty Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets" roleURI="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets">
        <link:definition>2123107 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables" roleURI="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables">
        <link:definition>2324305 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails" roleURI="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails">
        <link:definition>2425412 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" roleURI="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails">
        <link:definition>2426413 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleRoyaltyAssetsNet" roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet">
        <link:definition>2127108 - Disclosure - Intangible Royalty Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleRoyaltyAssetsNetTables" roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables">
        <link:definition>2328306 - Disclosure - Intangible Royalty Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails">
        <link:definition>2429414 - Disclosure - Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleRoyaltyAssetsNetNarrativeDetails" roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails">
        <link:definition>2430415 - Disclosure - Intangible Royalty Assets, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonConsolidatedAffiliates" roleURI="http://royaltypharma.com/role/NonConsolidatedAffiliates">
        <link:definition>2131109 - Disclosure - Non-Consolidated Affiliates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonConsolidatedAffiliatesDetails" roleURI="http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails">
        <link:definition>2432416 - Disclosure - Non-Consolidated Affiliates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchDevelopmentRDFundingExpense" roleURI="http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense">
        <link:definition>2133110 - Disclosure - Research &amp; Development ("R&amp;D") Funding Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchDevelopmentRDFundingExpenseDetails" roleURI="http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails">
        <link:definition>2434417 - Disclosure - Research &amp; Development ("R&amp;D") Funding Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowings" roleURI="http://royaltypharma.com/role/Borrowings">
        <link:definition>2135111 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsTables" roleURI="http://royaltypharma.com/role/BorrowingsTables">
        <link:definition>2336307 - Disclosure - Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofBorrowingsDetails" roleURI="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails">
        <link:definition>2437418 - Disclosure - Borrowings - Schedule of Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofBorrowingsDetails_1" roleURI="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1">
        <link:definition>2437418 - Disclosure - Borrowings - Schedule of Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsNarrativeDetails" roleURI="http://royaltypharma.com/role/BorrowingsNarrativeDetails">
        <link:definition>2438419 - Disclosure - Borrowings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofRepaymentsofDebtbyYearDetails" roleURI="http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails">
        <link:definition>2439420 - Disclosure - Borrowings - Schedule of Repayments of Debt by Year (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://royaltypharma.com/role/ShareholdersEquity">
        <link:definition>2140112 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityTables" roleURI="http://royaltypharma.com/role/ShareholdersEquityTables">
        <link:definition>2341308 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityNarrativeDetails" roleURI="http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails">
        <link:definition>2442421 - Disclosure - Shareholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquitySummaryofNoncontrollingInterestsDetails" roleURI="http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails">
        <link:definition>2443422 - Disclosure - Shareholders' Equity - Summary of Noncontrolling Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://royaltypharma.com/role/EarningsPerShare">
        <link:definition>2144113 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://royaltypharma.com/role/EarningsPerShareTables">
        <link:definition>2345309 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://royaltypharma.com/role/EarningsPerShareDetails">
        <link:definition>2446423 - Disclosure - Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndirectCashFlow" roleURI="http://royaltypharma.com/role/IndirectCashFlow">
        <link:definition>2147114 - Disclosure - Indirect Cash Flow</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndirectCashFlowTables" roleURI="http://royaltypharma.com/role/IndirectCashFlowTables">
        <link:definition>2348310 - Disclosure - Indirect Cash Flow (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndirectCashFlowDetails" roleURI="http://royaltypharma.com/role/IndirectCashFlowDetails">
        <link:definition>2449424 - Disclosure - Indirect Cash Flow (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncome" roleURI="http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncome">
        <link:definition>2150115 - Disclosure - Accumulated Other Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeTables" roleURI="http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeTables">
        <link:definition>2351311 - Disclosure - Accumulated Other Comprehensive Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeDetails" roleURI="http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails">
        <link:definition>2452425 - Disclosure - Accumulated Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://royaltypharma.com/role/RelatedPartyTransactions">
        <link:definition>2153116 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://royaltypharma.com/role/RelatedPartyTransactionsTables">
        <link:definition>2354312 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://royaltypharma.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2455426 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://royaltypharma.com/role/CommitmentsandContingencies">
        <link:definition>2156117 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://royaltypharma.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2457427 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://royaltypharma.com/role/SubsequentEvents">
        <link:definition>2158118 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://royaltypharma.com/role/SubsequentEventsDetails">
        <link:definition>2459428 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash" abstract="false" name="RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_FundingAgreementsWithPfizerMember" abstract="true" name="FundingAgreementsWithPfizerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RedeemableStockRedemptionPricePerShare" abstract="false" name="RedeemableStockRedemptionPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain" abstract="true" name="DebtSecuritiesAvailableForSaleRedemptionPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_CysticFibrosisFranchiseMember" abstract="true" name="CysticFibrosisFranchiseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_TwoPointOneFivePercentSeniorNotesDue2031Member" abstract="true" name="TwoPointOneFivePercentSeniorNotesDue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount" abstract="false" name="PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_SaleOfStockNumberOfSharesNotConverted" abstract="false" name="SaleOfStockNumberOfSharesNotConverted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rprx_A2020EquityIncentivePlanMember" abstract="true" name="A2020EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PaymentsToAcquireRoyaltyInterestsUpfrontPayment" abstract="false" name="PaymentsToAcquireRoyaltyInterestsUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_ResearchAndDevelopmentRemainingFundingCommitment" abstract="false" name="ResearchAndDevelopmentRemainingFundingCommitment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_CommonStockExchangeRatio" abstract="false" name="CommonStockExchangeRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rprx_MorphoSysMember" abstract="true" name="MorphoSysMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_VertexMember" abstract="true" name="VertexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital" abstract="false" name="CollaborativeArrangementRightsAndObligationsPaymentOfCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member" abstract="true" name="ThreePointFiveFivePercentSeniorNotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments" abstract="false" name="PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate" abstract="false" name="DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rprx_LongTermFundingPartnershipNumberOfAdditionalPayments" abstract="false" name="LongTermFundingPartnershipNumberOfAdditionalPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rprx_AvillionIMember" abstract="true" name="AvillionIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_MerckAssetPhaseIIClinicalTrialMember" abstract="true" name="MerckAssetPhaseIIClinicalTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PurchaseCommitmentUpfrontPayment" abstract="false" name="PurchaseCommitmentUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff" abstract="false" name="FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DevelopmentFundingBondForwardMember" abstract="true" name="DevelopmentFundingBondForwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RelatedPartyTransactionRateAdjustedCashReceipts" abstract="false" name="RelatedPartyTransactionRateAdjustedCashReceipts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rprx_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" abstract="false" name="ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_RoyalPharmacySelectFinanceTrustMember" abstract="true" name="RoyalPharmacySelectFinanceTrustMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_FundingAgreementsWithSanofiMember" abstract="true" name="FundingAgreementsWithSanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_FundingAgreementWithBioCrystMember" abstract="true" name="FundingAgreementWithBioCrystMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod" abstract="false" name="DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest" abstract="false" name="OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_FinancialRoyaltyAssetsMember" abstract="true" name="FinancialRoyaltyAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member" abstract="true" name="OnePointTwoZeroPercentSeniorNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_FormerOperatingAndPersonnelPaymentsMember" abstract="true" name="FormerOperatingAndPersonnelPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DeferredSharesParOrStatedValuePerShare" abstract="false" name="DeferredSharesParOrStatedValuePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest" abstract="false" name="OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_OvernightBankFundingRateMember" abstract="true" name="OvernightBankFundingRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_TremfyaMember" abstract="true" name="TremfyaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_OtherFinancialRoyaltyAssetMember" abstract="true" name="OtherFinancialRoyaltyAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RoyaltyPharmaInvestmentsOldRPIMember" abstract="true" name="RoyaltyPharmaInvestmentsOldRPIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member" abstract="true" name="RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_SeniorUnsecuredRevolvingCreditFacilityMember" abstract="true" name="SeniorUnsecuredRevolvingCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_OptionIndexedToIssuersEquityTerm" abstract="false" name="OptionIndexedToIssuersEquityTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships" abstract="false" name="StockIssuedDuringPeriodSharesIssuedToPartnerships" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member" abstract="true" name="ThreePointThreeFivePercentSeniorNotesDue2051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_AvillionEntitiesMember" abstract="true" name="AvillionEntitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_AssignmentAgreementFundingObligationsMember" abstract="true" name="AssignmentAgreementFundingObligationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI" abstract="false" name="ProceedsFromIssuanceOfEquitySecuritiesFNNI" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember" abstract="true" name="RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" abstract="false" name="DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember" abstract="true" name="DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_ExchangeOfferTransactionMember" abstract="true" name="ExchangeOfferTransactionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_EPAHoldingsMember" abstract="true" name="EPAHoldingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DeferredSharesSharesOutstanding" abstract="false" name="DeferredSharesSharesOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rprx_ImbruvicaMember" abstract="true" name="ImbruvicaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_SeniorNotesDue2051Member" abstract="true" name="SeniorNotesDue2051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RoyaltyIncomeOtherMember" abstract="true" name="RoyaltyIncomeOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate" abstract="false" name="CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member" abstract="true" name="RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_GainLossOnDerivativeFinancialInstruments" abstract="false" name="GainLossOnDerivativeFinancialInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtInstrumentIssuanceAsAPercentOfPar" abstract="false" name="DebtInstrumentIssuanceAsAPercentOfPar" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rprx_IncreaseDecreaseInDebtSecuritiesAvailableForSale" abstract="false" name="IncreaseDecreaseInDebtSecuritiesAvailableForSale" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_ProceedsFromNoncontrollingInterestsOther" abstract="false" name="ProceedsFromNoncontrollingInterestsOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_TheNotesMember" abstract="true" name="TheNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RelatedPartyTransactionCumulativeFundingAmount" abstract="false" name="RelatedPartyTransactionCumulativeFundingAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage" abstract="false" name="DebtSecuritiesAvailableForSaleRedemptionPricePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSalePricePerShare" abstract="false" name="DebtSecuritiesAvailableForSalePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="rprx_ContinuingInvestorsPartnershipMember" abstract="true" name="ContinuingInvestorsPartnershipMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_EpizymeIncMember" abstract="true" name="EpizymeIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PaymentsForDistributionsToShareholdersAndUnitholders" abstract="false" name="PaymentsForDistributionsToShareholdersAndUnitholders" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_ClassBHoldersMember" abstract="true" name="ClassBHoldersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_LongTermPurchaseCommitmentAmountOutstanding" abstract="false" name="LongTermPurchaseCommitmentAmountOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_TysabriMember" abstract="true" name="TysabriMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DeferredSharesMember" abstract="true" name="DeferredSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PaymentOfDividendsToShareholders" abstract="false" name="PaymentOfDividendsToShareholders" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_PurchaseCommitmentAdditionalPayment" abstract="false" name="PurchaseCommitmentAdditionalPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_IPOSharesFromSellingShareholdersMember" abstract="true" name="IPOSharesFromSellingShareholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock" abstract="false" name="DebtSecuritiesAvailableForSalePolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" abstract="false" name="RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" abstract="false" name="DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" abstract="false" name="RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rprx_OnePointSevenFivePercentSeniorNotesDue2027Member" abstract="true" name="OnePointSevenFivePercentSeniorNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RPHoldingsMember" abstract="true" name="RPHoldingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_NoncontrollingInterestTransfersOfInterests" abstract="false" name="NoncontrollingInterestTransfersOfInterests" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_OptionIndexedToIssuersEquityValue" abstract="false" name="OptionIndexedToIssuersEquityValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" abstract="false" name="InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" abstract="false" name="ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_TreasuryRateLockContractsMember" abstract="true" name="TreasuryRateLockContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_LongTermFundingPartnershipInitialPayment" abstract="false" name="LongTermFundingPartnershipInitialPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_SettlementsWithEquityMethodInvestments" abstract="false" name="SettlementsWithEquityMethodInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_PaymentsForOperatingCostsAndProfessionalServices" abstract="false" name="PaymentsForOperatingCostsAndProfessionalServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member" abstract="true" name="ThreePointThreeZeroPercentSeniorNotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember" abstract="true" name="LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_AccruedPurchaseObligationCurrent" abstract="false" name="AccruedPurchaseObligationCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DeferredSharesSharesIssued" abstract="false" name="DeferredSharesSharesIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rprx_IndividualLicenseesConcentrationRiskMember" abstract="true" name="IndividualLicenseesConcentrationRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PaymentsForCollateralPostedOnDerivativeInstruments" abstract="false" name="PaymentsForCollateralPostedOnDerivativeInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable" abstract="false" name="IncreaseDecreaseInOtherRoyaltyIncomeReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment" abstract="false" name="ProceedsFromNoncontrollingInterestsResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation" abstract="false" name="StockholdersEquitySharesEffectOfExchangeAndReallocation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rprx_UnitHoldersAndShareholdersContributionsMember" abstract="true" name="UnitHoldersAndShareholdersContributionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_AvillionIIMember" abstract="true" name="AvillionIIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_LegacyInvestorsPartnershipsAndRPSFTMember" abstract="true" name="LegacyInvestorsPartnershipsAndRPSFTMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_CollaborativeArrangementRightsAndObligationsExpectedReturn" abstract="false" name="CollaborativeArrangementRightsAndObligationsExpectedReturn" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" abstract="false" name="FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm" abstract="false" name="CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rprx_OtherRoyaltyIncomeReceivableCurrent" abstract="false" name="OtherRoyaltyIncomeReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_SaleOfStockNumberOfSharesAvailableToConvert" abstract="false" name="SaleOfStockNumberOfSharesAvailableToConvert" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rprx_PaymentsToTerminateDerivativeInstruments" abstract="false" name="PaymentsToTerminateDerivativeInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_AssetsFairValueDisclosureCurrent" abstract="false" name="AssetsFairValueDisclosureCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" abstract="false" name="DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rprx_AccruedRoyaltyReceivable" abstract="false" name="AccruedRoyaltyReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember" abstract="true" name="AcquisitionOfLimitedPartnershipInterestsInAffiliateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis" abstract="true" name="DebtSecuritiesAvailableForSaleRedemptionPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="rprx_PaymentsToNoncontrollingInterestsOther" abstract="false" name="PaymentsToNoncontrollingInterestsOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" abstract="false" name="FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_RelatedPartyTransactionAnnualIncreasePercentage" abstract="false" name="RelatedPartyTransactionAnnualIncreasePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod" abstract="false" name="DebtSecuritiesAvailableForSaleRestrictionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rprx_NumberOfClassesOfVotingStock" abstract="false" name="NumberOfClassesOfVotingStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rprx_RelatedPartyTransactionInitialTerm" abstract="false" name="RelatedPartyTransactionInitialTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments" abstract="false" name="DebtSecuritiesAvailableForSaleQuarterlyPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_IncreaseDecreaseInAccruedRoyaltyReceivable" abstract="false" name="IncreaseDecreaseInAccruedRoyaltyReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_PaymentsToAcquireEquitySecuritiesFNNI" abstract="false" name="PaymentsToAcquireEquitySecuritiesFNNI" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_PaymentsForMilestones" abstract="false" name="PaymentsForMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" abstract="false" name="FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_LongTermFundingPartnershipNumberOfTranches" abstract="false" name="LongTermFundingPartnershipNumberOfTranches" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rprx_NumberOfNoncontrollingInterestsCreated" abstract="false" name="NumberOfNoncontrollingInterestsCreated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember" abstract="true" name="LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RoyaltyAssetsPolicyPolicyTextBlock" abstract="false" name="RoyaltyAssetsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rprx_MilestonePaymentAccruedButNotPaid" abstract="false" name="MilestonePaymentAccruedButNotPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_FinancingReceivablesFairValueDisclosure" abstract="false" name="FinancingReceivablesFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_EpizymeCommonStockWarrantMember" abstract="true" name="EpizymeCommonStockWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember" abstract="true" name="DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PabloLegorretaMember" abstract="true" name="PabloLegorretaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" abstract="false" name="RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_PaymentsToAcquireRoyaltyInterestsAggregateAmount" abstract="false" name="PaymentsToAcquireRoyaltyInterestsAggregateAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_RelatedPartyTransactionRateValueOfSecurityInvestments" abstract="false" name="RelatedPartyTransactionRateValueOfSecurityInvestments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" abstract="false" name="FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_BristolMyersSquibbMember" abstract="true" name="BristolMyersSquibbMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PointSevenFivePercentSeniorNotesDue2023Member" abstract="true" name="PointSevenFivePercentSeniorNotesDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" abstract="false" name="PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_StockIssuedDuringPeriodValueIssuedForRegistration" abstract="false" name="StockIssuedDuringPeriodValueIssuedForRegistration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment" abstract="false" name="PaymentsToAcquireEquityInvestmentsUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_PromactaMember" abstract="true" name="PromactaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_NetIncomeLossAttributableToParentPriorToOffering" abstract="false" name="NetIncomeLossAttributableToParentPriorToOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_ClassRRedeemableStockMember" abstract="true" name="ClassRRedeemableStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_StockholdersEquityValueEffectOfExchangeAndReallocation" abstract="false" name="StockholdersEquityValueEffectOfExchangeAndReallocation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_StockIssuedDuringPeriodValueIssuedToPartnerships" abstract="false" name="StockIssuedDuringPeriodValueIssuedToPartnerships" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember" abstract="true" name="LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_AssignmentAgreementBenefitOfPaymentStreamMember" abstract="true" name="AssignmentAgreementBenefitOfPaymentStreamMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_IntangibleRoyaltyAssetsMember" abstract="true" name="IntangibleRoyaltyAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_PaymentsForUpfrontDevelopmentStageFunding" abstract="false" name="PaymentsForUpfrontDevelopmentStageFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_LongTermFundingPartnershipAmount" abstract="false" name="LongTermFundingPartnershipAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" abstract="false" name="DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rprx_OperatingAndPersonnelPaymentsMember" abstract="true" name="OperatingAndPersonnelPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RPI2019IntermediateFinanceMember" abstract="true" name="RPI2019IntermediateFinanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_IPOSharesFromCompanyMember" abstract="true" name="IPOSharesFromCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_SeniorNotesDue2031Member" abstract="true" name="SeniorNotesDue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn" abstract="false" name="CollaborativeArrangementRightsAndObligationsPeriodOfReturn" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments" abstract="false" name="ProceedsFromCollateralReceivedOnDerivativeInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" abstract="false" name="LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DPPIVPatentsMember" abstract="true" name="DPPIVPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_AZAssetPhaseIIAndPhaseIIIClinicalTrialMember" abstract="true" name="AZAssetPhaseIIAndPhaseIIIClinicalTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember" abstract="true" name="RoyaltyDistributionPayableToRPSelectFinanceTrustMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_NoncontrollingInterestIncreaseFromContributions" abstract="false" name="NoncontrollingInterestIncreaseFromContributions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleFixedPayment" abstract="false" name="DebtSecuritiesAvailableForSaleFixedPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" abstract="false" name="FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_OldCreditFacilityMember" abstract="true" name="OldCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RoyaltyPharmaCollectionTrustMember" abstract="true" name="RoyaltyPharmaCollectionTrustMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_NumberOfNoncontrollingInterests" abstract="false" name="NumberOfNoncontrollingInterests" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rprx_IPOContinuingInvestorsPartnershipsMember" abstract="true" name="IPOContinuingInvestorsPartnershipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod" abstract="false" name="DebtSecuritiesAvailableForSaleChangeInControlEventPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod" abstract="false" name="DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rprx_EvrysdiMember" abstract="true" name="EvrysdiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables" abstract="false" name="IncreaseDecreaseInCashCollectionsOnFinancingReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_PaymentsForOngoingDevelopmentStageFunding" abstract="false" name="PaymentsForOngoingDevelopmentStageFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member" abstract="true" name="TwoPointTwoZeroPercentSeniorNotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_XtandiMember" abstract="true" name="XtandiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_OtherCommitmentsPercentage" abstract="false" name="OtherCommitmentsPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rprx_EquityMethodInvestmentsUnfundedCommitments" abstract="false" name="EquityMethodInvestmentsUnfundedCommitments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" abstract="false" name="DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rprx_DeferredSharesValueIssued" abstract="false" name="DeferredSharesValueIssued" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_BioCrystPharmaceuticalsIncMember" abstract="true" name="BioCrystPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid" abstract="false" name="ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_PaymentsToAcquireWarrants" abstract="false" name="PaymentsToAcquireWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_StockIssuedDuringPeriodSharesIssuedForRegistration" abstract="false" name="StockIssuedDuringPeriodSharesIssuedForRegistration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rprx_RPIFTSeniorSecuredCreditFacilitiesMember" abstract="true" name="RPIFTSeniorSecuredCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" abstract="false" name="FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_LegacyInvestorsPartnershipsMember" abstract="true" name="LegacyInvestorsPartnershipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" abstract="false" name="ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_IncreaseDecreaseInFinancialRoyaltyAssets" abstract="false" name="IncreaseDecreaseInFinancialRoyaltyAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_PurchasingAndDonatingVentilatorsMember" abstract="true" name="PurchasingAndDonatingVentilatorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_RepaymentsOfLongTermDebtScheduledPayments" abstract="false" name="RepaymentsOfLongTermDebtScheduledPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_AccruedPurchaseObligationEquityInvestment" abstract="false" name="AccruedPurchaseObligationEquityInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rprx_AgreementWithMSCIMember" abstract="true" name="AgreementWithMSCIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rprx_AssetsFairValueDisclosureNoncurrent" abstract="false" name="AssetsFairValueDisclosureNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>rprx-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:ca5bf1b5-7b51-40b4-bf4b-78f0f34b00d0,g:ba501133-7b9f-46c5-b0d4-2c55034547ac-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="rprx-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_dc02046d-a4ed-457b-b232-ff3ea080fa74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_79bf6822-3735-482d-a556-22ec11de7db8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_dc02046d-a4ed-457b-b232-ff3ea080fa74" xlink:to="loc_us-gaap_Liabilities_79bf6822-3735-482d-a556-22ec11de7db8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5a951846-4e7b-4c3a-b14e-74450b5f31ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_dc02046d-a4ed-457b-b232-ff3ea080fa74" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5a951846-4e7b-4c3a-b14e-74450b5f31ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ca2c8302-8f72-433c-8f7c-e0d513664013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_dc02046d-a4ed-457b-b232-ff3ea080fa74" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ca2c8302-8f72-433c-8f7c-e0d513664013" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a28c3415-a546-4dc5-86e8-e7178b57cd50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b0c1f845-68c6-4c44-af90-69e9233f07a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a28c3415-a546-4dc5-86e8-e7178b57cd50" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b0c1f845-68c6-4c44-af90-69e9233f07a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_c9ef5f67-370a-45b6-a000-5ad59f4e76b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a28c3415-a546-4dc5-86e8-e7178b57cd50" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_c9ef5f67-370a-45b6-a000-5ad59f4e76b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AccruedRoyaltyReceivable_e5074596-36fb-468e-8f4b-a7142dc7f377" xlink:href="rprx-20211231.xsd#rprx_AccruedRoyaltyReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a28c3415-a546-4dc5-86e8-e7178b57cd50" xlink:to="loc_rprx_AccruedRoyaltyReceivable_e5074596-36fb-468e-8f4b-a7142dc7f377" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e61ae8c5-9195-499a-be18-2e41fb54f0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a28c3415-a546-4dc5-86e8-e7178b57cd50" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e61ae8c5-9195-499a-be18-2e41fb54f0c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherRoyaltyIncomeReceivableCurrent_c73eb417-3b57-4c3a-b352-1ea03f1a8e35" xlink:href="rprx-20211231.xsd#rprx_OtherRoyaltyIncomeReceivableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a28c3415-a546-4dc5-86e8-e7178b57cd50" xlink:to="loc_rprx_OtherRoyaltyIncomeReceivableCurrent_c73eb417-3b57-4c3a-b352-1ea03f1a8e35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_23086a83-48e2-4ce1-af66-7101968d0679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a28c3415-a546-4dc5-86e8-e7178b57cd50" xlink:to="loc_us-gaap_OtherAssetsCurrent_23086a83-48e2-4ce1-af66-7101968d0679" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt_069a6455-5aef-427d-a868-92647776ede2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a28c3415-a546-4dc5-86e8-e7178b57cd50" xlink:to="loc_us-gaap_TradingSecuritiesDebt_069a6455-5aef-427d-a868-92647776ede2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_63479088-0411-49ef-a674-8f5d2f798957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_48492d1c-b3f0-4629-981b-d99002c3e845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_63479088-0411-49ef-a674-8f5d2f798957" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_48492d1c-b3f0-4629-981b-d99002c3e845" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_d0205d14-8e65-4ac7-9260-3dd3d4b84ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_63479088-0411-49ef-a674-8f5d2f798957" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_d0205d14-8e65-4ac7-9260-3dd3d4b84ae4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_cb80a851-e8d6-4068-8311-00e64590bc39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_63479088-0411-49ef-a674-8f5d2f798957" xlink:to="loc_us-gaap_InterestPayableCurrent_cb80a851-e8d6-4068-8311-00e64590bc39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AccruedPurchaseObligationCurrent_a13117fb-6091-4089-af63-d3139b2a9165" xlink:href="rprx-20211231.xsd#rprx_AccruedPurchaseObligationCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_63479088-0411-49ef-a674-8f5d2f798957" xlink:to="loc_rprx_AccruedPurchaseObligationCurrent_a13117fb-6091-4089-af63-d3139b2a9165" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_8cf40b31-8673-4710-a975-b8b2996dac6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_63479088-0411-49ef-a674-8f5d2f798957" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_8cf40b31-8673-4710-a975-b8b2996dac6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d1bf63e4-ac58-4741-8d81-9a68d9c0db5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3e53bc80-e82b-46e6-ace3-6759917219e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d1bf63e4-ac58-4741-8d81-9a68d9c0db5e" xlink:to="loc_us-gaap_CommonStockValue_3e53bc80-e82b-46e6-ace3-6759917219e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesValueIssued_0ee881ea-6249-4f80-b12f-c1d326cd2774" xlink:href="rprx-20211231.xsd#rprx_DeferredSharesValueIssued"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d1bf63e4-ac58-4741-8d81-9a68d9c0db5e" xlink:to="loc_rprx_DeferredSharesValueIssued_0ee881ea-6249-4f80-b12f-c1d326cd2774" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f3f69792-4765-406f-91ec-786c6ba7edec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d1bf63e4-ac58-4741-8d81-9a68d9c0db5e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f3f69792-4765-406f-91ec-786c6ba7edec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fb23627c-66eb-4f25-b080-e55cfc847c07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d1bf63e4-ac58-4741-8d81-9a68d9c0db5e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fb23627c-66eb-4f25-b080-e55cfc847c07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_0e619fb3-0052-4656-9daf-cbda4503ac05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d1bf63e4-ac58-4741-8d81-9a68d9c0db5e" xlink:to="loc_us-gaap_MinorityInterest_0e619fb3-0052-4656-9daf-cbda4503ac05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71310b7d-5f3d-4371-a395-07c032180a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d1bf63e4-ac58-4741-8d81-9a68d9c0db5e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71310b7d-5f3d-4371-a395-07c032180a4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_b614bda6-f026-4b4f-abad-3ae6625a4c83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d1bf63e4-ac58-4741-8d81-9a68d9c0db5e" xlink:to="loc_us-gaap_TreasuryStockValue_b614bda6-f026-4b4f-abad-3ae6625a4c83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8c26f5ec-a00c-42fa-aa39-888996c0943d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4c3ac571-430c-4616-bfe7-16158dfdea05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8c26f5ec-a00c-42fa-aa39-888996c0943d" xlink:to="loc_us-gaap_AssetsCurrent_4c3ac571-430c-4616-bfe7-16158dfdea05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_69bc99ba-a240-4c4b-8412-07a97944252f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8c26f5ec-a00c-42fa-aa39-888996c0943d" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_69bc99ba-a240-4c4b-8412-07a97944252f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9f45b28f-b06c-4dec-8708-acb6412b943a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8c26f5ec-a00c-42fa-aa39-888996c0943d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9f45b28f-b06c-4dec-8708-acb6412b943a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_f861089a-3721-4795-88f5-428449179d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8c26f5ec-a00c-42fa-aa39-888996c0943d" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_f861089a-3721-4795-88f5-428449179d48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_06083dbd-45c3-4fa8-8a06-53ccc9bf2faa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8c26f5ec-a00c-42fa-aa39-888996c0943d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_06083dbd-45c3-4fa8-8a06-53ccc9bf2faa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_13321c23-f335-4837-af70-04eeaf00a6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8c26f5ec-a00c-42fa-aa39-888996c0943d" xlink:to="loc_us-gaap_EquityMethodInvestments_13321c23-f335-4837-af70-04eeaf00a6ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a0ce4ec2-cff7-4ad1-9429-094e888010d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8c26f5ec-a00c-42fa-aa39-888996c0943d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a0ce4ec2-cff7-4ad1-9429-094e888010d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_752e9e7b-ca8b-4d4a-a140-d4d4bff7acb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_745d45a3-c117-46a0-8fd2-a0e93ac09675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_752e9e7b-ca8b-4d4a-a140-d4d4bff7acb5" xlink:to="loc_us-gaap_LiabilitiesCurrent_745d45a3-c117-46a0-8fd2-a0e93ac09675" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_dd94dfe4-bd19-4f5e-a631-b4bdaa8cba42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_752e9e7b-ca8b-4d4a-a140-d4d4bff7acb5" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_dd94dfe4-bd19-4f5e-a631-b4bdaa8cba42" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="rprx-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_21a9e4ef-ab5d-4803-8284-22008791f344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cb80e8d9-148a-4b0c-b81b-a194d73396ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_21a9e4ef-ab5d-4803-8284-22008791f344" xlink:to="loc_us-gaap_Revenues_cb80e8d9-148a-4b0c-b81b-a194d73396ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_fb25100a-4055-40dd-916a-e5c619cd6351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_21a9e4ef-ab5d-4803-8284-22008791f344" xlink:to="loc_us-gaap_CostsAndExpenses_fb25100a-4055-40dd-916a-e5c619cd6351" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_18166bbe-788d-4cdf-b7ea-0aaf2df1afc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d1bd7590-8d5b-49cd-a820-0b0423ac8d30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_18166bbe-788d-4cdf-b7ea-0aaf2df1afc5" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d1bd7590-8d5b-49cd-a820-0b0423ac8d30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_79db11f9-314e-4953-9065-4a51a336e8c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_18166bbe-788d-4cdf-b7ea-0aaf2df1afc5" xlink:to="loc_us-gaap_InterestExpense_79db11f9-314e-4953-9065-4a51a336e8c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_9d9d75e9-9511-4151-8a5b-d5eb1fefe7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_18166bbe-788d-4cdf-b7ea-0aaf2df1afc5" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_9d9d75e9-9511-4151-8a5b-d5eb1fefe7ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d0cc711e-476d-4486-801c-975978c84875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_18166bbe-788d-4cdf-b7ea-0aaf2df1afc5" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d0cc711e-476d-4486-801c-975978c84875" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_ea01f0ce-dd67-4dc9-b0c3-a78414f56f28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_18166bbe-788d-4cdf-b7ea-0aaf2df1afc5" xlink:to="loc_us-gaap_InvestmentIncomeNet_ea01f0ce-dd67-4dc9-b0c3-a78414f56f28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a49c0fe3-7fec-4037-9526-15f065744d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_18166bbe-788d-4cdf-b7ea-0aaf2df1afc5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a49c0fe3-7fec-4037-9526-15f065744d0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_f40c64c9-1b6e-4455-b87a-c4647a2daa48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_18166bbe-788d-4cdf-b7ea-0aaf2df1afc5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_f40c64c9-1b6e-4455-b87a-c4647a2daa48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_64290065-2181-493c-aacd-7a3f9b76eb68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLoanAndLeaseLosses_a59688ab-0dd7-4ec6-9a13-f6d5668a79f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForLoanAndLeaseLosses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_64290065-2181-493c-aacd-7a3f9b76eb68" xlink:to="loc_us-gaap_ProvisionForLoanAndLeaseLosses_a59688ab-0dd7-4ec6-9a13-f6d5668a79f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d17c579e-ce92-4975-b10f-fc488b260f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_64290065-2181-493c-aacd-7a3f9b76eb68" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d17c579e-ce92-4975-b10f-fc488b260f32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1867b10f-1844-4cc9-8645-06518b8a9c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_64290065-2181-493c-aacd-7a3f9b76eb68" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1867b10f-1844-4cc9-8645-06518b8a9c7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1831945e-9053-4bd9-a46c-0c4db3562377" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_64290065-2181-493c-aacd-7a3f9b76eb68" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1831945e-9053-4bd9-a46c-0c4db3562377" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_07781b68-cbac-45ad-9e5c-c2912d03f43c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_64290065-2181-493c-aacd-7a3f9b76eb68" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_07781b68-cbac-45ad-9e5c-c2912d03f43c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_db9efd7f-2c1c-4774-b0c4-f6a103d3b233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d9a06d3-839d-4fdb-b7eb-643a235960b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_db9efd7f-2c1c-4774-b0c4-f6a103d3b233" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d9a06d3-839d-4fdb-b7eb-643a235960b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ac8a8ed0-0e30-412c-be73-6b75b43a7609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_db9efd7f-2c1c-4774-b0c4-f6a103d3b233" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ac8a8ed0-0e30-412c-be73-6b75b43a7609" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4fb3e5cb-ea42-45ed-99c8-1c8ba148eab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1c5cfc04-199f-48d5-aae2-99896315f7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_4fb3e5cb-ea42-45ed-99c8-1c8ba148eab2" xlink:to="loc_us-gaap_ProfitLoss_1c5cfc04-199f-48d5-aae2-99896315f7ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8e4e0fc1-821a-4a7e-b931-e00cef707397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_4fb3e5cb-ea42-45ed-99c8-1c8ba148eab2" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8e4e0fc1-821a-4a7e-b931-e00cef707397" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ac01d4d3-1468-45ea-a371-585b2707c763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e7b117d7-fa65-4e74-bf30-10964fae1fab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ac01d4d3-1468-45ea-a371-585b2707c763" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e7b117d7-fa65-4e74-bf30-10964fae1fab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b8321976-91f8-49f6-81db-90dada308476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ac01d4d3-1468-45ea-a371-585b2707c763" xlink:to="loc_us-gaap_OperatingIncomeLoss_b8321976-91f8-49f6-81db-90dada308476" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="rprx-20211231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f28f5246-f0e2-449b-b8a4-56ad8c77da59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_99501a4d-abbc-4005-9e63-0848af008189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f28f5246-f0e2-449b-b8a4-56ad8c77da59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_99501a4d-abbc-4005-9e63-0848af008189" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_5e8bc51c-9590-4e30-9d1c-1304ef803e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f28f5246-f0e2-449b-b8a4-56ad8c77da59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_5e8bc51c-9590-4e30-9d1c-1304ef803e9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c4251992-265c-43f5-a89e-2de2c4d5f7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f28f5246-f0e2-449b-b8a4-56ad8c77da59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c4251992-265c-43f5-a89e-2de2c4d5f7e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_91cf9ca9-1755-4696-afa6-fc0a046c8c44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_29a39317-5cf3-4214-a447-fa96039f152d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_91cf9ca9-1755-4696-afa6-fc0a046c8c44" xlink:to="loc_us-gaap_ProfitLoss_29a39317-5cf3-4214-a447-fa96039f152d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d4811237-e664-4c3d-8955-06acb2f590f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_91cf9ca9-1755-4696-afa6-fc0a046c8c44" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d4811237-e664-4c3d-8955-06acb2f590f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cc94dd64-49d7-4115-8374-77f164172330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0f43fb4b-f4f7-4f61-a477-e0c7fff9c05a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cc94dd64-49d7-4115-8374-77f164172330" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0f43fb4b-f4f7-4f61-a477-e0c7fff9c05a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_d98f0416-4737-433c-858f-1deb68798b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cc94dd64-49d7-4115-8374-77f164172330" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_d98f0416-4737-433c-858f-1deb68798b3d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="rprx-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43255e1f-88b1-48c2-af60-d95dce18e2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6982390f-1fb2-404a-827a-e7d68c250fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43255e1f-88b1-48c2-af60-d95dce18e2fa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6982390f-1fb2-404a-827a-e7d68c250fa4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dbf3f781-8ed7-49a8-9877-68fd795ae203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43255e1f-88b1-48c2-af60-d95dce18e2fa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dbf3f781-8ed7-49a8-9877-68fd795ae203" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aeb1425b-0d57-447e-9577-f99c6c4b81a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43255e1f-88b1-48c2-af60-d95dce18e2fa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aeb1425b-0d57-447e-9577-f99c6c4b81a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77627e5a-d105-4020-b665-439e3721cc19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_75b6a2af-1c2e-4855-b8d9-2f7bfe205efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77627e5a-d105-4020-b665-439e3721cc19" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_75b6a2af-1c2e-4855-b8d9-2f7bfe205efd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_e7fb26a0-da83-4db0-91e4-6899aa6a9b60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77627e5a-d105-4020-b665-439e3721cc19" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_e7fb26a0-da83-4db0-91e4-6899aa6a9b60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireEquitySecuritiesFNNI_ca3fa39d-7103-4f1c-863b-38d6b6fe3be5" xlink:href="rprx-20211231.xsd#rprx_PaymentsToAcquireEquitySecuritiesFNNI"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77627e5a-d105-4020-b665-439e3721cc19" xlink:to="loc_rprx_PaymentsToAcquireEquitySecuritiesFNNI_ca3fa39d-7103-4f1c-863b-38d6b6fe3be5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_7d39c10e-5b33-4f51-9676-51c365bbc99d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77627e5a-d105-4020-b665-439e3721cc19" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_7d39c10e-5b33-4f51-9676-51c365bbc99d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_da772818-86b2-4696-8ee2-f12d0c84c395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77627e5a-d105-4020-b665-439e3721cc19" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_da772818-86b2-4696-8ee2-f12d0c84c395" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2e5a16ce-d6d7-4781-8c79-ac49fb9305c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77627e5a-d105-4020-b665-439e3721cc19" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2e5a16ce-d6d7-4781-8c79-ac49fb9305c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_48be175c-a5a5-4c09-87f1-90403cad0f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77627e5a-d105-4020-b665-439e3721cc19" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_48be175c-a5a5-4c09-87f1-90403cad0f5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireFinanceReceivables_8b53c527-50c5-4068-a022-c70e838cd1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireFinanceReceivables"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77627e5a-d105-4020-b665-439e3721cc19" xlink:to="loc_us-gaap_PaymentsToAcquireFinanceReceivables_8b53c527-50c5-4068-a022-c70e838cd1a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForMilestones_c9f45cd4-9394-472f-9223-ddaa001a1261" xlink:href="rprx-20211231.xsd#rprx_PaymentsForMilestones"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77627e5a-d105-4020-b665-439e3721cc19" xlink:to="loc_rprx_PaymentsForMilestones_c9f45cd4-9394-472f-9223-ddaa001a1261" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireWarrants_5810b035-d58c-4751-a878-771dee7f704b" xlink:href="rprx-20211231.xsd#rprx_PaymentsToAcquireWarrants"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77627e5a-d105-4020-b665-439e3721cc19" xlink:to="loc_rprx_PaymentsToAcquireWarrants_5810b035-d58c-4751-a878-771dee7f704b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI_87961052-e4ef-4ac4-835b-7162e224e961" xlink:href="rprx-20211231.xsd#rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77627e5a-d105-4020-b665-439e3721cc19" xlink:to="loc_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI_87961052-e4ef-4ac4-835b-7162e224e961" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5a72ca7-d0f1-4b05-b616-11d4956bfd20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables_f471d44f-0210-4627-868f-73a07760b1e4" xlink:href="rprx-20211231.xsd#rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5a72ca7-d0f1-4b05-b616-11d4956bfd20" xlink:to="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables_f471d44f-0210-4627-868f-73a07760b1e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets_dc92753c-7030-4a3d-bab6-bffca418bb7f" xlink:href="rprx-20211231.xsd#rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5a72ca7-d0f1-4b05-b616-11d4956bfd20" xlink:to="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets_dc92753c-7030-4a3d-bab6-bffca418bb7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables_7b795256-fc68-487b-a118-880772db353b" xlink:href="rprx-20211231.xsd#rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5a72ca7-d0f1-4b05-b616-11d4956bfd20" xlink:to="loc_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables_7b795256-fc68-487b-a118-880772db353b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_e5128e98-a3b4-412f-b38f-ba14178d7cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5a72ca7-d0f1-4b05-b616-11d4956bfd20" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_e5128e98-a3b4-412f-b38f-ba14178d7cdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_999e11b9-2fdd-49b6-87ae-5b834bb68624" xlink:href="rprx-20211231.xsd#rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5a72ca7-d0f1-4b05-b616-11d4956bfd20" xlink:to="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_999e11b9-2fdd-49b6-87ae-5b834bb68624" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForCollateralPostedOnDerivativeInstruments_26017c45-617d-4504-b4dd-0d42e01a8104" xlink:href="rprx-20211231.xsd#rprx_PaymentsForCollateralPostedOnDerivativeInstruments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5a72ca7-d0f1-4b05-b616-11d4956bfd20" xlink:to="loc_rprx_PaymentsForCollateralPostedOnDerivativeInstruments_26017c45-617d-4504-b4dd-0d42e01a8104" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToTerminateDerivativeInstruments_bf923465-ac40-4614-bb5a-b21cdc17f4fc" xlink:href="rprx-20211231.xsd#rprx_PaymentsToTerminateDerivativeInstruments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5a72ca7-d0f1-4b05-b616-11d4956bfd20" xlink:to="loc_rprx_PaymentsToTerminateDerivativeInstruments_bf923465-ac40-4614-bb5a-b21cdc17f4fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_9074cc55-ff86-4148-bbba-ac707d9fd0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5a72ca7-d0f1-4b05-b616-11d4956bfd20" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_9074cc55-ff86-4148-bbba-ac707d9fd0e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForOngoingDevelopmentStageFunding_8ed30ec4-f0dc-432a-b1bc-4b5782384c61" xlink:href="rprx-20211231.xsd#rprx_PaymentsForOngoingDevelopmentStageFunding"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5a72ca7-d0f1-4b05-b616-11d4956bfd20" xlink:to="loc_rprx_PaymentsForOngoingDevelopmentStageFunding_8ed30ec4-f0dc-432a-b1bc-4b5782384c61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForOperatingCostsAndProfessionalServices_1aa0371f-fce7-47e8-813e-5ab68bfbb8bd" xlink:href="rprx-20211231.xsd#rprx_PaymentsForOperatingCostsAndProfessionalServices"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5a72ca7-d0f1-4b05-b616-11d4956bfd20" xlink:to="loc_rprx_PaymentsForOperatingCostsAndProfessionalServices_1aa0371f-fce7-47e8-813e-5ab68bfbb8bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_13e58a2c-b18c-428d-aeed-32c2a8fce7de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5a72ca7-d0f1-4b05-b616-11d4956bfd20" xlink:to="loc_us-gaap_InterestPaidNet_13e58a2c-b18c-428d-aeed-32c2a8fce7de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForUpfrontDevelopmentStageFunding_8b1be44f-9459-4f20-862a-f19fe2630f7d" xlink:href="rprx-20211231.xsd#rprx_PaymentsForUpfrontDevelopmentStageFunding"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5a72ca7-d0f1-4b05-b616-11d4956bfd20" xlink:to="loc_rprx_PaymentsForUpfrontDevelopmentStageFunding_8b1be44f-9459-4f20-862a-f19fe2630f7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92e18c63-d0f0-43f2-bdb5-f5c9d03e400d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForDistributionsToShareholdersAndUnitholders_10fe5646-f65d-49ba-9f51-43d0f9c5d0c2" xlink:href="rprx-20211231.xsd#rprx_PaymentsForDistributionsToShareholdersAndUnitholders"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92e18c63-d0f0-43f2-bdb5-f5c9d03e400d" xlink:to="loc_rprx_PaymentsForDistributionsToShareholdersAndUnitholders_10fe5646-f65d-49ba-9f51-43d0f9c5d0c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_9bc371c4-a87a-4609-bba7-87395afc3179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92e18c63-d0f0-43f2-bdb5-f5c9d03e400d" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_9bc371c4-a87a-4609-bba7-87395afc3179" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToNoncontrollingInterestsOther_aa51ea42-3b0e-4f85-b735-d3f8e0d77695" xlink:href="rprx-20211231.xsd#rprx_PaymentsToNoncontrollingInterestsOther"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92e18c63-d0f0-43f2-bdb5-f5c9d03e400d" xlink:to="loc_rprx_PaymentsToNoncontrollingInterestsOther_aa51ea42-3b0e-4f85-b735-d3f8e0d77695" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentOfDividendsToShareholders_f302f738-cbba-48e6-bae8-f2e12bf4137a" xlink:href="rprx-20211231.xsd#rprx_PaymentOfDividendsToShareholders"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92e18c63-d0f0-43f2-bdb5-f5c9d03e400d" xlink:to="loc_rprx_PaymentOfDividendsToShareholders_f302f738-cbba-48e6-bae8-f2e12bf4137a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment_17c40bcb-2b7f-4199-b146-a2cd9b79b1ba" xlink:href="rprx-20211231.xsd#rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92e18c63-d0f0-43f2-bdb5-f5c9d03e400d" xlink:to="loc_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment_17c40bcb-2b7f-4199-b146-a2cd9b79b1ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromNoncontrollingInterestsOther_e1777bd8-451d-4d73-943e-be323f4bcfb4" xlink:href="rprx-20211231.xsd#rprx_ProceedsFromNoncontrollingInterestsOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92e18c63-d0f0-43f2-bdb5-f5c9d03e400d" xlink:to="loc_rprx_ProceedsFromNoncontrollingInterestsOther_e1777bd8-451d-4d73-943e-be323f4bcfb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RepaymentsOfLongTermDebtScheduledPayments_5ae95ff5-550c-414d-82a5-e65ff2234c1c" xlink:href="rprx-20211231.xsd#rprx_RepaymentsOfLongTermDebtScheduledPayments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92e18c63-d0f0-43f2-bdb5-f5c9d03e400d" xlink:to="loc_rprx_RepaymentsOfLongTermDebtScheduledPayments_5ae95ff5-550c-414d-82a5-e65ff2234c1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_f26eea9f-7fe0-445a-bd10-5608424dbaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92e18c63-d0f0-43f2-bdb5-f5c9d03e400d" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_f26eea9f-7fe0-445a-bd10-5608424dbaf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5b4cbf8f-0c67-41c0-9afb-fc9d0db719c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92e18c63-d0f0-43f2-bdb5-f5c9d03e400d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5b4cbf8f-0c67-41c0-9afb-fc9d0db719c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_5f10e7fa-86cd-40c0-86e3-f3d046718085" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92e18c63-d0f0-43f2-bdb5-f5c9d03e400d" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_5f10e7fa-86cd-40c0-86e3-f3d046718085" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f6bf0ffd-4cc0-4a0e-9cea-aa3ff957f9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92e18c63-d0f0-43f2-bdb5-f5c9d03e400d" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f6bf0ffd-4cc0-4a0e-9cea-aa3ff957f9ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_397bf568-a27a-4c85-85ed-f4aba53b6403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92e18c63-d0f0-43f2-bdb5-f5c9d03e400d" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_397bf568-a27a-4c85-85ed-f4aba53b6403" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_930a7364-36e2-4206-bcd7-4c2e0b033216" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_563ab3ec-cbda-4f63-a961-abbd892cc61e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_930a7364-36e2-4206-bcd7-4c2e0b033216" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_563ab3ec-cbda-4f63-a961-abbd892cc61e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a37adec5-5c7a-48c2-8faa-e3205d61b8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_930a7364-36e2-4206-bcd7-4c2e0b033216" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a37adec5-5c7a-48c2-8faa-e3205d61b8a0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssetsFairValueDisclosureCurrent_cedd47f0-3319-416c-8a51-87b521bc1614" xlink:href="rprx-20211231.xsd#rprx_AssetsFairValueDisclosureCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e049565f-829a-464d-9d55-6739ebd91683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_AssetsFairValueDisclosureCurrent_cedd47f0-3319-416c-8a51-87b521bc1614" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e049565f-829a-464d-9d55-6739ebd91683" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt_00e7278f-2ba4-469c-be55-4992fcd13291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_AssetsFairValueDisclosureCurrent_cedd47f0-3319-416c-8a51-87b521bc1614" xlink:to="loc_us-gaap_TradingSecuritiesDebt_00e7278f-2ba4-469c-be55-4992fcd13291" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_cbc37ee6-ac66-4fb2-9771-cf2afcd792cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_AssetsFairValueDisclosureCurrent_cedd47f0-3319-416c-8a51-87b521bc1614" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_cbc37ee6-ac66-4fb2-9771-cf2afcd792cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssetsFairValueDisclosureNoncurrent_c954a9a2-b731-4ab4-8d43-edf023362521" xlink:href="rprx-20211231.xsd#rprx_AssetsFairValueDisclosureNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_c1144850-58ed-455a-bc3e-3ef075e69111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_AssetsFairValueDisclosureNoncurrent_c954a9a2-b731-4ab4-8d43-edf023362521" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_c1144850-58ed-455a-bc3e-3ef075e69111" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_2f49a3a2-0115-452e-852b-9f698be8fd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_AssetsFairValueDisclosureNoncurrent_c954a9a2-b731-4ab4-8d43-edf023362521" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_2f49a3a2-0115-452e-852b-9f698be8fd0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_f012fe3b-4b99-46fe-a6f0-9a6e7fe0a574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_AssetsFairValueDisclosureNoncurrent_c954a9a2-b731-4ab4-8d43-edf023362521" xlink:to="loc_us-gaap_DerivativeAssets_f012fe3b-4b99-46fe-a6f0-9a6e7fe0a574" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_bf9463ae-52e5-43c4-a0db-f72768fe4b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_f09ec5f6-ebea-45b2-8169-81f24262f09e" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NotesReceivableNet_bf9463ae-52e5-43c4-a0db-f72768fe4b75" xlink:to="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_f09ec5f6-ebea-45b2-8169-81f24262f09e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_8166bdd5-12e9-47cd-810f-a905ce915c13" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NotesReceivableNet_bf9463ae-52e5-43c4-a0db-f72768fe4b75" xlink:to="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_8166bdd5-12e9-47cd-810f-a905ce915c13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_f1aaf022-0c0d-4862-b870-3913b55f410a" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_8e0d5a42-b68a-453d-9951-05d4915bd776" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_f1aaf022-0c0d-4862-b870-3913b55f410a" xlink:to="loc_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_8e0d5a42-b68a-453d-9951-05d4915bd776" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross_c6dc25ee-c4b1-4732-9f65-e03f2944433e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_f1aaf022-0c0d-4862-b870-3913b55f410a" xlink:to="loc_us-gaap_NotesReceivableGross_c6dc25ee-c4b1-4732-9f65-e03f2944433e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1859a943-b541-491c-ab34-fb8e9f9bcace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e7991f1a-6b0d-4bc8-a5da-5ab46a6a46da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1859a943-b541-491c-ab34-fb8e9f9bcace" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e7991f1a-6b0d-4bc8-a5da-5ab46a6a46da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3f0436a4-4655-4488-a796-e53dedc65405" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1859a943-b541-491c-ab34-fb8e9f9bcace" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3f0436a4-4655-4488-a796-e53dedc65405" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#BorrowingsScheduleofBorrowingsDetails"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2ee2e08c-6f25-41f5-8d24-1e2f372a19b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_cf476989-17d7-4bb2-b6c6-5d178e10de2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2ee2e08c-6f25-41f5-8d24-1e2f372a19b8" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_cf476989-17d7-4bb2-b6c6-5d178e10de2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_f720acfb-fe58-4405-abf9-432dccba7051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2ee2e08c-6f25-41f5-8d24-1e2f372a19b8" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_f720acfb-fe58-4405-abf9-432dccba7051" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1" xlink:type="simple" xlink:href="rprx-20211231.xsd#BorrowingsScheduleofBorrowingsDetails_1"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3dfc57d0-730f-427e-96ff-c4502ff27c47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f3ef92e3-82e1-40d5-a1b1-465cc72f9011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3dfc57d0-730f-427e-96ff-c4502ff27c47" xlink:to="loc_us-gaap_LongTermDebtCurrent_f3ef92e3-82e1-40d5-a1b1-465cc72f9011" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_88f01ff6-5b85-4960-aff6-e1817640928c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3dfc57d0-730f-427e-96ff-c4502ff27c47" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_88f01ff6-5b85-4960-aff6-e1817640928c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#BorrowingsScheduleofRepaymentsofDebtbyYearDetails"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_4247b36a-9734-49bd-bed0-68592a4a0d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_fb23c131-9626-43fb-92b1-8c5f99a57ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_4247b36a-9734-49bd-bed0-68592a4a0d5f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_fb23c131-9626-43fb-92b1-8c5f99a57ca6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_7e65f1ed-7142-4512-9d5e-bc56832172b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_4247b36a-9734-49bd-bed0-68592a4a0d5f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_7e65f1ed-7142-4512-9d5e-bc56832172b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0f79a7bb-9b86-423e-a70c-f17dbf285f50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_4247b36a-9734-49bd-bed0-68592a4a0d5f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0f79a7bb-9b86-423e-a70c-f17dbf285f50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_baa668ee-58e7-401c-86be-d9368c5c25fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_4247b36a-9734-49bd-bed0-68592a4a0d5f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_baa668ee-58e7-401c-86be-d9368c5c25fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a59612ab-c2f3-4517-b11a-22cdd71fbaeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_4247b36a-9734-49bd-bed0-68592a4a0d5f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a59612ab-c2f3-4517-b11a-22cdd71fbaeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_cb9b596c-26e1-4d49-89b9-21400177049e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_4247b36a-9734-49bd-bed0-68592a4a0d5f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_cb9b596c-26e1-4d49-89b9-21400177049e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#EarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_cc904df9-b8bc-4cc6-9a57-9e28ba72fbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e6533da8-ba1d-4627-8ff8-1ce9ffc57ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_cc904df9-b8bc-4cc6-9a57-9e28ba72fbdb" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e6533da8-ba1d-4627-8ff8-1ce9ffc57ef1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f3387113-b401-48f4-9233-1cac143cd9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_cc904df9-b8bc-4cc6-9a57-9e28ba72fbdb" xlink:to="loc_us-gaap_ProfitLoss_f3387113-b401-48f4-9233-1cac143cd9bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NetIncomeLossAttributableToParentPriorToOffering_8790d4f5-5999-4c4c-8d60-5757f346f7e7" xlink:href="rprx-20211231.xsd#rprx_NetIncomeLossAttributableToParentPriorToOffering"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_cc904df9-b8bc-4cc6-9a57-9e28ba72fbdb" xlink:to="loc_rprx_NetIncomeLossAttributableToParentPriorToOffering_8790d4f5-5999-4c4c-8d60-5757f346f7e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_0f15a279-5338-4d20-b6f6-ab171be94d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4c18e8e7-bfd1-4ffc-8880-070975ce55d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_0f15a279-5338-4d20-b6f6-ab171be94d90" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4c18e8e7-bfd1-4ffc-8880-070975ce55d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5591a2c4-58a7-4f23-999e-75c2b285cd84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_0f15a279-5338-4d20-b6f6-ab171be94d90" xlink:to="loc_us-gaap_ProfitLoss_5591a2c4-58a7-4f23-999e-75c2b285cd84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NetIncomeLossAttributableToParentPriorToOffering_a325247c-c447-47a4-827b-e9f58687910a" xlink:href="rprx-20211231.xsd#rprx_NetIncomeLossAttributableToParentPriorToOffering"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_0f15a279-5338-4d20-b6f6-ab171be94d90" xlink:to="loc_rprx_NetIncomeLossAttributableToParentPriorToOffering_a325247c-c447-47a4-827b-e9f58687910a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6117936d-04ad-4855-89f8-0d46c126dc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cf30b0d7-df94-41b1-8107-d2f4dd6458c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6117936d-04ad-4855-89f8-0d46c126dc2e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cf30b0d7-df94-41b1-8107-d2f4dd6458c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_d2c6765f-e2cf-4cee-846f-2043c9b2a82a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6117936d-04ad-4855-89f8-0d46c126dc2e" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_d2c6765f-e2cf-4cee-846f-2043c9b2a82a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IndirectCashFlowDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#IndirectCashFlowDetails"/>
  <link:calculationLink xlink:role="http://royaltypharma.com/role/IndirectCashFlowDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_888d1719-2c15-4168-85e4-17ae3d3d372e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_888d1719-2c15-4168-85e4-17ae3d3d372e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_bbf85cf8-a9a0-4fe9-b465-c6d5ccd66b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_bbf85cf8-a9a0-4fe9-b465-c6d5ccd66b2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_635f86fb-06a9-4a7f-b90d-c1a70cd44415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_635f86fb-06a9-4a7f-b90d-c1a70cd44415" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_827b8dd9-9bb6-440c-84ed-6833f4123004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:to="loc_us-gaap_ShareBasedCompensation_827b8dd9-9bb6-440c-84ed-6833f4123004" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_069fce45-fb9a-41c3-9d7b-15926a449e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:to="loc_us-gaap_ProfitLoss_069fce45-fb9a-41c3-9d7b-15926a449e1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInDebtSecuritiesAvailableForSale_76a5d6bb-c8bd-4146-8348-bdf1587543db" xlink:href="rprx-20211231.xsd#rprx_IncreaseDecreaseInDebtSecuritiesAvailableForSale"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:to="loc_rprx_IncreaseDecreaseInDebtSecuritiesAvailableForSale_76a5d6bb-c8bd-4146-8348-bdf1587543db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable_7351a68a-99ab-48f3-9d4b-3249da30522a" xlink:href="rprx-20211231.xsd#rprx_IncreaseDecreaseInAccruedRoyaltyReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:to="loc_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable_7351a68a-99ab-48f3-9d4b-3249da30522a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_0f2ec105-4e6d-4153-94c7-4cc148a8863b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_0f2ec105-4e6d-4153-94c7-4cc148a8863b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables_61b2fc4a-b78a-4f98-a00c-5e8fd1810466" xlink:href="rprx-20211231.xsd#rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:to="loc_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables_61b2fc4a-b78a-4f98-a00c-5e8fd1810466" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_32addb3d-0bb4-450d-81e0-300a4a67c893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_32addb3d-0bb4-450d-81e0-300a4a67c893" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a9861487-db4c-4a9f-841d-7bf8c4aa7e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a9861487-db4c-4a9f-841d-7bf8c4aa7e2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_e00dfef3-4378-421a-88f3-77255b722c71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_e00dfef3-4378-421a-88f3-77255b722c71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLoanAndLeaseLosses_86f3a2f1-c74b-4f32-a88f-62278f0fb23c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForLoanAndLeaseLosses"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:to="loc_us-gaap_ProvisionForLoanAndLeaseLosses_86f3a2f1-c74b-4f32-a88f-62278f0fb23c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_bad695b4-27fc-4ac4-9c06-b953f3e84a97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_bad695b4-27fc-4ac4-9c06-b953f3e84a97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_aeb7b3be-dbcc-4329-b3ac-16d34c6420bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_aeb7b3be-dbcc-4329-b3ac-16d34c6420bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_b7816151-673d-4001-a860-04e360752cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_b7816151-673d-4001-a860-04e360752cf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable_ff22e240-b945-40ef-87a4-a86b439c58d5" xlink:href="rprx-20211231.xsd#rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:to="loc_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable_ff22e240-b945-40ef-87a4-a86b439c58d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_1b061376-6680-41c9-a896-d2fb18b351ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_1b061376-6680-41c9-a896-d2fb18b351ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss_13708463-6174-4dda-a747-3e324e41e833" xlink:href="rprx-20211231.xsd#rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:to="loc_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss_13708463-6174-4dda-a747-3e324e41e833" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_1958a8ce-52f9-4836-944e-235230003190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:calculationArc order="20" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_1958a8ce-52f9-4836-944e-235230003190" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_fe1dd7b7-3173-4ada-a5a3-501da9203f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:to="loc_us-gaap_AssetImpairmentCharges_fe1dd7b7-3173-4ada-a5a3-501da9203f9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_GainLossOnDerivativeFinancialInstruments_49dbbcf3-8966-427b-bf3c-ed8d734c1214" xlink:href="rprx-20211231.xsd#rprx_GainLossOnDerivativeFinancialInstruments"/>
    <link:calculationArc order="22" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:to="loc_rprx_GainLossOnDerivativeFinancialInstruments_49dbbcf3-8966-427b-bf3c-ed8d734c1214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInFinancialRoyaltyAssets_c563f0dd-d3c4-4f7e-a779-1225c5110fe5" xlink:href="rprx-20211231.xsd#rprx_IncreaseDecreaseInFinancialRoyaltyAssets"/>
    <link:calculationArc order="23" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:to="loc_rprx_IncreaseDecreaseInFinancialRoyaltyAssets_c563f0dd-d3c4-4f7e-a779-1225c5110fe5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_9d4aa4ad-5cbe-4712-9645-2f2c013b420e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:calculationArc order="24" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d296ad39-c5ad-47d2-9e21-3307fb852110" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_9d4aa4ad-5cbe-4712-9645-2f2c013b420e" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>rprx-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:ca5bf1b5-7b51-40b4-bf4b-78f0f34b00d0,g:ba501133-7b9f-46c5-b0d4-2c55034547ac-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://royaltypharma.com/role/Cover" xlink:type="simple" xlink:href="rprx-20211231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/Cover" xlink:type="extended" id="icd22032bb5bb42c9bcd43b2141e98c7a_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ecb6c2d1-31e8-4a9d-8583-d4c7096d5d3e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_DocumentType_ecb6c2d1-31e8-4a9d-8583-d4c7096d5d3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_6e5f2032-c5ce-403f-8b8e-3f3cfcc5c831" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_DocumentAnnualReport_6e5f2032-c5ce-403f-8b8e-3f3cfcc5c831" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a4f619a3-9f5f-4be7-8f47-7311e7395d91" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_DocumentPeriodEndDate_a4f619a3-9f5f-4be7-8f47-7311e7395d91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_36cbf107-49a7-4396-a56d-c61960f46c55" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_CurrentFiscalYearEndDate_36cbf107-49a7-4396-a56d-c61960f46c55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f8c38a7b-aa22-4e44-97a8-e194c82712b5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_DocumentTransitionReport_f8c38a7b-aa22-4e44-97a8-e194c82712b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_609eb283-012e-4628-9d92-9581f0984ca5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityFileNumber_609eb283-012e-4628-9d92-9581f0984ca5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_aba2b2dd-b8d1-407f-867d-b5983d8a8e48" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityRegistrantName_aba2b2dd-b8d1-407f-867d-b5983d8a8e48" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_cd0f0a28-6c31-42bc-9637-bdd69b7996e5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityIncorporationStateCountryCode_cd0f0a28-6c31-42bc-9637-bdd69b7996e5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c49ce067-d04a-4bd7-85e3-10b74e53bed1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityTaxIdentificationNumber_c49ce067-d04a-4bd7-85e3-10b74e53bed1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b5d7f311-6f60-4bd1-ac76-45becdcd59bb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityAddressAddressLine1_b5d7f311-6f60-4bd1-ac76-45becdcd59bb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_01ac4cdb-bc2d-4a82-96ce-05d9fcf6f1d5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityAddressCityOrTown_01ac4cdb-bc2d-4a82-96ce-05d9fcf6f1d5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c55f23c1-a8e1-4ed0-a1c9-d9a39147e331" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityAddressStateOrProvince_c55f23c1-a8e1-4ed0-a1c9-d9a39147e331" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_678da046-9183-4ec4-a0e0-e98a7884971d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityAddressPostalZipCode_678da046-9183-4ec4-a0e0-e98a7884971d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_bb0d4e58-725f-4a86-869b-e75a5188e343" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_CityAreaCode_bb0d4e58-725f-4a86-869b-e75a5188e343" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_77bfc734-36a4-405c-9235-34166d26e602" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_LocalPhoneNumber_77bfc734-36a4-405c-9235-34166d26e602" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a31020cc-fc6f-4628-8c36-d98eee37b361" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_Security12bTitle_a31020cc-fc6f-4628-8c36-d98eee37b361" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_28f60e53-a877-4130-b1e6-0f2aceaf8003" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_TradingSymbol_28f60e53-a877-4130-b1e6-0f2aceaf8003" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_41c0f21b-d7cd-48f2-8967-0bcb94879b84" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_SecurityExchangeName_41c0f21b-d7cd-48f2-8967-0bcb94879b84" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_bc8e0e2f-85e4-4642-b264-2c73acda1bfc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_bc8e0e2f-85e4-4642-b264-2c73acda1bfc" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_1d6897eb-e3cb-48d3-94f9-d51a0b634e72" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityVoluntaryFilers_1d6897eb-e3cb-48d3-94f9-d51a0b634e72" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_45c8919e-3158-4311-9c46-32efe26ea0a4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityCurrentReportingStatus_45c8919e-3158-4311-9c46-32efe26ea0a4" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6030176d-c601-4619-bf48-8e95cffc4434" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityInteractiveDataCurrent_6030176d-c601-4619-bf48-8e95cffc4434" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_ae667c59-91b6-4b43-abaa-908021d16d5e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityFilerCategory_ae667c59-91b6-4b43-abaa-908021d16d5e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_cc5272cc-6178-4009-a53a-e745bda32325" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntitySmallBusiness_cc5272cc-6178-4009-a53a-e745bda32325" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1f27cbb8-e9c3-4f67-8046-644b97faf37e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityEmergingGrowthCompany_1f27cbb8-e9c3-4f67-8046-644b97faf37e" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_1d6b03fc-892a-4b1b-9996-bc1f0d11c551" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_IcfrAuditorAttestationFlag_1d6b03fc-892a-4b1b-9996-bc1f0d11c551" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b084a4ef-e3d1-40dd-9b89-aeab9f5ae677" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityShellCompany_b084a4ef-e3d1-40dd-9b89-aeab9f5ae677" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_e2051e08-804d-4858-a0c6-a4b3b4e01672" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityPublicFloat_e2051e08-804d-4858-a0c6-a4b3b4e01672" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c01f5e12-9ac7-442a-aeef-5c906839f4c7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c01f5e12-9ac7-442a-aeef-5c906839f4c7" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_316cfed3-4174-4edd-a8bb-efbee63a3260" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_316cfed3-4174-4edd-a8bb-efbee63a3260" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_44e15b53-24fc-47f4-8655-8019a19c9330" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityCentralIndexKey_44e15b53-24fc-47f4-8655-8019a19c9330" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_3e4fe46e-b020-4376-92df-03b52f8ca25b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_DocumentFiscalYearFocus_3e4fe46e-b020-4376-92df-03b52f8ca25b" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_a6bd135d-7e81-48d5-92b6-d096afe5c276" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_DocumentFiscalPeriodFocus_a6bd135d-7e81-48d5-92b6-d096afe5c276" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_521b1159-1232-4669-8a97-44e879998c3c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_AmendmentFlag_521b1159-1232-4669-8a97-44e879998c3c" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_7300679b-c60a-4226-8f58-bc5821743b22" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_DocumentInformationTable_7300679b-c60a-4226-8f58-bc5821743b22" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6020aac5-8c12-42f1-b7af-537c408ad38c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_7300679b-c60a-4226-8f58-bc5821743b22" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6020aac5-8c12-42f1-b7af-537c408ad38c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6020aac5-8c12-42f1-b7af-537c408ad38c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6020aac5-8c12-42f1-b7af-537c408ad38c" xlink:to="loc_us-gaap_ClassOfStockDomain_6020aac5-8c12-42f1-b7af-537c408ad38c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_80fd84df-0f12-4c5b-b43d-0071c1a1b817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6020aac5-8c12-42f1-b7af-537c408ad38c" xlink:to="loc_us-gaap_ClassOfStockDomain_80fd84df-0f12-4c5b-b43d-0071c1a1b817" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_a2c22ace-5320-40e2-ba49-24788b216986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_80fd84df-0f12-4c5b-b43d-0071c1a1b817" xlink:to="loc_us-gaap_CommonClassAMember_a2c22ace-5320-40e2-ba49-24788b216986" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_05f22e4c-90be-4cb9-8534-c5fde8228db4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_80fd84df-0f12-4c5b-b43d-0071c1a1b817" xlink:to="loc_us-gaap_CommonClassBMember_05f22e4c-90be-4cb9-8534-c5fde8228db4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="rprx-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i3d63fa48fe214a6db8cc996067f7a5c9_ConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_379d7fbf-12ab-4f89-8491-0049399e6582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_97eef486-71a4-47f0-b80c-2c7fb330a1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_379d7fbf-12ab-4f89-8491-0049399e6582" xlink:to="loc_us-gaap_AssetsAbstract_97eef486-71a4-47f0-b80c-2c7fb330a1cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_da804a29-6b0c-44d9-a165-a8e09c813f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_97eef486-71a4-47f0-b80c-2c7fb330a1cf" xlink:to="loc_us-gaap_AssetsCurrentAbstract_da804a29-6b0c-44d9-a165-a8e09c813f0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_af5a14d6-0c12-49ed-a26e-88dbd09f899b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da804a29-6b0c-44d9-a165-a8e09c813f0b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_af5a14d6-0c12-49ed-a26e-88dbd09f899b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt_bbe3d3b7-48f7-4285-a2d2-98eedbdb14f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da804a29-6b0c-44d9-a165-a8e09c813f0b" xlink:to="loc_us-gaap_TradingSecuritiesDebt_bbe3d3b7-48f7-4285-a2d2-98eedbdb14f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_c2b61232-58f0-4334-bdd1-f1ce56bea3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da804a29-6b0c-44d9-a165-a8e09c813f0b" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_c2b61232-58f0-4334-bdd1-f1ce56bea3a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AccruedRoyaltyReceivable_d76d534e-e142-43d2-afd2-fc9207a8a921" xlink:href="rprx-20211231.xsd#rprx_AccruedRoyaltyReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da804a29-6b0c-44d9-a165-a8e09c813f0b" xlink:to="loc_rprx_AccruedRoyaltyReceivable_d76d534e-e142-43d2-afd2-fc9207a8a921" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c132dcb0-bde3-4454-b53b-6cd8ff1266cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da804a29-6b0c-44d9-a165-a8e09c813f0b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c132dcb0-bde3-4454-b53b-6cd8ff1266cb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherRoyaltyIncomeReceivableCurrent_e040232e-023b-427d-9ef9-e29db3af4116" xlink:href="rprx-20211231.xsd#rprx_OtherRoyaltyIncomeReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da804a29-6b0c-44d9-a165-a8e09c813f0b" xlink:to="loc_rprx_OtherRoyaltyIncomeReceivableCurrent_e040232e-023b-427d-9ef9-e29db3af4116" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_37fb386d-2ab8-4d46-9108-5c32d4d9e243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da804a29-6b0c-44d9-a165-a8e09c813f0b" xlink:to="loc_us-gaap_OtherAssetsCurrent_37fb386d-2ab8-4d46-9108-5c32d4d9e243" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4d18f7fd-937e-4bac-bb8f-3cb90236672d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da804a29-6b0c-44d9-a165-a8e09c813f0b" xlink:to="loc_us-gaap_AssetsCurrent_4d18f7fd-937e-4bac-bb8f-3cb90236672d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_ab021ebf-bc7a-4e78-924a-67c54ad9c190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_97eef486-71a4-47f0-b80c-2c7fb330a1cf" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_ab021ebf-bc7a-4e78-924a-67c54ad9c190" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4d965246-9a46-4aa4-a7a9-8917710df626" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_97eef486-71a4-47f0-b80c-2c7fb330a1cf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4d965246-9a46-4aa4-a7a9-8917710df626" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_b96c8ad1-c54c-47c0-a603-204035f74b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_97eef486-71a4-47f0-b80c-2c7fb330a1cf" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_b96c8ad1-c54c-47c0-a603-204035f74b28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_d7189a9e-63b1-4579-a673-a991127813f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_97eef486-71a4-47f0-b80c-2c7fb330a1cf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_d7189a9e-63b1-4579-a673-a991127813f7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_51a2c9ed-6c34-4a69-bf29-4c6a06723f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_97eef486-71a4-47f0-b80c-2c7fb330a1cf" xlink:to="loc_us-gaap_EquityMethodInvestments_51a2c9ed-6c34-4a69-bf29-4c6a06723f87" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_da460cca-c88d-4d99-bffc-f5998aa9692c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_97eef486-71a4-47f0-b80c-2c7fb330a1cf" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_da460cca-c88d-4d99-bffc-f5998aa9692c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7cd98b40-bc83-46a7-915a-3744add01890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_97eef486-71a4-47f0-b80c-2c7fb330a1cf" xlink:to="loc_us-gaap_Assets_7cd98b40-bc83-46a7-915a-3744add01890" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15f33c41-50da-40df-93af-3093b6fe477f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_379d7fbf-12ab-4f89-8491-0049399e6582" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15f33c41-50da-40df-93af-3093b6fe477f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_b4d9266e-808c-417b-bb91-4b2a1c3b43d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15f33c41-50da-40df-93af-3093b6fe477f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_b4d9266e-808c-417b-bb91-4b2a1c3b43d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_0da97c58-d228-4a5a-a086-cb511cdcb40b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b4d9266e-808c-417b-bb91-4b2a1c3b43d6" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_0da97c58-d228-4a5a-a086-cb511cdcb40b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_10e63121-cf11-4d81-8718-1d9b83c80f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b4d9266e-808c-417b-bb91-4b2a1c3b43d6" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_10e63121-cf11-4d81-8718-1d9b83c80f8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_b17fb0b4-5ec5-48e6-980f-bc1388ccf024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b4d9266e-808c-417b-bb91-4b2a1c3b43d6" xlink:to="loc_us-gaap_InterestPayableCurrent_b17fb0b4-5ec5-48e6-980f-bc1388ccf024" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AccruedPurchaseObligationCurrent_3da93739-3327-4613-8739-91f00c19c2b2" xlink:href="rprx-20211231.xsd#rprx_AccruedPurchaseObligationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b4d9266e-808c-417b-bb91-4b2a1c3b43d6" xlink:to="loc_rprx_AccruedPurchaseObligationCurrent_3da93739-3327-4613-8739-91f00c19c2b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_cd99e4ae-8ace-42ed-8418-8c16d0f49e52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b4d9266e-808c-417b-bb91-4b2a1c3b43d6" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_cd99e4ae-8ace-42ed-8418-8c16d0f49e52" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_532bb326-e8bd-4b4d-b75f-fca37d4b6ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b4d9266e-808c-417b-bb91-4b2a1c3b43d6" xlink:to="loc_us-gaap_LiabilitiesCurrent_532bb326-e8bd-4b4d-b75f-fca37d4b6ccb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3df6080c-3eef-4271-a8cd-482fc92e6b21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15f33c41-50da-40df-93af-3093b6fe477f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3df6080c-3eef-4271-a8cd-482fc92e6b21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d49ecf5e-8da6-4c10-ba9f-e9f19c991c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15f33c41-50da-40df-93af-3093b6fe477f" xlink:to="loc_us-gaap_Liabilities_d49ecf5e-8da6-4c10-ba9f-e9f19c991c23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_878e96c6-0719-49a5-b5f4-b18617672c69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15f33c41-50da-40df-93af-3093b6fe477f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_878e96c6-0719-49a5-b5f4-b18617672c69" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_323bf0dc-8588-4712-8b27-dfe3815657ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15f33c41-50da-40df-93af-3093b6fe477f" xlink:to="loc_us-gaap_StockholdersEquityAbstract_323bf0dc-8588-4712-8b27-dfe3815657ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c1d90460-9086-4280-9184-f6dd76a3af15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_323bf0dc-8588-4712-8b27-dfe3815657ac" xlink:to="loc_us-gaap_CommonStockValue_c1d90460-9086-4280-9184-f6dd76a3af15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesValueIssued_fc95c69c-2c31-424d-b5ba-a3fc0b57485b" xlink:href="rprx-20211231.xsd#rprx_DeferredSharesValueIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_323bf0dc-8588-4712-8b27-dfe3815657ac" xlink:to="loc_rprx_DeferredSharesValueIssued_fc95c69c-2c31-424d-b5ba-a3fc0b57485b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_bb9015d9-1ac9-472f-ad4a-5c45b92aba13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_323bf0dc-8588-4712-8b27-dfe3815657ac" xlink:to="loc_us-gaap_AdditionalPaidInCapital_bb9015d9-1ac9-472f-ad4a-5c45b92aba13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cf38f34d-9e5e-40a9-8c34-7272a77f05c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_323bf0dc-8588-4712-8b27-dfe3815657ac" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cf38f34d-9e5e-40a9-8c34-7272a77f05c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_62e94208-5109-4061-a3e1-ec32cdfcb558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_323bf0dc-8588-4712-8b27-dfe3815657ac" xlink:to="loc_us-gaap_MinorityInterest_62e94208-5109-4061-a3e1-ec32cdfcb558" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_15e3a1c8-56f6-45b3-936d-fd35f8685fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_323bf0dc-8588-4712-8b27-dfe3815657ac" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_15e3a1c8-56f6-45b3-936d-fd35f8685fa9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_50e5e2ea-3679-463a-b19f-ee41170921cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_323bf0dc-8588-4712-8b27-dfe3815657ac" xlink:to="loc_us-gaap_TreasuryStockValue_50e5e2ea-3679-463a-b19f-ee41170921cc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d5e3ade0-5df6-4f45-ad45-d31dc5282a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_323bf0dc-8588-4712-8b27-dfe3815657ac" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d5e3ade0-5df6-4f45-ad45-d31dc5282a1e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9d19a1af-80a2-4cf3-9b7c-f2b7dcf9dd00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15f33c41-50da-40df-93af-3093b6fe477f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9d19a1af-80a2-4cf3-9b7c-f2b7dcf9dd00" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a42f52d5-bba9-4ee4-8554-dcc084f77c12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_379d7fbf-12ab-4f89-8491-0049399e6582" xlink:to="loc_us-gaap_StatementTable_a42f52d5-bba9-4ee4-8554-dcc084f77c12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6ec523a7-0692-475c-9af4-894e7423061c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a42f52d5-bba9-4ee4-8554-dcc084f77c12" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6ec523a7-0692-475c-9af4-894e7423061c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6ec523a7-0692-475c-9af4-894e7423061c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6ec523a7-0692-475c-9af4-894e7423061c" xlink:to="loc_us-gaap_ClassOfStockDomain_6ec523a7-0692-475c-9af4-894e7423061c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fb2c7ebd-d1ab-49b8-ae34-d748fb1beee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6ec523a7-0692-475c-9af4-894e7423061c" xlink:to="loc_us-gaap_ClassOfStockDomain_fb2c7ebd-d1ab-49b8-ae34-d748fb1beee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_6ed9376b-cf0e-4039-8854-0f5b1992ac5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_fb2c7ebd-d1ab-49b8-ae34-d748fb1beee2" xlink:to="loc_us-gaap_CommonClassAMember_6ed9376b-cf0e-4039-8854-0f5b1992ac5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_8756a310-c601-44bb-883b-57976f8181b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_fb2c7ebd-d1ab-49b8-ae34-d748fb1beee2" xlink:to="loc_us-gaap_CommonClassBMember_8756a310-c601-44bb-883b-57976f8181b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember_dd777bdc-27e4-455c-8fc1-f379fe195e23" xlink:href="rprx-20211231.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_fb2c7ebd-d1ab-49b8-ae34-d748fb1beee2" xlink:to="loc_rprx_ClassRRedeemableStockMember_dd777bdc-27e4-455c-8fc1-f379fe195e23" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="rprx-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i93c0a4b45fc74e94ab0176f670e0d473_ConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_845a702f-c5bc-427c-9ac4-1e3bc855fe31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a4e6d989-34fc-493b-89ba-b24a687c37bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_845a702f-c5bc-427c-9ac4-1e3bc855fe31" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a4e6d989-34fc-493b-89ba-b24a687c37bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_602f8aff-f520-4d55-a10c-6b5e2854e9db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_845a702f-c5bc-427c-9ac4-1e3bc855fe31" xlink:to="loc_us-gaap_CommonStockSharesIssued_602f8aff-f520-4d55-a10c-6b5e2854e9db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b9c76088-6db4-4325-abd0-6bfece40fa47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_845a702f-c5bc-427c-9ac4-1e3bc855fe31" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b9c76088-6db4-4325-abd0-6bfece40fa47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesParOrStatedValuePerShare_37ef4f6a-0555-416d-933a-dc2d49e865c0" xlink:href="rprx-20211231.xsd#rprx_DeferredSharesParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_845a702f-c5bc-427c-9ac4-1e3bc855fe31" xlink:to="loc_rprx_DeferredSharesParOrStatedValuePerShare_37ef4f6a-0555-416d-933a-dc2d49e865c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesSharesIssued_604cd83e-7080-40f6-b5e5-c19a14c08c6b" xlink:href="rprx-20211231.xsd#rprx_DeferredSharesSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_845a702f-c5bc-427c-9ac4-1e3bc855fe31" xlink:to="loc_rprx_DeferredSharesSharesIssued_604cd83e-7080-40f6-b5e5-c19a14c08c6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesSharesOutstanding_047e412c-e087-482b-afa4-4c6097d7b705" xlink:href="rprx-20211231.xsd#rprx_DeferredSharesSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_845a702f-c5bc-427c-9ac4-1e3bc855fe31" xlink:to="loc_rprx_DeferredSharesSharesOutstanding_047e412c-e087-482b-afa4-4c6097d7b705" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6275bc1f-aaf0-48a1-a422-4c9e62fa0c94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_845a702f-c5bc-427c-9ac4-1e3bc855fe31" xlink:to="loc_us-gaap_StatementTable_6275bc1f-aaf0-48a1-a422-4c9e62fa0c94" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ee342c3c-c760-431b-aa93-1104b477e40f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6275bc1f-aaf0-48a1-a422-4c9e62fa0c94" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ee342c3c-c760-431b-aa93-1104b477e40f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ee342c3c-c760-431b-aa93-1104b477e40f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ee342c3c-c760-431b-aa93-1104b477e40f" xlink:to="loc_us-gaap_ClassOfStockDomain_ee342c3c-c760-431b-aa93-1104b477e40f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3b3e472d-7189-41ae-a794-c0d2657df2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ee342c3c-c760-431b-aa93-1104b477e40f" xlink:to="loc_us-gaap_ClassOfStockDomain_3b3e472d-7189-41ae-a794-c0d2657df2bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_af07e7ff-8bcf-4012-b289-cd1d1c14b18e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3b3e472d-7189-41ae-a794-c0d2657df2bb" xlink:to="loc_us-gaap_CommonClassAMember_af07e7ff-8bcf-4012-b289-cd1d1c14b18e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_7e931521-78ad-43b7-82a6-c14c4a6e76ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3b3e472d-7189-41ae-a794-c0d2657df2bb" xlink:to="loc_us-gaap_CommonClassBMember_7e931521-78ad-43b7-82a6-c14c4a6e76ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember_cde5acef-8072-4580-a611-19c1c6155688" xlink:href="rprx-20211231.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3b3e472d-7189-41ae-a794-c0d2657df2bb" xlink:to="loc_rprx_ClassRRedeemableStockMember_cde5acef-8072-4580-a611-19c1c6155688" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="rprx-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="if4e2dd5b66df4ea1ab1e3c462853d67c_ConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9b4a2f98-7087-4feb-bba8-32ad19848c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:to="loc_us-gaap_Revenues_9b4a2f98-7087-4feb-bba8-32ad19848c46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_40a4896f-da66-4730-9a50-dd0b61848409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:to="loc_us-gaap_OperatingExpensesAbstract_40a4896f-da66-4730-9a50-dd0b61848409" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLoanAndLeaseLosses_0f8155b5-ce09-4a2e-89df-e3765a28f4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForLoanAndLeaseLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_40a4896f-da66-4730-9a50-dd0b61848409" xlink:to="loc_us-gaap_ProvisionForLoanAndLeaseLosses_0f8155b5-ce09-4a2e-89df-e3765a28f4bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f7e6750b-1b74-4d57-bb99-8509306d039b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_40a4896f-da66-4730-9a50-dd0b61848409" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f7e6750b-1b74-4d57-bb99-8509306d039b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_a73ba091-ea0c-46e4-b6b1-7d53bd6433c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_40a4896f-da66-4730-9a50-dd0b61848409" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_a73ba091-ea0c-46e4-b6b1-7d53bd6433c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c9552414-8b17-4c5c-a69a-692ea9885208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_40a4896f-da66-4730-9a50-dd0b61848409" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c9552414-8b17-4c5c-a69a-692ea9885208" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_77482040-3f7f-4811-8400-72ad051fdbea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_40a4896f-da66-4730-9a50-dd0b61848409" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_77482040-3f7f-4811-8400-72ad051fdbea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_112ed2e2-94d5-445c-9493-e39db972f403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_40a4896f-da66-4730-9a50-dd0b61848409" xlink:to="loc_us-gaap_CostsAndExpenses_112ed2e2-94d5-445c-9493-e39db972f403" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_67febf44-eafd-471a-9efa-6063c296087b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:to="loc_us-gaap_OperatingIncomeLoss_67febf44-eafd-471a-9efa-6063c296087b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_6c4b875f-20f6-4649-851d-6fa6feecbd79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_6c4b875f-20f6-4649-851d-6fa6feecbd79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f7618f97-f65f-49f7-b776-0058bfc8173b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6c4b875f-20f6-4649-851d-6fa6feecbd79" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f7618f97-f65f-49f7-b776-0058bfc8173b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e976be32-6f85-4ebc-9a0b-4d09d437ee28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6c4b875f-20f6-4649-851d-6fa6feecbd79" xlink:to="loc_us-gaap_InterestExpense_e976be32-6f85-4ebc-9a0b-4d09d437ee28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_78aede15-1c0e-4154-9f21-feed48d4d3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6c4b875f-20f6-4649-851d-6fa6feecbd79" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_78aede15-1c0e-4154-9f21-feed48d4d3c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6da940e9-f908-4d70-8f65-91a211160a24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6c4b875f-20f6-4649-851d-6fa6feecbd79" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6da940e9-f908-4d70-8f65-91a211160a24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_78b2535a-3165-4fa8-a42e-50449bcf6e25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6c4b875f-20f6-4649-851d-6fa6feecbd79" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_78b2535a-3165-4fa8-a42e-50449bcf6e25" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_8659219f-028c-4bb6-b5d1-874c5cfed900" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6c4b875f-20f6-4649-851d-6fa6feecbd79" xlink:to="loc_us-gaap_InvestmentIncomeNet_8659219f-028c-4bb6-b5d1-874c5cfed900" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4ca32604-8ec0-40f7-ad20-24b75aae13ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6c4b875f-20f6-4649-851d-6fa6feecbd79" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4ca32604-8ec0-40f7-ad20-24b75aae13ee" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d5b1741f-810a-4db1-93a3-13e3beec32c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6c4b875f-20f6-4649-851d-6fa6feecbd79" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d5b1741f-810a-4db1-93a3-13e3beec32c5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ffd742b8-9a74-48a0-997e-133025197597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ffd742b8-9a74-48a0-997e-133025197597" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5a57be8b-311c-40e9-96cf-e15fa2982a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5a57be8b-311c-40e9-96cf-e15fa2982a7f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f8568939-0d09-4d65-999a-6213379921bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:to="loc_us-gaap_ProfitLoss_f8568939-0d09-4d65-999a-6213379921bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_124ed472-abd4-4480-be51-4e49e6c36862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_124ed472-abd4-4480-be51-4e49e6c36862" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6e3906f4-13e0-41f9-8082-96450a8159a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:to="loc_us-gaap_NetIncomeLoss_6e3906f4-13e0-41f9-8082-96450a8159a9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_8aeb50e3-ecf0-48d0-8a10-4631b5302a54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_8aeb50e3-ecf0-48d0-8a10-4631b5302a54" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7ff4f5b1-e75d-448c-b865-9ed235bc2ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_8aeb50e3-ecf0-48d0-8a10-4631b5302a54" xlink:to="loc_us-gaap_EarningsPerShareBasic_7ff4f5b1-e75d-448c-b865-9ed235bc2ef9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9620e72a-96c1-43a6-b4df-f4a0a78ff820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_8aeb50e3-ecf0-48d0-8a10-4631b5302a54" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9620e72a-96c1-43a6-b4df-f4a0a78ff820" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ace0162b-8f49-4151-97d9-1e6c660f9745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ace0162b-8f49-4151-97d9-1e6c660f9745" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3fa5f0b7-9655-4cf1-b4a4-78a74c6a58dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ace0162b-8f49-4151-97d9-1e6c660f9745" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3fa5f0b7-9655-4cf1-b4a4-78a74c6a58dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_edc9d8d8-1899-4086-85e5-48fe4b26f80b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ace0162b-8f49-4151-97d9-1e6c660f9745" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_edc9d8d8-1899-4086-85e5-48fe4b26f80b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a44211ab-9ce0-49ec-aee8-15031e46aea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:to="loc_us-gaap_StatementTable_a44211ab-9ce0-49ec-aee8-15031e46aea8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_df800a45-4eb3-4a6a-9ee3-560a8a2f1245" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a44211ab-9ce0-49ec-aee8-15031e46aea8" xlink:to="loc_srt_ProductOrServiceAxis_df800a45-4eb3-4a6a-9ee3-560a8a2f1245" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_df800a45-4eb3-4a6a-9ee3-560a8a2f1245_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_df800a45-4eb3-4a6a-9ee3-560a8a2f1245" xlink:to="loc_srt_ProductsAndServicesDomain_df800a45-4eb3-4a6a-9ee3-560a8a2f1245_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c034b598-be9a-46f8-8053-6a635bf2c5f6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_df800a45-4eb3-4a6a-9ee3-560a8a2f1245" xlink:to="loc_srt_ProductsAndServicesDomain_c034b598-be9a-46f8-8053-6a635bf2c5f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancialRoyaltyAssetsMember_ccc74c0b-7ca5-4cbe-b471-6b3b90a286d3" xlink:href="rprx-20211231.xsd#rprx_FinancialRoyaltyAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c034b598-be9a-46f8-8053-6a635bf2c5f6" xlink:to="loc_rprx_FinancialRoyaltyAssetsMember_ccc74c0b-7ca5-4cbe-b471-6b3b90a286d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IntangibleRoyaltyAssetsMember_d8910a2b-7783-4598-aec4-a9ddbc82e61e" xlink:href="rprx-20211231.xsd#rprx_IntangibleRoyaltyAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c034b598-be9a-46f8-8053-6a635bf2c5f6" xlink:to="loc_rprx_IntangibleRoyaltyAssetsMember_d8910a2b-7783-4598-aec4-a9ddbc82e61e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyIncomeOtherMember_09b61b58-c68d-4c5e-96a5-4de2d1b97808" xlink:href="rprx-20211231.xsd#rprx_RoyaltyIncomeOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c034b598-be9a-46f8-8053-6a635bf2c5f6" xlink:to="loc_rprx_RoyaltyIncomeOtherMember_09b61b58-c68d-4c5e-96a5-4de2d1b97808" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="rprx-20211231.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended" id="i51bb2bf782b74e7198be43d58cea8645_ConsolidatedStatementsofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6d3d6e5d-ba2d-4799-bb40-ef64caae3578" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6d3d6e5d-ba2d-4799-bb40-ef64caae3578" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_06a07737-f3ad-4a88-8b27-e216c718fe9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_SharesOutstanding_06a07737-f3ad-4a88-8b27-e216c718fe9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8dd172e6-eed6-43ba-8f81-64edb644b0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8dd172e6-eed6-43ba-8f81-64edb644b0aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_003e33dc-49aa-421c-85a3-18a0d73b59ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_003e33dc-49aa-421c-85a3-18a0d73b59ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_27867743-2ee1-4627-bcde-3a7e5d0f3047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_ProfitLoss_27867743-2ee1-4627-bcde-3a7e5d0f3047" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c1446f21-3df4-448e-b2d3-711543577b45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c1446f21-3df4-448e-b2d3-711543577b45" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_971f9331-14a1-42e5-bc75-48d478ba8d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_971f9331-14a1-42e5-bc75-48d478ba8d6d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_b6e71ccb-2a8e-40d0-820d-d2d6a6904a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_b6e71ccb-2a8e-40d0-820d-d2d6a6904a49" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestIncreaseFromContributions_7efedf19-9a08-43e6-a5fc-20b222b351cc" xlink:href="rprx-20211231.xsd#rprx_NoncontrollingInterestIncreaseFromContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_rprx_NoncontrollingInterestIncreaseFromContributions_7efedf19-9a08-43e6-a5fc-20b222b351cc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestTransfersOfInterests_948ff574-fae9-4c63-9a3e-eccac8d822c4" xlink:href="rprx-20211231.xsd#rprx_NoncontrollingInterestTransfersOfInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_rprx_NoncontrollingInterestTransfersOfInterests_948ff574-fae9-4c63-9a3e-eccac8d822c4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_703f7308-d2cb-4c1a-906c-d03e564eaeeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_703f7308-d2cb-4c1a-906c-d03e564eaeeb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration_65d1c7f6-3783-4aaa-ae28-7146585c190e" xlink:href="rprx-20211231.xsd#rprx_StockIssuedDuringPeriodSharesIssuedForRegistration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration_65d1c7f6-3783-4aaa-ae28-7146585c190e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockIssuedDuringPeriodValueIssuedForRegistration_3be71060-24dc-4f69-bb7a-14fb55c1d3a4" xlink:href="rprx-20211231.xsd#rprx_StockIssuedDuringPeriodValueIssuedForRegistration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_rprx_StockIssuedDuringPeriodValueIssuedForRegistration_3be71060-24dc-4f69-bb7a-14fb55c1d3a4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships_ea12c609-540c-4ec3-a420-184f20a9a0b5" xlink:href="rprx-20211231.xsd#rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships_ea12c609-540c-4ec3-a420-184f20a9a0b5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships_f5ba346e-f0df-4d95-91a8-4917f3f67fd2" xlink:href="rprx-20211231.xsd#rprx_StockIssuedDuringPeriodValueIssuedToPartnerships"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships_f5ba346e-f0df-4d95-91a8-4917f3f67fd2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation_918a2f1f-5713-4331-83dc-14b471969cc6" xlink:href="rprx-20211231.xsd#rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation_918a2f1f-5713-4331-83dc-14b471969cc6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation_0182979c-99d6-45ed-86ae-b66dbfac5060" xlink:href="rprx-20211231.xsd#rprx_StockholdersEquityValueEffectOfExchangeAndReallocation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation_0182979c-99d6-45ed-86ae-b66dbfac5060" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_60ce67a0-b391-42a4-8655-9fc52a1833fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_60ce67a0-b391-42a4-8655-9fc52a1833fc" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7d038102-d569-4b3d-a04e-5744daf60bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7d038102-d569-4b3d-a04e-5744daf60bf5" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_88e30d57-8d48-4865-8f32-ac02606fa979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_88e30d57-8d48-4865-8f32-ac02606fa979" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_824445fd-44b9-44b0-abe9-c25365b25395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_824445fd-44b9-44b0-abe9-c25365b25395" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_1362817d-e2b0-4be8-b2f7-a82a17822cce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_1362817d-e2b0-4be8-b2f7-a82a17822cce" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_152cc7f3-ad30-46b1-83b7-d2d5f9e1447c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_StockholdersEquityOther_152cc7f3-ad30-46b1-83b7-d2d5f9e1447c" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCash_c81ea6a1-0d84-4fdc-b624-63409b711112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_DividendsCash_c81ea6a1-0d84-4fdc-b624-63409b711112" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_b456a5c0-ebde-4da7-9f68-58506deb5d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_b456a5c0-ebde-4da7-9f68-58506deb5d18" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_4ce125eb-0a3a-407f-ae57-b162392c9e73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_929413de-beec-4ac9-a83f-b40a5013bdb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_543c8721-2501-4729-9df3-ad71e7111a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6d3d6e5d-ba2d-4799-bb40-ef64caae3578" xlink:to="loc_us-gaap_StatementTable_543c8721-2501-4729-9df3-ad71e7111a5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c7392574-27b3-4edd-a027-8710d6cb567c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_543c8721-2501-4729-9df3-ad71e7111a5e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c7392574-27b3-4edd-a027-8710d6cb567c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c7392574-27b3-4edd-a027-8710d6cb567c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c7392574-27b3-4edd-a027-8710d6cb567c" xlink:to="loc_us-gaap_EquityComponentDomain_c7392574-27b3-4edd-a027-8710d6cb567c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1711a459-7ec3-4553-b03a-b9de234df351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c7392574-27b3-4edd-a027-8710d6cb567c" xlink:to="loc_us-gaap_EquityComponentDomain_1711a459-7ec3-4553-b03a-b9de234df351" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d1ddb68c-cd34-42f3-894f-02c642e6ba2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1711a459-7ec3-4553-b03a-b9de234df351" xlink:to="loc_us-gaap_CommonStockMember_d1ddb68c-cd34-42f3-894f-02c642e6ba2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesMember_13e0244e-5795-49a8-8d83-d8226c1a49ad" xlink:href="rprx-20211231.xsd#rprx_DeferredSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1711a459-7ec3-4553-b03a-b9de234df351" xlink:to="loc_rprx_DeferredSharesMember_13e0244e-5795-49a8-8d83-d8226c1a49ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_cc8d99cb-db8d-4e19-b2a2-5580ed37acc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1711a459-7ec3-4553-b03a-b9de234df351" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_cc8d99cb-db8d-4e19-b2a2-5580ed37acc3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_UnitHoldersAndShareholdersContributionsMember_9c903b9b-94e8-42ab-90b2-996fbdfda0f6" xlink:href="rprx-20211231.xsd#rprx_UnitHoldersAndShareholdersContributionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1711a459-7ec3-4553-b03a-b9de234df351" xlink:to="loc_rprx_UnitHoldersAndShareholdersContributionsMember_9c903b9b-94e8-42ab-90b2-996fbdfda0f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_76cd25d6-05d0-4a44-adb7-c3e26b9810f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1711a459-7ec3-4553-b03a-b9de234df351" xlink:to="loc_us-gaap_RetainedEarningsMember_76cd25d6-05d0-4a44-adb7-c3e26b9810f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_1b43bc82-0310-4124-afe7-473a6f8254ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1711a459-7ec3-4553-b03a-b9de234df351" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_1b43bc82-0310-4124-afe7-473a6f8254ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_88305db8-6553-49eb-a25d-748b9d0499a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1711a459-7ec3-4553-b03a-b9de234df351" xlink:to="loc_us-gaap_NoncontrollingInterestMember_88305db8-6553-49eb-a25d-748b9d0499a9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_aadce750-7d42-466d-a4ed-17efd71a40c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1711a459-7ec3-4553-b03a-b9de234df351" xlink:to="loc_us-gaap_TreasuryStockMember_aadce750-7d42-466d-a4ed-17efd71a40c0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9a87886f-e6d0-4fbb-bdc6-42c6be092aac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_543c8721-2501-4729-9df3-ad71e7111a5e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9a87886f-e6d0-4fbb-bdc6-42c6be092aac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9a87886f-e6d0-4fbb-bdc6-42c6be092aac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9a87886f-e6d0-4fbb-bdc6-42c6be092aac" xlink:to="loc_us-gaap_ClassOfStockDomain_9a87886f-e6d0-4fbb-bdc6-42c6be092aac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d65495c9-d182-4bb3-9ecc-2881f69d6958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9a87886f-e6d0-4fbb-bdc6-42c6be092aac" xlink:to="loc_us-gaap_ClassOfStockDomain_d65495c9-d182-4bb3-9ecc-2881f69d6958" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_684873e9-d5a9-41c2-aa3d-461ba193a676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d65495c9-d182-4bb3-9ecc-2881f69d6958" xlink:to="loc_us-gaap_CommonClassAMember_684873e9-d5a9-41c2-aa3d-461ba193a676" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_8c46b0a0-912e-4151-a2f6-f0171767463b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d65495c9-d182-4bb3-9ecc-2881f69d6958" xlink:to="loc_us-gaap_CommonClassBMember_8c46b0a0-912e-4151-a2f6-f0171767463b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember_b4b4980b-e888-40ed-b89c-e525d818e06f" xlink:href="rprx-20211231.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d65495c9-d182-4bb3-9ecc-2881f69d6958" xlink:to="loc_rprx_ClassRRedeemableStockMember_b4b4980b-e888-40ed-b89c-e525d818e06f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_70e8e570-af25-4551-ae20-0bbca657ef77" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_543c8721-2501-4729-9df3-ad71e7111a5e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_70e8e570-af25-4551-ae20-0bbca657ef77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_70e8e570-af25-4551-ae20-0bbca657ef77_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_70e8e570-af25-4551-ae20-0bbca657ef77" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_70e8e570-af25-4551-ae20-0bbca657ef77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_82d7baa1-a404-4fc0-8693-f13af7c4def7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_70e8e570-af25-4551-ae20-0bbca657ef77" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_82d7baa1-a404-4fc0-8693-f13af7c4def7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3bec45f1-e9fe-43e4-b625-03c67b7ab478" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_82d7baa1-a404-4fc0-8693-f13af7c4def7" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3bec45f1-e9fe-43e4-b625-03c67b7ab478" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/OrganizationandPurposeDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#OrganizationandPurposeDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/OrganizationandPurposeDetails" xlink:type="extended" id="i0bd2ab14c1354f6f84609fe448b33ef1_OrganizationandPurposeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_1d43b0dd-be9c-40ce-81d5-58547938c1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_7abfb165-5980-4451-b9a5-37d7654c66e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1d43b0dd-be9c-40ce-81d5-58547938c1e9" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_7abfb165-5980-4451-b9a5-37d7654c66e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_5e47594d-326b-4902-82d6-514b8937d792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1d43b0dd-be9c-40ce-81d5-58547938c1e9" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_5e47594d-326b-4902-82d6-514b8937d792" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_0411c78f-72b5-4734-9467-4ed4e2950561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1d43b0dd-be9c-40ce-81d5-58547938c1e9" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_0411c78f-72b5-4734-9467-4ed4e2950561" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_86e7d9c7-b5d6-4c34-9967-109aec7806a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1d43b0dd-be9c-40ce-81d5-58547938c1e9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_86e7d9c7-b5d6-4c34-9967-109aec7806a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_28ce0951-7a47-43e2-ac3c-3c2e1302de65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1d43b0dd-be9c-40ce-81d5-58547938c1e9" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_28ce0951-7a47-43e2-ac3c-3c2e1302de65" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b66fb585-45f2-488a-a0b5-008c8667877f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1d43b0dd-be9c-40ce-81d5-58547938c1e9" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b66fb585-45f2-488a-a0b5-008c8667877f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4ee5968b-9dac-42cc-8863-c47af3de55f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1d43b0dd-be9c-40ce-81d5-58547938c1e9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4ee5968b-9dac-42cc-8863-c47af3de55f0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_e05b004f-32a0-4c1a-883a-1ddaf1cee615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1d43b0dd-be9c-40ce-81d5-58547938c1e9" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_e05b004f-32a0-4c1a-883a-1ddaf1cee615" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SaleOfStockNumberOfSharesAvailableToConvert_dccfc82c-324c-4a89-8550-690570d355eb" xlink:href="rprx-20211231.xsd#rprx_SaleOfStockNumberOfSharesAvailableToConvert"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1d43b0dd-be9c-40ce-81d5-58547938c1e9" xlink:to="loc_rprx_SaleOfStockNumberOfSharesAvailableToConvert_dccfc82c-324c-4a89-8550-690570d355eb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SaleOfStockNumberOfSharesNotConverted_693f469f-2598-461b-a5da-5523fa1a2602" xlink:href="rprx-20211231.xsd#rprx_SaleOfStockNumberOfSharesNotConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1d43b0dd-be9c-40ce-81d5-58547938c1e9" xlink:to="loc_rprx_SaleOfStockNumberOfSharesNotConverted_693f469f-2598-461b-a5da-5523fa1a2602" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_afc998d0-83a2-4168-b13e-18fc8c13d16b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1d43b0dd-be9c-40ce-81d5-58547938c1e9" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_afc998d0-83a2-4168-b13e-18fc8c13d16b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5b4cc016-d386-4c4e-96f1-7867af9e80ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_afc998d0-83a2-4168-b13e-18fc8c13d16b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5b4cc016-d386-4c4e-96f1-7867af9e80ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5b4cc016-d386-4c4e-96f1-7867af9e80ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5b4cc016-d386-4c4e-96f1-7867af9e80ae" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5b4cc016-d386-4c4e-96f1-7867af9e80ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5e67622d-7387-4da7-a697-f08a7f7b7c63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5b4cc016-d386-4c4e-96f1-7867af9e80ae" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5e67622d-7387-4da7-a697-f08a7f7b7c63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ExchangeOfferTransactionMember_011e78b7-5bb4-4205-89e4-721806c66511" xlink:href="rprx-20211231.xsd#rprx_ExchangeOfferTransactionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5e67622d-7387-4da7-a697-f08a7f7b7c63" xlink:to="loc_rprx_ExchangeOfferTransactionMember_011e78b7-5bb4-4205-89e4-721806c66511" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_d8506b2b-b283-45ac-939e-6d5195202163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5e67622d-7387-4da7-a697-f08a7f7b7c63" xlink:to="loc_us-gaap_IPOMember_d8506b2b-b283-45ac-939e-6d5195202163" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IPOSharesFromCompanyMember_bb5caad7-c052-4203-8d1f-6c7548346ebd" xlink:href="rprx-20211231.xsd#rprx_IPOSharesFromCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5e67622d-7387-4da7-a697-f08a7f7b7c63" xlink:to="loc_rprx_IPOSharesFromCompanyMember_bb5caad7-c052-4203-8d1f-6c7548346ebd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IPOSharesFromSellingShareholdersMember_1c593a2d-fdb0-46f5-a0f4-013ac591c782" xlink:href="rprx-20211231.xsd#rprx_IPOSharesFromSellingShareholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5e67622d-7387-4da7-a697-f08a7f7b7c63" xlink:to="loc_rprx_IPOSharesFromSellingShareholdersMember_1c593a2d-fdb0-46f5-a0f4-013ac591c782" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IPOContinuingInvestorsPartnershipsMember_9361ad1e-7555-415f-b564-fc375cca5999" xlink:href="rprx-20211231.xsd#rprx_IPOContinuingInvestorsPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5e67622d-7387-4da7-a697-f08a7f7b7c63" xlink:to="loc_rprx_IPOContinuingInvestorsPartnershipsMember_9361ad1e-7555-415f-b564-fc375cca5999" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5801884c-6169-47c8-b9fb-0760d0a23a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_afc998d0-83a2-4168-b13e-18fc8c13d16b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5801884c-6169-47c8-b9fb-0760d0a23a73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5801884c-6169-47c8-b9fb-0760d0a23a73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5801884c-6169-47c8-b9fb-0760d0a23a73" xlink:to="loc_us-gaap_ClassOfStockDomain_5801884c-6169-47c8-b9fb-0760d0a23a73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1398a4f3-cb51-4cd6-961c-1187489a73ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5801884c-6169-47c8-b9fb-0760d0a23a73" xlink:to="loc_us-gaap_ClassOfStockDomain_1398a4f3-cb51-4cd6-961c-1187489a73ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_b0f2ddd5-4d9a-45db-ba96-a82b84c09877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1398a4f3-cb51-4cd6-961c-1187489a73ee" xlink:to="loc_us-gaap_CommonClassAMember_b0f2ddd5-4d9a-45db-ba96-a82b84c09877" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_13ee719c-4f10-4c75-b64b-3310cd34e195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1398a4f3-cb51-4cd6-961c-1187489a73ee" xlink:to="loc_us-gaap_CommonClassBMember_13ee719c-4f10-4c75-b64b-3310cd34e195" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f0406f70-c2c1-4b97-a29d-c022c734be4a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_afc998d0-83a2-4168-b13e-18fc8c13d16b" xlink:to="loc_dei_LegalEntityAxis_f0406f70-c2c1-4b97-a29d-c022c734be4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f0406f70-c2c1-4b97-a29d-c022c734be4a_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_f0406f70-c2c1-4b97-a29d-c022c734be4a" xlink:to="loc_dei_EntityDomain_f0406f70-c2c1-4b97-a29d-c022c734be4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2fbf8be6-3130-4c8e-b3f4-126aaf58def0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_f0406f70-c2c1-4b97-a29d-c022c734be4a" xlink:to="loc_dei_EntityDomain_2fbf8be6-3130-4c8e-b3f4-126aaf58def0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember_586b9318-e134-40a8-ac82-01a6547c6024" xlink:href="rprx-20211231.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2fbf8be6-3130-4c8e-b3f4-126aaf58def0" xlink:to="loc_rprx_LegacyInvestorsPartnershipsMember_586b9318-e134-40a8-ac82-01a6547c6024" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember_fcc1794f-6302-4411-b54d-a92755e35cc9" xlink:href="rprx-20211231.xsd#rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2fbf8be6-3130-4c8e-b3f4-126aaf58def0" xlink:to="loc_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember_fcc1794f-6302-4411-b54d-a92755e35cc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPI2019IntermediateFinanceMember_aedba752-30df-466b-b5e7-f8b8eea18d01" xlink:href="rprx-20211231.xsd#rprx_RPI2019IntermediateFinanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2fbf8be6-3130-4c8e-b3f4-126aaf58def0" xlink:to="loc_rprx_RPI2019IntermediateFinanceMember_aedba752-30df-466b-b5e7-f8b8eea18d01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_97ee97c3-d00b-4ef9-92b8-17270cffd683" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_afc998d0-83a2-4168-b13e-18fc8c13d16b" xlink:to="loc_srt_OwnershipAxis_97ee97c3-d00b-4ef9-92b8-17270cffd683" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_97ee97c3-d00b-4ef9-92b8-17270cffd683_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_97ee97c3-d00b-4ef9-92b8-17270cffd683" xlink:to="loc_srt_OwnershipDomain_97ee97c3-d00b-4ef9-92b8-17270cffd683_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f07aa010-8870-481c-94fb-3f13068fcac4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_97ee97c3-d00b-4ef9-92b8-17270cffd683" xlink:to="loc_srt_OwnershipDomain_f07aa010-8870-481c-94fb-3f13068fcac4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember_e83bc0b5-a180-4ded-9514-e66720cd72c6" xlink:href="rprx-20211231.xsd#rprx_RoyaltyPharmaInvestmentsOldRPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_f07aa010-8870-481c-94fb-3f13068fcac4" xlink:to="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember_e83bc0b5-a180-4ded-9514-e66720cd72c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyPharmaCollectionTrustMember_4ae01e68-809d-4352-bfa0-8db0b452fb13" xlink:href="rprx-20211231.xsd#rprx_RoyaltyPharmaCollectionTrustMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_f07aa010-8870-481c-94fb-3f13068fcac4" xlink:to="loc_rprx_RoyaltyPharmaCollectionTrustMember_4ae01e68-809d-4352-bfa0-8db0b452fb13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b38527ff-4886-4a20-becc-91b86fdb6249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_afc998d0-83a2-4168-b13e-18fc8c13d16b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b38527ff-4886-4a20-becc-91b86fdb6249" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b38527ff-4886-4a20-becc-91b86fdb6249_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b38527ff-4886-4a20-becc-91b86fdb6249" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b38527ff-4886-4a20-becc-91b86fdb6249_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d57a7e3c-5b23-4fed-a92b-041757749860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b38527ff-4886-4a20-becc-91b86fdb6249" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d57a7e3c-5b23-4fed-a92b-041757749860" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_9015f2ca-92ff-4a5d-b2c8-7c115f94510f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d57a7e3c-5b23-4fed-a92b-041757749860" xlink:to="loc_us-gaap_SecuredDebtMember_9015f2ca-92ff-4a5d-b2c8-7c115f94510f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d24a75f0-708e-4967-b60c-d06e9eb2b0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_afc998d0-83a2-4168-b13e-18fc8c13d16b" xlink:to="loc_us-gaap_DebtInstrumentAxis_d24a75f0-708e-4967-b60c-d06e9eb2b0e7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d24a75f0-708e-4967-b60c-d06e9eb2b0e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d24a75f0-708e-4967-b60c-d06e9eb2b0e7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d24a75f0-708e-4967-b60c-d06e9eb2b0e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d65abab9-2ca3-4780-9c75-63301145f13f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d24a75f0-708e-4967-b60c-d06e9eb2b0e7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d65abab9-2ca3-4780-9c75-63301145f13f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member_472a7a69-5d92-4174-9546-86c94cd24f6f" xlink:href="rprx-20211231.xsd#rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d65abab9-2ca3-4780-9c75-63301145f13f" xlink:to="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member_472a7a69-5d92-4174-9546-86c94cd24f6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member_16f62b8c-55ce-4a80-95bd-71acab0e6267" xlink:href="rprx-20211231.xsd#rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d65abab9-2ca3-4780-9c75-63301145f13f" xlink:to="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member_16f62b8c-55ce-4a80-95bd-71acab0e6267" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OldCreditFacilityMember_ed6af125-b478-4e5d-be41-1c1740969965" xlink:href="rprx-20211231.xsd#rprx_OldCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d65abab9-2ca3-4780-9c75-63301145f13f" xlink:to="loc_rprx_OldCreditFacilityMember_ed6af125-b478-4e5d-be41-1c1740969965" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIFTSeniorSecuredCreditFacilitiesMember_56d347e7-9866-4dd6-a161-f38184ba46d8" xlink:href="rprx-20211231.xsd#rprx_RPIFTSeniorSecuredCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d65abab9-2ca3-4780-9c75-63301145f13f" xlink:to="loc_rprx_RPIFTSeniorSecuredCreditFacilitiesMember_56d347e7-9866-4dd6-a161-f38184ba46d8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="i3907daa2ba2045d4b69d966ab2b9407a_SummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_53e65d87-5ee1-4b35-a897-f5fb56456921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_241f4826-3605-4b82-b07e-bd95c71fc69d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_53e65d87-5ee1-4b35-a897-f5fb56456921" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_241f4826-3605-4b82-b07e-bd95c71fc69d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NumberOfNoncontrollingInterestsCreated_683c8f13-2653-483b-b4a4-998139a3e395" xlink:href="rprx-20211231.xsd#rprx_NumberOfNoncontrollingInterestsCreated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_53e65d87-5ee1-4b35-a897-f5fb56456921" xlink:to="loc_rprx_NumberOfNoncontrollingInterestsCreated_683c8f13-2653-483b-b4a4-998139a3e395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt_ebd47afa-0257-42c3-a724-a3759a6d53ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_53e65d87-5ee1-4b35-a897-f5fb56456921" xlink:to="loc_us-gaap_TradingSecuritiesDebt_ebd47afa-0257-42c3-a724-a3759a6d53ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d209c4ae-ec71-49a8-88fe-a048bff8fb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_53e65d87-5ee1-4b35-a897-f5fb56456921" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d209c4ae-ec71-49a8-88fe-a048bff8fb9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2569a9a8-f500-4119-a00c-2d2055ad476a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_53e65d87-5ee1-4b35-a897-f5fb56456921" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2569a9a8-f500-4119-a00c-2d2055ad476a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_191610ce-8551-4851-89ca-c53c1c6bf576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_53e65d87-5ee1-4b35-a897-f5fb56456921" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_191610ce-8551-4851-89ca-c53c1c6bf576" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34bcde04-f459-452f-aba1-46809800bcbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_53e65d87-5ee1-4b35-a897-f5fb56456921" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34bcde04-f459-452f-aba1-46809800bcbe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_617b1a76-9197-483a-89a1-59cb9ac5e020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_53e65d87-5ee1-4b35-a897-f5fb56456921" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_617b1a76-9197-483a-89a1-59cb9ac5e020" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_b250f3de-d28b-441a-b491-64d108f1787f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_53e65d87-5ee1-4b35-a897-f5fb56456921" xlink:to="loc_us-gaap_NumberOfOperatingSegments_b250f3de-d28b-441a-b491-64d108f1787f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c9477989-c9be-4418-8f08-81d2950ab61e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_53e65d87-5ee1-4b35-a897-f5fb56456921" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c9477989-c9be-4418-8f08-81d2950ab61e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac0ee0f6-fc4b-458a-817a-5e167164a9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_53e65d87-5ee1-4b35-a897-f5fb56456921" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac0ee0f6-fc4b-458a-817a-5e167164a9fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_25b822df-9ac2-4010-a3d6-db71fc20788d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac0ee0f6-fc4b-458a-817a-5e167164a9fd" xlink:to="loc_dei_LegalEntityAxis_25b822df-9ac2-4010-a3d6-db71fc20788d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_25b822df-9ac2-4010-a3d6-db71fc20788d_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_25b822df-9ac2-4010-a3d6-db71fc20788d" xlink:to="loc_dei_EntityDomain_25b822df-9ac2-4010-a3d6-db71fc20788d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f918f8e5-5b70-4681-849f-d10899dc5d11" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_25b822df-9ac2-4010-a3d6-db71fc20788d" xlink:to="loc_dei_EntityDomain_f918f8e5-5b70-4681-849f-d10899dc5d11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember_06a37f7d-4906-4726-87a0-5eb6eea71051" xlink:href="rprx-20211231.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_f918f8e5-5b70-4681-849f-d10899dc5d11" xlink:to="loc_rprx_LegacyInvestorsPartnershipsMember_06a37f7d-4906-4726-87a0-5eb6eea71051" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ContinuingInvestorsPartnershipMember_a62ea524-5296-4ca3-b48f-9de08a8f3264" xlink:href="rprx-20211231.xsd#rprx_ContinuingInvestorsPartnershipMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_f918f8e5-5b70-4681-849f-d10899dc5d11" xlink:to="loc_rprx_ContinuingInvestorsPartnershipMember_a62ea524-5296-4ca3-b48f-9de08a8f3264" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e9d84353-ac48-43f6-b49e-06adb23699bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac0ee0f6-fc4b-458a-817a-5e167164a9fd" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e9d84353-ac48-43f6-b49e-06adb23699bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e9d84353-ac48-43f6-b49e-06adb23699bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e9d84353-ac48-43f6-b49e-06adb23699bb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e9d84353-ac48-43f6-b49e-06adb23699bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_184d62a8-85a5-427f-adf2-5d7a0a84953a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e9d84353-ac48-43f6-b49e-06adb23699bb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_184d62a8-85a5-427f-adf2-5d7a0a84953a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_30aad6e0-f189-495c-b916-72f685b8db10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_184d62a8-85a5-427f-adf2-5d7a0a84953a" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_30aad6e0-f189-495c-b916-72f685b8db10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_519651a4-f554-4fb8-b125-a3348d9c87e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac0ee0f6-fc4b-458a-817a-5e167164a9fd" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_519651a4-f554-4fb8-b125-a3348d9c87e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_519651a4-f554-4fb8-b125-a3348d9c87e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_519651a4-f554-4fb8-b125-a3348d9c87e4" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_519651a4-f554-4fb8-b125-a3348d9c87e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3a59f854-50f2-4bf8-ae45-a529bb683396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_519651a4-f554-4fb8-b125-a3348d9c87e4" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3a59f854-50f2-4bf8-ae45-a529bb683396" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember_e76034bb-ba1f-4e87-b441-df45beddcebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3a59f854-50f2-4bf8-ae45-a529bb683396" xlink:to="loc_us-gaap_FinanceReceivablesMember_e76034bb-ba1f-4e87-b441-df45beddcebe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3f5c6029-afa4-44d0-af4f-21c8bcb7011a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac0ee0f6-fc4b-458a-817a-5e167164a9fd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3f5c6029-afa4-44d0-af4f-21c8bcb7011a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3f5c6029-afa4-44d0-af4f-21c8bcb7011a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3f5c6029-afa4-44d0-af4f-21c8bcb7011a" xlink:to="loc_us-gaap_EquityComponentDomain_3f5c6029-afa4-44d0-af4f-21c8bcb7011a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_99f42e2b-e90d-4585-8d55-bc73ab6073f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3f5c6029-afa4-44d0-af4f-21c8bcb7011a" xlink:to="loc_us-gaap_EquityComponentDomain_99f42e2b-e90d-4585-8d55-bc73ab6073f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3db8633b-bd22-48ab-b888-03eaa3f0f1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_99f42e2b-e90d-4585-8d55-bc73ab6073f0" xlink:to="loc_us-gaap_RetainedEarningsMember_3db8633b-bd22-48ab-b888-03eaa3f0f1aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_cf69030c-3704-4334-a2c7-fd5887cf81d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_99f42e2b-e90d-4585-8d55-bc73ab6073f0" xlink:to="loc_us-gaap_NoncontrollingInterestMember_cf69030c-3704-4334-a2c7-fd5887cf81d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_33445ee9-fc2f-4237-ae7d-90d39b2352aa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac0ee0f6-fc4b-458a-817a-5e167164a9fd" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_33445ee9-fc2f-4237-ae7d-90d39b2352aa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_33445ee9-fc2f-4237-ae7d-90d39b2352aa_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_33445ee9-fc2f-4237-ae7d-90d39b2352aa" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_33445ee9-fc2f-4237-ae7d-90d39b2352aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b9b55774-7a6a-41c3-a1f0-a0303a029994" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_33445ee9-fc2f-4237-ae7d-90d39b2352aa" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b9b55774-7a6a-41c3-a1f0-a0303a029994" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_d0d0be2e-3c19-4e9d-84c0-df1c313bf0b8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b9b55774-7a6a-41c3-a1f0-a0303a029994" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_d0d0be2e-3c19-4e9d-84c0-df1c313bf0b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_e66df2f2-dfe1-4fd3-9a83-f67cb0bf858b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac0ee0f6-fc4b-458a-817a-5e167164a9fd" xlink:to="loc_srt_OwnershipAxis_e66df2f2-dfe1-4fd3-9a83-f67cb0bf858b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_e66df2f2-dfe1-4fd3-9a83-f67cb0bf858b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_e66df2f2-dfe1-4fd3-9a83-f67cb0bf858b" xlink:to="loc_srt_OwnershipDomain_e66df2f2-dfe1-4fd3-9a83-f67cb0bf858b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_480f68bc-f3cd-4edb-9a97-9e26eb66442d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_e66df2f2-dfe1-4fd3-9a83-f67cb0bf858b" xlink:to="loc_srt_OwnershipDomain_480f68bc-f3cd-4edb-9a97-9e26eb66442d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember_c761a1bf-a256-4751-b6b0-ec41205cf397" xlink:href="rprx-20211231.xsd#rprx_RoyaltyPharmaInvestmentsOldRPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_480f68bc-f3cd-4edb-9a97-9e26eb66442d" xlink:to="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember_c761a1bf-a256-4751-b6b0-ec41205cf397" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPHoldingsMember_eeb9760c-3a5c-4a17-a3c8-033e9dc78f1a" xlink:href="rprx-20211231.xsd#rprx_RPHoldingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_480f68bc-f3cd-4edb-9a97-9e26eb66442d" xlink:to="loc_rprx_RPHoldingsMember_eeb9760c-3a5c-4a17-a3c8-033e9dc78f1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c807067f-b78d-4dcb-b23a-ca1b73d0d410" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac0ee0f6-fc4b-458a-817a-5e167164a9fd" xlink:to="loc_srt_MajorCustomersAxis_c807067f-b78d-4dcb-b23a-ca1b73d0d410" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c807067f-b78d-4dcb-b23a-ca1b73d0d410_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_c807067f-b78d-4dcb-b23a-ca1b73d0d410" xlink:to="loc_srt_NameOfMajorCustomerDomain_c807067f-b78d-4dcb-b23a-ca1b73d0d410_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0b754cb6-f50b-4221-bc54-6e3ae25885e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_c807067f-b78d-4dcb-b23a-ca1b73d0d410" xlink:to="loc_srt_NameOfMajorCustomerDomain_0b754cb6-f50b-4221-bc54-6e3ae25885e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_VertexMember_bab37316-9c47-4546-907d-486238c70701" xlink:href="rprx-20211231.xsd#rprx_VertexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0b754cb6-f50b-4221-bc54-6e3ae25885e8" xlink:to="loc_rprx_VertexMember_bab37316-9c47-4546-907d-486238c70701" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_f6113c11-0d6e-4a24-a7df-52ceae1a9601" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac0ee0f6-fc4b-458a-817a-5e167164a9fd" xlink:to="loc_srt_RestatementAxis_f6113c11-0d6e-4a24-a7df-52ceae1a9601" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_f6113c11-0d6e-4a24-a7df-52ceae1a9601_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_f6113c11-0d6e-4a24-a7df-52ceae1a9601" xlink:to="loc_srt_RestatementDomain_f6113c11-0d6e-4a24-a7df-52ceae1a9601_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_305cc2b2-70ba-495f-9c88-123663166731" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_f6113c11-0d6e-4a24-a7df-52ceae1a9601" xlink:to="loc_srt_RestatementDomain_305cc2b2-70ba-495f-9c88-123663166731" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_4a3a8837-ccda-45cf-89be-2fcebbc3f6fc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_305cc2b2-70ba-495f-9c88-123663166731" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_4a3a8837-ccda-45cf-89be-2fcebbc3f6fc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#AvailableforSaleDebtSecuritiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" xlink:type="extended" id="id758d16131fc4c8b87332b3e4c34b1a2_AvailableforSaleDebtSecuritiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_fae439a1-ce67-4c6d-aab7-3325c05b6a57" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_fae439a1-ce67-4c6d-aab7-3325c05b6a57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSalePricePerShare_d3941d80-0396-479b-94a6-04d0fdc2fc38" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSalePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:to="loc_rprx_DebtSecuritiesAvailableForSalePricePerShare_d3941d80-0396-479b-94a6-04d0fdc2fc38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c4b861dc-acd9-45ce-b3ce-a4c323c263a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c4b861dc-acd9-45ce-b3ce-a4c323c263a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage_0b738cbb-d155-41ff-8fcf-99f4f79f2d04" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage_0b738cbb-d155-41ff-8fcf-99f4f79f2d04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate_279af1a3-8c92-4992-8606-98e1e65b4ad5" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate_279af1a3-8c92-4992-8606-98e1e65b4ad5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod_c5c19752-3da9-4199-9e0e-c9494a19b0a1" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod_c5c19752-3da9-4199-9e0e-c9494a19b0a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod_43743b79-0169-4d26-ba58-458b11d2ed01" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod_43743b79-0169-4d26-ba58-458b11d2ed01" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_6883c748-ffa3-49f1-baf3-f826f6c4545f" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_6883c748-ffa3-49f1-baf3-f826f6c4545f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_d2ba1171-e9f1-49a1-a4e4-b6f010381550" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_d2ba1171-e9f1-49a1-a4e4-b6f010381550" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_f543ba25-97ad-4876-bcc0-788694a808e1" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_f543ba25-97ad-4876-bcc0-788694a808e1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate_af3d6330-d585-498e-b2b4-a50f38638674" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate_af3d6330-d585-498e-b2b4-a50f38638674" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1b32bc2f-8a2c-48c3-9eb3-ed3fa45763e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1b32bc2f-8a2c-48c3-9eb3-ed3fa45763e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_91a18015-285d-41b0-ae3a-19c177893759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1b32bc2f-8a2c-48c3-9eb3-ed3fa45763e3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_91a18015-285d-41b0-ae3a-19c177893759" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_91a18015-285d-41b0-ae3a-19c177893759_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_91a18015-285d-41b0-ae3a-19c177893759" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_91a18015-285d-41b0-ae3a-19c177893759_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ab2b6677-0f31-4c62-ac72-51a837b47a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_91a18015-285d-41b0-ae3a-19c177893759" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ab2b6677-0f31-4c62-ac72-51a837b47a52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_0b03400b-fe6b-48dc-9990-70e1c39cb9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ab2b6677-0f31-4c62-ac72-51a837b47a52" xlink:to="loc_us-gaap_PreferredStockMember_0b03400b-fe6b-48dc-9990-70e1c39cb9a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_cf01425f-cc1d-426a-8385-8b20ccd249fd" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1b32bc2f-8a2c-48c3-9eb3-ed3fa45763e3" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_cf01425f-cc1d-426a-8385-8b20ccd249fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_cf01425f-cc1d-426a-8385-8b20ccd249fd_default" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_cf01425f-cc1d-426a-8385-8b20ccd249fd" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_cf01425f-cc1d-426a-8385-8b20ccd249fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_936a55d7-6fb6-4940-b0a7-40b9c6bef140" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_cf01425f-cc1d-426a-8385-8b20ccd249fd" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_936a55d7-6fb6-4940-b0a7-40b9c6bef140" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_eb62a321-559b-486f-8ac8-8612749e19df" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_936a55d7-6fb6-4940-b0a7-40b9c6bef140" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_eb62a321-559b-486f-8ac8-8612749e19df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember_100837f4-0f74-4d34-ab5c-603d0d55a110" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_936a55d7-6fb6-4940-b0a7-40b9c6bef140" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember_100837f4-0f74-4d34-ab5c-603d0d55a110" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_03276f2e-2c8c-4743-8ca8-4bdb41af5fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1b32bc2f-8a2c-48c3-9eb3-ed3fa45763e3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_03276f2e-2c8c-4743-8ca8-4bdb41af5fb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_03276f2e-2c8c-4743-8ca8-4bdb41af5fb1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_03276f2e-2c8c-4743-8ca8-4bdb41af5fb1" xlink:to="loc_us-gaap_ClassOfStockDomain_03276f2e-2c8c-4743-8ca8-4bdb41af5fb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_42704204-3ab7-486c-aefa-7a4693768fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_03276f2e-2c8c-4743-8ca8-4bdb41af5fb1" xlink:to="loc_us-gaap_ClassOfStockDomain_42704204-3ab7-486c-aefa-7a4693768fdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_ec72856f-9f08-4b06-8e9a-42c308137abd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_42704204-3ab7-486c-aefa-7a4693768fdd" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_ec72856f-9f08-4b06-8e9a-42c308137abd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_1b79d60c-46d0-4461-b916-17b91999dc89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_42704204-3ab7-486c-aefa-7a4693768fdd" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_1b79d60c-46d0-4461-b916-17b91999dc89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3ef2d7bf-8f7d-42c0-8cab-4b948c94d101" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1b32bc2f-8a2c-48c3-9eb3-ed3fa45763e3" xlink:to="loc_srt_RangeAxis_3ef2d7bf-8f7d-42c0-8cab-4b948c94d101" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3ef2d7bf-8f7d-42c0-8cab-4b948c94d101_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3ef2d7bf-8f7d-42c0-8cab-4b948c94d101" xlink:to="loc_srt_RangeMember_3ef2d7bf-8f7d-42c0-8cab-4b948c94d101_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8d97ea51-b149-4dfe-a124-4673a885e1bc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3ef2d7bf-8f7d-42c0-8cab-4b948c94d101" xlink:to="loc_srt_RangeMember_8d97ea51-b149-4dfe-a124-4673a885e1bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_40914993-05b4-45f3-8b6d-e4ab9306ecb9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8d97ea51-b149-4dfe-a124-4673a885e1bc" xlink:to="loc_srt_MaximumMember_40914993-05b4-45f3-8b6d-e4ab9306ecb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ce3c0474-9877-465c-af49-dfa5e2d40194" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1b32bc2f-8a2c-48c3-9eb3-ed3fa45763e3" xlink:to="loc_srt_CounterpartyNameAxis_ce3c0474-9877-465c-af49-dfa5e2d40194" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ce3c0474-9877-465c-af49-dfa5e2d40194_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ce3c0474-9877-465c-af49-dfa5e2d40194" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ce3c0474-9877-465c-af49-dfa5e2d40194_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22e9539e-b2e5-4e49-9421-f5e5cf824ce8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ce3c0474-9877-465c-af49-dfa5e2d40194" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22e9539e-b2e5-4e49-9421-f5e5cf824ce8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MorphoSysMember_08178db3-78fb-4902-a3c3-846b40378397" xlink:href="rprx-20211231.xsd#rprx_MorphoSysMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22e9539e-b2e5-4e49-9421-f5e5cf824ce8" xlink:to="loc_rprx_MorphoSysMember_08178db3-78fb-4902-a3c3-846b40378397" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_56d72e96-79fd-4dd2-92ec-fedebfc5cb99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1b32bc2f-8a2c-48c3-9eb3-ed3fa45763e3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_56d72e96-79fd-4dd2-92ec-fedebfc5cb99" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_56d72e96-79fd-4dd2-92ec-fedebfc5cb99_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_56d72e96-79fd-4dd2-92ec-fedebfc5cb99" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_56d72e96-79fd-4dd2-92ec-fedebfc5cb99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df4b504d-3877-40ff-9dc0-5fc3bfabb6af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_56d72e96-79fd-4dd2-92ec-fedebfc5cb99" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df4b504d-3877-40ff-9dc0-5fc3bfabb6af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_6370ccd3-e17d-409f-8981-388be825b688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df4b504d-3877-40ff-9dc0-5fc3bfabb6af" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_6370ccd3-e17d-409f-8981-388be825b688" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended" id="i7c28079d170f4cafb57e2a5c5151532b_AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_21b8d8bc-41a5-49d0-bee2-4da597b041db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0c98d3d2-e70e-4b2f-a0b9-8faa264ac26f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_21b8d8bc-41a5-49d0-bee2-4da597b041db" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0c98d3d2-e70e-4b2f-a0b9-8faa264ac26f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_25196e08-2b83-4fa0-a42d-aea7308f1b55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_21b8d8bc-41a5-49d0-bee2-4da597b041db" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_25196e08-2b83-4fa0-a42d-aea7308f1b55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8a3292bc-74d9-4b9a-a2aa-a40c860d09a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_21b8d8bc-41a5-49d0-bee2-4da597b041db" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8a3292bc-74d9-4b9a-a2aa-a40c860d09a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ba8b488e-d4df-4e29-9470-77c103a7b7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_21b8d8bc-41a5-49d0-bee2-4da597b041db" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ba8b488e-d4df-4e29-9470-77c103a7b7b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_cd116c7c-441f-418d-939d-8a5e36a6177c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_21b8d8bc-41a5-49d0-bee2-4da597b041db" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_cd116c7c-441f-418d-939d-8a5e36a6177c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_9ae372d1-d050-43f4-9458-1037f6292edb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_21b8d8bc-41a5-49d0-bee2-4da597b041db" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_9ae372d1-d050-43f4-9458-1037f6292edb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_40e784b6-c1f6-44e5-90cd-c47865c0aad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_9ae372d1-d050-43f4-9458-1037f6292edb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_40e784b6-c1f6-44e5-90cd-c47865c0aad0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_40e784b6-c1f6-44e5-90cd-c47865c0aad0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_40e784b6-c1f6-44e5-90cd-c47865c0aad0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_40e784b6-c1f6-44e5-90cd-c47865c0aad0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c2f0bb5-484d-466e-bc88-77e065d119f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_40e784b6-c1f6-44e5-90cd-c47865c0aad0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c2f0bb5-484d-466e-bc88-77e065d119f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_e44f3ff8-393a-42ae-8d4f-91d098e895e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c2f0bb5-484d-466e-bc88-77e065d119f7" xlink:to="loc_us-gaap_PreferredStockMember_e44f3ff8-393a-42ae-8d4f-91d098e895e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_a33ed6b6-0c9f-42f7-844c-99a7ae19ff58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c2f0bb5-484d-466e-bc88-77e065d119f7" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_a33ed6b6-0c9f-42f7-844c-99a7ae19ff58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_e54f5d73-a8a6-42c5-b487-243ecf569bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c2f0bb5-484d-466e-bc88-77e065d119f7" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_e54f5d73-a8a6-42c5-b487-243ecf569bfa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_c4faa4c3-ca62-44fe-90e8-e6ff3f14dbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c2f0bb5-484d-466e-bc88-77e065d119f7" xlink:to="loc_us-gaap_ForwardContractsMember_c4faa4c3-ca62-44fe-90e8-e6ff3f14dbb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DevelopmentFundingBondForwardMember_87430da5-e594-4f25-89ca-8b87665f3391" xlink:href="rprx-20211231.xsd#rprx_DevelopmentFundingBondForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c2f0bb5-484d-466e-bc88-77e065d119f7" xlink:to="loc_rprx_DevelopmentFundingBondForwardMember_87430da5-e594-4f25-89ca-8b87665f3391" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#DerivativeInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" xlink:type="extended" id="i742d12b879dc4841badde4c8f5449fca_DerivativeInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_318e60fa-b37c-48ee-9c45-80d8348f59f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_us-gaap_DerivativeNotionalAmount_318e60fa-b37c-48ee-9c45-80d8348f59f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToTerminateDerivativeInstruments_ef7ae888-4f9a-4121-a793-b14a3c39f9d9" xlink:href="rprx-20211231.xsd#rprx_PaymentsToTerminateDerivativeInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_rprx_PaymentsToTerminateDerivativeInstruments_ef7ae888-4f9a-4121-a793-b14a3c39f9d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_53f81c3b-3b38-469a-8356-7e8154f42255" xlink:href="rprx-20211231.xsd#rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_53f81c3b-3b38-469a-8356-7e8154f42255" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_748e5aff-f23f-43aa-a55a-a486a512e7df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_748e5aff-f23f-43aa-a55a-a486a512e7df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_768ae082-cf55-40a3-9192-6bf1de4fdd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_768ae082-cf55-40a3-9192-6bf1de4fdd7d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment_a276cc89-7b10-436b-a481-67f8c2f9ea21" xlink:href="rprx-20211231.xsd#rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment_a276cc89-7b10-436b-a481-67f8c2f9ea21" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6a701efc-aeec-4e56-9770-21f44b9010c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6a701efc-aeec-4e56-9770-21f44b9010c5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_919b4a8c-a631-4332-b082-93dc568ed24d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_919b4a8c-a631-4332-b082-93dc568ed24d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_90079aef-909b-428c-9612-e0518b0253f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_90079aef-909b-428c-9612-e0518b0253f5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OptionIndexedToIssuersEquityTerm_c9c85a1b-a1d5-467d-b645-cb15a15a39fb" xlink:href="rprx-20211231.xsd#rprx_OptionIndexedToIssuersEquityTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_rprx_OptionIndexedToIssuersEquityTerm_c9c85a1b-a1d5-467d-b645-cb15a15a39fb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OptionIndexedToIssuersEquityValue_3dad96b0-7415-431b-93e6-73599f20b588" xlink:href="rprx-20211231.xsd#rprx_OptionIndexedToIssuersEquityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_rprx_OptionIndexedToIssuersEquityValue_3dad96b0-7415-431b-93e6-73599f20b588" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityStrikePrice1_ba59baaf-853c-4b45-a214-d1a55079c096" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityStrikePrice1_ba59baaf-853c-4b45-a214-d1a55079c096" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_273fbcad-98db-4f45-b920-e64e0cc1d768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_273fbcad-98db-4f45-b920-e64e0cc1d768" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fce35f22-38de-41f7-9c15-1ebb589bc0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fce35f22-38de-41f7-9c15-1ebb589bc0e6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b940b756-8cf4-49a7-b320-60b43356afb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b940b756-8cf4-49a7-b320-60b43356afb6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_dc788761-e035-472b-b586-07e11e7bd3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b940b756-8cf4-49a7-b320-60b43356afb6" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_dc788761-e035-472b-b586-07e11e7bd3b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_dc788761-e035-472b-b586-07e11e7bd3b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_dc788761-e035-472b-b586-07e11e7bd3b7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_dc788761-e035-472b-b586-07e11e7bd3b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_34a80004-b709-4d8c-a1f2-c1c6cd7a3250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_dc788761-e035-472b-b586-07e11e7bd3b7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_34a80004-b709-4d8c-a1f2-c1c6cd7a3250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TreasuryRateLockContractsMember_75b8bfa5-c781-462f-b01b-b5d388b5eb20" xlink:href="rprx-20211231.xsd#rprx_TreasuryRateLockContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_34a80004-b709-4d8c-a1f2-c1c6cd7a3250" xlink:to="loc_rprx_TreasuryRateLockContractsMember_75b8bfa5-c781-462f-b01b-b5d388b5eb20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_e1258bca-4c7d-4534-b5dc-1c40c26a1604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_34a80004-b709-4d8c-a1f2-c1c6cd7a3250" xlink:to="loc_us-gaap_InterestRateSwapMember_e1258bca-4c7d-4534-b5dc-1c40c26a1604" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_091916d6-74fb-4b42-adc4-6dbfe1ab3a00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_34a80004-b709-4d8c-a1f2-c1c6cd7a3250" xlink:to="loc_us-gaap_WarrantMember_091916d6-74fb-4b42-adc4-6dbfe1ab3a00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_c3c00ee5-45a2-4c18-ab8e-00c0b34dab86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_34a80004-b709-4d8c-a1f2-c1c6cd7a3250" xlink:to="loc_us-gaap_ForwardContractsMember_c3c00ee5-45a2-4c18-ab8e-00c0b34dab86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8e604767-4240-41e5-bb42-c1a9e90861d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b940b756-8cf4-49a7-b320-60b43356afb6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8e604767-4240-41e5-bb42-c1a9e90861d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8e604767-4240-41e5-bb42-c1a9e90861d7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8e604767-4240-41e5-bb42-c1a9e90861d7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8e604767-4240-41e5-bb42-c1a9e90861d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7b930ff6-d06b-49f1-be6a-78297f07d11b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8e604767-4240-41e5-bb42-c1a9e90861d7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7b930ff6-d06b-49f1-be6a-78297f07d11b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EpizymeIncMember_16780a34-5d45-4e97-a410-44e312fb407f" xlink:href="rprx-20211231.xsd#rprx_EpizymeIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7b930ff6-d06b-49f1-be6a-78297f07d11b" xlink:to="loc_rprx_EpizymeIncMember_16780a34-5d45-4e97-a410-44e312fb407f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_503259c8-890c-4688-b694-d837bba883f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b940b756-8cf4-49a7-b320-60b43356afb6" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_503259c8-890c-4688-b694-d837bba883f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_503259c8-890c-4688-b694-d837bba883f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_503259c8-890c-4688-b694-d837bba883f3" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_503259c8-890c-4688-b694-d837bba883f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_ba9f91c8-513d-4a75-bfd3-16cc01ef9fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_503259c8-890c-4688-b694-d837bba883f3" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_ba9f91c8-513d-4a75-bfd3-16cc01ef9fc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PutOptionMember_b0da40dd-57d2-4f08-b7f2-19f6c37df73c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PutOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_ba9f91c8-513d-4a75-bfd3-16cc01ef9fc1" xlink:to="loc_us-gaap_PutOptionMember_b0da40dd-57d2-4f08-b7f2-19f6c37df73c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_16effc2c-06bf-4004-b009-83739e8dcd43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b940b756-8cf4-49a7-b320-60b43356afb6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_16effc2c-06bf-4004-b009-83739e8dcd43" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_16effc2c-06bf-4004-b009-83739e8dcd43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_16effc2c-06bf-4004-b009-83739e8dcd43" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_16effc2c-06bf-4004-b009-83739e8dcd43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d915a4c9-7dc8-4a9c-82d2-a335c734af7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_16effc2c-06bf-4004-b009-83739e8dcd43" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d915a4c9-7dc8-4a9c-82d2-a335c734af7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EpizymeCommonStockWarrantMember_c504ac93-d5b3-4070-80b4-ae5c29e8efa3" xlink:href="rprx-20211231.xsd#rprx_EpizymeCommonStockWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d915a4c9-7dc8-4a9c-82d2-a335c734af7b" xlink:to="loc_rprx_EpizymeCommonStockWarrantMember_c504ac93-d5b3-4070-80b4-ae5c29e8efa3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6073305f-a06f-43fe-934b-29c82598b55a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b940b756-8cf4-49a7-b320-60b43356afb6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6073305f-a06f-43fe-934b-29c82598b55a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6073305f-a06f-43fe-934b-29c82598b55a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6073305f-a06f-43fe-934b-29c82598b55a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6073305f-a06f-43fe-934b-29c82598b55a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_91d1c061-81ed-400b-957b-91e8e533ef41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6073305f-a06f-43fe-934b-29c82598b55a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_91d1c061-81ed-400b-957b-91e8e533ef41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_65efd1e8-86b6-4ce5-94d1-9e6b1dfd7702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_91d1c061-81ed-400b-957b-91e8e533ef41" xlink:to="loc_us-gaap_PreferredStockMember_65efd1e8-86b6-4ce5-94d1-9e6b1dfd7702" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_af8cd58f-2578-4801-816c-287c74b1a805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_91d1c061-81ed-400b-957b-91e8e533ef41" xlink:to="loc_us-gaap_InterestRateSwapMember_af8cd58f-2578-4801-816c-287c74b1a805" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b1ae3815-382c-4adc-89f0-91b16dd5f780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b940b756-8cf4-49a7-b320-60b43356afb6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b1ae3815-382c-4adc-89f0-91b16dd5f780" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b1ae3815-382c-4adc-89f0-91b16dd5f780_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b1ae3815-382c-4adc-89f0-91b16dd5f780" xlink:to="loc_us-gaap_ClassOfStockDomain_b1ae3815-382c-4adc-89f0-91b16dd5f780_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fafce787-4dd2-4ba1-bc41-f6e433e42f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b1ae3815-382c-4adc-89f0-91b16dd5f780" xlink:to="loc_us-gaap_ClassOfStockDomain_fafce787-4dd2-4ba1-bc41-f6e433e42f2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_8418bb8c-c38e-42c7-a502-e8dbfa529c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_fafce787-4dd2-4ba1-bc41-f6e433e42f2c" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_8418bb8c-c38e-42c7-a502-e8dbfa529c8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_58d6ae9a-b8b0-4713-8e0c-60573b008b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b940b756-8cf4-49a7-b320-60b43356afb6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_58d6ae9a-b8b0-4713-8e0c-60573b008b1b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58d6ae9a-b8b0-4713-8e0c-60573b008b1b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_58d6ae9a-b8b0-4713-8e0c-60573b008b1b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58d6ae9a-b8b0-4713-8e0c-60573b008b1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_005a06b1-cd27-4cf9-8d7e-d842e20eb760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_58d6ae9a-b8b0-4713-8e0c-60573b008b1b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_005a06b1-cd27-4cf9-8d7e-d842e20eb760" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c1e8adac-35fe-4aa9-baa4-d2d2fc4647e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_005a06b1-cd27-4cf9-8d7e-d842e20eb760" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c1e8adac-35fe-4aa9-baa4-d2d2fc4647e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_52d187d6-90b5-4040-85b9-83f9daebaa1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b940b756-8cf4-49a7-b320-60b43356afb6" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_52d187d6-90b5-4040-85b9-83f9daebaa1f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_52d187d6-90b5-4040-85b9-83f9daebaa1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_52d187d6-90b5-4040-85b9-83f9daebaa1f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_52d187d6-90b5-4040-85b9-83f9daebaa1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9285967a-e5d7-40c0-945c-2330e14bd69e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_52d187d6-90b5-4040-85b9-83f9daebaa1f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9285967a-e5d7-40c0-945c-2330e14bd69e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ec1f0d8b-2560-47e3-8199-0f52abcf00bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9285967a-e5d7-40c0-945c-2330e14bd69e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ec1f0d8b-2560-47e3-8199-0f52abcf00bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" xlink:type="extended" id="i2e649f65a2db43fea848965a59fbf18c_DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b94798cb-edad-454f-b3b7-03f8d17074f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_916fee8a-68b8-4c45-bd35-3e44dd7ebb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b94798cb-edad-454f-b3b7-03f8d17074f2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_916fee8a-68b8-4c45-bd35-3e44dd7ebb2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_3d647a54-dc5c-4833-b1d8-33e5d9574625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b94798cb-edad-454f-b3b7-03f8d17074f2" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_3d647a54-dc5c-4833-b1d8-33e5d9574625" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_442ffe36-0147-4e6a-8203-2872fe63224b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b94798cb-edad-454f-b3b7-03f8d17074f2" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_442ffe36-0147-4e6a-8203-2872fe63224b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts_a72de12e-5d0b-4a43-a2ea-6ee1d324191c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b94798cb-edad-454f-b3b7-03f8d17074f2" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts_a72de12e-5d0b-4a43-a2ea-6ee1d324191c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_484329a3-f0b0-4a52-aa05-6dddcb2a96ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b94798cb-edad-454f-b3b7-03f8d17074f2" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_484329a3-f0b0-4a52-aa05-6dddcb2a96ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_651317b0-237e-4cd7-ae3d-e1b22c802897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_484329a3-f0b0-4a52-aa05-6dddcb2a96ae" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_651317b0-237e-4cd7-ae3d-e1b22c802897" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_651317b0-237e-4cd7-ae3d-e1b22c802897_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_651317b0-237e-4cd7-ae3d-e1b22c802897" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_651317b0-237e-4cd7-ae3d-e1b22c802897_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_76c104cb-fb6c-4566-b83f-69597f5d6742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_651317b0-237e-4cd7-ae3d-e1b22c802897" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_76c104cb-fb6c-4566-b83f-69597f5d6742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_04b24486-a197-43dd-bfb5-cc749170cdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_76c104cb-fb6c-4566-b83f-69597f5d6742" xlink:to="loc_us-gaap_InterestRateSwapMember_04b24486-a197-43dd-bfb5-cc749170cdf9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_ab87d303-4239-4145-988c-6bc1b9040b83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_76c104cb-fb6c-4566-b83f-69597f5d6742" xlink:to="loc_us-gaap_WarrantMember_ab87d303-4239-4145-988c-6bc1b9040b83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_e7410ce8-660c-43c2-8155-2590f5a4ad70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_76c104cb-fb6c-4566-b83f-69597f5d6742" xlink:to="loc_us-gaap_ForwardContractsMember_e7410ce8-660c-43c2-8155-2590f5a4ad70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TreasuryRateLockContractsMember_54a72b1d-0584-4337-9519-83a62c560741" xlink:href="rprx-20211231.xsd#rprx_TreasuryRateLockContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_76c104cb-fb6c-4566-b83f-69597f5d6742" xlink:to="loc_rprx_TreasuryRateLockContractsMember_54a72b1d-0584-4337-9519-83a62c560741" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_44c02515-7e90-469d-911e-f9d60bffe151" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_484329a3-f0b0-4a52-aa05-6dddcb2a96ae" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_44c02515-7e90-469d-911e-f9d60bffe151" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_44c02515-7e90-469d-911e-f9d60bffe151_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_44c02515-7e90-469d-911e-f9d60bffe151" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_44c02515-7e90-469d-911e-f9d60bffe151_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bfda96c1-dc74-42a8-b9a8-1427e1fbd3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_44c02515-7e90-469d-911e-f9d60bffe151" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bfda96c1-dc74-42a8-b9a8-1427e1fbd3b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsMember_d9d36581-ac1a-4987-8336-4c421db3e2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bfda96c1-dc74-42a8-b9a8-1427e1fbd3b8" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsMember_d9d36581-ac1a-4987-8336-4c421db3e2fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_2b4a1baf-b319-4512-98d1-c8ba2f5f132a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bfda96c1-dc74-42a8-b9a8-1427e1fbd3b8" xlink:to="loc_us-gaap_InterestExpenseMember_2b4a1baf-b319-4512-98d1-c8ba2f5f132a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_8314d618-0c81-4f29-9678-7401facd6990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_484329a3-f0b0-4a52-aa05-6dddcb2a96ae" xlink:to="loc_us-gaap_HedgingDesignationAxis_8314d618-0c81-4f29-9678-7401facd6990" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_8314d618-0c81-4f29-9678-7401facd6990_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_8314d618-0c81-4f29-9678-7401facd6990" xlink:to="loc_us-gaap_HedgingDesignationDomain_8314d618-0c81-4f29-9678-7401facd6990_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_02ed3402-a754-47ba-ba31-c5cf5cbb01c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_8314d618-0c81-4f29-9678-7401facd6990" xlink:to="loc_us-gaap_HedgingDesignationDomain_02ed3402-a754-47ba-ba31-c5cf5cbb01c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2eefe6f5-49a2-4920-9c38-443c43cc6ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_02ed3402-a754-47ba-ba31-c5cf5cbb01c0" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2eefe6f5-49a2-4920-9c38-443c43cc6ef9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_77072cb7-4639-4f99-a97c-6b8e29dc67fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_02ed3402-a754-47ba-ba31-c5cf5cbb01c0" xlink:to="loc_us-gaap_NondesignatedMember_77072cb7-4639-4f99-a97c-6b8e29dc67fd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" xlink:type="extended" id="ibd86c9e9f7d444f4a192baa09352f16f_FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e39cb102-06b9-4481-8ee6-f335f3817263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_5b38ee41-4121-4068-aff4-d285653ee4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e39cb102-06b9-4481-8ee6-f335f3817263" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_5b38ee41-4121-4068-aff4-d285653ee4eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_cc918810-51c1-42f2-ace1-f27d3260f81f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5b38ee41-4121-4068-aff4-d285653ee4eb" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_cc918810-51c1-42f2-ace1-f27d3260f81f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt_e6948033-6aa0-4774-b257-bd6a4ac24956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5b38ee41-4121-4068-aff4-d285653ee4eb" xlink:to="loc_us-gaap_TradingSecuritiesDebt_e6948033-6aa0-4774-b257-bd6a4ac24956" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_766fe835-fb1d-4ecf-af12-dec71fbcb5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5b38ee41-4121-4068-aff4-d285653ee4eb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_766fe835-fb1d-4ecf-af12-dec71fbcb5cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssetsFairValueDisclosureCurrent_94516fc5-1fd2-41a3-9264-4d7e6220c66e" xlink:href="rprx-20211231.xsd#rprx_AssetsFairValueDisclosureCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5b38ee41-4121-4068-aff4-d285653ee4eb" xlink:to="loc_rprx_AssetsFairValueDisclosureCurrent_94516fc5-1fd2-41a3-9264-4d7e6220c66e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_f1735206-1045-4f3e-84ea-85ea10256f74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5b38ee41-4121-4068-aff4-d285653ee4eb" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_f1735206-1045-4f3e-84ea-85ea10256f74" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_d77e483d-d15a-452e-93c7-475023ef69d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5b38ee41-4121-4068-aff4-d285653ee4eb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_d77e483d-d15a-452e-93c7-475023ef69d0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_ca7944ae-92a8-47ee-a346-691329edf665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5b38ee41-4121-4068-aff4-d285653ee4eb" xlink:to="loc_us-gaap_DerivativeAssets_ca7944ae-92a8-47ee-a346-691329edf665" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssetsFairValueDisclosureNoncurrent_cf19d02c-4d7d-45bd-82ac-cdbf4abe4669" xlink:href="rprx-20211231.xsd#rprx_AssetsFairValueDisclosureNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5b38ee41-4121-4068-aff4-d285653ee4eb" xlink:to="loc_rprx_AssetsFairValueDisclosureNoncurrent_cf19d02c-4d7d-45bd-82ac-cdbf4abe4669" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_9edb1b9f-6a3f-4a06-bac4-9c193f0311e8" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e39cb102-06b9-4481-8ee6-f335f3817263" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_9edb1b9f-6a3f-4a06-bac4-9c193f0311e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_a255b3a9-23a7-4716-bf45-66ee914bc524" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e39cb102-06b9-4481-8ee6-f335f3817263" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_a255b3a9-23a7-4716-bf45-66ee914bc524" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fbcafbc-56f3-4805-b06a-83ab8aa5781a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e39cb102-06b9-4481-8ee6-f335f3817263" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fbcafbc-56f3-4805-b06a-83ab8aa5781a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_6e428895-fd14-4934-955b-65ee883b8a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fbcafbc-56f3-4805-b06a-83ab8aa5781a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_6e428895-fd14-4934-955b-65ee883b8a6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6e428895-fd14-4934-955b-65ee883b8a6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_6e428895-fd14-4934-955b-65ee883b8a6d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6e428895-fd14-4934-955b-65ee883b8a6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35ef2931-9d22-487a-8830-a6c8d04be5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_6e428895-fd14-4934-955b-65ee883b8a6d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35ef2931-9d22-487a-8830-a6c8d04be5e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_81f5d85a-4957-471a-8602-e599c99178b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35ef2931-9d22-487a-8830-a6c8d04be5e8" xlink:to="loc_us-gaap_MoneyMarketFundsMember_81f5d85a-4957-471a-8602-e599c99178b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_49a7b7d8-4959-4e77-923a-df79b3b786c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35ef2931-9d22-487a-8830-a6c8d04be5e8" xlink:to="loc_us-gaap_CommercialPaperMember_49a7b7d8-4959-4e77-923a-df79b3b786c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_862eac28-9236-4307-a611-1ed64ddab08e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35ef2931-9d22-487a-8830-a6c8d04be5e8" xlink:to="loc_us-gaap_CertificatesOfDepositMember_862eac28-9236-4307-a611-1ed64ddab08e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5c22f15a-d6ce-4051-a4b1-8b271ca33de7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fbcafbc-56f3-4805-b06a-83ab8aa5781a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5c22f15a-d6ce-4051-a4b1-8b271ca33de7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5c22f15a-d6ce-4051-a4b1-8b271ca33de7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5c22f15a-d6ce-4051-a4b1-8b271ca33de7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5c22f15a-d6ce-4051-a4b1-8b271ca33de7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c10e8e18-2615-4a97-9fa1-ab37f5f80c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5c22f15a-d6ce-4051-a4b1-8b271ca33de7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c10e8e18-2615-4a97-9fa1-ab37f5f80c22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_fb3b387d-42b1-4e19-99e3-023b6b9d6b98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c10e8e18-2615-4a97-9fa1-ab37f5f80c22" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_fb3b387d-42b1-4e19-99e3-023b6b9d6b98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_88598fdc-f336-4251-9e91-b8940b930b11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c10e8e18-2615-4a97-9fa1-ab37f5f80c22" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_88598fdc-f336-4251-9e91-b8940b930b11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1142c017-e11e-4df8-998f-81d620273cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c10e8e18-2615-4a97-9fa1-ab37f5f80c22" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1142c017-e11e-4df8-998f-81d620273cbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0497af01-f33f-4713-b06f-271c87383ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fbcafbc-56f3-4805-b06a-83ab8aa5781a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0497af01-f33f-4713-b06f-271c87383ebc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0497af01-f33f-4713-b06f-271c87383ebc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0497af01-f33f-4713-b06f-271c87383ebc" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0497af01-f33f-4713-b06f-271c87383ebc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7f7ae25d-2eaf-497d-a119-494e9e5e361f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0497af01-f33f-4713-b06f-271c87383ebc" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7f7ae25d-2eaf-497d-a119-494e9e5e361f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f26caaba-0984-48e3-b9f8-8534e41d9fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7f7ae25d-2eaf-497d-a119-494e9e5e361f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f26caaba-0984-48e3-b9f8-8534e41d9fbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6fe40b7f-68f5-4583-a611-6d9bfc163f81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fbcafbc-56f3-4805-b06a-83ab8aa5781a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6fe40b7f-68f5-4583-a611-6d9bfc163f81" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fe40b7f-68f5-4583-a611-6d9bfc163f81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6fe40b7f-68f5-4583-a611-6d9bfc163f81" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fe40b7f-68f5-4583-a611-6d9bfc163f81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a04a9805-00d1-41c2-9e03-ec25d0fcd243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6fe40b7f-68f5-4583-a611-6d9bfc163f81" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a04a9805-00d1-41c2-9e03-ec25d0fcd243" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_a431edb3-63c8-4ad1-b5ef-dd5c9357aacc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a04a9805-00d1-41c2-9e03-ec25d0fcd243" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_a431edb3-63c8-4ad1-b5ef-dd5c9357aacc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f45c4f68-151c-4b67-9cbc-1ad22fcdd12b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a04a9805-00d1-41c2-9e03-ec25d0fcd243" xlink:to="loc_us-gaap_CommercialPaperMember_f45c4f68-151c-4b67-9cbc-1ad22fcdd12b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_8823542a-dd48-4fb1-a4da-3599381d18d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a04a9805-00d1-41c2-9e03-ec25d0fcd243" xlink:to="loc_us-gaap_CertificatesOfDepositMember_8823542a-dd48-4fb1-a4da-3599381d18d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_a1f2c880-bdb4-46c5-bef1-4f661c4497e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a04a9805-00d1-41c2-9e03-ec25d0fcd243" xlink:to="loc_us-gaap_ForwardContractsMember_a1f2c880-bdb4-46c5-bef1-4f661c4497e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_7bd8c9f1-9adb-40f7-9d67-8b0d17131e66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a04a9805-00d1-41c2-9e03-ec25d0fcd243" xlink:to="loc_us-gaap_WarrantMember_7bd8c9f1-9adb-40f7-9d67-8b0d17131e66" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_106f9728-79ce-40c1-b23a-ab6c9a256a82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a04a9805-00d1-41c2-9e03-ec25d0fcd243" xlink:to="loc_us-gaap_InterestRateSwapMember_106f9728-79ce-40c1-b23a-ab6c9a256a82" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5149052d-a2bc-42d0-8d24-9440cc61961b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fbcafbc-56f3-4805-b06a-83ab8aa5781a" xlink:to="loc_srt_CounterpartyNameAxis_5149052d-a2bc-42d0-8d24-9440cc61961b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5149052d-a2bc-42d0-8d24-9440cc61961b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5149052d-a2bc-42d0-8d24-9440cc61961b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5149052d-a2bc-42d0-8d24-9440cc61961b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e4e04ec6-b9cc-43f4-9cab-e3886f6818dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5149052d-a2bc-42d0-8d24-9440cc61961b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e4e04ec6-b9cc-43f4-9cab-e3886f6818dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MorphoSysMember_191659b3-df28-406f-8dcc-3398746e1201" xlink:href="rprx-20211231.xsd#rprx_MorphoSysMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e4e04ec6-b9cc-43f4-9cab-e3886f6818dd" xlink:to="loc_rprx_MorphoSysMember_191659b3-df28-406f-8dcc-3398746e1201" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_257f828d-b06d-4d9a-b6a0-dae951c5cf83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fbcafbc-56f3-4805-b06a-83ab8aa5781a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_257f828d-b06d-4d9a-b6a0-dae951c5cf83" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_257f828d-b06d-4d9a-b6a0-dae951c5cf83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_257f828d-b06d-4d9a-b6a0-dae951c5cf83" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_257f828d-b06d-4d9a-b6a0-dae951c5cf83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb4c8817-2ae8-488c-9391-3a4aeea8ecab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_257f828d-b06d-4d9a-b6a0-dae951c5cf83" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb4c8817-2ae8-488c-9391-3a4aeea8ecab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d6fec4d2-04e5-4161-bb85-bac37e60da3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb4c8817-2ae8-488c-9391-3a4aeea8ecab" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d6fec4d2-04e5-4161-bb85-bac37e60da3d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" xlink:type="extended" id="i9ef9b9033c964986b0c97658c55d1384_FairValueMeasurementsandFinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8643c216-d65e-4753-9a17-4c949aa85cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss_2c3a0b86-723e-482a-b8cc-e980ca2a794e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8643c216-d65e-4753-9a17-4c949aa85cd7" xlink:to="loc_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss_2c3a0b86-723e-482a-b8cc-e980ca2a794e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage_25125182-2ace-4720-b109-062ddbcac769" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8643c216-d65e-4753-9a17-4c949aa85cd7" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage_25125182-2ace-4720-b109-062ddbcac769" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments_a18efc06-12fd-422b-8164-8d353ebed48c" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8643c216-d65e-4753-9a17-4c949aa85cd7" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments_a18efc06-12fd-422b-8164-8d353ebed48c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleFixedPayment_02e64395-1309-47c4-9d05-853775450d91" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleFixedPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8643c216-d65e-4753-9a17-4c949aa85cd7" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleFixedPayment_02e64395-1309-47c4-9d05-853775450d91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod_ae053b40-8de2-4348-ac34-b158428a1c40" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8643c216-d65e-4753-9a17-4c949aa85cd7" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod_ae053b40-8de2-4348-ac34-b158428a1c40" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital_f2537b5b-b037-4d4c-835c-cea7167116ef" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8643c216-d65e-4753-9a17-4c949aa85cd7" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital_f2537b5b-b037-4d4c-835c-cea7167116ef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_d7c2f71b-eac5-4c39-bc24-34bb0093ebb8" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8643c216-d65e-4753-9a17-4c949aa85cd7" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_d7c2f71b-eac5-4c39-bc24-34bb0093ebb8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod_ef7208b3-0583-46ea-ab49-b989ad918e01" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8643c216-d65e-4753-9a17-4c949aa85cd7" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod_ef7208b3-0583-46ea-ab49-b989ad918e01" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_16ca4d00-c304-41e4-a2e1-d630c8cf94f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8643c216-d65e-4753-9a17-4c949aa85cd7" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_16ca4d00-c304-41e4-a2e1-d630c8cf94f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a0740cf3-da27-4f98-b2d2-ef58b42a94ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_16ca4d00-c304-41e4-a2e1-d630c8cf94f8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a0740cf3-da27-4f98-b2d2-ef58b42a94ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a0740cf3-da27-4f98-b2d2-ef58b42a94ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a0740cf3-da27-4f98-b2d2-ef58b42a94ee" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a0740cf3-da27-4f98-b2d2-ef58b42a94ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4f87ede7-2ac2-4bf7-bcf2-d859741c9c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a0740cf3-da27-4f98-b2d2-ef58b42a94ee" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4f87ede7-2ac2-4bf7-bcf2-d859741c9c5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_38382d96-26df-4f4a-9812-e2e46e036691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4f87ede7-2ac2-4bf7-bcf2-d859741c9c5e" xlink:to="loc_us-gaap_PreferredStockMember_38382d96-26df-4f4a-9812-e2e46e036691" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_979eba40-2036-4705-a9f8-cdae36ffd69e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_16ca4d00-c304-41e4-a2e1-d630c8cf94f8" xlink:to="loc_srt_RangeAxis_979eba40-2036-4705-a9f8-cdae36ffd69e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_979eba40-2036-4705-a9f8-cdae36ffd69e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_979eba40-2036-4705-a9f8-cdae36ffd69e" xlink:to="loc_srt_RangeMember_979eba40-2036-4705-a9f8-cdae36ffd69e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7af997b4-d0a0-4999-80da-7173bae035d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_979eba40-2036-4705-a9f8-cdae36ffd69e" xlink:to="loc_srt_RangeMember_7af997b4-d0a0-4999-80da-7173bae035d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_792dd41c-b4c7-4121-b0d7-1b9814e4b8da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7af997b4-d0a0-4999-80da-7173bae035d2" xlink:to="loc_srt_MaximumMember_792dd41c-b4c7-4121-b0d7-1b9814e4b8da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ab3356db-c141-41e9-bcd4-a2b6c8239f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_16ca4d00-c304-41e4-a2e1-d630c8cf94f8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ab3356db-c141-41e9-bcd4-a2b6c8239f6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ab3356db-c141-41e9-bcd4-a2b6c8239f6b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ab3356db-c141-41e9-bcd4-a2b6c8239f6b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ab3356db-c141-41e9-bcd4-a2b6c8239f6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_66514746-8ca7-4097-9831-6f1c32152e54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ab3356db-c141-41e9-bcd4-a2b6c8239f6b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_66514746-8ca7-4097-9831-6f1c32152e54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ee1f2dc5-12d3-4332-b2e1-46ef751c6739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_66514746-8ca7-4097-9831-6f1c32152e54" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ee1f2dc5-12d3-4332-b2e1-46ef751c6739" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_436336b2-86bf-4a84-b4c8-e2b3e8859ffd" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_16ca4d00-c304-41e4-a2e1-d630c8cf94f8" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_436336b2-86bf-4a84-b4c8-e2b3e8859ffd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_436336b2-86bf-4a84-b4c8-e2b3e8859ffd_default" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_436336b2-86bf-4a84-b4c8-e2b3e8859ffd" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_436336b2-86bf-4a84-b4c8-e2b3e8859ffd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_7e17d0d3-e28e-47a1-a9d8-72626981dd55" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_436336b2-86bf-4a84-b4c8-e2b3e8859ffd" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_7e17d0d3-e28e-47a1-a9d8-72626981dd55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_1f433a62-ba25-45d9-881e-42809a311653" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_7e17d0d3-e28e-47a1-a9d8-72626981dd55" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_1f433a62-ba25-45d9-881e-42809a311653" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_63b18683-c483-4819-9872-3a90c2e13169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_16ca4d00-c304-41e4-a2e1-d630c8cf94f8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_63b18683-c483-4819-9872-3a90c2e13169" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_63b18683-c483-4819-9872-3a90c2e13169_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_63b18683-c483-4819-9872-3a90c2e13169" xlink:to="loc_us-gaap_ClassOfStockDomain_63b18683-c483-4819-9872-3a90c2e13169_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a9e9bc31-1baf-426b-8700-0fdd9d72cb43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_63b18683-c483-4819-9872-3a90c2e13169" xlink:to="loc_us-gaap_ClassOfStockDomain_a9e9bc31-1baf-426b-8700-0fdd9d72cb43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_ae14f62d-c8f2-4476-af57-64acc624b283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a9e9bc31-1baf-426b-8700-0fdd9d72cb43" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_ae14f62d-c8f2-4476-af57-64acc624b283" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_859fee3b-7e97-459c-ad54-21c19ec90caf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_16ca4d00-c304-41e4-a2e1-d630c8cf94f8" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_859fee3b-7e97-459c-ad54-21c19ec90caf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_859fee3b-7e97-459c-ad54-21c19ec90caf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_859fee3b-7e97-459c-ad54-21c19ec90caf" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_859fee3b-7e97-459c-ad54-21c19ec90caf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_44f2e197-6917-4ee1-8606-cf7a622668fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_859fee3b-7e97-459c-ad54-21c19ec90caf" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_44f2e197-6917-4ee1-8606-cf7a622668fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_4ad98f2f-2367-4025-9843-2263d0889947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_44f2e197-6917-4ee1-8606-cf7a622668fa" xlink:to="loc_us-gaap_EquitySecuritiesMember_4ad98f2f-2367-4025-9843-2263d0889947" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d86ce1a2-382b-46d3-8e20-d046193d0a3c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_16ca4d00-c304-41e4-a2e1-d630c8cf94f8" xlink:to="loc_srt_CounterpartyNameAxis_d86ce1a2-382b-46d3-8e20-d046193d0a3c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d86ce1a2-382b-46d3-8e20-d046193d0a3c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d86ce1a2-382b-46d3-8e20-d046193d0a3c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d86ce1a2-382b-46d3-8e20-d046193d0a3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b917f089-e5ff-4a23-99db-79f900ecae14" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d86ce1a2-382b-46d3-8e20-d046193d0a3c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b917f089-e5ff-4a23-99db-79f900ecae14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_BioCrystPharmaceuticalsIncMember_dd9b737d-3e6c-4208-9097-4c2086276731" xlink:href="rprx-20211231.xsd#rprx_BioCrystPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b917f089-e5ff-4a23-99db-79f900ecae14" xlink:to="loc_rprx_BioCrystPharmaceuticalsIncMember_dd9b737d-3e6c-4208-9097-4c2086276731" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" xlink:type="extended" id="i96b2487e4a464083be93bc275db7bc58_FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_85c7ce58-6255-4d04-9ae5-f4ad586a2069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a1af04db-20a6-4c9c-ad7c-1acbfb9e869a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_85c7ce58-6255-4d04-9ae5-f4ad586a2069" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a1af04db-20a6-4c9c-ad7c-1acbfb9e869a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_10f6b94c-b4b5-464f-aa98-ec258a757695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a1af04db-20a6-4c9c-ad7c-1acbfb9e869a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_10f6b94c-b4b5-464f-aa98-ec258a757695" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_2dfb9609-3b0b-406c-b0bf-1c38be287613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a1af04db-20a6-4c9c-ad7c-1acbfb9e869a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_2dfb9609-3b0b-406c-b0bf-1c38be287613" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_91998910-df5f-4e91-99c3-42401351e1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a1af04db-20a6-4c9c-ad7c-1acbfb9e869a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_91998910-df5f-4e91-99c3-42401351e1e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_4c986940-3a31-4707-bcd0-aab6b25b224a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a1af04db-20a6-4c9c-ad7c-1acbfb9e869a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_4c986940-3a31-4707-bcd0-aab6b25b224a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_a376d701-d530-4301-99dd-629eadab973b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a1af04db-20a6-4c9c-ad7c-1acbfb9e869a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_a376d701-d530-4301-99dd-629eadab973b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_f34445d3-a2de-42e9-973d-63242df39ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a1af04db-20a6-4c9c-ad7c-1acbfb9e869a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_f34445d3-a2de-42e9-973d-63242df39ac5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3_c3d82425-3945-4e5f-9f1c-a5ab1b03a232" xlink:href="rprx-20211231.xsd#rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a1af04db-20a6-4c9c-ad7c-1acbfb9e869a" xlink:to="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3_c3d82425-3945-4e5f-9f1c-a5ab1b03a232" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_718f196b-d5cd-4143-863b-b342a5f32ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a1af04db-20a6-4c9c-ad7c-1acbfb9e869a" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_718f196b-d5cd-4143-863b-b342a5f32ac1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions_017fbc23-77ee-45ea-a5a9-34b3581bdabf" xlink:href="rprx-20211231.xsd#rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a1af04db-20a6-4c9c-ad7c-1acbfb9e869a" xlink:to="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions_017fbc23-77ee-45ea-a5a9-34b3581bdabf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_424c74a8-32bb-47dc-9050-8f17a6e011f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_af10d8a6-4816-4a05-9f56-d69c43cb98db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_85c7ce58-6255-4d04-9ae5-f4ad586a2069" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_af10d8a6-4816-4a05-9f56-d69c43cb98db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4b88d82b-e926-4444-ae15-491bff7af7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_85c7ce58-6255-4d04-9ae5-f4ad586a2069" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4b88d82b-e926-4444-ae15-491bff7af7a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_f12397f3-ff83-4bd6-afee-91e70205d594" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4b88d82b-e926-4444-ae15-491bff7af7a2" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_f12397f3-ff83-4bd6-afee-91e70205d594" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f12397f3-ff83-4bd6-afee-91e70205d594_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f12397f3-ff83-4bd6-afee-91e70205d594" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f12397f3-ff83-4bd6-afee-91e70205d594_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_83f2bd2a-4ea1-4326-b39a-5bb0ad9b9e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f12397f3-ff83-4bd6-afee-91e70205d594" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_83f2bd2a-4ea1-4326-b39a-5bb0ad9b9e61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_f3db92d6-d6e6-483f-ad73-095cf522b607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_83f2bd2a-4ea1-4326-b39a-5bb0ad9b9e61" xlink:to="loc_us-gaap_EquitySecuritiesMember_f3db92d6-d6e6-483f-ad73-095cf522b607" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_da413687-3a12-460d-aa8e-6ae1355371b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_83f2bd2a-4ea1-4326-b39a-5bb0ad9b9e61" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_da413687-3a12-460d-aa8e-6ae1355371b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_27280e23-729d-41f6-9e8e-077e46fadb91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_83f2bd2a-4ea1-4326-b39a-5bb0ad9b9e61" xlink:to="loc_us-gaap_ForwardContractsMember_27280e23-729d-41f6-9e8e-077e46fadb91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_c72e59e9-3031-4406-82ba-5d43af9ead4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_83f2bd2a-4ea1-4326-b39a-5bb0ad9b9e61" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_c72e59e9-3031-4406-82ba-5d43af9ead4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d57b9e9-381e-49b0-99f2-db8130a07c48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4b88d82b-e926-4444-ae15-491bff7af7a2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d57b9e9-381e-49b0-99f2-db8130a07c48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d57b9e9-381e-49b0-99f2-db8130a07c48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d57b9e9-381e-49b0-99f2-db8130a07c48" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d57b9e9-381e-49b0-99f2-db8130a07c48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e83264d-0c11-4109-85df-42a69bf80534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d57b9e9-381e-49b0-99f2-db8130a07c48" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e83264d-0c11-4109-85df-42a69bf80534" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6f1a2669-43c7-427d-b631-b1c9f5a02e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e83264d-0c11-4109-85df-42a69bf80534" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6f1a2669-43c7-427d-b631-b1c9f5a02e4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e58f0548-1424-41d2-884a-2636c9dd00b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e83264d-0c11-4109-85df-42a69bf80534" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e58f0548-1424-41d2-884a-2636c9dd00b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b26f07eb-06a9-41c2-9a54-b53cd13748c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4b88d82b-e926-4444-ae15-491bff7af7a2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b26f07eb-06a9-41c2-9a54-b53cd13748c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b26f07eb-06a9-41c2-9a54-b53cd13748c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b26f07eb-06a9-41c2-9a54-b53cd13748c0" xlink:to="loc_us-gaap_ClassOfStockDomain_b26f07eb-06a9-41c2-9a54-b53cd13748c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d1ea1d4f-63a1-4989-a6a1-d6bbdd281aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b26f07eb-06a9-41c2-9a54-b53cd13748c0" xlink:to="loc_us-gaap_ClassOfStockDomain_d1ea1d4f-63a1-4989-a6a1-d6bbdd281aa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_607fb949-eab5-47de-80ff-6d74ea67449e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d1ea1d4f-63a1-4989-a6a1-d6bbdd281aa9" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_607fb949-eab5-47de-80ff-6d74ea67449e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_4c8afc8d-1490-4a2c-b25d-cc5a8ad0d003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d1ea1d4f-63a1-4989-a6a1-d6bbdd281aa9" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_4c8afc8d-1490-4a2c-b25d-cc5a8ad0d003" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" xlink:type="extended" id="i0dd1e6274e8c45819b73465b8f453b8e_FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_d0a1d670-cf35-49fa-a42a-d42e3c16e3da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivablesFairValueDisclosure_ce45672a-26b6-44d8-8b13-1d31426bc7ad" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivablesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_d0a1d670-cf35-49fa-a42a-d42e3c16e3da" xlink:to="loc_rprx_FinancingReceivablesFairValueDisclosure_ce45672a-26b6-44d8-8b13-1d31426bc7ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_00115f4c-5a2a-4c51-9469-c036ac6a2527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_d0a1d670-cf35-49fa-a42a-d42e3c16e3da" xlink:to="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_00115f4c-5a2a-4c51-9469-c036ac6a2527" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_22bdc120-98ea-4919-87cc-e2d00413043e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_00115f4c-5a2a-4c51-9469-c036ac6a2527" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_22bdc120-98ea-4919-87cc-e2d00413043e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_22bdc120-98ea-4919-87cc-e2d00413043e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_22bdc120-98ea-4919-87cc-e2d00413043e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_22bdc120-98ea-4919-87cc-e2d00413043e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b7ab7f52-a1b2-42f1-b0a9-0dcd789a43f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_22bdc120-98ea-4919-87cc-e2d00413043e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b7ab7f52-a1b2-42f1-b0a9-0dcd789a43f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_90060fa3-a97e-46c8-b472-31bea2ebacbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b7ab7f52-a1b2-42f1-b0a9-0dcd789a43f1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_90060fa3-a97e-46c8-b472-31bea2ebacbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_669154d3-6b6a-49e5-83d1-8f0c9b9ff62e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_00115f4c-5a2a-4c51-9469-c036ac6a2527" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_669154d3-6b6a-49e5-83d1-8f0c9b9ff62e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_669154d3-6b6a-49e5-83d1-8f0c9b9ff62e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_669154d3-6b6a-49e5-83d1-8f0c9b9ff62e" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_669154d3-6b6a-49e5-83d1-8f0c9b9ff62e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_13297722-8baf-46d0-9f0f-4aeec04d20ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_669154d3-6b6a-49e5-83d1-8f0c9b9ff62e" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_13297722-8baf-46d0-9f0f-4aeec04d20ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c5b5fdd5-69b1-48b3-bbbb-a019d6589678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_13297722-8baf-46d0-9f0f-4aeec04d20ea" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c5b5fdd5-69b1-48b3-bbbb-a019d6589678" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_f75e20fd-339c-4088-bb52-2918af569d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c5b5fdd5-69b1-48b3-bbbb-a019d6589678" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_f75e20fd-339c-4088-bb52-2918af569d6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_865ae975-7a26-4ad8-894d-ca2654633d85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c5b5fdd5-69b1-48b3-bbbb-a019d6589678" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_865ae975-7a26-4ad8-894d-ca2654633d85" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" xlink:type="extended" id="i7f654f2dd5944981b1877fa9a6e4e7fc_FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0722f954-57ac-47cb-b86e-f0ab43b897ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross_d2156111-4768-4b22-83c0-3fa99b0ed0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0722f954-57ac-47cb-b86e-f0ab43b897ff" xlink:to="loc_us-gaap_NotesReceivableGross_d2156111-4768-4b22-83c0-3fa99b0ed0aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_e078e7d9-57df-4e97-a727-0415cd6cbec9" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0722f954-57ac-47cb-b86e-f0ab43b897ff" xlink:to="loc_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_e078e7d9-57df-4e97-a727-0415cd6cbec9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_88fe99a0-6413-46f2-9dac-59dd95712045" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0722f954-57ac-47cb-b86e-f0ab43b897ff" xlink:to="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_88fe99a0-6413-46f2-9dac-59dd95712045" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_a1ca714e-5d69-4be3-975c-04ad743b99c2" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0722f954-57ac-47cb-b86e-f0ab43b897ff" xlink:to="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_a1ca714e-5d69-4be3-975c-04ad743b99c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_a90b0383-ff68-4739-b0c1-e378ad0f8818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0722f954-57ac-47cb-b86e-f0ab43b897ff" xlink:to="loc_us-gaap_NotesReceivableNet_a90b0383-ff68-4739-b0c1-e378ad0f8818" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents_7a20eba7-509a-4c32-8572-214e61d52461" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0722f954-57ac-47cb-b86e-f0ab43b897ff" xlink:to="loc_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents_7a20eba7-509a-4c32-8572-214e61d52461" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c0091dd9-b2ea-4c11-a1e2-2626e7c21a13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0722f954-57ac-47cb-b86e-f0ab43b897ff" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c0091dd9-b2ea-4c11-a1e2-2626e7c21a13" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_7da3b168-9336-45bf-a810-de95b417cff2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c0091dd9-b2ea-4c11-a1e2-2626e7c21a13" xlink:to="loc_srt_MajorCustomersAxis_7da3b168-9336-45bf-a810-de95b417cff2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7da3b168-9336-45bf-a810-de95b417cff2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_7da3b168-9336-45bf-a810-de95b417cff2" xlink:to="loc_srt_NameOfMajorCustomerDomain_7da3b168-9336-45bf-a810-de95b417cff2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_441a3604-7284-45be-b45b-10844b6358d5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_7da3b168-9336-45bf-a810-de95b417cff2" xlink:to="loc_srt_NameOfMajorCustomerDomain_441a3604-7284-45be-b45b-10844b6358d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CysticFibrosisFranchiseMember_a6224227-a268-4c46-b6cc-74e32b38de56" xlink:href="rprx-20211231.xsd#rprx_CysticFibrosisFranchiseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_441a3604-7284-45be-b45b-10844b6358d5" xlink:to="loc_rprx_CysticFibrosisFranchiseMember_a6224227-a268-4c46-b6cc-74e32b38de56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TysabriMember_ac79309e-775d-44ca-b80c-c4a080b94f1e" xlink:href="rprx-20211231.xsd#rprx_TysabriMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_441a3604-7284-45be-b45b-10844b6358d5" xlink:to="loc_rprx_TysabriMember_ac79309e-775d-44ca-b80c-c4a080b94f1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ImbruvicaMember_998215e8-2e64-4293-93ca-aa25834bdc3a" xlink:href="rprx-20211231.xsd#rprx_ImbruvicaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_441a3604-7284-45be-b45b-10844b6358d5" xlink:to="loc_rprx_ImbruvicaMember_998215e8-2e64-4293-93ca-aa25834bdc3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_XtandiMember_03b74a82-e447-4f86-b777-474d4c5d9b1f" xlink:href="rprx-20211231.xsd#rprx_XtandiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_441a3604-7284-45be-b45b-10844b6358d5" xlink:to="loc_rprx_XtandiMember_03b74a82-e447-4f86-b777-474d4c5d9b1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TremfyaMember_d8564193-ba02-4462-aaca-aa68a2201334" xlink:href="rprx-20211231.xsd#rprx_TremfyaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_441a3604-7284-45be-b45b-10844b6358d5" xlink:to="loc_rprx_TremfyaMember_d8564193-ba02-4462-aaca-aa68a2201334" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EvrysdiMember_09510800-aa03-48e5-9593-9bcebfd64269" xlink:href="rprx-20211231.xsd#rprx_EvrysdiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_441a3604-7284-45be-b45b-10844b6358d5" xlink:to="loc_rprx_EvrysdiMember_09510800-aa03-48e5-9593-9bcebfd64269" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PromactaMember_be02a07f-ad1b-4fa0-a424-0bf82bd53874" xlink:href="rprx-20211231.xsd#rprx_PromactaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_441a3604-7284-45be-b45b-10844b6358d5" xlink:to="loc_rprx_PromactaMember_be02a07f-ad1b-4fa0-a424-0bf82bd53874" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherFinancialRoyaltyAssetMember_971d72fe-ea2a-4d59-94cc-24c11650b9e9" xlink:href="rprx-20211231.xsd#rprx_OtherFinancialRoyaltyAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_441a3604-7284-45be-b45b-10844b6358d5" xlink:to="loc_rprx_OtherFinancialRoyaltyAssetMember_971d72fe-ea2a-4d59-94cc-24c11650b9e9" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails" xlink:type="extended" id="ib566ca4901e84221815f948bf855029c_CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_7d9c0310-4d0a-481a-a117-ec86c27ef468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_384a8b6a-cfa9-4f76-a7c3-3cb7588b4b35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_7d9c0310-4d0a-481a-a117-ec86c27ef468" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_384a8b6a-cfa9-4f76-a7c3-3cb7588b4b35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_f69f9471-ac3d-4d34-9dbe-1474b24ce373" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_7d9c0310-4d0a-481a-a117-ec86c27ef468" xlink:to="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_f69f9471-ac3d-4d34-9dbe-1474b24ce373" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c96e79e0-42fe-4004-8ae5-03332b15733d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_f69f9471-ac3d-4d34-9dbe-1474b24ce373" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c96e79e0-42fe-4004-8ae5-03332b15733d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c96e79e0-42fe-4004-8ae5-03332b15733d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c96e79e0-42fe-4004-8ae5-03332b15733d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c96e79e0-42fe-4004-8ae5-03332b15733d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5ceeb8eb-a58a-40a9-a7e4-d4dbf1898751" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c96e79e0-42fe-4004-8ae5-03332b15733d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5ceeb8eb-a58a-40a9-a7e4-d4dbf1898751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_97d77f60-84f1-41fc-8767-fe745bf53086" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5ceeb8eb-a58a-40a9-a7e4-d4dbf1898751" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_97d77f60-84f1-41fc-8767-fe745bf53086" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_12adb9c5-6b47-4f81-a4ab-3a36ab323574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_f69f9471-ac3d-4d34-9dbe-1474b24ce373" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_12adb9c5-6b47-4f81-a4ab-3a36ab323574" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_12adb9c5-6b47-4f81-a4ab-3a36ab323574_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_12adb9c5-6b47-4f81-a4ab-3a36ab323574" xlink:to="loc_us-gaap_EquityComponentDomain_12adb9c5-6b47-4f81-a4ab-3a36ab323574_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6a573f84-494f-46db-81da-99eaee078239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_12adb9c5-6b47-4f81-a4ab-3a36ab323574" xlink:to="loc_us-gaap_EquityComponentDomain_6a573f84-494f-46db-81da-99eaee078239" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_898277ae-6284-4ad9-856a-557b0efa3d42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6a573f84-494f-46db-81da-99eaee078239" xlink:to="loc_us-gaap_RetainedEarningsMember_898277ae-6284-4ad9-856a-557b0efa3d42" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" xlink:type="extended" id="ic8f23d952ada4da0956118f168d9815d_CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_3b6475d2-3691-404a-9dc8-5f1d79f2d779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses_1b1a49c9-3565-4cfc-ae27-7bc50156841a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_3b6475d2-3691-404a-9dc8-5f1d79f2d779" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses_1b1a49c9-3565-4cfc-ae27-7bc50156841a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense_54e0a930-f335-4d54-a062-7c4ebaac8f91" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_3b6475d2-3691-404a-9dc8-5f1d79f2d779" xlink:to="loc_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense_54e0a930-f335-4d54-a062-7c4ebaac8f91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense_18b30f25-79f1-4ebd-8d5e-869b658075e9" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_3b6475d2-3691-404a-9dc8-5f1d79f2d779" xlink:to="loc_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense_18b30f25-79f1-4ebd-8d5e-869b658075e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableChangeInPresentValueExpenseReversal_bd8dc35a-47d3-476f-9b82-988f560a79d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableChangeInPresentValueExpenseReversal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_3b6475d2-3691-404a-9dc8-5f1d79f2d779" xlink:to="loc_us-gaap_FinancingReceivableChangeInPresentValueExpenseReversal_bd8dc35a-47d3-476f-9b82-988f560a79d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs_bb9d6db5-3195-4ed3-9535-79e3f9aa36e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_3b6475d2-3691-404a-9dc8-5f1d79f2d779" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs_bb9d6db5-3195-4ed3-9535-79e3f9aa36e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLoanLossesExpensed_7c6e2f71-36e9-480b-a019-152c61dc3e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForLoanLossesExpensed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_3b6475d2-3691-404a-9dc8-5f1d79f2d779" xlink:to="loc_us-gaap_ProvisionForLoanLossesExpensed_7c6e2f71-36e9-480b-a019-152c61dc3e5e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses_9d06d40c-54bf-481f-ae92-d319a3c46586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff_753076da-6d79-48e8-8f70-a21ffcc39469" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_3b6475d2-3691-404a-9dc8-5f1d79f2d779" xlink:to="loc_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff_753076da-6d79-48e8-8f70-a21ffcc39469" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_dda5577e-a0d0-43a9-a13e-891967e459f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_3b6475d2-3691-404a-9dc8-5f1d79f2d779" xlink:to="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_dda5577e-a0d0-43a9-a13e-891967e459f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1ce92c7a-518f-49bf-91fe-35184b3a8401" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_dda5577e-a0d0-43a9-a13e-891967e459f5" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1ce92c7a-518f-49bf-91fe-35184b3a8401" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1ce92c7a-518f-49bf-91fe-35184b3a8401_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1ce92c7a-518f-49bf-91fe-35184b3a8401" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1ce92c7a-518f-49bf-91fe-35184b3a8401_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7cda0aa2-13d5-4bd6-89ee-845a19512b36" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1ce92c7a-518f-49bf-91fe-35184b3a8401" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7cda0aa2-13d5-4bd6-89ee-845a19512b36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_2cb28d45-f725-41e1-82dc-5e33016db8b0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7cda0aa2-13d5-4bd6-89ee-845a19512b36" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_2cb28d45-f725-41e1-82dc-5e33016db8b0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" xlink:type="extended" id="i78c78b7b941441ac8a4de85adc579b72_IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7dc29fcf-929f-46ca-b275-d3d2e5d2c788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_af3cdfef-a8fe-4e9b-a863-2154497db0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7dc29fcf-929f-46ca-b275-d3d2e5d2c788" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_af3cdfef-a8fe-4e9b-a863-2154497db0ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_098aa143-4e33-4261-bea8-6dcaa1c1a30e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7dc29fcf-929f-46ca-b275-d3d2e5d2c788" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_098aa143-4e33-4261-bea8-6dcaa1c1a30e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_80af27d5-ab1b-4f5e-971f-c8de9a92d433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7dc29fcf-929f-46ca-b275-d3d2e5d2c788" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_80af27d5-ab1b-4f5e-971f-c8de9a92d433" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_061434c4-6005-45ff-88f2-84fab7cadd1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7dc29fcf-929f-46ca-b275-d3d2e5d2c788" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_061434c4-6005-45ff-88f2-84fab7cadd1d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a910d1ca-e41f-4d15-a38b-ae6eed19d747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_061434c4-6005-45ff-88f2-84fab7cadd1d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a910d1ca-e41f-4d15-a38b-ae6eed19d747" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a910d1ca-e41f-4d15-a38b-ae6eed19d747_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a910d1ca-e41f-4d15-a38b-ae6eed19d747" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a910d1ca-e41f-4d15-a38b-ae6eed19d747_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0525bdbd-1b5e-4271-b772-4e4d137162d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a910d1ca-e41f-4d15-a38b-ae6eed19d747" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0525bdbd-1b5e-4271-b772-4e4d137162d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DPPIVPatentsMember_19b2d439-895d-4611-873f-95064575f487" xlink:href="rprx-20211231.xsd#rprx_DPPIVPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0525bdbd-1b5e-4271-b772-4e4d137162d3" xlink:to="loc_rprx_DPPIVPatentsMember_19b2d439-895d-4611-873f-95064575f487" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#IntangibleRoyaltyAssetsNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" xlink:type="extended" id="i32122f06a505444b86dfb38802062cbe_IntangibleRoyaltyAssetsNetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4bda21e6-c845-4f12-aace-79d12750bfc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f2cea427-2538-4658-aed3-b2325971626b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4bda21e6-c845-4f12-aace-79d12750bfc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f2cea427-2538-4658-aed3-b2325971626b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3a552787-5369-4dff-9ec3-964a16169582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4bda21e6-c845-4f12-aace-79d12750bfc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3a552787-5369-4dff-9ec3-964a16169582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_67f703ab-cc44-4a00-b8fb-6b9360e9f1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4bda21e6-c845-4f12-aace-79d12750bfc8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_67f703ab-cc44-4a00-b8fb-6b9360e9f1f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_18c40379-1cfb-4282-ad57-1ce0c96cc4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4bda21e6-c845-4f12-aace-79d12750bfc8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_18c40379-1cfb-4282-ad57-1ce0c96cc4b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_865570a9-86e6-46a8-acc1-3760fab1d609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_18c40379-1cfb-4282-ad57-1ce0c96cc4b0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_865570a9-86e6-46a8-acc1-3760fab1d609" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_865570a9-86e6-46a8-acc1-3760fab1d609_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_865570a9-86e6-46a8-acc1-3760fab1d609" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_865570a9-86e6-46a8-acc1-3760fab1d609_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eaa724b3-6f05-4ec2-b469-4fabdb005351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_865570a9-86e6-46a8-acc1-3760fab1d609" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eaa724b3-6f05-4ec2-b469-4fabdb005351" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DPPIVPatentsMember_e1b486cd-083f-4991-bf1f-b89887f52ca8" xlink:href="rprx-20211231.xsd#rprx_DPPIVPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eaa724b3-6f05-4ec2-b469-4fabdb005351" xlink:to="loc_rprx_DPPIVPatentsMember_e1b486cd-083f-4991-bf1f-b89887f52ca8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9c7ec2e3-a5bc-462a-bd7b-93546008dbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_18c40379-1cfb-4282-ad57-1ce0c96cc4b0" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9c7ec2e3-a5bc-462a-bd7b-93546008dbb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9c7ec2e3-a5bc-462a-bd7b-93546008dbb0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9c7ec2e3-a5bc-462a-bd7b-93546008dbb0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9c7ec2e3-a5bc-462a-bd7b-93546008dbb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d216b932-b681-46f8-bd20-e65e931b1f68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9c7ec2e3-a5bc-462a-bd7b-93546008dbb0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d216b932-b681-46f8-bd20-e65e931b1f68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_bfa9b713-6223-453b-8f70-42ae2febaec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d216b932-b681-46f8-bd20-e65e931b1f68" xlink:to="loc_us-gaap_SalesRevenueNetMember_bfa9b713-6223-453b-8f70-42ae2febaec3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_8bb07d5e-0f45-4d92-a62a-1b646e01e632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_18c40379-1cfb-4282-ad57-1ce0c96cc4b0" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_8bb07d5e-0f45-4d92-a62a-1b646e01e632" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8bb07d5e-0f45-4d92-a62a-1b646e01e632_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8bb07d5e-0f45-4d92-a62a-1b646e01e632" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8bb07d5e-0f45-4d92-a62a-1b646e01e632_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f3094727-b94c-453c-bb67-988055159dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8bb07d5e-0f45-4d92-a62a-1b646e01e632" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f3094727-b94c-453c-bb67-988055159dc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IndividualLicenseesConcentrationRiskMember_73223b52-56b1-40de-a6f1-126a9df53a31" xlink:href="rprx-20211231.xsd#rprx_IndividualLicenseesConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f3094727-b94c-453c-bb67-988055159dc0" xlink:to="loc_rprx_IndividualLicenseesConcentrationRiskMember_73223b52-56b1-40de-a6f1-126a9df53a31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e20d9efd-269f-4f26-8a05-643213c55112" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_18c40379-1cfb-4282-ad57-1ce0c96cc4b0" xlink:to="loc_srt_ProductOrServiceAxis_e20d9efd-269f-4f26-8a05-643213c55112" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e20d9efd-269f-4f26-8a05-643213c55112_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e20d9efd-269f-4f26-8a05-643213c55112" xlink:to="loc_srt_ProductsAndServicesDomain_e20d9efd-269f-4f26-8a05-643213c55112_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_773459e4-6426-43cd-83fe-b77eb1e8c415" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e20d9efd-269f-4f26-8a05-643213c55112" xlink:to="loc_srt_ProductsAndServicesDomain_773459e4-6426-43cd-83fe-b77eb1e8c415" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IntangibleRoyaltyAssetsMember_5a450e2a-29b6-4aff-86a7-d57842eb3cee" xlink:href="rprx-20211231.xsd#rprx_IntangibleRoyaltyAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_773459e4-6426-43cd-83fe-b77eb1e8c415" xlink:to="loc_rprx_IntangibleRoyaltyAssetsMember_5a450e2a-29b6-4aff-86a7-d57842eb3cee" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#NonConsolidatedAffiliatesDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" xlink:type="extended" id="i80f1593c41884ee7aa4235c071b563f0_NonConsolidatedAffiliatesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9a319968-a4c8-47a1-86c9-2981d5bf1e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_dabb2dc1-2091-49e6-a8fa-1b5e996bb1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9a319968-a4c8-47a1-86c9-2981d5bf1e1c" xlink:to="loc_us-gaap_EquityMethodInvestments_dabb2dc1-2091-49e6-a8fa-1b5e996bb1a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6aa75001-9776-49d4-8237-563568467280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9a319968-a4c8-47a1-86c9-2981d5bf1e1c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6aa75001-9776-49d4-8237-563568467280" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_47d335e2-68e1-4839-a88f-5b72316b1624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9a319968-a4c8-47a1-86c9-2981d5bf1e1c" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_47d335e2-68e1-4839-a88f-5b72316b1624" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_dca58c8a-a1a8-4b7d-9187-a728d9b75ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9a319968-a4c8-47a1-86c9-2981d5bf1e1c" xlink:to="loc_us-gaap_OtherCommitment_dca58c8a-a1a8-4b7d-9187-a728d9b75ec2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherCommitmentsPercentage_d103d2cb-af4a-434f-84af-5819624b9e28" xlink:href="rprx-20211231.xsd#rprx_OtherCommitmentsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9a319968-a4c8-47a1-86c9-2981d5bf1e1c" xlink:to="loc_rprx_OtherCommitmentsPercentage_d103d2cb-af4a-434f-84af-5819624b9e28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_da15b927-216a-4383-be97-38698010bbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9a319968-a4c8-47a1-86c9-2981d5bf1e1c" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_da15b927-216a-4383-be97-38698010bbe3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EquityMethodInvestmentsUnfundedCommitments_e13d61da-93a5-4772-820e-48167c5ca0e7" xlink:href="rprx-20211231.xsd#rprx_EquityMethodInvestmentsUnfundedCommitments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9a319968-a4c8-47a1-86c9-2981d5bf1e1c" xlink:to="loc_rprx_EquityMethodInvestmentsUnfundedCommitments_e13d61da-93a5-4772-820e-48167c5ca0e7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7cb1a3a4-b479-465f-9699-c1586f748126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9a319968-a4c8-47a1-86c9-2981d5bf1e1c" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7cb1a3a4-b479-465f-9699-c1586f748126" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_96032d2d-c41e-41ec-a596-696447647281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7cb1a3a4-b479-465f-9699-c1586f748126" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_96032d2d-c41e-41ec-a596-696447647281" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_96032d2d-c41e-41ec-a596-696447647281_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_96032d2d-c41e-41ec-a596-696447647281" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_96032d2d-c41e-41ec-a596-696447647281_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_75df2543-179d-47fa-ad23-36afb43ba976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_96032d2d-c41e-41ec-a596-696447647281" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_75df2543-179d-47fa-ad23-36afb43ba976" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_a66ca174-66f7-4c16-b926-c4f621ebc65b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_75df2543-179d-47fa-ad23-36afb43ba976" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_a66ca174-66f7-4c16-b926-c4f621ebc65b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d34d5a38-adf0-4908-bc49-2a96f717d83b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7cb1a3a4-b479-465f-9699-c1586f748126" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d34d5a38-adf0-4908-bc49-2a96f717d83b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_d34d5a38-adf0-4908-bc49-2a96f717d83b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d34d5a38-adf0-4908-bc49-2a96f717d83b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_d34d5a38-adf0-4908-bc49-2a96f717d83b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8f1ac400-eb2c-44cf-a845-46e299547048" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d34d5a38-adf0-4908-bc49-2a96f717d83b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8f1ac400-eb2c-44cf-a845-46e299547048" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember_a757c44d-f06d-4368-80e9-193b2b803747" xlink:href="rprx-20211231.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8f1ac400-eb2c-44cf-a845-46e299547048" xlink:to="loc_rprx_LegacyInvestorsPartnershipsMember_a757c44d-f06d-4368-80e9-193b2b803747" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionEntitiesMember_73a86e5f-13b4-412d-852c-a579571da0c7" xlink:href="rprx-20211231.xsd#rprx_AvillionEntitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8f1ac400-eb2c-44cf-a845-46e299547048" xlink:to="loc_rprx_AvillionEntitiesMember_73a86e5f-13b4-412d-852c-a579571da0c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionIMember_3ba945ad-fcb4-4ef7-ae8e-2d0b92edfb7f" xlink:href="rprx-20211231.xsd#rprx_AvillionIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8f1ac400-eb2c-44cf-a845-46e299547048" xlink:to="loc_rprx_AvillionIMember_3ba945ad-fcb4-4ef7-ae8e-2d0b92edfb7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionIIMember_f6ef2289-29b4-4fab-be70-6dc6b91fceac" xlink:href="rprx-20211231.xsd#rprx_AvillionIIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8f1ac400-eb2c-44cf-a845-46e299547048" xlink:to="loc_rprx_AvillionIIMember_f6ef2289-29b4-4fab-be70-6dc6b91fceac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_3f5befbd-e328-47d8-a251-01bf5271e32a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7cb1a3a4-b479-465f-9699-c1586f748126" xlink:to="loc_us-gaap_OtherCommitmentsAxis_3f5befbd-e328-47d8-a251-01bf5271e32a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_3f5befbd-e328-47d8-a251-01bf5271e32a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_3f5befbd-e328-47d8-a251-01bf5271e32a" xlink:to="loc_us-gaap_OtherCommitmentsDomain_3f5befbd-e328-47d8-a251-01bf5271e32a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_40bdfdb2-c69f-431c-ba0d-be0c86460ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_3f5befbd-e328-47d8-a251-01bf5271e32a" xlink:to="loc_us-gaap_OtherCommitmentsDomain_40bdfdb2-c69f-431c-ba0d-be0c86460ea7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MerckAssetPhaseIIClinicalTrialMember_f8d3efaa-6d18-4933-8b57-391cc3b14aee" xlink:href="rprx-20211231.xsd#rprx_MerckAssetPhaseIIClinicalTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_40bdfdb2-c69f-431c-ba0d-be0c86460ea7" xlink:to="loc_rprx_MerckAssetPhaseIIClinicalTrialMember_f8d3efaa-6d18-4933-8b57-391cc3b14aee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AZAssetPhaseIIAndPhaseIIIClinicalTrialMember_6270c453-79f6-40c6-b42d-1d81fc5ccfa0" xlink:href="rprx-20211231.xsd#rprx_AZAssetPhaseIIAndPhaseIIIClinicalTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_40bdfdb2-c69f-431c-ba0d-be0c86460ea7" xlink:to="loc_rprx_AZAssetPhaseIIAndPhaseIIIClinicalTrialMember_6270c453-79f6-40c6-b42d-1d81fc5ccfa0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#ResearchDevelopmentRDFundingExpenseDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" xlink:type="extended" id="i1d1a286989cd41149732aeb8d48c696d_ResearchDevelopmentRDFundingExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4113d76d-ca98-4bde-b57f-1a8130583022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ba845457-178f-4af3-9c86-52747ecfc0da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4113d76d-ca98-4bde-b57f-1a8130583022" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ba845457-178f-4af3-9c86-52747ecfc0da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid_1964e893-456a-4a74-b9b4-f0ca29c2965f" xlink:href="rprx-20211231.xsd#rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4113d76d-ca98-4bde-b57f-1a8130583022" xlink:to="loc_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid_1964e893-456a-4a74-b9b4-f0ca29c2965f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ResearchAndDevelopmentRemainingFundingCommitment_b7446cd3-1363-4a7c-8631-a8eb6b342b53" xlink:href="rprx-20211231.xsd#rprx_ResearchAndDevelopmentRemainingFundingCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4113d76d-ca98-4bde-b57f-1a8130583022" xlink:to="loc_rprx_ResearchAndDevelopmentRemainingFundingCommitment_b7446cd3-1363-4a7c-8631-a8eb6b342b53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_52fb8263-22f9-4c46-8ee3-1056c7d0e4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4113d76d-ca98-4bde-b57f-1a8130583022" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_52fb8263-22f9-4c46-8ee3-1056c7d0e4b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ee852c88-39e0-4ef0-8c78-cffdde5366d5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_52fb8263-22f9-4c46-8ee3-1056c7d0e4b6" xlink:to="loc_srt_CounterpartyNameAxis_ee852c88-39e0-4ef0-8c78-cffdde5366d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ee852c88-39e0-4ef0-8c78-cffdde5366d5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ee852c88-39e0-4ef0-8c78-cffdde5366d5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ee852c88-39e0-4ef0-8c78-cffdde5366d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cadf449-0e3b-4427-b70f-3969b2dbf764" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ee852c88-39e0-4ef0-8c78-cffdde5366d5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cadf449-0e3b-4427-b70f-3969b2dbf764" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MorphoSysMember_0d05981b-3573-49f0-8966-3417b9eef5c9" xlink:href="rprx-20211231.xsd#rprx_MorphoSysMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cadf449-0e3b-4427-b70f-3969b2dbf764" xlink:to="loc_rprx_MorphoSysMember_0d05981b-3573-49f0-8966-3417b9eef5c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingAgreementsWithSanofiMember_c68d53c4-a709-4ce2-9c71-6a0483277c8e" xlink:href="rprx-20211231.xsd#rprx_FundingAgreementsWithSanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cadf449-0e3b-4427-b70f-3969b2dbf764" xlink:to="loc_rprx_FundingAgreementsWithSanofiMember_c68d53c4-a709-4ce2-9c71-6a0483277c8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingAgreementWithBioCrystMember_52867ced-a2b7-4985-a7c8-77da6be9a791" xlink:href="rprx-20211231.xsd#rprx_FundingAgreementWithBioCrystMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cadf449-0e3b-4427-b70f-3969b2dbf764" xlink:to="loc_rprx_FundingAgreementWithBioCrystMember_52867ced-a2b7-4985-a7c8-77da6be9a791" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingAgreementsWithPfizerMember_a51f4020-f869-45dd-8ac5-cad69bd2917b" xlink:href="rprx-20211231.xsd#rprx_FundingAgreementsWithPfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cadf449-0e3b-4427-b70f-3969b2dbf764" xlink:to="loc_rprx_FundingAgreementsWithPfizerMember_a51f4020-f869-45dd-8ac5-cad69bd2917b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7503833c-7a74-4d43-99f3-94fa3be80d11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_52fb8263-22f9-4c46-8ee3-1056c7d0e4b6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7503833c-7a74-4d43-99f3-94fa3be80d11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7503833c-7a74-4d43-99f3-94fa3be80d11_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7503833c-7a74-4d43-99f3-94fa3be80d11" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7503833c-7a74-4d43-99f3-94fa3be80d11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10f7021e-82eb-4c21-abbd-d0567c38e722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7503833c-7a74-4d43-99f3-94fa3be80d11" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10f7021e-82eb-4c21-abbd-d0567c38e722" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_BioCrystPharmaceuticalsIncMember_67b6e301-2b32-4273-848a-deda442889d1" xlink:href="rprx-20211231.xsd#rprx_BioCrystPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10f7021e-82eb-4c21-abbd-d0567c38e722" xlink:to="loc_rprx_BioCrystPharmaceuticalsIncMember_67b6e301-2b32-4273-848a-deda442889d1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#BorrowingsScheduleofBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" xlink:type="extended" id="i5026db1f4ec04524a029766920d1e60a_BorrowingsScheduleofBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_57a76760-14e8-4178-ad25-2bcfaa4e5dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_199512dc-e88d-404c-b605-78da437a364f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57a76760-14e8-4178-ad25-2bcfaa4e5dd1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_199512dc-e88d-404c-b605-78da437a364f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dca4ebed-8a22-4371-85cf-89345d6b0c03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57a76760-14e8-4178-ad25-2bcfaa4e5dd1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dca4ebed-8a22-4371-85cf-89345d6b0c03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentIssuanceAsAPercentOfPar_01169700-6077-41f3-bcb9-aa5f307c2c73" xlink:href="rprx-20211231.xsd#rprx_DebtInstrumentIssuanceAsAPercentOfPar"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57a76760-14e8-4178-ad25-2bcfaa4e5dd1" xlink:to="loc_rprx_DebtInstrumentIssuanceAsAPercentOfPar_01169700-6077-41f3-bcb9-aa5f307c2c73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_6901e93c-27d7-40fe-bcf5-0d1c329a2b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57a76760-14e8-4178-ad25-2bcfaa4e5dd1" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_6901e93c-27d7-40fe-bcf5-0d1c329a2b6f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_86c1977a-e053-47e7-b822-e6b7476ba090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57a76760-14e8-4178-ad25-2bcfaa4e5dd1" xlink:to="loc_us-gaap_LongTermDebt_86c1977a-e053-47e7-b822-e6b7476ba090" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_e80fca08-b5fe-454a-9072-a79b07c4f8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57a76760-14e8-4178-ad25-2bcfaa4e5dd1" xlink:to="loc_us-gaap_LongTermDebtCurrent_e80fca08-b5fe-454a-9072-a79b07c4f8a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f0f37657-d64e-4443-ad6e-33e6e15c0d30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57a76760-14e8-4178-ad25-2bcfaa4e5dd1" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f0f37657-d64e-4443-ad6e-33e6e15c0d30" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d704521d-3161-4644-b89a-3668f3c01a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57a76760-14e8-4178-ad25-2bcfaa4e5dd1" xlink:to="loc_us-gaap_DebtInstrumentTable_d704521d-3161-4644-b89a-3668f3c01a47" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_60d58e24-6437-4965-8023-20536c098b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d704521d-3161-4644-b89a-3668f3c01a47" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_60d58e24-6437-4965-8023-20536c098b2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_60d58e24-6437-4965-8023-20536c098b2d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_60d58e24-6437-4965-8023-20536c098b2d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_60d58e24-6437-4965-8023-20536c098b2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9d66d6e5-4262-49b2-8281-453d9a599ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_60d58e24-6437-4965-8023-20536c098b2d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9d66d6e5-4262-49b2-8281-453d9a599ac2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_32b79da6-ff0d-42d1-94f3-f3830ddd72cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9d66d6e5-4262-49b2-8281-453d9a599ac2" xlink:to="loc_us-gaap_UnsecuredDebtMember_32b79da6-ff0d-42d1-94f3-f3830ddd72cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2ed1300f-8d7d-4f10-84bb-9ccaca3ba47e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d704521d-3161-4644-b89a-3668f3c01a47" xlink:to="loc_us-gaap_DebtInstrumentAxis_2ed1300f-8d7d-4f10-84bb-9ccaca3ba47e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2ed1300f-8d7d-4f10-84bb-9ccaca3ba47e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2ed1300f-8d7d-4f10-84bb-9ccaca3ba47e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2ed1300f-8d7d-4f10-84bb-9ccaca3ba47e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5d8a6c8b-66ae-4a71-9d54-356428e53961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2ed1300f-8d7d-4f10-84bb-9ccaca3ba47e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5d8a6c8b-66ae-4a71-9d54-356428e53961" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PointSevenFivePercentSeniorNotesDue2023Member_cffb7cde-8ac9-4d9a-bdce-481b1673c853" xlink:href="rprx-20211231.xsd#rprx_PointSevenFivePercentSeniorNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5d8a6c8b-66ae-4a71-9d54-356428e53961" xlink:to="loc_rprx_PointSevenFivePercentSeniorNotesDue2023Member_cffb7cde-8ac9-4d9a-bdce-481b1673c853" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member_f7d59e97-1bc6-4d75-9a17-ba5d6784b60c" xlink:href="rprx-20211231.xsd#rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5d8a6c8b-66ae-4a71-9d54-356428e53961" xlink:to="loc_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member_f7d59e97-1bc6-4d75-9a17-ba5d6784b60c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member_e12886d8-47da-4233-9cb3-d5ecbecce143" xlink:href="rprx-20211231.xsd#rprx_OnePointSevenFivePercentSeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5d8a6c8b-66ae-4a71-9d54-356428e53961" xlink:to="loc_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member_e12886d8-47da-4233-9cb3-d5ecbecce143" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member_1e240bf1-8576-442d-880a-06afd75919fb" xlink:href="rprx-20211231.xsd#rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5d8a6c8b-66ae-4a71-9d54-356428e53961" xlink:to="loc_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member_1e240bf1-8576-442d-880a-06afd75919fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member_76a57a28-a93e-46a3-89a0-70110cf9727e" xlink:href="rprx-20211231.xsd#rprx_TwoPointOneFivePercentSeniorNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5d8a6c8b-66ae-4a71-9d54-356428e53961" xlink:to="loc_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member_76a57a28-a93e-46a3-89a0-70110cf9727e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member_5f273c07-b162-46fd-b89b-8a10a6a861c0" xlink:href="rprx-20211231.xsd#rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5d8a6c8b-66ae-4a71-9d54-356428e53961" xlink:to="loc_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member_5f273c07-b162-46fd-b89b-8a10a6a861c0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member_a233621f-961c-4f83-9119-e72b17349ab4" xlink:href="rprx-20211231.xsd#rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5d8a6c8b-66ae-4a71-9d54-356428e53961" xlink:to="loc_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member_a233621f-961c-4f83-9119-e72b17349ab4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member_e2d335d4-b9c9-484f-9b01-589eead1e288" xlink:href="rprx-20211231.xsd#rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5d8a6c8b-66ae-4a71-9d54-356428e53961" xlink:to="loc_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member_e2d335d4-b9c9-484f-9b01-589eead1e288" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#BorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/BorrowingsNarrativeDetails" xlink:type="extended" id="i133b23fff46740fda0c469d007a1d440_BorrowingsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1d536c69-b959-4157-843a-53ceafc62329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1d536c69-b959-4157-843a-53ceafc62329" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_c98eca55-0943-45ce-9dee-24ef3da67a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_c98eca55-0943-45ce-9dee-24ef3da67a2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_5f6c5ca0-de0d-48f0-900f-97923c87c13d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_5f6c5ca0-de0d-48f0-900f-97923c87c13d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_8d5de69c-f687-4aed-b638-9bba38bd2088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_8d5de69c-f687-4aed-b638-9bba38bd2088" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_8dda9dc2-587f-4b66-9a05-d3f222400b01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_8dda9dc2-587f-4b66-9a05-d3f222400b01" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_2bbad6d7-cd70-4e72-a233-41b031f5f1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_2bbad6d7-cd70-4e72-a233-41b031f5f1b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_486774ba-7e4e-400b-b064-f3885f30cad1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_us-gaap_LongTermDebtFairValue_486774ba-7e4e-400b-b064-f3885f30cad1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_9c0f8a65-131d-436e-9ebb-9237171a049c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_us-gaap_DebtInstrumentTerm_9c0f8a65-131d-436e-9ebb-9237171a049c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_6346eaf5-a350-457c-9a36-54c1ad048f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_6346eaf5-a350-457c-9a36-54c1ad048f08" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_65a7b95f-c14c-4e7e-80ae-3bd9aaf1a21c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_65a7b95f-c14c-4e7e-80ae-3bd9aaf1a21c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio_c49028a8-14c1-4d7e-9c03-6285c3e2305c" xlink:href="rprx-20211231.xsd#rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio_c49028a8-14c1-4d7e-9c03-6285c3e2305c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition_26e547e0-dfa2-4e5c-8e77-e20442dc8d9d" xlink:href="rprx-20211231.xsd#rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition_26e547e0-dfa2-4e5c-8e77-e20442dc8d9d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio_0ea4f995-471b-4c28-95fa-9b8092e0ab79" xlink:href="rprx-20211231.xsd#rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio_0ea4f995-471b-4c28-95fa-9b8092e0ab79" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_216fb1be-b3c4-4eaa-85b0-54c319e23728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_216fb1be-b3c4-4eaa-85b0-54c319e23728" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_79dac364-deb9-4ec3-9b5f-50709ad54b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_us-gaap_DebtInstrumentTable_79dac364-deb9-4ec3-9b5f-50709ad54b46" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2442a0ad-0dbd-4b48-a8c8-c2e1633f8b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_79dac364-deb9-4ec3-9b5f-50709ad54b46" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2442a0ad-0dbd-4b48-a8c8-c2e1633f8b1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2442a0ad-0dbd-4b48-a8c8-c2e1633f8b1e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2442a0ad-0dbd-4b48-a8c8-c2e1633f8b1e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2442a0ad-0dbd-4b48-a8c8-c2e1633f8b1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_64fc0796-648a-4ad4-914a-1347e37bc2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2442a0ad-0dbd-4b48-a8c8-c2e1633f8b1e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_64fc0796-648a-4ad4-914a-1347e37bc2ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_591c9ff9-266d-4714-b28c-8c0b6ff44bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_64fc0796-648a-4ad4-914a-1347e37bc2ef" xlink:to="loc_us-gaap_SeniorNotesMember_591c9ff9-266d-4714-b28c-8c0b6ff44bb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_c60a972b-f3e3-4fe2-bc65-c2763b1f63ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_64fc0796-648a-4ad4-914a-1347e37bc2ef" xlink:to="loc_us-gaap_UnsecuredDebtMember_c60a972b-f3e3-4fe2-bc65-c2763b1f63ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_bf457963-dd37-4dc9-b3f8-25ab850fe108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_64fc0796-648a-4ad4-914a-1347e37bc2ef" xlink:to="loc_us-gaap_SecuredDebtMember_bf457963-dd37-4dc9-b3f8-25ab850fe108" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_de0c1fa8-d5eb-42f2-bd57-180faf057ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_79dac364-deb9-4ec3-9b5f-50709ad54b46" xlink:to="loc_us-gaap_DebtInstrumentAxis_de0c1fa8-d5eb-42f2-bd57-180faf057ea5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_de0c1fa8-d5eb-42f2-bd57-180faf057ea5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_de0c1fa8-d5eb-42f2-bd57-180faf057ea5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_de0c1fa8-d5eb-42f2-bd57-180faf057ea5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e9210dee-63fa-4fca-9a30-0222ec272a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_de0c1fa8-d5eb-42f2-bd57-180faf057ea5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e9210dee-63fa-4fca-9a30-0222ec272a73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorNotesDue2031Member_2383a23f-5141-4b38-83ce-9b81e9909144" xlink:href="rprx-20211231.xsd#rprx_SeniorNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9210dee-63fa-4fca-9a30-0222ec272a73" xlink:to="loc_rprx_SeniorNotesDue2031Member_2383a23f-5141-4b38-83ce-9b81e9909144" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorNotesDue2051Member_20009b1d-08e1-4714-a410-6b465ac6934e" xlink:href="rprx-20211231.xsd#rprx_SeniorNotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9210dee-63fa-4fca-9a30-0222ec272a73" xlink:to="loc_rprx_SeniorNotesDue2051Member_20009b1d-08e1-4714-a410-6b465ac6934e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TheNotesMember_c3df51f6-6070-4548-8fd7-912212e8be69" xlink:href="rprx-20211231.xsd#rprx_TheNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9210dee-63fa-4fca-9a30-0222ec272a73" xlink:to="loc_rprx_TheNotesMember_c3df51f6-6070-4548-8fd7-912212e8be69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorUnsecuredRevolvingCreditFacilityMember_e3ef5c2d-86d4-4139-8061-8f0181d88921" xlink:href="rprx-20211231.xsd#rprx_SeniorUnsecuredRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9210dee-63fa-4fca-9a30-0222ec272a73" xlink:to="loc_rprx_SeniorUnsecuredRevolvingCreditFacilityMember_e3ef5c2d-86d4-4139-8061-8f0181d88921" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member_55e3e279-1764-4cb2-8bfb-5b57e6512229" xlink:href="rprx-20211231.xsd#rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9210dee-63fa-4fca-9a30-0222ec272a73" xlink:to="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member_55e3e279-1764-4cb2-8bfb-5b57e6512229" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member_7cc570f9-599d-4f52-a055-40e6afc35787" xlink:href="rprx-20211231.xsd#rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9210dee-63fa-4fca-9a30-0222ec272a73" xlink:to="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member_7cc570f9-599d-4f52-a055-40e6afc35787" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_cb200336-59b7-4e09-a56f-8fe193cac95d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_79dac364-deb9-4ec3-9b5f-50709ad54b46" xlink:to="loc_us-gaap_VariableRateAxis_cb200336-59b7-4e09-a56f-8fe193cac95d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_cb200336-59b7-4e09-a56f-8fe193cac95d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_cb200336-59b7-4e09-a56f-8fe193cac95d" xlink:to="loc_us-gaap_VariableRateDomain_cb200336-59b7-4e09-a56f-8fe193cac95d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_bf73820f-dc00-4109-a18f-a553780a4f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_cb200336-59b7-4e09-a56f-8fe193cac95d" xlink:to="loc_us-gaap_VariableRateDomain_bf73820f-dc00-4109-a18f-a553780a4f89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsPurchasedMember_e988468e-0a5d-4b69-bd4e-b0ffe9bf2409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsPurchasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_bf73820f-dc00-4109-a18f-a553780a4f89" xlink:to="loc_us-gaap_FederalFundsPurchasedMember_e988468e-0a5d-4b69-bd4e-b0ffe9bf2409" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OvernightBankFundingRateMember_550db269-69e9-4169-bc0b-48711e312fa3" xlink:href="rprx-20211231.xsd#rprx_OvernightBankFundingRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_bf73820f-dc00-4109-a18f-a553780a4f89" xlink:to="loc_rprx_OvernightBankFundingRateMember_550db269-69e9-4169-bc0b-48711e312fa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_15580d22-1205-45cc-b578-8664a909e381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_bf73820f-dc00-4109-a18f-a553780a4f89" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_15580d22-1205-45cc-b578-8664a909e381" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b84a9c5e-2271-46bd-ad93-f69822d14209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_79dac364-deb9-4ec3-9b5f-50709ad54b46" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b84a9c5e-2271-46bd-ad93-f69822d14209" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_b84a9c5e-2271-46bd-ad93-f69822d14209_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b84a9c5e-2271-46bd-ad93-f69822d14209" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_b84a9c5e-2271-46bd-ad93-f69822d14209_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_dc075789-53cf-486f-bd84-5529b62ad495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b84a9c5e-2271-46bd-ad93-f69822d14209" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_dc075789-53cf-486f-bd84-5529b62ad495" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_e1c2093b-07fd-4da0-bf4c-950bac493b38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_dc075789-53cf-486f-bd84-5529b62ad495" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_e1c2093b-07fd-4da0-bf4c-950bac493b38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_e1c3aedc-087b-43bd-9154-3ba42c912275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_dc075789-53cf-486f-bd84-5529b62ad495" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_e1c3aedc-087b-43bd-9154-3ba42c912275" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_b6aecccf-8fc5-4ced-8c8f-d02eedfb3e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_79dac364-deb9-4ec3-9b5f-50709ad54b46" xlink:to="loc_us-gaap_CreditFacilityAxis_b6aecccf-8fc5-4ced-8c8f-d02eedfb3e0e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b6aecccf-8fc5-4ced-8c8f-d02eedfb3e0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_b6aecccf-8fc5-4ced-8c8f-d02eedfb3e0e" xlink:to="loc_us-gaap_CreditFacilityDomain_b6aecccf-8fc5-4ced-8c8f-d02eedfb3e0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a2afae2d-47c1-4483-8e88-a4991d7cf7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_b6aecccf-8fc5-4ced-8c8f-d02eedfb3e0e" xlink:to="loc_us-gaap_CreditFacilityDomain_a2afae2d-47c1-4483-8e88-a4991d7cf7f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_f5579d32-f5b2-4234-b5db-ad259e244785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_a2afae2d-47c1-4483-8e88-a4991d7cf7f1" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_f5579d32-f5b2-4234-b5db-ad259e244785" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e491fc1a-2f19-4039-be85-4b371fb82c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_79dac364-deb9-4ec3-9b5f-50709ad54b46" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e491fc1a-2f19-4039-be85-4b371fb82c08" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e491fc1a-2f19-4039-be85-4b371fb82c08_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e491fc1a-2f19-4039-be85-4b371fb82c08" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e491fc1a-2f19-4039-be85-4b371fb82c08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55a8e30a-2b63-42db-b313-e84d1eb66804" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e491fc1a-2f19-4039-be85-4b371fb82c08" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55a8e30a-2b63-42db-b313-e84d1eb66804" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a90df032-06c1-4b00-8574-cfba2e67e377" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55a8e30a-2b63-42db-b313-e84d1eb66804" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a90df032-06c1-4b00-8574-cfba2e67e377" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_bdd7ab6c-eb53-4387-a3c8-8e7b54caba8a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_79dac364-deb9-4ec3-9b5f-50709ad54b46" xlink:to="loc_dei_LegalEntityAxis_bdd7ab6c-eb53-4387-a3c8-8e7b54caba8a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bdd7ab6c-eb53-4387-a3c8-8e7b54caba8a_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_bdd7ab6c-eb53-4387-a3c8-8e7b54caba8a" xlink:to="loc_dei_EntityDomain_bdd7ab6c-eb53-4387-a3c8-8e7b54caba8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1f3a979e-1d40-48db-97a2-38065084288b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_bdd7ab6c-eb53-4387-a3c8-8e7b54caba8a" xlink:to="loc_dei_EntityDomain_1f3a979e-1d40-48db-97a2-38065084288b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPI2019IntermediateFinanceMember_7e4d5dfa-3ce0-44f5-aac7-5f14d524eaa8" xlink:href="rprx-20211231.xsd#rprx_RPI2019IntermediateFinanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1f3a979e-1d40-48db-97a2-38065084288b" xlink:to="loc_rprx_RPI2019IntermediateFinanceMember_7e4d5dfa-3ce0-44f5-aac7-5f14d524eaa8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#BorrowingsScheduleofRepaymentsofDebtbyYearDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" xlink:type="extended" id="i41328ea07cb7476f80fa809db28f6efa_BorrowingsScheduleofRepaymentsofDebtbyYearDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_66e6a56e-45cf-4ba5-b17d-7b2ebf5fd1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6ac6841d-c692-472f-8743-1f24d39a1583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_66e6a56e-45cf-4ba5-b17d-7b2ebf5fd1b3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6ac6841d-c692-472f-8743-1f24d39a1583" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_003fd317-bcd5-4c38-a9ad-b2f51465bd41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_66e6a56e-45cf-4ba5-b17d-7b2ebf5fd1b3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_003fd317-bcd5-4c38-a9ad-b2f51465bd41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_e019626f-7b4f-49ff-ad81-0fab21431f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_66e6a56e-45cf-4ba5-b17d-7b2ebf5fd1b3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_e019626f-7b4f-49ff-ad81-0fab21431f26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_c7541026-eb2e-4858-9972-ec8e8e8bfdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_66e6a56e-45cf-4ba5-b17d-7b2ebf5fd1b3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_c7541026-eb2e-4858-9972-ec8e8e8bfdc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_4276456a-45d3-4787-acff-5a4a21a7f16a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_66e6a56e-45cf-4ba5-b17d-7b2ebf5fd1b3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_4276456a-45d3-4787-acff-5a4a21a7f16a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_6fe529e7-5ddd-4f92-ae22-f667cd996cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_66e6a56e-45cf-4ba5-b17d-7b2ebf5fd1b3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_6fe529e7-5ddd-4f92-ae22-f667cd996cb3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_72712e14-5e3d-4199-b02e-eafce6d9f498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_66e6a56e-45cf-4ba5-b17d-7b2ebf5fd1b3" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_72712e14-5e3d-4199-b02e-eafce6d9f498" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1b6251a7-1ef5-41c8-b37a-390f3f627674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_66e6a56e-45cf-4ba5-b17d-7b2ebf5fd1b3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1b6251a7-1ef5-41c8-b37a-390f3f627674" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1e2ee028-62d1-46ce-86e8-08cff2aa8d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_66e6a56e-45cf-4ba5-b17d-7b2ebf5fd1b3" xlink:to="loc_us-gaap_DebtInstrumentTable_1e2ee028-62d1-46ce-86e8-08cff2aa8d8d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_294dd128-21b9-4573-930c-d640f91bef5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1e2ee028-62d1-46ce-86e8-08cff2aa8d8d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_294dd128-21b9-4573-930c-d640f91bef5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_294dd128-21b9-4573-930c-d640f91bef5e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_294dd128-21b9-4573-930c-d640f91bef5e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_294dd128-21b9-4573-930c-d640f91bef5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b94bcb8c-4b8d-4c83-a896-c0cb5f06c9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_294dd128-21b9-4573-930c-d640f91bef5e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b94bcb8c-4b8d-4c83-a896-c0cb5f06c9e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_69db65e0-d19d-405f-bd5b-c21fcd914549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b94bcb8c-4b8d-4c83-a896-c0cb5f06c9e3" xlink:to="loc_us-gaap_UnsecuredDebtMember_69db65e0-d19d-405f-bd5b-c21fcd914549" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_071d3397-f722-4863-bdd7-a546ff3e7c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1e2ee028-62d1-46ce-86e8-08cff2aa8d8d" xlink:to="loc_us-gaap_DebtInstrumentAxis_071d3397-f722-4863-bdd7-a546ff3e7c9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_071d3397-f722-4863-bdd7-a546ff3e7c9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_071d3397-f722-4863-bdd7-a546ff3e7c9b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_071d3397-f722-4863-bdd7-a546ff3e7c9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_10fc4a38-0ec3-432d-bb3b-d84ea7f79a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_071d3397-f722-4863-bdd7-a546ff3e7c9b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_10fc4a38-0ec3-432d-bb3b-d84ea7f79a32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TheNotesMember_afd1bded-ae3d-4e16-82b7-81ef954cecd6" xlink:href="rprx-20211231.xsd#rprx_TheNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_10fc4a38-0ec3-432d-bb3b-d84ea7f79a32" xlink:to="loc_rprx_TheNotesMember_afd1bded-ae3d-4e16-82b7-81ef954cecd6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended" id="i091a419059344e1c8883eb3b8fdccc2b_ShareholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NumberOfClassesOfVotingStock_9473bc4f-884c-447c-bd97-4c1d16aeae96" xlink:href="rprx-20211231.xsd#rprx_NumberOfClassesOfVotingStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_rprx_NumberOfClassesOfVotingStock_9473bc4f-884c-447c-bd97-4c1d16aeae96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_dcd8e085-983c-430f-b560-d66341484739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_dcd8e085-983c-430f-b560-d66341484739" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_ed63c525-ad5e-475a-8b78-7f26b810393c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_ed63c525-ad5e-475a-8b78-7f26b810393c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c26f241f-a9e0-4ebb-919b-e812d8bdc00f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c26f241f-a9e0-4ebb-919b-e812d8bdc00f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_8104f7f6-00c9-4b24-833e-a7211595e7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_SharesOutstanding_8104f7f6-00c9-4b24-833e-a7211595e7ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RedeemableStockRedemptionPricePerShare_64ab2a61-a5dc-44aa-90a6-e66db91a3b9f" xlink:href="rprx-20211231.xsd#rprx_RedeemableStockRedemptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_rprx_RedeemableStockRedemptionPricePerShare_64ab2a61-a5dc-44aa-90a6-e66db91a3b9f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NumberOfNoncontrollingInterests_fd43db6a-c244-4a08-a3d9-6ac405a54325" xlink:href="rprx-20211231.xsd#rprx_NumberOfNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_rprx_NumberOfNoncontrollingInterests_fd43db6a-c244-4a08-a3d9-6ac405a54325" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_19bde8ee-2369-4ae4-89eb-a07e506209e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_19bde8ee-2369-4ae4-89eb-a07e506209e7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_64bc104b-3bc2-4df9-b744-c1ddccab6718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_DividendsCommonStockCash_64bc104b-3bc2-4df9-b744-c1ddccab6718" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_3b1a8b14-6999-4966-8dd8-d9a8cd96e008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_3b1a8b14-6999-4966-8dd8-d9a8cd96e008" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c6fb8b55-3c82-4fa2-94ca-13fa12c54856" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c6fb8b55-3c82-4fa2-94ca-13fa12c54856" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_818d3d08-71ba-4996-b672-61a003861ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_818d3d08-71ba-4996-b672-61a003861ffb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_51ffe1b7-dbf7-441b-8f5f-8ac1250f138b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_51ffe1b7-dbf7-441b-8f5f-8ac1250f138b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5c415f40-47fa-4283-b535-b39fb381a0be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5c415f40-47fa-4283-b535-b39fb381a0be" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1e38d37c-4ee0-4728-bbea-0e774b8b1b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1e38d37c-4ee0-4728-bbea-0e774b8b1b8a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e9ccbdd6-2498-4493-9ffe-b0b279d70843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e9ccbdd6-2498-4493-9ffe-b0b279d70843" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_454c0060-828d-4787-a9e2-fce45548e543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e9ccbdd6-2498-4493-9ffe-b0b279d70843" xlink:to="loc_us-gaap_StatementClassOfStockAxis_454c0060-828d-4787-a9e2-fce45548e543" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_454c0060-828d-4787-a9e2-fce45548e543_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_454c0060-828d-4787-a9e2-fce45548e543" xlink:to="loc_us-gaap_ClassOfStockDomain_454c0060-828d-4787-a9e2-fce45548e543_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4d9d10f9-6b15-4e4e-8da7-727ed7b2bdce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_454c0060-828d-4787-a9e2-fce45548e543" xlink:to="loc_us-gaap_ClassOfStockDomain_4d9d10f9-6b15-4e4e-8da7-727ed7b2bdce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_52fe8dac-5130-48e1-a69e-8b6cfb189c24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4d9d10f9-6b15-4e4e-8da7-727ed7b2bdce" xlink:to="loc_us-gaap_CommonClassAMember_52fe8dac-5130-48e1-a69e-8b6cfb189c24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_1ff1a693-45a7-42fc-93b7-ded538d3252f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4d9d10f9-6b15-4e4e-8da7-727ed7b2bdce" xlink:to="loc_us-gaap_CommonClassBMember_1ff1a693-45a7-42fc-93b7-ded538d3252f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember_6d255f76-357c-4232-b356-4004ab736359" xlink:href="rprx-20211231.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4d9d10f9-6b15-4e4e-8da7-727ed7b2bdce" xlink:to="loc_rprx_ClassRRedeemableStockMember_6d255f76-357c-4232-b356-4004ab736359" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_52e4848f-e929-4db8-a9f4-b2f24513c532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e9ccbdd6-2498-4493-9ffe-b0b279d70843" xlink:to="loc_us-gaap_PlanNameAxis_52e4848f-e929-4db8-a9f4-b2f24513c532" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_52e4848f-e929-4db8-a9f4-b2f24513c532_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_52e4848f-e929-4db8-a9f4-b2f24513c532" xlink:to="loc_us-gaap_PlanNameDomain_52e4848f-e929-4db8-a9f4-b2f24513c532_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2eeabf79-50e6-4654-958f-b83c23f563cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_52e4848f-e929-4db8-a9f4-b2f24513c532" xlink:to="loc_us-gaap_PlanNameDomain_2eeabf79-50e6-4654-958f-b83c23f563cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_A2020EquityIncentivePlanMember_cc3cab38-e381-4098-9a04-1d1642942064" xlink:href="rprx-20211231.xsd#rprx_A2020EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2eeabf79-50e6-4654-958f-b83c23f563cf" xlink:to="loc_rprx_A2020EquityIncentivePlanMember_cc3cab38-e381-4098-9a04-1d1642942064" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4005047c-c3de-4465-8997-c07c5ab42037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e9ccbdd6-2498-4493-9ffe-b0b279d70843" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4005047c-c3de-4465-8997-c07c5ab42037" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4005047c-c3de-4465-8997-c07c5ab42037_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4005047c-c3de-4465-8997-c07c5ab42037" xlink:to="loc_us-gaap_EquityComponentDomain_4005047c-c3de-4465-8997-c07c5ab42037_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e065d550-b721-4f71-8170-28b3e3b30349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4005047c-c3de-4465-8997-c07c5ab42037" xlink:to="loc_us-gaap_EquityComponentDomain_e065d550-b721-4f71-8170-28b3e3b30349" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesMember_77f1f90d-c970-4bc4-9840-c4ba9526e96c" xlink:href="rprx-20211231.xsd#rprx_DeferredSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e065d550-b721-4f71-8170-28b3e3b30349" xlink:to="loc_rprx_DeferredSharesMember_77f1f90d-c970-4bc4-9840-c4ba9526e96c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e5e46de3-dffb-47d5-8131-4eaf10aed6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e9ccbdd6-2498-4493-9ffe-b0b279d70843" xlink:to="loc_us-gaap_AwardTypeAxis_e5e46de3-dffb-47d5-8131-4eaf10aed6bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5e46de3-dffb-47d5-8131-4eaf10aed6bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e5e46de3-dffb-47d5-8131-4eaf10aed6bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5e46de3-dffb-47d5-8131-4eaf10aed6bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ee92fe6-fd0f-4808-a04d-1383c8bfbc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e5e46de3-dffb-47d5-8131-4eaf10aed6bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ee92fe6-fd0f-4808-a04d-1383c8bfbc0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c3281bf0-a3c2-4593-a3ef-ffd0066f482f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ee92fe6-fd0f-4808-a04d-1383c8bfbc0a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c3281bf0-a3c2-4593-a3ef-ffd0066f482f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ebf73061-9556-458a-a32f-578751f5e7d7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e9ccbdd6-2498-4493-9ffe-b0b279d70843" xlink:to="loc_dei_LegalEntityAxis_ebf73061-9556-458a-a32f-578751f5e7d7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ebf73061-9556-458a-a32f-578751f5e7d7_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_ebf73061-9556-458a-a32f-578751f5e7d7" xlink:to="loc_dei_EntityDomain_ebf73061-9556-458a-a32f-578751f5e7d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_72f22bf8-967f-4c20-bf94-c65b196aea6d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_ebf73061-9556-458a-a32f-578751f5e7d7" xlink:to="loc_dei_EntityDomain_72f22bf8-967f-4c20-bf94-c65b196aea6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IPOContinuingInvestorsPartnershipsMember_d36cde6b-f29e-4c87-8457-de9f9dd3b654" xlink:href="rprx-20211231.xsd#rprx_IPOContinuingInvestorsPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_72f22bf8-967f-4c20-bf94-c65b196aea6d" xlink:to="loc_rprx_IPOContinuingInvestorsPartnershipsMember_d36cde6b-f29e-4c87-8457-de9f9dd3b654" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ContinuingInvestorsPartnershipMember_90ceb336-e815-414f-a1d2-34dd46bddf23" xlink:href="rprx-20211231.xsd#rprx_ContinuingInvestorsPartnershipMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_72f22bf8-967f-4c20-bf94-c65b196aea6d" xlink:to="loc_rprx_ContinuingInvestorsPartnershipMember_90ceb336-e815-414f-a1d2-34dd46bddf23" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#ShareholdersEquitySummaryofNoncontrollingInterestsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" xlink:type="extended" id="idf0d68eb8066439ab09da0e09beb57cc_ShareholdersEquitySummaryofNoncontrollingInterestsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6290d4ed-d9d6-42db-9e96-771c033a056d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6290d4ed-d9d6-42db-9e96-771c033a056d" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fc050273-f3bd-49b8-bbf5-7ae99ec3e4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fc050273-f3bd-49b8-bbf5-7ae99ec3e4a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestIncreaseFromContributions_2a85946e-f1af-40f0-b450-f0651cd7371c" xlink:href="rprx-20211231.xsd#rprx_NoncontrollingInterestIncreaseFromContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:to="loc_rprx_NoncontrollingInterestIncreaseFromContributions_2a85946e-f1af-40f0-b450-f0651cd7371c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestTransfersOfInterests_32d0fe22-a960-4432-8c8f-0fe39839e9bf" xlink:href="rprx-20211231.xsd#rprx_NoncontrollingInterestTransfersOfInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:to="loc_rprx_NoncontrollingInterestTransfersOfInterests_32d0fe22-a960-4432-8c8f-0fe39839e9bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0169cf85-4a28-4b79-905c-c3b06ff4e8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0169cf85-4a28-4b79-905c-c3b06ff4e8d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c3fd43ae-b7cd-461a-a6a4-52de4405d1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:to="loc_us-gaap_ProfitLoss_c3fd43ae-b7cd-461a-a6a4-52de4405d1b8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation_27e26e8e-4590-429e-8f3f-b42c9cc1eb37" xlink:href="rprx-20211231.xsd#rprx_StockholdersEquityValueEffectOfExchangeAndReallocation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:to="loc_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation_27e26e8e-4590-429e-8f3f-b42c9cc1eb37" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_77c32f18-444d-4408-a174-ea3bcfb65f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_77c32f18-444d-4408-a174-ea3bcfb65f9f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_97f4c82b-17c0-4efb-b56d-ce0e03fe7d27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:to="loc_us-gaap_StockholdersEquityOther_97f4c82b-17c0-4efb-b56d-ce0e03fe7d27" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_16f41fa1-8941-4d9d-8988-e9a6b2b2534b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_16f41fa1-8941-4d9d-8988-e9a6b2b2534b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_e278ebbc-c690-4def-ab06-906a50b4f259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_e278ebbc-c690-4def-ab06-906a50b4f259" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_89ba3f7c-c24f-46dc-b48a-bac0352cdf82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_9ef88860-5ca5-4785-a41c-2c55a18b747a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6290d4ed-d9d6-42db-9e96-771c033a056d" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_9ef88860-5ca5-4785-a41c-2c55a18b747a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_fc45943d-5014-49ca-ab36-c3b914ab6f75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_6290d4ed-d9d6-42db-9e96-771c033a056d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_fc45943d-5014-49ca-ab36-c3b914ab6f75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_018dc882-205a-44f9-817a-747c617951a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc45943d-5014-49ca-ab36-c3b914ab6f75" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_018dc882-205a-44f9-817a-747c617951a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_018dc882-205a-44f9-817a-747c617951a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_018dc882-205a-44f9-817a-747c617951a0" xlink:to="loc_us-gaap_EquityComponentDomain_018dc882-205a-44f9-817a-747c617951a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eff81eda-829b-4c9c-a694-b27b689752fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_018dc882-205a-44f9-817a-747c617951a0" xlink:to="loc_us-gaap_EquityComponentDomain_eff81eda-829b-4c9c-a694-b27b689752fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_8e10629f-7888-479f-9f6a-fff84fad9cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_eff81eda-829b-4c9c-a694-b27b689752fb" xlink:to="loc_us-gaap_NoncontrollingInterestMember_8e10629f-7888-479f-9f6a-fff84fad9cdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f6092da6-b1c6-4360-bf7b-9e6d2de0747a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc45943d-5014-49ca-ab36-c3b914ab6f75" xlink:to="loc_dei_LegalEntityAxis_f6092da6-b1c6-4360-bf7b-9e6d2de0747a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f6092da6-b1c6-4360-bf7b-9e6d2de0747a_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_f6092da6-b1c6-4360-bf7b-9e6d2de0747a" xlink:to="loc_dei_EntityDomain_f6092da6-b1c6-4360-bf7b-9e6d2de0747a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a966d7cf-cb42-4143-b62a-55b0291d38ea" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_f6092da6-b1c6-4360-bf7b-9e6d2de0747a" xlink:to="loc_dei_EntityDomain_a966d7cf-cb42-4143-b62a-55b0291d38ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyalPharmacySelectFinanceTrustMember_e2793508-e9dd-4bb2-8dd7-39dac90d32f1" xlink:href="rprx-20211231.xsd#rprx_RoyalPharmacySelectFinanceTrustMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a966d7cf-cb42-4143-b62a-55b0291d38ea" xlink:to="loc_rprx_RoyalPharmacySelectFinanceTrustMember_e2793508-e9dd-4bb2-8dd7-39dac90d32f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember_1aff88a0-fefb-4e68-a0b1-1b2d1d3cc0d3" xlink:href="rprx-20211231.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a966d7cf-cb42-4143-b62a-55b0291d38ea" xlink:to="loc_rprx_LegacyInvestorsPartnershipsMember_1aff88a0-fefb-4e68-a0b1-1b2d1d3cc0d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ContinuingInvestorsPartnershipMember_e9d299f3-3bd3-4793-995f-debb66d9c7c0" xlink:href="rprx-20211231.xsd#rprx_ContinuingInvestorsPartnershipMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a966d7cf-cb42-4143-b62a-55b0291d38ea" xlink:to="loc_rprx_ContinuingInvestorsPartnershipMember_e9d299f3-3bd3-4793-995f-debb66d9c7c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EPAHoldingsMember_612b345d-1e25-4afb-b9e8-da3e8e1b962d" xlink:href="rprx-20211231.xsd#rprx_EPAHoldingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a966d7cf-cb42-4143-b62a-55b0291d38ea" xlink:to="loc_rprx_EPAHoldingsMember_612b345d-1e25-4afb-b9e8-da3e8e1b962d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_6a1aef73-166f-4c31-b3e2-91d52d4d4924" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc45943d-5014-49ca-ab36-c3b914ab6f75" xlink:to="loc_srt_OwnershipAxis_6a1aef73-166f-4c31-b3e2-91d52d4d4924" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_6a1aef73-166f-4c31-b3e2-91d52d4d4924_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_6a1aef73-166f-4c31-b3e2-91d52d4d4924" xlink:to="loc_srt_OwnershipDomain_6a1aef73-166f-4c31-b3e2-91d52d4d4924_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9eda10ef-f0a0-444a-a44f-222e697325c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_6a1aef73-166f-4c31-b3e2-91d52d4d4924" xlink:to="loc_srt_OwnershipDomain_9eda10ef-f0a0-444a-a44f-222e697325c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPHoldingsMember_f29d09f5-7a9e-4b75-8d8e-a5d654d5fcdf" xlink:href="rprx-20211231.xsd#rprx_RPHoldingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_9eda10ef-f0a0-444a-a44f-222e697325c3" xlink:to="loc_rprx_RPHoldingsMember_f29d09f5-7a9e-4b75-8d8e-a5d654d5fcdf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#EarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/EarningsPerShareDetails" xlink:type="extended" id="i6a9c6c3dcaa94e2faefd5a9c9b50760c_EarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_86f0431a-a9c2-4c3a-9d6a-19cda61c6dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_527c2e98-eb7b-4100-bcc6-88e2c6d6dfe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_86f0431a-a9c2-4c3a-9d6a-19cda61c6dd2" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_527c2e98-eb7b-4100-bcc6-88e2c6d6dfe4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_65d5375b-534e-4c3f-ab14-d7a31e48fdbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_527c2e98-eb7b-4100-bcc6-88e2c6d6dfe4" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_65d5375b-534e-4c3f-ab14-d7a31e48fdbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8ac50d57-2cb2-42c2-b9d4-a557ba4bcf90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_65d5375b-534e-4c3f-ab14-d7a31e48fdbf" xlink:to="loc_us-gaap_ProfitLoss_8ac50d57-2cb2-42c2-b9d4-a557ba4bcf90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NetIncomeLossAttributableToParentPriorToOffering_645a1da6-a8ed-406f-85fc-3d6376d1640b" xlink:href="rprx-20211231.xsd#rprx_NetIncomeLossAttributableToParentPriorToOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_65d5375b-534e-4c3f-ab14-d7a31e48fdbf" xlink:to="loc_rprx_NetIncomeLossAttributableToParentPriorToOffering_645a1da6-a8ed-406f-85fc-3d6376d1640b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5079970e-711a-4060-a445-141146a4947c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_65d5375b-534e-4c3f-ab14-d7a31e48fdbf" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5079970e-711a-4060-a445-141146a4947c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_820181cc-86dd-4bea-b7db-c6ac678c2fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_65d5375b-534e-4c3f-ab14-d7a31e48fdbf" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_820181cc-86dd-4bea-b7db-c6ac678c2fe5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_032dbdaf-b5af-41ae-bc68-ff3ef1f70a75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_65d5375b-534e-4c3f-ab14-d7a31e48fdbf" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_032dbdaf-b5af-41ae-bc68-ff3ef1f70a75" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_0b76cfe5-2235-4f89-be29-eb40f6f37045" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_527c2e98-eb7b-4100-bcc6-88e2c6d6dfe4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_0b76cfe5-2235-4f89-be29-eb40f6f37045" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a4d41e8c-41d3-4523-ada0-891cedfe12af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_0b76cfe5-2235-4f89-be29-eb40f6f37045" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a4d41e8c-41d3-4523-ada0-891cedfe12af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_aa8e1d48-e26a-4a8c-9ab8-3dc32f34204a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_0b76cfe5-2235-4f89-be29-eb40f6f37045" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_aa8e1d48-e26a-4a8c-9ab8-3dc32f34204a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c901c78-daad-46ef-baa7-ede8027477e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_0b76cfe5-2235-4f89-be29-eb40f6f37045" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c901c78-daad-46ef-baa7-ede8027477e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b1b29227-504a-4371-a797-34ceae7e3d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_0b76cfe5-2235-4f89-be29-eb40f6f37045" xlink:to="loc_us-gaap_EarningsPerShareBasic_b1b29227-504a-4371-a797-34ceae7e3d17" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_51eaf117-9163-49d0-8dcd-12e99386c0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_0b76cfe5-2235-4f89-be29-eb40f6f37045" xlink:to="loc_us-gaap_EarningsPerShareDiluted_51eaf117-9163-49d0-8dcd-12e99386c0d1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_8765b00b-9835-4bf9-a183-48555e42bcc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_86f0431a-a9c2-4c3a-9d6a-19cda61c6dd2" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_8765b00b-9835-4bf9-a183-48555e42bcc3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_afa800f5-c50c-479c-bebb-5c4b0a64dc2e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_8765b00b-9835-4bf9-a183-48555e42bcc3" xlink:to="loc_srt_CounterpartyNameAxis_afa800f5-c50c-479c-bebb-5c4b0a64dc2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_afa800f5-c50c-479c-bebb-5c4b0a64dc2e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_afa800f5-c50c-479c-bebb-5c4b0a64dc2e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_afa800f5-c50c-479c-bebb-5c4b0a64dc2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7e226cb-bbd6-4021-98d0-71781c72f5ac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_afa800f5-c50c-479c-bebb-5c4b0a64dc2e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7e226cb-bbd6-4021-98d0-71781c72f5ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassBHoldersMember_bb6299e7-e099-4011-9516-8c7ee670f9e5" xlink:href="rprx-20211231.xsd#rprx_ClassBHoldersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7e226cb-bbd6-4021-98d0-71781c72f5ac" xlink:to="loc_rprx_ClassBHoldersMember_bb6299e7-e099-4011-9516-8c7ee670f9e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsAndRPSFTMember_b3e58881-93ae-4630-a0ff-4ddaae360be5" xlink:href="rprx-20211231.xsd#rprx_LegacyInvestorsPartnershipsAndRPSFTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7e226cb-bbd6-4021-98d0-71781c72f5ac" xlink:to="loc_rprx_LegacyInvestorsPartnershipsAndRPSFTMember_b3e58881-93ae-4630-a0ff-4ddaae360be5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c5f09426-993f-42ff-aa31-5374c3f51e96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_8765b00b-9835-4bf9-a183-48555e42bcc3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c5f09426-993f-42ff-aa31-5374c3f51e96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c5f09426-993f-42ff-aa31-5374c3f51e96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c5f09426-993f-42ff-aa31-5374c3f51e96" xlink:to="loc_us-gaap_ClassOfStockDomain_c5f09426-993f-42ff-aa31-5374c3f51e96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dc1e9d0e-57e3-4830-b172-b85de403e7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c5f09426-993f-42ff-aa31-5374c3f51e96" xlink:to="loc_us-gaap_ClassOfStockDomain_dc1e9d0e-57e3-4830-b172-b85de403e7a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_bef697cd-cd43-47d7-96c8-980f9996f531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_dc1e9d0e-57e3-4830-b172-b85de403e7a0" xlink:to="loc_us-gaap_CommonClassAMember_bef697cd-cd43-47d7-96c8-980f9996f531" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#AccumulatedOtherComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended" id="i6337665d759341048b87d72c17b7169a_AccumulatedOtherComprehensiveIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_7248f0b6-acbe-4a70-9dd3-68ecbcc1dfae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a9ae4f56-a0b0-4c2a-b236-94e800ae72da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_7248f0b6-acbe-4a70-9dd3-68ecbcc1dfae" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a9ae4f56-a0b0-4c2a-b236-94e800ae72da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_769feb9a-cf46-4bc2-a710-ad170d0ab4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a9ae4f56-a0b0-4c2a-b236-94e800ae72da" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_769feb9a-cf46-4bc2-a710-ad170d0ab4a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_78f4492a-6b11-46dd-9dc9-336cfec45950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a9ae4f56-a0b0-4c2a-b236-94e800ae72da" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_78f4492a-6b11-46dd-9dc9-336cfec45950" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_61a84f92-b76b-4a63-b096-526305c83544" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a9ae4f56-a0b0-4c2a-b236-94e800ae72da" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_61a84f92-b76b-4a63-b096-526305c83544" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest_7057617f-9550-40bc-ba98-561e048f95a1" xlink:href="rprx-20211231.xsd#rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a9ae4f56-a0b0-4c2a-b236-94e800ae72da" xlink:to="loc_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest_7057617f-9550-40bc-ba98-561e048f95a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest_7aaa06b3-ae7b-4a65-9aba-7c6b127d80a7" xlink:href="rprx-20211231.xsd#rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a9ae4f56-a0b0-4c2a-b236-94e800ae72da" xlink:to="loc_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest_7aaa06b3-ae7b-4a65-9aba-7c6b127d80a7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1771d764-4ad5-4695-953a-5224d803dd1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_3dc78755-c311-4c3f-b20c-0664169ccc80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_7248f0b6-acbe-4a70-9dd3-68ecbcc1dfae" xlink:to="loc_us-gaap_InvestmentIncomeNet_3dc78755-c311-4c3f-b20c-0664169ccc80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_bda21fa9-b5f4-4934-85c9-bfd758eca45a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_7248f0b6-acbe-4a70-9dd3-68ecbcc1dfae" xlink:to="loc_us-gaap_InterestIncomeOperating_bda21fa9-b5f4-4934-85c9-bfd758eca45a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ae4ddf7d-3513-4abd-9104-8bc0d67ebfba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_7248f0b6-acbe-4a70-9dd3-68ecbcc1dfae" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ae4ddf7d-3513-4abd-9104-8bc0d67ebfba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d44156b8-1f05-4363-a201-ad9f9abd424a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ae4ddf7d-3513-4abd-9104-8bc0d67ebfba" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d44156b8-1f05-4363-a201-ad9f9abd424a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d44156b8-1f05-4363-a201-ad9f9abd424a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d44156b8-1f05-4363-a201-ad9f9abd424a" xlink:to="loc_us-gaap_EquityComponentDomain_d44156b8-1f05-4363-a201-ad9f9abd424a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_de6a5fda-d71f-4a87-a0ac-4ec810564e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d44156b8-1f05-4363-a201-ad9f9abd424a" xlink:to="loc_us-gaap_EquityComponentDomain_de6a5fda-d71f-4a87-a0ac-4ec810564e8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8a5b6def-8eb4-4614-bad3-bb9cf432acfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_de6a5fda-d71f-4a87-a0ac-4ec810564e8e" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8a5b6def-8eb4-4614-bad3-bb9cf432acfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_a1d5e0a4-a605-42af-b274-3951b1781b38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8a5b6def-8eb4-4614-bad3-bb9cf432acfd" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_a1d5e0a4-a605-42af-b274-3951b1781b38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember_cee94621-9892-4d14-a6e0-2a68080089d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8a5b6def-8eb4-4614-bad3-bb9cf432acfd" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember_cee94621-9892-4d14-a6e0-2a68080089d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_1548ab50-9d93-430d-a1c6-e6fdff53d013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_de6a5fda-d71f-4a87-a0ac-4ec810564e8e" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_1548ab50-9d93-430d-a1c6-e6fdff53d013" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ec63df5d-7ed6-4cbe-a4af-d0e29d3f5375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_de6a5fda-d71f-4a87-a0ac-4ec810564e8e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ec63df5d-7ed6-4cbe-a4af-d0e29d3f5375" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_aea154a1-b3d0-4be1-96ae-6ee769e8b3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ae4ddf7d-3513-4abd-9104-8bc0d67ebfba" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_aea154a1-b3d0-4be1-96ae-6ee769e8b3f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_aea154a1-b3d0-4be1-96ae-6ee769e8b3f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_aea154a1-b3d0-4be1-96ae-6ee769e8b3f2" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_aea154a1-b3d0-4be1-96ae-6ee769e8b3f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_15a0fba3-68a5-40a1-9c4d-dbfae961bc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_aea154a1-b3d0-4be1-96ae-6ee769e8b3f2" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_15a0fba3-68a5-40a1-9c4d-dbfae961bc1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_fe88607e-392b-444f-a917-07b57e12a724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_15a0fba3-68a5-40a1-9c4d-dbfae961bc1c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_fe88607e-392b-444f-a917-07b57e12a724" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i6b3fa15571894030a1cae3f1ccf6d1af_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionRateAdjustedCashReceipts_b3b8f9ae-552a-47c0-bc9c-1cb37caa3c96" xlink:href="rprx-20211231.xsd#rprx_RelatedPartyTransactionRateAdjustedCashReceipts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_rprx_RelatedPartyTransactionRateAdjustedCashReceipts_b3b8f9ae-552a-47c0-bc9c-1cb37caa3c96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments_4c3f8b8f-2c11-4293-84a6-a6d2f86101d1" xlink:href="rprx-20211231.xsd#rprx_RelatedPartyTransactionRateValueOfSecurityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments_4c3f8b8f-2c11-4293-84a6-a6d2f86101d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount_dbb2fd56-5899-41d6-8f42-e0257b4b0011" xlink:href="rprx-20211231.xsd#rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount_dbb2fd56-5899-41d6-8f42-e0257b4b0011" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent_7e79266f-b1e5-4241-8753-30358c9b0c62" xlink:href="rprx-20211231.xsd#rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent_7e79266f-b1e5-4241-8753-30358c9b0c62" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionAnnualIncreasePercentage_d7be75f7-9306-44ce-9262-171ee07d3d91" xlink:href="rprx-20211231.xsd#rprx_RelatedPartyTransactionAnnualIncreasePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_rprx_RelatedPartyTransactionAnnualIncreasePercentage_d7be75f7-9306-44ce-9262-171ee07d3d91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_7f887d5d-9c0d-475e-af5b-6ca40962904e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_7f887d5d-9c0d-475e-af5b-6ca40962904e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesNoncurrent_64afdbd5-3730-4de7-86a4-48f01b79e3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_us-gaap_DueToRelatedPartiesNoncurrent_64afdbd5-3730-4de7-86a4-48f01b79e3bb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_1653f5a3-12c2-4e16-bd05-b00f7a77bccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_us-gaap_EquityMethodInvestments_1653f5a3-12c2-4e16-bd05-b00f7a77bccf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_83766d22-8327-4b08-a993-7eccaebafd5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_83766d22-8327-4b08-a993-7eccaebafd5c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionCumulativeFundingAmount_1de9e9b5-570c-4779-a7ac-76d25cf209e3" xlink:href="rprx-20211231.xsd#rprx_RelatedPartyTransactionCumulativeFundingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_rprx_RelatedPartyTransactionCumulativeFundingAmount_1de9e9b5-570c-4779-a7ac-76d25cf209e3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_ce71db9d-f592-4d9d-aa24-69be529fad6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_us-gaap_NotesReceivableNet_ce71db9d-f592-4d9d-aa24-69be529fad6e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionInitialTerm_8737b488-0ad7-4d55-bdae-2451c348c4e3" xlink:href="rprx-20211231.xsd#rprx_RelatedPartyTransactionInitialTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_rprx_RelatedPartyTransactionInitialTerm_8737b488-0ad7-4d55-bdae-2451c348c4e3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_cdd02430-b822-4420-a2d1-a2b6d29606b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_us-gaap_DueFromRelatedParties_cdd02430-b822-4420-a2d1-a2b6d29606b2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_64a048c7-e5b8-4d94-816e-90077c8fb0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_64a048c7-e5b8-4d94-816e-90077c8fb0b9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired_7f563aed-cf18-45f7-9b64-49a5407cc86e" xlink:href="rprx-20211231.xsd#rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired_7f563aed-cf18-45f7-9b64-49a5407cc86e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d3c95915-9f61-4f0a-8b5f-32453e19b059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d3c95915-9f61-4f0a-8b5f-32453e19b059" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fcdabc1a-3c4b-492d-8676-ad2638f84fad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fcdabc1a-3c4b-492d-8676-ad2638f84fad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c2f49ac7-89df-4adb-9ee3-5b6b7a127316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fcdabc1a-3c4b-492d-8676-ad2638f84fad" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c2f49ac7-89df-4adb-9ee3-5b6b7a127316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c2f49ac7-89df-4adb-9ee3-5b6b7a127316_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c2f49ac7-89df-4adb-9ee3-5b6b7a127316" xlink:to="loc_us-gaap_RelatedPartyDomain_c2f49ac7-89df-4adb-9ee3-5b6b7a127316_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e7de7fff-721a-403e-b0eb-7f5f95d46588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c2f49ac7-89df-4adb-9ee3-5b6b7a127316" xlink:to="loc_us-gaap_RelatedPartyDomain_e7de7fff-721a-403e-b0eb-7f5f95d46588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember_3d95c7ec-7f85-4667-ae59-16257f661217" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e7de7fff-721a-403e-b0eb-7f5f95d46588" xlink:to="loc_srt_ManagementMember_3d95c7ec-7f85-4667-ae59-16257f661217" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_8d2dc3aa-253a-406e-ae1c-9103aed1dc7f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e7de7fff-721a-403e-b0eb-7f5f95d46588" xlink:to="loc_srt_AffiliatedEntityMember_8d2dc3aa-253a-406e-ae1c-9103aed1dc7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PabloLegorretaMember_0dcb014d-175b-4a8b-85e9-b62593c66c2d" xlink:href="rprx-20211231.xsd#rprx_PabloLegorretaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e7de7fff-721a-403e-b0eb-7f5f95d46588" xlink:to="loc_rprx_PabloLegorretaMember_0dcb014d-175b-4a8b-85e9-b62593c66c2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_403becac-79cb-438b-aed4-6207ac31c6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fcdabc1a-3c4b-492d-8676-ad2638f84fad" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_403becac-79cb-438b-aed4-6207ac31c6c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_403becac-79cb-438b-aed4-6207ac31c6c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_403becac-79cb-438b-aed4-6207ac31c6c6" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_403becac-79cb-438b-aed4-6207ac31c6c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_95a0f72c-18eb-42fd-bdb1-c4a861011100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_403becac-79cb-438b-aed4-6207ac31c6c6" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_95a0f72c-18eb-42fd-bdb1-c4a861011100" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OperatingAndPersonnelPaymentsMember_d0ba52de-53dd-4b75-884a-c0926091ecae" xlink:href="rprx-20211231.xsd#rprx_OperatingAndPersonnelPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_95a0f72c-18eb-42fd-bdb1-c4a861011100" xlink:to="loc_rprx_OperatingAndPersonnelPaymentsMember_d0ba52de-53dd-4b75-884a-c0926091ecae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FormerOperatingAndPersonnelPaymentsMember_b14aba0e-36ff-4dd1-9ab3-185fa5ac5d71" xlink:href="rprx-20211231.xsd#rprx_FormerOperatingAndPersonnelPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_95a0f72c-18eb-42fd-bdb1-c4a861011100" xlink:to="loc_rprx_FormerOperatingAndPersonnelPaymentsMember_b14aba0e-36ff-4dd1-9ab3-185fa5ac5d71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember_38ec9c66-b3f2-4f25-a95a-8cd3721bf2ed" xlink:href="rprx-20211231.xsd#rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_95a0f72c-18eb-42fd-bdb1-c4a861011100" xlink:to="loc_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember_38ec9c66-b3f2-4f25-a95a-8cd3721bf2ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember_288956d6-4f06-4a5a-bf24-972181d1c578" xlink:href="rprx-20211231.xsd#rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_95a0f72c-18eb-42fd-bdb1-c4a861011100" xlink:to="loc_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember_288956d6-4f06-4a5a-bf24-972181d1c578" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssignmentAgreementBenefitOfPaymentStreamMember_5f808fa6-d308-45de-8812-f854112eb592" xlink:href="rprx-20211231.xsd#rprx_AssignmentAgreementBenefitOfPaymentStreamMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_95a0f72c-18eb-42fd-bdb1-c4a861011100" xlink:to="loc_rprx_AssignmentAgreementBenefitOfPaymentStreamMember_5f808fa6-d308-45de-8812-f854112eb592" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssignmentAgreementFundingObligationsMember_4af6987c-c728-456b-bccc-dd31cf9d6901" xlink:href="rprx-20211231.xsd#rprx_AssignmentAgreementFundingObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_95a0f72c-18eb-42fd-bdb1-c4a861011100" xlink:to="loc_rprx_AssignmentAgreementFundingObligationsMember_4af6987c-c728-456b-bccc-dd31cf9d6901" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AgreementWithMSCIMember_df65cec2-2854-44ad-aa15-606e2238b4f2" xlink:href="rprx-20211231.xsd#rprx_AgreementWithMSCIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_95a0f72c-18eb-42fd-bdb1-c4a861011100" xlink:to="loc_rprx_AgreementWithMSCIMember_df65cec2-2854-44ad-aa15-606e2238b4f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PurchasingAndDonatingVentilatorsMember_1bdbe1ff-e707-484e-9f9c-b9be7c9428d7" xlink:href="rprx-20211231.xsd#rprx_PurchasingAndDonatingVentilatorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_95a0f72c-18eb-42fd-bdb1-c4a861011100" xlink:to="loc_rprx_PurchasingAndDonatingVentilatorsMember_1bdbe1ff-e707-484e-9f9c-b9be7c9428d7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember_f798659b-82aa-4cde-92c8-88a80083288a" xlink:href="rprx-20211231.xsd#rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_95a0f72c-18eb-42fd-bdb1-c4a861011100" xlink:to="loc_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember_f798659b-82aa-4cde-92c8-88a80083288a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_40c663c4-124c-4f27-a546-1ff752f52123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fcdabc1a-3c4b-492d-8676-ad2638f84fad" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_40c663c4-124c-4f27-a546-1ff752f52123" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_40c663c4-124c-4f27-a546-1ff752f52123_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_40c663c4-124c-4f27-a546-1ff752f52123" xlink:to="loc_us-gaap_EquityComponentDomain_40c663c4-124c-4f27-a546-1ff752f52123_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d409d2c9-f96f-42c0-8472-7117c2cfbfc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_40c663c4-124c-4f27-a546-1ff752f52123" xlink:to="loc_us-gaap_EquityComponentDomain_d409d2c9-f96f-42c0-8472-7117c2cfbfc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_91417eab-45ec-4691-b7e8-17d86ea070aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d409d2c9-f96f-42c0-8472-7117c2cfbfc1" xlink:to="loc_us-gaap_TreasuryStockMember_91417eab-45ec-4691-b7e8-17d86ea070aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_5fd52e6a-250c-4c9b-8afb-7e5e960c36c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d409d2c9-f96f-42c0-8472-7117c2cfbfc1" xlink:to="loc_us-gaap_NoncontrollingInterestMember_5fd52e6a-250c-4c9b-8afb-7e5e960c36c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_19890328-3a63-4828-828f-0247b53a970d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fcdabc1a-3c4b-492d-8676-ad2638f84fad" xlink:to="loc_srt_CounterpartyNameAxis_19890328-3a63-4828-828f-0247b53a970d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19890328-3a63-4828-828f-0247b53a970d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_19890328-3a63-4828-828f-0247b53a970d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19890328-3a63-4828-828f-0247b53a970d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_80924c8b-38d7-4c1f-9df1-5919e16e9409" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_19890328-3a63-4828-828f-0247b53a970d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_80924c8b-38d7-4c1f-9df1-5919e16e9409" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_BristolMyersSquibbMember_b3b6d7c6-841f-4682-a53b-add38bfa7775" xlink:href="rprx-20211231.xsd#rprx_BristolMyersSquibbMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_80924c8b-38d7-4c1f-9df1-5919e16e9409" xlink:to="loc_rprx_BristolMyersSquibbMember_b3b6d7c6-841f-4682-a53b-add38bfa7775" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_65024fcd-eaf7-435c-9877-339e0b29f1c5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fcdabc1a-3c4b-492d-8676-ad2638f84fad" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_65024fcd-eaf7-435c-9877-339e0b29f1c5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_65024fcd-eaf7-435c-9877-339e0b29f1c5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_65024fcd-eaf7-435c-9877-339e0b29f1c5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_65024fcd-eaf7-435c-9877-339e0b29f1c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_24e50407-0b12-48d8-8355-4bb71ec6ffb5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_65024fcd-eaf7-435c-9877-339e0b29f1c5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_24e50407-0b12-48d8-8355-4bb71ec6ffb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EpizymeIncMember_a63b174c-22c4-4c31-a46e-caee50735d7f" xlink:href="rprx-20211231.xsd#rprx_EpizymeIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_24e50407-0b12-48d8-8355-4bb71ec6ffb5" xlink:to="loc_rprx_EpizymeIncMember_a63b174c-22c4-4c31-a46e-caee50735d7f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i7c4aa7c878f04318b61098b6af26b8c9_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_f70597f3-0f53-4adf-b27c-2238b87113bb" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_f70597f3-0f53-4adf-b27c-2238b87113bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_a3a29b54-ddd0-416d-b4c5-de82cba5fb05" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_a3a29b54-ddd0-416d-b4c5-de82cba5fb05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm_0efb3c15-e594-473a-9ac7-4c9434dc3f84" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm_0efb3c15-e594-473a-9ac7-4c9434dc3f84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsExpectedReturn_2814a9ea-da51-4463-a66d-a5eaa3fbde9b" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsExpectedReturn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsExpectedReturn_2814a9ea-da51-4463-a66d-a5eaa3fbde9b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_d6cc3094-32de-441e-9ea4-05e6477c66f0" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_d6cc3094-32de-441e-9ea4-05e6477c66f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_6d0ffe38-c5c0-448d-9ebd-b2f2e7d65674" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_6d0ffe38-c5c0-448d-9ebd-b2f2e7d65674" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate_6d6e0214-9f91-44a1-a648-0f6d6663a8a3" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate_6d6e0214-9f91-44a1-a648-0f6d6663a8a3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount_9d655c68-8bf2-4d5c-b1ce-2550fe019b30" xlink:href="rprx-20211231.xsd#rprx_PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_rprx_PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount_9d655c68-8bf2-4d5c-b1ce-2550fe019b30" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermPurchaseCommitmentAmountOutstanding_96b69206-8088-47d0-85a4-77eb086d5cdb" xlink:href="rprx-20211231.xsd#rprx_LongTermPurchaseCommitmentAmountOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_rprx_LongTermPurchaseCommitmentAmountOutstanding_96b69206-8088-47d0-85a4-77eb086d5cdb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_ac3c72e2-3fe4-4b8c-a479-bf4dd5c9739a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_ac3c72e2-3fe4-4b8c-a479-bf4dd5c9739a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PurchaseCommitmentUpfrontPayment_df1ebe6f-d761-4c41-b6b5-16c7f8897610" xlink:href="rprx-20211231.xsd#rprx_PurchaseCommitmentUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_rprx_PurchaseCommitmentUpfrontPayment_df1ebe6f-d761-4c41-b6b5-16c7f8897610" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PurchaseCommitmentAdditionalPayment_a2766f66-c0cc-474b-8df6-8116dc53bde1" xlink:href="rprx-20211231.xsd#rprx_PurchaseCommitmentAdditionalPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_rprx_PurchaseCommitmentAdditionalPayment_a2766f66-c0cc-474b-8df6-8116dc53bde1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_0a11437c-5db8-49a5-b210-73c2abb2e1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_0a11437c-5db8-49a5-b210-73c2abb2e1d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_d68b1a91-378b-491d-993e-e0e23e447bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_0a11437c-5db8-49a5-b210-73c2abb2e1d6" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_d68b1a91-378b-491d-993e-e0e23e447bf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_d68b1a91-378b-491d-993e-e0e23e447bf3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_d68b1a91-378b-491d-993e-e0e23e447bf3" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_d68b1a91-378b-491d-993e-e0e23e447bf3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_c872066e-47c5-4e65-b726-89c62747ed61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_d68b1a91-378b-491d-993e-e0e23e447bf3" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_c872066e-47c5-4e65-b726-89c62747ed61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember_d8d62ce4-e8e5-4498-8073-8812e7b059c7" xlink:href="rprx-20211231.xsd#rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_c872066e-47c5-4e65-b726-89c62747ed61" xlink:to="loc_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember_d8d62ce4-e8e5-4498-8073-8812e7b059c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember_f6233bfe-10c3-441c-9c9f-94a39455d8bb" xlink:href="rprx-20211231.xsd#rprx_LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_c872066e-47c5-4e65-b726-89c62747ed61" xlink:to="loc_rprx_LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember_f6233bfe-10c3-441c-9c9f-94a39455d8bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_184017d9-a827-45be-a6cb-fcb68d36c0f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_0a11437c-5db8-49a5-b210-73c2abb2e1d6" xlink:to="loc_srt_CounterpartyNameAxis_184017d9-a827-45be-a6cb-fcb68d36c0f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184017d9-a827-45be-a6cb-fcb68d36c0f2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_184017d9-a827-45be-a6cb-fcb68d36c0f2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184017d9-a827-45be-a6cb-fcb68d36c0f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_371de749-5645-4357-9c0c-d6a155e9fc99" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_184017d9-a827-45be-a6cb-fcb68d36c0f2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_371de749-5645-4357-9c0c-d6a155e9fc99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MorphoSysMember_888b34b7-a669-459d-a546-c75d8b700e13" xlink:href="rprx-20211231.xsd#rprx_MorphoSysMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_371de749-5645-4357-9c0c-d6a155e9fc99" xlink:to="loc_rprx_MorphoSysMember_888b34b7-a669-459d-a546-c75d8b700e13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d155f417-23ba-4b2a-b62d-2c9f29bb3581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_0a11437c-5db8-49a5-b210-73c2abb2e1d6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d155f417-23ba-4b2a-b62d-2c9f29bb3581" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d155f417-23ba-4b2a-b62d-2c9f29bb3581_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d155f417-23ba-4b2a-b62d-2c9f29bb3581" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d155f417-23ba-4b2a-b62d-2c9f29bb3581_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4a648c77-bca5-425d-bfdd-b38341e42aed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d155f417-23ba-4b2a-b62d-2c9f29bb3581" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4a648c77-bca5-425d-bfdd-b38341e42aed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_f4424614-7e10-455a-97c6-79fc5dbd36be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4a648c77-bca5-425d-bfdd-b38341e42aed" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_f4424614-7e10-455a-97c6-79fc5dbd36be" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://royaltypharma.com/role/SubsequentEventsDetails" xlink:type="extended" id="ia3610841538e44909e1c9f65b7738955_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_935d025a-e0f4-4b9d-bb58-87ba59463a48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireRoyaltyInterestsAggregateAmount_b3f4495a-f8a3-4ed0-9a88-44f592932087" xlink:href="rprx-20211231.xsd#rprx_PaymentsToAcquireRoyaltyInterestsAggregateAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_935d025a-e0f4-4b9d-bb58-87ba59463a48" xlink:to="loc_rprx_PaymentsToAcquireRoyaltyInterestsAggregateAmount_b3f4495a-f8a3-4ed0-9a88-44f592932087" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireRoyaltyInterestsUpfrontPayment_13f6db8a-7ade-4392-9e80-51c7d1de5976" xlink:href="rprx-20211231.xsd#rprx_PaymentsToAcquireRoyaltyInterestsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_935d025a-e0f4-4b9d-bb58-87ba59463a48" xlink:to="loc_rprx_PaymentsToAcquireRoyaltyInterestsUpfrontPayment_13f6db8a-7ade-4392-9e80-51c7d1de5976" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments_4472cfac-123e-495d-b03b-d7392be244a2" xlink:href="rprx-20211231.xsd#rprx_PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_935d025a-e0f4-4b9d-bb58-87ba59463a48" xlink:to="loc_rprx_PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments_4472cfac-123e-495d-b03b-d7392be244a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments_86af69a9-2b7d-48b4-9c6a-aadc28b5fa57" xlink:href="rprx-20211231.xsd#rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_935d025a-e0f4-4b9d-bb58-87ba59463a48" xlink:to="loc_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments_86af69a9-2b7d-48b4-9c6a-aadc28b5fa57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipAmount_ce81f436-7494-4ca1-8c48-3297a45069fe" xlink:href="rprx-20211231.xsd#rprx_LongTermFundingPartnershipAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_935d025a-e0f4-4b9d-bb58-87ba59463a48" xlink:to="loc_rprx_LongTermFundingPartnershipAmount_ce81f436-7494-4ca1-8c48-3297a45069fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipNumberOfTranches_15ddd688-5767-46d7-afa3-4f8dc35dee37" xlink:href="rprx-20211231.xsd#rprx_LongTermFundingPartnershipNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_935d025a-e0f4-4b9d-bb58-87ba59463a48" xlink:to="loc_rprx_LongTermFundingPartnershipNumberOfTranches_15ddd688-5767-46d7-afa3-4f8dc35dee37" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipInitialPayment_bc2b9a69-db1d-4170-a77f-941cad91329b" xlink:href="rprx-20211231.xsd#rprx_LongTermFundingPartnershipInitialPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_935d025a-e0f4-4b9d-bb58-87ba59463a48" xlink:to="loc_rprx_LongTermFundingPartnershipInitialPayment_bc2b9a69-db1d-4170-a77f-941cad91329b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipNumberOfAdditionalPayments_f3946cc5-cf4f-47ef-8b8e-22f4bdfa4ffb" xlink:href="rprx-20211231.xsd#rprx_LongTermFundingPartnershipNumberOfAdditionalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_935d025a-e0f4-4b9d-bb58-87ba59463a48" xlink:to="loc_rprx_LongTermFundingPartnershipNumberOfAdditionalPayments_f3946cc5-cf4f-47ef-8b8e-22f4bdfa4ffb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_5ff4bc35-5524-4605-92d4-3b8b14a17b59" xlink:href="rprx-20211231.xsd#rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_935d025a-e0f4-4b9d-bb58-87ba59463a48" xlink:to="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_5ff4bc35-5524-4605-92d4-3b8b14a17b59" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_e091923a-4aa0-4bd1-9ceb-9ee2be3ba959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_935d025a-e0f4-4b9d-bb58-87ba59463a48" xlink:to="loc_us-gaap_SubsequentEventTable_e091923a-4aa0-4bd1-9ceb-9ee2be3ba959" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_035b3c4a-9fec-4f77-833d-9091bbfd62b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e091923a-4aa0-4bd1-9ceb-9ee2be3ba959" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_035b3c4a-9fec-4f77-833d-9091bbfd62b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_035b3c4a-9fec-4f77-833d-9091bbfd62b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_035b3c4a-9fec-4f77-833d-9091bbfd62b5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_035b3c4a-9fec-4f77-833d-9091bbfd62b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d57b33a0-4f59-4aa5-8ed1-a257aa5e2d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_035b3c4a-9fec-4f77-833d-9091bbfd62b5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d57b33a0-4f59-4aa5-8ed1-a257aa5e2d5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e7ad42b1-e7f8-4c88-af54-cd9ad0d6afa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d57b33a0-4f59-4aa5-8ed1-a257aa5e2d5c" xlink:to="loc_us-gaap_SubsequentEventMember_e7ad42b1-e7f8-4c88-af54-cd9ad0d6afa7" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>rprx-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:ca5bf1b5-7b51-40b4-bf4b-78f0f34b00d0,g:ba501133-7b9f-46c5-b0d4-2c55034547ac-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_HedgingDesignationDomain_3868db91-4c25-4661-a2dd-64983ec35bea_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent_79ee002b-462e-40fb-8a79-7572b4307f1f_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial royalty assets, net</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_cf2efa98-9d23-4d39-838d-237151790b1a_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsForMilestones_90d804b4-7640-4714-ac1c-89c79f5e1a9d_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsForMilestones" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_rprx_PaymentsForMilestones_label_en-US" xlink:label="lab_rprx_PaymentsForMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Milestones</link:label>
    <link:label id="lab_rprx_PaymentsForMilestones_documentation_en-US" xlink:label="lab_rprx_PaymentsForMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForMilestones" xlink:href="rprx-20211231.xsd#rprx_PaymentsForMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsForMilestones" xlink:to="lab_rprx_PaymentsForMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_3dea8279-8d87-43c6-be89-afaa18d21948_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains on Available for Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_835c250f-97ba-45cc-99c5-b6d9b5c1525f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_22dc7782-d357-4b4d-afe8-8dfd388f1df3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_68a66876-fc84-427f-b2b5-80674600af39_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RoyalPharmacySelectFinanceTrustMember_55a5ff2b-27f4-4784-87bf-54d9f0da729e_terseLabel_en-US" xlink:label="lab_rprx_RoyalPharmacySelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPSFT</link:label>
    <link:label id="lab_rprx_RoyalPharmacySelectFinanceTrustMember_label_en-US" xlink:label="lab_rprx_RoyalPharmacySelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royal Pharmacy Select Finance Trust [Member]</link:label>
    <link:label id="lab_rprx_RoyalPharmacySelectFinanceTrustMember_documentation_en-US" xlink:label="lab_rprx_RoyalPharmacySelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royal Pharmacy Select Finance Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyalPharmacySelectFinanceTrustMember" xlink:href="rprx-20211231.xsd#rprx_RoyalPharmacySelectFinanceTrustMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RoyalPharmacySelectFinanceTrustMember" xlink:to="lab_rprx_RoyalPharmacySelectFinanceTrustMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2873c35a-d251-47c8-9a42-eafd8309eb58_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1374329f-32b3-4d8a-bbc9-78e4949e5db3_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale debt securities, current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member_cb022d78-af2a-4315-af7b-db7d25bfc338_terseLabel_en-US" xlink:label="lab_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Five Percent Senior Notes Due 2051</link:label>
    <link:label id="lab_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member_label_en-US" xlink:label="lab_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Five Percent Senior Notes Due 2051 [Member]</link:label>
    <link:label id="lab_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member_documentation_en-US" xlink:label="lab_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Five Percent Senior Notes Due 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member" xlink:href="rprx-20211231.xsd#rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member" xlink:to="lab_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RPHoldingsMember_3aa19ee4-7721-4f16-8806-476e9a8303ec_terseLabel_en-US" xlink:label="lab_rprx_RPHoldingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RP Holdings</link:label>
    <link:label id="lab_rprx_RPHoldingsMember_label_en-US" xlink:label="lab_rprx_RPHoldingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RP Holdings [Member]</link:label>
    <link:label id="lab_rprx_RPHoldingsMember_documentation_en-US" xlink:label="lab_rprx_RPHoldingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RP Holdings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPHoldingsMember" xlink:href="rprx-20211231.xsd#rprx_RPHoldingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RPHoldingsMember" xlink:to="lab_rprx_RPHoldingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_NoncontrollingInterestIncreaseFromContributions_07b3ee0d-b8fa-4bc1-90aa-3225e4c40b11_terseLabel_en-US" xlink:label="lab_rprx_NoncontrollingInterestIncreaseFromContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions</link:label>
    <link:label id="lab_rprx_NoncontrollingInterestIncreaseFromContributions_label_en-US" xlink:label="lab_rprx_NoncontrollingInterestIncreaseFromContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Contributions</link:label>
    <link:label id="lab_rprx_NoncontrollingInterestIncreaseFromContributions_documentation_en-US" xlink:label="lab_rprx_NoncontrollingInterestIncreaseFromContributions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestIncreaseFromContributions" xlink:href="rprx-20211231.xsd#rprx_NoncontrollingInterestIncreaseFromContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_NoncontrollingInterestIncreaseFromContributions" xlink:to="lab_rprx_NoncontrollingInterestIncreaseFromContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_2e25e64f-3739-4e37-b89a-9f6f1ca8dfe3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c7ca320e-5bf8-48da-9fd2-e798a338c1f6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_99e5c2c2-1d94-425a-b548-2d776d7e087b_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RoyaltyPharmaCollectionTrustMember_7109545f-9a8a-4269-9f98-537ada474871_terseLabel_en-US" xlink:label="lab_rprx_RoyaltyPharmaCollectionTrustMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPCT</link:label>
    <link:label id="lab_rprx_RoyaltyPharmaCollectionTrustMember_label_en-US" xlink:label="lab_rprx_RoyaltyPharmaCollectionTrustMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma Collection Trust [Member]</link:label>
    <link:label id="lab_rprx_RoyaltyPharmaCollectionTrustMember_documentation_en-US" xlink:label="lab_rprx_RoyaltyPharmaCollectionTrustMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma Collection Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyPharmaCollectionTrustMember" xlink:href="rprx-20211231.xsd#rprx_RoyaltyPharmaCollectionTrustMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RoyaltyPharmaCollectionTrustMember" xlink:to="lab_rprx_RoyaltyPharmaCollectionTrustMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_4f9735b8-d62c-4ac4-a40f-b90ed4dadc3e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Repayments of Debt by Year</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2dcd91df-29b2-43ec-92a8-3ed2d691fdc6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_ea462d89-9664-478b-b75b-848be71b0047_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_66ad75fc-0423-4d02-a05e-773987e96412_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared and paid</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_85570352-6f4b-407c-8ca8-871fa2e78a70_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_f4b677a2-3417-4efb-839d-7b689f6e4675_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ProceedsFromNoncontrollingInterestsOther_c79e422d-ba5f-498d-bb75-24584f9fe365_terseLabel_en-US" xlink:label="lab_rprx_ProceedsFromNoncontrollingInterestsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from non-controlling interest- other</link:label>
    <link:label id="lab_rprx_ProceedsFromNoncontrollingInterestsOther_label_en-US" xlink:label="lab_rprx_ProceedsFromNoncontrollingInterestsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Noncontrolling Interests, Other</link:label>
    <link:label id="lab_rprx_ProceedsFromNoncontrollingInterestsOther_documentation_en-US" xlink:label="lab_rprx_ProceedsFromNoncontrollingInterestsOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Noncontrolling Interests, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromNoncontrollingInterestsOther" xlink:href="rprx-20211231.xsd#rprx_ProceedsFromNoncontrollingInterestsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ProceedsFromNoncontrollingInterestsOther" xlink:to="lab_rprx_ProceedsFromNoncontrollingInterestsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7baa4127-7a33-40e0-929e-d58f9c3cd867_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ExchangeOfferTransactionMember_557c6f2a-9cb7-4e8f-a48a-b1e973b0bbc3_terseLabel_en-US" xlink:label="lab_rprx_ExchangeOfferTransactionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Offer Transaction</link:label>
    <link:label id="lab_rprx_ExchangeOfferTransactionMember_label_en-US" xlink:label="lab_rprx_ExchangeOfferTransactionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Offer Transaction [Member]</link:label>
    <link:label id="lab_rprx_ExchangeOfferTransactionMember_documentation_en-US" xlink:label="lab_rprx_ExchangeOfferTransactionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Offer Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ExchangeOfferTransactionMember" xlink:href="rprx-20211231.xsd#rprx_ExchangeOfferTransactionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ExchangeOfferTransactionMember" xlink:to="lab_rprx_ExchangeOfferTransactionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RoyaltyPharmaInvestmentsOldRPIMember_ec02b395-6465-40d9-bb43-722f0451212e_terseLabel_en-US" xlink:label="lab_rprx_RoyaltyPharmaInvestmentsOldRPIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Old RPI</link:label>
    <link:label id="lab_rprx_RoyaltyPharmaInvestmentsOldRPIMember_label_en-US" xlink:label="lab_rprx_RoyaltyPharmaInvestmentsOldRPIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma Investments (Old RPI) [Member]</link:label>
    <link:label id="lab_rprx_RoyaltyPharmaInvestmentsOldRPIMember_documentation_en-US" xlink:label="lab_rprx_RoyaltyPharmaInvestmentsOldRPIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma Investments (Old RPI)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember" xlink:href="rprx-20211231.xsd#rprx_RoyaltyPharmaInvestmentsOldRPIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember" xlink:to="lab_rprx_RoyaltyPharmaInvestmentsOldRPIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation_daf2078e-c5c5-4027-ac38-a6161d3db1c7_terseLabel_en-US" xlink:label="lab_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange by Continuing Investors of Class B shares for Class A shares and reallocation of historical equity (in shares)</link:label>
    <link:label id="lab_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation_label_en-US" xlink:label="lab_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Shares, Effect Of Exchange And Reallocation</link:label>
    <link:label id="lab_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation_documentation_en-US" xlink:label="lab_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Shares, Effect Of Exchange And Reallocation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation" xlink:href="rprx-20211231.xsd#rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation" xlink:to="lab_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member_5b92ffa1-ff64-49ed-938d-43c64c35e5a6_terseLabel_en-US" xlink:label="lab_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point One Five percent Senior Notes Due 2031</link:label>
    <link:label id="lab_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member_label_en-US" xlink:label="lab_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point One Five percent Senior Notes Due 2031 [Member]</link:label>
    <link:label id="lab_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member_documentation_en-US" xlink:label="lab_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point One Five percent Senior Notes Due 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member" xlink:href="rprx-20211231.xsd#rprx_TwoPointOneFivePercentSeniorNotesDue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member" xlink:to="lab_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RelatedPartyTransactionAnnualIncreasePercentage_44e7dfe4-8744-44d0-b660-45050ed7336b_terseLabel_en-US" xlink:label="lab_rprx_RelatedPartyTransactionAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in quarterly installment payments (as a percent)</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionAnnualIncreasePercentage_label_en-US" xlink:label="lab_rprx_RelatedPartyTransactionAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Annual Increase, Percentage</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionAnnualIncreasePercentage_documentation_en-US" xlink:label="lab_rprx_RelatedPartyTransactionAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Annual Increase, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionAnnualIncreasePercentage" xlink:href="rprx-20211231.xsd#rprx_RelatedPartyTransactionAnnualIncreasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RelatedPartyTransactionAnnualIncreasePercentage" xlink:to="lab_rprx_RelatedPartyTransactionAnnualIncreasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_28216af7-ada9-4007-a9e0-c94541d5a642_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_TheNotesMember_9d1c30af-349d-4f27-97eb-f98f90288980_terseLabel_en-US" xlink:label="lab_rprx_TheNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Notes</link:label>
    <link:label id="lab_rprx_TheNotesMember_label_en-US" xlink:label="lab_rprx_TheNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Notes [Member]</link:label>
    <link:label id="lab_rprx_TheNotesMember_documentation_en-US" xlink:label="lab_rprx_TheNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TheNotesMember" xlink:href="rprx-20211231.xsd#rprx_TheNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_TheNotesMember" xlink:to="lab_rprx_TheNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_ed774bcc-7144-4df0-80ed-142693e102e2_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial royalty assets</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c16a7d3f-2e16-4d89-83b4-23e3f1442132_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_b6cb98f9-162f-486e-afda-69c206cddd2d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_cadf2329-6697-49d7-bbc2-864bc269b0cb_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2bcad612-3023-4d06-bf05-b78bfb4297fa_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0a9c55af-55db-41da-ac31-43726730e7f0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_0c108ba5-36a8-4168-827c-5e10f139a07f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships_9765205f-cc9f-4ce9-9327-c83e06fe9eef_terseLabel_en-US" xlink:label="lab_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class B ordinary shares to Continuing Investors Partnerships</link:label>
    <link:label id="lab_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships_label_en-US" xlink:label="lab_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued To Partnerships</link:label>
    <link:label id="lab_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships_documentation_en-US" xlink:label="lab_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued To Partnerships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships" xlink:href="rprx-20211231.xsd#rprx_StockIssuedDuringPeriodValueIssuedToPartnerships"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships" xlink:to="lab_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_a838297e-f506-42f1-82fb-9d5efc66a832_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_50b51021-7c8b-40f5-8085-e9d732a43e91_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_fdd72c91-c168-4c21-acb3-0f2ce6118ac6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available for Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable_78b6b5fa-66f8-4ae6-b8a2-d1334ab7c335_negatedTerseLabel_en-US" xlink:label="lab_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other royalty income receivable</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable_label_en-US" xlink:label="lab_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Other Royalty Income Receivable</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable_documentation_en-US" xlink:label="lab_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Other Royalty Income Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable" xlink:href="rprx-20211231.xsd#rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable" xlink:to="lab_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AuditInformationAbstract_label_en-US" xlink:label="lab_rprx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_rprx_AuditInformationAbstract_documentation_en-US" xlink:label="lab_rprx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AuditInformationAbstract" xlink:href="rprx-20211231.xsd#rprx_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AuditInformationAbstract" xlink:to="lab_rprx_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_8118e98b-c459-409f-9325-4ef737617d4e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_b6968e02-84b3-4b61-8a0a-e306076a9586_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsAndRPSFTMember_9ff3bb55-6955-4f95-a89d-53989fe1d50c_terseLabel_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsAndRPSFTMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Investors Partnerships and RPSFT</link:label>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsAndRPSFTMember_label_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsAndRPSFTMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Investors Partnerships and RPSFT [Member]</link:label>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsAndRPSFTMember_documentation_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsAndRPSFTMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Investors Partnerships and RPSFT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsAndRPSFTMember" xlink:href="rprx-20211231.xsd#rprx_LegacyInvestorsPartnershipsAndRPSFTMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LegacyInvestorsPartnershipsAndRPSFTMember" xlink:to="lab_rprx_LegacyInvestorsPartnershipsAndRPSFTMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_EpizymeIncMember_e67dd501-30e9-4bfb-8ce0-2d15c30416f0_terseLabel_en-US" xlink:label="lab_rprx_EpizymeIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment In Epizyme Inc.</link:label>
    <link:label id="lab_rprx_EpizymeIncMember_label_en-US" xlink:label="lab_rprx_EpizymeIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epizyme Inc. [Member]</link:label>
    <link:label id="lab_rprx_EpizymeIncMember_documentation_en-US" xlink:label="lab_rprx_EpizymeIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epizyme Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EpizymeIncMember" xlink:href="rprx-20211231.xsd#rprx_EpizymeIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_EpizymeIncMember" xlink:to="lab_rprx_EpizymeIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_NoncontrollingInterestTransfersOfInterests_81875db2-0088-4cd1-88f3-99eb581da892_terseLabel_en-US" xlink:label="lab_rprx_NoncontrollingInterestTransfersOfInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of interests</link:label>
    <link:label id="lab_rprx_NoncontrollingInterestTransfersOfInterests_label_en-US" xlink:label="lab_rprx_NoncontrollingInterestTransfersOfInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Transfers Of Interests</link:label>
    <link:label id="lab_rprx_NoncontrollingInterestTransfersOfInterests_documentation_en-US" xlink:label="lab_rprx_NoncontrollingInterestTransfersOfInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Transfers Of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestTransfersOfInterests" xlink:href="rprx-20211231.xsd#rprx_NoncontrollingInterestTransfersOfInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_NoncontrollingInterestTransfersOfInterests" xlink:to="lab_rprx_NoncontrollingInterestTransfersOfInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PutOptionMember_dad92dad-a98e-43fd-b726-552800815069_terseLabel_en-US" xlink:label="lab_us-gaap_PutOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put Option</link:label>
    <link:label id="lab_us-gaap_PutOptionMember_label_en-US" xlink:label="lab_us-gaap_PutOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PutOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PutOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PutOptionMember" xlink:to="lab_us-gaap_PutOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_217d6e5c-7a89-4b83-9acf-0495b621aa1a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CysticFibrosisFranchiseMember_00122856-8ca5-49fc-814c-1dd5b5639280_terseLabel_en-US" xlink:label="lab_rprx_CysticFibrosisFranchiseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cystic fibrosis franchise</link:label>
    <link:label id="lab_rprx_CysticFibrosisFranchiseMember_label_en-US" xlink:label="lab_rprx_CysticFibrosisFranchiseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cystic Fibrosis Franchise [Member]</link:label>
    <link:label id="lab_rprx_CysticFibrosisFranchiseMember_documentation_en-US" xlink:label="lab_rprx_CysticFibrosisFranchiseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cystic Fibrosis Franchise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CysticFibrosisFranchiseMember" xlink:href="rprx-20211231.xsd#rprx_CysticFibrosisFranchiseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CysticFibrosisFranchiseMember" xlink:to="lab_rprx_CysticFibrosisFranchiseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForLoanLossesExpensed_d4069665-8cc6-488b-80fb-c3c4fb39821f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForLoanLossesExpensed" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period provision for credit losses, net</link:label>
    <link:label id="lab_us-gaap_ProvisionForLoanLossesExpensed_label_en-US" xlink:label="lab_us-gaap_ProvisionForLoanLossesExpensed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Credit Loss, Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLoanLossesExpensed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForLoanLossesExpensed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForLoanLossesExpensed" xlink:to="lab_us-gaap_ProvisionForLoanLossesExpensed" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RelatedPartyTransactionRateAdjustedCashReceipts_524062fc-9213-4a4f-9c0c-d364ef985d92_terseLabel_en-US" xlink:label="lab_rprx_RelatedPartyTransactionRateAdjustedCashReceipts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly payments to affiliates, percent of adjusted cash receipts (as a percent)</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionRateAdjustedCashReceipts_label_en-US" xlink:label="lab_rprx_RelatedPartyTransactionRateAdjustedCashReceipts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Rate, Adjusted Cash Receipts</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionRateAdjustedCashReceipts_documentation_en-US" xlink:label="lab_rprx_RelatedPartyTransactionRateAdjustedCashReceipts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Rate, Adjusted Cash Receipts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionRateAdjustedCashReceipts" xlink:href="rprx-20211231.xsd#rprx_RelatedPartyTransactionRateAdjustedCashReceipts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RelatedPartyTransactionRateAdjustedCashReceipts" xlink:to="lab_rprx_RelatedPartyTransactionRateAdjustedCashReceipts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_71ef6ef2-31d4-4e12-bfbb-487f6b043b15_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_38c6fd6c-30f4-4965-beb2-36587a90fb38_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains on available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_ad5f0dd2-15ed-4bb1-ae25-23b31428b963_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Interest Payable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_dd86c264-601e-47e3-b56d-c5543cabb0d4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2ff9217-92fb-42af-ad1e-acf0d08fd254_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RPI2019IntermediateFinanceMember_7363b6d0-8562-4db9-adb8-80ebc769d90d_terseLabel_en-US" xlink:label="lab_rprx_RPI2019IntermediateFinanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI Intermediate FT</link:label>
    <link:label id="lab_rprx_RPI2019IntermediateFinanceMember_label_en-US" xlink:label="lab_rprx_RPI2019IntermediateFinanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI 2019 Intermediate Finance [Member]</link:label>
    <link:label id="lab_rprx_RPI2019IntermediateFinanceMember_documentation_en-US" xlink:label="lab_rprx_RPI2019IntermediateFinanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI 2019 Intermediate Finance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPI2019IntermediateFinanceMember" xlink:href="rprx-20211231.xsd#rprx_RPI2019IntermediateFinanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RPI2019IntermediateFinanceMember" xlink:to="lab_rprx_RPI2019IntermediateFinanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b0da413d-b7ac-4ae0-a80e-aadaa33867c2_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_a86dcd6c-553f-48ca-ab02-abea1e63e6ce_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_e0a6b364-7c08-46cd-b770-59efee68feb0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition_3625495a-b1eb-45cd-b7fa-84dc3babff17_terseLabel_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum consolidated leverage ratio following qualifying material acquisition</link:label>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition_label_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition</link:label>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition_documentation_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" xlink:href="rprx-20211231.xsd#rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" xlink:to="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid_781f6714-5918-481c-b26c-0fee0d20b5c0_terseLabel_en-US" xlink:label="lab_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment and premium paid</link:label>
    <link:label id="lab_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid_label_en-US" xlink:label="lab_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Upfront Payment and Premium Paid</link:label>
    <link:label id="lab_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid_documentation_en-US" xlink:label="lab_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Upfront Payment and Premium Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid" xlink:href="rprx-20211231.xsd#rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid" xlink:to="lab_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_e9d556a4-0879-4dad-9410-51f69c09296e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingPartnershipNumberOfTranches_bac76fa8-f16e-446d-8470-565f08391257_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term funding partnership, number of tranches</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipNumberOfTranches_label_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Number of Tranches</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipNumberOfTranches_documentation_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Number of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipNumberOfTranches" xlink:href="rprx-20211231.xsd#rprx_LongTermFundingPartnershipNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingPartnershipNumberOfTranches" xlink:to="lab_rprx_LongTermFundingPartnershipNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate_c3ed6cca-dc67-4990-8914-5b91c15a08c5_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption default, interest rate</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption Default, Interest Rate</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption Default, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense_f9ef291d-a02e-41d1-8a82-d15bc8f37ebd_negatedTerseLabel_en-US" xlink:label="lab_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</link:label>
    <link:label id="lab_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense_label_en-US" xlink:label="lab_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense</link:label>
    <link:label id="lab_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense_documentation_en-US" xlink:label="lab_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" xlink:to="lab_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_7234bb46-505b-439f-8c65-6b620b5b9b8e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_4a26af90-d515-45f9-bbc9-e0aa8def4c9b_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption, Period One</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period One [Member]</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_dd52c20a-072c-4166-86be-6c0d3d967009_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_b30867d2-c844-4fa5-99d7-b55b4cee1b76_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_bb49e44d-bd43-4a40-b6e0-8ce0035f70a9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual licensees exceeding 10% or more of revenue (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a6b0270b-a90e-41eb-9f18-5aedfcc14209_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCash_1cba4df9-2d84-4dd7-9259-0962aaeeccc9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_DividendsCash_label_en-US" xlink:label="lab_us-gaap_DividendsCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCash" xlink:to="lab_us-gaap_DividendsCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_dd6f3190-54c5-47b0-be1d-5fd884622116_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_e08445dc-3680-41c9-8f75-3d2384494023_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_a3304b83-3a86-43ad-8ee7-9b8851049986_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_62d96f25-f5b3-4601-afa2-805039b078a6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RelatedPartyTransactionCumulativeFundingAmount_48cd1dae-68ba-454e-9985-63ad1fc61777_terseLabel_en-US" xlink:label="lab_rprx_RelatedPartyTransactionCumulativeFundingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative funding amount</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionCumulativeFundingAmount_label_en-US" xlink:label="lab_rprx_RelatedPartyTransactionCumulativeFundingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Cumulative Funding Amount</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionCumulativeFundingAmount_documentation_en-US" xlink:label="lab_rprx_RelatedPartyTransactionCumulativeFundingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Cumulative Funding Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionCumulativeFundingAmount" xlink:href="rprx-20211231.xsd#rprx_RelatedPartyTransactionCumulativeFundingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RelatedPartyTransactionCumulativeFundingAmount" xlink:to="lab_rprx_RelatedPartyTransactionCumulativeFundingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AvillionIIMember_d919e525-7538-471e-9d67-af89a353fd20_terseLabel_en-US" xlink:label="lab_rprx_AvillionIIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion II</link:label>
    <link:label id="lab_rprx_AvillionIIMember_label_en-US" xlink:label="lab_rprx_AvillionIIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion II [Member]</link:label>
    <link:label id="lab_rprx_AvillionIIMember_documentation_en-US" xlink:label="lab_rprx_AvillionIIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion II</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionIIMember" xlink:href="rprx-20211231.xsd#rprx_AvillionIIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AvillionIIMember" xlink:to="lab_rprx_AvillionIIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_4187830a-31f6-4632-be19-09975b3c7e86_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage (as a percent)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4fcaecb2-9031-417e-93d7-20e566efac7d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermPurchaseCommitmentAmountOutstanding_451ce554-fb6a-46f6-9b53-da5e3653a425_terseLabel_en-US" xlink:label="lab_rprx_LongTermPurchaseCommitmentAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining commitment</link:label>
    <link:label id="lab_rprx_LongTermPurchaseCommitmentAmountOutstanding_label_en-US" xlink:label="lab_rprx_LongTermPurchaseCommitmentAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Purchase Commitment, Amount Outstanding</link:label>
    <link:label id="lab_rprx_LongTermPurchaseCommitmentAmountOutstanding_documentation_en-US" xlink:label="lab_rprx_LongTermPurchaseCommitmentAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Purchase Commitment, Amount Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermPurchaseCommitmentAmountOutstanding" xlink:href="rprx-20211231.xsd#rprx_LongTermPurchaseCommitmentAmountOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermPurchaseCommitmentAmountOutstanding" xlink:to="lab_rprx_LongTermPurchaseCommitmentAmountOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d5d25b90-4b77-46f3-ad79-dc84f9793d28_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember_929e8b3b-de69-416d-b339-ad7ccf791562_terseLabel_en-US" xlink:label="lab_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Distribution Payable to Legacy Investors Partnerships</link:label>
    <link:label id="lab_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember_label_en-US" xlink:label="lab_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Distribution Payable to Legacy Investors Partnerships [Member]</link:label>
    <link:label id="lab_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember_documentation_en-US" xlink:label="lab_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Distribution Payable to Legacy Investors Partnerships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember" xlink:href="rprx-20211231.xsd#rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember" xlink:to="lab_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital_1efa6dba-b81e-47a3-b1ee-d1bcc7474b74_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, weighted average cost of capital</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_b6f02b1d-aeb4-4e6b-970d-dffbbc1339f2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions from non-consolidated affiliates</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment_4a8e6634-0e8b-423f-a2f0-8047b8c2227b_terseLabel_en-US" xlink:label="lab_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment for equity investment</link:label>
    <link:label id="lab_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment_label_en-US" xlink:label="lab_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Investments, Upfront Payment</link:label>
    <link:label id="lab_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment_documentation_en-US" xlink:label="lab_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Investments, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment" xlink:href="rprx-20211231.xsd#rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment" xlink:to="lab_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_c9f97621-2272-42f3-8846-90ae3ef76974_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_A2020EquityIncentivePlanMember_950ea425-5b2d-4dde-8e3c-05c728a79739_terseLabel_en-US" xlink:label="lab_rprx_A2020EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Equity Incentive Plan</link:label>
    <link:label id="lab_rprx_A2020EquityIncentivePlanMember_label_en-US" xlink:label="lab_rprx_A2020EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_rprx_A2020EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_rprx_A2020EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_A2020EquityIncentivePlanMember" xlink:href="rprx-20211231.xsd#rprx_A2020EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_A2020EquityIncentivePlanMember" xlink:to="lab_rprx_A2020EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_5d2db6cb-7ca6-4265-bde3-3b6f264905e6_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period [Domain]</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period [Domain]</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsExpectedReturn_844373ac-2932-423e-932a-4df7d7a2c850_terseLabel_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsExpectedReturn" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return (as a percent)</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsExpectedReturn_label_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsExpectedReturn" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Expected Return</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsExpectedReturn_documentation_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsExpectedReturn" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Expected Return</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsExpectedReturn" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsExpectedReturn"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CollaborativeArrangementRightsAndObligationsExpectedReturn" xlink:to="lab_rprx_CollaborativeArrangementRightsAndObligationsExpectedReturn" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_125f943b-dd09-4be5-aa6b-ce1dbae15f47_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_TreasuryRateLockContractsMember_e2750fd2-afc4-4c10-a3e8-9df4dd9969dd_terseLabel_en-US" xlink:label="lab_rprx_TreasuryRateLockContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Rate Lock Contracts</link:label>
    <link:label id="lab_rprx_TreasuryRateLockContractsMember_label_en-US" xlink:label="lab_rprx_TreasuryRateLockContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Rate Lock Contracts [Member]</link:label>
    <link:label id="lab_rprx_TreasuryRateLockContractsMember_documentation_en-US" xlink:label="lab_rprx_TreasuryRateLockContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Rate Lock Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TreasuryRateLockContractsMember" xlink:href="rprx-20211231.xsd#rprx_TreasuryRateLockContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_TreasuryRateLockContractsMember" xlink:to="lab_rprx_TreasuryRateLockContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_3c6d6a12-5f4b-4768-8321-e874fec2eb59_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average coupon rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_664f08f5-d6b6-4d61-9236-36a45fb3fa0d_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_c7d6b98c-b640-4972-af33-e0eb14b3bc19_terseLabel_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Reclassification, Adjustment</link:label>
    <link:label id="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_label_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Reclassification, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:to="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_dd9a5901-7cfb-4e66-a70e-44c9d8c4e58b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_c055d8c2-e039-4e5b-b233-6a0975d9244f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research &amp; Development ("R&amp;D") Funding Expense</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForLoanAndLeaseLosses_8cab3145-26fd-440f-b2f0-78b24080dcc9_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForLoanAndLeaseLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for changes in expected cash flows from financial royalty assets</link:label>
    <link:label id="lab_us-gaap_ProvisionForLoanAndLeaseLosses_label_en-US" xlink:label="lab_us-gaap_ProvisionForLoanAndLeaseLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for Loan and Lease Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLoanAndLeaseLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForLoanAndLeaseLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForLoanAndLeaseLosses" xlink:to="lab_us-gaap_ProvisionForLoanAndLeaseLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_7394500f-caeb-4a96-a5eb-bf1fd69516a9_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OtherCommitmentsPercentage_5bbe71b6-854d-45f2-b306-dc3ed3033719_terseLabel_en-US" xlink:label="lab_rprx_OtherCommitmentsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other commitments, percentage of costs (as a percent)</link:label>
    <link:label id="lab_rprx_OtherCommitmentsPercentage_label_en-US" xlink:label="lab_rprx_OtherCommitmentsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments, Percentage</link:label>
    <link:label id="lab_rprx_OtherCommitmentsPercentage_documentation_en-US" xlink:label="lab_rprx_OtherCommitmentsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherCommitmentsPercentage" xlink:href="rprx-20211231.xsd#rprx_OtherCommitmentsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OtherCommitmentsPercentage" xlink:to="lab_rprx_OtherCommitmentsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_78f2702f-5ac3-45be-95ae-95b2cd9182a2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b086e4eb-9e64-4ad1-a4b1-f2adf7b85465_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Class A ordinary share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablesTextBlock_3cbcf306-fdd4-4940-aa8b-ad333aa2e120_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Royalty Assets, Net</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablesTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivables [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablesTextBlock" xlink:to="lab_us-gaap_FinancingReceivablesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_deb2c7a2-14af-4990-a062-960449736ff0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Category of Item Purchased [Domain]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Category of Item Purchased [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_cd1f4d39-0426-46ef-b794-78cf7a618bcd_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_6a18df7d-4192-46b2-8627-a386ddfb387c_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for current expected credit losses</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss, Financial Instrument [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7e93e058-cfcd-41fa-abe7-06418419ec57_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents_a3b60915-f8ea-4831-b50b-4a4710d4674a_terseLabel_en-US" xlink:label="lab_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate royalty amount when patents cease</link:label>
    <link:label id="lab_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents_label_en-US" xlink:label="lab_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents</link:label>
    <link:label id="lab_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents_documentation_en-US" xlink:label="lab_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" xlink:to="lab_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_c848c6c7-d32b-4ef3-a06f-ed15756210fe_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedParties_8209e855-0832-4287-82b1-b299be165a4a_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due from related parties</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedParties" xlink:to="lab_us-gaap_DueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_8226b59c-d845-4bdd-b10b-9c8b94107603_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_8c808e2c-9072-4d8e-8003-e43c6a34d8bd_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on derivatives</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_8e28a399-bb0a-4adc-93b9-a62807e0058a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses on derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_SeniorNotesDue2031Member_7b53c790-8055-48aa-b7e0-d52d42d0d5a8_terseLabel_en-US" xlink:label="lab_rprx_SeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2031</link:label>
    <link:label id="lab_rprx_SeniorNotesDue2031Member_label_en-US" xlink:label="lab_rprx_SeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2031 [Member]</link:label>
    <link:label id="lab_rprx_SeniorNotesDue2031Member_documentation_en-US" xlink:label="lab_rprx_SeniorNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorNotesDue2031Member" xlink:href="rprx-20211231.xsd#rprx_SeniorNotesDue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_SeniorNotesDue2031Member" xlink:to="lab_rprx_SeniorNotesDue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense_f17e2f22-9128-4465-a01b-2e0e9d0bd01b_terseLabel_en-US" xlink:label="lab_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</link:label>
    <link:label id="lab_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense_label_en-US" xlink:label="lab_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense</link:label>
    <link:label id="lab_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense_documentation_en-US" xlink:label="lab_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" xlink:to="lab_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_86cd1c7e-20f4-46ad-a016-9643e22523c7_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireFinanceReceivables_a5a77ac5-aad0-444a-a267-9c74cf49aa92_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireFinanceReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of financial royalty assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireFinanceReceivables_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireFinanceReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Finance Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireFinanceReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireFinanceReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireFinanceReceivables" xlink:to="lab_us-gaap_PaymentsToAcquireFinanceReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_8dcf255d-eb83-42b1-a84b-aedacd81a637_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_f6a0787a-cbc7-44f2-927b-4bdebd3235e6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_8ae6ddde-3c9e-45ba-b902-a99e93b81382_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development funding expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_a9668ec3-2df5-4f58-a816-0e1e9354dc11_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DevelopmentFundingBondForwardMember_d0267f03-8f52-4fd6-a461-3835499712a5_terseLabel_en-US" xlink:label="lab_rprx_DevelopmentFundingBondForwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Funding Bond Forward</link:label>
    <link:label id="lab_rprx_DevelopmentFundingBondForwardMember_label_en-US" xlink:label="lab_rprx_DevelopmentFundingBondForwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Funding Bond Forward [Member]</link:label>
    <link:label id="lab_rprx_DevelopmentFundingBondForwardMember_documentation_en-US" xlink:label="lab_rprx_DevelopmentFundingBondForwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Funding Bond Forward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DevelopmentFundingBondForwardMember" xlink:href="rprx-20211231.xsd#rprx_DevelopmentFundingBondForwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DevelopmentFundingBondForwardMember" xlink:to="lab_rprx_DevelopmentFundingBondForwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_b4124422-4fde-43de-a60c-05127586c994_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ClassRRedeemableStockMember_139c16e2-fbc0-4c56-ab36-a5fcc2e4463d_terseLabel_en-US" xlink:label="lab_rprx_ClassRRedeemableStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class R Redeemable Stock</link:label>
    <link:label id="lab_rprx_ClassRRedeemableStockMember_label_en-US" xlink:label="lab_rprx_ClassRRedeemableStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class R Redeemable Stock [Member]</link:label>
    <link:label id="lab_rprx_ClassRRedeemableStockMember_documentation_en-US" xlink:label="lab_rprx_ClassRRedeemableStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class R Redeemable Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember" xlink:href="rprx-20211231.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ClassRRedeemableStockMember" xlink:to="lab_rprx_ClassRRedeemableStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_56433601-f425-432e-9735-fdc68067da37_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_7fa1da40-0ada-416b-a2de-101d56d4010a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_3dc1f987-c4fa-48df-8e8d-dff23aaf933f_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt carrying value</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_d845644a-645c-4c95-b5fd-562abefafc5b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions from non-consolidated affiliates</link:label>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution, Return of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:to="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_23951e9d-efb8-4edd-b4b6-d3cdf85494cf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_049b594d-8468-40f2-8d99-bbca65721bac_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AccruedPurchaseObligationEquityInvestment_91888448-aa00-4d61-bbc0-7a8961c6ea7e_terseLabel_en-US" xlink:label="lab_rprx_AccruedPurchaseObligationEquityInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued purchase obligation - Tazverik</link:label>
    <link:label id="lab_rprx_AccruedPurchaseObligationEquityInvestment_label_en-US" xlink:label="lab_rprx_AccruedPurchaseObligationEquityInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Purchase Obligation, Equity Investment</link:label>
    <link:label id="lab_rprx_AccruedPurchaseObligationEquityInvestment_documentation_en-US" xlink:label="lab_rprx_AccruedPurchaseObligationEquityInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Purchase Obligation, Equity Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AccruedPurchaseObligationEquityInvestment" xlink:href="rprx-20211231.xsd#rprx_AccruedPurchaseObligationEquityInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AccruedPurchaseObligationEquityInvestment" xlink:to="lab_rprx_AccruedPurchaseObligationEquityInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSalePricePerShare_24ef96fc-9796-44e4-ae2a-225a3e4be447_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSalePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share (in USD per share)</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSalePricePerShare_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSalePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Price Per Share</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSalePricePerShare_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSalePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSalePricePerShare" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSalePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSalePricePerShare" xlink:to="lab_rprx_DebtSecuritiesAvailableForSalePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_db4ca4d3-fe41-44cf-a9aa-6000ee119bcb_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionRate_d411573f-16fa-4ec2-a156-03d3f067c2a3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party, rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionRate_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionRate" xlink:to="lab_us-gaap_RelatedPartyTransactionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_4069f647-c7a0-423a-9a59-fcb448e73fcc_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cumulative Allowance for Changes in Expected Cash Flows</link:label>
    <link:label id="lab_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:to="lab_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_166942ed-3975-44e1-8d0d-43d60ac5f000_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_8edec69a-5cb9-4bf0-b762-23953cfb7fe8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OvernightBankFundingRateMember_a28b6a6e-4a49-48df-aa1f-1965c724423f_terseLabel_en-US" xlink:label="lab_rprx_OvernightBankFundingRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overnight Bank Funding Rate</link:label>
    <link:label id="lab_rprx_OvernightBankFundingRateMember_label_en-US" xlink:label="lab_rprx_OvernightBankFundingRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overnight Bank Funding Rate [Member]</link:label>
    <link:label id="lab_rprx_OvernightBankFundingRateMember_documentation_en-US" xlink:label="lab_rprx_OvernightBankFundingRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overnight Bank Funding Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OvernightBankFundingRateMember" xlink:href="rprx-20211231.xsd#rprx_OvernightBankFundingRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OvernightBankFundingRateMember" xlink:to="lab_rprx_OvernightBankFundingRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesNoncurrent_4222acc2-2e25-4c60-b7fa-25b6a8b0e169_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total distribution payable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_499b2900-9af1-4aff-b9cd-3039de44c5bb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense/(income)</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceReceivablesMember_c219fb3b-5656-49de-9e75-8b218f5c8df0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of Financial royalty assets</link:label>
    <link:label id="lab_us-gaap_FinanceReceivablesMember_label_en-US" xlink:label="lab_us-gaap_FinanceReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceReceivablesMember" xlink:to="lab_us-gaap_FinanceReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_8b0defac-0394-4e05-be03-9ded9ef03c9f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0622c0e5-7fd1-4d83-9c52-464c47569be4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AccruedRoyaltyReceivable_8939ea5c-57eb-4ad1-a48f-e09baebd2657_terseLabel_en-US" xlink:label="lab_rprx_AccruedRoyaltyReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalty receivable</link:label>
    <link:label id="lab_rprx_AccruedRoyaltyReceivable_label_en-US" xlink:label="lab_rprx_AccruedRoyaltyReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalty Receivable</link:label>
    <link:label id="lab_rprx_AccruedRoyaltyReceivable_documentation_en-US" xlink:label="lab_rprx_AccruedRoyaltyReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalty Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AccruedRoyaltyReceivable" xlink:href="rprx-20211231.xsd#rprx_AccruedRoyaltyReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AccruedRoyaltyReceivable" xlink:to="lab_rprx_AccruedRoyaltyReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_c98534ce-49b3-4a7e-9975-2efe707d54e0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of Class A ordinary shares upon IPO, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_714c623e-8765-4b4c-b7d3-45941df1f5a5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5f94b679-ee9d-488b-ac40-c2d04fa30c17_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_7a76501c-a737-44af-9f4e-2051b413b451_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_f0d94346-0c2c-4d94-9229-2076d10bc98d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury interests</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_6e5fa48e-ed2d-4675-ab09-e40dd22bc328_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury interests</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_c4d5e570-5705-49f2-98c0-63b4e5e07096_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_93f397e2-3e1d-42e5-87a9-650414dad9d4_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_e23b72d9-aec4-40af-b7f0-53e3238fbedf_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_205d30c5-83cb-4c1b-9824-598248998067_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d0060b79-18c9-47fc-a76a-503b1864e608_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_86cb0454-a4ef-43b3-b9d6-ad1d9b4dfb7f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Purpose</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ContinuingInvestorsPartnershipMember_741da5bc-23c3-48d4-a42f-5d3cf07bdb91_terseLabel_en-US" xlink:label="lab_rprx_ContinuingInvestorsPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Investors Partnerships</link:label>
    <link:label id="lab_rprx_ContinuingInvestorsPartnershipMember_label_en-US" xlink:label="lab_rprx_ContinuingInvestorsPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Investors Partnership [Member]</link:label>
    <link:label id="lab_rprx_ContinuingInvestorsPartnershipMember_documentation_en-US" xlink:label="lab_rprx_ContinuingInvestorsPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Investors Partnership</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ContinuingInvestorsPartnershipMember" xlink:href="rprx-20211231.xsd#rprx_ContinuingInvestorsPartnershipMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ContinuingInvestorsPartnershipMember" xlink:to="lab_rprx_ContinuingInvestorsPartnershipMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_MerckAssetPhaseIIClinicalTrialMember_509e5f96-8a6c-4493-a119-a8ac7d8fed72_terseLabel_en-US" xlink:label="lab_rprx_MerckAssetPhaseIIClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Asset - Phase II Clinical Trial</link:label>
    <link:label id="lab_rprx_MerckAssetPhaseIIClinicalTrialMember_label_en-US" xlink:label="lab_rprx_MerckAssetPhaseIIClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Asset - Phase II Clinical Trial [Member]</link:label>
    <link:label id="lab_rprx_MerckAssetPhaseIIClinicalTrialMember_documentation_en-US" xlink:label="lab_rprx_MerckAssetPhaseIIClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Asset - Phase II Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MerckAssetPhaseIIClinicalTrialMember" xlink:href="rprx-20211231.xsd#rprx_MerckAssetPhaseIIClinicalTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_MerckAssetPhaseIIClinicalTrialMember" xlink:to="lab_rprx_MerckAssetPhaseIIClinicalTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_SaleOfStockNumberOfSharesNotConverted_c0b4082a-f043-4141-93b1-b83854079dae_terseLabel_en-US" xlink:label="lab_rprx_SaleOfStockNumberOfSharesNotConverted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares converted (in shares)</link:label>
    <link:label id="lab_rprx_SaleOfStockNumberOfSharesNotConverted_label_en-US" xlink:label="lab_rprx_SaleOfStockNumberOfSharesNotConverted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Number Of Shares Not Converted</link:label>
    <link:label id="lab_rprx_SaleOfStockNumberOfSharesNotConverted_documentation_en-US" xlink:label="lab_rprx_SaleOfStockNumberOfSharesNotConverted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Number Of Shares Not Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SaleOfStockNumberOfSharesNotConverted" xlink:href="rprx-20211231.xsd#rprx_SaleOfStockNumberOfSharesNotConverted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_SaleOfStockNumberOfSharesNotConverted" xlink:to="lab_rprx_SaleOfStockNumberOfSharesNotConverted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_578603d7-3fd7-4da4-b9fe-373a1cd4ee9d_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff_71782332-abda-4fbb-9112-e523995c02ff_terseLabel_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Writeoff related to financial royalty asset</link:label>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff_label_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss, Financial Royalty Asset, Writeoff</link:label>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff_documentation_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Financial Royalty Asset, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff" xlink:to="lab_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss_d0386c0c-ca81-431d-b371-3f6c4a4c1ffb_negatedTerseLabel_en-US" xlink:label="lab_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income accretion</link:label>
    <link:label id="lab_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss_label_en-US" xlink:label="lab_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss)</link:label>
    <link:label id="lab_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss_documentation_en-US" xlink:label="lab_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" xlink:href="rprx-20211231.xsd#rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" xlink:to="lab_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_ba6a8ab9-174c-4d40-b863-2754f38476d3_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_EpizymeCommonStockWarrantMember_386f6049-0b69-4312-b231-ad3940be9840_terseLabel_en-US" xlink:label="lab_rprx_EpizymeCommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epizyme Common Stock Warrant</link:label>
    <link:label id="lab_rprx_EpizymeCommonStockWarrantMember_label_en-US" xlink:label="lab_rprx_EpizymeCommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epizyme Common Stock Warrant [Member]</link:label>
    <link:label id="lab_rprx_EpizymeCommonStockWarrantMember_documentation_en-US" xlink:label="lab_rprx_EpizymeCommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epizyme Common Stock Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EpizymeCommonStockWarrantMember" xlink:href="rprx-20211231.xsd#rprx_EpizymeCommonStockWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_EpizymeCommonStockWarrantMember" xlink:to="lab_rprx_EpizymeCommonStockWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_d75f957b-d386-4f31-83ae-dbb53c392cd4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_ff9b9af5-9996-4986-b4e0-ba6b6098f816_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d75a704-2ec6-46a0-9b50-feb7c0878b26_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AssignmentAgreementBenefitOfPaymentStreamMember_67b17fe7-0810-49f8-9158-d8e3f150613d_terseLabel_en-US" xlink:label="lab_rprx_AssignmentAgreementBenefitOfPaymentStreamMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement - Benefit of Payment Stream</link:label>
    <link:label id="lab_rprx_AssignmentAgreementBenefitOfPaymentStreamMember_label_en-US" xlink:label="lab_rprx_AssignmentAgreementBenefitOfPaymentStreamMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement - Benefit of Payment Stream [Member]</link:label>
    <link:label id="lab_rprx_AssignmentAgreementBenefitOfPaymentStreamMember_documentation_en-US" xlink:label="lab_rprx_AssignmentAgreementBenefitOfPaymentStreamMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement - Benefit of Payment Stream</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssignmentAgreementBenefitOfPaymentStreamMember" xlink:href="rprx-20211231.xsd#rprx_AssignmentAgreementBenefitOfPaymentStreamMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AssignmentAgreementBenefitOfPaymentStreamMember" xlink:to="lab_rprx_AssignmentAgreementBenefitOfPaymentStreamMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_6936c345-b7cb-4cc1-8a66-8e8c71c7c4f9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_d76cff0c-2b6f-435b-bc85-2e4433c6f459_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_00ffe648-072a-4d40-8543-093fe51d8865_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancialRoyaltyAssetsMember_ee972486-7f60-471e-8fb0-ed4efa7ff6db_terseLabel_en-US" xlink:label="lab_rprx_FinancialRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from financial royalty assets</link:label>
    <link:label id="lab_rprx_FinancialRoyaltyAssetsMember_label_en-US" xlink:label="lab_rprx_FinancialRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Royalty Assets [Member]</link:label>
    <link:label id="lab_rprx_FinancialRoyaltyAssetsMember_documentation_en-US" xlink:label="lab_rprx_FinancialRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Royalty Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancialRoyaltyAssetsMember" xlink:href="rprx-20211231.xsd#rprx_FinancialRoyaltyAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancialRoyaltyAssetsMember" xlink:to="lab_rprx_FinancialRoyaltyAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_bd3b70a2-e510-4e65-8b65-f3a2746bf68f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:to="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_EvrysdiMember_b691cbb0-f790-4e98-9d0c-c38b0fdb6972_terseLabel_en-US" xlink:label="lab_rprx_EvrysdiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evrysdi</link:label>
    <link:label id="lab_rprx_EvrysdiMember_label_en-US" xlink:label="lab_rprx_EvrysdiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evrysdi [Member]</link:label>
    <link:label id="lab_rprx_EvrysdiMember_documentation_en-US" xlink:label="lab_rprx_EvrysdiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evrysdi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EvrysdiMember" xlink:href="rprx-20211231.xsd#rprx_EvrysdiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_EvrysdiMember" xlink:to="lab_rprx_EvrysdiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DeferredSharesMember_3ea4829e-2190-4ef5-ba41-8393ddb1ad6b_terseLabel_en-US" xlink:label="lab_rprx_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares</link:label>
    <link:label id="lab_rprx_DeferredSharesMember_fac04429-ef8a-45dd-8d67-601a279f6c27_verboseLabel_en-US" xlink:label="lab_rprx_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares</link:label>
    <link:label id="lab_rprx_DeferredSharesMember_label_en-US" xlink:label="lab_rprx_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares [Member]</link:label>
    <link:label id="lab_rprx_DeferredSharesMember_documentation_en-US" xlink:label="lab_rprx_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesMember" xlink:href="rprx-20211231.xsd#rprx_DeferredSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DeferredSharesMember" xlink:to="lab_rprx_DeferredSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_ebaf2888-35db-4b36-a33e-8cc5454353bb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInterestReceived" xlink:to="lab_us-gaap_ProceedsFromInterestReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_StockIssuedDuringPeriodValueIssuedForRegistration_4b9940b1-dd6f-428e-b7fb-a2fb2219968c_terseLabel_en-US" xlink:label="lab_rprx_StockIssuedDuringPeriodValueIssuedForRegistration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial share issuance upon registration of Royalty Pharma plc</link:label>
    <link:label id="lab_rprx_StockIssuedDuringPeriodValueIssuedForRegistration_label_en-US" xlink:label="lab_rprx_StockIssuedDuringPeriodValueIssuedForRegistration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued For Registration</link:label>
    <link:label id="lab_rprx_StockIssuedDuringPeriodValueIssuedForRegistration_documentation_en-US" xlink:label="lab_rprx_StockIssuedDuringPeriodValueIssuedForRegistration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued For Registration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockIssuedDuringPeriodValueIssuedForRegistration" xlink:href="rprx-20211231.xsd#rprx_StockIssuedDuringPeriodValueIssuedForRegistration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_StockIssuedDuringPeriodValueIssuedForRegistration" xlink:to="lab_rprx_StockIssuedDuringPeriodValueIssuedForRegistration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_3c3099b1-5385-42a2-a51d-bda1bb566ac9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_d3ab7052-5b3d-463d-9f42-6601b9980ca6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_02e57695-43b2-4dc6-a596-f5b0718c8e27_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class A ordinary shares sold in IPO, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FormerOperatingAndPersonnelPaymentsMember_2c5c16ae-caff-4135-a252-14e2ba3d5f40_terseLabel_en-US" xlink:label="lab_rprx_FormerOperatingAndPersonnelPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Operating and Personnel Payments</link:label>
    <link:label id="lab_rprx_FormerOperatingAndPersonnelPaymentsMember_label_en-US" xlink:label="lab_rprx_FormerOperatingAndPersonnelPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Operating and Personnel Payments [Member]</link:label>
    <link:label id="lab_rprx_FormerOperatingAndPersonnelPaymentsMember_documentation_en-US" xlink:label="lab_rprx_FormerOperatingAndPersonnelPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Operating and Personnel Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FormerOperatingAndPersonnelPaymentsMember" xlink:href="rprx-20211231.xsd#rprx_FormerOperatingAndPersonnelPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FormerOperatingAndPersonnelPaymentsMember" xlink:to="lab_rprx_FormerOperatingAndPersonnelPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_cf4dcc36-1f9e-4b1c-84fa-8bdb08442d7a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from intangible royalty assets and Accrued royalty receivable</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_ae0e55a0-1be3-465c-b0a2-d26ec0e46026_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_51dfba97-69d2-448e-b038-7c14e98df4fe_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indirect Cash Flow</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_fc67ebb6-28af-4f0e-a350-5c405b6f988f_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_aa8a9d29-19db-4e2f-b88e-ce7ae65b7401_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_1c5df6f5-e9f5-460d-b1e8-d7d56a178b54_terseLabel_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of return</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_label_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Period of Return</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_documentation_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Period of Return</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn" xlink:to="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_a6fcf28e-63d2-46bc-9f86-ed2218a8053d_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_161cd03a-a0c6-4ccb-9d27-35b7c2d2545a_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_e378807a-1da7-4117-8e30-be8fc9f42e9c_terseLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_NumberOfNoncontrollingInterestsCreated_44e56302-ae63-44c6-9688-5610fa6810c2_terseLabel_en-US" xlink:label="lab_rprx_NumberOfNoncontrollingInterestsCreated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of noncontrolling interests created</link:label>
    <link:label id="lab_rprx_NumberOfNoncontrollingInterestsCreated_label_en-US" xlink:label="lab_rprx_NumberOfNoncontrollingInterestsCreated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Noncontrolling Interests Created</link:label>
    <link:label id="lab_rprx_NumberOfNoncontrollingInterestsCreated_documentation_en-US" xlink:label="lab_rprx_NumberOfNoncontrollingInterestsCreated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Noncontrolling Interests Created</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NumberOfNoncontrollingInterestsCreated" xlink:href="rprx-20211231.xsd#rprx_NumberOfNoncontrollingInterestsCreated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_NumberOfNoncontrollingInterestsCreated" xlink:to="lab_rprx_NumberOfNoncontrollingInterestsCreated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_8b653fe0-8d42-45b7-a3d2-581e2919a9c5_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_3010e28e-c7f0-4ca2-b780-3f9d8f713f05_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentTextBlock_dfd94c13-726c-4c0e-ab33-419f3914d0b2_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss, Financial Instrument [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossFinancialInstrumentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_6357f013-1549-45a4-8658-d764e079505f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and personnel payments incurred</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_e2d63a9e-1162-4e28-a230-fe5307cf5063_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation_c196b6ca-e922-4ff4-8f4d-47c8c525b45c_terseLabel_en-US" xlink:label="lab_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</link:label>
    <link:label id="lab_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation_label_en-US" xlink:label="lab_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Value, Effect Of Exchange And Reallocation</link:label>
    <link:label id="lab_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation_documentation_en-US" xlink:label="lab_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Value, Effect Of Exchange And Reallocation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation" xlink:href="rprx-20211231.xsd#rprx_StockholdersEquityValueEffectOfExchangeAndReallocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation" xlink:to="lab_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_3969db3d-08a2-4ffa-9a6f-4c2cc36b1d2a_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receipt of contribution of investments in Legacy Investors Partnerships</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Divestiture, Amount of Consideration Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:to="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_0c227fbc-ef51-40ec-9dd5-bb330d68d1d9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f989d984-3976-4add-a49e-90fde9f6d6f0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class A ordinary shares sold in initial public offering, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount_42d76cf5-9e06-4897-94ee-068dca7c1aca_terseLabel_en-US" xlink:label="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount calculated for operating and personal payment</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount_label_en-US" xlink:label="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Operating and Personal Payment Calculation, Amount</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount_documentation_en-US" xlink:label="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Operating and Personal Payment Calculation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" xlink:href="rprx-20211231.xsd#rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" xlink:to="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest_cf741087-f28d-4d94-9623-6c6eada0e6f3_terseLabel_en-US" xlink:label="lab_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from non-controlling interest</link:label>
    <link:label id="lab_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest_label_en-US" xlink:label="lab_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss) Reclassification Adjustment, Attributable From Noncontrolling Interest</link:label>
    <link:label id="lab_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest_documentation_en-US" xlink:label="lab_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss) Reclassification Adjustment, Attributable From Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest" xlink:href="rprx-20211231.xsd#rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest" xlink:to="lab_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IndividualLicenseesConcentrationRiskMember_f738c5d9-9271-46b9-b2b7-2ce2c50bfe80_terseLabel_en-US" xlink:label="lab_rprx_IndividualLicenseesConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual Licensees Concentration List</link:label>
    <link:label id="lab_rprx_IndividualLicenseesConcentrationRiskMember_label_en-US" xlink:label="lab_rprx_IndividualLicenseesConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual Licensees Concentration Risk [Member]</link:label>
    <link:label id="lab_rprx_IndividualLicenseesConcentrationRiskMember_documentation_en-US" xlink:label="lab_rprx_IndividualLicenseesConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual Licensees Concentration Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IndividualLicenseesConcentrationRiskMember" xlink:href="rprx-20211231.xsd#rprx_IndividualLicenseesConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IndividualLicenseesConcentrationRiskMember" xlink:to="lab_rprx_IndividualLicenseesConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_812cb593-e357-461b-a92e-bf07690b6a22_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_df29ece0-2287-40fc-8343-46ca0a4e683a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_0bd46eaf-d18d-4a3f-8a7d-ebc641f1d039_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense/(income), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_8caf1175-0ab3-495b-9638-304f6f8769ec_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for purchase of royalties</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_27ff3806-9df2-4d84-be6b-e46208ea764c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized share based compensation expense, period of recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_c3c542fd-8b16-436d-a5f5-41ff18bc987a_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2c1ff71d-74e5-44c3-b19e-f6b2bb8c6e4c_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of preparation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_7f792086-7b09-4c36-9679-1d916b9495e8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_0a425dbf-07a9-4ccc-b839-61600e6d4a16_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9a1caf6d-b7d3-492c-8dba-d2d1f3d7d300_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3110df09-d9e5-410b-8adb-a0c62846e818_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_22478fe6-fc0c-4d18-8731-f292cffdaa06_terseLabel_en-US" xlink:label="lab_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative collateral received</link:label>
    <link:label id="lab_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_label_en-US" xlink:label="lab_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Collateral Received On Derivative Instruments</link:label>
    <link:label id="lab_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_documentation_en-US" xlink:label="lab_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Collateral Received On Derivative Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments" xlink:href="rprx-20211231.xsd#rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments" xlink:to="lab_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_aca7770b-4543-458e-ab30-0709780bb70e_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_a8bb72bb-be05-4a58-bbdd-90f190e2e63a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs and other</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_e2f15890-ae23-40d4-89bd-bb7c6f6d13aa_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_c3cdebe5-8391-4c7e-ab8c-2796e6849676_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:to="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsToAcquireEquitySecuritiesFNNI_b385d723-02a4-4fdf-85c3-5793d4353248_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsToAcquireEquitySecuritiesFNNI" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equity securities</link:label>
    <link:label id="lab_rprx_PaymentsToAcquireEquitySecuritiesFNNI_label_en-US" xlink:label="lab_rprx_PaymentsToAcquireEquitySecuritiesFNNI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Securities, FN-NI</link:label>
    <link:label id="lab_rprx_PaymentsToAcquireEquitySecuritiesFNNI_documentation_en-US" xlink:label="lab_rprx_PaymentsToAcquireEquitySecuritiesFNNI" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Securities, FN-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireEquitySecuritiesFNNI" xlink:href="rprx-20211231.xsd#rprx_PaymentsToAcquireEquitySecuritiesFNNI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsToAcquireEquitySecuritiesFNNI" xlink:to="lab_rprx_PaymentsToAcquireEquitySecuritiesFNNI" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_78e9d058-342b-4414-83bd-84638a1e41ad_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_51d2434c-b46e-4286-a356-fdb8c7795178_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_7a737ffd-a45e-47a0-8486-47dd14337fed_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_96be09d6-0155-4cae-90c8-2088a6b954c7_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2b78ee4f-310b-4574-acd8-05d49638bee3_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested RSUs (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_f24e8b57-4ba5-4bc4-9196-444d4e97be60_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses/(income), net</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_6a2297ac-0b0f-4ed6-a562-ba0db6078c2f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity for the year</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_60aed2fa-b888-4fee-9ce3-bbd0e7d5dcea_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_33195777-4cef-4051-bfbd-d72edcca81f0_terseLabel_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum commitment to fund collaborative arrangement</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_label_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_documentation_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" xlink:to="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b408916d-8586-4571-9deb-f9814ecf7e17_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_db49e29c-771a-4b44-addd-7a940979f8af_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod_5c7c12ae-39ca-4a73-a4bc-9918a2b7411b_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on selling common stock, period</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Restriction Period</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Restriction Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PointSevenFivePercentSeniorNotesDue2023Member_853952a7-fd63-4289-b29a-8a8cc72e58ca_terseLabel_en-US" xlink:label="lab_rprx_PointSevenFivePercentSeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Point Seven Five Percent Senior Notes Due 2023</link:label>
    <link:label id="lab_rprx_PointSevenFivePercentSeniorNotesDue2023Member_label_en-US" xlink:label="lab_rprx_PointSevenFivePercentSeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Point Seven Five Percent Senior Notes Due 2023 [Member]</link:label>
    <link:label id="lab_rprx_PointSevenFivePercentSeniorNotesDue2023Member_documentation_en-US" xlink:label="lab_rprx_PointSevenFivePercentSeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Point Seven Five Percent Senior Notes Due 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PointSevenFivePercentSeniorNotesDue2023Member" xlink:href="rprx-20211231.xsd#rprx_PointSevenFivePercentSeniorNotesDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PointSevenFivePercentSeniorNotesDue2023Member" xlink:to="lab_rprx_PointSevenFivePercentSeniorNotesDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_d4f98ad5-fb97-4075-8c21-059c17f87bc7_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares purchased (in shares)</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Number Of Shares Purchased</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Number Of Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_00b90cd0-3eb9-44d1-bd84-cc5b4890a301_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DPPIVPatentsMember_548b31c2-dccb-4365-968f-c468feac94fc_terseLabel_en-US" xlink:label="lab_rprx_DPPIVPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DPP-IV patents</link:label>
    <link:label id="lab_rprx_DPPIVPatentsMember_label_en-US" xlink:label="lab_rprx_DPPIVPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DPP-IV Patents [Member]</link:label>
    <link:label id="lab_rprx_DPPIVPatentsMember_documentation_en-US" xlink:label="lab_rprx_DPPIVPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DPP-IV Patents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DPPIVPatentsMember" xlink:href="rprx-20211231.xsd#rprx_DPPIVPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DPPIVPatentsMember" xlink:to="lab_rprx_DPPIVPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_463ee488-4968-4671-b73e-adaf8a0dc896_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_f65e096d-b28a-43c0-b1c3-af9f2ea6c33b_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_68072d60-e615-4eb7-a208-7613adebe029_terseLabel_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of capital</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_label_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Payment of Capital</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_documentation_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Payment of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital" xlink:to="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_a75852ce-7170-488a-8f45-c91c3f398dba_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_3667e2f1-d71d-4b9b-8d20-28ecde4facf3_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_2c2eef23-2499-41af-a811-d3b11107bb71_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease/(increase) in operating assets:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CommonStockExchangeRatio_2577d07c-fd90-4076-838e-3ed58a1da21b_terseLabel_en-US" xlink:label="lab_rprx_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange ratio</link:label>
    <link:label id="lab_rprx_CommonStockExchangeRatio_label_en-US" xlink:label="lab_rprx_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Exchange Ratio</link:label>
    <link:label id="lab_rprx_CommonStockExchangeRatio_documentation_en-US" xlink:label="lab_rprx_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Exchange Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CommonStockExchangeRatio" xlink:href="rprx-20211231.xsd#rprx_CommonStockExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CommonStockExchangeRatio" xlink:to="lab_rprx_CommonStockExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_71b1844f-d1a9-4f27-bdf1-4d9f62259778_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AvillionEntitiesMember_4db515be-f365-4b74-8a77-3c5bfe4a1c75_terseLabel_en-US" xlink:label="lab_rprx_AvillionEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion Entities</link:label>
    <link:label id="lab_rprx_AvillionEntitiesMember_label_en-US" xlink:label="lab_rprx_AvillionEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion Entities [Member]</link:label>
    <link:label id="lab_rprx_AvillionEntitiesMember_documentation_en-US" xlink:label="lab_rprx_AvillionEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion Entities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionEntitiesMember" xlink:href="rprx-20211231.xsd#rprx_AvillionEntitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AvillionEntitiesMember" xlink:to="lab_rprx_AvillionEntitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_adb2fbc6-0577-41e3-b702-b4d8709bd596_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Value, net</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_b47231c6-eec1-4691-8430-16b53641fdb3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_c8904657-e631-4506-ad59-b85ec6fdd858_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of loss on interest rate swaps</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_SeniorUnsecuredRevolvingCreditFacilityMember_2be1d643-19ca-4f51-8266-66b6e9106c96_terseLabel_en-US" xlink:label="lab_rprx_SeniorUnsecuredRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Revolving Credit Facility</link:label>
    <link:label id="lab_rprx_SeniorUnsecuredRevolvingCreditFacilityMember_label_en-US" xlink:label="lab_rprx_SeniorUnsecuredRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_rprx_SeniorUnsecuredRevolvingCreditFacilityMember_documentation_en-US" xlink:label="lab_rprx_SeniorUnsecuredRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Revolving Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorUnsecuredRevolvingCreditFacilityMember" xlink:href="rprx-20211231.xsd#rprx_SeniorUnsecuredRevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_SeniorUnsecuredRevolvingCreditFacilityMember" xlink:to="lab_rprx_SeniorUnsecuredRevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtInstrumentIssuanceAsAPercentOfPar_5b8adbd0-4f2d-4ba3-92f5-2c76e1fe8fc4_terseLabel_en-US" xlink:label="lab_rprx_DebtInstrumentIssuanceAsAPercentOfPar" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issued as a percent of par value (as a percent)</link:label>
    <link:label id="lab_rprx_DebtInstrumentIssuanceAsAPercentOfPar_label_en-US" xlink:label="lab_rprx_DebtInstrumentIssuanceAsAPercentOfPar" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Issuance As A Percent Of Par</link:label>
    <link:label id="lab_rprx_DebtInstrumentIssuanceAsAPercentOfPar_documentation_en-US" xlink:label="lab_rprx_DebtInstrumentIssuanceAsAPercentOfPar" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Issuance As A Percent Of Par</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentIssuanceAsAPercentOfPar" xlink:href="rprx-20211231.xsd#rprx_DebtInstrumentIssuanceAsAPercentOfPar"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtInstrumentIssuanceAsAPercentOfPar" xlink:to="lab_rprx_DebtInstrumentIssuanceAsAPercentOfPar" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member_1b6abe3e-a69f-4543-9887-f516350e9a34_terseLabel_en-US" xlink:label="lab_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Five Five Percent Senior Notes Due 2050</link:label>
    <link:label id="lab_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member_label_en-US" xlink:label="lab_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Five Five Percent Senior Notes Due 2050 [Member]</link:label>
    <link:label id="lab_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member_documentation_en-US" xlink:label="lab_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Five Five Percent Senior Notes Due 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member" xlink:href="rprx-20211231.xsd#rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member" xlink:to="lab_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsForUpfrontDevelopmentStageFunding_e7f2185a-af1d-4781-b17a-06d700fe1d15_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsForUpfrontDevelopmentStageFunding" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront development-stage funding payments</link:label>
    <link:label id="lab_rprx_PaymentsForUpfrontDevelopmentStageFunding_label_en-US" xlink:label="lab_rprx_PaymentsForUpfrontDevelopmentStageFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Upfront Development Stage Funding</link:label>
    <link:label id="lab_rprx_PaymentsForUpfrontDevelopmentStageFunding_documentation_en-US" xlink:label="lab_rprx_PaymentsForUpfrontDevelopmentStageFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Upfront Development Stage Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForUpfrontDevelopmentStageFunding" xlink:href="rprx-20211231.xsd#rprx_PaymentsForUpfrontDevelopmentStageFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsForUpfrontDevelopmentStageFunding" xlink:to="lab_rprx_PaymentsForUpfrontDevelopmentStageFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_2784b755-eab4-4769-966f-8fad6956d54c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_94e44549-634e-411a-9bdd-9230ba0d7171_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_1d3f61c6-009a-4dcc-9c6b-1fa7ca6d3d94_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest_32ab7dd2-ff82-45f2-a1f0-5778b0212aaf_negatedTerseLabel_en-US" xlink:label="lab_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification to non-controlling interest</link:label>
    <link:label id="lab_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment, Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest_documentation_en-US" xlink:label="lab_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest" xlink:href="rprx-20211231.xsd#rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest" xlink:to="lab_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLoansAndLeasesReceivablePolicy_d730557d-ef3d-4631-b420-db9efe355c88_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial royalty assets, net</link:label>
    <link:label id="lab_us-gaap_FinanceLoansAndLeasesReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLoansAndLeasesReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:to="lab_us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PabloLegorretaMember_6ab274ba-6cb1-413a-92f7-18b16d35f1b9_terseLabel_en-US" xlink:label="lab_rprx_PabloLegorretaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pablo Legorreta</link:label>
    <link:label id="lab_rprx_PabloLegorretaMember_label_en-US" xlink:label="lab_rprx_PabloLegorretaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pablo Legorreta [Member]</link:label>
    <link:label id="lab_rprx_PabloLegorretaMember_documentation_en-US" xlink:label="lab_rprx_PabloLegorretaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pablo Legorreta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PabloLegorretaMember" xlink:href="rprx-20211231.xsd#rprx_PabloLegorretaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PabloLegorretaMember" xlink:to="lab_rprx_PabloLegorretaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_eeecbffc-fcbc-4ef6-b70a-8a5fc05c6580_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio_e62a5ab2-6175-4e4b-91b3-483f4eb491e7_terseLabel_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum consolidated coverage ratio</link:label>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio_label_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio</link:label>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio_documentation_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" xlink:href="rprx-20211231.xsd#rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" xlink:to="lab_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_5029f073-89c6-4140-974d-b06aecd80588_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_815c728e-da03-4c01-a31b-76372cec5ec2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_56959fce-110b-4bf7-898b-7fa400fb6af9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent_ce694af7-4d08-4da1-aaf6-590b53f94e38_terseLabel_en-US" xlink:label="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent for calculating operating and personal payment</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent_label_en-US" xlink:label="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Operating and Personal Payment Calculation, Percent</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent_documentation_en-US" xlink:label="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Operating and Personal Payment Calculation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" xlink:href="rprx-20211231.xsd#rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" xlink:to="lab_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_85461afd-a150-45d9-805e-25a1db9ea30a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_e0ec967e-7d96-491b-a408-7119cfe6087b_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_48fbdf09-0352-4b41-9653-3512a4b68153_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_720be60a-6190-4adb-8c7d-c83b9cba9319_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer to Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_d6aed11f-600b-43c9-a470-3853fe8d7700_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7a0cb4c8-1b00-4ebd-a6cc-caa4bacd90ab_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_504973ce-0909-4bc8-91f8-27bd07834752_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member_786f81cd-f5c1-4b97-bb88-c84998232bc8_terseLabel_en-US" xlink:label="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1</link:label>
    <link:label id="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member_label_en-US" xlink:label="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1 [Member]</link:label>
    <link:label id="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member_documentation_en-US" xlink:label="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member" xlink:href="rprx-20211231.xsd#rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member" xlink:to="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_UnitHoldersAndShareholdersContributionsMember_9eee3f45-2ae3-41ba-85d7-343178d4b0d7_terseLabel_en-US" xlink:label="lab_rprx_UnitHoldersAndShareholdersContributionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unitholders&#8217;/ Shareholders&#8217; Contributions</link:label>
    <link:label id="lab_rprx_UnitHoldersAndShareholdersContributionsMember_label_en-US" xlink:label="lab_rprx_UnitHoldersAndShareholdersContributionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unit Holders' and Shareholders' Contributions [Member]</link:label>
    <link:label id="lab_rprx_UnitHoldersAndShareholdersContributionsMember_documentation_en-US" xlink:label="lab_rprx_UnitHoldersAndShareholdersContributionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unit Holders' and Shareholders' Contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_UnitHoldersAndShareholdersContributionsMember" xlink:href="rprx-20211231.xsd#rprx_UnitHoldersAndShareholdersContributionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_UnitHoldersAndShareholdersContributionsMember" xlink:to="lab_rprx_UnitHoldersAndShareholdersContributionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_0cee2aac-f52d-4f32-b263-710ee8448829_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount paid to CEO</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_8b8e3db4-5c17-427c-92d4-f8011056c993_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_6ad40458-1b3e-41b8-9868-1c1b33ab69a8_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_afd2526e-7ca9-4933-853e-0174607e643d_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Interests</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_b4fb4dcc-747d-4dea-ba1d-7053de1a03ca_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_SeniorNotesDue2051Member_3bdccea2-0c42-436b-ab7e-c42badd91ce4_terseLabel_en-US" xlink:label="lab_rprx_SeniorNotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2051</link:label>
    <link:label id="lab_rprx_SeniorNotesDue2051Member_label_en-US" xlink:label="lab_rprx_SeniorNotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2051 [Member]</link:label>
    <link:label id="lab_rprx_SeniorNotesDue2051Member_documentation_en-US" xlink:label="lab_rprx_SeniorNotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorNotesDue2051Member" xlink:href="rprx-20211231.xsd#rprx_SeniorNotesDue2051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_SeniorNotesDue2051Member" xlink:to="lab_rprx_SeniorNotesDue2051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AZAssetPhaseIIAndPhaseIIIClinicalTrialMember_60bf216c-9225-417c-8cb8-ef7fc95021af_terseLabel_en-US" xlink:label="lab_rprx_AZAssetPhaseIIAndPhaseIIIClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AZ Asset - Phase II and Phase III Clinical Trial</link:label>
    <link:label id="lab_rprx_AZAssetPhaseIIAndPhaseIIIClinicalTrialMember_label_en-US" xlink:label="lab_rprx_AZAssetPhaseIIAndPhaseIIIClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AZ Asset - Phase II and Phase III Clinical Trial [Member]</link:label>
    <link:label id="lab_rprx_AZAssetPhaseIIAndPhaseIIIClinicalTrialMember_documentation_en-US" xlink:label="lab_rprx_AZAssetPhaseIIAndPhaseIIIClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AZ Asset - Phase II and Phase III Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AZAssetPhaseIIAndPhaseIIIClinicalTrialMember" xlink:href="rprx-20211231.xsd#rprx_AZAssetPhaseIIAndPhaseIIIClinicalTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AZAssetPhaseIIAndPhaseIIIClinicalTrialMember" xlink:to="lab_rprx_AZAssetPhaseIIAndPhaseIIIClinicalTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_9ef7310f-6340-4a57-9ba7-29e71de2358a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_67f2599b-35ed-47c3-afd4-d715a3a8c66b_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses on derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4d649c46-b172-4ee2-aa6d-03a1ce167ca7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_436eb8d4-e09a-445e-aa44-69bc0f370eb2_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6e45d0d0-b788-49c3-accf-2915d6890a6b_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsToAcquireWarrants_5d7e7cf7-6407-44a1-b352-7d2b22f62e54_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsToAcquireWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of warrants</link:label>
    <link:label id="lab_rprx_PaymentsToAcquireWarrants_label_en-US" xlink:label="lab_rprx_PaymentsToAcquireWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Warrants</link:label>
    <link:label id="lab_rprx_PaymentsToAcquireWarrants_documentation_en-US" xlink:label="lab_rprx_PaymentsToAcquireWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireWarrants" xlink:href="rprx-20211231.xsd#rprx_PaymentsToAcquireWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsToAcquireWarrants" xlink:to="lab_rprx_PaymentsToAcquireWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember_ecbfaf79-7650-4406-ae54-0cd617d12090_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain/(loss) on available for sale debt securities, noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_b505f8a6-0548-4234-8a43-976c41041c21_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term funding partnership, additional payments, aggregate amount</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_label_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Additional Payments, Aggregate Amount</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_documentation_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Additional Payments, Aggregate Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" xlink:href="rprx-20211231.xsd#rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" xlink:to="lab_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_051553ed-0b61-433b-bfb7-2b57f1a12982_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charge</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_99975874-b77c-4db0-9725-c89ffd59b3b7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase additional shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio_fdeca922-0886-4f6b-9272-2091e5946318_terseLabel_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum consolidated leverage ratio</link:label>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio_label_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio</link:label>
    <link:label id="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio_documentation_en-US" xlink:label="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" xlink:href="rprx-20211231.xsd#rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" xlink:to="lab_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_6175ecb7-a246-4081-bc50-9bbad1ad9f92_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableNet_a19f3fb9-68d5-4126-9c9f-a1ade4e4da8e_totalLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying value</link:label>
    <link:label id="lab_us-gaap_NotesReceivableNet_1f713c90-4e4b-4cce-9793-8cf70e5c6b66_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial royalty asset, net</link:label>
    <link:label id="lab_us-gaap_NotesReceivableNet_label_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableNet" xlink:to="lab_us-gaap_NotesReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_54a71354-edc1-47a1-8cfd-3189b1a7b3f3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-operating expense/(income), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_ef2837c6-6825-4dfb-8a84-82a96a3676df_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of outstanding Notes</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_18891575-8d27-48a9-8c20-02d50a0772a2_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember_0d6b8c5b-364f-40e4-9e59-9400c88e8fe7_terseLabel_en-US" xlink:label="lab_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Distribution Payable to RP Select Finance Trust</link:label>
    <link:label id="lab_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember_label_en-US" xlink:label="lab_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Distribution Payable to RP Select Finance Trust [Member]</link:label>
    <link:label id="lab_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember_documentation_en-US" xlink:label="lab_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Distribution Payable to RP Select Finance Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember" xlink:href="rprx-20211231.xsd#rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember" xlink:to="lab_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossAbstract_label_en-US" xlink:label="lab_us-gaap_CreditLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossAbstract" xlink:to="lab_us-gaap_CreditLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_668c479a-0a9c-44df-ab02-ea99640959c6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_72613ece-e1ad-47f6-b2b9-c13939f14e69_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_83e2d540-7177-4545-937b-62125c28a0b6_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsForDistributionsToShareholdersAndUnitholders_9bdbc81e-feba-44db-908f-0a1df781028b_negatedLabel_en-US" xlink:label="lab_rprx_PaymentsForDistributionsToShareholdersAndUnitholders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to shareholders/unitholders</link:label>
    <link:label id="lab_rprx_PaymentsForDistributionsToShareholdersAndUnitholders_label_en-US" xlink:label="lab_rprx_PaymentsForDistributionsToShareholdersAndUnitholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Distributions To Shareholders and Unitholders</link:label>
    <link:label id="lab_rprx_PaymentsForDistributionsToShareholdersAndUnitholders_documentation_en-US" xlink:label="lab_rprx_PaymentsForDistributionsToShareholdersAndUnitholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Distributions To Shareholders and Unitholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForDistributionsToShareholdersAndUnitholders" xlink:href="rprx-20211231.xsd#rprx_PaymentsForDistributionsToShareholdersAndUnitholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsForDistributionsToShareholdersAndUnitholders" xlink:to="lab_rprx_PaymentsForDistributionsToShareholdersAndUnitholders" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DeferredSharesParOrStatedValuePerShare_eb6c2ec0-a978-4a03-97e8-d2ad90d5cdf0_terseLabel_en-US" xlink:label="lab_rprx_DeferredSharesParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_rprx_DeferredSharesParOrStatedValuePerShare_label_en-US" xlink:label="lab_rprx_DeferredSharesParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares, Par or Stated Value Per Share</link:label>
    <link:label id="lab_rprx_DeferredSharesParOrStatedValuePerShare_documentation_en-US" xlink:label="lab_rprx_DeferredSharesParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesParOrStatedValuePerShare" xlink:href="rprx-20211231.xsd#rprx_DeferredSharesParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DeferredSharesParOrStatedValuePerShare" xlink:to="lab_rprx_DeferredSharesParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_c0787b41-5c6b-4fc2-824a-e9c94f66ab26_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_434a538f-9fa3-40cd-abc0-1a5fa66f6d83_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected amortization expense, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OldCreditFacilityMember_46ae0361-f02a-4901-99f8-4f34c9f17999_terseLabel_en-US" xlink:label="lab_rprx_OldCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Old Credit Facility</link:label>
    <link:label id="lab_rprx_OldCreditFacilityMember_label_en-US" xlink:label="lab_rprx_OldCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Old Credit Facility [Member]</link:label>
    <link:label id="lab_rprx_OldCreditFacilityMember_documentation_en-US" xlink:label="lab_rprx_OldCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Old Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OldCreditFacilityMember" xlink:href="rprx-20211231.xsd#rprx_OldCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OldCreditFacilityMember" xlink:to="lab_rprx_OldCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_811f3e59-1f36-4270-85a6-f4ca247c43aa_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RedeemableStockRedemptionPricePerShare_79d7a37f-2745-4b44-9101-a82b24134dd4_terseLabel_en-US" xlink:label="lab_rprx_RedeemableStockRedemptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable stock, redemption price (in euros per share)</link:label>
    <link:label id="lab_rprx_RedeemableStockRedemptionPricePerShare_label_en-US" xlink:label="lab_rprx_RedeemableStockRedemptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Stock, Redemption Price Per Share</link:label>
    <link:label id="lab_rprx_RedeemableStockRedemptionPricePerShare_documentation_en-US" xlink:label="lab_rprx_RedeemableStockRedemptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Stock, Redemption Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RedeemableStockRedemptionPricePerShare" xlink:href="rprx-20211231.xsd#rprx_RedeemableStockRedemptionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RedeemableStockRedemptionPricePerShare" xlink:to="lab_rprx_RedeemableStockRedemptionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e23e896b-be1c-432c-a945-fec78801be7e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_473a304f-6a09-4bc1-b615-c77072d316a2_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5697b598-5ad1-46dc-b2bd-0a1195d63080_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_1912a126-e150-4058-9bd3-03d1553c2d92_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" xlink:to="lab_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_EquityMethodInvestmentsUnfundedCommitments_80419096-2e51-4a82-a590-30dbee66c32c_terseLabel_en-US" xlink:label="lab_rprx_EquityMethodInvestmentsUnfundedCommitments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, unfunded commitments</link:label>
    <link:label id="lab_rprx_EquityMethodInvestmentsUnfundedCommitments_label_en-US" xlink:label="lab_rprx_EquityMethodInvestmentsUnfundedCommitments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Unfunded Commitments</link:label>
    <link:label id="lab_rprx_EquityMethodInvestmentsUnfundedCommitments_documentation_en-US" xlink:label="lab_rprx_EquityMethodInvestmentsUnfundedCommitments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Unfunded Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EquityMethodInvestmentsUnfundedCommitments" xlink:href="rprx-20211231.xsd#rprx_EquityMethodInvestmentsUnfundedCommitments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_EquityMethodInvestmentsUnfundedCommitments" xlink:to="lab_rprx_EquityMethodInvestmentsUnfundedCommitments" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentOfDividendsToShareholders_aa997e61-3fc4-456b-bd63-3d094aca26f0_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentOfDividendsToShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends to shareholders</link:label>
    <link:label id="lab_rprx_PaymentOfDividendsToShareholders_label_en-US" xlink:label="lab_rprx_PaymentOfDividendsToShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Dividends To Shareholders</link:label>
    <link:label id="lab_rprx_PaymentOfDividendsToShareholders_documentation_en-US" xlink:label="lab_rprx_PaymentOfDividendsToShareholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Dividends To Shareholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentOfDividendsToShareholders" xlink:href="rprx-20211231.xsd#rprx_PaymentOfDividendsToShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentOfDividendsToShareholders" xlink:to="lab_rprx_PaymentOfDividendsToShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_2f15b941-c3d1-4b6a-ae57-9f668cbad1f0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Consolidated Affiliates</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_165f1e48-d71d-4f58-ae07-9fedf3902150_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ManagementMember_4cf63ad2-81c8-4915-89e3-0c6e1301b200_terseLabel_en-US" xlink:label="lab_srt_ManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Manager</link:label>
    <link:label id="lab_srt_ManagementMember_label_en-US" xlink:label="lab_srt_ManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ManagementMember" xlink:to="lab_srt_ManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_0cf5f81e-11d2-4586-a3ad-7543e406fd73_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_da9c6bab-6d7e-4b87-bd9d-4306efcad321_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_7f38eef5-9258-471d-a858-65d65ad473fd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_45f34fb5-c745-491a-9354-f3c2717d8a2a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains included in earnings</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_9792c8d8-9555-46e9-ac93-091d10f1dbf6_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Royalty Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_0e65e078-24c1-45e7-9336-95e25c4c1f09_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in non-consolidated affiliates</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_66ca93c2-8fae-4a88-bcaa-011470903b37_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury interests</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_6fa3d71c-e65b-46e3-9e76-656907ad8b68_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_555c0f23-d257-46f0-9cd9-4fe7c0d0bf1f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_8591b5d4-2767-44ea-a597-90e39db69673_terseLabel_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum milestone payment</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_label_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_documentation_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" xlink:to="lab_rprx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancingReceivablesFairValueDisclosure_77feb9cb-5ab3-4388-bb26-17444e6c740c_terseLabel_en-US" xlink:label="lab_rprx_FinancingReceivablesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial royalty assets, net</link:label>
    <link:label id="lab_rprx_FinancingReceivablesFairValueDisclosure_label_en-US" xlink:label="lab_rprx_FinancingReceivablesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivables, Fair Value Disclosure</link:label>
    <link:label id="lab_rprx_FinancingReceivablesFairValueDisclosure_documentation_en-US" xlink:label="lab_rprx_FinancingReceivablesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivables, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivablesFairValueDisclosure" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivablesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancingReceivablesFairValueDisclosure" xlink:to="lab_rprx_FinancingReceivablesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_af90eefc-c4e2-41ac-a18f-6e71e59613ae_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of credit risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_4342f22f-9165-45cf-a25d-4bb34a63a9b7_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_480fdec8-2fc4-4821-acf3-eb56e9393654_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_b9789366-67df-496c-9448-215655254d2f_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_83753203-a785-4072-8adf-afc9e3f3ad3d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other exchanges (in shares)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOtherShares" xlink:to="lab_us-gaap_StockholdersEquityOtherShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_13e80dea-068e-4cd2-a283-aa78d01ebcb0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:to="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment_4973faaf-85cb-4397-b2ca-d9bece7860a2_terseLabel_en-US" xlink:label="lab_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from non-controlling interest- R&amp;D</link:label>
    <link:label id="lab_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment_label_en-US" xlink:label="lab_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Noncontrolling Interests, Research And Development</link:label>
    <link:label id="lab_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment_documentation_en-US" xlink:label="lab_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Noncontrolling Interests, Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment" xlink:href="rprx-20211231.xsd#rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment" xlink:to="lab_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_e0c03e69-7d90-4df4-b628-7a3e43462282_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_71559476-3fe8-4e7f-b309-7a17c65aa2dc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issued, amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_274f064d-8b56-47e0-80a9-43b75561371e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_45fb429e-3dbc-402c-848c-cadd7c060bf1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average effective interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_39bbb0e3-b90c-4614-8599-65fa0ffe75e6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_BristolMyersSquibbMember_238250a3-be19-44a9-b4e2-efcb613ef488_terseLabel_en-US" xlink:label="lab_rprx_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb</link:label>
    <link:label id="lab_rprx_BristolMyersSquibbMember_label_en-US" xlink:label="lab_rprx_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb [Member]</link:label>
    <link:label id="lab_rprx_BristolMyersSquibbMember_documentation_en-US" xlink:label="lab_rprx_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_BristolMyersSquibbMember" xlink:href="rprx-20211231.xsd#rprx_BristolMyersSquibbMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_BristolMyersSquibbMember" xlink:to="lab_rprx_BristolMyersSquibbMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IntangibleRoyaltyAssetsMember_1ce45a80-f15b-4d59-a33d-cb223663fd84_terseLabel_en-US" xlink:label="lab_rprx_IntangibleRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from intangible royalty assets</link:label>
    <link:label id="lab_rprx_IntangibleRoyaltyAssetsMember_label_en-US" xlink:label="lab_rprx_IntangibleRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Royalty Assets [Member]</link:label>
    <link:label id="lab_rprx_IntangibleRoyaltyAssetsMember_documentation_en-US" xlink:label="lab_rprx_IntangibleRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Royalty Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IntangibleRoyaltyAssetsMember" xlink:href="rprx-20211231.xsd#rprx_IntangibleRoyaltyAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IntangibleRoyaltyAssetsMember" xlink:to="lab_rprx_IntangibleRoyaltyAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_db51e0ae-6e44-40a8-af50-d79ec3c831d6_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_f19b15d9-bd1d-4768-bef3-1f070cb5ea73_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_706a9d91-78b2-49ee-9e57-eb1bf7d6ef4b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsToTerminateDerivativeInstruments_d8b2a19f-3df5-474f-ab81-28a8c5c0b728_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsToTerminateDerivativeInstruments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination payments on derivative instruments</link:label>
    <link:label id="lab_rprx_PaymentsToTerminateDerivativeInstruments_6dad9865-52ac-406f-9bbf-42c16e1252d4_verboseLabel_en-US" xlink:label="lab_rprx_PaymentsToTerminateDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap termination payments</link:label>
    <link:label id="lab_rprx_PaymentsToTerminateDerivativeInstruments_label_en-US" xlink:label="lab_rprx_PaymentsToTerminateDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Terminate Derivative Instruments</link:label>
    <link:label id="lab_rprx_PaymentsToTerminateDerivativeInstruments_documentation_en-US" xlink:label="lab_rprx_PaymentsToTerminateDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Terminate Derivative Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToTerminateDerivativeInstruments" xlink:href="rprx-20211231.xsd#rprx_PaymentsToTerminateDerivativeInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsToTerminateDerivativeInstruments" xlink:to="lab_rprx_PaymentsToTerminateDerivativeInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_d1be0d5c-9be4-4246-83ae-d7e20933a65d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Derivatives and Reclassifications</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_0cf39f78-5cbe-4604-b4b1-7afe63de1188_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in non-consolidated affiliates</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_cd957464-caeb-49af-b843-74af755a08ce_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts_653c08bc-757c-4304-a08b-ce28a36e7fe1_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative contracts</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives and Commodity Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_58729215-ad53-4d13-957f-67d5fe732314_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2af8c54c-99d8-42d4-a148-c6ea30d7b7ab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OptionIndexedToIssuersEquityTerm_0b227ffc-6ab5-425e-aa9d-c1f0f854e0f5_terseLabel_en-US" xlink:label="lab_rprx_OptionIndexedToIssuersEquityTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put option, term (in months)</link:label>
    <link:label id="lab_rprx_OptionIndexedToIssuersEquityTerm_label_en-US" xlink:label="lab_rprx_OptionIndexedToIssuersEquityTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Term</link:label>
    <link:label id="lab_rprx_OptionIndexedToIssuersEquityTerm_documentation_en-US" xlink:label="lab_rprx_OptionIndexedToIssuersEquityTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OptionIndexedToIssuersEquityTerm" xlink:href="rprx-20211231.xsd#rprx_OptionIndexedToIssuersEquityTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OptionIndexedToIssuersEquityTerm" xlink:to="lab_rprx_OptionIndexedToIssuersEquityTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IPOContinuingInvestorsPartnershipsMember_f73b4774-a9b9-442a-ab14-56bc292762cc_terseLabel_en-US" xlink:label="lab_rprx_IPOContinuingInvestorsPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering - Continuing Investors Partnerships Interests</link:label>
    <link:label id="lab_rprx_IPOContinuingInvestorsPartnershipsMember_label_en-US" xlink:label="lab_rprx_IPOContinuingInvestorsPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO - Continuing Investors Partnerships [Member]</link:label>
    <link:label id="lab_rprx_IPOContinuingInvestorsPartnershipsMember_documentation_en-US" xlink:label="lab_rprx_IPOContinuingInvestorsPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO - Continuing Investors Partnerships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IPOContinuingInvestorsPartnershipsMember" xlink:href="rprx-20211231.xsd#rprx_IPOContinuingInvestorsPartnershipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IPOContinuingInvestorsPartnershipsMember" xlink:to="lab_rprx_IPOContinuingInvestorsPartnershipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_MorphoSysMember_fb892b61-c37a-45eb-8282-a888704af8a6_terseLabel_en-US" xlink:label="lab_rprx_MorphoSysMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MorphoSys</link:label>
    <link:label id="lab_rprx_MorphoSysMember_label_en-US" xlink:label="lab_rprx_MorphoSysMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MorphoSys [Member]</link:label>
    <link:label id="lab_rprx_MorphoSysMember_documentation_en-US" xlink:label="lab_rprx_MorphoSysMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MorphoSys</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MorphoSysMember" xlink:href="rprx-20211231.xsd#rprx_MorphoSysMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_MorphoSysMember" xlink:to="lab_rprx_MorphoSysMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_72e16f05-8b51-4e4a-bf32-72a0cd4158d3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ClassBHoldersMember_f3a50fa1-1592-49fb-ae77-dc8e62d59142_terseLabel_en-US" xlink:label="lab_rprx_ClassBHoldersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Holders</link:label>
    <link:label id="lab_rprx_ClassBHoldersMember_label_en-US" xlink:label="lab_rprx_ClassBHoldersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Holders [Member]</link:label>
    <link:label id="lab_rprx_ClassBHoldersMember_documentation_en-US" xlink:label="lab_rprx_ClassBHoldersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassBHoldersMember" xlink:href="rprx-20211231.xsd#rprx_ClassBHoldersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ClassBHoldersMember" xlink:to="lab_rprx_ClassBHoldersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a6cbae99-446a-4874-b5d9-fc8c18d958c9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e3fd9845-0b31-4c1a-9be6-3a732fa05b73_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1744f1cb-d137-4268-80d5-6402e881ade9_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c0f7bcec-e96d-4380-89fd-f5cc15f2ca9e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_27337fcd-5592-4065-9936-65a0b3c0e171_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c01075e6-a123-4684-8bff-5e3080e8e53c_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative adjustment</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a26f12fe-9982-4b0e-8266-a1356ad96f52_negatedLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative adjustment to retained earnings</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_a458f71b-33d9-4ba7-aff9-dd110ea2f1fc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_42386772-16c2-4c30-9825-0f6475c0bdfe_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_21e7f624-3800-492e-9ac1-56a27502355e_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_047ef998-74d5-4b16-81b9-6dc4eaf0c1ed_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt, net of discount</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PurchaseCommitmentAdditionalPayment_06d4210e-5be2-4cdb-a51e-529b56d0d8b0_terseLabel_en-US" xlink:label="lab_rprx_PurchaseCommitmentAdditionalPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitment, additional payments</link:label>
    <link:label id="lab_rprx_PurchaseCommitmentAdditionalPayment_label_en-US" xlink:label="lab_rprx_PurchaseCommitmentAdditionalPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Additional Payment</link:label>
    <link:label id="lab_rprx_PurchaseCommitmentAdditionalPayment_documentation_en-US" xlink:label="lab_rprx_PurchaseCommitmentAdditionalPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Additional Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PurchaseCommitmentAdditionalPayment" xlink:href="rprx-20211231.xsd#rprx_PurchaseCommitmentAdditionalPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PurchaseCommitmentAdditionalPayment" xlink:to="lab_rprx_PurchaseCommitmentAdditionalPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_c621e7aa-42b7-4b45-8cb2-38004c585291_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_925e67da-a47f-4f81-b5b3-64355b2157c1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e650ede1-75d4-481f-aabe-3206722270e7_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AccruedPurchaseObligationCurrent_52c60427-1b47-49b0-9e6d-dc5d72d3316c_terseLabel_en-US" xlink:label="lab_rprx_AccruedPurchaseObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued purchase obligation</link:label>
    <link:label id="lab_rprx_AccruedPurchaseObligationCurrent_label_en-US" xlink:label="lab_rprx_AccruedPurchaseObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Purchase Obligation, Current</link:label>
    <link:label id="lab_rprx_AccruedPurchaseObligationCurrent_documentation_en-US" xlink:label="lab_rprx_AccruedPurchaseObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Purchase Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AccruedPurchaseObligationCurrent" xlink:href="rprx-20211231.xsd#rprx_AccruedPurchaseObligationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AccruedPurchaseObligationCurrent" xlink:to="lab_rprx_AccruedPurchaseObligationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c4164938-5b77-4c25-9658-414b55dbf6d3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_72711d8a-5af1-4a1f-b457-741e7e1ec597_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_b6f2031b-7a96-4da3-a986-ca251a5c9bf7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_a4d07bf5-c1fc-428f-bec5-8854b4b19e67_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c86b5266-6606-44fc-abaa-f44d41cc03df_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average Class A ordinary shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_520b31c0-c8e6-45b9-93e3-31cc891a0561_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_453daad1-ef8b-4091-8e76-34bba9203aa5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Balance Of Non-controlling Interests</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders Equity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_1cd98eaf-16f7-4fca-92e3-bcdec3e43d80_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period [Axis]</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period [Axis]</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_7103f4e9-50cf-4c19-85f3-23be4a0adafe_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5780b71c-8d02-46af-bea2-16d0f2f418fd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OptionIndexedToIssuersEquityValue_c88a62ba-7566-4f31-aaae-ec4188b98aee_terseLabel_en-US" xlink:label="lab_rprx_OptionIndexedToIssuersEquityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put option to sell additional common stock</link:label>
    <link:label id="lab_rprx_OptionIndexedToIssuersEquityValue_label_en-US" xlink:label="lab_rprx_OptionIndexedToIssuersEquityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed To Issuers Equity, Value</link:label>
    <link:label id="lab_rprx_OptionIndexedToIssuersEquityValue_documentation_en-US" xlink:label="lab_rprx_OptionIndexedToIssuersEquityValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed To Issuers Equity, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OptionIndexedToIssuersEquityValue" xlink:href="rprx-20211231.xsd#rprx_OptionIndexedToIssuersEquityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OptionIndexedToIssuersEquityValue" xlink:to="lab_rprx_OptionIndexedToIssuersEquityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_d288ada5-4830-4c30-b48e-ea330ba787b3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement of forwards</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_5b615df3-9106-4dd5-9b90-7b1dee76b6c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_15ccd3f9-6a1b-4670-a0a6-f350a04a66a9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_682d8a60-643e-47bc-9ad0-07614e0e9358_negatedNetLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_32af26e0-5221-463d-b458-7e90d4f3cb3a_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_NumberOfNoncontrollingInterests_719d3456-d26a-4f4f-b479-92a7697d4699_terseLabel_en-US" xlink:label="lab_rprx_NumberOfNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of noncontrolling interests</link:label>
    <link:label id="lab_rprx_NumberOfNoncontrollingInterests_label_en-US" xlink:label="lab_rprx_NumberOfNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Noncontrolling Interests</link:label>
    <link:label id="lab_rprx_NumberOfNoncontrollingInterests_documentation_en-US" xlink:label="lab_rprx_NumberOfNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NumberOfNoncontrollingInterests" xlink:href="rprx-20211231.xsd#rprx_NumberOfNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_NumberOfNoncontrollingInterests" xlink:to="lab_rprx_NumberOfNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_a157fe44-4cb7-4a2f-9d6c-0e32a58cb4f9_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleFixedPayment_cb4ffff1-6302-4f03-b0f6-5657c4612508_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleFixedPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, fixed payment amount</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleFixedPayment_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleFixedPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fixed Payment</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleFixedPayment_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleFixedPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fixed Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleFixedPayment" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleFixedPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleFixedPayment" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleFixedPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_85b7539f-5e07-4705-8c83-405daa0d88f9_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables_1bd14b98-b3c6-42bb-82db-6411ed6dc888_terseLabel_en-US" xlink:label="lab_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collected on financial royalty assets</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables_label_en-US" xlink:label="lab_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Collections On Financing Receivables</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables_documentation_en-US" xlink:label="lab_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Collections On Financing Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables" xlink:href="rprx-20211231.xsd#rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables" xlink:to="lab_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AvillionIMember_654f549a-d7c9-46a1-8819-0cf31b9ee230_terseLabel_en-US" xlink:label="lab_rprx_AvillionIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion I</link:label>
    <link:label id="lab_rprx_AvillionIMember_label_en-US" xlink:label="lab_rprx_AvillionIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion I [Member]</link:label>
    <link:label id="lab_rprx_AvillionIMember_documentation_en-US" xlink:label="lab_rprx_AvillionIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avillion I</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionIMember" xlink:href="rprx-20211231.xsd#rprx_AvillionIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AvillionIMember" xlink:to="lab_rprx_AvillionIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_b6ac0bf8-d0de-4fb1-8082-cf571264e666_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsPurchasedMember_b17cf460-7b08-429e-8cdc-606a3c3434dc_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsPurchasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Funds Rate</link:label>
    <link:label id="lab_us-gaap_FederalFundsPurchasedMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsPurchasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Funds Purchased [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsPurchasedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsPurchasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsPurchasedMember" xlink:to="lab_us-gaap_FederalFundsPurchasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OtherFinancialRoyaltyAssetMember_4147f7a2-16f3-4269-8a81-b1a50ddfbfd2_terseLabel_en-US" xlink:label="lab_rprx_OtherFinancialRoyaltyAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_rprx_OtherFinancialRoyaltyAssetMember_label_en-US" xlink:label="lab_rprx_OtherFinancialRoyaltyAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Royalty Asset [Member]</link:label>
    <link:label id="lab_rprx_OtherFinancialRoyaltyAssetMember_documentation_en-US" xlink:label="lab_rprx_OtherFinancialRoyaltyAssetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Royalty Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherFinancialRoyaltyAssetMember" xlink:href="rprx-20211231.xsd#rprx_OtherFinancialRoyaltyAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OtherFinancialRoyaltyAssetMember" xlink:to="lab_rprx_OtherFinancialRoyaltyAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_68fd4a6d-a184-4396-b95f-b0f161ceed22_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_78be0b15-4f02-4d72-809d-92898f6a2860_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss [Line Items]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_EPAHoldingsMember_a33a22d6-c9c5-4541-9a87-eabc461995fe_terseLabel_en-US" xlink:label="lab_rprx_EPAHoldingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPA Holdings</link:label>
    <link:label id="lab_rprx_EPAHoldingsMember_label_en-US" xlink:label="lab_rprx_EPAHoldingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPA Holdings [Member]</link:label>
    <link:label id="lab_rprx_EPAHoldingsMember_documentation_en-US" xlink:label="lab_rprx_EPAHoldingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPA Holdings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EPAHoldingsMember" xlink:href="rprx-20211231.xsd#rprx_EPAHoldingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_EPAHoldingsMember" xlink:to="lab_rprx_EPAHoldingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate_c7de7c87-c247-4c38-98d9-db0d452d0143_terseLabel_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of return start date</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate_label_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Period of Return, Start Date</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate_documentation_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Period of Return, Start Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate" xlink:to="lab_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets_9f649acc-ec1b-42e3-918c-1e1fec1ed78b_terseLabel_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collections from intangible royalty assets</link:label>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets_label_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Cash Collections From Royalties Received On Intangible Assets</link:label>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets_documentation_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Cash Collections From Royalties Received On Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" xlink:href="rprx-20211231.xsd#rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" xlink:to="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2bcc265a-bcec-455b-842f-a54cb6333a66_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation and related issuance of Class A ordinary shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_08dd9895-96a8-4c82-96ee-a59eca05f03b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon occurrence of a change of control triggering event</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_d0d14413-6da7-4bcc-a9e2-b3d93e89b50e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other exchanges</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_534af2e6-967b-490d-93a1-6b706bdc37ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains on available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RepaymentsOfLongTermDebtScheduledPayments_e56a0a50-b1b8-4ab3-a982-9272b58237d4_negatedTerseLabel_en-US" xlink:label="lab_rprx_RepaymentsOfLongTermDebtScheduledPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scheduled repayments of long-term debt</link:label>
    <link:label id="lab_rprx_RepaymentsOfLongTermDebtScheduledPayments_label_en-US" xlink:label="lab_rprx_RepaymentsOfLongTermDebtScheduledPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Long-term Debt, Scheduled Payments</link:label>
    <link:label id="lab_rprx_RepaymentsOfLongTermDebtScheduledPayments_documentation_en-US" xlink:label="lab_rprx_RepaymentsOfLongTermDebtScheduledPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Long-term Debt, Scheduled Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RepaymentsOfLongTermDebtScheduledPayments" xlink:href="rprx-20211231.xsd#rprx_RepaymentsOfLongTermDebtScheduledPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RepaymentsOfLongTermDebtScheduledPayments" xlink:to="lab_rprx_RepaymentsOfLongTermDebtScheduledPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a50939a5-b86f-448a-8573-e9b868c5ae72_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments_bdf482c8-74a7-48ea-879d-420f35e23f0b_terseLabel_en-US" xlink:label="lab_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire royalty interests, additional milestone payments</link:label>
    <link:label id="lab_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments_label_en-US" xlink:label="lab_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Royalty Interest, Additional Milestone Payments</link:label>
    <link:label id="lab_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments_documentation_en-US" xlink:label="lab_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Royalty Interest, Additional Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" xlink:href="rprx-20211231.xsd#rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" xlink:to="lab_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3c880698-b85e-4ea8-9c6b-f06b9f18f7f0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b2b287c9-fb72-47bb-af58-7037122e0c1c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_cb1e8544-eb37-4c7e-a77c-cdc6f5463869_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RoyaltyIncomeOtherMember_fd53ee14-1648-4cb5-83df-84a92f8b4946_terseLabel_en-US" xlink:label="lab_rprx_RoyaltyIncomeOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other royalty income</link:label>
    <link:label id="lab_rprx_RoyaltyIncomeOtherMember_label_en-US" xlink:label="lab_rprx_RoyaltyIncomeOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Other [Member]</link:label>
    <link:label id="lab_rprx_RoyaltyIncomeOtherMember_documentation_en-US" xlink:label="lab_rprx_RoyaltyIncomeOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyIncomeOtherMember" xlink:href="rprx-20211231.xsd#rprx_RoyaltyIncomeOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RoyaltyIncomeOtherMember" xlink:to="lab_rprx_RoyaltyIncomeOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_14bedcd7-581f-417f-91c3-4d8baa8c3c35_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_b862723d-2aee-4816-acc5-4b3aaf2de117_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Category of Item Purchased [Axis]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Category of Item Purchased [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IncreaseDecreaseInDebtSecuritiesAvailableForSale_9762e33d-06ea-4cd5-9982-2e0a5e90dc41_negatedTerseLabel_en-US" xlink:label="lab_rprx_IncreaseDecreaseInDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale debt securities</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_rprx_IncreaseDecreaseInDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Debt Securities, Available For Sale</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInDebtSecuritiesAvailableForSale_documentation_en-US" xlink:label="lab_rprx_IncreaseDecreaseInDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Debt Securities, Available For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInDebtSecuritiesAvailableForSale" xlink:href="rprx-20211231.xsd#rprx_IncreaseDecreaseInDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IncreaseDecreaseInDebtSecuritiesAvailableForSale" xlink:to="lab_rprx_IncreaseDecreaseInDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_18a671b0-0d9d-4547-97ea-14733a0663f1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_d6abb259-3ceb-47d5-a69b-e73896ac4b84_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale debt securities, noncurrent</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4ef84283-6ee7-4e38-bdfc-34246f375db9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation and related issuances of Class A ordinary shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember_1f3d53ba-5d3a-44a6-9975-8a866321cdf4_terseLabel_en-US" xlink:label="lab_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Agreement With Biohaven Pharmaceuticals</link:label>
    <link:label id="lab_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember_label_en-US" xlink:label="lab_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Purchase Commitment, Funding Agreement With Biohaven Pharmaceuticals [Member]</link:label>
    <link:label id="lab_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember_documentation_en-US" xlink:label="lab_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Purchase Commitment, Funding Agreement With Biohaven Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember" xlink:href="rprx-20211231.xsd#rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember" xlink:to="lab_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_203f6fed-23b8-49b5-a6a5-ab4f25d710dd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other commitment</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_e6b199e2-d6b7-4043-b762-82ecc573115e_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Shares</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8264e080-052a-47bc-9e18-b87437560b91_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_f79671ae-5ead-4fca-9b70-d614f65e9de6_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RoyaltyAssetsPolicyPolicyTextBlock_5be0648b-c207-41e0-984b-b9d1ce416617_terseLabel_en-US" xlink:label="lab_rprx_RoyaltyAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty assets</link:label>
    <link:label id="lab_rprx_RoyaltyAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_rprx_RoyaltyAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Assets, Policy [Policy Text Block]</link:label>
    <link:label id="lab_rprx_RoyaltyAssetsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_rprx_RoyaltyAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Assets, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyAssetsPolicyPolicyTextBlock" xlink:href="rprx-20211231.xsd#rprx_RoyaltyAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RoyaltyAssetsPolicyPolicyTextBlock" xlink:to="lab_rprx_RoyaltyAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm_a5a057a7-98a9-4e91-a289-7b130ed7241d_terseLabel_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of capital term</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm_label_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Payment of Capital, Term</link:label>
    <link:label id="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm_documentation_en-US" xlink:label="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Payment of Capital, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm" xlink:to="lab_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_8617c2ef-99bd-426a-84b8-d746cc46b866_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_0051d2f0-e753-4b07-9d12-9a44c1760b74_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_24feab85-0047-4aa8-8683-a71a50beb7ea_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated net income before tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_4c595e90-de4b-4db6-a095-72e02c0474b5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3_be953fb1-5df2-4089-9f90-3ea73cbbe0df_terseLabel_en-US" xlink:label="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains on available for sale debt securities</link:label>
    <link:label id="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3_label_en-US" xlink:label="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss), After Transfer To Level 3</link:label>
    <link:label id="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3_documentation_en-US" xlink:label="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss), After Transfer To Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3" xlink:href="rprx-20211231.xsd#rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3" xlink:to="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PromactaMember_07ef3118-2b69-415f-b866-e2c362c2b338_terseLabel_en-US" xlink:label="lab_rprx_PromactaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promacta</link:label>
    <link:label id="lab_rprx_PromactaMember_label_en-US" xlink:label="lab_rprx_PromactaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promacta [Member]</link:label>
    <link:label id="lab_rprx_PromactaMember_documentation_en-US" xlink:label="lab_rprx_PromactaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promacta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PromactaMember" xlink:href="rprx-20211231.xsd#rprx_PromactaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PromactaMember" xlink:to="lab_rprx_PromactaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_b105642c-e1b6-49ce-9453-08a2e6763b9d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_926beffb-3036-4381-9f58-c281dd863119_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_694ed8c5-2af2-4544-9d35-7cbec8c5d22c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swaps</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cadfecf9-6338-429f-98fc-8d4d35ace73f_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FundingAgreementWithBioCrystMember_13e9a4d7-1e25-4c2a-8731-9834b5cbed61_terseLabel_en-US" xlink:label="lab_rprx_FundingAgreementWithBioCrystMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Agreement With BioCryst</link:label>
    <link:label id="lab_rprx_FundingAgreementWithBioCrystMember_label_en-US" xlink:label="lab_rprx_FundingAgreementWithBioCrystMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Agreement With BioCryst [Member]</link:label>
    <link:label id="lab_rprx_FundingAgreementWithBioCrystMember_documentation_en-US" xlink:label="lab_rprx_FundingAgreementWithBioCrystMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Agreement With BioCryst</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingAgreementWithBioCrystMember" xlink:href="rprx-20211231.xsd#rprx_FundingAgreementWithBioCrystMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FundingAgreementWithBioCrystMember" xlink:to="lab_rprx_FundingAgreementWithBioCrystMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0fc261c1-4b73-43c6-97dc-36d12f73088f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangible assets, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_e30789b3-896f-49a6-b999-7229eb8cc7a5_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_98567d58-a0be-4674-8046-61afeb8f1b25_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_SettlementsWithEquityMethodInvestments_62ec1f2d-9e09-4a2c-ae75-a4b951d9c0f3_terseLabel_en-US" xlink:label="lab_rprx_SettlementsWithEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement of Epizyme forward purchase contract</link:label>
    <link:label id="lab_rprx_SettlementsWithEquityMethodInvestments_label_en-US" xlink:label="lab_rprx_SettlementsWithEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements With Equity Method Investments</link:label>
    <link:label id="lab_rprx_SettlementsWithEquityMethodInvestments_documentation_en-US" xlink:label="lab_rprx_SettlementsWithEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements With Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SettlementsWithEquityMethodInvestments" xlink:href="rprx-20211231.xsd#rprx_SettlementsWithEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_SettlementsWithEquityMethodInvestments" xlink:to="lab_rprx_SettlementsWithEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityStrikePrice1_8bce86b8-e131-4914-be0e-fdd11db06f8a_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put option, selling price, maximum (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityStrikePrice1_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Strike Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_ed90f872-0e48-4b55-a294-8538010bb3a6_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_157322b8-1f4d-4167-88a6-0bfccdf00e60_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_da25284c-f296-4ce5-9623-8dbd9a258c52_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_b190bd99-fbd9-4a70-bd0c-d926abd71a8a_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_0ffebeeb-061d-4838-9637-9a88f4876123_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain/(loss) on available for sale debt securities, including noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_318623e6-0fcc-4f69-adbd-884e6aa824ad_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_1b50df82-f2fe-409e-9686-767c5b552803_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_9fdd2f08-5849-407f-a73b-6c40a865a279_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_e5bac056-49fe-4ebf-8621-4a7e550fe97a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IPOSharesFromCompanyMember_21cdc3a6-a074-42ee-8ace-1c92b55bf376_terseLabel_en-US" xlink:label="lab_rprx_IPOSharesFromCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO - Shares From Company</link:label>
    <link:label id="lab_rprx_IPOSharesFromCompanyMember_label_en-US" xlink:label="lab_rprx_IPOSharesFromCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO - Shares From Company [Member]</link:label>
    <link:label id="lab_rprx_IPOSharesFromCompanyMember_documentation_en-US" xlink:label="lab_rprx_IPOSharesFromCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO - Shares From Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IPOSharesFromCompanyMember" xlink:href="rprx-20211231.xsd#rprx_IPOSharesFromCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IPOSharesFromCompanyMember" xlink:to="lab_rprx_IPOSharesFromCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_fc63458a-b299-4fda-a81f-7ad3dc80d82c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PurchasingAndDonatingVentilatorsMember_edf3621d-cf3c-4ec0-9f88-a411c7cda04c_terseLabel_en-US" xlink:label="lab_rprx_PurchasingAndDonatingVentilatorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchasing And Donating Ventilators</link:label>
    <link:label id="lab_rprx_PurchasingAndDonatingVentilatorsMember_label_en-US" xlink:label="lab_rprx_PurchasingAndDonatingVentilatorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchasing And Donating Ventilators [Member]</link:label>
    <link:label id="lab_rprx_PurchasingAndDonatingVentilatorsMember_documentation_en-US" xlink:label="lab_rprx_PurchasingAndDonatingVentilatorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchasing And Donating Ventilators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PurchasingAndDonatingVentilatorsMember" xlink:href="rprx-20211231.xsd#rprx_PurchasingAndDonatingVentilatorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PurchasingAndDonatingVentilatorsMember" xlink:to="lab_rprx_PurchasingAndDonatingVentilatorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_e3bce9d2-83d8-45b9-a69e-20d6ce0b4d09_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_96f0ac22-e6b7-461a-80a3-e0bdb310cb67_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Royalty Pharma plc - basic and diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_XtandiMember_3b66da45-38c0-4a89-b1b7-22bc8ea6a4b9_terseLabel_en-US" xlink:label="lab_rprx_XtandiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xtandi</link:label>
    <link:label id="lab_rprx_XtandiMember_label_en-US" xlink:label="lab_rprx_XtandiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xtandi [Member]</link:label>
    <link:label id="lab_rprx_XtandiMember_documentation_en-US" xlink:label="lab_rprx_XtandiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xtandi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_XtandiMember" xlink:href="rprx-20211231.xsd#rprx_XtandiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_XtandiMember" xlink:to="lab_rprx_XtandiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f1ceff4c-2a8c-4bf9-8f4b-4fb210f81ec3_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Royalty Pharma plc - basic and diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_667186d8-3618-4dba-b384-61e9924c3ac0_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_492900fd-31cc-4de4-b580-dc9e9a124815_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4b24fa55-6ea6-4249-9c5a-7ad89def2302_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development funding expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_6a2c159a-0ec1-448a-bb11-72c95c39cdca_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_05eea1d7-6d26-4e41-84c1-57412e0cb3f5_totalLabel_en-US" xlink:label="lab_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying value, before cumulative allowance for credit losses</link:label>
    <link:label id="lab_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_label_en-US" xlink:label="lab_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows</link:label>
    <link:label id="lab_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_documentation_en-US" xlink:label="lab_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" xlink:to="lab_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_bfb6d9a3-ff70-4616-b404-9fae055c0d04_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, stated rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_fa03bf97-b4d3-4178-81f6-51d1b1dbaa3d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Financial Royalty Assets, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_3895da0a-87c3-4a1a-bff3-886648b0b921_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_d2780c8d-9c5c-4842-9fc8-a230fde871fd_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs_e9adadfc-2130-413a-ace5-f0e8b7f99778_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of credit loss allowance</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs" xlink:to="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments_54b27694-2fd7-4b3e-a920-c46885e7f85c_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, quarterly payments</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Quarterly Payments</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Quarterly Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4f3a8160-7e69-4726-a044-7ddc373ccdbb_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3663dd8d-6927-4e24-8628-18bf783bab6b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: net income attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_NetIncomeLossAttributableToParentPriorToOffering_ecec12fe-1a83-48aa-a119-1efd9c323575_terseLabel_en-US" xlink:label="lab_rprx_NetIncomeLossAttributableToParentPriorToOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: net income attributable to Continuing Investors Partnerships prior to the IPO</link:label>
    <link:label id="lab_rprx_NetIncomeLossAttributableToParentPriorToOffering_label_en-US" xlink:label="lab_rprx_NetIncomeLossAttributableToParentPriorToOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Prior To Offering</link:label>
    <link:label id="lab_rprx_NetIncomeLossAttributableToParentPriorToOffering_documentation_en-US" xlink:label="lab_rprx_NetIncomeLossAttributableToParentPriorToOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Prior To Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NetIncomeLossAttributableToParentPriorToOffering" xlink:href="rprx-20211231.xsd#rprx_NetIncomeLossAttributableToParentPriorToOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_NetIncomeLossAttributableToParentPriorToOffering" xlink:to="lab_rprx_NetIncomeLossAttributableToParentPriorToOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash_1c68e298-324c-4afa-9eaa-30979eab0de8_terseLabel_en-US" xlink:label="lab_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt by contributions from non-controlling interest</link:label>
    <link:label id="lab_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash_label_en-US" xlink:label="lab_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Long Term Debt, Contributions From Noncontrolling Interest, Noncash</link:label>
    <link:label id="lab_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash_documentation_en-US" xlink:label="lab_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Long Term Debt, Contributions From Noncontrolling Interest, Noncash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash" xlink:href="rprx-20211231.xsd#rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash" xlink:to="lab_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_51c6dcd5-4cf5-417d-99d2-dc78edb85164_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables_6db34733-4aec-4e7d-b892-dab056a1be7c_terseLabel_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collections from financial royalty assets</link:label>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables_label_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Cash Collections From Royalties Received On Financing Receivables</link:label>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables_documentation_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Cash Collections From Royalties Received On Financing Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" xlink:href="rprx-20211231.xsd#rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" xlink:to="lab_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_df2a028d-3cb0-49f9-a418-aeb761e454aa_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_4dc94138-468a-4c0c-abc0-38cc57367e16_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_dc448758-f81b-4952-abbf-3fee96f8d65b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee or Group of Investees</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_0a3cc61e-3c1f-4ef5-b8b8-b0772d0f647a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4d5e9b48-02e7-4818-9029-dfefc1398183_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingPartnershipAmount_d5b9be94-1045-4bfa-8b6e-b7fabb7fde64_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term funding partnership, amount</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipAmount_label_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Amount</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipAmount_documentation_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipAmount" xlink:href="rprx-20211231.xsd#rprx_LongTermFundingPartnershipAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingPartnershipAmount" xlink:to="lab_rprx_LongTermFundingPartnershipAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_5c81177a-62a4-4c30-a724-2d44c846076a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_16ea0a42-0078-461d-9248-0dfb32bde47e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of unrealized gains on available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_713ac412-8c0d-468a-b921-df0842c67923_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of unrealized losses on available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8ceed5fd-ba07-4a27-81f5-8ec053c60709_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_eca106b9-bd8f-4cd8-9afb-fe964ba513b2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DeferredSharesValueIssued_e33fb741-3dd9-459d-845e-d8aa4ed0a774_terseLabel_en-US" xlink:label="lab_rprx_DeferredSharesValueIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred shares, $0.000001 par value, 361,170 and 316,407 issued and outstanding, respectively</link:label>
    <link:label id="lab_rprx_DeferredSharesValueIssued_label_en-US" xlink:label="lab_rprx_DeferredSharesValueIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares, Value, Issued</link:label>
    <link:label id="lab_rprx_DeferredSharesValueIssued_documentation_en-US" xlink:label="lab_rprx_DeferredSharesValueIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesValueIssued" xlink:href="rprx-20211231.xsd#rprx_DeferredSharesValueIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DeferredSharesValueIssued" xlink:to="lab_rprx_DeferredSharesValueIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_77739a91-16b6-4479-ab2c-0792b3d23643_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_f8bb4301-266e-4903-ba5e-1b34dd343b2f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_af13d030-a944-4b8d-8359-6c2707893e3d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_56ea1f91-28bf-4731-a987-b2a8f88594a8_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average Class A ordinary shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_7e960c83-f133-47a0-9457-3710555ef3fa_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e566b450-62e3-45b2-8c14-a9f3bce0567d_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Class A ordinary share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b4f30d8d-ef9c-46ac-878a-f235763cd7b1_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_VertexMember_6250bbd0-b996-4cbc-bc78-48dc1458522e_terseLabel_en-US" xlink:label="lab_rprx_VertexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vertex</link:label>
    <link:label id="lab_rprx_VertexMember_label_en-US" xlink:label="lab_rprx_VertexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vertex [Member]</link:label>
    <link:label id="lab_rprx_VertexMember_documentation_en-US" xlink:label="lab_rprx_VertexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vertex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_VertexMember" xlink:href="rprx-20211231.xsd#rprx_VertexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_VertexMember" xlink:to="lab_rprx_VertexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_60d003ec-5970-4f7b-a236-36f7b957f3d0_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution payable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_aa41fbd2-b4a4-415e-8198-8c1e7cc67f40_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration_598c24e7-3d6f-4d30-b7a0-8280697a628e_terseLabel_en-US" xlink:label="lab_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial share issuance upon registration of Royalty Pharma plc (in shares)</link:label>
    <link:label id="lab_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration_label_en-US" xlink:label="lab_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued For Registration</link:label>
    <link:label id="lab_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration_documentation_en-US" xlink:label="lab_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued For Registration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration" xlink:href="rprx-20211231.xsd#rprx_StockIssuedDuringPeriodSharesIssuedForRegistration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration" xlink:to="lab_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_a1296b86-ea23-4beb-a65e-1bd8739dfdc7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_53f48750-c97e-4ec9-98ae-eeccd465a550_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible royalty assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_2509c726-69bc-4ceb-aaef-66e2d519f12c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting standards update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember_7461b58e-f46c-4de7-9f9c-33b8f9806ec2_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption, Period Two</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period Two [Member]</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_ac6dc6d2-7f42-4bc6-83de-9e2a233bc897_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_7c01a8f6-b4b5-4281-a6e7-20bab9e811f6_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to controlling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RPIFTSeniorSecuredCreditFacilitiesMember_33ec2037-6736-40af-8f61-400c4e19afca_terseLabel_en-US" xlink:label="lab_rprx_RPIFTSeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPIFT Senior Secured Credit Facilities</link:label>
    <link:label id="lab_rprx_RPIFTSeniorSecuredCreditFacilitiesMember_label_en-US" xlink:label="lab_rprx_RPIFTSeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPIFT Senior Secured Credit Facilities [Member]</link:label>
    <link:label id="lab_rprx_RPIFTSeniorSecuredCreditFacilitiesMember_documentation_en-US" xlink:label="lab_rprx_RPIFTSeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPIFT Senior Secured Credit Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIFTSeniorSecuredCreditFacilitiesMember" xlink:href="rprx-20211231.xsd#rprx_RPIFTSeniorSecuredCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RPIFTSeniorSecuredCreditFacilitiesMember" xlink:to="lab_rprx_RPIFTSeniorSecuredCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1e0eaa1a-acf4-451d-ba35-a3439ee9d62e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5ea24583-d8ae-474f-82dd-b8771eb3bc81_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in other comprehensive income/(loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_7397825d-18f9-4748-a1ed-b5d05f171b0e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury interests</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_91f7d1fd-36f7-4292-a951-071514d51f3a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_7e74d123-128b-4a81-9065-168d96cfdbc0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in losses/(earnings) of non-consolidated affiliates</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_7b81d892-94e4-4c19-bed1-1821454458d8_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in income (loss) of non-consolidated affiliates</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_eb3787bf-1043-4115-a5fd-837868e4cb8f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_6c8b966e-0a41-4784-bd2b-179536d8691f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating expenses</link:label>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_label_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Cost and Expense, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCostAndExpenseOperating" xlink:to="lab_us-gaap_OtherCostAndExpenseOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DeferredSharesSharesOutstanding_34692490-077b-4a1c-ad21-b658870c5af8_terseLabel_en-US" xlink:label="lab_rprx_DeferredSharesSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_rprx_DeferredSharesSharesOutstanding_label_en-US" xlink:label="lab_rprx_DeferredSharesSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares, Shares, Outstanding</link:label>
    <link:label id="lab_rprx_DeferredSharesSharesOutstanding_documentation_en-US" xlink:label="lab_rprx_DeferredSharesSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesSharesOutstanding" xlink:href="rprx-20211231.xsd#rprx_DeferredSharesSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DeferredSharesSharesOutstanding" xlink:to="lab_rprx_DeferredSharesSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships_e6006ed1-548a-495c-b1d8-03859aadbad3_terseLabel_en-US" xlink:label="lab_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class B shares to Continuing Investor Partnerships (in shares)</link:label>
    <link:label id="lab_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships_label_en-US" xlink:label="lab_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued To Partnerships</link:label>
    <link:label id="lab_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships_documentation_en-US" xlink:label="lab_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued To Partnerships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships" xlink:href="rprx-20211231.xsd#rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships" xlink:to="lab_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_b23682d5-7e5a-4825-bff4-d17c166eb17b_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_f7fb74b3-7003-490a-8629-3287c102afb6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements and Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member_5ac557fc-1bc0-4451-9e10-5fe59b9acf94_terseLabel_en-US" xlink:label="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1</link:label>
    <link:label id="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member_label_en-US" xlink:label="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1 [Member]</link:label>
    <link:label id="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member_documentation_en-US" xlink:label="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member" xlink:href="rprx-20211231.xsd#rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member" xlink:to="lab_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember_2b93b86d-ea6d-40cc-8da1-09fc446b6816_terseLabel_en-US" xlink:label="lab_rprx_LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Of Eisai Royalties</link:label>
    <link:label id="lab_rprx_LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember_label_en-US" xlink:label="lab_rprx_LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Purchase Commitment, Purchase Of Eisai Royalties [Member]</link:label>
    <link:label id="lab_rprx_LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember_documentation_en-US" xlink:label="lab_rprx_LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Purchase Commitment, Purchase Of Eisai Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember" xlink:href="rprx-20211231.xsd#rprx_LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember" xlink:to="lab_rprx_LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_7d2e8cdd-c8d6-43fb-825a-15d0d59ded38_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_963ba0f6-bbcd-4b49-a27f-d35c4e4deec4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_de2acd85-7868-4496-92d9-86bbdd80641e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_164b15f6-ee73-454f-866c-9e9a0f2b20ee_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_0522fb48-0a52-4403-b210-c35779e5afbe_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember_a263eb11-4202-483d-84f2-9384eac31efd_terseLabel_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPSFT</link:label>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember_label_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Investors Partnerships and Royalty Pharma Select Finance Trust [Member]</link:label>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember_documentation_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Investors Partnerships and Royalty Pharma Select Finance Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember" xlink:href="rprx-20211231.xsd#rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember" xlink:to="lab_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d031b45c-e27a-4a54-883e-b38e1c441209_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_bdde9b12-a9c5-458e-8cc2-16106e6faa6c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RelatedPartyTransactionInitialTerm_297d5633-c8cf-411b-80dc-a9bf25a18de1_terseLabel_en-US" xlink:label="lab_rprx_RelatedPartyTransactionInitialTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial term</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionInitialTerm_label_en-US" xlink:label="lab_rprx_RelatedPartyTransactionInitialTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Initial Term</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionInitialTerm_documentation_en-US" xlink:label="lab_rprx_RelatedPartyTransactionInitialTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Initial Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionInitialTerm" xlink:href="rprx-20211231.xsd#rprx_RelatedPartyTransactionInitialTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RelatedPartyTransactionInitialTerm" xlink:to="lab_rprx_RelatedPartyTransactionInitialTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_a05c7f09-fb01-4380-b8e6-6528000729ec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer from level 2</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82721a2f-847a-4134-95c7-73bb3ae568be_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_b6c84ae5-2b5f-4f13-97c4-78e29891a167_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage following IPO</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage of Ownership after Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_32ef2baf-3121-4595-9d15-848c9b4b45bf_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassBMember_bb6dbd76-4635-4505-b16b-0a4cad7854ea_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class B</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_label_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_62ca66bf-b80e-460e-a432-d75aded1d76b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_6e4c2c74-0047-4790-a4a2-44ecf52e8b21_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized under plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_TysabriMember_cef95882-0048-41df-988b-fd02ec69eb3a_terseLabel_en-US" xlink:label="lab_rprx_TysabriMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tysabri</link:label>
    <link:label id="lab_rprx_TysabriMember_label_en-US" xlink:label="lab_rprx_TysabriMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tysabri [Member]</link:label>
    <link:label id="lab_rprx_TysabriMember_documentation_en-US" xlink:label="lab_rprx_TysabriMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tysabri</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TysabriMember" xlink:href="rprx-20211231.xsd#rprx_TysabriMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_TysabriMember" xlink:to="lab_rprx_TysabriMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_b87e9d8d-b06f-4c07-922d-d1831de40c5d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsForOngoingDevelopmentStageFunding_1d5faa00-d45f-4377-8f1d-5d9c183a1a46_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsForOngoingDevelopmentStageFunding" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ongoing development-stage funding payments</link:label>
    <link:label id="lab_rprx_PaymentsForOngoingDevelopmentStageFunding_label_en-US" xlink:label="lab_rprx_PaymentsForOngoingDevelopmentStageFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Ongoing Development Stage Funding</link:label>
    <link:label id="lab_rprx_PaymentsForOngoingDevelopmentStageFunding_documentation_en-US" xlink:label="lab_rprx_PaymentsForOngoingDevelopmentStageFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Ongoing Development Stage Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForOngoingDevelopmentStageFunding" xlink:href="rprx-20211231.xsd#rprx_PaymentsForOngoingDevelopmentStageFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsForOngoingDevelopmentStageFunding" xlink:to="lab_rprx_PaymentsForOngoingDevelopmentStageFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingPartnershipInitialPayment_82456fd9-2d36-4654-8f0a-a92906838d8b_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipInitialPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term funding partnership, initial payment</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipInitialPayment_label_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipInitialPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Initial Payment</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipInitialPayment_documentation_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipInitialPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Initial Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipInitialPayment" xlink:href="rprx-20211231.xsd#rprx_LongTermFundingPartnershipInitialPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingPartnershipInitialPayment" xlink:to="lab_rprx_LongTermFundingPartnershipInitialPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_SaleOfStockNumberOfSharesAvailableToConvert_15af0287-cf79-4791-bb90-bd24ae9ab897_verboseLabel_en-US" xlink:label="lab_rprx_SaleOfStockNumberOfSharesAvailableToConvert" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available to convert (in shares)</link:label>
    <link:label id="lab_rprx_SaleOfStockNumberOfSharesAvailableToConvert_label_en-US" xlink:label="lab_rprx_SaleOfStockNumberOfSharesAvailableToConvert" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Available To Convert</link:label>
    <link:label id="lab_rprx_SaleOfStockNumberOfSharesAvailableToConvert_documentation_en-US" xlink:label="lab_rprx_SaleOfStockNumberOfSharesAvailableToConvert" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Available To Convert</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SaleOfStockNumberOfSharesAvailableToConvert" xlink:href="rprx-20211231.xsd#rprx_SaleOfStockNumberOfSharesAvailableToConvert"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_SaleOfStockNumberOfSharesAvailableToConvert" xlink:to="lab_rprx_SaleOfStockNumberOfSharesAvailableToConvert" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_2e7a9da6-8942-4f69-8615-5d9b70575b64_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a31dc9cf-9418-4b35-8112-a99465c4f7e3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8a647c12-987b-4e9f-9064-33875215b152_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Schedule of Non-cash Investing/Financing Activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_166c1a64-28b0-4c2e-b512-3a46efac3541_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment [Line Items]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingSecuritiesDebt_e2467a82-e875-4dc7-bcd2-10ff87977c92_terseLabel_en-US" xlink:label="lab_us-gaap_TradingSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_TradingSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_TradingSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecuritiesDebt" xlink:to="lab_us-gaap_TradingSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_acf74371-51fd-4693-9a9e-418570ce5c9d_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:to="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_b7d193d8-d49f-416c-92ce-ed8eae9dece0_negatedLabel_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative allowance for changes in expected cash flows</link:label>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_label_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows</link:label>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_documentation_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" xlink:to="lab_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_ef5f6ab5-e77c-481b-96ac-1c540b1b52b1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity and Share-based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_75449c78-5ccc-4628-ad89-f034ef9385b8_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income/(Loss)</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_13c9fd86-eb0e-481f-8ef0-58ae40c1c5f8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Borrowings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_01966782-e071-494a-be3c-6377610ba27f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_d07c9620-6109-43b2-a5ea-49fd55b5f592_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains on equity securities</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_08164b34-384e-4240-9028-cb54fefcd3f7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_b92a3dbb-7f07-4ce9-9f7c-cb47316d2d06_verboseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of outstanding debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b0249b5d-ede8-4c76-a909-bf83eb6fa237_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_64357516-6172-49b8-a817-bd40f182506a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage_161dbcdf-200c-48be-a269-97b7452c4045_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price, percentage</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption Price, Percentage</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_ec3f222d-1d54-4738-bd65-c671752d0dca_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_aca25ec2-9898-4d24-8f1a-ea7348b8d01b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses/(gains) on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_4afb3742-b5f6-4c53-bba9-fac02a7ead5c_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income and other revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_f3e111e8-dd5e-4c26-b46f-ffde7ac7f595_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses on Interest Rate Swaps</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0cf2d38a-d613-4061-8785-bd99e81d260b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrant (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1af708ea-891b-4cf7-8bff-a91b3e0fbd44_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification to net income</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsMember_eb3f8646-0e86-401c-a16f-fc15bc14d337_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses on derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsMember_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Instruments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsMember" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member_a71f5f5f-eead-4a3c-8160-fbfa06617e65_terseLabel_en-US" xlink:label="lab_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Seven Five Percent Senior Notes Due 2027</link:label>
    <link:label id="lab_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member_label_en-US" xlink:label="lab_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Seven Five Percent Senior Notes Due 2027 [Member]</link:label>
    <link:label id="lab_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member_documentation_en-US" xlink:label="lab_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Seven Five Percent Senior Notes Due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member" xlink:href="rprx-20211231.xsd#rprx_OnePointSevenFivePercentSeniorNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member" xlink:to="lab_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_b66761e2-826c-4568-98ca-b28869830c71_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FundingAgreementsWithPfizerMember_08a1547a-46fe-4200-9334-6d49659a7ad3_terseLabel_en-US" xlink:label="lab_rprx_FundingAgreementsWithPfizerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Agreements With Pfizer</link:label>
    <link:label id="lab_rprx_FundingAgreementsWithPfizerMember_label_en-US" xlink:label="lab_rprx_FundingAgreementsWithPfizerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Agreements With Pfizer [Member]</link:label>
    <link:label id="lab_rprx_FundingAgreementsWithPfizerMember_documentation_en-US" xlink:label="lab_rprx_FundingAgreementsWithPfizerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Agreements With Pfizer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingAgreementsWithPfizerMember" xlink:href="rprx-20211231.xsd#rprx_FundingAgreementsWithPfizerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FundingAgreementsWithPfizerMember" xlink:to="lab_rprx_FundingAgreementsWithPfizerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_0ec26e41-af21-4620-9c3a-555f173b9b48_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DeferredSharesSharesIssued_ba736797-e567-41b3-ad22-868c97a5054a_terseLabel_en-US" xlink:label="lab_rprx_DeferredSharesSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred stock, issued (in shares)</link:label>
    <link:label id="lab_rprx_DeferredSharesSharesIssued_label_en-US" xlink:label="lab_rprx_DeferredSharesSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares, Shares, Issued</link:label>
    <link:label id="lab_rprx_DeferredSharesSharesIssued_documentation_en-US" xlink:label="lab_rprx_DeferredSharesSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesSharesIssued" xlink:href="rprx-20211231.xsd#rprx_DeferredSharesSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DeferredSharesSharesIssued" xlink:to="lab_rprx_DeferredSharesSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_2ee8d0e4-813a-448b-b91f-814ef7a563c0_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of warrant (in years)</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_912b7004-fbb4-4d32-8189-a04b2f5c7100_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_3f55a8be-d993-466d-b780-4880d7f53625_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired_0f18b6e4-7b8d-44b1-a2e7-e4c7bbf4839e_terseLabel_en-US" xlink:label="lab_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of limited partnership interest acquired (in shares)</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired_label_en-US" xlink:label="lab_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Number of Partnership Interests Acquired</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired_documentation_en-US" xlink:label="lab_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Number of Partnership Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" xlink:href="rprx-20211231.xsd#rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" xlink:to="lab_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_510ac556-c0ec-4c17-b313-8a46600139c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_029a0fb2-2f3d-4ea3-82ea-104662fb42d4_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1954346c-4b34-4442-99da-a1d92fbdc7d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables_b94a503d-cb9d-49be-a9ae-ebfe43168b08_terseLabel_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other royalty cash collections</link:label>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables_label_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Cash Collections From Other Royalties Received On Financing Receivables</link:label>
    <link:label id="lab_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables_documentation_en-US" xlink:label="lab_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Cash Collections From Other Royalties Received On Financing Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" xlink:href="rprx-20211231.xsd#rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" xlink:to="lab_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_70401721-bea0-4eff-b9ae-38b27021bf24_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_GainLossOnDerivativeFinancialInstruments_9e4c433b-76ac-484e-bef4-ca641a06922d_negatedTerseLabel_en-US" xlink:label="lab_rprx_GainLossOnDerivativeFinancialInstruments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination of derivative financial instruments</link:label>
    <link:label id="lab_rprx_GainLossOnDerivativeFinancialInstruments_label_en-US" xlink:label="lab_rprx_GainLossOnDerivativeFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Derivative Financial Instruments</link:label>
    <link:label id="lab_rprx_GainLossOnDerivativeFinancialInstruments_documentation_en-US" xlink:label="lab_rprx_GainLossOnDerivativeFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Derivative Financial Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_GainLossOnDerivativeFinancialInstruments" xlink:href="rprx-20211231.xsd#rprx_GainLossOnDerivativeFinancialInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_GainLossOnDerivativeFinancialInstruments" xlink:to="lab_rprx_GainLossOnDerivativeFinancialInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_54fd96c8-7aef-4cf4-aaf5-895259c30fd4_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_5fb76f84-0765-4447-a179-fab92d38edcb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_08ce522a-a8e8-4b96-a3bb-370a7ff17b73_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Class A ordinary share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_MilestonePaymentAccruedButNotPaid_0df3a002-79ad-4244-b876-5c754e45b97e_terseLabel_en-US" xlink:label="lab_rprx_MilestonePaymentAccruedButNotPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payable - Erleada</link:label>
    <link:label id="lab_rprx_MilestonePaymentAccruedButNotPaid_label_en-US" xlink:label="lab_rprx_MilestonePaymentAccruedButNotPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Accrued But Not Paid</link:label>
    <link:label id="lab_rprx_MilestonePaymentAccruedButNotPaid_documentation_en-US" xlink:label="lab_rprx_MilestonePaymentAccruedButNotPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Accrued But Not Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MilestonePaymentAccruedButNotPaid" xlink:href="rprx-20211231.xsd#rprx_MilestonePaymentAccruedButNotPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_MilestonePaymentAccruedButNotPaid" xlink:to="lab_rprx_MilestonePaymentAccruedButNotPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_8b6f9877-fabf-4bb8-bbce-605c751323f5_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest (percentage)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LongTermFundingPartnershipNumberOfAdditionalPayments_8b09e57c-b291-4ee0-9ce0-3d8f84122c9d_terseLabel_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipNumberOfAdditionalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term funding partnership, number of additional payments</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipNumberOfAdditionalPayments_label_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipNumberOfAdditionalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Number of Additional Payments</link:label>
    <link:label id="lab_rprx_LongTermFundingPartnershipNumberOfAdditionalPayments_documentation_en-US" xlink:label="lab_rprx_LongTermFundingPartnershipNumberOfAdditionalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Funding Partnership, Number of Additional Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipNumberOfAdditionalPayments" xlink:href="rprx-20211231.xsd#rprx_LongTermFundingPartnershipNumberOfAdditionalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LongTermFundingPartnershipNumberOfAdditionalPayments" xlink:to="lab_rprx_LongTermFundingPartnershipNumberOfAdditionalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_da5fa9d8-3cd8-4d04-88cd-9fa14dff6da6_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange offering, ownership percentage</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage of Ownership before Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_50a28ca9-1511-47e9-ba48-5989ae6de58c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment [Table]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_1c993784-5a7a-41c4-8709-baddd2098e7b_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_13382294-322c-4037-937d-b1ad3bf0e478_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member_34d0ec34-98fa-48ef-9ad7-5ab785950c82_terseLabel_en-US" xlink:label="lab_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Two Zero Percent Senior Notes Due 2025</link:label>
    <link:label id="lab_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member_label_en-US" xlink:label="lab_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Two Zero Percent Senior Notes Due 2025 [Member]</link:label>
    <link:label id="lab_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member_documentation_en-US" xlink:label="lab_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Two Zero Percent Senior Notes Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member" xlink:href="rprx-20211231.xsd#rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member" xlink:to="lab_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_41b40cae-3cc7-4c0d-b3c4-d95beeff5811_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_6892ad38-f018-4a23-9883-3621f63ce630_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_e8867344-e7b4-4717-ae8f-80a08f93ee89_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_c67b8edf-f6cd-4bbb-a3c2-7ad05d7dc8f9_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6a53dd91-80a3-4b6a-8e4d-793d2b0270b4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_a17f5e3e-be1d-44b5-a1d2-29983d580fc9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_3744c37b-2a53-462c-ab15-9a9108fef458_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IncreaseDecreaseInFinancialRoyaltyAssets_badc72f6-4c79-451d-a5cc-b163bb74f20d_negatedTerseLabel_en-US" xlink:label="lab_rprx_IncreaseDecreaseInFinancialRoyaltyAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from financial royalty assets</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInFinancialRoyaltyAssets_label_en-US" xlink:label="lab_rprx_IncreaseDecreaseInFinancialRoyaltyAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Financial Royalty Assets</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInFinancialRoyaltyAssets_documentation_en-US" xlink:label="lab_rprx_IncreaseDecreaseInFinancialRoyaltyAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Financial Royalty Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInFinancialRoyaltyAssets" xlink:href="rprx-20211231.xsd#rprx_IncreaseDecreaseInFinancialRoyaltyAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IncreaseDecreaseInFinancialRoyaltyAssets" xlink:to="lab_rprx_IncreaseDecreaseInFinancialRoyaltyAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_183657d0-b4bd-4258-9c23-8ecec17056ba_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e96f2825-cc2d-4f0a-8640-5739f552e27d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AssetsFairValueDisclosureNoncurrent_12375312-0c70-4344-8aa5-75cdbb920332_totalLabel_en-US" xlink:label="lab_rprx_AssetsFairValueDisclosureNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_rprx_AssetsFairValueDisclosureNoncurrent_label_en-US" xlink:label="lab_rprx_AssetsFairValueDisclosureNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure, Noncurrent</link:label>
    <link:label id="lab_rprx_AssetsFairValueDisclosureNoncurrent_documentation_en-US" xlink:label="lab_rprx_AssetsFairValueDisclosureNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssetsFairValueDisclosureNoncurrent" xlink:href="rprx-20211231.xsd#rprx_AssetsFairValueDisclosureNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AssetsFairValueDisclosureNoncurrent" xlink:to="lab_rprx_AssetsFairValueDisclosureNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableChangeInPresentValueExpenseReversal_82036753-1cb4-4487-86bd-a9702fd93fec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableChangeInPresentValueExpenseReversal" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of cumulative allowance</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableChangeInPresentValueExpenseReversal_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableChangeInPresentValueExpenseReversal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Change in Present Value, Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableChangeInPresentValueExpenseReversal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableChangeInPresentValueExpenseReversal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableChangeInPresentValueExpenseReversal" xlink:to="lab_us-gaap_FinancingReceivableChangeInPresentValueExpenseReversal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9379a1e3-9f21-4f73-a4d9-791dfdd8d102_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_def24116-f460-4cd8-9274-aae2e92c41d7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars/pounds per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ResearchAndDevelopmentRemainingFundingCommitment_9853cc99-ea45-47bc-a2bf-5a54d70ac230_terseLabel_en-US" xlink:label="lab_rprx_ResearchAndDevelopmentRemainingFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining commitment for R&amp;D funding agreement</link:label>
    <link:label id="lab_rprx_ResearchAndDevelopmentRemainingFundingCommitment_label_en-US" xlink:label="lab_rprx_ResearchAndDevelopmentRemainingFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development, Remaining Funding Commitment</link:label>
    <link:label id="lab_rprx_ResearchAndDevelopmentRemainingFundingCommitment_documentation_en-US" xlink:label="lab_rprx_ResearchAndDevelopmentRemainingFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development, Remaining Funding Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ResearchAndDevelopmentRemainingFundingCommitment" xlink:href="rprx-20211231.xsd#rprx_ResearchAndDevelopmentRemainingFundingCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ResearchAndDevelopmentRemainingFundingCommitment" xlink:to="lab_rprx_ResearchAndDevelopmentRemainingFundingCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_af2b2c8a-5db2-4ab1-9135-c2c2b0b354f2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f5174712-20de-4e30-a790-43dc9eb32d61_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_edc3ac10-4010-40e9-9ad0-d986d81f6a67_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior to the applicable par call date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_c405431b-790b-481b-b6c6-85d141b5c9f4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_d7bd17c8-6fd9-4d83-a84c-05c6d7b9c7b0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_eceec12a-9106-46f0-9978-d125b7b6c7e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Royalty Interests</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_c65f624d-dad4-4329-bc72-78bb5de69271_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_28ab852a-bb6c-420d-8ff7-3916ea82f6aa_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR)</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AgreementWithMSCIMember_bbc35f9c-b8d4-45de-85a2-6a2a984728da_terseLabel_en-US" xlink:label="lab_rprx_AgreementWithMSCIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement with MSCI</link:label>
    <link:label id="lab_rprx_AgreementWithMSCIMember_label_en-US" xlink:label="lab_rprx_AgreementWithMSCIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement with MSCI [Member]</link:label>
    <link:label id="lab_rprx_AgreementWithMSCIMember_documentation_en-US" xlink:label="lab_rprx_AgreementWithMSCIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement with MSCI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AgreementWithMSCIMember" xlink:href="rprx-20211231.xsd#rprx_AgreementWithMSCIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AgreementWithMSCIMember" xlink:to="lab_rprx_AgreementWithMSCIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_54d308b0-111f-4bf0-a545-d246354582e0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_3dafc5a9-e335-40a6-b30d-87430c415167_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease)/increase in operating liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_9c48045b-0106-4f3e-b7d4-4d9d6d57cdfc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains on available for sale debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a57778af-c299-450e-898f-f47c6b017ec8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_25204a5a-b086-480e-8217-a01d7b78f9fb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod_c67b9490-76e7-4359-b36a-5aa6f8a22773_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in control event, period</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Change In Control Event, Period</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Change In Control Event, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5a812385-fe0e-49ad-b28b-edbcb9ecee2d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8ce67846-75e5-4340-a976-704cda1f780b_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average Class A ordinary shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_4ec7353a-d8d4-447a-a9f0-89816027981b_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the year</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_96638b82-c4ac-459c-9488-95c6c9a7f66c_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the year</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member_94b361de-5297-4355-abc6-b6c4a9ae6c92_terseLabel_en-US" xlink:label="lab_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Percent Senior Notes Due 2030</link:label>
    <link:label id="lab_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member_label_en-US" xlink:label="lab_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Percent Senior Notes Due 2030 [Member]</link:label>
    <link:label id="lab_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member_documentation_en-US" xlink:label="lab_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Percent Senior Notes Due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member" xlink:href="rprx-20211231.xsd#rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member" xlink:to="lab_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_37da1c1f-4351-4aa2-85c2-2dff1308dfea_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive (loss)/income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_d3db6f65-cbac-4ea1-85d3-39cdcd4869c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsToNoncontrollingInterestsOther_7cc88bc0-da07-442a-a5ef-1982cc6b03f9_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsToNoncontrollingInterestsOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to non-controlling interest- other</link:label>
    <link:label id="lab_rprx_PaymentsToNoncontrollingInterestsOther_label_en-US" xlink:label="lab_rprx_PaymentsToNoncontrollingInterestsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Noncontrolling Interests, Other</link:label>
    <link:label id="lab_rprx_PaymentsToNoncontrollingInterestsOther_documentation_en-US" xlink:label="lab_rprx_PaymentsToNoncontrollingInterestsOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Noncontrolling Interests, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToNoncontrollingInterestsOther" xlink:href="rprx-20211231.xsd#rprx_PaymentsToNoncontrollingInterestsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsToNoncontrollingInterestsOther" xlink:to="lab_rprx_PaymentsToNoncontrollingInterestsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_bb42250b-2eed-4174-aaee-252d7334eb9c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requisite service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_0275be02-5e7e-4a9c-ad8e-67e706e5863b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest payable</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_00bc8fd1-6210-4670-a3e3-62e1daba4cca_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_0f68f7d6-e49a-4eeb-aa1e-80bb92b54446_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_85a84235-20b9-4879-a688-3cb089a7d8df_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ImbruvicaMember_8b9c8cc6-6f0a-4739-84e6-f8fc35cf0c06_terseLabel_en-US" xlink:label="lab_rprx_ImbruvicaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imbruvica</link:label>
    <link:label id="lab_rprx_ImbruvicaMember_label_en-US" xlink:label="lab_rprx_ImbruvicaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imbruvica [Member]</link:label>
    <link:label id="lab_rprx_ImbruvicaMember_documentation_en-US" xlink:label="lab_rprx_ImbruvicaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imbruvica</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ImbruvicaMember" xlink:href="rprx-20211231.xsd#rprx_ImbruvicaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ImbruvicaMember" xlink:to="lab_rprx_ImbruvicaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d42e115f-1b83-4a19-8b15-9a9404f9dc61_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate (percentage)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_f748e721-ca3f-4ff1-8c9c-dbd113db54fa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsToAcquireRoyaltyInterestsAggregateAmount_b44f204f-ed3a-423e-8030-43e99173b558_terseLabel_en-US" xlink:label="lab_rprx_PaymentsToAcquireRoyaltyInterestsAggregateAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire royalty interests</link:label>
    <link:label id="lab_rprx_PaymentsToAcquireRoyaltyInterestsAggregateAmount_label_en-US" xlink:label="lab_rprx_PaymentsToAcquireRoyaltyInterestsAggregateAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Royalty Interests, Aggregate Amount</link:label>
    <link:label id="lab_rprx_PaymentsToAcquireRoyaltyInterestsAggregateAmount_documentation_en-US" xlink:label="lab_rprx_PaymentsToAcquireRoyaltyInterestsAggregateAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Royalty Interests, Aggregate Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireRoyaltyInterestsAggregateAmount" xlink:href="rprx-20211231.xsd#rprx_PaymentsToAcquireRoyaltyInterestsAggregateAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsToAcquireRoyaltyInterestsAggregateAmount" xlink:to="lab_rprx_PaymentsToAcquireRoyaltyInterestsAggregateAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_94c0f1e0-6085-4975-83bd-5f576d43efbd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_35ee0d9f-0d08-4624-9ba2-9f87001d864d_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_42aa3f07-a86e-4eda-bc1d-78fbba951d5d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in non-consolidated affiliates</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_4d932e7c-1fba-4172-944e-41db977b2a49_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_NumberOfClassesOfVotingStock_6931f922-ecd2-4e63-a74c-102e10840980_terseLabel_en-US" xlink:label="lab_rprx_NumberOfClassesOfVotingStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of classes of voting shares</link:label>
    <link:label id="lab_rprx_NumberOfClassesOfVotingStock_label_en-US" xlink:label="lab_rprx_NumberOfClassesOfVotingStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Classes Of Voting Stock</link:label>
    <link:label id="lab_rprx_NumberOfClassesOfVotingStock_documentation_en-US" xlink:label="lab_rprx_NumberOfClassesOfVotingStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Classes Of Voting Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NumberOfClassesOfVotingStock" xlink:href="rprx-20211231.xsd#rprx_NumberOfClassesOfVotingStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_NumberOfClassesOfVotingStock" xlink:to="lab_rprx_NumberOfClassesOfVotingStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_b0e66be4-2fe8-4275-a5e0-d66064a3579e_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f80c457c-b5dd-4f02-af01-c2af66e06c7a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_4fdd2fac-226f-46dc-872b-82190b56f479_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d6350074-c6a0-4168-90d3-754aece5df58_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis_19eeb6de-a9df-4a50-b3ea-29ba17bec1c8_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_795a1e33-d6b8-4b23-a431-f0b797b5ab61_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5933d355-94eb-4724-98b8-1854a5a916f5_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow from investing</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_b5a37ecb-06f4-45a6-8966-8b9c51c1b627_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_307fecd5-bb79-4641-8f52-5facfd479850_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI_98f517f4-f04e-4a34-b3b5-27c8daf9fe4b_terseLabel_en-US" xlink:label="lab_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from equity securities</link:label>
    <link:label id="lab_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI_label_en-US" xlink:label="lab_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Equity Securities, FN-NI</link:label>
    <link:label id="lab_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI_documentation_en-US" xlink:label="lab_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Equity Securities, FN-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI" xlink:href="rprx-20211231.xsd#rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI" xlink:to="lab_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_92252994-8351-471c-bb8f-e9200a03a785_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions_e47d6bb0-7dd8-4a8f-bebd-ba07e6413079_terseLabel_en-US" xlink:label="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption</link:label>
    <link:label id="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions_label_en-US" xlink:label="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions</link:label>
    <link:label id="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions_documentation_en-US" xlink:label="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" xlink:href="rprx-20211231.xsd#rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" xlink:to="lab_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_8006c099-043f-4ab2-8c33-1d4cf597590b_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_aecfa592-0e55-4443-b738-4d77ccaabeaa_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_d89c7312-36af-46ca-a57d-9d2079611927_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_b03e7dc2-6b30-4d65-9ccd-527c07d12781_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsForCollateralPostedOnDerivativeInstruments_1958ee0e-3e9f-41d6-8e6d-a80cbb9f0ce8_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsForCollateralPostedOnDerivativeInstruments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative collateral posted</link:label>
    <link:label id="lab_rprx_PaymentsForCollateralPostedOnDerivativeInstruments_label_en-US" xlink:label="lab_rprx_PaymentsForCollateralPostedOnDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Collateral Posted On Derivative Instruments</link:label>
    <link:label id="lab_rprx_PaymentsForCollateralPostedOnDerivativeInstruments_documentation_en-US" xlink:label="lab_rprx_PaymentsForCollateralPostedOnDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Collateral Posted On Derivative Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForCollateralPostedOnDerivativeInstruments" xlink:href="rprx-20211231.xsd#rprx_PaymentsForCollateralPostedOnDerivativeInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsForCollateralPostedOnDerivativeInstruments" xlink:to="lab_rprx_PaymentsForCollateralPostedOnDerivativeInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_7d745e96-5dc4-4c7d-b679-db2b65e23a69_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2981e944-20e3-4b75-8299-9ccdae5d84ad_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_5b21424a-2910-4423-b16b-a9b675bfaf32_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Equity Securities, FV-NI [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Equity Securities, FV-NI [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IPOSharesFromSellingShareholdersMember_010bfe9f-5f7a-46d1-bc26-97d34f5b238f_terseLabel_en-US" xlink:label="lab_rprx_IPOSharesFromSellingShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO - Shares From Selling Shareholders</link:label>
    <link:label id="lab_rprx_IPOSharesFromSellingShareholdersMember_label_en-US" xlink:label="lab_rprx_IPOSharesFromSellingShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO - Shares From Selling Shareholders [Member]</link:label>
    <link:label id="lab_rprx_IPOSharesFromSellingShareholdersMember_documentation_en-US" xlink:label="lab_rprx_IPOSharesFromSellingShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO - Shares From Selling Shareholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IPOSharesFromSellingShareholdersMember" xlink:href="rprx-20211231.xsd#rprx_IPOSharesFromSellingShareholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IPOSharesFromSellingShareholdersMember" xlink:to="lab_rprx_IPOSharesFromSellingShareholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_59683c3b-be37-41bb-b6c6-14225172c17d_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments_9db0b8fd-c4f2-4186-a86c-98217fc6e5e6_terseLabel_en-US" xlink:label="lab_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly payments to affiliates, percent of security investment (as a percent)</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments_label_en-US" xlink:label="lab_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Rate, Value Of Security Investments</link:label>
    <link:label id="lab_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments_documentation_en-US" xlink:label="lab_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Rate, Value Of Security Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments" xlink:href="rprx-20211231.xsd#rprx_RelatedPartyTransactionRateValueOfSecurityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments" xlink:to="lab_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember_08124dfe-3ec5-40e2-992b-16c77f2fe596_terseLabel_en-US" xlink:label="lab_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Of Limited Partnership Interests In Affiliate</link:label>
    <link:label id="lab_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember_label_en-US" xlink:label="lab_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Of Limited Partnership Interests In Affiliate [Member]</link:label>
    <link:label id="lab_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember_documentation_en-US" xlink:label="lab_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Of Limited Partnership Interests In Affiliate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember" xlink:href="rprx-20211231.xsd#rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember" xlink:to="lab_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_f8ffeadd-946c-4af3-8839-cef88b200191_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_5e044477-659b-4bc2-a742-57d3badc4d36_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6db0f8fd-c95a-4b3a-84d2-48d22b553666_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2bd5e6f2-9542-4a7b-90ea-8c58b1034d7e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0502086e-2021-4738-a77f-d6a3325a360d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized discount and loan issuance costs on long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OperatingAndPersonnelPaymentsMember_fa4a79c7-47b1-46c8-ad9b-f42f4e8da13f_terseLabel_en-US" xlink:label="lab_rprx_OperatingAndPersonnelPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Personnel Payments</link:label>
    <link:label id="lab_rprx_OperatingAndPersonnelPaymentsMember_label_en-US" xlink:label="lab_rprx_OperatingAndPersonnelPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Personnel Payments [Member]</link:label>
    <link:label id="lab_rprx_OperatingAndPersonnelPaymentsMember_documentation_en-US" xlink:label="lab_rprx_OperatingAndPersonnelPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Personnel Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OperatingAndPersonnelPaymentsMember" xlink:href="rprx-20211231.xsd#rprx_OperatingAndPersonnelPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OperatingAndPersonnelPaymentsMember" xlink:to="lab_rprx_OperatingAndPersonnelPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableGross_fc5d5848-6e43-430a-aa13-da705e435827_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Value</link:label>
    <link:label id="lab_us-gaap_NotesReceivableGross_label_en-US" xlink:label="lab_us-gaap_NotesReceivableGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableGross" xlink:to="lab_us-gaap_NotesReceivableGross" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments_67ca5b81-ebd3-4824-8a94-9d6466252568_terseLabel_en-US" xlink:label="lab_rprx_PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire royalty interests, number of additional payments</link:label>
    <link:label id="lab_rprx_PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments_label_en-US" xlink:label="lab_rprx_PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Royalty Interests, Number Of Additional Payments</link:label>
    <link:label id="lab_rprx_PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments_documentation_en-US" xlink:label="lab_rprx_PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Royalty Interests, Number Of Additional Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments" xlink:href="rprx-20211231.xsd#rprx_PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments" xlink:to="lab_rprx_PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_BioCrystPharmaceuticalsIncMember_ecfe54d0-6613-4f9c-acff-6d292248a800_terseLabel_en-US" xlink:label="lab_rprx_BioCrystPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioCryst Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_rprx_BioCrystPharmaceuticalsIncMember_label_en-US" xlink:label="lab_rprx_BioCrystPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioCryst Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_rprx_BioCrystPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_rprx_BioCrystPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioCryst Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_BioCrystPharmaceuticalsIncMember" xlink:href="rprx-20211231.xsd#rprx_BioCrystPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_BioCrystPharmaceuticalsIncMember" xlink:to="lab_rprx_BioCrystPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_034507f9-ee1e-4dc3-b4d3-2b3f790144b5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_OtherRoyaltyIncomeReceivableCurrent_bc7ae41b-03d0-4e4d-9e96-eb29dad55770_terseLabel_en-US" xlink:label="lab_rprx_OtherRoyaltyIncomeReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other royalty income receivable</link:label>
    <link:label id="lab_rprx_OtherRoyaltyIncomeReceivableCurrent_label_en-US" xlink:label="lab_rprx_OtherRoyaltyIncomeReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Royalty Income Receivable, Current</link:label>
    <link:label id="lab_rprx_OtherRoyaltyIncomeReceivableCurrent_documentation_en-US" xlink:label="lab_rprx_OtherRoyaltyIncomeReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Royalty Income Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherRoyaltyIncomeReceivableCurrent" xlink:href="rprx-20211231.xsd#rprx_OtherRoyaltyIncomeReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_OtherRoyaltyIncomeReceivableCurrent" xlink:to="lab_rprx_OtherRoyaltyIncomeReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_62a1f4fa-5e73-4d68-82a1-e8b41123caed_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_eecad9d8-a071-41f3-93e1-c148d7fe89d2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PurchaseCommitmentUpfrontPayment_1ab0bf20-b5f3-4477-9213-d5eab7f798c4_terseLabel_en-US" xlink:label="lab_rprx_PurchaseCommitmentUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitment, upfront payment</link:label>
    <link:label id="lab_rprx_PurchaseCommitmentUpfrontPayment_label_en-US" xlink:label="lab_rprx_PurchaseCommitmentUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Upfront Payment</link:label>
    <link:label id="lab_rprx_PurchaseCommitmentUpfrontPayment_documentation_en-US" xlink:label="lab_rprx_PurchaseCommitmentUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PurchaseCommitmentUpfrontPayment" xlink:href="rprx-20211231.xsd#rprx_PurchaseCommitmentUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PurchaseCommitmentUpfrontPayment" xlink:to="lab_rprx_PurchaseCommitmentUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod_6b181563-325d-4cae-b9d4-015f46cb1308_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Default period</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Default Period</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption, Default Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7fe1d081-c7ff-4c8d-bd39-02ba809d0fb4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently adopted and issued accounting standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsToAcquireRoyaltyInterestsUpfrontPayment_21d41544-98b1-4454-ad44-5647b21a35d6_terseLabel_en-US" xlink:label="lab_rprx_PaymentsToAcquireRoyaltyInterestsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire royalty interests, upfront payment</link:label>
    <link:label id="lab_rprx_PaymentsToAcquireRoyaltyInterestsUpfrontPayment_label_en-US" xlink:label="lab_rprx_PaymentsToAcquireRoyaltyInterestsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Royalty Interests, Upfront Payment</link:label>
    <link:label id="lab_rprx_PaymentsToAcquireRoyaltyInterestsUpfrontPayment_documentation_en-US" xlink:label="lab_rprx_PaymentsToAcquireRoyaltyInterestsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Royalty Interests, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireRoyaltyInterestsUpfrontPayment" xlink:href="rprx-20211231.xsd#rprx_PaymentsToAcquireRoyaltyInterestsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsToAcquireRoyaltyInterestsUpfrontPayment" xlink:to="lab_rprx_PaymentsToAcquireRoyaltyInterestsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount_3cf4f018-bb50-4570-a987-8858a2ffcf16_terseLabel_en-US" xlink:label="lab_rprx_PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitment, purchase of committed, non-contingent Commercial Launch Preferred Equity payable</link:label>
    <link:label id="lab_rprx_PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount_label_en-US" xlink:label="lab_rprx_PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Committed Non-Contingent Commercial Launch Preferred Equity, Amount</link:label>
    <link:label id="lab_rprx_PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount_documentation_en-US" xlink:label="lab_rprx_PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Committed Non-Contingent Commercial Launch Preferred Equity, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount" xlink:href="rprx-20211231.xsd#rprx_PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount" xlink:to="lab_rprx_PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_d0855174-7331-406f-b087-dafa2e58391f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AssignmentAgreementFundingObligationsMember_ffa26c94-6c48-4ec7-b40a-a70a87bc8a59_terseLabel_en-US" xlink:label="lab_rprx_AssignmentAgreementFundingObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement - Funding Obligations</link:label>
    <link:label id="lab_rprx_AssignmentAgreementFundingObligationsMember_label_en-US" xlink:label="lab_rprx_AssignmentAgreementFundingObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement - Funding Obligations [Member]</link:label>
    <link:label id="lab_rprx_AssignmentAgreementFundingObligationsMember_documentation_en-US" xlink:label="lab_rprx_AssignmentAgreementFundingObligationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement - Funding Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssignmentAgreementFundingObligationsMember" xlink:href="rprx-20211231.xsd#rprx_AssignmentAgreementFundingObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AssignmentAgreementFundingObligationsMember" xlink:to="lab_rprx_AssignmentAgreementFundingObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss_be3c0a55-bdc7-4df0-92f8-16c704220514_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on equity securities still held</link:label>
    <link:label id="lab_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" xlink:to="lab_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_27762dad-2c4d-49c4-a67f-66046987acbd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized share based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_e6ff85da-7cd4-4c74-9851-8fbe72387ea1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_TremfyaMember_ec25252e-27e0-40f7-989a-858be9b2b884_terseLabel_en-US" xlink:label="lab_rprx_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfya</link:label>
    <link:label id="lab_rprx_TremfyaMember_label_en-US" xlink:label="lab_rprx_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfya [Member]</link:label>
    <link:label id="lab_rprx_TremfyaMember_documentation_en-US" xlink:label="lab_rprx_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfya</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TremfyaMember" xlink:href="rprx-20211231.xsd#rprx_TremfyaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_TremfyaMember" xlink:to="lab_rprx_TremfyaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock_80b59741-0942-457d-b516-01483d4359dd_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities and Available for sale debt securities</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Policy [Policy Text Block]</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock" xlink:to="lab_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_1a87a70a-0a97-4cba-9507-4f5676b1c8f7_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_6087be15-0fcf-4d2e-a1a7-06d4c7316a50_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_1e97ae2a-bc74-499f-9280-8bb917c6e069_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses_486f5c06-0111-4e00-be12-b09681802eb0_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses_fd9ade1f-5176-4683-9d56-f6ba0d3b3942_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:to="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_cdfeef74-b051-4938-af22-c9fec1b6d3a7_negatedLabel_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative allowance for credit losses</link:label>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_label_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)</link:label>
    <link:label id="lab_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_documentation_en-US" xlink:label="lab_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" xlink:to="lab_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_AssetsFairValueDisclosureCurrent_3746ff67-6ebf-436e-9323-0f745f9d41e9_totalLabel_en-US" xlink:label="lab_rprx_AssetsFairValueDisclosureCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_rprx_AssetsFairValueDisclosureCurrent_label_en-US" xlink:label="lab_rprx_AssetsFairValueDisclosureCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure, Current</link:label>
    <link:label id="lab_rprx_AssetsFairValueDisclosureCurrent_documentation_en-US" xlink:label="lab_rprx_AssetsFairValueDisclosureCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssetsFairValueDisclosureCurrent" xlink:href="rprx-20211231.xsd#rprx_AssetsFairValueDisclosureCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_AssetsFairValueDisclosureCurrent" xlink:to="lab_rprx_AssetsFairValueDisclosureCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_1c8cf342-5210-40a0-a468-38289855e9f9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Shares</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_9c4556aa-8349-49bc-9b5a-4b00c9242713_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible royalty assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_59534ee2-819a-407b-9e2e-44c9c755bc84_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_65213d3a-6c19-4874-bb90-7a5163f0b1ff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of loss reclassified from AOCI into income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_5097f2d5-edf5-4a80-8842-71901c4af0ce_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsMember_8ae6672c-f323-4f95-8588-4b534b2a77be_terseLabel_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Investors Partnerships</link:label>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsMember_label_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Investors Partnerships [Member]</link:label>
    <link:label id="lab_rprx_LegacyInvestorsPartnershipsMember_documentation_en-US" xlink:label="lab_rprx_LegacyInvestorsPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Investors Partnerships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember" xlink:href="rprx-20211231.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_LegacyInvestorsPartnershipsMember" xlink:to="lab_rprx_LegacyInvestorsPartnershipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_53876993-8a90-4bd5-beda-c1acf5652520_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable_ba6791ba-7653-48b2-bc74-e74e135e2001_negatedTerseLabel_en-US" xlink:label="lab_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalty receivable</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable_label_en-US" xlink:label="lab_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Royalty Receivable</link:label>
    <link:label id="lab_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable_documentation_en-US" xlink:label="lab_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Royalty Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable" xlink:href="rprx-20211231.xsd#rprx_IncreaseDecreaseInAccruedRoyaltyReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable" xlink:to="lab_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod_ec34a2f8-ddcb-4653-b5e7-d9012bfb7cc8_terseLabel_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption default, threshold period</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod_label_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption Default, Threshold Period</link:label>
    <link:label id="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod_documentation_en-US" xlink:label="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Redemption Default, Threshold Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod" xlink:to="lab_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_PaymentsForOperatingCostsAndProfessionalServices_9434e786-c3f4-4b92-9dae-acbdef640d4e_negatedTerseLabel_en-US" xlink:label="lab_rprx_PaymentsForOperatingCostsAndProfessionalServices" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for operating and professional costs</link:label>
    <link:label id="lab_rprx_PaymentsForOperatingCostsAndProfessionalServices_label_en-US" xlink:label="lab_rprx_PaymentsForOperatingCostsAndProfessionalServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Operating Costs and Professional Services</link:label>
    <link:label id="lab_rprx_PaymentsForOperatingCostsAndProfessionalServices_documentation_en-US" xlink:label="lab_rprx_PaymentsForOperatingCostsAndProfessionalServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Operating Costs and Professional Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForOperatingCostsAndProfessionalServices" xlink:href="rprx-20211231.xsd#rprx_PaymentsForOperatingCostsAndProfessionalServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_PaymentsForOperatingCostsAndProfessionalServices" xlink:to="lab_rprx_PaymentsForOperatingCostsAndProfessionalServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ef804d8-aab7-4778-a16f-a5607c68d744_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile consolidated net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForwardContractsMember_3648f87f-e8cb-4e99-a47a-edbc469feb75_terseLabel_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forwards</link:label>
    <link:label id="lab_us-gaap_ForwardContractsMember_label_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForwardContractsMember" xlink:to="lab_us-gaap_ForwardContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_008c8a33-4ff9-4b7e-a7f9-23da40d5e12e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member_facf7149-52f9-4dd3-bac7-28c3dd607a87_terseLabel_en-US" xlink:label="lab_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Zero Percent Senior Notes Due 2040</link:label>
    <link:label id="lab_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member_label_en-US" xlink:label="lab_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Zero Percent Senior Notes Due 2040 [Member]</link:label>
    <link:label id="lab_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member_documentation_en-US" xlink:label="lab_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Zero Percent Senior Notes Due 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member" xlink:href="rprx-20211231.xsd#rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member" xlink:to="lab_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rprx_FundingAgreementsWithSanofiMember_0bebf714-c268-4746-b483-e1c4d37db50e_terseLabel_en-US" xlink:label="lab_rprx_FundingAgreementsWithSanofiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Agreements With Sanofi</link:label>
    <link:label id="lab_rprx_FundingAgreementsWithSanofiMember_label_en-US" xlink:label="lab_rprx_FundingAgreementsWithSanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Agreements With Sanofi [Member]</link:label>
    <link:label id="lab_rprx_FundingAgreementsWithSanofiMember_documentation_en-US" xlink:label="lab_rprx_FundingAgreementsWithSanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Agreements With Sanofi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingAgreementsWithSanofiMember" xlink:href="rprx-20211231.xsd#rprx_FundingAgreementsWithSanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rprx_FundingAgreementsWithSanofiMember" xlink:to="lab_rprx_FundingAgreementsWithSanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_b250a296-e117-434d-b830-6db7c4c33c93_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_ddcf3063-117a-4a1d-a310-b64985a340cd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_8e40c06b-1071-4f51-9728-950675d6b171_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_c3e43ca1-79ed-4f5d-bd72-773cf70995e7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_df1604be-9bd7-4993-9566-4b9371648df0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ad13a755-a2ef-4e92-9a47-b092582c354d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201613Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-13 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>rprx-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:ca5bf1b5-7b51-40b4-bf4b-78f0f34b00d0,g:ba501133-7b9f-46c5-b0d4-2c55034547ac-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://royaltypharma.com/role/Cover" xlink:type="simple" xlink:href="rprx-20211231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a24193da-e7d4-4ce3-9e65-86303e9fec14" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_7300679b-c60a-4226-8f58-bc5821743b22" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a24193da-e7d4-4ce3-9e65-86303e9fec14" xlink:to="loc_dei_DocumentInformationTable_7300679b-c60a-4226-8f58-bc5821743b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6020aac5-8c12-42f1-b7af-537c408ad38c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_7300679b-c60a-4226-8f58-bc5821743b22" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6020aac5-8c12-42f1-b7af-537c408ad38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_80fd84df-0f12-4c5b-b43d-0071c1a1b817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6020aac5-8c12-42f1-b7af-537c408ad38c" xlink:to="loc_us-gaap_ClassOfStockDomain_80fd84df-0f12-4c5b-b43d-0071c1a1b817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_a2c22ace-5320-40e2-ba49-24788b216986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_80fd84df-0f12-4c5b-b43d-0071c1a1b817" xlink:to="loc_us-gaap_CommonClassAMember_a2c22ace-5320-40e2-ba49-24788b216986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_05f22e4c-90be-4cb9-8534-c5fde8228db4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_80fd84df-0f12-4c5b-b43d-0071c1a1b817" xlink:to="loc_us-gaap_CommonClassBMember_05f22e4c-90be-4cb9-8534-c5fde8228db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_7300679b-c60a-4226-8f58-bc5821743b22" xlink:to="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ecb6c2d1-31e8-4a9d-8583-d4c7096d5d3e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_DocumentType_ecb6c2d1-31e8-4a9d-8583-d4c7096d5d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_6e5f2032-c5ce-403f-8b8e-3f3cfcc5c831" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_DocumentAnnualReport_6e5f2032-c5ce-403f-8b8e-3f3cfcc5c831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a4f619a3-9f5f-4be7-8f47-7311e7395d91" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_DocumentPeriodEndDate_a4f619a3-9f5f-4be7-8f47-7311e7395d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_36cbf107-49a7-4396-a56d-c61960f46c55" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_CurrentFiscalYearEndDate_36cbf107-49a7-4396-a56d-c61960f46c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f8c38a7b-aa22-4e44-97a8-e194c82712b5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_DocumentTransitionReport_f8c38a7b-aa22-4e44-97a8-e194c82712b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_609eb283-012e-4628-9d92-9581f0984ca5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityFileNumber_609eb283-012e-4628-9d92-9581f0984ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_aba2b2dd-b8d1-407f-867d-b5983d8a8e48" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityRegistrantName_aba2b2dd-b8d1-407f-867d-b5983d8a8e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_cd0f0a28-6c31-42bc-9637-bdd69b7996e5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityIncorporationStateCountryCode_cd0f0a28-6c31-42bc-9637-bdd69b7996e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c49ce067-d04a-4bd7-85e3-10b74e53bed1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityTaxIdentificationNumber_c49ce067-d04a-4bd7-85e3-10b74e53bed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b5d7f311-6f60-4bd1-ac76-45becdcd59bb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityAddressAddressLine1_b5d7f311-6f60-4bd1-ac76-45becdcd59bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_01ac4cdb-bc2d-4a82-96ce-05d9fcf6f1d5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityAddressCityOrTown_01ac4cdb-bc2d-4a82-96ce-05d9fcf6f1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c55f23c1-a8e1-4ed0-a1c9-d9a39147e331" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityAddressStateOrProvince_c55f23c1-a8e1-4ed0-a1c9-d9a39147e331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_678da046-9183-4ec4-a0e0-e98a7884971d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityAddressPostalZipCode_678da046-9183-4ec4-a0e0-e98a7884971d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_bb0d4e58-725f-4a86-869b-e75a5188e343" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_CityAreaCode_bb0d4e58-725f-4a86-869b-e75a5188e343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_77bfc734-36a4-405c-9235-34166d26e602" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_LocalPhoneNumber_77bfc734-36a4-405c-9235-34166d26e602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a31020cc-fc6f-4628-8c36-d98eee37b361" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_Security12bTitle_a31020cc-fc6f-4628-8c36-d98eee37b361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_28f60e53-a877-4130-b1e6-0f2aceaf8003" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_TradingSymbol_28f60e53-a877-4130-b1e6-0f2aceaf8003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_41c0f21b-d7cd-48f2-8967-0bcb94879b84" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_SecurityExchangeName_41c0f21b-d7cd-48f2-8967-0bcb94879b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_bc8e0e2f-85e4-4642-b264-2c73acda1bfc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_bc8e0e2f-85e4-4642-b264-2c73acda1bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_1d6897eb-e3cb-48d3-94f9-d51a0b634e72" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityVoluntaryFilers_1d6897eb-e3cb-48d3-94f9-d51a0b634e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_45c8919e-3158-4311-9c46-32efe26ea0a4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityCurrentReportingStatus_45c8919e-3158-4311-9c46-32efe26ea0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6030176d-c601-4619-bf48-8e95cffc4434" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityInteractiveDataCurrent_6030176d-c601-4619-bf48-8e95cffc4434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_ae667c59-91b6-4b43-abaa-908021d16d5e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityFilerCategory_ae667c59-91b6-4b43-abaa-908021d16d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_cc5272cc-6178-4009-a53a-e745bda32325" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntitySmallBusiness_cc5272cc-6178-4009-a53a-e745bda32325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1f27cbb8-e9c3-4f67-8046-644b97faf37e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityEmergingGrowthCompany_1f27cbb8-e9c3-4f67-8046-644b97faf37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_1d6b03fc-892a-4b1b-9996-bc1f0d11c551" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_IcfrAuditorAttestationFlag_1d6b03fc-892a-4b1b-9996-bc1f0d11c551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b084a4ef-e3d1-40dd-9b89-aeab9f5ae677" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityShellCompany_b084a4ef-e3d1-40dd-9b89-aeab9f5ae677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_e2051e08-804d-4858-a0c6-a4b3b4e01672" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityPublicFloat_e2051e08-804d-4858-a0c6-a4b3b4e01672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c01f5e12-9ac7-442a-aeef-5c906839f4c7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c01f5e12-9ac7-442a-aeef-5c906839f4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_316cfed3-4174-4edd-a8bb-efbee63a3260" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_316cfed3-4174-4edd-a8bb-efbee63a3260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_44e15b53-24fc-47f4-8655-8019a19c9330" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_EntityCentralIndexKey_44e15b53-24fc-47f4-8655-8019a19c9330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_3e4fe46e-b020-4376-92df-03b52f8ca25b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_DocumentFiscalYearFocus_3e4fe46e-b020-4376-92df-03b52f8ca25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_a6bd135d-7e81-48d5-92b6-d096afe5c276" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_DocumentFiscalPeriodFocus_a6bd135d-7e81-48d5-92b6-d096afe5c276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_521b1159-1232-4669-8a97-44e879998c3c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_48888dc9-67d5-4ae5-b880-c138538dbc55" xlink:to="loc_dei_AmendmentFlag_521b1159-1232-4669-8a97-44e879998c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AuditInformation" xlink:type="simple" xlink:href="rprx-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AuditInformationAbstract_63948b78-b125-42d7-8d84-6840dd9fbc94" xlink:href="rprx-20211231.xsd#rprx_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_1faa0fa5-d1f0-460d-9a7b-e418704a90bb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rprx_AuditInformationAbstract_63948b78-b125-42d7-8d84-6840dd9fbc94" xlink:to="loc_dei_AuditorFirmId_1faa0fa5-d1f0-460d-9a7b-e418704a90bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_8ebe6e7a-9e7f-49fd-b9fd-e6d854ae2257" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rprx_AuditInformationAbstract_63948b78-b125-42d7-8d84-6840dd9fbc94" xlink:to="loc_dei_AuditorName_8ebe6e7a-9e7f-49fd-b9fd-e6d854ae2257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_414a1f5b-c1e8-464c-a8b1-212a6103f4dc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rprx_AuditInformationAbstract_63948b78-b125-42d7-8d84-6840dd9fbc94" xlink:to="loc_dei_AuditorLocation_414a1f5b-c1e8-464c-a8b1-212a6103f4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="rprx-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_95fb3722-e5e5-40b4-9af4-b016a0c2a542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a42f52d5-bba9-4ee4-8554-dcc084f77c12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_95fb3722-e5e5-40b4-9af4-b016a0c2a542" xlink:to="loc_us-gaap_StatementTable_a42f52d5-bba9-4ee4-8554-dcc084f77c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6ec523a7-0692-475c-9af4-894e7423061c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a42f52d5-bba9-4ee4-8554-dcc084f77c12" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6ec523a7-0692-475c-9af4-894e7423061c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fb2c7ebd-d1ab-49b8-ae34-d748fb1beee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6ec523a7-0692-475c-9af4-894e7423061c" xlink:to="loc_us-gaap_ClassOfStockDomain_fb2c7ebd-d1ab-49b8-ae34-d748fb1beee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_6ed9376b-cf0e-4039-8854-0f5b1992ac5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_fb2c7ebd-d1ab-49b8-ae34-d748fb1beee2" xlink:to="loc_us-gaap_CommonClassAMember_6ed9376b-cf0e-4039-8854-0f5b1992ac5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_8756a310-c601-44bb-883b-57976f8181b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_fb2c7ebd-d1ab-49b8-ae34-d748fb1beee2" xlink:to="loc_us-gaap_CommonClassBMember_8756a310-c601-44bb-883b-57976f8181b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember_dd777bdc-27e4-455c-8fc1-f379fe195e23" xlink:href="rprx-20211231.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_fb2c7ebd-d1ab-49b8-ae34-d748fb1beee2" xlink:to="loc_rprx_ClassRRedeemableStockMember_dd777bdc-27e4-455c-8fc1-f379fe195e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_379d7fbf-12ab-4f89-8491-0049399e6582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a42f52d5-bba9-4ee4-8554-dcc084f77c12" xlink:to="loc_us-gaap_StatementLineItems_379d7fbf-12ab-4f89-8491-0049399e6582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_97eef486-71a4-47f0-b80c-2c7fb330a1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_379d7fbf-12ab-4f89-8491-0049399e6582" xlink:to="loc_us-gaap_AssetsAbstract_97eef486-71a4-47f0-b80c-2c7fb330a1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_da804a29-6b0c-44d9-a165-a8e09c813f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_97eef486-71a4-47f0-b80c-2c7fb330a1cf" xlink:to="loc_us-gaap_AssetsCurrentAbstract_da804a29-6b0c-44d9-a165-a8e09c813f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_af5a14d6-0c12-49ed-a26e-88dbd09f899b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da804a29-6b0c-44d9-a165-a8e09c813f0b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_af5a14d6-0c12-49ed-a26e-88dbd09f899b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt_bbe3d3b7-48f7-4285-a2d2-98eedbdb14f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da804a29-6b0c-44d9-a165-a8e09c813f0b" xlink:to="loc_us-gaap_TradingSecuritiesDebt_bbe3d3b7-48f7-4285-a2d2-98eedbdb14f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_c2b61232-58f0-4334-bdd1-f1ce56bea3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da804a29-6b0c-44d9-a165-a8e09c813f0b" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_c2b61232-58f0-4334-bdd1-f1ce56bea3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AccruedRoyaltyReceivable_d76d534e-e142-43d2-afd2-fc9207a8a921" xlink:href="rprx-20211231.xsd#rprx_AccruedRoyaltyReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da804a29-6b0c-44d9-a165-a8e09c813f0b" xlink:to="loc_rprx_AccruedRoyaltyReceivable_d76d534e-e142-43d2-afd2-fc9207a8a921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c132dcb0-bde3-4454-b53b-6cd8ff1266cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da804a29-6b0c-44d9-a165-a8e09c813f0b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c132dcb0-bde3-4454-b53b-6cd8ff1266cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherRoyaltyIncomeReceivableCurrent_e040232e-023b-427d-9ef9-e29db3af4116" xlink:href="rprx-20211231.xsd#rprx_OtherRoyaltyIncomeReceivableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da804a29-6b0c-44d9-a165-a8e09c813f0b" xlink:to="loc_rprx_OtherRoyaltyIncomeReceivableCurrent_e040232e-023b-427d-9ef9-e29db3af4116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_37fb386d-2ab8-4d46-9108-5c32d4d9e243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da804a29-6b0c-44d9-a165-a8e09c813f0b" xlink:to="loc_us-gaap_OtherAssetsCurrent_37fb386d-2ab8-4d46-9108-5c32d4d9e243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4d18f7fd-937e-4bac-bb8f-3cb90236672d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da804a29-6b0c-44d9-a165-a8e09c813f0b" xlink:to="loc_us-gaap_AssetsCurrent_4d18f7fd-937e-4bac-bb8f-3cb90236672d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_ab021ebf-bc7a-4e78-924a-67c54ad9c190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_97eef486-71a4-47f0-b80c-2c7fb330a1cf" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_ab021ebf-bc7a-4e78-924a-67c54ad9c190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4d965246-9a46-4aa4-a7a9-8917710df626" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_97eef486-71a4-47f0-b80c-2c7fb330a1cf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4d965246-9a46-4aa4-a7a9-8917710df626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_b96c8ad1-c54c-47c0-a603-204035f74b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_97eef486-71a4-47f0-b80c-2c7fb330a1cf" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_b96c8ad1-c54c-47c0-a603-204035f74b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_d7189a9e-63b1-4579-a673-a991127813f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_97eef486-71a4-47f0-b80c-2c7fb330a1cf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_d7189a9e-63b1-4579-a673-a991127813f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_51a2c9ed-6c34-4a69-bf29-4c6a06723f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_97eef486-71a4-47f0-b80c-2c7fb330a1cf" xlink:to="loc_us-gaap_EquityMethodInvestments_51a2c9ed-6c34-4a69-bf29-4c6a06723f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_da460cca-c88d-4d99-bffc-f5998aa9692c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_97eef486-71a4-47f0-b80c-2c7fb330a1cf" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_da460cca-c88d-4d99-bffc-f5998aa9692c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7cd98b40-bc83-46a7-915a-3744add01890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_97eef486-71a4-47f0-b80c-2c7fb330a1cf" xlink:to="loc_us-gaap_Assets_7cd98b40-bc83-46a7-915a-3744add01890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15f33c41-50da-40df-93af-3093b6fe477f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_379d7fbf-12ab-4f89-8491-0049399e6582" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15f33c41-50da-40df-93af-3093b6fe477f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_b4d9266e-808c-417b-bb91-4b2a1c3b43d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15f33c41-50da-40df-93af-3093b6fe477f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_b4d9266e-808c-417b-bb91-4b2a1c3b43d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_0da97c58-d228-4a5a-a086-cb511cdcb40b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b4d9266e-808c-417b-bb91-4b2a1c3b43d6" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_0da97c58-d228-4a5a-a086-cb511cdcb40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_10e63121-cf11-4d81-8718-1d9b83c80f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b4d9266e-808c-417b-bb91-4b2a1c3b43d6" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_10e63121-cf11-4d81-8718-1d9b83c80f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_b17fb0b4-5ec5-48e6-980f-bc1388ccf024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b4d9266e-808c-417b-bb91-4b2a1c3b43d6" xlink:to="loc_us-gaap_InterestPayableCurrent_b17fb0b4-5ec5-48e6-980f-bc1388ccf024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AccruedPurchaseObligationCurrent_3da93739-3327-4613-8739-91f00c19c2b2" xlink:href="rprx-20211231.xsd#rprx_AccruedPurchaseObligationCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b4d9266e-808c-417b-bb91-4b2a1c3b43d6" xlink:to="loc_rprx_AccruedPurchaseObligationCurrent_3da93739-3327-4613-8739-91f00c19c2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_cd99e4ae-8ace-42ed-8418-8c16d0f49e52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b4d9266e-808c-417b-bb91-4b2a1c3b43d6" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_cd99e4ae-8ace-42ed-8418-8c16d0f49e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_532bb326-e8bd-4b4d-b75f-fca37d4b6ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b4d9266e-808c-417b-bb91-4b2a1c3b43d6" xlink:to="loc_us-gaap_LiabilitiesCurrent_532bb326-e8bd-4b4d-b75f-fca37d4b6ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3df6080c-3eef-4271-a8cd-482fc92e6b21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15f33c41-50da-40df-93af-3093b6fe477f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3df6080c-3eef-4271-a8cd-482fc92e6b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d49ecf5e-8da6-4c10-ba9f-e9f19c991c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15f33c41-50da-40df-93af-3093b6fe477f" xlink:to="loc_us-gaap_Liabilities_d49ecf5e-8da6-4c10-ba9f-e9f19c991c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_878e96c6-0719-49a5-b5f4-b18617672c69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15f33c41-50da-40df-93af-3093b6fe477f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_878e96c6-0719-49a5-b5f4-b18617672c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_323bf0dc-8588-4712-8b27-dfe3815657ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15f33c41-50da-40df-93af-3093b6fe477f" xlink:to="loc_us-gaap_StockholdersEquityAbstract_323bf0dc-8588-4712-8b27-dfe3815657ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c1d90460-9086-4280-9184-f6dd76a3af15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_323bf0dc-8588-4712-8b27-dfe3815657ac" xlink:to="loc_us-gaap_CommonStockValue_c1d90460-9086-4280-9184-f6dd76a3af15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesValueIssued_fc95c69c-2c31-424d-b5ba-a3fc0b57485b" xlink:href="rprx-20211231.xsd#rprx_DeferredSharesValueIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_323bf0dc-8588-4712-8b27-dfe3815657ac" xlink:to="loc_rprx_DeferredSharesValueIssued_fc95c69c-2c31-424d-b5ba-a3fc0b57485b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_bb9015d9-1ac9-472f-ad4a-5c45b92aba13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_323bf0dc-8588-4712-8b27-dfe3815657ac" xlink:to="loc_us-gaap_AdditionalPaidInCapital_bb9015d9-1ac9-472f-ad4a-5c45b92aba13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cf38f34d-9e5e-40a9-8c34-7272a77f05c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_323bf0dc-8588-4712-8b27-dfe3815657ac" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cf38f34d-9e5e-40a9-8c34-7272a77f05c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_62e94208-5109-4061-a3e1-ec32cdfcb558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_323bf0dc-8588-4712-8b27-dfe3815657ac" xlink:to="loc_us-gaap_MinorityInterest_62e94208-5109-4061-a3e1-ec32cdfcb558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_15e3a1c8-56f6-45b3-936d-fd35f8685fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_323bf0dc-8588-4712-8b27-dfe3815657ac" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_15e3a1c8-56f6-45b3-936d-fd35f8685fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_50e5e2ea-3679-463a-b19f-ee41170921cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_323bf0dc-8588-4712-8b27-dfe3815657ac" xlink:to="loc_us-gaap_TreasuryStockValue_50e5e2ea-3679-463a-b19f-ee41170921cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d5e3ade0-5df6-4f45-ad45-d31dc5282a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_323bf0dc-8588-4712-8b27-dfe3815657ac" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d5e3ade0-5df6-4f45-ad45-d31dc5282a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9d19a1af-80a2-4cf3-9b7c-f2b7dcf9dd00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15f33c41-50da-40df-93af-3093b6fe477f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9d19a1af-80a2-4cf3-9b7c-f2b7dcf9dd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="rprx-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4f03da3f-ab90-40c2-8093-e8b4283a6a82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6275bc1f-aaf0-48a1-a422-4c9e62fa0c94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4f03da3f-ab90-40c2-8093-e8b4283a6a82" xlink:to="loc_us-gaap_StatementTable_6275bc1f-aaf0-48a1-a422-4c9e62fa0c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ee342c3c-c760-431b-aa93-1104b477e40f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6275bc1f-aaf0-48a1-a422-4c9e62fa0c94" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ee342c3c-c760-431b-aa93-1104b477e40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3b3e472d-7189-41ae-a794-c0d2657df2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ee342c3c-c760-431b-aa93-1104b477e40f" xlink:to="loc_us-gaap_ClassOfStockDomain_3b3e472d-7189-41ae-a794-c0d2657df2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_af07e7ff-8bcf-4012-b289-cd1d1c14b18e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3b3e472d-7189-41ae-a794-c0d2657df2bb" xlink:to="loc_us-gaap_CommonClassAMember_af07e7ff-8bcf-4012-b289-cd1d1c14b18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_7e931521-78ad-43b7-82a6-c14c4a6e76ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3b3e472d-7189-41ae-a794-c0d2657df2bb" xlink:to="loc_us-gaap_CommonClassBMember_7e931521-78ad-43b7-82a6-c14c4a6e76ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember_cde5acef-8072-4580-a611-19c1c6155688" xlink:href="rprx-20211231.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3b3e472d-7189-41ae-a794-c0d2657df2bb" xlink:to="loc_rprx_ClassRRedeemableStockMember_cde5acef-8072-4580-a611-19c1c6155688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_845a702f-c5bc-427c-9ac4-1e3bc855fe31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6275bc1f-aaf0-48a1-a422-4c9e62fa0c94" xlink:to="loc_us-gaap_StatementLineItems_845a702f-c5bc-427c-9ac4-1e3bc855fe31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a4e6d989-34fc-493b-89ba-b24a687c37bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_845a702f-c5bc-427c-9ac4-1e3bc855fe31" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a4e6d989-34fc-493b-89ba-b24a687c37bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_602f8aff-f520-4d55-a10c-6b5e2854e9db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_845a702f-c5bc-427c-9ac4-1e3bc855fe31" xlink:to="loc_us-gaap_CommonStockSharesIssued_602f8aff-f520-4d55-a10c-6b5e2854e9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b9c76088-6db4-4325-abd0-6bfece40fa47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_845a702f-c5bc-427c-9ac4-1e3bc855fe31" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b9c76088-6db4-4325-abd0-6bfece40fa47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesParOrStatedValuePerShare_37ef4f6a-0555-416d-933a-dc2d49e865c0" xlink:href="rprx-20211231.xsd#rprx_DeferredSharesParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_845a702f-c5bc-427c-9ac4-1e3bc855fe31" xlink:to="loc_rprx_DeferredSharesParOrStatedValuePerShare_37ef4f6a-0555-416d-933a-dc2d49e865c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesSharesIssued_604cd83e-7080-40f6-b5e5-c19a14c08c6b" xlink:href="rprx-20211231.xsd#rprx_DeferredSharesSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_845a702f-c5bc-427c-9ac4-1e3bc855fe31" xlink:to="loc_rprx_DeferredSharesSharesIssued_604cd83e-7080-40f6-b5e5-c19a14c08c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesSharesOutstanding_047e412c-e087-482b-afa4-4c6097d7b705" xlink:href="rprx-20211231.xsd#rprx_DeferredSharesSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_845a702f-c5bc-427c-9ac4-1e3bc855fe31" xlink:to="loc_rprx_DeferredSharesSharesOutstanding_047e412c-e087-482b-afa4-4c6097d7b705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="rprx-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_0fd1c90c-d9d6-4478-91f2-0a80288da07b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a44211ab-9ce0-49ec-aee8-15031e46aea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0fd1c90c-d9d6-4478-91f2-0a80288da07b" xlink:to="loc_us-gaap_StatementTable_a44211ab-9ce0-49ec-aee8-15031e46aea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_df800a45-4eb3-4a6a-9ee3-560a8a2f1245" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a44211ab-9ce0-49ec-aee8-15031e46aea8" xlink:to="loc_srt_ProductOrServiceAxis_df800a45-4eb3-4a6a-9ee3-560a8a2f1245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c034b598-be9a-46f8-8053-6a635bf2c5f6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_df800a45-4eb3-4a6a-9ee3-560a8a2f1245" xlink:to="loc_srt_ProductsAndServicesDomain_c034b598-be9a-46f8-8053-6a635bf2c5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancialRoyaltyAssetsMember_ccc74c0b-7ca5-4cbe-b471-6b3b90a286d3" xlink:href="rprx-20211231.xsd#rprx_FinancialRoyaltyAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c034b598-be9a-46f8-8053-6a635bf2c5f6" xlink:to="loc_rprx_FinancialRoyaltyAssetsMember_ccc74c0b-7ca5-4cbe-b471-6b3b90a286d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IntangibleRoyaltyAssetsMember_d8910a2b-7783-4598-aec4-a9ddbc82e61e" xlink:href="rprx-20211231.xsd#rprx_IntangibleRoyaltyAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c034b598-be9a-46f8-8053-6a635bf2c5f6" xlink:to="loc_rprx_IntangibleRoyaltyAssetsMember_d8910a2b-7783-4598-aec4-a9ddbc82e61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyIncomeOtherMember_09b61b58-c68d-4c5e-96a5-4de2d1b97808" xlink:href="rprx-20211231.xsd#rprx_RoyaltyIncomeOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c034b598-be9a-46f8-8053-6a635bf2c5f6" xlink:to="loc_rprx_RoyaltyIncomeOtherMember_09b61b58-c68d-4c5e-96a5-4de2d1b97808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a44211ab-9ce0-49ec-aee8-15031e46aea8" xlink:to="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9b4a2f98-7087-4feb-bba8-32ad19848c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:to="loc_us-gaap_Revenues_9b4a2f98-7087-4feb-bba8-32ad19848c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_40a4896f-da66-4730-9a50-dd0b61848409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:to="loc_us-gaap_OperatingExpensesAbstract_40a4896f-da66-4730-9a50-dd0b61848409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLoanAndLeaseLosses_0f8155b5-ce09-4a2e-89df-e3765a28f4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForLoanAndLeaseLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_40a4896f-da66-4730-9a50-dd0b61848409" xlink:to="loc_us-gaap_ProvisionForLoanAndLeaseLosses_0f8155b5-ce09-4a2e-89df-e3765a28f4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f7e6750b-1b74-4d57-bb99-8509306d039b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_40a4896f-da66-4730-9a50-dd0b61848409" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f7e6750b-1b74-4d57-bb99-8509306d039b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_a73ba091-ea0c-46e4-b6b1-7d53bd6433c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_40a4896f-da66-4730-9a50-dd0b61848409" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_a73ba091-ea0c-46e4-b6b1-7d53bd6433c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c9552414-8b17-4c5c-a69a-692ea9885208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_40a4896f-da66-4730-9a50-dd0b61848409" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c9552414-8b17-4c5c-a69a-692ea9885208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_77482040-3f7f-4811-8400-72ad051fdbea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_40a4896f-da66-4730-9a50-dd0b61848409" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_77482040-3f7f-4811-8400-72ad051fdbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_112ed2e2-94d5-445c-9493-e39db972f403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_40a4896f-da66-4730-9a50-dd0b61848409" xlink:to="loc_us-gaap_CostsAndExpenses_112ed2e2-94d5-445c-9493-e39db972f403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_67febf44-eafd-471a-9efa-6063c296087b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:to="loc_us-gaap_OperatingIncomeLoss_67febf44-eafd-471a-9efa-6063c296087b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_6c4b875f-20f6-4649-851d-6fa6feecbd79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_6c4b875f-20f6-4649-851d-6fa6feecbd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f7618f97-f65f-49f7-b776-0058bfc8173b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6c4b875f-20f6-4649-851d-6fa6feecbd79" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f7618f97-f65f-49f7-b776-0058bfc8173b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e976be32-6f85-4ebc-9a0b-4d09d437ee28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6c4b875f-20f6-4649-851d-6fa6feecbd79" xlink:to="loc_us-gaap_InterestExpense_e976be32-6f85-4ebc-9a0b-4d09d437ee28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_78aede15-1c0e-4154-9f21-feed48d4d3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6c4b875f-20f6-4649-851d-6fa6feecbd79" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_78aede15-1c0e-4154-9f21-feed48d4d3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6da940e9-f908-4d70-8f65-91a211160a24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6c4b875f-20f6-4649-851d-6fa6feecbd79" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6da940e9-f908-4d70-8f65-91a211160a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_78b2535a-3165-4fa8-a42e-50449bcf6e25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6c4b875f-20f6-4649-851d-6fa6feecbd79" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_78b2535a-3165-4fa8-a42e-50449bcf6e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_8659219f-028c-4bb6-b5d1-874c5cfed900" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6c4b875f-20f6-4649-851d-6fa6feecbd79" xlink:to="loc_us-gaap_InvestmentIncomeNet_8659219f-028c-4bb6-b5d1-874c5cfed900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4ca32604-8ec0-40f7-ad20-24b75aae13ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6c4b875f-20f6-4649-851d-6fa6feecbd79" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4ca32604-8ec0-40f7-ad20-24b75aae13ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d5b1741f-810a-4db1-93a3-13e3beec32c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6c4b875f-20f6-4649-851d-6fa6feecbd79" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d5b1741f-810a-4db1-93a3-13e3beec32c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ffd742b8-9a74-48a0-997e-133025197597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ffd742b8-9a74-48a0-997e-133025197597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5a57be8b-311c-40e9-96cf-e15fa2982a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5a57be8b-311c-40e9-96cf-e15fa2982a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f8568939-0d09-4d65-999a-6213379921bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:to="loc_us-gaap_ProfitLoss_f8568939-0d09-4d65-999a-6213379921bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_124ed472-abd4-4480-be51-4e49e6c36862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_124ed472-abd4-4480-be51-4e49e6c36862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6e3906f4-13e0-41f9-8082-96450a8159a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:to="loc_us-gaap_NetIncomeLoss_6e3906f4-13e0-41f9-8082-96450a8159a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_8aeb50e3-ecf0-48d0-8a10-4631b5302a54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_8aeb50e3-ecf0-48d0-8a10-4631b5302a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7ff4f5b1-e75d-448c-b865-9ed235bc2ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_8aeb50e3-ecf0-48d0-8a10-4631b5302a54" xlink:to="loc_us-gaap_EarningsPerShareBasic_7ff4f5b1-e75d-448c-b865-9ed235bc2ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9620e72a-96c1-43a6-b4df-f4a0a78ff820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_8aeb50e3-ecf0-48d0-8a10-4631b5302a54" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9620e72a-96c1-43a6-b4df-f4a0a78ff820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ace0162b-8f49-4151-97d9-1e6c660f9745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6cb35901-c0ba-4301-8be9-b71c97ddc9fd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ace0162b-8f49-4151-97d9-1e6c660f9745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3fa5f0b7-9655-4cf1-b4a4-78a74c6a58dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ace0162b-8f49-4151-97d9-1e6c660f9745" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3fa5f0b7-9655-4cf1-b4a4-78a74c6a58dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_edc9d8d8-1899-4086-85e5-48fe4b26f80b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ace0162b-8f49-4151-97d9-1e6c660f9745" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_edc9d8d8-1899-4086-85e5-48fe4b26f80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="rprx-20211231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3f4346cb-ba67-479b-8b79-ce6c739d3f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_434f8122-5efa-496d-940b-4a57e5898098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3f4346cb-ba67-479b-8b79-ce6c739d3f7f" xlink:to="loc_us-gaap_ProfitLoss_434f8122-5efa-496d-940b-4a57e5898098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3098fa5a-514e-4383-94a6-37cc1890a35a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3f4346cb-ba67-479b-8b79-ce6c739d3f7f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3098fa5a-514e-4383-94a6-37cc1890a35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_4101e172-f235-4325-aee0-613e5eb89ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3098fa5a-514e-4383-94a6-37cc1890a35a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_4101e172-f235-4325-aee0-613e5eb89ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e25b8d4a-64fd-40d5-b641-03d0b8e2d888" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3098fa5a-514e-4383-94a6-37cc1890a35a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e25b8d4a-64fd-40d5-b641-03d0b8e2d888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_6538795b-449c-4bbd-9e02-ca5a415d01f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3098fa5a-514e-4383-94a6-37cc1890a35a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_6538795b-449c-4bbd-9e02-ca5a415d01f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_50a6a155-e715-48d5-a0ad-d262c3e79079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3098fa5a-514e-4383-94a6-37cc1890a35a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_50a6a155-e715-48d5-a0ad-d262c3e79079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a88ff711-09f7-4c10-af16-4d3dd2e7670e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3f4346cb-ba67-479b-8b79-ce6c739d3f7f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a88ff711-09f7-4c10-af16-4d3dd2e7670e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_aa0e4fcf-7ba1-4b03-805f-51fecf8e6e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3f4346cb-ba67-479b-8b79-ce6c739d3f7f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_aa0e4fcf-7ba1-4b03-805f-51fecf8e6e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b6c60b93-954b-445f-85aa-bc76d801687f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3f4346cb-ba67-479b-8b79-ce6c739d3f7f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_b6c60b93-954b-445f-85aa-bc76d801687f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="rprx-20211231.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_22e209e7-9c79-4c6f-b2ef-5629da406c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_543c8721-2501-4729-9df3-ad71e7111a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_22e209e7-9c79-4c6f-b2ef-5629da406c0d" xlink:to="loc_us-gaap_StatementTable_543c8721-2501-4729-9df3-ad71e7111a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c7392574-27b3-4edd-a027-8710d6cb567c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_543c8721-2501-4729-9df3-ad71e7111a5e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c7392574-27b3-4edd-a027-8710d6cb567c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1711a459-7ec3-4553-b03a-b9de234df351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c7392574-27b3-4edd-a027-8710d6cb567c" xlink:to="loc_us-gaap_EquityComponentDomain_1711a459-7ec3-4553-b03a-b9de234df351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d1ddb68c-cd34-42f3-894f-02c642e6ba2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1711a459-7ec3-4553-b03a-b9de234df351" xlink:to="loc_us-gaap_CommonStockMember_d1ddb68c-cd34-42f3-894f-02c642e6ba2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesMember_13e0244e-5795-49a8-8d83-d8226c1a49ad" xlink:href="rprx-20211231.xsd#rprx_DeferredSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1711a459-7ec3-4553-b03a-b9de234df351" xlink:to="loc_rprx_DeferredSharesMember_13e0244e-5795-49a8-8d83-d8226c1a49ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_cc8d99cb-db8d-4e19-b2a2-5580ed37acc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1711a459-7ec3-4553-b03a-b9de234df351" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_cc8d99cb-db8d-4e19-b2a2-5580ed37acc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_UnitHoldersAndShareholdersContributionsMember_9c903b9b-94e8-42ab-90b2-996fbdfda0f6" xlink:href="rprx-20211231.xsd#rprx_UnitHoldersAndShareholdersContributionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1711a459-7ec3-4553-b03a-b9de234df351" xlink:to="loc_rprx_UnitHoldersAndShareholdersContributionsMember_9c903b9b-94e8-42ab-90b2-996fbdfda0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_76cd25d6-05d0-4a44-adb7-c3e26b9810f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1711a459-7ec3-4553-b03a-b9de234df351" xlink:to="loc_us-gaap_RetainedEarningsMember_76cd25d6-05d0-4a44-adb7-c3e26b9810f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_1b43bc82-0310-4124-afe7-473a6f8254ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1711a459-7ec3-4553-b03a-b9de234df351" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_1b43bc82-0310-4124-afe7-473a6f8254ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_88305db8-6553-49eb-a25d-748b9d0499a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1711a459-7ec3-4553-b03a-b9de234df351" xlink:to="loc_us-gaap_NoncontrollingInterestMember_88305db8-6553-49eb-a25d-748b9d0499a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_aadce750-7d42-466d-a4ed-17efd71a40c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1711a459-7ec3-4553-b03a-b9de234df351" xlink:to="loc_us-gaap_TreasuryStockMember_aadce750-7d42-466d-a4ed-17efd71a40c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9a87886f-e6d0-4fbb-bdc6-42c6be092aac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_543c8721-2501-4729-9df3-ad71e7111a5e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9a87886f-e6d0-4fbb-bdc6-42c6be092aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d65495c9-d182-4bb3-9ecc-2881f69d6958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9a87886f-e6d0-4fbb-bdc6-42c6be092aac" xlink:to="loc_us-gaap_ClassOfStockDomain_d65495c9-d182-4bb3-9ecc-2881f69d6958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_684873e9-d5a9-41c2-aa3d-461ba193a676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d65495c9-d182-4bb3-9ecc-2881f69d6958" xlink:to="loc_us-gaap_CommonClassAMember_684873e9-d5a9-41c2-aa3d-461ba193a676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_8c46b0a0-912e-4151-a2f6-f0171767463b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d65495c9-d182-4bb3-9ecc-2881f69d6958" xlink:to="loc_us-gaap_CommonClassBMember_8c46b0a0-912e-4151-a2f6-f0171767463b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember_b4b4980b-e888-40ed-b89c-e525d818e06f" xlink:href="rprx-20211231.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d65495c9-d182-4bb3-9ecc-2881f69d6958" xlink:to="loc_rprx_ClassRRedeemableStockMember_b4b4980b-e888-40ed-b89c-e525d818e06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_70e8e570-af25-4551-ae20-0bbca657ef77" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_543c8721-2501-4729-9df3-ad71e7111a5e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_70e8e570-af25-4551-ae20-0bbca657ef77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_82d7baa1-a404-4fc0-8693-f13af7c4def7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_70e8e570-af25-4551-ae20-0bbca657ef77" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_82d7baa1-a404-4fc0-8693-f13af7c4def7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3bec45f1-e9fe-43e4-b625-03c67b7ab478" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_82d7baa1-a404-4fc0-8693-f13af7c4def7" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3bec45f1-e9fe-43e4-b625-03c67b7ab478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6d3d6e5d-ba2d-4799-bb40-ef64caae3578" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_543c8721-2501-4729-9df3-ad71e7111a5e" xlink:to="loc_us-gaap_StatementLineItems_6d3d6e5d-ba2d-4799-bb40-ef64caae3578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6d3d6e5d-ba2d-4799-bb40-ef64caae3578" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_06a07737-f3ad-4a88-8b27-e216c718fe9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_SharesOutstanding_06a07737-f3ad-4a88-8b27-e216c718fe9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8dd172e6-eed6-43ba-8f81-64edb644b0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8dd172e6-eed6-43ba-8f81-64edb644b0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_003e33dc-49aa-421c-85a3-18a0d73b59ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_003e33dc-49aa-421c-85a3-18a0d73b59ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_27867743-2ee1-4627-bcde-3a7e5d0f3047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_ProfitLoss_27867743-2ee1-4627-bcde-3a7e5d0f3047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c1446f21-3df4-448e-b2d3-711543577b45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c1446f21-3df4-448e-b2d3-711543577b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_971f9331-14a1-42e5-bc75-48d478ba8d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_971f9331-14a1-42e5-bc75-48d478ba8d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_b6e71ccb-2a8e-40d0-820d-d2d6a6904a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_b6e71ccb-2a8e-40d0-820d-d2d6a6904a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestIncreaseFromContributions_7efedf19-9a08-43e6-a5fc-20b222b351cc" xlink:href="rprx-20211231.xsd#rprx_NoncontrollingInterestIncreaseFromContributions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_rprx_NoncontrollingInterestIncreaseFromContributions_7efedf19-9a08-43e6-a5fc-20b222b351cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestTransfersOfInterests_948ff574-fae9-4c63-9a3e-eccac8d822c4" xlink:href="rprx-20211231.xsd#rprx_NoncontrollingInterestTransfersOfInterests"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_rprx_NoncontrollingInterestTransfersOfInterests_948ff574-fae9-4c63-9a3e-eccac8d822c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_703f7308-d2cb-4c1a-906c-d03e564eaeeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_703f7308-d2cb-4c1a-906c-d03e564eaeeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration_65d1c7f6-3783-4aaa-ae28-7146585c190e" xlink:href="rprx-20211231.xsd#rprx_StockIssuedDuringPeriodSharesIssuedForRegistration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration_65d1c7f6-3783-4aaa-ae28-7146585c190e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockIssuedDuringPeriodValueIssuedForRegistration_3be71060-24dc-4f69-bb7a-14fb55c1d3a4" xlink:href="rprx-20211231.xsd#rprx_StockIssuedDuringPeriodValueIssuedForRegistration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_rprx_StockIssuedDuringPeriodValueIssuedForRegistration_3be71060-24dc-4f69-bb7a-14fb55c1d3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships_ea12c609-540c-4ec3-a420-184f20a9a0b5" xlink:href="rprx-20211231.xsd#rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships_ea12c609-540c-4ec3-a420-184f20a9a0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships_f5ba346e-f0df-4d95-91a8-4917f3f67fd2" xlink:href="rprx-20211231.xsd#rprx_StockIssuedDuringPeriodValueIssuedToPartnerships"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships_f5ba346e-f0df-4d95-91a8-4917f3f67fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation_918a2f1f-5713-4331-83dc-14b471969cc6" xlink:href="rprx-20211231.xsd#rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation_918a2f1f-5713-4331-83dc-14b471969cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation_0182979c-99d6-45ed-86ae-b66dbfac5060" xlink:href="rprx-20211231.xsd#rprx_StockholdersEquityValueEffectOfExchangeAndReallocation"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation_0182979c-99d6-45ed-86ae-b66dbfac5060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_60ce67a0-b391-42a4-8655-9fc52a1833fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_60ce67a0-b391-42a4-8655-9fc52a1833fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7d038102-d569-4b3d-a04e-5744daf60bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7d038102-d569-4b3d-a04e-5744daf60bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_88e30d57-8d48-4865-8f32-ac02606fa979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_88e30d57-8d48-4865-8f32-ac02606fa979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_824445fd-44b9-44b0-abe9-c25365b25395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_824445fd-44b9-44b0-abe9-c25365b25395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_1362817d-e2b0-4be8-b2f7-a82a17822cce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_1362817d-e2b0-4be8-b2f7-a82a17822cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_152cc7f3-ad30-46b1-83b7-d2d5f9e1447c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_StockholdersEquityOther_152cc7f3-ad30-46b1-83b7-d2d5f9e1447c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCash_c81ea6a1-0d84-4fdc-b624-63409b711112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCash"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_DividendsCash_c81ea6a1-0d84-4fdc-b624-63409b711112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_b456a5c0-ebde-4da7-9f68-58506deb5d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_b456a5c0-ebde-4da7-9f68-58506deb5d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_4ce125eb-0a3a-407f-ae57-b162392c9e73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_SharesOutstanding_4ce125eb-0a3a-407f-ae57-b162392c9e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_929413de-beec-4ac9-a83f-b40a5013bdb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165650-b4cf-49cb-80f4-c2ddc61fe62e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_929413de-beec-4ac9-a83f-b40a5013bdb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="simple" xlink:href="rprx-20211231.xsd#ConsolidatedStatementsofShareholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d1d17c39-3bf5-4d4f-a25f-de142eaba18b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_af0cf6c0-1def-481e-ab03-1324453fff2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d1d17c39-3bf5-4d4f-a25f-de142eaba18b" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_af0cf6c0-1def-481e-ab03-1324453fff2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="rprx-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_8c4b7299-880a-41ed-90bf-1ed519684434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_479b97f2-0e72-4e8b-b21b-2b24229e1eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8c4b7299-880a-41ed-90bf-1ed519684434" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_479b97f2-0e72-4e8b-b21b-2b24229e1eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables_17d5bd0e-c136-45c1-b80b-58047762cc1e" xlink:href="rprx-20211231.xsd#rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_479b97f2-0e72-4e8b-b21b-2b24229e1eb4" xlink:to="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables_17d5bd0e-c136-45c1-b80b-58047762cc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets_a0c2e259-435b-447d-af06-434693b288fb" xlink:href="rprx-20211231.xsd#rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_479b97f2-0e72-4e8b-b21b-2b24229e1eb4" xlink:to="loc_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets_a0c2e259-435b-447d-af06-434693b288fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables_5495d49a-e515-4170-90b1-4e399a9676f2" xlink:href="rprx-20211231.xsd#rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_479b97f2-0e72-4e8b-b21b-2b24229e1eb4" xlink:to="loc_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables_5495d49a-e515-4170-90b1-4e399a9676f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_0ea28acc-b79e-4f98-864d-f8236614dbba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_479b97f2-0e72-4e8b-b21b-2b24229e1eb4" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_0ea28acc-b79e-4f98-864d-f8236614dbba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_91e9944b-dd3f-42f4-928c-18d5be92f9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_479b97f2-0e72-4e8b-b21b-2b24229e1eb4" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_91e9944b-dd3f-42f4-928c-18d5be92f9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_e053b5d8-8871-4a28-ae93-72a8cc348690" xlink:href="rprx-20211231.xsd#rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_479b97f2-0e72-4e8b-b21b-2b24229e1eb4" xlink:to="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_e053b5d8-8871-4a28-ae93-72a8cc348690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForCollateralPostedOnDerivativeInstruments_ed7d812f-c358-43a1-9eea-c63141452a01" xlink:href="rprx-20211231.xsd#rprx_PaymentsForCollateralPostedOnDerivativeInstruments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_479b97f2-0e72-4e8b-b21b-2b24229e1eb4" xlink:to="loc_rprx_PaymentsForCollateralPostedOnDerivativeInstruments_ed7d812f-c358-43a1-9eea-c63141452a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToTerminateDerivativeInstruments_d920c678-cfe9-4302-a005-c878c9b41fd9" xlink:href="rprx-20211231.xsd#rprx_PaymentsToTerminateDerivativeInstruments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_479b97f2-0e72-4e8b-b21b-2b24229e1eb4" xlink:to="loc_rprx_PaymentsToTerminateDerivativeInstruments_d920c678-cfe9-4302-a005-c878c9b41fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForOngoingDevelopmentStageFunding_97513869-82a4-48a4-a5bc-460da6e92eba" xlink:href="rprx-20211231.xsd#rprx_PaymentsForOngoingDevelopmentStageFunding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_479b97f2-0e72-4e8b-b21b-2b24229e1eb4" xlink:to="loc_rprx_PaymentsForOngoingDevelopmentStageFunding_97513869-82a4-48a4-a5bc-460da6e92eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForUpfrontDevelopmentStageFunding_e2f30998-62c9-4149-9171-64f9795ad970" xlink:href="rprx-20211231.xsd#rprx_PaymentsForUpfrontDevelopmentStageFunding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_479b97f2-0e72-4e8b-b21b-2b24229e1eb4" xlink:to="loc_rprx_PaymentsForUpfrontDevelopmentStageFunding_e2f30998-62c9-4149-9171-64f9795ad970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForOperatingCostsAndProfessionalServices_96b53d0f-7f1c-4766-9ec4-b0e398d3e252" xlink:href="rprx-20211231.xsd#rprx_PaymentsForOperatingCostsAndProfessionalServices"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_479b97f2-0e72-4e8b-b21b-2b24229e1eb4" xlink:to="loc_rprx_PaymentsForOperatingCostsAndProfessionalServices_96b53d0f-7f1c-4766-9ec4-b0e398d3e252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_ff7f0cfa-9cb1-402c-ac5d-f202ed12cbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_479b97f2-0e72-4e8b-b21b-2b24229e1eb4" xlink:to="loc_us-gaap_InterestPaidNet_ff7f0cfa-9cb1-402c-ac5d-f202ed12cbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_45650a2d-2980-4f81-b2d2-311f06e3ab98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_479b97f2-0e72-4e8b-b21b-2b24229e1eb4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_45650a2d-2980-4f81-b2d2-311f06e3ab98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8d39c9ea-cc1a-43e3-9040-3e2192c9dbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8c4b7299-880a-41ed-90bf-1ed519684434" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8d39c9ea-cc1a-43e3-9040-3e2192c9dbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_9b738db6-a0c1-4b17-8e3b-bad3a1673578" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8d39c9ea-cc1a-43e3-9040-3e2192c9dbc1" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_9b738db6-a0c1-4b17-8e3b-bad3a1673578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_c4a7aca3-7803-4bfe-a454-d522885dfc57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8d39c9ea-cc1a-43e3-9040-3e2192c9dbc1" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_c4a7aca3-7803-4bfe-a454-d522885dfc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireEquitySecuritiesFNNI_8c0e99c3-5c44-4e25-a261-863ff4c97303" xlink:href="rprx-20211231.xsd#rprx_PaymentsToAcquireEquitySecuritiesFNNI"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8d39c9ea-cc1a-43e3-9040-3e2192c9dbc1" xlink:to="loc_rprx_PaymentsToAcquireEquitySecuritiesFNNI_8c0e99c3-5c44-4e25-a261-863ff4c97303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI_6f876d76-7687-463a-8e77-0548ee98e7d6" xlink:href="rprx-20211231.xsd#rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8d39c9ea-cc1a-43e3-9040-3e2192c9dbc1" xlink:to="loc_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI_6f876d76-7687-463a-8e77-0548ee98e7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_56fccd8d-e5de-4cfa-8c01-6197f28376f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8d39c9ea-cc1a-43e3-9040-3e2192c9dbc1" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_56fccd8d-e5de-4cfa-8c01-6197f28376f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_3eb4f994-e0c0-4030-99ed-71ae39dc7a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8d39c9ea-cc1a-43e3-9040-3e2192c9dbc1" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_3eb4f994-e0c0-4030-99ed-71ae39dc7a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_0b492980-5851-4044-a45d-debd402cd388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8d39c9ea-cc1a-43e3-9040-3e2192c9dbc1" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_0b492980-5851-4044-a45d-debd402cd388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_caf8e857-10a2-4fad-bf4e-349a0aafad04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8d39c9ea-cc1a-43e3-9040-3e2192c9dbc1" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_caf8e857-10a2-4fad-bf4e-349a0aafad04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireWarrants_c9e03d91-6a4b-45aa-bc67-31f6538d6e16" xlink:href="rprx-20211231.xsd#rprx_PaymentsToAcquireWarrants"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8d39c9ea-cc1a-43e3-9040-3e2192c9dbc1" xlink:to="loc_rprx_PaymentsToAcquireWarrants_c9e03d91-6a4b-45aa-bc67-31f6538d6e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireFinanceReceivables_cac81de4-da9d-4478-875c-459d2127fa57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireFinanceReceivables"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8d39c9ea-cc1a-43e3-9040-3e2192c9dbc1" xlink:to="loc_us-gaap_PaymentsToAcquireFinanceReceivables_cac81de4-da9d-4478-875c-459d2127fa57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForMilestones_06d32941-18e9-4f19-830e-d46ea75b59d0" xlink:href="rprx-20211231.xsd#rprx_PaymentsForMilestones"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8d39c9ea-cc1a-43e3-9040-3e2192c9dbc1" xlink:to="loc_rprx_PaymentsForMilestones_06d32941-18e9-4f19-830e-d46ea75b59d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f4fec0a5-2604-4347-bc95-28a071a8a689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8d39c9ea-cc1a-43e3-9040-3e2192c9dbc1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f4fec0a5-2604-4347-bc95-28a071a8a689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_57c0c3c5-7f08-47a9-a024-e017ba0d2c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8c4b7299-880a-41ed-90bf-1ed519684434" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_57c0c3c5-7f08-47a9-a024-e017ba0d2c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsForDistributionsToShareholdersAndUnitholders_7f6fe6b8-5e02-4556-86b2-62e14e7a31e0" xlink:href="rprx-20211231.xsd#rprx_PaymentsForDistributionsToShareholdersAndUnitholders"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_57c0c3c5-7f08-47a9-a024-e017ba0d2c59" xlink:to="loc_rprx_PaymentsForDistributionsToShareholdersAndUnitholders_7f6fe6b8-5e02-4556-86b2-62e14e7a31e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_4cc3ea50-e00d-432b-9140-cece84ad90df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_57c0c3c5-7f08-47a9-a024-e017ba0d2c59" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_4cc3ea50-e00d-432b-9140-cece84ad90df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToNoncontrollingInterestsOther_671ea1b1-8971-4e8f-aa24-87f43b910430" xlink:href="rprx-20211231.xsd#rprx_PaymentsToNoncontrollingInterestsOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_57c0c3c5-7f08-47a9-a024-e017ba0d2c59" xlink:to="loc_rprx_PaymentsToNoncontrollingInterestsOther_671ea1b1-8971-4e8f-aa24-87f43b910430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentOfDividendsToShareholders_a9852d98-a460-48dd-9917-f16171475a6b" xlink:href="rprx-20211231.xsd#rprx_PaymentOfDividendsToShareholders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_57c0c3c5-7f08-47a9-a024-e017ba0d2c59" xlink:to="loc_rprx_PaymentOfDividendsToShareholders_a9852d98-a460-48dd-9917-f16171475a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment_643e04f5-ee5a-459b-86d2-25dcd9856d9f" xlink:href="rprx-20211231.xsd#rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_57c0c3c5-7f08-47a9-a024-e017ba0d2c59" xlink:to="loc_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment_643e04f5-ee5a-459b-86d2-25dcd9856d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromNoncontrollingInterestsOther_c7893c75-8927-4d53-bbc8-cd02273831f6" xlink:href="rprx-20211231.xsd#rprx_ProceedsFromNoncontrollingInterestsOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_57c0c3c5-7f08-47a9-a024-e017ba0d2c59" xlink:to="loc_rprx_ProceedsFromNoncontrollingInterestsOther_c7893c75-8927-4d53-bbc8-cd02273831f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RepaymentsOfLongTermDebtScheduledPayments_e4eeb933-d726-43a7-8bb4-d474c0cbabf2" xlink:href="rprx-20211231.xsd#rprx_RepaymentsOfLongTermDebtScheduledPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_57c0c3c5-7f08-47a9-a024-e017ba0d2c59" xlink:to="loc_rprx_RepaymentsOfLongTermDebtScheduledPayments_e4eeb933-d726-43a7-8bb4-d474c0cbabf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_122aecdc-cbe5-4332-8315-1af327b50256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_57c0c3c5-7f08-47a9-a024-e017ba0d2c59" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_122aecdc-cbe5-4332-8315-1af327b50256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_49df2f19-6763-45ad-b9dc-2b0c08b8338a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_57c0c3c5-7f08-47a9-a024-e017ba0d2c59" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_49df2f19-6763-45ad-b9dc-2b0c08b8338a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_c1fb3e01-91eb-4d98-80da-a9f53a44b72e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_57c0c3c5-7f08-47a9-a024-e017ba0d2c59" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_c1fb3e01-91eb-4d98-80da-a9f53a44b72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1b521ff0-c968-45f8-9515-f946f8b2a5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_57c0c3c5-7f08-47a9-a024-e017ba0d2c59" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1b521ff0-c968-45f8-9515-f946f8b2a5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4fa7e0d2-9a91-4623-a677-696d4f6df1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_57c0c3c5-7f08-47a9-a024-e017ba0d2c59" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4fa7e0d2-9a91-4623-a677-696d4f6df1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c3742e61-182f-4c6d-ae31-9347e40bc79d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_57c0c3c5-7f08-47a9-a024-e017ba0d2c59" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c3742e61-182f-4c6d-ae31-9347e40bc79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a1b2d34d-bce9-40f0-852b-ab47e605830f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8c4b7299-880a-41ed-90bf-1ed519684434" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a1b2d34d-bce9-40f0-852b-ab47e605830f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6f6bf0ea-2d1f-40b9-96e7-c3f4a7419450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8c4b7299-880a-41ed-90bf-1ed519684434" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6f6bf0ea-2d1f-40b9-96e7-c3f4a7419450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0d3a0d8d-1469-4f24-ae23-97d2c9abc6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8c4b7299-880a-41ed-90bf-1ed519684434" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0d3a0d8d-1469-4f24-ae23-97d2c9abc6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/OrganizationandPurpose" xlink:type="simple" xlink:href="rprx-20211231.xsd#OrganizationandPurpose"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/OrganizationandPurpose" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d4206400-29de-469b-b2c6-15cd7f8386ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_10ed045a-ced5-466f-a983-2383097f142d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d4206400-29de-469b-b2c6-15cd7f8386ee" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_10ed045a-ced5-466f-a983-2383097f142d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/OrganizationandPurposeDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#OrganizationandPurposeDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/OrganizationandPurposeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b3902bc-dcc7-460b-b173-11193998a5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_afc998d0-83a2-4168-b13e-18fc8c13d16b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b3902bc-dcc7-460b-b173-11193998a5c4" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_afc998d0-83a2-4168-b13e-18fc8c13d16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5b4cc016-d386-4c4e-96f1-7867af9e80ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_afc998d0-83a2-4168-b13e-18fc8c13d16b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5b4cc016-d386-4c4e-96f1-7867af9e80ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5e67622d-7387-4da7-a697-f08a7f7b7c63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5b4cc016-d386-4c4e-96f1-7867af9e80ae" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5e67622d-7387-4da7-a697-f08a7f7b7c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ExchangeOfferTransactionMember_011e78b7-5bb4-4205-89e4-721806c66511" xlink:href="rprx-20211231.xsd#rprx_ExchangeOfferTransactionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5e67622d-7387-4da7-a697-f08a7f7b7c63" xlink:to="loc_rprx_ExchangeOfferTransactionMember_011e78b7-5bb4-4205-89e4-721806c66511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_d8506b2b-b283-45ac-939e-6d5195202163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5e67622d-7387-4da7-a697-f08a7f7b7c63" xlink:to="loc_us-gaap_IPOMember_d8506b2b-b283-45ac-939e-6d5195202163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IPOSharesFromCompanyMember_bb5caad7-c052-4203-8d1f-6c7548346ebd" xlink:href="rprx-20211231.xsd#rprx_IPOSharesFromCompanyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5e67622d-7387-4da7-a697-f08a7f7b7c63" xlink:to="loc_rprx_IPOSharesFromCompanyMember_bb5caad7-c052-4203-8d1f-6c7548346ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IPOSharesFromSellingShareholdersMember_1c593a2d-fdb0-46f5-a0f4-013ac591c782" xlink:href="rprx-20211231.xsd#rprx_IPOSharesFromSellingShareholdersMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5e67622d-7387-4da7-a697-f08a7f7b7c63" xlink:to="loc_rprx_IPOSharesFromSellingShareholdersMember_1c593a2d-fdb0-46f5-a0f4-013ac591c782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IPOContinuingInvestorsPartnershipsMember_9361ad1e-7555-415f-b564-fc375cca5999" xlink:href="rprx-20211231.xsd#rprx_IPOContinuingInvestorsPartnershipsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5e67622d-7387-4da7-a697-f08a7f7b7c63" xlink:to="loc_rprx_IPOContinuingInvestorsPartnershipsMember_9361ad1e-7555-415f-b564-fc375cca5999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5801884c-6169-47c8-b9fb-0760d0a23a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_afc998d0-83a2-4168-b13e-18fc8c13d16b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5801884c-6169-47c8-b9fb-0760d0a23a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1398a4f3-cb51-4cd6-961c-1187489a73ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5801884c-6169-47c8-b9fb-0760d0a23a73" xlink:to="loc_us-gaap_ClassOfStockDomain_1398a4f3-cb51-4cd6-961c-1187489a73ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_b0f2ddd5-4d9a-45db-ba96-a82b84c09877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1398a4f3-cb51-4cd6-961c-1187489a73ee" xlink:to="loc_us-gaap_CommonClassAMember_b0f2ddd5-4d9a-45db-ba96-a82b84c09877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_13ee719c-4f10-4c75-b64b-3310cd34e195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1398a4f3-cb51-4cd6-961c-1187489a73ee" xlink:to="loc_us-gaap_CommonClassBMember_13ee719c-4f10-4c75-b64b-3310cd34e195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f0406f70-c2c1-4b97-a29d-c022c734be4a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_afc998d0-83a2-4168-b13e-18fc8c13d16b" xlink:to="loc_dei_LegalEntityAxis_f0406f70-c2c1-4b97-a29d-c022c734be4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2fbf8be6-3130-4c8e-b3f4-126aaf58def0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_f0406f70-c2c1-4b97-a29d-c022c734be4a" xlink:to="loc_dei_EntityDomain_2fbf8be6-3130-4c8e-b3f4-126aaf58def0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember_586b9318-e134-40a8-ac82-01a6547c6024" xlink:href="rprx-20211231.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2fbf8be6-3130-4c8e-b3f4-126aaf58def0" xlink:to="loc_rprx_LegacyInvestorsPartnershipsMember_586b9318-e134-40a8-ac82-01a6547c6024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember_fcc1794f-6302-4411-b54d-a92755e35cc9" xlink:href="rprx-20211231.xsd#rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2fbf8be6-3130-4c8e-b3f4-126aaf58def0" xlink:to="loc_rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember_fcc1794f-6302-4411-b54d-a92755e35cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPI2019IntermediateFinanceMember_aedba752-30df-466b-b5e7-f8b8eea18d01" xlink:href="rprx-20211231.xsd#rprx_RPI2019IntermediateFinanceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2fbf8be6-3130-4c8e-b3f4-126aaf58def0" xlink:to="loc_rprx_RPI2019IntermediateFinanceMember_aedba752-30df-466b-b5e7-f8b8eea18d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_97ee97c3-d00b-4ef9-92b8-17270cffd683" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_afc998d0-83a2-4168-b13e-18fc8c13d16b" xlink:to="loc_srt_OwnershipAxis_97ee97c3-d00b-4ef9-92b8-17270cffd683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f07aa010-8870-481c-94fb-3f13068fcac4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_97ee97c3-d00b-4ef9-92b8-17270cffd683" xlink:to="loc_srt_OwnershipDomain_f07aa010-8870-481c-94fb-3f13068fcac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember_e83bc0b5-a180-4ded-9514-e66720cd72c6" xlink:href="rprx-20211231.xsd#rprx_RoyaltyPharmaInvestmentsOldRPIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_f07aa010-8870-481c-94fb-3f13068fcac4" xlink:to="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember_e83bc0b5-a180-4ded-9514-e66720cd72c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyPharmaCollectionTrustMember_4ae01e68-809d-4352-bfa0-8db0b452fb13" xlink:href="rprx-20211231.xsd#rprx_RoyaltyPharmaCollectionTrustMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_f07aa010-8870-481c-94fb-3f13068fcac4" xlink:to="loc_rprx_RoyaltyPharmaCollectionTrustMember_4ae01e68-809d-4352-bfa0-8db0b452fb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b38527ff-4886-4a20-becc-91b86fdb6249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_afc998d0-83a2-4168-b13e-18fc8c13d16b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b38527ff-4886-4a20-becc-91b86fdb6249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d57a7e3c-5b23-4fed-a92b-041757749860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b38527ff-4886-4a20-becc-91b86fdb6249" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d57a7e3c-5b23-4fed-a92b-041757749860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_9015f2ca-92ff-4a5d-b2c8-7c115f94510f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d57a7e3c-5b23-4fed-a92b-041757749860" xlink:to="loc_us-gaap_SecuredDebtMember_9015f2ca-92ff-4a5d-b2c8-7c115f94510f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d24a75f0-708e-4967-b60c-d06e9eb2b0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_afc998d0-83a2-4168-b13e-18fc8c13d16b" xlink:to="loc_us-gaap_DebtInstrumentAxis_d24a75f0-708e-4967-b60c-d06e9eb2b0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d65abab9-2ca3-4780-9c75-63301145f13f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d24a75f0-708e-4967-b60c-d06e9eb2b0e7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d65abab9-2ca3-4780-9c75-63301145f13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member_472a7a69-5d92-4174-9546-86c94cd24f6f" xlink:href="rprx-20211231.xsd#rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d65abab9-2ca3-4780-9c75-63301145f13f" xlink:to="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member_472a7a69-5d92-4174-9546-86c94cd24f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member_16f62b8c-55ce-4a80-95bd-71acab0e6267" xlink:href="rprx-20211231.xsd#rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d65abab9-2ca3-4780-9c75-63301145f13f" xlink:to="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member_16f62b8c-55ce-4a80-95bd-71acab0e6267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OldCreditFacilityMember_ed6af125-b478-4e5d-be41-1c1740969965" xlink:href="rprx-20211231.xsd#rprx_OldCreditFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d65abab9-2ca3-4780-9c75-63301145f13f" xlink:to="loc_rprx_OldCreditFacilityMember_ed6af125-b478-4e5d-be41-1c1740969965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIFTSeniorSecuredCreditFacilitiesMember_56d347e7-9866-4dd6-a161-f38184ba46d8" xlink:href="rprx-20211231.xsd#rprx_RPIFTSeniorSecuredCreditFacilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d65abab9-2ca3-4780-9c75-63301145f13f" xlink:to="loc_rprx_RPIFTSeniorSecuredCreditFacilitiesMember_56d347e7-9866-4dd6-a161-f38184ba46d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_1d43b0dd-be9c-40ce-81d5-58547938c1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_afc998d0-83a2-4168-b13e-18fc8c13d16b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_1d43b0dd-be9c-40ce-81d5-58547938c1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_7abfb165-5980-4451-b9a5-37d7654c66e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1d43b0dd-be9c-40ce-81d5-58547938c1e9" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_7abfb165-5980-4451-b9a5-37d7654c66e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_5e47594d-326b-4902-82d6-514b8937d792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1d43b0dd-be9c-40ce-81d5-58547938c1e9" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_5e47594d-326b-4902-82d6-514b8937d792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_0411c78f-72b5-4734-9467-4ed4e2950561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1d43b0dd-be9c-40ce-81d5-58547938c1e9" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_0411c78f-72b5-4734-9467-4ed4e2950561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_86e7d9c7-b5d6-4c34-9967-109aec7806a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1d43b0dd-be9c-40ce-81d5-58547938c1e9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_86e7d9c7-b5d6-4c34-9967-109aec7806a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_28ce0951-7a47-43e2-ac3c-3c2e1302de65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1d43b0dd-be9c-40ce-81d5-58547938c1e9" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_28ce0951-7a47-43e2-ac3c-3c2e1302de65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b66fb585-45f2-488a-a0b5-008c8667877f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1d43b0dd-be9c-40ce-81d5-58547938c1e9" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b66fb585-45f2-488a-a0b5-008c8667877f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4ee5968b-9dac-42cc-8863-c47af3de55f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1d43b0dd-be9c-40ce-81d5-58547938c1e9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4ee5968b-9dac-42cc-8863-c47af3de55f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_e05b004f-32a0-4c1a-883a-1ddaf1cee615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1d43b0dd-be9c-40ce-81d5-58547938c1e9" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_e05b004f-32a0-4c1a-883a-1ddaf1cee615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SaleOfStockNumberOfSharesAvailableToConvert_dccfc82c-324c-4a89-8550-690570d355eb" xlink:href="rprx-20211231.xsd#rprx_SaleOfStockNumberOfSharesAvailableToConvert"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1d43b0dd-be9c-40ce-81d5-58547938c1e9" xlink:to="loc_rprx_SaleOfStockNumberOfSharesAvailableToConvert_dccfc82c-324c-4a89-8550-690570d355eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SaleOfStockNumberOfSharesNotConverted_693f469f-2598-461b-a5da-5523fa1a2602" xlink:href="rprx-20211231.xsd#rprx_SaleOfStockNumberOfSharesNotConverted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1d43b0dd-be9c-40ce-81d5-58547938c1e9" xlink:to="loc_rprx_SaleOfStockNumberOfSharesNotConverted_693f469f-2598-461b-a5da-5523fa1a2602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="rprx-20211231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_803e0d40-c5be-484d-a198-901add702611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_ec6c25f0-0755-4caa-8045-da4fe77b103f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_803e0d40-c5be-484d-a198-901add702611" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_ec6c25f0-0755-4caa-8045-da4fe77b103f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="rprx-20211231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9b54ee7a-44ba-4a0e-b11c-c103cd4bb676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ba286c3f-802f-4c4b-b132-06a5d04570d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b54ee7a-44ba-4a0e-b11c-c103cd4bb676" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ba286c3f-802f-4c4b-b132-06a5d04570d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_07c8fc6c-dfa0-43fc-beff-2143fecc90a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b54ee7a-44ba-4a0e-b11c-c103cd4bb676" xlink:to="loc_us-gaap_UseOfEstimates_07c8fc6c-dfa0-43fc-beff-2143fecc90a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_20a02d17-78ec-4d01-9d4f-6696b8af5933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b54ee7a-44ba-4a0e-b11c-c103cd4bb676" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_20a02d17-78ec-4d01-9d4f-6696b8af5933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_85847d8b-be0c-4547-891e-cbc805ef9c39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b54ee7a-44ba-4a0e-b11c-c103cd4bb676" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_85847d8b-be0c-4547-891e-cbc805ef9c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_4a4c465d-818c-445e-86ad-313c867dbf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b54ee7a-44ba-4a0e-b11c-c103cd4bb676" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_4a4c465d-818c-445e-86ad-313c867dbf6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_cb719d45-c302-4635-b77f-e1f2901040e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b54ee7a-44ba-4a0e-b11c-c103cd4bb676" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_cb719d45-c302-4635-b77f-e1f2901040e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyAssetsPolicyPolicyTextBlock_656ea706-b609-4407-9c83-f7217d2662f9" xlink:href="rprx-20211231.xsd#rprx_RoyaltyAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b54ee7a-44ba-4a0e-b11c-c103cd4bb676" xlink:to="loc_rprx_RoyaltyAssetsPolicyPolicyTextBlock_656ea706-b609-4407-9c83-f7217d2662f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLoansAndLeasesReceivablePolicy_889a85c2-68b0-4879-9386-2edff654974c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLoansAndLeasesReceivablePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b54ee7a-44ba-4a0e-b11c-c103cd4bb676" xlink:to="loc_us-gaap_FinanceLoansAndLeasesReceivablePolicy_889a85c2-68b0-4879-9386-2edff654974c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_f209bcb6-a062-444d-8dc6-f7908f240962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b54ee7a-44ba-4a0e-b11c-c103cd4bb676" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_f209bcb6-a062-444d-8dc6-f7908f240962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_99fed343-4fa3-4a83-b8c7-1c1cb5abd97e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b54ee7a-44ba-4a0e-b11c-c103cd4bb676" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_99fed343-4fa3-4a83-b8c7-1c1cb5abd97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_9b0ba7fb-6a42-4af5-918e-2be8531c3daa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b54ee7a-44ba-4a0e-b11c-c103cd4bb676" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_9b0ba7fb-6a42-4af5-918e-2be8531c3daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_cdb6a73b-4e99-4671-aa44-1070f15f355a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b54ee7a-44ba-4a0e-b11c-c103cd4bb676" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_cdb6a73b-4e99-4671-aa44-1070f15f355a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_40a98958-6817-4eb5-b410-278dd431f6d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b54ee7a-44ba-4a0e-b11c-c103cd4bb676" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_40a98958-6817-4eb5-b410-278dd431f6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock_1d2bf71e-30f9-45c7-b3ec-2872a0552e49" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b54ee7a-44ba-4a0e-b11c-c103cd4bb676" xlink:to="loc_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock_1d2bf71e-30f9-45c7-b3ec-2872a0552e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_019b0262-5fb0-4bf8-b66f-532b5ef775e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b54ee7a-44ba-4a0e-b11c-c103cd4bb676" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_019b0262-5fb0-4bf8-b66f-532b5ef775e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_7ce2fba5-7165-4ba1-9739-807553a1ee92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b54ee7a-44ba-4a0e-b11c-c103cd4bb676" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_7ce2fba5-7165-4ba1-9739-807553a1ee92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_09760f26-833c-401a-bfb1-24140006a683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b54ee7a-44ba-4a0e-b11c-c103cd4bb676" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_09760f26-833c-401a-bfb1-24140006a683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_28460af9-c8a2-44f4-8d50-ec727d70fa3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b54ee7a-44ba-4a0e-b11c-c103cd4bb676" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_28460af9-c8a2-44f4-8d50-ec727d70fa3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_79c3548a-a4a1-4a1c-8e2c-4bb655d21785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b54ee7a-44ba-4a0e-b11c-c103cd4bb676" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_79c3548a-a4a1-4a1c-8e2c-4bb655d21785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a5d2e5ce-04fd-427d-9e44-1eb483547c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b54ee7a-44ba-4a0e-b11c-c103cd4bb676" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a5d2e5ce-04fd-427d-9e44-1eb483547c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_a8f8a59c-7325-4cd9-a3c1-3a9ffcf879e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b54ee7a-44ba-4a0e-b11c-c103cd4bb676" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_a8f8a59c-7325-4cd9-a3c1-3a9ffcf879e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c303ff0b-ce08-45d7-b789-96bff6a914ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac0ee0f6-fc4b-458a-817a-5e167164a9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c303ff0b-ce08-45d7-b789-96bff6a914ed" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac0ee0f6-fc4b-458a-817a-5e167164a9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_25b822df-9ac2-4010-a3d6-db71fc20788d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac0ee0f6-fc4b-458a-817a-5e167164a9fd" xlink:to="loc_dei_LegalEntityAxis_25b822df-9ac2-4010-a3d6-db71fc20788d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f918f8e5-5b70-4681-849f-d10899dc5d11" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_25b822df-9ac2-4010-a3d6-db71fc20788d" xlink:to="loc_dei_EntityDomain_f918f8e5-5b70-4681-849f-d10899dc5d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember_06a37f7d-4906-4726-87a0-5eb6eea71051" xlink:href="rprx-20211231.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_f918f8e5-5b70-4681-849f-d10899dc5d11" xlink:to="loc_rprx_LegacyInvestorsPartnershipsMember_06a37f7d-4906-4726-87a0-5eb6eea71051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ContinuingInvestorsPartnershipMember_a62ea524-5296-4ca3-b48f-9de08a8f3264" xlink:href="rprx-20211231.xsd#rprx_ContinuingInvestorsPartnershipMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_f918f8e5-5b70-4681-849f-d10899dc5d11" xlink:to="loc_rprx_ContinuingInvestorsPartnershipMember_a62ea524-5296-4ca3-b48f-9de08a8f3264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e9d84353-ac48-43f6-b49e-06adb23699bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac0ee0f6-fc4b-458a-817a-5e167164a9fd" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e9d84353-ac48-43f6-b49e-06adb23699bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_184d62a8-85a5-427f-adf2-5d7a0a84953a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e9d84353-ac48-43f6-b49e-06adb23699bb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_184d62a8-85a5-427f-adf2-5d7a0a84953a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_30aad6e0-f189-495c-b916-72f685b8db10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_184d62a8-85a5-427f-adf2-5d7a0a84953a" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_30aad6e0-f189-495c-b916-72f685b8db10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_519651a4-f554-4fb8-b125-a3348d9c87e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac0ee0f6-fc4b-458a-817a-5e167164a9fd" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_519651a4-f554-4fb8-b125-a3348d9c87e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3a59f854-50f2-4bf8-ae45-a529bb683396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_519651a4-f554-4fb8-b125-a3348d9c87e4" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3a59f854-50f2-4bf8-ae45-a529bb683396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember_e76034bb-ba1f-4e87-b441-df45beddcebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3a59f854-50f2-4bf8-ae45-a529bb683396" xlink:to="loc_us-gaap_FinanceReceivablesMember_e76034bb-ba1f-4e87-b441-df45beddcebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3f5c6029-afa4-44d0-af4f-21c8bcb7011a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac0ee0f6-fc4b-458a-817a-5e167164a9fd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3f5c6029-afa4-44d0-af4f-21c8bcb7011a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_99f42e2b-e90d-4585-8d55-bc73ab6073f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3f5c6029-afa4-44d0-af4f-21c8bcb7011a" xlink:to="loc_us-gaap_EquityComponentDomain_99f42e2b-e90d-4585-8d55-bc73ab6073f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3db8633b-bd22-48ab-b888-03eaa3f0f1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_99f42e2b-e90d-4585-8d55-bc73ab6073f0" xlink:to="loc_us-gaap_RetainedEarningsMember_3db8633b-bd22-48ab-b888-03eaa3f0f1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_cf69030c-3704-4334-a2c7-fd5887cf81d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_99f42e2b-e90d-4585-8d55-bc73ab6073f0" xlink:to="loc_us-gaap_NoncontrollingInterestMember_cf69030c-3704-4334-a2c7-fd5887cf81d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_33445ee9-fc2f-4237-ae7d-90d39b2352aa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac0ee0f6-fc4b-458a-817a-5e167164a9fd" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_33445ee9-fc2f-4237-ae7d-90d39b2352aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b9b55774-7a6a-41c3-a1f0-a0303a029994" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_33445ee9-fc2f-4237-ae7d-90d39b2352aa" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b9b55774-7a6a-41c3-a1f0-a0303a029994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_d0d0be2e-3c19-4e9d-84c0-df1c313bf0b8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b9b55774-7a6a-41c3-a1f0-a0303a029994" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_d0d0be2e-3c19-4e9d-84c0-df1c313bf0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_e66df2f2-dfe1-4fd3-9a83-f67cb0bf858b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac0ee0f6-fc4b-458a-817a-5e167164a9fd" xlink:to="loc_srt_OwnershipAxis_e66df2f2-dfe1-4fd3-9a83-f67cb0bf858b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_480f68bc-f3cd-4edb-9a97-9e26eb66442d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_e66df2f2-dfe1-4fd3-9a83-f67cb0bf858b" xlink:to="loc_srt_OwnershipDomain_480f68bc-f3cd-4edb-9a97-9e26eb66442d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember_c761a1bf-a256-4751-b6b0-ec41205cf397" xlink:href="rprx-20211231.xsd#rprx_RoyaltyPharmaInvestmentsOldRPIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_480f68bc-f3cd-4edb-9a97-9e26eb66442d" xlink:to="loc_rprx_RoyaltyPharmaInvestmentsOldRPIMember_c761a1bf-a256-4751-b6b0-ec41205cf397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPHoldingsMember_eeb9760c-3a5c-4a17-a3c8-033e9dc78f1a" xlink:href="rprx-20211231.xsd#rprx_RPHoldingsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_480f68bc-f3cd-4edb-9a97-9e26eb66442d" xlink:to="loc_rprx_RPHoldingsMember_eeb9760c-3a5c-4a17-a3c8-033e9dc78f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c807067f-b78d-4dcb-b23a-ca1b73d0d410" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac0ee0f6-fc4b-458a-817a-5e167164a9fd" xlink:to="loc_srt_MajorCustomersAxis_c807067f-b78d-4dcb-b23a-ca1b73d0d410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0b754cb6-f50b-4221-bc54-6e3ae25885e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_c807067f-b78d-4dcb-b23a-ca1b73d0d410" xlink:to="loc_srt_NameOfMajorCustomerDomain_0b754cb6-f50b-4221-bc54-6e3ae25885e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_VertexMember_bab37316-9c47-4546-907d-486238c70701" xlink:href="rprx-20211231.xsd#rprx_VertexMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0b754cb6-f50b-4221-bc54-6e3ae25885e8" xlink:to="loc_rprx_VertexMember_bab37316-9c47-4546-907d-486238c70701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_f6113c11-0d6e-4a24-a7df-52ceae1a9601" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac0ee0f6-fc4b-458a-817a-5e167164a9fd" xlink:to="loc_srt_RestatementAxis_f6113c11-0d6e-4a24-a7df-52ceae1a9601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_305cc2b2-70ba-495f-9c88-123663166731" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_f6113c11-0d6e-4a24-a7df-52ceae1a9601" xlink:to="loc_srt_RestatementDomain_305cc2b2-70ba-495f-9c88-123663166731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_4a3a8837-ccda-45cf-89be-2fcebbc3f6fc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_305cc2b2-70ba-495f-9c88-123663166731" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_4a3a8837-ccda-45cf-89be-2fcebbc3f6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_53e65d87-5ee1-4b35-a897-f5fb56456921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ac0ee0f6-fc4b-458a-817a-5e167164a9fd" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_53e65d87-5ee1-4b35-a897-f5fb56456921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_241f4826-3605-4b82-b07e-bd95c71fc69d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_53e65d87-5ee1-4b35-a897-f5fb56456921" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_241f4826-3605-4b82-b07e-bd95c71fc69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NumberOfNoncontrollingInterestsCreated_683c8f13-2653-483b-b4a4-998139a3e395" xlink:href="rprx-20211231.xsd#rprx_NumberOfNoncontrollingInterestsCreated"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_53e65d87-5ee1-4b35-a897-f5fb56456921" xlink:to="loc_rprx_NumberOfNoncontrollingInterestsCreated_683c8f13-2653-483b-b4a4-998139a3e395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt_ebd47afa-0257-42c3-a724-a3759a6d53ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_53e65d87-5ee1-4b35-a897-f5fb56456921" xlink:to="loc_us-gaap_TradingSecuritiesDebt_ebd47afa-0257-42c3-a724-a3759a6d53ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d209c4ae-ec71-49a8-88fe-a048bff8fb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_53e65d87-5ee1-4b35-a897-f5fb56456921" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d209c4ae-ec71-49a8-88fe-a048bff8fb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2569a9a8-f500-4119-a00c-2d2055ad476a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_53e65d87-5ee1-4b35-a897-f5fb56456921" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2569a9a8-f500-4119-a00c-2d2055ad476a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_191610ce-8551-4851-89ca-c53c1c6bf576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_53e65d87-5ee1-4b35-a897-f5fb56456921" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_191610ce-8551-4851-89ca-c53c1c6bf576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34bcde04-f459-452f-aba1-46809800bcbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_53e65d87-5ee1-4b35-a897-f5fb56456921" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34bcde04-f459-452f-aba1-46809800bcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_617b1a76-9197-483a-89a1-59cb9ac5e020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_53e65d87-5ee1-4b35-a897-f5fb56456921" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_617b1a76-9197-483a-89a1-59cb9ac5e020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_b250f3de-d28b-441a-b491-64d108f1787f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_53e65d87-5ee1-4b35-a897-f5fb56456921" xlink:to="loc_us-gaap_NumberOfOperatingSegments_b250f3de-d28b-441a-b491-64d108f1787f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c9477989-c9be-4418-8f08-81d2950ab61e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_53e65d87-5ee1-4b35-a897-f5fb56456921" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c9477989-c9be-4418-8f08-81d2950ab61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecurities" xlink:type="simple" xlink:href="rprx-20211231.xsd#AvailableforSaleDebtSecurities"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/AvailableforSaleDebtSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5f606c01-7654-4324-8edd-bdf143b4216a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_5b32f107-2550-4a42-9c59-2acff5d83e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5f606c01-7654-4324-8edd-bdf143b4216a" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_5b32f107-2550-4a42-9c59-2acff5d83e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables" xlink:type="simple" xlink:href="rprx-20211231.xsd#AvailableforSaleDebtSecuritiesTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5c840eaa-a62f-4226-a293-cbd967a7e597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_49347cfd-672b-4fe2-b06b-943ce7b62f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5c840eaa-a62f-4226-a293-cbd967a7e597" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_49347cfd-672b-4fe2-b06b-943ce7b62f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#AvailableforSaleDebtSecuritiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7d106539-b90f-400c-8948-30614214b280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1b32bc2f-8a2c-48c3-9eb3-ed3fa45763e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7d106539-b90f-400c-8948-30614214b280" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1b32bc2f-8a2c-48c3-9eb3-ed3fa45763e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_91a18015-285d-41b0-ae3a-19c177893759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1b32bc2f-8a2c-48c3-9eb3-ed3fa45763e3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_91a18015-285d-41b0-ae3a-19c177893759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ab2b6677-0f31-4c62-ac72-51a837b47a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_91a18015-285d-41b0-ae3a-19c177893759" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ab2b6677-0f31-4c62-ac72-51a837b47a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_0b03400b-fe6b-48dc-9990-70e1c39cb9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ab2b6677-0f31-4c62-ac72-51a837b47a52" xlink:to="loc_us-gaap_PreferredStockMember_0b03400b-fe6b-48dc-9990-70e1c39cb9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_cf01425f-cc1d-426a-8385-8b20ccd249fd" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1b32bc2f-8a2c-48c3-9eb3-ed3fa45763e3" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_cf01425f-cc1d-426a-8385-8b20ccd249fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_936a55d7-6fb6-4940-b0a7-40b9c6bef140" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_cf01425f-cc1d-426a-8385-8b20ccd249fd" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_936a55d7-6fb6-4940-b0a7-40b9c6bef140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_eb62a321-559b-486f-8ac8-8612749e19df" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_936a55d7-6fb6-4940-b0a7-40b9c6bef140" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_eb62a321-559b-486f-8ac8-8612749e19df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember_100837f4-0f74-4d34-ab5c-603d0d55a110" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_936a55d7-6fb6-4940-b0a7-40b9c6bef140" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember_100837f4-0f74-4d34-ab5c-603d0d55a110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_03276f2e-2c8c-4743-8ca8-4bdb41af5fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1b32bc2f-8a2c-48c3-9eb3-ed3fa45763e3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_03276f2e-2c8c-4743-8ca8-4bdb41af5fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_42704204-3ab7-486c-aefa-7a4693768fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_03276f2e-2c8c-4743-8ca8-4bdb41af5fb1" xlink:to="loc_us-gaap_ClassOfStockDomain_42704204-3ab7-486c-aefa-7a4693768fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_ec72856f-9f08-4b06-8e9a-42c308137abd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_42704204-3ab7-486c-aefa-7a4693768fdd" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_ec72856f-9f08-4b06-8e9a-42c308137abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_1b79d60c-46d0-4461-b916-17b91999dc89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_42704204-3ab7-486c-aefa-7a4693768fdd" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_1b79d60c-46d0-4461-b916-17b91999dc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3ef2d7bf-8f7d-42c0-8cab-4b948c94d101" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1b32bc2f-8a2c-48c3-9eb3-ed3fa45763e3" xlink:to="loc_srt_RangeAxis_3ef2d7bf-8f7d-42c0-8cab-4b948c94d101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8d97ea51-b149-4dfe-a124-4673a885e1bc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3ef2d7bf-8f7d-42c0-8cab-4b948c94d101" xlink:to="loc_srt_RangeMember_8d97ea51-b149-4dfe-a124-4673a885e1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_40914993-05b4-45f3-8b6d-e4ab9306ecb9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8d97ea51-b149-4dfe-a124-4673a885e1bc" xlink:to="loc_srt_MaximumMember_40914993-05b4-45f3-8b6d-e4ab9306ecb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ce3c0474-9877-465c-af49-dfa5e2d40194" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1b32bc2f-8a2c-48c3-9eb3-ed3fa45763e3" xlink:to="loc_srt_CounterpartyNameAxis_ce3c0474-9877-465c-af49-dfa5e2d40194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22e9539e-b2e5-4e49-9421-f5e5cf824ce8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ce3c0474-9877-465c-af49-dfa5e2d40194" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22e9539e-b2e5-4e49-9421-f5e5cf824ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MorphoSysMember_08178db3-78fb-4902-a3c3-846b40378397" xlink:href="rprx-20211231.xsd#rprx_MorphoSysMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22e9539e-b2e5-4e49-9421-f5e5cf824ce8" xlink:to="loc_rprx_MorphoSysMember_08178db3-78fb-4902-a3c3-846b40378397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_56d72e96-79fd-4dd2-92ec-fedebfc5cb99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1b32bc2f-8a2c-48c3-9eb3-ed3fa45763e3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_56d72e96-79fd-4dd2-92ec-fedebfc5cb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df4b504d-3877-40ff-9dc0-5fc3bfabb6af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_56d72e96-79fd-4dd2-92ec-fedebfc5cb99" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df4b504d-3877-40ff-9dc0-5fc3bfabb6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_6370ccd3-e17d-409f-8981-388be825b688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df4b504d-3877-40ff-9dc0-5fc3bfabb6af" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_6370ccd3-e17d-409f-8981-388be825b688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_1b32bc2f-8a2c-48c3-9eb3-ed3fa45763e3" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_fae439a1-ce67-4c6d-aab7-3325c05b6a57" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_fae439a1-ce67-4c6d-aab7-3325c05b6a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSalePricePerShare_d3941d80-0396-479b-94a6-04d0fdc2fc38" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSalePricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:to="loc_rprx_DebtSecuritiesAvailableForSalePricePerShare_d3941d80-0396-479b-94a6-04d0fdc2fc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c4b861dc-acd9-45ce-b3ce-a4c323c263a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c4b861dc-acd9-45ce-b3ce-a4c323c263a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage_0b738cbb-d155-41ff-8fcf-99f4f79f2d04" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage_0b738cbb-d155-41ff-8fcf-99f4f79f2d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate_279af1a3-8c92-4992-8606-98e1e65b4ad5" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate_279af1a3-8c92-4992-8606-98e1e65b4ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod_c5c19752-3da9-4199-9e0e-c9494a19b0a1" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod_c5c19752-3da9-4199-9e0e-c9494a19b0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod_43743b79-0169-4d26-ba58-458b11d2ed01" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod_43743b79-0169-4d26-ba58-458b11d2ed01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_6883c748-ffa3-49f1-baf3-f826f6c4545f" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_6883c748-ffa3-49f1-baf3-f826f6c4545f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_d2ba1171-e9f1-49a1-a4e4-b6f010381550" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_d2ba1171-e9f1-49a1-a4e4-b6f010381550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_f543ba25-97ad-4876-bcc0-788694a808e1" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_f543ba25-97ad-4876-bcc0-788694a808e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate_af3d6330-d585-498e-b2b4-a50f38638674" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_7d4d0f8c-875e-47ea-9d50-902fc739b8fe" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate_af3d6330-d585-498e-b2b4-a50f38638674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_74b5506d-5dca-4894-95e2-a1ad2e69f7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_9ae372d1-d050-43f4-9458-1037f6292edb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_74b5506d-5dca-4894-95e2-a1ad2e69f7b9" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_9ae372d1-d050-43f4-9458-1037f6292edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_40e784b6-c1f6-44e5-90cd-c47865c0aad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_9ae372d1-d050-43f4-9458-1037f6292edb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_40e784b6-c1f6-44e5-90cd-c47865c0aad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c2f0bb5-484d-466e-bc88-77e065d119f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_40e784b6-c1f6-44e5-90cd-c47865c0aad0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c2f0bb5-484d-466e-bc88-77e065d119f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_e44f3ff8-393a-42ae-8d4f-91d098e895e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c2f0bb5-484d-466e-bc88-77e065d119f7" xlink:to="loc_us-gaap_PreferredStockMember_e44f3ff8-393a-42ae-8d4f-91d098e895e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_a33ed6b6-0c9f-42f7-844c-99a7ae19ff58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c2f0bb5-484d-466e-bc88-77e065d119f7" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_a33ed6b6-0c9f-42f7-844c-99a7ae19ff58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_e54f5d73-a8a6-42c5-b487-243ecf569bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c2f0bb5-484d-466e-bc88-77e065d119f7" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_e54f5d73-a8a6-42c5-b487-243ecf569bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_c4faa4c3-ca62-44fe-90e8-e6ff3f14dbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c2f0bb5-484d-466e-bc88-77e065d119f7" xlink:to="loc_us-gaap_ForwardContractsMember_c4faa4c3-ca62-44fe-90e8-e6ff3f14dbb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DevelopmentFundingBondForwardMember_87430da5-e594-4f25-89ca-8b87665f3391" xlink:href="rprx-20211231.xsd#rprx_DevelopmentFundingBondForwardMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c2f0bb5-484d-466e-bc88-77e065d119f7" xlink:to="loc_rprx_DevelopmentFundingBondForwardMember_87430da5-e594-4f25-89ca-8b87665f3391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_21b8d8bc-41a5-49d0-bee2-4da597b041db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_9ae372d1-d050-43f4-9458-1037f6292edb" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_21b8d8bc-41a5-49d0-bee2-4da597b041db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0c98d3d2-e70e-4b2f-a0b9-8faa264ac26f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_21b8d8bc-41a5-49d0-bee2-4da597b041db" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0c98d3d2-e70e-4b2f-a0b9-8faa264ac26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_25196e08-2b83-4fa0-a42d-aea7308f1b55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_21b8d8bc-41a5-49d0-bee2-4da597b041db" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_25196e08-2b83-4fa0-a42d-aea7308f1b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8a3292bc-74d9-4b9a-a2aa-a40c860d09a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_21b8d8bc-41a5-49d0-bee2-4da597b041db" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8a3292bc-74d9-4b9a-a2aa-a40c860d09a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ba8b488e-d4df-4e29-9470-77c103a7b7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_21b8d8bc-41a5-49d0-bee2-4da597b041db" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ba8b488e-d4df-4e29-9470-77c103a7b7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_cd116c7c-441f-418d-939d-8a5e36a6177c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_21b8d8bc-41a5-49d0-bee2-4da597b041db" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_cd116c7c-441f-418d-939d-8a5e36a6177c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/DerivativeInstruments" xlink:type="simple" xlink:href="rprx-20211231.xsd#DerivativeInstruments"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7635724f-727c-404f-ad9a-193de9a52ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_87491117-8875-4911-a269-d56febc2c92c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7635724f-727c-404f-ad9a-193de9a52ff8" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_87491117-8875-4911-a269-d56febc2c92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/DerivativeInstrumentsTables" xlink:type="simple" xlink:href="rprx-20211231.xsd#DerivativeInstrumentsTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_155edbf3-87cf-4f4f-bcf2-e09f2a2c278b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_f997cd55-aafd-41c0-844e-4fae96565e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_155edbf3-87cf-4f4f-bcf2-e09f2a2c278b" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_f997cd55-aafd-41c0-844e-4fae96565e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#DerivativeInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f70fc0e6-ce55-4e96-a97f-5954326a51f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b940b756-8cf4-49a7-b320-60b43356afb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f70fc0e6-ce55-4e96-a97f-5954326a51f7" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b940b756-8cf4-49a7-b320-60b43356afb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_dc788761-e035-472b-b586-07e11e7bd3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b940b756-8cf4-49a7-b320-60b43356afb6" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_dc788761-e035-472b-b586-07e11e7bd3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_34a80004-b709-4d8c-a1f2-c1c6cd7a3250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_dc788761-e035-472b-b586-07e11e7bd3b7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_34a80004-b709-4d8c-a1f2-c1c6cd7a3250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TreasuryRateLockContractsMember_75b8bfa5-c781-462f-b01b-b5d388b5eb20" xlink:href="rprx-20211231.xsd#rprx_TreasuryRateLockContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_34a80004-b709-4d8c-a1f2-c1c6cd7a3250" xlink:to="loc_rprx_TreasuryRateLockContractsMember_75b8bfa5-c781-462f-b01b-b5d388b5eb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_e1258bca-4c7d-4534-b5dc-1c40c26a1604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_34a80004-b709-4d8c-a1f2-c1c6cd7a3250" xlink:to="loc_us-gaap_InterestRateSwapMember_e1258bca-4c7d-4534-b5dc-1c40c26a1604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_091916d6-74fb-4b42-adc4-6dbfe1ab3a00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_34a80004-b709-4d8c-a1f2-c1c6cd7a3250" xlink:to="loc_us-gaap_WarrantMember_091916d6-74fb-4b42-adc4-6dbfe1ab3a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_c3c00ee5-45a2-4c18-ab8e-00c0b34dab86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_34a80004-b709-4d8c-a1f2-c1c6cd7a3250" xlink:to="loc_us-gaap_ForwardContractsMember_c3c00ee5-45a2-4c18-ab8e-00c0b34dab86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8e604767-4240-41e5-bb42-c1a9e90861d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b940b756-8cf4-49a7-b320-60b43356afb6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8e604767-4240-41e5-bb42-c1a9e90861d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7b930ff6-d06b-49f1-be6a-78297f07d11b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8e604767-4240-41e5-bb42-c1a9e90861d7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7b930ff6-d06b-49f1-be6a-78297f07d11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EpizymeIncMember_16780a34-5d45-4e97-a410-44e312fb407f" xlink:href="rprx-20211231.xsd#rprx_EpizymeIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7b930ff6-d06b-49f1-be6a-78297f07d11b" xlink:to="loc_rprx_EpizymeIncMember_16780a34-5d45-4e97-a410-44e312fb407f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_503259c8-890c-4688-b694-d837bba883f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b940b756-8cf4-49a7-b320-60b43356afb6" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_503259c8-890c-4688-b694-d837bba883f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_ba9f91c8-513d-4a75-bfd3-16cc01ef9fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_503259c8-890c-4688-b694-d837bba883f3" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_ba9f91c8-513d-4a75-bfd3-16cc01ef9fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PutOptionMember_b0da40dd-57d2-4f08-b7f2-19f6c37df73c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PutOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_ba9f91c8-513d-4a75-bfd3-16cc01ef9fc1" xlink:to="loc_us-gaap_PutOptionMember_b0da40dd-57d2-4f08-b7f2-19f6c37df73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_16effc2c-06bf-4004-b009-83739e8dcd43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b940b756-8cf4-49a7-b320-60b43356afb6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_16effc2c-06bf-4004-b009-83739e8dcd43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d915a4c9-7dc8-4a9c-82d2-a335c734af7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_16effc2c-06bf-4004-b009-83739e8dcd43" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d915a4c9-7dc8-4a9c-82d2-a335c734af7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EpizymeCommonStockWarrantMember_c504ac93-d5b3-4070-80b4-ae5c29e8efa3" xlink:href="rprx-20211231.xsd#rprx_EpizymeCommonStockWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d915a4c9-7dc8-4a9c-82d2-a335c734af7b" xlink:to="loc_rprx_EpizymeCommonStockWarrantMember_c504ac93-d5b3-4070-80b4-ae5c29e8efa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6073305f-a06f-43fe-934b-29c82598b55a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b940b756-8cf4-49a7-b320-60b43356afb6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6073305f-a06f-43fe-934b-29c82598b55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_91d1c061-81ed-400b-957b-91e8e533ef41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6073305f-a06f-43fe-934b-29c82598b55a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_91d1c061-81ed-400b-957b-91e8e533ef41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_65efd1e8-86b6-4ce5-94d1-9e6b1dfd7702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_91d1c061-81ed-400b-957b-91e8e533ef41" xlink:to="loc_us-gaap_PreferredStockMember_65efd1e8-86b6-4ce5-94d1-9e6b1dfd7702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_af8cd58f-2578-4801-816c-287c74b1a805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_91d1c061-81ed-400b-957b-91e8e533ef41" xlink:to="loc_us-gaap_InterestRateSwapMember_af8cd58f-2578-4801-816c-287c74b1a805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b1ae3815-382c-4adc-89f0-91b16dd5f780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b940b756-8cf4-49a7-b320-60b43356afb6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b1ae3815-382c-4adc-89f0-91b16dd5f780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fafce787-4dd2-4ba1-bc41-f6e433e42f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b1ae3815-382c-4adc-89f0-91b16dd5f780" xlink:to="loc_us-gaap_ClassOfStockDomain_fafce787-4dd2-4ba1-bc41-f6e433e42f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_8418bb8c-c38e-42c7-a502-e8dbfa529c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_fafce787-4dd2-4ba1-bc41-f6e433e42f2c" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_8418bb8c-c38e-42c7-a502-e8dbfa529c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_58d6ae9a-b8b0-4713-8e0c-60573b008b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b940b756-8cf4-49a7-b320-60b43356afb6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_58d6ae9a-b8b0-4713-8e0c-60573b008b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_005a06b1-cd27-4cf9-8d7e-d842e20eb760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_58d6ae9a-b8b0-4713-8e0c-60573b008b1b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_005a06b1-cd27-4cf9-8d7e-d842e20eb760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c1e8adac-35fe-4aa9-baa4-d2d2fc4647e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_005a06b1-cd27-4cf9-8d7e-d842e20eb760" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c1e8adac-35fe-4aa9-baa4-d2d2fc4647e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_52d187d6-90b5-4040-85b9-83f9daebaa1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b940b756-8cf4-49a7-b320-60b43356afb6" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_52d187d6-90b5-4040-85b9-83f9daebaa1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9285967a-e5d7-40c0-945c-2330e14bd69e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_52d187d6-90b5-4040-85b9-83f9daebaa1f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9285967a-e5d7-40c0-945c-2330e14bd69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ec1f0d8b-2560-47e3-8199-0f52abcf00bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9285967a-e5d7-40c0-945c-2330e14bd69e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ec1f0d8b-2560-47e3-8199-0f52abcf00bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_b940b756-8cf4-49a7-b320-60b43356afb6" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_318e60fa-b37c-48ee-9c45-80d8348f59f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_us-gaap_DerivativeNotionalAmount_318e60fa-b37c-48ee-9c45-80d8348f59f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToTerminateDerivativeInstruments_ef7ae888-4f9a-4121-a793-b14a3c39f9d9" xlink:href="rprx-20211231.xsd#rprx_PaymentsToTerminateDerivativeInstruments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_rprx_PaymentsToTerminateDerivativeInstruments_ef7ae888-4f9a-4121-a793-b14a3c39f9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_53f81c3b-3b38-469a-8356-7e8154f42255" xlink:href="rprx-20211231.xsd#rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments_53f81c3b-3b38-469a-8356-7e8154f42255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_748e5aff-f23f-43aa-a55a-a486a512e7df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_748e5aff-f23f-43aa-a55a-a486a512e7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_768ae082-cf55-40a3-9192-6bf1de4fdd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_768ae082-cf55-40a3-9192-6bf1de4fdd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment_a276cc89-7b10-436b-a481-67f8c2f9ea21" xlink:href="rprx-20211231.xsd#rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment_a276cc89-7b10-436b-a481-67f8c2f9ea21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6a701efc-aeec-4e56-9770-21f44b9010c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6a701efc-aeec-4e56-9770-21f44b9010c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_919b4a8c-a631-4332-b082-93dc568ed24d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_919b4a8c-a631-4332-b082-93dc568ed24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_90079aef-909b-428c-9612-e0518b0253f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_90079aef-909b-428c-9612-e0518b0253f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OptionIndexedToIssuersEquityTerm_c9c85a1b-a1d5-467d-b645-cb15a15a39fb" xlink:href="rprx-20211231.xsd#rprx_OptionIndexedToIssuersEquityTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_rprx_OptionIndexedToIssuersEquityTerm_c9c85a1b-a1d5-467d-b645-cb15a15a39fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OptionIndexedToIssuersEquityValue_3dad96b0-7415-431b-93e6-73599f20b588" xlink:href="rprx-20211231.xsd#rprx_OptionIndexedToIssuersEquityValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_rprx_OptionIndexedToIssuersEquityValue_3dad96b0-7415-431b-93e6-73599f20b588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityStrikePrice1_ba59baaf-853c-4b45-a214-d1a55079c096" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityStrikePrice1_ba59baaf-853c-4b45-a214-d1a55079c096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_273fbcad-98db-4f45-b920-e64e0cc1d768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_273fbcad-98db-4f45-b920-e64e0cc1d768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fce35f22-38de-41f7-9c15-1ebb589bc0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b15a37fa-fc79-4c0d-9fb4-bc4524ed60f1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fce35f22-38de-41f7-9c15-1ebb589bc0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ab15bef3-61e9-4623-91b3-88af1f44a441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_484329a3-f0b0-4a52-aa05-6dddcb2a96ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ab15bef3-61e9-4623-91b3-88af1f44a441" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_484329a3-f0b0-4a52-aa05-6dddcb2a96ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_651317b0-237e-4cd7-ae3d-e1b22c802897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_484329a3-f0b0-4a52-aa05-6dddcb2a96ae" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_651317b0-237e-4cd7-ae3d-e1b22c802897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_76c104cb-fb6c-4566-b83f-69597f5d6742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_651317b0-237e-4cd7-ae3d-e1b22c802897" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_76c104cb-fb6c-4566-b83f-69597f5d6742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_04b24486-a197-43dd-bfb5-cc749170cdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_76c104cb-fb6c-4566-b83f-69597f5d6742" xlink:to="loc_us-gaap_InterestRateSwapMember_04b24486-a197-43dd-bfb5-cc749170cdf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_ab87d303-4239-4145-988c-6bc1b9040b83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_76c104cb-fb6c-4566-b83f-69597f5d6742" xlink:to="loc_us-gaap_WarrantMember_ab87d303-4239-4145-988c-6bc1b9040b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_e7410ce8-660c-43c2-8155-2590f5a4ad70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_76c104cb-fb6c-4566-b83f-69597f5d6742" xlink:to="loc_us-gaap_ForwardContractsMember_e7410ce8-660c-43c2-8155-2590f5a4ad70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TreasuryRateLockContractsMember_54a72b1d-0584-4337-9519-83a62c560741" xlink:href="rprx-20211231.xsd#rprx_TreasuryRateLockContractsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_76c104cb-fb6c-4566-b83f-69597f5d6742" xlink:to="loc_rprx_TreasuryRateLockContractsMember_54a72b1d-0584-4337-9519-83a62c560741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_44c02515-7e90-469d-911e-f9d60bffe151" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_484329a3-f0b0-4a52-aa05-6dddcb2a96ae" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_44c02515-7e90-469d-911e-f9d60bffe151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bfda96c1-dc74-42a8-b9a8-1427e1fbd3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_44c02515-7e90-469d-911e-f9d60bffe151" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bfda96c1-dc74-42a8-b9a8-1427e1fbd3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsMember_d9d36581-ac1a-4987-8336-4c421db3e2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bfda96c1-dc74-42a8-b9a8-1427e1fbd3b8" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsMember_d9d36581-ac1a-4987-8336-4c421db3e2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_2b4a1baf-b319-4512-98d1-c8ba2f5f132a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bfda96c1-dc74-42a8-b9a8-1427e1fbd3b8" xlink:to="loc_us-gaap_InterestExpenseMember_2b4a1baf-b319-4512-98d1-c8ba2f5f132a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_8314d618-0c81-4f29-9678-7401facd6990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_484329a3-f0b0-4a52-aa05-6dddcb2a96ae" xlink:to="loc_us-gaap_HedgingDesignationAxis_8314d618-0c81-4f29-9678-7401facd6990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_02ed3402-a754-47ba-ba31-c5cf5cbb01c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_8314d618-0c81-4f29-9678-7401facd6990" xlink:to="loc_us-gaap_HedgingDesignationDomain_02ed3402-a754-47ba-ba31-c5cf5cbb01c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2eefe6f5-49a2-4920-9c38-443c43cc6ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_02ed3402-a754-47ba-ba31-c5cf5cbb01c0" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2eefe6f5-49a2-4920-9c38-443c43cc6ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_77072cb7-4639-4f99-a97c-6b8e29dc67fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_02ed3402-a754-47ba-ba31-c5cf5cbb01c0" xlink:to="loc_us-gaap_NondesignatedMember_77072cb7-4639-4f99-a97c-6b8e29dc67fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b94798cb-edad-454f-b3b7-03f8d17074f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_484329a3-f0b0-4a52-aa05-6dddcb2a96ae" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b94798cb-edad-454f-b3b7-03f8d17074f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_916fee8a-68b8-4c45-bd35-3e44dd7ebb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b94798cb-edad-454f-b3b7-03f8d17074f2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_916fee8a-68b8-4c45-bd35-3e44dd7ebb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_3d647a54-dc5c-4833-b1d8-33e5d9574625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b94798cb-edad-454f-b3b7-03f8d17074f2" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_3d647a54-dc5c-4833-b1d8-33e5d9574625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_442ffe36-0147-4e6a-8203-2872fe63224b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b94798cb-edad-454f-b3b7-03f8d17074f2" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_442ffe36-0147-4e6a-8203-2872fe63224b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts_a72de12e-5d0b-4a43-a2ea-6ee1d324191c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b94798cb-edad-454f-b3b7-03f8d17074f2" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts_a72de12e-5d0b-4a43-a2ea-6ee1d324191c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments" xlink:type="simple" xlink:href="rprx-20211231.xsd#FairValueMeasurementsandFinancialInstruments"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d4bbfd4c-fb0e-4613-945c-0f37b31d53fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_be0c8f06-780d-4164-8175-6a2a94e19778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d4bbfd4c-fb0e-4613-945c-0f37b31d53fd" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_be0c8f06-780d-4164-8175-6a2a94e19778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables" xlink:type="simple" xlink:href="rprx-20211231.xsd#FairValueMeasurementsandFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2a59123a-0f5c-4331-a090-c12c06f9464d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d044afee-f2cb-400a-9ae8-900dccbcfabf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2a59123a-0f5c-4331-a090-c12c06f9464d" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d044afee-f2cb-400a-9ae8-900dccbcfabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2831d591-6592-4ebf-bced-1260af0bd974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2a59123a-0f5c-4331-a090-c12c06f9464d" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2831d591-6592-4ebf-bced-1260af0bd974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_be8af7d4-ff26-409f-a58a-cf99c4a404bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2a59123a-0f5c-4331-a090-c12c06f9464d" xlink:to="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_be8af7d4-ff26-409f-a58a-cf99c4a404bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a21ff32d-c3a9-4c98-8077-ee2ff2b30fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fbcafbc-56f3-4805-b06a-83ab8aa5781a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a21ff32d-c3a9-4c98-8077-ee2ff2b30fbc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fbcafbc-56f3-4805-b06a-83ab8aa5781a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_6e428895-fd14-4934-955b-65ee883b8a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fbcafbc-56f3-4805-b06a-83ab8aa5781a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_6e428895-fd14-4934-955b-65ee883b8a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35ef2931-9d22-487a-8830-a6c8d04be5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_6e428895-fd14-4934-955b-65ee883b8a6d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35ef2931-9d22-487a-8830-a6c8d04be5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_81f5d85a-4957-471a-8602-e599c99178b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35ef2931-9d22-487a-8830-a6c8d04be5e8" xlink:to="loc_us-gaap_MoneyMarketFundsMember_81f5d85a-4957-471a-8602-e599c99178b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_49a7b7d8-4959-4e77-923a-df79b3b786c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35ef2931-9d22-487a-8830-a6c8d04be5e8" xlink:to="loc_us-gaap_CommercialPaperMember_49a7b7d8-4959-4e77-923a-df79b3b786c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_862eac28-9236-4307-a611-1ed64ddab08e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35ef2931-9d22-487a-8830-a6c8d04be5e8" xlink:to="loc_us-gaap_CertificatesOfDepositMember_862eac28-9236-4307-a611-1ed64ddab08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5c22f15a-d6ce-4051-a4b1-8b271ca33de7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fbcafbc-56f3-4805-b06a-83ab8aa5781a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5c22f15a-d6ce-4051-a4b1-8b271ca33de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c10e8e18-2615-4a97-9fa1-ab37f5f80c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5c22f15a-d6ce-4051-a4b1-8b271ca33de7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c10e8e18-2615-4a97-9fa1-ab37f5f80c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_fb3b387d-42b1-4e19-99e3-023b6b9d6b98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c10e8e18-2615-4a97-9fa1-ab37f5f80c22" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_fb3b387d-42b1-4e19-99e3-023b6b9d6b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_88598fdc-f336-4251-9e91-b8940b930b11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c10e8e18-2615-4a97-9fa1-ab37f5f80c22" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_88598fdc-f336-4251-9e91-b8940b930b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1142c017-e11e-4df8-998f-81d620273cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c10e8e18-2615-4a97-9fa1-ab37f5f80c22" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1142c017-e11e-4df8-998f-81d620273cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0497af01-f33f-4713-b06f-271c87383ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fbcafbc-56f3-4805-b06a-83ab8aa5781a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0497af01-f33f-4713-b06f-271c87383ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7f7ae25d-2eaf-497d-a119-494e9e5e361f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0497af01-f33f-4713-b06f-271c87383ebc" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7f7ae25d-2eaf-497d-a119-494e9e5e361f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f26caaba-0984-48e3-b9f8-8534e41d9fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7f7ae25d-2eaf-497d-a119-494e9e5e361f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f26caaba-0984-48e3-b9f8-8534e41d9fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6fe40b7f-68f5-4583-a611-6d9bfc163f81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fbcafbc-56f3-4805-b06a-83ab8aa5781a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6fe40b7f-68f5-4583-a611-6d9bfc163f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a04a9805-00d1-41c2-9e03-ec25d0fcd243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6fe40b7f-68f5-4583-a611-6d9bfc163f81" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a04a9805-00d1-41c2-9e03-ec25d0fcd243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_a431edb3-63c8-4ad1-b5ef-dd5c9357aacc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a04a9805-00d1-41c2-9e03-ec25d0fcd243" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_a431edb3-63c8-4ad1-b5ef-dd5c9357aacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f45c4f68-151c-4b67-9cbc-1ad22fcdd12b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a04a9805-00d1-41c2-9e03-ec25d0fcd243" xlink:to="loc_us-gaap_CommercialPaperMember_f45c4f68-151c-4b67-9cbc-1ad22fcdd12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_8823542a-dd48-4fb1-a4da-3599381d18d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a04a9805-00d1-41c2-9e03-ec25d0fcd243" xlink:to="loc_us-gaap_CertificatesOfDepositMember_8823542a-dd48-4fb1-a4da-3599381d18d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_a1f2c880-bdb4-46c5-bef1-4f661c4497e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a04a9805-00d1-41c2-9e03-ec25d0fcd243" xlink:to="loc_us-gaap_ForwardContractsMember_a1f2c880-bdb4-46c5-bef1-4f661c4497e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_7bd8c9f1-9adb-40f7-9d67-8b0d17131e66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a04a9805-00d1-41c2-9e03-ec25d0fcd243" xlink:to="loc_us-gaap_WarrantMember_7bd8c9f1-9adb-40f7-9d67-8b0d17131e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_106f9728-79ce-40c1-b23a-ab6c9a256a82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a04a9805-00d1-41c2-9e03-ec25d0fcd243" xlink:to="loc_us-gaap_InterestRateSwapMember_106f9728-79ce-40c1-b23a-ab6c9a256a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5149052d-a2bc-42d0-8d24-9440cc61961b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fbcafbc-56f3-4805-b06a-83ab8aa5781a" xlink:to="loc_srt_CounterpartyNameAxis_5149052d-a2bc-42d0-8d24-9440cc61961b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e4e04ec6-b9cc-43f4-9cab-e3886f6818dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5149052d-a2bc-42d0-8d24-9440cc61961b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e4e04ec6-b9cc-43f4-9cab-e3886f6818dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MorphoSysMember_191659b3-df28-406f-8dcc-3398746e1201" xlink:href="rprx-20211231.xsd#rprx_MorphoSysMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e4e04ec6-b9cc-43f4-9cab-e3886f6818dd" xlink:to="loc_rprx_MorphoSysMember_191659b3-df28-406f-8dcc-3398746e1201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_257f828d-b06d-4d9a-b6a0-dae951c5cf83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fbcafbc-56f3-4805-b06a-83ab8aa5781a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_257f828d-b06d-4d9a-b6a0-dae951c5cf83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb4c8817-2ae8-488c-9391-3a4aeea8ecab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_257f828d-b06d-4d9a-b6a0-dae951c5cf83" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb4c8817-2ae8-488c-9391-3a4aeea8ecab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d6fec4d2-04e5-4161-bb85-bac37e60da3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb4c8817-2ae8-488c-9391-3a4aeea8ecab" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d6fec4d2-04e5-4161-bb85-bac37e60da3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e39cb102-06b9-4481-8ee6-f335f3817263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fbcafbc-56f3-4805-b06a-83ab8aa5781a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e39cb102-06b9-4481-8ee6-f335f3817263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_5b38ee41-4121-4068-aff4-d285653ee4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e39cb102-06b9-4481-8ee6-f335f3817263" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_5b38ee41-4121-4068-aff4-d285653ee4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_cc918810-51c1-42f2-ace1-f27d3260f81f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5b38ee41-4121-4068-aff4-d285653ee4eb" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_cc918810-51c1-42f2-ace1-f27d3260f81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt_e6948033-6aa0-4774-b257-bd6a4ac24956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5b38ee41-4121-4068-aff4-d285653ee4eb" xlink:to="loc_us-gaap_TradingSecuritiesDebt_e6948033-6aa0-4774-b257-bd6a4ac24956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_766fe835-fb1d-4ecf-af12-dec71fbcb5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5b38ee41-4121-4068-aff4-d285653ee4eb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_766fe835-fb1d-4ecf-af12-dec71fbcb5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssetsFairValueDisclosureCurrent_94516fc5-1fd2-41a3-9264-4d7e6220c66e" xlink:href="rprx-20211231.xsd#rprx_AssetsFairValueDisclosureCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5b38ee41-4121-4068-aff4-d285653ee4eb" xlink:to="loc_rprx_AssetsFairValueDisclosureCurrent_94516fc5-1fd2-41a3-9264-4d7e6220c66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_f1735206-1045-4f3e-84ea-85ea10256f74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5b38ee41-4121-4068-aff4-d285653ee4eb" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_f1735206-1045-4f3e-84ea-85ea10256f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_d77e483d-d15a-452e-93c7-475023ef69d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5b38ee41-4121-4068-aff4-d285653ee4eb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_d77e483d-d15a-452e-93c7-475023ef69d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_ca7944ae-92a8-47ee-a346-691329edf665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5b38ee41-4121-4068-aff4-d285653ee4eb" xlink:to="loc_us-gaap_DerivativeAssets_ca7944ae-92a8-47ee-a346-691329edf665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssetsFairValueDisclosureNoncurrent_cf19d02c-4d7d-45bd-82ac-cdbf4abe4669" xlink:href="rprx-20211231.xsd#rprx_AssetsFairValueDisclosureNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5b38ee41-4121-4068-aff4-d285653ee4eb" xlink:to="loc_rprx_AssetsFairValueDisclosureNoncurrent_cf19d02c-4d7d-45bd-82ac-cdbf4abe4669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_9edb1b9f-6a3f-4a06-bac4-9c193f0311e8" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e39cb102-06b9-4481-8ee6-f335f3817263" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_9edb1b9f-6a3f-4a06-bac4-9c193f0311e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_a255b3a9-23a7-4716-bf45-66ee914bc524" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e39cb102-06b9-4481-8ee6-f335f3817263" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_a255b3a9-23a7-4716-bf45-66ee914bc524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d2b2c9f3-f196-41ee-820f-0d4e710f96b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_16ca4d00-c304-41e4-a2e1-d630c8cf94f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d2b2c9f3-f196-41ee-820f-0d4e710f96b2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_16ca4d00-c304-41e4-a2e1-d630c8cf94f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a0740cf3-da27-4f98-b2d2-ef58b42a94ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_16ca4d00-c304-41e4-a2e1-d630c8cf94f8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a0740cf3-da27-4f98-b2d2-ef58b42a94ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4f87ede7-2ac2-4bf7-bcf2-d859741c9c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a0740cf3-da27-4f98-b2d2-ef58b42a94ee" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4f87ede7-2ac2-4bf7-bcf2-d859741c9c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_38382d96-26df-4f4a-9812-e2e46e036691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4f87ede7-2ac2-4bf7-bcf2-d859741c9c5e" xlink:to="loc_us-gaap_PreferredStockMember_38382d96-26df-4f4a-9812-e2e46e036691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_979eba40-2036-4705-a9f8-cdae36ffd69e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_16ca4d00-c304-41e4-a2e1-d630c8cf94f8" xlink:to="loc_srt_RangeAxis_979eba40-2036-4705-a9f8-cdae36ffd69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7af997b4-d0a0-4999-80da-7173bae035d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_979eba40-2036-4705-a9f8-cdae36ffd69e" xlink:to="loc_srt_RangeMember_7af997b4-d0a0-4999-80da-7173bae035d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_792dd41c-b4c7-4121-b0d7-1b9814e4b8da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7af997b4-d0a0-4999-80da-7173bae035d2" xlink:to="loc_srt_MaximumMember_792dd41c-b4c7-4121-b0d7-1b9814e4b8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ab3356db-c141-41e9-bcd4-a2b6c8239f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_16ca4d00-c304-41e4-a2e1-d630c8cf94f8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ab3356db-c141-41e9-bcd4-a2b6c8239f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_66514746-8ca7-4097-9831-6f1c32152e54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ab3356db-c141-41e9-bcd4-a2b6c8239f6b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_66514746-8ca7-4097-9831-6f1c32152e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ee1f2dc5-12d3-4332-b2e1-46ef751c6739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_66514746-8ca7-4097-9831-6f1c32152e54" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ee1f2dc5-12d3-4332-b2e1-46ef751c6739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_436336b2-86bf-4a84-b4c8-e2b3e8859ffd" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_16ca4d00-c304-41e4-a2e1-d630c8cf94f8" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_436336b2-86bf-4a84-b4c8-e2b3e8859ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_7e17d0d3-e28e-47a1-a9d8-72626981dd55" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis_436336b2-86bf-4a84-b4c8-e2b3e8859ffd" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_7e17d0d3-e28e-47a1-a9d8-72626981dd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_1f433a62-ba25-45d9-881e-42809a311653" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain_7e17d0d3-e28e-47a1-a9d8-72626981dd55" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember_1f433a62-ba25-45d9-881e-42809a311653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_63b18683-c483-4819-9872-3a90c2e13169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_16ca4d00-c304-41e4-a2e1-d630c8cf94f8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_63b18683-c483-4819-9872-3a90c2e13169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a9e9bc31-1baf-426b-8700-0fdd9d72cb43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_63b18683-c483-4819-9872-3a90c2e13169" xlink:to="loc_us-gaap_ClassOfStockDomain_a9e9bc31-1baf-426b-8700-0fdd9d72cb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_ae14f62d-c8f2-4476-af57-64acc624b283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a9e9bc31-1baf-426b-8700-0fdd9d72cb43" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_ae14f62d-c8f2-4476-af57-64acc624b283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_859fee3b-7e97-459c-ad54-21c19ec90caf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_16ca4d00-c304-41e4-a2e1-d630c8cf94f8" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_859fee3b-7e97-459c-ad54-21c19ec90caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_44f2e197-6917-4ee1-8606-cf7a622668fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_859fee3b-7e97-459c-ad54-21c19ec90caf" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_44f2e197-6917-4ee1-8606-cf7a622668fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_4ad98f2f-2367-4025-9843-2263d0889947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_44f2e197-6917-4ee1-8606-cf7a622668fa" xlink:to="loc_us-gaap_EquitySecuritiesMember_4ad98f2f-2367-4025-9843-2263d0889947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d86ce1a2-382b-46d3-8e20-d046193d0a3c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_16ca4d00-c304-41e4-a2e1-d630c8cf94f8" xlink:to="loc_srt_CounterpartyNameAxis_d86ce1a2-382b-46d3-8e20-d046193d0a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b917f089-e5ff-4a23-99db-79f900ecae14" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d86ce1a2-382b-46d3-8e20-d046193d0a3c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b917f089-e5ff-4a23-99db-79f900ecae14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_BioCrystPharmaceuticalsIncMember_dd9b737d-3e6c-4208-9097-4c2086276731" xlink:href="rprx-20211231.xsd#rprx_BioCrystPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b917f089-e5ff-4a23-99db-79f900ecae14" xlink:to="loc_rprx_BioCrystPharmaceuticalsIncMember_dd9b737d-3e6c-4208-9097-4c2086276731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8643c216-d65e-4753-9a17-4c949aa85cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_16ca4d00-c304-41e4-a2e1-d630c8cf94f8" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8643c216-d65e-4753-9a17-4c949aa85cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss_2c3a0b86-723e-482a-b8cc-e980ca2a794e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8643c216-d65e-4753-9a17-4c949aa85cd7" xlink:to="loc_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss_2c3a0b86-723e-482a-b8cc-e980ca2a794e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage_25125182-2ace-4720-b109-062ddbcac769" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8643c216-d65e-4753-9a17-4c949aa85cd7" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage_25125182-2ace-4720-b109-062ddbcac769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments_a18efc06-12fd-422b-8164-8d353ebed48c" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8643c216-d65e-4753-9a17-4c949aa85cd7" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments_a18efc06-12fd-422b-8164-8d353ebed48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleFixedPayment_02e64395-1309-47c4-9d05-853775450d91" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleFixedPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8643c216-d65e-4753-9a17-4c949aa85cd7" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleFixedPayment_02e64395-1309-47c4-9d05-853775450d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod_ae053b40-8de2-4348-ac34-b158428a1c40" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8643c216-d65e-4753-9a17-4c949aa85cd7" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod_ae053b40-8de2-4348-ac34-b158428a1c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital_f2537b5b-b037-4d4c-835c-cea7167116ef" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8643c216-d65e-4753-9a17-4c949aa85cd7" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital_f2537b5b-b037-4d4c-835c-cea7167116ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_d7c2f71b-eac5-4c39-bc24-34bb0093ebb8" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8643c216-d65e-4753-9a17-4c949aa85cd7" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased_d7c2f71b-eac5-4c39-bc24-34bb0093ebb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod_ef7208b3-0583-46ea-ab49-b989ad918e01" xlink:href="rprx-20211231.xsd#rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8643c216-d65e-4753-9a17-4c949aa85cd7" xlink:to="loc_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod_ef7208b3-0583-46ea-ab49-b989ad918e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_36e2b28c-620a-43c1-acba-3c36de24f403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4b88d82b-e926-4444-ae15-491bff7af7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_36e2b28c-620a-43c1-acba-3c36de24f403" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4b88d82b-e926-4444-ae15-491bff7af7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_f12397f3-ff83-4bd6-afee-91e70205d594" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4b88d82b-e926-4444-ae15-491bff7af7a2" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_f12397f3-ff83-4bd6-afee-91e70205d594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_83f2bd2a-4ea1-4326-b39a-5bb0ad9b9e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f12397f3-ff83-4bd6-afee-91e70205d594" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_83f2bd2a-4ea1-4326-b39a-5bb0ad9b9e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_f3db92d6-d6e6-483f-ad73-095cf522b607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_83f2bd2a-4ea1-4326-b39a-5bb0ad9b9e61" xlink:to="loc_us-gaap_EquitySecuritiesMember_f3db92d6-d6e6-483f-ad73-095cf522b607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_da413687-3a12-460d-aa8e-6ae1355371b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_83f2bd2a-4ea1-4326-b39a-5bb0ad9b9e61" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_da413687-3a12-460d-aa8e-6ae1355371b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_27280e23-729d-41f6-9e8e-077e46fadb91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_83f2bd2a-4ea1-4326-b39a-5bb0ad9b9e61" xlink:to="loc_us-gaap_ForwardContractsMember_27280e23-729d-41f6-9e8e-077e46fadb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_c72e59e9-3031-4406-82ba-5d43af9ead4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_83f2bd2a-4ea1-4326-b39a-5bb0ad9b9e61" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_c72e59e9-3031-4406-82ba-5d43af9ead4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d57b9e9-381e-49b0-99f2-db8130a07c48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4b88d82b-e926-4444-ae15-491bff7af7a2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d57b9e9-381e-49b0-99f2-db8130a07c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e83264d-0c11-4109-85df-42a69bf80534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d57b9e9-381e-49b0-99f2-db8130a07c48" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e83264d-0c11-4109-85df-42a69bf80534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6f1a2669-43c7-427d-b631-b1c9f5a02e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e83264d-0c11-4109-85df-42a69bf80534" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6f1a2669-43c7-427d-b631-b1c9f5a02e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e58f0548-1424-41d2-884a-2636c9dd00b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e83264d-0c11-4109-85df-42a69bf80534" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e58f0548-1424-41d2-884a-2636c9dd00b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b26f07eb-06a9-41c2-9a54-b53cd13748c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4b88d82b-e926-4444-ae15-491bff7af7a2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b26f07eb-06a9-41c2-9a54-b53cd13748c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d1ea1d4f-63a1-4989-a6a1-d6bbdd281aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b26f07eb-06a9-41c2-9a54-b53cd13748c0" xlink:to="loc_us-gaap_ClassOfStockDomain_d1ea1d4f-63a1-4989-a6a1-d6bbdd281aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_607fb949-eab5-47de-80ff-6d74ea67449e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d1ea1d4f-63a1-4989-a6a1-d6bbdd281aa9" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_607fb949-eab5-47de-80ff-6d74ea67449e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_4c8afc8d-1490-4a2c-b25d-cc5a8ad0d003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d1ea1d4f-63a1-4989-a6a1-d6bbdd281aa9" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_4c8afc8d-1490-4a2c-b25d-cc5a8ad0d003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_85c7ce58-6255-4d04-9ae5-f4ad586a2069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4b88d82b-e926-4444-ae15-491bff7af7a2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_85c7ce58-6255-4d04-9ae5-f4ad586a2069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a1af04db-20a6-4c9c-ad7c-1acbfb9e869a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_85c7ce58-6255-4d04-9ae5-f4ad586a2069" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a1af04db-20a6-4c9c-ad7c-1acbfb9e869a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_10f6b94c-b4b5-464f-aa98-ec258a757695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a1af04db-20a6-4c9c-ad7c-1acbfb9e869a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_10f6b94c-b4b5-464f-aa98-ec258a757695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_2dfb9609-3b0b-406c-b0bf-1c38be287613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a1af04db-20a6-4c9c-ad7c-1acbfb9e869a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_2dfb9609-3b0b-406c-b0bf-1c38be287613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_91998910-df5f-4e91-99c3-42401351e1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a1af04db-20a6-4c9c-ad7c-1acbfb9e869a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_91998910-df5f-4e91-99c3-42401351e1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_4c986940-3a31-4707-bcd0-aab6b25b224a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a1af04db-20a6-4c9c-ad7c-1acbfb9e869a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_4c986940-3a31-4707-bcd0-aab6b25b224a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_a376d701-d530-4301-99dd-629eadab973b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a1af04db-20a6-4c9c-ad7c-1acbfb9e869a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_a376d701-d530-4301-99dd-629eadab973b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_f34445d3-a2de-42e9-973d-63242df39ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a1af04db-20a6-4c9c-ad7c-1acbfb9e869a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_f34445d3-a2de-42e9-973d-63242df39ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3_c3d82425-3945-4e5f-9f1c-a5ab1b03a232" xlink:href="rprx-20211231.xsd#rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a1af04db-20a6-4c9c-ad7c-1acbfb9e869a" xlink:to="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3_c3d82425-3945-4e5f-9f1c-a5ab1b03a232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_718f196b-d5cd-4143-863b-b342a5f32ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a1af04db-20a6-4c9c-ad7c-1acbfb9e869a" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_718f196b-d5cd-4143-863b-b342a5f32ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions_017fbc23-77ee-45ea-a5a9-34b3581bdabf" xlink:href="rprx-20211231.xsd#rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a1af04db-20a6-4c9c-ad7c-1acbfb9e869a" xlink:to="loc_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions_017fbc23-77ee-45ea-a5a9-34b3581bdabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_424c74a8-32bb-47dc-9050-8f17a6e011f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a1af04db-20a6-4c9c-ad7c-1acbfb9e869a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_424c74a8-32bb-47dc-9050-8f17a6e011f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_af10d8a6-4816-4a05-9f56-d69c43cb98db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_85c7ce58-6255-4d04-9ae5-f4ad586a2069" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_af10d8a6-4816-4a05-9f56-d69c43cb98db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_aab3c1cb-b2d5-4979-ba47-2ee24f4131e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_00115f4c-5a2a-4c51-9469-c036ac6a2527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_aab3c1cb-b2d5-4979-ba47-2ee24f4131e6" xlink:to="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_00115f4c-5a2a-4c51-9469-c036ac6a2527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_22bdc120-98ea-4919-87cc-e2d00413043e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_00115f4c-5a2a-4c51-9469-c036ac6a2527" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_22bdc120-98ea-4919-87cc-e2d00413043e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b7ab7f52-a1b2-42f1-b0a9-0dcd789a43f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_22bdc120-98ea-4919-87cc-e2d00413043e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b7ab7f52-a1b2-42f1-b0a9-0dcd789a43f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_90060fa3-a97e-46c8-b472-31bea2ebacbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b7ab7f52-a1b2-42f1-b0a9-0dcd789a43f1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_90060fa3-a97e-46c8-b472-31bea2ebacbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_669154d3-6b6a-49e5-83d1-8f0c9b9ff62e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_00115f4c-5a2a-4c51-9469-c036ac6a2527" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_669154d3-6b6a-49e5-83d1-8f0c9b9ff62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_13297722-8baf-46d0-9f0f-4aeec04d20ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_669154d3-6b6a-49e5-83d1-8f0c9b9ff62e" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_13297722-8baf-46d0-9f0f-4aeec04d20ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c5b5fdd5-69b1-48b3-bbbb-a019d6589678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_13297722-8baf-46d0-9f0f-4aeec04d20ea" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c5b5fdd5-69b1-48b3-bbbb-a019d6589678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_f75e20fd-339c-4088-bb52-2918af569d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c5b5fdd5-69b1-48b3-bbbb-a019d6589678" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_f75e20fd-339c-4088-bb52-2918af569d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_865ae975-7a26-4ad8-894d-ca2654633d85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c5b5fdd5-69b1-48b3-bbbb-a019d6589678" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_865ae975-7a26-4ad8-894d-ca2654633d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_d0a1d670-cf35-49fa-a42a-d42e3c16e3da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_00115f4c-5a2a-4c51-9469-c036ac6a2527" xlink:to="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_d0a1d670-cf35-49fa-a42a-d42e3c16e3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivablesFairValueDisclosure_ce45672a-26b6-44d8-8b13-1d31426bc7ad" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivablesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_d0a1d670-cf35-49fa-a42a-d42e3c16e3da" xlink:to="loc_rprx_FinancingReceivablesFairValueDisclosure_ce45672a-26b6-44d8-8b13-1d31426bc7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssetsNet" xlink:type="simple" xlink:href="rprx-20211231.xsd#FinancialRoyaltyAssetsNet"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FinancialRoyaltyAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_e9987032-0b59-4144-9a5e-411f1cc6c125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesTextBlock_1f237c11-fffc-454e-a52a-2bca8b97296a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_e9987032-0b59-4144-9a5e-411f1cc6c125" xlink:to="loc_us-gaap_FinancingReceivablesTextBlock_1f237c11-fffc-454e-a52a-2bca8b97296a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssetsNetTables" xlink:type="simple" xlink:href="rprx-20211231.xsd#FinancialRoyaltyAssetsNetTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FinancialRoyaltyAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_4f72079c-ef4d-4975-a9df-aadb68021c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_18d3b20d-dbbe-46be-b834-8f9c414280f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_4f72079c-ef4d-4975-a9df-aadb68021c1a" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_18d3b20d-dbbe-46be-b834-8f9c414280f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_6ded899e-dfb1-4d05-a18a-5996cc392f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c0091dd9-b2ea-4c11-a1e2-2626e7c21a13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_6ded899e-dfb1-4d05-a18a-5996cc392f36" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c0091dd9-b2ea-4c11-a1e2-2626e7c21a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_7da3b168-9336-45bf-a810-de95b417cff2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c0091dd9-b2ea-4c11-a1e2-2626e7c21a13" xlink:to="loc_srt_MajorCustomersAxis_7da3b168-9336-45bf-a810-de95b417cff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_441a3604-7284-45be-b45b-10844b6358d5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_7da3b168-9336-45bf-a810-de95b417cff2" xlink:to="loc_srt_NameOfMajorCustomerDomain_441a3604-7284-45be-b45b-10844b6358d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CysticFibrosisFranchiseMember_a6224227-a268-4c46-b6cc-74e32b38de56" xlink:href="rprx-20211231.xsd#rprx_CysticFibrosisFranchiseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_441a3604-7284-45be-b45b-10844b6358d5" xlink:to="loc_rprx_CysticFibrosisFranchiseMember_a6224227-a268-4c46-b6cc-74e32b38de56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TysabriMember_ac79309e-775d-44ca-b80c-c4a080b94f1e" xlink:href="rprx-20211231.xsd#rprx_TysabriMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_441a3604-7284-45be-b45b-10844b6358d5" xlink:to="loc_rprx_TysabriMember_ac79309e-775d-44ca-b80c-c4a080b94f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ImbruvicaMember_998215e8-2e64-4293-93ca-aa25834bdc3a" xlink:href="rprx-20211231.xsd#rprx_ImbruvicaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_441a3604-7284-45be-b45b-10844b6358d5" xlink:to="loc_rprx_ImbruvicaMember_998215e8-2e64-4293-93ca-aa25834bdc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_XtandiMember_03b74a82-e447-4f86-b777-474d4c5d9b1f" xlink:href="rprx-20211231.xsd#rprx_XtandiMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_441a3604-7284-45be-b45b-10844b6358d5" xlink:to="loc_rprx_XtandiMember_03b74a82-e447-4f86-b777-474d4c5d9b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TremfyaMember_d8564193-ba02-4462-aaca-aa68a2201334" xlink:href="rprx-20211231.xsd#rprx_TremfyaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_441a3604-7284-45be-b45b-10844b6358d5" xlink:to="loc_rprx_TremfyaMember_d8564193-ba02-4462-aaca-aa68a2201334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EvrysdiMember_09510800-aa03-48e5-9593-9bcebfd64269" xlink:href="rprx-20211231.xsd#rprx_EvrysdiMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_441a3604-7284-45be-b45b-10844b6358d5" xlink:to="loc_rprx_EvrysdiMember_09510800-aa03-48e5-9593-9bcebfd64269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PromactaMember_be02a07f-ad1b-4fa0-a424-0bf82bd53874" xlink:href="rprx-20211231.xsd#rprx_PromactaMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_441a3604-7284-45be-b45b-10844b6358d5" xlink:to="loc_rprx_PromactaMember_be02a07f-ad1b-4fa0-a424-0bf82bd53874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherFinancialRoyaltyAssetMember_971d72fe-ea2a-4d59-94cc-24c11650b9e9" xlink:href="rprx-20211231.xsd#rprx_OtherFinancialRoyaltyAssetMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_441a3604-7284-45be-b45b-10844b6358d5" xlink:to="loc_rprx_OtherFinancialRoyaltyAssetMember_971d72fe-ea2a-4d59-94cc-24c11650b9e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0722f954-57ac-47cb-b86e-f0ab43b897ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c0091dd9-b2ea-4c11-a1e2-2626e7c21a13" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0722f954-57ac-47cb-b86e-f0ab43b897ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross_d2156111-4768-4b22-83c0-3fa99b0ed0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0722f954-57ac-47cb-b86e-f0ab43b897ff" xlink:to="loc_us-gaap_NotesReceivableGross_d2156111-4768-4b22-83c0-3fa99b0ed0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_e078e7d9-57df-4e97-a727-0415cd6cbec9" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0722f954-57ac-47cb-b86e-f0ab43b897ff" xlink:to="loc_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows_e078e7d9-57df-4e97-a727-0415cd6cbec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_88fe99a0-6413-46f2-9dac-59dd95712045" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0722f954-57ac-47cb-b86e-f0ab43b897ff" xlink:to="loc_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows_88fe99a0-6413-46f2-9dac-59dd95712045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_a1ca714e-5d69-4be3-975c-04ad743b99c2" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0722f954-57ac-47cb-b86e-f0ab43b897ff" xlink:to="loc_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal_a1ca714e-5d69-4be3-975c-04ad743b99c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_a90b0383-ff68-4739-b0c1-e378ad0f8818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0722f954-57ac-47cb-b86e-f0ab43b897ff" xlink:to="loc_us-gaap_NotesReceivableNet_a90b0383-ff68-4739-b0c1-e378ad0f8818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents_7a20eba7-509a-4c32-8572-214e61d52461" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0722f954-57ac-47cb-b86e-f0ab43b897ff" xlink:to="loc_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents_7a20eba7-509a-4c32-8572-214e61d52461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets" xlink:type="simple" xlink:href="rprx-20211231.xsd#CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_5e4c7ac5-b8c6-40ea-9165-c2251f338d46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentTextBlock_948485fb-d201-4fe4-ab16-68c2f7bff76e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossFinancialInstrumentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_5e4c7ac5-b8c6-40ea-9165-c2251f338d46" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentTextBlock_948485fb-d201-4fe4-ab16-68c2f7bff76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables" xlink:type="simple" xlink:href="rprx-20211231.xsd#CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_8cd40c45-61a8-438d-8320-cde5d421de67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_26e2ea45-99eb-43ba-ab45-a85ce1220a64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_8cd40c45-61a8-438d-8320-cde5d421de67" xlink:to="loc_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_26e2ea45-99eb-43ba-ab45-a85ce1220a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_6786a2e7-cfdc-415c-8b99-ba21212ef766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_f69f9471-ac3d-4d34-9dbe-1474b24ce373" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_6786a2e7-cfdc-415c-8b99-ba21212ef766" xlink:to="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_f69f9471-ac3d-4d34-9dbe-1474b24ce373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c96e79e0-42fe-4004-8ae5-03332b15733d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_f69f9471-ac3d-4d34-9dbe-1474b24ce373" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c96e79e0-42fe-4004-8ae5-03332b15733d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5ceeb8eb-a58a-40a9-a7e4-d4dbf1898751" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c96e79e0-42fe-4004-8ae5-03332b15733d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5ceeb8eb-a58a-40a9-a7e4-d4dbf1898751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_97d77f60-84f1-41fc-8767-fe745bf53086" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5ceeb8eb-a58a-40a9-a7e4-d4dbf1898751" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_97d77f60-84f1-41fc-8767-fe745bf53086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_12adb9c5-6b47-4f81-a4ab-3a36ab323574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_f69f9471-ac3d-4d34-9dbe-1474b24ce373" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_12adb9c5-6b47-4f81-a4ab-3a36ab323574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6a573f84-494f-46db-81da-99eaee078239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_12adb9c5-6b47-4f81-a4ab-3a36ab323574" xlink:to="loc_us-gaap_EquityComponentDomain_6a573f84-494f-46db-81da-99eaee078239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_898277ae-6284-4ad9-856a-557b0efa3d42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6a573f84-494f-46db-81da-99eaee078239" xlink:to="loc_us-gaap_RetainedEarningsMember_898277ae-6284-4ad9-856a-557b0efa3d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_7d9c0310-4d0a-481a-a117-ec86c27ef468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_f69f9471-ac3d-4d34-9dbe-1474b24ce373" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_7d9c0310-4d0a-481a-a117-ec86c27ef468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_384a8b6a-cfa9-4f76-a7c3-3cb7588b4b35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_7d9c0310-4d0a-481a-a117-ec86c27ef468" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_384a8b6a-cfa9-4f76-a7c3-3cb7588b4b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_614dc87d-1c4e-44f8-84b7-c4f3a3307405" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_dda5577e-a0d0-43a9-a13e-891967e459f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_614dc87d-1c4e-44f8-84b7-c4f3a3307405" xlink:to="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_dda5577e-a0d0-43a9-a13e-891967e459f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1ce92c7a-518f-49bf-91fe-35184b3a8401" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_dda5577e-a0d0-43a9-a13e-891967e459f5" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1ce92c7a-518f-49bf-91fe-35184b3a8401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7cda0aa2-13d5-4bd6-89ee-845a19512b36" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1ce92c7a-518f-49bf-91fe-35184b3a8401" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7cda0aa2-13d5-4bd6-89ee-845a19512b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_2cb28d45-f725-41e1-82dc-5e33016db8b0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7cda0aa2-13d5-4bd6-89ee-845a19512b36" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_2cb28d45-f725-41e1-82dc-5e33016db8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_3b6475d2-3691-404a-9dc8-5f1d79f2d779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_dda5577e-a0d0-43a9-a13e-891967e459f5" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_3b6475d2-3691-404a-9dc8-5f1d79f2d779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses_1b1a49c9-3565-4cfc-ae27-7bc50156841a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_3b6475d2-3691-404a-9dc8-5f1d79f2d779" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses_1b1a49c9-3565-4cfc-ae27-7bc50156841a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense_54e0a930-f335-4d54-a062-7c4ebaac8f91" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_3b6475d2-3691-404a-9dc8-5f1d79f2d779" xlink:to="loc_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense_54e0a930-f335-4d54-a062-7c4ebaac8f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense_18b30f25-79f1-4ebd-8d5e-869b658075e9" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_3b6475d2-3691-404a-9dc8-5f1d79f2d779" xlink:to="loc_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense_18b30f25-79f1-4ebd-8d5e-869b658075e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableChangeInPresentValueExpenseReversal_bd8dc35a-47d3-476f-9b82-988f560a79d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableChangeInPresentValueExpenseReversal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_3b6475d2-3691-404a-9dc8-5f1d79f2d779" xlink:to="loc_us-gaap_FinancingReceivableChangeInPresentValueExpenseReversal_bd8dc35a-47d3-476f-9b82-988f560a79d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs_bb9d6db5-3195-4ed3-9535-79e3f9aa36e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_3b6475d2-3691-404a-9dc8-5f1d79f2d779" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs_bb9d6db5-3195-4ed3-9535-79e3f9aa36e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLoanLossesExpensed_7c6e2f71-36e9-480b-a019-152c61dc3e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForLoanLossesExpensed"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_3b6475d2-3691-404a-9dc8-5f1d79f2d779" xlink:to="loc_us-gaap_ProvisionForLoanLossesExpensed_7c6e2f71-36e9-480b-a019-152c61dc3e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses_9d06d40c-54bf-481f-ae92-d319a3c46586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_3b6475d2-3691-404a-9dc8-5f1d79f2d779" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses_9d06d40c-54bf-481f-ae92-d319a3c46586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff_753076da-6d79-48e8-8f70-a21ffcc39469" xlink:href="rprx-20211231.xsd#rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_3b6475d2-3691-404a-9dc8-5f1d79f2d779" xlink:to="loc_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff_753076da-6d79-48e8-8f70-a21ffcc39469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet" xlink:type="simple" xlink:href="rprx-20211231.xsd#IntangibleRoyaltyAssetsNet"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f66bb332-0c65-47f9-9180-5fe52f14226d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_38157c07-6b0a-4775-9372-572afb43442a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f66bb332-0c65-47f9-9180-5fe52f14226d" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_38157c07-6b0a-4775-9372-572afb43442a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables" xlink:type="simple" xlink:href="rprx-20211231.xsd#IntangibleRoyaltyAssetsNetTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5f8d2b69-750e-463d-b490-63535578fe38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_3b6c238d-9599-4d0b-a09d-f39fe084f5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5f8d2b69-750e-463d-b490-63535578fe38" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_3b6c238d-9599-4d0b-a09d-f39fe084f5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ce8e485d-a201-4858-8978-9033f7bb3a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_061434c4-6005-45ff-88f2-84fab7cadd1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ce8e485d-a201-4858-8978-9033f7bb3a8b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_061434c4-6005-45ff-88f2-84fab7cadd1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a910d1ca-e41f-4d15-a38b-ae6eed19d747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_061434c4-6005-45ff-88f2-84fab7cadd1d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a910d1ca-e41f-4d15-a38b-ae6eed19d747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0525bdbd-1b5e-4271-b772-4e4d137162d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a910d1ca-e41f-4d15-a38b-ae6eed19d747" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0525bdbd-1b5e-4271-b772-4e4d137162d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DPPIVPatentsMember_19b2d439-895d-4611-873f-95064575f487" xlink:href="rprx-20211231.xsd#rprx_DPPIVPatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0525bdbd-1b5e-4271-b772-4e4d137162d3" xlink:to="loc_rprx_DPPIVPatentsMember_19b2d439-895d-4611-873f-95064575f487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7dc29fcf-929f-46ca-b275-d3d2e5d2c788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_061434c4-6005-45ff-88f2-84fab7cadd1d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7dc29fcf-929f-46ca-b275-d3d2e5d2c788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_af3cdfef-a8fe-4e9b-a863-2154497db0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7dc29fcf-929f-46ca-b275-d3d2e5d2c788" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_af3cdfef-a8fe-4e9b-a863-2154497db0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_098aa143-4e33-4261-bea8-6dcaa1c1a30e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7dc29fcf-929f-46ca-b275-d3d2e5d2c788" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_098aa143-4e33-4261-bea8-6dcaa1c1a30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_80af27d5-ab1b-4f5e-971f-c8de9a92d433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7dc29fcf-929f-46ca-b275-d3d2e5d2c788" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_80af27d5-ab1b-4f5e-971f-c8de9a92d433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#IntangibleRoyaltyAssetsNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8af02358-fa6c-467d-afce-d0f23cbd17b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_18c40379-1cfb-4282-ad57-1ce0c96cc4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8af02358-fa6c-467d-afce-d0f23cbd17b6" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_18c40379-1cfb-4282-ad57-1ce0c96cc4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_865570a9-86e6-46a8-acc1-3760fab1d609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_18c40379-1cfb-4282-ad57-1ce0c96cc4b0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_865570a9-86e6-46a8-acc1-3760fab1d609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eaa724b3-6f05-4ec2-b469-4fabdb005351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_865570a9-86e6-46a8-acc1-3760fab1d609" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eaa724b3-6f05-4ec2-b469-4fabdb005351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DPPIVPatentsMember_e1b486cd-083f-4991-bf1f-b89887f52ca8" xlink:href="rprx-20211231.xsd#rprx_DPPIVPatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eaa724b3-6f05-4ec2-b469-4fabdb005351" xlink:to="loc_rprx_DPPIVPatentsMember_e1b486cd-083f-4991-bf1f-b89887f52ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9c7ec2e3-a5bc-462a-bd7b-93546008dbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_18c40379-1cfb-4282-ad57-1ce0c96cc4b0" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9c7ec2e3-a5bc-462a-bd7b-93546008dbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d216b932-b681-46f8-bd20-e65e931b1f68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9c7ec2e3-a5bc-462a-bd7b-93546008dbb0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d216b932-b681-46f8-bd20-e65e931b1f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_bfa9b713-6223-453b-8f70-42ae2febaec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d216b932-b681-46f8-bd20-e65e931b1f68" xlink:to="loc_us-gaap_SalesRevenueNetMember_bfa9b713-6223-453b-8f70-42ae2febaec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_8bb07d5e-0f45-4d92-a62a-1b646e01e632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_18c40379-1cfb-4282-ad57-1ce0c96cc4b0" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_8bb07d5e-0f45-4d92-a62a-1b646e01e632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f3094727-b94c-453c-bb67-988055159dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8bb07d5e-0f45-4d92-a62a-1b646e01e632" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f3094727-b94c-453c-bb67-988055159dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IndividualLicenseesConcentrationRiskMember_73223b52-56b1-40de-a6f1-126a9df53a31" xlink:href="rprx-20211231.xsd#rprx_IndividualLicenseesConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f3094727-b94c-453c-bb67-988055159dc0" xlink:to="loc_rprx_IndividualLicenseesConcentrationRiskMember_73223b52-56b1-40de-a6f1-126a9df53a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e20d9efd-269f-4f26-8a05-643213c55112" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_18c40379-1cfb-4282-ad57-1ce0c96cc4b0" xlink:to="loc_srt_ProductOrServiceAxis_e20d9efd-269f-4f26-8a05-643213c55112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_773459e4-6426-43cd-83fe-b77eb1e8c415" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e20d9efd-269f-4f26-8a05-643213c55112" xlink:to="loc_srt_ProductsAndServicesDomain_773459e4-6426-43cd-83fe-b77eb1e8c415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IntangibleRoyaltyAssetsMember_5a450e2a-29b6-4aff-86a7-d57842eb3cee" xlink:href="rprx-20211231.xsd#rprx_IntangibleRoyaltyAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_773459e4-6426-43cd-83fe-b77eb1e8c415" xlink:to="loc_rprx_IntangibleRoyaltyAssetsMember_5a450e2a-29b6-4aff-86a7-d57842eb3cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4bda21e6-c845-4f12-aace-79d12750bfc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_18c40379-1cfb-4282-ad57-1ce0c96cc4b0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4bda21e6-c845-4f12-aace-79d12750bfc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f2cea427-2538-4658-aed3-b2325971626b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4bda21e6-c845-4f12-aace-79d12750bfc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f2cea427-2538-4658-aed3-b2325971626b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3a552787-5369-4dff-9ec3-964a16169582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4bda21e6-c845-4f12-aace-79d12750bfc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3a552787-5369-4dff-9ec3-964a16169582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_67f703ab-cc44-4a00-b8fb-6b9360e9f1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4bda21e6-c845-4f12-aace-79d12750bfc8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_67f703ab-cc44-4a00-b8fb-6b9360e9f1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/NonConsolidatedAffiliates" xlink:type="simple" xlink:href="rprx-20211231.xsd#NonConsolidatedAffiliates"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/NonConsolidatedAffiliates" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_48c69860-e34c-46ae-81f1-ca2e226468c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_821a500a-b0aa-49d6-be4e-4331535424aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_48c69860-e34c-46ae-81f1-ca2e226468c6" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_821a500a-b0aa-49d6-be4e-4331535424aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#NonConsolidatedAffiliatesDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_f7140e1b-216c-4049-892b-91ecad39e09a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7cb1a3a4-b479-465f-9699-c1586f748126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_f7140e1b-216c-4049-892b-91ecad39e09a" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7cb1a3a4-b479-465f-9699-c1586f748126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_96032d2d-c41e-41ec-a596-696447647281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7cb1a3a4-b479-465f-9699-c1586f748126" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_96032d2d-c41e-41ec-a596-696447647281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_75df2543-179d-47fa-ad23-36afb43ba976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_96032d2d-c41e-41ec-a596-696447647281" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_75df2543-179d-47fa-ad23-36afb43ba976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_a66ca174-66f7-4c16-b926-c4f621ebc65b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_75df2543-179d-47fa-ad23-36afb43ba976" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_a66ca174-66f7-4c16-b926-c4f621ebc65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d34d5a38-adf0-4908-bc49-2a96f717d83b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7cb1a3a4-b479-465f-9699-c1586f748126" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d34d5a38-adf0-4908-bc49-2a96f717d83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8f1ac400-eb2c-44cf-a845-46e299547048" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d34d5a38-adf0-4908-bc49-2a96f717d83b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8f1ac400-eb2c-44cf-a845-46e299547048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember_a757c44d-f06d-4368-80e9-193b2b803747" xlink:href="rprx-20211231.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8f1ac400-eb2c-44cf-a845-46e299547048" xlink:to="loc_rprx_LegacyInvestorsPartnershipsMember_a757c44d-f06d-4368-80e9-193b2b803747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionEntitiesMember_73a86e5f-13b4-412d-852c-a579571da0c7" xlink:href="rprx-20211231.xsd#rprx_AvillionEntitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8f1ac400-eb2c-44cf-a845-46e299547048" xlink:to="loc_rprx_AvillionEntitiesMember_73a86e5f-13b4-412d-852c-a579571da0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionIMember_3ba945ad-fcb4-4ef7-ae8e-2d0b92edfb7f" xlink:href="rprx-20211231.xsd#rprx_AvillionIMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8f1ac400-eb2c-44cf-a845-46e299547048" xlink:to="loc_rprx_AvillionIMember_3ba945ad-fcb4-4ef7-ae8e-2d0b92edfb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AvillionIIMember_f6ef2289-29b4-4fab-be70-6dc6b91fceac" xlink:href="rprx-20211231.xsd#rprx_AvillionIIMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8f1ac400-eb2c-44cf-a845-46e299547048" xlink:to="loc_rprx_AvillionIIMember_f6ef2289-29b4-4fab-be70-6dc6b91fceac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_3f5befbd-e328-47d8-a251-01bf5271e32a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7cb1a3a4-b479-465f-9699-c1586f748126" xlink:to="loc_us-gaap_OtherCommitmentsAxis_3f5befbd-e328-47d8-a251-01bf5271e32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_40bdfdb2-c69f-431c-ba0d-be0c86460ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_3f5befbd-e328-47d8-a251-01bf5271e32a" xlink:to="loc_us-gaap_OtherCommitmentsDomain_40bdfdb2-c69f-431c-ba0d-be0c86460ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MerckAssetPhaseIIClinicalTrialMember_f8d3efaa-6d18-4933-8b57-391cc3b14aee" xlink:href="rprx-20211231.xsd#rprx_MerckAssetPhaseIIClinicalTrialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_40bdfdb2-c69f-431c-ba0d-be0c86460ea7" xlink:to="loc_rprx_MerckAssetPhaseIIClinicalTrialMember_f8d3efaa-6d18-4933-8b57-391cc3b14aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AZAssetPhaseIIAndPhaseIIIClinicalTrialMember_6270c453-79f6-40c6-b42d-1d81fc5ccfa0" xlink:href="rprx-20211231.xsd#rprx_AZAssetPhaseIIAndPhaseIIIClinicalTrialMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_40bdfdb2-c69f-431c-ba0d-be0c86460ea7" xlink:to="loc_rprx_AZAssetPhaseIIAndPhaseIIIClinicalTrialMember_6270c453-79f6-40c6-b42d-1d81fc5ccfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9a319968-a4c8-47a1-86c9-2981d5bf1e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7cb1a3a4-b479-465f-9699-c1586f748126" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9a319968-a4c8-47a1-86c9-2981d5bf1e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_dabb2dc1-2091-49e6-a8fa-1b5e996bb1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9a319968-a4c8-47a1-86c9-2981d5bf1e1c" xlink:to="loc_us-gaap_EquityMethodInvestments_dabb2dc1-2091-49e6-a8fa-1b5e996bb1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6aa75001-9776-49d4-8237-563568467280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9a319968-a4c8-47a1-86c9-2981d5bf1e1c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6aa75001-9776-49d4-8237-563568467280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_47d335e2-68e1-4839-a88f-5b72316b1624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9a319968-a4c8-47a1-86c9-2981d5bf1e1c" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_47d335e2-68e1-4839-a88f-5b72316b1624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_dca58c8a-a1a8-4b7d-9187-a728d9b75ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9a319968-a4c8-47a1-86c9-2981d5bf1e1c" xlink:to="loc_us-gaap_OtherCommitment_dca58c8a-a1a8-4b7d-9187-a728d9b75ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherCommitmentsPercentage_d103d2cb-af4a-434f-84af-5819624b9e28" xlink:href="rprx-20211231.xsd#rprx_OtherCommitmentsPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9a319968-a4c8-47a1-86c9-2981d5bf1e1c" xlink:to="loc_rprx_OtherCommitmentsPercentage_d103d2cb-af4a-434f-84af-5819624b9e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_da15b927-216a-4383-be97-38698010bbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9a319968-a4c8-47a1-86c9-2981d5bf1e1c" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_da15b927-216a-4383-be97-38698010bbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EquityMethodInvestmentsUnfundedCommitments_e13d61da-93a5-4772-820e-48167c5ca0e7" xlink:href="rprx-20211231.xsd#rprx_EquityMethodInvestmentsUnfundedCommitments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9a319968-a4c8-47a1-86c9-2981d5bf1e1c" xlink:to="loc_rprx_EquityMethodInvestmentsUnfundedCommitments_e13d61da-93a5-4772-820e-48167c5ca0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense" xlink:type="simple" xlink:href="rprx-20211231.xsd#ResearchDevelopmentRDFundingExpense"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_84851fae-e1ad-43eb-b0e2-70b6e7b875b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_bf673da1-c3c9-4a29-b80f-e00b391e7efe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_84851fae-e1ad-43eb-b0e2-70b6e7b875b0" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_bf673da1-c3c9-4a29-b80f-e00b391e7efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#ResearchDevelopmentRDFundingExpenseDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_975b2972-fbd8-4044-b992-8e779366dc0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_52fb8263-22f9-4c46-8ee3-1056c7d0e4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_975b2972-fbd8-4044-b992-8e779366dc0b" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_52fb8263-22f9-4c46-8ee3-1056c7d0e4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ee852c88-39e0-4ef0-8c78-cffdde5366d5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_52fb8263-22f9-4c46-8ee3-1056c7d0e4b6" xlink:to="loc_srt_CounterpartyNameAxis_ee852c88-39e0-4ef0-8c78-cffdde5366d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cadf449-0e3b-4427-b70f-3969b2dbf764" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ee852c88-39e0-4ef0-8c78-cffdde5366d5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cadf449-0e3b-4427-b70f-3969b2dbf764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MorphoSysMember_0d05981b-3573-49f0-8966-3417b9eef5c9" xlink:href="rprx-20211231.xsd#rprx_MorphoSysMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cadf449-0e3b-4427-b70f-3969b2dbf764" xlink:to="loc_rprx_MorphoSysMember_0d05981b-3573-49f0-8966-3417b9eef5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingAgreementsWithSanofiMember_c68d53c4-a709-4ce2-9c71-6a0483277c8e" xlink:href="rprx-20211231.xsd#rprx_FundingAgreementsWithSanofiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cadf449-0e3b-4427-b70f-3969b2dbf764" xlink:to="loc_rprx_FundingAgreementsWithSanofiMember_c68d53c4-a709-4ce2-9c71-6a0483277c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingAgreementWithBioCrystMember_52867ced-a2b7-4985-a7c8-77da6be9a791" xlink:href="rprx-20211231.xsd#rprx_FundingAgreementWithBioCrystMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cadf449-0e3b-4427-b70f-3969b2dbf764" xlink:to="loc_rprx_FundingAgreementWithBioCrystMember_52867ced-a2b7-4985-a7c8-77da6be9a791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FundingAgreementsWithPfizerMember_a51f4020-f869-45dd-8ac5-cad69bd2917b" xlink:href="rprx-20211231.xsd#rprx_FundingAgreementsWithPfizerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0cadf449-0e3b-4427-b70f-3969b2dbf764" xlink:to="loc_rprx_FundingAgreementsWithPfizerMember_a51f4020-f869-45dd-8ac5-cad69bd2917b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7503833c-7a74-4d43-99f3-94fa3be80d11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_52fb8263-22f9-4c46-8ee3-1056c7d0e4b6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7503833c-7a74-4d43-99f3-94fa3be80d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10f7021e-82eb-4c21-abbd-d0567c38e722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7503833c-7a74-4d43-99f3-94fa3be80d11" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10f7021e-82eb-4c21-abbd-d0567c38e722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_BioCrystPharmaceuticalsIncMember_67b6e301-2b32-4273-848a-deda442889d1" xlink:href="rprx-20211231.xsd#rprx_BioCrystPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10f7021e-82eb-4c21-abbd-d0567c38e722" xlink:to="loc_rprx_BioCrystPharmaceuticalsIncMember_67b6e301-2b32-4273-848a-deda442889d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4113d76d-ca98-4bde-b57f-1a8130583022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_52fb8263-22f9-4c46-8ee3-1056c7d0e4b6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4113d76d-ca98-4bde-b57f-1a8130583022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ba845457-178f-4af3-9c86-52747ecfc0da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4113d76d-ca98-4bde-b57f-1a8130583022" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ba845457-178f-4af3-9c86-52747ecfc0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid_1964e893-456a-4a74-b9b4-f0ca29c2965f" xlink:href="rprx-20211231.xsd#rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4113d76d-ca98-4bde-b57f-1a8130583022" xlink:to="loc_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid_1964e893-456a-4a74-b9b4-f0ca29c2965f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ResearchAndDevelopmentRemainingFundingCommitment_b7446cd3-1363-4a7c-8631-a8eb6b342b53" xlink:href="rprx-20211231.xsd#rprx_ResearchAndDevelopmentRemainingFundingCommitment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4113d76d-ca98-4bde-b57f-1a8130583022" xlink:to="loc_rprx_ResearchAndDevelopmentRemainingFundingCommitment_b7446cd3-1363-4a7c-8631-a8eb6b342b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/Borrowings" xlink:type="simple" xlink:href="rprx-20211231.xsd#Borrowings"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/Borrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2edfc430-054d-4c4d-a25d-f50f94f4085a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_659a0032-8c7e-4b50-a8cc-9d331e857ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2edfc430-054d-4c4d-a25d-f50f94f4085a" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_659a0032-8c7e-4b50-a8cc-9d331e857ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsTables" xlink:type="simple" xlink:href="rprx-20211231.xsd#BorrowingsTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/BorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_63cf28f2-5a35-4485-8a9a-90c2b2ad986a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_3a7d970a-8b6b-4e4f-b31a-e586fe88dd51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_63cf28f2-5a35-4485-8a9a-90c2b2ad986a" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_3a7d970a-8b6b-4e4f-b31a-e586fe88dd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ebf933f6-04b5-4348-bdd0-f389ff00389e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_63cf28f2-5a35-4485-8a9a-90c2b2ad986a" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ebf933f6-04b5-4348-bdd0-f389ff00389e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#BorrowingsScheduleofBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_36c4c95e-8df6-4558-85a4-ad3bd889beed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d704521d-3161-4644-b89a-3668f3c01a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_36c4c95e-8df6-4558-85a4-ad3bd889beed" xlink:to="loc_us-gaap_DebtInstrumentTable_d704521d-3161-4644-b89a-3668f3c01a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_60d58e24-6437-4965-8023-20536c098b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d704521d-3161-4644-b89a-3668f3c01a47" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_60d58e24-6437-4965-8023-20536c098b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9d66d6e5-4262-49b2-8281-453d9a599ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_60d58e24-6437-4965-8023-20536c098b2d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9d66d6e5-4262-49b2-8281-453d9a599ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_32b79da6-ff0d-42d1-94f3-f3830ddd72cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9d66d6e5-4262-49b2-8281-453d9a599ac2" xlink:to="loc_us-gaap_UnsecuredDebtMember_32b79da6-ff0d-42d1-94f3-f3830ddd72cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2ed1300f-8d7d-4f10-84bb-9ccaca3ba47e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d704521d-3161-4644-b89a-3668f3c01a47" xlink:to="loc_us-gaap_DebtInstrumentAxis_2ed1300f-8d7d-4f10-84bb-9ccaca3ba47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5d8a6c8b-66ae-4a71-9d54-356428e53961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2ed1300f-8d7d-4f10-84bb-9ccaca3ba47e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5d8a6c8b-66ae-4a71-9d54-356428e53961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PointSevenFivePercentSeniorNotesDue2023Member_cffb7cde-8ac9-4d9a-bdce-481b1673c853" xlink:href="rprx-20211231.xsd#rprx_PointSevenFivePercentSeniorNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5d8a6c8b-66ae-4a71-9d54-356428e53961" xlink:to="loc_rprx_PointSevenFivePercentSeniorNotesDue2023Member_cffb7cde-8ac9-4d9a-bdce-481b1673c853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member_f7d59e97-1bc6-4d75-9a17-ba5d6784b60c" xlink:href="rprx-20211231.xsd#rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5d8a6c8b-66ae-4a71-9d54-356428e53961" xlink:to="loc_rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member_f7d59e97-1bc6-4d75-9a17-ba5d6784b60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member_e12886d8-47da-4233-9cb3-d5ecbecce143" xlink:href="rprx-20211231.xsd#rprx_OnePointSevenFivePercentSeniorNotesDue2027Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5d8a6c8b-66ae-4a71-9d54-356428e53961" xlink:to="loc_rprx_OnePointSevenFivePercentSeniorNotesDue2027Member_e12886d8-47da-4233-9cb3-d5ecbecce143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member_1e240bf1-8576-442d-880a-06afd75919fb" xlink:href="rprx-20211231.xsd#rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5d8a6c8b-66ae-4a71-9d54-356428e53961" xlink:to="loc_rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member_1e240bf1-8576-442d-880a-06afd75919fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member_76a57a28-a93e-46a3-89a0-70110cf9727e" xlink:href="rprx-20211231.xsd#rprx_TwoPointOneFivePercentSeniorNotesDue2031Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5d8a6c8b-66ae-4a71-9d54-356428e53961" xlink:to="loc_rprx_TwoPointOneFivePercentSeniorNotesDue2031Member_76a57a28-a93e-46a3-89a0-70110cf9727e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member_5f273c07-b162-46fd-b89b-8a10a6a861c0" xlink:href="rprx-20211231.xsd#rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5d8a6c8b-66ae-4a71-9d54-356428e53961" xlink:to="loc_rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member_5f273c07-b162-46fd-b89b-8a10a6a861c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member_a233621f-961c-4f83-9119-e72b17349ab4" xlink:href="rprx-20211231.xsd#rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5d8a6c8b-66ae-4a71-9d54-356428e53961" xlink:to="loc_rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member_a233621f-961c-4f83-9119-e72b17349ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member_e2d335d4-b9c9-484f-9b01-589eead1e288" xlink:href="rprx-20211231.xsd#rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5d8a6c8b-66ae-4a71-9d54-356428e53961" xlink:to="loc_rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member_e2d335d4-b9c9-484f-9b01-589eead1e288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_57a76760-14e8-4178-ad25-2bcfaa4e5dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d704521d-3161-4644-b89a-3668f3c01a47" xlink:to="loc_us-gaap_DebtInstrumentLineItems_57a76760-14e8-4178-ad25-2bcfaa4e5dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_199512dc-e88d-404c-b605-78da437a364f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57a76760-14e8-4178-ad25-2bcfaa4e5dd1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_199512dc-e88d-404c-b605-78da437a364f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dca4ebed-8a22-4371-85cf-89345d6b0c03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57a76760-14e8-4178-ad25-2bcfaa4e5dd1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dca4ebed-8a22-4371-85cf-89345d6b0c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentIssuanceAsAPercentOfPar_01169700-6077-41f3-bcb9-aa5f307c2c73" xlink:href="rprx-20211231.xsd#rprx_DebtInstrumentIssuanceAsAPercentOfPar"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57a76760-14e8-4178-ad25-2bcfaa4e5dd1" xlink:to="loc_rprx_DebtInstrumentIssuanceAsAPercentOfPar_01169700-6077-41f3-bcb9-aa5f307c2c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_6901e93c-27d7-40fe-bcf5-0d1c329a2b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57a76760-14e8-4178-ad25-2bcfaa4e5dd1" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_6901e93c-27d7-40fe-bcf5-0d1c329a2b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_86c1977a-e053-47e7-b822-e6b7476ba090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57a76760-14e8-4178-ad25-2bcfaa4e5dd1" xlink:to="loc_us-gaap_LongTermDebt_86c1977a-e053-47e7-b822-e6b7476ba090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_e80fca08-b5fe-454a-9072-a79b07c4f8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57a76760-14e8-4178-ad25-2bcfaa4e5dd1" xlink:to="loc_us-gaap_LongTermDebtCurrent_e80fca08-b5fe-454a-9072-a79b07c4f8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f0f37657-d64e-4443-ad6e-33e6e15c0d30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_57a76760-14e8-4178-ad25-2bcfaa4e5dd1" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f0f37657-d64e-4443-ad6e-33e6e15c0d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1" xlink:type="simple" xlink:href="rprx-20211231.xsd#BorrowingsScheduleofBorrowingsDetails_1"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#BorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_63233ffb-98fa-421f-8f84-b955f9776d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_79dac364-deb9-4ec3-9b5f-50709ad54b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_63233ffb-98fa-421f-8f84-b955f9776d0b" xlink:to="loc_us-gaap_DebtInstrumentTable_79dac364-deb9-4ec3-9b5f-50709ad54b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2442a0ad-0dbd-4b48-a8c8-c2e1633f8b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_79dac364-deb9-4ec3-9b5f-50709ad54b46" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2442a0ad-0dbd-4b48-a8c8-c2e1633f8b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_64fc0796-648a-4ad4-914a-1347e37bc2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2442a0ad-0dbd-4b48-a8c8-c2e1633f8b1e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_64fc0796-648a-4ad4-914a-1347e37bc2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_591c9ff9-266d-4714-b28c-8c0b6ff44bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_64fc0796-648a-4ad4-914a-1347e37bc2ef" xlink:to="loc_us-gaap_SeniorNotesMember_591c9ff9-266d-4714-b28c-8c0b6ff44bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_c60a972b-f3e3-4fe2-bc65-c2763b1f63ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_64fc0796-648a-4ad4-914a-1347e37bc2ef" xlink:to="loc_us-gaap_UnsecuredDebtMember_c60a972b-f3e3-4fe2-bc65-c2763b1f63ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_bf457963-dd37-4dc9-b3f8-25ab850fe108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_64fc0796-648a-4ad4-914a-1347e37bc2ef" xlink:to="loc_us-gaap_SecuredDebtMember_bf457963-dd37-4dc9-b3f8-25ab850fe108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_de0c1fa8-d5eb-42f2-bd57-180faf057ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_79dac364-deb9-4ec3-9b5f-50709ad54b46" xlink:to="loc_us-gaap_DebtInstrumentAxis_de0c1fa8-d5eb-42f2-bd57-180faf057ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e9210dee-63fa-4fca-9a30-0222ec272a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_de0c1fa8-d5eb-42f2-bd57-180faf057ea5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e9210dee-63fa-4fca-9a30-0222ec272a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorNotesDue2031Member_2383a23f-5141-4b38-83ce-9b81e9909144" xlink:href="rprx-20211231.xsd#rprx_SeniorNotesDue2031Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9210dee-63fa-4fca-9a30-0222ec272a73" xlink:to="loc_rprx_SeniorNotesDue2031Member_2383a23f-5141-4b38-83ce-9b81e9909144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorNotesDue2051Member_20009b1d-08e1-4714-a410-6b465ac6934e" xlink:href="rprx-20211231.xsd#rprx_SeniorNotesDue2051Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9210dee-63fa-4fca-9a30-0222ec272a73" xlink:to="loc_rprx_SeniorNotesDue2051Member_20009b1d-08e1-4714-a410-6b465ac6934e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TheNotesMember_c3df51f6-6070-4548-8fd7-912212e8be69" xlink:href="rprx-20211231.xsd#rprx_TheNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9210dee-63fa-4fca-9a30-0222ec272a73" xlink:to="loc_rprx_TheNotesMember_c3df51f6-6070-4548-8fd7-912212e8be69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SeniorUnsecuredRevolvingCreditFacilityMember_e3ef5c2d-86d4-4139-8061-8f0181d88921" xlink:href="rprx-20211231.xsd#rprx_SeniorUnsecuredRevolvingCreditFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9210dee-63fa-4fca-9a30-0222ec272a73" xlink:to="loc_rprx_SeniorUnsecuredRevolvingCreditFacilityMember_e3ef5c2d-86d4-4139-8061-8f0181d88921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member_55e3e279-1764-4cb2-8bfb-5b57e6512229" xlink:href="rprx-20211231.xsd#rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9210dee-63fa-4fca-9a30-0222ec272a73" xlink:to="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member_55e3e279-1764-4cb2-8bfb-5b57e6512229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member_7cc570f9-599d-4f52-a055-40e6afc35787" xlink:href="rprx-20211231.xsd#rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9210dee-63fa-4fca-9a30-0222ec272a73" xlink:to="loc_rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member_7cc570f9-599d-4f52-a055-40e6afc35787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_cb200336-59b7-4e09-a56f-8fe193cac95d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_79dac364-deb9-4ec3-9b5f-50709ad54b46" xlink:to="loc_us-gaap_VariableRateAxis_cb200336-59b7-4e09-a56f-8fe193cac95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_bf73820f-dc00-4109-a18f-a553780a4f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_cb200336-59b7-4e09-a56f-8fe193cac95d" xlink:to="loc_us-gaap_VariableRateDomain_bf73820f-dc00-4109-a18f-a553780a4f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsPurchasedMember_e988468e-0a5d-4b69-bd4e-b0ffe9bf2409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsPurchasedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_bf73820f-dc00-4109-a18f-a553780a4f89" xlink:to="loc_us-gaap_FederalFundsPurchasedMember_e988468e-0a5d-4b69-bd4e-b0ffe9bf2409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OvernightBankFundingRateMember_550db269-69e9-4169-bc0b-48711e312fa3" xlink:href="rprx-20211231.xsd#rprx_OvernightBankFundingRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_bf73820f-dc00-4109-a18f-a553780a4f89" xlink:to="loc_rprx_OvernightBankFundingRateMember_550db269-69e9-4169-bc0b-48711e312fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_15580d22-1205-45cc-b578-8664a909e381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_bf73820f-dc00-4109-a18f-a553780a4f89" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_15580d22-1205-45cc-b578-8664a909e381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b84a9c5e-2271-46bd-ad93-f69822d14209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_79dac364-deb9-4ec3-9b5f-50709ad54b46" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b84a9c5e-2271-46bd-ad93-f69822d14209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_dc075789-53cf-486f-bd84-5529b62ad495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b84a9c5e-2271-46bd-ad93-f69822d14209" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_dc075789-53cf-486f-bd84-5529b62ad495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_e1c2093b-07fd-4da0-bf4c-950bac493b38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_dc075789-53cf-486f-bd84-5529b62ad495" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_e1c2093b-07fd-4da0-bf4c-950bac493b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_e1c3aedc-087b-43bd-9154-3ba42c912275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_dc075789-53cf-486f-bd84-5529b62ad495" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_e1c3aedc-087b-43bd-9154-3ba42c912275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_b6aecccf-8fc5-4ced-8c8f-d02eedfb3e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_79dac364-deb9-4ec3-9b5f-50709ad54b46" xlink:to="loc_us-gaap_CreditFacilityAxis_b6aecccf-8fc5-4ced-8c8f-d02eedfb3e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a2afae2d-47c1-4483-8e88-a4991d7cf7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_b6aecccf-8fc5-4ced-8c8f-d02eedfb3e0e" xlink:to="loc_us-gaap_CreditFacilityDomain_a2afae2d-47c1-4483-8e88-a4991d7cf7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_f5579d32-f5b2-4234-b5db-ad259e244785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_a2afae2d-47c1-4483-8e88-a4991d7cf7f1" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_f5579d32-f5b2-4234-b5db-ad259e244785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e491fc1a-2f19-4039-be85-4b371fb82c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_79dac364-deb9-4ec3-9b5f-50709ad54b46" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e491fc1a-2f19-4039-be85-4b371fb82c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55a8e30a-2b63-42db-b313-e84d1eb66804" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e491fc1a-2f19-4039-be85-4b371fb82c08" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55a8e30a-2b63-42db-b313-e84d1eb66804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a90df032-06c1-4b00-8574-cfba2e67e377" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55a8e30a-2b63-42db-b313-e84d1eb66804" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a90df032-06c1-4b00-8574-cfba2e67e377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_bdd7ab6c-eb53-4387-a3c8-8e7b54caba8a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_79dac364-deb9-4ec3-9b5f-50709ad54b46" xlink:to="loc_dei_LegalEntityAxis_bdd7ab6c-eb53-4387-a3c8-8e7b54caba8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1f3a979e-1d40-48db-97a2-38065084288b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_bdd7ab6c-eb53-4387-a3c8-8e7b54caba8a" xlink:to="loc_dei_EntityDomain_1f3a979e-1d40-48db-97a2-38065084288b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPI2019IntermediateFinanceMember_7e4d5dfa-3ce0-44f5-aac7-5f14d524eaa8" xlink:href="rprx-20211231.xsd#rprx_RPI2019IntermediateFinanceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1f3a979e-1d40-48db-97a2-38065084288b" xlink:to="loc_rprx_RPI2019IntermediateFinanceMember_7e4d5dfa-3ce0-44f5-aac7-5f14d524eaa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_79dac364-deb9-4ec3-9b5f-50709ad54b46" xlink:to="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1d536c69-b959-4157-843a-53ceafc62329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1d536c69-b959-4157-843a-53ceafc62329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_c98eca55-0943-45ce-9dee-24ef3da67a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_c98eca55-0943-45ce-9dee-24ef3da67a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_5f6c5ca0-de0d-48f0-900f-97923c87c13d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_5f6c5ca0-de0d-48f0-900f-97923c87c13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_8d5de69c-f687-4aed-b638-9bba38bd2088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_8d5de69c-f687-4aed-b638-9bba38bd2088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_8dda9dc2-587f-4b66-9a05-d3f222400b01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_8dda9dc2-587f-4b66-9a05-d3f222400b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_2bbad6d7-cd70-4e72-a233-41b031f5f1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_2bbad6d7-cd70-4e72-a233-41b031f5f1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_486774ba-7e4e-400b-b064-f3885f30cad1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_us-gaap_LongTermDebtFairValue_486774ba-7e4e-400b-b064-f3885f30cad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_9c0f8a65-131d-436e-9ebb-9237171a049c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_us-gaap_DebtInstrumentTerm_9c0f8a65-131d-436e-9ebb-9237171a049c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_6346eaf5-a350-457c-9a36-54c1ad048f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_6346eaf5-a350-457c-9a36-54c1ad048f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_65a7b95f-c14c-4e7e-80ae-3bd9aaf1a21c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_65a7b95f-c14c-4e7e-80ae-3bd9aaf1a21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio_c49028a8-14c1-4d7e-9c03-6285c3e2305c" xlink:href="rprx-20211231.xsd#rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio_c49028a8-14c1-4d7e-9c03-6285c3e2305c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition_26e547e0-dfa2-4e5c-8e77-e20442dc8d9d" xlink:href="rprx-20211231.xsd#rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition_26e547e0-dfa2-4e5c-8e77-e20442dc8d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio_0ea4f995-471b-4c28-95fa-9b8092e0ab79" xlink:href="rprx-20211231.xsd#rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio_0ea4f995-471b-4c28-95fa-9b8092e0ab79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_216fb1be-b3c4-4eaa-85b0-54c319e23728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_841ab305-5e2b-4212-9da2-a73c483a6752" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_216fb1be-b3c4-4eaa-85b0-54c319e23728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#BorrowingsScheduleofRepaymentsofDebtbyYearDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3388568f-ab54-484b-a0c4-a8f5053b6720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1e2ee028-62d1-46ce-86e8-08cff2aa8d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3388568f-ab54-484b-a0c4-a8f5053b6720" xlink:to="loc_us-gaap_DebtInstrumentTable_1e2ee028-62d1-46ce-86e8-08cff2aa8d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_294dd128-21b9-4573-930c-d640f91bef5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1e2ee028-62d1-46ce-86e8-08cff2aa8d8d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_294dd128-21b9-4573-930c-d640f91bef5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b94bcb8c-4b8d-4c83-a896-c0cb5f06c9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_294dd128-21b9-4573-930c-d640f91bef5e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b94bcb8c-4b8d-4c83-a896-c0cb5f06c9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_69db65e0-d19d-405f-bd5b-c21fcd914549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b94bcb8c-4b8d-4c83-a896-c0cb5f06c9e3" xlink:to="loc_us-gaap_UnsecuredDebtMember_69db65e0-d19d-405f-bd5b-c21fcd914549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_071d3397-f722-4863-bdd7-a546ff3e7c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1e2ee028-62d1-46ce-86e8-08cff2aa8d8d" xlink:to="loc_us-gaap_DebtInstrumentAxis_071d3397-f722-4863-bdd7-a546ff3e7c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_10fc4a38-0ec3-432d-bb3b-d84ea7f79a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_071d3397-f722-4863-bdd7-a546ff3e7c9b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_10fc4a38-0ec3-432d-bb3b-d84ea7f79a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_TheNotesMember_afd1bded-ae3d-4e16-82b7-81ef954cecd6" xlink:href="rprx-20211231.xsd#rprx_TheNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_10fc4a38-0ec3-432d-bb3b-d84ea7f79a32" xlink:to="loc_rprx_TheNotesMember_afd1bded-ae3d-4e16-82b7-81ef954cecd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_66e6a56e-45cf-4ba5-b17d-7b2ebf5fd1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1e2ee028-62d1-46ce-86e8-08cff2aa8d8d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_66e6a56e-45cf-4ba5-b17d-7b2ebf5fd1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6ac6841d-c692-472f-8743-1f24d39a1583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_66e6a56e-45cf-4ba5-b17d-7b2ebf5fd1b3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6ac6841d-c692-472f-8743-1f24d39a1583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_003fd317-bcd5-4c38-a9ad-b2f51465bd41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_66e6a56e-45cf-4ba5-b17d-7b2ebf5fd1b3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_003fd317-bcd5-4c38-a9ad-b2f51465bd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_e019626f-7b4f-49ff-ad81-0fab21431f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_66e6a56e-45cf-4ba5-b17d-7b2ebf5fd1b3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_e019626f-7b4f-49ff-ad81-0fab21431f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_c7541026-eb2e-4858-9972-ec8e8e8bfdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_66e6a56e-45cf-4ba5-b17d-7b2ebf5fd1b3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_c7541026-eb2e-4858-9972-ec8e8e8bfdc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_4276456a-45d3-4787-acff-5a4a21a7f16a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_66e6a56e-45cf-4ba5-b17d-7b2ebf5fd1b3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_4276456a-45d3-4787-acff-5a4a21a7f16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_6fe529e7-5ddd-4f92-ae22-f667cd996cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_66e6a56e-45cf-4ba5-b17d-7b2ebf5fd1b3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_6fe529e7-5ddd-4f92-ae22-f667cd996cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_72712e14-5e3d-4199-b02e-eafce6d9f498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_66e6a56e-45cf-4ba5-b17d-7b2ebf5fd1b3" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_72712e14-5e3d-4199-b02e-eafce6d9f498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1b6251a7-1ef5-41c8-b37a-390f3f627674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_66e6a56e-45cf-4ba5-b17d-7b2ebf5fd1b3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1b6251a7-1ef5-41c8-b37a-390f3f627674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="rprx-20211231.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_949dc2f5-bbe3-44bc-a566-cd1f67ee9ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_09aef0fa-be35-41f1-8650-70b889b0511b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_949dc2f5-bbe3-44bc-a566-cd1f67ee9ce4" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_09aef0fa-be35-41f1-8650-70b889b0511b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="rprx-20211231.xsd#ShareholdersEquityTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a0a907c6-83ba-4199-ae0a-e1b25673afcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_d0577fa5-ece9-47da-b365-a1965cd63820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a0a907c6-83ba-4199-ae0a-e1b25673afcb" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_d0577fa5-ece9-47da-b365-a1965cd63820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f33ece3c-4af0-4de9-935a-3e96484be3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e9ccbdd6-2498-4493-9ffe-b0b279d70843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f33ece3c-4af0-4de9-935a-3e96484be3ba" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e9ccbdd6-2498-4493-9ffe-b0b279d70843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_454c0060-828d-4787-a9e2-fce45548e543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e9ccbdd6-2498-4493-9ffe-b0b279d70843" xlink:to="loc_us-gaap_StatementClassOfStockAxis_454c0060-828d-4787-a9e2-fce45548e543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4d9d10f9-6b15-4e4e-8da7-727ed7b2bdce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_454c0060-828d-4787-a9e2-fce45548e543" xlink:to="loc_us-gaap_ClassOfStockDomain_4d9d10f9-6b15-4e4e-8da7-727ed7b2bdce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_52fe8dac-5130-48e1-a69e-8b6cfb189c24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4d9d10f9-6b15-4e4e-8da7-727ed7b2bdce" xlink:to="loc_us-gaap_CommonClassAMember_52fe8dac-5130-48e1-a69e-8b6cfb189c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_1ff1a693-45a7-42fc-93b7-ded538d3252f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4d9d10f9-6b15-4e4e-8da7-727ed7b2bdce" xlink:to="loc_us-gaap_CommonClassBMember_1ff1a693-45a7-42fc-93b7-ded538d3252f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassRRedeemableStockMember_6d255f76-357c-4232-b356-4004ab736359" xlink:href="rprx-20211231.xsd#rprx_ClassRRedeemableStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4d9d10f9-6b15-4e4e-8da7-727ed7b2bdce" xlink:to="loc_rprx_ClassRRedeemableStockMember_6d255f76-357c-4232-b356-4004ab736359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_52e4848f-e929-4db8-a9f4-b2f24513c532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e9ccbdd6-2498-4493-9ffe-b0b279d70843" xlink:to="loc_us-gaap_PlanNameAxis_52e4848f-e929-4db8-a9f4-b2f24513c532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2eeabf79-50e6-4654-958f-b83c23f563cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_52e4848f-e929-4db8-a9f4-b2f24513c532" xlink:to="loc_us-gaap_PlanNameDomain_2eeabf79-50e6-4654-958f-b83c23f563cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_A2020EquityIncentivePlanMember_cc3cab38-e381-4098-9a04-1d1642942064" xlink:href="rprx-20211231.xsd#rprx_A2020EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2eeabf79-50e6-4654-958f-b83c23f563cf" xlink:to="loc_rprx_A2020EquityIncentivePlanMember_cc3cab38-e381-4098-9a04-1d1642942064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4005047c-c3de-4465-8997-c07c5ab42037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e9ccbdd6-2498-4493-9ffe-b0b279d70843" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4005047c-c3de-4465-8997-c07c5ab42037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e065d550-b721-4f71-8170-28b3e3b30349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4005047c-c3de-4465-8997-c07c5ab42037" xlink:to="loc_us-gaap_EquityComponentDomain_e065d550-b721-4f71-8170-28b3e3b30349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_DeferredSharesMember_77f1f90d-c970-4bc4-9840-c4ba9526e96c" xlink:href="rprx-20211231.xsd#rprx_DeferredSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e065d550-b721-4f71-8170-28b3e3b30349" xlink:to="loc_rprx_DeferredSharesMember_77f1f90d-c970-4bc4-9840-c4ba9526e96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e5e46de3-dffb-47d5-8131-4eaf10aed6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e9ccbdd6-2498-4493-9ffe-b0b279d70843" xlink:to="loc_us-gaap_AwardTypeAxis_e5e46de3-dffb-47d5-8131-4eaf10aed6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ee92fe6-fd0f-4808-a04d-1383c8bfbc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e5e46de3-dffb-47d5-8131-4eaf10aed6bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ee92fe6-fd0f-4808-a04d-1383c8bfbc0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c3281bf0-a3c2-4593-a3ef-ffd0066f482f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ee92fe6-fd0f-4808-a04d-1383c8bfbc0a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c3281bf0-a3c2-4593-a3ef-ffd0066f482f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ebf73061-9556-458a-a32f-578751f5e7d7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e9ccbdd6-2498-4493-9ffe-b0b279d70843" xlink:to="loc_dei_LegalEntityAxis_ebf73061-9556-458a-a32f-578751f5e7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_72f22bf8-967f-4c20-bf94-c65b196aea6d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_ebf73061-9556-458a-a32f-578751f5e7d7" xlink:to="loc_dei_EntityDomain_72f22bf8-967f-4c20-bf94-c65b196aea6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IPOContinuingInvestorsPartnershipsMember_d36cde6b-f29e-4c87-8457-de9f9dd3b654" xlink:href="rprx-20211231.xsd#rprx_IPOContinuingInvestorsPartnershipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_72f22bf8-967f-4c20-bf94-c65b196aea6d" xlink:to="loc_rprx_IPOContinuingInvestorsPartnershipsMember_d36cde6b-f29e-4c87-8457-de9f9dd3b654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ContinuingInvestorsPartnershipMember_90ceb336-e815-414f-a1d2-34dd46bddf23" xlink:href="rprx-20211231.xsd#rprx_ContinuingInvestorsPartnershipMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_72f22bf8-967f-4c20-bf94-c65b196aea6d" xlink:to="loc_rprx_ContinuingInvestorsPartnershipMember_90ceb336-e815-414f-a1d2-34dd46bddf23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e9ccbdd6-2498-4493-9ffe-b0b279d70843" xlink:to="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NumberOfClassesOfVotingStock_9473bc4f-884c-447c-bd97-4c1d16aeae96" xlink:href="rprx-20211231.xsd#rprx_NumberOfClassesOfVotingStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_rprx_NumberOfClassesOfVotingStock_9473bc4f-884c-447c-bd97-4c1d16aeae96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_dcd8e085-983c-430f-b560-d66341484739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_dcd8e085-983c-430f-b560-d66341484739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_ed63c525-ad5e-475a-8b78-7f26b810393c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_ed63c525-ad5e-475a-8b78-7f26b810393c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c26f241f-a9e0-4ebb-919b-e812d8bdc00f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c26f241f-a9e0-4ebb-919b-e812d8bdc00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_8104f7f6-00c9-4b24-833e-a7211595e7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_SharesOutstanding_8104f7f6-00c9-4b24-833e-a7211595e7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RedeemableStockRedemptionPricePerShare_64ab2a61-a5dc-44aa-90a6-e66db91a3b9f" xlink:href="rprx-20211231.xsd#rprx_RedeemableStockRedemptionPricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_rprx_RedeemableStockRedemptionPricePerShare_64ab2a61-a5dc-44aa-90a6-e66db91a3b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NumberOfNoncontrollingInterests_fd43db6a-c244-4a08-a3d9-6ac405a54325" xlink:href="rprx-20211231.xsd#rprx_NumberOfNoncontrollingInterests"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_rprx_NumberOfNoncontrollingInterests_fd43db6a-c244-4a08-a3d9-6ac405a54325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_19bde8ee-2369-4ae4-89eb-a07e506209e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_19bde8ee-2369-4ae4-89eb-a07e506209e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_64bc104b-3bc2-4df9-b744-c1ddccab6718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_DividendsCommonStockCash_64bc104b-3bc2-4df9-b744-c1ddccab6718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_3b1a8b14-6999-4966-8dd8-d9a8cd96e008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_3b1a8b14-6999-4966-8dd8-d9a8cd96e008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c6fb8b55-3c82-4fa2-94ca-13fa12c54856" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c6fb8b55-3c82-4fa2-94ca-13fa12c54856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_818d3d08-71ba-4996-b672-61a003861ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_818d3d08-71ba-4996-b672-61a003861ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_51ffe1b7-dbf7-441b-8f5f-8ac1250f138b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_51ffe1b7-dbf7-441b-8f5f-8ac1250f138b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5c415f40-47fa-4283-b535-b39fb381a0be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5c415f40-47fa-4283-b535-b39fb381a0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1e38d37c-4ee0-4728-bbea-0e774b8b1b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fb24f75e-acc1-46e4-bff8-7a77ce5c2a64" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1e38d37c-4ee0-4728-bbea-0e774b8b1b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#ShareholdersEquitySummaryofNoncontrollingInterestsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_29b76c3d-c936-4240-aa5e-e998316cee0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_fc45943d-5014-49ca-ab36-c3b914ab6f75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_29b76c3d-c936-4240-aa5e-e998316cee0e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_fc45943d-5014-49ca-ab36-c3b914ab6f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_018dc882-205a-44f9-817a-747c617951a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc45943d-5014-49ca-ab36-c3b914ab6f75" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_018dc882-205a-44f9-817a-747c617951a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eff81eda-829b-4c9c-a694-b27b689752fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_018dc882-205a-44f9-817a-747c617951a0" xlink:to="loc_us-gaap_EquityComponentDomain_eff81eda-829b-4c9c-a694-b27b689752fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_8e10629f-7888-479f-9f6a-fff84fad9cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_eff81eda-829b-4c9c-a694-b27b689752fb" xlink:to="loc_us-gaap_NoncontrollingInterestMember_8e10629f-7888-479f-9f6a-fff84fad9cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f6092da6-b1c6-4360-bf7b-9e6d2de0747a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc45943d-5014-49ca-ab36-c3b914ab6f75" xlink:to="loc_dei_LegalEntityAxis_f6092da6-b1c6-4360-bf7b-9e6d2de0747a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a966d7cf-cb42-4143-b62a-55b0291d38ea" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_f6092da6-b1c6-4360-bf7b-9e6d2de0747a" xlink:to="loc_dei_EntityDomain_a966d7cf-cb42-4143-b62a-55b0291d38ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyalPharmacySelectFinanceTrustMember_e2793508-e9dd-4bb2-8dd7-39dac90d32f1" xlink:href="rprx-20211231.xsd#rprx_RoyalPharmacySelectFinanceTrustMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a966d7cf-cb42-4143-b62a-55b0291d38ea" xlink:to="loc_rprx_RoyalPharmacySelectFinanceTrustMember_e2793508-e9dd-4bb2-8dd7-39dac90d32f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsMember_1aff88a0-fefb-4e68-a0b1-1b2d1d3cc0d3" xlink:href="rprx-20211231.xsd#rprx_LegacyInvestorsPartnershipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a966d7cf-cb42-4143-b62a-55b0291d38ea" xlink:to="loc_rprx_LegacyInvestorsPartnershipsMember_1aff88a0-fefb-4e68-a0b1-1b2d1d3cc0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ContinuingInvestorsPartnershipMember_e9d299f3-3bd3-4793-995f-debb66d9c7c0" xlink:href="rprx-20211231.xsd#rprx_ContinuingInvestorsPartnershipMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a966d7cf-cb42-4143-b62a-55b0291d38ea" xlink:to="loc_rprx_ContinuingInvestorsPartnershipMember_e9d299f3-3bd3-4793-995f-debb66d9c7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EPAHoldingsMember_612b345d-1e25-4afb-b9e8-da3e8e1b962d" xlink:href="rprx-20211231.xsd#rprx_EPAHoldingsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a966d7cf-cb42-4143-b62a-55b0291d38ea" xlink:to="loc_rprx_EPAHoldingsMember_612b345d-1e25-4afb-b9e8-da3e8e1b962d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_6a1aef73-166f-4c31-b3e2-91d52d4d4924" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc45943d-5014-49ca-ab36-c3b914ab6f75" xlink:to="loc_srt_OwnershipAxis_6a1aef73-166f-4c31-b3e2-91d52d4d4924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9eda10ef-f0a0-444a-a44f-222e697325c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_6a1aef73-166f-4c31-b3e2-91d52d4d4924" xlink:to="loc_srt_OwnershipDomain_9eda10ef-f0a0-444a-a44f-222e697325c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RPHoldingsMember_f29d09f5-7a9e-4b75-8d8e-a5d654d5fcdf" xlink:href="rprx-20211231.xsd#rprx_RPHoldingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_9eda10ef-f0a0-444a-a44f-222e697325c3" xlink:to="loc_rprx_RPHoldingsMember_f29d09f5-7a9e-4b75-8d8e-a5d654d5fcdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6290d4ed-d9d6-42db-9e96-771c033a056d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fc45943d-5014-49ca-ab36-c3b914ab6f75" xlink:to="loc_us-gaap_ClassOfStockLineItems_6290d4ed-d9d6-42db-9e96-771c033a056d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6290d4ed-d9d6-42db-9e96-771c033a056d" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fc050273-f3bd-49b8-bbf5-7ae99ec3e4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fc050273-f3bd-49b8-bbf5-7ae99ec3e4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestIncreaseFromContributions_2a85946e-f1af-40f0-b450-f0651cd7371c" xlink:href="rprx-20211231.xsd#rprx_NoncontrollingInterestIncreaseFromContributions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:to="loc_rprx_NoncontrollingInterestIncreaseFromContributions_2a85946e-f1af-40f0-b450-f0651cd7371c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NoncontrollingInterestTransfersOfInterests_32d0fe22-a960-4432-8c8f-0fe39839e9bf" xlink:href="rprx-20211231.xsd#rprx_NoncontrollingInterestTransfersOfInterests"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:to="loc_rprx_NoncontrollingInterestTransfersOfInterests_32d0fe22-a960-4432-8c8f-0fe39839e9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0169cf85-4a28-4b79-905c-c3b06ff4e8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0169cf85-4a28-4b79-905c-c3b06ff4e8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c3fd43ae-b7cd-461a-a6a4-52de4405d1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:to="loc_us-gaap_ProfitLoss_c3fd43ae-b7cd-461a-a6a4-52de4405d1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation_27e26e8e-4590-429e-8f3f-b42c9cc1eb37" xlink:href="rprx-20211231.xsd#rprx_StockholdersEquityValueEffectOfExchangeAndReallocation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:to="loc_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation_27e26e8e-4590-429e-8f3f-b42c9cc1eb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_77c32f18-444d-4408-a174-ea3bcfb65f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_77c32f18-444d-4408-a174-ea3bcfb65f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_97f4c82b-17c0-4efb-b56d-ce0e03fe7d27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:to="loc_us-gaap_StockholdersEquityOther_97f4c82b-17c0-4efb-b56d-ce0e03fe7d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_16f41fa1-8941-4d9d-8988-e9a6b2b2534b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_16f41fa1-8941-4d9d-8988-e9a6b2b2534b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_e278ebbc-c690-4def-ab06-906a50b4f259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_e278ebbc-c690-4def-ab06-906a50b4f259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_89ba3f7c-c24f-46dc-b48a-bac0352cdf82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_afacf5e2-9c09-447e-94ed-8da5ad569023" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_89ba3f7c-c24f-46dc-b48a-bac0352cdf82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_9ef88860-5ca5-4785-a41c-2c55a18b747a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6290d4ed-d9d6-42db-9e96-771c033a056d" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_9ef88860-5ca5-4785-a41c-2c55a18b747a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/EarningsPerShare" xlink:type="simple" xlink:href="rprx-20211231.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_773cd60e-97eb-4d02-b5a8-027d349ba943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_a228795f-64f8-4fa7-82e9-69920af69be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_773cd60e-97eb-4d02-b5a8-027d349ba943" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_a228795f-64f8-4fa7-82e9-69920af69be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="rprx-20211231.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_71021eb8-9d20-411a-950b-7266e389e2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e08fd2e2-64e6-45a4-b161-735efb781dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_71021eb8-9d20-411a-950b-7266e389e2b8" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e08fd2e2-64e6-45a4-b161-735efb781dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#EarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8adfd2f5-6f03-42b1-8639-2030ccbefe43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CommonStockExchangeRatio_84e4ce94-0203-49ef-b197-b4d24bf81e81" xlink:href="rprx-20211231.xsd#rprx_CommonStockExchangeRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8adfd2f5-6f03-42b1-8639-2030ccbefe43" xlink:to="loc_rprx_CommonStockExchangeRatio_84e4ce94-0203-49ef-b197-b4d24bf81e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_8765b00b-9835-4bf9-a183-48555e42bcc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8adfd2f5-6f03-42b1-8639-2030ccbefe43" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_8765b00b-9835-4bf9-a183-48555e42bcc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_afa800f5-c50c-479c-bebb-5c4b0a64dc2e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_8765b00b-9835-4bf9-a183-48555e42bcc3" xlink:to="loc_srt_CounterpartyNameAxis_afa800f5-c50c-479c-bebb-5c4b0a64dc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7e226cb-bbd6-4021-98d0-71781c72f5ac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_afa800f5-c50c-479c-bebb-5c4b0a64dc2e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7e226cb-bbd6-4021-98d0-71781c72f5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_ClassBHoldersMember_bb6299e7-e099-4011-9516-8c7ee670f9e5" xlink:href="rprx-20211231.xsd#rprx_ClassBHoldersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7e226cb-bbd6-4021-98d0-71781c72f5ac" xlink:to="loc_rprx_ClassBHoldersMember_bb6299e7-e099-4011-9516-8c7ee670f9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LegacyInvestorsPartnershipsAndRPSFTMember_b3e58881-93ae-4630-a0ff-4ddaae360be5" xlink:href="rprx-20211231.xsd#rprx_LegacyInvestorsPartnershipsAndRPSFTMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7e226cb-bbd6-4021-98d0-71781c72f5ac" xlink:to="loc_rprx_LegacyInvestorsPartnershipsAndRPSFTMember_b3e58881-93ae-4630-a0ff-4ddaae360be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c5f09426-993f-42ff-aa31-5374c3f51e96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_8765b00b-9835-4bf9-a183-48555e42bcc3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c5f09426-993f-42ff-aa31-5374c3f51e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dc1e9d0e-57e3-4830-b172-b85de403e7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c5f09426-993f-42ff-aa31-5374c3f51e96" xlink:to="loc_us-gaap_ClassOfStockDomain_dc1e9d0e-57e3-4830-b172-b85de403e7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_bef697cd-cd43-47d7-96c8-980f9996f531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_dc1e9d0e-57e3-4830-b172-b85de403e7a0" xlink:to="loc_us-gaap_CommonClassAMember_bef697cd-cd43-47d7-96c8-980f9996f531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_86f0431a-a9c2-4c3a-9d6a-19cda61c6dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_8765b00b-9835-4bf9-a183-48555e42bcc3" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_86f0431a-a9c2-4c3a-9d6a-19cda61c6dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_527c2e98-eb7b-4100-bcc6-88e2c6d6dfe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_86f0431a-a9c2-4c3a-9d6a-19cda61c6dd2" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_527c2e98-eb7b-4100-bcc6-88e2c6d6dfe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_65d5375b-534e-4c3f-ab14-d7a31e48fdbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_527c2e98-eb7b-4100-bcc6-88e2c6d6dfe4" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_65d5375b-534e-4c3f-ab14-d7a31e48fdbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8ac50d57-2cb2-42c2-b9d4-a557ba4bcf90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_65d5375b-534e-4c3f-ab14-d7a31e48fdbf" xlink:to="loc_us-gaap_ProfitLoss_8ac50d57-2cb2-42c2-b9d4-a557ba4bcf90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_NetIncomeLossAttributableToParentPriorToOffering_645a1da6-a8ed-406f-85fc-3d6376d1640b" xlink:href="rprx-20211231.xsd#rprx_NetIncomeLossAttributableToParentPriorToOffering"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_65d5375b-534e-4c3f-ab14-d7a31e48fdbf" xlink:to="loc_rprx_NetIncomeLossAttributableToParentPriorToOffering_645a1da6-a8ed-406f-85fc-3d6376d1640b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5079970e-711a-4060-a445-141146a4947c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_65d5375b-534e-4c3f-ab14-d7a31e48fdbf" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5079970e-711a-4060-a445-141146a4947c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_820181cc-86dd-4bea-b7db-c6ac678c2fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_65d5375b-534e-4c3f-ab14-d7a31e48fdbf" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_820181cc-86dd-4bea-b7db-c6ac678c2fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_032dbdaf-b5af-41ae-bc68-ff3ef1f70a75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_65d5375b-534e-4c3f-ab14-d7a31e48fdbf" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_032dbdaf-b5af-41ae-bc68-ff3ef1f70a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_0b76cfe5-2235-4f89-be29-eb40f6f37045" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_527c2e98-eb7b-4100-bcc6-88e2c6d6dfe4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_0b76cfe5-2235-4f89-be29-eb40f6f37045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a4d41e8c-41d3-4523-ada0-891cedfe12af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_0b76cfe5-2235-4f89-be29-eb40f6f37045" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a4d41e8c-41d3-4523-ada0-891cedfe12af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_aa8e1d48-e26a-4a8c-9ab8-3dc32f34204a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_0b76cfe5-2235-4f89-be29-eb40f6f37045" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_aa8e1d48-e26a-4a8c-9ab8-3dc32f34204a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c901c78-daad-46ef-baa7-ede8027477e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_0b76cfe5-2235-4f89-be29-eb40f6f37045" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c901c78-daad-46ef-baa7-ede8027477e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b1b29227-504a-4371-a797-34ceae7e3d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_0b76cfe5-2235-4f89-be29-eb40f6f37045" xlink:to="loc_us-gaap_EarningsPerShareBasic_b1b29227-504a-4371-a797-34ceae7e3d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_51eaf117-9163-49d0-8dcd-12e99386c0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_0b76cfe5-2235-4f89-be29-eb40f6f37045" xlink:to="loc_us-gaap_EarningsPerShareDiluted_51eaf117-9163-49d0-8dcd-12e99386c0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IndirectCashFlow" xlink:type="simple" xlink:href="rprx-20211231.xsd#IndirectCashFlow"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/IndirectCashFlow" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_26fb4f70-1a7d-4cc4-820e-143f3e942fae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_5df53dd4-094b-41ca-ac42-5c89123af83f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_26fb4f70-1a7d-4cc4-820e-143f3e942fae" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_5df53dd4-094b-41ca-ac42-5c89123af83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IndirectCashFlowTables" xlink:type="simple" xlink:href="rprx-20211231.xsd#IndirectCashFlowTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/IndirectCashFlowTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_c8b2fa38-488c-4f7d-bd8b-6205bfa89e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_a608334c-1af8-40a8-82b8-2019140e3f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_c8b2fa38-488c-4f7d-bd8b-6205bfa89e2c" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_a608334c-1af8-40a8-82b8-2019140e3f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/IndirectCashFlowDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#IndirectCashFlowDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/IndirectCashFlowDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_8418c78d-2f9c-4ee3-a37c-6afe094c86bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_158eba9b-5966-4e76-bace-38edbe516be8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_8418c78d-2f9c-4ee3-a37c-6afe094c86bb" xlink:to="loc_us-gaap_ProfitLoss_158eba9b-5966-4e76-bace-38edbe516be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5660d788-e590-473e-9c09-fad2d5109d84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_8418c78d-2f9c-4ee3-a37c-6afe094c86bb" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5660d788-e590-473e-9c09-fad2d5109d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInFinancialRoyaltyAssets_dfcc098f-6be6-4a47-842a-0b441b2ada3d" xlink:href="rprx-20211231.xsd#rprx_IncreaseDecreaseInFinancialRoyaltyAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5660d788-e590-473e-9c09-fad2d5109d84" xlink:to="loc_rprx_IncreaseDecreaseInFinancialRoyaltyAssets_dfcc098f-6be6-4a47-842a-0b441b2ada3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLoanAndLeaseLosses_77f30651-27ca-412f-baa4-9fb7e88a8a98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForLoanAndLeaseLosses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5660d788-e590-473e-9c09-fad2d5109d84" xlink:to="loc_us-gaap_ProvisionForLoanAndLeaseLosses_77f30651-27ca-412f-baa4-9fb7e88a8a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_47acc858-07ca-410f-b3a5-952078d8762c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5660d788-e590-473e-9c09-fad2d5109d84" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_47acc858-07ca-410f-b3a5-952078d8762c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_fd1ed8ad-e0b1-4227-a61d-18cf1a920cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5660d788-e590-473e-9c09-fad2d5109d84" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_fd1ed8ad-e0b1-4227-a61d-18cf1a920cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_480b5bb9-dba5-4c7c-8e6a-4d844c600d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5660d788-e590-473e-9c09-fad2d5109d84" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_480b5bb9-dba5-4c7c-8e6a-4d844c600d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4cc2ee93-2caa-4e48-b273-54d55a432db7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5660d788-e590-473e-9c09-fad2d5109d84" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4cc2ee93-2caa-4e48-b273-54d55a432db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_59797d8e-3b75-40e6-a116-02982e64dca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5660d788-e590-473e-9c09-fad2d5109d84" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_59797d8e-3b75-40e6-a116-02982e64dca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_a047cacd-d31d-47ab-af48-f71f276be0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5660d788-e590-473e-9c09-fad2d5109d84" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_a047cacd-d31d-47ab-af48-f71f276be0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7b80bc5f-3c36-4030-9f6b-fd6071d54a42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5660d788-e590-473e-9c09-fad2d5109d84" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7b80bc5f-3c36-4030-9f6b-fd6071d54a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d3a8b507-ab95-4c95-95e7-89725a9d073d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5660d788-e590-473e-9c09-fad2d5109d84" xlink:to="loc_us-gaap_ShareBasedCompensation_d3a8b507-ab95-4c95-95e7-89725a9d073d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss_6bfc5e8d-c47c-481a-b1aa-b2fd2bef887a" xlink:href="rprx-20211231.xsd#rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5660d788-e590-473e-9c09-fad2d5109d84" xlink:to="loc_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss_6bfc5e8d-c47c-481a-b1aa-b2fd2bef887a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_5dbd38f4-0b3e-4e97-9c87-ed7d3c74d453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5660d788-e590-473e-9c09-fad2d5109d84" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_5dbd38f4-0b3e-4e97-9c87-ed7d3c74d453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_1be6f8ff-376f-441c-ba6a-39424bf05982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5660d788-e590-473e-9c09-fad2d5109d84" xlink:to="loc_us-gaap_AssetImpairmentCharges_1be6f8ff-376f-441c-ba6a-39424bf05982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_GainLossOnDerivativeFinancialInstruments_28f4c0e0-c114-430f-bbf3-8b8c8f59584e" xlink:href="rprx-20211231.xsd#rprx_GainLossOnDerivativeFinancialInstruments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5660d788-e590-473e-9c09-fad2d5109d84" xlink:to="loc_rprx_GainLossOnDerivativeFinancialInstruments_28f4c0e0-c114-430f-bbf3-8b8c8f59584e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_b539adfe-f90d-482a-b15b-b9219c9bdc51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5660d788-e590-473e-9c09-fad2d5109d84" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_b539adfe-f90d-482a-b15b-b9219c9bdc51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_9813e0a4-848a-4866-a624-031b7014d96a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_8418c78d-2f9c-4ee3-a37c-6afe094c86bb" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_9813e0a4-848a-4866-a624-031b7014d96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables_e47333b1-268c-4ca7-9fa4-112447ef96c0" xlink:href="rprx-20211231.xsd#rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_9813e0a4-848a-4866-a624-031b7014d96a" xlink:to="loc_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables_e47333b1-268c-4ca7-9fa4-112447ef96c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInDebtSecuritiesAvailableForSale_4f5e9fb4-03cc-4e08-9b23-a186672e9b26" xlink:href="rprx-20211231.xsd#rprx_IncreaseDecreaseInDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_9813e0a4-848a-4866-a624-031b7014d96a" xlink:to="loc_rprx_IncreaseDecreaseInDebtSecuritiesAvailableForSale_4f5e9fb4-03cc-4e08-9b23-a186672e9b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable_6b3f4353-10b8-4ecb-bb9f-91d3e0c80b03" xlink:href="rprx-20211231.xsd#rprx_IncreaseDecreaseInAccruedRoyaltyReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_9813e0a4-848a-4866-a624-031b7014d96a" xlink:to="loc_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable_6b3f4353-10b8-4ecb-bb9f-91d3e0c80b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_a9525043-89a7-45fb-a6f6-6ff46511622c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_9813e0a4-848a-4866-a624-031b7014d96a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_a9525043-89a7-45fb-a6f6-6ff46511622c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable_f1056932-b71f-4f25-aa75-4abb2ada30a7" xlink:href="rprx-20211231.xsd#rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_9813e0a4-848a-4866-a624-031b7014d96a" xlink:to="loc_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable_f1056932-b71f-4f25-aa75-4abb2ada30a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_a55d5d98-bfa4-4abe-a269-7bfbdb44f87f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_9813e0a4-848a-4866-a624-031b7014d96a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_a55d5d98-bfa4-4abe-a269-7bfbdb44f87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_43e3ee11-751c-43c3-98eb-e97baaeb84aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_8418c78d-2f9c-4ee3-a37c-6afe094c86bb" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_43e3ee11-751c-43c3-98eb-e97baaeb84aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_981adbe8-8145-4579-981a-a279d62832fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_43e3ee11-751c-43c3-98eb-e97baaeb84aa" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_981adbe8-8145-4579-981a-a279d62832fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_b8ed2973-f8e0-4195-9114-694e5fe1f745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_43e3ee11-751c-43c3-98eb-e97baaeb84aa" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_b8ed2973-f8e0-4195-9114-694e5fe1f745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4ef5a74-66f4-4593-91c8-8f7fbfa4dfe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_8418c78d-2f9c-4ee3-a37c-6afe094c86bb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4ef5a74-66f4-4593-91c8-8f7fbfa4dfe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f617cc10-eac8-415d-b69d-94b7362c0bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_8418c78d-2f9c-4ee3-a37c-6afe094c86bb" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f617cc10-eac8-415d-b69d-94b7362c0bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_304c8e2f-b2af-4cbb-ade4-bc82c9896088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f617cc10-eac8-415d-b69d-94b7362c0bd2" xlink:to="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_304c8e2f-b2af-4cbb-ade4-bc82c9896088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_SettlementsWithEquityMethodInvestments_07464475-d046-4874-aaab-2f443a475768" xlink:href="rprx-20211231.xsd#rprx_SettlementsWithEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f617cc10-eac8-415d-b69d-94b7362c0bd2" xlink:to="loc_rprx_SettlementsWithEquityMethodInvestments_07464475-d046-4874-aaab-2f443a475768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AccruedPurchaseObligationEquityInvestment_de8ff40d-eaf8-4a41-ba37-19382d6f282d" xlink:href="rprx-20211231.xsd#rprx_AccruedPurchaseObligationEquityInvestment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f617cc10-eac8-415d-b69d-94b7362c0bd2" xlink:to="loc_rprx_AccruedPurchaseObligationEquityInvestment_de8ff40d-eaf8-4a41-ba37-19382d6f282d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash_978c706e-5461-4e9d-a212-13373dd26944" xlink:href="rprx-20211231.xsd#rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f617cc10-eac8-415d-b69d-94b7362c0bd2" xlink:to="loc_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash_978c706e-5461-4e9d-a212-13373dd26944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MilestonePaymentAccruedButNotPaid_51d1569d-1824-46b0-8753-31430addcc7d" xlink:href="rprx-20211231.xsd#rprx_MilestonePaymentAccruedButNotPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f617cc10-eac8-415d-b69d-94b7362c0bd2" xlink:to="loc_rprx_MilestonePaymentAccruedButNotPaid_51d1569d-1824-46b0-8753-31430addcc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="simple" xlink:href="rprx-20211231.xsd#AccumulatedOtherComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3ee480f1-f04f-4151-bb14-afdc546f7aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_5ca87d0e-9648-4451-901a-762326a9165d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3ee480f1-f04f-4151-bb14-afdc546f7aea" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_5ca87d0e-9648-4451-901a-762326a9165d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="simple" xlink:href="rprx-20211231.xsd#AccumulatedOtherComprehensiveIncomeTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_10029050-9fba-4b5c-b113-6659c48f0a20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_97a30be8-2584-491d-92a2-979e7c438ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_10029050-9fba-4b5c-b113-6659c48f0a20" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_97a30be8-2584-491d-92a2-979e7c438ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#AccumulatedOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_435ca22d-86d9-435e-8fda-f57acb136864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ae4ddf7d-3513-4abd-9104-8bc0d67ebfba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_435ca22d-86d9-435e-8fda-f57acb136864" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ae4ddf7d-3513-4abd-9104-8bc0d67ebfba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d44156b8-1f05-4363-a201-ad9f9abd424a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ae4ddf7d-3513-4abd-9104-8bc0d67ebfba" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d44156b8-1f05-4363-a201-ad9f9abd424a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_de6a5fda-d71f-4a87-a0ac-4ec810564e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d44156b8-1f05-4363-a201-ad9f9abd424a" xlink:to="loc_us-gaap_EquityComponentDomain_de6a5fda-d71f-4a87-a0ac-4ec810564e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8a5b6def-8eb4-4614-bad3-bb9cf432acfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_de6a5fda-d71f-4a87-a0ac-4ec810564e8e" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8a5b6def-8eb4-4614-bad3-bb9cf432acfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_a1d5e0a4-a605-42af-b274-3951b1781b38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8a5b6def-8eb4-4614-bad3-bb9cf432acfd" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_a1d5e0a4-a605-42af-b274-3951b1781b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember_cee94621-9892-4d14-a6e0-2a68080089d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8a5b6def-8eb4-4614-bad3-bb9cf432acfd" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember_cee94621-9892-4d14-a6e0-2a68080089d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_1548ab50-9d93-430d-a1c6-e6fdff53d013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_de6a5fda-d71f-4a87-a0ac-4ec810564e8e" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_1548ab50-9d93-430d-a1c6-e6fdff53d013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ec63df5d-7ed6-4cbe-a4af-d0e29d3f5375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_de6a5fda-d71f-4a87-a0ac-4ec810564e8e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ec63df5d-7ed6-4cbe-a4af-d0e29d3f5375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_aea154a1-b3d0-4be1-96ae-6ee769e8b3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ae4ddf7d-3513-4abd-9104-8bc0d67ebfba" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_aea154a1-b3d0-4be1-96ae-6ee769e8b3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_15a0fba3-68a5-40a1-9c4d-dbfae961bc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_aea154a1-b3d0-4be1-96ae-6ee769e8b3f2" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_15a0fba3-68a5-40a1-9c4d-dbfae961bc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_fe88607e-392b-444f-a917-07b57e12a724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_15a0fba3-68a5-40a1-9c4d-dbfae961bc1c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_fe88607e-392b-444f-a917-07b57e12a724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_7248f0b6-acbe-4a70-9dd3-68ecbcc1dfae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ae4ddf7d-3513-4abd-9104-8bc0d67ebfba" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_7248f0b6-acbe-4a70-9dd3-68ecbcc1dfae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a9ae4f56-a0b0-4c2a-b236-94e800ae72da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_7248f0b6-acbe-4a70-9dd3-68ecbcc1dfae" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a9ae4f56-a0b0-4c2a-b236-94e800ae72da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_769feb9a-cf46-4bc2-a710-ad170d0ab4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a9ae4f56-a0b0-4c2a-b236-94e800ae72da" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_769feb9a-cf46-4bc2-a710-ad170d0ab4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_78f4492a-6b11-46dd-9dc9-336cfec45950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a9ae4f56-a0b0-4c2a-b236-94e800ae72da" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_78f4492a-6b11-46dd-9dc9-336cfec45950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_61a84f92-b76b-4a63-b096-526305c83544" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a9ae4f56-a0b0-4c2a-b236-94e800ae72da" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_61a84f92-b76b-4a63-b096-526305c83544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest_7057617f-9550-40bc-ba98-561e048f95a1" xlink:href="rprx-20211231.xsd#rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a9ae4f56-a0b0-4c2a-b236-94e800ae72da" xlink:to="loc_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest_7057617f-9550-40bc-ba98-561e048f95a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest_7aaa06b3-ae7b-4a65-9aba-7c6b127d80a7" xlink:href="rprx-20211231.xsd#rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a9ae4f56-a0b0-4c2a-b236-94e800ae72da" xlink:to="loc_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest_7aaa06b3-ae7b-4a65-9aba-7c6b127d80a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1771d764-4ad5-4695-953a-5224d803dd1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_a9ae4f56-a0b0-4c2a-b236-94e800ae72da" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1771d764-4ad5-4695-953a-5224d803dd1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_3dc78755-c311-4c3f-b20c-0664169ccc80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_7248f0b6-acbe-4a70-9dd3-68ecbcc1dfae" xlink:to="loc_us-gaap_InvestmentIncomeNet_3dc78755-c311-4c3f-b20c-0664169ccc80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_bda21fa9-b5f4-4934-85c9-bfd758eca45a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_7248f0b6-acbe-4a70-9dd3-68ecbcc1dfae" xlink:to="loc_us-gaap_InterestIncomeOperating_bda21fa9-b5f4-4934-85c9-bfd758eca45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="rprx-20211231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_a3c92fea-d573-42b2-9a2d-6efeebc35f23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1f69d2fe-d1b2-414c-a456-07f65ccf386b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_a3c92fea-d573-42b2-9a2d-6efeebc35f23" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1f69d2fe-d1b2-414c-a456-07f65ccf386b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="rprx-20211231.xsd#RelatedPartyTransactionsTables"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_509e5659-74f4-4b0f-8e02-d1e13780f1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_a91cbabf-2d58-4344-a71c-e3381ebffa8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_509e5659-74f4-4b0f-8e02-d1e13780f1eb" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_a91cbabf-2d58-4344-a71c-e3381ebffa8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_addb5fbd-a652-4ada-83c0-02fcd0212dba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fcdabc1a-3c4b-492d-8676-ad2638f84fad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_addb5fbd-a652-4ada-83c0-02fcd0212dba" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fcdabc1a-3c4b-492d-8676-ad2638f84fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c2f49ac7-89df-4adb-9ee3-5b6b7a127316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fcdabc1a-3c4b-492d-8676-ad2638f84fad" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c2f49ac7-89df-4adb-9ee3-5b6b7a127316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e7de7fff-721a-403e-b0eb-7f5f95d46588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c2f49ac7-89df-4adb-9ee3-5b6b7a127316" xlink:to="loc_us-gaap_RelatedPartyDomain_e7de7fff-721a-403e-b0eb-7f5f95d46588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember_3d95c7ec-7f85-4667-ae59-16257f661217" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e7de7fff-721a-403e-b0eb-7f5f95d46588" xlink:to="loc_srt_ManagementMember_3d95c7ec-7f85-4667-ae59-16257f661217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_8d2dc3aa-253a-406e-ae1c-9103aed1dc7f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e7de7fff-721a-403e-b0eb-7f5f95d46588" xlink:to="loc_srt_AffiliatedEntityMember_8d2dc3aa-253a-406e-ae1c-9103aed1dc7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PabloLegorretaMember_0dcb014d-175b-4a8b-85e9-b62593c66c2d" xlink:href="rprx-20211231.xsd#rprx_PabloLegorretaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e7de7fff-721a-403e-b0eb-7f5f95d46588" xlink:to="loc_rprx_PabloLegorretaMember_0dcb014d-175b-4a8b-85e9-b62593c66c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_403becac-79cb-438b-aed4-6207ac31c6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fcdabc1a-3c4b-492d-8676-ad2638f84fad" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_403becac-79cb-438b-aed4-6207ac31c6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_95a0f72c-18eb-42fd-bdb1-c4a861011100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_403becac-79cb-438b-aed4-6207ac31c6c6" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_95a0f72c-18eb-42fd-bdb1-c4a861011100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_OperatingAndPersonnelPaymentsMember_d0ba52de-53dd-4b75-884a-c0926091ecae" xlink:href="rprx-20211231.xsd#rprx_OperatingAndPersonnelPaymentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_95a0f72c-18eb-42fd-bdb1-c4a861011100" xlink:to="loc_rprx_OperatingAndPersonnelPaymentsMember_d0ba52de-53dd-4b75-884a-c0926091ecae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_FormerOperatingAndPersonnelPaymentsMember_b14aba0e-36ff-4dd1-9ab3-185fa5ac5d71" xlink:href="rprx-20211231.xsd#rprx_FormerOperatingAndPersonnelPaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_95a0f72c-18eb-42fd-bdb1-c4a861011100" xlink:to="loc_rprx_FormerOperatingAndPersonnelPaymentsMember_b14aba0e-36ff-4dd1-9ab3-185fa5ac5d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember_38ec9c66-b3f2-4f25-a95a-8cd3721bf2ed" xlink:href="rprx-20211231.xsd#rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_95a0f72c-18eb-42fd-bdb1-c4a861011100" xlink:to="loc_rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember_38ec9c66-b3f2-4f25-a95a-8cd3721bf2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember_288956d6-4f06-4a5a-bf24-972181d1c578" xlink:href="rprx-20211231.xsd#rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_95a0f72c-18eb-42fd-bdb1-c4a861011100" xlink:to="loc_rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember_288956d6-4f06-4a5a-bf24-972181d1c578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssignmentAgreementBenefitOfPaymentStreamMember_5f808fa6-d308-45de-8812-f854112eb592" xlink:href="rprx-20211231.xsd#rprx_AssignmentAgreementBenefitOfPaymentStreamMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_95a0f72c-18eb-42fd-bdb1-c4a861011100" xlink:to="loc_rprx_AssignmentAgreementBenefitOfPaymentStreamMember_5f808fa6-d308-45de-8812-f854112eb592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AssignmentAgreementFundingObligationsMember_4af6987c-c728-456b-bccc-dd31cf9d6901" xlink:href="rprx-20211231.xsd#rprx_AssignmentAgreementFundingObligationsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_95a0f72c-18eb-42fd-bdb1-c4a861011100" xlink:to="loc_rprx_AssignmentAgreementFundingObligationsMember_4af6987c-c728-456b-bccc-dd31cf9d6901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AgreementWithMSCIMember_df65cec2-2854-44ad-aa15-606e2238b4f2" xlink:href="rprx-20211231.xsd#rprx_AgreementWithMSCIMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_95a0f72c-18eb-42fd-bdb1-c4a861011100" xlink:to="loc_rprx_AgreementWithMSCIMember_df65cec2-2854-44ad-aa15-606e2238b4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PurchasingAndDonatingVentilatorsMember_1bdbe1ff-e707-484e-9f9c-b9be7c9428d7" xlink:href="rprx-20211231.xsd#rprx_PurchasingAndDonatingVentilatorsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_95a0f72c-18eb-42fd-bdb1-c4a861011100" xlink:to="loc_rprx_PurchasingAndDonatingVentilatorsMember_1bdbe1ff-e707-484e-9f9c-b9be7c9428d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember_f798659b-82aa-4cde-92c8-88a80083288a" xlink:href="rprx-20211231.xsd#rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_95a0f72c-18eb-42fd-bdb1-c4a861011100" xlink:to="loc_rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember_f798659b-82aa-4cde-92c8-88a80083288a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_40c663c4-124c-4f27-a546-1ff752f52123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fcdabc1a-3c4b-492d-8676-ad2638f84fad" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_40c663c4-124c-4f27-a546-1ff752f52123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d409d2c9-f96f-42c0-8472-7117c2cfbfc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_40c663c4-124c-4f27-a546-1ff752f52123" xlink:to="loc_us-gaap_EquityComponentDomain_d409d2c9-f96f-42c0-8472-7117c2cfbfc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_91417eab-45ec-4691-b7e8-17d86ea070aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d409d2c9-f96f-42c0-8472-7117c2cfbfc1" xlink:to="loc_us-gaap_TreasuryStockMember_91417eab-45ec-4691-b7e8-17d86ea070aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_5fd52e6a-250c-4c9b-8afb-7e5e960c36c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d409d2c9-f96f-42c0-8472-7117c2cfbfc1" xlink:to="loc_us-gaap_NoncontrollingInterestMember_5fd52e6a-250c-4c9b-8afb-7e5e960c36c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_19890328-3a63-4828-828f-0247b53a970d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fcdabc1a-3c4b-492d-8676-ad2638f84fad" xlink:to="loc_srt_CounterpartyNameAxis_19890328-3a63-4828-828f-0247b53a970d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_80924c8b-38d7-4c1f-9df1-5919e16e9409" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_19890328-3a63-4828-828f-0247b53a970d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_80924c8b-38d7-4c1f-9df1-5919e16e9409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_BristolMyersSquibbMember_b3b6d7c6-841f-4682-a53b-add38bfa7775" xlink:href="rprx-20211231.xsd#rprx_BristolMyersSquibbMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_80924c8b-38d7-4c1f-9df1-5919e16e9409" xlink:to="loc_rprx_BristolMyersSquibbMember_b3b6d7c6-841f-4682-a53b-add38bfa7775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_65024fcd-eaf7-435c-9877-339e0b29f1c5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fcdabc1a-3c4b-492d-8676-ad2638f84fad" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_65024fcd-eaf7-435c-9877-339e0b29f1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_24e50407-0b12-48d8-8355-4bb71ec6ffb5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_65024fcd-eaf7-435c-9877-339e0b29f1c5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_24e50407-0b12-48d8-8355-4bb71ec6ffb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_EpizymeIncMember_a63b174c-22c4-4c31-a46e-caee50735d7f" xlink:href="rprx-20211231.xsd#rprx_EpizymeIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_24e50407-0b12-48d8-8355-4bb71ec6ffb5" xlink:to="loc_rprx_EpizymeIncMember_a63b174c-22c4-4c31-a46e-caee50735d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fcdabc1a-3c4b-492d-8676-ad2638f84fad" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionRateAdjustedCashReceipts_b3b8f9ae-552a-47c0-bc9c-1cb37caa3c96" xlink:href="rprx-20211231.xsd#rprx_RelatedPartyTransactionRateAdjustedCashReceipts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_rprx_RelatedPartyTransactionRateAdjustedCashReceipts_b3b8f9ae-552a-47c0-bc9c-1cb37caa3c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments_4c3f8b8f-2c11-4293-84a6-a6d2f86101d1" xlink:href="rprx-20211231.xsd#rprx_RelatedPartyTransactionRateValueOfSecurityInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments_4c3f8b8f-2c11-4293-84a6-a6d2f86101d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount_dbb2fd56-5899-41d6-8f42-e0257b4b0011" xlink:href="rprx-20211231.xsd#rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount_dbb2fd56-5899-41d6-8f42-e0257b4b0011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent_7e79266f-b1e5-4241-8753-30358c9b0c62" xlink:href="rprx-20211231.xsd#rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent_7e79266f-b1e5-4241-8753-30358c9b0c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionAnnualIncreasePercentage_d7be75f7-9306-44ce-9262-171ee07d3d91" xlink:href="rprx-20211231.xsd#rprx_RelatedPartyTransactionAnnualIncreasePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_rprx_RelatedPartyTransactionAnnualIncreasePercentage_d7be75f7-9306-44ce-9262-171ee07d3d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_7f887d5d-9c0d-475e-af5b-6ca40962904e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_7f887d5d-9c0d-475e-af5b-6ca40962904e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesNoncurrent_64afdbd5-3730-4de7-86a4-48f01b79e3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_us-gaap_DueToRelatedPartiesNoncurrent_64afdbd5-3730-4de7-86a4-48f01b79e3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_1653f5a3-12c2-4e16-bd05-b00f7a77bccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_us-gaap_EquityMethodInvestments_1653f5a3-12c2-4e16-bd05-b00f7a77bccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_83766d22-8327-4b08-a993-7eccaebafd5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_83766d22-8327-4b08-a993-7eccaebafd5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionCumulativeFundingAmount_1de9e9b5-570c-4779-a7ac-76d25cf209e3" xlink:href="rprx-20211231.xsd#rprx_RelatedPartyTransactionCumulativeFundingAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_rprx_RelatedPartyTransactionCumulativeFundingAmount_1de9e9b5-570c-4779-a7ac-76d25cf209e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_ce71db9d-f592-4d9d-aa24-69be529fad6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_us-gaap_NotesReceivableNet_ce71db9d-f592-4d9d-aa24-69be529fad6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionInitialTerm_8737b488-0ad7-4d55-bdae-2451c348c4e3" xlink:href="rprx-20211231.xsd#rprx_RelatedPartyTransactionInitialTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_rprx_RelatedPartyTransactionInitialTerm_8737b488-0ad7-4d55-bdae-2451c348c4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_cdd02430-b822-4420-a2d1-a2b6d29606b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_us-gaap_DueFromRelatedParties_cdd02430-b822-4420-a2d1-a2b6d29606b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_64a048c7-e5b8-4d94-816e-90077c8fb0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_64a048c7-e5b8-4d94-816e-90077c8fb0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired_7f563aed-cf18-45f7-9b64-49a5407cc86e" xlink:href="rprx-20211231.xsd#rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired_7f563aed-cf18-45f7-9b64-49a5407cc86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d3c95915-9f61-4f0a-8b5f-32453e19b059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b482fe88-d6bc-4868-a330-decfc6321ee9" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d3c95915-9f61-4f0a-8b5f-32453e19b059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="rprx-20211231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a008cc7e-2450-4dda-b9be-86f05307c80a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8e9596e1-b0fe-4b78-98fb-2a801e00b2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a008cc7e-2450-4dda-b9be-86f05307c80a" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8e9596e1-b0fe-4b78-98fb-2a801e00b2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c6cae256-e6f7-4b54-90b0-278484157fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_0a11437c-5db8-49a5-b210-73c2abb2e1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c6cae256-e6f7-4b54-90b0-278484157fd7" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_0a11437c-5db8-49a5-b210-73c2abb2e1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_d68b1a91-378b-491d-993e-e0e23e447bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_0a11437c-5db8-49a5-b210-73c2abb2e1d6" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_d68b1a91-378b-491d-993e-e0e23e447bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_c872066e-47c5-4e65-b726-89c62747ed61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_d68b1a91-378b-491d-993e-e0e23e447bf3" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_c872066e-47c5-4e65-b726-89c62747ed61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember_d8d62ce4-e8e5-4498-8073-8812e7b059c7" xlink:href="rprx-20211231.xsd#rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_c872066e-47c5-4e65-b726-89c62747ed61" xlink:to="loc_rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember_d8d62ce4-e8e5-4498-8073-8812e7b059c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember_f6233bfe-10c3-441c-9c9f-94a39455d8bb" xlink:href="rprx-20211231.xsd#rprx_LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_c872066e-47c5-4e65-b726-89c62747ed61" xlink:to="loc_rprx_LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember_f6233bfe-10c3-441c-9c9f-94a39455d8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_184017d9-a827-45be-a6cb-fcb68d36c0f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_0a11437c-5db8-49a5-b210-73c2abb2e1d6" xlink:to="loc_srt_CounterpartyNameAxis_184017d9-a827-45be-a6cb-fcb68d36c0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_371de749-5645-4357-9c0c-d6a155e9fc99" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_184017d9-a827-45be-a6cb-fcb68d36c0f2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_371de749-5645-4357-9c0c-d6a155e9fc99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_MorphoSysMember_888b34b7-a669-459d-a546-c75d8b700e13" xlink:href="rprx-20211231.xsd#rprx_MorphoSysMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_371de749-5645-4357-9c0c-d6a155e9fc99" xlink:to="loc_rprx_MorphoSysMember_888b34b7-a669-459d-a546-c75d8b700e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d155f417-23ba-4b2a-b62d-2c9f29bb3581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_0a11437c-5db8-49a5-b210-73c2abb2e1d6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d155f417-23ba-4b2a-b62d-2c9f29bb3581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4a648c77-bca5-425d-bfdd-b38341e42aed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d155f417-23ba-4b2a-b62d-2c9f29bb3581" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4a648c77-bca5-425d-bfdd-b38341e42aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_f4424614-7e10-455a-97c6-79fc5dbd36be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4a648c77-bca5-425d-bfdd-b38341e42aed" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_f4424614-7e10-455a-97c6-79fc5dbd36be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_0a11437c-5db8-49a5-b210-73c2abb2e1d6" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_f70597f3-0f53-4adf-b27c-2238b87113bb" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_f70597f3-0f53-4adf-b27c-2238b87113bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_a3a29b54-ddd0-416d-b4c5-de82cba5fb05" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital_a3a29b54-ddd0-416d-b4c5-de82cba5fb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm_0efb3c15-e594-473a-9ac7-4c9434dc3f84" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm_0efb3c15-e594-473a-9ac7-4c9434dc3f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsExpectedReturn_2814a9ea-da51-4463-a66d-a5eaa3fbde9b" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsExpectedReturn"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsExpectedReturn_2814a9ea-da51-4463-a66d-a5eaa3fbde9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_d6cc3094-32de-441e-9ea4-05e6477c66f0" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund_d6cc3094-32de-441e-9ea4-05e6477c66f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_6d0ffe38-c5c0-448d-9ebd-b2f2e7d65674" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn_6d0ffe38-c5c0-448d-9ebd-b2f2e7d65674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate_6d6e0214-9f91-44a1-a648-0f6d6663a8a3" xlink:href="rprx-20211231.xsd#rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate_6d6e0214-9f91-44a1-a648-0f6d6663a8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount_9d655c68-8bf2-4d5c-b1ce-2550fe019b30" xlink:href="rprx-20211231.xsd#rprx_PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_rprx_PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount_9d655c68-8bf2-4d5c-b1ce-2550fe019b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermPurchaseCommitmentAmountOutstanding_96b69206-8088-47d0-85a4-77eb086d5cdb" xlink:href="rprx-20211231.xsd#rprx_LongTermPurchaseCommitmentAmountOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_rprx_LongTermPurchaseCommitmentAmountOutstanding_96b69206-8088-47d0-85a4-77eb086d5cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_ac3c72e2-3fe4-4b8c-a479-bf4dd5c9739a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_ac3c72e2-3fe4-4b8c-a479-bf4dd5c9739a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PurchaseCommitmentUpfrontPayment_df1ebe6f-d761-4c41-b6b5-16c7f8897610" xlink:href="rprx-20211231.xsd#rprx_PurchaseCommitmentUpfrontPayment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_rprx_PurchaseCommitmentUpfrontPayment_df1ebe6f-d761-4c41-b6b5-16c7f8897610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PurchaseCommitmentAdditionalPayment_a2766f66-c0cc-474b-8df6-8116dc53bde1" xlink:href="rprx-20211231.xsd#rprx_PurchaseCommitmentAdditionalPayment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_52a6a159-322b-4848-9294-bc04b95ac00c" xlink:to="loc_rprx_PurchaseCommitmentAdditionalPayment_a2766f66-c0cc-474b-8df6-8116dc53bde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/SubsequentEvents" xlink:type="simple" xlink:href="rprx-20211231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0c749e06-95fe-4805-baab-0dc184885b66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_7267717d-ce7d-4763-8c55-f34cce7c8a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0c749e06-95fe-4805-baab-0dc184885b66" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_7267717d-ce7d-4763-8c55-f34cce7c8a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://royaltypharma.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="rprx-20211231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://royaltypharma.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_3e23dc50-ca72-406e-bc3f-7efec72b5a93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_e091923a-4aa0-4bd1-9ceb-9ee2be3ba959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_3e23dc50-ca72-406e-bc3f-7efec72b5a93" xlink:to="loc_us-gaap_SubsequentEventTable_e091923a-4aa0-4bd1-9ceb-9ee2be3ba959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_035b3c4a-9fec-4f77-833d-9091bbfd62b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e091923a-4aa0-4bd1-9ceb-9ee2be3ba959" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_035b3c4a-9fec-4f77-833d-9091bbfd62b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d57b33a0-4f59-4aa5-8ed1-a257aa5e2d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_035b3c4a-9fec-4f77-833d-9091bbfd62b5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d57b33a0-4f59-4aa5-8ed1-a257aa5e2d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e7ad42b1-e7f8-4c88-af54-cd9ad0d6afa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d57b33a0-4f59-4aa5-8ed1-a257aa5e2d5c" xlink:to="loc_us-gaap_SubsequentEventMember_e7ad42b1-e7f8-4c88-af54-cd9ad0d6afa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_935d025a-e0f4-4b9d-bb58-87ba59463a48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e091923a-4aa0-4bd1-9ceb-9ee2be3ba959" xlink:to="loc_us-gaap_SubsequentEventLineItems_935d025a-e0f4-4b9d-bb58-87ba59463a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireRoyaltyInterestsAggregateAmount_b3f4495a-f8a3-4ed0-9a88-44f592932087" xlink:href="rprx-20211231.xsd#rprx_PaymentsToAcquireRoyaltyInterestsAggregateAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_935d025a-e0f4-4b9d-bb58-87ba59463a48" xlink:to="loc_rprx_PaymentsToAcquireRoyaltyInterestsAggregateAmount_b3f4495a-f8a3-4ed0-9a88-44f592932087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireRoyaltyInterestsUpfrontPayment_13f6db8a-7ade-4392-9e80-51c7d1de5976" xlink:href="rprx-20211231.xsd#rprx_PaymentsToAcquireRoyaltyInterestsUpfrontPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_935d025a-e0f4-4b9d-bb58-87ba59463a48" xlink:to="loc_rprx_PaymentsToAcquireRoyaltyInterestsUpfrontPayment_13f6db8a-7ade-4392-9e80-51c7d1de5976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments_4472cfac-123e-495d-b03b-d7392be244a2" xlink:href="rprx-20211231.xsd#rprx_PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_935d025a-e0f4-4b9d-bb58-87ba59463a48" xlink:to="loc_rprx_PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments_4472cfac-123e-495d-b03b-d7392be244a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments_86af69a9-2b7d-48b4-9c6a-aadc28b5fa57" xlink:href="rprx-20211231.xsd#rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_935d025a-e0f4-4b9d-bb58-87ba59463a48" xlink:to="loc_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments_86af69a9-2b7d-48b4-9c6a-aadc28b5fa57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipAmount_ce81f436-7494-4ca1-8c48-3297a45069fe" xlink:href="rprx-20211231.xsd#rprx_LongTermFundingPartnershipAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_935d025a-e0f4-4b9d-bb58-87ba59463a48" xlink:to="loc_rprx_LongTermFundingPartnershipAmount_ce81f436-7494-4ca1-8c48-3297a45069fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipNumberOfTranches_15ddd688-5767-46d7-afa3-4f8dc35dee37" xlink:href="rprx-20211231.xsd#rprx_LongTermFundingPartnershipNumberOfTranches"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_935d025a-e0f4-4b9d-bb58-87ba59463a48" xlink:to="loc_rprx_LongTermFundingPartnershipNumberOfTranches_15ddd688-5767-46d7-afa3-4f8dc35dee37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipInitialPayment_bc2b9a69-db1d-4170-a77f-941cad91329b" xlink:href="rprx-20211231.xsd#rprx_LongTermFundingPartnershipInitialPayment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_935d025a-e0f4-4b9d-bb58-87ba59463a48" xlink:to="loc_rprx_LongTermFundingPartnershipInitialPayment_bc2b9a69-db1d-4170-a77f-941cad91329b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipNumberOfAdditionalPayments_f3946cc5-cf4f-47ef-8b8e-22f4bdfa4ffb" xlink:href="rprx-20211231.xsd#rprx_LongTermFundingPartnershipNumberOfAdditionalPayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_935d025a-e0f4-4b9d-bb58-87ba59463a48" xlink:to="loc_rprx_LongTermFundingPartnershipNumberOfAdditionalPayments_f3946cc5-cf4f-47ef-8b8e-22f4bdfa4ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_5ff4bc35-5524-4605-92d4-3b8b14a17b59" xlink:href="rprx-20211231.xsd#rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_935d025a-e0f4-4b9d-bb58-87ba59463a48" xlink:to="loc_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount_5ff4bc35-5524-4605-92d4-3b8b14a17b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>rprx-20211231_g1.jpg
<TEXT>
begin 644 rprx-20211231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QI<V$@4FEN
M86QD:0    60 P "    %   $*:0!  "    %   $+J2D0 "     S$Q  "2
MD@ "     S$Q  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MF-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:*
M'>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F
M-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '
M>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-
MZ_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>
M8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z
M_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8
MWK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_
MI3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8W
MK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* )HV+9R:?4</>I* "BBB@ HHHH 1CA3
MCTJ'S&]?TJ9ONGZ57H =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4
M>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH
M =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>
M8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH
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M8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH
M=YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8
MWK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =
MYC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8W
MK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =Y
MC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK
M^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC
M>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^
ME-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>
MOZ4>8WK^E-HH =YC>OZ4>8WK^E-HH FC8MG)I]1P]ZDH **** "BBB@ HHHH
M **** "BBB@ HHHH *1ONGZ4M(WW3]* *]%%% !1110 4444 %%%% !1110
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M#X&MH9Y-1A@,UQ*5"QQ#8' !ZL2&'; SUSQ76T %%%% !1110 4444 %%%%
M!1110 4444 2P]ZDJ.'O4E !1110 4444 (WW3]*KU8;[I^E5Z "BBB@ HHH
MH **** "BH[BXBM+66XN9%BAA0R22,<!5 R2?8"O%+G]I 2R75UX?\$:KJNB
M6;E9]3#%%0#N0$8+QS\S XZXH ]OHKE=*^(_A[5OAZ_C*.Y:'2XHV>?S5^>)
MEX*%1GYLX  SG(QUKSFV_:5M_M%O=:GX/U2QT"ZE,4.JL^Y6(//R[ IQSD*Y
M(QWH ]PHKC/'_P 3]$^'_A^VU*]WWKWW_'E;VY&9^ =V3P% (Y]QP:Y+0?CZ
MESXEL]&\8>$]1\,27[!;66Y8LKD\ G<B$ D@9 (YYXYH ]@HK/UW7=-\-:+<
M:KK5TEK9VZEGD<]?0 =R>@ Y-<O\+/B0/B9H5[J2Z6=-6UNC;B,W'F[_ )5;
M=G:N/O=.?K0!W%%%?.]U^U;]FNYH/^$-W>5(R;O[4QG!QG_4T ?1%%>,>!OV
MC](\6>(K71M3T>72)[R016\OVD31LYZ*QVJ1DX X/)%>ST %%%% !1110 45
M'<2^1:RS8W>6A;&<9P,UYY\/?B_;>-O"6M^(+[2SI%KH^YI@+@W!*+&79N$7
MH >,&@#T>BN<\#>-+/Q[X<_MO3;>:WM6G>*-9\;V"G&2!D#/IDUT= !117#?
M%3XD?\*ST"SU/^RO[3^TW7V?R_M/D[?E9LYVMG[O3% '<T5\YK^UFI<;_!A"
MYY(U3) ^GDU[#\/?B#I7Q&\/'4])22!HI/*N+:;&^)\9[=01T/\ (Y% '5T4
M44 %%%% !117'7OC/6;7XF6GAF'PA?7&F3H&?7%+^3$=K'!_=E>H ^^.M '8
MT444 %%<C:_$72[[XG7'@FSAGDOK2W,]S,P"QIC:0H[L?G'M[FNNH ***KZA
M=?8=-NKO9YGV>%Y=F<;MH)QGMTH L45\Y?\ #6?_ %)?_E5_^TUV7PY^/^D>
M.]?CT2[TN72+^<,8 TXFCD(&=N["D-@$CC'&,YQD ];HHHH **S?$6K?V!X7
MU76/)^T?V?9S77D[]OF>6A;;G!QG&,X->"?\-9_]27_Y5?\ [30!]&T5XOX%
M_:%_X377I]-_X1C[%Y-G-=>9_:'F9\M<[<>6.OKFNO\ A7\2/^%F:!>:G_97
M]F?9KK[/Y?VGSMWRJV<[5Q][IB@#N:*** "BBB@ HHHH **** "BBB@ HHKD
MO'WQ%TOX?65G+J<,]Q/?RF&VAA ^9AC)+'A0,CU/L: .MHKD?B!XPU?P?I]I
M<:'X3O?$TD\I1X;,OF( 9W';&_';H*ZN%VD@C=T,;,H)0]5)'2@!]%%% !17
M&?$_XB6_PU\+QZK-9_;YIKA8(;43>5O)!).[:V  #V]!WI?AC\1+;XE>%Y-5
MAL_L$T-PT$UJ9O,V$ $'=M7((([>H[4 =E1110 4444 %%%% !1110 4444
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M>60.LB9 )5AC."1D$#K]< 'I%%%% !1110 445S'Q$\9?\(%X*NO$'V#[?\
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MOD6\DI1W$:EML:[F; S@#N?:ODI;CQ?J?Q)G\6^-/AEK_B Y_P!%L'M9HH8
M#\JD>4VX*.W&3DG.: -KP?X>U3P[^SKXX\17\3P2:]"HBA*E2(@Q7?CL#YK?
M@ >]=/X3MH?^&-;LF-3YFGWTC9[L)I,'\-H_*NLT76M7^*_A'Q+HGB'P??\
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M'7IFNJ^!?A_5M*U+Q1X^\0:;_9%E>Q220VQ3R_E+F5BJGD(  !GK^%=EX>\
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MME=P^IK173?&OQ=^*VA:MK_A>Y\,Z/H,BR,MT&!<JX<A2RJ6+%5' P #SGJ
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M"2ZMGB64>9*<J6 #<$=/44 <;X/;6OBU\>-.\7P:"-)T^R=)9Y8P2F$R0"^
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MF[*XP2O!QUR?7%<CH.C:WI_PGU7PC!\,]3_X22X\Q)=4DM%6-HB<Y$IY8@#
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M,P7SAM*L@)X!(.1GC( ]Z /'-2U[Q3X'TFP\3V/Q:L_$=Z[H;S1OMXG";N2
MN]MP'0D*I':O7_&6H:WXF\(>']3T+Q+I_A71+^.*YU&^N+KRIUC=58)$VW (
M!;J0<@#@9SYQIMYK]S]@TN/X!:3]MC*I=7=WIBQPR@#!(8QA4.><[F[\5K_&
M#P;K+^*/!^K6WAIM6\/Z5%''<Z-ID7F+$0^YU6, 94K@#C'R<XS0!CZ7XUG\
M/?'+1M#\*>.-2\4Z%?M%%<_VE=&YVN[,I"N0.@"L"O'..>:^E*^:=:L-=U?X
MU>$?$MCX"U;2-"M98+>*,6.'CC24LTDD<>1$,RG@]0I]\?2U !1110 4444
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MR<]MY+#/^U0!Y-XNN[WP]X3O=1U?XO74_C*.7<FG:3J9:T'S@;/*51@[<GG
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M)4G[V%&./7HK/PWJWPM^._VGP]H]Y=>%/$0"W"6-J\B6;$]6V@[0K'(Z#:[
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M,'//.:]"L=(U>[^"OBA[OP%IGAS5+VPDBBM=(M@LMR-AQNC49!R>%))Z\#N
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M(;6TA6&%!_"JC ^O3K5NB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH EA[U)4</>I* "BBB@ HHHH 1ONGZ
M57JPWW3]*KT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOA3\,O\ A6.DW]E_:_\ :GVR=9=_V;R=F%QC&]LUWM% !1110 4444 %%%%
M$-W US8SP)*T+2QL@D7JA(QD>XKS+P5\$U\-^,AXH\1>);WQ+JD2E;>6Z0CR
M\C;DEG<L0"0.0!GITKU.B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** )8>]25'#WJ2@ HHHH ****
M"BBB@ HHHH **** "BBB@ I&^Z?I2T4 5J*LT4 5J*LT4 5J*LT4 5J*LT4
M5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*L
MT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5
MJ*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT
M4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J
M*LT4 5J*LT4 1P]ZDHHH **** "BBB@!&^Z?I5>K-% %:BK-% %:BK-% %:B
MK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-%
M%:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK
M-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %
M:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-
M% %:BK-% %:BK-% %:I8>]244 %%%% !1110 4C?=/TI:* *U%6:* *U%6:*
M *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%
M6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:*
M*U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6
M:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *
MU%6:* *U%6:* *U%6:* *U%6:* (X>]2444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5E:KXI\/Z%,L6MZ[IFG2,,JEW>1Q$CZ,16=\1O$<WA+X<ZUK=KM^T
M6ML3"6&0)&(521WPS XKEOAY\*/#<?@^SU#Q+I-MK>M:I EW?7>IQ"X<R2*&
M(&\';C..,'CF@#TJUN[>^MDN+*>*X@D&4EB<.K#V(X-2UXUH>G1_#;]H*'PY
MH9:#0/$U@]REB7)2&YCW%B@/3Y4_\>]AC,\/^-?B')\:/%=L/#;7CQP6V[1Y
M-=40V(\M?F1BFUBV=QPHZ\YQ0![(WB324\5IX::[QJ\EI]M6V\MN8=Q7=NQM
M^\",9S[5J5XIXS\1CPS^TQ872:?=:E<S^&!;VMG:)EYI6N9"!D\*, DL>  :
MZ_PK\2+S5O&$OA;Q3X9N/#>LBV^UP0O<I<1SQ9P2LB@#.>W/0\\4 =Y17"ZM
M\1+X^*;OP]X+\-3>([[3E4W\ANTM8+8L,JAD8'+$#H!_(XN^$O'L/B>UU6*X
MTZ?2]7T9]E_IMPZLT1*EE(8<,K '#>U '6T5Y5X,^,6K>.TT^;0? UY)9O,L
M.I7;7J+'9$OCY=R@S87#D*!C.*]5H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBFR2)%&7E=41>K,< 4 .HKG
MK_Q[X9T[(GU>!V'\,&93_P".YKG+SXRZ+%D65C>7)'=@L:G\<D_I6L:-26R(
M=2"W9Z)17C]U\:;]R?L6DVT0[>=(TG\MM9,_Q:\3S$^7):P?]<X,X_[Z)K58
M2JS-UX'NU%?/<GQ)\62GG5V7V6&-?Y+5=O'GBACSK5U^! _I5_4Y]T3]8CV/
MHRBOEW7_ (N>-]*UEK2SUME@2&%@KV\3G+1(Q^8J3U)[U3C^.7CI/O:E#)_O
M6R?T I?5*G=&OM$?5U%?,=K^T-XQ@&)X-,N1W+P,#_XZP'Z5M6?[2E[&H%_X
M<@F/]Z*Z,?Z%34O"U4/GB?05%>0:;^T9X<N JZEIM_9N3R4"R(/QR#^E==IG
MQ8\$:J0+?Q!:Q,>UUF#\/G K*5&I'=#YDSL:*AMKNWO8%FLYXIXG&5>)PRD>
MQ%35D4%%%% !1110 4444 %%%% !1110 4444 %%%% !6?>ZI%I-O-=:M+'!
M;*P"O]:ON2$)4;B!P/6J5[;V^H:<(=4LA/'(PW1%=P!SUIKS,JG-RODW_#YE
MF*XCGMTFMV$B2)O0@_>!&15+0[Z_O[-Y-4T\V$JRLJQEL[E'0U9,$,,49MX%
M8P+MB5>-HZ8%4;O^W3XALS9^0-+V'[0'^_GVID3E*+4G?T7GU^1KT445)T!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '+?$SP[/XK
M^&FN:-9J&N;FV)@4X^:12'5>?5E S[US7P\^+'A>X\%6%KK^M6FCZOIUNMK?
M6FHS""198QM; <@G.,\9/.#S7IU9&I>$O#FLW0N=8\/Z7?W"]);JRCE<?BP)
MH \VT"]3XD?'A/%&CHTOA[PY8O:07S(0MS<OD/LSU 5B,^WHPJ#3];TGPK^T
MIXUG\1ZG::9%?:?:26[W<HB60+&BD M@$Y4\#^AKV.WMX;2W2"UAC@AC&$CC
M4*JCT ' JEJ/A[1=8N8;C5]'L+^:#_4RW5JDK1\Y^4L"1^% 'GUU_P G7V?_
M &*1_P#2EZ=XD _X:4\&''/]F7@S_P !->C'3+!M574VLK8Z@L7D+=F)?-$>
M<[-^,[<\XSC-$FF6$VI0ZC-96\E[ C)#<M$IDC4]0K8R >X% '@6BZ19V?Q4
M\;Z9XE\;ZSX5NKG4FOK1;:_2UBNX9"S!@74ABHP.#^'!QWG@C0?"UA>>*-1\
M.>*[SQ-J%S!''J%Q<WD=SMVHP0;T0#. 1U/0=*[O5?#^C:]&B:YI-CJ21G*+
M>6R3!?IN!Q4UCI>GZ79_9-,L;:SMO^>-O"L:?]\@ 4 >?_L]J!\"O#Y  )-R
M3@=?])EKTJJVGZ;8Z181V.E6=O8VD6?+M[:)8XTR23A5  R23]35F@ HHIDL
ML<$9>:18T49+,< 4 /HKGK_Q[X9T[B?5X'/I 3+^'RYKG;OXR:)$&%I9WEPP
MZ$JJ*?Q)S^E:QHU);(AU(+=GH=%>17/QJN6!%IHT49[&2<O^@ K-F^,/B.3(
MCAL(O=8F)_5C6JPM5]#-UX'M]%>!2?%'Q6YRM_''[+ G]0:O>'?B#XGO_$-I
M;7>I[X9&(9?(C&>">H7--X2HE>Z$L1%NQ[?17R4/C9\0!UU[/ULX/_B*LV_Q
MV\=0G+W]O/\ ]=+5/Z 4_J=3R-/:(^K**^:+?]HOQ9&0+BPTJ9>^(I%8_COQ
M^E;MG^TLWRB_\,C_ &GAO/Y*4_K4/"U5T'SQ/>J*\LT[]H/P?=L%O$U"P]6E
M@#J/^^"3^E=?I/Q"\):V%_L[7[*1V.%C>3RW/_ 6P?TK*5*<=T5S)G244@(8
M94@CVI:S&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M5C:[XLT?P[&3J=XJR8RL*?-(W_ 1_,\5YEKOQ@U&[W1:';K8Q=I9,/(?PZ#]
M?K6U.A.ILC.52,=SUV^U&STVW,^H74-M$/XY7"C]:XC5_B_HMD633(9M0D'1
M@/+C_,\_I7C5Y?W>HW!GO[F6YE/\<KEC^M05W0P<5\3N<LL1)_"=KJGQ6\1W
MY*VLD-A'TQ"F6(]V;/Z8KD[W4K[4I/,U"\GNG[&:0MC\ZK45U1IQA\*,)2E+
M=A1115DA1110 5L^$?\ D;+'_?/_ *":QJV?"/\ R-EC_OG_ -!-3/X65'XD
M>0T444SK"BBB@ HHHH U]&\6:_X>=6T;5[NT"G.R.4[#]4/RG\17HFA?M#^)
M+ JFMVEKJL0^\X'DR'\5^7_QVO)**SE3A/XD-2:/JOP]\<O!^ME([JZDTF=L
M#9>KA,_[XRH'N2*]"@N(;J!)K:5)HG&Y7C8,K#U!%?"5;&@>+=>\+W ET+5+
MBSYR45LQL?=#E3^(KEG@T_A9:J=S[9HKPCPG^T4K;+;QC8;#T-Y9C(^K1G]2
M"?I7LVB>(-)\1V(O-#OX;V ]6B;E3Z,.JGV(%<4Z4Z?Q(U4D]C1HHHK(8444
M4 %%%>1IXU^(_B+X@>*=#\&V_A>.UT":*(MJJW D<.K$8,9P>4;L.HZT >N4
M5POP[\>W_BC4=;T+Q)I<>FZ[H4J)=)!)OAE5P2KH3R <=#G@CGD@=U0 4444
M %%%% !17G7Q,\:^)/#OB/PKH7A&#2I+S7Y9X_,U19#&GEA"/]601G>?7I6;
MJ?COXA^ XTU'X@:#HU]H?F*MS>Z!++NM 2 &9)>6&3VQ]>F0#U>BN>US6=9&
MEZ7>^#-,@UM+RXB,K-<K$J6S#)E4G&[C' YYZ&NAH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ&ZO+:QMVGO9X
M[>%?O22N%4?B: )J*\]USXO:38[HM(ADU"4<;S^[C'XD9/Y8]Z\_UCXD>)-7
MW*;W['"W_+.U&S_Q[[WZUTPPM26^AA*O"/F>XZGX@TG1DW:GJ$%OQD*[C<?H
MO4UQ^I_&'1+7<NG6]Q?,.C8\M#^)Y_2O%6=G<L[%F8Y))R325UQP<%\6IA+$
M2>QZ#?\ QBUNXW+8VMK:*>A(,C#\3@?I7.7GCCQ-?G,^LW2^T+>5_P"@XK!H
MKIC2IQV1BZDWNR2>YGNI-]S-),Y_BD8L?S-1T45H0%%%% &%\1?^1TE_Z\K+
M_P!)(JY>NH^(O_(Z2_\ 7E9?^DD5<O41^%':%*K%&#*2I'0@]*2BJ W-/\:>
M)M*VC3]?U&%%Y$8N6*#_ ("3C]*ZW2_CSXVT]O\ 2KFUU%>FVYMP,?BFW]<U
MYM142IPENAW:/H#1_P!I*T<JFO:%-",8:6TE$F3Z[6QC\S7H6B?%3P;KVU;/
M7+>*5@/W5UF%L^@W8!/T)KX]HKGEA:;VT*4V?>"L&4%2"#T(I:^+- \;^)/#
M#+_8FL7-O&I_U.[?'_WPV5_2O5O#7[1LJ;(?%FEB0=#=6/!_%&./Q!'TKEGA
M)QVU+4TSWVBL'PWXW\.^+(=^A:G#<.!EH2=DB_5#@_CTK>KE::=F:!1112 *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***X[
MQ=\1M-\-A[:UVWNHCCRD;Y8S_MG^@Y^G6JC"4W:),I**NSJ;[4+33+5KG4+F
M*VA7J\C #Z>Y]J\L\3?%^23?;>&8O+3D&[F7YC[JO;ZG\A7 ZYXBU/Q%>?:-
M5N6E(/R1CA(QZ*.W\ZS*]*EA8QUGJSCG7;TB37E[<ZA=/<WT\EQ,YRSR-DFH
M:**[3F"BBB@ HHHH **** "BBB@ HHHH Y;QA_R,TO\ UPM__1"5AUN>,/\
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M6\#R2;VN3 KR] -N6R,<=,=S73>-91K'P_T37[^VCAU2XE:-W1=ID0;N2/\
M@(/X\=:'-J236C!135TSSVBO9;;[5#XCTC2;.#?X6ETP--^Y!A<%&)=GQU)Q
MW[^]<7HD4?A/01XDO45M0N@4TN!Q]WL9B/0=O7\<U"K7Z%.G8XZBG22/-*\L
MKL\CL69F.2Q/4FFUN9!1110 5L^$?^1LL?\ ?/\ Z":QJV?"/_(V6/\ OG_T
M$U,_A94?B1Y#1113.L**** "BBB@ HHHH **** "KNDZSJ6A7Z7NCWLUG<+T
MDA?!/L?4>QXJE11ON![YX)_:$5VCLO&T 0G"C4+=./JZ#I]5_(5[98:C9ZK9
M1WFFW,5U;2C*2Q.&5OQ%?"]=#X2\<:[X+OOM&B792-F!EMI,M%+_ +R_U&#[
MUQ5<+&6L-#2,VMS[0HK@/ 'Q;T7QLJVLA&G:J!\UK*XQ)[QM_%].OMWKOZ\Z
M490=I&J:>P5\^Z&_CJ/XO?$Q_A_'H<K+=6YN4U8R[F.V38(]A S][.XX^[[U
M]!5Q'@SP5J'AWQ_XTUR]GMI+;7Y[>2V2)F+H(PX.\%0 ?G&,$U(SGO@6EOJ-
MGKWB.^N9Y_$]_?&'68YHA']FDBR!$J@GY0#UZGOTQ7(Z_;?#6^AUAK'2_%7B
MK4XC-OURTCN+C[/,,GB4$( I]!C [BO2]*\#:AHWQ8U[7;*>V&A:]:)]KMB[
M"5;E> ZC&,$%L\YRQKGM ^'?C[PSX<E\&Z3K>AIX>9I5CU"2WD:^CCD)+#9_
MJRW)Y)_#I@ Y_P 2:K>ZQ^Q;]NU*X>XNI+:W5YG.6?;>(H)/<X R>]=%_P (
MG8?#3P+J?CB*6ZU/Q3'I3M-J-U.[^<[ $90G:%5MN !D 8S4UU\+]9G_ &<E
M\ +=6(U41(GG&1_(RMR)?O;-WW1C[O6O0;_1+?5_"T^AZFN^WNK0VLP4XR"N
MTX/\C0!\[Z?8Z#JO@B+4+[PKX^U#Q7=V8N!K\5C<,PG9=RM&ZMM\L$\8&".>
M]>[?#N]UG4/AWHUSXG@F@U9K<+=)<1&.3<I*Y92 02 #T[URVB^'?BEX6TB#
M0-(U/PQ?Z;9H(;6\U"*=;A(QPJLB?*V!@#YA7HFF0WEOI5M%JETEW>)$HGG2
M/RUD?')"\X&>U 'E_P 4O^2S?"O_ *_+S_T&&NW^(?V8_#/Q+]OV_9_[+N=^
M[_KDV/QST]\5SOQ,\%>)/$7B/PKKOA&?2H[S0)9Y/+U1I!&_F! /]6"3C8?3
MK6?J/@7X@^.X4T[X@:]H]CHID5KBRT"*7==*.=K22<J,XZ9H XR_%POP'^$X
MNB=Y\06&,_W/WQ3_ ,=VUT_Q9TYW\=:5J'BK1]3USP1'8M'/:Z>78076\GSI
M8T(++MP,]L'Z'J?'W@6X\1Z/X:T_03:6D.BZQ:WICE+*H@A5EV)M!YPPP#@<
M=:M^([?Q_'K'VGP?>Z%-9/$%:SU>.1?*<9^=9(\DYXX([<&@#DKWQ/HGA+]G
M_6-=^'&I2WME",69EF:4VCR.D80!_F4*7#;6R>?0UP$NEZ))X+^U:9X2^(#^
M,#:B:+7OL%R9)+G;D,6W$;"W'0\'UYKU/0?A0D'@/Q%H?B.]2[N?$EU->7TM
MM'Y<<4DF"/+4]E(!&:CTS1OBSHVEP:-;:IX6NK6U00PZC<Q7'VCRU& 6C'RE
M@!_>^N>X!#XCOM)O?A?X;N_BC<:E8S3I"T^FVIDBDO+@QX,31H-Y&23M&,'&
M:XSPO<Z5HWQT\,V7@O0]>\-Z=JMO=)?6>I6\L,5SLB+HZ*Y.2"HR1[>IKT7Q
MQX&UO7V\,ZOH^IV8\0>'7:2-[V$BWN6=5#[E7)7)4$8SCGZUGV_@CQKJ?Q,\
M.>+O%.I:.1I(N$:QT]) D:20L@*LPR[%B,YV@ <9H Y;QM8:9:?$[6+_ .+.
MD:IJ/AR>.$:3?P&5[;3P%Q(&$9!1BW.[D^E:OQ.\3?\ "._"/0+3PGJU_=V^
MKW<%A'J-O)Y]RT# EBC=6D(4*._/8UT^O:=\2Y+S4+;0]1\.7&EWFX1MJ,$J
MSVJL,%0$RLF.<$X]\U1D^#]N?A!I?@R+5)([O29!=6>I"/F.Y#L^_;GIEV&,
M]#UR* /-=:M['1+6UU/X7^!O'&F^(K6XC?SIM.N=EXF?G2;)(8$9/3K79?%G
M3G?QUI6H>*M'U/7/!$=BT<]KIY=A!=;R?.EC0@LNW SVP?H>CL[;XL2RP6^I
M7_A2WMT=?.N[6&>2:10><(V$4D>Y'-:/B.W\?QZQ]I\'WNA363Q!6L]7CD7R
MG&?G62/).>.".W!H =\-V\--X01O!.I2WVCM*QA$L[2&VSC,0W_,H'7:W(W>
M]=77'_#GP5<>#-+U+^TKV*\U'5M0EU&[>"/RXED?&513SM&.]=A0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%4M9U%=(T*_U
M*1=R6=M)<,,XR$4M_2@"/5?$.C:"J-KFKV&FJ_W3>7*0AOIN(S4^GZG8:O:+
M=:5?6U];M]V:VF61#_P)217DWPF\":7XI\,KXV\<V$&N:WKCO.S7\0FCACW%
M41$8$ 8&?Q S@57UW1+/X7?&/PIJ7A2(:=IGB.X.FZC81'$+.<"-@G0'+=NF
MWCJ<@'M=9>H^)-)TG6]+TC4+OR;[5VD6RA\MF\TQ@,_(!"X!'4BO)?%/B[QQ
M9_M!:7I^G:-)- +*?R--&L".&_0;_P!\WRX1ACH03QUYIWQ2\0OHWCWX7:WK
MFG30SQ_;FFL+4_:)!*T42B)" -Y+,%!X!SVH ]LHKSK2?BAJ7_"8Z?X?\8>#
M[OPX^K!_[.G>[CN$F*C)5MH^1L8XY.2,]:T_$_C^72O$D/AKPYH<_B#79(/M
M+VL<ZP1V\.<;Y)&R%R>@P?U&0#LJ*X[PGX]?7/$%[X=UW1IM!UZSA%PUG).L
MRRPDX\R.1<!AG / QGZXY>Q^-&JZ[J6J:;X7\"7FK7NE7TUO<JE\D42Q(VU9
M/,=0-S$-B/K\IY- 'K-%%% !1110 57O;ZUTZU:YO[B.WA0?,\C!17%>*_BE
MI^C%[72 M_>+P6!_=1GW/<^P_,5Y#K.OZGK]V;C5;IYVS\JDX5/8+T%==+"R
MGK+1&$Z\8Z+4])\1_&&.,O;^&K?S3T^U3@A?^ KU/U./H:\SU76M2UNY\_5;
MR6Y?MO/"_0=!^%4:*]&G2A3^%''*I*>X4445J9A1110 4444 %%%% !1110!
MA?$7_D=)?^O*R_\ 22*N7KJ/B+_R.DO_ %Y67_I)%7+U$?A1VA1115 %%%%
M!1110 4444 203RVTZ36TKPRQG<DD;%64^H(Z5ZAX1^//B'0REOKP_MFS'&Z
M0[9T'L_\7_ N3ZBO*Z*B<(S5I(:;6Q]F>$_B!X=\9P[M%OE,X&7M)ODF3ZKW
M^HR/>NEKX2M[B:TN$GM9I()HSN22-BK*?4$<BO9/ WQ_O=/\NQ\91M?6W"B]
MB4"5!_M+T8>XP?J:X*F$:UAJ:QGW/HFBJ6DZQI^O:='?Z/=Q7EK)]V2)LC/H
M?0^QY%7:X=C0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&FK1."4W-W844459 4444 %%%% !1110 4444 %%%% !1110!RWC#_D9I?\
MKA;_ /HA*PZW/&'_ ",TO_7"W_\ 1"5AU*V.Q;!1113&%%%% !1110 4444
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M1_Y&RQ_WS_Z":QJV?"/_ "-EC_OG_P!!-3/X65'XD>0T444SK"BBB@ HHHH
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M_I)%7+UU'Q%_Y'27_KRLO_22*N7J(_"CM"BBBJ **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6!XI\7Z?X5M4>\+2S
M2'"01D;B.Y^@H\7>*[7PKI)N)<27,F5@@SR[>OT'<_XUX#JFJ7>LZC+?:A*9
M9I#R3T [ #L!6D(<VK(E*Q>\6_;KC6#J%[=_;H;P;[:Z481TS]T#^$KT*]C]
M<G"K5TS4TMX9+'48VN--G.9(U^]$W021YZ,/R8<'U%?5-+DTR=!O6>WF7?;W
M"#Y9D]1Z'L0>0>#7K4:B:Y3@J0:=RE1116YD%%%% !1110 4444 %%%% !11
M10 4444 %;/A'_D;+'_?/_H)K&K9\(_\C98_[Y_]!-3/X65'XD>0T444SK"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KL?A]\1M3\!ZH&A9KC396_TB
MT+<'_:7T;^??L1QU%3**DK,$['V]X?\ $&G>)]%AU31[A9[:8=NJ'NK#L1Z5
MIU\??#OX@WW@/7!-&6FTZ<@75MG[P_O+_M#]>GN/K72=5L]<TFWU+39EGM;A
M-\;J>"/\?;M7D5J+I/R.B,KERBBBL"@HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH ***XGQ]X]B\-VYLM/99=3E7@=1 #_$WO
MZ#\3QUN$)3ERQ)E)15V+XZ^($'AJ%K*PVSZFXX7JL(/\3>_H/Q^OAUY>W.H7
MDEU>S///(<N[G)/^?2F3SRW-P\]Q(TLLC%G=SDL3U)-,KV*5&-):;GG5*CFP
MHHHK8S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#"^(O_(Z2_P#7E9?^
MDD5<O74?$7_D=)?^O*R_])(JY>HC\*.T****H HHHH **** "BBB@ HHHH *
M*** "BBB@ KV#X5?&2;0Y(=$\4S-+IIPD-TQRUOZ!O5??M].GC]%1.$9JTAI
MM'W=%+'/"DL+K)'(H9'4Y# ]"#3Z^9/A)\69O"]U%HOB"9I-%D.V.1N3:,>X
M_P!CU';J.X/TS%+'/"DL+K)&X#*ZG(8'N#7CU:4J<K,WC)-#J***R*"BBB@
MHHHH **** "L ^,](_X3I?"8F)U(VYGP,;1WV9_O;<MCT%2>+_$UKX0\+7FL
MWOS+ G[N,'F1SPJ_B?TS7QT_B75'\5?\)$UT_P#:7VG[3YN?XLYQ].V.F.*Z
MJ&']JFV:TZ?/=GW!16%X-\4VOC'PK9ZQ:;5,RXFB#9,,@X93^/YC![UNUS--
M.S,VK.P4444A!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWD,$!D&6AMMIV[/0$ 9QZ#UH [_PQXR\/>,K%[OPSJL&H11D"01DAX\]-R,
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M34S^%E1^)'D-%%%,ZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9V6[C.2%W'N <#\!0]*FC]0^QK\B;P'X:L-19M1\0H6T_P Z.TACW%3-,[
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MQ"N#@!<C<Q(P!GGFO0M,\<Z/X@\8V&M:?I&IW'C&2T^Q0VP*?9/-*%#(3G<
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M$C\@*Z,/3]I/78RJSY(G*R2/-*\LK%Y'8LS,<EB>I--HHKV3S0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH POB+_ ,CI+_UY67_I
M)%7+UU'Q%_Y'27_KRLO_ $DBKEZB/PH[0HHHJ@"BBB@ HHHH **** "BBB@
MI\$\MM<1SVTKPS1,'CDC8JR,#D$$<@@]Z910!O?\)WXN_P"AIUK_ ,&,O_Q5
M9ESJNH7FI#4;N_NI[X,K"YEF9I,KC:=Q.<C QZ8JI1244MD!/>WUWJ5Y)=ZC
M=37=S)C?-/(7=L# RQY/  I;74+VQ2=+*[GMEN8S%.L,K()4/56P>1['BJ]%
M%D!)!<36MPD]K+)#-&VY)(V*LI]01R#5G4M9U/69$DU?4;N_=!A&NIVE*CT!
M8G%4J*++< HHHI@>Y?L^^.?)N)/"6HR_NY29K L?NMU>,?7[P^C>M>_U\*V-
M[<:=?P7ME*T-Q;R+)%(O56!R#7V;X+\3P>+_  C8ZQ!M5IDQ-&#_ *N0<,OY
MYQZC![UYF*I\LN==3:$KJQNU'<-*EO(UO&)954E(V;:&;' SSCZU)17$:'@-
M_P##SXOW^HW%V_B!(C/(7\N+49%1,GH !P!4'_"L?B[_ -#(?_!I+_A7T+17
M5]9GV7W&OM7V/GK_ (5C\7?^AD/_ (-)?\*/^%8_%W_H9#_X-)?\*^A:*/K4
M^R^X/:L^>O\ A6/Q=_Z&0_\ @TE_PH_X5C\7?^AD/_@TE_PKZ%HH^M3[+[@]
MJSP&Q^'?Q?L=0@NE\0)*89%<)+J,C*V#G!!'(KWJV:9[6)KJ-8IV0&1$;<JM
MCD X&1GOBI**RJ574W1,I.6X4445D0%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 445#>7<5A8SW=RVV*"-I'/H ,F@#R?XQ:_YU[;:' _R0#SIP/[Y'RC\!D_\
M"%>8U;U;49=7U>ZU"X_UEQ*9",YQD\#\!Q^%5*]VE#D@HGESES2;"BBBM" H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y;QA_P C
M-+_UPM__ $0E8=;GC#_D9I?^N%O_ .B$K#J5L=BV"BBBF,**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *ZCX<^*#X1\=Z?J3.5MB_DW7H8
MFX)/TX;_ ("*Y>G(CRR*D:L[L<*JC))],4I)25F&Q]W(P=%9>0PR*6N#^$/B
M"75_ ]O8ZC\FIZ8BP7$3D;PO(C9AU!('?DD$UWE>%*+C)IG2G=!1114C"BBB
M@ HHHH **** ,[4$NXYA/:L=N/F4=OPK-FM8M<T^9&C8F:2,SM'<-'\JG.00
M>.G3O6AJ.K"TU6PT\Q%_MQ==^?N8&>G>C3-.-D+A"@4,>-O0UY+HU\/CH3IM
M\D[W71?Y:FL*T)PE'[4;?YGG4_B/7O$.IW&E^$K=;.V5SN, "L03@NS=L^W-
M>EZ-92Z=HMK:7$QGEBC"O(3G<>]<#X:TF[\#17>JW]M\UY<);I#O&<,_WB?Z
M5Z77T%=KX8['S^5PG)RJUY-U'T?17=K+SL%%%%<I[84444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1THKG/'FMG0O"%W<1OM
MGE'D0D'!W-W'N!D_A32N[ >/^/\ 7O[>\6W$D3;K:W_<0X/!"]3^)R?IBN9H
MHKL2LK'/N%%%%, HHHH **** "BBB@ HHHH *Z"VEB\26L>GWTBQ:G$H2SNG
M.!,!TB<_^@M^!XQCGZ*:;3NA-)JS">"6VN)(+B-HI8V*NCC!4CJ"*971)(GB
MBW2UN65-9B4);SN<"[4=(W/]_LK'KT/8US\D;Q2-'*C(Z$JRL,%2.H(KNIU%
M-').#BQM%%%:$!1110 4444 %;/A'_D;+'_?/_H)K&K9\(_\C98_[Y_]!-3/
MX65'XD>0T444SK"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KV[]G;Q7Y&HWOABZ?Y+@&YM0?[X&'4?5<'_@)KQ&M#0=8GT#Q!8Z
MM:?ZVSF64#.-P!Y7Z$9'XUG5ASP<1Q=G<^X:*K:=?P:IIEM?V;[[>YB66-L=
M589!_6K->&=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "N#^+>L&P\*)8Q-B6_DV'UV+RWZ[1^-=Y7A/Q7U4ZAXS>V1LQ6,:Q
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MT444SK"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ^G?V?\ Q%_:O@.32YGW3Z5,4 [^4_S*3^.\?1:]4KY:^ VO'2?B/'92
M/B#4X6@8$X&\#<I_0C_@5?4M>/B8<M1^9O!W04445SEA1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5E^)=7&A>&[W43C=#$=@/0N>%'YD5J5Y?\ &;5_+L['2(VYE8SR
M@>@X4?0DG_OFM:,.>:B14ERQ;/)'=I9&DD8L[$EF)Y)/>DHHKW#RPHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,+XB_\CI+
M_P!>5E_Z215R]=1\1?\ D=)?^O*R_P#22*N7J(_"CM"BBBJ **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /H+]G/Q*9].U#PY.^6M
MF^U6X)_@8@.![!L'_@=>WU\=_##Q!_PC7Q&TJ]=ML$DOV>?)P-C_ "Y/L"0W
M_ :^Q*\G%0Y:E^YO!W04445REA1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% #)YDMK>2>4[8XT+L?0 9-?+M_=OJ&I7-Y+R]Q*TK?5C
MG^M>_P#Q#U Z=X#U)U.'E00+[[R%/Z$U\\UZ6#CHY'%B7JD%%%%=YRA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <MXP_Y&
M:7_KA;_^B$K#K<\8?\C-+_UPM_\ T0E8=2MCL6P4444QA1110 4444 %%%%
M!1110 4458M+"ZOV9;.WDEV#+E1P@]6/0#W/% %>BM(V%C9_\A"^65Q_RPLL
M2'/H9/NCZKO^E+_;'V;C2;2*SQTF/[R;V.\_=/N@6E?L!'%HUTT*SW.RSMV&
M5EN6V!AZJOWG'^Z#4F[2+/[B2ZE*.\F8H?R!WL/?*'VK/EEDGE:29VDD8Y9W
M.23[FF46?4"[<ZO=W,)@#K!;GK!;J(XSCID#[Q]VR?>J5%%/8 HHHH ****
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M10 4444 %%%% !1110 4444 %%%% '(_$^^^Q> [Q0VU[ADA7WRP)'_?(->
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M>2DK#&"W))Z#OZ>@K/\ ^$JOD\&_\(U;Q6]O9//]HN)(E82W+#[H<DX('&
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M POB+_R.DO\ UY67_I)%7+UU'Q%_Y'27_KRLO_22*N7J(_"CM"BBBJ ****
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M3--=3232M]YY&+,?J37J,WPX\,R_\>]WJUK_ +YCG_D$JA-\*[1O^//Q(/\
MMZL6C_\ 0&>G[.2^RQ^T@^IYS17<3?"K5E&;75-)NO0+.\9_\B(HJC-\-/%<
M0RNF+<#M]FNH9B?P1B:EZ;E)I['*T5KW?A/Q%8+NO=!U.!?[TEI(H_,C%9+*
MR,5=2K#J",$4DT]AB4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$8].AP.@PCXN\7R>$&\5_P#"Q_#L5[]F^VKX=6& Q!=NX0F0MYF_''7KQ[T
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MTA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!U:>U= /S%9E6FGL 4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2A$0= !T%244-MBA2A!WB@HHHI&H4444 %%%% !1110 4444 %%%% !1110
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M'AF__M;23I<O-Y9*9+4]Y(NKQ_5>6'MN]JGK%73Y9;HQE&ST"BBBJ("BBB@
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M.>'48N2EL:1KR;M8]GB4)"BJ,!5  ]*=117RIZ@4444 %%%% !1110 4444
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MN*$>5<V3%[.Z3S8'/]WNI]U.5/N*X)1]G*W1[?Y?U^A,U?WBM11109!1110
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M_:.I6)-T0%DDBE:/S5'9MI&:=:?#_P -6,=NEIIPB2VO?MT*K*^$FP!N'/3
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M')*3D[L****LD*VI_P#0O!-M%TDU*Z:=N?\ EG$-B_@6:3_OFL9068*H)).
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MHBE5C6@IPV84445!J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,XDO=2=HM-MB/.=?O2$](T]6;]!DG@52U?5)-7OS.\:PQJHC@@3[L,8Z*/\
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MOOV]!:***Y38**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ#]3S=%K[C"BBBJ$%%%% !1110 445H:'81ZAJL<=RQ2UC#37+C^&)!N8_7
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ML%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM[H/AK['J4:QS>>SX5PPP0.X^E>HJL8X%13][FOYGANA.69N<H^ZXVOT]#S
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MF%M(><_+$H3(^I4G\:D\+8@U634GV[=-@>Z&[IO Q&/^_C)6'77A(WFY=A]
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MJI5,7MR:OJ[+7Y!3PN_/HNFNWS.$T;P1J\_B:+7O%^IQW=Q;@>3#!D*I[9X
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M/"QM23[Z_P!?(<M[!111742%%%% !1110 4444 %%%% !1110 4444 %%%%
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MVK9KP\9CG5]RG\/YG?1PZA[TMPHHHKRSK"BBB@ HHHH **** "BBB@ HHHH
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M:T_$SK:O:Z+$05TY")B.=UPV#)S[85/^ 5M1ASS2(G+EC<PJ***]8XPHHHH
M**** "BBB@#<\-<IK*_WM+F_0J?Z5@UN^&#_ *1J0_O:9<_^BR?Z5A5W8/[0
MWL@HHHKO)"BBB@ HHHH **** "M/P_K!T75DN&0RV[J8KF$''F1GJ/KW![$"
MLRBIE%23BQ['H=[;+;7&(I!+!(HDAE'21#R#_GH<BJ]5/"E__:6GMHDYS<0[
MI;$D]>[Q?C]X>X([U;K@5TW&6Z_JYE.-GH%%%%40%6=/T^YU.\2ULXR\C?DH
M]3Z"K&C:'>:Y=^3:)\@_UDI^Z@_Q]J]6T70K30[,0VJ9=L>9*1\SG_/:N#%8
MR-!66LCHHT74=WL0^'O#MMH-GMCQ)<./WLI')]AZ"MBBBOFISE4DY2>IZL8J
M*L@HHHJ!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:L 8Z45\[B,54KOWMNQZ=.E&FM HHHKE-0HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_JVKD?V;IUS<*3C>D9VCZMT%=AI7P=U^\*MJ,MOIZ9PP9O,<?@.#_P!]5[F
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MJ<HJ[&I)NR-6BBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-_$_GPXWHAPD^.F\=\5U2J%4*HP , #M1*<4O<W8*,F_>Z'G%QO/QMU+RO\
M6?V'\N/7)Q7.?#*W\82>&93X?U'1X5^U2^>EQ S2B3=SN(->JCPY9#Q4?$"^
M8+QK?[.WS?*5SD<>M9.H_#G2+S5)-1LI[W2KN8YEDL)S'YA]2.AJU5C;E]/P
M)=-WOZE$V'Q+=2IUC0UR,9%J^1^M;G@WPV?"^@?8I;DW4\DSW$\VW;OD<Y)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#+USPUI'B.W
M6'6;*.Y"_=8Y#+]&'(KQSQ-XT\8>#M=FT6"\6"TML+:*;=#^YZ)R1D\#&?4&
MO=ZR=>\,:1XEMEAUFS6<(<H^2KI]&'/X5I":3][5'!B\-*K&]%\LN^U_4\*C
M^*_C2:5(XM15G=@JJ+6/))[?=KV7P]X.T[3VCU6]L8GUN=5ENKAOF_?'ERH/
M"_,3T I=$^'_ (;\/W?VK3].7SQ]V29C(4]UST/N.:Z6G.:?PJQGA,)5A[V(
MES/IUM]X5A1^#-$B\92^*H[5AJ\T?EO/YKX*[0N-N=O11VK=HK(],I1Z18Q-
M?M%;HC:@VZZ91@R'8$Y/^Z!^OK7,CX3>#AX9/A\:;)_9K7?VTQ?:9,^;LV;M
MV[/W>V<5V=% '#Z1\'?!6AZO;:GINER17=K()(G-U*VUAWP6P:VO#G@K0O"=
MU?W&A6C6\NHN'N2TSOO(+$?>)Q]X]/6MZB@#G+/P#X<T_P 376O65AY%]>*R
MW&R5A'*&^]NCSM.>O3KS7,ZO\!?!&K:@;M;:ZL&9BSQV<VV-C_ND''T&*])H
MH Y,_#+PJ8]%C.GOMT-B]@/M$G[HEP_//S?, ><UH>*?!VA^,[&&T\16?VJ*
M&3S(\2,A5L8ZJ0:W** (+*TBT^P@L[??Y4$8C3>Y9MH&!DGD_C4]%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>rprx-20211231_g2.jpg
<TEXT>
begin 644 rprx-20211231_g2.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ,_!F0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[Z@A6[=$ANK:>0E@H+JV 0"-ZE0WW0#]CZ*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW-GLNM0NL#%_?1,!OC$:)' &SPKEL$*B>2_%[]H!OB[_ ,%';?X8>,!J]_\
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M"]WXONWCM+07 N[2S6,QWD=W-<2^=*@S)(C_ "INP9.>!D@'PIH?P;TG7/\
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MUXC_ ,$H--MM&_;N^*FGV4*V]G::%JL$$*YPD:ZI9JJCZ  5];_L"^!?C9\
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M3]H3X%>,/ ER(UFU2R;[%-(,B"[3YX)/H)%7..J[AWKU"B@#\=/^"5_[33_
MZ_\ B3\-/%,%QE89M6TS2F(6:34H<12V4:D_ZV;$8 ]8CGK7ZM_"7P;<^!?
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M . !2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG_L$ZE_Z<;:NRI@Z<)5HIOW$K?/Y&:J-J/F?IU=7"V=M+/()&2)"["*-I'(
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M=:G]G=!S-2Y7U/T#HKP_5/VNO"4=YXJ3P_I&O^-K+PJF_7-3\/6T,EK8@9+
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MEC4DCFM*^%<*LH4U=)V)C.\4V>]T445PFH4444 %%%% !1110 4444 %%%%
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M89Z5<L-6@G*479"4XO9GN5%%%<Q84444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAAM\Q8P^..#M^FOA!^R[X:^#\MC+!KGBCQ3+IRLFG?\ "3:LUW'IX8%6^SQ
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M[?&K_P *_P#^TUO[.E_/^#(O+L?1U%?./_#%W_5=OC5_X5__ -IH_P"&+O\
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M*_\ ^TT>SI?S_@PO+L?1U%?./_#%W_5=OC5_X5__ -IH_P"&+O\ JNWQJ_\
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M +31[.E_/^#"\NQ]'45\X_\ #%W_ %7;XU?^%?\ _::/^&+O^J[?&K_PK_\
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M2#:"-L1V+M4YR1W(%3*%-*\97?H--]4>@4445@4%%%% !1110 4444 %%%%
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M /[31_PQ=_U7;XU?^%?_ /::/9TOY_P87EV/HZBOG'_AB[_JNWQJ_P#"O_\
MM-'_  Q=_P!5V^-7_A7_ /VFCV=+^?\ !A>78^CJ*^<?^&+O^J[?&K_PK_\
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M_A7_ /VFCV=+^?\ !A>78^CJ*^<?^&+O^J[?&K_PK_\ [31_PQ=_U7;XU?\
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M7EV/HZBOG'_AB[_JNWQJ_P#"O_\ M-'_  Q=_P!5V^-7_A7_ /VFCV=+^?\
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M%_M"X_YZ?^.C_"C^T+C_ )Z?^.C_  H VJ*Q?[0N/^>G_CH_PH_M"X_YZ?\
MCH_PH VJ*Q?[0N/^>G_CH_PH_M"X_P">G_CH_P * -JBL7^T+C_GI_XZ/\*/
M[0N/^>G_ (Z/\* -JBL7^T+C_GI_XZ/\*/[0N/\ GI_XZ/\ "@#:HK%_M"X_
MYZ?^.C_"C^T+C_GI_P".C_"@#:HK%_M"X_YZ?^.C_"C^T+C_ )Z?^.C_  H
MVJ*Q?[0N/^>G_CH_PH_M"X_YZ?\ CH_PH VJ*Q?[0N/^>G_CH_PH_M"X_P">
MG_CH_P * -JBL7^T+C_GI_XZ/\*/[0N/^>G_ (Z/\* -JBL7^T+C_GI_XZ/\
M*/[0N/\ GI_XZ/\ "@#:HK%_M"X_YZ?^.C_"C^T+C_GI_P".C_"@#:HK%_M"
MX_YZ?^.C_"C^T+C_ )Z?^.C_  H VJ*Q?[0N/^>G_CH_PH_M"X_YZ?\ CH_P
MH VJ*Q?[0N/^>G_CH_PH_M"X_P">G_CH_P * -JBL7^T+C_GI_XZ/\*/[0N/
M^>G_ (Z/\* -JBL7^T+C_GI_XZ/\*/[0N/\ GI_XZ/\ "@#:HK%_M"X_YZ?^
M.C_"C^T+C_GI_P".C_"@#:HK%_M"X_YZ?^.C_"C^T+C_ )Z?^.C_  H VJ*Q
M?[0N/^>G_CH_PH_M"X_YZ?\ CH_PH VJ*Q?[0N/^>G_CH_PH_M"X_P">G_CH
M_P * -JBL7^T+C_GI_XZ/\*/[0N/^>G_ (Z/\* -JBL7^T+C_GI_XZ/\*/[0
MN/\ GI_XZ/\ "@#:HK%_M"X_YZ?^.C_"C^T+C_GI_P".C_"@#:HJ.!B\,;'D
ME03^524 %%%% !17FOCOQAJ^C?&;X7Z%9W?DZ5K7]J?;[?RT;SO)ME>+YB"R
MX8D_*1GOFO2JIJUGW%<****D8445B_VA<?\ /3_QT?X4 ;5%8O\ :%Q_ST_\
M='^%']H7'_/3_P ='^% &U16+_:%Q_ST_P#'1_A1_:%Q_P ]/_'1_A0!M45B
M_P!H7'_/3_QT?X4?VA<?\]/_ !T?X4 ;5%8O]H7'_/3_ ,='^%']H7'_ #T_
M\='^% &U16+_ &A<?\]/_'1_A1_:%Q_ST_\ '1_A0!M45B_VA<?\]/\ QT?X
M4?VA<?\ /3_QT?X4 ;5%8O\ :%Q_ST_\='^%']H7'_/3_P ='^% &U16+_:%
MQ_ST_P#'1_A1_:%Q_P ]/_'1_A0!M45B_P!H7'_/3_QT?X4?VA<?\]/_ !T?
MX4 ;5%8O]H7'_/3_ ,='^%']H7'_ #T_\='^% &U16+_ &A<?\]/_'1_A1_:
M%Q_ST_\ '1_A0!M45B_VA<?\]/\ QT?X4?VA<?\ /3_QT?X4 ;5%8O\ :%Q_
MST_\='^%']H7'_/3_P ='^% &U16+_:%Q_ST_P#'1_A1_:%Q_P ]/_'1_A0!
MM45B_P!H7'_/3_QT?X4?VA<?\]/_ !T?X4 ;5%8O]H7'_/3_ ,='^%']H7'_
M #T_\='^% &U16+_ &A<?\]/_'1_A1_:%Q_ST_\ '1_A0!M45B_VA<?\]/\
MQT?X4?VA<?\ /3_QT?X4 ;5%8O\ :%Q_ST_\='^%']H7'_/3_P ='^% &U16
M+_:%Q_ST_P#'1_A1_:%Q_P ]/_'1_A0!M45B_P!H7'_/3_QT?X4?VA<?\]/_
M !T?X4 ;5%8O]H7'_/3_ ,='^%']H7'_ #T_\='^% &U16+_ &A<?\]/_'1_
MA1_:%Q_ST_\ '1_A0!M45B_VA<?\]/\ QT?X4?VA<?\ /3_QT?X4 ;5%8O\
M:%Q_ST_\='^%']H7'_/3_P ='^% &U16+_:%Q_ST_P#'1_A1_:%Q_P ]/_'1
M_A0!M45B_P!H7'_/3_QT?X4?VA<?\]/_ !T?X4 ;5%8O]H7'_/3_ ,='^%']
MH7'_ #T_\='^% &U16+_ &A<?\]/_'1_A1_:%Q_ST_\ '1_A0!M45B_VA<?\
M]/\ QT?X4?VA<?\ /3_QT?X4 ;5%8O\ :%Q_ST_\='^%']H7'_/3_P ='^%
M&U16+_:%Q_ST_P#'1_A1_:%Q_P ]/_'1_A0!M45B_P!H7'_/3_QT?X4?VA<?
M\]/_ !T?X4 ;5%8O]H7'_/3_ ,='^%']H7'_ #T_\='^% &U16+_ &A<?\]/
M_'1_A1_:%Q_ST_\ '1_A0!M45B_VA<?\]/\ QT?X4?VA<?\ /3_QT?X4 ;5%
M8O\ :%Q_ST_\='^%']H7'_/3_P ='^% &U16+_:%Q_ST_P#'1_A1_:%Q_P ]
M/_'1_A0!M45B_P!H7'_/3_QT?X4?VA<?\]/_ !T?X4 ;5%8O]H7'_/3_ ,='
M^%']H7'_ #T_\='^% &U16+_ &A<?\]/_'1_A1_:%Q_ST_\ '1_A0!M45B_V
MA<?\]/\ QT?X4?VA<?\ /3_QT?X4 ;5%8O\ :%Q_ST_\='^%']H7'_/3_P =
M'^% &U16+_:%Q_ST_P#'1_A1_:%Q_P ]/_'1_A0!M45B_P!H7'_/3_QT?X4?
MVA<?\]/_ !T?X4 ;5%8O]H7'_/3_ ,='^%']H7'_ #T_\='^% &U16+_ &A<
M?\]/_'1_A1_:%Q_ST_\ '1_A0!M45B_VA<?\]/\ QT?X5M4 %%%% !1110!B
MZA_Q^2?A_(56JSJ'_'Y)^'\A5:@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** -ZV_X]XO\ <'\JEJ*V_P"/
M>+_<'\JEH **** .4\1?$"W\.^//"'A>2TEFG\1_;/*N%8!8?L\0D;<.IR#@
M8KJZY3Q%H7AO4/'GA#4M3O(X?$.G_;/[(MVN5C:;S(@L^V,G,FU "<?=ZUU=
M4[65A!1114C"N<KHZYR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "NCKG*Z.@ HHHH **** ,74/^/R3\
M/Y"JU6=0_P"/R3\/Y"JU !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ;UM_Q[Q?[@_E4M16W_'O%_N#^52T
M %%%% ' ^,? .H>(?BM\//$UM-;)8>'?[1^UQRLPE?[1 L:>6 I!P1SDCCIF
MN^KS7QWK&N6?QF^%]A837*:->_VI_:4<2DQ/LME:+S#CC#9Q[UZ55RO97_K4
ME;L****@H*YRNCKG* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *Z.N<KHZ "BBB@ HHHH Q=0_P"/R3\/
MY"JU6=0_X_)/P_D*K4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!O6W_'O%_N#^52U%;?\>\7^X/Y5+0 4
M444 <;XH^(?_  C?Q$\$^%O[/^T?\))]M_TOSMOV?[/")/N;3OW9QU&.O-=E
M7*>(K3PK-X\\(3ZLT8\3P_;/[##2NK',0%QM4':WR8SN!QVQ75U3M96$NH44
M45(PKG*Z.N<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /EOXC?M?:GJ'[1%I\#/A1I.GZSXR5&FUC6M::3^SM(C5 [!HXRKS.%
M*Y"NH#,JYR6VTOC5^U'X[_9)USPO=_%*RT'Q3X UV[^PR>(/"]C<:?/ILVW=
MB2VEGN/-4@.PV."0C<9 #?-7[&6EW?@7_@J-\9-*\2*8M5U"#6'M6F',WFWT
M%S&ZY_O0!FX[$^]>L?\ !8O4K*#]F;0+&8+)?77B>W-M'QN&RWN=[@>@#;>/
M[X]: /I+X]?M-^#?@%\(9/'VJW\%]:W%N)-'LX)@)-5D=0T21'G@@@E\$*N6
M(.,'Q[_@H-^U5\0/V3]%\*ZYX1M_#6I6&K7$EE-9ZU87$DJ2*I<2+)'<1C:1
MQM*9!&=QS@?(G[?7P]F\%_L8_LXQZ[IL,/BRSLX;"YN)(%%U%&+;>+9G^]M0
MMC;G&037I7_!7OPAH7@7X(?#71_#>B:=X>TB'6[EHK#2K2.V@0M"68K&@"@D
MDDX')- 'Z745^;'AG23\&/\ @K5H_AGP]J6J/IOB31G?6#J%_+<R7TGV"XF,
MDC.QR?,A5L?=7)"A1@#F?"MUXP_:Z_:$_:1T&[TG0-:\1:8)](\-S>)-7FL3
MX7CBGGA2XLXX[68F99%@=W!B;(QN_>' !^IM%?EE_P %*/"^M:/^Q[\'/^$V
MOM)\1^.]+U0Z5>Z_IS&<3!89E=1,R*YR8H]X(&70Y&17TGK7[&+V'@'QMXI\
M >*-?C^*GBKP@FD/J&H:HY@FD)CD=U&,PN^S8-K!(PWR*HS0!]=45^?_ .P;
M\1]&D^+$7@'Q9X!NOAC\6O#.A7.G/IMDAATS4X'DMGENC!R%N6^SPDR@D2J2
MVYAL"_H!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!71USE='0 4444 %%%% &+J'_'Y)^'\A5:K.H?\ 'Y)^'\A5:@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@G!'?:G\);/Q!\+[?P/K6N:UJMI']FWZHT\=M?R^1.DT>9+>.,(<QJNZ-5;
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M\VX9B&A^SPK(NT=#DG!S7<5RGB*[\*P^//"$&K+&?$\WVS^PRT3LPQ$#<;6
MVK\F,[B,]LUU=4]D)=0HHHJ1A7.5T=<Y0 4444 %%%% !1110 4444 %%%%
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MU#PMH=WIR:PUO&9/L9M;SSU=P.0CJQ7/0,F,Y89 /?/CI\#M>^%_P'\0^*O
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M+B^62LSJO?5!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1K8V?G<_O?)V;-_)^;&>364W[,?P=>UCM6^$W@=K:-VE2$^&[,HKL%#,%\O
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M6O)=>\27_B2Z\Z]FW!?N1)Q'&/11_DUFR2/-(SR,SNQRS,<DGU)IM !1110
M4444 %%%% !1110 4444 %%%% !7&_'[_DV?XJ_]@N#_ -*X:[*N-^/W_)L_
MQ5_[!<'_ *5PUT8?^-#U7YDR^%GY4T445^AGDA1110 4444 %%%% !1110 4
M444 %7-(UB_\/ZG;:EI=[<:=J%LXD@NK65HI8F'1E92"#[BJ=%(#]%_V7_\
M@I%!J"VGAGXNR+;W&%BM_%44?RN<X ND'0_]-%&/[P'+5][03Q75O#<6\T=S
M;3HLL4\+AXY$(RK*PX(((((K^?*OI/\ 97_;7\2?L]7*:/J2S>)/ TKYDTMY
M/WMH2>9+9CPI[E#\K<_=)W5\_C,K4KSH:/M_D==.M;21^OM%<_X!^('A_P"*
M7A&P\3>%]2CU31KU<QS)PR,/O1R+U1UZ%3S705\LTXNSW.T****0!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% &];?\>\7^X/Y5+45M_Q[Q?[@_E4M !1110!P/C'Q]J'A[XK?
M#SPS;0VSV'B+^T?M<DJL94^SP+(GED, ,D\Y!XZ8KOJY3Q%KOAO3_'GA#3=3
MLXYO$.H?;/[(N&ME=H?+B#3[9",Q[D(!Q][I75U3V6@EU"BBBI&%<Y71USE
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M[V33M1TW4(A%=V%U']^*5 2 1GJI*GL3@UZ%7S5^Q/\ L_>(O@SI_P 0M?\
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MP_\ I%<5^=-?:97_ +LO5GG5OC"BBBO7, HHHH **** "BBB@ HHHH ****
M"BBB@ KZ9_9!_;,U;]GO4DT+6C/J_@"ZEW368.Z6P=CS-!D_BT? ;KP>:^9J
M*QJTH5H.$U=%1DXNZ/W\\+^*-(\;>'K'7= U&WU;1[Z/S+>\MFW(Z_S!!X*G
M!!!! (K4K\:/V4_VKM>_9O\ %B*SS:GX+OI1_:FC%LC!X\Z'/W95'X,!@]BO
M[!^%O%.D^-_#FG:_H-]'J6CZA")[6ZA/RNI_D0<@@\@@@\BOBL9@Y867>+V9
MZ-.HIKS-2BBBO/-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "NCKG*Z.@ HHHH **** ,74/\ C\D_
M#^0JM5G4/^/R3\/Y"JU !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %.1#(P51DFFUQ?Q&\7?V7;OI%E)B[E&+F1?\ EFI_
M@'N>_M]: ,CXA>-A?,^DZ=)_H:'$\RG_ %S#L/\ 9'ZUP5%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %<;\?O\ DV?XJ_\ 8+@_]*X:[*N-
M^/W_ ";/\5?^P7!_Z5PUT8?^-#U7YDR^%GY4T445^AGDA1110 4444 %%%%
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MB@ HHHH **** "BBB@ HHHH **** -ZV_P"/>+_<'\JEJ*V_X]XO]P?RJ6@
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M_C\D_#^0JM0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAY]NL<>T=_F!SZ5Z)5/9:B74****D85SE='7.4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5ROQ!\5?V!I_V&V?&H72?,
MP/,,9[_4]O;\*Z'5-4@T/3;C4+GF*$<)W=C]U1]3^F:\*U/4I]7U">\N7WSS
M-N8]OH/8=* *M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU6=0_P"/R3\/Y"JU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5P7Q4\1>1#'HD#_.V);H@_BJ?^S'\*[;4=2BT73KG4)^8[=-V
MW^\W15_$XKP6^O)M1O)KJ=]\TSEW;U).: (**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "N-^/W_)L_Q5_P"P7!_Z5PUV5<;\?O\
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M@ HHHH *XWX_?\FS_%7_ +!<'_I7#795QOQ^_P"39_BK_P!@N#_TKAKHP_\
M&AZK\R9?"S\J:***_0SR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH [SX%_%>^^"7Q6\.^,;'>_]GW(-S I_X^+=OEFB/;YD+ 9Z
M'![5^YFFZE9ZUIMEJ6G3K=:=?01W5K<)]V2)U#(P]BI!K^?>OU7_ .":WQ@;
MQY\%[KPE?3^9JGA*<11;C\S64I9HOKM<2+[#97SV;4.:"K+IOZ'50E9\I]<T
M445\J=P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:5_NHB@EF/L #0!^;'_!4OXK?VOX[\._#VTF_P!'T.W^WWZ*>MU.!Y:M[K$
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M='7.5T= !1110 4444 8NH?\?DGX?R%5JLZA_P ?DGX?R%5J "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** ([J]73+*ZO7^[;1-+@]R!P/
MQ.*^?9)&FD9W.YV)8L>Y->P?$F^^Q>$98P<-=S)#_P !'S'^0_.O': "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XWX_?
M\FS_ !5_[!<'_I7#795QOQ^_Y-G^*O\ V"X/_2N&NC#_ ,:'JOS)E\+/RIHH
MHK]#/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH _3G_@EG\0/[:^%?BCP?-+NGT/45O(%;KY%PN"!["2)R?^NE?:]?D[_P
M32\:_P#",_M)0Z1))L@\1:9<V&UON^8BB=#]?W+ ?[WO7ZQ5\3F5/V>);[ZG
MHT97@%%%%>4;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD7!%?,U*4Z,N6HK,[(R4E=$%%%%9%!1110 4444 %%%% 'AO[>W_ ":_H_\
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M** ,74/^/R3\/Y"JU6=0_P"/R3\/Y"JU !1110 4444 %%%% !1110 4444
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MSC?&64G.#Q7RF)P-7#:M77<[H5(S-.BE8%201@C@@TE>>:GAO[>W_)K^C_\
M8XP_^D5Q7YTU^BW[>W_)K^C_ /8XP_\ I%<5^=-?:97_ +LO5GG5OC"BBBO7
M, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *5':-
ME92593D$=0:2B@#^@'P]K0\2>'=(UA<%=1LH+P8Z8DC5_P#V:K]>??L[ZE_:
MW[/WPSNL[F;PUIZ,?5EMT4_JIKT&OS><>6;CV/76J"BBBH&%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !71USE='0 4444 %%%%
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M]C@'X?:H<_I7XNU];D_\&7K^B.'$?$@HHHKWCE"BBB@ HHHH **** "BBB@
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M5G=D59*4KH****](Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH _:_]CV8W'[+OPU<G/_$JV?\ ?,LB_P!*]AKQ/]BG=_PR
ME\.-W7[%-^7VF;'Z5[97YYB/XT_5_F>K#X4%%%%<Y84444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %='7.5T= !1110 4444 8NH?\
M?DGX?R%5JLZA_P ?DGX?R%5J "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *=&GF;D_O(R_F#3:FM#BZB_WL4 ?.-%27,)M[B6(]4<J?P.*CH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **EM;6:^G2&WB
M>>9SA8XU+,?P%7-7.A^"5W>)=1Q=CD:1IY$MR>GWSG;'USR<XZ"MJ-&IB)JG
M2BV_(SG4C37--V15L[&XU&X6"U@DN)FZ1QJ6-6-8N/#_ ('S_P )#J'VB_7_
M )@^FL))@?21_NQ_3DXZ5P/B3XT:OJ5N]CHT4?AK2VX:&Q8F:0<?ZR;[S=^F
MT8."#7GU?<8'AENT\9*WDOU?^7WGA8C-5\-%?-_Y'JB?$#7_ (CZI%X=T;R?
M"^C3$F9+5BH2%02\D\Q^9@JYSD@'TK\_/VK/C=!\9/B&D6B,\?@GP_$=.T*!
M@R[H@<O<,#_'*^7/ .-@/*U]!_M2_$H_!OX4Q^"]/E\KQAXTMA-J;*"'LM))
M.V'/9YV'(Y^12"!N!KX3KMG&CS\M"*4(Z*W5]7Y]E\^Y5&,^7GJ.\G^78***
M*#<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ K]4?\ @EM"8_V<]=<C'F>*;C'T%I:#^>:_*ZOUO_X)MZ?]A_9;L)<8^V:M
M>W'UP5C_ /:=>-FKMAOFCHH?&?4-%%%?&GH!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ;UM_Q[Q?[@_E4M16W_ ![Q?[@_
ME4M !1110!RGB+7?#>G^//"&FZG9QS>(=0^V?V1<-;*[0^7$&GVR$9CW(0#C
M[W2NKKE/$7P_M_$7CSPAXHDNY89_#GVSRK=5!6;[1$(VW'J, 9&*ZNJ=K*P@
MHHHJ1A7.5T=<Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!XU^V5#]H_99^)*8SC35?_ +YFC/\ 2OQ4K]ROVDM-_M;]G?XFV^-Q_P"$
M<OY0/4I"SC]5K\-:^LR=_NI+S_0X<1\2"BBBO?.4**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9XJM_LOB;58L8"W4F/IN./TK*KJOB;;^1XRO' PLRQRC\4&?U!KE: "BBB@
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M=,T2RLY!C'SI BL3[Y!KY_.)6IQCW?\ 7YG5AUJV=31117RAW!1110 4444
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M./H<>(Z,Y"BBBOICC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN4@LVU0"-I&.^:ZNJ=K*PEU"BBBI&%<Y71USE !1110 4444 %%%% !1110
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MS?E;[]#6FKS1^A=%%%?!'IA1110 4444 %%%% !1110 4444 %%%% !1110
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M>+YB"RX8D_*1GOFO2JN5[*_]:DK=A1114%!7.5T=<Y0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5\]?M\?#_P#X3_\ 9A\3&./S+S07
MBUN#CH(B5F/MB&24_A7T+5;4]*M->TN]TN_C\ZPO[>2TN8_[\4BE''X@FM:-
M1TJD9KHR9+F31_/Q172?$CP3>?#;Q_XB\*WX/VK1[^:R=B,;]CD!Q[, &'L1
M7-U^B)J2NCR0HHHJ@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M444 %%%% &+J'_'Y)^'\A5:K.H?\?DGX?R%5J "BBB@ HHHH **** "BBB@
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MB@ KW?\ 8E^$Y^+G[1/AJSFA\W2=)D_MG4,C*^3 0RJ?9Y#&GT<UX17ZD_\
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M "/.K1Y97[A1117K& 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM!NDDM=)E%YXCNK=P5N=2Q@09'5(!QC.-Y;(!2ODFOCJU;ZU5=7IM'T[_/\
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MV;$X6V0G]\P(&))3\[<9Y523M!KPLRKZ?5H]=_3M\_RN>I@J/-+VLMEMZ_\
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M4%!7.5T=<Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3Y%=[A1117E&XR>:.VADFE<1Q1J7=FZ  9)KR1OVN_@PK$'XD:""#@_Z3_\
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M[IIQ>06DFYH#N*_,.W((_"NN)V@D\"OSS_X)K?\ );/C-_UU_P#;F2OT,(W
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M /)/V8OVFM!_:F^(GA7Q1I2K9:G#X1U"VU?22^Y[*Y%W8DKGNC?>1NX/."&
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MF^%]_80W+Z-9?VI_:4D3$1)OME6+S!GG+9Q[UZ55RV0EU"BBBH&%<Y71USE
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M@ HHHH **** "BO"?VK_ -K3P_\ LL^%]/GO+"?Q#XHUJ1K?1O#]FP62[D&
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M VL_$WQ.2WUWQ"A$L&A(PEL;1NQE/29Q_=^X/]O@CZ1^"?[/_@G]G_0O[/\
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M!!J1DNE(/&0KQL<]0R\\<?J17$_%[X+^#?COX0E\,^-]$AUO2F<2HLA9)(9
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M\$[KX4IXV\;CP9<:HNKO:FXT\R>>%"\2?8]VTX4X]5'N" ?-_P#P40V>+/\
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M>)J7[=GP-^!C:3:V?PGAT\W[^&+>!8M/O)"MT0)(% 1XT,"!4((!W_WC5O\
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MXE_D*.%5.K[2.WGT]#Y>_P""B1QXJ^"G_8P#^:5S_P"U!^SKXX^$?Q(3XJ_
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M7V5]_P -#:K1=6,8-V2W/SX_:$^%O[3WQM\+VZ>+/!WAX1:*6O()]+DC2XC
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M'I_ZAB_^A-7QI^T]XD\8?MA_'1O!7PVL8]<T+P:3+,LDH2VGG# .SDD C(V
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MTB]U:QL]6U/S/L%A<7*)/=^6NZ3RHR=S[5.3M!P.30!IT444 %%%% !1110
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MH6OI"BMJ=:I2UA)HEQ4MT?G-XT_X)1:S;^9)X1\?:?J ZI;:U:26K#V\R,R
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M5^BE% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@"&\L[?4;.>TNX([JUGC:*6"9
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *Z.N<KHZ "BBB@ HHHH Q=0_X_)/P_D*K59U#_C\D
M_#^0JM0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% &];?\ 'O%_N#^52U%;?\>\7^X/Y5+0 4444 >:^.]8
MURS^,WPOL+":Y31KW^U/[2CB4F)]ELK1>8<<8;./>O2JXWQ1\0_^$;^(G@GP
MM_9_VC_A)/MO^E^=M^S_ &>$2?<VG?NSCJ,=>:[*KELA+J%%%%0,*YRNCKG*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *Z.N<KHZ "BBB@ HHHH Q=0_X_)/P_D*K59U#_C\D_#^0JM0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% &];?\>\7^X/Y5+45M_P >\7^X/Y5+0 4444 <IXBM/"LWCSPA
M/JS1CQ/#]L_L,-*ZL<Q 7&U0=K?)C.X'';%=77#^+/A_<>(OB;X#\41W<<,'
MAS[?YMNRDM-]HA6-=IZ#!&3FNXJGLA+J%%%%2,*YRNCKG* "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z
M.N<KHZ "BBB@ HHHH C:&-VRT:L?4J*3[-#_ ,\D_P"^17S_ /%7]H7Q'X&\
M>ZIHEA9:7+:6OE;'N(I&<[HD<Y(D ZL>U<G_ ,-9>+O^@=HO_?B;_P".U]'2
MR#&UJ<:L$K22:U[GF3S&A"3@V[KR/JS[-#_SR3_OD4?9H?\ GDG_ 'R*^4_^
M&LO%W_0.T7_OQ-_\=H_X:R\7?] [1?\ OQ-_\=K7_5O']E]Y']IX?N_N/JS[
M-#_SR3_OD4?9H?\ GDG_ 'R*^4_^&LO%W_0.T7_OQ-_\=H_X:R\7?] [1?\
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M?V7WA_:>'[O[CZL^S0_\\D_[Y%'V:'_GDG_?(KY3_P"&LO%W_0.T7_OQ-_\
M':/^&LO%W_0.T7_OQ-_\=H_U;Q_9?>']IX?N_N/JS[-#_P \D_[Y%'V:'_GD
MG_?(KY3_ .&LO%W_ $#M%_[\3?\ QVC_ (:R\7?] [1?^_$W_P =H_U;Q_9?
M>']IX?N_N/JS[-#_ ,\D_P"^11]FA_YY)_WR*^4_^&LO%W_0.T7_ +\3?_':
M/^&LO%W_ $#M%_[\3?\ QVC_ %;Q_9?>']IX?N_N/JS[-#_SR3_OD4?9H?\
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M7?\ 0.T7_OQ-_P#':/\ 5O']E]X?VGA^[^X^K/LT/_/)/^^11]FA_P">2?\
M?(KY3_X:R\7?] [1?^_$W_QVC_AK+Q=_T#M%_P"_$W_QVC_5O']E]X?VGA^[
M^X^K/LT/_/)/^^11]FA_YY)_WR*^4_\ AK+Q=_T#M%_[\3?_ !VC_AK+Q=_T
M#M%_[\3?_':/]6\?V7WA_:>'[O[CZL^S0_\ /)/^^11]FA_YY)_WR*^4_P#A
MK+Q=_P! [1?^_$W_ ,=H_P"&LO%W_0.T7_OQ-_\ ':/]6\?V7WA_:>'[O[CZ
ML^S0_P#/)/\ OD4?9H?^>2?]\BOE/_AK+Q=_T#M%_P"_$W_QVC_AK+Q=_P!
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MT#M%_P"_$W_QVC_5O']E]X?VGA^[^X^K/LT/_/)/^^11]FA_YY)_WR*^4_\
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M^11]FA_YY)_WR*^4_P#AK+Q=_P! [1?^_$W_ ,=H_P"&LO%W_0.T7_OQ-_\
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MW_QVC_5O']E]X?VGA^[^X^K/LT/_ #R3_OD4?9H?^>2?]\BOE/\ X:R\7?\
M0.T7_OQ-_P#':/\ AK+Q=_T#M%_[\3?_ !VC_5O']E]X?VGA^[^X^K/LT/\
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M_$W_ ,=H_P"&LO%W_0.T7_OQ-_\ ':/]6\?V7WA_:>'[O[CZL^S0_P#/)/\
MOD5+7R=_PUEXN_Z!VB_]^)O_ ([7UC7EX[+<1E_+[=+WKVL^UO\ ,ZZ&*IXF
M_L^@4445Y9UA1110!\5_M$?\EB\0?]N__I/%7G%>C_M$?\EB\0?]N_\ Z3Q5
MYQ7[AEW^Y4?\,?R1\%B?X\_5_F%%%%>@<X4444 %%%% !1110 4444 %%%%
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MCFJ7BKP1K'@NX6WUB&"UN2>8%O(99%XR"R(Y*@@\$@9J%B*,JGLE-<W:ZO\
M</V<U'G<7;O8PJ*Z[2_A3XEUK16U:RM+6?3D3?)<#4;8",8S\^9,H<=FP17(
MU<*U.HVH23:WL]O4F4)12<E:X45J>&_#.H^+M433M+BCGO9 62*2>.(OCJ%+
ML 3[#G@^AJUXN\"ZYX$NH+?7+'[#-.ADC7S8Y-R@XSE&..:7MJ:J*DY+F[7U
M^X?)+EY[:=S!HHHK8@**** "BBB@ HHHH **** "BGPQ/<2I%$C22.P5409+
M$\  =S7<0_!/Q;-IQN18Q)/YJ1BPDN8TNCN1G!\LG(X4_*?F] 0"1A5KTJ-O
M:R2OW9<:<ZGPJYPE%7/[%U#^U!IIL;@:B7\O[(8F$NX_P[<9S76:E\$?&^D:
M7)J%UH$R6L:[W9)8W95[DHK%OTI3Q%&FTIS2OM=K7T'&G.5W&+=CAZ*NZ-HM
M_P"(=0BL--M);V[E.$AA7)/O[#W/%=)XB^#_ (P\)Z8VHZIHDMO9KC?*DL<H
M3/=@C$@>YISKTJ<U3G-*3V3:NPC3G).2BVD<=1178^'OA#XK\5Z4-2TG3HKZ
MSYS)'>P94CJ&4OE3[$ TZE:G17-5DHKS=A1A*H[05SCJ**W_  EX#U[QU-<Q
M:'I[7[VZAY<.B!0<XY8@9.#QUX-7.I"E%SJ.R75Z"C&4GRQ5V8%%=9X9^%?B
MCQA]K&DZ:+F2SE,-Q$US#%)$X[,CN&'IG&,@CL:?H?PG\4^)+S4K33M.CN;K
M3IVM[J'[9 KQ.IP<@N"1D$;AP<'!K"6*P\;J51*V^JT]2U1J.UHO7R.0HKI=
M/^&_B/5O$]WX>M--:;6+0,T]N)8QL"D DL6V]6'?O6)JFEW>B:C<6%] ]M>6
M[F.6&0<JP_SU[UK&M3G+EC)-VOOT[^A+A**NUH5:***U("BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /O?X:_\DZ\*
M_P#8*M?_ $2M=)7-_#7_ ))UX5_[!5K_ .B5KI*_!\1_&GZO\S]!I_!'T"BB
MBN<T.4\17?A6'QYX0@U98SXGF^V?V&6B=F&(@;C:P&U?DQG<1GMFNKKC?%'P
M\_X23XB>"?%/]H?9_P#A&_MO^B>3N^T?:(1']_<-FW&>ASTXKLJIVLK"74**
M**D85^<E?HW7YR5^@<)_\O\ _MW_ -N/G,X_Y=_/] HHHK] /G0HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ:\LKC3[@P74$MM,
M K&.9"C , RG![$$$>H(J&DFFKH HHHI@%%%% !1110 4444 %%%% !1110
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M:MI]XQ03K%Y15L9 (W-D$9(.>QJ5?@NNE1^'X_$>M'1=0UR3R[2SCLS.4S@
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M@W(&!+.!G<5X*^AS7!7WPMUWQ9\7M6\/)J']IWD<OFW>J7"; %(4ERH)Q]X
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MVM^!A2P]*<J;<?B;5M>AQVE_LVC6UUJVL/%EE=:MIDK126<<!*@\[ [[OE)
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MO_6I*W84445!05^<E?HW7YR5^@<)_P#+_P#[=_\ ;CYS./\ EW\_T"BBBOT
M^="BBB@ HHHH **** "BBB@ HHHH *]U\%?%G6O&GQDT*&._N[;1/,,,5@LA
M1"@B(^=5.&)(SSG&>*\*KO/@7_R5GPY_UW;_ -%M7EYC1IU,/.I-7<8RMY77
M_ .O#5)1J1BGHVOS/3?VBO'GB#P;\2M);2-5NK2)-/CF-LLK>0[>;*"6CSM;
M( '([#TKS;Q!X=UKXF:YJWBG3--:'2KR[PDU[/%;KO; V!G<!CGC@FNJ_:R_
MY*+IW_8*C_\ 1TU='^T!;VEE\'?!EOIS*;!7B,10Y#+Y!PWN3DG/N:\#!5%A
MZ.$]E%<]1-7MTWUVOY:]ST*\74G6YGI'6QXK'X UF/Q9;^';Z!-)U&9U4?;Y
M%B0 GAMQ."/3;G)X&3Q7H7QJ^%-OX$T/P[;V#6CO!;RM>7,L\44UQ(67E49@
M[@9( 4' _,^@_'*WLVG^&MR^W^TC?PHIS\S1Y0M]0&V_3=[US?[7G_(6\-_]
M<)O_ $)*JAF%;&8C"N_*I<UUTNKK_ANWF*IAH4:=7JU;\3RC1_A;XGUV*SDM
M--'^FJ7M4N+F*!YU R6C21U9ACG(!XJ_\/%UGP3\6M$L9/M&EWW]H06EU"3M
M+1O(@9&'0J00?3H1V->[VZZC#KGPW?Q<MM_;KR2QV5K8QE%A01#>TKDMN8#8
M-J[5!8GYL5R'Q: '[2GA3 ZSZ?G_ +_U<,RJ8J<J%2*<7"3T\FUOU7R6HI86
M-)*I%NZ:_%7^1C_M9?\ )1=._P"P5'_Z.FKG/V?]8OK#XG:/:VUY/!:W<I6X
MACD(28!'*[EZ-C)QGIFNC_:R_P"2BZ=_V"H__1TU<C\"_P#DK/AS_KNW_HMJ
MWPZ4LELU]A_DS.HVL=I_,CT_]HCQ_K_@OXE:6=)U.>W@&G1RM:%R8)&\Z7.Z
M,_*<@ 9ZX'6I?C!\/]*\7?#6T\=Z/81Z=?\ V>*[N8;=0%DC<#=D#C<I.=W<
M YSQCF?VLO\ DHNG?]@J/_T=-7I7B?4$\(_LU6]OJ \FZN-+BM$@8X<R.HXP
M>X&21_LFO&A>A0P-6@K3;L[=5UOW_0[I?O*E>%3X4K^C/FS0/A_KWB:Q-[86
M(:S$JP"XGGC@C:0G 16D90S$X&!D\BJ-YX9U:PUUM%GT^X355D$7V0(3(6/0
M #KGMCK7T-\4['2=/^!_@YC8WE_I<(MW#6%RMN59H2?,<F)QR2>PY;KSBN9B
M\?:W\3OBMX8UGP_X=ATS5(8I8TEO)&F@EC 8,S$*APH9AP<Y('6O<HYE7K1E
M64%R+FW=K..U]>O730\^>%IP:AS/FT^=]_ZN>>R?"#Q:MC>72Z4)XK/BY6WN
MH99(2!DAHT<L#CG!&:];_9'U.[DF\06+W,CV<2121P,Q*(Q+ D#L3@9QUP*]
M$^&:6D/C[QY;JOFZBK6;7]TJ>7%+*R2'$<>3M4>Y))9LD\5YC^R'_P A;Q)_
MUPA_]">O'QF.GC<%B858KW5!K_MZSZM_\-T1VT</&A7I2B]^;\#Q7QE_R.&N
M_P#7_/\ ^C&KZ-_9E^(EUXFTN_\ #NIW<D]U9H)+:5WS(83\I7/7Y3MP?]H>
ME?.7C+_D<-=_Z_Y__1C5I?"_Q<W@?QSI6JEBMNDOEW !/,3?*_UP#GZ@5[^/
MP:QN Y$O>237JO\ /8\[#UG0Q'-TOJ6]4TGQ)IOQ6ETQ=1O6\0K>BWCOVG;S
MFSA5<OG."A!Z\*:V?'/B3Q%\9O&+:3I7VC5;.U)2TMXR-K*@VF=SP 6ZY/3=
MBO4OVA-+LO#=T?&<$JC4;RS.FP(HY\QACS@1W$1D7/KLK,_9MAMH?AQXSNXB
MHU'YU9@?F6,0DI]!N+_E[5Y:QT982.8*"<HI16FS;L_DNGS1U_5VJSPW-H]?
MET^9XGK?@#7O#VFIJ-Y8@Z>[F,7=M/'<1!@<%2\;, <\8)ZU]!^%]3N]5_9=
MU26\N9+J5;2ZC$DS%FVJQ"C)[ <?2L3X)V]G>? 7QM%J&/L?F7#.2,[<6Z$,
M/<$ CW K2\#_ /)K&K?]>]Y_Z$U8YAB95TJ=1*].K%776^OG\]33#4E3]Z+T
ME!L\0;X5>*$\*_\ "1_V<C:+Y0G^U)=0L-AXSM#[LYX(QD'@BC7_ (5^)_#&
MAIK.HZ<D6F2%0ES'=PRJV[E2-CG(/KTKVSP]_P FEW?_ %QN/_2AJ/B=_P F
MR>&_^N-C_P"BZZXYKB/;*FTK>T<-GMWWW,7@Z?)S)OX>;^M#QQ?@SXRDT:'5
M8M&-S83",QRV]S#+OWL%7"JY)Y8=N.^,&F:M\'?&6B75A;W>@W"RWTGE0+$R
M2AFQG!*,0O )YQP">@->PVMY/8_L@^;;S/!+M9-\;%3M:_*L,CL02#[&K_C&
M^N;;]ES3)(IY(I'M+6-G1B"5+*",^A''TXJ%FN*]IRVC;VCI[/Y/?^O(?U2C
MRWU^%2Z?=L>!>+OAQXD\"QV\FN:7)8QW!(CDWI(I(YQE"0#['GK4FB_##Q-X
M@L;:[LM,W073,EL9IXH3.0"2(U=@7X!^Z#T->X_$RWBU+]GCP;)>S2*J&P=Y
M<Y.#$5).<YX8G\!5OX_7FG>#=6\$ZK)I%Y=PZ:Y-I]DNU@@C9&C948&)\@A1
MT*\ _A5/-J]50IQBN>3FO+W?)M;Z=12P=./-)M\J2?W_ "_0^7[JUFL;J6WN
M(G@N(F*212*596!P00>AKL/"?A?PMXFT@0W7B7^P=?\ ,;"W\6;21<?+^\'W
M#ZEORJO\4/%7_";>+)-:.D-HK74,;&%I"_F8&!(#M7(( [=NM6/"?PU.O:0-
M9U/7-.\/:+YC1BXNY-TLC*,D1Q#EC[9%>W4J/ZO&=63IRTVL]>W6_P C@C']
MXXP7,ONT[]+$/BGX3^)O",)N;K3S<Z?C<NH6+>= 5QG=N7H/]X"O2/V>_",&
MN>$_%%[ITENOBN/]S9RW #?9@4RK@8.TL=PW8XV_7.9I/Q4\.?"NWGMO!\6I
M:U=2 AKS4YVCMB2!RMNI&?\ @6#[UQMKXV\3:;KTGC:R*V4EQ<&&22VC58&8
M*K&-D'8C!YZ\G.037FU%C,90E2DE':S>G-ULXZM)]=?D=4?84:BFM>ZWMYWT
M_KJ>@_$KQ]JOAWQ!X@\.Z_!)?Z=>:7%' MP@D:"X-J@\V-FZCS=V2#UR1R.=
M;X#VNN>#O LNOZ1X9?Q'<ZM<,A5+Q(/*ABR ?F!))<OP!_".:[?Q=>Z'\4O!
M_B33M0MTBU31;".\-PZX$326XF5T;J%SD$>WTKQ+P[\9/B!X%T73?W1;0P@C
MM%O+ +"ZCLLBJI;Z[C7CT8SQF#="E349)QYDVTI:735N^CW6QVS<:-?VDI-K
M6S6ZU\^VQJ_%KXH:Q\2YM,\)S^'IO#MS]M0M#<3,S.[?(F047 ^8^N<CTKM?
M&#-\-O'WP[\-:*?L^D3-'!=6ZC"W7F2+&S2@<.<<\]#5?QQXXT;QEX+\%>-;
MFV%A?6NMQ1NOWR%5BTB[L<KA5;I[=ZG^-C!_C5\-V4AE-S;D$=#_ *2M9PLW
M2H*GR12J7CNN9+N]_+L5*_OU.;F;Y;/R9CWWP9TP_M"V^E10*NB2VXU9[51\
MJJ"5,8_V3(O3L&Q6[X9F_P"$P^+GC?P=JR+=^'EMF\FQ;B.W\MHT4Q#HAPY.
M5QR :Z2]\3VR_M'V&G-(FX:*]N/7S6?S=I_X @(^ON*Y?X9?\G+^-_\ KVG_
M /1T%<SK5JM%RJO6-)->O-OZ^9KR0A-*&SFT_NV/G+Q#I+:#K^IZ8S^8UE<R
MVQ?&-Q1RN?TK=\,_"GQ1XRTMM1T;3DO;16*,ZW<*E6'4%6<,..>1WJK\1M63
M7/'WB"^C9'AFOIC&T?1D#$*?Q %>Z_LG,5\,^)B#@B="#_P U];CL96PF!6(
MBES>[>_GOM8\?#T85L0Z;VU/&+SX/^,=/T+^V+C0;F.PVARV5+A3T)C!WCKW
M''>FZM\(_%^@Z"=9O]#GM]/"AVD9T+(#T+(&W+U[@8[U[C^SSJ5W+\*/%=U)
M<RR7(N;B032.6;=Y"'=D]\\U0^$MS/J7[.OCDW,TD[*;\AI&+'_CV1SR?5B3
M]2:\Z>:8JG*:DHM0G&+T>JE\]&OGZ'3'"4I*+3?O)OIT^1SWA]O%-A\"=3L(
M?"=C?:/<Q27+:NM] VQ, LS1ABQ=<''(*D 8R,5VGA?4[O5?V7=4EO+F2ZE6
MTNHQ),Q9MJL0HR>P''TJG\,O^39/$G_7&^_]%T_P/_R:QJW_ %[WG_H35Y>)
MDI\Z<4FJRU5]?O;_  LCKI+EMKO!D]CJEYK'[*MW<WUS)=W'V:5#+,Q9B%G*
MJ"3UP !^%<9K_P#PE.G_  %BTFZ\*6<>CP&.7^VH;^"4%6E!5E1&)W$L%+ G
M@GBNI\/?\FEW?_7&X_\ 2AJJ?\V=_P"?^@A3IR5*H[137UBW73S5FMO.Z%)<
M\5K_ ,NSQ71/A[K_ (ATLZE9V*_V?Y@A%U<W$5O&SDX"JTC*&.>,#O4%WX*U
MK3_$4>A7=BUGJDC!4AN9$B#9Z8=B%P>@.<$\5[C^T!;VEE\'?!EOIS*;!7B,
M10Y#+Y!PWN3DG/N:T/VA+>S:U\ 7+[?[2-RB*<_,T>$+?4!MOTW>]>O1S:K4
ME3]U6FYI;W7+M?77SV..>#A%2UUC;YW/()/@/X[BOH;1O#\AGE1I%VW$++@$
M Y8/M7J, D9YQT-<KK/A?5?#^MMI&H6,MOJ095^SD LQ;[NW&0<YXQ7U?\5K
M^YB^*'PUM4GD2VDO)9'B5L*S ( 2.^ S#\37DO[4<LEO\4;&6!FCF33X71DX
M8,)),$>]3E^:8C%5*<*BC:<6]+]&UW?8>)PE.C&3BW[K2^]7/-?%G@+7O LE
MJFN:<]@;I2T.YT<.!C/*D\C(XZ\BL"NM^(7B#QAKEQ9+XO-ZLT,9^S)>6OV<
M[3C) VKG.!S[50\%C0%UAIO$AE?3H(7E%M#N#7,@QMBW#[N<Y)XX'6O?I5*B
MH*=:SE_=U3]+GG3C%U.6&B\_U,&O5_V;?#NE>(?'TBZFD4[VUJT]M;S+N5I
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M4)_[763SA>,VY]WJ2>O'&#QCCI4OBKQEK/C;4$O=;OGOKE$\M6950*N<X"J
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M@HHHKH,PHHHH **** "BBB@ HHHH **** "OT;K\Y*_1NOS_ (L_Y<?]O?\
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M0O\ KS;_ -#-%:I4CF=&FIOEDI:=-%_6]PIQB\+.5M4UJ>#4445[YYP4444
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MT027<I!9MJ@$;2,=\UU=4[65A+J%%%%2,*_.2OT;K\Y*_0.$_P#E_P#]N_\
MMQ\YG'_+OY_H%%%%?H!\Z%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!TGP_U+1]
M#\3Z?JNKS7R1V%S%=1Q6-NDIE9&#;26D7:,@<\]^E=Y\;/B=X7^*,=C<6?\
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M//P_X)^<E%?HW11_K9_TX_\ )O\ [4/['_Z>?A_P3F_AK_R3KPK_ -@JU_\
M1*UTE%%?!U)^TG*?=W/H8QY8J/8****S*/._&W@G4]=^+WPU\16J1G3=!_M+
M[:S/AAY]NL<>T=_F!SZ5Z)113;O9=A6"BBBD,*_.2OT;HKZ#*<V_LOG]SFYK
M=;;7\GW/.QF#^M\OO6M?H?G)17Z-T5]!_K9_TX_\F_\ M3S?['_Z>?A_P3\Y
M**_1NBC_ %L_Z<?^3?\ VH?V/_T\_#_@GYR45^C=%'^MG_3C_P F_P#M0_L?
M_IY^'_!/SDHK]&Z*/];/^G'_ )-_]J']C_\ 3S\/^"?G)17Z-T4?ZV?]./\
MR;_[4/['_P"GGX?\$_.2BOT;HH_UL_Z<?^3?_:A_8_\ T\_#_@GYR45^C=%'
M^MG_ $X_\F_^U#^Q_P#IY^'_  3\Y**_1NBC_6S_ *<?^3?_ &H?V/\ ]//P
M_P""?G)17Z-T4?ZV?]./_)O_ +4/['_Z>?A_P3\Y**_1NBC_ %L_Z<?^3?\
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M_IY^'_!/SDHK]&Z*/];/^G'_ )-_]J']C_\ 3S\/^"?G)17Z-T4?ZV?]./\
MR;_[4/['_P"GGX?\$_.2BOT;HH_UL_Z<?^3?_:A_8_\ T\_#_@GYR45^C=%'
M^MG_ $X_\F_^U#^Q_P#IY^'_  3\Y**_1NBC_6S_ *<?^3?_ &H?V/\ ]//P
M_P""?G)17Z-T4?ZV?]./_)O_ +4/['_Z>?A_P3\Y**_1NBC_ %L_Z<?^3?\
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@;^U.3W.7EOUOO;R78]+!X/ZIS>]>]N@4445\^>B?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>rprx-20211231_g3.jpg
<TEXT>
begin 644 rprx-20211231_g3.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +K!K0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS4]3N+:YLW5X94?1[A@ZLO!!SG(ZYH _8NBBB@ HHHH **** "BBB@ HHHH
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M(,FT?=WB7XU>"_"-CH5SJ>N1QOKR!])L8();B]OP4W_N+6-6FD(7DA4)'?%
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MY!_\$0?^2F_$W_L#VO\ Z.:OU\H **** "BBB@ HHHH **** "BBB@ HHHH
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M+W2]*L-,FT?74T>QAM8%C\JT>UG<QIC&$#01_+C&2.G?Q?\ X+:?\EX\!_\
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M*4#-MXVJ!N.%11DXS0!\G_MY:3X+\-_M6?!_Q[-X[U__ (6-9R6EII'P_P!
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M#XLL-<BU?4I%GU#1X=0V:9>RB1)0TT07<X\V*.0H7\LNBDJ<5](T44 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ9\1?!>A>*=%F^T:3K-E#?VLG<QR('7/H0#@CL017Y;_ +6'[67Q9\0?MO>
M/ -IX(GM+/PQK]E?:?X/EU6VBFUNY)#0R3W",\4>Y6^5<D)N);)X7U3_ ((W
M_M 1>,?A#JWPOU*\4ZQX5G:YT^&1OGDL)F+':"<MY<Q<'T$L8KQ3]I"1;7_@
ML=X,DF80QMJ^@X>0[0<QQ*.3[\?6@#]3/A/XF\6>+O!%GJ?C;P7_ ,(!XBE>
M19]!_M6+4O(57(1O/B 1MR@-@#C.#TKL*JZ;JMEK5H+K3[RWO[4N\8FMI5D3
M<CE'7<I(RK*RD=BI!Y%<;\</B?#\(?AGK'B+RUN]355M=)T_.'O]0E(CM;9!
MU)>5D7CH,GH#0!^:7_!6K3/$WQ:L[OQKIDGF^ ?A[JZ>&'B4'Y[Z:,275SDG
M&Q'^RVW0_.'YX-?</[ OQX'[0?[,/A37;FY^TZ]IT?\ 8^KLS[G-U %4NQ]9
M$,<G_;2N+N/@1\5=6_9BU#X/:IX)\!WT&IZ;-!?:Q)XUO!+-?3,TTE\8_P"Q
MR/,-RQF"[C@X&3C-?%7_  2B^+5[\"?VD/%7P;\6R#3%UR1[,03M@0ZM:LRA
M 3P-Z^:O^TRQ@9XH _27]HG]JGP[^S[?>%M!DL+KQ-XX\5WD=CH?AO3W1);F
M1W"!Y)'.V*/<RKO.>3P#AB//_#/[=/V/]IY?@5\1/!'_  B/BNZ$?]GW^DZJ
M=4L+HO#YJC>T$#ID;ESL(W*0<#FOCC_@HYKNI_!G_@H9\+/B7K%M-/X9LXM,
MNH)%4D-#;W3FYA7_ &P&+8_Z:J>]?I>E]\+/%.I>$_'H_P"$7U75+]5MO#_B
M$Q02W<HD!/EVTV"_*EB50\#<3@ T >>?$C]L32_#WQVTKX+^"]";QQ\2;R,S
M7%I]L%G8Z9&(_-W75QLD9#LPVU8W."O=E!\X\0?\%%I? 7QZT+X->+_AC=:7
MXXU37=/TH2V.L)=:9]GNY8T6ZCG:*.1\"3.PPKRI!93T^5_V1]2F\$_\%:/B
M58^-)S;ZUJEWK5M:/='_ %LDDZSP;2<8#P+E ,<%0!SBLS]KC7-.US_@K7\,
M6TZ_MK];;7O#-M,UM*L@CE6\C+(Q!.&&1D'D9H ^S?VW/V\-6_8QU[PU!<_#
MFU\5Z1X@BG:RO8_$+6DP>#RO-62$VCA0/.CP0YSD\#%5/VM/V_M7_99T?P'K
MDOPTMO$NA^+;'[1!<1^(S;36\P2-WB>,VC@@"5=KAN<-E5P,_.__  7,LYGL
M_@O=+&3;QOK$3R=@S"R*C\0C?E7*?\%9/%FC:I\%_P!G?3K+5+2[OO[+:^-O
M!*KN('MK8)*0.BL0P!/7:V.AH ^OOVS/C79V?[(6E>,_$?PJT[X@>!=?LK*Y
MUG1;OQ!)8S6AG\E[?RG2W8R8=\%P8V7:I .X[:?P+_:M^'/PU_8)T[XIVW@G
M_A O!NFM/:6?A?3;LWLC2BZ>)465U0N\CY=F89&6))P37%_MO?\ **O2/^P-
MX<_]"MJXS]FCPW\/_''_  2[\*>%/B5=SZ9X>\0:[-ID6J6[(K6-W)J$GV>8
MLYPJAP 2<C#$'@D@ ^G])_:L\2_V3\.=7UCX<0G1/'FHV-CIFK>'?$*:G:V@
MN6&#>.8(C&P7=@1B5"RA#(I(-?-_[>GQZ\'?#O\ :1\$Z=\2/@!I/CC4;80W
M7A[Q"OBF6%A"TY4":W%MM.V16/EN9$YR#R:\"L?"?QM_X)I_'3P?X8FOHO&?
MPW\4:U;I:V.P36FH,L\7*0.2;:[0M&RLI^\$^9P*Z/\ X+"?\G3?"?\ [!$'
M_I=)0![;_P %9_VG/B!\)?!-EX)\-Z+/HFC^*8Y;:Y\5M<PEIXPJ^;;6\:N9
M$RK@-(ZKP2$S]X=KX'^,OQ/M/V.M4OO%OP T]/"V@>#;:40ZCXRMY$U[3%LF
M^T.%BMY#$WE(K>7(!N$A&X%<'QS_ (+B(Q\'?"=PIVB_U %L< F.# _0_E7T
MWXEUS3M1_P""=GB.TM+^UNKJ#X1O--!#,KO&DFCR>6S*#D!MCX)X.UL=#0!Q
M'_!,WXP?#KQI\(?&EUX+^&EG\(] T;4O,O(O[9DU 3,T.]II)Y45@%48P20
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M4^"]-\6ZSXDN9;F^U;6X%GO%#<)'#*1N@2- B((RI 0$DL2Q^!O^"/?PKO\
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M[!(SCBL:U_9%^$VF_"6X^&6G^%/[*\$W4OG76FZ;J5W:-=MMVGSYHI5EF!&
M1([ X7(.!CV&B@#QWX*_LC?"K]G75KS4?AYX=NO#D]['Y5S&FMW\\$PSD%H9
M9WC+#LQ7<,G!&3E-?_9"^$WB+6-;U.;PO)I]SKHQJZ:+JU[ID&I@DDBZAMIH
MXYP26SYBMG<<]37L=% '*Z7\+?"WA_P"W@K1=(C\/^&3;O;+8Z+(]AY:/G<4
MDA9'1CDG>K!LG.<\UY%X&_X)_P#P+^&6IW.H^$O"FI>'+ZYM9+*:XTWQ1JT#
MR0R+M=&*W0R._L0&&" 1]#T4 >!?#+]B?X'_ +/?B0^,?!WAB?PKJ5I!)YM[
M'X@U$Q&';EQ*CW!C=,#=AU(!4'J 1Y1K?PGNOVUOVG/"/C[5=/N+3X-_#U6D
MT3[? T,GB"_9U9YDC8!A:JT4/S,!YGE_+N5R1]J44 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\W>,O\ @G5^
MS[\0O%6I^)/$G@6XUC7-3G:XN[ZY\0ZF7E<]_P#CYP .  ,      "ND^"_[
M%OP:_9Z\63^)? '@Q=!UN:T>Q>Z;4KRZ/DLZ.RA9YG4$F-/F !X(S@D'VVB@
M#C/B%\'?"'Q1N-+NO$6DFXU+2G=]/U6SNIK*_LBXVOY-U Z31[AP0K@$=<T_
MX;?"/PA\(=-O++PEH<.D1WUPUW>3!WFN+R8]99YY&:25S_>=B?>NPHH \?\
MBY^R;\,_CQ=33>/-+UCQ##)(DOV";Q-JD5BCH@16CM8[E88SM')1 222<DDF
MW\'/V8?AW\ &9? 6F:IH5HRNIT\^(=1N;++$%F^S37#Q!\@?/LW=>>37JM%
M'S=XR_X)U?L^_$+Q5J?B3Q)X%N-8US4YVN+N^N?$.IEY7/?_ (^< #@ #
M    KI/@O^Q;\&OV>O%D_B7P!X,70=;FM'L7NFU*\NCY+.CLH6>9U!)C3Y@
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M )X R<*JC)QFO4Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** &R/Y<;OC.T$XK/_ +8_Z9?^/?\ UJNW/_'O+_N'^58- &C_ &Q_TR_\
M>_\ K4?VQ_TR_P#'O_K5G44 :/\ ;'_3+_Q[_P"M1_;'_3+_ ,>_^M6=10!H
M_P!L?],O_'O_ *U']L?],O\ Q[_ZU9U% &C_ &Q_TR_\>_\ K4?VQ_TR_P#'
MO_K5G44 :/\ ;'_3+_Q[_P"M1_;'_3+_ ,>_^M6=10!H_P!L?],O_'O_ *U'
M]L?],O\ Q[_ZU9U% &C_ &Q_TR_\>_\ K4?VQ_TR_P#'O_K5G44 :/\ ;'_3
M+_Q[_P"M1_;'_3+_ ,>_^M6=10!H_P!L?],O_'O_ *U']L?],O\ Q[_ZU9U%
M &C_ &Q_TR_\>_\ K4?VQ_TR_P#'O_K5G44 :/\ ;'_3+_Q[_P"M1_;'_3+_
M ,>_^M6=10!H_P!L?],O_'O_ *U']L?],O\ Q[_ZU9U% &C_ &Q_TR_\>_\
MK4?VQ_TR_P#'O_K5G44 :/\ ;'_3+_Q[_P"M1_;'_3+_ ,>_^M6=10!H_P!L
M?],O_'O_ *U']L?],O\ Q[_ZU9U% &C_ &Q_TR_\>_\ K4?VQ_TR_P#'O_K5
MG44 :/\ ;'_3+_Q[_P"M1_;'_3+_ ,>_^M6=10!H_P!L?],O_'O_ *U']L?]
M,O\ Q[_ZU9U% &C_ &Q_TR_\>_\ K4?VQ_TR_P#'O_K5G44 :/\ ;'_3+_Q[
M_P"M1_;'_3+_ ,>_^M6=10!H_P!L?],O_'O_ *U']L?],O\ Q[_ZU9U% &C_
M &Q_TR_\>_\ K4?VQ_TR_P#'O_K5G44 :/\ ;'_3+_Q[_P"M1_;'_3+_ ,>_
M^M6=10!H_P!L?],O_'O_ *U']L?],O\ Q[_ZU9U% &C_ &Q_TR_\>_\ K4?V
MQ_TR_P#'O_K5G44 :/\ ;'_3+_Q[_P"M1_;'_3+_ ,>_^M6=10!H_P!L?],O
M_'O_ *U']L?],O\ Q[_ZU9U% &C_ &Q_TR_\>_\ K4?VQ_TR_P#'O_K5G44
M:/\ ;'_3+_Q[_P"M1_;'_3+_ ,>_^M6=10!H_P!L?],O_'O_ *U']L?],O\
MQ[_ZU9U% &C_ &Q_TR_\>_\ K4?VQ_TR_P#'O_K5G44 :/\ ;'_3+_Q[_P"M
M1_;'_3+_ ,>_^M6=10!H_P!L?],O_'O_ *U']L?],O\ Q[_ZU9U% &C_ &Q_
MTR_\>_\ K4?VQ_TR_P#'O_K5G44 :/\ ;'_3+_Q[_P"M1_;'_3+_ ,>_^M6=
M10!H_P!L?],O_'O_ *U']L?],O\ Q[_ZU9U% &C_ &Q_TR_\>_\ K4?VQ_TR
M_P#'O_K5G44 :/\ ;'_3+_Q[_P"M1_;'_3+_ ,>_^M6=10!H_P!L?],O_'O_
M *U']L?],O\ Q[_ZU9U% &C_ &Q_TR_\>_\ K4?VQ_TR_P#'O_K5G44 :/\
M;'_3+_Q[_P"M1_;'_3+_ ,>_^M6=10!H_P!L?],O_'O_ *U']L?],O\ Q[_Z
MU9U% &C_ &Q_TR_\>_\ K4?VQ_TR_P#'O_K5G44 :/\ ;'_3+_Q[_P"M1_;'
M_3+_ ,>_^M6=10!H_P!L?],O_'O_ *U']L?],O\ Q[_ZU9U% &C_ &Q_TR_\
M>_\ K4?VQ_TR_P#'O_K5G44 :/\ ;'_3+_Q[_P"M1_;'_3+_ ,>_^M6=10!J
M1ZIYDB)Y6-Q SN_^M5^L"V_X^(O]\?SK?H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@"I=WWV60)LW9&<YQ4']L?\ 3+_Q[_ZU1ZM_Q\+_ +G]
M35*@#1_MC_IE_P"/?_6H_MC_ *9?^/?_ %JSJ* -'^V/^F7_ (]_]:C^V/\
MIE_X]_\ 6K.HH T?[8_Z9?\ CW_UJ/[8_P"F7_CW_P!:LZB@#1_MC_IE_P"/
M?_6H_MC_ *9?^/?_ %JSJ* -'^V/^F7_ (]_]:C^V/\ IE_X]_\ 6K.HH T?
M[8_Z9?\ CW_UJ/[8_P"F7_CW_P!:LZB@#1_MC_IE_P"/?_6H_MC_ *9?^/?_
M %JSJ* -'^V/^F7_ (]_]:C^V/\ IE_X]_\ 6K.HH T?[8_Z9?\ CW_UJ/[8
M_P"F7_CW_P!:LZB@#1_MC_IE_P"/?_6H_MC_ *9?^/?_ %JSJ* -'^V/^F7_
M (]_]:C^V/\ IE_X]_\ 6K.HH T?[8_Z9?\ CW_UJ/[8_P"F7_CW_P!:LZB@
M#1_MC_IE_P"/?_6H_MC_ *9?^/?_ %JSJ* -'^V/^F7_ (]_]:C^V/\ IE_X
M]_\ 6K.HH T?[8_Z9?\ CW_UJ/[8_P"F7_CW_P!:LZB@#1_MC_IE_P"/?_6H
M_MC_ *9?^/?_ %JSJ* -'^V/^F7_ (]_]:C^V/\ IE_X]_\ 6K.HH T?[8_Z
M9?\ CW_UJ/[8_P"F7_CW_P!:LZB@#1_MC_IE_P"/?_6H_MC_ *9?^/?_ %JS
MJ* -'^V/^F7_ (]_]:C^V/\ IE_X]_\ 6K.HH T?[8_Z9?\ CW_UJ/[8_P"F
M7_CW_P!:LZB@#1_MC_IE_P"/?_6H_MC_ *9?^/?_ %JSJ* -'^V/^F7_ (]_
M]:C^V/\ IE_X]_\ 6K.HH T?[8_Z9?\ CW_UJ/[8_P"F7_CW_P!:LZB@#1_M
MC_IE_P"/?_6H_MC_ *9?^/?_ %JSJ* -'^V/^F7_ (]_]:C^V/\ IE_X]_\
M6K.HH T?[8_Z9?\ CW_UJ/[8_P"F7_CW_P!:LZB@#1_MC_IE_P"/?_6H_MC_
M *9?^/?_ %JSJ* -'^V/^F7_ (]_]:C^V/\ IE_X]_\ 6K.HH T?[8_Z9?\
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MLZB@#1_MC_IE_P"/?_6H_MC_ *9?^/?_ %JSJ* -'^V/^F7_ (]_]:C^V/\
MIE_X]_\ 6K.HH W+2Y^U1E]NW!QC.:GJEI/_ ![M_O\ ]!5V@ HHHH ****
M(KG_ (]Y?]P_RK!K>N?^/>7_ '#_ "K!H **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"2V_X^(O]\?SK?K
MMO\ CXB_WQ_.M^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,G
M5O\ CX7_ '/ZFJ57=6_X^%_W/ZFJ5 !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 :VD_P#'NW^__05=JEI/
M_'NW^_\ T%7: "BBB@ HHHH BN?^/>7_ '#_ "K!K>N?^/>7_</\JP: "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3-IVH3WFR>+B6UF6TD,<T9[,K8/H1D'()! /1]<^+'AC0? $7C:6]N+[PQ+
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M6TA);Y!/# \?F?(Q,>[<!@D8()]/M;F.\M8;B%M\,J"1&P1E2,@X/M7Y,?\
M!03X@?$3XI?LD?"?QCXNA\.1Z7XBU-=3M;?189XI;'=;RF**0R2.)BT;%BZB
M/:5QM;.1^K/A?_D6M)_Z](?_ $ 4 :=%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!K:3_P >[?[_ /05=JEI/_'NW^__ $%7: "BBB@ HHHH BN?^/>7_</\JP:W
MKG_CWE_W#_*L&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW%44^-OP[D\4S^&4\>^&&\26[2K-HZZS;&\C,2,\H:'?O!14=FR/E"DG !H
M[2BN5M_BQX*O?!=[XOM?%VAWGA6R#M<ZU:ZA%-:1;/O[I58J".XSGD5Y'^S+
M^V5X1_:7U[QA9Z1J.G6JZ?J;6NCV,]RJ:AJ%HD,;/=^0S;]A=G PO  S@Y
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M]V_W_P"@J[5+2?\ CW;_ '_Z"KM !1110 4444 17/\ Q[R_[A_E6#6]<_\
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M[,&K:[JG_!+OX[6>I^=-HEC).FEM,,JN4A>5$S_"'(;_ 'G;OFOTG\=?L]^
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M0H&T8N?!W]E?X9? /4M4OO F@7.B3:I%Y5[&VL7UU#<#<&W/%-,Z%P0</MW
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M110 4444 26W_'Q%_OC^=;]8%M_Q\1?[X_G6_0 4444 %%%% !1110 4444
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M_N[.=8[@-<+91!I716EMW:2-&QL4'!V ^UI^P=\!(_!<?A1?AOIPT6.\6_\
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M1R* /T4_9_USXF^(OAW#>?%OPYI?A;Q@;F57T_1YQ-"(01Y;9$D@#$9R [=
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M@ HHHH **** "BBB@ HHHH **** "BBB@#6TG_CW;_?_ *"KM4M)_P"/=O\
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M110 4444 %%%% $EM_Q\1?[X_G6_6!;?\?$7^^/YUOT %%%% !1110 4444
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M1&.4 JQ0!EPW#D@@?9'QT_;$U'X'_M#?#KX:W7@>WU6P\;7MI:6>M1:VT<D
MEN$@=I+<VQ&49\@"0[@!RI.  ?35%?-/P:_;"OOB?^U%XY^#&H^"H-#O/"UG
M/=OJUMK)NX[CRYH(PHC-O&5W"X#9R<%2.<YK);]N/4/%=GXKU[X9_##4OB1X
M/\,:M'H][>Z7>L+^ZE.-\EG9I!(9HT#*2S/'D,"!C) !]645\"?MP?'OXC:/
M\?/@1X"T6QL+#0->U_2-46VN+V2&YOY8[V I;W;")A;QB7;G8)C\H;ML/W?H
MTNH3Z3:2:M:VUEJ;1*;FWL[EKB&.3'S*DK1QEU!Z,44GT% $>O>(=*\+Z9+J
M6M:G9Z1IT/\ K+N_G2"),^KL0!^=<YX?^-7P]\66=[=Z'X\\,ZS:6,;2W4^G
MZQ;SQP(!DM(R.0H ZDX%? 'P9\2']MC_ (*#>+9O&)&J>!O ,5V^A^';L;[7
M?'.EO'*\)&TLVYY23DA@@Y"\?:7[27[-_AW]H+X=S:/<Z=8QZ[8A9]$U*2,*
MUG<1D-&H=066-B-K* 1M8G!(% 'L%%?//Q&_:U_X1_XK>)OAOX0\,1^)O%WA
MO06\0ZA!J>I-ID#P!5?RX)1!-YDNUT.&")\P&_(;;F>&?VU(/'_[)NL_&OPM
MX3-U_8J3MJ&@ZGJ/V5D,"AI@DZPR!SM*E?D&[.#M- 'TS17P.G_!506OPY\'
M>/-4^$&KV/A/6=3ETN]U1=5C>.UE1F.V &)7N#Y:[S\L: Y4.S*P'T-\=OVI
M+#X1^,/ O@G1=&_X2[QQXRN%CTS31>"TMTAS@SS3[)-J=<;48G:V!QR =]X7
M^-OP[\;:ZVB>'?'OAC7]9568Z=I>LVUS< +]X^6CEL#OQQ6UH_C;P[XAUC5=
M(TK7M+U/5=)<1ZA8V=Y'+/9L>BS1JQ:,G!X8#I7YT_!W4M1U;_@KYXTN=7T<
M:#J9TC9<6"SB=$==/M%+)(%7>CXWJQ525<$JIR!ZG^R-\8/ VK?M ?'U4^%^
MG_#GQ-HL]Q-XHUZUUZ;48;V6&XE69U5X8Q&F]7DRJC=G)7- 'UOXV^)W@[X:
MPVDOB_Q9H?A6*[9EMWUO4H;-9BH!8(9&7<1D9QTR*U]"U_3/%&CVFK:-J-IJ
M^E7:>;;WUC.L\$R'HR.I*L/<&OSN_:Q_:=U#]I#]A_XD^(-#\"/:_#Z34K73
MK/7;C4E-V[17]LWGO:>4!'$Q'E@B5GW, 4QEAZC\(?VC-"_9Q_8?^!^HZQ:3
MWUSKD5KH]A!&=D?G2%SOFDP?+C4*22%9O16YP ?9]%?._P *?VM)_&G[07B_
MX+^)_",?AGQOX?M5O0UAJAU"PNHBD3@K*8874[9XS@Q]ST(Q7A'[/_QV^*GQ
M0_;\^(FEZKIVA2V_AFP?1FTV/5YXK;3[5;V(330-]F8W,S$ X=80V%&Y H
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M ,P*^;:*^AEP_ETMJ=OF_P#,\59CB5]K\$?5=E^T=X*O,>8^I6)_Z;VH8?\
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MJU[XL?#'PEXZTS0Q;?$KPT/$&C76AQ30M8N1*_V:X$LC^;\D7^L79\Q V8Y
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M **** "BBB@#)U;_ (^%_P!S^IJE5W5O^/A?]S^IJE0 4444 %%%% !1110
M5Y3\<_VDO"OP'72++4H[[7/%.N2^1H_AC1(1/J%_)G'R)D!4!/+L0/3)XKU:
MOS3\"Z/XD^.7_!2;XV7<'B>\\*:_X7TB:QT&_CL[>Z-GM:*%"$GC==C!Y&(
M#$3-AES0!]JQ_&37/"/PO\4>._B9X1A\#:9HUJUZMG;ZNNI7<D:J21($B2-'
M)VJJK(X)/)7OYU\(?VVK?X@?$3P7X3\1>$CX3G\<:&=?\-7$>IB\6Y@S(?*G
M'E1^3,4B9]H+K@@;]W%><?LO?$?7?V__ -E'XB>"OB*R6>OPRR:+<ZM:P*F]
MBHDAF:(84.CCYE7 .T8QDXRM/_9ZUOX#ZY\._B9\2KW2=03X9^'D\+^&M%\,
M23S76OWTC2Q6X821H(W<3J@C7>-P+EPH(H ^NO%'Q4.E_$WPWX%T;2_[<UK4
M4:^U'_2/)32M.7*_:I#L;)>0"../@N=YR C$=]7Q'_PL;QC\)/C9X0^&&G1Z
M)>?&SXG6]QXC\1>(-:AFN;&Q2*&=H+.&..2-FB1;:2%/W@ VER&,AKVO]C?]
MI:/]JKX+VWC%M-72-3@O)=-U&SB<O$EQ&J-F,GG:R21M@\C<1DXR0#W&BO(/
MC1^UO\)_V>]<L='^('BO^P-2OK;[7;P_V==W.^+<4W;H8G ^92,$@\5WGP[^
M(?A_XK>"]+\6>%=0_M3P_J:-):7GDR0^8H9D)V2*K#YE(Y Z4 >&_%#]K;4+
M'QAXC\)?#?P]8>)M9\+ZIH.GZW=:OJ!L[6&34KZ*WC@CV([O(0YR^-D1.X^8
M5\IO0OA[\>+;Q)X \1^)/%NB77@"7PWJ$^FZO9:E*L_V>2((Q9'CR)$99$*D
M#YMPP#D9^-/VYOV6==\.^-)?CY\'->(UQ]:TR+5= CD\U;O4%OK>.V*+RKM]
MI%ONADXW+NSD;:^F?V(_VC3^TM\*;_Q!J&@1^'/%=AJ3Z;KUK#$422[CBC'F
MC/S<IL7:Q++LVY(4$@$W[.?[9?A/]J#QSXST3P=I^H#3/#<<#'5;Y?)^UM(T
MB_)"1N51Y><OACGE1BO?Z_/G_@GNH7]L+]K8 8 \2S  ?]A"^K]!J /FV3]O
M#X?ZE^T-X=^$'AN.\\0ZWJ5S)!=:A$AAL[/9%)(0&89E;]WCY!MY^_D8KZ2K
M\^?V@% _X*W_  +(&"?#2D^_S:I7Z#4 ?,TW[8FHZ;^V;I?P#U'P1;1'4HI;
MFW\06VMM*/)6UFN$+6YMEPY$.TJ)"%W9#-CGZ1U*ZDL=/NKB*VDO)88FD2WB
M(#RL 2$&>,GISZU^<?Q,TM-:_P""Q7@JQDGNK:*;1)%>2SG:"7;_ &9>$A9%
M(9,CC<I##/!!P1T7P5^)'BM?BW^TW\&=4\5:_K?A[P]I]UJ.B:A>:K.=2L .
M1&MV'\X@>:F&+DCR_P#:.0#V/4/VO/&&B_LN^(?BYK?P<U#PO?Z)?&&?POX@
MU)[2>6VWQH+B-S;$G+2 !6C4':Y#$;2W*_$C_@H1?> ?V7_AW\:8_AS!J.F^
M*KM[&;2V\0&&6RE_?&/:_P!E82JRV\I)(0J=@ ;)*_-/PK\?^*/B-_P2G^..
MI>+/$FK^*-1BUUK>.\UF^ENYDB"Z:PC#R,Q"AG8[<XRQ/<U@_M#?\HD_@3_V
M,:?^@:G0!^B?CGX^>)_#>H?"V/0_A;K7B_3_ !BT7]H:CIDI,.AQN(SOE(C(
M( D)RQC&$/.>*]JK\VOVM/&WBGP'\5/V48_#GBWQ%H=IKL>GV^IV&GZS<PVE
MU&DUHH#P+((SD2N"=OS @'.!CT6_^*VO?'+_ (*$Z]\'KO6];T+P+X5T-KC[
M)H.IS:;->W92!S++- R2E1]HP$W;?W8)')R ?<%%?FO\'OVB/&7Q@_8G^.\&
MO^)-9/BCX?K</I_B.POY;*]=%C=X#)+ R%V5HG#9X<%=P)R3X5K?Q>^,7@O]
MCWX4_%V+XP^+;K5YO$MU81V$]\TEO)"C3/FY+$O<L6B(Q(Q0(54*""S '[.T
M56TN]_M+3;2[V>7]HA279G.W<H.,]^M6: "BBB@ HHH9@J.[,J1HI9G8@*H
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M&J.J3,?^F+_=F'LOS8Y*BOF\1E];#ZVNNZ.N%6,CVZBE(*G!&#25YIL%%%%
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M6O$.JW>LZK<MNEN[V4R2-[9/0#L!P!P*R***^@225D<@4444P"BBB@ HHHH
M**** "BBB@ K]!O@Y_R:=\+/^OG6/_2I:_/FOT&^#G_)IWPL_P"OG6/_ $J6
MM</_ +U1]7_Z3(YL5_ G\OS1I4445]@?-A1110 4444 %%%% !1110 4444
M;_@_QWK?@6_^U:1>O!N_UD#?-%*/1D/!^O4=B*^E?AW\;M%\=F*SN=NCZTW
MMY&_=3'_ *9N>Y_NGGTS7R717BYAE.'S!7FK2[K?Y]SNP^,JX9^Z[KL??+*5
M8AA@CL:2OF_X8_M"76B"'3/$QDU#35PD=X/FG@'O_?7Z\CMGI7T79WEOJ5G#
M>6=Q'=V<Z[XIX6W*X]C_ $K\NQ^6U\OGRU5H]GT?]=CZS#XJGB8WAOV/,_VF
M_@C_ ,-&? _Q)\._[:_X1[^V?LW_ !,OLOVGR?)N8I_]7O3=GRMOWAC=GG&#
MX]XX_8/G\5? WX6^!M-^)FJ>&=<^'^6L/$6FVA3S7*[2YA$H*D#H1)QEASNK
MZRHKRCK/"OA9^S+>>&_&NG>./B)X\U#XJ>-]+LFT_3-2O[""RM].B?\ UAAM
MXA@2..&D9F8CC/7/IWQ*\,:OXT\$ZIH>B>(7\*WVH1_9SJT-OYTT$3$"4Q#<
MH60IN"N<[&(;:V,'IZ* //\ 7/@7X1USX*77PJ.G?8_"$VE_V4MM;':T4>W"
MNK$']X& ?<<Y89.>:\F^#G[%-O\ #OXA>#_%OB+Q8WBV\\%:%_PCOAJ"/319
M):6_[P>9-^]D,TVR5DW#8N#]S/-?3-% !1110!YU\8OA3J'Q*7PS>:+XLO/!
MVO>'=2_M*RO[:WCN(W8Q20O%-$^-\;)(P(#*>X(->8_#K]D_5(_B%HOC3XD>
M)-/\2ZIX;U36-1T.ST;3FL[6&6_FWR7$H>21WD("X3=MC[%R-Y^DZ* /.OBM
M\(1\5O$'P_N;S5?LVC^%];77IM+^S[_M\\4;K; OO&P1R/YGW6R57IC-4_VB
M/A)XD^,W@:'0_"_Q'UCX8ZA'>QW+:MHJEI)8USF)MKHVTY!^5QR!D,.*]1HH
M ^?O&W[*<VK?%KPG\5/#/C.;0OB'H>FKI-Q?ZCIZWUIJT 5E/VFW22$ESN8[
MD=,';Q\HK3^!'[,%A\'_ !MXT\=ZGK+^*?'WBZ?S-2U;[*+2%(\Y$,$ 9_+3
M('WG=CM7)XKVZB@#R[]I3X$V?[27PGOO >H:M/HMC?75K-/=6T2R2[(IDD*J
M&. 6"X#'.,YP<8KRFU_8;_MBV^'&@>,_&H\3^!/A]*)M%T.+2!:2SL@ A^VS
M^<XFV* ,)'$&YW Y-?4]% 'RW\0/V-M>\9_M::#\<;;X@:?IUUH<<=M9Z++X
M=>=# J2*RR2B\0LY\Z3#!5 ^7Y3@Y@^'?[&?BCX<_M->,OC-:_$;2KO4_$]M
M<VMQI<WAB00Q)(T;IL87V[*O!"3G[P#CY2P*_5=% 'QA\(O^"?WB/X0_#OXM
M^$;+XH:;?VOQ#L)+2YN+CPLZO:.X:-W0"^PP,4TZA3T<QMDA&1]KP'_P3^T[
M1_V8=8^"/B[Q4GB?0+B[-_8:E8Z4;"[L9RV[?EIYE<AL8X7Y2P.=V1]:T4 ?
M-WA?]C^:;XH>!O&_Q \81>,K[P/IRZ=H%K9Z.-.AC(! GG!FE,LN,'*E%!4$
M*,5@6?[&'BS3?VJ_$7QUL_B7I*Z[JUO):IILWA:1[>"/[.D$.2+X,S(L418\
M;B&X7<-OUA10!\T_L6?L>WW[(&D^(]*_X36#Q;INL3QW07^QC92PRJNW._[1
M(&4KVV@YYSVKZ6HHH **** "BBB@ HHHH DMO^/B+_?'\ZWZP+;_ (^(O]\?
MSK?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#)U;_ (^%_P!S
M^IJE5W5O^/A?]S^IJE0 4444 %%%% !1110 5X#XP_97=_CQ+\8? 'BE/!7C
M6^T]M+U7[7IG]HV6H0E5"L\0EB82+Y<1#!\?NDRIYS[]10!Y1^S7^SEX=_9D
M^'I\,:#/<ZC-<W3W^HZI>X\^]N7 #.V.% "J HZ =R23L:M\*3XD^+ND^,]:
MU3[?I^A6K)HFABVVQ6EW)E9KQW+'S93'B-/E7RU,F,ER1W]% 'AWQH_9E'Q&
M^*G@[XG^&_$2>$OB!X7M[BRM=0N-/%_;S6\T<D;)+#YD9)432E2'&"YR&Z5T
M/[-_[/N@?LS?"NP\$^'IKB\@AE>YN;ZZP);JX?&^1@.!P%4 =%51DG)/J%%
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MRYX:TWU[>3_S/K\'C8XE<LM)&[1117S9Z84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 26W_'Q%_OC^=;]8%M
M_P ?$7^^/YUOT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!DZM
M_P ?"_[G]35*KNK?\?"_[G]35*@ HHHH **** "BBB@ HHHH **** "BBB@
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M.OBL1AYX:?)/_AST8S4U="4445REA1110 4444 %%%% !1110 4444 %%%%
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MOZN7J***^=/2"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6R@<$_? _O#YOM:OA:]">'FX3/3C)25T%%%%<Y04444 %%%% !1110 4444
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MBB@ HHHH **** )+;_CXB_WQ_.M^L"V_X^(O]\?SK?H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#)U;_CX7_<_J:I5=U;_CX7_<_J:I4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M);1_,YZT^5674Y:BBBOL3SPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K]!O@Y_R:=\+/^OG6/_2I:_/FOT&^#G_)IWPL_P"OG6/_ $J6
MM</_ +U1]7_Z3(YL5_ G\OS1I4445]@?-A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% $]C?3Z;>07=K*T%S ZR12H<%6!R"/QK[-^'GC:#
MX@^%;;5HPJ70_<WD*_\ +.8#GCT;[P^N.U?%=>B_ _X@#P/XN6*[EV:1J.+>
MZR?E0Y^23_@)/Y%J^<SS+_KV'<H+WXZKS[K^NIZ> Q/L*MI?"SZSHITB&-RI
MZ@XIM?D1]D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!);?\?$7^^/YUOU@6W_'Q%_OC^=;] !1110 4444 %%%% !1110
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MD\M?"M>#5_WB7^%?G(]C#_P_F_T"BBB@Z HHHH **** "BBB@ HHHH ****
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M% !1110 4444 %%%% !1110!]<? _P ;?\)GX'ABGDWZGI6VUGR>73'[I_Q
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M5PC.HU)'/6;25@_X7U\8_P#HJWC+_P **\_^.4?\+Z^,?_15O&7_ (45Y_\
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MC+$%]67$@_1#^=?3U?D?$%'V6/DU]I)_I^:/LLMGSX=+MH%%%%?-GIA1110
M4444 %%%% !1110 5^#OQZ_Y.5^*W_8T:M_Z625^\5?@[\>O^3E?BM_V-&K?
M^EDE>YE/\5G-7V.1HHHKZ\X HHHH **** /NM?V7O"7[-T/P9/C3PQ)XY\7>
M-M;M;>X%Y,ZZ5I*F6'=$R1D>=(1+@!V*-Y;_ "E1AN7\8?#_ .#OQ2OOC3I^
ME:'<?#SQSX).K:C;0Z;<M-IVK06TKAAY4F?)88'R1L% ;*@A=H^Q/V7?VJ/
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MQHTG_P!+(ZY&NN^ O_)ROPI_[&C2?_2R.N;$?PI%P^)'[Q4445^>GJA1110
M4444 %%%% !1110 4444 %%%% !7C7[9'C;_ (0+]F3Q_J"2>7<75A_9<.."
M6N6$)Q[A'=O^ U[+7Q7_ ,%4?$QT_P"#OA'05?:VJ:VUT0#RR00L"/ING0_@
M*[,'#VF(A'S,ZCM%L_,.BBBOOSRPHHHH **** "BBB@ HHHH **** "BBB@
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M?^/=O]_^@J[0 4444 %%%% $5S_Q[R_[A_E6#6]<_P#'O+_N'^58- !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S7Q.\1'PA\,
MO&.O!MC:7HM[>JPZ[HX'88]\@5TM>,?MG:Q_87[*_P 2+K=MWZ>EK_W^GCBQ
M_P"/UK1CSU(Q[M$R=DV?BM1117Z,>2%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5^@WP<_Y-.^%G_7SK'_ *5+7Y\U^@WP
M<_Y-.^%G_7SK'_I4M:X?_>J/J_\ TF1S8K^!/Y?FC2HHHK[ ^;"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH [#X/ZA_9OQ.
M\-39V[KU(2?:3Y#_ .A5]DLNUB/0XKX4T&\_LW7-.N\E?(N(Y=P[;6!_I7W?
M=+MN)!_M&OSCBJ%JM*?=-?<_^"?391+W)Q\R*BBBOACWPHHHH **** "BBB@
M HHHH *_!WX]?\G*_%;_ +&C5O\ TLDK]XJ_!WX]?\G*_%;_ +&C5O\ TLDK
MW,I_BLYJ^QR-%%%?7G %%%% !1110!]'7WP3O/@3^UY\/=%,5VVD7&NZ/>Z7
M>W0!-S"\T+$[E !*L60X Y7IR*^\/!WQYN/$GP8_:#E^(RPW.A>&-8UG1H+F
M9%07EM\ZQVQ[/(-RQ@XYWH#DY)_/CPC^VI\4]!N/#L&KZ^?%.A:1=V]P--UB
MSM;EI$B=6V+/-"[HQ" "0'<IP1R*YKXU?M&^,OC?J%RFKZG-!X=^WSWMCH,(
MCCMK7S'9@"(T02.H8CS&7<<L?XC7CU,+5KN*J6TZ_/\ 4Z(S4;V/T3_X)X^,
M=+^(W[)5YX#@G3^U]&6^L+FU+@/Y=R\LL<F.NT^:RY]4:O,?^"2MK=:/JGQ=
MAO8I+3[.-/CN%F!41R(UT"&ST(YZ].:^"O 7Q$\2_"_Q'#KWA36KO0M6B4H+
MFT?:64D$HPZ.I(&58$' XKM/%G[4WQ0\:Z'JFCZEXH,6G:K(9M1ATRQMK#[<
MY&UC.;>)#+D8!WDYP,]*53 S?M(Q:M.S]-;_ #!5%HWT/3+KX&Z_^VE^TI\4
M[[X=RZ7%I$.IS73:EJ-P8[<H\C+&PV([$R;'<84C .2.,R?![]@3Q-\1OBQX
MZ\!:YX@LO"VI>$HH6N9$B^V"=IANA,8#)\C)ABQ.5W*"N20/$OA/\;O''P.U
MBZU/P/X@GT*[NXA#<;(XYHY5!R-T<BLA(.<$C(R<$9.;.D_M!?$70_B3?>/[
M+Q9J$'BZ^)^U:D&4M." -CH1L* *H"%=HVK@# QU2IXA7C3DDK*W>_F1>&[1
M[1X'_8W^-_PQ_:(\*VEMX:O?,L=6@N$\0V +:>(4D4M(9A@*NW=E&PQ&1M.<
M5TG_  5"^,&D_$#XOZ-X9T>YBO8?"MK+#=W$+;E%W*ZF2+.,'8L<>2"<,67@
MJ:\E\5?MQ?'+QEI,VF:E\0KY;28;7%A;6]DY'IYD$:,!Z\\]*\+J:="I*I&K
M7M>*TL#DE%QB%?KZD;2?\$RL(I8_\(&3A1G@09)_(5^05>F:;^TM\3]&D\.M
M8^,]2M(_#]G_ &?IUM"56WBM\8*-%MV2 C&2ZL3A<DX&'B\/+$<G*]G<*<E&
M]S[/_P""3*_\(_X9^+GB+4F2PT)38!M0N'"1+Y*73S98G@(LB,2>,,*YG]B?
MQQ!\2OV_?'/BFU&+/5H-4NK;*;3Y+3Q^7D>NS;GWS7RGXH_:+^(/B_P>/"=[
MKR6GACS#*VCZ/I]KIEK(Q))+QVT<:ODG.&!YP>H%1_";]H+QU\#6NW\$:K:Z
M+<77^NNCI5G<3LO'R>;+$[A. =H(7/.,UA/"3G[6>G-/3R7X%*HERKHCZU_;
MP_Y/R^&/_7#1_P#TX2UZY_P5F_Y(3X5_[&2/_P!);BOA+7/VQOBMXF\1:9KV
MKZWI6IZWIAW66H77AK2Y)[<]1L<VV1@G(]#R.:L>,/VUOC!\0M';2?$WB2PU
M_368/]EU#P]IDR!AT8!K<X(]1S6<<'64J3T]SS?^17M(VEYGZ+:7_P HTG_[
M)[-_Z2-7!?\ !)7_ )(_XS_[#H_])XZ^-%_;Q^-\>BC1U\7VJZ2(/LPL!X?T
MT0"+&WR_+^S;=N.-N,8JAX-_;3^+_P /-).F>&/$>G^'].:1IC:Z;X=TR",N
MW5B%MAD_T '05D\!6=*=/3WG?=_Y#]K'F3['V'^PGXVTK1_VL?V@/#-W/'#J
MFM:S<7%DK\&46]W=>8BGUQ,&QW"$_P )KSSP9I]RO_!6"Z0P2;EUF^G88Z1F
MQE8,?8AA^8KX^\6?%KQ5XS\;+XPU#4U@\3*0XU/2K2'3I=X)/F$VR1@R9)^<
M_,>,G@5W<G[9GQ@EO)[[_A+(X]5GM?L,FKPZ38QZ@T Z1FZ6$38!Y'S\'GK7
M0\'4YI3C;WHV?Y=B?:*R3Z,^C?\ @HOX[TOQ%^U)\//#]@T4]WH'V=;Z6/!*
M2S7"N(F/JJ!6_P"VGUKU_P#X*S?\D)\*_P#8R1_^DMQ7YD^&_'FN>%?&5OXK
ML;Q9?$$$[72WFH6\5Z3,V<R,LZNKOEBVY@2&PPP0#7JOBK]MWXR>.M+&F>(O
M$]CKFG"5)_LNH>'M,GB\Q#E6VM;$9!_F1WI?4IPE2Y&K0_KL'M$U*_4^_P#]
ML?\ Y1[-_P!@W1/_ $=;5^1=>]:Y^W3\;/$V@W6B:MXNM=1T>ZB\B:QN= TU
MX73^Z5-OC' ^F!7@M=&"P\\/!QG;5WT(J24G=!1117HF04444 %==\!?^3E?
MA3_V-&D_^ED=<C77? 7_ ).5^%/_ &-&D_\ I9'7-B/X4BX?$C]XJ***_/3U
M0HHHH **** "BBB@ HHHH **** "BBB@ K\U/^"KGB,W/Q*\#>']Q*6&C27V
M.P:>=E/XXMU_2OTKK\E/^"E&K?VA^U)JEKNS_9VF6-KCTS$)<?\ D7]:]C*H
M\V)OV3.>N_</EJBBBOLSSPHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ^I_V'_BA!'JVH_"C7+A8M)\4RK-I-Q*0%L]65=L1R3P)E
M B/4D^7CN:]WO+2;3[N>UN(VAN(7:.2-ARK X(/N"*_.6WN);.XBG@E>">)@
M\<L;%61@<A@1R"#WK]'?#7CZ/X[?"O2/B%'L&N1,NE>)8(QC9>HHV7& !A9D
M ;@8#;ER2#7;@*WL:WLW\,_PE_P5^*\SS\;1YX>T6Z_+_@'I7@^,:CJWP5O%
M'.G:GK%@YQ_?MO.4?JWYFOR4K]>_@S&NI:;HD:C,NE^)A=L?1);"YC_F@_*O
MR$KSIKEQ=6/;]7)_J=5#6C%_UHDOT"BBBM#8**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#]:O\ @FKKQUG]E^VM2^[^R=9O
M+(+G[H;RY\?G,:^IJ^&?^"46K"X^'OQ!TO>Q-IJEK=;<<#S8G7/7OY/IV'X?
M<U?!8Z/+B9KS_,].F[P04445PFH4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!K:3_Q[M_O_P!!5VJ6D_\ 'NW^_P#T%7: "BBB@ HHHH B
MN?\ CWE_W#_*L&MZY_X]Y?\ </\ *L&@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *^:O\ @HI?&S_93\0Q9P+J^L83[XG#_P#L
ME?2M?*/_  4TE:/]F2-0<"3Q!:*?<>7.?Z"NS!J^(AZHSJ? S\G:***^_/+"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_
M0;X.?\FG?"S_ *^=8_\ 2I:_/FOT&^#G_)IWPL_Z^=8_]*EK7#_[U1]7_P"D
MR.;%?P)_+\T:5%%%?8'S84444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7WK!<?;+:WN/^>T*2?FH/]:^"J^ZM!?S/#NCO_>L
M;<_^0EKX/BM>Y1?F_P!#Z#*'[TUZ%ZBBBOSL^E"BBB@ HHHH **** "BBB@
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M>?E8=/3(I 4**^G?^"AW@WP]X&^/%EIWAC0[#P]I;:#:3"ST^W6%-S-)EB%
MRQ &6/)Q7S%65*HJL%-=2I+E=@HHHK8D**** "BBB@ HHHH **[[PQ\&]:\2
M?"GQE\0MK6OA[PY]FA,TD1(NKB:>.,1(>!\JN78\X^08^?(X&I4E*Z70=@HH
MHJA!1110 5UWP%_Y.5^%/_8T:3_Z61UR-==\!?\ DY7X4_\ 8T:3_P"ED=<V
M(_A2+A\2/WBHHHK\]/5"BBB@ HHHH **** "BBB@ HHHH **** "OQD_;DOW
MU+]J[XB2R'++>QP?A';Q1C]%%?LXO45^)O[7UQ]J_:>^)C]<:W<)_P!\MM_I
M7O9/_&D_+]3EQ'PH\@HHHKZTX0HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *]P_9'^,UO\)_B4;'7)BO@KQ-&-+UM3TB0G]U<CD
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MGR-7LI/IDNO_ +-79@_]XAZF=3X&?DC1117WYY84444 %%%% !1110 4444
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MGZ%U^#OQZ_Y.5^*W_8T:M_Z625]K_P##VK_JE7_EQ?\ W+7P/XV\7?\ "?\
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M4 %%%% !1110 4444 =9\,/BIXG^#?BV'Q+X1U1])UB*&6!9E19%*2(58,C
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M]17LY75]V5!_9U7H_P#)W^5CQ<=3Y9JHNOYE6BBBO</,"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@">QM6OKVWME^]-(L8^I.*^]
M;A569E4853M ]AQ7Q/\ #6R_M'XA>&[?&5?48-P_V1("?T!K[6D.Z1C[U^=<
M53O4I0[)O[[?Y'TN41]V<O0;7 _&_P""^B?'SP)+X3\076H6>G27$=P9=-D1
M)MR$D#+HXQSSQ7?45\-&3A)2CNCWVKZ,^-_^'6'PH_Z&#QE_X&VG_P BT?\
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M""BBB@ HHHH *U?ASX5M/'7QD\#>&[^2:&QUC6;'3KB2V8+*L<UPL;%"00&
M8XR",]C6577? 7_DY7X4_P#8T:3_ .ED=<^(;5-M%QW/T:_X=8?"C_H8/&7_
M (&VG_R+1_PZP^%'_0P>,O\ P-M/_D6OLBBOBOKV)_G9Z/LX=CXW_P"'6'PH
M_P"A@\9?^!MI_P#(M'_#K#X4?]#!XR_\#;3_ .1:^R**/KV)_G8>SAV/C?\
MX=8?"C_H8/&7_@;:?_(M'_#K#X4?]#!XR_\  VT_^1:^R**/KV)_G8>SAV/C
M?_AUA\*/^A@\9?\ @;:?_(M'_#K#X4?]#!XR_P# VT_^1:^R**/KV)_G8>SA
MV/C?_AUA\*/^A@\9?^!MI_\ (M?FGX&^'OB7XF:Y'H_A;1+S7-1?GR;.(ML'
M]YVZ(O\ M,0/>OWTKGO WP]\-?#/0X]'\+:)9Z'IR<^39Q!=Y_O.W5V_VF)/
MO790S.I2C+G]YO8SE14K6T/A7X&_\$O?^/?5/BEJWH_]@Z/)_P".RS_H1&/H
M]?=7@;X>^&OAGH<>C^%M$L]#TY.?)LX@N\_WG;J[?[3$GWKH:*X*^*JXA_O'
M\NAK&$8;!1117(6%?CY_P4+TTZ?^UMXT<+MCNDL;A??-G""?^^@U?L'7Y;?\
M%2M"_L_X^Z)J2K^[U+P] [-ZR1S3(1_WR$_.O:RF5L1;NF<]?X#XXHHHK[$\
M\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH _1;_@DSIICT?XH:@5XEFTVW5O\ =%RS#_QY:^^J^/O^"7>@_P!G
M_L^ZUJ3+B34?$$VT^L<<$*C_ ,>+U]@U\)F$N;$S?];'ITM((****\\U"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -;2?^/=O]_\ H*NU
M2TG_ (]V_P!_^@J[0 4444 %%%% $5S_ ,>\O^X?Y5@UO7/_ ![R_P"X?Y5@
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)[*
M'4K>:RN1NM[F-H)!ZJZE3^AI]*K%6!'44 ?S_>(=%G\-Z_J>D70Q=:?=2VLH
MQCYT<JWZ@UGU[C^VWX/;P7^U'X_M1'LAO+[^U(B.C+<HLQ(_X$[#Z@UX=7Z-
M3G[2$9]T>1)6=@HHHK404444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% #HY&C=71BCJ<AE."#ZBOTDTWQ@/C!\+?"7Q%4[[Z^A
M_LO6\<[=1MU"LQ]/-CV2 >YK\V:^JOV$/&RW6O>(?A=?2A;;Q1!]ITLR$ 1Z
MG;J7C )^[YD?F(3W^44Z=7ZO5C6Z+?T>_P!V_P C&M3]M3<.O3U_K0]NHI65
MHV*L"K*<%2,$&DK[0^8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#TO]G?3!J'Q0L9F&Y+*&:Y;\$*K_ ./.M?5M> _LKZ63<^(]
M4*X"116J-Z[V+,!_WPOYU[]7Y/Q)5]ICW'^5)?K^I]?ED.7#W[O_ ( 4445\
MN>L%%%% !1110 4444 %%%% !7X._'K_ ).5^*W_ &-&K?\ I9)7[Q5^#OQZ
M_P"3E?BM_P!C1JW_ *625[F4_P 5G-7V.1HHHKZ\X KW']D?X_:=\ _B%J%Q
MXBTIM;\(Z]ITFDZO8HJLS0N0=P5N&Q@@J2 5=N^*\.KU/X">'_!OBFX\:Z7X
MRU^P\,1W'A\KI6J:A&72*_\ MMH8@-JLPW*)%9E&5C:0G@&L*RC*FU-714;I
MZ'T]XB_8KT+QG;0_$_\ 9B\8V^LII]Q'>PZ#<2AKBTGC(D54:3D."%(CG4'N
M6.0*Y3]B"^L])\"_M 6NH>$M*N=1TWP9J,TUQ?)<+=2J(G#VDA65?+B)'S",
M(Y.,OE5QC?LPZ"_[/?QDM/&^N_$7PGI_A?24E-X='\1V][/JL31.!#%:PNTK
M9?8<2H@& W516I^SC\4O#/B_XF?M"IJNL6'@U/B+HVKIIMSK=PEO:P2W,KE(
MY)"< @2_CL;V!\N:GR3@WS)6L^N^S[FZM=/8\D\$:O\ "F;0?'7B;Q'H%J?$
MR);0^&_ ]J^H)ILKLRK-*\PE>8[0"^QIER2P!Y4)W/[1GP3\/:!^S[\-?B5I
M7A*Z^'^KZU<3V&J>'YY+EX]ZE]DT?VAFD56$98 D\.O/&6ZSX"Z#X-\(_#7X
MF:9X?^(_@_2/C%;W-O#IWB?4[Q;:U6U(C,ZV-Q*/O9\]#(B[CA2, JU6/C)J
MWA;Q'^Q;X2T2X^*VC>(?$V@:U>W5[BXEGO+V9S/M$<;@2,FZ11YSA5V@L,\*
M='4?M5RWM?SVMV[?C<FWNZG+_$OX??#K]F67X9Z%XG\%)XWN]<TF#6]>U:74
M;J+RXYG9?)LO(E1,Q[&.Z17W97IGCH?BA^QOX.T_]J+PU\(/"<GB""6^_P!/
MO]4U*^@GB2Q\MI',:K"A1P(Y%&]F!.SUKU6W^'.H>)_AC\(;73_$?PE\51Z+
MH-K?VY^(MY=07]G++N951(2NZV 541)E8'RB2#QCS"[USQ]^S+^UMX6^*/Q;
MU&Q\1V/B+STN-4T*9;JVFMS$(G2,;5(\D20MM &0  3DUC&I.5^67O)2Z[OI
M9%N*ZK30C^'/P@^$_C/4->T#QAIO@OX?:2UFQT?Q7;?$>SO;Z*92H47,*WKQ
M2%\EB4BC VD#J"/CG4;,Z;J%U:--#<&"5HC-;R"2)]I(W(PX93C((ZBOK?XD
M_LX? [PWKE]XTL/C1H.I>!?-^W1^%]-D6?5Y%+9%G&BOE<YVB1PNP'+#@FOE
M"SLO^$@U^"TM1:Z?]NN5BB%Q<"&W@WOA=\LC81%R,N[8 &2>IKOP\E*\E)M>
M=]/O_$RFNA[1^SA"OP^\->-_C!=+MD\-VG]FZ 7X\S5[M6CC9<\,88O-E*\X
MPA]*]E_::@3]HO\ 9%^'OQJ@VS^(_#JKX?\ $<@V[VPP17?'_30HX'I==*Y#
MXS:[K?[/_P ,_A]X7^&WQ,TLZ;!!)<ZW?>"/%,1N+K59V)D$J02"1HHXXXT1
MV7&!R02!7H?[%?QBO?'WA_XB>&/C)\1;*X\$:YIS62W'B[Q1$+N&XP 1#'/+
MYFPI(6W#"AHUP<[L<E1R_P!Y71_.VUK?B7&WP'SK^SQ\']+\=:9XY\:>)1-<
M>$O ^G+?WNGVLACFOYI"RV]N'P?+1F1MSC) ' R<B]J&J?!3QA\"]<NSHR>
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M;X>>'[CQ+X)^*GAWPSX_T[6)K&ZTAO%EA#%>6JPP/%+&[2^1.F^28$,Q4[0
M,JPJ3]N#X@^&?B+XX\,7^F2:3?>*XM$@B\4:IH)S87-_U;RFZ2;02-X)!!5<
MG97;"3]OO=._?3U6UNS,FO=/F^BBBO1,@KKO@+_R<K\*?^QHTG_TLCKD:Z[X
M"_\ )ROPI_[&C2?_ $LCKFQ'\*1</B1^\5%%%?GIZH4444 %%%% !1110 44
M44 %%%% !1110 5\"?\ !6#POYFD?#GQ)&G^IFO--F;UW".2,?\ CLOYU]]U
M\T?\%%/![>*_V7-8NHTWS:#?VNJ* .=NXP/^2SDG_=KOP,_9XF#\[??H955>
M#/R&HHHK[P\P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHJ:SLYM0O(+6VC::XGD6*.->K,QP /J32 _9?]A_PN/"
MG[*_@*!EVSWEO+J,I_O>=,\B'_OV4_*O<ZRO"/AN/P7X1T'P["5,.CZ=;Z<A
M7H1%$L8/_CM:M?G5:?M*DI]V>M%6204445D4%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 :VD_\>[?[_\ 05=JEI/_ ![M_O\ ]!5V@ HH
MHH **** (KG_ (]Y?]P_RK!K>N?^/>7_ '#_ "K!H **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\W?^"K/@?['XV\$>,(H
M\)J6GRZ;.RCCS()-ZD^Y6?'T3VKX1K]?_P#@H-\._P#A/?V9M;NHHO,OO#EQ
M%K,.!\VQ28YA]/+D9C_N"OR K[7+*GM,.EVT/.K1M,****]8P"BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %>U?L9^!3\0OVF/ >GM%YMM:WZZG<9^Z([8&8[O
M8E O_ J\5K[[_P""4WP^\[6O''CF>+Y;6WBT>T=AD%I&$LV/<+'$/I)7%C*G
MLJ$Y>7YFE-<TDC]%F;<Q/J<TE%%? GJ!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!K:3_P >[?[_ /05=JEI/_'NW^__ $%7: "B
MBB@ HHHH BN?^/>7_</\JP:WKG_CWE_W#_*L&@ HHHH **** "BBB@ HHHH
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MT?Z?CI\SDQ5/VE)VW6O^?]>1U5%%%?7'SH4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7J'[.WAO^W/B%#>R)NM]*B:[;TW_=C'UW'=_P !KR^O
MJG]G?PJ?#_@,ZA,NVZUB3SN1R(4RL8_$EF^A%>#GF*^JX*;6\M%\]_PN>A@*
M7M:\>RU/3Z***_'3[4**** "BBB@ HHHH **** "BBB@ K\'?CU_R<K\5O\
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MH7A6W\06VJQZ?!=:Y!KE]!<_9;B:&.46R&*"+)C#D,QSDG "[3GSGPOX;O\
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M3<)75H_J1._*KKN4:***](Q"BBB@ KKO@+_R<K\*?^QHTG_TLCKD:Z[X"_\
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M_P CLP\=Y"4445\P=@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 :VD_\>[?[_P#05=JEI/\ Q[M_O_T%7: "BBB@ HHHH BN?^/>
M7_</\JP:WKG_ (]Y?]P_RK!H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KR+]K#X/-\<O@1XC\.6T/G:Q @U+2EQDFZA!
M*JONZ%X_^!UZ[2JQ1@PX(.16E.;IS4X[H37,K,_GO92C%6!5@<$'J*2OI?\
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MEOL_5?U?T/F<12]C4<>G0****[3G"BBB@ HHHH **** "BBB@ HHHH ****
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MM?#>GS.1/JEY#--' H!.2D*.[$XP %ZD9*C+#)HI/8#Z:_;R\=>!?BY\6/\
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M>3I>DVD=E;*>NQ%"[CZL<9)[DDUKU^?XFL\15E4?4]6$>6*04445S%A1110
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M>@]G+L>'T5[BO_!/_P#:-=@H\!Y).!_Q.--_^/U8_P"'>/[2G_0@?^5G3?\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &MI/_ ![M_O\
M]!5VJ6D_\>[?[_\ 05=H **** "BBB@"*Y_X]Y?]P_RK!K>N?^/>7_</\JP:
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ0>"".,5U8;$3PU13B1.*FK,_GPHK[!_;F_8U/P=U"7QOX,M7D\#7LO^DV:
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MBN<K[1-25T><%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK*P!!]C7V%#$4\1'FILX)0<'9E6BBBNH@**** "BBB@ HHHH **** "BBB@
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MA?\ :@^&?BSQLG@ZV\1OIWBR09BT37M-N])O)>"?DBNXHF?@'[H/W3Z&O5*
M/B[_ (*<?!'XB?M!_#_PGX8^'_A"X\07%GJAU*YN_M]G;0Q*(I(PG[Z9&+$N
M#PI& ><\5](_"KP#H&C:?!XBB\ 6'@WQ9J-LJ:HYL[-;^1EX(FGMV=9,D;L^
M8W49P<@>@44 <'=? +X8WWB5O$5S\./"5QX@:Y%XVK2Z':M=F<-N$IE,>[?N
M .[.<\YKJ?$GA?1O&.D3Z5K^DV.N:7.,2V.I6R7$$G^\C@J?Q%8/Q3^+?ACX
M+^%W\1^+KJ\L-$B;;->6NEW5ZD''WI?L\4AC3MO<!<D#.2!5GX8_$[PU\9/
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M[D*RB8@)S(%=QO/.&(SR:[&&&.WA2**-8HD&%1% 4#T %/HH **** "BBB@
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M[NYT^&-9 SRM"[Q;Y-\:X5V.(5RQKZNH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *4,R]"1^-)10 [S7_OM^='F/_>;\Z;10 [S7_OM
M^=(6+=3FDHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** )+;_CXB_P!\?SK?K MO^/B+_?'\ZWZ "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH R=6_X^%_W/ZFJ57=6_P"/A?\ <_J:I4 %%%%
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M% !1110 4444 9.K?\?"_P"Y_4U2J[JW_'PO^Y_4U2H **** "BBB@ HHHH
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M;#K_ (@\*>*=)MI+.VU;P_=I&_D2,&>*2*6.2*12RJ<.AY4'L* /C7_@FO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(N[<!BH/C-\&O"WQ[^'^H>#?&%DU[H]X5<^5(8Y8I%.4DC<?=8'\""0002*
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MA72/&7Q@TOXH:G\4?B%)XVTI%BL-1BGTR,6L:ERL:1BQV;?WDF05.=[9SDT
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M%T8@, <9QD#TKX%^,'[(;_L5_$SP#\4O@KK&I6&G7GB&RT35?#MQ.9UDBN)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% $EM_Q\1?[X_G6_6!;?\?$7^^/YUOT %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!DZM_Q\+_N?U-4JNZM_P ?"_[G]35*@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** -;2?^/=O]_\ H*NU2TG_ (]V_P!_^@J[0 4444 %%%% $5S_ ,>\
MO^X?Y5@UO7/_ ![R_P"X?Y5@T %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!);?\?$7^^/YUOU@6W_'Q%_O
MC^=;] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9.K?\?"_P"Y
M_4U2J[JW_'PO^Y_4U2H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#6TG_CW;_?_H*NU2TG_CW;_?\ Z"KM
M !1110 4444 17/_ ![R_P"X?Y5@UO7/_'O+_N'^58- !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 26W_'
MQ%_OC^=;]8%M_P ?$7^^/YUOT %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!DZM_P ?"_[G]35*KNK?\?"_[G]35*@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/#_&MJB@#%_L^X_YY_\ CP_QH_L^X_YY_P#CP_QK:HH Q?[/N/\ GG_X\/\
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ML^X_YY_^/#_&MJB@#%_L^X_YY_\ CP_QH_L^X_YY_P#CP_QK:HH Q?[/N/\
MGG_X\/\ &C^S[C_GG_X\/\:VJ* ,7^S[C_GG_P"/#_&C^S[C_GG_ ./#_&MJ
MB@#%_L^X_P">?_CP_P :/[/N/^>?_CP_QK:HH Q?[/N/^>?_ (\/\:/[/N/^
M>?\ X\/\:VJ* ,7^S[C_ )Y_^/#_ !H_L^X_YY_^/#_&MJB@#%_L^X_YY_\
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M^/#_ !H_L^X_YY_^/#_&MJB@#%_L^X_YY_\ CP_QH_L^X_YY_P#CP_QK:HH
MQ?[/N/\ GG_X\/\ &C^S[C_GG_X\/\:VJ* ,7^S[C_GG_P"/#_&C^S[C_GG_
M ./#_&MJB@#%_L^X_P">?_CP_P :/[/N/^>?_CP_QK:HH Q?[/N/^>?_ (\/
M\:/[/N/^>?\ X\/\:VJ* ,7^S[C_ )Y_^/#_ !H_L^X_YY_^/#_&MJB@#%_L
M^X_YY_\ CP_QH_L^X_YY_P#CP_QK:HH Q?[/N/\ GG_X\/\ &C^S[C_GG_X\
M/\:VJ* ,7^S[C_GG_P"/#_&C^S[C_GG_ ./#_&MJB@#%_L^X_P">?_CP_P :
M/[/N/^>?_CP_QK:HH Q?[/N/^>?_ (\/\:/[/N/^>?\ X\/\:VJ* ,7^S[C_
M )Y_^/#_ !H_L^X_YY_^/#_&MJB@#%_L^X_YY_\ CP_QH_L^X_YY_P#CP_QK
M:HH Q?[/N/\ GG_X\/\ &C^S[C_GG_X\/\:VJ* ,7^S[C_GG_P"/#_&C^S[C
M_GG_ ./#_&MJB@#%_L^X_P">?_CP_P :/[/N/^>?_CP_QK:HH Q?[/N/^>?_
M (\/\:/[/N/^>?\ X\/\:VJ* ,7^S[C_ )Y_^/#_ !H_L^X_YY_^/#_&MJB@
M#%_L^X_YY_\ CP_QH_L^X_YY_P#CP_QK:HH Q?[/N/\ GG_X\/\ &C^S[C_G
?G_X\/\:VJ* *NGPO!"RNNT[L]?85:HHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>rprx-20211231_g4.jpg
<TEXT>
begin 644 rprx-20211231_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUZ/_ ,%VM,T_6?\ @Y1_8<TS7-.M[J":7PV)[:XB$D;_ /%27!P588(R.XH
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M:_ZW<QM#9"8I'Y,GFR!=D.!YK)N7/O?[._[:/[+/[5O[/J?M3_ 3XV:)KO@
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M6"&"$2[+AUVN>3\^?\&PEU;:?_P5/_;T-_<QP#_A/2F9G"_,VO:LBKSW+,%
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M#4O$>NZ1#J::;$^I^&=;GTZ_MC_PB)8/#<P,LD3 @<@X(R""I(/,?LP:]?\
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M)\.S1Z#J1GN)X71)G:W-L)HH8S(@:=T6/)P&)&*_/S_@A[C_ (A1_P!H_/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCP-^SWI%I\*=9LY[?6O"[33O_:/G8\V:>X:0SR3G:A$QD\Q?+3:R[$V^Z44
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M=#O_ (HZ>EA\4X/!GC34]%M?&-J@8"/48+.>..<D/(K2 +(RR.K.0[ _2U%
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M_"K]D3X>7_A7PW?Z@;Z?19O%^JZG;I<, K21I?W4XA+ +N\O;NVC.<"O8Z*
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M?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
MMJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\
M MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8
MHK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\
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M;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\
MP+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_
M  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH
MV**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_
M (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:@#8HK
M'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_  +:C_A!
M](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A
M!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\
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M0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<1D^U=E2I3HPYYM)=WHC&,)3ERQ5V6Z*1'25!)&X96&593D$4M6FFB0HHHH
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M9\Q_+!$LS=MK$9&!T]L$W]>U>^\5?#F[U;X::E#-<7=BS:=<!B!DCMQD,.<
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M?C/2&622VTG4_$T=M E_92$1:E8BZMIIA#(,)- K!EW,&P/C)^T1\3/VL/\
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M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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MZ1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\
MP@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\ X%M1_P (/I'_
M #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\
M_-[_ .!;4?\ "#Z1_P _-[_X%M0!L45C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_
M (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\ P@^D?\_-
M[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6
MU &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;
M4?\ "#Z1_P _-[_X%M0!L45C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L4
M5C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P
M@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U &Q16/_
M ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\ "#Z1
M_P _-[_X%M0!L45C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'
M_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[
M_P"!;4 ;%%8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/
MS>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X
M%M0!L45C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@
M6U'_  @^D?\ /S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;
M%%8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?
M\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M0!L45C
M_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^
MD?\ /S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z
M1_S\WO\ X%M1_P (/I'_ #\WO_@6U &Q17+ZC8^!=)U.VT74?$DD-Y>.%M;5
M]0/F2'V7.<>_2LWQGX;\9V-Y!%X&T&.^A:(F>6\UEXRC9X4 #TYS_+OPXC,,
M-AZ4YJ\^1I-03G)-]XQN^M]MM3HI86K5G&.D;ZIR:BOO=D=U17'>#?"GB"]L
MYG\<:=]AG67$*66J/*&3'4D]#FJ$G[/>B:G>7%_XC\7:W>22SL8@EZ8EBBS\
ML8 ZX'?OZ"N:MC\=/#4ZF#P[FY7TF_9\J7\UTY7?1<OFVM+ZPPV'C5E"O54;
M?RKGOZ6:7KJ>@57M-6TK4+B:UL-3MYY;9@MQ'#,K-$3G 8 Y7H>OH:YCQ;\,
M;W4M!&E^%/%%SITY=%>ZED:4^5T8#D8;'0^W;.1)X9^#?@KPE9_9-%AN(F95
M$\PG(>8C/S.1U/)^F3BMGB,PEF$:4:25)*\IM[MWM&"5VVG\3ERI*UKWTA4\
M,L*YN?OMV44NG5R?Y)7\[=>J#*Q(5@2IPP!Z&EK@_$/P%T:^O)M=\+^(]3TC
M5)>6NX;DR+(0,#>C'YAP. 16O:^$--TG2+<^)O$$AG")'/<F[,222G X!/&3
MT&:6'Q>-=>I#%4>2,=5-24HR5]-^6496U:<>5=),*M'#JG&5*IS-[QLTT_Q3
M79WOW2.EK"U'XB^&-/\ %=IX)6YDN=2NV.;>TC,AMU )WRX^XO0<^N>G-9/A
M:W\%?$73;V;2)=3DLX[B2U,\D[*EQ@89HSGYEY(S[59\/?!KP+X5B:+0+*>V
M\S'FNERVY_JW4UC/$XW'*E4R^4/92UE-W;LGM&*23YM5S.6FZ4BXTJ&'YXXE
M2YUHHZ+7NWNK=K:]T;6I^*_#.C73V6K:]:6TT=J;EXYIU4K"#@N0>V>,TZP\
M3:#J?A]/%5GJD3:<\!F%VQVH(P,ECNQC&#G/3%<_XA^"7@/Q5<VUUKMI<7#V
MK$Q[[DG(/\)]1G!QZCZYT)OAUX;N+-M.G6X>W:/8T#3DH5QC;CICVK6F\X>+
MJ\Z@J:7N6YN9NRUET23NK*[>_N[.9+ JC#EYN?[6UDO+JV]];6VUW+T?BSPM
M+/#;0^)+!Y+E]MO&EVA,C8SA0#SP":S/'VK>/K?[+HWP_P!!BFN;TL)-2NW
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M)SY-'*-G>%^B>EVNUNI\CVW_  2Q\?>)+H'XD_M#-<PQ1GR/*LY;APQ_ZZR
M*.AXSG&..M?7W@WPQ8^"O"&E>#=,.;;2=.@L[<XQE(HU1>/HHJ'_ (0?2/\
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M)\6R?$#P_=:=X%A=K?28KV^ D&TYBDA,>?,W*27).!N W93;7M7_  @^D?\
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MNP@MHVD:1HX(@BEV.6; '4DDD]R:FHHH **** "BBB@ HHHH **** "BBB@
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M?X^?"/PIJC_&7Q.[0ZI<"YLM#FF\^2VD?YY97DR=K.6^9 2-P+$Y//IGQM^
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MBBOF#ZD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML[*SA:6ZN[F4)'$BC)9F/  %87PM^,GPV^-.E7FN?#+Q/'JEI8WS6EQ/'$Z
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MGJ,'[+K@_CO^SG\-_P!HC2=.TOQ_9S;M+OTN;2ZM)/+F49'F1;L9".!@@<\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-O<QDA@X"G:>GWEZY/6J7B7X)>"?%.KW.MW[ZC%-> ?:A:ZC(B2D+MR5SCH
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M-NWO.*ZK6VO7J<U\*_A#\/?@OX6A\(?#KPW!86D8'F.HS+</W>1SR['U/T&
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M"+E)4K^XJDE9SBNFE]+;VM9*PM%%%?%'VX4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME%D&2"D@( ?L<9X)*_2WQ%LO&VK:7!HG@J[CLVO+CR[[46;Y[6#:2S(.['
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MM-H\NJNWHM>K,\?EF19?B,SJUG&G15XV5IR?V;*^FO6^]ENSZ?5510B*  ,
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MA[!O$XVIRKHOM2?:*W;_ "W=EJ88C$T<+3YZCM^;]#VRL/QQ\2/ _P -]/\
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M?T&0 ?\ 9)KD_P!G_P#9=T'X/2IXFU>]&HZ\T)0SJ"(;8,/F6,'DG'!<\D=
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M']CW]GO]J7X,>.[]OBG\2H-3\-Q:?]BL;)M4GN=VU@T<D2N (0N64@\_,1C
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M^PMMC)+0S8')P"R-COGKBD_:=^(+?'KQWHGPR^%5TNJ01(TJFW;"S7# D\G
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M^'AHG[*__!8[PE^SG\%/#-CX>\"_$WX ZEJ.J^%=$M$M[&#5='U&UCM]06%
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M&ZX\?_!"'QII=_I[:I<63&SDEF_=SD<"0A02IX.4(!#*0<"OGS5?^"@/P_\
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MPMRUJ57+IRKT=8/64>WFCZ!_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J\"UO\
M;7T.S3PTVD>&K>Y,D*2^)P8 #&2"K119_B!R^3QC:.YQ[[X?O_#'BK1+7Q%H
M'V:YL[R$2V\T<8PRG\.#V(/(((-?89+Q3D?$%:I2P-93E!)M>4DFFN]KV=MG
MH^AW8?&8?%2<:<KM!_PF/AC_ *#4'_?5'_"8^&/^@U!_WU7+:W\8O .A?%[3
M_A#=VT'VN^MB[7&U=L,QP8HCQU<;C^*#G=QVO]G:?_SXP_\ ?H5ZN%Q^#QLZ
ML*$U)TY<LK=)))M/[_TW3-H5:=1M1=[.S]2G_P )CX8_Z#4'_?5'_"8^&/\
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M6CA4"%@/D8 #C:P4@>U?.WPR^('C/]EOQ/'\+OB[X<B.C75R9([P)O\ *#$
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M@#Z:3\1N(H1A*,,)AZVK:;=:G#L[Z<T[Z-)<MM;,['_:N*232A&7_@27^;_
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M?$7=IMB=L!ANY+F21?\ 8#@!!VR<GV(KVBZ^ ?PDN_!B^!9?!5F+)(0D<BQ
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M]'PKQ)A>(LLC53M6BDJL'I*$^J:>J5T[/]4SKP>+ABJ*?VENNS*W_"8^&/\
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MY-C:27$O[L?=12Q[>@KYY_8C\$:?XLUG7OBGXFTZ.ZN8KM8[*65=P25]SRL
M>-V&3![9/K7P7&>,S#$U\-D.!DH3Q7/S3ZPIQ5Y-+O).R_2]UYN/J59RAAJ;
MLYWN^R6_WGH_[.7A3PI\(OAS;Z7>:I;C5+W%SJKALD2$<1Y]$'R^F=Q[UWW_
M  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*^ORW+\+E. I8/#JT
M*:45\NK\WNWU>IW4:4*%)4X;(\^^*_PT^"GQ@A\WQ+/%%?I%L@U.U?9-&.2
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M_P!!J#_OJC_A,?#'_0:@_P"^J\Q\%_M=?!/Q7K-[I>HQ#1XX-S6EWJ,2A+E
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M)'%%"NR&-47T5<"@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M27ME%,UM-YUN9$#>7)M*[UST.&89]S4U%:RC&2LU<JR84444P"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KRSQC^R3\-O&WQ*_X3_5#-'#,-]_I=O\ )'=39_UA8<KD
M?> QD\Y'.?4Z*\W,\GRO.J4:6.I*I&+4DI*]FOZU6S6C31E6H4<1%*I&Z6IY
MC\:_V9O"7Q+\(6NC>&;*RT:^TWC3IX+<)&J$_-&P4<J>OJ&Y[G.7\*_V,_A[
MX'E;4O%\J^(KQXRH6[M@MO'D<D1DG<>>K$^H ->Q45Y57@WAFOFJS&IAHNJD
ME_=TT3Y?A;2TNU=65MC"6 P<JWM7!7_KIL>:V_[(OP"@FN97\%&47)^Y)?S8
MB'HF'!'ZGWQQ7/WO[#/PI?6K;5-,U/4[>"*Y22>PEE66.5 P)0$@,N1QG)ZU
M[512K\%<)8B*C/ T]'?2*B^^\;/Y;!++\%)6=-?=;\A$1(T$<:!54850, #T
MI:**^HV.P**** .)^-OP0\,?&CPX=/U*-;?48%)T[4U3+PM_=/\ >0]U_$8-
M>$'X._M=SZ?;_!6[OY$T%F(%RMVAMUB'9G7]X4YXC/X+QQ]6T5\;GO ^49[C
M/K4I3I5&N6;IRY?:1T]V>FJTMW];*W!B<NH8FISMM/9V=KKLSY,^-'[.5U^S
MUHFB_$OP1X@O+NXL+Y/[0N)54"*7(,;JJCY4W J02WWE&>:[;QI^W#X4;X>I
M+X)M;AO$-Y!L-O+ 0EC(0 7+'A\$G:!G..<=*]YO+.SU&UDL=0M8YX)5*RPS
M1AD=3U!!X(KBO#_[.'P=\,>,3XWT;PA#'=\&&)F+0P/G.](SPK?3@8X KP:W
M!>=9/BZBX;K0H4*ZC&<9*3<&E;GIZN\FN_76^S7-++\10F_JDE&,K73OIYKS
M/G+5/V7/&"?!>\^,/B*^N1JY)O)=,FCRYMR06DD)Y#X)<CL!SSP.GT3]M+QB
MWA'1/"/@WP0^J^($LQ#=RSQO*)'3*J4CC.YR5 8G(Y)X/6OIN\M+;4+26PO8
M%EAGC:.6-QD.I&"#[$&N2^$_P-\!?!VRDA\+Z>7NI\_:-1NL-,XSG;G'RJ..
M!CIDY/-<L?#W,LGS"G_86)]A3G3Y:TG[TFXNZDD].:5VNBBKVWUA975H55]6
MGRIJTGN].OJ_P/%KC]I+]IWX>75IXA^)WP_"Z1-+MDB?3S!G/.T/D[&] PYP
M>*]*MOVQ/@//H8UB7Q1-%)@;K!["7SE8C[O"E3]0V/>O2-5TK3-<TZ;2-9L(
M;JUN$*3V]Q&'1U/8@\&O/I/V1_@')JRZM_PA.W;R;9;Z80L?4KN_08'M7JK)
M>.\GJ..78V&(A+?ZQS.47U<90W7D]%T74V^KYE0=J5123_FO=>ECS_XX_M>?
M#CQ5\,]4\)>"SJ,M]J5OY"R26@CCC0L-^XEL\IN P#R:[O\ 9!\,?\(W\"],
MEDCVRZE++>RC'7<VU#_WPB5T6D? GX.:'="]TWX;:0LH^Z\EFLA7W&_.#[BN
MKCCCAC6**-551A548 'H*[,FX>SU9^\WSBM"=14W3C&G%J,4Y<S=V[WZ;;,T
MP^%Q/UGV]>2;M9)+S%HHHK[D]$**** "BBB@"*RL;+3;86>GVD<$2DE8HD"J
M"223@>I)/U-<A\;/@CX9^-/AS^S-4 M[^W!.G:DB9>!O0_WD/=?Q&#S7:45Q
M8[+L%F6"EA,334J<E9Q>UOTMT:U3U1G4I4ZM-PFKI]#YBTG]CGXJS>,M$T[Q
MWXG@U3PY839.R_D?R81\QB6.0#8'*A2%R!G/:O??B)\,?!_Q1\,MX5\5Z=OM
MP0T$D.%DMV'1HVP=IQQTP1P0:Z"BO"R?@W(<EPM?#TH.<*UN=3?-=)64=?LI
M;)WM??8YZ& PV'A*,5=2WOK\CR;QK^QO\(?%&EV5AHEE)HDMEM4W-D=S3QYR
M1)OSN8\X<\CCJ!BMS3?V8?@7IMA%8+\/;.?RD"^=<EGD<^K$GDFN]HKII\)<
M,4L1*M'!T^:22?N*UEM96LODE?KL4L%@U)R5-7]#Y=^)7@?Q=^RA\2E^*_PU
MM#+X=NWV7-IDE(@QRT$G<*3RC=C@'D?-KW/[?VF_\)!&MGX!G_LH0MYSRW ^
MT&3;\N /E"@\'DD@YXQ@_0>J:7IVMZ=/I&KV4=S:W,9CG@F3<KJ>""#7*>)/
M@%\+O$/@-_A['X7MK&R^];O9Q!9()<8$H;J6]2<Y'!S7R.*X0XERJK6?#N,5
M&C)\ZI2BFE/K&+:?+"77MM:QPSP.+H2E]5GRQ>MFNO9=DSYT^'_P(\8?M*V'
MB/XLZ[K#6]U<SR'304^2ZG )*9/W8U^5 1G'_ <5J_!K]KJ3X4^$T^'GC[PQ
M?7<NEW#0PR12*KPQ X\IE;NIW <],#C%?3'A'PMI'@GPS8^$]"@\NTL+=8H5
M[G'5CZDG))[DFH==\ >"/$UI<V6O>$]/N8[M2+CS+5=SYZG<!D'OD'(/-<V$
M\/<RRFG1Q>5XOV6+Y9*K*2YXU92?,[I[6EHG:]K.U]YAE=:@HSHSM.WO-ZWO
MK^8WP+X_\)_$C08_$?@_5X[NV?APO#Q-W1U/*L/0_49'-;-?+?C3X>_$/]DC
MQH?B+\,C-?>&YR!=P2Y81IG_ %4V.W/RR=CP>?O>L> _VM/@UXTLX/MOB./1
M[V11YMGJ>4"-Z"4C81Z'(/J!TKWLEXSI3K2R_.N7#8N&ZD[0FNDJ<GHT^U[K
MSL=.'Q\7+V6(]R:^Y^:9Z914=K=VM_;)>6-S'-#(NZ.6)PRL/4$<&I*^Y34E
M=;'H[A1113 **\W^,7[3'@_X->*-.\,ZSI]Q>/=1&6\-HZEK6/.$8J<;BQ#<
M9! &>XKR_P 6_MK^+'\>3WWPXT!;_P -V$ %Q'<6K!I1D9F+ 9B&2%&>.Y&3
M@?'9OQ[PODU:5&O6O4C)1E&*;DKJ]VNJ2^)J]MM]#@KYE@\/)QE+5.S2W/IB
MBOF9?VF?VE/B5<3:I\*?AP(]-@!&([)KDY]#(<!F_P!E0#]:I7O[4GQ^^(R6
M_P -/"'@[^S_ !"TA2]GM(F$O&.B2#$ '\3,3CU6O*GXH<.J-X0JRYOX=J<K
M57>UH-[OUM]^AB\XPJ6BD^VCU]#ZFHKYJEL/V]/!^?(OWU-)AM)5[6XV,> ?
MG 88]?N^M0W'B_\ ;;^$T']N^)],;5=/7]Y<)+##<J@/)W& [T ]<[15R\0J
M='7$9;BH)?$W2TBN[:EMYC_M11^*E-=_=V/INBOER?XS_M%?M+7C>'OA9HS:
M+IZHJWMQ;3D!21SON" 5'HJ -C^]4NI?LZ?M+_#..'QAX*^(4NJWELP+VEM=
M2%L=\++\LJ^JGD^A[1_Q$"IBTZ^6Y?6KX>.]1+EOWY(R]Z=OD[Z.VXO[3<_>
MI4I2BNNWW+J?3U%?.>@_MH>-_".K)HGQO^&<UF2.9K6VD@E _O>5*<./<,/;
MTJ#XB?MUZ=JOAO4-'\ ^&[^TO+B,Q6NH74B#R@>"^U2<-C..>#@]L5O/Q-X0
MAA959UW&4;^XXR4[I7M9K=[)WM?J4\WP*@Y.5FNEG<]N\'?%3PMXY\4Z[X4T
M"Y\V;0)HXKJ0$;79@V=OJ%92I]Q]*Z6OCGX#Z[J?[//QEMD^)&[3K35=(#7C
M39.R.1/-C<@#.X,H4CJ"6%>NWW[<GPL77+;2-&TK4KJ*:Z2*:_E188HT9@#(
M 26.!S@J.E<?#OB)EF(RMU,XJQH5U.47!Z-:WC[OQ646E>VZ9&%S2E*C>NU&
M5VK?EH>TT4=>E%?I9ZP4444 %%%% !1110 45QGQJ^-'A_X+>'[?6-7C,\]W
M=)%;6:-AI%R/,?Z*N3]2H[UU]G=VVH6D5_93K+#/&LD4B'(=2,@CV(-<=+,,
M'6QM3"0FG4IJ+E'JE*_+?UL_P[HS56G*HX)ZJU_F24445V&@5SWBCXL?#3P6
MYA\4>.=,LY5.&MY+M3*/^ #+?I2_%3QU:?#7X?ZIXTNMI-E;$P1MTDF/RQK^
M+$#Z9KY7\"?LZ:U\4?A#KWQ;NKVZ?56GDETR 8VW>P[IF;C+%CN5<$?,ISG-
M?"\5\4YEE6+A@,KH*M7<)U&FVE&$>MEJW)W25UJK=3SL;C*M&:IT8\TK-^B7
M^9]?7NN:+IJ1R:CJ]K;K,,Q-/<*@<<=,GGJ/SK(\2_%?X<^$M'EUW7/&6GQP
M0C)\NY61V/95522Q/H!7R-X&M?%_[37C'PY\/=;U)TM=&TMH&NHUW&*W0D[R
M#U8YCCSWPOO7L%C^P-X$@O(IK_QKJD\*.#)"L4:;QZ;N<9KQ<OXVXHXDH3KY
M-E\94K\JG.HH^]RIN\;)M1;Z/7O<YZ688S%Q<L/236UV^OH<_P#M/_M#^%_B
M=X TOP=\-=1ENGU6]#7\!A9)$"$;(F4]2SL",9'R=:\X^'OP=\3Z_P#&>V^#
M'B19%BT[49)=2A60F..-0ID=?3>JHH;OE*^A]-_8\^&WA_XCZ9X\\.3W-M!I
M]QY[:3*WFQLZ@["KL=RX;#8);..U>A67@3P[I_C>^^(-M9@:EJ%E%:W$OJD9
M)!'N<J#[1KZ5X]7@#/\ B3.%F&>2BI1G"+C!^Y*E"+;MU]^=M'9KWG;8P>68
MK%U_:XAJ]TK+9Q2_5_J:-OI>FVDQN;73X(Y#&$,D<0#%1T7('0>E3T45^U1C
M&"M%6/H$DB*SL;'3XC!I]G% A=G*0QA06)R3@=R>2:EHHIQC&*LE9 DD?.W[
M;OA*ZT'4] ^-'AY!%=6ETMO<S(O(=3YD#G'H5<9/^R*]S\">,-,\?>$-/\7Z
M1*K0W]JLNU6SY;$?,A]U;*GW%.\9^#M!\?>&;OPEXEM!-9WD6R1>A4]0RGLP
M."#ZBOF.'2?VFOV8?[;T[PG8O=Z!#*;AKY[998=@'^M SE#MP&'^SW S7YEF
M57$<%\25LS5&53"8E)S]FN9TZD$_>:_EDMW??5[*_D592P&+E6Y6X3WMT:Z_
M,^L*"0.">O2O,? /[2'AS5?@9_PM3Q7=QQ3V"&#4K>+ 9[E<81%]7RK =MWH
M":\+\5>./VB_C#;S?&G2[6YL]&\.W(FLX[-\1P%3RRJ>9BH/SL00 3T&17I9
MOX@95E^$HU<-"5>=6/M%""U5/>4Y;\J2OOU5M-6M:^9T:4(N"<FU>R[=WV/L
M*BO.O@I^T5X,^*/A6*[U+6+/3]6@0+J-C/.(\,.-Z;C\R'KWQG!]_0;:\M+R
MW%Y:74<L3#*RQN&4CUR.*^LRW-<OS?"PQ&$J*<9*ZL_S6Z:V:>ST9VTJU*O!
M3@[IDE([I&ADD<*JC+,QP /6O&/BO^V=X+\&7DGA_P #V)U_44?8TD<FVV1O
M3>,F0^RC'^U7G&K_ !%^+/[8/B"V\!^&-..C:3"BOJ@CG9XU]7E;"[A_=C[G
MUZCY'-/$3(<)7>$P3>)Q-U&-.%WS2?3GLXJWVM7;L<5;-,-"7)3]^?1+OZ['
M?_%C]L:R\,>*4\)?#'0HO$4\8/VJ>.5FCW==D>P'>0,Y(X'3GG')ZE^U;^T@
MT7_"40?"E;31[-PUV[Z5<%&7H0TK' ^H QQG->O?!K]G;P)\&(VO-(66]U.:
M/9/J=V!OQW5%'"*?3DGN3BN]=$D0QR(&5AAE89!'I7)3X?XWS6G*OC<Q>'E)
MMJG2C%QA_*G+>7]Y;/N9K"YA63E4J\K?1+;Y]?,\%TO]OOP+/)&FL>!]5MU9
M1YKV\L<NT^P)7(]_TKW/2-2@UG2K76+5)%BN[=)HUE7:P5E# $=C@\BLW4_A
MO\/=9M39:KX'TBXB;JDNG1D?4?+P?>MF-$B011H%50 J@8 'I7TV18/B7"3F
MLTQ4:\6ER\L%!IZWO;2VUOF=>&IXN#?MIJ7;2PM%%%?1G6%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 RXMX+N![6Z@22*12LD<BAE93P00
M>HKR3Q7^Q;\(O$7B*#7-.BN=+B$X>\T^S?\ <SKU*@'F+/\ LG&.@'6O7J*\
MK-<CRC.Z<88^A&HHNZYEJO1[J_5;/J8UL/0Q"M4BF>4W_P"RCX%?XNZ5\0]*
MM(+2PLH@USI$<6(Y)XP!"P'0#NP[E!UW-7JU%%5EV3Y9E,JKP=)0]I+FE;J[
M)?):;+2[;ZA2H4:#ER*UW=A1117IFP4444 %%%% !1110 4444 %<MXA^"7P
MG\5ZO+KWB+P'I]U>3X,UQ)%\SD  $X/)P!S74T5S8K!8/'4U#$TXSBG>TDI*
M_>S3U(G3IU%::37F>(_&W]CWP1KOAJXU;X9:*--UBVBWPVT$A\FZQU0JQ(5B
M.A&.<9]1?_9"^,U]\1O"$WA3Q+.7U;0@D;2R'Y[B Y"LV>K*1M8_[I/)KU^O
ME/XM2^(/V9/VC)?''@_3DEM=<MY)H;5P?+E,G$D1V\\2[7 '8J*_->(<+A>"
M,VH9[@X>SH2?L\1&"M%QE\,^5:7C+>VKNEU=_)Q4(9?7CB::M%Z22_!V\CW[
MXT?%[0?@UX/D\2:JHFN9"8].L0^&N)<=/91U9NP]R ?#? ?A'XP_M(_%31OB
M_P".M#AM-$L)HG@+*8XWBC<R*D:$EGRQY8\$9YX JQX+^!_Q;_:!\7V_Q%^/
M,DMIID3!H=-E0QO)'G(C2/K$A[L?F(]<[A]*VUM;V=O'9VD"111($BBC4!44
M#   Z #M6E#!9EQWC5B\<IT<#!Q=.D[*51IWYZBU:CVCU6JMNW&G5S*ISU+Q
MIK9=7YOR'T445^GGL!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^<R7+7$GF.PQ@)N/)103@'/4YR2:Z'2]+T[1-.@TC2+*.VM;:,1P00IM5%'
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M-]VWU;U?4ZZ5&E0@H05D@HHHKT#4**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *KW6D:3?7MOJ5[IEO-<6A8VL\L*L\.[&[82,KG SCKBK%%3*$9JT
ME=?Y:K\1-)[A1115#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#%\4_#
MOP-XXN;6[\7^%;+4I+(M]F-Y '";L9&#P0<#@Y'%:6FZ5I>C6BV&CZ;;VD"?
M=AMH5C0?0* *L45A#"X6G7E6C!*<MY)*[Z:O=Z=R5""DY):L****W*"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\
MT&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_
M -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!
MC_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/
M^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !
MC_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0
M;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\
MT&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/
M]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_X
MT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/
M^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!N
MR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0
M;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V
M+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1
M]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_X
MUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+
M_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!N
MR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O
M&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V
M+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6
MQ10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_
M  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+
M_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;
M_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O
M&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%
M% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\
M 8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_
M  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_
M -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;
M_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44
M 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !
MC_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\
MT&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_
M -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!
MC_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/
M^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !
MC_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0
M;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\
MT&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/
M]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_X
MT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/
M^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!N
MR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0
M;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V
M+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1
M]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_X
MUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+
M_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!N
MR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O
M&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V
M+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6
MQ10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_
M  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+
M_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;
M_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O
M&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%
M% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBO!/VUOVW;;]EF?2OA_X3\'6_B#QSXE\*>)/$'A_2M2U3[#9?8M$M(KB
M]EFG"2/D>?;HD<<;N[2Y^1$>1 #WNBN.^"_Q)\5?$C0]3;QU\,[KPGK6B:W-
MIFI:9/?)=0R.B1R)<6TZ!?.MY(Y8W1F2-^2KQHRE1V- !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\
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M;4?\(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%%
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M[_X%M6Q10!C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5L44 8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;5L44 8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\
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M #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
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M(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\
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MM"O+CX4?#/0/&]M+XN\>7&EOJ-CJ,&HSFVF@&G226EZHL#&(2&0,7+S)M57
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M?#V?P4O]LZ49[MKPZ4NK"Y^?3Q<.S;&@,K1.8?,5?F/I/[#/[)GC?]D;P_\
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M#S?'/1'L+WX30> ?^$(7P/*LJ6<.IS:BEQ]N_M @S>9.Z'_1]I4#@'D_1%%
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MD2[@NZ1PHR3@#)]30!\W?'W]AOXI_'#X2? [X>Q_'[0=+U'X0>/_  _XIO\
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M &5_B=^R!JNO:CKGA#XDSZ_9-;S$1R:-X>U![D0:+:O\Q6"UCNIA%G.UY78
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MK:QF3?%(T;2W+(<S)Y/U3965GIMG%IVGVL<%O!$L<$,2!4C11A54#@    4
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MB6TUU8)%"QDBE"21+, 261OH_P &>#_#7P]\'Z3X \&:1%I^CZ'IL&GZ380
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M0O$/BGQ3#&/MFM0:WXC:QO-*EE'SO:?8;I;:.W)*1K:6Q50T$97Z#_X*,_\
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MH;1(B/+CEN[:.)8XP57[Y;=M.T@''!(KY!\'_L5_\%+?#_Q5U?XA:M_P4O\
M!$\'B778;CQ"MC^SOY6H'3(Y24TRUNYM<G6UCCB:2.(F&0(\LDS))+)*T@!\
M[^()YOVEOV=O^"AG[4WC^3R_&OPO\=>*M ^%WB# ^U>$8/"^AVMWI\MC(?FM
MF-\TMVY0CS&E^;(P!Z+^TU^S1^S'^W!_P3IM?VS_ -J;X3OXI^(7C+X,:1=^
M",32"^T+6KW38'LK/1%5E^RW,NHS(0ZX>221%D9HXT5/7/BO_P $V)/&B?&O
MP#X"^+J>&O 7[1%Q'<_%#0DT-IKM9Y+.*PU*2PN!.B6[7ME!#$YDBE\MU:5=
MQ?:K/C=^Q=^VKXF^,VB^-OV<OVU? ?@+P?X0T.'3O _@;5_@9)K::*RP^3+=
M+/\ VU;K).T9,*OY2F* F-,>9.TP!Y5_P5;^%_COPU_P0/U7P;\>_%ESK_C;
MPG\//#$'B/7HM0E7^T-7@GT^&ZNF*LOFB242L=X(.\Y'-??U?./[67[%/QD_
M:Q_X)_:C^QMXM_:;L4\2^(--M(/$WQ$N_ 8E2ZECN8[F62'3X;R%;=6>,*B&
M:3RTP"TC#>?H71XM7@TNWAU^^MKF]6("ZN+.U:"*1\<LD;22% 3T4NQ'J: +
M-%%% !1110 5\"_M]?\ !.;X*W7CCP!\2_@-X?GM/VD]=^,^D:OHWQ.CO93J
M\=A#J,5QK!N90V6TN'2_M%LMLW[@&6T@ W2H&^^J^0=2_8L_X*7S?&7Q3\5=
M"_X*7^!]-C\2W?E0Q)^SMY]YI&E*W[JPM;B;7'1 @+/O:%@\KM(Z-P@ /)7T
M;3/VQ_C1^WAJ_P 9+1+EOAM;6G@[X;SSC]_X5B@\/KJ+WUC)]ZUN9+VZ%Q]H
MCVR9MK;YCY$>-'PW\'_V6/\ @HC_ ,$N_AY^VW_P4>^'7_";:EJWP)TJ:6*[
M#LUC?2VH,L^DP1X\G4+NYE4(\0\YV^S1(3M53[C\6?V -;\1^.OB_P")_@U\
M8H?"-K\>_"UGH_Q)BFT$WMQ'-;VLEB-2L)//C6"Z>QD$!\U)H]UO;R[?DD2;
M$^+?[!G[5#:W\/M!_9'_ &OO!?PW^'OPO\,6FE>#_ NN_!F3Q"MM-;PK!'>/
M.=8M1))'"HCBS'^[#.V2S;@ >5_M6_!CXO\ @/\ X-M?%GPP_:J\47VM>/O"
MG[-=RWB346U65I3JEMI;-B29'!N3&X"EG+"1H]YR3FON/X/_ /))?"W_ &+E
MC_Z(2O'?CG^R%\<OVA_^">_BW]C;XF_M/:=?^+/'/A?4M$\1?$9_ (2$QWOG
M*S0:;%>H(A'%(L<8,[G$8+F1BQ/L_P ,/#.O>"OAUH?@_P 4:]::I?Z5I<-I
M<ZC8Z<UI%<-&@3>L+RRF,$ ?*9'Y[T ;M%%% !1110 5\"_\%3?^"<WP5\?>
M#F^)?PO\/SK^TSXI^(6E?\*N^)B7LO\ ;6DWJWT<A$,JL/*TZST]+EY(% C,
M,,C%7F?<_P!]5\D?$+]CC_@I/KOQ^\3?&SX=_P#!1WP#H,6JHUEX;TW4?V>&
MU*7P[I>5(M()WUU%9G=5EFE\I3-(J;E\N*&*( X_PMX6\-_MP?\ !4']J?X/
M?M":#;ZWX;^%O@/P?X9\%:;?0AX]-.LV%YJ&H7\ ;/E74C&UC$ZX=19H PQ7
M'?L8_#_]G7_@I9_P24^$O[67_!4#P_:^/8-/^%TT&JMXLEDDLX'M)[FVN=86
M-"/]-N(X(V-P,RKC$)0R/O\ I'QI^Q-XULOC)XI^.WP#^-T/AGQ%\0?AY8^%
M/'M]K'AW[>;Y['SQ8ZO$L4]NL=[$EW<H<AHW#Q?*OE8?B?'7_!./X_\ A7P+
M\)_@?^Q9^UCX6^''PY^$F@6MGI7A3Q3\)'\2-J-];X$&H74PU6S61X]HD1#$
M5$[-.=TBPF$ Y+P9\!_BG\-_^#?S6O@[^TIJVO7GB/2?@;XCFF&KZK*-1L8?
MLU[<6%G<2HP9IK6V:V@?DC?;GD@ U]&_\$^_^3"_@C_V2'PU_P"FNVK+UG]F
M_P#:)\>_L6^,/V<?B]^T]I7B'QKXST#5M*O_ !ZGP^%G8VT5[%) HATN*]RH
MBA=0 UTQ=PSEL-L7M_V8?A'KWP!_9U\#_ SQ)XQM/$%UX-\*V&A_VU9:.U@E
MXEI;I DOD-/.8RRQ@D>8PR3CCB@#NJ*** "BBB@ KX3_ ."N/_!/3]GWXN_!
M#QK\58O!%QJWQ^\236]A\&/%ZZE+'J^BZ_A5TR'39HV#65M"\9N9Q%A?+2[G
MES\[#[LKY4^,G[(G_!1#QI^TAJ?QS^%?_!03P'X:T[[%]A\*>'=8^ ,FKMH-
MJ<&4).=<A$DTS!3)+Y2%@D:@*JA: .%T?24_::_X*U>,?V<OVD--L/&/A?X3
M_L\:%]BT;6[!);*]U;6;JZ6^U3R'!3S6ALXX%;&8T>95($K@\G^P#\+/@C^W
M_P#\$TO!_B[_ (*'VD'C_1/AI=>*_#[_ /"<WIETV:WTO5[NRCU:[$A"SW*6
M=G$OVF4LR'SW4JTKD_1^K_L:_$32?C/HG[3OPR^-UA;_ !'3X6Q^!_&6N>(O
M"OVJU\1012BXM[][:WN+<0W,-RUS(JJ_ELEW+$0,1O'Y[XD_X)H?''P-\ /A
M=^S#^QU^UOH/@;P;\/4:XU>S\8_"QO$DOBG4VF>Y-Y=LFIV2 &ZDENC"(RAG
M8,>$50 1_L%_L[^*?AS_ ,$I;[X,_%6Y\0MH]S;>)[CPAI&N:C<KJ6D^%Y[V
M[FT>PGE9A.LD=@ULK(Y#1Y,)&$Q78_\ !&:1Y?\ @DU^SC+*Y9F^#7A\LS')
M)^PQ<FNZ^'7P<_:?T[X ^(_A[\;/VG]%\:>--=-TMMXLA^'0TS3]/AEA2)(4
MTZ.^=W5-KN2UR69Y6Y50J"7]AC]F[7OV/?V1_A_^RWK_ ,0[3Q6W@#PO9Z%:
MZ]::"VFB[M[:)8HW>!KBXVN57+$28)/ % 'K%%%% !1110 5\8_\%7?V#/V5
M?C5\"?B-\8?B[\-)_%GQ%N_#IT[X57YNY/[3T766B6+2[71F5E^R2R:@8Y2Z
MXWO(QF8Q( GV=7R_^T-^R;^WS\3?VC8_C3\'OV[_  /X2T32K 6_A3PIKOP+
MDULZ3*Z%;F[^T?VU;B6YE#-'YOE*8X<QH%$D[3 'DN@:/XW^)/\ P4Z^%?[$
M7[6%]9^.=+^&W['T/BK7;?5;=;FRUWQ7=:G#I,^HS12J5F9(K6ZV%U.S[?(1
M@M5/]@'X/?"G]MG]EWQ;\&_VP-)7QOX*^!?QY\>>"M#T7Q3<M-IU]IVFZHT>
MG3WB.=MR;2U)@B,FY54;R#(JNOT#?_L9_$J'XE_#S]IG2/CGI]U\7?"7@.\\
M)>*O%.L>$\V'BFPNY(+F8/96]Q$;7R[VWCG@5)6\M&EB8OYGFKP?B?\ X)I?
M&SPQ^S5X9_9K_9>_:ST/PC8Q>(]1\0_$O4?%OPO.OOXWU*]NI+RX-PD>I6:P
MV\EU-([V_P"\#HL4+,8ED24 M?\ !)K]G5_AA^R%XE^'%S-JQ^&^O?$?Q%??
M"30=1U&X\[2O!D]SC3[5'9O-2!T62XB0MN6&ZC5L$,HC_P""#D?D_P#!);X.
M1>9(^W2]1&^60NS8U6\Y+,26/J3R:]G_ &?/AG^U;X!\"ZW9_M!_M1:'\0?%
M-]>%]'U?3_AP-$T[3+<1*J1?8DOII)F\SS'>0W +!U4! F6R/^">7[)WB;]A
MW]DKPM^RYXF^*=CXR;PJMS':Z]9>&GTKSXYKF6XP\#75SA@TK#<'P0!P* /:
MZ*** "BBB@ KY8_X*1?L2_L7_'3X6>,?C#^UY\-'\9S:?X4>Q\+PW$DDEQI$
M[!E@CTB-"#%J%Q=2QHLD8\^60P1994C0?4]?-/[4W[*W[<?QD^.VC?%#X)?M
MN>"_!7A_P[9_\2/PGK_P4DU\07[J5DU!I_[9MEDFV,T<9\H>4CN%YD=F /GG
MP)X>^-EY^U/^QS_P3[_; UM?%;>%/V=-3\7_ !%M]5<7EMX@\1VD>G:;$;G?
ME;O[,US<R*S@[I628C>B,N]^PG\'_AW^UQX-^.G[(_[0FAMXG^&_P7_:<\0Z
M%X6\(:A*S:;-I?V:TOK2PN8\_P"D6]FU_,D-NY,2+';?+^XBV^Z:I^Q;\4M8
MUOX3?'3Q#\?K#6?C'\+X=7M;CQG=^$!;:?K]CJ@_TNQEL(+@-!"&CM7AVSNT
M36B;C+ODW\?XG_X)P?&W1/V<]1^"W[.O[6&B^$M9\;_$/4_&/Q=\4Z[\-'U=
M?%=Y?S>=<6RVR:E;?9+0@1P>5YDK&V@CA9V!D:0 B_X)-?LZ:;\&OAC\6_#W
MP^DO;/X->)OBMJ=Y\&/#QU"8QZ=H#6MM#*]FY;?#9SWT=]/;JA">3)'+&<2@
MTW_@AAIMKHO[ ,>BV <6]E\6_B%;VXEE:1A&GB_5U4%F)9L  9))->R?LS?"
M3]K'X9:#KMO^T7^U1X?^(.HW<<$7ALZ%\,5\/:?HT<:.,&V6^N'G9F=2Q,R#
M;$BJJ'<S9O[ '[)GC#]BWX%7/P5\5_%G3O&/F>+]=UZWU/3_  M)I7EMJFJ7
M6I2Q-&]Y<[PDETZJP9?E49!.30![?1110 4444 %?/O[<?[''[$_[07AC5?B
M;^W-X"M?%WAGP[X7EC@TW76EEM=(7,C3W=I#&05O90T<8E3,W[F-(BI9@_T%
M7SG^V!^R]^V9\>/BAX8\6? K]LGPAX$\.^&4^TQ>%O$/P=?Q"MWJ@?,=]+*-
M6M%8P@#R8S&5CD)ERTBQ-$ ?)WP\\+?'[P9J'_!/7_@GA^U?JU_K<&MZ'XK\
M1?$;2O$-P+F34'T;38Y=*TR^8Y6Y^RMJ$#.IW(\VGQO\VT&O1/V3_A9X&^/W
MQB_:G_X)]_%+2I-4^%/PQ^-.F7^A>$3*R:?-8:IH5OJ,FBR1+@-817TTMPMM
MP@)5"#$/+KVK6/V)_B[XRTKX6?$OXH?M&V'B'XS_  G\5:AK&C^/4\$K8:==
M07T,UI=::VFQW+&.V>SE2/(N&D$UO%.6;!C; \0?\$]_CCI'P7\>>&?@)^U=
MI?@[X@?%GX@R>*/B9X_O/A_+J OD>..#^S[.V34K=[*!;:WM[97\^218UD8,
M)9/-4 R/^"7/[,GASX">._V@K?X%6L^B_ S7OB!;)\+?"MK=RBRL9H+".'6;
MK3QNS!:S:AYJ(J$+OM9'C 1T)7_@C1HNG^&_AW\>?#NDI(MI8?M8?$"WM(Y9
MWE,<2:EM1-SDL0J@ 9)X KUG]E#X&_M8_!VUU*P_:$_:I\+^.K*/3+6Q\(:/
MX2^$T?A>PT2.(.&)B6^NFGR/)15#QI&L1 4ER1!^P[^R7XW_ &2=+^(VF>,/
MB[I?BT>/?BMKGC>-].\)R:5_9\NIW!GEM2'O;GSE1L!7^0X!R#G@ ]RHHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LWQ?XO\.^ _
M#MQXK\5ZA]DT^TV?:+CR7DV[G5%^5 6.68#@=ZTJ\V_:[_Y-X\0_]NG_ *5P
MUY>>8VKEF2XG&4DG*E3G-)[7C%M7LT[76MFO4QQ%25'#SFMTF_N0?\-=_L\?
M]%"_\I-W_P#&J/\ AKO]GC_HH7_E)N__ (U7Q)17\Y_\1KXJ_P"?-'_P&?\
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MEI\$$_:.^*'P*\3>*_!Z:C;6%_?>%KVS$]G<3LZQAX;B6,LA*J-RD\N.,9(
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MBI59OEA%[7ZM^4>MMVTM+W7O\.Y'//,;[-NT(ZR?EV7F_P#-^1UGC/\ :_\
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MKN6SO=$N;>QM)+F=X+^VE;S'&U$,$D<,HW[RFS:S_1E !1110 4444 %%%%
M!116+\2?$7B;PA\.M?\ %G@OP1/XFUG2]%NKO2?#=M=I;R:M<QPL\5HDLGR1
MM*ZK&';Y5+Y/ H VJ*\X^#?QS\2>(?V7=(_:'_:4^&#_  EOV\+MK/C#PQKN
MLQ71\-I'&TDRS7**JLL:*6+;5('WE4@@>CT %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,MNUN86CC@2"$QED@\V2>1I#&.E_8;^#W_!0G]G7]OK]KCXW?%7]C.*Z\/\
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M7OPZWZROO)2?7Y,_DGQ'R3/LMSV>(Q\W4C4?N3Z6Z1MM%Q7V?FBE7T)^P?\
MM4^._A%X[LOAC_9M[KGA_7+U8O[)M4,DUM,YQYT _5EZ$ G@C->$>'/#FN^+
M]=M/#'AC2I[[4+Z=8;2TMTW/*YZ #^O0#DU^D/[&?[&>A?LYZ$OB?Q/'!?>+
M[Z#%W=@;DL4/6"$_^A/U8\=.IXAYUD>79'/#XZ"J2J+W8=;])7WBHOK\D'AQ
MDF?9EGT,1@)NG&F_?GTMUC;:3DNGS9[M7Y6?MN_LU?\ !4?_ ()P?MT>/O\
M@I__ ,$Q_"=G\7/!/Q0CL+GXR? V\+"^DN+.W$"W>G[?G=C&&(\K=(KRL##,
MFT)^J=?(W@WXO_MT? #]HSXQ6_Q)_8^\5>.OA7K/CB/4/AUXD\$:WIMQJ-E
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M6BV.G[6O;F&&W>..T-NT<TJ!/LK!"Z>67]0_X)I_!'Q_!\!-1\7?MC?LP_\
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M[?2:M=Q-)(W5G$<,463SB(9K[M\9>$/#7Q!\(:KX"\9Z/#J&CZYIL^GZM87
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M#;ZE93:A97$$4D]BLLZK '2;</.6=5>-TV$8:MC]MS]K+_@J/^R'^SS\$/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB/VC/"'B+QY\&M9\*>%-/\
MM>H7?V?[/;^<D>[;<1.WS.0HPJD\GM7;T5QYC@J69Y?6P=5M1JQE!M;VDFG:
MZ:O9Z73]#.K3C6I2@]FFOO/B3_AD3]H?_HGO_E6M/_CM'_#(G[0__1/?_*M:
M?_':^VZ*_*_^(*<*_P#/ZM_X%#_Y6>-_J_@_YI?>O\CXD_X9$_:'_P"B>_\
ME6M/_CM=O^SG^SG\9? ?QET;Q7XK\'?9-/M/M'VBX_M"WDV[K>5%^5)"QRS
M<#O7U)179EWA#PUEF84<92JUG*E*,TG*%KQ::O:FG:ZULUZFE+(\)1JQFI2N
MFGNNGR"BBBOU0]D**** /'/VY?V6?'7[7WP3C^%/PZ_:M\??!O4X=>M-2C\7
M_#G4/L]\RPEMUJYXWPR!LLF1ED3.Y0R-T/[,7[-W@G]E;X46_P +/!FM:UK#
MM>W&H:YXE\3ZA]KU37=2N',EQ?7D^!YLTC'G 55541%1$51Z%10 4444 %>
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MX@XKQ.=0]C"/)2[7NWZO]/ST"BBBOTT^3"BBB@ HHHH **** "BBB@ HHHH
MR?'G@'P-\4O!VH_#SXF>#=+\0Z!J]JUMJNB:W81W5I>0MUCEBD!213Z,"*\P
M_9K_ &(/AA^Q_9)X._9P\8^+/#G@>&YDGM/APVK)?:/9/(2T@MOMD4MS:QEF
M+^3#.D*L25C&2#[+10 4444 %%%% !1110 5\Q?"G_@GIXJ^&G_!1#QS_P %
M#)OVA$U'5/B%X<LM!UWPJ?"2Q64-C:;/L_V>07)E28;,L[F16WO\@^79].T4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313994312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 11, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Royalty Pharma plc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1535773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">110 East 59th Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">883-0200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A ordinary shares, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RPRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant&#8217;s definitive proxy statement for the 2022 Annual General Meeting of Shareholders, or Proxy Statement, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant&#8217;s fiscal year ended December 31, 2021. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, the Proxy Statement shall not be deemed to be filed as part hereof.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001802768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,963,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,212,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887315661096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Dublin, Ireland<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887315291048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,541,048<span></span>
</td>
<td class="nump">$ 1,008,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">581,872<span></span>
</td>
<td class="nump">983,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Financial royalty assets</a></td>
<td class="nump">614,351<span></span>
</td>
<td class="nump">587,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_AccruedRoyaltyReceivable', window );">Accrued royalty receivable</a></td>
<td class="nump">53,286<span></span>
</td>
<td class="nump">33,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="nump">66,000<span></span>
</td>
<td class="nump">69,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_OtherRoyaltyIncomeReceivableCurrent', window );">Other royalty income receivable</a></td>
<td class="nump">15,023<span></span>
</td>
<td class="nump">6,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">6,631<span></span>
</td>
<td class="nump">8,596<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">2,878,211<span></span>
</td>
<td class="nump">2,696,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Financial royalty assets, net</a></td>
<td class="nump">13,718,245<span></span>
</td>
<td class="nump">12,368,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible royalty assets, net</a></td>
<td class="nump">5,670<span></span>
</td>
<td class="nump">28,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="nump">269,800<span></span>
</td>
<td class="nump">298,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="nump">204,400<span></span>
</td>
<td class="nump">163,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in non-consolidated affiliates</a></td>
<td class="nump">435,394<span></span>
</td>
<td class="nump">454,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4,145<span></span>
</td>
<td class="nump">9,997<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">17,515,865<span></span>
</td>
<td class="nump">16,020,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Distribution payable to non-controlling interest</a></td>
<td class="nump">107,934<span></span>
</td>
<td class="nump">126,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">5,620<span></span>
</td>
<td class="nump">10,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">57,696<span></span>
</td>
<td class="nump">42,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_AccruedPurchaseObligationCurrent', window );">Accrued purchase obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,600<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">171,250<span></span>
</td>
<td class="nump">307,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">7,096,070<span></span>
</td>
<td class="nump">5,816,584<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">7,267,320<span></span>
</td>
<td class="nump">6,124,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DeferredSharesValueIssued', window );">Deferred shares, $0.000001 par value, 361,170 and 316,407 issued and outstanding, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">3,507,533<span></span>
</td>
<td class="nump">2,865,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">2,255,179<span></span>
</td>
<td class="nump">1,920,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="nump">4,471,951<span></span>
</td>
<td class="nump">5,077,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">16,491<span></span>
</td>
<td class="nump">34,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury interests</a></td>
<td class="num">(2,715)<span></span>
</td>
<td class="num">(2,317)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">10,248,545<span></span>
</td>
<td class="nump">9,895,815<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">17,515,865<span></span>
</td>
<td class="nump">16,020,286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember', window );">Class R Redeemable Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_AccruedPurchaseObligationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Purchase Obligation, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_AccruedPurchaseObligationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_AccruedRoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Royalty Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_AccruedRoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DeferredSharesValueIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Shares, Value, Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DeferredSharesValueIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_OtherRoyaltyIncomeReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Royalty Income Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_OtherRoyaltyIncomeReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887314021144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical)<br> shares in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DeferredSharesParOrStatedValuePerShare', window );">Deferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DeferredSharesSharesIssued', window );">Deferred stock, issued (in shares)</a></td>
<td class="nump">361,170<span></span>
</td>
<td class="nump">361,170<span></span>
</td>
<td class="nump">316,407<span></span>
</td>
<td class="nump">316,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DeferredSharesSharesOutstanding', window );">Deferred stock, outstanding (in shares)</a></td>
<td class="nump">361,170<span></span>
</td>
<td class="nump">361,170<span></span>
</td>
<td class="nump">316,407<span></span>
</td>
<td class="nump">316,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars/pounds per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">432,963<span></span>
</td>
<td class="nump">432,963<span></span>
</td>
<td class="nump">388,135<span></span>
</td>
<td class="nump">388,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">432,963<span></span>
</td>
<td class="nump">432,963<span></span>
</td>
<td class="nump">388,135<span></span>
</td>
<td class="nump">388,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars/pounds per share) | $ / shares</a></td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">174,213<span></span>
</td>
<td class="nump">174,213<span></span>
</td>
<td class="nump">218,976<span></span>
</td>
<td class="nump">218,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">174,213<span></span>
</td>
<td class="nump">174,213<span></span>
</td>
<td class="nump">218,976<span></span>
</td>
<td class="nump">218,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember', window );">Class R Redeemable Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars/pounds per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DeferredSharesParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Shares, Par or Stated Value Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DeferredSharesParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DeferredSharesSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Shares, Shares, Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DeferredSharesSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DeferredSharesSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Shares, Shares, Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DeferredSharesSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887315509128">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total income and other revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,289,463<span></span>
</td>
<td class="nump">$ 2,122,353<span></span>
</td>
<td class="nump">$ 1,814,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForLoanAndLeaseLosses', window );">Provision for changes in expected cash flows from financial royalty assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">452,842<span></span>
</td>
<td class="nump">230,839<span></span>
</td>
<td class="num">(1,019,321)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development funding expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200,084<span></span>
</td>
<td class="nump">26,289<span></span>
</td>
<td class="nump">83,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,996<span></span>
</td>
<td class="nump">23,058<span></span>
</td>
<td class="nump">23,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">182,826<span></span>
</td>
<td class="nump">181,715<span></span>
</td>
<td class="nump">103,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">65,053<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses/(income), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">858,748<span></span>
</td>
<td class="nump">526,954<span></span>
</td>
<td class="num">(808,922)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,430,715<span></span>
</td>
<td class="nump">1,595,399<span></span>
</td>
<td class="nump">2,623,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other expense/(income)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in losses/(earnings) of non-consolidated affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,490<span></span>
</td>
<td class="num">(44,459)<span></span>
</td>
<td class="nump">32,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">166,142<span></span>
</td>
<td class="nump">157,059<span></span>
</td>
<td class="nump">268,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Losses on derivative financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,532<span></span>
</td>
<td class="nump">42,076<span></span>
</td>
<td class="nump">39,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Losses/(gains) on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">48,066<span></span>
</td>
<td class="num">(247,073)<span></span>
</td>
<td class="num">(155,749)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(17,859)<span></span>
</td>
<td class="num">(18,600)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(53,535)<span></span>
</td>
<td class="num">(28,379)<span></span>
</td>
<td class="num">(22,329)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other non-operating expense/(income), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,678<span></span>
</td>
<td class="nump">32,821<span></span>
</td>
<td class="num">(393)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense/(income), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">189,514<span></span>
</td>
<td class="num">(106,555)<span></span>
</td>
<td class="nump">161,757<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Consolidated net income before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,241,201<span></span>
</td>
<td class="nump">1,701,954<span></span>
</td>
<td class="nump">2,461,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Consolidated net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,241,201<span></span>
</td>
<td class="nump">1,701,954<span></span>
</td>
<td class="nump">2,461,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to non-controlling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">621,473<span></span>
</td>
<td class="nump">726,914<span></span>
</td>
<td class="nump">112,884<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to controlling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 619,728<span></span>
</td>
<td class="nump">$ 975,040<span></span>
</td>
<td class="nump">2,348,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Earnings per Class A ordinary share</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1.49<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1.49<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average Class A ordinary shares outstanding</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">414,794<span></span>
</td>
<td class="nump">375,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">414,802<span></span>
</td>
<td class="nump">375,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rprx_FinancialRoyaltyAssetsMember', window );">Income from financial royalty assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total income and other revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,065,083<span></span>
</td>
<td class="nump">$ 1,959,975<span></span>
</td>
<td class="nump">1,648,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rprx_IntangibleRoyaltyAssetsMember', window );">Revenue from intangible royalty assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total income and other revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">171,248<span></span>
</td>
<td class="nump">143,382<span></span>
</td>
<td class="nump">145,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rprx_RoyaltyIncomeOtherMember', window );">Other royalty income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total income and other revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 53,132<span></span>
</td>
<td class="nump">$ 18,996<span></span>
</td>
<td class="nump">$ 19,642<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents earnings per Class A ordinary share and weighted average Class A ordinary shares outstanding for the period from June 16, 2020 through December 31, 2020 following our initial public offering (&#8220;IPO&#8221;) in the year ended December 31, 2020. See Note 13&#8211;Earnings per Share.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForLoanAndLeaseLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to estimated loss from loan and lease transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.11)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForLoanAndLeaseLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rprx_FinancialRoyaltyAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rprx_FinancialRoyaltyAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rprx_IntangibleRoyaltyAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rprx_IntangibleRoyaltyAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rprx_RoyaltyIncomeOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rprx_RoyaltyIncomeOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313536536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 1,241,201<span></span>
</td>
<td class="nump">$ 1,701,954<span></span>
</td>
<td class="nump">$ 2,461,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Changes in other comprehensive income/(loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax', window );">Reclassification of loss on interest rate swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,066<span></span>
</td>
<td class="nump">6,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="nump">11,600<span></span>
</td>
<td class="nump">83,120<span></span>
</td>
<td class="nump">6,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="num">(50,896)<span></span>
</td>
<td class="num">(20,551)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive (loss)/income</a></td>
<td class="num">(39,296)<span></span>
</td>
<td class="nump">66,635<span></span>
</td>
<td class="nump">12,348<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">1,201,905<span></span>
</td>
<td class="nump">1,768,589<span></span>
</td>
<td class="nump">2,473,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to non-controlling interest</a></td>
<td class="nump">604,323<span></span>
</td>
<td class="nump">739,787<span></span>
</td>
<td class="nump">112,884<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to controlling interest</a></td>
<td class="nump">$ 597,582<span></span>
</td>
<td class="nump">$ 1,028,802<span></span>
</td>
<td class="nump">$ 2,360,883<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887307194568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Class R Redeemable Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Common Class A</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Common Class B</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Class R Redeemable Stock</div>
</th>
<th class="th"><div>Deferred Shares</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Unitholders&#8217;/ Shareholders&#8217; Contributions</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th">
<div>Retained Earnings </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income/(Loss)</div></th>
<th class="th"><div>Non-Controlling Interest</div></th>
<th class="th"><div>Treasury Interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 4,552,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,282,516<span></span>
</td>
<td class="nump">$ 1,215,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,255)<span></span>
</td>
<td class="nump">$ 63,865<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="num">(880,142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(739,276)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(140,866)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">2,461,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,348,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="nump">6,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax', window );">Reclassification of loss on interest rate swaps</a></td>
<td class="nump">6,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury interests</a></td>
<td class="num">$ (4,266)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,266)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting standards update [Extensible List]</a></td>
<td class="text">Accounting Standards Update 2016-13 [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">6,141,438<span></span>
</td>
<td class="num">$ (192,705)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,282,516<span></span>
</td>
<td class="nump">2,825,212<span></span>
</td>
<td class="num">$ (192,705)<span></span>
</td>
<td class="nump">2,093<span></span>
</td>
<td class="nump">35,883<span></span>
</td>
<td class="num">(4,266)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="num">(1,105,765)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(313,408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(792,357)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">1,701,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="nump">83,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,617<span></span>
</td>
<td class="nump">22,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax', window );">Reclassification of loss on interest rate swaps</a></td>
<td class="nump">4,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="nump">1,482,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,174,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestTransfersOfInterests', window );">Transfer of interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,037,161)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,037,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration', window );">Initial share issuance upon registration of Royalty Pharma plc (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_StockIssuedDuringPeriodValueIssuedForRegistration', window );">Initial share issuance upon registration of Royalty Pharma plc</a></td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships', window );">Issuance of Class B shares to Continuing Investor Partnerships (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships', window );">Issuance of Class B ordinary shares to Continuing Investors Partnerships</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation', window );">Effect of exchange by Continuing Investors of Class B shares for Class A shares and reallocation of historical equity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294,176<span></span>
</td>
<td class="num">(294,176)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation', window );">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,402,762<span></span>
</td>
<td class="num">(2,553,001)<span></span>
</td>
<td class="num">(1,261,014)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,022)<span></span>
</td>
<td class="nump">2,433,098<span></span>
</td>
<td class="nump">2,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Class A ordinary shares sold in initial public offering, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A ordinary shares sold in IPO, net of offering costs</a></td>
<td class="nump">1,908,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">758,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share based compensation and related issuance of Class A ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation and related issuances of Class A ordinary shares</a></td>
<td class="nump">5,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Other exchanges (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,231<span></span>
</td>
<td class="num">(22,231)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,562<span></span>
</td>
<td class="num">(309,566)<span></span>
</td>
<td class="num">(198)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCash', window );">Dividends</a></td>
<td class="num">(112,490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(112,490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="num">(20,551)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,921)<span></span>
</td>
<td class="num">(9,630)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388,135<span></span>
</td>
<td class="nump">218,976<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">316,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">9,895,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,865,964<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,920,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,395<span></span>
</td>
<td class="nump">5,077,036<span></span>
</td>
<td class="num">(2,317)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="num">(614,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(614,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">1,241,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">619,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">621,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="nump">11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,335<span></span>
</td>
<td class="nump">5,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax', window );">Reclassification of loss on interest rate swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="nump">48,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share based compensation and related issuance of Class A ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation and related issuances of Class A ordinary shares</a></td>
<td class="nump">2,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Other exchanges (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,763<span></span>
</td>
<td class="num">(44,763)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">639,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,242<span></span>
</td>
<td class="num">(642,974)<span></span>
</td>
<td class="num">(398)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCash', window );">Dividends</a></td>
<td class="num">(285,184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(285,184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized gains on available for sale debt securities</a></td>
<td class="num">(50,896)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,481)<span></span>
</td>
<td class="num">(22,415)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">432,963<span></span>
</td>
<td class="nump">174,213<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">361,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 10,248,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,507,533<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,255,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,491<span></span>
</td>
<td class="nump">$ 4,471,951<span></span>
</td>
<td class="num">$ (2,715)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_NoncontrollingInterestIncreaseFromContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Increase from Contributions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_NoncontrollingInterestIncreaseFromContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_NoncontrollingInterestTransfersOfInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Transfers Of Interests</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_NoncontrollingInterestTransfersOfInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_StockIssuedDuringPeriodSharesIssuedForRegistration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Issued For Registration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_StockIssuedDuringPeriodSharesIssuedForRegistration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Issued To Partnerships</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_StockIssuedDuringPeriodValueIssuedForRegistration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Issued For Registration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_StockIssuedDuringPeriodValueIssuedForRegistration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_StockIssuedDuringPeriodValueIssuedToPartnerships">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Issued To Partnerships</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_StockIssuedDuringPeriodValueIssuedToPartnerships</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity, Shares, Effect Of Exchange And Reallocation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity, Value, Effect Of Exchange And Reallocation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_StockholdersEquityValueEffectOfExchangeAndReallocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(1)<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(2)<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(01)<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOtherShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of increase (decrease) in shares of stock classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOtherShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887316558296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Dividends paid (in dollars per share)</a></td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313657080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables', window );">Cash collections from financial royalty assets</a></td>
<td class="nump">$ 2,315,854<span></span>
</td>
<td class="nump">$ 2,121,923<span></span>
</td>
<td class="nump">$ 1,934,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets', window );">Cash collections from intangible royalty assets</a></td>
<td class="nump">151,158<span></span>
</td>
<td class="nump">143,753<span></span>
</td>
<td class="nump">143,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables', window );">Other royalty cash collections</a></td>
<td class="nump">44,123<span></span>
</td>
<td class="nump">18,305<span></span>
</td>
<td class="nump">27,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Distributions from non-consolidated affiliates</a></td>
<td class="nump">34,384<span></span>
</td>
<td class="nump">42,334<span></span>
</td>
<td class="nump">14,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Interest received</a></td>
<td class="nump">3,135<span></span>
</td>
<td class="nump">7,704<span></span>
</td>
<td class="nump">20,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments', window );">Derivative collateral received</a></td>
<td class="nump">34,660<span></span>
</td>
<td class="nump">45,252<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsForCollateralPostedOnDerivativeInstruments', window );">Derivative collateral posted</a></td>
<td class="num">(34,660)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(45,630)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsToTerminateDerivativeInstruments', window );">Termination payments on derivative instruments</a></td>
<td class="num">(16,093)<span></span>
</td>
<td class="num">(35,448)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsForOngoingDevelopmentStageFunding', window );">Ongoing development-stage funding payments</a></td>
<td class="num">(6,876)<span></span>
</td>
<td class="num">(20,479)<span></span>
</td>
<td class="num">(83,036)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsForUpfrontDevelopmentStageFunding', window );">Upfront development-stage funding payments</a></td>
<td class="num">(193,208)<span></span>
</td>
<td class="num">(5,810)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsForOperatingCostsAndProfessionalServices', window );">Payments for operating and professional costs</a></td>
<td class="num">(184,511)<span></span>
</td>
<td class="num">(179,709)<span></span>
</td>
<td class="num">(88,524)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="num">(130,430)<span></span>
</td>
<td class="num">(103,196)<span></span>
</td>
<td class="num">(254,964)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">2,017,536<span></span>
</td>
<td class="nump">2,034,629<span></span>
</td>
<td class="nump">1,667,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Distributions from non-consolidated affiliates</a></td>
<td class="nump">523<span></span>
</td>
<td class="nump">15,084<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Investments in non-consolidated affiliates</a></td>
<td class="num">(34,855)<span></span>
</td>
<td class="num">(40,155)<span></span>
</td>
<td class="num">(27,042)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsToAcquireEquitySecuritiesFNNI', window );">Purchases of equity securities</a></td>
<td class="num">(135,134)<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
<td class="num">(78,999)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI', window );">Proceeds from equity securities</a></td>
<td class="nump">115,957<span></span>
</td>
<td class="nump">384,840<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of available for sale debt securities</a></td>
<td class="num">(70,441)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(125,121)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from available for sale debt securities</a></td>
<td class="nump">62,500<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(1,196,579)<span></span>
</td>
<td class="num">(1,705,283)<span></span>
</td>
<td class="num">(817,402)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">1,597,851<span></span>
</td>
<td class="nump">815,440<span></span>
</td>
<td class="nump">725,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsToAcquireWarrants', window );">Purchase of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,840)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireFinanceReceivables', window );">Acquisitions of financial royalty assets</a></td>
<td class="num">(2,191,502)<span></span>
</td>
<td class="num">(2,182,246)<span></span>
</td>
<td class="num">(1,721,291)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsForMilestones', window );">Milestone payments</a></td>
<td class="num">(18,600)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(250,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,870,280)<span></span>
</td>
<td class="num">(2,759,320)<span></span>
</td>
<td class="num">(2,153,625)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsForDistributionsToShareholdersAndUnitholders', window );">Distributions to shareholders/unitholders</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(285,353)<span></span>
</td>
<td class="num">(739,276)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Distributions to non-controlling interest</a></td>
<td class="num">(479,604)<span></span>
</td>
<td class="num">(543,952)<span></span>
</td>
<td class="num">(154,084)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsToNoncontrollingInterestsOther', window );">Distributions to non-controlling interest- other</a></td>
<td class="num">(153,800)<span></span>
</td>
<td class="num">(181,135)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentOfDividendsToShareholders', window );">Dividends to shareholders</a></td>
<td class="num">(285,184)<span></span>
</td>
<td class="num">(112,490)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment', window );">Contributions from non-controlling interest- R&amp;D</a></td>
<td class="nump">7,339<span></span>
</td>
<td class="nump">8,482<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_ProceedsFromNoncontrollingInterestsOther', window );">Contributions from non-controlling interest- other</a></td>
<td class="nump">36,874<span></span>
</td>
<td class="nump">58,957<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_RepaymentsOfLongTermDebtScheduledPayments', window );">Scheduled repayments of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(94,200)<span></span>
</td>
<td class="num">(294,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,116,196)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt, net of discount</a></td>
<td class="nump">1,272,533<span></span>
</td>
<td class="nump">11,891,030<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs and other</a></td>
<td class="num">(13,046)<span></span>
</td>
<td class="num">(46,715)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,266)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of Class A ordinary shares upon IPO, net of offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,908,744<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by/(used in) financing activities</a></td>
<td class="nump">385,112<span></span>
</td>
<td class="nump">1,487,172<span></span>
</td>
<td class="num">(1,191,626)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">532,368<span></span>
</td>
<td class="nump">762,481<span></span>
</td>
<td class="num">(1,678,012)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">1,008,680<span></span>
</td>
<td class="nump">246,199<span></span>
</td>
<td class="nump">1,924,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">$ 1,541,048<span></span>
</td>
<td class="nump">$ 1,008,680<span></span>
</td>
<td class="nump">$ 246,199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentOfDividendsToShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Of Dividends To Shareholders</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentOfDividendsToShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsForCollateralPostedOnDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Collateral Posted On Derivative Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsForCollateralPostedOnDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsForDistributionsToShareholdersAndUnitholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Distributions To Shareholders and Unitholders</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsForDistributionsToShareholdersAndUnitholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsForMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsForMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsForOngoingDevelopmentStageFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Ongoing Development Stage Funding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsForOngoingDevelopmentStageFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsForOperatingCostsAndProfessionalServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Operating Costs and Professional Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsForOperatingCostsAndProfessionalServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsForUpfrontDevelopmentStageFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Upfront Development Stage Funding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsForUpfrontDevelopmentStageFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsToAcquireEquitySecuritiesFNNI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Equity Securities, FN-NI</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsToAcquireEquitySecuritiesFNNI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsToAcquireWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsToAcquireWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsToNoncontrollingInterestsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Noncontrolling Interests, Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsToNoncontrollingInterestsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsToTerminateDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Terminate Derivative Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsToTerminateDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Cash Collections From Other Royalties Received On Financing Receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Cash Collections From Royalties Received On Financing Receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Cash Collections From Royalties Received On Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collateral Received On Derivative Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Equity Securities, FN-NI</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromNoncontrollingInterestsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Noncontrolling Interests, Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromNoncontrollingInterestsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Noncontrolling Interests, Research And Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RepaymentsOfLongTermDebtScheduledPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Long-term Debt, Scheduled Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RepaymentsOfLongTermDebtScheduledPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireFinanceReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of amounts due from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireFinanceReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=SL94080555-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest received on loans and other debt instruments during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3337-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313439880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Purpose<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Purpose</a></td>
<td class="text">Organization and Purpose <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Royalty Pharma plc is an English public limited company incorporated under the laws of England and Wales that was created for the purpose of consolidating our predecessor entities and facilitating the IPO of our Class A ordinary shares that was completed in June 2020. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following our IPO, we control Royalty Pharma Holdings Ltd. (&#8220;RP Holdings&#8221;), a private limited company incorporated under the laws of England and Wales and U.K. tax resident through our ownership of RP Holdings&#8217; Class A ordinary shares (the &#8220;RP Holdings Class A Interests&#8221;) and RP Holdings&#8217; Class B ordinary shares (the &#8220;RP Holdings Class B Interests&#8221;). We conduct our business through RP Holdings and its subsidiaries and include RP Holdings and its subsidiaries in our consolidated financial statements. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV (&#8220;RPI 2019 ICAV&#8221;), which is an Irish collective asset management entity formed to facilitate our Exchange Offer Transactions (defined below), and is the successor to Royalty Pharma Investments, an Irish unit trust (&#8220;Old RPI&#8221;), for accounting and financial reporting purposes. RP Holdings is owned by RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the &#8220;Continuing Investors Partnerships&#8221;), and Royalty Pharma plc. Old RPI is a unit trust established in August 2011 under the laws of Ireland and authorized by the Central Bank of Ireland pursuant to the Unit Trusts Act, 1990. Prior to the Exchange Offer Transactions, Old RPI was owned by various partnerships (the &#8220;Legacy Investors Partnerships&#8221;).  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RP Management, LLC (the &#8220;Manager&#8221;), a Delaware limited liability company, is an external adviser which is responsible for our management. RP Management (Ireland) Ltd. (&#8220;RP Ireland&#8221;), is the manager of Old RPI and equivalent to the board of directors of a company or general partner of a partnership and is responsible for the day to day operations of Old RPI. Its functions can be delegated to third parties. RP Ireland delegated responsibility for investment management of Old RPI to its parent company, the Manager, in accordance with the investment objectives and policies of Old RPI. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Royalty Pharma,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Royalty Pharma plc and its subsidiaries on a consolidated basis. After the consummation of the Reorganization Transactions (defined below) and before the consummation of the IPO, &#8220;Royalty Pharma,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to RPI 2019 ICAV. Prior to the Reorganization Transactions, &#8220;Royalty Pharma,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Old RPI.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. We fund innovation in the biopharmaceutical industry both directly and indirectly&#8212;directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reorganization Transactions </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our IPO, we consummated an exchange offer on February 11, 2020 (the &#8220;Exchange Date&#8221;). Through the exchange offer, investors representing 82% of the aggregate limited partnership in the Legacy Investors Partnerships, exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in the Continuing Investors Partnerships. The exchange offer transaction together with (i) the concurrent incurrence of indebtedness under our new credit facility and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the &#8220;Exchange Offer Transactions.&#8221;</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Exchange Offer Transactions, we own, through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (&#8220;RPI Intermediate FT&#8221;), an 82% economic interest in Old RPI. Through our 82% indirect ownership of Old RPI, we are legally entitled to 82% of the economics of Old RPI&#8217;s wholly-owned subsidiaries, RPI Finance Trust, a Delaware statutory trust (&#8220;RPIFT&#8221;) and RPI Acquisitions (Ireland), Limited (&#8220;RPI Acquisitions&#8221;), an Irish private limited company, and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (&#8220;RPCT&#8221;). The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (&#8220;RPSFT&#8221;), which is wholly owned by Royalty Pharma Select, an Irish unit trust. From the Exchange Date until the expiration of the Legacy Investors Partnerships&#8217; investment period on June 30, 2020 (the &#8220;Legacy Date&#8221;), the Legacy Investors Partnerships were offered to participate proportionately in any investment made by Old RPI. Following the Legacy Date, Old RPI ceased making new investments and each of Old RPI and the Legacy Investors Partnerships became legacy entities. Since the Legacy Date, we have made and plan to make new investments through our subsidiaries, including RPI Intermediate FT. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Exchange Offer Transactions, the Legacy Investors Partnerships and RPI Intermediate FT entered into new credit facilities in the amount of $1.3&#160;billion and $6.0&#160;billion, respectively, the proceeds of which were used to repay the $6.3&#160;billion outstanding debt of RPIFT and, in the case of RPI Intermediate FT, were also available to be used to fund investments. As part of the new credit facilities, RPI Intermediate FT repaid $5.2&#160;billion, its pro rata portion of RPIFT&#8217;s outstanding debt and accrued interest. RPIFT also terminated all outstanding interest rate swaps in connection with the debt refinancing. </span></div><div style="margin-bottom:1pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to, and as a condition precedent to the closing of the IPO, various reorganization transactions became effective, including the following:</span></div><div style="margin-bottom:1pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Exchange Offer Transactions (as described above); and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the execution of a new management agreement with the Manager (the &#8220;Management Agreement&#8221;).</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We refer to these transactions collectively as the &#8220;Reorganization Transactions.&#8221;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As Old RPI is our predecessor for financial reporting purposes, we have recorded Old RPI&#8217;s assets and liabilities at the carrying value reflected on Old RPI&#8217;s balance sheet as of the Exchange Date. The references in the following notes for the periods prior to the Exchange Date refer to the financial results of Old RPI for the same periods. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IPO</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2020, we completed our IPO on the Nasdaq Global Select Market under the ticker symbol &#8220;RPRX&#8221;, in which we issued 89,334&#160;thousand Class A ordinary shares at a price to the public of $28.00 per Class A ordinary share, of which 71,652&#160;thousand Class A ordinary shares and 17,682&#160;thousand Class A ordinary shares were offered by the Company and selling shareholders, respectively. We used the net proceeds from the IPO to acquire RP Holdings Class A Interests and, as a result, we own 100% of RP Holdings Class A Interests.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon consummation of the IPO, certain of the Continuing Investors agreed to exchange, pursuant to the Exchange Offer Transactions, interests in the Continuing Investors Partnerships represented by their ownership of 294,176&#160;thousand RP Holdings Class B Interests into an aggregate of 294,176&#160;thousand Class A ordinary shares of Royalty Pharma plc. Upon completion of the exchange, Royalty Pharma plc indirectly owned 294,176&#160;thousand RP Holdings Class B Interests. The remaining investors in the Continuing Investors Partnerships who did not elect to exchange into Class A ordinary shares held 241,207&#160;thousand newly issued Class B ordinary shares of Royalty Pharma plc. As a result, the Continuing Investors Partnerships held a number of our Class B ordinary shares equal to the number of RP Holdings Class B Interests indirectly held by them at such time which are exchangeable on a one-for-one basis for Class A ordinary shares of Royalty Pharma plc.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313443032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of preparation and use of estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The precise extent to which the COVID-19 pandemic will impact our operational and financial performance will depend on various factors. To date, certain marketers of some of our portfolio products have commented that the performance of these products have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not resulted in a material effect to our results of operations and liquidity and we do not believe it is reasonably likely to in the future. Due to the nature of our business, the effect of the COVID-19 pandemic may not be fully reflected in certain of our results of operations until future periods.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of consolidation</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity&#8217;s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net income attributable to non-controlling interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in our consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following management&#8217;s determination that a high degree of common ownership existed in Royalty Pharma both before and after the Exchange Date, Royalty Pharma recognized Old RPI&#8217;s assets and liabilities at the carrying value reflected on Old RPI&#8217;s balance sheet as of the Exchange Date. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Exchange Offer Transactions, our only historical non-controlling interest was attributable to a de minimis interest in RPCT held by RPSFT. As a result of the Exchange Offer Transactions in February 2020, a new non-controlling interest was created related to the Legacy Investors Partnerships&#8217; ownership of approximately 18% in Old RPI. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following the consummation of our IPO in June 2020, two new non-controlling interests were created: (1) a non-controlling interest related to the Continuing Investors Partnerships&#8217; ownership in RP Holdings through their ownership of the RP Holdings Class B Interests, which amounted to approximately 29% as of December 31, 2021, and (2) a non-controlling interest related to RPI EPA Holdings, LP (&#8220;EPA Holdings&#8221;), an affiliate of the Manager through its ownership of the  RP Holdings&#8217; Class C ordinary share (the &#8220;RP Holdings Class C Special Interest&#8221;). Income will not be allocated to the latter non-controlling interest until certain conditions are met.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All intercompany transactions and balances have been eliminated in consolidation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adjustment to prior period presentation </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the preparation of our condensed consolidated interim financial statements for the three months ended September 30, 2020, we identified an adjustment to the classification of our short-term investments on our consolidated balance sheets, as of December 31, 2019, based on the original maturity dates of the investments. The adjustment resulted in an increase of $37.5 million to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Marketable securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and a corresponding decrease to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on the consolidated balance sheet as of December 31, 2019. In addition, the adjustment resulted in an increase of $388.0 million and $350.5 million in cash activity related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Purchases of marketable securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Proceeds from sales and maturities of marketable securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, respectively, within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash used in investing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for the year ended December 31, 2019, with a net impact on net cash flow from investing of $37.5 million. The adjustment had no effect on our reported total income and revenues, consolidated net income, total assets, or shareholders&#8217; equity for any period. In addition, the adjustment does not impact net cash provided by operating activities in any period. We evaluated the adjustment and determined that, based on quantitative and qualitative analysis, it was not material to the consolidated financial statements as of and for the year ended December 31, 2019.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to the current period presentation.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, financial royalty assets and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances at December 31, 2021 and 2020 were held with State Street and Bank of America. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, AbbVie, Bristol Myers Squibb, Gilead, Johnson &amp; Johnson, Lilly, Merck, Pfizer, Novartis, Biogen, Roche and Vertex. For the years ended December 31, 2021 and 2020, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for 32% and 27% of our current portion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, representing the largest individual receivable balance in both years.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment information</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our chief operating decision maker is our Chief Executive Officer who reviews financial information presented on a consolidated basis to allocate resources, evaluates financial performance and makes overall operating decisions. As such, we concluded that we operate as one single reportable segment, which is primarily focused on acquiring biopharmaceutical royalties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An acquisition of a royalty asset provides the buyer with contractual rights to cash flows relating to royalties from the sales of patent-protected biopharmaceutical products. These acquisitions entitle us to receive a portion of income from the sale of patent-protected biopharmaceutical products by unrelated biopharmaceutical companies. For the majority of our royalties, our rights are protective in nature. In other words, we do not own the intellectual property and we do not have the right to commercialize the underlying products. These contractual cash flow rights have yield components that most closely resemble loans and are classified as financial royalty assets.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the limited instances where we possess rights to exploit the underlying patents, rights to the intellectual property related to the biopharmaceutical products, or the ability to influence the amount or duration of future royalty payments, these royalties are classified as intangible assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial royalty assets, net</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we analogize to the accounting guidance within Accounting Standards Codification 310 (&#8220;ASC&#8221;), Receivables, as it most closely aligns with the underlying economics of our financial royalty assets. Therefore, such financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Imputation of Interest</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is reviewed and adjusted each reporting period as differences between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows. Income is calculated by multiplying the carrying value of the financial royalty asset by the effective interest rate. The carrying value of a financial royalty asset is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by the interest income accrual and decreased by cash receipts in the period to arrive at the ending balance. If the ending balance is greater than the net present value of the expected future cash flows, a provision is recorded to reduce the asset balance to the net present value. The provision is recorded through the income statement as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected cash flows from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the carrying value of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is presented net of the cumulative allowance for changes in expected future cash flows.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The application of the prospective approach to measure financial royalty assets requires management&#8217;s judgment in forecasting the expected future cash flows of the underlying royalties. The amounts and duration of forecasted expected future cash flows used to calculate and measure interest income are largely impacted by sell-side equity research analyst coverage, commercial performance of the product, and royalty duration, each discussed in further detail below.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Analyst coverage.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Forecasts of expected future cash flows are developed from sales projections of the underlying biopharmaceutical products as published in sell-side equity research analyst reports. In projecting future cash flows, our policy is to rely on sell-side research analysts&#8217; consensus sales forecasts for a product to derive annual sales projections for each financial royalty asset over the periods for which we are entitled to royalties or milestones. These forecasts are based on input from internal and external market research that analyzes factors such as growth in global economies, industry trends and product life cycles. When royalty-bearing biopharmaceutical products have no coverage, limited sell-side equity research analyst coverage or where sell-side equity research analyst consensus sales estimates are not available for the full term of the royalty, particularly for the later years in a product&#8217;s life, management uses reasonable judgment to make assumptions about the growth or decline in the sales of these products based on historical data, market trends and management&#8217;s own expertise. For the majority of the portfolio of financial royalty assets, management utilizes statistical curves based on historical trends to project future sales when sell-side equity research analyst consensus sales estimates end or are not available for the full term of the royalty. In other cases, management may develop and apply growth rate estimates from existing sell-side equity research analysts&#8217; consensus sales forecasts to project future sales for products that cannot be modeled through the statistical curves, such as those where the entrance of a biosimilar is expected to impact future sales. Based on the level of detail in sell-side equity research analyst models, management can also be required to apply assumptions to the sales forecasts to estimate the quarterly and geographical allocation from annual sales projections and, for franchised products, to estimate the product mix and pricing mix, or to exclude from projections sales forecasts for unapproved products or indications. Our contractual royalty terms, rates, and any milestones are then applied to the adjusted sales projections to calculate the expected royalty or milestone payments over the term of the financial royalty asset&#8217;s life, forming the basis for our forecast of expected future cash flows used to calculate and measure interest income.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Commercial performance.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The approval of a product for use in new indications can extend the date through which we are entitled to royalties or milestones on that product. For certain financial royalty assets, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and whose sales were previously not reflected in expected future cash flows. We generally do not recognize income from, or forecast sales for, unapproved products or indications. If a product is removed from all or a portion of a market, subsequent sell-side equity research analysts&#8217; consensus sales forecasts will reflect the expected drop in sales. Both the new cash flow streams and the cessation of cash flow streams related to a product&#8217;s performance in the market over the royalty term can materially affect our forecast of expected future cash flows.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Royalty duration. </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The duration of a royalty can be based on a number of factors, such as regulatory and marketing approval dates, patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, the entry of generics or a contractual date arising from litigation, which are all impacted by the time in the product&#8217;s life cycle at which we acquire the royalty. Royalty duration varies by geography as United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms. Products may be covered by a number of patents and, for products whose royalty term is linked to the existence of valid patents, management is required to make judgments about the patent providing the strongest patent protection to align the period over which management forecasts expected future cash flows to the royalty term. It is common for the latest expiring patent in effect at the date we acquire a financial royalty asset to be extended, adjusted or replaced with newer dated patents subsequent to our acquisition of a royalty due to new information, resulting in changes to the royalty duration in later periods. Patents may expire earlier than expected at the time of the acquisition due to the loss of patent protection, loss of data exclusivity on intellectual property, contractual licensing terms limiting royalty payments based on time from product launch, due to recent legal developments or litigation. Macroeconomic factors, such as changes in economies or the competitive landscape, including the unexpected loss of exclusivity to the products underlying our portfolio of royalties, changes in government legislation, product life cycles, industry consolidations and other changes beyond our control could result in a positive or negative impact on our forecast of expected future cash flows.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the preparation of the forecasted expected future cash flows, which relies on the sources and variables discussed above, management is required to make assumptions around the following forecast inputs: (1) estimates of the duration of the royalty, which includes consideration of the strength of patent protection and anticipated entry of generics, (2) product growth rates and sales trends in outer years, (3) the product and pricing mix for franchised products, and (4) the geographical allocation of annual sales data from sell-side equity research analysts&#8217; models. The most sensitive of these assumptions relates to management&#8217;s estimate of the royalty duration in the final years of an asset&#8217;s life. In some cases, patent protection may extend to a later period than the expiration date management has estimated. Management may apply a shorter royalty term in this situation if, based on its experience and expertise, management believes that it is more likely that the associated patents are subject to opposition or infringement, that the market for a particular product may shift based on pipeline approvals and products, or that product sales may be harmed by competition from generics. For products providing perpetual royalties, management applies judgment in establishing the duration over which it forecasts expected future cash flows. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A shortened royalty term can result in a reduction in the effective interest rate, a decline in the carrying value of the financial royalty asset, a decline in income from financial royalty assets, significant reductions in royalty payments compared to expectations, or a permanent impairment. Additionally, royalty payments may occasionally continue beyond the estimated royalty expiration date for such reasons we cannot foresee such as excess inventory in the channel or additional scope of patent protection identified after expiry, including royalties we may become entitled to from new indications, new compounds, or for new regulatory jurisdictional approvals.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter and for which the estimates are derived from the latest external publicly available sell-side equity research analyst reports, reported in arrears. </span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cumulative allowance and Provision for changes in expected cash flows from financial royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate financial royalty assets for impairment on an individual basis by comparing the effective interest rate at each reporting date to that of the prior period. If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected), we record a provision for the change in expected cash flows. The provision is measured as the difference between the financial royalty asset&#8217;s amortized cost basis and the net present value of the expected future cash flows, calculated based on the prior period&#8217;s effective interest rate. The amount recognized as provision expense increases the financial royalty asset&#8217;s cumulative allowance, which reduces the net carrying value of the financial royalty asset.</span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance for the increase in the present value of cash flows expected to be collected, resulting in a non-cash credit to the provision line on the income statement. We also recalculate the amount of accretable yield to be received based on the revised remaining future cash flows. The adjustment to the accretable yield is treated as a change in estimate and is recognized prospectively over the remaining life of the financial royalty asset by adjusting the effective interest rate used to calculate income.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Movements in the cumulative allowance for changes in expected future cash flows, which forms part of the </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line item on the consolidated balance sheet, are accompanied by corresponding changes to the provision. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. Recoveries of previously written-off amounts are credited to the allowance. In some cases, when a financial royalty asset&#8217;s contractual cash flows expire, the final royalty payment may differ from the remaining net carrying value. We account for this non-cash true-up at the end of the royalty term as either </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected cash flows from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of operations.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income from financial royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. The accretable yield is recognized as income at the effective rate of return over the expected life of financial royalty assets. After acquisition of a financial royalty asset, if we are not able to reliably estimate expected cash flows for a product or if we have not completed the required funding obligations payable over time for an approved product, a financial royalty asset is placed in non-accrual status (e.g., for royalties from products that have not yet received FDA approval or for accelerated royalties). Such financial royalty assets are held at cost and no income is recognized until the reasonable expectation of the timing of the future cash flows to be collected is available or until funding obligations payable over time for an approved product are complete. We evaluate such financial royalty assets held at cost for impairment based on, among other factors, a review of development progress, clinical trial results, and publicly available information around regulatory discussions and approval status. An impairment loss is recognized if, based on current information and events, it is probable that we will be unable to collect amounts due according to the contractual terms of the financial royalty asset, and the amount of loss can be reasonably estimated.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When royalties are received for financial royalty assets that have been fully amortized, such income is recognized as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for current expected credit losses</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 1, 2020, we adopted ASU 2016-13, </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(&#8220;ASU 2016-13&#8221;) which requires earlier recognition of credit losses. We now recognize an allowance for current expected credit losses on our portfolio of financial royalty assets with limited protective rights. The credit loss allowance is estimated using the probability of default and loss given default method. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the probability of default of the marketers responsible for paying our royalties and the resulting loss given default. The allowance for current expected credit losses is presented net within the non-current portion of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated balance sheets. Any subsequent movement in the allowance for credit losses is recorded as part of the </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Provision for changes in expected future cash flows from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated statements of operations.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Refer to Note 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">for further information.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible royalty assets, net</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currently, our only intangible royalty assets are the Januvia and Janumet (&#8220;DPP-IV&#8221;) patents. The DPP-IV patents are finite-life intangible royalty assets whose cost is amortized using the straight-line method over the expected lives of the patents, the majority of which terminate at various dates through 2022. The amortization period commenced concurrent with the sale of the product underlying the royalty asset.</span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management reviews the performance of intangible royalty assets periodically for impairment as required by ASC 360-10,</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Property, Plant, and Equipment - Overall</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The test for recoverability is performed by comparing the carrying value of the intangible royalty asset with the estimated future undiscounted cash flows generated through royalty payments from sales of the underlying DPP-IV products. When evaluating indicators of impairment, we consider factors such as competitive environment and the product&#8217;s life cycle stage, recent and prospective sales trends, collectability concerns, and any potential rebate chargebacks that may occur at the end of a royalty&#8217;s term. An impairment loss is recognized if the carrying value of the intangible royalty asset is not recoverable and its carrying amount exceeds its fair value.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from intangible royalty assets and Accrued royalty receivable</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We earn royalties on sales by our licensees of DPP-IV products covered under patents that we own. We do not have future performance obligations under these license arrangements. Royalty revenue from sales of DPP-IV products is recognized in the period the product is sold. However, under the license agreements, licensees generally provide royalty reports and payments on a one quarter lag. Thus, the accrued royalty receivable is based on an analysis of historical royalties received and sell-side equity research analysts&#8217; projected sales, adjusted for any changes in estimates. Royalty-bearing sales are net of certain rebates and other discounts, as permitted under the terms of the license agreements. Because rebates are generally invoiced and paid in arrears by the marketer, royalty reports often reflect deductions in current periods for rebates related to prior periods which we do not have the ability to estimate.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical estimates that could cause a change in estimated future cash flows include changes in product demand and market growth assumptions, a change in the pricing strategy of the marketer or reimbursement coverage, and changes in country-specific contractual or patent expiry dates. Actual royalty receipts may differ from estimates and any differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically on the basis of royalty receipts.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestone payments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain acquisition agreements provide for future incoming or outgoing contingent payments based on the commercial, regulatory or clinical performance of the related biopharmaceutical product generally over a multi-year period. For purposes of measuring income from financial royalty assets, commercial milestones payable or receivable are reflected in the cash flows used to forecast expected future cash flows in the period in which the milestone criteria is projected to be satisfied based on sell-side equity research analysts&#8217; consensus sales forecasts. Milestones based on regulatory approval or clinical criteria are generally not reflected in the expected future cash flows until such approval is achieved.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts related to outgoing contingent milestone payments are not considered contractual obligations as they are contingent on the successful completion of the defined milestones. Payments under these agreements generally become due and payable upon achievement of certain commercial milestones, and when the contingency is resolved.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial instruments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain financial instruments reflected in the consolidated balance sheets, (e.g., cash and cash equivalents, certain other assets, accounts payable and certain other liabilities) are recorded at cost, which approximates fair value due to their short-term nature. The fair values of financial instruments other than </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are determined through a combination of management estimates and information obtained from third parties using the latest market data. The fair value of financial instruments is determined utilizing the valuation techniques appropriate to the type of instrument as discussed in Note 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair Value Measurements and Financial Instruments.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and cash equivalents and Marketable securities</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include cash held at banks and all highly liquid financial instruments with original maturities of 90 days or less. We invest excess cash in marketable debt securities that are classified as trading securities and reported at fair value. </span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity securities and Available for sale debt securities</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our equity securities are measured and recorded at fair value with unrealized gains and losses recorded in earnings. Our equity securities represent investments in publicly traded equity securities. Available for sale debt securities are measured at fair value. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The unrealized change in fair value of available for sale debt securities for which we elected the fair value option is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on the consolidated statements of operations. The </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">unrealized change in fair value for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biohaven Series A Preferred Share is</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> included in </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accumulated other comprehensive income </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(&#8220;AOCI&#8221;) and are reclassified to earnings as interest income is recognized. Interest income is recognized when we can reliably estimate forecasted cash flows. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decline in the market value of any available for sale debt security below its cost that is deemed to have resulted from a credit loss results in a reduction in carrying amount to fair value and is recognized in earnings. The determination of whether a decline in fair value below the amortized cost basis for an available for sale debt security has resulted from a credit loss requires significant judgment and requires consolidation of available quantitative and qualitative evidence in evaluating the potential impairment. Factors evaluated to determine whether a decline in the fair value below the amortized cost basis has resulted from a credit loss include: the extent to which fair value is less than the amortized cost basis, adverse conditions related to the security, an industry, or geographic area, the payment structure of the security, failure of the issuer to make scheduled payments, any changes to the rating of the security by a rating agency, the remaining payment terms of the security, prepayment speeds, the financial condition of the issuer expected defaults, our intent not to sell, and an evaluation as to whether it is more likely than not that we will have to sell before recovery of the cost basis. Assumptions associated with these factors are subject to future market and economic conditions, which could differ from management&#8217;s assessment.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may elect to apply the fair value option for certain investments in debt securities where the fair value option better aligns with the economics of such investment. Upon such election, the entire investment is measured at fair value on a recurring basis, with movements in fair value recognized in earnings.</span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivatives are measured at fair value on the consolidated balance sheets with movements in fair value recognized in earnings. Prior to 2017, RPIFT applied hedge accounting to its interest rate swap agreements. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the discontinuation of hedge accounting, the AOCI previously recorded on the cash flow hedges was reversed out of other comprehensive income in line with terms of the associated swap contract until the termination of all of our interest rate swaps in February 2020. This reclassification adjustment is shown on the consolidated statements of operations as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Losses on derivative financial instruments</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment in non-consolidated affiliates</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Investments in entities that provide us with the ability to exercise significant influence, but not a controlling financial interest, and where we are not the primary beneficiary are accounted for under the equity method. Investments accounted for under the equity method are initially recorded at fair value. If there is a difference between the fair value and the carrying amount of the equity method investment at inception, we quantify the basis difference and amortize it in a rational manner over the life of the investment. Subsequently, we recognize through earnings our proportionate share of the investee&#8217;s net income or loss, net of any adjustment to reflect the amortization of basis differences. We generally record our share of the results of our investees one quarter in arrears within </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Equity in losses/(earnings) of non-consolidated affiliates</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in the consolidated statements of operations. The investment is reflected as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investments in non-consolidated affiliates</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated balance sheet.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have variable interests in entities formed for the purposes of entering into co-development arrangements for potential biopharmaceutical products (the &#8220;Avillion entities&#8221;). The Avillion entities are variable interest entities for which we are not the primary beneficiary as we do not have the power to direct the activities that most significantly influence the economic performance of the entity. In determining whether we are the primary beneficiary of an entity, management applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant. Management continuously assesses whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of one or more of its investees.</span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">When we have committed to provide further support to the investee through capital call commitments and the investment has been reduced to zero, we provide for additional losses, resulting in a negative equity method investment, which is presented as a liability on the consolidated balance sheets.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development funding expense</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We enter into transactions where we agree to fund a portion of the research and development (&#8220;R&amp;D&#8221;) performed by our partners for products undergoing late-stage clinical trials in exchange for future royalties or milestones if the products are successfully developed and commercialized. In accordance with ASC 730, </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and Development</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we account for the funded amounts as R&amp;D expense when we have the ability to obtain the results of the R&amp;D, the transfer of financial risk is genuine and substantive and, at the time of entering into the transaction, it is not yet probable that the product will receive regulatory approval. We may pay funded amounts upfront or over time as the underlying products undergo clinical trials.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty payments owed to the Company on successfully commercialized products generated from R&amp;D arrangements are recognized as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the same period in which the sale of the product occurs. Fixed or milestone payments receivable based on the achievement of contractual criteria for products arising out of our R&amp;D arrangements are also recognized as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the period that the milestone threshold is met. Milestone thresholds are typically not triggered until after all funding obligations have been completed.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically assess if our activities, as conducted through our subsidiaries, and as currently contemplated, constitute being engaged in the conduct of a trade or business within the United States. Neither the U.S. Internal Revenue Code (&#8220;the Code&#8221;) nor the applicable Treasury regulations provide a general definition of what constitutes being engaged in the conduct of a trade or business within the United States, and the limited case law on the subject does not provide definitive guidance. Based on our periodic assessment, we believe that we are not engaged in the conduct of a trade or business within the United States, and as such, we do not record a provision for U. S. federal income tax for the years presented in the consolidated financial statements.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe we are not engaged in the conduct of a trade or business within the United States or subject to U.S. taxation in that regard, we are subject to U. S. federal withholding tax on certain fixed or determinable annual or periodical gains, profits and income, such as royalties from sources within the United States, unless reduced or eliminated under an applicable tax treaty or provision of the Code. Generally, this tax is imposed by withholding 30% of the payments, or deemed payments, that are subject to this tax. We believe our subsidiaries are eligible for benefits under the U.S.-Ireland income tax treaty, and, under that treaty, are not be subject to any U.S. withholding taxes on U.S.-source royalty payments. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, because we believe that we are not engaged in the conduct of a trade or business within the United States and our subsidiaries are eligible for benefits under the U.S.-Ireland tax treaty, we do not record a provision for income taxes. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While we do not currently record a provision for income taxes, we are party to certain arrangements that will give rise to a tax provision in the future. We currently have funding arrangements in place that allow our counterparties to draw on capital over a prescribed period of time. When such funding arrangements are drawn and we begin to recognize income from these funding arrangements, such activities will be subject to U.S. taxation and we will record a provision for income taxes in accordance with ASC 740, </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. We also entered into an arrangement with MSCI during 2021 as discussed in Note 16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Related Party Transactions that will become subject to U.S. taxation when we begin to recognize revenue from this transaction.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate so as to be treated solely as resident in the U.K. for tax purposes. As a U.K. tax resident company, we are subject to U.K. corporation tax on our worldwide taxable profits and gains. U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. As such, we do not record a provision for U.K. income taxes with respect to the dividends received from RP Holdings or with respect to the dividends received by RP Holdings from RPI. </span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the U.K.&#8217;s &#8220;controlled foreign companies&#8221; rules (the &#8220;U.K. CFC Rules&#8221;). The U.K. CFC Rules, broadly, can impose a charge to U.K. tax on U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the &#8220;Controlled Foreign Company&#8221;) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI (which is Irish tax resident) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Old RPI (which is Irish tax resident and which is held indirectly by us through our participation in RP Holdings)</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, will be Controlled Foreign Companies for U.K. tax purposes. We are therefore required to apply the CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis.  We do not expect material U.K. corporation tax charges to arise under the U.K. CFC Rules in respect of our royalty assets and we therefore do not record a provision for U.K. income taxes.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings per share</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share (&#8220;EPS&#8221;) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include the outstanding Class B ordinary shares, Class B ordinary shares contingently issuable to RPI EPA Holdings, LP (&#8220;EPA Holdings&#8221;) related to Equity Performance Awards and unvested restricted share units (&#8220;RSUs&#8221;) issued under our 2020 Independent Director Equity Incentive Plan (&#8220;Equity Incentive Plan&#8221;). We include potentially dilutive shares in the denominator to compute diluted EPS if (i) the inclusion of the ordinary shares is dilutive for the respective reporting periods, and (ii) contingencies are satisfied as of the end of the reporting period for ordinary shares that are contingently issuable.  We use the &#8220;if-converted&#8221; method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no Class A ordinary shares or Class B ordinary shares outstanding prior to June 16, 2020; therefore, no earnings per share information has been presented for any period prior to that date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting standards</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model (ASU 2016-13). Accordingly, these financial assets are presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model.  With certain exceptions, adjustments are applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retained earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $192.7&#160;million to recognize an allowance for current expected credit losses on our financial royalty assets. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued a new accounting standard that eliminates, adds and modified certain disclosures requirements for fair value measurements under Topic 820 (ASU 2018-13). The ASU modifies the disclosures by removing the requirement to disclose the amount and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers. The ASU expands the disclosure requirements for Level 3 fair value measurements, primarily focused on changes in unrealized gains and losses included in other comprehensive income/(loss). We adopted this standard as of January 1, 2020 with no material impact on our consolidated financial statements and accompanying notes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313300872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available for Sale Debt Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Available for Sale Debt Securities</a></td>
<td class="text">Available for Sale Debt Securities <div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series A Biohaven Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 5, 2019, RPIFT funded the purchase of 2,495 Series A Biohaven Preferred Shares from Biohaven Pharmaceutical Holding Company Ltd. (&#8220;Biohaven&#8221;) at a price of $50,100.00 per preferred share, for a total of $125.0&#160;million (the &#8220;First Tranche&#8221;). The approval of Nurtec ODT by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in February 2020 results in a payment due to us of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments beginning in the three months ended March 31, 2021 through the three months ended December 31, 2024. In the three months ended March 31, 2021, we began receiving payments from the quarterly redemption of the Series A Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to redeem, in a single payment, any outstanding Series A Biohaven Preferred Shares at a price equal to two times the original purchase price of the Series A Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series A Biohaven Preferred Shares, in a single payment, at a price equal to two times the original purchase price. In the event that Biohaven defaults on any obligation to redeem Series A Biohaven Preferred Shares when required, the redemption amount shall accrue interest at the rate of 18% annually until the redemption price for such unredeemed Series A Biohaven Preferred Shares is paid in full, subject to applicable law. If any such default continues for at least one year, we will be entitled to convert all unredeemed Series A Biohaven Preferred Shares into common shares equal to the redemption price, plus accrued interest, divided by the five-day volume-weighted trading price immediately preceding the conversion date. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Series A Biohaven Preferred Shares are classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in our consolidated balance sheets. The unrealized change in the fair value of the Series A Biohaven Preferred Shares is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on the consolidated statements of comprehensive income.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series B Biohaven Preferred Shares </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 7, 2020 we entered into a Series B Biohaven Preferred Share Purchase Agreement (&#8220;Series B Biohaven Preferred Share Agreement&#8221;) with Biohaven where we committed to acquire 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share (the &#8220;Commercial Launch Preferred Equity&#8221;), for a total of $200.0&#160;million payable on a quarterly basis between the three months ended March 31, 2021 and the three months ended December 31, 2024. Our commitment to purchase the Series B Biohaven Preferred Shares is recognized as the Series B Forwards. In return, Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between March 31, 2025 and December 31, 2030 at a price equal to approximately 1.8 times the original purchase price of the Series B Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to issue to us all unissued Series B Biohaven Preferred Shares and to redeem, in a single payment, any outstanding Series B Biohaven Preferred Shares at a price equal to approximately 1.8 times the Series B original issue price per share. Biohaven may redeem at their election, any outstanding Series B Biohaven Preferred Shares, in a single payment, at a price equal to approximately 1.8 times the original issue price for the Series B Biohaven Preferred Shares. In the event that Biohaven defaults on any obligation to redeem Series B Biohaven Preferred Shares, the redemption amount shall accrue interest on the applicable original issue price at the rate of 18% annually until the redemption price for such unredeemed Series B Biohaven Preferred Shares is paid in full, subject to applicable law. If any such default continues for at least one year, we will be entitled to convert any or all unredeemed Series B Biohaven Preferred Shares into common shares equal to the redemption price, plus accrued interest, divided by the five-day volume-weighted trading price immediately preceding the conversion date. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended March 31, 2021, we began purchasing the Series B Biohaven Preferred Shares. As of December 31, 2021, we have acquired 1,406 shares of Series B Biohaven Preferred Shares. We have elected the fair value option to account for the Series B Forwards and the Series B Biohaven Preferred Shares, which are recorded in aggregate on the consolidated balance sheets as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe the fair value option most accurately reflects the nature of these instruments. The unrealized change in fair value of the Series B Biohaven Preferred Shares and Series B Forwards is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statements of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MorphoSys Development Funding Bonds</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys AG (&#8220;MorphoSys&#8221;) to support MorphoSys&#8217; acquisition of Constellation Pharmaceuticals, Inc. (&#8220;Constellation&#8221;), which closed on July 15, 2021. As part of the funding agreement, we agreed to provide MorphoSys up to $350&#160;million of capital (the &#8220;Development Funding Bonds&#8221;), which MorphoSys may draw over a one-year period from the close of its acquisition of Constellation. MorphoSys is required to draw a minimum of $150&#160;million. As of December 31, 2021, MorphoSys has not drawn any amount under the Development Funding Bonds. Our commitment to fund at least $150&#160;million of the Development Funding Bonds is recognized as the Development Funding Bond Forward. Once drawn, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years, with the first payment beginning two years after the funding. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have elected the fair value option to account for the Development Funding Bond Forward as it most accurately reflects the nature of the instrument. The Development Funding Bond Forward is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in our consolidated balance sheet. The unrealized change in fair value of the Development Funding Bond Forward is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Unrealized gains on available for sale debt securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on the consolidated statements of operations.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below summarizes our available for sale debt securities recorded at fair value as of December 31, 2021 and 2020 (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.287%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Biohaven Preferred Shares</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series B Biohaven Preferred Shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series B Forwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development Funding Bond Forward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">204,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65,891</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">270,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">204,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">270,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Biohaven Preferred Shares</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series B Forwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">145,647</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">87,353</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">233,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">69,984</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">163,016</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">233,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)Cost for Series A Biohaven Preferred Shares represents amortized cost. Cost for Series B Biohaven Preferred Shares represents the amounts paid to purchase the instruments. There were no costs associated with the Series B Forwards and Development Funding Bond Forward.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313348760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text">Derivative Instruments<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically managed the impact of foreign currency exchange rate and interest rate risk through various financial instruments, including derivative instruments such as treasury rate lock contracts, interest rate swap contracts and foreign currency forward contracts. Our policy is to use derivatives strategically to hedge existing and future interest rate exposure and to minimize volatility in cash flow arising from our exposure to interest rate risk and foreign currency risk. We may also acquire other financial instruments that are classified as derivatives. We do not enter into derivative instruments for trading or speculative purposes. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury rate lock contracts</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2021, we entered into treasury rate lock contracts with notional amounts totaling $600.0&#160;million to manage the impact of fluctuations in the underlying benchmark interest rate associated with the 2021 Notes (as further discussed and defined in Note 11&#8211;Borrowings). The treasury rate lock contracts were not designated as hedge instruments. All of the treasury rate lock contracts had collateral requirements. The treasury rate lock contracts were unwound and settled in connection with the issuance of the 2021 Notes and the resulting net loss was recognized in earnings in the year ended December 31, 2021. We paid $16.1&#160;million in July 2021 to terminate our treasury rate lock contracts.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate swaps</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2020, RPIFT terminated all outstanding interest rate swaps in connection with the Exchange Offer Transactions. We paid $35.4&#160;million to terminate these swaps and reclaimed $45.3&#160;million of collateral that was held by the respective counterparties. During the years ended December 31, 2020 and 2019, we recorded unrealized losses of $10.9 million and $72.6&#160;million, respectively, on interest rate swaps in the consolidated statements of operations. We did not enter into any interest rate swaps subsequent to the February 2020 termination discussed above and as of December 31, 2021, we do not hold any interest rate swap contracts. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Epizyme put option and warrant</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, RPIFT made an equity investment in Epizyme, Inc. (&#8220;Epizyme&#8221;) of $100.0&#160;million. Under the terms of the agreement with Epizyme, we made an upfront payment of $100.0&#160;million for (1) shares of Epizyme common stock, (2) a warrant to purchase an additional 2.5&#160;million shares of Epizyme common stock at $20 per share over a three-year term and (3) Epizyme&#8217;s royalty on sales of Tazverik in Japan payable by Eisai Co., Ltd (&#8220;Eisai&#8221;). In addition, Epizyme had an 18 month put option to sell an additional $50.0&#160;million of its common stock to RPIFT at then prevailing prices, not to exceed $20 per share. On December 31, 2019, Epizyme notified RPIFT of its intention to exercise the put option. As a result, we recorded a forward purchase contract equal to the difference between the market value and exercise price of $11.5&#160;million within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets at December 31, 2019. The exercise of the put option was settled in February 2020.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrant was recognized at fair value of $5.4&#160;million within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets at December 31, 2020. The fair value of the warrant was not material as of December 31, 2021. We recorded an unrealized loss of $5.4&#160;million, an unrealized loss of $25.4&#160;million and an unrealized gain of $22.0&#160;million on derivative contracts related to the change in fair value of the warrant on the consolidated statements of operations for the years ended December 31, 2021, 2020 and 2019, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of derivatives and reclassifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below summarize the change in fair value of the derivatives for the years ended December 31, 2021, 2020 and 2019 and the line items within the consolidated statements of operations where the gains or losses on these derivatives are recorded (in thousands). </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.190%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location on Consolidated Statements of Operations</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Derivatives in hedging relationships (1)</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest Rate Swaps:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount of loss reclassified from accumulated other comprehensive income into income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense/(income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest Rate Swaps:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense/(income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,977)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward purchase contract:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of forward purchase contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury rate lock contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of treasury rate lock contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;Certain interest rate swaps were previously designated as cash flow hedges. These swaps became ineffective as debt refinancings occurred between 2013 and 2016. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income</span> were released into earnings.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887318451672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Financial Instruments</a></td>
<td class="text">Fair Value Measurements and Financial Instruments <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair value hierarchy</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives and available for sale debt securities are reported at their respective fair values in our consolidated balance sheets. For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. Long-term debt and financial royalty assets are reported at their amortized costs in our consolidated balance sheets but for which fair values are disclosed. The remaining financial instruments are reported in our consolidated balance sheets at amounts that approximate current fair values.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and liabilities measured at fair value on a recurring basis</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes financial assets and financial liabilities that we measured at fair value on a recurring basis at the dates indicated, classified in accordance with the fair value hierarchy described above (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">444,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">444,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">598,253</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">636,823</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,301,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">24,302</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,134,957</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">69,984</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,229,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current assets</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">226,787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">247,413</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">474,200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">298,689</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,439</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">163,016</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">467,144</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The balance as of December 31, 2021 includes Series B Forwards and the Development Funding Bond Forward, recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the consolidated balance sheet, related to our obligations to fund acquisitions of the Series B Biohaven Preferred Shares and $150&#160;million of the Development Funding Bonds, respectively. The balance as of December 31, 2020 relates to Series B Forwards, recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the consolidated balance sheet. See Note 3&#8211;Available for Sale Debt Securities for additional discussion. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the Epizyme transaction as described in Note 4&#8211;Derivative Instruments and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the consolidated balance sheets as of December 31, 2021 and 2020. The fair value of the warrant was not material as of December 31, 2021. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021, 2020 and 2019, we recognized a loss of $60.1&#160;million, a loss of $85.4&#160;million and a gain of $104.4&#160;million, on equity securities still held as of December 31, 2021, respectively.  </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables presented below summarize the change in the combined fair value (current and non-current) of Level 3 financial instruments, which relate to equity securities and available for sale debt securities, including the underlying debt securities and related forwards (in thousands). </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Equity Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at the beginning of the year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the year</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43,013</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Debt Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at the beginning of the year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement of forwards (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer to Level 2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(184,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer from Level 2 (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Redemption</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the year</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">253,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">214,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Forwards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at the beginning of the year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement of forwards (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the year</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">For the year ended December 31, 2021, the unrealized gains on available for sale debt securities is comprised of $11.6&#160;million related to Series A Biohaven Preferred Shares as recorded on the consolidated statements of comprehensive income and $1.3&#160;million related to the Series B Biohaven Preferred Shares as recorded on the consolidated statements of operations. For the year ended December 31, 2020, the unrealized gains on available for sale debt securities related to the Series A Biohaven Preferred Shares as recorded on the consolidated statements of comprehensive income, including $52.7&#160;million prior to transferring out of Level 3 and then $15.9&#160;million after transferring back to Level 3. &#160;&#160;&#160;&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value attributed to the Series B Forwards that were settled in the period as the Series B Biohaven Preferred Shares were acquired, which is included in the fair value of the Series B Biohaven Preferred Shares. See Note 3&#8211;Available for Sale Debt Securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes $14.5&#160;million of unrealized gains on available for sale debt securities included in other comprehensive income while the Series A Biohaven Preferred Shares was classified as a Level 2 asset.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the consolidated statements of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation inputs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a discussion of the valuation inputs used for financial instruments classified as Level 2 and Level 3 measurements in the fair value hierarchy.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Series A Biohaven Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the Series A Biohaven Preferred Shares as of December 31, 2021 and 2020 was based on the cash flows due to us from Biohaven of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments of $15.6&#160;million following the FDA approval and starting one-year after FDA approval, through December 31, 2024. The FDA approved Nurtec ODT in February 2020, at which point we became entitled to receive a fixed payment amount of $250.0&#160;million payable in equal quarterly payments from March 31, 2021 through December 31, 2024. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Series A Biohaven Preferred Shares as of December 31, 2021 and 2020 was calculated using probability-adjusted discounted cash flow calculations incorporating Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability of a change of control event occurring during the investment term, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over a four-year time period and developing a risk-adjusted discount rate requires significant judgement. Our estimate of a risk adjusted discount rate of 9.5% and 8.3% as of December 31, 2021 and 2020, respectively, could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series A Biohaven Preferred Shares, which would mean that the estimated fair value could be significantly higher or lower.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to February 2020, we measured our investment in the Series A Biohaven Preferred Shares using a Black-Derman- Toy lattice model, which included the use of Level 3 fair value measurements and inputs. In February 2020, when Nurtec ODT received FDA approval, we began measuring the fair value of the Series A Biohaven Preferred Shares using a discounted cash flow analysis that relied on observable inputs, and therefore, we transferred the Series A Biohaven Preferred Shares from a Level 3 to a Level 2 asset. During the three months ended December 31, 2020, information pertaining to Biohaven&#8217;s issuance of debt and its effective interest rate became available and we refined our valuation of the Series A Biohaven Preferred shares as of December 31, 2020 to incorporate this significant unobservable input. As a result, we reclassified the investment from a Level 2 to a Level 3 asset during the three months ended December 31, 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Series B Biohaven Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the Series B Biohaven Preferred Shares and Series B Forwards as of December 31, 2021 and the fair value of the Series B Forwards as of December 31, 2020 were based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability that there will be a change of control event in different periods of time, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over the duration of the Series B Biohaven Preferred Shares and developing a risk-adjusted discount rate requires significant judgement. Our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than the timing of an actual change of control event, and if so, would mean that the estimated fair value could be significantly higher or lower than the fair value determined by management at any particular date. Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series B Biohaven Preferred Shares or the Series B Forwards, which would mean that the estimated fair value could be significantly higher or lower.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">MorphoSys Development Funding Bonds</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the Development Funding Bond Forward as of December 31, 2021 was based on a discounted cash flow calculation using an estimated risk-adjusted discount rate, which is a Level 3 fair value input. Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower. We have elected the fair value option to account for the Development Funding Bond Forward as it most accurately reflects the nature of the instrument. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BioCryst Equity Securities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2021, we purchased 3,846&#160;thousand shares of common stock in BioCryst Pharmaceuticals, Inc.(&#8220;BioCryst&#8221;), which was calculated based on the volume-weighted average price of BioCryst common stock over a period preceding the closing of the transaction. As part of the transaction, we are restricted from selling the common stock for six months following the close of the transaction. The fair value of the BioCryst common stock as of December 31, 2021 was based on the closing stock price and adjusted for the transfer restriction, which was determined by calculating the value of a put option over the common stock to match the duration of the transfer restriction. This methodology includes the use of Level 3 inputs, including the estimated volatility of the BioCryst common stock, which requires the use of significant judgement. Our estimated volatility could be reasonably different than the actual volatility for the common stock which would mean that the estimated fair value for the common stock could be significantly higher or lower than the fair value determined by management at any particular date.    </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other financial instruments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use third party pricing services for Level 2 inputs used to value cash equivalents, marketable securities, derivative instruments and borrowings, which provide documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. Warrants are valued using a Black-Scholes option pricing model which considers observable and unobservable inputs. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial assets not measured at fair value</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial royalty assets are measured and carried on the consolidated balance sheets at amortized cost using the effective interest method. The fair value of financial royalty assets is calculated by management using the forecasted royalty payments we expect to receive based on the projected product sales for all royalty bearing products as estimated by sell-side equity research analysts&#8217; consensus sales forecasts or, where such consensus sales forecasts are not available, management uses reasonable judgment to make assumptions about the projected product sales. These projected future royalty payments by asset along with any projected incoming or outgoing milestone payments are then discounted to a present value using appropriate individual discount rates. The fair value of our financial royalty assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. Estimated fair values based on Level 3 inputs and related carrying values for our financial royalty assets as of December 31, 2021 and 2020 are presented below (in thousands).</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial royalty assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,047,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,332,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,718,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,955,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887430792312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Royalty Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivablesTextBlock', window );">Financial Royalty Assets, Net</a></td>
<td class="text">Financial Royalty Assets, Net<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consist of contractual rights to cash flows relating to royalty payments derived from the expected sales of patent-protected biopharmaceutical products that entitle us and our subsidiaries to receive a portion of income from the sale of such products by third parties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets at December 31, 2021 and 2020 are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration (a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 7)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value (e)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,335,641&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,287,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,846,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,829,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,438,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(236,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,201,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,100,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(172,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 (d)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020-2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,697,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(909,916)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,787,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,027,541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,384,141)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,643,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less: Cumulative allowance for credit losses (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(310,804)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,332,596</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt">Dates shown represent our estimates as of current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt">Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3&#160;billion. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:9.13pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7&#8211;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration (a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 7)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value (e) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,274,896&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,274,896&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,003,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112,720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,891,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,406,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46,872)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,359,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,150,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(145,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,004,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025-2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 (d)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020-2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,022,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(634,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,387,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,219,101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(940,107)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,278,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less: Cumulative allowance for credit losses (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(323,717)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,955,277</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:9.13pt">Dates shown represent our estimates as of current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt">Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3&#160;billion.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7&#8211;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2196772<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2196816<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887396514728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossAbstract', window );"><strong>Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentTextBlock', window );">Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets</a></td>
<td class="text">Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets<div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative allowance for changes in expected future cash flows from financial royalty assets is presented net within the non-current portion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated balance sheets and includes the following activities:</span></div><div style="margin-top:3pt;text-indent:22.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the movement in the cumulative allowance related to changes in forecasted royalty payments we expect to receive based on projected product sales for royalty bearing products as estimated by sell-side equity research analysts&#8217; </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">consensus sales forecasts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the movement in the cumulative allowance for current expected credit losses.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The periodic movement in the cumulative allowance is presented on the consolidated statements of operations as the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected cash flows from financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Retained earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of $192.7&#160;million to recognize an allowance for current expected credit losses on our portfolio of financial royalty assets with limited protective rights. The current period provision for changes in expected cash flows from financial royalty assets reflects the activity for the period primarily new financial royalty assets and changes in the underlying cash flow forecasts used in the effective interest model to measure income from our financial royalty assets. </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Refer to Note 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Summary of Significant Accounting Policies for further information.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:78.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.734%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Activity for the Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,982,897)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(322,717)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,342,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(868,418)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative adjustment for adoption of ASU 2016-13</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(192,705)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(645,612)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">570,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of credit loss allowance (b)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision expense for credit losses, net (c)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(156,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,263,824)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(912,710)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">446,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision income for credit losses, net (c)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,694,945)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;Relates to amounts removed from the allowance at the end of a royalty asset&#8217;s life to bring the account balance to zero. Write-offs solely impact the asset account and allowance account; there is no impact on the consolidated statements of operations.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;Relates to amounts reversed out of the credit loss allowance associated with omecamtiv mecarbil as a result of the write-off of the related financial royalty asset balance of $90.2&#160;million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%">(c) &#160;&#160;&#160;&#160;In the year ended December 31, 2020, the provision for credit losses was primarily related to certain additions to our portfolio of financial royalty assets with limited protective rights in 2020, mainly the final tranche of Tazverik. In the year ended December 31, 2021,the provision income for credit losses was primarily related to a significant decline in the financial asset value for Tazverik, which was offset by increases in our portfolio of financial royalty assets with limited protective rights in 2021, primarily related to zavegepant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922895-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919272-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919236-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919269-210447<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313716776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Royalty Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Royalty Assets, Net</a></td>
<td class="text">Intangible Royalty Assets, Net<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following schedules of the intangible royalty assets present the cost, accumulated amortization and net carrying value as of December 31, 2021 and 2020 (in thousands).</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,546&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,546&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">577,550&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,666&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">577,550&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,666&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our DPP-IV patents associated with the intangible royalty assets terminate at various dates through 2022. The weighted average remaining life of the intangible royalty assets is less than one year. We project amortization expense will be $5.7&#160;million in 2022.</span></div>Our revenue is tied to underlying patent protected sales of DPP-IV products of various licensees. Such revenue from royalty assets is earned from sales occurring primarily in the United States and Europe; however, we do not have the ability to disaggregate our royalty revenue from licensees based on the geography of the underlying sales, as this level of information is not always included in royalty reports provided to us. The marketers paying us royalties on these products do not always provide, and are not necessarily required to provide, the breakdown of product sales by geography. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for 86%, 97%  and 91% of our revenues from intangible royalty assets in the years ended December 31, 2021,  2020 and 2019, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313272440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-Consolidated Affiliates<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Non-Consolidated Affiliates</a></td>
<td class="text">Non-Consolidated Affiliates<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Legacy SLP Interest</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Exchange Offer Transactions, we acquired a special limited partnership interest in the Legacy Investors Partnerships (the &#8220;Legacy SLP Interest&#8221;) from the Continuing Investors Partnerships for $303.7&#160;million in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and an income allocation on a similar basis. Our income allocation is equal to the general partner&#8217;s former contractual rights to the income of the Legacy Investors Partnerships, net of amortization of the basis difference. The Legacy SLP Interest is treated as an equity method investment as our Manager is also the Manager of the Legacy Investors Partnerships and has the ability to exercise significant influence. The Legacy Investors Partnerships no longer participate in investment opportunities from June 30, 2020 and, as such, the value of the Legacy SLP Interest is expected to decline over time. The Legacy Investors Partnerships also own a non-controlling interest in Old RPI. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income allocation from the Legacy SLP Interest is based on an estimate, as the Legacy Investors Partnerships are private partnerships that are expected to report on a lag subsequent to the date of this annual report. Management&#8217;s estimate of equity in earnings from the Legacy SLP Interest for the current period will be updated for historical results in the subsequent period. During the years ended December 31, 2021 and 2020, we recorded an income allocation of $8.9&#160;million and $62.0&#160;million, respectively, within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity in losses/(earnings) of non-consolidated affiliates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We received cash distributions from the Legacy SLP Interest of $21.0&#160;million and $22.7&#160;million during the years ended December 31, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Avillion Entities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our partnership interests in Avillion Financing I, LP (&#8220;Avillion I&#8221;) and BAv Financing II, LP (&#8220;Avillion II&#8221;, or, together, the &#8220;Avillion Entities&#8221;) as equity method investments because RPIFT has the ability to exercise significant influence over the entities. We recorded a loss allocation from the Avillion Entities of $28.4&#160;million, $17.6&#160;million and $32.5&#160;million within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Equity in losses/(earnings) of non-consolidated affiliates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the years ended December 31, 2021, 2020 and 2019, respectively. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 19, 2017, the FDA approved a supplemental New Drug Application for Pfizer&#8217;s Bosulif. Avillion I is eligible to receive fixed payments from Pfizer based on this approval. Subsequent to the asset sale, the only operations of Avillion I are the collection of cash and unwinding of discount on the series of fixed annual payments due from Pfizer. We received distributions from Avillion I of $13.4&#160;million during each of the years ended December 31, 2021 and 2020, and $14.1&#160;million in the year ended December 31, 2019 in connection with Avillion I&#8217;s receipt of the fixed annual payments due under its co-development agreement with Pfizer. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, RPIFT entered into an agreement with Avillion II, which was amended in 2019, to invest approximately $19.0&#160;million to fund approximately 50% of the costs of a Phase 2 clinical trial for the use of Merck KGaA&#8217;s anti-IL 17 nanobody M1095 (the &#8220;Merck KGaA Asset&#8221;) for the treatment of psoriasis in exchange for certain milestone and royalty payments. Our involvement in the development for the Merck KGaA Asset ceased in the year ended December 31, 2020, for which we received a distribution of $21.3&#160;million from Avillion II. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, RPIFT entered into an additional agreement, which was amended in July 2021, to increase our investment up to $122.5&#160;million from $105.0&#160;million in Avillion II over multiple years to fund approximately 44% of the costs of Phase 2 and 3 clinical trials to advance PT027 through a global clinical development program for the treatment of asthma in exchange for royalties, a series of success-based milestones and other potential payments.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, RPIFT had $11.2&#160;million and $28.6&#160;million respectively, of unfunded commitments related to the Avillion Entities. Our maximum exposure to loss at any particular reporting date is limited to the current carrying value of the investment plus the unfunded commitments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313249320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research &amp; Development ("R&amp;D") Funding Expense<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Research &amp; Development ("R&amp;D") Funding Expense</a></td>
<td class="text">Research &amp; Development (&#8220;R&amp;D&#8221;) Funding Expense <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D funding expense consists of upfront and ongoing R&amp;D payments we have made to counterparties to acquire royalties and/or milestones on development-stage product candidates. Ongoing R&amp;D payments are made as the related development-stage product candidates undergo clinical trials with our counterparties. During the year ended December 31, 2021, 2020, and 2019 we did not enter into any new ongoing R&amp;D funding arrangements. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognized R&amp;D funding expense of $200.1&#160;million during the year ended December 31, 2021, comprised of $6.9&#160;million in ongoing R&amp;D expenses, primarily under our co-funding agreement with Sanofi, and $193.2&#160;million in upfront R&amp;D funding. As part of a long-term strategic funding partnership with MorphoSys, which closed on July 15, 2021 (as further discussed in Note 17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commitments and Contingencies), we allocated $90.0&#160;million of the upfront payment to R&amp;D funding expense, representing two development-stage products acquired in exchange for future royalties. Additionally, we made an upfront payment of $103.2&#160;million to BioCryst to acquire a royalty on a development-stage product in November 2021. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized R&amp;D funding expense of $26.3&#160;million during the year ended December 31, 2020, of which $20.5&#160;million related to ongoing development-stage funding payments, primarily under our co-funding agreement with Sanofi and $5.8&#160;million related to upfront funding for a royalty on a development-stage product that we acquired from BioCryst. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $83.0&#160;million of R&amp;D funding expense during the year ended December 31, 2019, of which $18.2&#160;million and $62.8&#160;million related to our funding agreements with both Sanofi and Pfizer, respectively. We completed our funding commitments in the fourth quarter of 2019 under our agreement with Pfizer. We did not have upfront development-stage R&amp;D funding expense in 2019.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we have a remaining commitment of $10.7&#160;million related to our R&amp;D funding agreement with Sanofi.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313341976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings</a></td>
<td class="text">Borrowings<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Our borrowings at December 31, 2021 and 2020 consisted of the following (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Issuance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 0.75% (issued at 99.322% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.20% (issued at 98.875% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.75% (issued at 98.284% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 2.20% (issued at 97.760% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$600,000, 2.15% (issued at 98.263% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.30% (issued at 95.556% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.55% (issued at 95.306% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$700,000, 3.35% (issued at 97.565% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(203,930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(183,416)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt carrying value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,096,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,816,584</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,096,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,816,584&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Senior Unsecured Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 26, 2021, we issued $1.3&#160;billion of senior unsecured notes (the &#8220;2021 Notes&#8221;) comprised of $600.0&#160;million principal amount of notes due September 2031 and $700.0&#160;million principal amount of notes due September 2051. Interest on each series of the 2021 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year, beginning on March 2, 2022. The 2021 Notes were issued at a total discount of $27.5&#160;million and we capitalized approximately $12.3&#160;million in debt issuance costs primarily composed of underwriting fees. The 2021 Notes have a weighted average coupon rate and a weighted average effective interest rate of 2.80% and 3.06%, respectively.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 2, 2020, we issued $6.0&#160;billion of senior unsecured notes (the &#8220;2020 Notes&#8221; and, together with the 2021 Notes, the &#8220;Notes&#8221;). We used the net proceeds from the 2020 Notes offering, together with available cash on hand, to repay in full the senior secured credit facilities. Interest on each series of the 2020 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year. The 2020 Notes were issued at a total discount of $149.0&#160;million and we capitalized approximately $40.4&#160;million in debt issuance costs primarily comprised of underwriting fees. The 2020 Notes have a weighted average coupon rate and a weighted average effective interest rate of 2.125% and 2.50%, respectively.&#160;&#160;&#160;&#160;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 3, 2021, we completed an exchange offer for the 2020 Notes where certain holders elected to tender their unregistered outstanding notes for freely tradable exchange notes that were registered under the Securities Act of 1933. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Notes may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the treasury rate, plus a make-whole premium as defined in the indenture. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon the occurrence of a change of control triggering event and downgrade in the rating of our Notes by two of three credit agencies, the holders may require us to repurchase all or part of their Notes at a price equal to 101% of the aggregate principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.  </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary. We are required to comply with certain covenants under our Notes and, </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">as of December 31, 2021, we were in compliance with all applicable covenants.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2021 and 2020, the estimated fair value of our outstanding Notes using Level 2 inputs was approximately $7.2&#160;billion and $6.2&#160;billion, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Senior Unsecured Revolving Credit Facility</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 15, 2021, we entered into an amended and restated revolving credit agreement (the &#8220;Credit Agreement&#8221;). The Credit Agreement amends and restates the existing credit agreement that our subsidiary, RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) with borrowing capacity of up to $1.5&#160;billion for general corporate purposes. The Credit Agreement extends the maturity of the Revolving Credit Facility to September 15, 2026. As of </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2021 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2020, there were no outstanding borrowings under the Revolving Credit Facility.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Revolving Credit Facility is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent&#8217;s prime rate, (2) the federal funds effective rate and the overnight bank funding rate, plus 0.5% and (3) the one month adjusted LIBOR, plus 1% or (b) the Eurocurrency Rate or the Alternative Currency Daily Rate (each as defined in the Credit Agreement), plus in each case, the applicable margin. The applicable margin for the Revolving Credit Facility varies based on our public debt rating. Accordingly, the interest rates for the Revolving Credit Facility fluctuates during the term of the facility based on changes in the applicable interest rate and future changes in our public debt rating.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Credit Agreement that governs the Revolving Credit Facility contains certain customary covenants, that among other things, require us to maintain (i) a consolidated leverage ratio at or below 4.00 to 1.00 (or at or below 4.50 to 1.00 following a qualifying material acquisition) of consolidated funded debt to consolidated EBITDA, each as defined and calculated with the ratio level calculated with further adjustments as set forth in the Credit Agreement and (ii) a consolidated coverage ratio at or above 2.50 to 1.00 of consolidated EBITDA to consolidated interest expense, each as defined and calculated with further adjustments as set forth in the Credit Agreement. All obligations under the Revolving Credit Facility are unconditionally guaranteed by us. As of </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, RP Holdings was in compliance with these covenants. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Secured Credit Facilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 11, 2020, in connection with the Exchange Offer Transactions (as discussed in Note 1&#8211;Organization and Purpose) and using funds contributed by RPI Intermediate FT and the Legacy Investors Partnerships, RPIFT repaid its outstanding debt and accrued interest, and terminated all outstanding interest rate swaps. RPI Intermediate FT, as borrower, entered into a term loan credit agreement with Bank of America, N.A., as administrative agent, the lenders party thereto from time to time and the other parties thereto. The senior secured credit facilities consisted of a term loan A and term loan B in the amounts of $3.20&#160;billion and $2.84&#160;billion, respectively. In September 2020, we repaid in full the outstanding principal amounts of term loans under the senior secured credit facilities with net proceeds from the 2020 Notes and available cash on hand. Upon refinancing our senior secured credit facilities in September 2020, we recorded a loss on debt extinguishment of $25.1&#160;million as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other non-operating expense/(income), net,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> which primarily consisted of unamortized loan issuance costs and original issue discount related to our senior secured credit facilities.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RPIFT Senior Secured Credit Facilities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The RPIFT Senior Secured Credit Facilities were repaid in full in February 2020 in connection with the Exchange Offer Transactions. We recorded a loss on debt extinguishment of $5.4&#160;million as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other non-operating expense/(income), net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">during the year ended December 31, 2020. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Principal Payments on the Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The future principal payments for our borrowings as of December 31, 2021 over the next five years and thereafter are as follows (in thousands):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,300,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>(1)  &#160;&#160;&#160;&#160;Excludes unamortized debt discount and issuance costs of $203.9 million as of December 31, 2021, which are amortized through interest expense over the remaining life of the underlying debt obligations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313457368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders&#8217; Equity<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital structure</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following the completion of our IPO as discussed in Note 1&#8211;Organization and Purpose, we have two classes of voting shares: Class A ordinary shares and Class B ordinary shares, each of which has one vote per ordinary share. The Class A ordinary shares and Class B ordinary shares vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law. Our Class B ordinary shares are not publicly traded and holders of Class B ordinary shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up of the Company. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An exchange agreement entered into by us, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP and EPA Holdings (the &#8220;Exchange Agreement&#8221;) governs the exchange of RP Holdings Class B Interests held by the Continuing Investors Partnerships for Class A ordinary shares. Pursuant to the Exchange Agreement, RP Holdings Class B interests are exchangeable on a one-for-one basis for Class A ordinary shares on a quarterly basis. As of December 31, 2021, we have outstanding 432,963&#160;thousand Class A ordinary shares and 174,213&#160;thousand Class B ordinary shares. Each such exchange also results in the re-designation of the same number of our Class B ordinary shares as deferred shares. As of December 31, 2021, we have outstanding deferred shares of 361,170 thousand. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have in issue 50 thousand Class R redeemable shares, which do not entitle the holder to voting or dividend rights. The purpose of the Class R redeemable shares was to ensure Royalty Pharma Limited had sufficient sterling denominated share capital at the time it was re-registered as a public limited company to Royalty Pharma plc, as required by the U.K. Companies Act. The Class R redeemable shares may be redeemed at our option in the future. Any such redemption would be at the nominal value of &#163;1 each.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-controlling interests</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The only non-controlling interest in the year ended December 31, 2019 related to RPSFT, for which the net change in the related balance is as presented in the statements of shareholders&#8217; equity. The net change in the balance of our four non-controlling interests for the years ended December 31, 2021 and 2020 is as follows (in thousands): </span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.334%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,165,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,174,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer of interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,037,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,037,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112,339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(594,592)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(792,357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income prior to IPO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,433,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,433,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Class A ordinary shares sold in IPO, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(309,566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(309,566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income subsequent to IPO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">581,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized losses on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,018)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,939,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,125,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,077,036</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;Related to the Continuing Investors Partnerships&#8217; ownership of approximately 36% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2020. Royalty Pharma plc owns the remaining 64% of RP Holdings through its ownership of RP Holdings Class A Interests and Class B Interests as of December 31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:32.479%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.481%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,939,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,125,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,077,036</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56,490)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(425,050)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(133,433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(614,973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(642,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(642,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized losses on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,946)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,415)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,809,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,649,154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,471,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;Related to the Continuing Investors Partnerships&#8217; ownership of approximately 29% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2021. Royalty Pharma plc owns the remaining 71% of RP Holdings through its ownership of RP Holdings Class A Interests  and Class B Interests as of December 31, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">RP Holdings Class C Special Interest held by EPA Holdings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EPA Holdings is entitled to Equity Performance Awards (as defined below) through its RP Holdings Class C Special Interest based on our performance, as determined on a portfolio-by-portfolio basis. Investments made during each two-year period will be grouped together as separate portfolios (each, a &#8220;Portfolio&#8221;). Subject to certain conditions, at the end of each fiscal quarter, EPA Holdings is entitled to a distribution from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the &#8220;Equity Performance Awards&#8221;). The Equity Performance Awards will be allocated and paid by RP Holdings to EPA Holdings as the holder of the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests for which we will issue the same number of Class B ordinary shares, which may be subsequently exchanged for our Class A ordinary shares. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently expect any material Equity Performance Awards to be payable until the performance conditions discussed above are met.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of Class A ordinary shares are entitled to receive dividends subject to approval by the board of directors. The holders of Class B ordinary shares do not have any rights to receive dividends; however the RP Holdings Class B Interests are entitled to dividends and distributions from RP Holdings, our consolidated subsidiary. In the year ended December 31, 2021, we declared and paid four quarterly cash dividends of $0.17 per Class A ordinary share for an aggregate amount of $285.2&#160;million to holders</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our Class A ordinary shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Independent Directors Equity Incentive Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2020, our 2020 Independent Director Equity Incentive Plan was approved and became effective, whereby 800 thousand Class A ordinary shares have been reserved for future issuance to our independent directors. As of December 31, 2021, approximately 620&#160;thousand shares remain reserved for future issuance under the Equity Incentive Plan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSU activity and share-based compensation</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant RSUs to our independent directors under the 2020 Independent Director Equity Incentive Plan. Share-based compensation expense is recognized based on estimated fair value of the award on the grant date and amortized on a straight-line basis over the requisite service period of generally one year as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statement of comprehensive income. The estimated fair value of RSUs is based on the closing price of our Class A ordinary shares on the grant date.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized share-based compensation of approximately $3.1&#160;million and $5.7&#160;million for the years ended December 31, 2021 and 2020, which is recorded as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span> in the consolidated statement of operations. There were no share-based awards or related expenses in periods prior to the IPO. As of December 31, 2021, the total unrecognized share-based compensation expense related to total outstanding RSUs was less than $1.0&#160;million, which we expect to recognize in the next six months.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887317183208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings per ShareBasic earnings per share (&#8220;EPS&#8221;) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to us, including the impact of potentially dilutive securities, by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include the outstanding Class B ordinary shares, Class B ordinary shares contingently issuable to EPA Holdings related to Equity Performance Awards, and unvested RSUs issued under our Equity Incentive Plan. We use the &#8220;if-converted&#8221; method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs.<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Class B ordinary shares, Class R redeemable shares, and deferred shares do not share in the earnings or losses attributable to us and are therefore not participating securities. As such, separate presentation of basic and diluted earnings per share for Class B ordinary shares, Class R redeemable shares, and deferred shares under the two-class method has not been presented. Our Class B ordinary shares are, however, considered potentially dilutive shares of Class A ordinary shares because shares of Class B ordinary shares, together with the related RP Holdings Class B Interests, are exchangeable into Class A ordinary shares on a one-for-one basis. For the years ended December 31, 2021 and 2020, Class B ordinary shares contingently issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact. Additionally, Class B ordinary shares in issue were evaluated under the if-converted method for potential dilutive effects and were determined to be anti-dilutive for the years ended December 31, 2021 and 2020, and therefore were excluded from the computation of diluted earnings per shares of Class A ordinary share. As of December 31, 2021 and 2020, we had 607,176&#160;thousand and 607,111&#160;thousand fully diluted Class A ordinary shares outstanding, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings per Class A ordinary share for the year ended December 31, 2021 (in thousands, except per share amounts).</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,241,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Legacy Investors Partnerships and RPSFT</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">619,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Dilutive effect&#160;of unvested RSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414,802&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.49&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prior to the IPO, our capital structure mainly included unitholder interests. We analyzed the calculation of earnings per interest for periods prior to the IPO and determined that the resultant values would not be meaningful to the users of these consolidated financial statements. Therefore, the basic and diluted earnings per share for the year ended December 31, 2020 are only applicable for the period from June 16, 2020 to December 31, 2020, which represents the period in which we had outstanding Class A ordinary shares. The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings per Class A ordinary share for the year ended December 31, 2020 (in thousands, except per share amounts).</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,701,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships prior to the IPO (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships subsequent to the IPO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Legacy Investors Partnerships and RPSFT</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,198&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Dilutive effect&#160;of unvested RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares&#160;outstanding - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.32&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1) &#160;&#160;&#160;&#160;Reflected as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Net income attributable to controlling interest </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">on the consolidated statements of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887317179864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indirect Cash Flow<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Indirect Cash Flow</a></td>
<td class="text">Indirect Cash Flow<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,241,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,701,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,461,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile consolidated net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,065,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,959,975)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,648,837)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,019,321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses/(gains) on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(247,073)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(155,749)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in losses/(earnings) of non-consolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44,459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions from non-consolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50,896)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,859)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination of derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,093)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Decrease/(increase) in operating assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collected on financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,315,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,121,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,934,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued royalty receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty income receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41,028)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Decrease)/increase in operating liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(766)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,017,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,034,629</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,667,239</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash investing and financing activities are summarized below (in thousands).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental Schedule of Non-cash Investing/Financing Activities:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receipt of contribution of investment in Legacy Investors Partnerships (Note 9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303,679&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement of Epizyme forward purchase contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued purchase obligation - Tazverik (Note 17)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayments of long-term debt by contributions from non-controlling interest (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,103,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Milestone payable - Erleada (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1) Related to the pro rata portion of RPIFT&#8217;s outstanding debt repaid by the Legacy Investors Partnerships.</span></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2) Related to the achievement of a sales-based milestone that was not paid as of December 31, 2020 as recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> on the consolidated balance sheet.</span></div></td></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI http://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313344472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Income</a></td>
<td class="text">Accumulated Other Comprehensive Income<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, the only component of accumulated other comprehensive income related to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gains on available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the Series A Biohaven Preferred Shares. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were released into earnings. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive income as of December 31, 2021 and 2020 are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains on Available for Sale Debt Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Losses on Interest Rate Swaps</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(4,066)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,093</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification to net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,921)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,066&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,855)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Activity for the year</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification to non-controlling interest</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification from non-controlling interest</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">34,395</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">34,395</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification to net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,481)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,481)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Activity for the year</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification from non-controlling interest</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,491</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,491</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reclassification of unrealized gains on available for sale debt securities of $50.9&#160;million in the year ended December 31, 2021 is presented within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest incom</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e on the consolidated statements of operations, including $28.5&#160;million attributable to controlling interest noted in the table above and $22.4&#160;million attributable to the non-controlling interest. The total reclassification of unrealized gains on available for sale debt securities of $20.6&#160;million in the year ended December 31, 2020 is presented within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest incom</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e on the consolidated statements of operations, including $10.9&#160;million attributable to controlling interest noted in the table above and $9.6&#160;million attributable to the non-controlling interest.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313283272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Manager</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Manager is the investment manager of Royalty Pharma and its subsidiaries. The Manager is an affiliate of RP Ireland, the administrator of RPIFT, RPI Intermediate FT and RPSFT. The sole member of the Manager, Pablo Legorreta, holds an interest in us and serves as our Chief Executive Officer and Chairman of the board of directors, and as a director on the board of directors of RP Holdings.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Exchange Offer Transactions (discussed in Note 1&#8211;Organization and Purpose), the Manager entered into Management Agreements with us and our subsidiaries, the Continuing Investors Partnerships, and with the Legacy Investors Partnerships. Pursuant to the Management Agreements, we pay quarterly operating and personnel expenses to the Manager or its affiliates (&#8220;Operating and Personnel Payments&#8221;) equal to 6.5% of the Adjusted Cash Receipts (both, as defined in the Management Agreement) for such quarter and 0.25% of the value of our security investments under GAAP as of the end of such quarter. The operating and personnel payments for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected in our consolidated net income, is calculated as the greater of $1&#160;million per quarter and 0.3125% of Royalty Investments (as defined in the limited partnership agreements of the Legacy Investor Partnerships) during the previous twelve calendar months. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Exchange Date, the Manager received operating and personnel payments payable in equal quarterly installments that increased by 5% annually on a compounded basis under the terms of its management agreement with Old RPI and the Legacy Investors Partnerships. RP Ireland receives an annual management fee payable in advance by Old RPI in equal quarterly installments under terms of the limited partnership agreements of the Legacy Investors Partnerships. After the Exchange Date, operating and personnel payments were calculated in accordance with the methodology discussed in the paragraph above. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021, 2020 and 2019, total operating and personnel payments incurred were $145.2&#160;million, $112.5&#160;million and $60.0&#160;million, respectively, including the amounts attributable to Old RPI, and were recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution Payable to Non-Controlling Interest</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution payable to non-controlling interest represents the contractual cash flows required to be distributed based on the Legacy Investors Partnerships&#8217; non-controlling interest in Old RPI and RPSFT&#8217;s non-controlling interest in RPCT. The distribution payable to non-controlling interest as of December 31, 2021 and 2020 included the following (in thousands). </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to Legacy Investors Partnerships</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to RPSFT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total distribution payable to non-controlling interest</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,934&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,366&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition from Epizyme </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, in connection with a royalty acquisition and an equity investment in Epizyme made by RPIFT, Pablo Legorreta, our Chief Executive Officer, was appointed as a director of Epizyme, for which he received, and continues to receive, compensation in cash and shares of Epizyme, all of which are and will continue to be contributed to the Manager and used to reduce costs and expenses which would otherwise be billed to us or our affiliates. We continue to hold Epizyme common stock as of December 31, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition from Bristol Myers Squibb</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2017, RPI Acquisitions, a consolidated subsidiary, entered into a purchase agreement with Bristol Myers Squibb (&#8220;BMS&#8221;) to acquire from BMS a percentage of its future royalties on worldwide sales of Onglyza, Farxiga and related diabetes products marketed by AstraZeneca (the &#8220;Purchase Agreement&#8221;). We agreed to make payments to BMS based on sales of the products over eight quarters beginning with the first quarter of 2018 in exchange for a high single-digit royalty on worldwide sales of the products from 2020 through 2025. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 8, 2017, RPI Acquisitions entered into a purchase, sale and assignment agreement (&#8220;Assignment Agreement&#8221;) with a wholly owned subsidiary of BioPharma Credit PLC (&#8220;BPCR&#8221;), an affiliate of us. We considered BPCR as a related party due to the sole member of the Manager having significant influence over BPCR&#8217;s investment manager. Under the terms of the Assignment Agreement, RPI Acquisitions assigned the benefit of 50% of the payment stream acquired from BMS to BPCR in consideration for BPCR meeting 50% of the funding obligations owed to BMS under the Purchase Agreement. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began making installment payments to BMS in 2018 and completed our funding requirement, net of the assigned funding obligations, totaling $162.4&#160;million in the three months ended March 31, 2020. We began to measure this financial royalty asset using the effective interest method once our installment funding obligation was completed and we received our first royalty payment in the three months ended June 30, 2020. As of December 31, 2021 and 2020, the financial royalty asset of $130.9&#160;million and $150.6&#160;million, respectively, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets represents only our right to the future payment streams acquired from BMS. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other transactions</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Henry Fernandez, the lead independent director of our board of directors, serves as the chairman and chief executive officer of MSCI, Inc (&#8220;MSCI&#8221;). On April 16, 2021, we entered into an agreement with MSCI with an initial term of seven years to assist MSCI in the design of a classification framework and index methodologies in order to expand MSCI&#8217;s thematic index suite with the launch of new indexes. In return, we will receive a percentage of MSCI&#8217;s revenues from those indexes. No amounts were due from MSCI as of December 31, 2021. The financial statement impact associated with this transaction was not material for the year ended December 31, 2021.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the year ended December 31, 2020, we reimbursed Pablo Legorreta approximately $1.0&#160;million for the cost of purchasing and donating ventilators to hospitals on behalf of Royalty Pharma. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Exchange Offer Transactions, we acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy Investors Partnerships own a non-controlling interest in Old RPI. Refer to Note 9&#8211;Non-Consolidated Affiliates for additional discussion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RPIFT owns 27,210 limited partnership interests in the Continuing Investors Partnership whose only substantive operations are their investment in our subsidiaries. The total investment of $4.3&#160;million is recorded as treasury interests, of which $1.6&#160;million and $1.9&#160;million are held by non-controlling interest as of December 31, 2021 and 2020, respectively.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its ownership percentage of RP Holdings relative to the Company, each Continuing Investor Partnership pays a pro rata portion of any costs and expenses in connection with the contemplation of, formation of, listing and ongoing operation of us and any of our subsidiaries, including any third-party expenses of managing us and any of our subsidiaries, such as accounting, audit, legal, reporting, compliance, administration (including directors&#8217; fees), financial advisory, consulting, investor relations and insurance expenses relating to our affairs and those of any subsidiary.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313335592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of its business, we may enter into contracts or agreements that contain customary indemnifications relating to such things as confidentiality agreements and representations as to corporate existence and authority to enter into contracts. The maximum exposure under such agreements is indeterminable until a claim, if any, is made. However, no such claims have been made against us to date and we believe that the likelihood of such proceedings taking place in the future is remote.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys to support MorphoSys&#8217; acquisition of Constellation, which closed on July 15, 2021. As part of the funding agreement, we agreed to make additional milestone payments of up to $150.0&#160;million and provide up to $350.0&#160;million of Development Funding Bonds, which MorphoSys may draw over a one-year period from the close of its acquisition of Constellation. MorphoSys is required to draw a minimum of $150.0&#160;million, for which we have recognized the Development Funding Bond Forward within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> on the consolidated balance sheet as of December 31, 2021 (See Note 3&#8211;Available for Sale Debt Securities for additional discussion). Once drawn, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years, with the first payment beginning two years after the funding. As of December 31, 2021, MorphoSys has not drawn any amount under the Development Funding Bonds.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 7, 2020, we entered into a funding agreement with Biohaven, including the Series B Biohaven Preferred Share Agreement, to fund the development of zavegepant and the commercialization of Nurtec ODT in exchange for royalties and success-based milestones. Pursuant to the Series B Biohaven Preferred Share Agreement, we agreed to provide further support for the ongoing launch of Nurtec ODT with the purchase of committed, non-contingent Commercial Launch Preferred Equity for a total of $200.0&#160;million payable on a quarterly basis between March 31, 2021 and December 31, 2024. In return, Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between March 31, 2025 and December 31, 2030. During the three months ended March 30, 2021, we began purchasing the Series B Biohaven Preferred Shares. We have a remaining commitment of $129.6&#160;million under the Commercial Launch Preferred Equity, for which we have recognized the Series B Forwards within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated balance sheet as of December 31, 2021. See Note 3&#8211;Available for Sale Debt Securities for additional discussion.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, RPIFT agreed to pay $330.0&#160;million to purchase Eisai&#8217;s royalties on future worldwide sales of Tazverik, a novel targeted therapy in late-stage clinical development that was approved by the FDA in January 2020 for epithelioid sarcoma, and with the potential to be approved in several cancer indications. Under the terms of our agreement with Eisai, we acquired Eisai&#8217;s future worldwide royalties on net sales by Epizyme of Tazverik outside of Japan, for an upfront payment of $110.0&#160;million plus up to an additional $220.0&#160;million for the remainder of the royalty upon FDA approval of Tazverik for certain indications. The FDA approval of Tazverik in January 2020 triggered our obligation to fund the second $110.0&#160;million tranche in November 2020. On November 4, 2021, we funded the final $110.0&#160;million tranche. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have commitments to advance funds to counterparties through our investment in the Avillion Entities and R&amp;D arrangements. Please refer to Note 9&#8211;Non-Consolidated Affiliates and Note 10&#8211;Research &amp; Development (&#8220;R&amp;D&#8221;) Funding Expense, respectively, for details of these arrangements. We also have requirements to make Operating and Personnel Payments over the life of the management agreement as described in Note 16&#8211;Related Party Transactions, which are variable and primarily based on cash receipts.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to legal actions with respect to a variety of matters in the ordinary course of business. Some of these proceedings may be based on complex claims involving substantial uncertainties and unascertainable damages. Unless otherwise noted, it is not possible to determine the probability of loss or estimate damages, and therefore we have not established accruals for any of these proceedings in our consolidated balance sheets as of December 31, 2021 and 2020. When we determine that a loss is both probable and reasonably estimable, we record a liability, and, if the liability is material, we disclose the amount of the liability reserved. We do not believe the outcome of any existing legal proceedings to which we are a party, either individually or in the aggregate, will adversely affect our business, financial condition or results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313234392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsIn January 2022, we acquired a royalty interest in aficamten from Cytokinetics, Incorporated (&#8220;Cytokinetics&#8221;) for $150.0&#160;million, comprised of an upfront payment of $50&#160;million and two additional $50&#160;million payments which are conditional upon the initiation of potential pivotal clinical trials for obstructive hypertrophic cardiomyopathy and nonobstructive hypertrophic cardiomyopathy, respectively. Additionally, we will provide Cytokinetics long-term capital of up to $300&#160;million (&#8220;Cytokinetics Commercial Launch Funding&#8221;) to support further development of aficamten and potential commercialization of omecamtiv mecarbil. The Cytokinetics Commercial Launch Funding is available in five tranches, including an initial tranche of $50&#160;million funded upon closing and four additional tranches in the aggregate amount of $250&#160;million upon the occurrence of certain regulatory and clinical development milestones.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313727496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of preparation</a></td>
<td class="text">The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The precise extent to which the COVID-19 pandemic will impact our operational and financial performance will depend on various factors. To date, certain marketers of some of our portfolio products have commented that the performance of these products have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not resulted in a material effect to our results of operations and liquidity and we do not believe it is reasonably likely to in the future. Due to the nature of our business, the effect of the COVID-19 pandemic may not be fully reflected in certain of our results of operations until future periods.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of consolidation</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity&#8217;s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net income attributable to non-controlling interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in our consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following management&#8217;s determination that a high degree of common ownership existed in Royalty Pharma both before and after the Exchange Date, Royalty Pharma recognized Old RPI&#8217;s assets and liabilities at the carrying value reflected on Old RPI&#8217;s balance sheet as of the Exchange Date. </span></div>All intercompany transactions and balances have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text">Certain prior period amounts have been reclassified to conform to the current period presentation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk</a></td>
<td class="text">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, financial royalty assets and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances at December 31, 2021 and 2020 were held with State Street and Bank of America. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, AbbVie, Bristol Myers Squibb, Gilead, Johnson &amp; Johnson, Lilly, Merck, Pfizer, Novartis, Biogen, Roche and Vertex.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">Our chief operating decision maker is our Chief Executive Officer who reviews financial information presented on a consolidated basis to allocate resources, evaluates financial performance and makes overall operating decisions. As such, we concluded that we operate as one single reportable segment, which is primarily focused on acquiring biopharmaceutical royalties.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_RoyaltyAssetsPolicyPolicyTextBlock', window );">Royalty assets</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An acquisition of a royalty asset provides the buyer with contractual rights to cash flows relating to royalties from the sales of patent-protected biopharmaceutical products. These acquisitions entitle us to receive a portion of income from the sale of patent-protected biopharmaceutical products by unrelated biopharmaceutical companies. For the majority of our royalties, our rights are protective in nature. In other words, we do not own the intellectual property and we do not have the right to commercialize the underlying products. These contractual cash flow rights have yield components that most closely resemble loans and are classified as financial royalty assets.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the limited instances where we possess rights to exploit the underlying patents, rights to the intellectual property related to the biopharmaceutical products, or the ability to influence the amount or duration of future royalty payments, these royalties are classified as intangible assets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLoansAndLeasesReceivablePolicy', window );">Financial royalty assets, net</a></td>
<td class="text"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we analogize to the accounting guidance within Accounting Standards Codification 310 (&#8220;ASC&#8221;), Receivables, as it most closely aligns with the underlying economics of our financial royalty assets. Therefore, such financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Imputation of Interest</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is reviewed and adjusted each reporting period as differences between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows. Income is calculated by multiplying the carrying value of the financial royalty asset by the effective interest rate. The carrying value of a financial royalty asset is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by the interest income accrual and decreased by cash receipts in the period to arrive at the ending balance. If the ending balance is greater than the net present value of the expected future cash flows, a provision is recorded to reduce the asset balance to the net present value. The provision is recorded through the income statement as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected cash flows from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the carrying value of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is presented net of the cumulative allowance for changes in expected future cash flows.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The application of the prospective approach to measure financial royalty assets requires management&#8217;s judgment in forecasting the expected future cash flows of the underlying royalties. The amounts and duration of forecasted expected future cash flows used to calculate and measure interest income are largely impacted by sell-side equity research analyst coverage, commercial performance of the product, and royalty duration, each discussed in further detail below.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Analyst coverage.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Forecasts of expected future cash flows are developed from sales projections of the underlying biopharmaceutical products as published in sell-side equity research analyst reports. In projecting future cash flows, our policy is to rely on sell-side research analysts&#8217; consensus sales forecasts for a product to derive annual sales projections for each financial royalty asset over the periods for which we are entitled to royalties or milestones. These forecasts are based on input from internal and external market research that analyzes factors such as growth in global economies, industry trends and product life cycles. When royalty-bearing biopharmaceutical products have no coverage, limited sell-side equity research analyst coverage or where sell-side equity research analyst consensus sales estimates are not available for the full term of the royalty, particularly for the later years in a product&#8217;s life, management uses reasonable judgment to make assumptions about the growth or decline in the sales of these products based on historical data, market trends and management&#8217;s own expertise. For the majority of the portfolio of financial royalty assets, management utilizes statistical curves based on historical trends to project future sales when sell-side equity research analyst consensus sales estimates end or are not available for the full term of the royalty. In other cases, management may develop and apply growth rate estimates from existing sell-side equity research analysts&#8217; consensus sales forecasts to project future sales for products that cannot be modeled through the statistical curves, such as those where the entrance of a biosimilar is expected to impact future sales. Based on the level of detail in sell-side equity research analyst models, management can also be required to apply assumptions to the sales forecasts to estimate the quarterly and geographical allocation from annual sales projections and, for franchised products, to estimate the product mix and pricing mix, or to exclude from projections sales forecasts for unapproved products or indications. Our contractual royalty terms, rates, and any milestones are then applied to the adjusted sales projections to calculate the expected royalty or milestone payments over the term of the financial royalty asset&#8217;s life, forming the basis for our forecast of expected future cash flows used to calculate and measure interest income.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Commercial performance.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The approval of a product for use in new indications can extend the date through which we are entitled to royalties or milestones on that product. For certain financial royalty assets, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and whose sales were previously not reflected in expected future cash flows. We generally do not recognize income from, or forecast sales for, unapproved products or indications. If a product is removed from all or a portion of a market, subsequent sell-side equity research analysts&#8217; consensus sales forecasts will reflect the expected drop in sales. Both the new cash flow streams and the cessation of cash flow streams related to a product&#8217;s performance in the market over the royalty term can materially affect our forecast of expected future cash flows.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Royalty duration. </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The duration of a royalty can be based on a number of factors, such as regulatory and marketing approval dates, patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, the entry of generics or a contractual date arising from litigation, which are all impacted by the time in the product&#8217;s life cycle at which we acquire the royalty. Royalty duration varies by geography as United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms. Products may be covered by a number of patents and, for products whose royalty term is linked to the existence of valid patents, management is required to make judgments about the patent providing the strongest patent protection to align the period over which management forecasts expected future cash flows to the royalty term. It is common for the latest expiring patent in effect at the date we acquire a financial royalty asset to be extended, adjusted or replaced with newer dated patents subsequent to our acquisition of a royalty due to new information, resulting in changes to the royalty duration in later periods. Patents may expire earlier than expected at the time of the acquisition due to the loss of patent protection, loss of data exclusivity on intellectual property, contractual licensing terms limiting royalty payments based on time from product launch, due to recent legal developments or litigation. Macroeconomic factors, such as changes in economies or the competitive landscape, including the unexpected loss of exclusivity to the products underlying our portfolio of royalties, changes in government legislation, product life cycles, industry consolidations and other changes beyond our control could result in a positive or negative impact on our forecast of expected future cash flows.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the preparation of the forecasted expected future cash flows, which relies on the sources and variables discussed above, management is required to make assumptions around the following forecast inputs: (1) estimates of the duration of the royalty, which includes consideration of the strength of patent protection and anticipated entry of generics, (2) product growth rates and sales trends in outer years, (3) the product and pricing mix for franchised products, and (4) the geographical allocation of annual sales data from sell-side equity research analysts&#8217; models. The most sensitive of these assumptions relates to management&#8217;s estimate of the royalty duration in the final years of an asset&#8217;s life. In some cases, patent protection may extend to a later period than the expiration date management has estimated. Management may apply a shorter royalty term in this situation if, based on its experience and expertise, management believes that it is more likely that the associated patents are subject to opposition or infringement, that the market for a particular product may shift based on pipeline approvals and products, or that product sales may be harmed by competition from generics. For products providing perpetual royalties, management applies judgment in establishing the duration over which it forecasts expected future cash flows. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A shortened royalty term can result in a reduction in the effective interest rate, a decline in the carrying value of the financial royalty asset, a decline in income from financial royalty assets, significant reductions in royalty payments compared to expectations, or a permanent impairment. Additionally, royalty payments may occasionally continue beyond the estimated royalty expiration date for such reasons we cannot foresee such as excess inventory in the channel or additional scope of patent protection identified after expiry, including royalties we may become entitled to from new indications, new compounds, or for new regulatory jurisdictional approvals.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter and for which the estimates are derived from the latest external publicly available sell-side equity research analyst reports, reported in arrears. </span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cumulative allowance and Provision for changes in expected cash flows from financial royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate financial royalty assets for impairment on an individual basis by comparing the effective interest rate at each reporting date to that of the prior period. If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected), we record a provision for the change in expected cash flows. The provision is measured as the difference between the financial royalty asset&#8217;s amortized cost basis and the net present value of the expected future cash flows, calculated based on the prior period&#8217;s effective interest rate. The amount recognized as provision expense increases the financial royalty asset&#8217;s cumulative allowance, which reduces the net carrying value of the financial royalty asset.</span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance for the increase in the present value of cash flows expected to be collected, resulting in a non-cash credit to the provision line on the income statement. We also recalculate the amount of accretable yield to be received based on the revised remaining future cash flows. The adjustment to the accretable yield is treated as a change in estimate and is recognized prospectively over the remaining life of the financial royalty asset by adjusting the effective interest rate used to calculate income.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Movements in the cumulative allowance for changes in expected future cash flows, which forms part of the </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line item on the consolidated balance sheet, are accompanied by corresponding changes to the provision. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. Recoveries of previously written-off amounts are credited to the allowance. In some cases, when a financial royalty asset&#8217;s contractual cash flows expire, the final royalty payment may differ from the remaining net carrying value. We account for this non-cash true-up at the end of the royalty term as either </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected cash flows from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of operations.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income from financial royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. The accretable yield is recognized as income at the effective rate of return over the expected life of financial royalty assets. After acquisition of a financial royalty asset, if we are not able to reliably estimate expected cash flows for a product or if we have not completed the required funding obligations payable over time for an approved product, a financial royalty asset is placed in non-accrual status (e.g., for royalties from products that have not yet received FDA approval or for accelerated royalties). Such financial royalty assets are held at cost and no income is recognized until the reasonable expectation of the timing of the future cash flows to be collected is available or until funding obligations payable over time for an approved product are complete. We evaluate such financial royalty assets held at cost for impairment based on, among other factors, a review of development progress, clinical trial results, and publicly available information around regulatory discussions and approval status. An impairment loss is recognized if, based on current information and events, it is probable that we will be unable to collect amounts due according to the contractual terms of the financial royalty asset, and the amount of loss can be reasonably estimated.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When royalties are received for financial royalty assets that have been fully amortized, such income is recognized as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock', window );">Allowance for current expected credit losses</a></td>
<td class="text"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 1, 2020, we adopted ASU 2016-13, </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(&#8220;ASU 2016-13&#8221;) which requires earlier recognition of credit losses. We now recognize an allowance for current expected credit losses on our portfolio of financial royalty assets with limited protective rights. The credit loss allowance is estimated using the probability of default and loss given default method. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the probability of default of the marketers responsible for paying our royalties and the resulting loss given default. The allowance for current expected credit losses is presented net within the non-current portion of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated balance sheets. Any subsequent movement in the allowance for credit losses is recorded as part of the </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Provision for changes in expected future cash flows from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated statements of operations.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible royalty assets, net</a></td>
<td class="text">Currently, our only intangible royalty assets are the Januvia and Janumet (&#8220;DPP-IV&#8221;) patents. The DPP-IV patents are finite-life intangible royalty assets whose cost is amortized using the straight-line method over the expected lives of the patents, the majority of which terminate at various dates through 2022. The amortization period commenced concurrent with the sale of the product underlying the royalty asset.<span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management reviews the performance of intangible royalty assets periodically for impairment as required by ASC 360-10,</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Property, Plant, and Equipment - Overall</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The test for recoverability is performed by comparing the carrying value of the intangible royalty asset with the estimated future undiscounted cash flows generated through royalty payments from sales of the underlying DPP-IV products. When evaluating indicators of impairment, we consider factors such as competitive environment and the product&#8217;s life cycle stage, recent and prospective sales trends, collectability concerns, and any potential rebate chargebacks that may occur at the end of a royalty&#8217;s term. An impairment loss is recognized if the carrying value of the intangible royalty asset is not recoverable and its carrying amount exceeds its fair value.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue from intangible royalty assets and Accrued royalty receivable</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We earn royalties on sales by our licensees of DPP-IV products covered under patents that we own. We do not have future performance obligations under these license arrangements. Royalty revenue from sales of DPP-IV products is recognized in the period the product is sold. However, under the license agreements, licensees generally provide royalty reports and payments on a one quarter lag. Thus, the accrued royalty receivable is based on an analysis of historical royalties received and sell-side equity research analysts&#8217; projected sales, adjusted for any changes in estimates. Royalty-bearing sales are net of certain rebates and other discounts, as permitted under the terms of the license agreements. Because rebates are generally invoiced and paid in arrears by the marketer, royalty reports often reflect deductions in current periods for rebates related to prior periods which we do not have the ability to estimate.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical estimates that could cause a change in estimated future cash flows include changes in product demand and market growth assumptions, a change in the pricing strategy of the marketer or reimbursement coverage, and changes in country-specific contractual or patent expiry dates. Actual royalty receipts may differ from estimates and any differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically on the basis of royalty receipts.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestone payments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain acquisition agreements provide for future incoming or outgoing contingent payments based on the commercial, regulatory or clinical performance of the related biopharmaceutical product generally over a multi-year period. For purposes of measuring income from financial royalty assets, commercial milestones payable or receivable are reflected in the cash flows used to forecast expected future cash flows in the period in which the milestone criteria is projected to be satisfied based on sell-side equity research analysts&#8217; consensus sales forecasts. Milestones based on regulatory approval or clinical criteria are generally not reflected in the expected future cash flows until such approval is achieved.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts related to outgoing contingent milestone payments are not considered contractual obligations as they are contingent on the successful completion of the defined milestones. Payments under these agreements generally become due and payable upon achievement of certain commercial milestones, and when the contingency is resolved.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Instruments</a></td>
<td class="text"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain financial instruments reflected in the consolidated balance sheets, (e.g., cash and cash equivalents, certain other assets, accounts payable and certain other liabilities) are recorded at cost, which approximates fair value due to their short-term nature. The fair values of financial instruments other than </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are determined through a combination of management estimates and information obtained from third parties using the latest market data. The fair value of financial instruments is determined utilizing the valuation techniques appropriate to the type of instrument as discussed in Note 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair Value Measurements and Financial Instruments.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text">Cash and cash equivalents include cash held at banks and all highly liquid financial instruments with original maturities of 90 days or less. We invest excess cash in marketable debt securities that are classified as trading securities and reported at fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock', window );">Equity securities and Available for sale debt securities</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our equity securities are measured and recorded at fair value with unrealized gains and losses recorded in earnings. Our equity securities represent investments in publicly traded equity securities. Available for sale debt securities are measured at fair value. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The unrealized change in fair value of available for sale debt securities for which we elected the fair value option is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on the consolidated statements of operations. The </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">unrealized change in fair value for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biohaven Series A Preferred Share is</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> included in </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accumulated other comprehensive income </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(&#8220;AOCI&#8221;) and are reclassified to earnings as interest income is recognized. Interest income is recognized when we can reliably estimate forecasted cash flows. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decline in the market value of any available for sale debt security below its cost that is deemed to have resulted from a credit loss results in a reduction in carrying amount to fair value and is recognized in earnings. The determination of whether a decline in fair value below the amortized cost basis for an available for sale debt security has resulted from a credit loss requires significant judgment and requires consolidation of available quantitative and qualitative evidence in evaluating the potential impairment. Factors evaluated to determine whether a decline in the fair value below the amortized cost basis has resulted from a credit loss include: the extent to which fair value is less than the amortized cost basis, adverse conditions related to the security, an industry, or geographic area, the payment structure of the security, failure of the issuer to make scheduled payments, any changes to the rating of the security by a rating agency, the remaining payment terms of the security, prepayment speeds, the financial condition of the issuer expected defaults, our intent not to sell, and an evaluation as to whether it is more likely than not that we will have to sell before recovery of the cost basis. Assumptions associated with these factors are subject to future market and economic conditions, which could differ from management&#8217;s assessment.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may elect to apply the fair value option for certain investments in debt securities where the fair value option better aligns with the economics of such investment. Upon such election, the entire investment is measured at fair value on a recurring basis, with movements in fair value recognized in earnings.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
<td class="text">All derivatives are measured at fair value on the consolidated balance sheets with movements in fair value recognized in earnings. Prior to 2017, RPIFT applied hedge accounting to its interest rate swap agreements. <span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the discontinuation of hedge accounting, the AOCI previously recorded on the cash flow hedges was reversed out of other comprehensive income in line with terms of the associated swap contract until the termination of all of our interest rate swaps in February 2020. This reclassification adjustment is shown on the consolidated statements of operations as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Losses on derivative financial instruments</span>.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Investments in non-consolidated affiliates</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Investments in entities that provide us with the ability to exercise significant influence, but not a controlling financial interest, and where we are not the primary beneficiary are accounted for under the equity method. Investments accounted for under the equity method are initially recorded at fair value. If there is a difference between the fair value and the carrying amount of the equity method investment at inception, we quantify the basis difference and amortize it in a rational manner over the life of the investment. Subsequently, we recognize through earnings our proportionate share of the investee&#8217;s net income or loss, net of any adjustment to reflect the amortization of basis differences. We generally record our share of the results of our investees one quarter in arrears within </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Equity in losses/(earnings) of non-consolidated affiliates</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in the consolidated statements of operations. The investment is reflected as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investments in non-consolidated affiliates</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated balance sheet.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have variable interests in entities formed for the purposes of entering into co-development arrangements for potential biopharmaceutical products (the &#8220;Avillion entities&#8221;). The Avillion entities are variable interest entities for which we are not the primary beneficiary as we do not have the power to direct the activities that most significantly influence the economic performance of the entity. In determining whether we are the primary beneficiary of an entity, management applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant. Management continuously assesses whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of one or more of its investees.</span></div>When we have committed to provide further support to the investee through capital call commitments and the investment has been reduced to zero, we provide for additional losses, resulting in a negative equity method investment, which is presented as a liability on the consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development funding expense</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We enter into transactions where we agree to fund a portion of the research and development (&#8220;R&amp;D&#8221;) performed by our partners for products undergoing late-stage clinical trials in exchange for future royalties or milestones if the products are successfully developed and commercialized. In accordance with ASC 730, </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and Development</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we account for the funded amounts as R&amp;D expense when we have the ability to obtain the results of the R&amp;D, the transfer of financial risk is genuine and substantive and, at the time of entering into the transaction, it is not yet probable that the product will receive regulatory approval. We may pay funded amounts upfront or over time as the underlying products undergo clinical trials.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty payments owed to the Company on successfully commercialized products generated from R&amp;D arrangements are recognized as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the same period in which the sale of the product occurs. Fixed or milestone payments receivable based on the achievement of contractual criteria for products arising out of our R&amp;D arrangements are also recognized as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the period that the milestone threshold is met. Milestone thresholds are typically not triggered until after all funding obligations have been completed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically assess if our activities, as conducted through our subsidiaries, and as currently contemplated, constitute being engaged in the conduct of a trade or business within the United States. Neither the U.S. Internal Revenue Code (&#8220;the Code&#8221;) nor the applicable Treasury regulations provide a general definition of what constitutes being engaged in the conduct of a trade or business within the United States, and the limited case law on the subject does not provide definitive guidance. Based on our periodic assessment, we believe that we are not engaged in the conduct of a trade or business within the United States, and as such, we do not record a provision for U. S. federal income tax for the years presented in the consolidated financial statements.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe we are not engaged in the conduct of a trade or business within the United States or subject to U.S. taxation in that regard, we are subject to U. S. federal withholding tax on certain fixed or determinable annual or periodical gains, profits and income, such as royalties from sources within the United States, unless reduced or eliminated under an applicable tax treaty or provision of the Code. Generally, this tax is imposed by withholding 30% of the payments, or deemed payments, that are subject to this tax. We believe our subsidiaries are eligible for benefits under the U.S.-Ireland income tax treaty, and, under that treaty, are not be subject to any U.S. withholding taxes on U.S.-source royalty payments. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, because we believe that we are not engaged in the conduct of a trade or business within the United States and our subsidiaries are eligible for benefits under the U.S.-Ireland tax treaty, we do not record a provision for income taxes. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While we do not currently record a provision for income taxes, we are party to certain arrangements that will give rise to a tax provision in the future. We currently have funding arrangements in place that allow our counterparties to draw on capital over a prescribed period of time. When such funding arrangements are drawn and we begin to recognize income from these funding arrangements, such activities will be subject to U.S. taxation and we will record a provision for income taxes in accordance with ASC 740, </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. We also entered into an arrangement with MSCI during 2021 as discussed in Note 16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Related Party Transactions that will become subject to U.S. taxation when we begin to recognize revenue from this transaction.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate so as to be treated solely as resident in the U.K. for tax purposes. As a U.K. tax resident company, we are subject to U.K. corporation tax on our worldwide taxable profits and gains. U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. As such, we do not record a provision for U.K. income taxes with respect to the dividends received from RP Holdings or with respect to the dividends received by RP Holdings from RPI. </span></div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the U.K.&#8217;s &#8220;controlled foreign companies&#8221; rules (the &#8220;U.K. CFC Rules&#8221;). The U.K. CFC Rules, broadly, can impose a charge to U.K. tax on U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the &#8220;Controlled Foreign Company&#8221;) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI (which is Irish tax resident) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Old RPI (which is Irish tax resident and which is held indirectly by us through our participation in RP Holdings)</span>, will be Controlled Foreign Companies for U.K. tax purposes. We are therefore required to apply the CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis.  We do not expect material U.K. corporation tax charges to arise under the U.K. CFC Rules in respect of our royalty assets and we therefore do not record a provision for U.K. income taxes.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per share</a></td>
<td class="text">Basic earnings per share (&#8220;EPS&#8221;) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include the outstanding Class B ordinary shares, Class B ordinary shares contingently issuable to RPI EPA Holdings, LP (&#8220;EPA Holdings&#8221;) related to Equity Performance Awards and unvested restricted share units (&#8220;RSUs&#8221;) issued under our 2020 Independent Director Equity Incentive Plan (&#8220;Equity Incentive Plan&#8221;). We include potentially dilutive shares in the denominator to compute diluted EPS if (i) the inclusion of the ordinary shares is dilutive for the respective reporting periods, and (ii) contingencies are satisfied as of the end of the reporting period for ordinary shares that are contingently issuable.  We use the &#8220;if-converted&#8221; method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted and issued accounting standards</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model (ASU 2016-13). Accordingly, these financial assets are presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model.  With certain exceptions, adjustments are applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retained earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $192.7&#160;million to recognize an allowance for current expected credit losses on our financial royalty assets. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued a new accounting standard that eliminates, adds and modified certain disclosures requirements for fair value measurements under Topic 820 (ASU 2018-13). The ASU modifies the disclosures by removing the requirement to disclose the amount and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers. The ASU expands the disclosure requirements for Level 3 fair value measurements, primarily focused on changes in unrealized gains and losses included in other comprehensive income/(loss). We adopted this standard as of January 1, 2020 with no material impact on our consolidated financial statements and accompanying notes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives and available for sale debt securities are reported at their respective fair values in our consolidated balance sheets. For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. Long-term debt and financial royalty assets are reported at their amortized costs in our consolidated balance sheets but for which fair values are disclosed. The remaining financial instruments are reported in our consolidated balance sheets at amounts that approximate current fair values.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available For Sale, Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RoyaltyAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Assets, Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RoyaltyAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 35<br> -Paragraph 7A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515542&amp;loc=SL120269220-210453<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3D<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL120267969-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922895-210455<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 35<br> -Paragraph 13A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515542&amp;loc=SL120267917-210453<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 35<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124266218&amp;loc=SL120267834-210445<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 30<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=124256539&amp;loc=SL120269210-210444<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919260-210447<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL120267845-210446<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919272-210447<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 30<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=124256539&amp;loc=SL120254536-210444<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3C<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL120267966-210447<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 30<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=124268681&amp;loc=SL120267897-210452<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3D<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267862-210455<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.M.Q4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122651532&amp;loc=SL122037091-237805<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3C<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267859-210455<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267853-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLoansAndLeasesReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (b,d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLoansAndLeasesReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313726296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available for Sale Debt Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Available for Sale Debt Securities</a></td>
<td class="text"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below summarizes our available for sale debt securities recorded at fair value as of December 31, 2021 and 2020 (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.287%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Biohaven Preferred Shares</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series B Biohaven Preferred Shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series B Forwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development Funding Bond Forward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">204,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65,891</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">270,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">204,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">270,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Biohaven Preferred Shares</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series B Forwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">145,647</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">87,353</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">233,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">69,984</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">163,016</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">233,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)Cost for Series A Biohaven Preferred Shares represents amortized cost. Cost for Series B Biohaven Preferred Shares represents the amounts paid to purchase the instruments. There were no costs associated with the Series B Forwards and Development Funding Bond Forward.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313318200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of Derivatives and Reclassifications</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below summarize the change in fair value of the derivatives for the years ended December 31, 2021, 2020 and 2019 and the line items within the consolidated statements of operations where the gains or losses on these derivatives are recorded (in thousands). </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.190%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location on Consolidated Statements of Operations</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Derivatives in hedging relationships (1)</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest Rate Swaps:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount of loss reclassified from accumulated other comprehensive income into income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense/(income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest Rate Swaps:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense/(income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,977)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward purchase contract:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of forward purchase contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury rate lock contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of treasury rate lock contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;Certain interest rate swaps were previously designated as cash flow hedges. These swaps became ineffective as debt refinancings occurred between 2013 and 2016. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income</span> were released into earnings.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887315560376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value Hierarchy</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes financial assets and financial liabilities that we measured at fair value on a recurring basis at the dates indicated, classified in accordance with the fair value hierarchy described above (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">444,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">444,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">598,253</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">636,823</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,301,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">24,302</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,134,957</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">69,984</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,229,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current assets</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">226,787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">247,413</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">474,200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">298,689</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,439</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">163,016</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">467,144</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The balance as of December 31, 2021 includes Series B Forwards and the Development Funding Bond Forward, recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the consolidated balance sheet, related to our obligations to fund acquisitions of the Series B Biohaven Preferred Shares and $150&#160;million of the Development Funding Bonds, respectively. The balance as of December 31, 2020 relates to Series B Forwards, recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the consolidated balance sheet. See Note 3&#8211;Available for Sale Debt Securities for additional discussion. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the Epizyme transaction as described in Note 4&#8211;Derivative Instruments and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span> in the consolidated balance sheets as of December 31, 2021 and 2020. The fair value of the warrant was not material as of December 31, 2021.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables presented below summarize the change in the combined fair value (current and non-current) of Level 3 financial instruments, which relate to equity securities and available for sale debt securities, including the underlying debt securities and related forwards (in thousands). </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Equity Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at the beginning of the year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the year</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43,013</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Debt Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at the beginning of the year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement of forwards (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer to Level 2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(184,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer from Level 2 (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Redemption</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the year</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">253,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">214,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Forwards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at the beginning of the year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement of forwards (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the year</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">For the year ended December 31, 2021, the unrealized gains on available for sale debt securities is comprised of $11.6&#160;million related to Series A Biohaven Preferred Shares as recorded on the consolidated statements of comprehensive income and $1.3&#160;million related to the Series B Biohaven Preferred Shares as recorded on the consolidated statements of operations. For the year ended December 31, 2020, the unrealized gains on available for sale debt securities related to the Series A Biohaven Preferred Shares as recorded on the consolidated statements of comprehensive income, including $52.7&#160;million prior to transferring out of Level 3 and then $15.9&#160;million after transferring back to Level 3. &#160;&#160;&#160;&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value attributed to the Series B Forwards that were settled in the period as the Series B Biohaven Preferred Shares were acquired, which is included in the fair value of the Series B Biohaven Preferred Shares. See Note 3&#8211;Available for Sale Debt Securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes $14.5&#160;million of unrealized gains on available for sale debt securities included in other comprehensive income while the Series A Biohaven Preferred Shares was classified as a Level 2 asset.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span>on the consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock', window );">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value</a></td>
<td class="text">Estimated fair values based on Level 3 inputs and related carrying values for our financial royalty assets as of December 31, 2021 and 2020 are presented below (in thousands).<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial royalty assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,047,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,332,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,718,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,955,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about fair value of asset and liability not measured at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2E<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498357-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313721272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Royalty Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Summary of Financial Royalty Assets, Net</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets at December 31, 2021 and 2020 are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration (a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 7)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value (e)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,335,641&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,287,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,846,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,829,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,438,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(236,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,201,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,100,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(172,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 (d)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020-2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,697,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(909,916)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,787,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,027,541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,384,141)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,643,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less: Cumulative allowance for credit losses (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(310,804)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,332,596</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt">Dates shown represent our estimates as of current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt">Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3&#160;billion. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:9.13pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7&#8211;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration (a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 7)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value (e) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,274,896&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,274,896&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,003,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112,720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,891,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,406,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46,872)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,359,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,150,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(145,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,004,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025-2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 (d)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020-2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,022,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(634,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,387,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,219,101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(940,107)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,278,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less: Cumulative allowance for credit losses (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(323,717)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,955,277</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:9.13pt">Dates shown represent our estimates as of current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt">Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3&#160;billion.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7&#8211;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313372120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossAbstract', window );"><strong>Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock', window );">Schedule of Cumulative Allowance for Changes in Expected Cash Flows</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:78.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.734%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Activity for the Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,982,897)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(322,717)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,342,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(868,418)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative adjustment for adoption of ASU 2016-13</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(192,705)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(645,612)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">570,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of credit loss allowance (b)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision expense for credit losses, net (c)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(156,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,263,824)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(912,710)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">446,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision income for credit losses, net (c)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,694,945)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;Relates to amounts removed from the allowance at the end of a royalty asset&#8217;s life to bring the account balance to zero. Write-offs solely impact the asset account and allowance account; there is no impact on the consolidated statements of operations.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;Relates to amounts reversed out of the credit loss allowance associated with omecamtiv mecarbil as a result of the write-off of the related financial royalty asset balance of $90.2&#160;million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%">(c) &#160;&#160;&#160;&#160;In the year ended December 31, 2020, the provision for credit losses was primarily related to certain additions to our portfolio of financial royalty assets with limited protective rights in 2020, mainly the final tranche of Tazverik. In the year ended December 31, 2021,the provision income for credit losses was primarily related to a significant decline in the financial asset value for Tazverik, which was offset by increases in our portfolio of financial royalty assets with limited protective rights in 2021, primarily related to zavegepant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313291480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Royalty Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Royalty Interests</a></td>
<td class="text"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following schedules of the intangible royalty assets present the cost, accumulated amortization and net carrying value as of December 31, 2021 and 2020 (in thousands).</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,546&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,546&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">577,550&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,666&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">577,550&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,666&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887316477560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Borrowings</a></td>
<td class="text"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Our borrowings at December 31, 2021 and 2020 consisted of the following (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Issuance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 0.75% (issued at 99.322% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.20% (issued at 98.875% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.75% (issued at 98.284% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 2.20% (issued at 97.760% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$600,000, 2.15% (issued at 98.263% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.30% (issued at 95.556% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.55% (issued at 95.306% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$700,000, 3.35% (issued at 97.565% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(203,930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(183,416)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt carrying value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,096,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,816,584</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,096,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,816,584&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Repayments of Debt by Year</a></td>
<td class="text">The future principal payments for our borrowings as of December 31, 2021 over the next five years and thereafter are as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,300,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>(1)  &#160;&#160;&#160;&#160;Excludes unamortized debt discount and issuance costs of $203.9 million as of December 31, 2021, which are amortized through interest expense over the remaining life of the underlying debt obligations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887308470808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Schedule of Balance Of Non-controlling Interests</a></td>
<td class="text">The net change in the balance of our four non-controlling interests for the years ended December 31, 2021 and 2020 is as follows (in thousands): <div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.334%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,165,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,174,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer of interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,037,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,037,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112,339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(594,592)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(792,357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income prior to IPO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,433,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,433,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Class A ordinary shares sold in IPO, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(309,566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(309,566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income subsequent to IPO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">581,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized losses on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,018)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,939,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,125,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,077,036</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;Related to the Continuing Investors Partnerships&#8217; ownership of approximately 36% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2020. Royalty Pharma plc owns the remaining 64% of RP Holdings through its ownership of RP Holdings Class A Interests and Class B Interests as of December 31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:32.479%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.481%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,939,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,125,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,077,036</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56,490)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(425,050)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(133,433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(614,973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(642,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(642,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized losses on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,946)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,415)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,809,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,649,154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,471,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;Related to the Continuing Investors Partnerships&#8217; ownership of approximately 29% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2021. Royalty Pharma plc owns the remaining 71% of RP Holdings through its ownership of RP Holdings Class A Interests  and Class B Interests as of December 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313300872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings per Class A ordinary share for the year ended December 31, 2021 (in thousands, except per share amounts).</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,241,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Legacy Investors Partnerships and RPSFT</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">619,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Dilutive effect&#160;of unvested RSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414,802&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.49&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings per Class A ordinary share for the year ended December 31, 2020 (in thousands, except per share amounts).<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,701,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships prior to the IPO (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships subsequent to the IPO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Legacy Investors Partnerships and RPSFT</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,198&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Dilutive effect&#160;of unvested RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares&#160;outstanding - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.32&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1) &#160;&#160;&#160;&#160;Reflected as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Net income attributable to controlling interest </span>on the consolidated statements of operations<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313444808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indirect Cash Flow (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Cash Flow, Supplemental Disclosures</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,241,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,701,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,461,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile consolidated net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,065,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,959,975)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,648,837)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,019,321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses/(gains) on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(247,073)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(155,749)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in losses/(earnings) of non-consolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44,459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions from non-consolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50,896)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,859)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination of derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,093)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Decrease/(increase) in operating assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collected on financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,315,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,121,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,934,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued royalty receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty income receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41,028)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Decrease)/increase in operating liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(766)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,017,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,034,629</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,667,239</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash investing and financing activities are summarized below (in thousands).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental Schedule of Non-cash Investing/Financing Activities:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receipt of contribution of investment in Legacy Investors Partnerships (Note 9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303,679&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement of Epizyme forward purchase contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued purchase obligation - Tazverik (Note 17)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayments of long-term debt by contributions from non-controlling interest (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,103,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Milestone payable - Erleada (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1) Related to the pro rata portion of RPIFT&#8217;s outstanding debt repaid by the Legacy Investors Partnerships.</span></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2) Related to the achievement of a sales-based milestone that was not paid as of December 31, 2020 as recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> on the consolidated balance sheet.</span></div></td></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313244680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive income as of December 31, 2021 and 2020 are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains on Available for Sale Debt Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Losses on Interest Rate Swaps</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(4,066)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,093</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification to net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,921)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,066&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,855)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Activity for the year</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification to non-controlling interest</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification from non-controlling interest</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">34,395</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">34,395</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification to net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,481)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,481)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Activity for the year</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification from non-controlling interest</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,491</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,491</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313903592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Party Transactions</a></td>
<td class="text">The distribution payable to non-controlling interest as of December 31, 2021 and 2020 included the following (in thousands). <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to Legacy Investors Partnerships</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to RPSFT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total distribution payable to non-controlling interest</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,934&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,366&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887307712888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Purpose (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 18, 2020</div></th>
<th class="th"><div>Feb. 11, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 02, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 11,116,196,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,840,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Debt | Old Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=rprx_RoyaltyPharmaCollectionTrustMember', window );">RPCT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember', window );">Legacy Investors Partnerships | Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember', window );">Legacy Investors Partnerships | Old RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember', window );">RPSFT | RPCT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rprx_RPI2019IntermediateFinanceMember', window );">RPI Intermediate FT | Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rprx_RPI2019IntermediateFinanceMember', window );">RPI Intermediate FT | Senior Secured Debt | RPIFT Senior Secured Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Ownership percentage following IPO</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rprx_ExchangeOfferTransactionMember', window );">Exchange Offer Transaction | Old RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rprx_ExchangeOfferTransactionMember', window );">Exchange Offer Transaction | Legacy Investors Partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction', window );">Exchange offering, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares)</a></td>
<td class="nump">89,334,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="nump">$ 28.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rprx_IPOSharesFromCompanyMember', window );">IPO - Shares From Company | Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares)</a></td>
<td class="nump">71,652,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rprx_IPOSharesFromSellingShareholdersMember', window );">IPO - Shares From Selling Shareholders | Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares)</a></td>
<td class="nump">17,682,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rprx_IPOContinuingInvestorsPartnershipsMember', window );">Public Stock Offering - Continuing Investors Partnerships Interests | Common Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_SaleOfStockNumberOfSharesAvailableToConvert', window );">Number of shares available to convert (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294,176,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_SaleOfStockNumberOfSharesNotConverted', window );">Number of shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,207,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_SaleOfStockNumberOfSharesAvailableToConvert">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Number of Shares Available To Convert</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_SaleOfStockNumberOfSharesAvailableToConvert</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_SaleOfStockNumberOfSharesNotConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Shares Not Converted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_SaleOfStockNumberOfSharesNotConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_OldCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_OldCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=rprx_RoyaltyPharmaCollectionTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=rprx_RoyaltyPharmaCollectionTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=rprx_RoyaltyPharmaInvestmentsOldRPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=rprx_RoyaltyPharmaInvestmentsOldRPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_RPI2019IntermediateFinanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_RPI2019IntermediateFinanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_RPIFTSeniorSecuredCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_RPIFTSeniorSecuredCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rprx_ExchangeOfferTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rprx_ExchangeOfferTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rprx_IPOSharesFromCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rprx_IPOSharesFromCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rprx_IPOSharesFromSellingShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rprx_IPOSharesFromSellingShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rprx_IPOContinuingInvestorsPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rprx_IPOContinuingInvestorsPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887308862872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>partnership</div>
</th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NumberOfNoncontrollingInterestsCreated', window );">Number of noncontrolling interests created | partnership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="nump">$ 581,872<span></span>
</td>
<td class="nump">$ 983,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="num">(1,541,048)<span></span>
</td>
<td class="num">(1,008,680)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of available for sale debt securities</a></td>
<td class="nump">1,196,579<span></span>
</td>
<td class="nump">1,705,283<span></span>
</td>
<td class="nump">$ 817,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">1,597,851<span></span>
</td>
<td class="nump">815,440<span></span>
</td>
<td class="nump">725,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flow from investing</a></td>
<td class="num">$ (1,870,280)<span></span>
</td>
<td class="num">(2,759,320)<span></span>
</td>
<td class="num">(2,153,625)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative adjustment</a></td>
<td class="nump">$ 10,248,545<span></span>
</td>
<td class="nump">9,895,815<span></span>
</td>
<td class="nump">6,141,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,552,079<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Revision of Prior Period, Reclassification, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flow from investing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(192,705)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative adjustment</a></td>
<td class="nump">2,255,179<span></span>
</td>
<td class="nump">1,920,635<span></span>
</td>
<td class="nump">2,825,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,215,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(192,705)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative adjustment</a></td>
<td class="nump">$ 4,471,951<span></span>
</td>
<td class="nump">$ 5,077,036<span></span>
</td>
<td class="nump">35,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interest | RP Holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest (percentage)</a></td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Current portion of Financial royalty assets | Vertex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember', window );">Legacy Investors Partnerships | Old RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember', window );">Legacy Investors Partnerships | Non-Controlling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative adjustment</a></td>
<td class="nump">$ 1,809,269<span></span>
</td>
<td class="nump">$ 1,939,509<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rprx_ContinuingInvestorsPartnershipMember', window );">Continuing Investors Partnerships | Non-Controlling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative adjustment</a></td>
<td class="nump">$ 2,649,154<span></span>
</td>
<td class="nump">$ 3,125,091<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rprx_ContinuingInvestorsPartnershipMember', window );">Continuing Investors Partnerships | Non-Controlling Interest | RP Holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest (percentage)</a></td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_NumberOfNoncontrollingInterestsCreated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Noncontrolling Interests Created</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_NumberOfNoncontrollingInterestsCreated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=rprx_RPHoldingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=rprx_RPHoldingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_FinanceReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_FinanceReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_VertexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_VertexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=rprx_RoyaltyPharmaInvestmentsOldRPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=rprx_RoyaltyPharmaInvestmentsOldRPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_ContinuingInvestorsPartnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_ContinuingInvestorsPartnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887309331976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available for Sale Debt Securities - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 02, 2021</div></th>
<th class="th"><div>Aug. 07, 2020</div></th>
<th class="th"><div>Apr. 05, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,441,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 125,121,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_MorphoSysMember', window );">MorphoSys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital', window );">Payment of capital</a></td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund', window );">Maximum commitment to fund collaborative arrangement</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn', window );">Period of return</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate', window );">Period of return start date</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares | Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased', window );">Number of shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSalePricePerShare', window );">Price per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate', window );">Redemption default, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod', window );">Default period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares | Series B Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased', window );">Number of shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSalePricePerShare', window );">Price per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate', window );">Redemption default, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod', window );">Redemption default, threshold period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares | Redemption, Period One | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares | Redemption, Period One | Debt Securities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares | Redemption, Period One | Series B Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares | Redemption, Period Two | Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares | Redemption, Period Two | Series B Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Payment of Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Period of Return</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Period of Return, Start Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Number Of Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSalePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSalePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Redemption Default, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Redemption, Default Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Redemption Default, Threshold Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Redemption Price, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_MorphoSysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_MorphoSysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis=rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis=rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis=rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis=rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887309268552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 204,509<span></span>
</td>
<td class="nump">$ 145,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">65,891<span></span>
</td>
<td class="nump">87,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">270,400<span></span>
</td>
<td class="nump">233,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities, current</a></td>
<td class="nump">66,000<span></span>
</td>
<td class="nump">69,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities, noncurrent</a></td>
<td class="nump">204,400<span></span>
</td>
<td class="nump">163,016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_SeriesAPreferredStockMember', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">134,068<span></span>
</td>
<td class="nump">145,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">29,432<span></span>
</td>
<td class="nump">68,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">163,500<span></span>
</td>
<td class="nump">214,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities, current</a></td>
<td class="nump">66,000<span></span>
</td>
<td class="nump">69,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities, noncurrent</a></td>
<td class="nump">97,500<span></span>
</td>
<td class="nump">144,416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">70,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">19,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">90,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities, noncurrent</a></td>
<td class="nump">90,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember', window );">Forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">12,300<span></span>
</td>
<td class="nump">18,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">12,300<span></span>
</td>
<td class="nump">18,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities, noncurrent</a></td>
<td class="nump">12,300<span></span>
</td>
<td class="nump">$ 18,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=rprx_DevelopmentFundingBondForwardMember', window );">Development Funding Bond Forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities, noncurrent</a></td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=rprx_DevelopmentFundingBondForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=rprx_DevelopmentFundingBondForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887309051336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsToTerminateDerivativeInstruments', window );">Swap termination payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,093,000<span></span>
</td>
<td class="nump">$ 35,448,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments', window );">Derivative collateral received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,660,000<span></span>
</td>
<td class="nump">45,252,000<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Unrealized gain (loss) on derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,532,000)<span></span>
</td>
<td class="num">(42,076,000)<span></span>
</td>
<td class="num">(39,138,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,145,000<span></span>
</td>
<td class="nump">9,997,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rprx_EpizymeCommonStockWarrantMember', window );">Epizyme Common Stock Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase additional shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_EpizymeIncMember', window );">Equity Investment In Epizyme Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment', window );">Upfront payment for equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_EpizymeIncMember', window );">Equity Investment In Epizyme Inc. | Epizyme Common Stock Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrant (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_EpizymeIncMember', window );">Equity Investment In Epizyme Inc. | Put Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_OptionIndexedToIssuersEquityTerm', window );">Put option, term (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_OptionIndexedToIssuersEquityValue', window );">Put option to sell additional common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityStrikePrice1', window );">Put option, selling price, maximum (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=rprx_TreasuryRateLockContractsMember', window );">Treasury Rate Lock Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsToTerminateDerivativeInstruments', window );">Swap termination payments</a></td>
<td class="nump">$ 16,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Unrealized gain (loss) on derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,900,000)<span></span>
</td>
<td class="num">(72,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Unrealized gain (loss) on derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,400,000)<span></span>
</td>
<td class="num">$ (25,400,000)<span></span>
</td>
<td class="nump">22,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember', window );">Forwards | Equity Investment In Epizyme Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_OptionIndexedToIssuersEquityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option Indexed to Issuer's Equity, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_OptionIndexedToIssuersEquityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_OptionIndexedToIssuersEquityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option Indexed To Issuers Equity, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_OptionIndexedToIssuersEquityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to Acquire Equity Investments, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsToTerminateDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Terminate Derivative Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsToTerminateDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collateral Received On Derivative Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityStrikePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90205-114008<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109262807&amp;loc=d3e22047-110879<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityStrikePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rprx_EpizymeCommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rprx_EpizymeCommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_EpizymeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_EpizymeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_PutOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_PutOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=rprx_TreasuryRateLockContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=rprx_TreasuryRateLockContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887307155624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments - Summary of Derivatives and Reclassifications (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap | Losses on derivative financial instruments | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of loss reclassified from AOCI into income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,066<span></span>
</td>
<td class="nump">$ 6,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Interest rate swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="nump">16,954<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap | Losses on derivative financial instruments | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Derivatives not designated as hedging instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,908<span></span>
</td>
<td class="nump">49,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap | Interest expense | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Interest rate swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="num">(9,565)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap | Interest expense | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Derivatives not designated as hedging instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">408<span></span>
</td>
<td class="num">(2,681)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrant | Losses on derivative financial instruments | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Derivatives not designated as hedging instruments</a></td>
<td class="nump">5,439<span></span>
</td>
<td class="nump">25,375<span></span>
</td>
<td class="num">(21,977)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember', window );">Forwards | Losses on derivative financial instruments | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts', window );">Change in fair value of derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="num">(11,500)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=rprx_TreasuryRateLockContractsMember', window );">Treasury Rate Lock Contracts | Losses on derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Derivatives not designated as hedging instruments</a></td>
<td class="nump">$ 16,093<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of open derivatives, commodity, or energy contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GainLossOnDerivativeInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GainLossOnDerivativeInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=rprx_TreasuryRateLockContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=rprx_TreasuryRateLockContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887306089544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 02, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 581,872,000<span></span>
</td>
<td class="nump">$ 983,279,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,000,000<span></span>
</td>
<td class="nump">69,984,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,800,000<span></span>
</td>
<td class="nump">298,689,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,400,000<span></span>
</td>
<td class="nump">163,016,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_MorphoSysMember', window );">MorphoSys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund', window );">Maximum commitment to fund collaborative arrangement</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember', window );">Forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,300,000<span></span>
</td>
<td class="nump">18,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,000,000<span></span>
</td>
<td class="nump">69,984,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_AssetsFairValueDisclosureCurrent', window );">Total current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,301,076,000<span></span>
</td>
<td class="nump">1,229,243,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,800,000<span></span>
</td>
<td class="nump">298,689,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,700,000<span></span>
</td>
<td class="nump">144,416,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_AssetsFairValueDisclosureNoncurrent', window );">Total non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474,200,000<span></span>
</td>
<td class="nump">467,144,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,754,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,457,000<span></span>
</td>
<td class="nump">444,554,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">374,415,000<span></span>
</td>
<td class="nump">505,971,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,700,000<span></span>
</td>
<td class="nump">18,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,439,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_AssetsFairValueDisclosureCurrent', window );">Total current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">598,253,000<span></span>
</td>
<td class="nump">24,302,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,787,000<span></span>
</td>
<td class="nump">298,689,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_AssetsFairValueDisclosureNoncurrent', window );">Total non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,787,000<span></span>
</td>
<td class="nump">298,689,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring | Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring | Forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_AssetsFairValueDisclosureCurrent', window );">Total current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">636,823,000<span></span>
</td>
<td class="nump">1,134,957,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_AssetsFairValueDisclosureNoncurrent', window );">Total non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,439,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,754,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,457,000<span></span>
</td>
<td class="nump">444,554,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">374,415,000<span></span>
</td>
<td class="nump">505,971,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | Forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,439,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,000,000<span></span>
</td>
<td class="nump">69,984,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_AssetsFairValueDisclosureCurrent', window );">Total current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,000,000<span></span>
</td>
<td class="nump">69,984,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,013,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,700,000<span></span>
</td>
<td class="nump">144,416,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_AssetsFairValueDisclosureNoncurrent', window );">Total non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247,413,000<span></span>
</td>
<td class="nump">163,016,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring | Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring | Forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,700,000<span></span>
</td>
<td class="nump">18,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">598,253,000<span></span>
</td>
<td class="nump">24,302,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">598,253,000<span></span>
</td>
<td class="nump">24,302,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,997,000<span></span>
</td>
<td class="nump">77,176,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,997,000<span></span>
</td>
<td class="nump">77,176,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,954,000<span></span>
</td>
<td class="nump">74,502,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,954,000<span></span>
</td>
<td class="nump">74,502,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_AssetsFairValueDisclosureCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets, Fair Value Disclosure, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_AssetsFairValueDisclosureCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_AssetsFairValueDisclosureNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets, Fair Value Disclosure, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_AssetsFairValueDisclosureNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_MorphoSysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_MorphoSysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887309229576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 05, 2019</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss', window );">Unrealized gain (loss) on equity securities still held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.1<span></span>
</td>
<td class="nump">$ 85.4<span></span>
</td>
<td class="num">$ (104.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod', window );">Restrictions on selling common stock, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | BioCryst Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased', window );">Number of shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,846,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares | Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments', window );">Preferred shares, quarterly payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleFixedPayment', window );">Preferred shares, fixed payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod', window );">Change in control event, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital', window );">Preferred shares, weighted average cost of capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased', window );">Number of shares purchased (in shares)</a></td>
<td class="nump">2,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares | Maximum | Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember', window );">Preferred Shares | Maximum | Redemption, Period One | Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Change In Control Event, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleFixedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Fixed Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleFixedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Number Of Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Quarterly Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Redemption Price, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Restriction Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in income from asset (liability) measured at fair value on recurring basis using unobservable input (level 3) and still held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_BioCrystPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_BioCrystPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis=rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis=rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887315352424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the beginning of the year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="nump">35,120<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss', window );">Gains on equity securities</a></td>
<td class="nump">7,893<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the end of the year</a></td>
<td class="nump">43,013<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the beginning of the year</a></td>
<td class="nump">214,400<span></span>
</td>
<td class="nump">131,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="nump">70,441<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss', window );">Gains on equity securities</a></td>
<td class="nump">12,900<span></span>
</td>
<td class="nump">52,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settlement of forwards</a></td>
<td class="nump">18,459<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Transfer to Level 2</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(184,005)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Transfer from level 2</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">198,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions', window );">Redemption</a></td>
<td class="num">(62,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the end of the year</a></td>
<td class="nump">253,700<span></span>
</td>
<td class="nump">214,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ForwardContractsMember', window );">Forwards | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the beginning of the year</a></td>
<td class="nump">18,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settlement of forwards</a></td>
<td class="num">(18,459)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Unrealized gains included in earnings</a></td>
<td class="nump">16,559<span></span>
</td>
<td class="nump">18,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at the end of the year</a></td>
<td class="nump">16,700<span></span>
</td>
<td class="nump">18,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | Level 3 | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="nump">11,600<span></span>
</td>
<td class="nump">52,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | Level 3 | Series B Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">$ 15,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="nump">$ 14,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss), After Transfer To Level 3</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3) and still held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AvailableforsaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887312127976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details) - Level 3 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems', window );"><strong>Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivablesFairValueDisclosure', window );">Financial royalty assets, net</a></td>
<td class="nump">$ 19,047,183<span></span>
</td>
<td class="nump">$ 18,718,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Carrying Value, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems', window );"><strong>Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivablesFairValueDisclosure', window );">Financial royalty assets, net</a></td>
<td class="nump">$ 14,332,596<span></span>
</td>
<td class="nump">$ 12,955,277<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivablesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivables, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivablesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887306055448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Royalty Assets, Net - Summary of Financial Royalty Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 16,027,541<span></span>
</td>
<td class="nump">$ 14,219,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="num">(1,384,141)<span></span>
</td>
<td class="num">(940,107)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="nump">14,643,400<span></span>
</td>
<td class="nump">13,278,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal', window );">Cumulative allowance for credit losses</a></td>
<td class="num">(310,804)<span></span>
</td>
<td class="num">(323,717)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Net carrying value</a></td>
<td class="nump">14,332,596<span></span>
</td>
<td class="nump">12,955,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_CysticFibrosisFranchiseMember', window );">Cystic fibrosis franchise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="nump">5,335,641<span></span>
</td>
<td class="nump">5,274,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="num">(48,636)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="nump">5,287,005<span></span>
</td>
<td class="nump">5,274,896<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_TysabriMember', window );">Tysabri</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="nump">1,846,069<span></span>
</td>
<td class="nump">2,003,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="num">(16,617)<span></span>
</td>
<td class="num">(112,720)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="nump">1,829,452<span></span>
</td>
<td class="nump">1,891,077<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_ImbruvicaMember', window );">Imbruvica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="nump">1,438,730<span></span>
</td>
<td class="nump">1,406,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="num">(236,871)<span></span>
</td>
<td class="num">(46,872)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="nump">1,201,859<span></span>
</td>
<td class="nump">1,359,419<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_XtandiMember', window );">Xtandi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="nump">1,100,065<span></span>
</td>
<td class="nump">1,150,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="num">(172,101)<span></span>
</td>
<td class="num">(145,565)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="nump">927,964<span></span>
</td>
<td class="nump">1,004,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_TremfyaMember', window );">Tremfya</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="nump">881,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="nump">881,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_EvrysdiMember', window );">Evrysdi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="nump">727,774<span></span>
</td>
<td class="nump">675,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="nump">727,774<span></span>
</td>
<td class="nump">675,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents', window );">Aggregate royalty amount when patents cease</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_PromactaMember', window );">Promacta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">686,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">686,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=rprx_OtherFinancialRoyaltyAssetMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Gross Carrying Value</a></td>
<td class="nump">4,697,591<span></span>
</td>
<td class="nump">3,022,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows', window );">Cumulative allowance for changes in expected cash flows</a></td>
<td class="num">(909,916)<span></span>
</td>
<td class="num">(634,950)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows', window );">Net carrying value, before cumulative allowance for credit losses</a></td>
<td class="nump">$ 3,787,675<span></span>
</td>
<td class="nump">$ 2,387,263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 79<br> -URI http://asc.fasb.org/extlink&amp;oid=124267575&amp;loc=SL82922352-210448<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 80<br> -URI http://asc.fasb.org/extlink&amp;oid=124267575&amp;loc=SL82922355-210448<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (1)<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (2)<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1404<br> -Paragraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_CysticFibrosisFranchiseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_CysticFibrosisFranchiseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_TysabriMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_TysabriMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_ImbruvicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_ImbruvicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_XtandiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_XtandiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_TremfyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_TremfyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_EvrysdiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_EvrysdiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_PromactaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_PromactaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rprx_OtherFinancialRoyaltyAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rprx_OtherFinancialRoyaltyAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887309277304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems', window );"><strong>Financing Receivable, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative adjustment to retained earnings</a></td>
<td class="num">$ (10,248,545)<span></span>
</td>
<td class="num">$ (9,895,815)<span></span>
</td>
<td class="num">$ (6,141,438)<span></span>
</td>
<td class="num">$ (4,552,079)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems', window );"><strong>Financing Receivable, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative adjustment to retained earnings</a></td>
<td class="num">$ (2,255,179)<span></span>
</td>
<td class="num">$ (1,920,635)<span></span>
</td>
<td class="num">(2,825,212)<span></span>
</td>
<td class="num">$ (1,215,953)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems', window );"><strong>Financing Receivable, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative adjustment to retained earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems', window );"><strong>Financing Receivable, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative adjustment to retained earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887313778488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems', window );"><strong>Financing Receivable, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLosses', window );">Beginning balance</a></td>
<td class="num">$ (1,263,824)<span></span>
</td>
<td class="num">$ (868,418)<span></span>
</td>
<td class="num">$ (1,982,897)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense', window );">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</a></td>
<td class="num">(912,710)<span></span>
</td>
<td class="num">(645,612)<span></span>
</td>
<td class="num">(322,717)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense', window );">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</a></td>
<td class="nump">446,955<span></span>
</td>
<td class="nump">570,959<span></span>
</td>
<td class="nump">1,342,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableChangeInPresentValueExpenseReversal', window );">Write-off of cumulative allowance</a></td>
<td class="nump">21,721<span></span>
</td>
<td class="nump">2,964<span></span>
</td>
<td class="nump">95,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs', window );">Write off of credit loss allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForLoanLossesExpensed', window );">Current period provision for credit losses, net</a></td>
<td class="nump">12,913<span></span>
</td>
<td class="num">(156,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLosses', window );">Ending balance</a></td>
<td class="num">$ (1,694,945)<span></span>
</td>
<td class="num">(1,263,824)<span></span>
</td>
<td class="num">(868,418)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff', window );">Writeoff related to financial royalty asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems', window );"><strong>Financing Receivable, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLosses', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (192,705)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLosses', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (192,705)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Financial Royalty Asset, Writeoff</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (3)<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (c)<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (1)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of writeoff of financing receivable, charged against allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 79<br> -URI http://asc.fasb.org/extlink&amp;oid=124267575&amp;loc=SL82922352-210448<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableChangeInPresentValueExpenseReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on financing receivable, from change in present value of expected cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919246-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82919204-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableChangeInPresentValueExpenseReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForLoanLossesExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of credit loss expense (reversal of expense) for financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForLoanLossesExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887315422648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 606,216<span></span>
</td>
<td class="nump">$ 606,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">600,546<span></span>
</td>
<td class="nump">577,550<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">5,670<span></span>
</td>
<td class="nump">28,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rprx_DPPIVPatentsMember', window );">DPP-IV patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">606,216<span></span>
</td>
<td class="nump">606,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">600,546<span></span>
</td>
<td class="nump">577,550<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 5,670<span></span>
</td>
<td class="nump">$ 28,666<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rprx_DPPIVPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rprx_DPPIVPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887308841976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Royalty Assets, Net - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | Individual Licensees Concentration List | Revenue from intangible royalty assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Individual licensees exceeding 10% or more of revenue (as a percent)</a></td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rprx_DPPIVPatentsMember', window );">DPP-IV patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible assets, useful life</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Projected amortization expense, 2022</a></td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=rprx_IndividualLicenseesConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=rprx_IndividualLicenseesConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rprx_IntangibleRoyaltyAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rprx_IntangibleRoyaltyAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rprx_DPPIVPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rprx_DPPIVPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887308899736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-Consolidated Affiliates (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Feb. 11, 2020</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in non-consolidated affiliates</a></td>
<td class="nump">$ 435,394<span></span>
</td>
<td class="nump">$ 454,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in income (loss) of non-consolidated affiliates</a></td>
<td class="num">(19,490)<span></span>
</td>
<td class="nump">44,459<span></span>
</td>
<td class="num">$ (32,517)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Distributions from non-consolidated affiliates</a></td>
<td class="nump">523<span></span>
</td>
<td class="nump">15,084<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Distributions from non-consolidated affiliates</a></td>
<td class="nump">34,384<span></span>
</td>
<td class="nump">42,334<span></span>
</td>
<td class="nump">14,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionIIMember', window );">Avillion II | Merck Asset - Phase II Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,000<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_OtherCommitmentsPercentage', window );">Other commitments, percentage of costs (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionIIMember', window );">Avillion II | AZ Asset - Phase II and Phase III Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_OtherCommitmentsPercentage', window );">Other commitments, percentage of costs (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember', window );">Equity Method Investment, Nonconsolidated Investee or Group of Investees | Legacy Investors Partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in non-consolidated affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 303,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in income (loss) of non-consolidated affiliates</a></td>
<td class="nump">8,900<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Distributions from non-consolidated affiliates</a></td>
<td class="nump">21,000<span></span>
</td>
<td class="nump">22,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember', window );">Equity Method Investment, Nonconsolidated Investee or Group of Investees | Avillion Entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in income (loss) of non-consolidated affiliates</a></td>
<td class="num">(28,400)<span></span>
</td>
<td class="num">(17,600)<span></span>
</td>
<td class="num">(32,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_EquityMethodInvestmentsUnfundedCommitments', window );">Equity method investment, unfunded commitments</a></td>
<td class="num">(11,200)<span></span>
</td>
<td class="nump">28,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember', window );">Equity Method Investment, Nonconsolidated Investee or Group of Investees | Avillion I</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Distributions from non-consolidated affiliates</a></td>
<td class="nump">$ 13,400<span></span>
</td>
<td class="nump">13,400<span></span>
</td>
<td class="nump">$ 14,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember', window );">Equity Method Investment, Nonconsolidated Investee or Group of Investees | Avillion II</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Distributions from non-consolidated affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_EquityMethodInvestmentsUnfundedCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Unfunded Commitments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_EquityMethodInvestmentsUnfundedCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_OtherCommitmentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Commitments, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_OtherCommitmentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=SL94080555-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionIIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionIIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=rprx_MerckAssetPhaseIIClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=rprx_MerckAssetPhaseIIClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=rprx_AZAssetPhaseIIAndPhaseIIIClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=rprx_AZAssetPhaseIIAndPhaseIIIClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_LegacyInvestorsPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_LegacyInvestorsPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rprx_AvillionIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887315390856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research &amp; Development ("R&amp;D") Funding Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development funding expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,084<span></span>
</td>
<td class="nump">$ 26,289<span></span>
</td>
<td class="nump">$ 83,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid', window );">Upfront payment and premium paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_MorphoSysMember', window );">MorphoSys</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development funding expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_MorphoSysMember', window );">MorphoSys | BioCryst Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development funding expense</a></td>
<td class="nump">$ 103,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_FundingAgreementsWithSanofiMember', window );">Funding Agreements With Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development funding expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900<span></span>
</td>
<td class="nump">20,500<span></span>
</td>
<td class="nump">18,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_ResearchAndDevelopmentRemainingFundingCommitment', window );">Remaining commitment for R&amp;D funding agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_FundingAgreementWithBioCrystMember', window );">Funding Agreement With BioCryst</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development funding expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_FundingAgreementsWithPfizerMember', window );">Funding Agreements With Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development funding expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Expense, Upfront Payment and Premium Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_ResearchAndDevelopmentRemainingFundingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development, Remaining Funding Commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_ResearchAndDevelopmentRemainingFundingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_MorphoSysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_MorphoSysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rprx_BioCrystPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rprx_BioCrystPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_FundingAgreementsWithSanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_FundingAgreementsWithSanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_FundingAgreementWithBioCrystMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_FundingAgreementWithBioCrystMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_FundingAgreementsWithPfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_FundingAgreementsWithPfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887305917048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Schedule of Borrowings (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="num">$ (203,930,000)<span></span>
</td>
<td class="num">$ (183,416,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt carrying value</a></td>
<td class="nump">7,096,070,000<span></span>
</td>
<td class="nump">5,816,584,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">7,096,070,000<span></span>
</td>
<td class="nump">5,816,584,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Point Seven Five Percent Senior Notes Due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate (as a percent)</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar', window );">Debt issued as a percent of par value (as a percent)</a></td>
<td class="nump">99.322%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | One Point Two Zero Percent Senior Notes Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate (as a percent)</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar', window );">Debt issued as a percent of par value (as a percent)</a></td>
<td class="nump">98.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | One Point Seven Five Percent Senior Notes Due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate (as a percent)</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar', window );">Debt issued as a percent of par value (as a percent)</a></td>
<td class="nump">98.284%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Two Point Two Zero Percent Senior Notes Due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate (as a percent)</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar', window );">Debt issued as a percent of par value (as a percent)</a></td>
<td class="nump">97.76%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Two Point One Five percent Senior Notes Due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate (as a percent)</a></td>
<td class="nump">2.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar', window );">Debt issued as a percent of par value (as a percent)</a></td>
<td class="nump">98.263%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Three Point Three Zero Percent Senior Notes Due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate (as a percent)</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar', window );">Debt issued as a percent of par value (as a percent)</a></td>
<td class="nump">95.556%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Three Point Five Five Percent Senior Notes Due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate (as a percent)</a></td>
<td class="nump">3.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar', window );">Debt issued as a percent of par value (as a percent)</a></td>
<td class="nump">95.306%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Three Point Three Five Percent Senior Notes Due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate (as a percent)</a></td>
<td class="nump">3.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar', window );">Debt issued as a percent of par value (as a percent)</a></td>
<td class="nump">97.565%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtInstrumentIssuanceAsAPercentOfPar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Issuance As A Percent Of Par</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtInstrumentIssuanceAsAPercentOfPar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_PointSevenFivePercentSeniorNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_PointSevenFivePercentSeniorNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_OnePointSevenFivePercentSeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_OnePointSevenFivePercentSeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_TwoPointOneFivePercentSeniorNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_TwoPointOneFivePercentSeniorNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887308030424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 18, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 02, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 26, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 11, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized discount and loan issuance costs on long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203,930,000<span></span>
</td>
<td class="nump">$ 183,416,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 358,000<span></span>
</td>
<td class="nump">30,272,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized discount and loan issuance costs on long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Senior Notes Due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Senior Notes Due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average coupon rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average effective interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.06%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | The Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average coupon rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average effective interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | The Notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value of outstanding Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200,000,000<span></span>
</td>
<td class="nump">6,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | The Notes | Prior to the applicable par call date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | The Notes | Upon occurrence of a change of control triggering event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Senior Unsecured Revolving Credit Facility | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio', window );">Maximum consolidated leverage ratio</a></td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition', window );">Maximum consolidated leverage ratio following qualifying material acquisition</a></td>
<td class="nump">4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio', window );">Minimum consolidated coverage ratio</a></td>
<td class="nump">2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Senior Unsecured Revolving Credit Facility | Federal Funds Rate | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (percentage)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Senior Unsecured Revolving Credit Facility | Overnight Bank Funding Rate | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (percentage)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Senior Unsecured Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (percentage)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,840,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1 | RPI Intermediate FT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_SeniorNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_SeniorNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_SeniorNotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_SeniorNotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_TheNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_TheNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_SeniorUnsecuredRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_SeniorUnsecuredRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsPurchasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsPurchasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=rprx_OvernightBankFundingRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=rprx_OvernightBankFundingRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_RPI2019IntermediateFinanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_RPI2019IntermediateFinanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887317542888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Schedule of Repayments of Debt by Year (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized discount and loan issuance costs on long-term debt</a></td>
<td class="nump">$ 203,930<span></span>
</td>
<td class="nump">$ 183,416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | The Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rprx_TheNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rprx_TheNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887301784216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>noncontrolling_interest </div>
<div>class </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 17, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>noncontrolling_interest </div>
<div>class </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>noncontrolling_interest </div>
<div>class </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 15, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NumberOfClassesOfVotingStock', window );">Number of classes of voting shares | class</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NumberOfNoncontrollingInterests', window );">Number of noncontrolling interests | noncontrolling_interest</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Dividends paid (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared and paid | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (285,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share based compensation expense | $</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share based compensation expense, period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=rprx_DeferredSharesMember', window );">Deferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, outstanding (in shares)</a></td>
<td class="nump">361,170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,170,000<span></span>
</td>
<td class="nump">361,170,000<span></span>
</td>
<td class="nump">316,407,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding</a></td>
<td class="nump">432,963,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,963,000<span></span>
</td>
<td class="nump">432,963,000<span></span>
</td>
<td class="nump">388,135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Number of shares authorized under plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="nump">620,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">620,000<span></span>
</td>
<td class="nump">620,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding</a></td>
<td class="nump">174,213,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,213,000<span></span>
</td>
<td class="nump">174,213,000<span></span>
</td>
<td class="nump">218,976,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember', window );">Class R Redeemable Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, outstanding (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_RedeemableStockRedemptionPricePerShare', window );">Redeemable stock, redemption price (in euros per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_NumberOfClassesOfVotingStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Classes Of Voting Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_NumberOfClassesOfVotingStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_NumberOfNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Noncontrolling Interests</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_NumberOfNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RedeemableStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable Stock, Redemption Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RedeemableStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=rprx_DeferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=rprx_DeferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rprx_A2020EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rprx_A2020EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rprx_ClassRRedeemableStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887306575192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Summary of Noncontrolling Interests (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 17, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,141,438<span></span>
</td>
<td class="nump">$ 9,895,815<span></span>
</td>
<td class="nump">$ 6,141,438<span></span>
</td>
<td class="nump">$ 4,552,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,539<span></span>
</td>
<td class="nump">1,482,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestTransfersOfInterests', window );">Transfer of interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(614,973)<span></span>
</td>
<td class="num">(1,105,765)<span></span>
</td>
<td class="num">(880,142)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,077,069<span></span>
</td>
<td class="nump">624,885<span></span>
</td>
<td class="nump">1,241,201<span></span>
</td>
<td class="nump">1,701,954<span></span>
</td>
<td class="nump">2,461,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation', window );">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A ordinary shares sold in IPO, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,908,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,600<span></span>
</td>
<td class="nump">83,120<span></span>
</td>
<td class="nump">6,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized losses on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,896)<span></span>
</td>
<td class="num">(20,551)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,895,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,248,545<span></span>
</td>
<td class="nump">9,895,815<span></span>
</td>
<td class="nump">6,141,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,883<span></span>
</td>
<td class="nump">5,077,036<span></span>
</td>
<td class="nump">35,883<span></span>
</td>
<td class="nump">63,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,539<span></span>
</td>
<td class="nump">1,174,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestTransfersOfInterests', window );">Transfer of interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,037,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(614,973)<span></span>
</td>
<td class="num">(792,357)<span></span>
</td>
<td class="num">(140,866)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 581,871<span></span>
</td>
<td class="nump">581,871<span></span>
</td>
<td class="nump">145,043<span></span>
</td>
<td class="nump">621,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation', window );">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,433,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A ordinary shares sold in IPO, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">758,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(642,974)<span></span>
</td>
<td class="num">(309,566)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,265<span></span>
</td>
<td class="nump">22,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized losses on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,415)<span></span>
</td>
<td class="num">(9,630)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,077,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,471,951<span></span>
</td>
<td class="nump">$ 5,077,036<span></span>
</td>
<td class="nump">35,883<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interest | RP Holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interest | RPSFT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,883<span></span>
</td>
<td class="nump">$ 12,436<span></span>
</td>
<td class="nump">$ 35,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestTransfersOfInterests', window );">Transfer of interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56,490)<span></span>
</td>
<td class="num">(112,339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">46,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,151<span></span>
</td>
<td class="nump">57,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation', window );">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A ordinary shares sold in IPO, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized losses on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,528<span></span>
</td>
<td class="nump">12,436<span></span>
</td>
<td class="nump">35,883<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interest | Legacy Investors Partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,939,509<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,148<span></span>
</td>
<td class="nump">1,165,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestTransfersOfInterests', window );">Transfer of interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,037,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(425,050)<span></span>
</td>
<td class="num">(594,592)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">218,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,892<span></span>
</td>
<td class="nump">266,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation', window );">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A ordinary shares sold in IPO, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,038<span></span>
</td>
<td class="nump">15,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized losses on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,946)<span></span>
</td>
<td class="num">(3,612)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,939,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,809,269<span></span>
</td>
<td class="nump">1,939,509<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interest | Continuing Investors Partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,125,091<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,391<span></span>
</td>
<td class="nump">9,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestTransfersOfInterests', window );">Transfer of interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(133,433)<span></span>
</td>
<td class="num">(85,426)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">316,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">297,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation', window );">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,433,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A ordinary shares sold in IPO, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">758,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(642,974)<span></span>
</td>
<td class="num">(309,566)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,227<span></span>
</td>
<td class="nump">7,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized losses on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,469)<span></span>
</td>
<td class="num">(6,018)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,125,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,649,154<span></span>
</td>
<td class="nump">$ 3,125,091<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interest | Continuing Investors Partnerships | RP Holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interest | EPA Holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NoncontrollingInterestTransfersOfInterests', window );">Transfer of interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation', window );">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A ordinary shares sold in IPO, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other exchanges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of unrealized losses on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_NoncontrollingInterestIncreaseFromContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Increase from Contributions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_NoncontrollingInterestIncreaseFromContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_NoncontrollingInterestTransfersOfInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Transfers Of Interests</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_NoncontrollingInterestTransfersOfInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_StockholdersEquityValueEffectOfExchangeAndReallocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity, Value, Effect Of Exchange And Reallocation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_StockholdersEquityValueEffectOfExchangeAndReallocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInMinorityInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInMinorityInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=rprx_RPHoldingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=rprx_RPHoldingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_RoyalPharmacySelectFinanceTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_RoyalPharmacySelectFinanceTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_LegacyInvestorsPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_ContinuingInvestorsPartnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_ContinuingInvestorsPartnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rprx_EPAHoldingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rprx_EPAHoldingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887308944312">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 17, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CommonStockExchangeRatio', window );">Exchange ratio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,077,069<span></span>
</td>
<td class="nump">$ 624,885<span></span>
</td>
<td class="nump">$ 1,241,201<span></span>
</td>
<td class="nump">$ 1,701,954<span></span>
</td>
<td class="nump">$ 2,461,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_NetIncomeLossAttributableToParentPriorToOffering', window );">Less: net income attributable to Continuing Investors Partnerships prior to the IPO</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">479,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: net income attributable to non-controlling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">621,473<span></span>
</td>
<td class="nump">726,914<span></span>
</td>
<td class="nump">$ 112,884<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income attributable to Royalty Pharma plc - basic and diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">619,728<span></span>
</td>
<td class="nump">495,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income attributable to Royalty Pharma plc - basic and diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 619,728<span></span>
</td>
<td class="nump">$ 495,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average Class A ordinary shares outstanding - basic (in shares) | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414,794<span></span>
</td>
<td class="nump">375,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Unvested RSUs (in shares) | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average Class A ordinary shares outstanding - diluted (in shares) | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414,802<span></span>
</td>
<td class="nump">375,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per Class A ordinary share - basic (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.49<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per Class A ordinary share - diluted (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.49<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average Class A ordinary shares outstanding - diluted (in shares) | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">607,176<span></span>
</td>
<td class="nump">607,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_ClassBHoldersMember', window );">Class B Holders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: net income attributable to non-controlling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 297,321<span></span>
</td>
<td class="nump">$ 316,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_LegacyInvestorsPartnershipsAndRPSFTMember', window );">Legacy Investors Partnerships and RPSFT</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: net income attributable to non-controlling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 324,152<span></span>
</td>
<td class="nump">$ 409,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents earnings per Class A ordinary share and weighted average Class A ordinary shares outstanding for the period from June 16, 2020 through December 31, 2020 following our initial public offering (&#8220;IPO&#8221;) in the year ended December 31, 2020. See Note 13&#8211;Earnings per Share.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CommonStockExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CommonStockExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_NetIncomeLossAttributableToParentPriorToOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income (Loss) Attributable to Parent, Prior To Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_NetIncomeLossAttributableToParentPriorToOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_ClassBHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_ClassBHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_LegacyInvestorsPartnershipsAndRPSFTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_LegacyInvestorsPartnershipsAndRPSFTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887315327432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indirect Cash Flow (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 17, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 1,077,069<span></span>
</td>
<td class="nump">$ 624,885<span></span>
</td>
<td class="nump">$ 1,241,201<span></span>
</td>
<td class="nump">$ 1,701,954<span></span>
</td>
<td class="nump">$ 2,461,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile consolidated net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_IncreaseDecreaseInFinancialRoyaltyAssets', window );">Income from financial royalty assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,065,083)<span></span>
</td>
<td class="num">(1,959,975)<span></span>
</td>
<td class="num">(1,648,837)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForLoanAndLeaseLosses', window );">Provision for changes in expected cash flows from financial royalty assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">452,842<span></span>
</td>
<td class="nump">230,839<span></span>
</td>
<td class="num">(1,019,321)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,996<span></span>
</td>
<td class="nump">23,058<span></span>
</td>
<td class="nump">23,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,162<span></span>
</td>
<td class="nump">11,715<span></span>
</td>
<td class="nump">12,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Losses on derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,532<span></span>
</td>
<td class="nump">42,076<span></span>
</td>
<td class="nump">39,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Losses/(gains) on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,066<span></span>
</td>
<td class="num">(247,073)<span></span>
</td>
<td class="num">(155,749)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in losses/(earnings) of non-consolidated affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,490<span></span>
</td>
<td class="num">(44,459)<span></span>
</td>
<td class="nump">32,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Distributions from non-consolidated affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,384<span></span>
</td>
<td class="nump">42,334<span></span>
</td>
<td class="nump">14,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358<span></span>
</td>
<td class="nump">30,272<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,443<span></span>
</td>
<td class="nump">5,428<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss', window );">Interest income accretion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,896)<span></span>
</td>
<td class="num">(20,551)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Unrealized gains on available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,859)<span></span>
</td>
<td class="num">(18,600)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">65,053<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_GainLossOnDerivativeFinancialInstruments', window );">Termination of derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,093)<span></span>
</td>
<td class="num">(34,952)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,461<span></span>
</td>
<td class="nump">9,621<span></span>
</td>
<td class="num">(2,122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Decrease/(increase) in operating assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables', window );">Cash collected on financial royalty assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,315,854<span></span>
</td>
<td class="nump">2,121,923<span></span>
</td>
<td class="nump">1,934,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_IncreaseDecreaseInDebtSecuritiesAvailableForSale', window );">Available for sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(150,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable', window );">Accrued royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,131)<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="nump">2,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable', window );">Other royalty income receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,012)<span></span>
</td>
<td class="num">(770)<span></span>
</td>
<td class="nump">7,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,857<span></span>
</td>
<td class="nump">34,986<span></span>
</td>
<td class="num">(41,028)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>(Decrease)/increase in operating liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,586)<span></span>
</td>
<td class="num">(766)<span></span>
</td>
<td class="nump">6,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,550<span></span>
</td>
<td class="nump">42,146<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,017,536<span></span>
</td>
<td class="nump">2,034,629<span></span>
</td>
<td class="nump">1,667,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Schedule of Non-cash Investing/Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1', window );">Receipt of contribution of investments in Legacy Investors Partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">303,679<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_SettlementsWithEquityMethodInvestments', window );">Settlement of Epizyme forward purchase contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_AccruedPurchaseObligationEquityInvestment', window );">Accrued purchase obligation - Tazverik</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash', window );">Repayments of long-term debt by contributions from non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,103,774<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_MilestonePaymentAccruedButNotPaid', window );">Milestone payable - Erleada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 18,600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_AccruedPurchaseObligationEquityInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Purchase Obligation, Equity Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_AccruedPurchaseObligationEquityInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_GainLossOnDerivativeFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Derivative Financial Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_GainLossOnDerivativeFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_IncreaseDecreaseInAccruedRoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Royalty Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_IncreaseDecreaseInAccruedRoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Cash Collections On Financing Receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_IncreaseDecreaseInDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Debt Securities, Available For Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_IncreaseDecreaseInDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_IncreaseDecreaseInFinancialRoyaltyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Financial Royalty Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_IncreaseDecreaseInFinancialRoyaltyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Other Royalty Income Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_MilestonePaymentAccruedButNotPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Accrued But Not Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_MilestonePaymentAccruedButNotPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Long Term Debt, Contributions From Noncontrolling Interest, Noncash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_SettlementsWithEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlements With Equity Method Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_SettlementsWithEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForLoanAndLeaseLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to estimated loss from loan and lease transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.11)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForLoanAndLeaseLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887306029464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">$ 9,895,815<span></span>
</td>
<td class="nump">$ 6,141,438<span></span>
</td>
<td class="nump">$ 4,552,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification to net income</a></td>
<td class="num">(28,481)<span></span>
</td>
<td class="num">(6,855)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Activity for the year</a></td>
<td class="nump">6,335<span></span>
</td>
<td class="nump">60,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest', window );">Reclassification from non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">10,248,545<span></span>
</td>
<td class="nump">9,895,815<span></span>
</td>
<td class="nump">6,141,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income</a></td>
<td class="nump">53,535<span></span>
</td>
<td class="nump">28,379<span></span>
</td>
<td class="nump">22,329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Unrealized gain/(loss) on available for sale debt securities, including noncontrolling interest | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income</a></td>
<td class="nump">50,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains on Available for Sale Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">34,395<span></span>
</td>
<td class="nump">6,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification to net income</a></td>
<td class="num">(28,481)<span></span>
</td>
<td class="num">(10,921)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Activity for the year</a></td>
<td class="nump">6,335<span></span>
</td>
<td class="nump">60,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest', window );">Reclassification to non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,022)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest', window );">Reclassification from non-controlling interest</a></td>
<td class="nump">4,242<span></span>
</td>
<td class="nump">2,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">16,491<span></span>
</td>
<td class="nump">34,395<span></span>
</td>
<td class="nump">6,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains on Available for Sale Debt Securities | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income</a></td>
<td class="nump">28,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember', window );">Unrealized gain/(loss) on available for sale debt securities, noncontrolling interest | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income</a></td>
<td class="nump">22,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember', window );">Unrealized Losses on Interest Rate Swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,066)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification to net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Activity for the year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest', window );">Reclassification to non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest', window );">Reclassification from non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,066)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Total Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">34,395<span></span>
</td>
<td class="nump">2,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest', window );">Reclassification to non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,022)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest', window );">Reclassification from non-controlling interest</a></td>
<td class="nump">4,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">$ 16,491<span></span>
</td>
<td class="nump">$ 34,395<span></span>
</td>
<td class="nump">$ 2,093<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss) Reclassification Adjustment, Attributable From Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Reclassification Adjustment, Attributable to Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887309194920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 16, 2021</div></th>
<th class="th"><div>Dec. 08, 2017</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Total distribution payable to non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,934,000<span></span>
</td>
<td class="nump">$ 126,366,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in non-consolidated affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,394,000<span></span>
</td>
<td class="nump">454,936,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Financial royalty asset, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,332,596,000<span></span>
</td>
<td class="nump">12,955,277,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,266,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,266,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=rprx_AgreementWithMSCIMember', window );">Agreement with MSCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_RelatedPartyTransactionInitialTerm', window );">Initial term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Amounts due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ManagementMember', window );">The Manager | Operating and Personnel Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_RelatedPartyTransactionRateAdjustedCashReceipts', window );">Quarterly payments to affiliates, percent of adjusted cash receipts (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments', window );">Quarterly payments to affiliates, percent of security investment (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount', window );">Amount calculated for operating and personal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent', window );">Percent for calculating operating and personal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ManagementMember', window );">The Manager | Former Operating and Personnel Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_RelatedPartyTransactionAnnualIncreasePercentage', window );">Increase in quarterly installment payments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty', window );">Operating and personnel payments incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,200,000<span></span>
</td>
<td class="nump">112,500,000<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Royalty Distribution Payable to Legacy Investors Partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Total distribution payable to non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,608,000<span></span>
</td>
<td class="nump">100,047,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Royalty Distribution Payable to RP Select Finance Trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Total distribution payable to non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,326,000<span></span>
</td>
<td class="nump">26,319,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Assignment Agreement - Benefit of Payment Stream | Bristol-Myers Squibb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Related party, rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Assignment Agreement - Funding Obligations | Bristol-Myers Squibb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Related party, rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_RelatedPartyTransactionCumulativeFundingAmount', window );">Cumulative funding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Financial royalty asset, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,900,000<span></span>
</td>
<td class="nump">150,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Acquisition Of Limited Partnership Interests In Affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired', window );">Number of limited partnership interest acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Acquisition Of Limited Partnership Interests In Affiliate | Treasury Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Acquisition Of Limited Partnership Interests In Affiliate | Non-Controlling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,600,000)<span></span>
</td>
<td class="num">(1,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rprx_PabloLegorretaMember', window );">Pablo Legorreta | Purchasing And Donating Ventilators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Amount paid to CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RelatedPartyTransactionAnnualIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Annual Increase, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RelatedPartyTransactionAnnualIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RelatedPartyTransactionCumulativeFundingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Cumulative Funding Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RelatedPartyTransactionCumulativeFundingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RelatedPartyTransactionInitialTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Initial Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RelatedPartyTransactionInitialTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Number of Partnership Interests Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Operating and Personal Payment Calculation, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Operating and Personal Payment Calculation, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RelatedPartyTransactionRateAdjustedCashReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Rate, Adjusted Cash Receipts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RelatedPartyTransactionRateAdjustedCashReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_RelatedPartyTransactionRateValueOfSecurityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Rate, Value Of Security Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_RelatedPartyTransactionRateValueOfSecurityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_AgreementWithMSCIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_AgreementWithMSCIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_OperatingAndPersonnelPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_OperatingAndPersonnelPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_FormerOperatingAndPersonnelPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_FormerOperatingAndPersonnelPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_AssignmentAgreementBenefitOfPaymentStreamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_AssignmentAgreementBenefitOfPaymentStreamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_AssignmentAgreementFundingObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_AssignmentAgreementFundingObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rprx_PabloLegorretaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rprx_PabloLegorretaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rprx_PurchasingAndDonatingVentilatorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rprx_PurchasingAndDonatingVentilatorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887308766632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 04, 2021</div></th>
<th class="th"><div>Jun. 02, 2021</div></th>
<th class="th"><div>Aug. 07, 2020</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rprx_MorphoSysMember', window );">MorphoSys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments', window );">Maximum milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital', window );">Payment of capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm', window );">Payment of capital term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsExpectedReturn', window );">Expected return (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund', window );">Maximum commitment to fund collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn', window );">Period of return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate', window );">Period of return start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember', window );">Funding Agreement With Biohaven Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount', window );">Purchase commitment, purchase of committed, non-contingent Commercial Launch Preferred Equity payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_LongTermPurchaseCommitmentAmountOutstanding', window );">Remaining commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=rprx_LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember', window );">Purchase Of Eisai Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Payment for purchase of royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PurchaseCommitmentUpfrontPayment', window );">Purchase commitment, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PurchaseCommitmentAdditionalPayment', window );">Purchase commitment, additional payments</a></td>
<td class="nump">$ 110,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000,000<span></span>
</td>
<td class="nump">$ 220,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementRightsAndObligationsExpectedReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Expected Return</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementRightsAndObligationsExpectedReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Payment of Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Payment of Capital, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Period of Return</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Period of Return, Start Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermPurchaseCommitmentAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Purchase Commitment, Amount Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermPurchaseCommitmentAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PurchaseCommitmentAdditionalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Commitment, Additional Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PurchaseCommitmentAdditionalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Commitment, Committed Non-Contingent Commercial Launch Preferred Equity, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PurchaseCommitmentUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Commitment, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PurchaseCommitmentUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rprx_MorphoSysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rprx_MorphoSysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=rprx_LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=rprx_LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887309048088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($) </div>
<div>tranche </div>
<div>payment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsToAcquireRoyaltyInterestsAggregateAmount', window );">Payments to acquire royalty interests</a></td>
<td class="nump">$ 150.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsToAcquireRoyaltyInterestsUpfrontPayment', window );">Payments to acquire royalty interests, upfront payment</a></td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments', window );">Payments to acquire royalty interests, number of additional payments | payment</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments', window );">Payments to acquire royalty interests, additional milestone payments</a></td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipAmount', window );">Long term funding partnership, amount</a></td>
<td class="nump">$ 300.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipNumberOfTranches', window );">Long term funding partnership, number of tranches | tranche</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipInitialPayment', window );">Long term funding partnership, initial payment</a></td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipNumberOfAdditionalPayments', window );">Long term funding partnership, number of additional payments | tranche</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount', window );">Long term funding partnership, additional payments, aggregate amount</a></td>
<td class="nump">$ 250.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Additional Payments, Aggregate Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipInitialPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Initial Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipInitialPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipNumberOfAdditionalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Number of Additional Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipNumberOfAdditionalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_LongTermFundingPartnershipNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Funding Partnership, Number of Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_LongTermFundingPartnershipNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Royalty Interest, Additional Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsToAcquireRoyaltyInterestsAggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Royalty Interests, Aggregate Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsToAcquireRoyaltyInterestsAggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Royalty Interests, Number Of Additional Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rprx_PaymentsToAcquireRoyaltyInterestsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Royalty Interests, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rprx_PaymentsToAcquireRoyaltyInterestsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887317201368">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_ProfitLoss</td>
<td class="nump">$ 479,842,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_ProfitLoss</td>
<td class="nump">$ 495,198,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>rprx-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rprx="http://royaltypharma.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rprx-20211231.xsd" xlink:type="simple"/>
    <context id="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i58e8c79f7b7640d089df3eefd8c4584f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1bcce023e17042be90c95db2fc81e685_I20220211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-11</instant>
        </period>
    </context>
    <context id="ia539779374e8435abf5929170c65ac83_I20220211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-11</instant>
        </period>
    </context>
    <context id="i4719611fdef547db987f7d2d30dadbc7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">rprx:LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i355f63584077498c9358681b1f440182_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i52867fbe6d2d4e9f9ef1cc8a39a6730d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7048c06f34e64e98a9f8db168c52ecf6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i46e28e4cc5cc4a16bbb2deb97423b415_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic092b803ad4d4d1bb1fc65733358f33f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i953778adf0344a989190761672294312_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icd2e4870b58b4b92961362030330fa39_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1bd23e9eb02461c8e78d787a6ed33aa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:FinancialRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i25b8e421f3694fbcaafdb0d3eaa6b71f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:FinancialRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i22755b6a900743c384bc4e39a0795f90_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:FinancialRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1452e9acf8c84b5fa30c3213757d431e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0297e01d516f433c9c55632b22b93b76_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i16e458adecdb45bfbf9b94d5656d1d13_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib8996266cd2b47c186f6cb14ad934f59_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:RoyaltyIncomeOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2caa252cd23b45869207612ea8852d80_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:RoyaltyIncomeOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i20e6b58350b843a5b8d17f5da029afa2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:RoyaltyIncomeOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaf79e602f6744689882e0662af486960_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7242e01e0d3e49c99430b9b17185b69d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i21cc13814c2346169554442b708375ad_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4278e9fc64b540edb08bf8d281986583_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="icc6628a62f9e40b48736982ad0adfbee_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ieb893068fb11474089dc46eccc39ab67_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibab3544b72654443a832b73062c67deb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:UnitHoldersAndShareholdersContributionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2d606c35a9d1498aa2be490653c9ef76_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i83390defcd6345cb9ec5d13109b97307_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia43c5365c0cb479391cb94db6dca5463_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifd82d6eb2e3a47a7b8091e80bc813a3b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifa26755fbc5e413fbf3122ec0db17370_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibb8081ea351a4070b344194caa18eee3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id719b4a4fe4147c580198f101363e139_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9aba922b7da5469cb7d51eeaebbde78c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i82e5c0912520456188cd5703e13cd8ec_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8a4cf2dc46aa4a0b98fcc0c810dc8893_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i580d0bd186a14217bc04733016854e77_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i19b48e73113548da88d30125b457bca0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7e3a705f76b44890a7020ab2ae505a43_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i315143a2dcd345708f419d259a93d568_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if3ecbb7d51644c5aad611d5a9b22c148_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:UnitHoldersAndShareholdersContributionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i830800ad2baf473c9739d42417c534c6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i602e6cc9310d4444b6d71a94d4089ae5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i66a738c1e19d441f908f46dd78470217_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3ff6f34aeece4e29977f6ac850691398_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id30f26bcb6cd4b64982e6cd53528c44e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i94ea8958cd1e4ee696d732dd9a041dca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:UnitHoldersAndShareholdersContributionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib04d3453e6dc4ca3a0b79e01ab3fe12a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie7ab9fefed164e08ac6ad01d99d06780_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2e6f9f489a134c76840c0b3b1b1954e4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7b0efd440f45499a9d75e2fbc4ff25a1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3422c7350bb14d2d869ff498fa12e855_D20200101-20200617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-17</endDate>
        </period>
    </context>
    <context id="i76f06ecc81464fc3ba1731d5296c531a_D20200101-20200617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-17</endDate>
        </period>
    </context>
    <context id="i7594b0b1464b4340a377c43cf71ef3c9_D20200101-20200617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-17</endDate>
        </period>
    </context>
    <context id="i7d52a6096c48447f93a4da355c6da2e3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4f4f3dd76bcf49369de9f193a116d553_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6a9ba8c328db404aa63b9d27dabe97d3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia045aaf00ae04e51a9df144d9df23caf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic835f9f0906c4a4cb5e88b614197540b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2120ee6be2e44acca10b4f204c1cddf2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ief437e0dfe9a4e449e52e28b7c5f4b71_D20200618-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id19e65b6c08c41b59cd152b688647d77_D20200618-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie1399e8120f4459da1c98eaec460657b_D20200618-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i026910ef30a142baa787995540a3555f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i00c7c0edff0e4ac2a68115eef01ff73d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idd3e01d69d404333b2e0170fe5853c55_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ief96e993bf2a4bad8348a1f2176e9808_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i68fb25a3dc3e456893c7bc42ba425cbd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if26943d0c125428899ab95101e2214b9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:UnitHoldersAndShareholdersContributionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7cb528cec9b5436688d56f37b5a8fdb8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i857c20e661b346998fb3a0f68c1afaf2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9a4c8ddad1f14b6b87799e8a6512c515_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i66335cce09fd4d5aa1361b620f554b05_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0bdb46f25b6846f5b9310b232d39718a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0f493fdc35c04ea9b3f1ab89b24ba7be_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8df459188f6346b8b8d77947f07ece9e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0c91bc2a7dfa43c18d941b318eb6c1a1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i20b582d2d470476abea2f967a5ff5d4d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie00bc8af28a248a3bab0ff42f302d437_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ideedfd0352184c20a5b0ac18ede8b733_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iec5b04d241a742c1bf88cb734be536cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i237eac50dc20448f9dc9e9bc7dce35cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i831945c7a36b4b9a9c9ce724bfbde784_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9cf16ec8ae244acb94018fe5616afde0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf5276dc05624d1c9f3c9eb9743788dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3cf92db35b544207b1e43d9e1641760f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rprx:UnitHoldersAndShareholdersContributionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibe420d445c0a4fd99c2d658b9393d0ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9443f77254524e56b4e02c6d9e30af84_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i03b5b882444a44ad9e231eaa7b05228b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i568f4691ddec40e6848d6b317d8a5792_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2cb0ee2d2cce4d55b7e14f29d979d9bc_D20200211-20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:ExchangeOfferTransactionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="idb95cff49c3e4b6483e5a57868295bb3_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaInvestmentsOldRPIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:ExchangeOfferTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="i41e5a726a82b47548d1f945e92636296_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaCollectionTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="idb7af162272940eead234259d17da45b_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaCollectionTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="i74a3535e1f304c089ec2b07d0bdc6f52_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="i196399f1da794ae7a1ec4de607513d77_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RPI2019IntermediateFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="ibabbf759907e4aee8080ea0173539d93_D20200211-20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OldCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="i70f4f8cb8c6d440883d5034075ba2017_D20200211-20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIFTSeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RPI2019IntermediateFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="i8f263e6903ec49b1bb03a648b164d00e_D20200618-20200618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-06-18</endDate>
        </period>
    </context>
    <context id="i0861ac581a4a474c88d227f3b54a6874_I20200618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-18</instant>
        </period>
    </context>
    <context id="iff33cf273b964edf907891fec81037d3_D20200618-20200618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:IPOSharesFromCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-06-18</endDate>
        </period>
    </context>
    <context id="ia342308de5774def81f37403f622bd7b_D20200618-20200618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:IPOSharesFromSellingShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-06-18</endDate>
        </period>
    </context>
    <context id="i414a5cb6c59c4311a4ff39f341e18444_D20200618-20200618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-06-18</endDate>
        </period>
    </context>
    <context id="i586b66d2b65b47dfaf4325e8b30978d9_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rprx:IPOContinuingInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4c1e7922bf5d4fb7a873526ac9e2acd2_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RoyaltyPharmaInvestmentsOldRPIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="ifb99eff80794423ca92bd7db72623f54_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6e7e9177eb1b4c9da6650b9f74990c36_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RPHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i89b6773bde7741e89cfa1ba14576b98f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9f493e893d9e41c9836fd0b92cee6bf2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id0a851bce2a945d59b0ed1c24aa99168_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:VertexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5b0975d860cd4ef59dd25d4eb5f1f7a6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:VertexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie7ffbb1b682a454ea429c1fb003ce9d8_D20190405-20190405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-05</startDate>
            <endDate>2019-04-05</endDate>
        </period>
    </context>
    <context id="ia849c0d494314af388e9fb0fc01f197d_D20190405-20190405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-05</startDate>
            <endDate>2019-04-05</endDate>
        </period>
    </context>
    <context id="i3f03e1e1f0254cb1bffbcef4de9ba54d_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i82b90b8f41a142668c8944a95809becc_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i1c9ec20561ed410bb20159b77b9b7247_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="i9aa7200994f445fd859a024412126926_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibdc9b73456ed4691907032f9740bfd6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i60d163174d8f44a18183225e8dcce57d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i98c2c17dcf19455ebbe7cea65ea027d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rprx:DevelopmentFundingBondForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icfc7e15ceae44635ac92046eaa0b27e9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icfad0763e8bb4821b3d973d0d57f0477_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3468b5dba8434479a8f400dd5c49c174_D20190405-20190405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodAxis">rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-05</startDate>
            <endDate>2019-04-05</endDate>
        </period>
    </context>
    <context id="i0cc5aaad296f4b2ebbafb25210d95261_D20190405-20190405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodAxis">rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-05</startDate>
            <endDate>2019-04-05</endDate>
        </period>
    </context>
    <context id="if92704d2e5e74022812f0c24cecf4b2e_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodAxis">rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="if1ba671053ae4c678a08effbbc36a0d6_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodAxis">rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i625666873b2d4977bdc6062d4f56c5df_D20210701-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rprx:TreasuryRateLockContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="i4106b129e51b45058ce78e36709ad420_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i25065e59308648fd8df2e62e3adccc34_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id3d1194dc3e540d18ba20eae1762f548_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:EpizymeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i7dfa9c83d55a4cd497bbc3d7fa0263f5_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:EpizymeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="iede0453e00c74915afde71174a783562_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rprx:EpizymeCommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i7cb61b17854748238238595ab84bc83d_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:EpizymeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rprx:EpizymeCommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="ia8411dbd9065417ea1c3895bc9dcf30d_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:EpizymeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:PutOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="if08b51e367da4f1b95ea56119a60ebc2_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:EpizymeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:PutOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i3b2fd60a894245f5a07e1097cd77b5a5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:EpizymeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3144c1b6231e4ae3b4870c4b3899f3bc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8655b88be914b679ef264228d3e1920_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa98c432df2e41d197b0bbeeda56b8f3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia2307a5ce88e48c2a06297ee38c8ff92_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if1e2a2af5b8c4eae95b037e3cda81bcf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i00b63eb6a93e410fa76fd2e629ddcb94_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i763fc198266c47f18427206c9825f562_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia35d113ea7024ba6950f218601bacf6d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifef0f1d7958a463da43eae42d4bfdcda_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i14182ec6f41e44f390626af261a6307c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i50aadab619674413a318d22a3934817f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i28aa4e83beed49649514ca87068e5ff6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5b1e737cb86341c5927dafb07d9750e7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i51d19c62ebf442779da8aeb40a4ab214_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib358915627fb4011bf72f88cea09f234_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i11eaf253ae3b4547aad0185800a4c0d2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i89b8a39a63294eebab3e3f0053f1e384_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i005aac99b4434d53866b784c5d193d69_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaef13cf1a72b4d638ba70defd6ec0717_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i17ed9cdd951d4b46941b7212a8ac2d44_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8604b93633cf417e954376d722a8dadd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifcf29dd183834411bbff2b3741c8ce8e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i72d6d03d3001450dae8929c471f09b33_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie89c03cbaa3a415f8d13313d6d33a664_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rprx:TreasuryRateLockContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia3c1f334b1114d27b5ab4a6b83b6d95b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rprx:TreasuryRateLockContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1cb8fcdaa4e94b9bb101f554c36c0944_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rprx:TreasuryRateLockContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GainLossOnDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i766dfe5e45ea4f72a26e59216bb302d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia020dbee158643459651f9ece93d0d05_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i75566fc435584c81949dbaf5d363ad0a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie446f1fa1f9b4244a2ca74087c37da2e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2dcc53a90d444210880be69baae720a5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia44ca4ca5b24467685453ef798071b9c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i88285f19e15c4b32ad8309928003f3bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib075989af1f74896bccaba43480cd27b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3416e4f9b18349ecad1f073e06dec3f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a89ba14dcfe4b38bdf299da4317bd92_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia9e6b9ca88f64d7a856e5091b1586275_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id9922aa0da964460ac7f278f5e9ce3bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd56db919beb4b91b95510f88bc8e307_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i55d925c488be4a8f8163990bbb352b7e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e3aa405803e46c2ae8f0944494d7a94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibc0c4c7c6cdc45479c7eb9dc86d86a1d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i30d5c89a92a5482d9d74e4bb2241752e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53c4649842db44e4a15eb412da6b88a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8c9704b6d9d7401fab5346287e978380_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i49b4a4e11f71489ab6998095636e4351_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i077a711c86ba4484a165902a8b44eeb1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib89be7641277478e8f7b293085ccc5d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia66c162bc44045988727b18f854dba73_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0d769bb3068b491086f572bdae712fb8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i04f203e10aa24bcfa8ec0905052a2b27_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7d667d912c354a0c9c379aefc62e6fa7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie404feec194c4015ae7728b646421169_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic527ce521bf44f7fb2922ba14cf8f680_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i088b28295ac64e85ab5dfa6a843058cf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i19d9bd3151754f33acff24aea97d4f03_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib7fb8fef2b7f4c048ec7656d0e9bd6fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a7676bf6609461692e1aa4be16e7345_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibfafac4f4f2a4e088f1da17e816e5e52_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id085ae202d524bdb9d5d849459675315_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48b720aa212947f48ab2d55101f95e2b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i28195bb07d164725b7b634f4d19d0532_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i809b4052446c46388345163c43a4aa56_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idb619f9a9745447ca9b38d75ccc38904_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i796b378a6f1c40c48579f653afadb541_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2f327e7169c8452880bd81a8f13ed03b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i248b66c121454f309190c31387007f6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8bb92f2605164dc8b141abf08c6f5b56_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i022c0d8159864ed7a2a1944cc714c2cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id26c9a8cd8884671b2c7a640a4b6d7df_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ac959fb66e143fcaddb2cb43efeae1a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee8b694599fb4dd39b9e68aadeed7ed0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie51f46e72bfd4d7e834c4fdb560fbee4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie7ec150c06fd4f4e91c18c223d223ea5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id1a1aa3351a743f085a5b2c2f8f8be34_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19a72b318bc84259bb294a3c971a4b85_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i04227885885f4891916e264c27f329ce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6fb80ebaf7cf4a41b7bb7ee7eecd1a0c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd91a77eb7224e71a43cdcab940fb6bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad06d81ace0f4a3fbccf1299e4f6f414_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee5dd61b76084db79478047617833a62_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i96f3647beb944cfb9113b173115bb16f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0b086c90802248e181f4562a5f891cef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8fd0b4b6026a47dfa690bc790142dc6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e710c51efc64f67a80cd232937add07_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc65e75ec15e4a8d9dae69a3405cb50d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8c452309c9434a04aed49ed1b90eadaf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic7ab09bfb5bd4da3a4014bc287abc1b4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i23b9ee584ca349bfb13948d7e36428be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia7b300d23f844817bdcfa222399539cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa7fcc31f05a4cd38338bef84fd13226_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if3b3d077c01141fabeaf491e1ebfa108_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie5aeecb6ade049569e8f33d8ba05292c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i94e2f508014f476987e71ff61fb7acc0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4190ee3791704e3cb28414c2e7b90290_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib55e7cd67be640bcbc6bf9021cbd80ab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i011c26d52667488b9a934f794e0b528f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i25d1766cd2c74c1d9a6e6b47a1ff4db5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5ccc4c3e02d8454db2beb623053c69a4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i361e783ed15347028eee1b52d6e057f6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if100f3b0b4694f76acfbd85a49861791_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i23115a36ef69401581d68e8923fad129_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id424947d5ae8418b9adaf58a03fddf26_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i98c2487e5b2648e7b109d6723b860233_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i77465b4fae3745838d33803f0ec0bbc7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6228c34e36964903b7d23917ea68a634_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia90e169e7f6c423bb0c4f735d01ae17b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib39b424185204ed8abf5c36761702ce7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3cc4a0220a37443eb7239af4691991c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5879c529f1044590b63a67bad0d16f8d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3565d1e114564c88a5bdaaff4011b9bd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id7177d9153404fb68d339079a331543f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if4e245eba01b40829373277b36665d51_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iae02917f54274b579c2894c8155d9e11_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia0e7d3e451a44f16bafd403564c15c33_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib406cf1143e641fd8a07fb8084d1848a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iae1bbd4d1fb242f38ccaf2f15e20b521_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifa9f1ac8ede24d5ea9cae25ddd1c125f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6de6823bdc2b4ac98c04ae502140745a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8c7c87185ab54de39f17a1a1526628ab_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i81dbcb5a23f349fe855015cfdaaa1937_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1c970570f47a4749aeb33f585934e58f_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BioCrystPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="i81db589362444c02b90538016ac19ba1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0f6dd75074a4324b2b360f729714ac3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id95940867f7f46d1832cf3e16823033c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9de83b17a2d84f7081715a46a48bb989_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i563d98aa4d6540f88726ebcbf9a18b2f_D20190405-20190405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodAxis">rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-05</startDate>
            <endDate>2019-04-05</endDate>
        </period>
    </context>
    <context id="i0c20ae236c2f417082e6a9e92e6d43b8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodAxis">rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i35db462f272349c080f522a5c4e7f55a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:CysticFibrosisFranchiseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i910a6938c4b04c46b87813b7b69e8dce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:TysabriMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ide9c8ac9b7834772b270536662c1c607_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:ImbruvicaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5d275aee32304e029188d994792d2f92_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:XtandiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4dea9589e6e74a59a7d713e718e4a80d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:TremfyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i65da27051b834e589474daa7e00772a9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:EvrysdiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i98a31ea009fd41ae9b93b9a0ba894b4b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:OtherFinancialRoyaltyAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i548f6928715a4fd7ad65b15d47cba2a8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:CysticFibrosisFranchiseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8bf9a6954f4b4608ac3db7c1a9515015_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:TysabriMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i60ad6794898d4cdc903f9017ab626e3f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:ImbruvicaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9ee684b3e062472b855ba68705d802d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:XtandiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib6afe0a950f444f6986eed827af96e29_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:PromactaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i653d2d4470454f40b058b645513ec385_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:EvrysdiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icd8901ad6baa4fe485e98132407e4d74_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rprx:OtherFinancialRoyaltyAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib6a50a564e8b4b0b934ac4b3000f4c8a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rprx:DPPIVPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc0fb3b2f3e24224b3fb2f9cc5ef7df9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rprx:DPPIVPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7d7161b299de4f37949a7b5dcce2e1f7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rprx:DPPIVPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i874783a606094b5b9faa8d9db9749829_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">rprx:IndividualLicenseesConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id875c4379b7740e39a9bb8d8d1ddfe28_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">rprx:IndividualLicenseesConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id6fb304c08604399aba5e92d08d1d6b7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rprx:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">rprx:IndividualLicenseesConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i05361955890f48e2a999133572daa6a8_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="i2fbdc80a9a134e2b9b74bd14842984f8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1f98a06986334cf4ac1ea37c17735d57_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i795acc0e43ad49819be20554560459e9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iff8840832b23407c89930ca87f5e3a14_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i28b1ff263ad7477ba427e73b282c6efc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1e5a064854514c4e9d147a383d33e903_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4f295d9e2c304799a502469a6920f5c2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i48ff7ddf47f44c04b36ecf13d3a578f4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia502c1c929d940d39390b7214482871a_I20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">rprx:MerckAssetPhaseIIClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="iecadc5607804420f9e9904632d1e8a25_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie3c9990279364489bd57aa8cf39a801b_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">rprx:MerckAssetPhaseIIClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="idfbcd815ad3241e08b3899f248245e53_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">rprx:MerckAssetPhaseIIClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i3cde2b63bf59491b8925224bea22907a_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionIIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">rprx:AZAssetPhaseIIAndPhaseIIIClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i47df9f0f55ed4282855d6acd42a023ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib68731c3079e4d3ca394ac6b77b028f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">rprx:AvillionEntitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i286e267288774fbe92ab611abb8069de_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:FundingAgreementsWithSanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i40bac185075247a39792ae4ffa91c2ce_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if273f44aa1484854b5d3ea003908542c_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rprx:BioCrystPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="i479dbbd40a7348a1919d32453a73a811_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:FundingAgreementsWithSanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9150e6c7578b456aad25125ca3f4404d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:FundingAgreementWithBioCrystMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i170879596f064c7ea75b778e24446320_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:FundingAgreementsWithSanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie35632bef26942e9a813a4eb6a249893_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:FundingAgreementsWithPfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4861f1f472c3491ba7a17eb5040be7f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:FundingAgreementsWithSanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9796b650407b44c3957bc1e7ffbd1229_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:PointSevenFivePercentSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7dc45b08ebac451f91ea39248eeab27b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:PointSevenFivePercentSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib2c6ec4ac80d4a6ba66238bf0a9eb4cb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:PointSevenFivePercentSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia2fafea4522943eca815863b7d3d8349_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b0aacd47d5b4487854882d7e7b776da_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia43476884d9241af8b829c570791446c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i43310a7b9e4c4cbb9b03ef370bd43b77_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointSevenFivePercentSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifee8d1bb44854cc4a3188d158569c76c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointSevenFivePercentSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9d33126321d44b4aabd868a581153c4b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:OnePointSevenFivePercentSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i12aa5c25ace14515980e127e89b84e78_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia4e846ac7a044335959896d695fb4eb6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibdaffc234a45408a8a359e973745feb8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c4c0408ec6340e9bdb1a602e36ce18b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointOneFivePercentSeniorNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd6ff013438940249c31fcaec596a041_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointOneFivePercentSeniorNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iafcd19db0e464d11b58358856023c8b3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TwoPointOneFivePercentSeniorNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i214ee7900f3d49228322f94559a11682_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd0fbf3fb9684880981bb0db110314f6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i273747e9c3c9428a95fbb9a2dc8580ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b8870452b5a460ba6814149888615ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i35930b3c5c694b58bdad83cb5488ec9f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icf88d4d19d624f61acc05f3da6e97e88_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4daec00bc1054f378d9fa9e9841e7e3b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeFivePercentSeniorNotesDue2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0162f5b487c74cacb76db77bc7f972bc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeFivePercentSeniorNotesDue2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i03b010a1e0b24651a9e2d279ef1f4a19_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:ThreePointThreeFivePercentSeniorNotesDue2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie681b3df9681426ba637a173be7ba1dc_I20210726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-26</instant>
        </period>
    </context>
    <context id="i68470da82fa849aabc13b3b1753af6d4_I20210726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-26</instant>
        </period>
    </context>
    <context id="i4d77b9cf09984cf791139a8ba06caf1e_I20210726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorNotesDue2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-26</instant>
        </period>
    </context>
    <context id="i4ce08489650c4f10a179aeb963c83319_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorNotesDue2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36b01c03000b44fbbe2d2aa0ad142157_I20200902">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-02</instant>
        </period>
    </context>
    <context id="ida43ed4cd5d84bc4bfff97ddd4ade4dd_I20200902">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RPI2019IntermediateFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-02</instant>
        </period>
    </context>
    <context id="i2faebe6b2bb249f9bacffbdee1da7d22_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i761809a342d742f8846055709c5f4ea7_D20200902-20200902">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-02</startDate>
            <endDate>2020-09-02</endDate>
        </period>
    </context>
    <context id="i02f715ec0012457ca0402d8dc7e85a1b_D20200902-20200902">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-02</startDate>
            <endDate>2020-09-02</endDate>
        </period>
    </context>
    <context id="i06737af3814f449197ef9f5868fd6001_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i32d8e5ca0cdc4cdcbf57357cd3014fc4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4141d72c0fa3426ea79348fd59066693_D20200918-20200918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-18</startDate>
            <endDate>2020-09-18</endDate>
        </period>
    </context>
    <context id="i8dc7c9c8b8c844b59270fcb640d8fbde_I20200918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-18</instant>
        </period>
    </context>
    <context id="ibecbcfc3dadd481d9155173824469951_D20200918-20200918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">rprx:OvernightBankFundingRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-18</startDate>
            <endDate>2020-09-18</endDate>
        </period>
    </context>
    <context id="ief16c63a8fed4314b8dbf9cd08433170_D20200918-20200918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsPurchasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-18</startDate>
            <endDate>2020-09-18</endDate>
        </period>
    </context>
    <context id="i8563b235bf8f445ab53d170d2ea1cc7d_D20200918-20200918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:SeniorUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-18</startDate>
            <endDate>2020-09-18</endDate>
        </period>
    </context>
    <context id="ieb917668901f4fa88d71cb0dad938ffc_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="i9fd1d6e21848456dba10bcb5be7800b7_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="i7fa1890df4f64955a27b5a2e7f1eb6f4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib99e303d9a2649bba418d9bec8ce14f3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rprx:TheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i466cdba264f14dbba8111c43a48fa933_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rprx:ClassRRedeemableStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7d508394642a4a0ab6e3a02929fd6dd4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7e834532d49b48d183dee4dfa980b04c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3b032830d76c44b9a92d95e245ce0a21_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2a47bfd8cfda47409c0410907da54f68_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if27b249e1d7e4d108a2f24ec3c67006f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icc89c3a01e3b4ee9876dc2317f1f1faa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i78eee2afc7d1460ab607760dbad7a025_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9a4eb1b3391f4185a844dba1b8ad1349_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if61940f2e40d400ead5fbf3844bb3dc0_D20200101-20200617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-17</endDate>
        </period>
    </context>
    <context id="if3642192137f47c8a326c30a5d6bbb91_D20200101-20200617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-17</endDate>
        </period>
    </context>
    <context id="i737c7ca0fc4741d4908eb966f08f3fa9_D20200101-20200617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-17</endDate>
        </period>
    </context>
    <context id="i882f3c7d9ced490c80ad72c747e61ae9_D20200101-20200617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-17</endDate>
        </period>
    </context>
    <context id="i4c5760f9e15d4ad292c0f7ae423767a7_D20200618-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifc1471d809d64fbb9f020dbcf89a38cc_D20200618-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9f82fba017484ebc85a41aa90b9dc063_D20200618-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id2d9b4e5e10d4c36a707ba0f30bd0fc7_D20200618-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie11ab38cff9248ce8459b4a78a07f67c_D20200618-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibdbce45f889b42cb99f32b9a959ebb1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id0317f1e1eed4aecbd740d3419ac7fd7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie11804f07d7c4f1ebc7cfa8b439e5803_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idbe6045b78dd46d38b235d59ba1967c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie3fe08cf37364580ab8e966ac247b010_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RPHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i88b0d9786c874e6f8a16be78aef6d637_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RPHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8496598191ee444d9545f8252ee00014_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0d8ada1253ef445f9cf1d4b92a7a6385_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if195a301ef504b6faade4870a19f4275_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8bac599d33534baa86881a2afa9afcc0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i79703258b5994db9b9b004b77c7e1c58_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:RoyalPharmacySelectFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b9c1b4135444d46968e0d3445750ae7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:LegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3166f885d1dd43e7ad16fe6b65c05bc0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:ContinuingInvestorsPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i90964cc296394e8cbcf965379f0538cd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rprx:EPAHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifbdd368fbe3941059a474c997b396f0a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">rprx:RPHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie53671576bce41518be8f910184feaec_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4cc52872c2794894927c82c640746a99_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i08c8a6f2c3554638b8b9e8e94b41d3ab_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic3af896a7f0c42529577ce561a976e90_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib32135ef98664a82a742199b45769f54_I20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rprx:A2020EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-15</instant>
        </period>
    </context>
    <context id="i9506994fe6124fe08c513652cc6fdd3c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rprx:A2020EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i941486f8afa342d49e11f69d4af24754_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iadabb8c442dd4ffcbc66a71a0fe7341b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia9eca6903b754336ab978b1c6859dbee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1da7232b999b4b67b6bf844dd97d818a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i850c4112163e4a4da3d1fd1aa181af6c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:ClassBHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i63532b6df7f947d8b3cff39df953d6f5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:LegacyInvestorsPartnershipsAndRPSFTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8a17c53123fa4e12b0b8749ed24171a4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:ClassBHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i07a6da6cb1b14ad78d9d0a893435f6a3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:LegacyInvestorsPartnershipsAndRPSFTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3a4d899516f7416083d6a452d72dff94_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i16167be66e5642fa8c58da773ea9dd57_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0c98f12437f9466181a216b35a41b08f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i197418bb01ba4a16bc643f9b8299428a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic0c9719a7e4c49a6888e5a5a55e6a756_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6b15a91be9e9493798198e66a8d123b0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icc74be5e7f2b4443888aa58295087c78_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i69d044ffec6446e0896ba4f3dde2181c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7ef6d97fcbd2450783139f7b7ee49dc4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i29031751451245b7b580c18872827fbb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib4f46b5e4015492f9d8f108c0637d93f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i85fa20a518334b9fa7796f9712ef4b1d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1006e57c6def4fd5ae9330e75305eda2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i16fdeeb9bb4649b8bb751998b5e4aa0d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea955efbad0b414690fc8195ca1de338_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i54dfb90328614a55aba5dfd030436f8a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if7ee447648cf4185a3ad39d6a4c5b190_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie65b03ddad0a41228c36c13d797b9715_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i56d5126b8d034d6caef67a58b8e9b69e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iedeb31da272b4fc68f60ac39c1f3cf68_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9dc56eeaf4e74cf0a58f82575803d294_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibe95870b105d4aadbf0f7ea315240ffe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:OperatingAndPersonnelPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i68845df194e84a7d80a8bd8a4940e91d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:OperatingAndPersonnelPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i97ca2cea9f6f43ddaa7f3e5b85bf3ea6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:FormerOperatingAndPersonnelPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie8e86ed407fe484e8200e769e2f1bb39_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:FormerOperatingAndPersonnelPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i645cb20517d04607a53311447c97b49a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:FormerOperatingAndPersonnelPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2e60ab1409db4a2697d00163b861a712_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i70b38d22ad90490ba1b7d51417e278e8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic7b7fdb0deff479196b3afda650a0570_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie31b0e40de594cdd9c6ae104e8a737c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibb1bbffa95a546f8bb9ed80b3df9b06b_D20171208-20171208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementBenefitOfPaymentStreamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-08</startDate>
            <endDate>2017-12-08</endDate>
        </period>
    </context>
    <context id="i61362e5f58b24b40a91040ec047f877f_D20171208-20171208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementFundingObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-08</startDate>
            <endDate>2017-12-08</endDate>
        </period>
    </context>
    <context id="i892f2facb5f94c52a537787b30d9bedb_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementFundingObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i67eff68d96604fa8be650fb4b9c29499_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementFundingObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i476f13cf218b4efabc6d088270acc46d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AssignmentAgreementFundingObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e9cfc8aaf7e4e8694cd83fe4460da68_D20210416-20210416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AgreementWithMSCIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-16</startDate>
            <endDate>2021-04-16</endDate>
        </period>
    </context>
    <context id="ib2947dd542964da4bc1a05e210e2204b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AgreementWithMSCIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9edec4e140234b36b02f7525c49128f0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:PurchasingAndDonatingVentilatorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rprx:PabloLegorretaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i577a0329d95541e3802de867916ac6d6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8cc96b6d6e9e4707b52d5a0f86086779_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id61bed594e7b481cb6b9d98f501ad606_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icb00ed73f9984375a78b3989a66be135_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib03c23cba7a244bb9c45ccd577d4c56b_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">rprx:LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="id128cc5ba3f14e5e9d39b99e553584ce_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">rprx:LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i745d2f50fe8b4f46a787612b29f6bed4_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">rprx:LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="id0a161191b444d5bac5c44aa63d77be4_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">rprx:LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i1895cd7ab821494986c2e4e15419aa87_D20211104-20211104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">rprx:LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-04</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="id0938578b1c44708b42aae9c1e2c0857_I20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rprx:MorphoSysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-02</instant>
        </period>
    </context>
    <context id="if022a6e3714949948eb2520d7c7ab729_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001802768</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="gbpPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:GBP</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="partnership">
        <measure>rprx:partnership</measure>
    </unit>
    <unit id="segment">
        <measure>rprx:segment</measure>
    </unit>
    <unit id="class">
        <measure>rprx:class</measure>
    </unit>
    <unit id="noncontrolling_interest">
        <measure>rprx:noncontrolling_interest</measure>
    </unit>
    <unit id="payment">
        <measure>rprx:payment</measure>
    </unit>
    <unit id="tranche">
        <measure>rprx:tranche</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY180L2ZyYWc6ZTcwNjE0ZGNjNDA5NGJmMTlmOTk3YjdiYTEzNTc2MDgvdGFibGU6N2Y2NTBlMjg3NWJjNDA1NmIxMDMxMGYwNjMyY2U1NTAvdGFibGVyYW5nZTo3ZjY1MGUyODc1YmM0MDU2YjEwMzEwZjA2MzJjZTU1MF8xLTEtMS0xLTA_576ec597-64ae-4b0d-8d2e-1d051c529ec6">0001802768</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY180L2ZyYWc6ZTcwNjE0ZGNjNDA5NGJmMTlmOTk3YjdiYTEzNTc2MDgvdGFibGU6N2Y2NTBlMjg3NWJjNDA1NmIxMDMxMGYwNjMyY2U1NTAvdGFibGVyYW5nZTo3ZjY1MGUyODc1YmM0MDU2YjEwMzEwZjA2MzJjZTU1MF8yLTEtMS0xLTA_bf13abf0-a769-42d9-8a3c-234984d864de">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY180L2ZyYWc6ZTcwNjE0ZGNjNDA5NGJmMTlmOTk3YjdiYTEzNTc2MDgvdGFibGU6N2Y2NTBlMjg3NWJjNDA1NmIxMDMxMGYwNjMyY2U1NTAvdGFibGVyYW5nZTo3ZjY1MGUyODc1YmM0MDU2YjEwMzEwZjA2MzJjZTU1MF8zLTEtMS0xLTA_9ffaeb2c-6668-4cf6-a2ed-c1d47c48bbd9">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY180L2ZyYWc6ZTcwNjE0ZGNjNDA5NGJmMTlmOTk3YjdiYTEzNTc2MDgvdGFibGU6N2Y2NTBlMjg3NWJjNDA1NmIxMDMxMGYwNjMyY2U1NTAvdGFibGVyYW5nZTo3ZjY1MGUyODc1YmM0MDU2YjEwMzEwZjA2MzJjZTU1MF80LTEtMS0xLTA_c76ea528-6827-48c7-b93e-5c81d9dc9041">false</dei:AmendmentFlag>
    <rprx:LongTermPurchaseCommitmentAmountOutstanding
      contextRef="i4719611fdef547db987f7d2d30dadbc7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY183Ni9mcmFnOjk4MzM2MDdhZWI5NTQxMmE5NDNjZmUyZDcyMTllZjBhL3RleHRyZWdpb246OTgzMzYwN2FlYjk1NDEyYTk0M2NmZTJkNzIxOWVmMGFfMTA5OTUxMTYzMzI0Mw_0666d905-8be3-4416-a66f-8e0d671d65c8"
      unitRef="usd">129600000</rprx:LongTermPurchaseCommitmentAmountOutstanding>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzExLTAtMS0xLTA_7826f12a-67da-4efa-9c4b-296fe436efc8">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <rprx:DebtSecuritiesAvailableForSaleRedemptionPricePercentage
      contextRef="i3468b5dba8434479a8f400dd5c49c174_D20190405-20190405"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzAvZnJhZzpiNmUzOGVmYzdkMmI0NmUzYjkxMDM2OTJhZWM4YmZmNy90ZXh0cmVnaW9uOmI2ZTM4ZWZjN2QyYjQ2ZTNiOTEwMzY5MmFlYzhiZmY3XzM5OQ_0ca1c62c-91b5-4d27-a427-11caf92896c8"
      unitRef="number">2</rprx:DebtSecuritiesAvailableForSaleRedemptionPricePercentage>
    <rprx:DebtSecuritiesAvailableForSaleRedemptionPricePercentage
      contextRef="i0cc5aaad296f4b2ebbafb25210d95261_D20190405-20190405"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzAvZnJhZzpiNmUzOGVmYzdkMmI0NmUzYjkxMDM2OTJhZWM4YmZmNy90ZXh0cmVnaW9uOmI2ZTM4ZWZjN2QyYjQ2ZTNiOTEwMzY5MmFlYzhiZmY3Xzc1MA_9078991a-5a7b-43d2-8a39-380179363f48"
      unitRef="number">2</rprx:DebtSecuritiesAvailableForSaleRedemptionPricePercentage>
    <rprx:DebtSecuritiesAvailableForSaleRedemptionPricePercentage
      contextRef="ie7ffbb1b682a454ea429c1fb003ce9d8_D20190405-20190405"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzAvZnJhZzpiNmUzOGVmYzdkMmI0NmUzYjkxMDM2OTJhZWM4YmZmNy90ZXh0cmVnaW9uOmI2ZTM4ZWZjN2QyYjQ2ZTNiOTEwMzY5MmFlYzhiZmY3Xzk0MA_df2aa2cb-44a6-492b-99fe-9fa44c1ffcec"
      unitRef="number">2</rprx:DebtSecuritiesAvailableForSaleRedemptionPricePercentage>
    <rprx:DebtSecuritiesAvailableForSaleRedemptionPricePercentage
      contextRef="if92704d2e5e74022812f0c24cecf4b2e_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzAvZnJhZzpiNmUzOGVmYzdkMmI0NmUzYjkxMDM2OTJhZWM4YmZmNy90ZXh0cmVnaW9uOmI2ZTM4ZWZjN2QyYjQ2ZTNiOTEwMzY5MmFlYzhiZmY3XzIzNDM_5caaa24c-f201-42b4-bee7-4bb4207c53ba"
      unitRef="number">1.80</rprx:DebtSecuritiesAvailableForSaleRedemptionPricePercentage>
    <rprx:DebtSecuritiesAvailableForSaleRedemptionPricePercentage
      contextRef="if1ba671053ae4c678a08effbbc36a0d6_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzAvZnJhZzpiNmUzOGVmYzdkMmI0NmUzYjkxMDM2OTJhZWM4YmZmNy90ZXh0cmVnaW9uOmI2ZTM4ZWZjN2QyYjQ2ZTNiOTEwMzY5MmFlYzhiZmY3XzI2Nzg_fc37ef66-812b-4b22-964a-36995b3b5c77"
      unitRef="number">1.80</rprx:DebtSecuritiesAvailableForSaleRedemptionPricePercentage>
    <rprx:DebtSecuritiesAvailableForSaleRedemptionPricePercentage
      contextRef="if1ba671053ae4c678a08effbbc36a0d6_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzAvZnJhZzpiNmUzOGVmYzdkMmI0NmUzYjkxMDM2OTJhZWM4YmZmNy90ZXh0cmVnaW9uOmI2ZTM4ZWZjN2QyYjQ2ZTNiOTEwMzY5MmFlYzhiZmY3XzI4NjE_f41984c4-4a58-4fdc-8e63-f40161319793"
      unitRef="number">1.80</rprx:DebtSecuritiesAvailableForSaleRedemptionPricePercentage>
    <rprx:DebtSecuritiesAvailableForSaleRedemptionPricePercentage
      contextRef="i563d98aa4d6540f88726ebcbf9a18b2f_D20190405-20190405"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjEvZnJhZzo4OThjZTk0NTliYzE0NWZhODNhMjk0NDI3NjdjY2VjNy90ZXh0cmVnaW9uOjg5OGNlOTQ1OWJjMTQ1ZmE4M2EyOTQ0Mjc2N2NjZWM3XzQ_939beab6-52db-48eb-a722-f9f0de90dab5"
      unitRef="number">2</rprx:DebtSecuritiesAvailableForSaleRedemptionPricePercentage>
    <rprx:DebtSecuritiesAvailableForSaleRedemptionPricePercentage
      contextRef="i0c20ae236c2f417082e6a9e92e6d43b8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjEvZnJhZzo4OThjZTk0NTliYzE0NWZhODNhMjk0NDI3NjdjY2VjNy90ZXh0cmVnaW9uOjg5OGNlOTQ1OWJjMTQ1ZmE4M2EyOTQ0Mjc2N2NjZWM3XzE2OA_2df5abe5-efc2-461b-98d8-a8b84e82d7e8"
      unitRef="number">1.80</rprx:DebtSecuritiesAvailableForSaleRedemptionPricePercentage>
    <rprx:CollaborativeArrangementRightsAndObligationsExpectedReturn
      contextRef="id0938578b1c44708b42aae9c1e2c0857_I20210602"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185MzQvZnJhZzplYWZjMmRjOGVmZDI0NWNjYjVjN2U3NGE2ZTBlMzY5MC90ZXh0cmVnaW9uOmVhZmMyZGM4ZWZkMjQ1Y2NiNWM3ZTc0YTZlMGUzNjkwXzI5Njg2ODEzOTQ5OTYw_e189498c-fefc-444d-a932-0e375c1d198f"
      unitRef="number">2.20</rprx:CollaborativeArrangementRightsAndObligationsExpectedReturn>
    <dei:DocumentType
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8zODY2_c63764f2-c2d1-4025-9678-22e323b99e1f">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6MGEwNTZlNDk5YTkxNDVkMzliMjkyZjYwNjFmNjFhYjMvdGFibGVyYW5nZTowYTA1NmU0OTlhOTE0NWQzOWIyOTJmNjA2MWY2MWFiM18wLTAtMS0xLTA_d9132102-c8b6-4aa4-ac2e-e0f57badb1e0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8xNDI5MzY1MTE2NTc1OQ_07669eac-a7a8-4f76-80b3-a1f86553dde3">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8xNDI5MzY1MTE2NTc1OQ_6e0da946-3b66-4e84-99e4-56bf1d812df8">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6OGRmNTkwMzgyN2RhNGY2OTk4YThlNzllZjY3NDliODcvdGFibGVyYW5nZTo4ZGY1OTAzODI3ZGE0ZjY5OThhOGU3OWVmNjc0OWI4N18wLTAtMS0xLTA_d03ed7ca-c75e-4d89-b961-ef32d7c406d6">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8zODcx_edaade14-a9a6-4a5a-b061-010277797bef">001-39329</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8zODc1_cc2c4eec-af4c-4d1b-9c6f-725204800df6">Royalty Pharma plc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6MGY3MDhjYzQ1MTU3NDY4YWJhOWYxYjZmYmIxNTEyMjUvdGFibGVyYW5nZTowZjcwOGNjNDUxNTc0NjhhYmE5ZjFiNmZiYjE1MTIyNV8wLTAtMS0xLTA_eb4af650-310f-41d3-9706-40070bf7d0b9">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6MGY3MDhjYzQ1MTU3NDY4YWJhOWYxYjZmYmIxNTEyMjUvdGFibGVyYW5nZTowZjcwOGNjNDUxNTc0NjhhYmE5ZjFiNmZiYjE1MTIyNV8wLTMtMS0xLTA_0f6218b3-c142-460f-a5f1-a1f62594ae64">98-1535773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6MGY3MDhjYzQ1MTU3NDY4YWJhOWYxYjZmYmIxNTEyMjUvdGFibGVyYW5nZTowZjcwOGNjNDUxNTc0NjhhYmE5ZjFiNmZiYjE1MTIyNV8zLTAtMS0xLTA_bae8dff2-83aa-4484-9a5f-738b2e454dcb">110 East 59th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6MGY3MDhjYzQ1MTU3NDY4YWJhOWYxYjZmYmIxNTEyMjUvdGFibGVyYW5nZTowZjcwOGNjNDUxNTc0NjhhYmE5ZjFiNmZiYjE1MTIyNV80LTAtMS0xLTAvdGV4dHJlZ2lvbjplNDBkMmJmNzQ2ZDE0MDAyYmE3N2FmODZiN2JkZWRmOF80_784c3c88-38a9-44a4-8ed8-be0cecb5a4e3">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6MGY3MDhjYzQ1MTU3NDY4YWJhOWYxYjZmYmIxNTEyMjUvdGFibGVyYW5nZTowZjcwOGNjNDUxNTc0NjhhYmE5ZjFiNmZiYjE1MTIyNV80LTAtMS0xLTAvdGV4dHJlZ2lvbjplNDBkMmJmNzQ2ZDE0MDAyYmE3N2FmODZiN2JkZWRmOF84_55d6f06d-82bf-4bec-8994-72e1993f23f6">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6MGY3MDhjYzQ1MTU3NDY4YWJhOWYxYjZmYmIxNTEyMjUvdGFibGVyYW5nZTowZjcwOGNjNDUxNTc0NjhhYmE5ZjFiNmZiYjE1MTIyNV80LTAtMS0xLTAvdGV4dHJlZ2lvbjplNDBkMmJmNzQ2ZDE0MDAyYmE3N2FmODZiN2JkZWRmOF8xMQ_d18081b1-3cb1-4d24-ad8f-1b0e3be1b0eb">10022</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8zODc2_330e9477-7568-4f50-9750-be2417b7e8a1">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8zODcz_3dc02531-ae1f-4569-a8ad-e3f699143e36">883-0200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6NGEyMzJmMjZhNjY2NDY2NjhiOTU1NDMzNWQ3ODZjMDYvdGFibGVyYW5nZTo0YTIzMmYyNmE2NjY0NjY2OGI5NTU0MzM1ZDc4NmMwNl8xLTAtMS0xLTA_832912c6-2ee8-4355-8722-b6704a2e32eb">Class A ordinary shares, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6NGEyMzJmMjZhNjY2NDY2NjhiOTU1NDMzNWQ3ODZjMDYvdGFibGVyYW5nZTo0YTIzMmYyNmE2NjY0NjY2OGI5NTU0MzM1ZDc4NmMwNl8xLTEtMS0xLTA_f2c51e36-ccb6-4dd8-8563-7415cfeb8225">RPRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6NGEyMzJmMjZhNjY2NDY2NjhiOTU1NDMzNWQ3ODZjMDYvdGFibGVyYW5nZTo0YTIzMmYyNmE2NjY0NjY2OGI5NTU0MzM1ZDc4NmMwNl8xLTItMS0xLTA_0a0060fd-471c-4d33-8e7d-6538c31e9a5e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8xNDI5MzY1MTE2NTc3MQ_4a001fa1-3ec5-4804-b27f-f30976a37f22">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8zODY5_d55ed5f6-1e03-46f2-9469-7904675ddef5">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8zODc0_6d76f63a-2a28-4f94-80cc-013d6b217839">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8zODY3_f6a70e36-bb4b-4993-9297-9d495a22265b">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6YzhiM2QzMjE1YTQxNGI0NjgzMzcwZDdhZDUxOWZmZGQvdGFibGVyYW5nZTpjOGIzZDMyMTVhNDE0YjQ2ODMzNzBkN2FkNTE5ZmZkZF8wLTAtMS0xLTE4_db3cf2d6-d9a2-42e8-9859-358f8985b207">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6YzhiM2QzMjE1YTQxNGI0NjgzMzcwZDdhZDUxOWZmZGQvdGFibGVyYW5nZTpjOGIzZDMyMTVhNDE0YjQ2ODMzNzBkN2FkNTE5ZmZkZF8xLTMtMS0xLTA_e17276b4-2a86-4177-b33e-f80a7be1aef9">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGFibGU6YzhiM2QzMjE1YTQxNGI0NjgzMzcwZDdhZDUxOWZmZGQvdGFibGVyYW5nZTpjOGIzZDMyMTVhNDE0YjQ2ODMzNzBkN2FkNTE5ZmZkZF8yLTMtMS0xLTA_8b255111-19c7-40a0-af42-2f231ba3187b">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8xNDI5MzY1MTE2NTc3Mg_de433ebb-7ac2-4a7e-a49d-d54824fc2e96">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8zODcw_d31c613b-a43c-49c5-a147-a3fbf929f740">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i58e8c79f7b7640d089df3eefd8c4584f_I20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8xNDI5MzY1MTE2NjIyNg_85ef1864-7abe-4043-950c-14edd217a9e0"
      unitRef="usd">16600000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i1bcce023e17042be90c95db2fc81e685_I20220211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8zMTgw_58cb1cc5-4304-4fb4-9c87-7cacaebd5d65"
      unitRef="shares">432963472</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ia539779374e8435abf5929170c65ac83_I20220211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8zMjIz_03c27806-674b-4d1b-8114-30b9474dd1da"
      unitRef="shares">174212681</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xL2ZyYWc6YWM1MWU0NGQ1YTJlNDMzN2FhYzEzYjM3MTZkYzVmZmQvdGV4dHJlZ2lvbjphYzUxZTQ0ZDVhMmU0MzM3YWFjMTNiMzcxNmRjNWZmZF8zODY1_01ce440a-1b20-45a7-b05a-c3c714cbc1bd">Portions of the registrant&#x2019;s definitive proxy statement for the 2022 Annual General Meeting of Shareholders, or Proxy Statement, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant&#x2019;s fiscal year ended December 31, 2021. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, the Proxy Statement shall not be deemed to be filed as part hereof.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185MS9mcmFnOjVkYWM2ZDg3N2NlYTRiMDViMTA3MDIyN2IzYTVlNmE1L3RhYmxlOmNmMmEyYTcyODcxZjQ4NzZiODJmODkyZTA0ZmNhNGVmL3RhYmxlcmFuZ2U6Y2YyYTJhNzI4NzFmNDg3NmI4MmY4OTJlMDRmY2E0ZWZfMC0wLTEtMS03Mzk5My90ZXh0cmVnaW9uOmUxODk3NDA5OTE1ODQ1OGJiMzk3N2Q0MTA5MmU0Yzk5XzE0MjkzNjUxMTYxMTg5_4afbef89-8e7a-4391-b235-4e03c96580b9">1411</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NC9mcmFnOmExMjk4N2Q3NmIxYzRhY2I4MmZhZjM0YWVlYmU5ZTNkL3RleHRyZWdpb246YTEyOTg3ZDc2YjFjNGFjYjgyZmFmMzRhZWViZTllM2RfMTQyOTM2NTExNjgyNDE_fec55b1e-4930-474b-99ef-61741186cefa">Ernst &amp; Young</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NC9mcmFnOmExMjk4N2Q3NmIxYzRhY2I4MmZhZjM0YWVlYmU5ZTNkL3RleHRyZWdpb246YTEyOTg3ZDc2YjFjNGFjYjgyZmFmMzRhZWViZTllM2RfMTQyOTM2NTExNjgyNDI_235f928f-c5e2-499b-a5e9-194ec506fd03">Dublin, Ireland</dei:AuditorLocation>
    <dei:AuditorName
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NC9mcmFnOmExMjk4N2Q3NmIxYzRhY2I4MmZhZjM0YWVlYmU5ZTNkL3RleHRyZWdpb246YTEyOTg3ZDc2YjFjNGFjYjgyZmFmMzRhZWViZTllM2RfMTY0OTI2NzQ1NzE3MA_d632d262-3987-49af-869b-010e7e0fd204">Ernst &amp; Young</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NC9mcmFnOmExMjk4N2Q3NmIxYzRhY2I4MmZhZjM0YWVlYmU5ZTNkL3RleHRyZWdpb246YTEyOTg3ZDc2YjFjNGFjYjgyZmFmMzRhZWViZTllM2RfMTY0OTI2NzQ1NzE3MQ_cb3da1e1-781a-40e7-8923-e8a67ec2c830">Dublin, Ireland</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNC0xLTEtMS0w_9d694a30-03a6-478a-9c3a-5077ea099a85"
      unitRef="usd">1541048000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNC0zLTEtMS0w_4c1fe4f2-d03b-44f4-9967-9870b4623fc2"
      unitRef="usd">1008680000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNi0xLTEtMS0w_0425e8d9-cb79-4949-ab6d-c8a17dea9d43"
      unitRef="usd">581872000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNi0zLTEtMS0w_90fcc6df-354a-4acf-842a-af536eb56846"
      unitRef="usd">983279000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNy0xLTEtMS0w_ac5237d5-df16-4044-8671-e55bafa1afad"
      unitRef="usd">614351000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNy0zLTEtMS0w_d10243fa-c441-4a0d-9a2b-b7d393b61848"
      unitRef="usd">587193000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <rprx:AccruedRoyaltyReceivable
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfOC0xLTEtMS0w_a9b0fa66-1075-4dc5-acec-4e4bd26b9cba"
      unitRef="usd">53286000</rprx:AccruedRoyaltyReceivable>
    <rprx:AccruedRoyaltyReceivable
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfOC0zLTEtMS0w_e0998049-6652-43ae-995a-bd2891237666"
      unitRef="usd">33155000</rprx:AccruedRoyaltyReceivable>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTAtMS0xLTEtMA_83f81064-7ded-427a-9c2e-f4dedd940207"
      unitRef="usd">66000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTAtMy0xLTEtMA_76b2b3b7-b0ec-4892-b929-41ff35836d4c"
      unitRef="usd">69984000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <rprx:OtherRoyaltyIncomeReceivableCurrent
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTItMS0xLTEtMA_b3b311ac-bf0a-4157-8cab-3b99059ec921"
      unitRef="usd">15023000</rprx:OtherRoyaltyIncomeReceivableCurrent>
    <rprx:OtherRoyaltyIncomeReceivableCurrent
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTItMy0xLTEtMA_f3a17d5d-0d92-4adc-8bcc-522610dd4865"
      unitRef="usd">6011000</rprx:OtherRoyaltyIncomeReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTMtMS0xLTEtMA_d3001db9-0723-4c21-a128-2a504550efbd"
      unitRef="usd">6631000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTMtMy0xLTEtMA_d6007bd6-ace6-40a4-861d-820e2b31e5fb"
      unitRef="usd">8596000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTQtMS0xLTEtMA_604e4198-9522-4b7c-9a0f-c9818507cfca"
      unitRef="usd">2878211000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTQtMy0xLTEtMA_33a24a65-4f5a-4726-b609-9a4b497e4528"
      unitRef="usd">2696898000</us-gaap:AssetsCurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTYtMS0xLTEtMA_eee8ee1e-cb1e-40f0-a108-f36749f05f69"
      unitRef="usd">13718245000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTYtMy0xLTEtMA_6149af87-156a-4795-92a9-1c3e58529156"
      unitRef="usd">12368084000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTctMS0xLTEtMA_760a89d7-6534-44ab-8a70-c6ef91eaf0d9"
      unitRef="usd">5670000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTctMy0xLTEtMA_6694b9da-70c5-43ae-8e08-b85f61400601"
      unitRef="usd">28666000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTgtMS0xLTEtMA_8ee46d5b-fdbb-4a45-9a3a-0a795d816b8a"
      unitRef="usd">269800000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTgtMy0xLTEtMA_5bbd0296-2443-4631-905f-83ac511ea7bc"
      unitRef="usd">298689000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTktMS0xLTEtMA_136eb21e-fc69-499e-ad4a-3cc1524da508"
      unitRef="usd">204400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMTktMy0xLTEtMA_525204f1-929a-48f4-b946-d6b07885fc75"
      unitRef="usd">163016000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:EquityMethodInvestments
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMjEtMS0xLTEtMA_b4ec4da8-6822-48bd-82da-fd539f16741e"
      unitRef="usd">435394000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMjEtMy0xLTEtMA_f1d073ae-2495-49e3-b62c-5271363f4452"
      unitRef="usd">454936000</us-gaap:EquityMethodInvestments>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMjItMS0xLTEtMA_7d331f1e-3a51-4676-a4da-9b4f4270e44a"
      unitRef="usd">4145000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMjItMy0xLTEtMA_e2ec82c4-4582-479d-9a53-a54eb0a067bc"
      unitRef="usd">9997000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMjQtMS0xLTEtMA_e8fc0ec8-fb60-4542-bc61-b04be12b6170"
      unitRef="usd">17515865000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMjQtMy0xLTEtMA_819f1491-9316-46b7-910b-9f661b07f6ba"
      unitRef="usd">16020286000</us-gaap:Assets>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMjgtMS0xLTEtMA_ec232924-de0d-477e-ac80-133cd3b5f4be"
      unitRef="usd">107934000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMjgtMy0xLTEtMA_f060a860-22c5-43c4-bb86-6a25c5cc3e85"
      unitRef="usd">126366000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMjktMS0xLTEtMA_80671de2-69cd-44ca-b2fa-689eebffac9d"
      unitRef="usd">5620000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMjktMy0xLTEtMA_304ddeb7-cdde-445c-9463-6cfbc8407aa2"
      unitRef="usd">10775000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMzAtMS0xLTEtMA_2755bf03-7f4c-4099-89ad-6109aa4d4b23"
      unitRef="usd">57696000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMzAtMy0xLTEtMA_fb49c03d-1f13-4530-8539-a1ed1361425a"
      unitRef="usd">42146000</us-gaap:InterestPayableCurrent>
    <rprx:AccruedPurchaseObligationCurrent
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMzEtMS0xLTEtMA_3376cf94-64a0-4137-bc51-00b630db14ff"
      unitRef="usd">0</rprx:AccruedPurchaseObligationCurrent>
    <rprx:AccruedPurchaseObligationCurrent
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMzEtMy0xLTEtMA_4b862bdb-2022-41b8-94dd-f3a55fcaa1cb"
      unitRef="usd">110000000</rprx:AccruedPurchaseObligationCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMzUtMS0xLTEtMA_173b5a2d-ac7d-4f02-a87f-0384219f67b8"
      unitRef="usd">0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMzUtMy0xLTEtMA_075d39a0-445f-4fc9-8e36-2b8d360f608f"
      unitRef="usd">18600000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMzYtMS0xLTEtMA_bb81736d-5f08-4666-9d98-fc48b1d0a345"
      unitRef="usd">171250000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMzYtMy0xLTEtMA_5236e29d-1f0b-4988-9019-473dfc2aa024"
      unitRef="usd">307887000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMzgtMS0xLTEtMA_9af5b3cf-4cba-4059-be75-bbfab14475f1"
      unitRef="usd">7096070000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfMzgtMy0xLTEtMA_79019cf9-dcce-4fda-82ea-427dd0ea3d3f"
      unitRef="usd">5816584000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:Liabilities
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDItMS0xLTEtMA_17901fff-bcb6-4467-8397-d47963eacdbf"
      unitRef="usd">7267320000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDItMy0xLTEtMA_924b1404-85d9-4a0f-941c-ff0ef2813e2d"
      unitRef="usd">6124471000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDQtMS0xLTEtMA_b11cd1cc-b5c3-443d-ab65-250a6bd10b1c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDQtMy0xLTEtMA_73baac1e-ca80-4a9c-8d74-a250abfd3470"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i52867fbe6d2d4e9f9ef1cc8a39a6730d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDctMC0xLTEtMC90ZXh0cmVnaW9uOmRhMjFhMzBiMWU1NjQ4YzM4YTJjOGQxNmE3MTkzMTk5XzI5_2603d842-4287-4df5-8826-e47e63411cd8"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7048c06f34e64e98a9f8db168c52ecf6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDctMC0xLTEtMC90ZXh0cmVnaW9uOmRhMjFhMzBiMWU1NjQ4YzM4YTJjOGQxNmE3MTkzMTk5XzI5_c5f5ee44-c395-4dfa-ac6f-df3b7cb5367c"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7048c06f34e64e98a9f8db168c52ecf6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDctMC0xLTEtMC90ZXh0cmVnaW9uOmRhMjFhMzBiMWU1NjQ4YzM4YTJjOGQxNmE3MTkzMTk5XzQz_174256d9-40e1-419a-9999-06861313b2f4"
      unitRef="shares">432963000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7048c06f34e64e98a9f8db168c52ecf6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDctMC0xLTEtMC90ZXh0cmVnaW9uOmRhMjFhMzBiMWU1NjQ4YzM4YTJjOGQxNmE3MTkzMTk5XzQz_89e0a581-128b-4e60-a782-3b64a40c15af"
      unitRef="shares">432963000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i52867fbe6d2d4e9f9ef1cc8a39a6730d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDctMC0xLTEtMC90ZXh0cmVnaW9uOmRhMjFhMzBiMWU1NjQ4YzM4YTJjOGQxNmE3MTkzMTk5XzUw_5100cda5-b7a0-480c-a30d-5601b373bd0e"
      unitRef="shares">388135000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i52867fbe6d2d4e9f9ef1cc8a39a6730d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDctMC0xLTEtMC90ZXh0cmVnaW9uOmRhMjFhMzBiMWU1NjQ4YzM4YTJjOGQxNmE3MTkzMTk5XzUw_c4f4588f-9940-4b28-b570-4d5fce9f410e"
      unitRef="shares">388135000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i7048c06f34e64e98a9f8db168c52ecf6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDctMS0xLTEtMA_d2b6b39e-a6f4-4dcc-afdc-7488a5dc2fce"
      unitRef="usd">43000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i52867fbe6d2d4e9f9ef1cc8a39a6730d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDctMy0xLTEtMA_e2a8c5ce-5d4c-4553-85f4-34865bf3d234"
      unitRef="usd">39000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i46e28e4cc5cc4a16bbb2deb97423b415_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDgtMC0xLTEtMC90ZXh0cmVnaW9uOjg4MGZiZDhjY2RkMDQwMDBiMDQyZDc4ZTY1MGQ3ZjRhXzIw_87a24fc4-06e3-49ab-a260-3da3c1874611"
      unitRef="usdPerShare">0.000001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic092b803ad4d4d1bb1fc65733358f33f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDgtMC0xLTEtMC90ZXh0cmVnaW9uOjg4MGZiZDhjY2RkMDQwMDBiMDQyZDc4ZTY1MGQ3ZjRhXzIw_feb12a08-d348-4a87-883c-a2191a1e4cdc"
      unitRef="usdPerShare">0.000001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic092b803ad4d4d1bb1fc65733358f33f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDgtMC0xLTEtMC90ZXh0cmVnaW9uOjg4MGZiZDhjY2RkMDQwMDBiMDQyZDc4ZTY1MGQ3ZjRhXzM0_a62c3fb5-69d8-499c-8e27-19b2342b76f7"
      unitRef="shares">174213000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic092b803ad4d4d1bb1fc65733358f33f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDgtMC0xLTEtMC90ZXh0cmVnaW9uOjg4MGZiZDhjY2RkMDQwMDBiMDQyZDc4ZTY1MGQ3ZjRhXzM0_fd8e2379-3270-4d45-a1a6-6a87d7e3b03c"
      unitRef="shares">174213000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i46e28e4cc5cc4a16bbb2deb97423b415_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDgtMC0xLTEtMC90ZXh0cmVnaW9uOjg4MGZiZDhjY2RkMDQwMDBiMDQyZDc4ZTY1MGQ3ZjRhXzQx_2203e53f-6bb0-478e-955d-d68ba4379cb4"
      unitRef="shares">218976000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i46e28e4cc5cc4a16bbb2deb97423b415_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDgtMC0xLTEtMC90ZXh0cmVnaW9uOjg4MGZiZDhjY2RkMDQwMDBiMDQyZDc4ZTY1MGQ3ZjRhXzQx_7146b2da-8763-4fda-9037-ec662e5bc938"
      unitRef="shares">218976000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ic092b803ad4d4d1bb1fc65733358f33f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDgtMS0xLTEtMA_4adf4eeb-782f-4469-b840-04cd32c7291e"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i46e28e4cc5cc4a16bbb2deb97423b415_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDgtMy0xLTEtMA_d1e3f447-fc88-4660-b8b2-b4a7b9e1d175"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i953778adf0344a989190761672294312_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDktMC0xLTEtMC90ZXh0cmVnaW9uOjNjODNjNjllYTU2MDQ0OGFiN2I0NDY1YWI3ZjZjZmQxXzMx_55616155-3ec7-421a-ac0a-b478ed7b291e"
      unitRef="gbpPerShare">1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="icd2e4870b58b4b92961362030330fa39_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDktMC0xLTEtMC90ZXh0cmVnaW9uOjNjODNjNjllYTU2MDQ0OGFiN2I0NDY1YWI3ZjZjZmQxXzMx_9a17a844-2d80-4ee1-a7f3-3ed3a983fec9"
      unitRef="gbpPerShare">1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="icd2e4870b58b4b92961362030330fa39_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDktMC0xLTEtMC90ZXh0cmVnaW9uOjNjODNjNjllYTU2MDQ0OGFiN2I0NDY1YWI3ZjZjZmQxXzQ1_2977bcf2-d1ce-4f10-882a-c5ab1c392980"
      unitRef="shares">50000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="icd2e4870b58b4b92961362030330fa39_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDktMC0xLTEtMC90ZXh0cmVnaW9uOjNjODNjNjllYTU2MDQ0OGFiN2I0NDY1YWI3ZjZjZmQxXzQ1_85d512d3-8fa2-47d0-bf5c-f73ef1190ea0"
      unitRef="shares">50000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i953778adf0344a989190761672294312_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDktMC0xLTEtMC90ZXh0cmVnaW9uOjNjODNjNjllYTU2MDQ0OGFiN2I0NDY1YWI3ZjZjZmQxXzUy_1e13a1a8-2be4-4388-865b-7f809676d1d2"
      unitRef="shares">50000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i953778adf0344a989190761672294312_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDktMC0xLTEtMC90ZXh0cmVnaW9uOjNjODNjNjllYTU2MDQ0OGFiN2I0NDY1YWI3ZjZjZmQxXzUy_cd8d5069-d352-4e4c-9b80-2098c0920c9e"
      unitRef="shares">50000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="icd2e4870b58b4b92961362030330fa39_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDktMS0xLTEtMA_282ef2b1-82d7-49a1-8898-11f71c35ed1c"
      unitRef="usd">63000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i953778adf0344a989190761672294312_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNDktMy0xLTEtMA_87d9439a-8232-49a3-ba35-6878c769116e"
      unitRef="usd">63000</us-gaap:CommonStockValue>
    <rprx:DeferredSharesParOrStatedValuePerShare
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyYmJkZWQ2ZGY4NTRhYTdiNTI2YzRiZmUyYzNmNTIzXzIx_55cdc29a-54b7-4ba6-b4a1-2e62b90da757"
      unitRef="usdPerShare">0.000001</rprx:DeferredSharesParOrStatedValuePerShare>
    <rprx:DeferredSharesParOrStatedValuePerShare
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyYmJkZWQ2ZGY4NTRhYTdiNTI2YzRiZmUyYzNmNTIzXzIx_c3f69ace-07ab-48ba-a9be-11d349ede039"
      unitRef="usdPerShare">0.000001</rprx:DeferredSharesParOrStatedValuePerShare>
    <rprx:DeferredSharesSharesOutstanding
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyYmJkZWQ2ZGY4NTRhYTdiNTI2YzRiZmUyYzNmNTIzXzM1_288614be-6041-44b2-9193-a54ad3886f54"
      unitRef="shares">361170000</rprx:DeferredSharesSharesOutstanding>
    <rprx:DeferredSharesSharesIssued
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyYmJkZWQ2ZGY4NTRhYTdiNTI2YzRiZmUyYzNmNTIzXzM1_da84e14c-2d6a-4459-875d-19e4afe52d5d"
      unitRef="shares">361170000</rprx:DeferredSharesSharesIssued>
    <rprx:DeferredSharesSharesOutstanding
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyYmJkZWQ2ZGY4NTRhYTdiNTI2YzRiZmUyYzNmNTIzXzQy_1b63c73a-0b65-4a49-b491-a794ff401547"
      unitRef="shares">316407000</rprx:DeferredSharesSharesOutstanding>
    <rprx:DeferredSharesSharesIssued
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTAtMC0xLTEtMC90ZXh0cmVnaW9uOjIyYmJkZWQ2ZGY4NTRhYTdiNTI2YzRiZmUyYzNmNTIzXzQy_96b97851-ae58-4833-99ce-2c2f5695021c"
      unitRef="shares">316407000</rprx:DeferredSharesSharesIssued>
    <rprx:DeferredSharesValueIssued
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTAtMS0xLTEtMA_ed119ae8-f4b0-42e3-a9ce-46e157db1e7e"
      unitRef="usd">0</rprx:DeferredSharesValueIssued>
    <rprx:DeferredSharesValueIssued
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTAtMy0xLTEtMA_d376ecda-f8bc-453b-83d6-c69b13dc289e"
      unitRef="usd">0</rprx:DeferredSharesValueIssued>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTEtMS0xLTEtMA_7ede3a2c-5f6d-4bf9-86ae-51888d4eb8c0"
      unitRef="usd">3507533000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTEtMy0xLTEtMA_4ca8eaf5-4ab2-4700-adf1-3531b1eb6d41"
      unitRef="usd">2865964000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTItMS0xLTEtMA_e0e84c37-733d-4f9e-95c8-124ed9e1aa85"
      unitRef="usd">2255179000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTItMy0xLTEtMA_b0e75f42-ad42-4971-88a7-1200e79c2a3a"
      unitRef="usd">1920635000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:MinorityInterest
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTMtMS0xLTEtMA_c741fbd8-fa6c-4980-a467-5e685175fce0"
      unitRef="usd">4471951000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTMtMy0xLTEtMA_d92de564-bda0-41c9-b80c-b637488e9edd"
      unitRef="usd">5077036000</us-gaap:MinorityInterest>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTQtMS0xLTEtMA_79cab78f-96a8-4186-9599-4e263805b2fb"
      unitRef="usd">16491000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTQtMy0xLTEtMA_3e139f17-0ccd-4900-9bee-94fee032c699"
      unitRef="usd">34395000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockValue
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTUtMS0xLTEtMA_8f809412-6531-4ae3-a18d-6fcb2ad00039"
      unitRef="usd">2715000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTUtMy0xLTEtMA_d49e1472-574a-4c85-bdee-61a0667b9e13"
      unitRef="usd">2317000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTctMS0xLTEtMA_2bcadd78-7797-44e8-bc48-84e456012c24"
      unitRef="usd">10248545000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTctMy0xLTEtMA_05cf52c1-ccbf-4a89-97d1-58f5a617e90c"
      unitRef="usd">9895815000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTktMS0xLTEtMA_668d0321-bffe-4c4f-bdc7-34b12f566098"
      unitRef="usd">17515865000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185Ny9mcmFnOjNmMTVlYjk3NWU3NTRlM2I4ZDhlZTBiZDJjMGE2M2IwL3RhYmxlOjFlYWIyNDRiY2U3OTQ4MTM4NjE1MThlMDM3MDJkZmQ3L3RhYmxlcmFuZ2U6MWVhYjI0NGJjZTc5NDgxMzg2MTUxOGUwMzcwMmRmZDdfNTktMy0xLTEtMA_1d929fac-64c6-4c29-968e-1d211ebd2f48"
      unitRef="usd">16020286000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="ie1bd23e9eb02461c8e78d787a6ed33aa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUtMS0xLTEtMA_d7f9d108-995d-4f5a-9de1-6f98862350d4"
      unitRef="usd">2065083000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i25b8e421f3694fbcaafdb0d3eaa6b71f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUtMy0xLTEtMA_bb496438-2e56-41df-9520-9ba9c556408a"
      unitRef="usd">1959975000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i22755b6a900743c384bc4e39a0795f90_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUtNS0xLTEtMA_9c95793b-1c6f-4051-8e9f-bb148583deb9"
      unitRef="usd">1648837000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1452e9acf8c84b5fa30c3213757d431e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzYtMS0xLTEtMA_6f369ba2-dadf-41a5-82f5-d11644e5343b"
      unitRef="usd">171248000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0297e01d516f433c9c55632b22b93b76_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzYtMy0xLTEtMA_382de8f3-23d1-4466-9273-de041fd4cbbe"
      unitRef="usd">143382000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i16e458adecdb45bfbf9b94d5656d1d13_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzYtNS0xLTEtMA_32060125-99d9-4d7f-9830-e1f1c1821d5d"
      unitRef="usd">145775000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib8996266cd2b47c186f6cb14ad934f59_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzctMS0xLTEtMzY4MzM_fb443aa6-7582-4c99-a35d-6d79135e4777"
      unitRef="usd">53132000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2caa252cd23b45869207612ea8852d80_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzctMy0xLTEtMzcwMDE_879623a2-345f-4bd4-b3e9-e53b0972930c"
      unitRef="usd">18996000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i20e6b58350b843a5b8d17f5da029afa2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzctNS0xLTEtMA_5f9e3718-913c-4e77-a42b-23c936c4f297"
      unitRef="usd">19642000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzgtMi0xLTEtMzY4MDQ_5441155e-13ee-463e-a6f6-6aecfbe883d1"
      unitRef="usd">2289463000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzgtMy0xLTEtMzcwMDE_6c397d08-0b1a-4740-bfd3-aac48fa112ac"
      unitRef="usd">2122353000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzgtNS0xLTEtMA_2a49f9d1-0c49-4993-88b8-c744a7f34869"
      unitRef="usd">1814254000</us-gaap:Revenues>
    <us-gaap:ProvisionForLoanAndLeaseLosses
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzExLTEtMS0xLTM3MDIx_682ff3e7-dcb3-4367-a9b9-835f0b2b9c51"
      unitRef="usd">452842000</us-gaap:ProvisionForLoanAndLeaseLosses>
    <us-gaap:ProvisionForLoanAndLeaseLosses
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzExLTMtMS0xLTM3MDAx_3d2df153-0789-4b59-a2d8-b0ee0139331b"
      unitRef="usd">230839000</us-gaap:ProvisionForLoanAndLeaseLosses>
    <us-gaap:ProvisionForLoanAndLeaseLosses
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzExLTUtMS0xLTM2OTI4_c2664419-f1a9-49df-8b03-920d58c64efe"
      unitRef="usd">-1019321000</us-gaap:ProvisionForLoanAndLeaseLosses>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzExLTEtMS0xLTA_c562cbc5-52f0-4cf0-83be-bfeecdbc6cb9"
      unitRef="usd">200084000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzExLTMtMS0xLTA_6f001109-e874-420c-9a35-8b29a07cc5a9"
      unitRef="usd">26289000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzExLTUtMS0xLTA_8713a984-c233-4006-bb62-2065edc4f60d"
      unitRef="usd">83036000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzEzLTEtMS0xLTA_60d65e7b-8449-4427-b051-6ee2e0810e76"
      unitRef="usd">22996000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzEzLTMtMS0xLTA_e5861b70-80d6-4377-bb62-31ca3387259e"
      unitRef="usd">23058000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzEzLTUtMS0xLTA_7aba3d47-ec0e-47a5-859b-edb28b8aa726"
      unitRef="usd">23924000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzE0LTEtMS0xLTA_93c7767e-a445-4abc-ba3e-abca276dabdf"
      unitRef="usd">182826000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzE0LTMtMS0xLTA_179abb64-ff15-4d2d-9b4e-825ec7e88f50"
      unitRef="usd">181715000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzE0LTUtMS0xLTA_fe8189ef-485f-48af-b3e2-d46d0053665f"
      unitRef="usd">103439000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzE1LTEtMS0xLTM3MDIx_04e243ba-1c06-4b59-800c-c39dfde5602d"
      unitRef="usd">0</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzE1LTMtMS0xLTM3MDAx_20ac799a-1363-4761-9b17-6eeb54c7e1cc"
      unitRef="usd">65053000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzE1LTUtMS0xLTA_269145df-bd27-4f6d-aa27-f11710a812eb"
      unitRef="usd">0</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:CostsAndExpenses
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzE2LTEtMS0xLTA_bf05ff64-b96d-432a-9f8f-699f955c4aaa"
      unitRef="usd">858748000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzE2LTMtMS0xLTA_bdbbf7e8-d78f-41a7-8bc5-0be6c0dcd283"
      unitRef="usd">526954000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzE2LTUtMS0xLTA_10d1698c-0260-489a-b1c6-05f3bbcce481"
      unitRef="usd">-808922000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzE4LTItMS0xLTM2ODA0_69aa1202-fb9a-4524-9246-2aeb2235097b"
      unitRef="usd">1430715000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzE4LTMtMS0xLTM3MDAx_7cb4b9e4-45cf-46f0-be34-a54247c4b682"
      unitRef="usd">1595399000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzE4LTUtMS0xLTA_c74cb7c4-8f30-4922-af0d-78911dacb4c1"
      unitRef="usd">2623176000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzIxLTEtMS0xLTA_78caa8fe-0a11-41fc-8486-e5487af73e5e"
      unitRef="usd">-19490000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzIxLTMtMS0xLTA_19e7a566-d9aa-426a-b5ac-954e7f58a523"
      unitRef="usd">44459000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzIxLTUtMS0xLTA_f576a628-b5ed-4aa4-bd8c-e714ca8ca692"
      unitRef="usd">-32517000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:InterestExpense
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzIyLTEtMS0xLTA_f68662f9-5956-4a1d-8cc7-962fa28dd265"
      unitRef="usd">166142000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzIyLTMtMS0xLTA_89542fc8-086b-46d7-8da3-503a6282f3c9"
      unitRef="usd">157059000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzIyLTUtMS0xLTA_f5a52cfd-99e2-4b51-90b0-70abf2cae4f5"
      unitRef="usd">268573000</us-gaap:InterestExpense>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI0LTEtMS0xLTA_9e6b24fb-041d-4658-82eb-af4b190702fe"
      unitRef="usd">-21532000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI0LTMtMS0xLTA_2060d33c-4858-4ebc-8c43-f652741e2a44"
      unitRef="usd">-42076000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI0LTUtMS0xLTA_7d37cf5d-f803-459d-bb83-365dcc08d2bc"
      unitRef="usd">-39138000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI1LTEtMS0xLTA_746543ba-69a9-4e9a-aeee-5aa3a9247ffc"
      unitRef="usd">-48066000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI1LTMtMS0xLTA_1c84e893-651f-48ac-82d1-655cdf511651"
      unitRef="usd">247073000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI1LTUtMS0xLTA_16b18594-ad04-4e7f-ab4c-d555bb850fe4"
      unitRef="usd">155749000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI3LTEtMS0xLTA_633d886b-58ad-4f6f-a9a7-461ab31ca16e"
      unitRef="usd">17859000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI3LTMtMS0xLTA_3b93c519-f4f9-42b2-a325-9941bbeee720"
      unitRef="usd">18600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI3LTUtMS0xLTA_b8c1255a-4e11-49f4-adf3-54445946121f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI4LTEtMS0xLTA_19a68bce-149f-4916-8790-fc8746bb5b12"
      unitRef="usd">53535000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI4LTMtMS0xLTA_1a7acb1c-568b-4c6d-9d69-e84e68635eab"
      unitRef="usd">28379000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI4LTUtMS0xLTA_c93a5dd9-3e16-4d0d-bf0f-d00552861dbd"
      unitRef="usd">22329000</us-gaap:InvestmentIncomeNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI5LTEtMS0xLTA_51b75f31-6849-4c43-b682-71e82c46a14b"
      unitRef="usd">-5678000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI5LTMtMS0xLTA_739bfb87-690c-4e23-bbb8-fc1b15165d9e"
      unitRef="usd">-32821000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzI5LTUtMS0xLTA_4a0da83d-0c9b-44cb-a473-4763b371b309"
      unitRef="usd">393000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzMwLTEtMS0xLTA_c106593c-8118-42fa-a654-3214f40ea1b4"
      unitRef="usd">-189514000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzMwLTMtMS0xLTA_9dc9ea89-5f24-4563-9ec4-d655690aa987"
      unitRef="usd">106555000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzMwLTUtMS0xLTA_20751982-e1c6-4099-b5ce-65fd83146a37"
      unitRef="usd">-161757000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzMxLTEtMS0xLTA_ed3a0269-fa84-477f-a0a1-959f29dd499c"
      unitRef="usd">1241201000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzMxLTMtMS0xLTA_161535f8-40d6-4ece-8a24-adde66b17e28"
      unitRef="usd">1701954000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzMxLTUtMS0xLTA_7de9195b-8f31-4fa3-92db-65845245c683"
      unitRef="usd">2461419000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzMyLTEtMS0xLTM3MDIx_94b6e703-c2ae-40f8-913c-7bd7d6732d6d"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzMyLTMtMS0xLTM3MDAx_53670c97-2362-45d9-ad22-1ed8afc89ba9"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzMyLTUtMS0xLTA_0a797dd6-aa8b-41d6-8984-219ecc269171"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzMzLTEtMS0xLTA_e566b9a8-907e-4b0a-80b9-20f3ab3d3028"
      unitRef="usd">1241201000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzMzLTMtMS0xLTA_dfb93ba0-8888-43dd-83d7-e7bf59953ef5"
      unitRef="usd">1701954000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzMzLTUtMS0xLTA_e29ceb65-973c-4f1e-b5f2-911a115b0028"
      unitRef="usd">2461419000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzM1LTEtMS0xLTA_afad235f-8878-44a6-b7b3-1f495e57b92a"
      unitRef="usd">621473000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzM1LTMtMS0xLTA_dc657c8d-3e09-42bb-95c6-e25de3034299"
      unitRef="usd">726914000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzM1LTUtMS0xLTA_2b5d0d32-e586-4a76-ade9-9b7a3ffc3073"
      unitRef="usd">112884000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzM3LTItMS0xLTM2ODA0_fe0ef37d-eef5-481b-abfb-3a53cf1bf7bd"
      unitRef="usd">619728000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzM3LTMtMS0xLTM3MDAx_fa77b827-7d41-4e73-9512-41a488ab71dc"
      unitRef="usd">975040000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzM3LTUtMS0xLTA_2cdc224f-9de0-448e-b5a1-23e990b1057d"
      unitRef="usd">2348535000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUyLTEtMS0xLTA_4ebc0264-fc9b-41e8-bd70-756d832684b4"
      unitRef="usdPerShare">1.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUyLTMtMS0xLTA_76e4811f-8f61-4261-8b05-1bb3b6605340"
      unitRef="usdPerShare">1.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUzLTEtMS0xLTA_c5f85727-ab8f-46b3-91e4-92ac158a0433"
      unitRef="usdPerShare">1.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUzLTMtMS0xLTA_a435e31d-dffb-4b96-ba18-64e6deef6779"
      unitRef="usdPerShare">1.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzU1LTEtMS0xLTM3MDIx_4990eee5-dee5-4619-8a5d-ff70d21298b6"
      unitRef="shares">414794000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzU1LTMtMS0xLTM3MDAx_492268b9-a345-4c82-840d-920ff3e1f7c8"
      unitRef="shares">375444000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzU2LTEtMS0xLTM3MDIx_5072f657-16e7-4822-913b-4fa5624a9150"
      unitRef="shares">414802000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzU2LTMtMS0xLTM3MDAx_e03bcac5-4b4c-4b66-a2e9-e6f0e4129fe4"
      unitRef="shares">375455000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzItMS0xLTEtNjY1Nzg_e566b9a8-907e-4b0a-80b9-20f3ab3d3028"
      unitRef="usd">1241201000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzItMy0xLTEtNjY1Nzg_dfb93ba0-8888-43dd-83d7-e7bf59953ef5"
      unitRef="usd">1701954000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzItNS0xLTEtNjY1Nzg_e29ceb65-973c-4f1e-b5f2-911a115b0028"
      unitRef="usd">2461419000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzMtMS0xLTEtNjY1NTE_28c266ab-8903-484d-8f86-9982dec4d103"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzMtMy0xLTEtNjY1NTE_3deaf153-afdd-4fc9-8879-3a2273a9b319"
      unitRef="usd">4066000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzMtNS0xLTEtNjY1NTE_755a87b9-b311-4660-b7ae-7f736f860286"
      unitRef="usd">6189000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzUtMS0xLTEtNjY1NTE_269b8b48-1935-42c5-aae3-9ce0ba57bed0"
      unitRef="usd">11600000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzUtMy0xLTEtNjY1NTE_c43871a4-faa8-4c45-81e5-23715ff2302a"
      unitRef="usd">83120000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzUtNS0xLTEtNjY1NTE_6824b867-8ddf-4a36-b3ee-707f31bba080"
      unitRef="usd">6159000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzYtMS0xLTEtNjY1NTE_f0dfd6aa-c820-4aee-a675-aad79beb01e2"
      unitRef="usd">50896000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzYtMy0xLTEtNjY1NTE_4d73328a-f720-41e9-925c-2c6a42318b1d"
      unitRef="usd">20551000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzYtNS0xLTEtNjY1NTE_5ab54148-8dd1-418d-b990-c80b5dd16e82"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzctMS0xLTEtNjY1NTE_a15b5631-bf4e-4310-8479-b111e695d943"
      unitRef="usd">-39296000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzctMy0xLTEtNjY1NTE_6447e9d7-a39c-4b18-a309-d65f1a6e751f"
      unitRef="usd">66635000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzctNS0xLTEtNjY1NTE_257c08de-2f2b-4db7-acdb-7d24965ea219"
      unitRef="usd">12348000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzgtMS0xLTEtNjY1NTE_00e38a34-63c2-4691-a5e0-052128e4bc2c"
      unitRef="usd">1201905000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzgtMy0xLTEtNjY1NTE_54838f41-7469-4a6d-b34c-41409ca2de79"
      unitRef="usd">1768589000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzgtNS0xLTEtNjY1NTE_310a6987-8494-457d-84a0-c5fd9acbc52d"
      unitRef="usd">2473767000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzEwLTEtMS0xLTY2NTUx_a14dea50-ef52-4b29-acd2-4db581ba9a19"
      unitRef="usd">604323000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzEwLTMtMS0xLTY2NTUx_aa6135af-6a9e-438e-a6e7-731055529071"
      unitRef="usd">739787000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzEwLTUtMS0xLTY2NTUx_c912c2fc-2830-4c7b-b066-76d61447b480"
      unitRef="usd">112884000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzEzLTEtMS0xLTY2NTUx_d0e04871-444a-4e17-b1a6-c57f5a0ed7b0"
      unitRef="usd">597582000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzEzLTMtMS0xLTY2NTUx_01dac687-1458-4f65-aff1-25d02f2deea6"
      unitRef="usd">1028802000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY185NDIvZnJhZzozNjM1MWY3MThlMTY0NTgyOTE1ZmRlZTczOTAyZDhlMi90YWJsZTowNjU4ZDVhOWM1NTI0MmUyOTE4MGRiYWI5NjdmYTc2YS90YWJsZXJhbmdlOjA2NThkNWE5YzU1MjQyZTI5MTgwZGJhYjk2N2ZhNzZhXzEzLTUtMS0xLTY2NTUx_f3307db6-38a2-42e8-bbe1-5926f4337bad"
      unitRef="usd">2360883000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i7242e01e0d3e49c99430b9b17185b69d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEtMS0xLTEtMA_b1791aee-9e18-4402-98cc-c6aca61ab7cf"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7242e01e0d3e49c99430b9b17185b69d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEtMi0xLTEtMA_7bb659f7-d8ae-4b00-aa4d-836ba7e48294"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i21cc13814c2346169554442b708375ad_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEtMy0xLTEtMA_486c8af2-d86c-4810-936a-2918869b6331"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i21cc13814c2346169554442b708375ad_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEtNC0xLTEtMA_84c99cd7-497c-445d-86f9-acaa6d3a13f5"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i4278e9fc64b540edb08bf8d281986583_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEtNS0xLTEtMA_94702175-822b-4e75-81a8-b02ce601ea8e"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4278e9fc64b540edb08bf8d281986583_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEtNi0xLTEtMA_50116f3d-edfd-4414-922d-09ad20213be1"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="icc6628a62f9e40b48736982ad0adfbee_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzItNy0xLTEtMzcyNzA_bc490fb3-37ef-4cc6-be0b-4fdc1819004f"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc6628a62f9e40b48736982ad0adfbee_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzItOC0xLTEtMzcyNzA_40db2132-3e48-4680-96e8-8545592544f1"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieb893068fb11474089dc46eccc39ab67_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzItOS0xLTEtMzcyNzA_c6175435-89da-4853-8cb9-aeb0dd8750ce"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibab3544b72654443a832b73062c67deb_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzItMTAtMS0xLTM3Mjcw_b22a4497-3bf6-4a2c-9c46-09442b088d8a"
      unitRef="usd">3282516000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2d606c35a9d1498aa2be490653c9ef76_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzItMTEtMS0xLTM3Mjcw_ba513724-8eea-421f-9936-03bd285a0670"
      unitRef="usd">1215953000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i83390defcd6345cb9ec5d13109b97307_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzItMTItMS0xLTM3Mjcw_c6ba3841-ffa9-4215-8cbb-e71ef42fc368"
      unitRef="usd">-10255000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia43c5365c0cb479391cb94db6dca5463_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzItMTMtMS0xLTM3Mjcw_3f47f019-dfdf-4409-9d42-8fcf36b7313d"
      unitRef="usd">63865000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifd82d6eb2e3a47a7b8091e80bc813a3b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzItMTQtMS0xLTM3Mjcw_f2895f21-6a61-40a9-aae2-34f5a3814661"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa26755fbc5e413fbf3122ec0db17370_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzItMTUtMS0xLTM3Mjcw_b275cdce-e3ff-4b00-9cd5-25a36a5918af"
      unitRef="usd">4552079000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ibb8081ea351a4070b344194caa18eee3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzMtMTEtMS0xLTM3Mjcw_19c533c4-0f6a-47a0-81d7-ee2f0105d040"
      unitRef="usd">739276000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="id719b4a4fe4147c580198f101363e139_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzMtMTMtMS0xLTM3Mjcw_d7b4ec79-eb49-4d65-bf65-a8cd141e856c"
      unitRef="usd">140866000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzMtMTUtMS0xLTM3Mjcw_0436376c-5416-4165-b2c7-2e7687dfb163"
      unitRef="usd">880142000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="ibb8081ea351a4070b344194caa18eee3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzQtMTEtMS0xLTM3Mjcw_b6e4436b-8c4f-4e06-9cad-fad2a657ab1a"
      unitRef="usd">2348535000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id719b4a4fe4147c580198f101363e139_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzQtMTMtMS0xLTM3Mjcw_eb23b964-11fe-49c7-8891-9f1d3bc7f284"
      unitRef="usd">112884000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzQtMTUtMS0xLTM3Mjcw_32a0882d-a2d0-4103-8d13-a0f8e049b7d2"
      unitRef="usd">2461419000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9aba922b7da5469cb7d51eeaebbde78c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzYtMTItMS0xLTM3Mjcw_426e79ad-7558-4e15-8457-66b817e40a20"
      unitRef="usd">6159000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzYtMTUtMS0xLTM3Mjcw_af4b81d9-573a-40fd-99c8-8b062fc63e9e"
      unitRef="usd">6159000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
      contextRef="i9aba922b7da5469cb7d51eeaebbde78c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzctMTItMS0xLTM3Mjcw_ca8a5044-7c24-4e7c-8415-87c13fbddf8a"
      unitRef="usd">6189000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzctMTUtMS0xLTM3Mjcw_28acc450-cb1c-4bad-a7c0-6266482d4aab"
      unitRef="usd">6189000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i82e5c0912520456188cd5703e13cd8ec_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzgtMTQtMS0xLTM3Mjcw_84de8752-d2fb-4b40-9ad5-e800050905bf"
      unitRef="usd">4266000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzgtMTUtMS0xLTM3Mjcw_ddcd294f-07e9-4485-8a02-b00daf39d0a8"
      unitRef="usd">4266000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:SharesOutstanding
      contextRef="i8a4cf2dc46aa4a0b98fcc0c810dc8893_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzgtMS0xLTEtMA_626b2d1b-bc49-4b76-bc2b-1d73902a0906"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8a4cf2dc46aa4a0b98fcc0c810dc8893_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzgtMi0xLTEtMA_b8bf4fcb-b24b-434e-bd3a-02933ab3c07b"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i580d0bd186a14217bc04733016854e77_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzgtMy0xLTEtMA_721ada7a-05d4-4c39-8efc-1fac7a7d9332"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i580d0bd186a14217bc04733016854e77_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzgtNC0xLTEtMA_b53106f2-5a39-42b3-a928-75877ec28fc0"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i19b48e73113548da88d30125b457bca0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzgtNS0xLTEtMA_4312ab99-42e3-45f1-8243-d6e95e7b4796"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i19b48e73113548da88d30125b457bca0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzgtNi0xLTEtMA_69b6dbe4-fec3-4181-9b3b-b9bc885062cb"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i7e3a705f76b44890a7020ab2ae505a43_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzktNy0xLTEtMzcyNzA_d6b2546c-3612-4d9b-826d-95e861681bcc"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7e3a705f76b44890a7020ab2ae505a43_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzktOC0xLTEtMzcyNzA_bb5066df-a8a6-48bf-850d-0484ff255a91"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i315143a2dcd345708f419d259a93d568_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzktOS0xLTEtMzcyNzA_dcab93fc-f4d3-4839-ac22-3b0b33a3d581"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if3ecbb7d51644c5aad611d5a9b22c148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzktMTAtMS0xLTM3Mjcw_9435a66a-f2bc-40c4-8df2-b5bdfd5699c5"
      unitRef="usd">3282516000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i830800ad2baf473c9739d42417c534c6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzktMTEtMS0xLTM3Mjcw_e2babe8d-fe04-4605-80e6-90d2db2d65ab"
      unitRef="usd">2825212000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i602e6cc9310d4444b6d71a94d4089ae5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzktMTItMS0xLTM3Mjcw_7bc81f7f-4e34-41cb-bd2b-51f9f697827e"
      unitRef="usd">2093000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i66a738c1e19d441f908f46dd78470217_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzktMTMtMS0xLTM3Mjcw_83beea66-1344-4401-ac48-8d9e1c6491e6"
      unitRef="usd">35883000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3ff6f34aeece4e29977f6ac850691398_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzktMTQtMS0xLTM3Mjcw_24a2e5a4-9842-435c-ad56-54299ba7dd8b"
      unitRef="usd">-4266000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id30f26bcb6cd4b64982e6cd53528c44e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzktMTUtMS0xLTM3Mjcw_e3485d66-1a3a-4ce5-bf7c-4e5071053ef4"
      unitRef="usd">6141438000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i94ea8958cd1e4ee696d732dd9a041dca_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEwLTEwLTEtMS0zNzI3MA_bcd99630-6c96-4dac-94fa-a7b3d824158c"
      unitRef="usd">307646000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEwLTEzLTEtMS0zNzI3MA_12afbf5f-2235-4080-8738-093790ce8bde"
      unitRef="usd">1174676000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEwLTE1LTEtMS0zNzI3MA_ccd1a049-fee3-428f-8b26-67632c7500d9"
      unitRef="usd">1482322000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestTransfersOfInterests
      contextRef="i94ea8958cd1e4ee696d732dd9a041dca_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzExLTEwLTEtMS0zNzI3MA_c3b840de-13cc-423d-b99e-556da9def24e"
      unitRef="usd">-1037161000</rprx:NoncontrollingInterestTransfersOfInterests>
    <rprx:NoncontrollingInterestTransfersOfInterests
      contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzExLTEzLTEtMS0zNzI3MA_846577ff-caad-433a-a76c-1445626ee5a1"
      unitRef="usd">1037161000</rprx:NoncontrollingInterestTransfersOfInterests>
    <rprx:NoncontrollingInterestTransfersOfInterests
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzExLTE1LTEtMS0zNzI3MA_a41146f0-8d78-4835-87ee-5fff6fc1cdd3"
      unitRef="usd">0</rprx:NoncontrollingInterestTransfersOfInterests>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib04d3453e6dc4ca3a0b79e01ab3fe12a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEyLTExLTEtMS0zNzI3MA_c11a1dc1-0340-4e47-bf51-3b9879ef58a3"
      unitRef="usd">-192705000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie7ab9fefed164e08ac6ad01d99d06780_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEyLTE1LTEtMS0zNzI3MA_87f3d236-8056-4bc6-96ca-35331a36f003"
      unitRef="usd">-192705000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i2e6f9f489a134c76840c0b3b1b1954e4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEzLTExLTEtMS0zNzI3MA_47b83a4c-46fb-4fd4-9442-7fc80a3bed18"
      unitRef="usd">313408000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEzLTEzLTEtMS0zNzI3MA_d9c78a6b-65f0-4986-9105-0d13862780bb"
      unitRef="usd">792357000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEzLTE1LTEtMS0zNzI3MA_d4a88cc2-e9a5-4cea-b14c-f3ed99649f62"
      unitRef="usd">1105765000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <rprx:StockIssuedDuringPeriodSharesIssuedForRegistration
      contextRef="i7b0efd440f45499a9d75e2fbc4ff25a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEzLTUtMS0xLTA_7980ea38-0cc5-44f5-9c0d-d7f313e671d1"
      unitRef="shares">50000</rprx:StockIssuedDuringPeriodSharesIssuedForRegistration>
    <rprx:StockIssuedDuringPeriodValueIssuedForRegistration
      contextRef="i7b0efd440f45499a9d75e2fbc4ff25a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzEzLTYtMS0xLTA_f61f20bb-f51c-42ac-bfbd-be6534fd3901"
      unitRef="usd">63000</rprx:StockIssuedDuringPeriodValueIssuedForRegistration>
    <rprx:StockIssuedDuringPeriodValueIssuedForRegistration
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE0LTE1LTEtMS0zNzI3MA_27aad126-a66e-4f14-81d0-fd46f7a2b54a"
      unitRef="usd">63000</rprx:StockIssuedDuringPeriodValueIssuedForRegistration>
    <us-gaap:ProfitLoss
      contextRef="i3422c7350bb14d2d869ff498fa12e855_D20200101-20200617"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE1LTExLTEtMS0zNzI3MA_0aaaac18-a545-4571-8710-4a2dfd238f08"
      unitRef="usd">479842000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i76f06ecc81464fc3ba1731d5296c531a_D20200101-20200617"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE1LTEzLTEtMS0zNzI3MA_e7b60033-26c3-447c-998a-adab0bc57230"
      unitRef="usd">145043000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7594b0b1464b4340a377c43cf71ef3c9_D20200101-20200617"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE1LTE1LTEtMS0zNzI3MA_1ac45b32-c644-472e-ae8a-e48cdd8b9125"
      unitRef="usd">624885000</us-gaap:ProfitLoss>
    <rprx:StockIssuedDuringPeriodSharesIssuedToPartnerships
      contextRef="i7d52a6096c48447f93a4da355c6da2e3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE1LTMtMS0xLTA_57da9f03-e093-43ce-866c-bccfce8a2579"
      unitRef="shares">535383000</rprx:StockIssuedDuringPeriodSharesIssuedToPartnerships>
    <rprx:StockIssuedDuringPeriodValueIssuedToPartnerships
      contextRef="i7d52a6096c48447f93a4da355c6da2e3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE1LTQtMS0xLTA_eb41c81a-b3ae-4ad1-9f30-d3e1f0702e78"
      unitRef="usd">1000</rprx:StockIssuedDuringPeriodValueIssuedToPartnerships>
    <rprx:StockIssuedDuringPeriodValueIssuedToPartnerships
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE2LTE1LTEtMS0zNzI3MA_0077ff86-44e7-4bec-8b1c-5aeb5748a1a1"
      unitRef="usd">1000</rprx:StockIssuedDuringPeriodValueIssuedToPartnerships>
    <rprx:StockholdersEquitySharesEffectOfExchangeAndReallocation
      contextRef="i4f4f3dd76bcf49369de9f193a116d553_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE3LTEtMS0xLTM3Mjcw_27a51168-4d70-4cec-bbf0-78567762c41b"
      unitRef="shares">294176000</rprx:StockholdersEquitySharesEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="i4f4f3dd76bcf49369de9f193a116d553_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE3LTItMS0xLTM3Mjcw_2cfd4ddc-613a-48cc-94e4-9147624bdaae"
      unitRef="usd">30000</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquitySharesEffectOfExchangeAndReallocation
      contextRef="i7d52a6096c48447f93a4da355c6da2e3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE3LTMtMS0xLTM3Mjcw_745d180f-f119-49ec-905a-6245dabadfdf"
      unitRef="shares">-294176000</rprx:StockholdersEquitySharesEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="i7d52a6096c48447f93a4da355c6da2e3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE3LTQtMS0xLTM3Mjcw_5d9ca4d7-6ea4-4fe5-8a56-d07bb7b913a4"
      unitRef="usd">-1000</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquitySharesEffectOfExchangeAndReallocation
      contextRef="i6a9ba8c328db404aa63b9d27dabe97d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE3LTctMS0xLTM3Mjcw_73dd1f9e-7b98-4dda-a2a5-43a22639e1ba"
      unitRef="shares">294176000</rprx:StockholdersEquitySharesEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="ia045aaf00ae04e51a9df144d9df23caf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE3LTktMS0xLTM3Mjcw_e9b0ad63-c013-4075-a502-6fb144017776"
      unitRef="usd">1402762000</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="i94ea8958cd1e4ee696d732dd9a041dca_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE3LTEwLTEtMS0zNzI3MA_9ccc0d96-9348-40dc-934c-271fdafacbfd"
      unitRef="usd">-2553001000</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="i2e6f9f489a134c76840c0b3b1b1954e4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE3LTExLTEtMS0zNzI3MA_35ec0a3a-845a-4070-bcbe-5c6f1ff47d37"
      unitRef="usd">-1261014000</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="ic835f9f0906c4a4cb5e88b614197540b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE3LTEyLTEtMS0zNzI3MA_cdeb575d-f2c6-47d0-b319-8ee0293b36a6"
      unitRef="usd">-24022000</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE3LTEzLTEtMS0zNzI3MA_678c483c-fce2-4122-af58-b1d15b2bbf34"
      unitRef="usd">2433098000</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="i2120ee6be2e44acca10b4f204c1cddf2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE3LTE0LTEtMS0zNzI3MA_ff8a9362-499c-4270-acad-0a16cbb0be4c"
      unitRef="usd">2147000</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE3LTE1LTEtMS0zNzI3MA_12e46f7e-a0d8-4148-be04-d519ef6c05c2"
      unitRef="usd">-1000</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i4f4f3dd76bcf49369de9f193a116d553_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE4LTEtMS0xLTM3Mjcw_cc810a82-5d5b-44e3-9fa5-5f11af9316d6"
      unitRef="shares">71652000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4f4f3dd76bcf49369de9f193a116d553_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE4LTItMS0xLTM3Mjcw_14dfdbd7-65df-47ae-a1c0-51a664dd57d9"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia045aaf00ae04e51a9df144d9df23caf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE4LTktMS0xLTM3Mjcw_42d53772-7b41-4aeb-a503-5a82c987701f"
      unitRef="usd">1150383000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE4LTEzLTEtMS0zNzI3MA_61154fbd-3b53-4eb3-a154-d3c43ac07961"
      unitRef="usd">758354000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzE4LTE1LTEtMS0zNzI3MA_d5358dd6-3e7c-4527-9c40-2753c6468415"
      unitRef="usd">1908744000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i4f4f3dd76bcf49369de9f193a116d553_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIwLTEtMS0xLTM3Mjcw_30bb0aa6-82c3-41ff-a7f1-2b67c2bf5101"
      unitRef="shares">76000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia045aaf00ae04e51a9df144d9df23caf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIwLTktMS0xLTM3Mjcw_e5833cd0-37db-4ea3-98d4-65fb35ae96f5"
      unitRef="usd">5428000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIwLTE1LTEtMS0zNzI3MA_9b3ae0a2-a30f-493c-9e57-13bcd9f7281d"
      unitRef="usd">5428000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i4f4f3dd76bcf49369de9f193a116d553_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIxLTEtMS0xLTM3Mjcw_16109214-55f9-4270-a8b6-2c13a6c606a4"
      unitRef="shares">22231000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i4f4f3dd76bcf49369de9f193a116d553_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIxLTItMS0xLTM3Mjcw_b64671e4-9b53-42a6-b670-5118c6f27d47"
      unitRef="usd">-2000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i7d52a6096c48447f93a4da355c6da2e3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIxLTMtMS0xLTM3Mjcw_02f8ad61-bbac-4d6a-b60d-9a79efc653bc"
      unitRef="shares">-22231000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i6a9ba8c328db404aa63b9d27dabe97d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIxLTctMS0xLTM3Mjcw_f49f0e23-6326-4f55-a1d7-3292a2a7f00d"
      unitRef="shares">22231000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="ia045aaf00ae04e51a9df144d9df23caf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIxLTktMS0xLTM3Mjcw_04493c88-d7c2-4f34-b38e-abb92545ea3f"
      unitRef="usd">-307391000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ic835f9f0906c4a4cb5e88b614197540b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIxLTEyLTEtMS0zNzI3MA_c4e57dd6-8918-4e0c-9820-55265ca77375"
      unitRef="usd">-2562000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIxLTEzLTEtMS0zNzI3MA_e7836cf6-c64b-41fe-96ed-856deb365e5f"
      unitRef="usd">309566000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i2120ee6be2e44acca10b4f204c1cddf2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIxLTE0LTEtMS0zNzI3MA_06f6d96a-158f-497a-953c-eac2773a145d"
      unitRef="usd">198000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIxLTE1LTEtMS0zNzI3MA_8940947d-c6fc-4968-ac4e-93a86d9b8d06"
      unitRef="usd">-191000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIxLTAtMS0xLTM3MTQ4L3RleHRyZWdpb246YWJiNWMxZGQxZTcxNGE5MzgxZjhmNjM2ZTIxZDQ3ZTVfMjc0ODc3OTA2OTUyMg_2681dd54-02b9-434f-bf43-46f8804f9d01"
      unitRef="usdPerShare">0.30</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCash
      contextRef="i2e6f9f489a134c76840c0b3b1b1954e4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIyLTExLTEtMS0zNzI3MA_d7ee22c1-2302-4204-a9f0-bc2b5c068941"
      unitRef="usd">112490000</us-gaap:DividendsCash>
    <us-gaap:DividendsCash
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIyLTE1LTEtMS0zNzI3MA_d1620864-6ca3-48c3-9a34-b340c746da96"
      unitRef="usd">112490000</us-gaap:DividendsCash>
    <us-gaap:ProfitLoss
      contextRef="ief437e0dfe9a4e449e52e28b7c5f4b71_D20200618-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIzLTExLTEtMS0zNzI3MA_3d2217ac-c80f-4fc2-9a87-b94c37db4793"
      unitRef="usd">495198000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id19e65b6c08c41b59cd152b688647d77_D20200618-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIzLTEzLTEtMS0zNzI3MA_63855a8e-0d72-4b24-87c0-f4f1c1782e2b"
      unitRef="usd">581871000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie1399e8120f4459da1c98eaec460657b_D20200618-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzIzLTE1LTEtMS0zNzI3MA_afbceb8b-2ed7-46df-8e42-bbcb6d6f7557"
      unitRef="usd">1077069000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
      contextRef="ic835f9f0906c4a4cb5e88b614197540b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI1LTEyLTEtMS0zNzI3MA_13d627a3-789c-4174-bd80-feae5b994cbf"
      unitRef="usd">4066000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI1LTE1LTEtMS0zNzI3MA_5d031770-4e5d-4f78-bd1e-fd9e59de2d26"
      unitRef="usd">4066000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic835f9f0906c4a4cb5e88b614197540b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI2LTEyLTEtMS0zNzI3MA_fa3f8d01-15bc-4f00-9192-e6d491cf57f4"
      unitRef="usd">60617000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI2LTEzLTEtMS0zNzI3MA_df065952-eb40-41a4-bf18-7dce290de353"
      unitRef="usd">22503000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI2LTE1LTEtMS0zNzI3MA_ec92eb58-dc4f-4e8b-babf-ae4587f0977d"
      unitRef="usd">83120000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ic835f9f0906c4a4cb5e88b614197540b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI3LTEyLTEtMS0zNzI3MA_d2d88965-731e-4230-bd65-9d881a01a71a"
      unitRef="usd">10921000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI3LTEzLTEtMS0zNzI3MA_1834ea4a-715d-40da-aa75-b6de201415be"
      unitRef="usd">9630000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI3LTE1LTEtMS0zNzI3MA_8d331261-6824-455c-9401-89dd32c24949"
      unitRef="usd">20551000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i026910ef30a142baa787995540a3555f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTEtMS0xLTM3Mjcw_536762ff-e6d8-49ff-8f8c-e33b46093578"
      unitRef="shares">388135000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i026910ef30a142baa787995540a3555f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTItMS0xLTM3Mjcw_1abdb801-be92-4d0d-89b9-f7fd9dbb2636"
      unitRef="usd">39000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i00c7c0edff0e4ac2a68115eef01ff73d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTMtMS0xLTM3Mjcw_83b8cf42-3dff-48f7-9ec6-8dafa9bc3621"
      unitRef="shares">218976000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i00c7c0edff0e4ac2a68115eef01ff73d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTQtMS0xLTM3Mjcw_ecbb24c1-bd28-4328-ad04-5d1d51398482"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="idd3e01d69d404333b2e0170fe5853c55_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTUtMS0xLTM3Mjcw_4585dd25-1e8d-4bf7-b6bf-8ac7d6724b7e"
      unitRef="shares">50000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idd3e01d69d404333b2e0170fe5853c55_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTYtMS0xLTM3Mjcw_92638ac5-10c7-4813-91f4-2c285a8720c3"
      unitRef="usd">63000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ief96e993bf2a4bad8348a1f2176e9808_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTctMS0xLTM3Mjcw_e6f1ffb0-2753-4837-8799-a1a088cfffd2"
      unitRef="shares">316407000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief96e993bf2a4bad8348a1f2176e9808_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTgtMS0xLTM3Mjcw_927a4f29-a64d-4151-892b-e41eebdfcc8e"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i68fb25a3dc3e456893c7bc42ba425cbd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTktMS0xLTM3Mjcw_e8099f4b-8e57-4020-8895-c95891fe30bc"
      unitRef="usd">2865964000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if26943d0c125428899ab95101e2214b9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTEwLTEtMS0zNzI3MA_fabd0c37-c7f5-4c42-8514-4be4e95060cf"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7cb528cec9b5436688d56f37b5a8fdb8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTExLTEtMS0zNzI3MA_f867290a-2dca-4e7b-8de5-8b15bb33e099"
      unitRef="usd">1920635000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i857c20e661b346998fb3a0f68c1afaf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTEyLTEtMS0zNzI3MA_bfc25c98-c127-4195-94de-08b4df7824d1"
      unitRef="usd">34395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9a4c8ddad1f14b6b87799e8a6512c515_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTEzLTEtMS0zNzI3MA_7a73bef9-fa1f-4c7b-9642-d9201969e656"
      unitRef="usd">5077036000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i66335cce09fd4d5aa1361b620f554b05_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTE0LTEtMS0zNzI3MA_5978d368-f296-4c13-8b89-92a74ba1546a"
      unitRef="usd">-2317000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo1ZWY2YWJiZDc0NTI0YzQ0OWE3NmIwMGQ0OWQzNDgzOS90YWJsZXJhbmdlOjVlZjZhYmJkNzQ1MjRjNDQ5YTc2YjAwZDQ5ZDM0ODM5XzI5LTE1LTEtMS0zNzI3MA_cd58b250-e681-408b-9268-6da2a5daa82d"
      unitRef="usd">9895815000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i026910ef30a142baa787995540a3555f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItMS0xLTEtMA_536762ff-e6d8-49ff-8f8c-e33b46093578"
      unitRef="shares">388135000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i026910ef30a142baa787995540a3555f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItMi0xLTEtMA_1abdb801-be92-4d0d-89b9-f7fd9dbb2636"
      unitRef="usd">39000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i00c7c0edff0e4ac2a68115eef01ff73d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItMy0xLTEtMA_83b8cf42-3dff-48f7-9ec6-8dafa9bc3621"
      unitRef="shares">218976000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i00c7c0edff0e4ac2a68115eef01ff73d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItNC0xLTEtMA_ecbb24c1-bd28-4328-ad04-5d1d51398482"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="idd3e01d69d404333b2e0170fe5853c55_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItNS0xLTEtMA_4585dd25-1e8d-4bf7-b6bf-8ac7d6724b7e"
      unitRef="shares">50000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idd3e01d69d404333b2e0170fe5853c55_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItNi0xLTEtMA_92638ac5-10c7-4813-91f4-2c285a8720c3"
      unitRef="usd">63000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ief96e993bf2a4bad8348a1f2176e9808_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItNy0xLTEtMA_e6f1ffb0-2753-4837-8799-a1a088cfffd2"
      unitRef="shares">316407000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief96e993bf2a4bad8348a1f2176e9808_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItOC0xLTEtMA_927a4f29-a64d-4151-892b-e41eebdfcc8e"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i68fb25a3dc3e456893c7bc42ba425cbd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItOS0xLTEtMA_e8099f4b-8e57-4020-8895-c95891fe30bc"
      unitRef="usd">2865964000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if26943d0c125428899ab95101e2214b9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItMTAtMS0xLTA_fabd0c37-c7f5-4c42-8514-4be4e95060cf"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7cb528cec9b5436688d56f37b5a8fdb8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItMTEtMS0xLTA_f867290a-2dca-4e7b-8de5-8b15bb33e099"
      unitRef="usd">1920635000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i857c20e661b346998fb3a0f68c1afaf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItMTItMS0xLTA_bfc25c98-c127-4195-94de-08b4df7824d1"
      unitRef="usd">34395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9a4c8ddad1f14b6b87799e8a6512c515_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItMTMtMS0xLTA_7a73bef9-fa1f-4c7b-9642-d9201969e656"
      unitRef="usd">5077036000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i66335cce09fd4d5aa1361b620f554b05_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItMTQtMS0xLTA_5978d368-f296-4c13-8b89-92a74ba1546a"
      unitRef="usd">-2317000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzItMTUtMS0xLTA_cd58b250-e681-408b-9268-6da2a5daa82d"
      unitRef="usd">9895815000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzMtMTMtMS0xLTA_c8ff36be-ad83-4855-8a3e-d657c8fc98af"
      unitRef="usd">48539000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzMtMTUtMS0xLTA_7aaa559a-f8e0-4bac-a1d7-4287c0b6e05a"
      unitRef="usd">48539000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzQtMTMtMS0xLTA_2a5c8ee5-ba23-422e-83d1-86bff6bff896"
      unitRef="usd">614973000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzQtMTUtMS0xLTA_73ff2e61-f4d6-4dd9-908f-d7fe7f859b33"
      unitRef="usd">614973000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzUtMC0xLTEtMC90ZXh0cmVnaW9uOjljZWRmYzQ1MWQ2YzRiZmFhOTVjNjg3MDg0Zjg4NWNlXzI3NDg3NzkwNjk1MTY_bebd342e-61b4-4f83-8948-df69341f863e"
      unitRef="usdPerShare">0.68</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCash
      contextRef="i0bdb46f25b6846f5b9310b232d39718a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzUtMTEtMS0xLTA_e352b650-7053-43f4-8609-e912af7f2095"
      unitRef="usd">285184000</us-gaap:DividendsCash>
    <us-gaap:DividendsCash
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzUtMTUtMS0xLTA_5b1dd3e2-bc61-4edb-8674-7a4bcf4edb14"
      unitRef="usd">285184000</us-gaap:DividendsCash>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i0f493fdc35c04ea9b3f1ab89b24ba7be_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzYtMS0xLTEtMA_054497a3-98c3-477a-839e-2a2c1104789f"
      unitRef="shares">44763000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i0f493fdc35c04ea9b3f1ab89b24ba7be_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzYtMi0xLTEtMA_555c85b6-268c-402b-b8f9-e50f6de2b81f"
      unitRef="usd">-4000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i8df459188f6346b8b8d77947f07ece9e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzYtMy0xLTEtMA_e45a9d34-b14b-4df4-b277-ba7629d03a7d"
      unitRef="shares">-44763000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i0c91bc2a7dfa43c18d941b318eb6c1a1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzYtNy0xLTEtMA_235791b2-9963-4032-9ddd-f46d5fddfeda"
      unitRef="shares">44763000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i20b582d2d470476abea2f967a5ff5d4d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzYtOS0xLTEtMA_5bdb0d80-38b0-4334-97a2-cca4372ef938"
      unitRef="usd">-639126000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ie00bc8af28a248a3bab0ff42f302d437_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzYtMTItMS0xLTA_f94d6c84-7129-4af8-a3c6-9a8f967e9153"
      unitRef="usd">-4242000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzYtMTMtMS0xLTA_1715bfc1-c6bc-497a-8cdf-d1b3ae9afe47"
      unitRef="usd">642974000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ideedfd0352184c20a5b0ac18ede8b733_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzYtMTQtMS0xLTA_cbd70200-cf08-48ff-bded-dfaff02c3946"
      unitRef="usd">398000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzYtMTUtMS0xLTA_423decf8-745e-44bc-b350-b166cdaf1bcf"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i0f493fdc35c04ea9b3f1ab89b24ba7be_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzctMS0xLTEtMA_bba100df-1b23-4834-b1f0-256bac6108c9"
      unitRef="shares">65000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i20b582d2d470476abea2f967a5ff5d4d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzctOS0xLTEtMA_4e15c644-e204-4ebe-8063-c732e660c093"
      unitRef="usd">2443000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzctMTUtMS0xLTA_a056e5ab-36fa-43a3-99b3-03055f61aaec"
      unitRef="usd">2443000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="i0bdb46f25b6846f5b9310b232d39718a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzEwLTExLTEtMS0w_fed22120-cfde-4cec-b017-1351ef1c3f50"
      unitRef="usd">619728000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzEwLTEzLTEtMS0w_abba22b9-d841-499a-87de-405954396de8"
      unitRef="usd">621473000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzEwLTE1LTEtMS0w_3161fa09-94b6-4313-9378-6c17876bb618"
      unitRef="usd">1241201000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie00bc8af28a248a3bab0ff42f302d437_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzEyLTEyLTEtMS0w_c5fb911d-d32d-499f-865b-0674309f4cbc"
      unitRef="usd">6335000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzEyLTEzLTEtMS0w_196d9538-5804-48ae-8617-30d28e2024df"
      unitRef="usd">5265000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzEyLTE1LTEtMS0w_a3434b82-86a8-48e4-b5e0-4ab558c3e3d2"
      unitRef="usd">11600000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ie00bc8af28a248a3bab0ff42f302d437_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzEzLTEyLTEtMS0w_ca0dcbc2-f673-478d-bd4f-8b51efecae20"
      unitRef="usd">28481000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzEzLTEzLTEtMS0w_d3e6b907-0fa0-4f3d-82b7-a73f3ff35a14"
      unitRef="usd">22415000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzEzLTE1LTEtMS0w_8f8166ea-daed-4cca-b894-deaad879d8d7"
      unitRef="usd">50896000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="iec5b04d241a742c1bf88cb734be536cb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTEtMS0xLTA_08e2bf4f-3a43-4b36-b475-522b2040ac10"
      unitRef="shares">432963000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iec5b04d241a742c1bf88cb734be536cb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTItMS0xLTA_5571e687-07f8-48d4-a005-6e5ee5ce7c1b"
      unitRef="usd">43000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i237eac50dc20448f9dc9e9bc7dce35cf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTMtMS0xLTA_ca3714a5-f17f-4abb-bcbf-d8f24242630a"
      unitRef="shares">174213000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i237eac50dc20448f9dc9e9bc7dce35cf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTQtMS0xLTA_5de63771-07ac-46a6-b877-35d709b7ee13"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i831945c7a36b4b9a9c9ce724bfbde784_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTUtMS0xLTA_7bd486e3-5881-42e9-875d-babf7ce67cbb"
      unitRef="shares">50000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i831945c7a36b4b9a9c9ce724bfbde784_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTYtMS0xLTA_15205949-b838-4946-b663-9bad83f11fc0"
      unitRef="usd">63000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i9cf16ec8ae244acb94018fe5616afde0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTctMS0xLTA_6c3a09b1-58c0-41df-bfcb-0b6589f75502"
      unitRef="shares">361170000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9cf16ec8ae244acb94018fe5616afde0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTgtMS0xLTA_fb5820ef-7a1d-46ef-880c-fd6c083d1fc3"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibf5276dc05624d1c9f3c9eb9743788dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTktMS0xLTA_9fc11a22-9062-48aa-8e95-a41b2f89a1c3"
      unitRef="usd">3507533000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3cf92db35b544207b1e43d9e1641760f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTEwLTEtMS0w_0d0c90e8-ba2c-452a-8838-f32f75f0faf0"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe420d445c0a4fd99c2d658b9393d0ef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTExLTEtMS0w_1e43a4ec-9feb-4bb5-9765-ff32232cfbab"
      unitRef="usd">2255179000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9443f77254524e56b4e02c6d9e30af84_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTEyLTEtMS0w_b2b6e4e6-639a-4373-b6ea-d39a81a8a689"
      unitRef="usd">16491000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i03b5b882444a44ad9e231eaa7b05228b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTEzLTEtMS0w_73d7b960-be4e-4033-b821-44a010be0593"
      unitRef="usd">4471951000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i568f4691ddec40e6848d6b317d8a5792_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTE0LTEtMS0w_f66b73ec-002a-4936-939f-620a43450972"
      unitRef="usd">-2715000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDMvZnJhZzo5NWU2ZjMwNGIxMmU0YWRkOWI4ODAxZWQ3MTE1ODdiOS90YWJsZTo4ZWUzMjZiMjQ1Y2I0MTQ3OGI5MTJiN2U4NjdlYTM3Yi90YWJsZXJhbmdlOjhlZTMyNmIyNDVjYjQxNDc4YjkxMmI3ZTg2N2VhMzdiXzE1LTE1LTEtMS0w_515c9dc9-95db-4999-b2d9-8f55f35e0777"
      unitRef="usd">10248545000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzMtMS0xLTEtMA_7f725826-cd24-48d1-8b3f-9260456fc14a"
      unitRef="usd">2315854000</rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables>
    <rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzMtMy0xLTEtMA_d2bdcb6b-f3af-4aed-bc19-58556c6c1627"
      unitRef="usd">2121923000</rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables>
    <rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzMtNS0xLTEtMA_c6777b08-5e6d-42bc-91dc-2744ce5a59e8"
      unitRef="usd">1934092000</rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables>
    <rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQtMS0xLTEtMA_3749f652-4232-47f9-bfd4-083b3bb96b2e"
      unitRef="usd">151158000</rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets>
    <rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQtMy0xLTEtMA_c462588b-7b9b-4dc0-aecf-57c8beed9801"
      unitRef="usd">143753000</rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets>
    <rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQtNS0xLTEtMA_a7687d34-ac77-49de-909e-f6240fbbc24f"
      unitRef="usd">143298000</rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets>
    <rprx:ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzUtMS0xLTEtMA_5ab94e47-fe8a-4a3b-be60-be1bbf6ec7de"
      unitRef="usd">44123000</rprx:ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables>
    <rprx:ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzUtMy0xLTEtMA_58617e16-ab8e-4088-a65d-a233c62f7077"
      unitRef="usd">18305000</rprx:ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables>
    <rprx:ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzUtNS0xLTEtMA_1aa1ad9e-fc96-4a07-9840-30054e1eb731"
      unitRef="usd">27448000</rprx:ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzYtMS0xLTEtMA_c849c70b-c3f3-4f02-ba8a-c7634473cc1c"
      unitRef="usd">34384000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzYtMy0xLTEtMA_e1df10db-3168-4818-a63e-d7950ee44fb4"
      unitRef="usd">42334000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzYtNS0xLTEtMA_00de7e39-0f46-4216-bfaa-3dca470ef1c6"
      unitRef="usd">14059000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzctMS0xLTEtMA_311826a9-3527-4ee3-88a4-74f4fd42ef94"
      unitRef="usd">3135000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzctMy0xLTEtMA_43fa87c6-4db6-4045-85da-5b0bdc5b90d9"
      unitRef="usd">7704000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzctNS0xLTEtMA_f24f440e-9d45-4956-a391-d7ab39a39dd4"
      unitRef="usd">20136000</us-gaap:ProceedsFromInterestReceived>
    <rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzgtMS0xLTEtMA_1adf9fc5-6d80-4beb-8b49-f87aa1c71644"
      unitRef="usd">34660000</rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments>
    <rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzgtMy0xLTEtMA_ef786605-f2d5-4f08-a5df-2e1229ab92d3"
      unitRef="usd">45252000</rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments>
    <rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzgtNS0xLTEtMA_53c539f1-f54f-45b5-ac80-f95e41145ae9"
      unitRef="usd">360000</rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments>
    <rprx:PaymentsForCollateralPostedOnDerivativeInstruments
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzktMS0xLTEtMA_4fef99f1-8216-4f90-97c6-3e4f53f7aa03"
      unitRef="usd">34660000</rprx:PaymentsForCollateralPostedOnDerivativeInstruments>
    <rprx:PaymentsForCollateralPostedOnDerivativeInstruments
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzktMy0xLTEtMA_5880bbd4-91b1-45dd-b969-649cb040e413"
      unitRef="usd">0</rprx:PaymentsForCollateralPostedOnDerivativeInstruments>
    <rprx:PaymentsForCollateralPostedOnDerivativeInstruments
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzktNS0xLTEtMA_cebf7f62-1d52-4e65-9fbd-55fa0fa2430c"
      unitRef="usd">45630000</rprx:PaymentsForCollateralPostedOnDerivativeInstruments>
    <rprx:PaymentsToTerminateDerivativeInstruments
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzEwLTEtMS0xLTA_638a0019-590d-47e3-be3c-40103003b126"
      unitRef="usd">16093000</rprx:PaymentsToTerminateDerivativeInstruments>
    <rprx:PaymentsToTerminateDerivativeInstruments
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzEwLTMtMS0xLTA_1ffea484-b69e-4bd6-a535-8790857894dd"
      unitRef="usd">35448000</rprx:PaymentsToTerminateDerivativeInstruments>
    <rprx:PaymentsToTerminateDerivativeInstruments
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzEwLTUtMS0xLTA_a72c517b-cacc-49b3-9e4b-09952d5b8dda"
      unitRef="usd">0</rprx:PaymentsToTerminateDerivativeInstruments>
    <rprx:PaymentsForOngoingDevelopmentStageFunding
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzExLTEtMS0xLTA_3fe72aed-3cfd-4231-bd6e-1e600ed9a358"
      unitRef="usd">6876000</rprx:PaymentsForOngoingDevelopmentStageFunding>
    <rprx:PaymentsForOngoingDevelopmentStageFunding
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzExLTMtMS0xLTA_0d43c84e-dc4f-4dab-baa2-3e7803376468"
      unitRef="usd">20479000</rprx:PaymentsForOngoingDevelopmentStageFunding>
    <rprx:PaymentsForOngoingDevelopmentStageFunding
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzExLTUtMS0xLTA_bb6cfc60-19e8-4916-ad61-55bc4097f019"
      unitRef="usd">83036000</rprx:PaymentsForOngoingDevelopmentStageFunding>
    <rprx:PaymentsForUpfrontDevelopmentStageFunding
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzEyLTEtMS0xLTA_3792d5d1-6001-454b-8fc9-b81a27058b64"
      unitRef="usd">193208000</rprx:PaymentsForUpfrontDevelopmentStageFunding>
    <rprx:PaymentsForUpfrontDevelopmentStageFunding
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzEyLTMtMS0xLTA_0bf655f4-875d-48a6-bfab-d3c2582bfbf8"
      unitRef="usd">5810000</rprx:PaymentsForUpfrontDevelopmentStageFunding>
    <rprx:PaymentsForUpfrontDevelopmentStageFunding
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzEyLTUtMS0xLTA_2c37a9c6-7c31-4d9f-a438-c04cc7c2cec9"
      unitRef="usd">0</rprx:PaymentsForUpfrontDevelopmentStageFunding>
    <rprx:PaymentsForOperatingCostsAndProfessionalServices
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzEzLTEtMS0xLTA_66e2a405-ffa2-4844-9974-a6c05c2aca3b"
      unitRef="usd">184511000</rprx:PaymentsForOperatingCostsAndProfessionalServices>
    <rprx:PaymentsForOperatingCostsAndProfessionalServices
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzEzLTMtMS0xLTA_24e05c43-8c2e-4c9d-90b7-debcd660a7a7"
      unitRef="usd">179709000</rprx:PaymentsForOperatingCostsAndProfessionalServices>
    <rprx:PaymentsForOperatingCostsAndProfessionalServices
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzEzLTUtMS0xLTA_91a6e829-4317-4567-a6d7-204eeb4889fe"
      unitRef="usd">88524000</rprx:PaymentsForOperatingCostsAndProfessionalServices>
    <us-gaap:InterestPaidNet
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzE1LTEtMS0xLTA_44fb3c97-f998-4021-a4c0-17d1424565fe"
      unitRef="usd">130430000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzE1LTMtMS0xLTA_cb926753-7ea6-472a-8dad-fb73e95dc2b1"
      unitRef="usd">103196000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzE1LTUtMS0xLTA_9a89a0b8-f6cf-4097-9f9a-195cdc3326e1"
      unitRef="usd">254964000</us-gaap:InterestPaidNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzE3LTEtMS0xLTA_0cab8fe7-4fac-45a8-8425-7636a6ebc4be"
      unitRef="usd">2017536000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzE3LTMtMS0xLTA_0e043c75-dbc7-4ab6-a101-e7795962781d"
      unitRef="usd">2034629000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzE3LTUtMS0xLTA_ef41dfd2-f00b-407f-82e7-55a79b3a36d4"
      unitRef="usd">1667239000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIwLTEtMS0xLTQzNzI0_5133144d-dcfe-480b-8f77-07241da08da0"
      unitRef="usd">523000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIwLTMtMS0xLTQzNzI0_f4d17bec-8910-4be1-b67d-5e60d277f70f"
      unitRef="usd">15084000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIwLTUtMS0xLTQzNzI0_d392f5db-920a-4a31-9f11-2d052bb263bd"
      unitRef="usd">0</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIwLTEtMS0xLTA_02f7994f-848b-40a3-a9e0-da029f06d4b4"
      unitRef="usd">34855000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIwLTMtMS0xLTA_5fe59b3b-cb2d-4789-8081-e759e13bf85b"
      unitRef="usd">40155000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIwLTUtMS0xLTA_da18cf1b-d04a-4f34-aa47-adac49b05535"
      unitRef="usd">27042000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <rprx:PaymentsToAcquireEquitySecuritiesFNNI
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIyLTEtMS0xLTA_e3c036a5-f773-4699-93c3-b83744773417"
      unitRef="usd">135134000</rprx:PaymentsToAcquireEquitySecuritiesFNNI>
    <rprx:PaymentsToAcquireEquitySecuritiesFNNI
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIyLTMtMS0xLTA_1e9ee606-a450-4a70-9569-38cc2ab90b6b"
      unitRef="usd">50000000</rprx:PaymentsToAcquireEquitySecuritiesFNNI>
    <rprx:PaymentsToAcquireEquitySecuritiesFNNI
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIyLTUtMS0xLTA_3f4fbe63-9d79-4aa4-8ea3-14f8e9d6ed3a"
      unitRef="usd">78999000</rprx:PaymentsToAcquireEquitySecuritiesFNNI>
    <rprx:ProceedsFromIssuanceOfEquitySecuritiesFNNI
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIzLTEtMS0xLTQzNzQ2_97f9eab5-d775-429b-b3d1-21c72b1ba2a1"
      unitRef="usd">115957000</rprx:ProceedsFromIssuanceOfEquitySecuritiesFNNI>
    <rprx:ProceedsFromIssuanceOfEquitySecuritiesFNNI
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIzLTMtMS0xLTQzNzQ2_8125bfaa-577c-471f-8f31-ab3a7fd53228"
      unitRef="usd">384840000</rprx:ProceedsFromIssuanceOfEquitySecuritiesFNNI>
    <rprx:ProceedsFromIssuanceOfEquitySecuritiesFNNI
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIzLTUtMS0xLTQzNzQ2_265e1ef4-94d0-4916-a24b-b84a62228d0e"
      unitRef="usd">0</rprx:ProceedsFromIssuanceOfEquitySecuritiesFNNI>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIzLTEtMS0xLTI1NjYy_1a015c40-815d-4644-86b4-b690314abba7"
      unitRef="usd">70441000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIzLTMtMS0xLTI1NjYy_584b75ab-dbb3-4969-94ec-51b3494d0742"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIzLTUtMS0xLTI1NjYy_a665d066-97ec-4c44-8997-6f68d5921caf"
      unitRef="usd">125121000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIzLTEtMS0xLTA_75d3abce-3527-476b-8090-ea98bfb44cd5"
      unitRef="usd">62500000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIzLTMtMS0xLTA_ac8a2266-ce59-4622-8d4f-7b8cac2ed301"
      unitRef="usd">3000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzIzLTUtMS0xLTA_d2429b60-09db-49f7-9483-0e82b2264f7f"
      unitRef="usd">150000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzI0LTEtMS0xLTA_67d702d8-c681-44b8-b8cf-7318af8f3998"
      unitRef="usd">1196579000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzI0LTMtMS0xLTA_647ecdb8-78a1-433e-be32-3bf6c1601745"
      unitRef="usd">1705283000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzI0LTUtMS0xLTA_60ff4185-836d-4897-8b31-05fd11bf5024"
      unitRef="usd">817402000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzI1LTEtMS0xLTA_e0048a31-d574-40ca-ab7e-74bebe9743e5"
      unitRef="usd">1597851000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzI1LTMtMS0xLTA_d57e4872-0037-42bf-a717-2068f785be1d"
      unitRef="usd">815440000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzI1LTUtMS0xLTA_a3ee2c4e-88e6-4c81-a4bb-1a5d475542ff"
      unitRef="usd">725070000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <rprx:PaymentsToAcquireWarrants
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzI4LTEtMS0xLTA_c1478bcd-3068-4e97-a1df-5e4a6b037185"
      unitRef="usd">0</rprx:PaymentsToAcquireWarrants>
    <rprx:PaymentsToAcquireWarrants
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzI4LTMtMS0xLTA_889c4d9f-40a7-4e16-b01e-e879eddfd22b"
      unitRef="usd">0</rprx:PaymentsToAcquireWarrants>
    <rprx:PaymentsToAcquireWarrants
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzI4LTUtMS0xLTA_1bb64627-52bf-4631-ae0c-e67f31015419"
      unitRef="usd">8840000</rprx:PaymentsToAcquireWarrants>
    <us-gaap:PaymentsToAcquireFinanceReceivables
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzI5LTEtMS0xLTA_21732f16-c0d4-4a43-9ea5-8d55c06d2749"
      unitRef="usd">2191502000</us-gaap:PaymentsToAcquireFinanceReceivables>
    <us-gaap:PaymentsToAcquireFinanceReceivables
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzI5LTMtMS0xLTA_db92e458-191d-41df-8c78-682e2e1e776f"
      unitRef="usd">2182246000</us-gaap:PaymentsToAcquireFinanceReceivables>
    <us-gaap:PaymentsToAcquireFinanceReceivables
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzI5LTUtMS0xLTA_617b9499-c7b0-4232-8850-55e901475f82"
      unitRef="usd">1721291000</us-gaap:PaymentsToAcquireFinanceReceivables>
    <rprx:PaymentsForMilestones
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzMwLTEtMS0xLTA_464f4237-f96e-4631-8da7-c72d19b8fa0f"
      unitRef="usd">18600000</rprx:PaymentsForMilestones>
    <rprx:PaymentsForMilestones
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzMwLTMtMS0xLTA_e36e26ae-f294-443c-835a-446c8d9daa45"
      unitRef="usd">0</rprx:PaymentsForMilestones>
    <rprx:PaymentsForMilestones
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzMwLTUtMS0xLTA_a836bf33-c5dc-4542-9b4c-54ed3af2a02e"
      unitRef="usd">250000000</rprx:PaymentsForMilestones>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzMxLTEtMS0xLTA_dc2a676b-10ac-4646-abf5-a6943289b121"
      unitRef="usd">-1870280000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzMxLTMtMS0xLTA_c4d858ae-14c3-40e7-a519-9d4e8bcdca22"
      unitRef="usd">-2759320000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzMxLTUtMS0xLTA_2f23c045-3ed5-40e6-96dd-d1a514fb0eeb"
      unitRef="usd">-2153625000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <rprx:PaymentsForDistributionsToShareholdersAndUnitholders
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM0LTEtMS0xLTA_4546ff2a-2ccf-4c82-9dde-a31a91a7e894"
      unitRef="usd">0</rprx:PaymentsForDistributionsToShareholdersAndUnitholders>
    <rprx:PaymentsForDistributionsToShareholdersAndUnitholders
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM0LTMtMS0xLTA_09b8d334-1a38-4e9d-bf51-e0b6fc9cc121"
      unitRef="usd">285353000</rprx:PaymentsForDistributionsToShareholdersAndUnitholders>
    <rprx:PaymentsForDistributionsToShareholdersAndUnitholders
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM0LTUtMS0xLTA_15b5fd34-32da-41c4-b017-a9ce10b6e0c4"
      unitRef="usd">739276000</rprx:PaymentsForDistributionsToShareholdersAndUnitholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM1LTEtMS0xLTA_9772da4f-f8bc-4e86-8094-4809988c026f"
      unitRef="usd">479604000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM1LTMtMS0xLTA_7066c4b7-c58c-46ba-8d2a-638f80e913f7"
      unitRef="usd">543952000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM1LTUtMS0xLTA_2efe94c0-bce7-4540-bb54-568b417d4978"
      unitRef="usd">154084000</us-gaap:PaymentsToMinorityShareholders>
    <rprx:PaymentsToNoncontrollingInterestsOther
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM2LTEtMS0xLTA_663e2415-c941-49c6-8a04-f40e9d4c80b0"
      unitRef="usd">153800000</rprx:PaymentsToNoncontrollingInterestsOther>
    <rprx:PaymentsToNoncontrollingInterestsOther
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM2LTMtMS0xLTA_9fb48a61-37c0-4b7c-a7c7-968e85422272"
      unitRef="usd">181135000</rprx:PaymentsToNoncontrollingInterestsOther>
    <rprx:PaymentsToNoncontrollingInterestsOther
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM2LTUtMS0xLTA_e1ac0988-de90-48e2-a3b9-f18930048c52"
      unitRef="usd">0</rprx:PaymentsToNoncontrollingInterestsOther>
    <rprx:PaymentOfDividendsToShareholders
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM3LTEtMS0xLTA_ca24b22c-e201-4a17-a6fd-997c76303adc"
      unitRef="usd">285184000</rprx:PaymentOfDividendsToShareholders>
    <rprx:PaymentOfDividendsToShareholders
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM3LTMtMS0xLTA_c3db5074-756e-4053-810e-6d1c183be262"
      unitRef="usd">112490000</rprx:PaymentOfDividendsToShareholders>
    <rprx:PaymentOfDividendsToShareholders
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM3LTUtMS0xLTA_209ced3c-38ad-40eb-9a1d-7dc2f7fe788f"
      unitRef="usd">0</rprx:PaymentOfDividendsToShareholders>
    <rprx:ProceedsFromNoncontrollingInterestsResearchAndDevelopment
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM5LTEtMS0xLTA_97d31d87-2aaf-4a3f-839f-991a77ba5cf3"
      unitRef="usd">7339000</rprx:ProceedsFromNoncontrollingInterestsResearchAndDevelopment>
    <rprx:ProceedsFromNoncontrollingInterestsResearchAndDevelopment
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM5LTMtMS0xLTA_ab763700-e327-46f9-baa3-4d24b1adebfb"
      unitRef="usd">8482000</rprx:ProceedsFromNoncontrollingInterestsResearchAndDevelopment>
    <rprx:ProceedsFromNoncontrollingInterestsResearchAndDevelopment
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzM5LTUtMS0xLTA_1e2eb6c5-e8d9-4e1b-a0bd-811f80b977d6"
      unitRef="usd">0</rprx:ProceedsFromNoncontrollingInterestsResearchAndDevelopment>
    <rprx:ProceedsFromNoncontrollingInterestsOther
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQwLTEtMS0xLTA_616135f9-fd6e-4b61-8ea2-adeb76932795"
      unitRef="usd">36874000</rprx:ProceedsFromNoncontrollingInterestsOther>
    <rprx:ProceedsFromNoncontrollingInterestsOther
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQwLTMtMS0xLTA_aadf01b2-8c84-4375-a0aa-e1b1038d3a2f"
      unitRef="usd">58957000</rprx:ProceedsFromNoncontrollingInterestsOther>
    <rprx:ProceedsFromNoncontrollingInterestsOther
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQwLTUtMS0xLTA_c7f2a44c-eb2c-4338-b771-36f21aafe2bb"
      unitRef="usd">0</rprx:ProceedsFromNoncontrollingInterestsOther>
    <rprx:RepaymentsOfLongTermDebtScheduledPayments
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQxLTEtMS0xLTA_8ce2f01c-9eaf-423b-af80-dad3b38a1cd8"
      unitRef="usd">0</rprx:RepaymentsOfLongTermDebtScheduledPayments>
    <rprx:RepaymentsOfLongTermDebtScheduledPayments
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQxLTMtMS0xLTA_86c53e74-c4b2-4897-80a0-9c354126ad52"
      unitRef="usd">94200000</rprx:RepaymentsOfLongTermDebtScheduledPayments>
    <rprx:RepaymentsOfLongTermDebtScheduledPayments
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQxLTUtMS0xLTA_afd2a6e3-168c-4200-8ed7-2ec3ef095e0b"
      unitRef="usd">294000000</rprx:RepaymentsOfLongTermDebtScheduledPayments>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQyLTEtMS0xLTA_f0a817af-69ec-4d46-b1d6-77d9ddd7ea36"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQyLTMtMS0xLTA_2d33c9b8-f30d-4589-b27f-082952930edb"
      unitRef="usd">11116196000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQyLTUtMS0xLTA_2bce69ab-39db-4b64-be5a-6e21d4f026d3"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQzLTEtMS0xLTA_54dc386c-1ec7-410f-abe0-a474f4135e12"
      unitRef="usd">1272533000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQzLTMtMS0xLTA_b563b76e-bb5f-442e-b29a-68bbac9530dc"
      unitRef="usd">11891030000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQzLTUtMS0xLTA_608b44ab-3434-4be8-84e0-f5bad850d7e1"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ0LTEtMS0xLTA_41f889ec-afb9-41d9-9e5a-a1256da1d917"
      unitRef="usd">13046000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ0LTMtMS0xLTA_d4df1eab-1536-4343-b04a-9047539a5924"
      unitRef="usd">46715000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ0LTUtMS0xLTA_659125d1-b8ae-4ccb-8307-797a04c3aa16"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ1LTEtMS0xLTA_0383f8f7-c12f-4a43-a0ec-8fa54af590f9"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ1LTMtMS0xLTA_b144e9be-5edf-4381-8a71-ffa7d990619b"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ1LTUtMS0xLTA_85310abe-d85d-4931-af40-09e901404286"
      unitRef="usd">4266000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ2LTEtMS0xLTA_978c0adf-b896-43ea-a261-d7b3420d0213"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ2LTMtMS0xLTA_aa772a64-581a-4329-963c-34165e51784b"
      unitRef="usd">1908744000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ2LTUtMS0xLTA_68e56d7b-4b17-40d7-8611-11824083917a"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ4LTEtMS0xLTA_3698356d-138d-4de9-9a16-7896f68c7346"
      unitRef="usd">385112000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ4LTMtMS0xLTA_9f3944ec-3d24-4c51-a04d-eaa6f2e3705a"
      unitRef="usd">1487172000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ4LTUtMS0xLTA_b301421d-064c-4b99-a163-6bf9f53aa6c2"
      unitRef="usd">-1191626000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ5LTEtMS0xLTA_13683180-007e-4c5a-9881-1f836df8cd47"
      unitRef="usd">532368000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ5LTMtMS0xLTA_9046bfb6-73b6-425d-abe1-716bf1f92099"
      unitRef="usd">762481000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzQ5LTUtMS0xLTA_6d26ff06-4c9b-4ed5-a671-40ab5c1de544"
      unitRef="usd">-1678012000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzUwLTEtMS0xLTA_15df8d23-7b04-40b3-ae4d-e2a0499e13cc"
      unitRef="usd">1008680000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id30f26bcb6cd4b64982e6cd53528c44e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzUwLTMtMS0xLTA_d15819c9-5187-46ea-8397-1ef8aa7d43b1"
      unitRef="usd">246199000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifa26755fbc5e413fbf3122ec0db17370_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzUwLTUtMS0xLTA_e2bfcc4e-eb0d-4ed4-9ff9-9d3edc9b9973"
      unitRef="usd">1924211000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzUxLTEtMS0xLTA_6f659d37-2434-41bc-8ab5-49725eac9125"
      unitRef="usd">1541048000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzUxLTMtMS0xLTA_16a53f7d-7112-464a-a497-4879fb584362"
      unitRef="usd">1008680000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id30f26bcb6cd4b64982e6cd53528c44e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDYvZnJhZzphMGI4Y2ZiM2FmMmQ0ZGRjOWViZGQzMTI5Mzg2NWExNC90YWJsZTpkOTlkODkzYzVhNzE0ODAxOTMzOTk1OTY3ODY2ZWIxYi90YWJsZXJhbmdlOmQ5OWQ4OTNjNWE3MTQ4MDE5MzM5OTU5Njc4NjZlYjFiXzUxLTUtMS0xLTA_7b7cacfc-461c-46d2-b5d7-c2fb31250d89"
      unitRef="usd">246199000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3Xzg4MDk_72cf4147-37f5-4184-8c04-05539d1c460b">Organization and Purpose &lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Royalty Pharma plc is an English public limited company incorporated under the laws of England and Wales that was created for the purpose of consolidating our predecessor entities and facilitating the IPO of our Class A ordinary shares that was completed in June 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Following our IPO, we control Royalty Pharma Holdings Ltd. (&#x201c;RP Holdings&#x201d;), a private limited company incorporated under the laws of England and Wales and U.K. tax resident through our ownership of RP Holdings&#x2019; Class A ordinary shares (the &#x201c;RP Holdings Class A Interests&#x201d;) and RP Holdings&#x2019; Class B ordinary shares (the &#x201c;RP Holdings Class B Interests&#x201d;). We conduct our business through RP Holdings and its subsidiaries and include RP Holdings and its subsidiaries in our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV (&#x201c;RPI 2019 ICAV&#x201d;), which is an Irish collective asset management entity formed to facilitate our Exchange Offer Transactions (defined below), and is the successor to Royalty Pharma Investments, an Irish unit trust (&#x201c;Old RPI&#x201d;), for accounting and financial reporting purposes. RP Holdings is owned by RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the &#x201c;Continuing Investors Partnerships&#x201d;), and Royalty Pharma plc. Old RPI is a unit trust established in August 2011 under the laws of Ireland and authorized by the Central Bank of Ireland pursuant to the Unit Trusts Act, 1990. Prior to the Exchange Offer Transactions, Old RPI was owned by various partnerships (the &#x201c;Legacy Investors Partnerships&#x201d;).  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RP Management, LLC (the &#x201c;Manager&#x201d;), a Delaware limited liability company, is an external adviser which is responsible for our management. RP Management (Ireland) Ltd. (&#x201c;RP Ireland&#x201d;), is the manager of Old RPI and equivalent to the board of directors of a company or general partner of a partnership and is responsible for the day to day operations of Old RPI. Its functions can be delegated to third parties. RP Ireland delegated responsibility for investment management of Old RPI to its parent company, the Manager, in accordance with the investment objectives and policies of Old RPI. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Royalty Pharma,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d; refer to Royalty Pharma plc and its subsidiaries on a consolidated basis. After the consummation of the Reorganization Transactions (defined below) and before the consummation of the IPO, &#x201c;Royalty Pharma,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d; refer to RPI 2019 ICAV. Prior to the Reorganization Transactions, &#x201c;Royalty Pharma,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d; refer to Old RPI.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. We fund innovation in the biopharmaceutical industry both directly and indirectly&#x2014;directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reorganization Transactions &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our IPO, we consummated an exchange offer on February 11, 2020 (the &#x201c;Exchange Date&#x201d;). Through the exchange offer, investors representing 82% of the aggregate limited partnership in the Legacy Investors Partnerships, exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in the Continuing Investors Partnerships. The exchange offer transaction together with (i) the concurrent incurrence of indebtedness under our new credit facility and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the &#x201c;Exchange Offer Transactions.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the Exchange Offer Transactions, we own, through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (&#x201c;RPI Intermediate FT&#x201d;), an 82% economic interest in Old RPI. Through our 82% indirect ownership of Old RPI, we are legally entitled to 82% of the economics of Old RPI&#x2019;s wholly-owned subsidiaries, RPI Finance Trust, a Delaware statutory trust (&#x201c;RPIFT&#x201d;) and RPI Acquisitions (Ireland), Limited (&#x201c;RPI Acquisitions&#x201d;), an Irish private limited company, and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (&#x201c;RPCT&#x201d;). The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (&#x201c;RPSFT&#x201d;), which is wholly owned by Royalty Pharma Select, an Irish unit trust. From the Exchange Date until the expiration of the Legacy Investors Partnerships&#x2019; investment period on June 30, 2020 (the &#x201c;Legacy Date&#x201d;), the Legacy Investors Partnerships were offered to participate proportionately in any investment made by Old RPI. Following the Legacy Date, Old RPI ceased making new investments and each of Old RPI and the Legacy Investors Partnerships became legacy entities. Since the Legacy Date, we have made and plan to make new investments through our subsidiaries, including RPI Intermediate FT. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Exchange Offer Transactions, the Legacy Investors Partnerships and RPI Intermediate FT entered into new credit facilities in the amount of $1.3&#160;billion and $6.0&#160;billion, respectively, the proceeds of which were used to repay the $6.3&#160;billion outstanding debt of RPIFT and, in the case of RPI Intermediate FT, were also available to be used to fund investments. As part of the new credit facilities, RPI Intermediate FT repaid $5.2&#160;billion, its pro rata portion of RPIFT&#x2019;s outstanding debt and accrued interest. RPIFT also terminated all outstanding interest rate swaps in connection with the debt refinancing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to, and as a condition precedent to the closing of the IPO, various reorganization transactions became effective, including the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the Exchange Offer Transactions (as described above); and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;the execution of a new management agreement with the Manager (the &#x201c;Management Agreement&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We refer to these transactions collectively as the &#x201c;Reorganization Transactions.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As Old RPI is our predecessor for financial reporting purposes, we have recorded Old RPI&#x2019;s assets and liabilities at the carrying value reflected on Old RPI&#x2019;s balance sheet as of the Exchange Date. The references in the following notes for the periods prior to the Exchange Date refer to the financial results of Old RPI for the same periods. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;IPO&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 18, 2020, we completed our IPO on the Nasdaq Global Select Market under the ticker symbol &#x201c;RPRX&#x201d;, in which we issued 89,334&#160;thousand Class A ordinary shares at a price to the public of $28.00 per Class A ordinary share, of which 71,652&#160;thousand Class A ordinary shares and 17,682&#160;thousand Class A ordinary shares were offered by the Company and selling shareholders, respectively. We used the net proceeds from the IPO to acquire RP Holdings Class A Interests and, as a result, we own 100% of RP Holdings Class A Interests.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon consummation of the IPO, certain of the Continuing Investors agreed to exchange, pursuant to the Exchange Offer Transactions, interests in the Continuing Investors Partnerships represented by their ownership of 294,176&#160;thousand RP Holdings Class B Interests into an aggregate of 294,176&#160;thousand Class A ordinary shares of Royalty Pharma plc. Upon completion of the exchange, Royalty Pharma plc indirectly owned 294,176&#160;thousand RP Holdings Class B Interests. The remaining investors in the Continuing Investors Partnerships who did not elect to exchange into Class A ordinary shares held 241,207&#160;thousand newly issued Class B ordinary shares of Royalty Pharma plc. As a result, the Continuing Investors Partnerships held a number of our Class B ordinary shares equal to the number of RP Holdings Class B Interests indirectly held by them at such time which are exchangeable on a one-for-one basis for Class A ordinary shares of Royalty Pharma plc.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction
      contextRef="i2cb0ee2d2cce4d55b7e14f29d979d9bc_D20200211-20200211"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzMzNjc_6103663d-f887-4dd9-a91b-b7afbd536ddb"
      unitRef="number">0.82</us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="idb95cff49c3e4b6483e5a57868295bb3_I20200211"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzQxNDQ_fd411d82-8b52-4a73-a3d0-6d19edf0c677"
      unitRef="number">0.82</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="idb95cff49c3e4b6483e5a57868295bb3_I20200211"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzQxODk_042ce3b4-1b4f-4ca9-b064-f163259a7acd"
      unitRef="number">0.82</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="idb95cff49c3e4b6483e5a57868295bb3_I20200211"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzQyNTA_afd7ca14-ef5e-41c5-b9eb-6bff1babff1a"
      unitRef="number">0.82</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i41e5a726a82b47548d1f945e92636296_I20200211"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzQ0NjY_dbd775a5-2b60-40a4-bc8b-eea3d6e66872"
      unitRef="number">0.66</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="idb7af162272940eead234259d17da45b_I20200211"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzQ1NTY_c830d717-7225-4854-964c-cc2abbdbff98"
      unitRef="number">0.34</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i74a3535e1f304c089ec2b07d0bdc6f52_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzE2NDkyNjc0NTE4MDQ_7ab38ef3-4419-46c8-a420-441d46326656"
      unitRef="usd">1300000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i196399f1da794ae7a1ec4de607513d77_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzE2NDkyNjc0NTE3NDQ_6224d0f8-314e-4bda-9e2e-60eb4af62eaa"
      unitRef="usd">6000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ibabbf759907e4aee8080ea0173539d93_D20200211-20200211"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzE2NDkyNjc0NTE4MTI_adc48e5f-2caf-4655-80df-b2999dfd7439"
      unitRef="usd">6300000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i70f4f8cb8c6d440883d5034075ba2017_D20200211-20200211"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzE2NDkyNjc0NTE4MjA_fa9379e1-91fb-470d-a7cb-190d7f392dd0"
      unitRef="usd">5200000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i8f263e6903ec49b1bb03a648b164d00e_D20200618-20200618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzY3MDk_eace8314-b480-4565-9532-7c34063aa0d4"
      unitRef="shares">89334000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i0861ac581a4a474c88d227f3b54a6874_I20200618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzY3NzQ_cae7c48c-d7cd-4f26-b12c-ae0459db5b65"
      unitRef="usdPerShare">28.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iff33cf273b964edf907891fec81037d3_D20200618-20200618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzY3OTc_764eed00-8018-4fe7-aa5f-94753f3f0b47"
      unitRef="shares">71652000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ia342308de5774def81f37403f622bd7b_D20200618-20200618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzY4MDQ_9b733fc5-b9da-4617-916c-93054e8c10cb"
      unitRef="shares">17682000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="i414a5cb6c59c4311a4ff39f341e18444_D20200618-20200618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3XzcyNzE_ddfa7d33-d46c-48a1-b337-baa31701789b"
      unitRef="number">1</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <rprx:SaleOfStockNumberOfSharesAvailableToConvert
      contextRef="i586b66d2b65b47dfaf4325e8b30978d9_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3Xzc1NjU_1473b47f-7ea5-419f-9d19-fe56caacd2ff"
      unitRef="shares">294176000</rprx:SaleOfStockNumberOfSharesAvailableToConvert>
    <rprx:SaleOfStockNumberOfSharesAvailableToConvert
      contextRef="i586b66d2b65b47dfaf4325e8b30978d9_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3Xzc2MTk_1473b47f-7ea5-419f-9d19-fe56caacd2ff"
      unitRef="shares">294176000</rprx:SaleOfStockNumberOfSharesAvailableToConvert>
    <rprx:SaleOfStockNumberOfSharesAvailableToConvert
      contextRef="i586b66d2b65b47dfaf4325e8b30978d9_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3Xzc3MzE_1473b47f-7ea5-419f-9d19-fe56caacd2ff"
      unitRef="shares">294176000</rprx:SaleOfStockNumberOfSharesAvailableToConvert>
    <rprx:SaleOfStockNumberOfSharesNotConverted
      contextRef="i586b66d2b65b47dfaf4325e8b30978d9_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTIvZnJhZzphYzUzMTdmNGVhMDY0MTAxYTdhMjRlNTgzNmNlODFkNy90ZXh0cmVnaW9uOmFjNTMxN2Y0ZWEwNjQxMDFhN2EyNGU1ODM2Y2U4MWQ3Xzc4OTQ_91d9d7c7-428e-46bf-bd5e-bfdd4d0bc02d"
      unitRef="shares">241207000</rprx:SaleOfStockNumberOfSharesNotConverted>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDIx_6d988321-3307-432d-9e9f-927ca259118a">Summary of Significant Accounting Policies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of preparation and use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The precise extent to which the COVID-19 pandemic will impact our operational and financial performance will depend on various factors. To date, certain marketers of some of our portfolio products have commented that the performance of these products have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not resulted in a material effect to our results of operations and liquidity and we do not believe it is reasonably likely to in the future. Due to the nature of our business, the effect of the COVID-19 pandemic may not be fully reflected in certain of our results of operations until future periods.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity&#x2019;s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Net income attributable to non-controlling interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; in our consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following management&#x2019;s determination that a high degree of common ownership existed in Royalty Pharma both before and after the Exchange Date, Royalty Pharma recognized Old RPI&#x2019;s assets and liabilities at the carrying value reflected on Old RPI&#x2019;s balance sheet as of the Exchange Date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Exchange Offer Transactions, our only historical non-controlling interest was attributable to a de minimis interest in RPCT held by RPSFT. As a result of the Exchange Offer Transactions in February 2020, a new non-controlling interest was created related to the Legacy Investors Partnerships&#x2019; ownership of approximately 18% in Old RPI. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Following the consummation of our IPO in June 2020, two new non-controlling interests were created: (1) a non-controlling interest related to the Continuing Investors Partnerships&#x2019; ownership in RP Holdings through their ownership of the RP Holdings Class B Interests, which amounted to approximately 29% as of December 31, 2021, and (2) a non-controlling interest related to RPI EPA Holdings, LP (&#x201c;EPA Holdings&#x201d;), an affiliate of the Manager through its ownership of the  RP Holdings&#x2019; Class C ordinary share (the &#x201c;RP Holdings Class C Special Interest&#x201d;). Income will not be allocated to the latter non-controlling interest until certain conditions are met.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All intercompany transactions and balances have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adjustment to prior period presentation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the preparation of our condensed consolidated interim financial statements for the three months ended September 30, 2020, we identified an adjustment to the classification of our short-term investments on our consolidated balance sheets, as of December 31, 2019, based on the original maturity dates of the investments. The adjustment resulted in an increase of $37.5 million to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt; Marketable securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; and a corresponding decrease to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;on the consolidated balance sheet as of December 31, 2019. In addition, the adjustment resulted in an increase of $388.0 million and $350.5 million in cash activity related to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Purchases of marketable securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt; Proceeds from sales and maturities of marketable securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, respectively, within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Net cash used in investing activities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; for the year ended December 31, 2019, with a net impact on net cash flow from investing of $37.5 million. The adjustment had no effect on our reported total income and revenues, consolidated net income, total assets, or shareholders&#x2019; equity for any period. In addition, the adjustment does not impact net cash provided by operating activities in any period. We evaluated the adjustment and determined that, based on quantitative and qualitative analysis, it was not material to the consolidated financial statements as of and for the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, financial royalty assets and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances at December 31, 2021 and 2020 were held with State Street and Bank of America. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, AbbVie, Bristol Myers Squibb, Gilead, Johnson &amp;amp; Johnson, Lilly, Merck, Pfizer, Novartis, Biogen, Roche and Vertex. For the years ended December 31, 2021 and 2020, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for 32% and 27% of our current portion of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial royalty assets, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively, representing the largest individual receivable balance in both years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment information&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our chief operating decision maker is our Chief Executive Officer who reviews financial information presented on a consolidated basis to allocate resources, evaluates financial performance and makes overall operating decisions. As such, we concluded that we operate as one single reportable segment, which is primarily focused on acquiring biopharmaceutical royalties.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An acquisition of a royalty asset provides the buyer with contractual rights to cash flows relating to royalties from the sales of patent-protected biopharmaceutical products. These acquisitions entitle us to receive a portion of income from the sale of patent-protected biopharmaceutical products by unrelated biopharmaceutical companies. For the majority of our royalties, our rights are protective in nature. In other words, we do not own the intellectual property and we do not have the right to commercialize the underlying products. These contractual cash flow rights have yield components that most closely resemble loans and are classified as financial royalty assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the limited instances where we possess rights to exploit the underlying patents, rights to the intellectual property related to the biopharmaceutical products, or the ability to influence the amount or duration of future royalty payments, these royalties are classified as intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial royalty assets, net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we analogize to the accounting guidance within Accounting Standards Codification 310 (&#x201c;ASC&#x201d;), Receivables, as it most closely aligns with the underlying economics of our financial royalty assets. Therefore, such financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Imputation of Interest&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is reviewed and adjusted each reporting period as differences between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows. Income is calculated by multiplying the carrying value of the financial royalty asset by the effective interest rate. The carrying value of a financial royalty asset is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by the interest income accrual and decreased by cash receipts in the period to arrive at the ending balance. If the ending balance is greater than the net present value of the expected future cash flows, a provision is recorded to reduce the asset balance to the net present value. The provision is recorded through the income statement as &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the carrying value of &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial royalty assets, net&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is presented net of the cumulative allowance for changes in expected future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The application of the prospective approach to measure financial royalty assets requires management&#x2019;s judgment in forecasting the expected future cash flows of the underlying royalties. The amounts and duration of forecasted expected future cash flows used to calculate and measure interest income are largely impacted by sell-side equity research analyst coverage, commercial performance of the product, and royalty duration, each discussed in further detail below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Analyst coverage.&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Forecasts of expected future cash flows are developed from sales projections of the underlying biopharmaceutical products as published in sell-side equity research analyst reports. In projecting future cash flows, our policy is to rely on sell-side research analysts&#x2019; consensus sales forecasts for a product to derive annual sales projections for each financial royalty asset over the periods for which we are entitled to royalties or milestones. These forecasts are based on input from internal and external market research that analyzes factors such as growth in global economies, industry trends and product life cycles. When royalty-bearing biopharmaceutical products have no coverage, limited sell-side equity research analyst coverage or where sell-side equity research analyst consensus sales estimates are not available for the full term of the royalty, particularly for the later years in a product&#x2019;s life, management uses reasonable judgment to make assumptions about the growth or decline in the sales of these products based on historical data, market trends and management&#x2019;s own expertise. For the majority of the portfolio of financial royalty assets, management utilizes statistical curves based on historical trends to project future sales when sell-side equity research analyst consensus sales estimates end or are not available for the full term of the royalty. In other cases, management may develop and apply growth rate estimates from existing sell-side equity research analysts&#x2019; consensus sales forecasts to project future sales for products that cannot be modeled through the statistical curves, such as those where the entrance of a biosimilar is expected to impact future sales. Based on the level of detail in sell-side equity research analyst models, management can also be required to apply assumptions to the sales forecasts to estimate the quarterly and geographical allocation from annual sales projections and, for franchised products, to estimate the product mix and pricing mix, or to exclude from projections sales forecasts for unapproved products or indications. Our contractual royalty terms, rates, and any milestones are then applied to the adjusted sales projections to calculate the expected royalty or milestone payments over the term of the financial royalty asset&#x2019;s life, forming the basis for our forecast of expected future cash flows used to calculate and measure interest income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Commercial performance.&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The approval of a product for use in new indications can extend the date through which we are entitled to royalties or milestones on that product. For certain financial royalty assets, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and whose sales were previously not reflected in expected future cash flows. We generally do not recognize income from, or forecast sales for, unapproved products or indications. If a product is removed from all or a portion of a market, subsequent sell-side equity research analysts&#x2019; consensus sales forecasts will reflect the expected drop in sales. Both the new cash flow streams and the cessation of cash flow streams related to a product&#x2019;s performance in the market over the royalty term can materially affect our forecast of expected future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Royalty duration. &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The duration of a royalty can be based on a number of factors, such as regulatory and marketing approval dates, patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, the entry of generics or a contractual date arising from litigation, which are all impacted by the time in the product&#x2019;s life cycle at which we acquire the royalty. Royalty duration varies by geography as United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms. Products may be covered by a number of patents and, for products whose royalty term is linked to the existence of valid patents, management is required to make judgments about the patent providing the strongest patent protection to align the period over which management forecasts expected future cash flows to the royalty term. It is common for the latest expiring patent in effect at the date we acquire a financial royalty asset to be extended, adjusted or replaced with newer dated patents subsequent to our acquisition of a royalty due to new information, resulting in changes to the royalty duration in later periods. Patents may expire earlier than expected at the time of the acquisition due to the loss of patent protection, loss of data exclusivity on intellectual property, contractual licensing terms limiting royalty payments based on time from product launch, due to recent legal developments or litigation. Macroeconomic factors, such as changes in economies or the competitive landscape, including the unexpected loss of exclusivity to the products underlying our portfolio of royalties, changes in government legislation, product life cycles, industry consolidations and other changes beyond our control could result in a positive or negative impact on our forecast of expected future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the preparation of the forecasted expected future cash flows, which relies on the sources and variables discussed above, management is required to make assumptions around the following forecast inputs: (1) estimates of the duration of the royalty, which includes consideration of the strength of patent protection and anticipated entry of generics, (2) product growth rates and sales trends in outer years, (3) the product and pricing mix for franchised products, and (4) the geographical allocation of annual sales data from sell-side equity research analysts&#x2019; models. The most sensitive of these assumptions relates to management&#x2019;s estimate of the royalty duration in the final years of an asset&#x2019;s life. In some cases, patent protection may extend to a later period than the expiration date management has estimated. Management may apply a shorter royalty term in this situation if, based on its experience and expertise, management believes that it is more likely that the associated patents are subject to opposition or infringement, that the market for a particular product may shift based on pipeline approvals and products, or that product sales may be harmed by competition from generics. For products providing perpetual royalties, management applies judgment in establishing the duration over which it forecasts expected future cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A shortened royalty term can result in a reduction in the effective interest rate, a decline in the carrying value of the financial royalty asset, a decline in income from financial royalty assets, significant reductions in royalty payments compared to expectations, or a permanent impairment. Additionally, royalty payments may occasionally continue beyond the estimated royalty expiration date for such reasons we cannot foresee such as excess inventory in the channel or additional scope of patent protection identified after expiry, including royalties we may become entitled to from new indications, new compounds, or for new regulatory jurisdictional approvals.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The current portion of &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial royalty assets, net&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter and for which the estimates are derived from the latest external publicly available sell-side equity research analyst reports, reported in arrears. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cumulative allowance and Provision for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate financial royalty assets for impairment on an individual basis by comparing the effective interest rate at each reporting date to that of the prior period. If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected), we record a provision for the change in expected cash flows. The provision is measured as the difference between the financial royalty asset&#x2019;s amortized cost basis and the net present value of the expected future cash flows, calculated based on the prior period&#x2019;s effective interest rate. The amount recognized as provision expense increases the financial royalty asset&#x2019;s cumulative allowance, which reduces the net carrying value of the financial royalty asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance for the increase in the present value of cash flows expected to be collected, resulting in a non-cash credit to the provision line on the income statement. We also recalculate the amount of accretable yield to be received based on the revised remaining future cash flows. The adjustment to the accretable yield is treated as a change in estimate and is recognized prospectively over the remaining life of the financial royalty asset by adjusting the effective interest rate used to calculate income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Movements in the cumulative allowance for changes in expected future cash flows, which forms part of the &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial royalty assets, net&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; line item on the consolidated balance sheet, are accompanied by corresponding changes to the provision. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. Recoveries of previously written-off amounts are credited to the allowance. In some cases, when a financial royalty asset&#x2019;s contractual cash flows expire, the final royalty payment may differ from the remaining net carrying value. We account for this non-cash true-up at the end of the royalty term as either &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or as &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from financial royalty assets&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income from financial royalty assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. The accretable yield is recognized as income at the effective rate of return over the expected life of financial royalty assets. After acquisition of a financial royalty asset, if we are not able to reliably estimate expected cash flows for a product or if we have not completed the required funding obligations payable over time for an approved product, a financial royalty asset is placed in non-accrual status (e.g., for royalties from products that have not yet received FDA approval or for accelerated royalties). Such financial royalty assets are held at cost and no income is recognized until the reasonable expectation of the timing of the future cash flows to be collected is available or until funding obligations payable over time for an approved product are complete. We evaluate such financial royalty assets held at cost for impairment based on, among other factors, a review of development progress, clinical trial results, and publicly available information around regulatory discussions and approval status. An impairment loss is recognized if, based on current information and events, it is probable that we will be unable to collect amounts due according to the contractual terms of the financial royalty asset, and the amount of loss can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When royalties are received for financial royalty assets that have been fully amortized, such income is recognized as &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other royalty income.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Allowance for current expected credit losses&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On January 1, 2020, we adopted ASU 2016-13, &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(&#x201c;ASU 2016-13&#x201d;) which requires earlier recognition of credit losses. We now recognize an allowance for current expected credit losses on our portfolio of financial royalty assets with limited protective rights. The credit loss allowance is estimated using the probability of default and loss given default method. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the probability of default of the marketers responsible for paying our royalties and the resulting loss given default. The allowance for current expected credit losses is presented net within the non-current portion of &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial royalty assets, net&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; on the consolidated balance sheets. Any subsequent movement in the allowance for credit losses is recorded as part of the &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Provision for changes in expected future cash flows from financial royalty assets&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Refer to Note 7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2013;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;for further information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible royalty assets, net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Currently, our only intangible royalty assets are the Januvia and Janumet (&#x201c;DPP-IV&#x201d;) patents. The DPP-IV patents are finite-life intangible royalty assets whose cost is amortized using the straight-line method over the expected lives of the patents, the majority of which terminate at various dates through 2022. The amortization period commenced concurrent with the sale of the product underlying the royalty asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management reviews the performance of intangible royalty assets periodically for impairment as required by ASC 360-10,&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Property, Plant, and Equipment - Overall&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The test for recoverability is performed by comparing the carrying value of the intangible royalty asset with the estimated future undiscounted cash flows generated through royalty payments from sales of the underlying DPP-IV products. When evaluating indicators of impairment, we consider factors such as competitive environment and the product&#x2019;s life cycle stage, recent and prospective sales trends, collectability concerns, and any potential rebate chargebacks that may occur at the end of a royalty&#x2019;s term. An impairment loss is recognized if the carrying value of the intangible royalty asset is not recoverable and its carrying amount exceeds its fair value.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue from intangible royalty assets and Accrued royalty receivable&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We earn royalties on sales by our licensees of DPP-IV products covered under patents that we own. We do not have future performance obligations under these license arrangements. Royalty revenue from sales of DPP-IV products is recognized in the period the product is sold. However, under the license agreements, licensees generally provide royalty reports and payments on a one quarter lag. Thus, the accrued royalty receivable is based on an analysis of historical royalties received and sell-side equity research analysts&#x2019; projected sales, adjusted for any changes in estimates. Royalty-bearing sales are net of certain rebates and other discounts, as permitted under the terms of the license agreements. Because rebates are generally invoiced and paid in arrears by the marketer, royalty reports often reflect deductions in current periods for rebates related to prior periods which we do not have the ability to estimate.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Critical estimates that could cause a change in estimated future cash flows include changes in product demand and market growth assumptions, a change in the pricing strategy of the marketer or reimbursement coverage, and changes in country-specific contractual or patent expiry dates. Actual royalty receipts may differ from estimates and any differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically on the basis of royalty receipts.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Milestone payments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain acquisition agreements provide for future incoming or outgoing contingent payments based on the commercial, regulatory or clinical performance of the related biopharmaceutical product generally over a multi-year period. For purposes of measuring income from financial royalty assets, commercial milestones payable or receivable are reflected in the cash flows used to forecast expected future cash flows in the period in which the milestone criteria is projected to be satisfied based on sell-side equity research analysts&#x2019; consensus sales forecasts. Milestones based on regulatory approval or clinical criteria are generally not reflected in the expected future cash flows until such approval is achieved.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts related to outgoing contingent milestone payments are not considered contractual obligations as they are contingent on the successful completion of the defined milestones. Payments under these agreements generally become due and payable upon achievement of certain commercial milestones, and when the contingency is resolved.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Certain financial instruments reflected in the consolidated balance sheets, (e.g., cash and cash equivalents, certain other assets, accounts payable and certain other liabilities) are recorded at cost, which approximates fair value due to their short-term nature. The fair values of financial instruments other than &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial royalty assets, net&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; are determined through a combination of management estimates and information obtained from third parties using the latest market data. The fair value of financial instruments is determined utilizing the valuation techniques appropriate to the type of instrument as discussed in Note 5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair Value Measurements and Financial Instruments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and cash equivalents and Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include cash held at banks and all highly liquid financial instruments with original maturities of 90 days or less. We invest excess cash in marketable debt securities that are classified as trading securities and reported at fair value. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity securities and Available for sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our equity securities are measured and recorded at fair value with unrealized gains and losses recorded in earnings. Our equity securities represent investments in publicly traded equity securities. Available for sale debt securities are measured at fair value. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The unrealized change in fair value of available for sale debt securities for which we elected the fair value option is recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Unrealized gains on available for sale debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;on the consolidated statements of operations. The &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;unrealized change in fair value for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Biohaven Series A Preferred Share is&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; included in &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accumulated other comprehensive income &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(&#x201c;AOCI&#x201d;) and are reclassified to earnings as interest income is recognized. Interest income is recognized when we can reliably estimate forecasted cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A decline in the market value of any available for sale debt security below its cost that is deemed to have resulted from a credit loss results in a reduction in carrying amount to fair value and is recognized in earnings. The determination of whether a decline in fair value below the amortized cost basis for an available for sale debt security has resulted from a credit loss requires significant judgment and requires consolidation of available quantitative and qualitative evidence in evaluating the potential impairment. Factors evaluated to determine whether a decline in the fair value below the amortized cost basis has resulted from a credit loss include: the extent to which fair value is less than the amortized cost basis, adverse conditions related to the security, an industry, or geographic area, the payment structure of the security, failure of the issuer to make scheduled payments, any changes to the rating of the security by a rating agency, the remaining payment terms of the security, prepayment speeds, the financial condition of the issuer expected defaults, our intent not to sell, and an evaluation as to whether it is more likely than not that we will have to sell before recovery of the cost basis. Assumptions associated with these factors are subject to future market and economic conditions, which could differ from management&#x2019;s assessment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may elect to apply the fair value option for certain investments in debt securities where the fair value option better aligns with the economics of such investment. Upon such election, the entire investment is measured at fair value on a recurring basis, with movements in fair value recognized in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All derivatives are measured at fair value on the consolidated balance sheets with movements in fair value recognized in earnings. Prior to 2017, RPIFT applied hedge accounting to its interest rate swap agreements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the discontinuation of hedge accounting, the AOCI previously recorded on the cash flow hedges was reversed out of other comprehensive income in line with terms of the associated swap contract until the termination of all of our interest rate swaps in February 2020. This reclassification adjustment is shown on the consolidated statements of operations as part of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Losses on derivative financial instruments&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investment in non-consolidated affiliates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Investments in entities that provide us with the ability to exercise significant influence, but not a controlling financial interest, and where we are not the primary beneficiary are accounted for under the equity method. Investments accounted for under the equity method are initially recorded at fair value. If there is a difference between the fair value and the carrying amount of the equity method investment at inception, we quantify the basis difference and amortize it in a rational manner over the life of the investment. Subsequently, we recognize through earnings our proportionate share of the investee&#x2019;s net income or loss, net of any adjustment to reflect the amortization of basis differences. We generally record our share of the results of our investees one quarter in arrears within &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Equity in losses/(earnings) of non-consolidated affiliates&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; in the consolidated statements of operations. The investment is reflected as &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Investments in non-consolidated affiliates&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We have variable interests in entities formed for the purposes of entering into co-development arrangements for potential biopharmaceutical products (the &#x201c;Avillion entities&#x201d;). The Avillion entities are variable interest entities for which we are not the primary beneficiary as we do not have the power to direct the activities that most significantly influence the economic performance of the entity. In determining whether we are the primary beneficiary of an entity, management applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant. Management continuously assesses whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of one or more of its investees.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;When we have committed to provide further support to the investee through capital call commitments and the investment has been reduced to zero, we provide for additional losses, resulting in a negative equity method investment, which is presented as a liability on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and development funding expense&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We enter into transactions where we agree to fund a portion of the research and development (&#x201c;R&amp;amp;D&#x201d;) performed by our partners for products undergoing late-stage clinical trials in exchange for future royalties or milestones if the products are successfully developed and commercialized. In accordance with ASC 730, &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Research and Development&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, we account for the funded amounts as R&amp;amp;D expense when we have the ability to obtain the results of the R&amp;amp;D, the transfer of financial risk is genuine and substantive and, at the time of entering into the transaction, it is not yet probable that the product will receive regulatory approval. We may pay funded amounts upfront or over time as the underlying products undergo clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty payments owed to the Company on successfully commercialized products generated from R&amp;amp;D arrangements are recognized as &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other royalty income&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the same period in which the sale of the product occurs. Fixed or milestone payments receivable based on the achievement of contractual criteria for products arising out of our R&amp;amp;D arrangements are also recognized as &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other royalty income&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the period that the milestone threshold is met. Milestone thresholds are typically not triggered until after all funding obligations have been completed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically assess if our activities, as conducted through our subsidiaries, and as currently contemplated, constitute being engaged in the conduct of a trade or business within the United States. Neither the U.S. Internal Revenue Code (&#x201c;the Code&#x201d;) nor the applicable Treasury regulations provide a general definition of what constitutes being engaged in the conduct of a trade or business within the United States, and the limited case law on the subject does not provide definitive guidance. Based on our periodic assessment, we believe that we are not engaged in the conduct of a trade or business within the United States, and as such, we do not record a provision for U. S. federal income tax for the years presented in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While we believe we are not engaged in the conduct of a trade or business within the United States or subject to U.S. taxation in that regard, we are subject to U. S. federal withholding tax on certain fixed or determinable annual or periodical gains, profits and income, such as royalties from sources within the United States, unless reduced or eliminated under an applicable tax treaty or provision of the Code. Generally, this tax is imposed by withholding 30% of the payments, or deemed payments, that are subject to this tax. We believe our subsidiaries are eligible for benefits under the U.S.-Ireland income tax treaty, and, under that treaty, are not be subject to any U.S. withholding taxes on U.S.-source royalty payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consequently, because we believe that we are not engaged in the conduct of a trade or business within the United States and our subsidiaries are eligible for benefits under the U.S.-Ireland tax treaty, we do not record a provision for income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;While we do not currently record a provision for income taxes, we are party to certain arrangements that will give rise to a tax provision in the future. We currently have funding arrangements in place that allow our counterparties to draw on capital over a prescribed period of time. When such funding arrangements are drawn and we begin to recognize income from these funding arrangements, such activities will be subject to U.S. taxation and we will record a provision for income taxes in accordance with ASC 740, &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. We also entered into an arrangement with MSCI during 2021 as discussed in Note 16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Related Party Transactions that will become subject to U.S. taxation when we begin to recognize revenue from this transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate so as to be treated solely as resident in the U.K. for tax purposes. As a U.K. tax resident company, we are subject to U.K. corporation tax on our worldwide taxable profits and gains. U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. As such, we do not record a provision for U.K. income taxes with respect to the dividends received from RP Holdings or with respect to the dividends received by RP Holdings from RPI. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also subject to the U.K.&#x2019;s &#x201c;controlled foreign companies&#x201d; rules (the &#x201c;U.K. CFC Rules&#x201d;). The U.K. CFC Rules, broadly, can impose a charge to U.K. tax on U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the &#x201c;Controlled Foreign Company&#x201d;) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI (which is Irish tax resident) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and Old RPI (which is Irish tax resident and which is held indirectly by us through our participation in RP Holdings)&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, will be Controlled Foreign Companies for U.K. tax purposes. We are therefore required to apply the CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis.  We do not expect material U.K. corporation tax charges to arise under the U.K. CFC Rules in respect of our royalty assets and we therefore do not record a provision for U.K. income taxes.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings per share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share (&#x201c;EPS&#x201d;) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include the outstanding Class B ordinary shares, Class B ordinary shares contingently issuable to RPI EPA Holdings, LP (&#x201c;EPA Holdings&#x201d;) related to Equity Performance Awards and unvested restricted share units (&#x201c;RSUs&#x201d;) issued under our 2020 Independent Director Equity Incentive Plan (&#x201c;Equity Incentive Plan&#x201d;). We include potentially dilutive shares in the denominator to compute diluted EPS if (i) the inclusion of the ordinary shares is dilutive for the respective reporting periods, and (ii) contingencies are satisfied as of the end of the reporting period for ordinary shares that are contingently issuable.  We use the &#x201c;if-converted&#x201d; method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;There were no Class A ordinary shares or Class B ordinary shares outstanding prior to June 16, 2020; therefore, no earnings per share information has been presented for any period prior to that date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently adopted accounting standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model (ASU 2016-13). Accordingly, these financial assets are presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model.  With certain exceptions, adjustments are applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Retained earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of $192.7&#160;million to recognize an allowance for current expected credit losses on our financial royalty assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued a new accounting standard that eliminates, adds and modified certain disclosures requirements for fair value measurements under Topic 820 (ASU 2018-13). The ASU modifies the disclosures by removing the requirement to disclose the amount and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers. The ASU expands the disclosure requirements for Level 3 fair value measurements, primarily focused on changes in unrealized gains and losses included in other comprehensive income/(loss). We adopted this standard as of January 1, 2020 with no material impact on our consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDI2_ac55ca6b-485e-4af4-aab0-4ddda317ebc4">The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;).</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDM5_44bd19fa-a67d-41da-8862-7a07f13b8da9">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The precise extent to which the COVID-19 pandemic will impact our operational and financial performance will depend on various factors. To date, certain marketers of some of our portfolio products have commented that the performance of these products have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not resulted in a material effect to our results of operations and liquidity and we do not believe it is reasonably likely to in the future. Due to the nature of our business, the effect of the COVID-19 pandemic may not be fully reflected in certain of our results of operations until future periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDI3_eec9304b-ade4-47d1-be67-602bef45da50">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity&#x2019;s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Net income attributable to non-controlling interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; in our consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following management&#x2019;s determination that a high degree of common ownership existed in Royalty Pharma both before and after the Exchange Date, Royalty Pharma recognized Old RPI&#x2019;s assets and liabilities at the carrying value reflected on Old RPI&#x2019;s balance sheet as of the Exchange Date. &lt;/span&gt;&lt;/div&gt;All intercompany transactions and balances have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i4c1e7922bf5d4fb7a873526ac9e2acd2_I20200229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzI0OTg_677f4cdb-6c80-4697-b4f5-1b7c13c3bc20"
      unitRef="number">0.18</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <rprx:NumberOfNoncontrollingInterestsCreated
      contextRef="ifb99eff80794423ca92bd7db72623f54_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzI1Njc_69e6027f-b93f-42ff-932b-4bc4a88575e7"
      unitRef="partnership">2</rprx:NumberOfNoncontrollingInterestsCreated>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i6e7e9177eb1b4c9da6650b9f74990c36_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQ5NDc4MDIzODE0MzE_ee2974d8-b42d-456b-8354-7c56154c6cc2"
      unitRef="number">0.29</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i89b6773bde7741e89cfa1ba14576b98f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzE2NDkyNjc0OTExNjQ_1c2c8a6e-b797-4c49-bb1e-a345c47c1254"
      unitRef="usd">37500000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i89b6773bde7741e89cfa1ba14576b98f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzE2NDkyNjc0OTExNjQ_a73842b3-66de-46b3-ac35-d9eeb2dae3ea"
      unitRef="usd">-37500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i9f493e893d9e41c9836fd0b92cee6bf2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzE2NDkyNjc0OTExNjg_3522fa8c-91c3-4e81-954f-7c55eadcbf61"
      unitRef="usd">388000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i9f493e893d9e41c9836fd0b92cee6bf2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzE2NDkyNjc0OTExNzI_c8bff732-ccc3-4d78-a5a5-2241915a6ad5"
      unitRef="usd">350500000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9f493e893d9e41c9836fd0b92cee6bf2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzE2NDkyNjc0OTExNzY_9302671e-09d4-46f8-b295-dbc307a15692"
      unitRef="usd">37500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzE0MjkzNjUxMjQ2NDcz_35cdb14b-6a78-4d04-8cba-b52824da5aa5">Certain prior period amounts have been reclassified to conform to the current period presentation.</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDMy_0b8c6c51-2e05-4420-a5ee-dbaa67e51aab">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, financial royalty assets and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances at December 31, 2021 and 2020 were held with State Street and Bank of America. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, AbbVie, Bristol Myers Squibb, Gilead, Johnson &amp;amp; Johnson, Lilly, Merck, Pfizer, Novartis, Biogen, Roche and Vertex.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id0a851bce2a945d59b0ed1c24aa99168_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzIxNDQwNDc2ODI1NDUy_ae9ed150-7afb-4461-809c-79098ccc4158"
      unitRef="number">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5b0975d860cd4ef59dd25d4eb5f1f7a6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzIxNDQwNDc2ODI1NDYw_a08f9099-0f49-4acb-bc57-eaaccb071a3e"
      unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDQx_ca4d46bc-9e7d-4fb5-ab47-758225f7f147">Our chief operating decision maker is our Chief Executive Officer who reviews financial information presented on a consolidated basis to allocate resources, evaluates financial performance and makes overall operating decisions. As such, we concluded that we operate as one single reportable segment, which is primarily focused on acquiring biopharmaceutical royalties.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzY3MDM_511541fc-9a50-4a95-8e7f-ae288df27d78"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <rprx:RoyaltyAssetsPolicyPolicyTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDIz_d31e77b9-6d39-42ab-84a2-2881b68c94db">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An acquisition of a royalty asset provides the buyer with contractual rights to cash flows relating to royalties from the sales of patent-protected biopharmaceutical products. These acquisitions entitle us to receive a portion of income from the sale of patent-protected biopharmaceutical products by unrelated biopharmaceutical companies. For the majority of our royalties, our rights are protective in nature. In other words, we do not own the intellectual property and we do not have the right to commercialize the underlying products. These contractual cash flow rights have yield components that most closely resemble loans and are classified as financial royalty assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the limited instances where we possess rights to exploit the underlying patents, rights to the intellectual property related to the biopharmaceutical products, or the ability to influence the amount or duration of future royalty payments, these royalties are classified as intangible assets.&lt;/span&gt;&lt;/div&gt;</rprx:RoyaltyAssetsPolicyPolicyTextBlock>
    <us-gaap:FinanceLoansAndLeasesReceivablePolicy
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDMx_e2f8865a-7d7a-4bf4-9bc0-a2b3b992f4dd">&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we analogize to the accounting guidance within Accounting Standards Codification 310 (&#x201c;ASC&#x201d;), Receivables, as it most closely aligns with the underlying economics of our financial royalty assets. Therefore, such financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Imputation of Interest&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is reviewed and adjusted each reporting period as differences between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows. Income is calculated by multiplying the carrying value of the financial royalty asset by the effective interest rate. The carrying value of a financial royalty asset is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by the interest income accrual and decreased by cash receipts in the period to arrive at the ending balance. If the ending balance is greater than the net present value of the expected future cash flows, a provision is recorded to reduce the asset balance to the net present value. The provision is recorded through the income statement as &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the carrying value of &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial royalty assets, net&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is presented net of the cumulative allowance for changes in expected future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The application of the prospective approach to measure financial royalty assets requires management&#x2019;s judgment in forecasting the expected future cash flows of the underlying royalties. The amounts and duration of forecasted expected future cash flows used to calculate and measure interest income are largely impacted by sell-side equity research analyst coverage, commercial performance of the product, and royalty duration, each discussed in further detail below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Analyst coverage.&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Forecasts of expected future cash flows are developed from sales projections of the underlying biopharmaceutical products as published in sell-side equity research analyst reports. In projecting future cash flows, our policy is to rely on sell-side research analysts&#x2019; consensus sales forecasts for a product to derive annual sales projections for each financial royalty asset over the periods for which we are entitled to royalties or milestones. These forecasts are based on input from internal and external market research that analyzes factors such as growth in global economies, industry trends and product life cycles. When royalty-bearing biopharmaceutical products have no coverage, limited sell-side equity research analyst coverage or where sell-side equity research analyst consensus sales estimates are not available for the full term of the royalty, particularly for the later years in a product&#x2019;s life, management uses reasonable judgment to make assumptions about the growth or decline in the sales of these products based on historical data, market trends and management&#x2019;s own expertise. For the majority of the portfolio of financial royalty assets, management utilizes statistical curves based on historical trends to project future sales when sell-side equity research analyst consensus sales estimates end or are not available for the full term of the royalty. In other cases, management may develop and apply growth rate estimates from existing sell-side equity research analysts&#x2019; consensus sales forecasts to project future sales for products that cannot be modeled through the statistical curves, such as those where the entrance of a biosimilar is expected to impact future sales. Based on the level of detail in sell-side equity research analyst models, management can also be required to apply assumptions to the sales forecasts to estimate the quarterly and geographical allocation from annual sales projections and, for franchised products, to estimate the product mix and pricing mix, or to exclude from projections sales forecasts for unapproved products or indications. Our contractual royalty terms, rates, and any milestones are then applied to the adjusted sales projections to calculate the expected royalty or milestone payments over the term of the financial royalty asset&#x2019;s life, forming the basis for our forecast of expected future cash flows used to calculate and measure interest income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Commercial performance.&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The approval of a product for use in new indications can extend the date through which we are entitled to royalties or milestones on that product. For certain financial royalty assets, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and whose sales were previously not reflected in expected future cash flows. We generally do not recognize income from, or forecast sales for, unapproved products or indications. If a product is removed from all or a portion of a market, subsequent sell-side equity research analysts&#x2019; consensus sales forecasts will reflect the expected drop in sales. Both the new cash flow streams and the cessation of cash flow streams related to a product&#x2019;s performance in the market over the royalty term can materially affect our forecast of expected future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Royalty duration. &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The duration of a royalty can be based on a number of factors, such as regulatory and marketing approval dates, patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, the entry of generics or a contractual date arising from litigation, which are all impacted by the time in the product&#x2019;s life cycle at which we acquire the royalty. Royalty duration varies by geography as United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms. Products may be covered by a number of patents and, for products whose royalty term is linked to the existence of valid patents, management is required to make judgments about the patent providing the strongest patent protection to align the period over which management forecasts expected future cash flows to the royalty term. It is common for the latest expiring patent in effect at the date we acquire a financial royalty asset to be extended, adjusted or replaced with newer dated patents subsequent to our acquisition of a royalty due to new information, resulting in changes to the royalty duration in later periods. Patents may expire earlier than expected at the time of the acquisition due to the loss of patent protection, loss of data exclusivity on intellectual property, contractual licensing terms limiting royalty payments based on time from product launch, due to recent legal developments or litigation. Macroeconomic factors, such as changes in economies or the competitive landscape, including the unexpected loss of exclusivity to the products underlying our portfolio of royalties, changes in government legislation, product life cycles, industry consolidations and other changes beyond our control could result in a positive or negative impact on our forecast of expected future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the preparation of the forecasted expected future cash flows, which relies on the sources and variables discussed above, management is required to make assumptions around the following forecast inputs: (1) estimates of the duration of the royalty, which includes consideration of the strength of patent protection and anticipated entry of generics, (2) product growth rates and sales trends in outer years, (3) the product and pricing mix for franchised products, and (4) the geographical allocation of annual sales data from sell-side equity research analysts&#x2019; models. The most sensitive of these assumptions relates to management&#x2019;s estimate of the royalty duration in the final years of an asset&#x2019;s life. In some cases, patent protection may extend to a later period than the expiration date management has estimated. Management may apply a shorter royalty term in this situation if, based on its experience and expertise, management believes that it is more likely that the associated patents are subject to opposition or infringement, that the market for a particular product may shift based on pipeline approvals and products, or that product sales may be harmed by competition from generics. For products providing perpetual royalties, management applies judgment in establishing the duration over which it forecasts expected future cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A shortened royalty term can result in a reduction in the effective interest rate, a decline in the carrying value of the financial royalty asset, a decline in income from financial royalty assets, significant reductions in royalty payments compared to expectations, or a permanent impairment. Additionally, royalty payments may occasionally continue beyond the estimated royalty expiration date for such reasons we cannot foresee such as excess inventory in the channel or additional scope of patent protection identified after expiry, including royalties we may become entitled to from new indications, new compounds, or for new regulatory jurisdictional approvals.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The current portion of &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial royalty assets, net&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter and for which the estimates are derived from the latest external publicly available sell-side equity research analyst reports, reported in arrears. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cumulative allowance and Provision for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate financial royalty assets for impairment on an individual basis by comparing the effective interest rate at each reporting date to that of the prior period. If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected), we record a provision for the change in expected cash flows. The provision is measured as the difference between the financial royalty asset&#x2019;s amortized cost basis and the net present value of the expected future cash flows, calculated based on the prior period&#x2019;s effective interest rate. The amount recognized as provision expense increases the financial royalty asset&#x2019;s cumulative allowance, which reduces the net carrying value of the financial royalty asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance for the increase in the present value of cash flows expected to be collected, resulting in a non-cash credit to the provision line on the income statement. We also recalculate the amount of accretable yield to be received based on the revised remaining future cash flows. The adjustment to the accretable yield is treated as a change in estimate and is recognized prospectively over the remaining life of the financial royalty asset by adjusting the effective interest rate used to calculate income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Movements in the cumulative allowance for changes in expected future cash flows, which forms part of the &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial royalty assets, net&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; line item on the consolidated balance sheet, are accompanied by corresponding changes to the provision. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. Recoveries of previously written-off amounts are credited to the allowance. In some cases, when a financial royalty asset&#x2019;s contractual cash flows expire, the final royalty payment may differ from the remaining net carrying value. We account for this non-cash true-up at the end of the royalty term as either &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or as &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from financial royalty assets&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income from financial royalty assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. The accretable yield is recognized as income at the effective rate of return over the expected life of financial royalty assets. After acquisition of a financial royalty asset, if we are not able to reliably estimate expected cash flows for a product or if we have not completed the required funding obligations payable over time for an approved product, a financial royalty asset is placed in non-accrual status (e.g., for royalties from products that have not yet received FDA approval or for accelerated royalties). Such financial royalty assets are held at cost and no income is recognized until the reasonable expectation of the timing of the future cash flows to be collected is available or until funding obligations payable over time for an approved product are complete. We evaluate such financial royalty assets held at cost for impairment based on, among other factors, a review of development progress, clinical trial results, and publicly available information around regulatory discussions and approval status. An impairment loss is recognized if, based on current information and events, it is probable that we will be unable to collect amounts due according to the contractual terms of the financial royalty asset, and the amount of loss can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When royalties are received for financial royalty assets that have been fully amortized, such income is recognized as &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other royalty income.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinanceLoansAndLeasesReceivablePolicy>
    <us-gaap:CreditLossFinancialInstrumentPolicyTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDM1_88471635-714e-4134-b992-2b6bc34e2824">&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On January 1, 2020, we adopted ASU 2016-13, &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(&#x201c;ASU 2016-13&#x201d;) which requires earlier recognition of credit losses. We now recognize an allowance for current expected credit losses on our portfolio of financial royalty assets with limited protective rights. The credit loss allowance is estimated using the probability of default and loss given default method. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the probability of default of the marketers responsible for paying our royalties and the resulting loss given default. The allowance for current expected credit losses is presented net within the non-current portion of &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial royalty assets, net&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; on the consolidated balance sheets. Any subsequent movement in the allowance for credit losses is recorded as part of the &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Provision for changes in expected future cash flows from financial royalty assets&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; on the consolidated statements of operations.&lt;/span&gt;</us-gaap:CreditLossFinancialInstrumentPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDI5_4e23b787-a260-4257-9679-d9d4269ced8a">Currently, our only intangible royalty assets are the Januvia and Janumet (&#x201c;DPP-IV&#x201d;) patents. The DPP-IV patents are finite-life intangible royalty assets whose cost is amortized using the straight-line method over the expected lives of the patents, the majority of which terminate at various dates through 2022. The amortization period commenced concurrent with the sale of the product underlying the royalty asset.&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management reviews the performance of intangible royalty assets periodically for impairment as required by ASC 360-10,&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Property, Plant, and Equipment - Overall&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The test for recoverability is performed by comparing the carrying value of the intangible royalty asset with the estimated future undiscounted cash flows generated through royalty payments from sales of the underlying DPP-IV products. When evaluating indicators of impairment, we consider factors such as competitive environment and the product&#x2019;s life cycle stage, recent and prospective sales trends, collectability concerns, and any potential rebate chargebacks that may occur at the end of a royalty&#x2019;s term. An impairment loss is recognized if the carrying value of the intangible royalty asset is not recoverable and its carrying amount exceeds its fair value.&lt;/span&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDQz_44342ddb-8291-48fa-87f8-70d3409a9f46">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We earn royalties on sales by our licensees of DPP-IV products covered under patents that we own. We do not have future performance obligations under these license arrangements. Royalty revenue from sales of DPP-IV products is recognized in the period the product is sold. However, under the license agreements, licensees generally provide royalty reports and payments on a one quarter lag. Thus, the accrued royalty receivable is based on an analysis of historical royalties received and sell-side equity research analysts&#x2019; projected sales, adjusted for any changes in estimates. Royalty-bearing sales are net of certain rebates and other discounts, as permitted under the terms of the license agreements. Because rebates are generally invoiced and paid in arrears by the marketer, royalty reports often reflect deductions in current periods for rebates related to prior periods which we do not have the ability to estimate.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Critical estimates that could cause a change in estimated future cash flows include changes in product demand and market growth assumptions, a change in the pricing strategy of the marketer or reimbursement coverage, and changes in country-specific contractual or patent expiry dates. Actual royalty receipts may differ from estimates and any differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically on the basis of royalty receipts.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Milestone payments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain acquisition agreements provide for future incoming or outgoing contingent payments based on the commercial, regulatory or clinical performance of the related biopharmaceutical product generally over a multi-year period. For purposes of measuring income from financial royalty assets, commercial milestones payable or receivable are reflected in the cash flows used to forecast expected future cash flows in the period in which the milestone criteria is projected to be satisfied based on sell-side equity research analysts&#x2019; consensus sales forecasts. Milestones based on regulatory approval or clinical criteria are generally not reflected in the expected future cash flows until such approval is achieved.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts related to outgoing contingent milestone payments are not considered contractual obligations as they are contingent on the successful completion of the defined milestones. Payments under these agreements generally become due and payable upon achievement of certain commercial milestones, and when the contingency is resolved.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDM4_dc148f29-a086-432c-a52a-2ae26f4d9de1">&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Certain financial instruments reflected in the consolidated balance sheets, (e.g., cash and cash equivalents, certain other assets, accounts payable and certain other liabilities) are recorded at cost, which approximates fair value due to their short-term nature. The fair values of financial instruments other than &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial royalty assets, net&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; are determined through a combination of management estimates and information obtained from third parties using the latest market data. The fair value of financial instruments is determined utilizing the valuation techniques appropriate to the type of instrument as discussed in Note 5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair Value Measurements and Financial Instruments.&lt;/span&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDQ1_e0101476-d76e-4c6c-8f9b-330e10b3ffb2">Cash and cash equivalents include cash held at banks and all highly liquid financial instruments with original maturities of 90 days or less. We invest excess cash in marketable debt securities that are classified as trading securities and reported at fair value.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <rprx:DebtSecuritiesAvailableForSalePolicyPolicyTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDM2_69081e90-88ca-4254-97eb-fc897a5e38c5">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our equity securities are measured and recorded at fair value with unrealized gains and losses recorded in earnings. Our equity securities represent investments in publicly traded equity securities. Available for sale debt securities are measured at fair value. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The unrealized change in fair value of available for sale debt securities for which we elected the fair value option is recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Unrealized gains on available for sale debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;on the consolidated statements of operations. The &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;unrealized change in fair value for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Biohaven Series A Preferred Share is&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; included in &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accumulated other comprehensive income &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(&#x201c;AOCI&#x201d;) and are reclassified to earnings as interest income is recognized. Interest income is recognized when we can reliably estimate forecasted cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A decline in the market value of any available for sale debt security below its cost that is deemed to have resulted from a credit loss results in a reduction in carrying amount to fair value and is recognized in earnings. The determination of whether a decline in fair value below the amortized cost basis for an available for sale debt security has resulted from a credit loss requires significant judgment and requires consolidation of available quantitative and qualitative evidence in evaluating the potential impairment. Factors evaluated to determine whether a decline in the fair value below the amortized cost basis has resulted from a credit loss include: the extent to which fair value is less than the amortized cost basis, adverse conditions related to the security, an industry, or geographic area, the payment structure of the security, failure of the issuer to make scheduled payments, any changes to the rating of the security by a rating agency, the remaining payment terms of the security, prepayment speeds, the financial condition of the issuer expected defaults, our intent not to sell, and an evaluation as to whether it is more likely than not that we will have to sell before recovery of the cost basis. Assumptions associated with these factors are subject to future market and economic conditions, which could differ from management&#x2019;s assessment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may elect to apply the fair value option for certain investments in debt securities where the fair value option better aligns with the economics of such investment. Upon such election, the entire investment is measured at fair value on a recurring basis, with movements in fair value recognized in earnings.&lt;/span&gt;&lt;/div&gt;</rprx:DebtSecuritiesAvailableForSalePolicyPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDM3_436a26d5-499f-4b71-a197-0512b8dd0062">All derivatives are measured at fair value on the consolidated balance sheets with movements in fair value recognized in earnings. Prior to 2017, RPIFT applied hedge accounting to its interest rate swap agreements. &lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the discontinuation of hedge accounting, the AOCI previously recorded on the cash flow hedges was reversed out of other comprehensive income in line with terms of the associated swap contract until the termination of all of our interest rate swaps in February 2020. This reclassification adjustment is shown on the consolidated statements of operations as part of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Losses on derivative financial instruments&lt;/span&gt;.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDMw_78d2b340-8ae3-4908-bf0d-93ee96876d7c">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Investments in entities that provide us with the ability to exercise significant influence, but not a controlling financial interest, and where we are not the primary beneficiary are accounted for under the equity method. Investments accounted for under the equity method are initially recorded at fair value. If there is a difference between the fair value and the carrying amount of the equity method investment at inception, we quantify the basis difference and amortize it in a rational manner over the life of the investment. Subsequently, we recognize through earnings our proportionate share of the investee&#x2019;s net income or loss, net of any adjustment to reflect the amortization of basis differences. We generally record our share of the results of our investees one quarter in arrears within &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Equity in losses/(earnings) of non-consolidated affiliates&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; in the consolidated statements of operations. The investment is reflected as &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Investments in non-consolidated affiliates&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We have variable interests in entities formed for the purposes of entering into co-development arrangements for potential biopharmaceutical products (the &#x201c;Avillion entities&#x201d;). The Avillion entities are variable interest entities for which we are not the primary beneficiary as we do not have the power to direct the activities that most significantly influence the economic performance of the entity. In determining whether we are the primary beneficiary of an entity, management applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant. Management continuously assesses whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of one or more of its investees.&lt;/span&gt;&lt;/div&gt;When we have committed to provide further support to the investee through capital call commitments and the investment has been reduced to zero, we provide for additional losses, resulting in a negative equity method investment, which is presented as a liability on the consolidated balance sheets.</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDMz_39eafcfa-ebaf-470a-81b5-3fafed6acfc2">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We enter into transactions where we agree to fund a portion of the research and development (&#x201c;R&amp;amp;D&#x201d;) performed by our partners for products undergoing late-stage clinical trials in exchange for future royalties or milestones if the products are successfully developed and commercialized. In accordance with ASC 730, &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Research and Development&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, we account for the funded amounts as R&amp;amp;D expense when we have the ability to obtain the results of the R&amp;amp;D, the transfer of financial risk is genuine and substantive and, at the time of entering into the transaction, it is not yet probable that the product will receive regulatory approval. We may pay funded amounts upfront or over time as the underlying products undergo clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty payments owed to the Company on successfully commercialized products generated from R&amp;amp;D arrangements are recognized as &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other royalty income&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the same period in which the sale of the product occurs. Fixed or milestone payments receivable based on the achievement of contractual criteria for products arising out of our R&amp;amp;D arrangements are also recognized as &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other royalty income&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the period that the milestone threshold is met. Milestone thresholds are typically not triggered until after all funding obligations have been completed.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDI0_2bf26074-3925-4bb4-9285-7e923e90f5bb">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically assess if our activities, as conducted through our subsidiaries, and as currently contemplated, constitute being engaged in the conduct of a trade or business within the United States. Neither the U.S. Internal Revenue Code (&#x201c;the Code&#x201d;) nor the applicable Treasury regulations provide a general definition of what constitutes being engaged in the conduct of a trade or business within the United States, and the limited case law on the subject does not provide definitive guidance. Based on our periodic assessment, we believe that we are not engaged in the conduct of a trade or business within the United States, and as such, we do not record a provision for U. S. federal income tax for the years presented in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While we believe we are not engaged in the conduct of a trade or business within the United States or subject to U.S. taxation in that regard, we are subject to U. S. federal withholding tax on certain fixed or determinable annual or periodical gains, profits and income, such as royalties from sources within the United States, unless reduced or eliminated under an applicable tax treaty or provision of the Code. Generally, this tax is imposed by withholding 30% of the payments, or deemed payments, that are subject to this tax. We believe our subsidiaries are eligible for benefits under the U.S.-Ireland income tax treaty, and, under that treaty, are not be subject to any U.S. withholding taxes on U.S.-source royalty payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consequently, because we believe that we are not engaged in the conduct of a trade or business within the United States and our subsidiaries are eligible for benefits under the U.S.-Ireland tax treaty, we do not record a provision for income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;While we do not currently record a provision for income taxes, we are party to certain arrangements that will give rise to a tax provision in the future. We currently have funding arrangements in place that allow our counterparties to draw on capital over a prescribed period of time. When such funding arrangements are drawn and we begin to recognize income from these funding arrangements, such activities will be subject to U.S. taxation and we will record a provision for income taxes in accordance with ASC 740, &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. We also entered into an arrangement with MSCI during 2021 as discussed in Note 16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Related Party Transactions that will become subject to U.S. taxation when we begin to recognize revenue from this transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate so as to be treated solely as resident in the U.K. for tax purposes. As a U.K. tax resident company, we are subject to U.K. corporation tax on our worldwide taxable profits and gains. U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. As such, we do not record a provision for U.K. income taxes with respect to the dividends received from RP Holdings or with respect to the dividends received by RP Holdings from RPI. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also subject to the U.K.&#x2019;s &#x201c;controlled foreign companies&#x201d; rules (the &#x201c;U.K. CFC Rules&#x201d;). The U.K. CFC Rules, broadly, can impose a charge to U.K. tax on U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the &#x201c;Controlled Foreign Company&#x201d;) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI (which is Irish tax resident) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and Old RPI (which is Irish tax resident and which is held indirectly by us through our participation in RP Holdings)&lt;/span&gt;, will be Controlled Foreign Companies for U.K. tax purposes. We are therefore required to apply the CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis.  We do not expect material U.K. corporation tax charges to arise under the U.K. CFC Rules in respect of our royalty assets and we therefore do not record a provision for U.K. income taxes.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDI1_ea6095b0-5223-4669-9c9f-da5fe8db94a3">Basic earnings per share (&#x201c;EPS&#x201d;) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include the outstanding Class B ordinary shares, Class B ordinary shares contingently issuable to RPI EPA Holdings, LP (&#x201c;EPA Holdings&#x201d;) related to Equity Performance Awards and unvested restricted share units (&#x201c;RSUs&#x201d;) issued under our 2020 Independent Director Equity Incentive Plan (&#x201c;Equity Incentive Plan&#x201d;). We include potentially dilutive shares in the denominator to compute diluted EPS if (i) the inclusion of the ordinary shares is dilutive for the respective reporting periods, and (ii) contingencies are satisfied as of the end of the reporting period for ordinary shares that are contingently issuable.  We use the &#x201c;if-converted&#x201d; method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzQzMDQ0_50f53c24-45d2-4144-9ca8-15077b1b4463">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model (ASU 2016-13). Accordingly, these financial assets are presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model.  With certain exceptions, adjustments are applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Retained earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of $192.7&#160;million to recognize an allowance for current expected credit losses on our financial royalty assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued a new accounting standard that eliminates, adds and modified certain disclosures requirements for fair value measurements under Topic 820 (ASU 2018-13). The ASU modifies the disclosures by removing the requirement to disclose the amount and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers. The ASU expands the disclosure requirements for Level 3 fair value measurements, primarily focused on changes in unrealized gains and losses included in other comprehensive income/(loss). We adopted this standard as of January 1, 2020 with no material impact on our consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib04d3453e6dc4ca3a0b79e01ab3fe12a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTUvZnJhZzpkNjIzZjU4Y2M0Nzg0Y2Q2OWIzNGRlYTU2ODQ1NDBkNi90ZXh0cmVnaW9uOmQ2MjNmNThjYzQ3ODRjZDY5YjM0ZGVhNTY4NDU0MGQ2XzE2NDkyNjc0OTA5MTk_aa4f397a-6877-45c0-b096-fe40ac0a87f1"
      unitRef="usd">-192700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzU2ODE_b27eb228-5bbf-4d3a-bcbb-7aac26143546">Available for Sale Debt Securities &lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Series A Biohaven Preferred Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On April 5, 2019, RPIFT funded the purchase of 2,495 Series A Biohaven Preferred Shares from Biohaven Pharmaceutical Holding Company Ltd. (&#x201c;Biohaven&#x201d;) at a price of $50,100.00 per preferred share, for a total of $125.0&#160;million (the &#x201c;First Tranche&#x201d;). The approval of Nurtec ODT by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) in February 2020 results in a payment due to us of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments beginning in the three months ended March 31, 2021 through the three months ended December 31, 2024. In the three months ended March 31, 2021, we began receiving payments from the quarterly redemption of the Series A Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to redeem, in a single payment, any outstanding Series A Biohaven Preferred Shares at a price equal to two times the original purchase price of the Series A Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series A Biohaven Preferred Shares, in a single payment, at a price equal to two times the original purchase price. In the event that Biohaven defaults on any obligation to redeem Series A Biohaven Preferred Shares when required, the redemption amount shall accrue interest at the rate of 18% annually until the redemption price for such unredeemed Series A Biohaven Preferred Shares is paid in full, subject to applicable law. If any such default continues for at least one year, we will be entitled to convert all unredeemed Series A Biohaven Preferred Shares into common shares equal to the redemption price, plus accrued interest, divided by the five-day volume-weighted trading price immediately preceding the conversion date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Series A Biohaven Preferred Shares are classified as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Available for sale debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; in our consolidated balance sheets. The unrealized change in the fair value of the Series A Biohaven Preferred Shares is recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Unrealized gains on available for sale debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;on the consolidated statements of comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Series B Biohaven Preferred Shares &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On August 7, 2020 we entered into a Series B Biohaven Preferred Share Purchase Agreement (&#x201c;Series B Biohaven Preferred Share Agreement&#x201d;) with Biohaven where we committed to acquire 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share (the &#x201c;Commercial Launch Preferred Equity&#x201d;), for a total of $200.0&#160;million payable on a quarterly basis between the three months ended March 31, 2021 and the three months ended December 31, 2024. Our commitment to purchase the Series B Biohaven Preferred Shares is recognized as the Series B Forwards. In return, Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between March 31, 2025 and December 31, 2030 at a price equal to approximately 1.8 times the original purchase price of the Series B Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to issue to us all unissued Series B Biohaven Preferred Shares and to redeem, in a single payment, any outstanding Series B Biohaven Preferred Shares at a price equal to approximately 1.8 times the Series B original issue price per share. Biohaven may redeem at their election, any outstanding Series B Biohaven Preferred Shares, in a single payment, at a price equal to approximately 1.8 times the original issue price for the Series B Biohaven Preferred Shares. In the event that Biohaven defaults on any obligation to redeem Series B Biohaven Preferred Shares, the redemption amount shall accrue interest on the applicable original issue price at the rate of 18% annually until the redemption price for such unredeemed Series B Biohaven Preferred Shares is paid in full, subject to applicable law. If any such default continues for at least one year, we will be entitled to convert any or all unredeemed Series B Biohaven Preferred Shares into common shares equal to the redemption price, plus accrued interest, divided by the five-day volume-weighted trading price immediately preceding the conversion date. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the three months ended March 31, 2021, we began purchasing the Series B Biohaven Preferred Shares. As of December 31, 2021, we have acquired 1,406 shares of Series B Biohaven Preferred Shares. We have elected the fair value option to account for the Series B Forwards and the Series B Biohaven Preferred Shares, which are recorded in aggregate on the consolidated balance sheets as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available for sale debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We believe the fair value option most accurately reflects the nature of these instruments. The unrealized change in fair value of the Series B Biohaven Preferred Shares and Series B Forwards is recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unrealized gains on available for sale debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MorphoSys Development Funding Bonds&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys AG (&#x201c;MorphoSys&#x201d;) to support MorphoSys&#x2019; acquisition of Constellation Pharmaceuticals, Inc. (&#x201c;Constellation&#x201d;), which closed on July 15, 2021. As part of the funding agreement, we agreed to provide MorphoSys up to $350&#160;million of capital (the &#x201c;Development Funding Bonds&#x201d;), which MorphoSys may draw over a one-year period from the close of its acquisition of Constellation. MorphoSys is required to draw a minimum of $150&#160;million. As of December 31, 2021, MorphoSys has not drawn any amount under the Development Funding Bonds. Our commitment to fund at least $150&#160;million of the Development Funding Bonds is recognized as the Development Funding Bond Forward. Once drawn, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years, with the first payment beginning two years after the funding. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We have elected the fair value option to account for the Development Funding Bond Forward as it most accurately reflects the nature of the instrument. The Development Funding Bond Forward is recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Available for sale debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; in our consolidated balance sheet. The unrealized change in fair value of the Development Funding Bond Forward is recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The table below summarizes our available for sale debt securities recorded at fair value as of December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.287%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Series A Biohaven Preferred Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Series B Biohaven Preferred Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Series B Forwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Development Funding Bond Forward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;204,509&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;65,891&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;270,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;66,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;204,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;270,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Series A Biohaven Preferred Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Series B Forwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;145,647&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;87,353&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;233,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;69,984&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;163,016&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;233,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)Cost for Series A Biohaven Preferred Shares represents amortized cost. Cost for Series B Biohaven Preferred Shares represents the amounts paid to purchase the instruments. There were no costs associated with the Series B Forwards and Development Funding Bond Forward.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased
      contextRef="ie7ffbb1b682a454ea429c1fb003ce9d8_D20190405-20190405"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzUyOA_678205c2-cfb1-4aa7-a2a4-e2dfbe01991a"
      unitRef="shares">2495</rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased>
    <rprx:DebtSecuritiesAvailableForSalePricePerShare
      contextRef="ie7ffbb1b682a454ea429c1fb003ce9d8_D20190405-20190405"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzU5NA_a5b32a54-282d-4a4b-b919-375a675350f3"
      unitRef="usdPerShare">50100</rprx:DebtSecuritiesAvailableForSalePricePerShare>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ia849c0d494314af388e9fb0fc01f197d_D20190405-20190405"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzYzMw_62a3c5e1-4474-4e79-ae4c-ca8c59935f03"
      unitRef="usd">125000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <rprx:DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate
      contextRef="ie7ffbb1b682a454ea429c1fb003ce9d8_D20190405-20190405"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzE0OTE_7a6a0db2-0f09-4539-a09d-e23f29624b96"
      unitRef="number">0.18</rprx:DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate>
    <rprx:DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod
      contextRef="ie7ffbb1b682a454ea429c1fb003ce9d8_D20190405-20190405"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzEwOTk1MTE2MzYzODY_7b432db8-89c6-471e-b424-a09d317bbe49">P1Y</rprx:DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod>
    <rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased
      contextRef="i3f03e1e1f0254cb1bffbcef4de9ba54d_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzIxNDE_ab8b1d02-3c2f-405e-9930-4ac6131b2a06"
      unitRef="shares">3992</rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased>
    <rprx:DebtSecuritiesAvailableForSalePricePerShare
      contextRef="i3f03e1e1f0254cb1bffbcef4de9ba54d_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzIyMDM_0425640d-f1ad-424e-9c41-ebbeca43fa32"
      unitRef="usdPerShare">50100</rprx:DebtSecuritiesAvailableForSalePricePerShare>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i82b90b8f41a142668c8944a95809becc_D20200807-20200807"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzIyODU_57be69e1-5029-4042-aed0-e37267451466"
      unitRef="usd">200000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <rprx:DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate
      contextRef="i3f03e1e1f0254cb1bffbcef4de9ba54d_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzM1MDc_ebedde15-60d0-492f-9697-8fec95b6f14f"
      unitRef="number">0.18</rprx:DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate>
    <rprx:DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod
      contextRef="i3f03e1e1f0254cb1bffbcef4de9ba54d_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzM2ODg_4973b2e2-1a23-467e-954c-38d5ce76fdda">P1Y</rprx:DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod>
    <rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased
      contextRef="i1c9ec20561ed410bb20159b77b9b7247_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzEwOTk1MTE2NDEwMzQ_e7dd1a1f-23a0-4f13-be3f-e7512d1ac8b7"
      unitRef="shares">1406</rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased>
    <rprx:CollaborativeArrangementRightsAndObligationsPaymentOfCapital
      contextRef="ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzEwOTk1MTE2NDEwOTc_0132b80f-f7f5-41af-afdb-0c37a4e94ddb"
      unitRef="usd">350000000</rprx:CollaborativeArrangementRightsAndObligationsPaymentOfCapital>
    <rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund
      contextRef="ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzEwOTk1MTE2NDExMTI_1ad35bfd-d202-48ee-bc20-0a93c18bc695"
      unitRef="usd">150000000</rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund>
    <rprx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments
      contextRef="ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzEwOTk1MTE2NDExMjc_b052fc2c-eabb-49e0-86c7-2a5de9b45af5"
      unitRef="usd">150000000</rprx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments>
    <rprx:CollaborativeArrangementRightsAndObligationsPeriodOfReturn
      contextRef="ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzE0MjkzNjUxMTc1NTM1_d73e5ad8-bd48-4b3c-9686-ea24b9976a9c">P9Y</rprx:CollaborativeArrangementRightsAndObligationsPeriodOfReturn>
    <rprx:CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate
      contextRef="ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzE0MjkzNjUxMTc1NTE2_33575444-a817-4161-9828-11358e1160d3">P2Y</rprx:CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90ZXh0cmVnaW9uOmMyMmU0NGZlNDQzNTQ1MWJhN2NkMzVmOWU2ZTlhYmVlXzE0MjkzNjUxMTc0Nzkx_abc284c7-f051-40b7-902a-9ab30ded2bb8">&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The table below summarizes our available for sale debt securities recorded at fair value as of December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.287%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Series A Biohaven Preferred Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Series B Biohaven Preferred Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Series B Forwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Development Funding Bond Forward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;204,509&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;65,891&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;270,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;66,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;204,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;270,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Series A Biohaven Preferred Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Series B Forwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;145,647&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;87,353&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;233,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;69,984&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;163,016&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;233,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)Cost for Series A Biohaven Preferred Shares represents amortized cost. Cost for Series B Biohaven Preferred Shares represents the amounts paid to purchase the instruments. There were no costs associated with the Series B Forwards and Development Funding Bond Forward.</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9aa7200994f445fd859a024412126926_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzItMS0xLTEtMjU3NjQ_437c07d9-2935-4d61-90a7-3b4fe97ce247"
      unitRef="usd">134068000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9aa7200994f445fd859a024412126926_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzItMy0xLTEtMjU3NjQ_125c70fb-f235-42d5-8e3e-2f087df4caba"
      unitRef="usd">29432000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9aa7200994f445fd859a024412126926_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzItNS0xLTEtMjU3NjQ_0564482c-300f-4879-b5ef-b545e78b7cc0"
      unitRef="usd">163500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i9aa7200994f445fd859a024412126926_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzItNy0xLTEtMzc5MzY_5ec675ac-49e6-4d66-99a2-3f5f34bd6083"
      unitRef="usd">66000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i9aa7200994f445fd859a024412126926_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzItOS0xLTEtMzc5NDM_d818c753-713d-4638-878b-229e846d777e"
      unitRef="usd">97500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9aa7200994f445fd859a024412126926_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzItMTEtMS0xLTM3OTUw_e81431a5-4057-487f-935c-9db388420a6c"
      unitRef="usd">163500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibdc9b73456ed4691907032f9740bfd6a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzMtMS0xLTEtMjU3NjQ_ca3e8e7d-0cf7-4d48-9c1f-e5afdab77577"
      unitRef="usd">70441000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibdc9b73456ed4691907032f9740bfd6a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzMtMy0xLTEtMjU3NjQ_a4443233-6235-42a4-8391-c03176a7718f"
      unitRef="usd">19759000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibdc9b73456ed4691907032f9740bfd6a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzMtNS0xLTEtMjU3NjQ_5311b02b-5f54-4fa8-b76d-e5571c6785a9"
      unitRef="usd">90200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibdc9b73456ed4691907032f9740bfd6a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzMtNy0xLTEtMzc5MzY_1e5bc225-8880-436c-8b7c-0f6f247cba25"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ibdc9b73456ed4691907032f9740bfd6a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzMtOS0xLTEtMzc5NDM_8a38e2e8-d5c0-41eb-a7bc-47110f04cf3c"
      unitRef="usd">90200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibdc9b73456ed4691907032f9740bfd6a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzMtMTEtMS0xLTM3OTUw_725e9965-340b-4684-9d19-800571f74762"
      unitRef="usd">90200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i60d163174d8f44a18183225e8dcce57d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzQtMS0xLTEtMjU3NjQ_60d90203-6887-4a95-998a-4ddfe2186cce"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i60d163174d8f44a18183225e8dcce57d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzQtMy0xLTEtMjU3NjQ_956cf625-8a0c-4431-8200-24d53bd38428"
      unitRef="usd">12300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i60d163174d8f44a18183225e8dcce57d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzQtNS0xLTEtMjU3NjQ_f1817faf-28ab-47b2-8d55-e23fe159a5b4"
      unitRef="usd">12300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i60d163174d8f44a18183225e8dcce57d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzQtNy0xLTEtMzc5MzY_d75d699a-cf66-4e2f-b205-9134aeed9ad7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i60d163174d8f44a18183225e8dcce57d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzQtOS0xLTEtMzc5NDM_931c7c3e-6737-4357-9ca1-c6457e5f5a4d"
      unitRef="usd">12300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i60d163174d8f44a18183225e8dcce57d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzQtMTEtMS0xLTM3OTUw_c71bb9bf-5feb-4d26-bc72-62f9948dd8ea"
      unitRef="usd">12300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i98c2c17dcf19455ebbe7cea65ea027d8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzUtMS0xLTEtMjU3NjQ_eed23ded-dea9-4525-9945-1b010c1d07f8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i98c2c17dcf19455ebbe7cea65ea027d8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzUtMy0xLTEtMjU3NjQ_8653994e-c799-41c1-b5e7-4b2dd5738238"
      unitRef="usd">4400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i98c2c17dcf19455ebbe7cea65ea027d8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzUtNS0xLTEtMjU3NjQ_4f49bb2f-3806-4281-aa85-7233af1d71f3"
      unitRef="usd">4400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i98c2c17dcf19455ebbe7cea65ea027d8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzUtNy0xLTEtMzc5MzY_d0235dfb-5f5d-4c45-9217-ae9fc379d527"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i98c2c17dcf19455ebbe7cea65ea027d8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzUtOS0xLTEtMzc5NDM_806d19a6-23da-4a51-bb43-20fe2d12d15b"
      unitRef="usd">4400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i98c2c17dcf19455ebbe7cea65ea027d8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzUtMTEtMS0xLTM3OTUw_eb7aaf34-f403-4031-a7f4-b1463e4282de"
      unitRef="usd">4400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzYtMS0xLTEtMjU3NjQ_232a647d-30e7-47ca-a21f-8f449a857575"
      unitRef="usd">204509000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzYtMy0xLTEtMjU3NjQ_c0b61da7-51eb-425b-a434-138701137916"
      unitRef="usd">65891000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzYtNS0xLTEtMjU3NjQ_6a15ad7f-9944-4242-b278-230214f72606"
      unitRef="usd">270400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzYtNy0xLTEtMzc5MzY_a4fca268-17e2-44f7-8a94-9e0fb0db19ff"
      unitRef="usd">66000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzYtOS0xLTEtMzc5NDM_d8ba2f87-f681-4096-b207-087e1026effc"
      unitRef="usd">204400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzYtMTEtMS0xLTM3OTUw_a25921ee-a114-4491-8679-6372d00f4825"
      unitRef="usd">270400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icfc7e15ceae44635ac92046eaa0b27e9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzktMS0xLTEtMzc4NzY_868b333a-d674-4e7c-92e8-e76399e326c3"
      unitRef="usd">145647000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icfc7e15ceae44635ac92046eaa0b27e9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzktMy0xLTEtMzc5MDE_0312d0da-20c2-4d56-88ef-31f32d9cac87"
      unitRef="usd">68753000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icfc7e15ceae44635ac92046eaa0b27e9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzktNS0xLTEtMzc5MjY_e3a4df15-dc26-49f9-b062-b6c18fb79043"
      unitRef="usd">214400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="icfc7e15ceae44635ac92046eaa0b27e9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzktNy0xLTEtMzc5MzY_6e1b6f6a-a2a3-47e3-92b5-d75011043391"
      unitRef="usd">69984000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="icfc7e15ceae44635ac92046eaa0b27e9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzktOS0xLTEtMzc5NDM_2075e2df-c840-4018-81ed-2578104c5c19"
      unitRef="usd">144416000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icfc7e15ceae44635ac92046eaa0b27e9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzktMTEtMS0xLTM3OTUw_41e6109b-f1b6-4de1-8d8b-4b36850e41b1"
      unitRef="usd">214400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icfad0763e8bb4821b3d973d0d57f0477_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzEwLTEtMS0xLTM3ODc2_b6ba909e-99d6-497c-ada0-75f32146d92e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icfad0763e8bb4821b3d973d0d57f0477_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzEwLTMtMS0xLTM3OTAx_2eded706-26a6-4bc3-864f-2531d1adc682"
      unitRef="usd">18600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icfad0763e8bb4821b3d973d0d57f0477_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzEwLTUtMS0xLTM3OTI2_0ab7aedf-66ac-4b16-b3cf-c235a8b45c21"
      unitRef="usd">18600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="icfad0763e8bb4821b3d973d0d57f0477_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzEwLTctMS0xLTM3OTM2_4293011f-7d59-4cba-8a01-20df01cec7e5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="icfad0763e8bb4821b3d973d0d57f0477_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzEwLTktMS0xLTM3OTQz_0dba668a-e217-4e2e-af28-3878d1405742"
      unitRef="usd">18600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icfad0763e8bb4821b3d973d0d57f0477_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzEwLTExLTEtMS0zNzk1MA_0c899c82-a91b-477b-998f-ab0d63f97106"
      unitRef="usd">18600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzExLTEtMS0xLTM3ODc2_6b7c823d-b99a-4b2b-b8c9-6cdd3614be9c"
      unitRef="usd">145647000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzExLTMtMS0xLTM3OTAx_8f435ca1-13f7-4f06-be3e-9751ecab4c03"
      unitRef="usd">87353000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzExLTUtMS0xLTM3OTI2_7f175058-c15a-4744-8f00-00a0634e32bd"
      unitRef="usd">233000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzExLTctMS0xLTM3OTM2_343126d9-4e67-4467-a658-bddbbb580ae8"
      unitRef="usd">69984000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzExLTktMS0xLTM3OTQz_a3eca214-9c72-4d5f-a3d4-4b0336304664"
      unitRef="usd">163016000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjcvZnJhZzpjMjJlNDRmZTQ0MzU0NTFiYTdjZDM1ZjllNmU5YWJlZS90YWJsZTpiZDAyNTRkMTFiYzE0MzY4YjZhNmVmODg2Y2NhOTM5MC90YWJsZXJhbmdlOmJkMDI1NGQxMWJjMTQzNjhiNmE2ZWY4ODZjY2E5MzkwXzExLTExLTEtMS0zNzk1MA_b20fd613-82e3-461e-94be-c6e0fe2f891c"
      unitRef="usd">233000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzY4Nzk_958ab400-ba28-4009-823b-db7f9f482be7">Derivative Instruments&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have historically managed the impact of foreign currency exchange rate and interest rate risk through various financial instruments, including derivative instruments such as treasury rate lock contracts, interest rate swap contracts and foreign currency forward contracts. Our policy is to use derivatives strategically to hedge existing and future interest rate exposure and to minimize volatility in cash flow arising from our exposure to interest rate risk and foreign currency risk. We may also acquire other financial instruments that are classified as derivatives. We do not enter into derivative instruments for trading or speculative purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Treasury rate lock contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In June 2021, we entered into treasury rate lock contracts with notional amounts totaling $600.0&#160;million to manage the impact of fluctuations in the underlying benchmark interest rate associated with the 2021 Notes (as further discussed and defined in Note 11&#x2013;Borrowings). The treasury rate lock contracts were not designated as hedge instruments. All of the treasury rate lock contracts had collateral requirements. The treasury rate lock contracts were unwound and settled in connection with the issuance of the 2021 Notes and the resulting net loss was recognized in earnings in the year ended December 31, 2021. We paid $16.1&#160;million in July 2021 to terminate our treasury rate lock contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest rate swaps&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In February 2020, RPIFT terminated all outstanding interest rate swaps in connection with the Exchange Offer Transactions. We paid $35.4&#160;million to terminate these swaps and reclaimed $45.3&#160;million of collateral that was held by the respective counterparties. During the years ended December 31, 2020 and 2019, we recorded unrealized losses of $10.9 million and $72.6&#160;million, respectively, on interest rate swaps in the consolidated statements of operations. We did not enter into any interest rate swaps subsequent to the February 2020 termination discussed above and as of December 31, 2021, we do not hold any interest rate swap contracts. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Epizyme put option and warrant&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, RPIFT made an equity investment in Epizyme, Inc. (&#x201c;Epizyme&#x201d;) of $100.0&#160;million. Under the terms of the agreement with Epizyme, we made an upfront payment of $100.0&#160;million for (1) shares of Epizyme common stock, (2) a warrant to purchase an additional 2.5&#160;million shares of Epizyme common stock at $20 per share over a three-year term and (3) Epizyme&#x2019;s royalty on sales of Tazverik in Japan payable by Eisai Co., Ltd (&#x201c;Eisai&#x201d;). In addition, Epizyme had an 18 month put option to sell an additional $50.0&#160;million of its common stock to RPIFT at then prevailing prices, not to exceed $20 per share. On December 31, 2019, Epizyme notified RPIFT of its intention to exercise the put option. As a result, we recorded a forward purchase contract equal to the difference between the market value and exercise price of $11.5&#160;million within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets at December 31, 2019. The exercise of the put option was settled in February 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The warrant was recognized at fair value of $5.4&#160;million within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets at December 31, 2020. The fair value of the warrant was not material as of December 31, 2021. We recorded an unrealized loss of $5.4&#160;million, an unrealized loss of $25.4&#160;million and an unrealized gain of $22.0&#160;million on derivative contracts related to the change in fair value of the warrant on the consolidated statements of operations for the years ended December 31, 2021, 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of derivatives and reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below summarize the change in fair value of the derivatives for the years ended December 31, 2021, 2020 and 2019 and the line items within the consolidated statements of operations where the gains or losses on these derivatives are recorded (in thousands). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location on Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Derivatives in hedging relationships (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest Rate Swaps:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amount of loss reclassified from accumulated other comprehensive income into income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense/(income)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest Rate Swaps:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense/(income)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,977)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forward purchase contract:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of forward purchase contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Treasury rate lock contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of treasury rate lock contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) &#160;&#160;&#160;&#160;Certain interest rate swaps were previously designated as cash flow hedges. These swaps became ineffective as debt refinancings occurred between 2013 and 2016. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive income&lt;/span&gt; were released into earnings.</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i58e8c79f7b7640d089df3eefd8c4584f_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzEwOTk1MTE2MzQ4MDg_bcc8873d-bf70-49cb-b2c8-0aac65d1c888"
      unitRef="usd">600000000</us-gaap:DerivativeNotionalAmount>
    <rprx:PaymentsToTerminateDerivativeInstruments
      contextRef="i625666873b2d4977bdc6062d4f56c5df_D20210701-20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzEwOTk1MTE2MzU0OTM_e0c40cc6-b1be-4a2b-a338-65d77853d6fa"
      unitRef="usd">16100000</rprx:PaymentsToTerminateDerivativeInstruments>
    <rprx:PaymentsToTerminateDerivativeInstruments
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzEwOTk1MTE2NDM0OTI_f3e86e39-5e13-4d67-bf6f-a6d5fb015091"
      unitRef="usd">35400000</rprx:PaymentsToTerminateDerivativeInstruments>
    <rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzEwOTk1MTE2NDM0OTk_e34e5b3b-7c04-420c-8ed6-9b1f1af2099c"
      unitRef="usd">45300000</rprx:ProceedsFromCollateralReceivedOnDerivativeInstruments>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i4106b129e51b45058ce78e36709ad420_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzEwOTk1MTE2NDMxNzc_bf7ec6a0-6c32-4943-bf66-e48b6ca7011c"
      unitRef="usd">-10900000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i25065e59308648fd8df2e62e3adccc34_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzEwOTk1MTE2NDMzMDY_83aba55e-0ffa-4e13-bb17-1b05d78b93ac"
      unitRef="usd">-72600000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id3d1194dc3e540d18ba20eae1762f548_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzM3MTA_b73b3258-0877-4215-ade7-e50b7ad592b5"
      unitRef="usd">100000000</us-gaap:EquitySecuritiesFvNi>
    <rprx:PaymentsToAcquireEquityInvestmentsUpfrontPayment
      contextRef="i7dfa9c83d55a4cd497bbc3d7fa0263f5_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzM3OTQ_497c31ab-e93c-4a1c-811d-5d248a0d5cb3"
      unitRef="usd">100000000</rprx:PaymentsToAcquireEquityInvestmentsUpfrontPayment>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="iede0453e00c74915afde71174a783562_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzM4Nzc_9a1bcd92-ab44-4e70-acbc-768bd848e25d"
      unitRef="shares">2500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7cb61b17854748238238595ab84bc83d_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzM5MTQ_0a0531c3-d7e1-45b1-bcdf-3dab414eaeb9"
      unitRef="usdPerShare">20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i7cb61b17854748238238595ab84bc83d_I20191130"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzY4ODA_5fbaf9c0-1a39-49dc-82a8-44fa124ba30b">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <rprx:OptionIndexedToIssuersEquityTerm
      contextRef="ia8411dbd9065417ea1c3895bc9dcf30d_D20191101-20191130"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzQwNzI_84dafe77-7dee-4af8-a358-25ed5cbbf715">P18M</rprx:OptionIndexedToIssuersEquityTerm>
    <rprx:OptionIndexedToIssuersEquityValue
      contextRef="if08b51e367da4f1b95ea56119a60ebc2_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzQxMTQ_f229a025-4a66-4769-9268-598d8c627b44"
      unitRef="usd">50000000</rprx:OptionIndexedToIssuersEquityValue>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1
      contextRef="ia8411dbd9065417ea1c3895bc9dcf30d_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzQxODc_e2819a8c-f263-452b-bf15-174f32d8116f"
      unitRef="usdPerShare">20</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3b2fd60a894245f5a07e1097cd77b5a5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzE0MjkzNjUxMTgzMjcy_db869675-790b-4571-9a7b-09520dc748c1"
      unitRef="usd">11500000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i3144c1b6231e4ae3b4870c4b3899f3bc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzEwOTk1MTE2NDMwNTI_b893d8d5-be1c-4cd6-89e2-b1188ed2ef43"
      unitRef="usd">5400000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="id8655b88be914b679ef264228d3e1920_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzE0MjkzNjUxMTgzNjk2_5094e637-4e36-4b9b-b69d-776769d75f44"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="iaa98c432df2e41d197b0bbeeda56b8f3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzEwOTk1MTE2NDMxNTY_44be00aa-b200-43c0-9e84-2fd642881235"
      unitRef="usd">-5400000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="ia2307a5ce88e48c2a06297ee38c8ff92_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzEwOTk1MTE2NDMxNjA_2fbd1ce0-3cce-499c-a4af-d6cfa93bbd56"
      unitRef="usd">-25400000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="if1e2a2af5b8c4eae95b037e3cda81bcf_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzE2NDkyNjc0NTk1MDQ_2b063e10-74d7-4f58-98e6-198952890818"
      unitRef="usd">22000000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90ZXh0cmVnaW9uOjUwZDY3NjdlNWJkNTQyMjE5MDFkNDczOWQ5ZTAwNDU1XzY4ODE_66c6c0be-8981-418a-89cd-6318316f6681">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below summarize the change in fair value of the derivatives for the years ended December 31, 2021, 2020 and 2019 and the line items within the consolidated statements of operations where the gains or losses on these derivatives are recorded (in thousands). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location on Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Derivatives in hedging relationships (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest Rate Swaps:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amount of loss reclassified from accumulated other comprehensive income into income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense/(income)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest Rate Swaps:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense/(income)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,977)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forward purchase contract:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of forward purchase contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Treasury rate lock contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of treasury rate lock contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) &#160;&#160;&#160;&#160;Certain interest rate swaps were previously designated as cash flow hedges. These swaps became ineffective as debt refinancings occurred between 2013 and 2016. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive income&lt;/span&gt; were released into earnings.</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i00b63eb6a93e410fa76fd2e629ddcb94_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzQtMS0xLTEtMA_f70bf3b8-3237-4a97-85bc-64d63f28ebda"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i763fc198266c47f18427206c9825f562_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzQtMy0xLTEtMA_c07749be-1e5c-4266-ba23-7d2a1ef5d071"
      unitRef="usd">4066000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ia35d113ea7024ba6950f218601bacf6d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzQtNS0xLTEtMA_457195bd-248b-4826-8b00-ec0e0c496bcd"
      unitRef="usd">6189000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i00b63eb6a93e410fa76fd2e629ddcb94_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzUtMS0xLTEtMA_ffdeb4e4-04bb-4f69-b7b6-f1526dfa19d2"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i763fc198266c47f18427206c9825f562_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzUtMy0xLTEtMA_44275470-37bb-4469-869f-9ff4e9de7c2a"
      unitRef="usd">-73000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ia35d113ea7024ba6950f218601bacf6d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzUtNS0xLTEtMA_4c0b5961-0c6f-4b7f-9038-b8b749dbd4c9"
      unitRef="usd">16954000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ifef0f1d7958a463da43eae42d4bfdcda_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzYtMS0xLTEtMA_09468c42-725a-46f3-8890-1c7fb1d32a87"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i14182ec6f41e44f390626af261a6307c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzYtMy0xLTEtMA_6f938239-4e2f-4dae-b96f-3cb4089b90e0"
      unitRef="usd">114000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i50aadab619674413a318d22a3934817f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzYtNS0xLTEtMA_7d06d218-a1a6-4979-a984-b4bc8d90e048"
      unitRef="usd">-9565000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i28aa4e83beed49649514ca87068e5ff6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzEwLTEtMS0xLTA_af5104ee-0346-464e-bb68-2320283d05ad"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i5b1e737cb86341c5927dafb07d9750e7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzEwLTMtMS0xLTA_dc852eed-3319-4357-b000-d0ef4eb14aeb"
      unitRef="usd">6908000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i51d19c62ebf442779da8aeb40a4ab214_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzEwLTUtMS0xLTA_fb94fa63-034f-4fc7-af58-a1f6a6ca2b96"
      unitRef="usd">49472000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ib358915627fb4011bf72f88cea09f234_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzExLTEtMS0xLTA_d8eac28a-38e0-48a0-9f3a-38805683916b"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i11eaf253ae3b4547aad0185800a4c0d2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzExLTMtMS0xLTA_3ef3df3b-00fe-41fa-a417-dc82006c28b7"
      unitRef="usd">408000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i89b8a39a63294eebab3e3f0053f1e384_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzExLTUtMS0xLTA_1ee9a856-519d-4649-8c0f-467e2736bf44"
      unitRef="usd">-2681000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i005aac99b4434d53866b784c5d193d69_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzE0LTEtMS0xLTA_c94f2452-5921-46ab-9d80-086192f22c3e"
      unitRef="usd">5439000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="iaef13cf1a72b4d638ba70defd6ec0717_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzE0LTMtMS0xLTA_5a50b7ca-8889-4ec8-a03d-b7ad6e437c27"
      unitRef="usd">25375000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i17ed9cdd951d4b46941b7212a8ac2d44_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzE0LTUtMS0xLTA_538e6d08-e13e-403b-8325-101d6e0efe21"
      unitRef="usd">-21977000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts
      contextRef="i8604b93633cf417e954376d722a8dadd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzE3LTEtMS0xLTA_be26ec36-e741-415c-8f0e-8d9d47363930"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts>
    <us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts
      contextRef="ifcf29dd183834411bbff2b3741c8ce8e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzE3LTMtMS0xLTA_03fba435-52df-4399-b82b-1fb8516cc98d"
      unitRef="usd">5800000</us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts>
    <us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts
      contextRef="i72d6d03d3001450dae8929c471f09b33_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzE3LTUtMS0xLTA_0926e983-1921-4e3e-aef6-58d56611f2d0"
      unitRef="usd">-11500000</us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ie89c03cbaa3a415f8d13313d6d33a664_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzE5LTEtMS0xLTM4MTc4_5c44f876-825d-4a9c-900c-03d6bbabf31a"
      unitRef="usd">16093000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ia3c1f334b1114d27b5ab4a6b83b6d95b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzE5LTMtMS0xLTM4MTg1_961a1b84-e019-498f-984b-53fc81fad476"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i1cb8fcdaa4e94b9bb101f554c36c0944_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMjQvZnJhZzo1MGQ2NzY3ZTViZDU0MjIxOTAxZDQ3MzlkOWUwMDQ1NS90YWJsZTo1OTQyYmVlZmRjZDY0YzU4OGE3MGRlNTExMTFkODEwMC90YWJsZXJhbmdlOjU5NDJiZWVmZGNkNjRjNTg4YTcwZGU1MTExMWQ4MTAwXzE5LTUtMS0xLTM4MTky_037d82aa-23c2-40d0-8c88-0e2ce5805b72"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzExMjM0_faf90485-a6ca-44b8-8bb7-b73f3f1331ee">Fair Value Measurements and Financial Instruments &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair value hierarchy&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives and available for sale debt securities are reported at their respective fair values in our consolidated balance sheets. For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. Long-term debt and financial royalty assets are reported at their amortized costs in our consolidated balance sheets but for which fair values are disclosed. The remaining financial instruments are reported in our consolidated balance sheets at amounts that approximate current fair values.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets and liabilities measured at fair value on a recurring basis&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes financial assets and financial liabilities that we measured at fair value on a recurring basis at the dates indicated, classified in accordance with the fair value hierarchy described above (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;598,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;598,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;444,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;444,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;505,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;505,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;598,253&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;636,823&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;66,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,301,076&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;24,302&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,134,957&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;69,984&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,229,243&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;298,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;298,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forwards (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;226,787&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;247,413&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;474,200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;298,689&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5,439&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;163,016&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;467,144&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The balance as of December 31, 2021 includes Series B Forwards and the Development Funding Bond Forward, recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available for sale debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; in the consolidated balance sheet, related to our obligations to fund acquisitions of the Series B Biohaven Preferred Shares and $150&#160;million of the Development Funding Bonds, respectively. The balance as of December 31, 2020 relates to Series B Forwards, recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available for sale debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; in the consolidated balance sheet. See Note 3&#x2013;Available for Sale Debt Securities for additional discussion. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Related to the Epizyme transaction as described in Note 4&#x2013;Derivative Instruments and recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; in the consolidated balance sheets as of December 31, 2021 and 2020. The fair value of the warrant was not material as of December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2021, 2020 and 2019, we recognized a loss of $60.1&#160;million, a loss of $85.4&#160;million and a gain of $104.4&#160;million, on equity securities still held as of December 31, 2021, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables presented below summarize the change in the combined fair value (current and non-current) of Level 3 financial instruments, which relate to equity securities and available for sale debt securities, including the underlying debt securities and related forwards (in thousands). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Equity Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gains on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43,013&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlement of forwards (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Transfer to Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(184,005)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Transfer from Level 2 (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;198,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Redemption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;253,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;214,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Forwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlement of forwards (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;18,600&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;For the year ended December 31, 2021, the unrealized gains on available for sale debt securities is comprised of $11.6&#160;million related to Series A Biohaven Preferred Shares as recorded on the consolidated statements of comprehensive income and $1.3&#160;million related to the Series B Biohaven Preferred Shares as recorded on the consolidated statements of operations. For the year ended December 31, 2020, the unrealized gains on available for sale debt securities related to the Series A Biohaven Preferred Shares as recorded on the consolidated statements of comprehensive income, including $52.7&#160;million prior to transferring out of Level 3 and then $15.9&#160;million after transferring back to Level 3. &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Reflects the fair value attributed to the Series B Forwards that were settled in the period as the Series B Biohaven Preferred Shares were acquired, which is included in the fair value of the Series B Biohaven Preferred Shares. See Note 3&#x2013;Available for Sale Debt Securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes $14.5&#160;million of unrealized gains on available for sale debt securities included in other comprehensive income while the Series A Biohaven Preferred Shares was classified as a Level 2 asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Recorded within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Unrealized gains on available for sale debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;on the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a discussion of the valuation inputs used for financial instruments classified as Level 2 and Level 3 measurements in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investment in Series A Biohaven Preferred Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of the Series A Biohaven Preferred Shares as of December 31, 2021 and 2020 was based on the cash flows due to us from Biohaven of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments of $15.6&#160;million following the FDA approval and starting one-year after FDA approval, through December 31, 2024. The FDA approved Nurtec ODT in February 2020, at which point we became entitled to receive a fixed payment amount of $250.0&#160;million payable in equal quarterly payments from March 31, 2021 through December 31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Series A Biohaven Preferred Shares as of December 31, 2021 and 2020 was calculated using probability-adjusted discounted cash flow calculations incorporating Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability of a change of control event occurring during the investment term, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over a four-year time period and developing a risk-adjusted discount rate requires significant judgement. Our estimate of a risk adjusted discount rate of 9.5% and 8.3% as of December 31, 2021 and 2020, respectively, could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series A Biohaven Preferred Shares, which would mean that the estimated fair value could be significantly higher or lower.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Prior to February 2020, we measured our investment in the Series A Biohaven Preferred Shares using a Black-Derman- Toy lattice model, which included the use of Level 3 fair value measurements and inputs. In February 2020, when Nurtec ODT received FDA approval, we began measuring the fair value of the Series A Biohaven Preferred Shares using a discounted cash flow analysis that relied on observable inputs, and therefore, we transferred the Series A Biohaven Preferred Shares from a Level 3 to a Level 2 asset. During the three months ended December 31, 2020, information pertaining to Biohaven&#x2019;s issuance of debt and its effective interest rate became available and we refined our valuation of the Series A Biohaven Preferred shares as of December 31, 2020 to incorporate this significant unobservable input. As a result, we reclassified the investment from a Level 2 to a Level 3 asset during the three months ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investment in Series B Biohaven Preferred Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of the Series B Biohaven Preferred Shares and Series B Forwards as of December 31, 2021 and the fair value of the Series B Forwards as of December 31, 2020 were based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability that there will be a change of control event in different periods of time, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over the duration of the Series B Biohaven Preferred Shares and developing a risk-adjusted discount rate requires significant judgement. Our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than the timing of an actual change of control event, and if so, would mean that the estimated fair value could be significantly higher or lower than the fair value determined by management at any particular date. Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series B Biohaven Preferred Shares or the Series B Forwards, which would mean that the estimated fair value could be significantly higher or lower.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;MorphoSys Development Funding Bonds&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of the Development Funding Bond Forward as of December 31, 2021 was based on a discounted cash flow calculation using an estimated risk-adjusted discount rate, which is a Level 3 fair value input. Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower. We have elected the fair value option to account for the Development Funding Bond Forward as it most accurately reflects the nature of the instrument. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;BioCryst Equity Securities &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2021, we purchased 3,846&#160;thousand shares of common stock in BioCryst Pharmaceuticals, Inc.(&#x201c;BioCryst&#x201d;), which was calculated based on the volume-weighted average price of BioCryst common stock over a period preceding the closing of the transaction. As part of the transaction, we are restricted from selling the common stock for six months following the close of the transaction. The fair value of the BioCryst common stock as of December 31, 2021 was based on the closing stock price and adjusted for the transfer restriction, which was determined by calculating the value of a put option over the common stock to match the duration of the transfer restriction. This methodology includes the use of Level 3 inputs, including the estimated volatility of the BioCryst common stock, which requires the use of significant judgement. Our estimated volatility could be reasonably different than the actual volatility for the common stock which would mean that the estimated fair value for the common stock could be significantly higher or lower than the fair value determined by management at any particular date.    &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use third party pricing services for Level 2 inputs used to value cash equivalents, marketable securities, derivative instruments and borrowings, which provide documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. Warrants are valued using a Black-Scholes option pricing model which considers observable and unobservable inputs. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial assets not measured at fair value&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial royalty assets are measured and carried on the consolidated balance sheets at amortized cost using the effective interest method. The fair value of financial royalty assets is calculated by management using the forecasted royalty payments we expect to receive based on the projected product sales for all royalty bearing products as estimated by sell-side equity research analysts&#x2019; consensus sales forecasts or, where such consensus sales forecasts are not available, management uses reasonable judgment to make assumptions about the projected product sales. These projected future royalty payments by asset along with any projected incoming or outgoing milestone payments are then discounted to a present value using appropriate individual discount rates. The fair value of our financial royalty assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. Estimated fair values based on Level 3 inputs and related carrying values for our financial royalty assets as of December 31, 2021 and 2020 are presented below (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Value, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Value, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financial royalty assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,047,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,332,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,718,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,955,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzExMjMy_d0925be1-5ba8-4d09-98a7-7e43aa45afe8">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives and available for sale debt securities are reported at their respective fair values in our consolidated balance sheets. For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. Long-term debt and financial royalty assets are reported at their amortized costs in our consolidated balance sheets but for which fair values are disclosed. The remaining financial instruments are reported in our consolidated balance sheets at amounts that approximate current fair values.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzExMjMz_adfbebda-36ff-4364-9f5f-792cdbb962f0">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes financial assets and financial liabilities that we measured at fair value on a recurring basis at the dates indicated, classified in accordance with the fair value hierarchy described above (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;598,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;598,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;444,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;444,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;505,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;505,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;598,253&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;636,823&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;66,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,301,076&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;24,302&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,134,957&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;69,984&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,229,243&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;298,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;298,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forwards (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;226,787&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;247,413&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;474,200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;298,689&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5,439&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;163,016&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;467,144&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The balance as of December 31, 2021 includes Series B Forwards and the Development Funding Bond Forward, recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available for sale debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; in the consolidated balance sheet, related to our obligations to fund acquisitions of the Series B Biohaven Preferred Shares and $150&#160;million of the Development Funding Bonds, respectively. The balance as of December 31, 2020 relates to Series B Forwards, recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available for sale debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; in the consolidated balance sheet. See Note 3&#x2013;Available for Sale Debt Securities for additional discussion. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Related to the Epizyme transaction as described in Note 4&#x2013;Derivative Instruments and recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt; in the consolidated balance sheets as of December 31, 2021 and 2020. The fair value of the warrant was not material as of December 31, 2021.</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i766dfe5e45ea4f72a26e59216bb302d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzYtMS0xLTEtMA_6a03bc5a-08fa-4d77-b50a-eed9ff9fa510"
      unitRef="usd">598253000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia020dbee158643459651f9ece93d0d05_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzYtMy0xLTEtMA_1522f75d-7e23-4dbd-a50c-5d19df1de279"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i75566fc435584c81949dbaf5d363ad0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzYtNS0xLTEtMA_89660903-333d-44f3-a997-5bb2b6af7958"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie446f1fa1f9b4244a2ca74087c37da2e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzYtNy0xLTEtMA_ce8efa50-1f21-414a-b0d4-df48cc71870a"
      unitRef="usd">598253000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2dcc53a90d444210880be69baae720a5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzYtOS0xLTEtNjE3MjM_dae06fb1-b238-46b6-ab03-e73758e26ef3"
      unitRef="usd">24302000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia44ca4ca5b24467685453ef798071b9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzYtMTEtMS0xLTYxNzY0_5c5884d8-97be-4ef6-a1ba-e33518e588d1"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i88285f19e15c4b32ad8309928003f3bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzYtMTMtMS0xLTYxNzgx_d02a0f87-9a60-4ac1-b38c-cc3842a37590"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib075989af1f74896bccaba43480cd27b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzYtMTUtMS0xLTYxNzkx_68bf7d34-1fcc-4541-8369-b69143d52a5a"
      unitRef="usd">24302000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3416e4f9b18349ecad1f073e06dec3f6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzctMS0xLTEtMA_2db918a0-87dd-4fad-a19d-9b1c52a594c9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8a89ba14dcfe4b38bdf299da4317bd92_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzctMy0xLTEtMA_095e8dfd-1880-47d6-bc1c-c1f0ab01e438"
      unitRef="usd">13997000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia9e6b9ca88f64d7a856e5091b1586275_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzctNS0xLTEtMA_64c24be5-7aa2-473d-a1cc-6d1ba4702247"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id9922aa0da964460ac7f278f5e9ce3bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzctNy0xLTEtMA_fbe2d5d9-3d7d-4fd3-bf13-cf9585b3b3f9"
      unitRef="usd">13997000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icd56db919beb4b91b95510f88bc8e307_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzctOS0xLTEtNjE3MjM_797aec94-e43d-4d49-8f9a-56e3a85187c4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i55d925c488be4a8f8163990bbb352b7e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzctMTEtMS0xLTYxNzY0_ef35a323-dec0-4325-8019-cfdfeec9f9c7"
      unitRef="usd">77176000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3e3aa405803e46c2ae8f0944494d7a94_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzctMTMtMS0xLTYxNzgx_994bb394-126c-43fd-bf02-6bcd5b58e9af"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibc0c4c7c6cdc45479c7eb9dc86d86a1d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzctMTUtMS0xLTYxNzkx_6f70bdb8-c5e2-44b4-8cc4-b3e0b882c678"
      unitRef="usd">77176000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i30d5c89a92a5482d9d74e4bb2241752e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzgtMS0xLTEtMA_ddffe92b-2135-47a9-abbc-daf2cfc0b50c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i53c4649842db44e4a15eb412da6b88a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzgtMy0xLTEtMA_7f73b767-0013-40fd-9895-2d265524e8f0"
      unitRef="usd">40954000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8c9704b6d9d7401fab5346287e978380_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzgtNS0xLTEtMA_08ca5235-20dd-4c3b-bd64-a21472177332"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i49b4a4e11f71489ab6998095636e4351_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzgtNy0xLTEtMA_7fa6b749-9043-4fc8-9053-8f5557e561bb"
      unitRef="usd">40954000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i077a711c86ba4484a165902a8b44eeb1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzgtOS0xLTEtNjE3MjM_dfab6ec4-9e11-4317-8810-fdcad3b23c79"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib89be7641277478e8f7b293085ccc5d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzgtMTEtMS0xLTYxNzY0_3a9d764a-e225-4f4d-9297-dd90110a3e9e"
      unitRef="usd">74502000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia66c162bc44045988727b18f854dba73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzgtMTMtMS0xLTYxNzgx_ebb63e13-dfeb-458e-a070-c866759dc9c9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0d769bb3068b491086f572bdae712fb8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzgtMTUtMS0xLTYxNzkx_39a49d88-a210-4b77-b68a-2a8a46ebb340"
      unitRef="usd">74502000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i04f203e10aa24bcfa8ec0905052a2b27_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEwLTEtMS0xLTA_5a094617-e494-40a4-a5f2-f40035b8b890"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i7d667d912c354a0c9c379aefc62e6fa7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEwLTMtMS0xLTA_297f3eb0-7eb4-4d9e-81a1-38246531d309"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="ie404feec194c4015ae7728b646421169_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEwLTUtMS0xLTA_ec8390f0-a478-4a68-9094-cd2793bab03d"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="ic527ce521bf44f7fb2922ba14cf8f680_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEwLTctMS0xLTA_d5b98dd5-6fd0-4aed-9873-eee6c3c4f072"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i088b28295ac64e85ab5dfa6a843058cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEwLTktMS0xLTYxNzIz_615c2918-f810-485b-bc8a-bfdf06991024"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i19d9bd3151754f33acff24aea97d4f03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEwLTExLTEtMS02MTc2NA_8b15d809-a295-48b2-b6ad-a4db59d0a4a8"
      unitRef="usd">32754000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="ib7fb8fef2b7f4c048ec7656d0e9bd6fe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEwLTEzLTEtMS02MTc4MQ_6529948e-4261-435e-b0a7-a2f62ddc6365"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i8a7676bf6609461692e1aa4be16e7345_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEwLTE1LTEtMS02MTc5MQ_b0fe7945-4ea0-4ec3-9d43-94282b02edf3"
      unitRef="usd">32754000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="ibfafac4f4f2a4e088f1da17e816e5e52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzExLTEtMS0xLTA_a1d6e701-5ef3-4f9f-a233-d4297bab0e54"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="id085ae202d524bdb9d5d849459675315_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzExLTMtMS0xLTA_ffa06773-f8a4-46d1-b2f3-4a7b560828be"
      unitRef="usd">207457000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i48b720aa212947f48ab2d55101f95e2b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzExLTUtMS0xLTA_0cbac99f-67d7-40ef-90af-60d9ba6637fe"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i28195bb07d164725b7b634f4d19d0532_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzExLTctMS0xLTA_e88388c6-17bd-48b7-a2e7-9cbb1b70002a"
      unitRef="usd">207457000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i809b4052446c46388345163c43a4aa56_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzExLTktMS0xLTYxNzIz_c39cce23-3703-47ef-b487-3ba53878a18d"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="idb619f9a9745447ca9b38d75ccc38904_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzExLTExLTEtMS02MTc2NA_c78d7506-88d7-4c7f-b63c-a860489ed6cb"
      unitRef="usd">444554000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i796b378a6f1c40c48579f653afadb541_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzExLTEzLTEtMS02MTc4MQ_b1392efb-7962-4a2c-96ee-6ab433aff064"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i2f327e7169c8452880bd81a8f13ed03b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzExLTE1LTEtMS02MTc5MQ_6bdbd125-7d8d-48aa-b80a-495979dfcd6a"
      unitRef="usd">444554000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i248b66c121454f309190c31387007f6a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEyLTEtMS0xLTA_d5a27131-8152-4661-85ba-5615f42f8324"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i8bb92f2605164dc8b141abf08c6f5b56_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEyLTMtMS0xLTA_21aad242-9496-4c20-a98e-7160417d62eb"
      unitRef="usd">374415000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i022c0d8159864ed7a2a1944cc714c2cf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEyLTUtMS0xLTA_a9fee7c9-5d5e-4121-aca0-7d5417c5ea4d"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="id26c9a8cd8884671b2c7a640a4b6d7df_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEyLTctMS0xLTA_787f9619-dfe6-468e-b429-f7616885d427"
      unitRef="usd">374415000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i5ac959fb66e143fcaddb2cb43efeae1a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEyLTktMS0xLTYxNzIz_ba0ca090-3c41-4571-b723-62b2a9478f3f"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="iee8b694599fb4dd39b9e68aadeed7ed0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEyLTExLTEtMS02MTc2NA_5a52d759-1b62-4f5c-9bd0-417b63cebbf6"
      unitRef="usd">505971000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="ie51f46e72bfd4d7e834c4fdb560fbee4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEyLTEzLTEtMS02MTc4MQ_992d5126-b2ae-451b-899c-0dca028f5011"
      unitRef="usd">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="ie7ec150c06fd4f4e91c18c223d223ea5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEyLTE1LTEtMS02MTc5MQ_c8a761d2-9487-4843-ba8b-8978895d851d"
      unitRef="usd">505971000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id1a1aa3351a743f085a5b2c2f8f8be34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEzLTEtMS0xLTA_8b335c8b-7321-4294-8309-fa7946b4aee7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i19a72b318bc84259bb294a3c971a4b85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEzLTMtMS0xLTA_ea7089ad-3ad2-48b1-9bae-ac3d18f1f763"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i04227885885f4891916e264c27f329ce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEzLTUtMS0xLTA_d562e010-86f2-4b37-9d98-4ccd2e7074a8"
      unitRef="usd">66000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6fb80ebaf7cf4a41b7bb7ee7eecd1a0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEzLTctMS0xLTA_baa77c7b-332d-4782-b99f-e0476d28032d"
      unitRef="usd">66000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="icd91a77eb7224e71a43cdcab940fb6bd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEzLTktMS0xLTYxNzIz_0f4b9b67-15b8-4329-8aec-d8473c81b759"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iad06d81ace0f4a3fbccf1299e4f6f414_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEzLTExLTEtMS02MTc2NA_f3d2c8d2-9e98-49cd-9c0b-33e1efac32e8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iee5dd61b76084db79478047617833a62_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEzLTEzLTEtMS02MTc4MQ_ca8b8822-c4ec-43ee-8891-066574b95cf1"
      unitRef="usd">69984000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i96f3647beb944cfb9113b173115bb16f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzEzLTE1LTEtMS02MTc5MQ_8f677231-cfd8-4188-a285-ac2d19850b7a"
      unitRef="usd">69984000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <rprx:AssetsFairValueDisclosureCurrent
      contextRef="id1a1aa3351a743f085a5b2c2f8f8be34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE1LTEtMS0xLTA_85f33d93-5355-4f90-b0bd-b3cba3589373"
      unitRef="usd">598253000</rprx:AssetsFairValueDisclosureCurrent>
    <rprx:AssetsFairValueDisclosureCurrent
      contextRef="i19a72b318bc84259bb294a3c971a4b85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE1LTMtMS0xLTA_fc503033-5aec-4d81-84ad-09f938d208cc"
      unitRef="usd">636823000</rprx:AssetsFairValueDisclosureCurrent>
    <rprx:AssetsFairValueDisclosureCurrent
      contextRef="i04227885885f4891916e264c27f329ce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE1LTUtMS0xLTA_97609ec0-c045-45d4-afce-c670de376e24"
      unitRef="usd">66000000</rprx:AssetsFairValueDisclosureCurrent>
    <rprx:AssetsFairValueDisclosureCurrent
      contextRef="i6fb80ebaf7cf4a41b7bb7ee7eecd1a0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE1LTctMS0xLTA_8a2423ef-4cc0-439a-afde-adef613461df"
      unitRef="usd">1301076000</rprx:AssetsFairValueDisclosureCurrent>
    <rprx:AssetsFairValueDisclosureCurrent
      contextRef="icd91a77eb7224e71a43cdcab940fb6bd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE1LTktMS0xLTYxNzIz_f7cd1dc8-9f6d-426c-99cf-40aa4e8c1ef9"
      unitRef="usd">24302000</rprx:AssetsFairValueDisclosureCurrent>
    <rprx:AssetsFairValueDisclosureCurrent
      contextRef="iad06d81ace0f4a3fbccf1299e4f6f414_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE1LTExLTEtMS02MTc2OQ_3d25193d-2076-45dd-a544-096e04ba0218"
      unitRef="usd">1134957000</rprx:AssetsFairValueDisclosureCurrent>
    <rprx:AssetsFairValueDisclosureCurrent
      contextRef="iee5dd61b76084db79478047617833a62_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE1LTEzLTEtMS02MTc4NA_066eebbc-1efe-4e55-948c-83a758dfb580"
      unitRef="usd">69984000</rprx:AssetsFairValueDisclosureCurrent>
    <rprx:AssetsFairValueDisclosureCurrent
      contextRef="i96f3647beb944cfb9113b173115bb16f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE1LTE1LTEtMS02MTc5NA_0c8052fa-9eed-4d62-b0ec-d5ce348821f2"
      unitRef="usd">1229243000</rprx:AssetsFairValueDisclosureCurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="id1a1aa3351a743f085a5b2c2f8f8be34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE3LTEtMS0xLTA_fd78744d-6d92-491f-8669-e262346e8a5d"
      unitRef="usd">226787000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i19a72b318bc84259bb294a3c971a4b85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE3LTMtMS0xLTA_cf5ebd76-2303-467d-8dcd-34711c45c968"
      unitRef="usd">0</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i04227885885f4891916e264c27f329ce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE3LTUtMS0xLTA_442f4ff4-25cc-4ed2-ab16-904800f4d511"
      unitRef="usd">43013000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i6fb80ebaf7cf4a41b7bb7ee7eecd1a0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE3LTctMS0xLTA_2efb0cbb-06ab-4713-bb48-4247aba42c23"
      unitRef="usd">269800000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="icd91a77eb7224e71a43cdcab940fb6bd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE3LTktMS0xLTYxNzIz_f1b27294-0298-4a01-bf0d-e21e5eda30b5"
      unitRef="usd">298689000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="iad06d81ace0f4a3fbccf1299e4f6f414_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE3LTExLTEtMS02MTc3NA_11d54d60-ef8a-4ef7-8072-efc547cb2b2b"
      unitRef="usd">0</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="iee5dd61b76084db79478047617833a62_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE3LTEzLTEtMS02MTc4Nw_be9d6290-b111-4849-b363-9c0ab015f5fd"
      unitRef="usd">0</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i96f3647beb944cfb9113b173115bb16f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE3LTE1LTEtMS02MTc5Nw_0dec620d-ae8a-4254-9be6-5b9cd2ef1d4d"
      unitRef="usd">298689000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id1a1aa3351a743f085a5b2c2f8f8be34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE4LTEtMS0xLTA_265a3824-e665-40b5-980b-97b2f80499d2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i19a72b318bc84259bb294a3c971a4b85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE4LTMtMS0xLTA_0e6542df-7b3b-45b7-a59d-97854e787221"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i04227885885f4891916e264c27f329ce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE4LTUtMS0xLTA_5dea1655-9486-4aba-8f36-960b4e796e26"
      unitRef="usd">187700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i6fb80ebaf7cf4a41b7bb7ee7eecd1a0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE4LTctMS0xLTA_5c656878-7966-40dd-818b-8ffa3a98dc4a"
      unitRef="usd">187700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="icd91a77eb7224e71a43cdcab940fb6bd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE4LTktMS0xLTYxNzIz_7a95afad-7b3f-4727-9df3-3279563b7705"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iad06d81ace0f4a3fbccf1299e4f6f414_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE4LTExLTEtMS02MTc3NA_618f39c6-7c47-4c21-a7d0-b7a905aef5a6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iee5dd61b76084db79478047617833a62_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE4LTEzLTEtMS02MTc4Nw_a8c3dbd2-17e2-4527-be3e-65c506a1d577"
      unitRef="usd">144416000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i96f3647beb944cfb9113b173115bb16f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE4LTE1LTEtMS02MTc5Nw_1fe070b6-d922-45e7-b58c-da9388d53d51"
      unitRef="usd">144416000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DerivativeAssets
      contextRef="i0b086c90802248e181f4562a5f891cef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE5LTEtMS0xLTA_be3fb8d9-f76a-4c28-8d3a-e85462775ca4"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i8fd0b4b6026a47dfa690bc790142dc6a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE5LTMtMS0xLTA_6314a15a-7e1c-42f0-8d97-de2b9216e819"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i4e710c51efc64f67a80cd232937add07_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE5LTUtMS0xLTA_a30d639d-4df4-4b59-8b28-4d96d2796f5c"
      unitRef="usd">16700000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="idc65e75ec15e4a8d9dae69a3405cb50d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE5LTctMS0xLTA_3e2231be-48ec-4d8b-b4eb-a99dbb5a8150"
      unitRef="usd">16700000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i8c452309c9434a04aed49ed1b90eadaf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE5LTktMS0xLTYxNzIz_83a64225-8491-47b7-929d-1d9af09abf5b"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ic7ab09bfb5bd4da3a4014bc287abc1b4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE5LTExLTEtMS02MTc3NA_196cf890-5396-4513-b11a-d965fbdea556"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i23b9ee584ca349bfb13948d7e36428be_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE5LTEzLTEtMS02MTc4Nw_fc5f3b42-0ea9-4342-8005-81a816ed21b1"
      unitRef="usd">18600000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ia7b300d23f844817bdcfa222399539cd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzE5LTE1LTEtMS02MTc5Nw_47de3cd3-91e7-4e9f-91cc-c20335648bf1"
      unitRef="usd">18600000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="iaa7fcc31f05a4cd38338bef84fd13226_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIwLTEtMS0xLTA_1b8c9b7b-fd2c-4e5c-8747-91fe7a83965e"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if3b3d077c01141fabeaf491e1ebfa108_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIwLTMtMS0xLTA_d32ec10e-68eb-4507-a469-c5a26846250c"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ie5aeecb6ade049569e8f33d8ba05292c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIwLTUtMS0xLTA_882f9631-1ecd-46bb-b5d9-799fbdbe97d9"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i94e2f508014f476987e71ff61fb7acc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIwLTctMS0xLTA_c6289ad2-f475-4728-94ec-f86dc2cdb7ba"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i4190ee3791704e3cb28414c2e7b90290_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIwLTktMS0xLTYxNzIz_f66d937a-d826-4c67-95fb-4f5e82a5dfb8"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ib55e7cd67be640bcbc6bf9021cbd80ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIwLTExLTEtMS02MTc3NA_6c6e49c1-314c-40e5-8a7c-d4a52d86dae9"
      unitRef="usd">5439000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i011c26d52667488b9a934f794e0b528f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIwLTEzLTEtMS02MTc4Nw_5d9135a0-90b7-4fc2-b645-833530e7721c"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i25d1766cd2c74c1d9a6e6b47a1ff4db5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIwLTE1LTEtMS02MTc5Nw_90dc41f9-f204-4da7-8c89-9bb62d12d82a"
      unitRef="usd">5439000</us-gaap:DerivativeAssets>
    <rprx:AssetsFairValueDisclosureNoncurrent
      contextRef="id1a1aa3351a743f085a5b2c2f8f8be34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIxLTEtMS0xLTM4MjIx_f1a79a89-d45f-47a4-a6a0-763efa110c65"
      unitRef="usd">226787000</rprx:AssetsFairValueDisclosureNoncurrent>
    <rprx:AssetsFairValueDisclosureNoncurrent
      contextRef="i19a72b318bc84259bb294a3c971a4b85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIxLTMtMS0xLTM4MjI4_4cbab1bc-cb91-442a-91d1-8f0c59c01250"
      unitRef="usd">0</rprx:AssetsFairValueDisclosureNoncurrent>
    <rprx:AssetsFairValueDisclosureNoncurrent
      contextRef="i04227885885f4891916e264c27f329ce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIxLTUtMS0xLTM4MjM1_386532cd-b270-401d-bade-2d7faf0d7a3c"
      unitRef="usd">247413000</rprx:AssetsFairValueDisclosureNoncurrent>
    <rprx:AssetsFairValueDisclosureNoncurrent
      contextRef="i6fb80ebaf7cf4a41b7bb7ee7eecd1a0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIxLTctMS0xLTM4MjQy_45edbe5c-9842-4c09-a31a-37b6e451c2c3"
      unitRef="usd">474200000</rprx:AssetsFairValueDisclosureNoncurrent>
    <rprx:AssetsFairValueDisclosureNoncurrent
      contextRef="icd91a77eb7224e71a43cdcab940fb6bd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIxLTktMS0xLTYxNzU4_9bbc062c-77a1-4641-ac4b-b55f85b704b8"
      unitRef="usd">298689000</rprx:AssetsFairValueDisclosureNoncurrent>
    <rprx:AssetsFairValueDisclosureNoncurrent
      contextRef="iad06d81ace0f4a3fbccf1299e4f6f414_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIxLTExLTEtMS02MTc3NA_a0f57172-5e77-481e-8313-cdbccd65ada9"
      unitRef="usd">5439000</rprx:AssetsFairValueDisclosureNoncurrent>
    <rprx:AssetsFairValueDisclosureNoncurrent
      contextRef="iee5dd61b76084db79478047617833a62_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIxLTEzLTEtMS02MTc4Nw_8494a329-9d13-44e2-a66b-16fd75686df7"
      unitRef="usd">163016000</rprx:AssetsFairValueDisclosureNoncurrent>
    <rprx:AssetsFairValueDisclosureNoncurrent
      contextRef="i96f3647beb944cfb9113b173115bb16f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTo3ZjQwYmUwNGU1MmU0YWZkYTdiZGEwMjRlOGE0ODI4MC90YWJsZXJhbmdlOjdmNDBiZTA0ZTUyZTRhZmRhN2JkYTAyNGU4YTQ4MjgwXzIxLTE1LTEtMS02MTc5Nw_b768be5a-5144-49a6-85c0-b60aeb719b71"
      unitRef="usd">467144000</rprx:AssetsFairValueDisclosureNoncurrent>
    <rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund
      contextRef="i5ccc4c3e02d8454db2beb623053c69a4_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzE0MjkzNjUxMjA1NDA0_0381931c-255d-488c-9127-96c9a37d1c0b"
      unitRef="usd">150000000</rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="id8655b88be914b679ef264228d3e1920_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzM4NDgyOTA3NDA3MjY_5094e637-4e36-4b9b-b69d-776769d75f44"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzU0OTc1NTgxNzM5NDc_e8c2dfa3-4ead-4de5-a6ec-8eacf9c9da7f"
      unitRef="usd">-60100000</us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss>
    <us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzU0OTc1NTgxNzM5NTY_81dd249b-f4e8-4502-b172-564be2f0f4fe"
      unitRef="usd">-85400000</us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss>
    <us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzU0OTc1NTgxNzM5NjU_cc92f326-d84f-4118-a92f-0e3e1d35e5cd"
      unitRef="usd">104400000</us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzExMjM2_57a683c2-e873-4013-8614-35e0f7714e70">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables presented below summarize the change in the combined fair value (current and non-current) of Level 3 financial instruments, which relate to equity securities and available for sale debt securities, including the underlying debt securities and related forwards (in thousands). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Equity Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gains on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43,013&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlement of forwards (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Transfer to Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(184,005)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Transfer from Level 2 (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;198,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Redemption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;253,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;214,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Forwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlement of forwards (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;18,600&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;For the year ended December 31, 2021, the unrealized gains on available for sale debt securities is comprised of $11.6&#160;million related to Series A Biohaven Preferred Shares as recorded on the consolidated statements of comprehensive income and $1.3&#160;million related to the Series B Biohaven Preferred Shares as recorded on the consolidated statements of operations. For the year ended December 31, 2020, the unrealized gains on available for sale debt securities related to the Series A Biohaven Preferred Shares as recorded on the consolidated statements of comprehensive income, including $52.7&#160;million prior to transferring out of Level 3 and then $15.9&#160;million after transferring back to Level 3. &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Reflects the fair value attributed to the Series B Forwards that were settled in the period as the Series B Biohaven Preferred Shares were acquired, which is included in the fair value of the Series B Biohaven Preferred Shares. See Note 3&#x2013;Available for Sale Debt Securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes $14.5&#160;million of unrealized gains on available for sale debt securities included in other comprehensive income while the Series A Biohaven Preferred Shares was classified as a Level 2 asset.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Recorded within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Unrealized gains on available for sale debt securities &lt;/span&gt;on the consolidated statements of operations.</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i361e783ed15347028eee1b52d6e057f6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZGM4MThiMjViN2U0NTEyYjdkNGI4YTgwYTVlNDZiYy90YWJsZXJhbmdlOjJkYzgxOGIyNWI3ZTQ1MTJiN2Q0YjhhODBhNWU0NmJjXzMtMS0xLTEtNjIxMDU_962df46f-d15a-434f-a8f9-b22970eec783"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="if100f3b0b4694f76acfbd85a49861791_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZGM4MThiMjViN2U0NTEyYjdkNGI4YTgwYTVlNDZiYy90YWJsZXJhbmdlOjJkYzgxOGIyNWI3ZTQ1MTJiN2Q0YjhhODBhNWU0NmJjXzMtMy0xLTEtNjIxMjA_8c698458-b834-4de5-9d4c-3283ffe60343"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="i23115a36ef69401581d68e8923fad129_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZGM4MThiMjViN2U0NTEyYjdkNGI4YTgwYTVlNDZiYy90YWJsZXJhbmdlOjJkYzgxOGIyNWI3ZTQ1MTJiN2Q0YjhhODBhNWU0NmJjXzQtMS0xLTEtNjIxMDU_6d153577-caf7-4a40-81ac-ef879e4e033a"
      unitRef="usd">35120000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="id424947d5ae8418b9adaf58a03fddf26_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZGM4MThiMjViN2U0NTEyYjdkNGI4YTgwYTVlNDZiYy90YWJsZXJhbmdlOjJkYzgxOGIyNWI3ZTQ1MTJiN2Q0YjhhODBhNWU0NmJjXzQtMy0xLTEtNjIxMjA_0f777713-135d-42bb-bc9e-e9da09b3a28f"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="i23115a36ef69401581d68e8923fad129_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZGM4MThiMjViN2U0NTEyYjdkNGI4YTgwYTVlNDZiYy90YWJsZXJhbmdlOjJkYzgxOGIyNWI3ZTQ1MTJiN2Q0YjhhODBhNWU0NmJjXzUtMS0xLTEtNjIxMDU_352d6358-c387-42bf-95bb-fbe98f357d91"
      unitRef="usd">7893000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="id424947d5ae8418b9adaf58a03fddf26_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZGM4MThiMjViN2U0NTEyYjdkNGI4YTgwYTVlNDZiYy90YWJsZXJhbmdlOjJkYzgxOGIyNWI3ZTQ1MTJiN2Q0YjhhODBhNWU0NmJjXzUtMy0xLTEtNjIxMjA_8d8bf8e0-a246-4f5c-a217-1f64b1f59402"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i98c2487e5b2648e7b109d6723b860233_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZGM4MThiMjViN2U0NTEyYjdkNGI4YTgwYTVlNDZiYy90YWJsZXJhbmdlOjJkYzgxOGIyNWI3ZTQ1MTJiN2Q0YjhhODBhNWU0NmJjXzctMS0xLTEtNjIxMTU_257e655d-b6d3-46c4-902c-9f72460e102f"
      unitRef="usd">43013000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i361e783ed15347028eee1b52d6e057f6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZGM4MThiMjViN2U0NTEyYjdkNGI4YTgwYTVlNDZiYy90YWJsZXJhbmdlOjJkYzgxOGIyNWI3ZTQ1MTJiN2Q0YjhhODBhNWU0NmJjXzctMy0xLTEtNjIxMjA_d51ac099-6ccf-4d86-bd81-abd11ca078de"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i77465b4fae3745838d33803f0ec0bbc7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzQtMS0xLTEtMA_976dc7cf-0ce5-486f-b47e-c42a091208e1"
      unitRef="usd">214400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i6228c34e36964903b7d23917ea68a634_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzQtMy0xLTEtMA_a9b62986-446d-4f56-9b7c-0de60babf100"
      unitRef="usd">131280000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="ia90e169e7f6c423bb0c4f735d01ae17b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzUtMS0xLTEtMA_d258a6e3-e6a5-4a9e-9043-672d36f789a1"
      unitRef="usd">70441000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="ib39b424185204ed8abf5c36761702ce7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzUtMy0xLTEtMA_e21bd8c6-e164-4a1d-b378-39357fd33acf"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="ia90e169e7f6c423bb0c4f735d01ae17b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzYtMS0xLTEtMA_2d462d6d-fe3a-4709-b110-1e10a69cc9af"
      unitRef="usd">12900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="ib39b424185204ed8abf5c36761702ce7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzYtMy0xLTEtMA_14e964c3-0fdd-41d1-9d4f-05d406d4c4ea"
      unitRef="usd">52725000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="ia90e169e7f6c423bb0c4f735d01ae17b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzctMS0xLTEtMzg0Mjg_b334f44d-81a8-4a81-a3c4-92f1503f83fb"
      unitRef="usd">18459000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="ib39b424185204ed8abf5c36761702ce7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzctMy0xLTEtMzg0Mzg_58dce253-1542-4009-ba27-fe953c22f42d"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="ia90e169e7f6c423bb0c4f735d01ae17b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzctMS0xLTEtMA_74603564-9950-458b-95b1-9de3619f920e"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="ib39b424185204ed8abf5c36761702ce7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzctMy0xLTEtMA_81c4c397-829b-4a91-98c7-ff5dbc3c4666"
      unitRef="usd">184005000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="ia90e169e7f6c423bb0c4f735d01ae17b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzgtMS0xLTEtMA_ab2c5566-9090-464c-ba65-f9bfe544d83c"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="ib39b424185204ed8abf5c36761702ce7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzgtMy0xLTEtMA_3cc258df-9ae8-4ba2-9c46-99949c231744"
      unitRef="usd">198526000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3
      contextRef="ia90e169e7f6c423bb0c4f735d01ae17b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzEwLTEtMS0xLTY4ODMx_b2e6dfd2-a627-4869-ba59-64e91821d50c"
      unitRef="usd">0</rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3>
    <rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3
      contextRef="ib39b424185204ed8abf5c36761702ce7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzEwLTMtMS0xLTY4ODM4_4e34238a-8272-45f8-9163-7764afaa5a29"
      unitRef="usd">15874000</rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3>
    <rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions
      contextRef="ia90e169e7f6c423bb0c4f735d01ae17b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzktMS0xLTEtMA_5ee97081-d6bd-4f89-9f93-1e4fc4164faf"
      unitRef="usd">-62500000</rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions>
    <rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions
      contextRef="ib39b424185204ed8abf5c36761702ce7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzktMy0xLTEtMA_25c2c7cb-37ec-4b64-b273-04f68fc41477"
      unitRef="usd">0</rprx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i3cc4a0220a37443eb7239af4691991c1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzEwLTEtMS0xLTA_1a7b771c-5d56-45d9-8621-cf4d8cabf9f8"
      unitRef="usd">253700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i77465b4fae3745838d33803f0ec0bbc7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTplMjVhNDhjMTM5MjM0Zjc5OTRmYmY2ZjgwMjM5NWU3Mi90YWJsZXJhbmdlOmUyNWE0OGMxMzkyMzRmNzk5NGZiZjZmODAyMzk1ZTcyXzEwLTMtMS0xLTA_b5ee9b66-e692-4934-8cfc-7f5a5a3e02db"
      unitRef="usd">214400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i5879c529f1044590b63a67bad0d16f8d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZTBkNWIzNWY0Y2Q0YWMwYjY1ODRlYzk2MWZmYzY1NS90YWJsZXJhbmdlOjJlMGQ1YjM1ZjRjZDRhYzBiNjU4NGVjOTYxZmZjNjU1XzMtMS0xLTEtMzg0NzY_ff3de0fd-a124-496a-9430-1fe28c4c0c8c"
      unitRef="usd">18600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i3565d1e114564c88a5bdaaff4011b9bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZTBkNWIzNWY0Y2Q0YWMwYjY1ODRlYzk2MWZmYzY1NS90YWJsZXJhbmdlOjJlMGQ1YjM1ZjRjZDRhYzBiNjU4NGVjOTYxZmZjNjU1XzMtMS0xLTEtMA_1064480f-246c-41e6-beb2-8b64300eb030"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="id7177d9153404fb68d339079a331543f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZTBkNWIzNWY0Y2Q0YWMwYjY1ODRlYzk2MWZmYzY1NS90YWJsZXJhbmdlOjJlMGQ1YjM1ZjRjZDRhYzBiNjU4NGVjOTYxZmZjNjU1XzUtMS0xLTEtMzg0NzY_958cb4bd-9cd7-462b-ae8f-5d7cfc42f6bc"
      unitRef="usd">16559000</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="if4e245eba01b40829373277b36665d51_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZTBkNWIzNWY0Y2Q0YWMwYjY1ODRlYzk2MWZmYzY1NS90YWJsZXJhbmdlOjJlMGQ1YjM1ZjRjZDRhYzBiNjU4NGVjOTYxZmZjNjU1XzUtMS0xLTEtMA_72a1dfc4-c438-48bf-a35d-eb05b135f150"
      unitRef="usd">18600000</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="id7177d9153404fb68d339079a331543f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZTBkNWIzNWY0Y2Q0YWMwYjY1ODRlYzk2MWZmYzY1NS90YWJsZXJhbmdlOjJlMGQ1YjM1ZjRjZDRhYzBiNjU4NGVjOTYxZmZjNjU1XzYtMS0xLTEtMzg0NzY_442c469e-7b65-4d4f-af79-346ced92420d"
      unitRef="usd">-18459000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="if4e245eba01b40829373277b36665d51_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZTBkNWIzNWY0Y2Q0YWMwYjY1ODRlYzk2MWZmYzY1NS90YWJsZXJhbmdlOjJlMGQ1YjM1ZjRjZDRhYzBiNjU4NGVjOTYxZmZjNjU1XzYtMS0xLTEtMA_2ef4727c-68b4-4b76-97eb-c55750a1933a"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="iae02917f54274b579c2894c8155d9e11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZTBkNWIzNWY0Y2Q0YWMwYjY1ODRlYzk2MWZmYzY1NS90YWJsZXJhbmdlOjJlMGQ1YjM1ZjRjZDRhYzBiNjU4NGVjOTYxZmZjNjU1XzctMS0xLTEtMzg0NzY_1bcf3ebb-3d87-41c5-a3cd-231a851a03ef"
      unitRef="usd">16700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i5879c529f1044590b63a67bad0d16f8d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZToyZTBkNWIzNWY0Y2Q0YWMwYjY1ODRlYzk2MWZmYzY1NS90YWJsZXJhbmdlOjJlMGQ1YjM1ZjRjZDRhYzBiNjU4NGVjOTYxZmZjNjU1XzctMS0xLTEtMA_2eb3fa92-5f99-4bde-a155-4ce6d1c5e6b3"
      unitRef="usd">18600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="ia0e7d3e451a44f16bafd403564c15c33_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzcxNDY4MjU2MTc1MTY_b7cdb581-aef5-4e93-bdb5-123538e82ea8"
      unitRef="usd">11600000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="ib406cf1143e641fd8a07fb8084d1848a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzcxNDY4MjU2MTc1MzU_28c41f7b-a0f5-40e7-8016-1b5c49769222"
      unitRef="usd">1300000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="iae1bbd4d1fb242f38ccaf2f15e20b521_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzE0MjkzNjUxMjA1NDMz_f4209b50-1de9-4121-a3c2-2dfb6d7f3e3f"
      unitRef="usd">52700000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="ifa9f1ac8ede24d5ea9cae25ddd1c125f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzE0MjkzNjUxMjA1NDE4_bc93b9d3-72bb-474c-aee7-d3cb189257c4"
      unitRef="usd">15900000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i6de6823bdc2b4ac98c04ae502140745a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzE2NDkyNjc0NjYzODk_c6bd6420-97c4-451b-a339-755990a19bbd"
      unitRef="usd">14500000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <rprx:DebtSecuritiesAvailableForSaleQuarterlyPayments
      contextRef="i8c7c87185ab54de39f17a1a1526628ab_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzM3NjI_4487b9b3-7b80-4000-82f7-746e8e289b2a"
      unitRef="usd">15600000</rprx:DebtSecuritiesAvailableForSaleQuarterlyPayments>
    <rprx:DebtSecuritiesAvailableForSaleFixedPayment
      contextRef="i8c7c87185ab54de39f17a1a1526628ab_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzQwMjQ_531f2c50-13ca-43d5-9c66-a385be2193ae"
      unitRef="usd">250000000</rprx:DebtSecuritiesAvailableForSaleFixedPayment>
    <rprx:DebtSecuritiesAvailableForSaleChangeInControlEventPeriod
      contextRef="i8c7c87185ab54de39f17a1a1526628ab_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzE0MjkzNjUxMjEyNDAy_cecb7457-e8ae-49cb-97cc-7cd10091fe5d">P4Y</rprx:DebtSecuritiesAvailableForSaleChangeInControlEventPeriod>
    <rprx:DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital
      contextRef="i8c7c87185ab54de39f17a1a1526628ab_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzEwOTk1MTE2NTExMzU_18e500e3-e692-47aa-8fb2-162b3b9adb7b"
      unitRef="number">0.095</rprx:DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital>
    <rprx:DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital
      contextRef="i81dbcb5a23f349fe855015cfdaaa1937_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzEwOTk1MTE2NTE2Nzk_1de21661-553a-44e7-a2d0-c986d99abf42"
      unitRef="number">0.083</rprx:DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital>
    <rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased
      contextRef="i1c970570f47a4749aeb33f585934e58f_D20211101-20211130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzEwOTk1MTE2NjI5Mzg_6c91bcc5-536a-4f79-b1d4-dd9c1705887f"
      unitRef="shares">3846000</rprx:DebtSecuritiesAvailableForSaleNumberOfSharesPurchased>
    <rprx:DebtSecuritiesAvailableForSaleRestrictionPeriod
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzE0MjkzNjUxMjEyMzg0_1abf02e9-c426-44ff-91b7-e19cb6cac6a9">P6M</rprx:DebtSecuritiesAvailableForSaleRestrictionPeriod>
    <us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90ZXh0cmVnaW9uOjY4YmEzYmJjMDE3MDRiOGE5NDdmYjZjMjc1NDk5NGRkXzExMjM1_3717424b-0101-4cfb-b1be-ed67cd8d68c7">Estimated fair values based on Level 3 inputs and related carrying values for our financial royalty assets as of December 31, 2021 and 2020 are presented below (in thousands).&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Value, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Value, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financial royalty assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,047,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,332,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,718,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,955,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock>
    <rprx:FinancingReceivablesFairValueDisclosure
      contextRef="i81db589362444c02b90538016ac19ba1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTozYjI2ZGZjYTliZjk0YWI1YTMwZGYyMTVhZjZmNTE2MS90YWJsZXJhbmdlOjNiMjZkZmNhOWJmOTRhYjVhMzBkZjIxNWFmNmY1MTYxXzItMS0xLTEtMA_9f4cdb84-9a5b-4b8c-8a5d-fb0a9f863e3b"
      unitRef="usd">19047183000</rprx:FinancingReceivablesFairValueDisclosure>
    <rprx:FinancingReceivablesFairValueDisclosure
      contextRef="ic0f6dd75074a4324b2b360f729714ac3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTozYjI2ZGZjYTliZjk0YWI1YTMwZGYyMTVhZjZmNTE2MS90YWJsZXJhbmdlOjNiMjZkZmNhOWJmOTRhYjVhMzBkZjIxNWFmNmY1MTYxXzItMy0xLTEtMA_91dbe1d7-a330-4d33-8bf5-7c17f18550c6"
      unitRef="usd">14332596000</rprx:FinancingReceivablesFairValueDisclosure>
    <rprx:FinancingReceivablesFairValueDisclosure
      contextRef="id95940867f7f46d1832cf3e16823033c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTozYjI2ZGZjYTliZjk0YWI1YTMwZGYyMTVhZjZmNTE2MS90YWJsZXJhbmdlOjNiMjZkZmNhOWJmOTRhYjVhMzBkZjIxNWFmNmY1MTYxXzItNS0xLTEtMA_2afadd6a-a30f-4c57-acbc-abbd68ce4cc9"
      unitRef="usd">18718179000</rprx:FinancingReceivablesFairValueDisclosure>
    <rprx:FinancingReceivablesFairValueDisclosure
      contextRef="i9de83b17a2d84f7081715a46a48bb989_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMTgvZnJhZzo2OGJhM2JiYzAxNzA0YjhhOTQ3ZmI2YzI3NTQ5OTRkZC90YWJsZTozYjI2ZGZjYTliZjk0YWI1YTMwZGYyMTVhZjZmNTE2MS90YWJsZXJhbmdlOjNiMjZkZmNhOWJmOTRhYjVhMzBkZjIxNWFmNmY1MTYxXzItNy0xLTEtMA_6b28e39b-d4f7-4b42-8739-8a1950e2930a"
      unitRef="usd">12955277000</rprx:FinancingReceivablesFairValueDisclosure>
    <us-gaap:FinancingReceivablesTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90ZXh0cmVnaW9uOmI1NDJkNjUwZjU0NTQ0MDRhNGU4YzgwNTE3OTQ0ODUxXzM2ODQ_bd5e340a-e16f-4c5f-b9d1-c2e44b44b3b5">Financial Royalty Assets, Net&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial royalty assets, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consist of contractual rights to cash flows relating to royalty payments derived from the expected sales of patent-protected biopharmaceutical products that entitle us and our subsidiaries to receive a portion of income from the sale of such products by third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets at December 31, 2021 and 2020 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Royalty Duration (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Allowance for Changes in Expected Cash Flows (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Value (e)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cystic fibrosis franchise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2037 (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,335,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(48,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,287,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tysabri&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,846,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,617)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,829,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Imbruvica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,438,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(236,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,201,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Xtandi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,100,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(172,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;927,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tremfya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2031-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;881,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;881,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Evrysdi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2030-2035 (d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;727,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;727,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020-2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,697,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(909,916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,787,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,027,541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,384,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,643,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Less: Cumulative allowance for credit losses (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(310,804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total financial royalty assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,332,596&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt"&gt;Dates shown represent our estimates as of current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt"&gt;Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt"&gt;Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3&#160;billion. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:9.13pt"&gt;The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7&#x2013;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Royalty Duration (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Allowance for Changes in Expected Cash Flows (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Value (e) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cystic fibrosis franchise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2037 (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,274,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,274,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tysabri&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,003,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(112,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,891,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Imbruvica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,406,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(46,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,359,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Xtandi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,150,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(145,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,004,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Promacta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025-2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;686,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;686,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Evrysdi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2030-2035 (d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;675,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;675,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020-2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,022,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(634,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,387,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,219,101&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(940,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;13,278,994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Less: Cumulative allowance for credit losses (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(323,717)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total financial royalty assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,955,277&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:9.13pt"&gt;Dates shown represent our estimates as of current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt"&gt;Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt"&gt;The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7&#x2013;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancingReceivablesTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90ZXh0cmVnaW9uOmI1NDJkNjUwZjU0NTQ0MDRhNGU4YzgwNTE3OTQ0ODUxXzM2ODU_045c3ddd-5018-441c-9817-05af149f4f37">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets at December 31, 2021 and 2020 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Royalty Duration (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Allowance for Changes in Expected Cash Flows (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Value (e)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cystic fibrosis franchise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2037 (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,335,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(48,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,287,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tysabri&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,846,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,617)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,829,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Imbruvica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,438,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(236,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,201,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Xtandi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,100,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(172,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;927,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tremfya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2031-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;881,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;881,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Evrysdi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2030-2035 (d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;727,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;727,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020-2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,697,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(909,916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,787,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,027,541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,384,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,643,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Less: Cumulative allowance for credit losses (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(310,804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total financial royalty assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,332,596&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt"&gt;Dates shown represent our estimates as of current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt"&gt;Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt"&gt;Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3&#160;billion. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:9.13pt"&gt;The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7&#x2013;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Royalty Duration (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Allowance for Changes in Expected Cash Flows (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Value (e) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cystic fibrosis franchise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2037 (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,274,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,274,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tysabri&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,003,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(112,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,891,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Imbruvica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,406,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(46,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,359,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Xtandi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,150,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(145,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,004,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Promacta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025-2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;686,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;686,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Evrysdi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2030-2035 (d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;675,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;675,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020-2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,022,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(634,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,387,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,219,101&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(940,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;13,278,994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Less: Cumulative allowance for credit losses (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(323,717)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total financial royalty assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,955,277&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:9.13pt"&gt;Dates shown represent our estimates as of current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt"&gt;Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt"&gt;The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7&#x2013;Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:NotesReceivableGross
      contextRef="i35db462f272349c080f522a5c4e7f55a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzEtNC0xLTEtMA_fb263ec1-f98f-4e6e-8cce-3c0b24adf0cd"
      unitRef="usd">5335641000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i35db462f272349c080f522a5c4e7f55a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzItNi0xLTEtMzg3NTI_f5e607c2-9572-4a11-b55e-5f1da95ba8a5"
      unitRef="usd">48636000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i35db462f272349c080f522a5c4e7f55a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzItOC0xLTEtMzg3NzA_d6ae959b-985f-4bb5-842b-ded499b68b81"
      unitRef="usd">5287005000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i910a6938c4b04c46b87813b7b69e8dce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzItNC0xLTEtMA_674a12cf-8fb5-4780-b19b-45e6a2bb365e"
      unitRef="usd">1846069000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i910a6938c4b04c46b87813b7b69e8dce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzItNi0xLTEtMA_100b5a91-4e4c-4251-b5ce-b51ed48994aa"
      unitRef="usd">16617000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i910a6938c4b04c46b87813b7b69e8dce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzItOC0xLTEtMA_4634bdc2-0473-4690-aa8d-0294930e21de"
      unitRef="usd">1829452000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="ide9c8ac9b7834772b270536662c1c607_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzMtNC0xLTEtMA_d462cbdd-1d41-42d0-8086-5ce7d4b21086"
      unitRef="usd">1438730000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="ide9c8ac9b7834772b270536662c1c607_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzMtNi0xLTEtMA_f86a503e-5169-44c0-94ee-1b9b2bf1177a"
      unitRef="usd">236871000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="ide9c8ac9b7834772b270536662c1c607_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzMtOC0xLTEtMA_f3f0969c-865b-498a-84ee-8c34febfbab6"
      unitRef="usd">1201859000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i5d275aee32304e029188d994792d2f92_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzQtNC0xLTEtMA_81bc5b0f-1379-4668-9cdc-df6e77a03284"
      unitRef="usd">1100065000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i5d275aee32304e029188d994792d2f92_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzQtNi0xLTEtMA_043f328b-6256-42ea-a590-60f0327a16c2"
      unitRef="usd">172101000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i5d275aee32304e029188d994792d2f92_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzQtOC0xLTEtMA_56e4253e-5e38-4093-a024-22127092352b"
      unitRef="usd">927964000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i4dea9589e6e74a59a7d713e718e4a80d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzUtNC0xLTEtMA_d4d91d25-4af0-47cd-a9f9-35957a200082"
      unitRef="usd">881671000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i4dea9589e6e74a59a7d713e718e4a80d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzUtNi0xLTEtMA_16c8688e-5dbc-4886-986a-d0a09bc6a599"
      unitRef="usd">0</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i4dea9589e6e74a59a7d713e718e4a80d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzUtOC0xLTEtMA_13a098f2-9d44-4198-8f6b-d090440ac1a5"
      unitRef="usd">881671000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i65da27051b834e589474daa7e00772a9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzYtNC0xLTEtMA_0a1a4af8-45ad-4576-b459-bd438979ef00"
      unitRef="usd">727774000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i65da27051b834e589474daa7e00772a9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzYtNi0xLTEtMA_6e62208c-6193-406e-b8b3-b7c4347ced8b"
      unitRef="usd">0</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i65da27051b834e589474daa7e00772a9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzYtOC0xLTEtMA_ae3d3b9c-3a91-40db-b3a9-4cfd21b198cc"
      unitRef="usd">727774000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i98a31ea009fd41ae9b93b9a0ba894b4b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzctNC0xLTEtMA_58923d57-51ca-4c92-97aa-08995528091a"
      unitRef="usd">4697591000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i98a31ea009fd41ae9b93b9a0ba894b4b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzctNi0xLTEtMA_aae74695-231c-4653-b87a-c0cc89f4ebf8"
      unitRef="usd">909916000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i98a31ea009fd41ae9b93b9a0ba894b4b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzctOC0xLTEtMA_67b3c7d8-5b5d-4000-95b8-82755636be90"
      unitRef="usd">3787675000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzgtNC0xLTEtMA_41819eda-cee6-4635-bf2f-81f84e199505"
      unitRef="usd">16027541000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzgtNi0xLTEtMA_ecb3bce2-fba2-4fe2-9361-fca178a0a464"
      unitRef="usd">1384141000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzgtOC0xLTEtMA_1e09f9d4-8495-4e05-9902-4c280e392fc3"
      unitRef="usd">14643400000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzktOC0xLTEtMA_a12ae4aa-93d1-4dde-9a04-240c5c0a8245"
      unitRef="usd">310804000</rprx:FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal>
    <us-gaap:NotesReceivableNet
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTpjMTUzODQ4MTVhMDY0ODc2OGFjZGU5YmU4NDMyYjZlNS90YWJsZXJhbmdlOmMxNTM4NDgxNWEwNjQ4NzY4YWNkZTliZTg0MzJiNmU1XzEwLTgtMS0xLTA_3032fe5c-79e6-4418-8aed-4ee9826c4901"
      unitRef="usd">14332596000</us-gaap:NotesReceivableNet>
    <rprx:FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents
      contextRef="i65da27051b834e589474daa7e00772a9_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90ZXh0cmVnaW9uOmI1NDJkNjUwZjU0NTQ0MDRhNGU4YzgwNTE3OTQ0ODUxXzEwOTk1MTE2MzE3MzQ_3ef68589-cd64-45c8-9c5f-6e51080af306"
      unitRef="usd">1300000000</rprx:FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents>
    <us-gaap:NotesReceivableGross
      contextRef="i548f6928715a4fd7ad65b15d47cba2a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzEtNC0xLTEtMA_001bb0de-3d25-4f4d-9117-5a0b56a7e3d3"
      unitRef="usd">5274896000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i548f6928715a4fd7ad65b15d47cba2a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzItNi0xLTEtMzg4NTI_7a7fb145-5bc7-4ea6-9830-5d0471bc9463"
      unitRef="usd">0</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i548f6928715a4fd7ad65b15d47cba2a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzItOC0xLTEtMzg4Njg_5edd8294-22f3-43b5-858e-69e98e798989"
      unitRef="usd">5274896000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i8bf9a6954f4b4608ac3db7c1a9515015_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzItNC0xLTEtMA_b57a090d-90f4-43ae-aff1-49ca76dbbcd9"
      unitRef="usd">2003797000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i8bf9a6954f4b4608ac3db7c1a9515015_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzItNi0xLTEtMA_b38780b8-655d-40e8-8480-acc2e7fb399c"
      unitRef="usd">112720000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i8bf9a6954f4b4608ac3db7c1a9515015_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzItOC0xLTEtMA_e53221d3-f743-4305-8245-6828a208f3f1"
      unitRef="usd">1891077000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i60ad6794898d4cdc903f9017ab626e3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzMtNC0xLTEtMA_d5a0c77c-9221-4990-84ee-40e49a6921a2"
      unitRef="usd">1406291000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i60ad6794898d4cdc903f9017ab626e3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzMtNi0xLTEtMA_e633ee62-1373-486e-a836-e084a5cc4f83"
      unitRef="usd">46872000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i60ad6794898d4cdc903f9017ab626e3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzMtOC0xLTEtMA_a869bd2b-017d-4266-b401-1f74c92a34d3"
      unitRef="usd">1359419000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i9ee684b3e062472b855ba68705d802d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzQtNC0xLTEtMA_ed2be63c-af01-4a7f-9e1a-9a7fd0c519bc"
      unitRef="usd">1150335000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i9ee684b3e062472b855ba68705d802d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzQtNi0xLTEtMA_b267ab62-0ef0-4d90-9d81-c4d35e4f69ee"
      unitRef="usd">145565000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i9ee684b3e062472b855ba68705d802d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzQtOC0xLTEtMA_78f8635b-7ffe-4447-a5e2-b6b47d1f80b2"
      unitRef="usd">1004770000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="ib6afe0a950f444f6986eed827af96e29_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzUtNC0xLTEtMA_63ed81a6-00d0-4947-805b-6ed60bfea6ae"
      unitRef="usd">686129000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="ib6afe0a950f444f6986eed827af96e29_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzUtNi0xLTEtMA_be4b64cd-6669-418f-9da5-9bbd7dd3c754"
      unitRef="usd">0</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="ib6afe0a950f444f6986eed827af96e29_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzUtOC0xLTEtMA_845c02ab-1530-410a-b4d2-4bbd79994cd2"
      unitRef="usd">686129000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i653d2d4470454f40b058b645513ec385_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzYtNC0xLTEtMA_973eb871-f7e8-43b4-bdae-d44e2926176a"
      unitRef="usd">675440000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i653d2d4470454f40b058b645513ec385_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzYtNi0xLTEtMA_56b5e710-6757-49a5-90b2-b028585b4d9b"
      unitRef="usd">0</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i653d2d4470454f40b058b645513ec385_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzYtOC0xLTEtMA_19e374f9-fa4e-4bb3-9ae9-0b1366609799"
      unitRef="usd">675440000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="icd8901ad6baa4fe485e98132407e4d74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzctNC0xLTEtMA_0fc96462-ba4b-4444-a1f8-a65c3ec7409d"
      unitRef="usd">3022213000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="icd8901ad6baa4fe485e98132407e4d74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzctNi0xLTEtMA_37dad9dc-36b7-4110-9e1a-3574604a7679"
      unitRef="usd">634950000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="icd8901ad6baa4fe485e98132407e4d74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzctOC0xLTEtMA_c048a54f-2569-4f48-abe3-ea04ded2f270"
      unitRef="usd">2387263000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <us-gaap:NotesReceivableGross
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzgtNC0xLTEtMA_4e58c861-d033-4908-bddd-ab1503e97ad5"
      unitRef="usd">14219101000</us-gaap:NotesReceivableGross>
    <rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzgtNi0xLTEtMA_d331ef12-5bbb-4dc4-b51b-11685b7308e6"
      unitRef="usd">940107000</rprx:FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzgtOC0xLTEtMA_5b33d43e-136f-4ce2-9cbb-6ae5d95e5b95"
      unitRef="usd">13278994000</rprx:FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows>
    <rprx:FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzktOC0xLTEtMA_3a1343d3-4f2a-46c1-8adc-f1ca6537bba1"
      unitRef="usd">323717000</rprx:FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal>
    <us-gaap:NotesReceivableNet
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90YWJsZTo3MDExZWZkNzA1ZjQ0ODE2YjA5NWJhOGNhZmU1ZDdiZi90YWJsZXJhbmdlOjcwMTFlZmQ3MDVmNDQ4MTZiMDk1YmE4Y2FmZTVkN2JmXzExLTgtMS0xLTM4ODY4_8b708ddf-8931-484b-806d-8701a5b302e0"
      unitRef="usd">12955277000</us-gaap:NotesReceivableNet>
    <rprx:FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents
      contextRef="i653d2d4470454f40b058b645513ec385_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzMvZnJhZzpiNTQyZDY1MGY1NDU0NDA0YTRlOGM4MDUxNzk0NDg1MS90ZXh0cmVnaW9uOmI1NDJkNjUwZjU0NTQ0MDRhNGU4YzgwNTE3OTQ0ODUxXzEwOTk1MTE2MzI0OTU_d0e5639f-89ae-4358-bdbb-5ef129dc5cd0"
      unitRef="usd">1300000000</rprx:FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents>
    <us-gaap:CreditLossFinancialInstrumentTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90ZXh0cmVnaW9uOjUwNGJmMGZmZDIwYjRjMWE5Y2NiNDc4NzJkOWE0N2EwXzI1ODk_b09c7423-bbd2-4863-88c7-9bbfc57c362c">Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets&lt;div style="margin-top:3pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cumulative allowance for changes in expected future cash flows from financial royalty assets is presented net within the non-current portion of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial royalty assets, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the consolidated balance sheets and includes the following activities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;the movement in the cumulative allowance related to changes in forecasted royalty payments we expect to receive based on projected product sales for royalty bearing products as estimated by sell-side equity research analysts&#x2019; &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;consensus sales forecasts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the movement in the cumulative allowance for current expected credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The periodic movement in the cumulative allowance is presented on the consolidated statements of operations as the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Retained earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; of $192.7&#160;million to recognize an allowance for current expected credit losses on our portfolio of financial royalty assets with limited protective rights. The current period provision for changes in expected cash flows from financial royalty assets reflects the activity for the period primarily new financial royalty assets and changes in the underlying cash flow forecasts used in the effective interest model to measure income from our financial royalty assets. &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Refer to Note 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Summary of Significant Accounting Policies for further information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.734%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Activity for the Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,982,897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(322,717)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,342,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Write-off of cumulative allowance (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(868,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cumulative adjustment for adoption of ASU 2016-13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(192,705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(645,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;570,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Write-off of cumulative allowance (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Write-off of credit loss allowance (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provision expense for credit losses, net (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(156,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,263,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(912,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;446,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Write-off of cumulative allowance (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provision income for credit losses, net (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,694,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(a) &#160;&#160;&#160;&#160;Relates to amounts removed from the allowance at the end of a royalty asset&#x2019;s life to bring the account balance to zero. Write-offs solely impact the asset account and allowance account; there is no impact on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(b) &#160;&#160;&#160;&#160;Relates to amounts reversed out of the credit loss allowance associated with omecamtiv mecarbil as a result of the write-off of the related financial royalty asset balance of $90.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%"&gt;(c) &#160;&#160;&#160;&#160;In the year ended December 31, 2020, the provision for credit losses was primarily related to certain additions to our portfolio of financial royalty assets with limited protective rights in 2020, mainly the final tranche of Tazverik. In the year ended December 31, 2021,the provision income for credit losses was primarily related to a significant decline in the financial asset value for Tazverik, which was offset by increases in our portfolio of financial royalty assets with limited protective rights in 2021, primarily related to zavegepant.&lt;/span&gt;&lt;/div&gt;</us-gaap:CreditLossFinancialInstrumentTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib04d3453e6dc4ca3a0b79e01ab3fe12a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90ZXh0cmVnaW9uOjUwNGJmMGZmZDIwYjRjMWE5Y2NiNDc4NzJkOWE0N2EwXzEwOTk1MTE2MzEyMDc_aa4f397a-6877-45c0-b096-fe40ac0a87f1"
      unitRef="usd">-192700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90ZXh0cmVnaW9uOjUwNGJmMGZmZDIwYjRjMWE5Y2NiNDc4NzJkOWE0N2EwXzI1OTE_dd15c2a6-3cb1-43b2-a3ec-1ab3c4dc115a">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.734%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Activity for the Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,982,897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(322,717)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,342,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Write-off of cumulative allowance (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(868,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cumulative adjustment for adoption of ASU 2016-13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(192,705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(645,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;570,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Write-off of cumulative allowance (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Write-off of credit loss allowance (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provision expense for credit losses, net (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(156,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,263,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(912,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;446,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Write-off of cumulative allowance (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provision income for credit losses, net (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,694,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(a) &#160;&#160;&#160;&#160;Relates to amounts removed from the allowance at the end of a royalty asset&#x2019;s life to bring the account balance to zero. Write-offs solely impact the asset account and allowance account; there is no impact on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(b) &#160;&#160;&#160;&#160;Relates to amounts reversed out of the credit loss allowance associated with omecamtiv mecarbil as a result of the write-off of the related financial royalty asset balance of $90.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%"&gt;(c) &#160;&#160;&#160;&#160;In the year ended December 31, 2020, the provision for credit losses was primarily related to certain additions to our portfolio of financial royalty assets with limited protective rights in 2020, mainly the final tranche of Tazverik. In the year ended December 31, 2021,the provision income for credit losses was primarily related to a significant decline in the financial asset value for Tazverik, which was offset by increases in our portfolio of financial royalty assets with limited protective rights in 2021, primarily related to zavegepant.&lt;/span&gt;&lt;/div&gt;</us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="ifa26755fbc5e413fbf3122ec0db17370_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzEtMS0xLTEtMA_2834455a-0d32-4ecb-8321-9f48cb6f4352"
      unitRef="usd">1982897000</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <rprx:FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzItMS0xLTEtMA_e0b96a8b-f368-448f-909c-3a2db4c489be"
      unitRef="usd">322717000</rprx:FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense>
    <rprx:FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzMtMS0xLTEtMA_82efe01c-3bb7-4aec-b7ea-d91370b68322"
      unitRef="usd">1342038000</rprx:FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense>
    <us-gaap:FinancingReceivableChangeInPresentValueExpenseReversal
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzQtMS0xLTEtMA_d557c6fb-4ffd-4da5-b023-a6a7a64e994f"
      unitRef="usd">-95158000</us-gaap:FinancingReceivableChangeInPresentValueExpenseReversal>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="id30f26bcb6cd4b64982e6cd53528c44e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzUtMS0xLTEtMA_83e20585-e484-494f-9710-a21949a64fac"
      unitRef="usd">868418000</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="ie7ab9fefed164e08ac6ad01d99d06780_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzYtMS0xLTEtMA_0cc1ddee-1aa9-4b90-ad8a-c72c3e23dd1d"
      unitRef="usd">192705000</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <rprx:FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzctMS0xLTEtMA_13b9111b-bf82-4c56-8117-7811d0104d5e"
      unitRef="usd">645612000</rprx:FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense>
    <rprx:FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzgtMS0xLTEtMA_31304a4d-15e8-494a-b8cb-c8bff3b0b48b"
      unitRef="usd">570959000</rprx:FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense>
    <us-gaap:FinancingReceivableChangeInPresentValueExpenseReversal
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzktMS0xLTEtMA_71625750-b684-42ac-b0bc-edcc0480825c"
      unitRef="usd">-2964000</us-gaap:FinancingReceivableChangeInPresentValueExpenseReversal>
    <us-gaap:FinancingReceivableAllowanceForCreditLossesWriteOffs
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzEwLTEtMS0xLTA_288605bf-f766-497b-9b72-1077e5bb8c01"
      unitRef="usd">25174000</us-gaap:FinancingReceivableAllowanceForCreditLossesWriteOffs>
    <us-gaap:ProvisionForLoanLossesExpensed
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzExLTEtMS0xLTA_38b0220c-0a6d-4391-8314-378952ae413f"
      unitRef="usd">156186000</us-gaap:ProvisionForLoanLossesExpensed>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzEyLTEtMS0xLTA_fd1874a9-5ee4-4b67-ab2c-6678ad61162f"
      unitRef="usd">1263824000</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <rprx:FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzE0LTEtMS0xLTA_aef2d718-ad6a-4d88-852e-541145913387"
      unitRef="usd">912710000</rprx:FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense>
    <rprx:FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzE1LTEtMS0xLTA_6e74c88c-d64d-4841-b35a-54242d2ca5cb"
      unitRef="usd">446955000</rprx:FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense>
    <us-gaap:FinancingReceivableChangeInPresentValueExpenseReversal
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzE2LTEtMS0xLTA_0e9fa3f4-5d84-4ea0-837c-0fb07ea33e4d"
      unitRef="usd">-21721000</us-gaap:FinancingReceivableChangeInPresentValueExpenseReversal>
    <us-gaap:ProvisionForLoanLossesExpensed
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzE4LTEtMS0xLTM4OTQ4_cb41fccc-659c-405d-94c1-2f59b8d72f1d"
      unitRef="usd">-12913000</us-gaap:ProvisionForLoanLossesExpensed>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90YWJsZTo0MGI5NThjMjlhNWY0ZDkyYTIxODg5OWMxNGJlNDVjZS90YWJsZXJhbmdlOjQwYjk1OGMyOWE1ZjRkOTJhMjE4ODk5YzE0YmU0NWNlXzE5LTEtMS0xLTM4OTQ4_0ed210da-3d30-469c-9f82-774e426276bf"
      unitRef="usd">1694945000</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <rprx:FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzYvZnJhZzo1MDRiZjBmZmQyMGI0YzFhOWNjYjQ3ODcyZDlhNDdhMC90ZXh0cmVnaW9uOjUwNGJmMGZmZDIwYjRjMWE5Y2NiNDc4NzJkOWE0N2EwXzE2NDkyNjc0NDUxNjE_a5eb2a80-35d0-4bbe-a4e3-f57c3572856a"
      unitRef="usd">90200000</rprx:FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90ZXh0cmVnaW9uOjk3NTY4NTM0ZDNmMjQ4MGE4YTVjYzc1NDhkYTk2YmI1XzEyNzc_cfef2b15-557b-4b1c-98ec-be8a834ee236">Intangible Royalty Assets, Net&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following schedules of the intangible royalty assets present the cost, accumulated amortization and net carrying value as of December 31, 2021 and 2020 (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;DPP-IV patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;DPP-IV patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;577,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;577,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of our DPP-IV patents associated with the intangible royalty assets terminate at various dates through 2022. The weighted average remaining life of the intangible royalty assets is less than one year. We project amortization expense will be $5.7&#160;million in 2022.&lt;/span&gt;&lt;/div&gt;Our revenue is tied to underlying patent protected sales of DPP-IV products of various licensees. Such revenue from royalty assets is earned from sales occurring primarily in the United States and Europe; however, we do not have the ability to disaggregate our royalty revenue from licensees based on the geography of the underlying sales, as this level of information is not always included in royalty reports provided to us. The marketers paying us royalties on these products do not always provide, and are not necessarily required to provide, the breakdown of product sales by geography. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for 86%, 97%  and 91% of our revenues from intangible royalty assets in the years ended December 31, 2021,  2020 and 2019, respectively.</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90ZXh0cmVnaW9uOjk3NTY4NTM0ZDNmMjQ4MGE4YTVjYzc1NDhkYTk2YmI1XzEyNzk_327a188b-e67c-400f-bd5d-6c9deea7372c">&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following schedules of the intangible royalty assets present the cost, accumulated amortization and net carrying value as of December 31, 2021 and 2020 (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;DPP-IV patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;DPP-IV patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;577,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;577,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib6a50a564e8b4b0b934ac4b3000f4c8a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90YWJsZTpiZGM1OWJkYzRlZTM0ZmRkYTc1ZDkwMWQ1OWM4Nzg1NC90YWJsZXJhbmdlOmJkYzU5YmRjNGVlMzRmZGRhNzVkOTAxZDU5Yzg3ODU0XzItMS0xLTEtMA_c9a489a0-49f9-4259-8d66-461141688dc2"
      unitRef="usd">606216000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib6a50a564e8b4b0b934ac4b3000f4c8a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90YWJsZTpiZGM1OWJkYzRlZTM0ZmRkYTc1ZDkwMWQ1OWM4Nzg1NC90YWJsZXJhbmdlOmJkYzU5YmRjNGVlMzRmZGRhNzVkOTAxZDU5Yzg3ODU0XzItMy0xLTEtMA_9f213e79-286d-49be-a33f-37ffbc8b0638"
      unitRef="usd">600546000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib6a50a564e8b4b0b934ac4b3000f4c8a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90YWJsZTpiZGM1OWJkYzRlZTM0ZmRkYTc1ZDkwMWQ1OWM4Nzg1NC90YWJsZXJhbmdlOmJkYzU5YmRjNGVlMzRmZGRhNzVkOTAxZDU5Yzg3ODU0XzItNS0xLTEtMA_b7b55a54-ef8f-499a-9e8b-408f1c8c3456"
      unitRef="usd">5670000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90YWJsZTpiZGM1OWJkYzRlZTM0ZmRkYTc1ZDkwMWQ1OWM4Nzg1NC90YWJsZXJhbmdlOmJkYzU5YmRjNGVlMzRmZGRhNzVkOTAxZDU5Yzg3ODU0XzQtMS0xLTEtMA_d203cb23-b2a9-45f7-b6da-94f81036520e"
      unitRef="usd">606216000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90YWJsZTpiZGM1OWJkYzRlZTM0ZmRkYTc1ZDkwMWQ1OWM4Nzg1NC90YWJsZXJhbmdlOmJkYzU5YmRjNGVlMzRmZGRhNzVkOTAxZDU5Yzg3ODU0XzQtMy0xLTEtMA_27899c46-62a2-4ac8-807a-60f8b50ae120"
      unitRef="usd">600546000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90YWJsZTpiZGM1OWJkYzRlZTM0ZmRkYTc1ZDkwMWQ1OWM4Nzg1NC90YWJsZXJhbmdlOmJkYzU5YmRjNGVlMzRmZGRhNzVkOTAxZDU5Yzg3ODU0XzQtNS0xLTEtMA_b4f5e599-73ca-48c1-b388-52b835d25b0e"
      unitRef="usd">5670000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="icc0fb3b2f3e24224b3fb2f9cc5ef7df9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90YWJsZTozNmE3YzM1YTcwNDU0ZGIwYmE4MjMyMzU2MzA5N2U5Yi90YWJsZXJhbmdlOjM2YTdjMzVhNzA0NTRkYjBiYTgyMzIzNTYzMDk3ZTliXzItMS0xLTEtMA_1c7d5f7b-b881-46f3-820c-06525e6caf7e"
      unitRef="usd">606216000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icc0fb3b2f3e24224b3fb2f9cc5ef7df9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90YWJsZTozNmE3YzM1YTcwNDU0ZGIwYmE4MjMyMzU2MzA5N2U5Yi90YWJsZXJhbmdlOjM2YTdjMzVhNzA0NTRkYjBiYTgyMzIzNTYzMDk3ZTliXzItMy0xLTEtMA_a1df0701-6540-45f5-81cb-036b02a95914"
      unitRef="usd">577550000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="icc0fb3b2f3e24224b3fb2f9cc5ef7df9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90YWJsZTozNmE3YzM1YTcwNDU0ZGIwYmE4MjMyMzU2MzA5N2U5Yi90YWJsZXJhbmdlOjM2YTdjMzVhNzA0NTRkYjBiYTgyMzIzNTYzMDk3ZTliXzItNS0xLTEtMA_a9b1ed13-4741-4235-ac92-2bb71dee11bf"
      unitRef="usd">28666000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90YWJsZTozNmE3YzM1YTcwNDU0ZGIwYmE4MjMyMzU2MzA5N2U5Yi90YWJsZXJhbmdlOjM2YTdjMzVhNzA0NTRkYjBiYTgyMzIzNTYzMDk3ZTliXzQtMS0xLTEtMA_209c9272-cbce-4b56-94a3-282a57fbbaf2"
      unitRef="usd">606216000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90YWJsZTozNmE3YzM1YTcwNDU0ZGIwYmE4MjMyMzU2MzA5N2U5Yi90YWJsZXJhbmdlOjM2YTdjMzVhNzA0NTRkYjBiYTgyMzIzNTYzMDk3ZTliXzQtMy0xLTEtMA_c5ce198f-2757-4b4a-93ed-d73a96027a39"
      unitRef="usd">577550000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90YWJsZTozNmE3YzM1YTcwNDU0ZGIwYmE4MjMyMzU2MzA5N2U5Yi90YWJsZXJhbmdlOjM2YTdjMzVhNzA0NTRkYjBiYTgyMzIzNTYzMDk3ZTliXzQtNS0xLTEtMA_d7db19bb-7804-471a-95d3-de4495275bcb"
      unitRef="usd">28666000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i7d7161b299de4f37949a7b5dcce2e1f7_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90ZXh0cmVnaW9uOjk3NTY4NTM0ZDNmMjQ4MGE4YTVjYzc1NDhkYTk2YmI1XzE0MjkzNjUxMTYyNTg2_c03e2e8b-44bd-44de-ab2a-b2a077fc846c">P1Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ib6a50a564e8b4b0b934ac4b3000f4c8a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90ZXh0cmVnaW9uOjk3NTY4NTM0ZDNmMjQ4MGE4YTVjYzc1NDhkYTk2YmI1XzQzNg_f47b1760-4e7f-4c3f-a534-9396da7ddd30"
      unitRef="usd">5700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i874783a606094b5b9faa8d9db9749829_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90ZXh0cmVnaW9uOjk3NTY4NTM0ZDNmMjQ4MGE4YTVjYzc1NDhkYTk2YmI1XzExNzc_52fc7cdc-98c4-4244-8e8c-94ccdb83ee86"
      unitRef="number">0.86</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id875c4379b7740e39a9bb8d8d1ddfe28_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90ZXh0cmVnaW9uOjk3NTY4NTM0ZDNmMjQ4MGE4YTVjYzc1NDhkYTk2YmI1XzExODI_dfae3ecf-8fc2-406f-b71b-f2668c552706"
      unitRef="number">0.97</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id6fb304c08604399aba5e92d08d1d6b7_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMzkvZnJhZzo5NzU2ODUzNGQzZjI0ODBhOGE1Y2M3NTQ4ZGE5NmJiNS90ZXh0cmVnaW9uOjk3NTY4NTM0ZDNmMjQ4MGE4YTVjYzc1NDhkYTk2YmI1XzExOTA_9fbd0129-b6a0-495c-b77c-bc1428ccb233"
      unitRef="number">0.91</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzQwOTU_249f20bd-ca2a-482b-9155-f202f64b81b7">Non-Consolidated Affiliates&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;The Legacy SLP Interest&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Exchange Offer Transactions, we acquired a special limited partnership interest in the Legacy Investors Partnerships (the &#x201c;Legacy SLP Interest&#x201d;) from the Continuing Investors Partnerships for $303.7&#160;million in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and an income allocation on a similar basis. Our income allocation is equal to the general partner&#x2019;s former contractual rights to the income of the Legacy Investors Partnerships, net of amortization of the basis difference. The Legacy SLP Interest is treated as an equity method investment as our Manager is also the Manager of the Legacy Investors Partnerships and has the ability to exercise significant influence. The Legacy Investors Partnerships no longer participate in investment opportunities from June 30, 2020 and, as such, the value of the Legacy SLP Interest is expected to decline over time. The Legacy Investors Partnerships also own a non-controlling interest in Old RPI. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income allocation from the Legacy SLP Interest is based on an estimate, as the Legacy Investors Partnerships are private partnerships that are expected to report on a lag subsequent to the date of this annual report. Management&#x2019;s estimate of equity in earnings from the Legacy SLP Interest for the current period will be updated for historical results in the subsequent period. During the years ended December 31, 2021 and 2020, we recorded an income allocation of $8.9&#160;million and $62.0&#160;million, respectively, within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity in losses/(earnings) of non-consolidated affiliates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We received cash distributions from the Legacy SLP Interest of $21.0&#160;million and $22.7&#160;million during the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;The Avillion Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for our partnership interests in Avillion Financing I, LP (&#x201c;Avillion I&#x201d;) and BAv Financing II, LP (&#x201c;Avillion II&#x201d;, or, together, the &#x201c;Avillion Entities&#x201d;) as equity method investments because RPIFT has the ability to exercise significant influence over the entities. We recorded a loss allocation from the Avillion Entities of $28.4&#160;million, $17.6&#160;million and $32.5&#160;million within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Equity in losses/(earnings) of non-consolidated affiliates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during the years ended December 31, 2021, 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 19, 2017, the FDA approved a supplemental New Drug Application for Pfizer&#x2019;s Bosulif. Avillion I is eligible to receive fixed payments from Pfizer based on this approval. Subsequent to the asset sale, the only operations of Avillion I are the collection of cash and unwinding of discount on the series of fixed annual payments due from Pfizer. We received distributions from Avillion I of $13.4&#160;million during each of the years ended December 31, 2021 and 2020, and $14.1&#160;million in the year ended December 31, 2019 in connection with Avillion I&#x2019;s receipt of the fixed annual payments due under its co-development agreement with Pfizer. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, RPIFT entered into an agreement with Avillion II, which was amended in 2019, to invest approximately $19.0&#160;million to fund approximately 50% of the costs of a Phase 2 clinical trial for the use of Merck KGaA&#x2019;s anti-IL 17 nanobody M1095 (the &#x201c;Merck KGaA Asset&#x201d;) for the treatment of psoriasis in exchange for certain milestone and royalty payments. Our involvement in the development for the Merck KGaA Asset ceased in the year ended December 31, 2020, for which we received a distribution of $21.3&#160;million from Avillion II. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, RPIFT entered into an additional agreement, which was amended in July 2021, to increase our investment up to $122.5&#160;million from $105.0&#160;million in Avillion II over multiple years to fund approximately 44% of the costs of Phase 2 and 3 clinical trials to advance PT027 through a global clinical development program for the treatment of asthma in exchange for royalties, a series of success-based milestones and other potential payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021 and 2020, RPIFT had $11.2&#160;million and $28.6&#160;million respectively, of unfunded commitments related to the Avillion Entities. Our maximum exposure to loss at any particular reporting date is limited to the current carrying value of the investment plus the unfunded commitments.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestments
      contextRef="i05361955890f48e2a999133572daa6a8_I20200211"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzI3Nw_4496cba5-42f0-49de-a2cd-86006e60f574"
      unitRef="usd">303700000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i2fbdc80a9a134e2b9b74bd14842984f8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDY2MTI_aa0bcdde-5d48-461e-8df0-5767485a44d6"
      unitRef="usd">8900000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1f98a06986334cf4ac1ea37c17735d57_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDY2MTY_6ecae9fb-5d5b-4744-b140-c7c07891729b"
      unitRef="usd">62000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i2fbdc80a9a134e2b9b74bd14842984f8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDY2OTA_a25b89ea-c7c9-4bbb-b4f0-59096e71be80"
      unitRef="usd">21000000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i1f98a06986334cf4ac1ea37c17735d57_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDY2OTQ_e4a88a7d-9d34-4a32-864e-a388c90cca3e"
      unitRef="usd">22700000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i795acc0e43ad49819be20554560459e9_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDY3MDc_d8b9002e-f179-4eb2-9af7-fd70f083ae54"
      unitRef="usd">-28400000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iff8840832b23407c89930ca87f5e3a14_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDY3MTE_d3323422-77bd-4f59-a227-bb916cd80159"
      unitRef="usd">-17600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i28b1ff263ad7477ba427e73b282c6efc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDY3MTU_0e0fc332-a01c-47e0-a11a-5b78c95e6617"
      unitRef="usd">-32500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i1e5a064854514c4e9d147a383d33e903_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDY3MzM_4f4a9aa7-711c-4faf-b16a-e0a57cb84c35"
      unitRef="usd">13400000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i4f295d9e2c304799a502469a6920f5c2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDY3MzM_dc00c8bb-303d-4bfe-94cb-14fe0272749d"
      unitRef="usd">13400000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i48ff7ddf47f44c04b36ecf13d3a578f4_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDc1NTA_338eedd1-460a-4d22-ac3b-bdd96d4d3f69"
      unitRef="usd">14100000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:OtherCommitment
      contextRef="ia502c1c929d940d39390b7214482871a_I20170331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzMwMjk_87c520a3-81d3-4dfd-8d36-12549003fd63"
      unitRef="usd">19000000</us-gaap:OtherCommitment>
    <rprx:OtherCommitmentsPercentage
      contextRef="ia502c1c929d940d39390b7214482871a_I20170331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzMwNTQ_637fc969-c6e4-4018-8a01-24919e779633"
      unitRef="number">0.50</rprx:OtherCommitmentsPercentage>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="iecadc5607804420f9e9904632d1e8a25_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDY3NzI_7ce64dff-6da8-4344-95a3-abd2500ee3bc"
      unitRef="usd">21300000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:OtherCommitment
      contextRef="ie3c9990279364489bd57aa8cf39a801b_I20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzEwOTk1MTE2MzI2MTg_139526c9-0202-4c99-b8e0-c1b74e7881e4"
      unitRef="usd">122500000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="idfbcd815ad3241e08b3899f248245e53_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE0MjkzNjUxMTY5NzIy_8a62e657-fe60-4b48-afc5-046a6a1e3047"
      unitRef="usd">105000000</us-gaap:OtherCommitment>
    <rprx:OtherCommitmentsPercentage
      contextRef="i3cde2b63bf59491b8925224bea22907a_I20180531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzM1NDc_f723cb89-93ec-48f6-b351-5846a41ec74a"
      unitRef="number">0.44</rprx:OtherCommitmentsPercentage>
    <rprx:EquityMethodInvestmentsUnfundedCommitments
      contextRef="i47df9f0f55ed4282855d6acd42a023ca_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDY3NDk_f2fb803d-2117-42ea-892d-7db250f72090"
      unitRef="usd">-11200000</rprx:EquityMethodInvestmentsUnfundedCommitments>
    <rprx:EquityMethodInvestmentsUnfundedCommitments
      contextRef="ib68731c3079e4d3ca394ac6b77b028f7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDIvZnJhZzo4ZmQ2NGNlNDY4MWI0MmFhYTgxZjYzMDZlMjVjZjg5OC90ZXh0cmVnaW9uOjhmZDY0Y2U0NjgxYjQyYWFhODFmNjMwNmUyNWNmODk4XzE2NDkyNjc0NDY3NTM_1987163c-f2fb-4d25-a582-23d0795902b4"
      unitRef="usd">28600000</rprx:EquityMethodInvestmentsUnfundedCommitments>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzE1NDA_aa947181-8f1f-40f3-932c-fce7f06343ad">Research &amp;amp; Development (&#x201c;R&amp;amp;D&#x201d;) Funding Expense &lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D funding expense consists of upfront and ongoing R&amp;amp;D payments we have made to counterparties to acquire royalties and/or milestones on development-stage product candidates. Ongoing R&amp;amp;D payments are made as the related development-stage product candidates undergo clinical trials with our counterparties. During the year ended December 31, 2021, 2020, and 2019 we did not enter into any new ongoing R&amp;amp;D funding arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We recognized R&amp;amp;D funding expense of $200.1&#160;million during the year ended December 31, 2021, comprised of $6.9&#160;million in ongoing R&amp;amp;D expenses, primarily under our co-funding agreement with Sanofi, and $193.2&#160;million in upfront R&amp;amp;D funding. As part of a long-term strategic funding partnership with MorphoSys, which closed on July 15, 2021 (as further discussed in Note 17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Commitments and Contingencies), we allocated $90.0&#160;million of the upfront payment to R&amp;amp;D funding expense, representing two development-stage products acquired in exchange for future royalties. Additionally, we made an upfront payment of $103.2&#160;million to BioCryst to acquire a royalty on a development-stage product in November 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized R&amp;amp;D funding expense of $26.3&#160;million during the year ended December 31, 2020, of which $20.5&#160;million related to ongoing development-stage funding payments, primarily under our co-funding agreement with Sanofi and $5.8&#160;million related to upfront funding for a royalty on a development-stage product that we acquired from BioCryst. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized $83.0&#160;million of R&amp;amp;D funding expense during the year ended December 31, 2019, of which $18.2&#160;million and $62.8&#160;million related to our funding agreements with both Sanofi and Pfizer, respectively. We completed our funding commitments in the fourth quarter of 2019 under our agreement with Pfizer. We did not have upfront development-stage R&amp;amp;D funding expense in 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, we have a remaining commitment of $10.7&#160;million related to our R&amp;amp;D funding agreement with Sanofi.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzIxOTkwMjMyNjcyNjg_1dd265f3-801a-47f1-86f1-a1c68def86fa"
      unitRef="usd">200100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i286e267288774fbe92ab611abb8069de_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzIxOTkwMjMyNjY2NjE_974050aa-2735-471b-a24d-fbe219f6f373"
      unitRef="usd">6900000</us-gaap:ResearchAndDevelopmentExpense>
    <rprx:ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzIxOTkwMjMyNjY3NDg_51661818-8b0b-4a49-972a-04388d6e3e1e"
      unitRef="usd">193200000</rprx:ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i40bac185075247a39792ae4ffa91c2ce_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzEwOTk1MTE2MzgyOTE_1069bed6-2ff8-4d4f-9e56-d68794d62341"
      unitRef="usd">90000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if273f44aa1484854b5d3ea003908542c_D20211101-20211130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzEwOTk1MTE2MzgzMDk_1c158e57-08b4-4e8e-b50f-a7399a32b995"
      unitRef="usd">103200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzE2NDkyNjc0NDQzMDc_98088dcd-97a2-4ae6-b0d7-a179ddaf30e4"
      unitRef="usd">26300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i479dbbd40a7348a1919d32453a73a811_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzQ5NDc4MDIzMzgwMTc_1b331233-ebf9-4aaa-b90f-f20d08cd4ed3"
      unitRef="usd">20500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9150e6c7578b456aad25125ca3f4404d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzE0MjkzNjUxMTcxMTM5_ec1aac3f-f6b0-42c6-8aaa-408a5c345ad7"
      unitRef="usd">5800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzE2NDkyNjc0NDYwNzM_1559dd5e-b1bb-42ff-b0e4-88adffca9da8"
      unitRef="usd">83000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i170879596f064c7ea75b778e24446320_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzE2NDkyNjc0NDYwOTQ_b442362e-27cf-44d7-8850-d85d59f9e260"
      unitRef="usd">18200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie35632bef26942e9a813a4eb6a249893_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzE2NDkyNjc0NDYxMTQ_05870d11-ebcf-46d1-a0b4-7c5f87932036"
      unitRef="usd">62800000</us-gaap:ResearchAndDevelopmentExpense>
    <rprx:ResearchAndDevelopmentRemainingFundingCommitment
      contextRef="i4861f1f472c3491ba7a17eb5040be7f6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDUvZnJhZzpiZmQ0OTQ5N2FmMTU0ZjQyYjBlY2NhOWU0ZjRlOTVlNC90ZXh0cmVnaW9uOmJmZDQ5NDk3YWYxNTRmNDJiMGVjY2E5ZTRmNGU5NWU0XzE2NDkyNjc0NDM5NDk_bdf8e7ea-0134-414f-9808-6f1d0f059600"
      unitRef="usd">10700000</rprx:ResearchAndDevelopmentRemainingFundingCommitment>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzgyMjU_7d2fe44a-48ed-4adc-b739-83e15fc63107">Borrowings&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;Our borrowings at December 31, 2021 and 2020 consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Type of Borrowing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Date of Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior Unsecured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 0.75% (issued at 99.322% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 1.20% (issued at 98.875% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 1.75% (issued at 98.284% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 2.20% (issued at 97.760% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$600,000, 2.15% (issued at 98.263% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 3.30% (issued at 95.556% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 3.55% (issued at 95.306% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$700,000, 3.35% (issued at 97.565% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(203,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(183,416)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total debt carrying value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,096,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,816,584&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,096,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,816,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Senior Unsecured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;July 26, 2021, we issued $1.3&#160;billion of senior unsecured notes (the &#x201c;2021 Notes&#x201d;) comprised of $600.0&#160;million principal amount of notes due September 2031 and $700.0&#160;million principal amount of notes due September 2051. Interest on each series of the 2021 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year, beginning on March 2, 2022. The 2021 Notes were issued at a total discount of $27.5&#160;million and we capitalized approximately $12.3&#160;million in debt issuance costs primarily composed of underwriting fees. The 2021 Notes have a weighted average coupon rate and a weighted average effective interest rate of 2.80% and 3.06%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On September 2, 2020, we issued $6.0&#160;billion of senior unsecured notes (the &#x201c;2020 Notes&#x201d; and, together with the 2021 Notes, the &#x201c;Notes&#x201d;). We used the net proceeds from the 2020 Notes offering, together with available cash on hand, to repay in full the senior secured credit facilities. Interest on each series of the 2020 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year. The 2020 Notes were issued at a total discount of $149.0&#160;million and we capitalized approximately $40.4&#160;million in debt issuance costs primarily comprised of underwriting fees. The 2020 Notes have a weighted average coupon rate and a weighted average effective interest rate of 2.125% and 2.50%, respectively.&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On August 3, 2021, we completed an exchange offer for the 2020 Notes where certain holders elected to tender their unregistered outstanding notes for freely tradable exchange notes that were registered under the Securities Act of 1933. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Notes may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the treasury rate, plus a make-whole premium as defined in the indenture. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Upon the occurrence of a change of control triggering event and downgrade in the rating of our Notes by two of three credit agencies, the holders may require us to repurchase all or part of their Notes at a price equal to 101% of the aggregate principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary. We are required to comply with certain covenants under our Notes and, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;as of December 31, 2021, we were in compliance with all applicable covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December 31, 2021 and 2020, the estimated fair value of our outstanding Notes using Level 2 inputs was approximately $7.2&#160;billion and $6.2&#160;billion, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%"&gt;Senior Unsecured Revolving Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On September 15, 2021, we entered into an amended and restated revolving credit agreement (the &#x201c;Credit Agreement&#x201d;). The Credit Agreement amends and restates the existing credit agreement that our subsidiary, RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured revolving credit facility (the &#x201c;Revolving Credit Facility&#x201d;) with borrowing capacity of up to $1.5&#160;billion for general corporate purposes. The Credit Agreement extends the maturity of the Revolving Credit Facility to September 15, 2026. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;December 31, 2021 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2020, there were no outstanding borrowings under the Revolving Credit Facility.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Revolving Credit Facility is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent&#x2019;s prime rate, (2) the federal funds effective rate and the overnight bank funding rate, plus 0.5% and (3) the one month adjusted LIBOR, plus 1% or (b) the Eurocurrency Rate or the Alternative Currency Daily Rate (each as defined in the Credit Agreement), plus in each case, the applicable margin. The applicable margin for the Revolving Credit Facility varies based on our public debt rating. Accordingly, the interest rates for the Revolving Credit Facility fluctuates during the term of the facility based on changes in the applicable interest rate and future changes in our public debt rating.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Credit Agreement that governs the Revolving Credit Facility contains certain customary covenants, that among other things, require us to maintain (i) a consolidated leverage ratio at or below 4.00 to 1.00 (or at or below 4.50 to 1.00 following a qualifying material acquisition) of consolidated funded debt to consolidated EBITDA, each as defined and calculated with the ratio level calculated with further adjustments as set forth in the Credit Agreement and (ii) a consolidated coverage ratio at or above 2.50 to 1.00 of consolidated EBITDA to consolidated interest expense, each as defined and calculated with further adjustments as set forth in the Credit Agreement. All obligations under the Revolving Credit Facility are unconditionally guaranteed by us. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;December 31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, RP Holdings was in compliance with these covenants. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Senior Secured Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On February 11, 2020, in connection with the Exchange Offer Transactions (as discussed in Note 1&#x2013;Organization and Purpose) and using funds contributed by RPI Intermediate FT and the Legacy Investors Partnerships, RPIFT repaid its outstanding debt and accrued interest, and terminated all outstanding interest rate swaps. RPI Intermediate FT, as borrower, entered into a term loan credit agreement with Bank of America, N.A., as administrative agent, the lenders party thereto from time to time and the other parties thereto. The senior secured credit facilities consisted of a term loan A and term loan B in the amounts of $3.20&#160;billion and $2.84&#160;billion, respectively. In September 2020, we repaid in full the outstanding principal amounts of term loans under the senior secured credit facilities with net proceeds from the 2020 Notes and available cash on hand. Upon refinancing our senior secured credit facilities in September 2020, we recorded a loss on debt extinguishment of $25.1&#160;million as part of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Other non-operating expense/(income), net,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; which primarily consisted of unamortized loan issuance costs and original issue discount related to our senior secured credit facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;RPIFT Senior Secured Credit Facilities &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The RPIFT Senior Secured Credit Facilities were repaid in full in February 2020 in connection with the Exchange Offer Transactions. We recorded a loss on debt extinguishment of $5.4&#160;million as part of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Other non-operating expense/(income), net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;during the year ended December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%"&gt;Principal Payments on the Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The future principal payments for our borrowings as of December 31, 2021 over the next five years and thereafter are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,300,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;(1)  &#160;&#160;&#160;&#160;Excludes unamortized debt discount and issuance costs of $203.9 million as of December 31, 2021, which are amortized through interest expense over the remaining life of the underlying debt obligations.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzgyMjI_88ca1aaf-6718-4679-90b8-16fdce3fe973">&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;Our borrowings at December 31, 2021 and 2020 consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Type of Borrowing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Date of Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior Unsecured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 0.75% (issued at 99.322% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 1.20% (issued at 98.875% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 1.75% (issued at 98.284% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 2.20% (issued at 97.760% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$600,000, 2.15% (issued at 98.263% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 3.30% (issued at 95.556% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,000,000, 3.55% (issued at 95.306% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$700,000, 3.35% (issued at 97.565% of par)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9/2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(203,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(183,416)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total debt carrying value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,096,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,816,584&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,096,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,816,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9796b650407b44c3957bc1e7ffbd1229_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzItMC0xLTEtMC90ZXh0cmVnaW9uOjhhNDMyZWJlNjM0MTRiMzBhNDQzMzZmYTM0M2Y5MTI2XzE2NDkyNjc0NDE3NTI_7c9b3782-be5b-4250-b5e3-6891590553af"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9796b650407b44c3957bc1e7ffbd1229_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzItMC0xLTEtMC90ZXh0cmVnaW9uOjhhNDMyZWJlNjM0MTRiMzBhNDQzMzZmYTM0M2Y5MTI2XzEwOTk1MTE2Mjc4NTE_0f0ad6cd-a7e5-458b-9904-41226e119004"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rprx:DebtInstrumentIssuanceAsAPercentOfPar
      contextRef="i7dc45b08ebac451f91ea39248eeab27b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzItMC0xLTEtMC90ZXh0cmVnaW9uOjhhNDMyZWJlNjM0MTRiMzBhNDQzMzZmYTM0M2Y5MTI2XzEwOTk1MTE2Mjc4NDM_b49f6492-b0ba-4959-b1cd-617d758b8c81"
      unitRef="number">0.99322</rprx:DebtInstrumentIssuanceAsAPercentOfPar>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9796b650407b44c3957bc1e7ffbd1229_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzItNi0xLTEtMA_bb1c3d81-86fd-4cf8-80cf-7fa7466758ea"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib2c6ec4ac80d4a6ba66238bf0a9eb4cb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzItOC0xLTEtMA_b804331c-349c-4a30-be79-3e5a60361975"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia2fafea4522943eca815863b7d3d8349_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzMtMC0xLTEtMC90ZXh0cmVnaW9uOjJkNTllMDExN2M4MTQ4NGQ4ODU1ZGRmODM4YzgxMjEyXzE2NDkyNjc0NDE3NTI_c810144c-910c-41ba-a8da-2f8b5d054e50"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia2fafea4522943eca815863b7d3d8349_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzMtMC0xLTEtMC90ZXh0cmVnaW9uOjJkNTllMDExN2M4MTQ4NGQ4ODU1ZGRmODM4YzgxMjEyXzEwOTk1MTE2Mjc4NTE_1350f426-c9e8-4313-8c5e-9df955114cc4"
      unitRef="number">0.0120</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rprx:DebtInstrumentIssuanceAsAPercentOfPar
      contextRef="i5b0aacd47d5b4487854882d7e7b776da_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzMtMC0xLTEtMC90ZXh0cmVnaW9uOjJkNTllMDExN2M4MTQ4NGQ4ODU1ZGRmODM4YzgxMjEyXzEwOTk1MTE2Mjc4NDM_a98a3b73-a68a-4b97-a89e-8d53295305cd"
      unitRef="number">0.98875</rprx:DebtInstrumentIssuanceAsAPercentOfPar>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia2fafea4522943eca815863b7d3d8349_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzMtNi0xLTEtMA_f9426238-6f06-4f25-9286-02514eb608a1"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia43476884d9241af8b829c570791446c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzMtOC0xLTEtMA_9edcf1a4-88fc-4f3e-b3ea-452a399d4c25"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i43310a7b9e4c4cbb9b03ef370bd43b77_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzQtMC0xLTEtMC90ZXh0cmVnaW9uOjBjYzNjMmQ4NmE2YzQxNWE5ZTgzZmM4YTc5MTZiMjJiXzE2NDkyNjc0NDE3NTI_61fd2c11-8d91-4a5b-b962-0d6ba4bbfb84"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i43310a7b9e4c4cbb9b03ef370bd43b77_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzQtMC0xLTEtMC90ZXh0cmVnaW9uOjBjYzNjMmQ4NmE2YzQxNWE5ZTgzZmM4YTc5MTZiMjJiXzEwOTk1MTE2Mjc4NTE_b1a6c48b-cb5b-4c4c-84ce-483f9e17ae1c"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rprx:DebtInstrumentIssuanceAsAPercentOfPar
      contextRef="ifee8d1bb44854cc4a3188d158569c76c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzQtMC0xLTEtMC90ZXh0cmVnaW9uOjBjYzNjMmQ4NmE2YzQxNWE5ZTgzZmM4YTc5MTZiMjJiXzEwOTk1MTE2Mjc4NDM_f83e35fc-8177-4eda-9936-5e49860cc6cf"
      unitRef="number">0.98284</rprx:DebtInstrumentIssuanceAsAPercentOfPar>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i43310a7b9e4c4cbb9b03ef370bd43b77_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzQtNi0xLTEtMA_2580df51-f3c8-4463-970a-74982c98190c"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9d33126321d44b4aabd868a581153c4b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzQtOC0xLTEtMA_0b709ecc-10ce-4007-ad76-d79579caf1b7"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i12aa5c25ace14515980e127e89b84e78_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzUtMC0xLTEtMC90ZXh0cmVnaW9uOmE0YTk3NGVhZmIzMzQ1OTA5NmNlMmI2Y2M0YzkwZDA1XzE2NDkyNjc0NDE3NDA_d294f6b3-77ca-4060-a48b-a1f69a12b6bf"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i12aa5c25ace14515980e127e89b84e78_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzUtMC0xLTEtMC90ZXh0cmVnaW9uOmE0YTk3NGVhZmIzMzQ1OTA5NmNlMmI2Y2M0YzkwZDA1XzEwOTk1MTE2Mjc4Mzk_8eaccde8-9b56-4559-8bf6-ecbcc8c2a197"
      unitRef="number">0.0220</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rprx:DebtInstrumentIssuanceAsAPercentOfPar
      contextRef="ia4e846ac7a044335959896d695fb4eb6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzUtMC0xLTEtMC90ZXh0cmVnaW9uOmE0YTk3NGVhZmIzMzQ1OTA5NmNlMmI2Y2M0YzkwZDA1XzEwOTk1MTE2Mjc4MzE_6f46f7c8-6779-49ad-8ccf-6a08fc712e07"
      unitRef="number">0.97760</rprx:DebtInstrumentIssuanceAsAPercentOfPar>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i12aa5c25ace14515980e127e89b84e78_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzUtNi0xLTEtMA_47e34677-84e3-4f97-9b24-94661535755e"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ibdaffc234a45408a8a359e973745feb8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzUtOC0xLTEtMA_ff0d93b1-ec8c-4e48-b469-63837416ac04"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4c4c0408ec6340e9bdb1a602e36ce18b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzYtMC0xLTEtMjY5NjkvdGV4dHJlZ2lvbjplNjkxZmJlNjczYmE0NTg4YjZjZTJhMTExYTM5MGU3MF8xNjQ5MjY3NDQxNzYy_7eb47c78-5dcc-4316-9671-fa19aef9d3fa"
      unitRef="usd">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4c4c0408ec6340e9bdb1a602e36ce18b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzYtMC0xLTEtMjY5NjkvdGV4dHJlZ2lvbjplNjkxZmJlNjczYmE0NTg4YjZjZTJhMTExYTM5MGU3MF8xMDk5NTExNjI3ODYz_2cd566d3-7b00-44f5-801e-9488727ef5f5"
      unitRef="number">0.0215</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rprx:DebtInstrumentIssuanceAsAPercentOfPar
      contextRef="ibd6ff013438940249c31fcaec596a041_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzYtMC0xLTEtMjY5NjkvdGV4dHJlZ2lvbjplNjkxZmJlNjczYmE0NTg4YjZjZTJhMTExYTM5MGU3MF8xMDk5NTExNjI3ODU1_ecaa9c97-490a-412a-aef0-0ad2365f4a4b"
      unitRef="number">0.98263</rprx:DebtInstrumentIssuanceAsAPercentOfPar>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4c4c0408ec6340e9bdb1a602e36ce18b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzYtNi0xLTEtNDA4OTQ_db6dba16-1e45-4c48-a239-1ea172a47358"
      unitRef="usd">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iafcd19db0e464d11b58358856023c8b3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzYtOC0xLTEtNDA4OTk_7c88d99c-b1a8-4de0-9d52-a117578c864f"
      unitRef="usd">0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i214ee7900f3d49228322f94559a11682_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzYtMC0xLTEtMC90ZXh0cmVnaW9uOjM2MTM5YzJlY2E1YTQ3Yzg4YjdkZmVkMjYxZjkwMGJjXzE2NDkyNjc0NDE3NDA_3c5e24d5-9262-443c-b94a-de00accd33bb"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i214ee7900f3d49228322f94559a11682_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzYtMC0xLTEtMC90ZXh0cmVnaW9uOjM2MTM5YzJlY2E1YTQ3Yzg4YjdkZmVkMjYxZjkwMGJjXzEwOTk1MTE2Mjc4Mzk_70c23006-ddf4-45ca-ae9c-14125445c2e1"
      unitRef="number">0.0330</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rprx:DebtInstrumentIssuanceAsAPercentOfPar
      contextRef="icd0fbf3fb9684880981bb0db110314f6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzYtMC0xLTEtMC90ZXh0cmVnaW9uOjM2MTM5YzJlY2E1YTQ3Yzg4YjdkZmVkMjYxZjkwMGJjXzEwOTk1MTE2Mjc4MzE_224504ce-a484-4784-b865-c650c39a8905"
      unitRef="number">0.95556</rprx:DebtInstrumentIssuanceAsAPercentOfPar>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i214ee7900f3d49228322f94559a11682_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzYtNi0xLTEtMA_7e611256-d6e9-437a-8cc8-8eb3c0a99924"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i273747e9c3c9428a95fbb9a2dc8580ff_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzYtOC0xLTEtMA_57afcf8d-7ca9-49f3-9aee-4f9ed232f602"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7b8870452b5a460ba6814149888615ae_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzctMC0xLTEtMC90ZXh0cmVnaW9uOjAzNTQ2ZjFkZWU4ZjQyNmY5YjMzNDQyNDI2Y2ZiNGEzXzE2NDkyNjc0NDE3NTI_7c0fb961-4cfa-46f0-b658-d984321be464"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7b8870452b5a460ba6814149888615ae_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzctMC0xLTEtMC90ZXh0cmVnaW9uOjAzNTQ2ZjFkZWU4ZjQyNmY5YjMzNDQyNDI2Y2ZiNGEzXzEwOTk1MTE2Mjc4NTE_a07073f5-04ba-4c83-b50e-bc5406731c70"
      unitRef="number">0.0355</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rprx:DebtInstrumentIssuanceAsAPercentOfPar
      contextRef="i35930b3c5c694b58bdad83cb5488ec9f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzctMC0xLTEtMC90ZXh0cmVnaW9uOjAzNTQ2ZjFkZWU4ZjQyNmY5YjMzNDQyNDI2Y2ZiNGEzXzEwOTk1MTE2Mjc4NDM_f3dff801-64b3-41b2-b76e-1a14f8d5068a"
      unitRef="number">0.95306</rprx:DebtInstrumentIssuanceAsAPercentOfPar>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7b8870452b5a460ba6814149888615ae_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzctNi0xLTEtMA_6997ab9e-648f-4533-98f1-3610ba6f1b1d"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="icf88d4d19d624f61acc05f3da6e97e88_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzctOC0xLTEtMA_c259f7dc-2307-41b6-bdd6-bc6c0d01b0c4"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4daec00bc1054f378d9fa9e9841e7e3b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzktMC0xLTEtNDA4NzUvdGV4dHJlZ2lvbjpkOTEyMDNjZWY5YmY0NzQ0ODA5NjZmMDhhMjNmMmJkNF8xNjQ5MjY3NDQxNzQ4_afb42656-54b0-4912-95a2-264595743f5e"
      unitRef="usd">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4daec00bc1054f378d9fa9e9841e7e3b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzktMC0xLTEtNDA4NzUvdGV4dHJlZ2lvbjpkOTEyMDNjZWY5YmY0NzQ0ODA5NjZmMDhhMjNmMmJkNF8xMDk5NTExNjI3ODQ5_0c86b3bc-1480-4113-b674-3345433a3b86"
      unitRef="number">0.0335</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rprx:DebtInstrumentIssuanceAsAPercentOfPar
      contextRef="i0162f5b487c74cacb76db77bc7f972bc_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzktMC0xLTEtNDA4NzUvdGV4dHJlZ2lvbjpkOTEyMDNjZWY5YmY0NzQ0ODA5NjZmMDhhMjNmMmJkNF8xMDk5NTExNjI3ODQx_39cb350a-da01-41d5-9384-4ea0958473c0"
      unitRef="number">0.97565</rprx:DebtInstrumentIssuanceAsAPercentOfPar>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4daec00bc1054f378d9fa9e9841e7e3b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzktNi0xLTEtNDA4OTQ_ba153801-dde3-474b-8f39-3414351db05c"
      unitRef="usd">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i03b010a1e0b24651a9e2d279ef1f4a19_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzktOC0xLTEtNDA4OTk_7a56acc0-dd0b-4596-9085-5c45ad9ec604"
      unitRef="usd">0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzExLTYtMS0xLTQwODk0_76dfc7c9-6618-4607-9cad-1296d026a2d4"
      unitRef="usd">203930000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzExLTgtMS0xLTQwODk5_2c685e95-9df2-4ae3-8a28-935fcdd8b956"
      unitRef="usd">183416000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzEwLTYtMS0xLTA_5e525e03-219e-4f6a-a331-48c5f5d55b77"
      unitRef="usd">7096070000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzEwLTgtMS0xLTA_be42f7e7-caae-43c7-83e3-8f475abdaff4"
      unitRef="usd">5816584000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzEzLTYtMS0xLTA_a35a3201-2135-43dc-9ea0-dcac8a216735"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzEzLTgtMS0xLTA_463b9df8-2dbd-48b2-82bf-e35b9eb26aed"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzE0LTYtMS0xLTA_33bc0422-b9a1-4b38-b188-cb698756addc"
      unitRef="usd">7096070000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTo3ODY2ODUxNGNjNTE0NWExODcxMDRlYTAxNGVkOTZiNC90YWJsZXJhbmdlOjc4NjY4NTE0Y2M1MTQ1YTE4NzEwNGVhMDE0ZWQ5NmI0XzE0LTgtMS0xLTA_c759c250-a88e-4157-bcf7-f7ff0822f396"
      unitRef="usd">5816584000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie681b3df9681426ba637a173be7ba1dc_I20210726"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2MzY2MzE_ffcdb4ca-28f0-4276-980a-a6a183c28408"
      unitRef="usd">1300000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i68470da82fa849aabc13b3b1753af6d4_I20210726"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2NDE0Nzk_a506a3d9-6634-4009-94b0-cddce2318b87"
      unitRef="usd">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4d77b9cf09984cf791139a8ba06caf1e_I20210726"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2NDE1MDE_0121aacd-9380-4de8-a7ad-cbfb999d94b8"
      unitRef="usd">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ie681b3df9681426ba637a173be7ba1dc_I20210726"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2NDE1MjE_53a99e6d-7993-4fd9-a6ba-597273779d6b"
      unitRef="usd">27500000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i4d77b9cf09984cf791139a8ba06caf1e_I20210726"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2NDE1NDA_04d4af42-753a-4da7-828a-5adf76fd296a"
      unitRef="usd">12300000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i4ce08489650c4f10a179aeb963c83319_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2NDE1NTI_c6451057-7501-48bc-98ef-2e1378209c82"
      unitRef="number">0.0280</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i4ce08489650c4f10a179aeb963c83319_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2NDE1NTg_bb4d6570-0653-4da4-9daa-253952e2f6af"
      unitRef="number">0.0306</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i36b01c03000b44fbbe2d2aa0ad142157_I20200902"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2NDMyOTY_ebfb3a19-f49d-467c-be77-6420be9f2e85"
      unitRef="usd">6000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ida43ed4cd5d84bc4bfff97ddd4ade4dd_I20200902"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2NDE1NjQ_ef4f2fdf-a22c-409d-8bd9-7b6301e76c9d"
      unitRef="usd">149000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i36b01c03000b44fbbe2d2aa0ad142157_I20200902"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2NDE1NzI_91926044-c61c-44a4-90b9-faf67de0969e"
      unitRef="usd">40400000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i2faebe6b2bb249f9bacffbdee1da7d22_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2Mzg2Njc_856b2e0c-af9f-43fd-8243-e466fd1bafed"
      unitRef="number">0.02125</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i2faebe6b2bb249f9bacffbdee1da7d22_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2Mzg2NzU_5b469b9b-dfaf-468b-aa3e-1d08fec65fd8"
      unitRef="number">0.0250</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i761809a342d742f8846055709c5f4ea7_D20200902-20200902"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzQ5NDc4MDIzNDA4NTI_0896c520-881a-492d-8ec0-748d77d14db3"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i02f715ec0012457ca0402d8dc7e85a1b_D20200902-20200902"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzQ5NDc4MDIzNDA4NTY_aa11583e-1cf0-4194-b06d-b462579ecbaa"
      unitRef="number">1.01</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="i06737af3814f449197ef9f5868fd6001_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzIxOTkwMjMyNzQ4MDc_f8404337-a04c-4b5e-8bbf-a43f50662ee9"
      unitRef="usd">7200000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i32d8e5ca0cdc4cdcbf57357cd3014fc4_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzE0MjkzNjUxMTgwOTU3_cc64d752-8b0e-4f98-8942-e65373fd9696"
      unitRef="usd">6200000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentTerm
      contextRef="i4141d72c0fa3426ea79348fd59066693_D20200918-20200918"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzE0MjkzNjUxMTgwOTg0_d9da4419-e4a5-471d-b548-4d7b809b41d5">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i8dc7c9c8b8c844b59270fcb640d8fbde_I20200918"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzE2NDkyNjc0NTc1NDM_45543491-0832-4cb5-920c-0cbeabd93167"
      unitRef="usd">1500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ibecbcfc3dadd481d9155173824469951_D20200918-20200918"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzM4ODk_5183cbe4-253f-4016-8c1a-bf8683c832c8"
      unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ief16c63a8fed4314b8dbf9cd08433170_D20200918-20200918"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzM4ODk_5f03c6d2-4741-4567-9aaa-40e82d9e08a4"
      unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i8563b235bf8f445ab53d170d2ea1cc7d_D20200918-20200918"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzM5MzU_d0afe17c-0892-4022-ac85-aaf12b3f0391"
      unitRef="number">0.01</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <rprx:DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio
      contextRef="i8dc7c9c8b8c844b59270fcb640d8fbde_I20200918"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzQ1NTc_45b45f2e-0419-4366-a3bc-cc9a46406a6e"
      unitRef="number">4.00</rprx:DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio>
    <rprx:DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition
      contextRef="i8dc7c9c8b8c844b59270fcb640d8fbde_I20200918"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzQ1ODQ_bf3de77d-251b-46ff-92a4-2a7f928070b9"
      unitRef="number">4.50</rprx:DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition>
    <rprx:DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio
      contextRef="i8dc7c9c8b8c844b59270fcb640d8fbde_I20200918"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzQ4Njg_36698647-a593-422d-a0a8-36eae51cfa3b"
      unitRef="number">2.50</rprx:DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ieb917668901f4fa88d71cb0dad938ffc_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzU5NTM_20968115-7fd7-4d59-9211-0828c08900af"
      unitRef="usd">3200000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9fd1d6e21848456dba10bcb5be7800b7_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzU5NjA_8ebc6700-1ab1-4496-8a99-9ed71889d919"
      unitRef="usd">2840000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i7fa1890df4f64955a27b5a2e7f1eb6f4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2NDI1NjU_36225710-aa35-45b7-b83a-9d9212cdf803"
      unitRef="usd">-25100000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ib99e303d9a2649bba418d9bec8ce14f3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzEwOTk1MTE2NDMyNjU_9c99ec76-575d-4765-bf07-9faa2752b11a"
      unitRef="usd">5400000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzgyMjQ_984ccaee-447a-4414-a5aa-4fa4c69ed2dc">The future principal payments for our borrowings as of December 31, 2021 over the next five years and thereafter are as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,300,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;(1)  &#160;&#160;&#160;&#160;Excludes unamortized debt discount and issuance costs of $203.9 million as of December 31, 2021, which are amortized through interest expense over the remaining life of the underlying debt obligations.</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i2faebe6b2bb249f9bacffbdee1da7d22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTphOTY5MGIyMDg0YjY0MzM2ODVhOTIxMzNhNDU2OTllZi90YWJsZXJhbmdlOmE5NjkwYjIwODRiNjQzMzY4NWE5MjEzM2E0NTY5OWVmXzMtMi0xLTEtMA_6daf9956-5c9a-4371-bdb8-0e2513fdc434"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i2faebe6b2bb249f9bacffbdee1da7d22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTphOTY5MGIyMDg0YjY0MzM2ODVhOTIxMzNhNDU2OTllZi90YWJsZXJhbmdlOmE5NjkwYjIwODRiNjQzMzY4NWE5MjEzM2E0NTY5OWVmXzQtMi0xLTEtMA_10e34750-b080-40f6-9a31-758820e28152"
      unitRef="usd">1000000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i2faebe6b2bb249f9bacffbdee1da7d22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTphOTY5MGIyMDg0YjY0MzM2ODVhOTIxMzNhNDU2OTllZi90YWJsZXJhbmdlOmE5NjkwYjIwODRiNjQzMzY4NWE5MjEzM2E0NTY5OWVmXzUtMi0xLTEtMA_b343844e-3a1e-4cd4-8f96-f63f23aee99c"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i2faebe6b2bb249f9bacffbdee1da7d22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTphOTY5MGIyMDg0YjY0MzM2ODVhOTIxMzNhNDU2OTllZi90YWJsZXJhbmdlOmE5NjkwYjIwODRiNjQzMzY4NWE5MjEzM2E0NTY5OWVmXzYtMi0xLTEtMA_e721e5ab-fc03-4956-9988-83f915f194fb"
      unitRef="usd">1000000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i2faebe6b2bb249f9bacffbdee1da7d22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTphOTY5MGIyMDg0YjY0MzM2ODVhOTIxMzNhNDU2OTllZi90YWJsZXJhbmdlOmE5NjkwYjIwODRiNjQzMzY4NWE5MjEzM2E0NTY5OWVmXzctMi0xLTEtMA_410cbec0-0a0a-40c0-8f42-061db67e2b28"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="i2faebe6b2bb249f9bacffbdee1da7d22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTphOTY5MGIyMDg0YjY0MzM2ODVhOTIxMzNhNDU2OTllZi90YWJsZXJhbmdlOmE5NjkwYjIwODRiNjQzMzY4NWE5MjEzM2E0NTY5OWVmXzgtMi0xLTEtMA_9a1215d4-25d5-457e-a819-4659b220e420"
      unitRef="usd">5300000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2faebe6b2bb249f9bacffbdee1da7d22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90YWJsZTphOTY5MGIyMDg0YjY0MzM2ODVhOTIxMzNhNDU2OTllZi90YWJsZXJhbmdlOmE5NjkwYjIwODRiNjQzMzY4NWE5MjEzM2E0NTY5OWVmXzktMy0xLTEtNDEyNjg_a661c006-d744-483f-8310-275d3ee6a7a8"
      unitRef="usd">7300000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNDgvZnJhZzpmNGRmMjQ3MDQzNjg0NWI0OTliNTRiNTEyOGUwNGZkMi90ZXh0cmVnaW9uOmY0ZGYyNDcwNDM2ODQ1YjQ5OWI1NGI1MTI4ZTA0ZmQyXzE0MjkzNjUxMTgxMzg0_07636a9b-8ea0-458f-9c36-18e085b75b3c"
      unitRef="usd">203900000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzU5ODg_942dc10d-4b80-486f-a79e-72e26864a6e5">Shareholders&#x2019; Equity&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Capital structure&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Following the completion of our IPO as discussed in Note 1&#x2013;Organization and Purpose, we have two classes of voting shares: Class A ordinary shares and Class B ordinary shares, each of which has one vote per ordinary share. The Class A ordinary shares and Class B ordinary shares vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law. Our Class B ordinary shares are not publicly traded and holders of Class B ordinary shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up of the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;An exchange agreement entered into by us, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP and EPA Holdings (the &#x201c;Exchange Agreement&#x201d;) governs the exchange of RP Holdings Class B Interests held by the Continuing Investors Partnerships for Class A ordinary shares. Pursuant to the Exchange Agreement, RP Holdings Class B interests are exchangeable on a one-for-one basis for Class A ordinary shares on a quarterly basis. As of December 31, 2021, we have outstanding 432,963&#160;thousand Class A ordinary shares and 174,213&#160;thousand Class B ordinary shares. Each such exchange also results in the re-designation of the same number of our Class B ordinary shares as deferred shares. As of December 31, 2021, we have outstanding deferred shares of 361,170 thousand. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we have in issue 50 thousand Class R redeemable shares, which do not entitle the holder to voting or dividend rights. The purpose of the Class R redeemable shares was to ensure Royalty Pharma Limited had sufficient sterling denominated share capital at the time it was re-registered as a public limited company to Royalty Pharma plc, as required by the U.K. Companies Act. The Class R redeemable shares may be redeemed at our option in the future. Any such redemption would be at the nominal value of &#xa3;1 each.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-controlling interests&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The only non-controlling interest in the year ended December 31, 2019 related to RPSFT, for which the net change in the related balance is as presented in the statements of shareholders&#x2019; equity. The net change in the balance of our four non-controlling interests for the years ended December 31, 2021 and 2020 is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Legacy Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Continuing Investors Partnerships (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;EPA Holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;35,883&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;35,883&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,165,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,174,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Transfer of interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,037,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,037,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(112,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(594,592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(85,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(792,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Income prior to IPO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,433,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,433,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Issuance of Class A ordinary shares sold in IPO, net of offering costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;758,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;758,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other exchanges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(309,566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(309,566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income subsequent to IPO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;316,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;581,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification of unrealized losses on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,436&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,939,509&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,125,091&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5,077,036&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) &#160;&#160;&#160;&#160;Related to the Continuing Investors Partnerships&#x2019; ownership of approximately 36% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2020. Royalty Pharma plc owns the remaining 64% of RP Holdings through its ownership of RP Holdings Class A Interests and Class B Interests as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.479%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.481%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Legacy Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Continuing Investors Partnerships (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;EPA Holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,436&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,939,509&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,125,091&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5,077,036&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(56,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(425,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(133,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(614,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other exchanges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(642,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(642,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;297,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;621,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification of unrealized losses on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,946)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;13,528&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,809,269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,649,154&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,471,951&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) &#160;&#160;&#160;&#160;Related to the Continuing Investors Partnerships&#x2019; ownership of approximately 29% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2021. Royalty Pharma plc owns the remaining 71% of RP Holdings through its ownership of RP Holdings Class A Interests  and Class B Interests as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;RP Holdings Class C Special Interest held by EPA Holdings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EPA Holdings is entitled to Equity Performance Awards (as defined below) through its RP Holdings Class C Special Interest based on our performance, as determined on a portfolio-by-portfolio basis. Investments made during each two-year period will be grouped together as separate portfolios (each, a &#x201c;Portfolio&#x201d;). Subject to certain conditions, at the end of each fiscal quarter, EPA Holdings is entitled to a distribution from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the &#x201c;Equity Performance Awards&#x201d;). The Equity Performance Awards will be allocated and paid by RP Holdings to EPA Holdings as the holder of the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests for which we will issue the same number of Class B ordinary shares, which may be subsequently exchanged for our Class A ordinary shares. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not currently expect any material Equity Performance Awards to be payable until the performance conditions discussed above are met.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The holders of Class A ordinary shares are entitled to receive dividends subject to approval by the board of directors. The holders of Class B ordinary shares do not have any rights to receive dividends; however the RP Holdings Class B Interests are entitled to dividends and distributions from RP Holdings, our consolidated subsidiary. In the year ended December 31, 2021, we declared and paid four quarterly cash dividends of $0.17 per Class A ordinary share for an aggregate amount of $285.2&#160;million to holders&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of our Class A ordinary shares&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Independent Directors Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 15, 2020, our 2020 Independent Director Equity Incentive Plan was approved and became effective, whereby 800 thousand Class A ordinary shares have been reserved for future issuance to our independent directors. As of December 31, 2021, approximately 620&#160;thousand shares remain reserved for future issuance under the Equity Incentive Plan. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;RSU activity and share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant RSUs to our independent directors under the 2020 Independent Director Equity Incentive Plan. Share-based compensation expense is recognized based on estimated fair value of the award on the grant date and amortized on a straight-line basis over the requisite service period of generally one year as part of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;General and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statement of comprehensive income. The estimated fair value of RSUs is based on the closing price of our Class A ordinary shares on the grant date.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized share-based compensation of approximately $3.1&#160;million and $5.7&#160;million for the years ended December 31, 2021 and 2020, which is recorded as part of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;General and administrative expenses&lt;/span&gt; in the consolidated statement of operations. There were no share-based awards or related expenses in periods prior to the IPO. As of December 31, 2021, the total unrecognized share-based compensation expense related to total outstanding RSUs was less than $1.0&#160;million, which we expect to recognize in the next six months.</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <rprx:NumberOfClassesOfVotingStock
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzE0MjkzNjUxMTc3OTg4_f8a0c3ff-522f-4f18-8f91-79f37506a5f4"
      unitRef="class">2</rprx:NumberOfClassesOfVotingStock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7048c06f34e64e98a9f8db168c52ecf6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzEwOTk1MTE2MzkwMzg_2fcde39a-b3bc-40cc-b7c4-820db8ee7a9d"
      unitRef="shares">432963000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic092b803ad4d4d1bb1fc65733358f33f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzEwOTk1MTE2MzkwNzQ_31a3d211-0af5-4b8d-b16b-ea7250bd682f"
      unitRef="shares">174213000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="i9cf16ec8ae244acb94018fe5616afde0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzEwOTk1MTE2MzY1ODQ_fd403936-c09e-433e-bfd7-f48cb3cf85c6"
      unitRef="shares">361170000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="icd2e4870b58b4b92961362030330fa39_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzEwNDY_02b3b614-6969-4275-9fdf-5b38846e6916"
      unitRef="shares">50000</us-gaap:SharesOutstanding>
    <rprx:RedeemableStockRedemptionPricePerShare
      contextRef="i466cdba264f14dbba8111c43a48fa933_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzE1MzE_73d2e95c-5416-44ad-a18e-7fa9bc3b17ff"
      unitRef="gbpPerShare">1</rprx:RedeemableStockRedemptionPricePerShare>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzU5OTA_96963cc4-5de9-4fb7-842a-7bf0ad7cfc52">The net change in the balance of our four non-controlling interests for the years ended December 31, 2021 and 2020 is as follows (in thousands): &lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Legacy Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Continuing Investors Partnerships (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;EPA Holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;35,883&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;35,883&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,165,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,174,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Transfer of interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,037,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,037,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(112,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(594,592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(85,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(792,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Income prior to IPO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,433,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,433,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Issuance of Class A ordinary shares sold in IPO, net of offering costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;758,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;758,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other exchanges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(309,566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(309,566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income subsequent to IPO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;316,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;581,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification of unrealized losses on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,436&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,939,509&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,125,091&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5,077,036&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) &#160;&#160;&#160;&#160;Related to the Continuing Investors Partnerships&#x2019; ownership of approximately 36% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2020. Royalty Pharma plc owns the remaining 64% of RP Holdings through its ownership of RP Holdings Class A Interests and Class B Interests as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.479%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.481%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Legacy Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Continuing Investors Partnerships (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;EPA Holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,436&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,939,509&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,125,091&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5,077,036&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(56,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(425,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(133,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(614,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other exchanges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(642,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(642,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;297,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;621,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification of unrealized losses on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,946)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;13,528&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,809,269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,649,154&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,471,951&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) &#160;&#160;&#160;&#160;Related to the Continuing Investors Partnerships&#x2019; ownership of approximately 29% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2021. Royalty Pharma plc owns the remaining 71% of RP Holdings through its ownership of RP Holdings Class A Interests  and Class B Interests as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <rprx:NumberOfNoncontrollingInterests
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzIzOTQ_d407c5af-3e15-4090-817e-4dce460efaa3"
      unitRef="noncontrolling_interest">4</rprx:NumberOfNoncontrollingInterests>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7d508394642a4a0ab6e3a02929fd6dd4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEtMS0xLTEtNzc2ODU_3788234a-f443-491a-8b9c-3c969769ada8"
      unitRef="usd">35883000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7e834532d49b48d183dee4dfa980b04c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEtMy0xLTEtNzc2ODU_0a813caf-17b5-40c8-ace0-b1f8fb98b218"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3b032830d76c44b9a92d95e245ce0a21_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEtNS0xLTEtNzc2ODU_9bd2564d-9556-42b7-9ddd-c7e411324660"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2a47bfd8cfda47409c0410907da54f68_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEtNy0xLTEtNzc2ODU_cc6d8788-0ef3-409e-81ad-5f01ae2c601e"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i66a738c1e19d441f908f46dd78470217_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEtOS0xLTEtNzc2ODU_22c3d4de-ad57-4014-bc02-98e5149a29c8"
      unitRef="usd">35883000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="if27b249e1d7e4d108a2f24ec3c67006f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzItMS0xLTEtNzc2ODU_0f86f5d8-f580-4489-b375-868c02b59221"
      unitRef="usd">0</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="icc89c3a01e3b4ee9876dc2317f1f1faa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzItMy0xLTEtNzc2ODU_ff616618-c42d-4519-85a8-5f6812e76b37"
      unitRef="usd">1165258000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i78eee2afc7d1460ab607760dbad7a025_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzItNS0xLTEtNzc2ODU_3afe44ea-ddcc-4b88-8400-4b27cd43269d"
      unitRef="usd">9418000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i9a4eb1b3391f4185a844dba1b8ad1349_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzItNy0xLTEtNzc2ODU_c3583c4d-0ff5-4d26-883c-61fe23e5aeda"
      unitRef="usd">0</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzItOS0xLTEtNzc2ODU_a79a132f-623a-4373-8f19-ca44e1a435c1"
      unitRef="usd">1174676000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestTransfersOfInterests
      contextRef="if27b249e1d7e4d108a2f24ec3c67006f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzMtMS0xLTEtNzc2ODU_b7384b45-acd8-49ac-bdc0-b0601c514711"
      unitRef="usd">0</rprx:NoncontrollingInterestTransfersOfInterests>
    <rprx:NoncontrollingInterestTransfersOfInterests
      contextRef="icc89c3a01e3b4ee9876dc2317f1f1faa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzMtMy0xLTEtNzc2ODU_798c4205-35fc-4462-b997-d4553864ab12"
      unitRef="usd">1037161000</rprx:NoncontrollingInterestTransfersOfInterests>
    <rprx:NoncontrollingInterestTransfersOfInterests
      contextRef="i78eee2afc7d1460ab607760dbad7a025_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzMtNS0xLTEtNzc2ODU_4e54e878-640b-48d8-a50b-89ad90940b41"
      unitRef="usd">0</rprx:NoncontrollingInterestTransfersOfInterests>
    <rprx:NoncontrollingInterestTransfersOfInterests
      contextRef="i9a4eb1b3391f4185a844dba1b8ad1349_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzMtNy0xLTEtNzc2ODU_7a972a2a-8647-4966-b832-e00b3c68c56d"
      unitRef="usd">0</rprx:NoncontrollingInterestTransfersOfInterests>
    <rprx:NoncontrollingInterestTransfersOfInterests
      contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzMtOS0xLTEtNzc2ODU_f3fe537f-82fa-407f-b855-f1a7eef57e0e"
      unitRef="usd">1037161000</rprx:NoncontrollingInterestTransfersOfInterests>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="if27b249e1d7e4d108a2f24ec3c67006f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzQtMS0xLTEtNzc2ODU_144b5ea1-30cd-43e4-a048-3a2dab28a36d"
      unitRef="usd">112339000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="icc89c3a01e3b4ee9876dc2317f1f1faa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzQtMy0xLTEtNzc2ODU_8cc0d5dd-1cc1-423d-9e2e-3729d22cfdde"
      unitRef="usd">594592000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i78eee2afc7d1460ab607760dbad7a025_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzQtNS0xLTEtNzc2ODU_54df474d-0548-4a0f-9be4-6c2dca627fb5"
      unitRef="usd">85426000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i9a4eb1b3391f4185a844dba1b8ad1349_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzQtNy0xLTEtNzc2ODU_1f005d68-8180-4b7f-8192-323719395320"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzQtOS0xLTEtNzc2ODU_b76d7bb4-96e2-44b8-8abb-a20ca3006df9"
      unitRef="usd">792357000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="if61940f2e40d400ead5fbf3844bb3dc0_D20200101-20200617"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzUtMS0xLTEtNzc2ODU_406c212d-5519-4584-8904-b1e3b31e525b"
      unitRef="usd">42151000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if3642192137f47c8a326c30a5d6bbb91_D20200101-20200617"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzUtMy0xLTEtNzc2ODU_1a64ebbc-d0eb-4a42-be68-3f581875a327"
      unitRef="usd">102892000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i737c7ca0fc4741d4908eb966f08f3fa9_D20200101-20200617"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzUtNS0xLTEtNzc2ODU_080cee13-93b3-4213-8262-5b64c45f596f"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i882f3c7d9ced490c80ad72c747e61ae9_D20200101-20200617"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzUtNy0xLTEtNzc2ODU_175246a4-5f4f-428a-bcb7-1cf4a6340e66"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i76f06ecc81464fc3ba1731d5296c531a_D20200101-20200617"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzUtOS0xLTEtNzc2ODU_767a728a-08c9-451b-a3bf-d19e221db6ab"
      unitRef="usd">145043000</us-gaap:ProfitLoss>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="if27b249e1d7e4d108a2f24ec3c67006f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzYtMS0xLTEtNzc2ODU_1bc1544f-4de3-4746-8c5a-3854c863667e"
      unitRef="usd">0</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="icc89c3a01e3b4ee9876dc2317f1f1faa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzYtMy0xLTEtNzc2ODU_319d68b0-70f7-4060-8914-b7e861cd2fcc"
      unitRef="usd">-750000</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="i78eee2afc7d1460ab607760dbad7a025_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzYtNS0xLTEtNzc2ODU_6621da9e-33e7-4fdb-b49a-ea5148183758"
      unitRef="usd">2433848000</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="i9a4eb1b3391f4185a844dba1b8ad1349_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzYtNy0xLTEtNzc2ODU_fb7efa72-e9d0-40ef-9efb-7dab99bbcf76"
      unitRef="usd">0</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <rprx:StockholdersEquityValueEffectOfExchangeAndReallocation
      contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzYtOS0xLTEtNzc2ODU_bcfe5adf-a142-42da-85a9-5bffbe73c633"
      unitRef="usd">2433098000</rprx:StockholdersEquityValueEffectOfExchangeAndReallocation>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if27b249e1d7e4d108a2f24ec3c67006f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzctMS0xLTEtNzc2ODU_38a26238-cf45-465f-a241-c6d73526669b"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="icc89c3a01e3b4ee9876dc2317f1f1faa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzctMy0xLTEtNzc2ODU_a9ebedd4-d890-4401-ad68-a7d0ca7ac256"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i78eee2afc7d1460ab607760dbad7a025_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzctNS0xLTEtNzc2ODU_f6b123d9-33e8-4dcd-8600-a6c599abd435"
      unitRef="usd">758354000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9a4eb1b3391f4185a844dba1b8ad1349_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzctNy0xLTEtNzc2ODU_c6638122-dd9f-4654-a2b6-99704b609a42"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzctOS0xLTEtNzc2ODU_a599ba89-87af-48d3-a95e-63bf368298e5"
      unitRef="usd">758354000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockholdersEquityOther
      contextRef="if27b249e1d7e4d108a2f24ec3c67006f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzgtMS0xLTEtNzc2ODU_febaf2f5-fb38-472b-a01e-8005becffb3c"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="icc89c3a01e3b4ee9876dc2317f1f1faa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzgtMy0xLTEtNzc2ODU_4d6871ce-2902-4413-935b-e494d68a7be5"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i78eee2afc7d1460ab607760dbad7a025_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzgtNS0xLTEtNzc2ODU_cec25680-beeb-4ed0-8b30-7c2c25639986"
      unitRef="usd">309566000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i9a4eb1b3391f4185a844dba1b8ad1349_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzgtNy0xLTEtNzc2ODU_65fe8ca3-1ed6-4b4a-ab3b-32949094c97b"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzgtOS0xLTEtNzc2ODU_1eb3ddf9-7b3f-4c00-a808-06a37e1146e9"
      unitRef="usd">309566000</us-gaap:StockholdersEquityOther>
    <us-gaap:ProfitLoss
      contextRef="i4c5760f9e15d4ad292c0f7ae423767a7_D20200618-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzktMS0xLTEtNzc2ODU_ad928195-3c59-4db0-a1b7-3a8383a3aaad"
      unitRef="usd">46741000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ifc1471d809d64fbb9f020dbcf89a38cc_D20200618-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzktMy0xLTEtNzc2ODU_84d0d71c-ae06-4dcf-bae9-c703135646ad"
      unitRef="usd">218137000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9f82fba017484ebc85a41aa90b9dc063_D20200618-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzktNS0xLTEtNzc2ODU_f3c5dc20-fcc7-44c1-b01c-29bcdf390bca"
      unitRef="usd">316993000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id2d9b4e5e10d4c36a707ba0f30bd0fc7_D20200618-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzktNy0xLTEtNzc2ODU_f0850633-6243-422c-be06-cbab30826fa5"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie11ab38cff9248ce8459b4a78a07f67c_D20200618-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzktOS0xLTEtNzc2ODU_035e3e51-084d-42d3-9cb5-00b41f867aaf"
      unitRef="usd">581871000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if27b249e1d7e4d108a2f24ec3c67006f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzExLTEtMS0xLTc3Njg1_a33085b3-40bd-487c-a34b-83ed71cf7a3f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icc89c3a01e3b4ee9876dc2317f1f1faa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzExLTMtMS0xLTc3Njg1_b927edd6-f72f-4e8f-867f-66999966ff1b"
      unitRef="usd">15015000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i78eee2afc7d1460ab607760dbad7a025_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzExLTUtMS0xLTc3Njg1_863b5985-57f7-455d-8535-507c62beea62"
      unitRef="usd">7488000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9a4eb1b3391f4185a844dba1b8ad1349_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzExLTctMS0xLTc3Njg1_57c84c6f-e91f-4ef2-b19e-97bbc6ac1e70"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzExLTktMS0xLTc3Njg1_618f21f2-c3c2-4341-9805-08d517a107d4"
      unitRef="usd">22503000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="if27b249e1d7e4d108a2f24ec3c67006f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEyLTEtMS0xLTc3Njg1_723865fa-368d-4381-b8d8-1e6327bf00f0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="icc89c3a01e3b4ee9876dc2317f1f1faa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEyLTMtMS0xLTc3Njg1_6e2679b3-b95e-459d-b79d-848e05d5354d"
      unitRef="usd">3612000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i78eee2afc7d1460ab607760dbad7a025_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEyLTUtMS0xLTc3Njg1_e8eebffa-35cb-4198-91e7-690e54970244"
      unitRef="usd">6018000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i9a4eb1b3391f4185a844dba1b8ad1349_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEyLTctMS0xLTc3Njg1_b85b4d02-3e37-4449-b0c3-c9664f42ec8a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i3c44ca6d34f54c739048bb62a0d4a660_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEyLTktMS0xLTc3Njg1_039fd8e6-067a-4607-a810-2042d5c0b738"
      unitRef="usd">9630000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibdbce45f889b42cb99f32b9a959ebb1b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEzLTEtMS0xLTc3Njg1_dbfec274-3956-41bb-b331-dd8ed6c46fa1"
      unitRef="usd">12436000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id0317f1e1eed4aecbd740d3419ac7fd7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEzLTMtMS0xLTc3Njg1_670c4652-ed1b-48ee-9e0c-b37927e13cb2"
      unitRef="usd">1939509000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie11804f07d7c4f1ebc7cfa8b439e5803_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEzLTUtMS0xLTc3Njg1_4ff59354-ca60-4b7f-855c-01adaa7bf8a2"
      unitRef="usd">3125091000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idbe6045b78dd46d38b235d59ba1967c1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEzLTctMS0xLTc3Njg1_ec4c889e-b640-4a36-9030-7457e899bb51"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9a4c8ddad1f14b6b87799e8a6512c515_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo2ZGZhMmRhMDlhZjY0YTVkODI1ZDlkNzQ3MTQwNzgwOC90YWJsZXJhbmdlOjZkZmEyZGEwOWFmNjRhNWQ4MjVkOWQ3NDcxNDA3ODA4XzEzLTktMS0xLTc3Njg1_13144793-3743-43d3-812a-c9b4e6e20987"
      unitRef="usd">5077036000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="ie3fe08cf37364580ab8e966ac247b010_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzU0OTc1NTgxNTQ1Njk_a52c6a37-288a-4fdd-9b49-d2dd3697691b"
      unitRef="number">0.36</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i88b0d9786c874e6f8a16be78aef6d637_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzU0OTc1NTgxNTQ2OTg_99adeca7-45e0-40df-abec-09b49f5753d7"
      unitRef="number">0.64</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibdbce45f889b42cb99f32b9a959ebb1b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzEtMS0xLTEtMA_c762c1b6-1bae-4b88-bd69-b5034dcf3d66"
      unitRef="usd">12436000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id0317f1e1eed4aecbd740d3419ac7fd7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzEtMy0xLTEtMA_5f843c0c-529f-4f4b-a868-6e42922350cb"
      unitRef="usd">1939509000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie11804f07d7c4f1ebc7cfa8b439e5803_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzEtNS0xLTEtMA_3b3bb020-d872-4a31-b884-b0ae8608ed01"
      unitRef="usd">3125091000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idbe6045b78dd46d38b235d59ba1967c1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzEtNy0xLTEtMA_01689969-88f3-4f74-a162-fe3e195cc935"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9a4c8ddad1f14b6b87799e8a6512c515_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzEtOS0xLTEtMA_5936fa1d-e5ef-4777-9e32-532fa303d1e9"
      unitRef="usd">5077036000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i8496598191ee444d9545f8252ee00014_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzItMS0xLTEtMA_0bf19dbd-b99d-40f4-9249-16bddc15c923"
      unitRef="usd">0</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i0d8ada1253ef445f9cf1d4b92a7a6385_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzItMy0xLTEtMA_904a363f-e3ae-4a79-8883-33ac14ed396c"
      unitRef="usd">35148000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="if195a301ef504b6faade4870a19f4275_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzItNS0xLTEtMA_6ccec034-07c4-4f95-b05d-f21e9acc9ba1"
      unitRef="usd">13391000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="i8bac599d33534baa86881a2afa9afcc0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzItNy0xLTEtMA_4b216385-f45b-414e-bad6-ff44de2e5a5d"
      unitRef="usd">0</rprx:NoncontrollingInterestIncreaseFromContributions>
    <rprx:NoncontrollingInterestIncreaseFromContributions
      contextRef="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzItOS0xLTEtMA_f7a33a57-1fc1-4b2c-b713-559cf213a198"
      unitRef="usd">48539000</rprx:NoncontrollingInterestIncreaseFromContributions>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i8496598191ee444d9545f8252ee00014_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzMtMS0xLTEtMA_a1034c1f-44be-4169-bce0-146dd964c0fd"
      unitRef="usd">56490000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i0d8ada1253ef445f9cf1d4b92a7a6385_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzMtMy0xLTEtMA_19c7c040-d972-40de-9f2e-e0f988dddeda"
      unitRef="usd">425050000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="if195a301ef504b6faade4870a19f4275_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzMtNS0xLTEtMA_f696be64-eb7d-43a8-9e0d-6f9197f8fccc"
      unitRef="usd">133433000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i8bac599d33534baa86881a2afa9afcc0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzMtNy0xLTEtMA_7370c769-2230-4be5-93a6-64951cad479a"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzMtOS0xLTEtMA_2f8a3537-3fab-47c1-a369-3de350335cf9"
      unitRef="usd">614973000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityOther
      contextRef="i8496598191ee444d9545f8252ee00014_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzQtMS0xLTEtMA_c82ac8e2-0482-4032-aa39-e1659cc11ca3"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i0d8ada1253ef445f9cf1d4b92a7a6385_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzQtMy0xLTEtMA_545d89bd-2a30-4409-aed7-20c74cfef9ce"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="if195a301ef504b6faade4870a19f4275_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzQtNS0xLTEtMA_7f9c09dd-ed85-4563-88cc-1a63b50a9934"
      unitRef="usd">642974000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i8bac599d33534baa86881a2afa9afcc0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzQtNy0xLTEtMA_40a54fa7-c56e-430d-b98b-4b98416e2640"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzQtOS0xLTEtMA_aa3e5bbf-5065-4e2c-bf03-e116670b7352"
      unitRef="usd">642974000</us-gaap:StockholdersEquityOther>
    <us-gaap:ProfitLoss
      contextRef="i8496598191ee444d9545f8252ee00014_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzUtMS0xLTEtMA_b989f3ad-627d-44bd-826a-3e045cc3ac77"
      unitRef="usd">57582000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0d8ada1253ef445f9cf1d4b92a7a6385_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzUtMy0xLTEtMA_53a4d704-3ea0-412d-92bf-6109e3d1e4d7"
      unitRef="usd">266570000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if195a301ef504b6faade4870a19f4275_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzUtNS0xLTEtMA_01391fc4-e347-4766-ae44-280408103474"
      unitRef="usd">297321000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8bac599d33534baa86881a2afa9afcc0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzUtNy0xLTEtMA_8987d8b4-76fa-4898-83fd-86d30b754248"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzUtOS0xLTEtMA_8b92aebe-a36e-4705-af54-dbfb836b615d"
      unitRef="usd">621473000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8496598191ee444d9545f8252ee00014_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzctMS0xLTEtMA_bc878abf-d321-42ad-9c60-8666f9ee4c65"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0d8ada1253ef445f9cf1d4b92a7a6385_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzctMy0xLTEtMA_8ec380f8-7b30-4794-8e74-d71cc1fdf714"
      unitRef="usd">2038000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if195a301ef504b6faade4870a19f4275_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzctNS0xLTEtMA_1c461458-9779-49d7-b6dc-b3100d91fe4d"
      unitRef="usd">3227000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8bac599d33534baa86881a2afa9afcc0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzctNy0xLTEtMA_a4eaa0a3-64e7-472f-a9df-fde102123b04"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzctOS0xLTEtMA_4e9b1ea0-de7f-49e9-a34c-8186ebdb7419"
      unitRef="usd">5265000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i8496598191ee444d9545f8252ee00014_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzgtMS0xLTEtMA_bce73554-2bcc-4607-a0a9-bad2f081ab1b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i0d8ada1253ef445f9cf1d4b92a7a6385_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzgtMy0xLTEtMA_8dce52e0-46c6-4c29-9c55-e6dce512b625"
      unitRef="usd">8946000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="if195a301ef504b6faade4870a19f4275_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzgtNS0xLTEtMA_bfa2eeb1-4f45-43d9-abb4-adeb6b8a0eb3"
      unitRef="usd">13469000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i8bac599d33534baa86881a2afa9afcc0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzgtNy0xLTEtMA_ce3de4b7-edd7-41d0-bdf6-7ce9555ce88e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ia24fadbf12214241bb7c8f88f6fb67ac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzgtOS0xLTEtMA_638ab67e-dfe0-4f5a-85e4-4f4548cd7863"
      unitRef="usd">22415000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i79703258b5994db9b9b004b77c7e1c58_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzEzLTEtMS0xLTA_bdbb04db-3cb7-4748-b0bc-f03507c57de3"
      unitRef="usd">13528000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3b9c1b4135444d46968e0d3445750ae7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzEzLTMtMS0xLTA_96b1fb46-ffd7-40a6-a565-c47bbf2a3f46"
      unitRef="usd">1809269000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3166f885d1dd43e7ad16fe6b65c05bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzEzLTUtMS0xLTA_fa19dd72-bab9-4d41-a35f-c7e4546160f4"
      unitRef="usd">2649154000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i90964cc296394e8cbcf965379f0538cd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzEzLTctMS0xLTA_b4090aa5-e0f3-4b8b-8cce-0db21af079ee"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i03b5b882444a44ad9e231eaa7b05228b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90YWJsZTo5YjYzODY0OGMyMjY0OTcxYjIzODk0MzAxYjIwNzU3ZC90YWJsZXJhbmdlOjliNjM4NjQ4YzIyNjQ5NzFiMjM4OTQzMDFiMjA3NTdkXzEzLTktMS0xLTA_c7ee470c-d0f4-4626-b7d4-03d10a643625"
      unitRef="usd">4471951000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i6e7e9177eb1b4c9da6650b9f74990c36_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzQ5NDc4MDIzMzY5ODQ_ee2974d8-b42d-456b-8354-7c56154c6cc2"
      unitRef="number">0.29</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="ifbdd368fbe3941059a474c997b396f0a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzQ5NDc4MDIzMzY5ODk_8e853ac0-8b32-4277-86be-f9c890a8b9fa"
      unitRef="number">0.71</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="ie53671576bce41518be8f910184feaec_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzEwOTk1MTE2MzgwMzM_8269d8c2-c9a4-4d1c-8375-acfe4263f3f8"
      unitRef="usdPerShare">0.17</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i4cc52872c2794894927c82c640746a99_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzEwOTk1MTE2MzgwMzM_ab034488-ef0c-4828-b5b6-bd751540a147"
      unitRef="usdPerShare">0.17</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i08c8a6f2c3554638b8b9e8e94b41d3ab_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzEwOTk1MTE2MzgwMzM_c96b7b62-e67d-4d5f-b282-f59b92505497"
      unitRef="usdPerShare">0.17</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="ic3af896a7f0c42529577ce561a976e90_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzEwOTk1MTE2MzgwMzM_d45971ea-f861-45da-84c0-ac6f1e4b8690"
      unitRef="usdPerShare">0.17</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzEwOTk1MTE2MzgxNDQ_f424c00a-a56a-42a6-a1d9-4ad9077cae99"
      unitRef="usd">285200000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="ib32135ef98664a82a742199b45769f54_I20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzQ3MTk_1b3c6976-8946-4846-b7af-25a43833af64"
      unitRef="shares">800000</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i9506994fe6124fe08c513652cc6fdd3c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzYwNDczMTM5Njk2NTA_c0064f57-68ad-4678-b163-cdb4c9147bd2"
      unitRef="shares">620000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzI5Njg2ODEzOTYzOTMw_78330c70-e106-4321-9dbb-676730393dbd">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzEwOTk1MTE2MzgxNTM_4231a368-2f66-4dd4-80f9-6288be7fba16"
      unitRef="usd">3100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzEwOTk1MTE2NDIzNDc_cecada3b-7d14-493e-904c-6d2d1f701c1c"
      unitRef="usd">5700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7594b0b1464b4340a377c43cf71ef3c9_D20200101-20200617"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzEwOTk1MTE2Mzc2NjQ_ec5a2813-4fe8-4532-a224-eae596f9ab23"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i941486f8afa342d49e11f69d4af24754_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzU4MzY_c3bbdb47-bc46-422e-a4d1-bb0bd14aa736"
      unitRef="usd">1000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iadabb8c442dd4ffcbc66a71a0fe7341b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTEvZnJhZzoxYzA0MTE1NWMzODU0YjcwYTlmYjkwYjQ3M2VhMzQ4NC90ZXh0cmVnaW9uOjFjMDQxMTU1YzM4NTRiNzBhOWZiOTBiNDczZWEzNDg0XzU4ODE_84757fa1-1d8f-4873-ad14-e4ee6a896be4">P6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90ZXh0cmVnaW9uOjZmYTQ4Y2ViYjhkYTRkZTU4OGJiNzIyYzI1ODFhMzJmXzI4NzM_33347339-8e19-44cd-b249-95fea340f755">Earnings per ShareBasic earnings per share (&#x201c;EPS&#x201d;) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to us, including the impact of potentially dilutive securities, by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include the outstanding Class B ordinary shares, Class B ordinary shares contingently issuable to EPA Holdings related to Equity Performance Awards, and unvested RSUs issued under our Equity Incentive Plan. We use the &#x201c;if-converted&#x201d; method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs.&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our Class B ordinary shares, Class R redeemable shares, and deferred shares do not share in the earnings or losses attributable to us and are therefore not participating securities. As such, separate presentation of basic and diluted earnings per share for Class B ordinary shares, Class R redeemable shares, and deferred shares under the two-class method has not been presented. Our Class B ordinary shares are, however, considered potentially dilutive shares of Class A ordinary shares because shares of Class B ordinary shares, together with the related RP Holdings Class B Interests, are exchangeable into Class A ordinary shares on a one-for-one basis. For the years ended December 31, 2021 and 2020, Class B ordinary shares contingently issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact. Additionally, Class B ordinary shares in issue were evaluated under the if-converted method for potential dilutive effects and were determined to be anti-dilutive for the years ended December 31, 2021 and 2020, and therefore were excluded from the computation of diluted earnings per shares of Class A ordinary share. As of December 31, 2021 and 2020, we had 607,176&#160;thousand and 607,111&#160;thousand fully diluted Class A ordinary shares outstanding, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings per Class A ordinary share for the year ended December 31, 2021 (in thousands, except per share amounts).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,241,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to Continuing Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;297,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to Legacy Investors Partnerships and RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to Royalty Pharma plc - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;619,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average Class A ordinary shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;414,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: Dilutive effect&#160;of unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average Class A ordinary shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;414,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per Class A ordinary share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per Class A ordinary share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prior to the IPO, our capital structure mainly included unitholder interests. We analyzed the calculation of earnings per interest for periods prior to the IPO and determined that the resultant values would not be meaningful to the users of these consolidated financial statements. Therefore, the basic and diluted earnings per share for the year ended December 31, 2020 are only applicable for the period from June 16, 2020 to December 31, 2020, which represents the period in which we had outstanding Class A ordinary shares. The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings per Class A ordinary share for the year ended December 31, 2020 (in thousands, except per share amounts).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated net income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,701,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to Continuing Investors Partnerships prior to the IPO (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;479,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to Continuing Investors Partnerships subsequent to the IPO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;316,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to Legacy Investors Partnerships and RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;409,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to Royalty Pharma plc - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average Class A ordinary shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;375,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: Dilutive effect&#160;of unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average Class A ordinary shares&#160;outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;375,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per Class A ordinary share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per Class A ordinary share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(1) &#160;&#160;&#160;&#160;Reflected as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Net income attributable to controlling interest &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <rprx:CommonStockExchangeRatio
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90ZXh0cmVnaW9uOjZmYTQ4Y2ViYjhkYTRkZTU4OGJiNzIyYzI1ODFhMzJmXzE0MjkzNjUxMTc2MDY4_ac188599-83a4-44a6-b8ab-8bb5cfd7703f"
      unitRef="number">1</rprx:CommonStockExchangeRatio>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia9eca6903b754336ab978b1c6859dbee_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90ZXh0cmVnaW9uOjZmYTQ4Y2ViYjhkYTRkZTU4OGJiNzIyYzI1ODFhMzJmXzQ5NDc4MDIzMzk5NTI_000bd3c3-f874-4ee8-b99b-1f43565b43f5"
      unitRef="shares">607176000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1da7232b999b4b67b6bf844dd97d818a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90ZXh0cmVnaW9uOjZmYTQ4Y2ViYjhkYTRkZTU4OGJiNzIyYzI1ODFhMzJmXzIxOTkwMjMyNzAzODI_739c7f25-5327-4fd9-8e4b-e1bb831d6669"
      unitRef="shares">607111000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90ZXh0cmVnaW9uOjZmYTQ4Y2ViYjhkYTRkZTU4OGJiNzIyYzI1ODFhMzJmXzI4NzE_cee13f84-2e9e-46df-9112-d56b3847c5e8">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings per Class A ordinary share for the year ended December 31, 2021 (in thousands, except per share amounts).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,241,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to Continuing Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;297,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to Legacy Investors Partnerships and RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to Royalty Pharma plc - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;619,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average Class A ordinary shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;414,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: Dilutive effect&#160;of unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average Class A ordinary shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;414,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per Class A ordinary share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per Class A ordinary share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings per Class A ordinary share for the year ended December 31, 2020 (in thousands, except per share amounts).&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated net income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,701,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to Continuing Investors Partnerships prior to the IPO (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;479,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to Continuing Investors Partnerships subsequent to the IPO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;316,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to Legacy Investors Partnerships and RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;409,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to Royalty Pharma plc - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average Class A ordinary shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;375,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: Dilutive effect&#160;of unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average Class A ordinary shares&#160;outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;375,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per Class A ordinary share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per Class A ordinary share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(1) &#160;&#160;&#160;&#160;Reflected as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Net income attributable to controlling interest &lt;/span&gt;on the consolidated statements of operations</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZTo2MWJmOTNiNTM0ZGY0NjNhYTMyMzVmNTE0ZjFlYTYwZC90YWJsZXJhbmdlOjYxYmY5M2I1MzRkZjQ2M2FhMzIzNWY1MTRmMWVhNjBkXzItMi0xLTEtMA_edef1784-677f-47f2-b8b5-cbed3d009267"
      unitRef="usd">1241201000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i850c4112163e4a4da3d1fd1aa181af6c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZTo2MWJmOTNiNTM0ZGY0NjNhYTMyMzVmNTE0ZjFlYTYwZC90YWJsZXJhbmdlOjYxYmY5M2I1MzRkZjQ2M2FhMzIzNWY1MTRmMWVhNjBkXzMtMi0xLTEtMA_3268093f-dc8e-4395-83db-17de43964739"
      unitRef="usd">297321000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i63532b6df7f947d8b3cff39df953d6f5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZTo2MWJmOTNiNTM0ZGY0NjNhYTMyMzVmNTE0ZjFlYTYwZC90YWJsZXJhbmdlOjYxYmY5M2I1MzRkZjQ2M2FhMzIzNWY1MTRmMWVhNjBkXzQtMi0xLTEtMA_6a090e72-b05b-41e4-97d5-8cbe52953b01"
      unitRef="usd">324152000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZTo2MWJmOTNiNTM0ZGY0NjNhYTMyMzVmNTE0ZjFlYTYwZC90YWJsZXJhbmdlOjYxYmY5M2I1MzRkZjQ2M2FhMzIzNWY1MTRmMWVhNjBkXzUtMi0xLTEtMA_1e93aada-34c2-49a1-ad68-2c2367ed328d"
      unitRef="usd">619728000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZTo2MWJmOTNiNTM0ZGY0NjNhYTMyMzVmNTE0ZjFlYTYwZC90YWJsZXJhbmdlOjYxYmY5M2I1MzRkZjQ2M2FhMzIzNWY1MTRmMWVhNjBkXzUtMi0xLTEtMA_b2803f86-019f-464f-81c6-6a60d2fc7b60"
      unitRef="usd">619728000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZTo2MWJmOTNiNTM0ZGY0NjNhYTMyMzVmNTE0ZjFlYTYwZC90YWJsZXJhbmdlOjYxYmY5M2I1MzRkZjQ2M2FhMzIzNWY1MTRmMWVhNjBkXzEwLTItMS0xLTA_731a78b7-15f6-4103-a6ce-d066890d40fa"
      unitRef="shares">414794000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZTo2MWJmOTNiNTM0ZGY0NjNhYTMyMzVmNTE0ZjFlYTYwZC90YWJsZXJhbmdlOjYxYmY5M2I1MzRkZjQ2M2FhMzIzNWY1MTRmMWVhNjBkXzEzLTItMS0xLTA_064311b4-b7e7-458e-ab94-f0f8e60d75ca"
      unitRef="shares">8000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZTo2MWJmOTNiNTM0ZGY0NjNhYTMyMzVmNTE0ZjFlYTYwZC90YWJsZXJhbmdlOjYxYmY5M2I1MzRkZjQ2M2FhMzIzNWY1MTRmMWVhNjBkXzE0LTItMS0xLTA_fa042ef0-64ed-45f2-8a5d-30b611768540"
      unitRef="shares">414802000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZTo2MWJmOTNiNTM0ZGY0NjNhYTMyMzVmNTE0ZjFlYTYwZC90YWJsZXJhbmdlOjYxYmY5M2I1MzRkZjQ2M2FhMzIzNWY1MTRmMWVhNjBkXzE2LTItMS0xLTA_f4bd3222-4655-426d-819d-d2e0288ec686"
      unitRef="usdPerShare">1.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZTo2MWJmOTNiNTM0ZGY0NjNhYTMyMzVmNTE0ZjFlYTYwZC90YWJsZXJhbmdlOjYxYmY5M2I1MzRkZjQ2M2FhMzIzNWY1MTRmMWVhNjBkXzE3LTItMS0xLTA_d14127d7-0451-46d8-b1dc-c59fb1a14dc7"
      unitRef="usdPerShare">1.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ProfitLoss
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZToyOGZjNGIxYWRkZDg0OTZkYWNlMDZhZjYwNjEyNzI0NC90YWJsZXJhbmdlOjI4ZmM0YjFhZGRkODQ5NmRhY2UwNmFmNjA2MTI3MjQ0XzEtMi0xLTEtNDQ4MzE_626a1599-1421-4450-a762-9e05b12efb84"
      unitRef="usd">1701954000</us-gaap:ProfitLoss>
    <rprx:NetIncomeLossAttributableToParentPriorToOffering
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZToyOGZjNGIxYWRkZDg0OTZkYWNlMDZhZjYwNjEyNzI0NC90YWJsZXJhbmdlOjI4ZmM0YjFhZGRkODQ5NmRhY2UwNmFmNjA2MTI3MjQ0XzItMi0xLTEtNDQ4MzE_be13cda0-1e8f-4a37-9059-4354a81107ec"
      unitRef="usd">479842000</rprx:NetIncomeLossAttributableToParentPriorToOffering>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i8a17c53123fa4e12b0b8749ed24171a4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZToyOGZjNGIxYWRkZDg0OTZkYWNlMDZhZjYwNjEyNzI0NC90YWJsZXJhbmdlOjI4ZmM0YjFhZGRkODQ5NmRhY2UwNmFmNjA2MTI3MjQ0XzMtMi0xLTEtNDQ4MzE_dae5aee9-49d1-4b08-9519-9003faf6dd14"
      unitRef="usd">316993000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i07a6da6cb1b14ad78d9d0a893435f6a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZToyOGZjNGIxYWRkZDg0OTZkYWNlMDZhZjYwNjEyNzI0NC90YWJsZXJhbmdlOjI4ZmM0YjFhZGRkODQ5NmRhY2UwNmFmNjA2MTI3MjQ0XzQtMi0xLTEtNDQ4MzE_62192ea0-5678-4235-b944-faabc7607ca8"
      unitRef="usd">409921000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZToyOGZjNGIxYWRkZDg0OTZkYWNlMDZhZjYwNjEyNzI0NC90YWJsZXJhbmdlOjI4ZmM0YjFhZGRkODQ5NmRhY2UwNmFmNjA2MTI3MjQ0XzUtMi0xLTEtNDQ4MzE_1698c43b-ee07-43cb-8cb5-2ad5e932a053"
      unitRef="usd">495198000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZToyOGZjNGIxYWRkZDg0OTZkYWNlMDZhZjYwNjEyNzI0NC90YWJsZXJhbmdlOjI4ZmM0YjFhZGRkODQ5NmRhY2UwNmFmNjA2MTI3MjQ0XzUtMi0xLTEtNDQ4MzE_2572e0ae-328b-43c1-b005-f76ab5ffa008"
      unitRef="usd">495198000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZToyOGZjNGIxYWRkZDg0OTZkYWNlMDZhZjYwNjEyNzI0NC90YWJsZXJhbmdlOjI4ZmM0YjFhZGRkODQ5NmRhY2UwNmFmNjA2MTI3MjQ0XzgtMi0xLTEtNDQ4MzE_fd5ae259-b910-447a-97ea-47d2dd7dfd2d"
      unitRef="shares">375444000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZToyOGZjNGIxYWRkZDg0OTZkYWNlMDZhZjYwNjEyNzI0NC90YWJsZXJhbmdlOjI4ZmM0YjFhZGRkODQ5NmRhY2UwNmFmNjA2MTI3MjQ0XzktMi0xLTEtNDQ4MzE_a150c3c9-9067-4dba-9780-58dfe9ebead8"
      unitRef="shares">11000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZToyOGZjNGIxYWRkZDg0OTZkYWNlMDZhZjYwNjEyNzI0NC90YWJsZXJhbmdlOjI4ZmM0YjFhZGRkODQ5NmRhY2UwNmFmNjA2MTI3MjQ0XzEwLTItMS0xLTQ0ODMx_69cd6970-d2e8-4341-ae53-4eea353cb7a3"
      unitRef="shares">375455000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZToyOGZjNGIxYWRkZDg0OTZkYWNlMDZhZjYwNjEyNzI0NC90YWJsZXJhbmdlOjI4ZmM0YjFhZGRkODQ5NmRhY2UwNmFmNjA2MTI3MjQ0XzEyLTItMS0xLTQ0ODMx_b88fed70-d894-49be-a12e-524b51b55087"
      unitRef="usdPerShare">1.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTQvZnJhZzo2ZmE0OGNlYmI4ZGE0ZGU1ODhiYjcyMmMyNTgxYTMyZi90YWJsZToyOGZjNGIxYWRkZDg0OTZkYWNlMDZhZjYwNjEyNzI0NC90YWJsZXJhbmdlOjI4ZmM0YjFhZGRkODQ5NmRhY2UwNmFmNjA2MTI3MjQ0XzEzLTItMS0xLTQ0ODM5_bc409532-25c1-4d2d-b336-95f371bd5cd1"
      unitRef="usdPerShare">1.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90ZXh0cmVnaW9uOjljNzMyNjk0NTVkMTQ3OWNiN2Q5NGE0YWQ2MDI3YTNiXzI0Nw_6c34cd4f-b421-49bd-a066-e5ab81a46434">Indirect Cash Flow&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash flow from operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Consolidated net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,241,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,701,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,461,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Adjustments to reconcile consolidated net income to net cash provided by operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,065,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,959,975)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,648,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Provision for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;452,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,019,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Losses/(gains) on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(247,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(155,749)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity in losses/(earnings) of non-consolidated affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44,459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Distributions from non-consolidated affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50,896)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impairment charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Termination of derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16,093)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Decrease/(increase) in operating assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash collected on financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,315,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,121,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,934,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(150,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued royalty receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other royalty income receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(41,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Decrease)/increase in operating liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net cash provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,017,536&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,034,629&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,667,239&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash investing and financing activities are summarized below (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Supplemental Schedule of Non-cash Investing/Financing Activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receipt of contribution of investment in Legacy Investors Partnerships (Note 9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlement of Epizyme forward purchase contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued purchase obligation - Tazverik (Note 17)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Repayments of long-term debt by contributions from non-controlling interest (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,103,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Milestone payable - Erleada (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1) Related to the pro rata portion of RPIFT&#x2019;s outstanding debt repaid by the Legacy Investors Partnerships.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2) Related to the achievement of a sales-based milestone that was not paid as of December 31, 2020 as recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90ZXh0cmVnaW9uOjljNzMyNjk0NTVkMTQ3OWNiN2Q5NGE0YWQ2MDI3YTNiXzI0OQ_3a298950-4a9f-4b86-b757-34e7ca4b49d2">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash flow from operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Consolidated net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,241,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,701,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,461,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Adjustments to reconcile consolidated net income to net cash provided by operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,065,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,959,975)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,648,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Provision for changes in expected cash flows from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;452,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,019,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Losses on derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Losses/(gains) on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(247,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(155,749)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity in losses/(earnings) of non-consolidated affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44,459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Distributions from non-consolidated affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50,896)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impairment charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Termination of derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16,093)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Decrease/(increase) in operating assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash collected on financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,315,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,121,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,934,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Available for sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(150,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued royalty receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other royalty income receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(41,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Decrease)/increase in operating liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net cash provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,017,536&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,034,629&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,667,239&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash investing and financing activities are summarized below (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Supplemental Schedule of Non-cash Investing/Financing Activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receipt of contribution of investment in Legacy Investors Partnerships (Note 9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlement of Epizyme forward purchase contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued purchase obligation - Tazverik (Note 17)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Repayments of long-term debt by contributions from non-controlling interest (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,103,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Milestone payable - Erleada (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1) Related to the pro rata portion of RPIFT&#x2019;s outstanding debt repaid by the Legacy Investors Partnerships.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2) Related to the achievement of a sales-based milestone that was not paid as of December 31, 2020 as recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:ProfitLoss
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzMtMS0xLTEtMA_126930c5-7db9-492a-ad2f-24b6b9344f2c"
      unitRef="usd">1241201000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzMtMy0xLTEtMA_07e8ea0e-810e-49ef-a20d-5ff1b828e219"
      unitRef="usd">1701954000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzMtNS0xLTEtMA_704d4874-f6d1-412d-b686-ff2c4d1db9be"
      unitRef="usd">2461419000</us-gaap:ProfitLoss>
    <rprx:IncreaseDecreaseInFinancialRoyaltyAssets
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzUtMS0xLTEtMA_df8bf917-55d5-4c3b-8884-ce4b4e49c7bf"
      unitRef="usd">2065083000</rprx:IncreaseDecreaseInFinancialRoyaltyAssets>
    <rprx:IncreaseDecreaseInFinancialRoyaltyAssets
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzUtMy0xLTEtMA_bdacf592-a349-4e23-8a9f-5b1bc95c533a"
      unitRef="usd">1959975000</rprx:IncreaseDecreaseInFinancialRoyaltyAssets>
    <rprx:IncreaseDecreaseInFinancialRoyaltyAssets
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzUtNS0xLTEtMA_7c4be487-2529-4fcd-9081-36214a826db6"
      unitRef="usd">1648837000</rprx:IncreaseDecreaseInFinancialRoyaltyAssets>
    <us-gaap:ProvisionForLoanAndLeaseLosses
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzYtMS0xLTEtMA_37b46cc9-f4d2-4e3c-86c3-7d9b6c361464"
      unitRef="usd">452842000</us-gaap:ProvisionForLoanAndLeaseLosses>
    <us-gaap:ProvisionForLoanAndLeaseLosses
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzYtMy0xLTEtMA_46767c4a-4471-463a-b08d-21a78c67a422"
      unitRef="usd">230839000</us-gaap:ProvisionForLoanAndLeaseLosses>
    <us-gaap:ProvisionForLoanAndLeaseLosses
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzYtNS0xLTEtMA_43851c5d-a905-4312-a9e9-1d82efc3db81"
      unitRef="usd">-1019321000</us-gaap:ProvisionForLoanAndLeaseLosses>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzctMS0xLTEtMA_c95c7686-8043-4252-9d37-836045d3d68b"
      unitRef="usd">22996000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzctMy0xLTEtMA_e9d31102-d9e2-445c-9b71-f0fb408c90c0"
      unitRef="usd">23058000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzctNS0xLTEtMA_15b7c81c-5069-40c5-b39a-e226a5ad8384"
      unitRef="usd">23924000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzgtMS0xLTEtMA_c18e867f-3e82-448a-8020-eaeeffc61644"
      unitRef="usd">20162000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzgtMy0xLTEtMA_592646f6-79b3-4ed7-9b06-f5bb3468ee9f"
      unitRef="usd">11715000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzgtNS0xLTEtMA_4fd654a4-b4ed-4d07-8952-63f0111780ca"
      unitRef="usd">12790000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzEwLTEtMS0xLTA_1759edbd-5e1c-4938-b421-790942095583"
      unitRef="usd">-21532000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzEwLTMtMS0xLTA_a15d1ba5-6393-4971-9bc2-5ade65360aa4"
      unitRef="usd">-42076000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzEwLTUtMS0xLTA_04eaa998-53c8-4602-a61a-7baf142cb81c"
      unitRef="usd">-39138000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzExLTEtMS0xLTA_cafaec6f-1648-486f-b2e3-f52a716fd071"
      unitRef="usd">-48066000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzExLTMtMS0xLTA_e21a8288-67a9-4dd7-aad7-215d360de070"
      unitRef="usd">247073000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzExLTUtMS0xLTA_42963be8-5a11-4727-a9d0-5806e640b757"
      unitRef="usd">155749000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzEyLTEtMS0xLTA_4e8d8a4d-c8e4-46e6-835e-76f47de42e97"
      unitRef="usd">-19490000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzEyLTMtMS0xLTA_14e13a41-f311-47e1-8c51-87574fcdcb9f"
      unitRef="usd">44459000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzEyLTUtMS0xLTA_eea9446b-2dc3-49e8-9b5f-2542761a9188"
      unitRef="usd">-32517000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzE1LTEtMS0xLTA_c3f72659-78e7-4437-965e-c30f9fb573d2"
      unitRef="usd">34384000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzE1LTMtMS0xLTA_b7920a1b-9f73-4cfa-89f3-c7952e31c15d"
      unitRef="usd">42334000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzE1LTUtMS0xLTA_77d3d4a4-efd0-474c-8454-489eb7e5e041"
      unitRef="usd">14059000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzE3LTEtMS0xLTA_8faffe66-e374-4203-8562-f79a5ffadfec"
      unitRef="usd">-358000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzE3LTMtMS0xLTA_4f939659-68b6-40df-b458-75363c32a806"
      unitRef="usd">-30272000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzE3LTUtMS0xLTA_948d539d-1f45-48d0-b89d-4dc143bfc6b1"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzE5LTEtMS0xLTA_e1027d9f-418a-424f-bd89-f0dae8a01b84"
      unitRef="usd">2443000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzE5LTMtMS0xLTA_848b6b05-a6ea-4588-9bf8-1bab5d5c19f8"
      unitRef="usd">5428000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzE5LTUtMS0xLTA_020c26c7-733f-4582-a3da-fdd8cf2bd0b8"
      unitRef="usd">0</us-gaap:ShareBasedCompensation>
    <rprx:InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzIwLTEtMS0xLTA_6c8c7c28-f4e6-4dd0-bc10-45def8e2c02e"
      unitRef="usd">50896000</rprx:InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss>
    <rprx:InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzIwLTMtMS0xLTA_03a9359e-a980-40a1-90dd-6c2e90859b2b"
      unitRef="usd">20551000</rprx:InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss>
    <rprx:InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzIwLTUtMS0xLTA_27838375-21b1-492a-9bbb-a90dc2379426"
      unitRef="usd">0</rprx:InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzIxLTEtMS0xLTA_553d5d22-6bcb-429d-839f-dd7b76a16e54"
      unitRef="usd">17859000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzIxLTMtMS0xLTA_68d1f2d7-bdaf-427a-b38a-eaa13555563e"
      unitRef="usd">18600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzIxLTUtMS0xLTA_e13aa453-bd5b-464d-895c-e338726688d4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:AssetImpairmentCharges
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzIyLTEtMS0xLTA_af5d0067-ca98-42a3-ab57-d8ec4e2f395b"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzIyLTMtMS0xLTA_1bd4c6be-0b5c-453b-941a-8c117d081b9c"
      unitRef="usd">65053000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzIyLTUtMS0xLTA_c934cdbc-549b-4648-85e8-9dd49486d424"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <rprx:GainLossOnDerivativeFinancialInstruments
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzIzLTEtMS0xLTA_c5ef718e-3ba8-479b-9edb-6824412a58cc"
      unitRef="usd">16093000</rprx:GainLossOnDerivativeFinancialInstruments>
    <rprx:GainLossOnDerivativeFinancialInstruments
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzIzLTMtMS0xLTA_df334dfd-d8e0-4d8a-a0c0-c796d9e07d78"
      unitRef="usd">34952000</rprx:GainLossOnDerivativeFinancialInstruments>
    <rprx:GainLossOnDerivativeFinancialInstruments
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzIzLTUtMS0xLTA_3495faf4-68e6-4ecf-9936-6ef03fc7aa51"
      unitRef="usd">0</rprx:GainLossOnDerivativeFinancialInstruments>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI0LTEtMS0xLTA_4f653c3a-2c73-49a2-a097-257ff217ff71"
      unitRef="usd">-4461000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI0LTMtMS0xLTA_652657ee-8fc9-4f77-b44a-3d0f46f0b08f"
      unitRef="usd">-9621000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI0LTUtMS0xLTA_c8e243fc-12a6-43c1-abe1-b4d45d3593ee"
      unitRef="usd">2122000</us-gaap:OtherNoncashIncomeExpense>
    <rprx:IncreaseDecreaseInCashCollectionsOnFinancingReceivables
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI3LTEtMS0xLTQyMDc1_b5c18e8c-3bb2-40c6-bbae-174d139026ad"
      unitRef="usd">2315854000</rprx:IncreaseDecreaseInCashCollectionsOnFinancingReceivables>
    <rprx:IncreaseDecreaseInCashCollectionsOnFinancingReceivables
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI3LTMtMS0xLTQyMDc1_3bb29d79-a53f-476c-88e2-6f34fbcb1fb0"
      unitRef="usd">2121923000</rprx:IncreaseDecreaseInCashCollectionsOnFinancingReceivables>
    <rprx:IncreaseDecreaseInCashCollectionsOnFinancingReceivables
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI3LTUtMS0xLTQyMDc1_bbe0a444-9fbf-4394-a60d-674adbab4438"
      unitRef="usd">1934092000</rprx:IncreaseDecreaseInCashCollectionsOnFinancingReceivables>
    <rprx:IncreaseDecreaseInDebtSecuritiesAvailableForSale
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI3LTEtMS0xLTA_ef32ae62-fbb6-4b36-a45d-c89cf440a121"
      unitRef="usd">0</rprx:IncreaseDecreaseInDebtSecuritiesAvailableForSale>
    <rprx:IncreaseDecreaseInDebtSecuritiesAvailableForSale
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI3LTMtMS0xLTA_8ad3c6a3-2e75-4440-8dff-57daa5e910fa"
      unitRef="usd">0</rprx:IncreaseDecreaseInDebtSecuritiesAvailableForSale>
    <rprx:IncreaseDecreaseInDebtSecuritiesAvailableForSale
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI3LTUtMS0xLTA_c5e47cff-15e1-4245-8a59-bf60c8a84bb7"
      unitRef="usd">150000000</rprx:IncreaseDecreaseInDebtSecuritiesAvailableForSale>
    <rprx:IncreaseDecreaseInAccruedRoyaltyReceivable
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI4LTEtMS0xLTA_6fe4381b-45df-45b1-a977-a22b8c0ef002"
      unitRef="usd">20131000</rprx:IncreaseDecreaseInAccruedRoyaltyReceivable>
    <rprx:IncreaseDecreaseInAccruedRoyaltyReceivable
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI4LTMtMS0xLTA_62307666-9529-4374-bd8c-bee37af69587"
      unitRef="usd">-370000</rprx:IncreaseDecreaseInAccruedRoyaltyReceivable>
    <rprx:IncreaseDecreaseInAccruedRoyaltyReceivable
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI4LTUtMS0xLTA_559e5db7-34f1-4e61-bede-564bedd76a62"
      unitRef="usd">-2471000</rprx:IncreaseDecreaseInAccruedRoyaltyReceivable>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI5LTEtMS0xLTA_508774a3-0028-42d2-935c-4e8d9884df9b"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI5LTMtMS0xLTA_740e1066-a310-4f2a-b7b2-7942d9d1eac8"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzI5LTUtMS0xLTA_edffde6b-afdb-4e6b-af1b-91629ed6a453"
      unitRef="usd">-150000000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <rprx:IncreaseDecreaseInOtherRoyaltyIncomeReceivable
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzMwLTEtMS0xLTA_dacc2c34-ed13-4c3e-9af0-787513f029be"
      unitRef="usd">9012000</rprx:IncreaseDecreaseInOtherRoyaltyIncomeReceivable>
    <rprx:IncreaseDecreaseInOtherRoyaltyIncomeReceivable
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzMwLTMtMS0xLTA_3cb8915d-88a3-4a3e-b3a7-a07b6ab74800"
      unitRef="usd">770000</rprx:IncreaseDecreaseInOtherRoyaltyIncomeReceivable>
    <rprx:IncreaseDecreaseInOtherRoyaltyIncomeReceivable
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzMwLTUtMS0xLTA_e55aa2db-5a5f-4d89-80a4-230bcd978e3d"
      unitRef="usd">-7390000</rprx:IncreaseDecreaseInOtherRoyaltyIncomeReceivable>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzMxLTEtMS0xLTA_8e93fc07-e438-453d-87bc-eccef2c5de9a"
      unitRef="usd">-1857000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzMxLTMtMS0xLTA_961e16d8-e753-4054-ac5e-3c85e2857f55"
      unitRef="usd">-34986000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzMxLTUtMS0xLTA_5171855f-d88e-45b3-889e-f06013343756"
      unitRef="usd">41028000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzMzLTEtMS0xLTA_616f3a89-11f8-484f-8104-008ff7184a96"
      unitRef="usd">-4586000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzMzLTMtMS0xLTA_879186b9-9230-442b-9b46-b4b53fd8e7b6"
      unitRef="usd">-766000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzMzLTUtMS0xLTA_c07d07d4-bdd0-4b4b-b8c3-6621ade9a775"
      unitRef="usd">6496000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzM0LTEtMS0xLTA_f610ec5e-58f8-485f-9508-557fe80df4f8"
      unitRef="usd">15550000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzM0LTMtMS0xLTA_b106acce-c078-4863-a7e8-66619d429be0"
      unitRef="usd">42146000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzM0LTUtMS0xLTA_7eb8a64c-02f7-44dd-a9e7-4371f83192cd"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzM3LTEtMS0xLTA_b3e67197-0cd7-4f8e-aeb7-d1dff4fd31ab"
      unitRef="usd">2017536000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzM3LTMtMS0xLTA_f25383bc-def2-48bb-9b41-be4d21eaa4c5"
      unitRef="usd">2034629000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTpmOTBjNjc3YzUwYjQ0ZDU3OWY1ODljODVkZjY5NTY1YS90YWJsZXJhbmdlOmY5MGM2NzdjNTBiNDRkNTc5ZjU4OWM4NWRmNjk1NjVhXzM3LTUtMS0xLTA_89b07614-5080-4223-b823-4e4d8256d311"
      unitRef="usd">1667239000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzItMS0xLTEtMA_bf20635c-f2ad-4b20-bd5e-a285bce703a6"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1>
    <us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzItMy0xLTEtMA_4c63919c-5420-4258-8d21-a902a2116028"
      unitRef="usd">303679000</us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1>
    <us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzItNS0xLTEtMA_a6707b85-1e24-40d5-af0f-c7fa9d1cb6a3"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1>
    <rprx:SettlementsWithEquityMethodInvestments
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzMtMS0xLTEtMA_e067a322-7312-43da-8c91-0c2b4c64f376"
      unitRef="usd">0</rprx:SettlementsWithEquityMethodInvestments>
    <rprx:SettlementsWithEquityMethodInvestments
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzMtMy0xLTEtMA_da38fe85-7b17-4546-849c-3991fde454ce"
      unitRef="usd">5700000</rprx:SettlementsWithEquityMethodInvestments>
    <rprx:SettlementsWithEquityMethodInvestments
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzMtNS0xLTEtMA_875dbd07-dcb1-4c65-860c-d84cb952ea29"
      unitRef="usd">0</rprx:SettlementsWithEquityMethodInvestments>
    <rprx:AccruedPurchaseObligationEquityInvestment
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzQtMS0xLTEtMA_52e7fd93-3ceb-4f59-b9b9-e3d5ee302a78"
      unitRef="usd">0</rprx:AccruedPurchaseObligationEquityInvestment>
    <rprx:AccruedPurchaseObligationEquityInvestment
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzQtMy0xLTEtMA_e0e27e17-1c3a-4790-ba95-7b1bfaa1f4d3"
      unitRef="usd">110000000</rprx:AccruedPurchaseObligationEquityInvestment>
    <rprx:AccruedPurchaseObligationEquityInvestment
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzQtNS0xLTEtMA_e2f83106-72e8-4ea3-af6e-8faaaf922066"
      unitRef="usd">0</rprx:AccruedPurchaseObligationEquityInvestment>
    <rprx:RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzUtMS0xLTEtMA_7b950188-fb90-4b9c-a304-e9f221700082"
      unitRef="usd">0</rprx:RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash>
    <rprx:RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzUtMy0xLTEtMA_8882389d-4fba-466a-815b-dd76939cfaa9"
      unitRef="usd">1103774000</rprx:RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash>
    <rprx:RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzUtNS0xLTEtMA_79c4074e-5f19-4beb-943a-9f81dd634560"
      unitRef="usd">0</rprx:RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash>
    <rprx:MilestonePaymentAccruedButNotPaid
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzctMS0xLTEtMA_852ad4c2-f8cb-404f-9952-125635724e7c"
      unitRef="usd">0</rprx:MilestonePaymentAccruedButNotPaid>
    <rprx:MilestonePaymentAccruedButNotPaid
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzctMy0xLTEtMA_a1c0be9c-6932-4b4b-8143-64077ed47899"
      unitRef="usd">18600000</rprx:MilestonePaymentAccruedButNotPaid>
    <rprx:MilestonePaymentAccruedButNotPaid
      contextRef="i3a47f26c6ae4415f9e3672de693d242c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNTcvZnJhZzo5YzczMjY5NDU1ZDE0NzljYjdkOTRhNGFkNjAyN2EzYi90YWJsZTo5MmQwYjU3ZjBmNTk0MTkyYjc1ZmZlMTQ1NzNkMzc5NC90YWJsZXJhbmdlOjkyZDBiNTdmMGY1OTQxOTJiNzVmZmUxNDU3M2QzNzk0XzctNS0xLTEtMA_43dfcb0f-30ce-4a3e-9626-c0b0304bb0e7"
      unitRef="usd">0</rprx:MilestonePaymentAccruedButNotPaid>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90ZXh0cmVnaW9uOjU4ZDlkNjYxYWEzYzQyY2NiZWVlNDYwMThhMjRkOTk3XzEwNDk_3c489225-16f5-4972-a535-6f9afbb2b058">Accumulated Other Comprehensive Income&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021 and 2020, the only component of accumulated other comprehensive income related to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unrealized gains on available for sale debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the Series A Biohaven Preferred Shares. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; were released into earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of accumulated other comprehensive income as of December 31, 2021 and 2020 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains on Available for Sale Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Losses on Interest Rate Swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6,159&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(4,066)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,093&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Activity for the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification from non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;34,395&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;34,395&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28,481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28,481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Activity for the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification from non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,491&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,491&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total reclassification of unrealized gains on available for sale debt securities of $50.9&#160;million in the year ended December 31, 2021 is presented within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest incom&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e on the consolidated statements of operations, including $28.5&#160;million attributable to controlling interest noted in the table above and $22.4&#160;million attributable to the non-controlling interest. The total reclassification of unrealized gains on available for sale debt securities of $20.6&#160;million in the year ended December 31, 2020 is presented within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest incom&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e on the consolidated statements of operations, including $10.9&#160;million attributable to controlling interest noted in the table above and $9.6&#160;million attributable to the non-controlling interest.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90ZXh0cmVnaW9uOjU4ZDlkNjYxYWEzYzQyY2NiZWVlNDYwMThhMjRkOTk3XzEwNDg_32b0ec71-570c-424d-8936-47ac9a96736a">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of accumulated other comprehensive income as of December 31, 2021 and 2020 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains on Available for Sale Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Losses on Interest Rate Swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6,159&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(4,066)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,093&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Activity for the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification from non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;34,395&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;34,395&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28,481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28,481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Activity for the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification from non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,491&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,491&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a4d899516f7416083d6a452d72dff94_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzQtMy0xLTEtMA_400a762c-22df-4bc3-a260-b74b31e6dc77"
      unitRef="usd">6159000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i16167be66e5642fa8c58da773ea9dd57_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzQtNS0xLTEtMA_9a951075-ccf6-487e-a2a4-74c3574ce630"
      unitRef="usd">-4066000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0c98f12437f9466181a216b35a41b08f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzQtNy0xLTEtMA_14a5250f-c031-439d-a070-a069b724a027"
      unitRef="usd">2093000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i197418bb01ba4a16bc643f9b8299428a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzUtMy0xLTEtMA_4656c297-0547-4aeb-ab57-e67d3e5ff100"
      unitRef="usd">10921000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ic0c9719a7e4c49a6888e5a5a55e6a756_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzUtNS0xLTEtMA_29f66461-19e8-43f8-acd7-bf1ad7e446dd"
      unitRef="usd">-4066000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzUtNy0xLTEtMA_1c65948b-6279-4248-a033-8f227baf2a7a"
      unitRef="usd">6855000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i197418bb01ba4a16bc643f9b8299428a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzYtMy0xLTEtMA_9a8f27fa-e6ee-4bcc-86a2-48df46fffa5a"
      unitRef="usd">60617000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ic0c9719a7e4c49a6888e5a5a55e6a756_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzYtNS0xLTEtMA_c0157ff8-fbd8-4716-ad28-d5677f10a15d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzYtNy0xLTEtMA_3e5d0afa-32c6-47e6-b0b0-a20fc8c63404"
      unitRef="usd">60617000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest
      contextRef="i197418bb01ba4a16bc643f9b8299428a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzctMy0xLTEtMA_601d8b0e-15a2-4ec1-b61e-923ea230daba"
      unitRef="usd">24022000</rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest>
    <rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest
      contextRef="ic0c9719a7e4c49a6888e5a5a55e6a756_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzctNS0xLTEtMA_0a35bc1d-4810-4772-bc61-be7198f8e2b8"
      unitRef="usd">0</rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest>
    <rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest
      contextRef="i6b15a91be9e9493798198e66a8d123b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzctNy0xLTEtMA_aedfb88f-35df-47cf-b331-d91ee076cb2b"
      unitRef="usd">24022000</rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest>
    <rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest
      contextRef="i197418bb01ba4a16bc643f9b8299428a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzgtMy0xLTEtMA_727dfc34-6033-468b-a6cc-55706c0aa0ca"
      unitRef="usd">2562000</rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest>
    <rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest
      contextRef="ic0c9719a7e4c49a6888e5a5a55e6a756_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzgtNS0xLTEtMA_c987dd59-feed-41c0-96c4-e47251a6c1c6"
      unitRef="usd">0</rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest>
    <rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest
      contextRef="iaf79e602f6744689882e0662af486960_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzgtNy0xLTEtMA_50a47990-3fdd-44e1-ab9d-68d7523428e1"
      unitRef="usd">2562000</rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc74be5e7f2b4443888aa58295087c78_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzktMy0xLTEtMA_6f016819-f88c-4731-9040-42e58bd2741f"
      unitRef="usd">34395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i69d044ffec6446e0896ba4f3dde2181c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzktNS0xLTEtMA_045c51c9-7aa2-417b-a05f-883575623428"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ef6d97fcbd2450783139f7b7ee49dc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzktNy0xLTEtMA_cf775fec-de79-4105-941f-6dc4172c0400"
      unitRef="usd">34395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i29031751451245b7b580c18872827fbb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzEwLTMtMS0xLTA_38ce0f91-f849-47cc-b6d3-3fa05d182c7d"
      unitRef="usd">28481000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ib4f46b5e4015492f9d8f108c0637d93f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzEwLTUtMS0xLTA_cf402c4a-6241-4ff6-989b-1294c29cb96d"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzEwLTctMS0xLTA_08d8ad92-9480-4e0d-be0e-6ccaba86b410"
      unitRef="usd">28481000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i29031751451245b7b580c18872827fbb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzExLTMtMS0xLTA_5dc8ada9-68ac-4d3d-b3b3-6f41130d73bc"
      unitRef="usd">6335000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ib4f46b5e4015492f9d8f108c0637d93f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzExLTUtMS0xLTA_eafdf055-a0d2-4c67-92d5-e5849acb1d73"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzExLTctMS0xLTA_9ba05e38-7e0f-40d9-a048-583bd56b95db"
      unitRef="usd">6335000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest
      contextRef="i29031751451245b7b580c18872827fbb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzEzLTMtMS0xLTA_1c887b1f-6b72-43c5-89df-256620f6d7eb"
      unitRef="usd">4242000</rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest>
    <rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest
      contextRef="ib4f46b5e4015492f9d8f108c0637d93f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzEzLTUtMS0xLTA_bf7415e1-792d-4ff5-8c45-69c3eda01668"
      unitRef="usd">0</rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest>
    <rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest
      contextRef="i85fa20a518334b9fa7796f9712ef4b1d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzEzLTctMS0xLTA_83be7181-15b2-4995-a128-99f7a5e86671"
      unitRef="usd">4242000</rprx:OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1006e57c6def4fd5ae9330e75305eda2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzE0LTMtMS0xLTA_cf8d85ad-c0b8-43c4-92c4-e48dfa04d575"
      unitRef="usd">16491000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i16fdeeb9bb4649b8bb751998b5e4aa0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzE0LTUtMS0xLTA_30421c6f-4519-4666-b64b-55af7d1ce40d"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iea955efbad0b414690fc8195ca1de338_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90YWJsZTo3OGQ2NzlmZGMxYmY0ZTQ1OTBjNTU5ZDNlMTBjNjdlMC90YWJsZXJhbmdlOjc4ZDY3OWZkYzFiZjRlNDU5MGM1NTlkM2UxMGM2N2UwXzE0LTctMS0xLTA_94476786-a8f7-4a17-905b-712538bc9028"
      unitRef="usd">16491000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:InvestmentIncomeNet
      contextRef="i54dfb90328614a55aba5dfd030436f8a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90ZXh0cmVnaW9uOjU4ZDlkNjYxYWEzYzQyY2NiZWVlNDYwMThhMjRkOTk3Xzg1OQ_d70e60ac-eeb1-428e-accf-d0b6871b147c"
      unitRef="usd">50900000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="if7ee447648cf4185a3ad39d6a4c5b190_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90ZXh0cmVnaW9uOjU4ZDlkNjYxYWEzYzQyY2NiZWVlNDYwMThhMjRkOTk3XzQ5NDc4MDIzMzE1ODE_2fae5112-1537-4b97-8e08-7bcc2b97e7b4"
      unitRef="usd">28500000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="ie65b03ddad0a41228c36c13d797b9715_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90ZXh0cmVnaW9uOjU4ZDlkNjYxYWEzYzQyY2NiZWVlNDYwMThhMjRkOTk3XzQ5NDc4MDIzMzE1ODk_2c2737aa-3a67-443f-9f55-c350d9855bf3"
      unitRef="usd">22400000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestIncomeOperating
      contextRef="i56d5126b8d034d6caef67a58b8e9b69e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90ZXh0cmVnaW9uOjU4ZDlkNjYxYWEzYzQyY2NiZWVlNDYwMThhMjRkOTk3XzQ5NDc4MDIzMzE1OTc_ec0d8843-68d1-433b-b6b7-3f0320b5aa13"
      unitRef="usd">20600000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="iedeb31da272b4fc68f60ac39c1f3cf68_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90ZXh0cmVnaW9uOjU4ZDlkNjYxYWEzYzQyY2NiZWVlNDYwMThhMjRkOTk3XzQ5NDc4MDIzMzE2MDU_3d402e86-3689-4eba-a8f9-91c73d0e891f"
      unitRef="usd">10900000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i9dc56eeaf4e74cf0a58f82575803d294_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjMvZnJhZzo1OGQ5ZDY2MWFhM2M0MmNjYmVlZTQ2MDE4YTI0ZDk5Ny90ZXh0cmVnaW9uOjU4ZDlkNjYxYWEzYzQyY2NiZWVlNDYwMThhMjRkOTk3XzQ5NDc4MDIzMzE2MTM_8685aa1b-b490-4a47-8e9d-8edfa1569619"
      unitRef="usd">9600000</us-gaap:InterestIncomeOperating>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzc0NTE_f21d891a-bcf9-4b33-962d-9b16c20720ba">Related Party Transactions&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;The Manager&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Manager is the investment manager of Royalty Pharma and its subsidiaries. The Manager is an affiliate of RP Ireland, the administrator of RPIFT, RPI Intermediate FT and RPSFT. The sole member of the Manager, Pablo Legorreta, holds an interest in us and serves as our Chief Executive Officer and Chairman of the board of directors, and as a director on the board of directors of RP Holdings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the Exchange Offer Transactions (discussed in Note 1&#x2013;Organization and Purpose), the Manager entered into Management Agreements with us and our subsidiaries, the Continuing Investors Partnerships, and with the Legacy Investors Partnerships. Pursuant to the Management Agreements, we pay quarterly operating and personnel expenses to the Manager or its affiliates (&#x201c;Operating and Personnel Payments&#x201d;) equal to 6.5% of the Adjusted Cash Receipts (both, as defined in the Management Agreement) for such quarter and 0.25% of the value of our security investments under GAAP as of the end of such quarter. The operating and personnel payments for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected in our consolidated net income, is calculated as the greater of $1&#160;million per quarter and 0.3125% of Royalty Investments (as defined in the limited partnership agreements of the Legacy Investor Partnerships) during the previous twelve calendar months. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Exchange Date, the Manager received operating and personnel payments payable in equal quarterly installments that increased by 5% annually on a compounded basis under the terms of its management agreement with Old RPI and the Legacy Investors Partnerships. RP Ireland receives an annual management fee payable in advance by Old RPI in equal quarterly installments under terms of the limited partnership agreements of the Legacy Investors Partnerships. After the Exchange Date, operating and personnel payments were calculated in accordance with the methodology discussed in the paragraph above. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2021, 2020 and 2019, total operating and personnel payments incurred were $145.2&#160;million, $112.5&#160;million and $60.0&#160;million, respectively, including the amounts attributable to Old RPI, and were recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;General and administrative expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Distribution Payable to Non-Controlling Interest&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The distribution payable to non-controlling interest represents the contractual cash flows required to be distributed based on the Legacy Investors Partnerships&#x2019; non-controlling interest in Old RPI and RPSFT&#x2019;s non-controlling interest in RPCT. The distribution payable to non-controlling interest as of December 31, 2021 and 2020 included the following (in thousands). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due to Legacy Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due to RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total distribution payable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition from Epizyme &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, in connection with a royalty acquisition and an equity investment in Epizyme made by RPIFT, Pablo Legorreta, our Chief Executive Officer, was appointed as a director of Epizyme, for which he received, and continues to receive, compensation in cash and shares of Epizyme, all of which are and will continue to be contributed to the Manager and used to reduce costs and expenses which would otherwise be billed to us or our affiliates. We continue to hold Epizyme common stock as of December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition from Bristol Myers Squibb&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2017, RPI Acquisitions, a consolidated subsidiary, entered into a purchase agreement with Bristol Myers Squibb (&#x201c;BMS&#x201d;) to acquire from BMS a percentage of its future royalties on worldwide sales of Onglyza, Farxiga and related diabetes products marketed by AstraZeneca (the &#x201c;Purchase Agreement&#x201d;). We agreed to make payments to BMS based on sales of the products over eight quarters beginning with the first quarter of 2018 in exchange for a high single-digit royalty on worldwide sales of the products from 2020 through 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On December 8, 2017, RPI Acquisitions entered into a purchase, sale and assignment agreement (&#x201c;Assignment Agreement&#x201d;) with a wholly owned subsidiary of BioPharma Credit PLC (&#x201c;BPCR&#x201d;), an affiliate of us. We considered BPCR as a related party due to the sole member of the Manager having significant influence over BPCR&#x2019;s investment manager. Under the terms of the Assignment Agreement, RPI Acquisitions assigned the benefit of 50% of the payment stream acquired from BMS to BPCR in consideration for BPCR meeting 50% of the funding obligations owed to BMS under the Purchase Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We began making installment payments to BMS in 2018 and completed our funding requirement, net of the assigned funding obligations, totaling $162.4&#160;million in the three months ended March 31, 2020. We began to measure this financial royalty asset using the effective interest method once our installment funding obligation was completed and we received our first royalty payment in the three months ended June 30, 2020. As of December 31, 2021 and 2020, the financial royalty asset of $130.9&#160;million and $150.6&#160;million, respectively, included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial royalty assets, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets represents only our right to the future payment streams acquired from BMS. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other transactions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Henry Fernandez, the lead independent director of our board of directors, serves as the chairman and chief executive officer of MSCI, Inc (&#x201c;MSCI&#x201d;). On April 16, 2021, we entered into an agreement with MSCI with an initial term of seven years to assist MSCI in the design of a classification framework and index methodologies in order to expand MSCI&#x2019;s thematic index suite with the launch of new indexes. In return, we will receive a percentage of MSCI&#x2019;s revenues from those indexes. No amounts were due from MSCI as of December 31, 2021. The financial statement impact associated with this transaction was not material for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the year ended December 31, 2020, we reimbursed Pablo Legorreta approximately $1.0&#160;million for the cost of purchasing and donating ventilators to hospitals on behalf of Royalty Pharma. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the Exchange Offer Transactions, we acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy Investors Partnerships own a non-controlling interest in Old RPI. Refer to Note 9&#x2013;Non-Consolidated Affiliates for additional discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RPIFT owns 27,210 limited partnership interests in the Continuing Investors Partnership whose only substantive operations are their investment in our subsidiaries. The total investment of $4.3&#160;million is recorded as treasury interests, of which $1.6&#160;million and $1.9&#160;million are held by non-controlling interest as of December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on its ownership percentage of RP Holdings relative to the Company, each Continuing Investor Partnership pays a pro rata portion of any costs and expenses in connection with the contemplation of, formation of, listing and ongoing operation of us and any of our subsidiaries, including any third-party expenses of managing us and any of our subsidiaries, such as accounting, audit, legal, reporting, compliance, administration (including directors&#x2019; fees), financial advisory, consulting, investor relations and insurance expenses relating to our affairs and those of any subsidiary.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <rprx:RelatedPartyTransactionRateAdjustedCashReceipts
      contextRef="ibe95870b105d4aadbf0f7ea315240ffe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzg2NA_69073312-2238-4146-ae1a-cd337e6236a1"
      unitRef="number">0.065</rprx:RelatedPartyTransactionRateAdjustedCashReceipts>
    <rprx:RelatedPartyTransactionRateValueOfSecurityInvestments
      contextRef="ibe95870b105d4aadbf0f7ea315240ffe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzk2OQ_ab3f4add-ed85-47f3-a485-403a50415fbd"
      unitRef="number">0.0025</rprx:RelatedPartyTransactionRateValueOfSecurityInvestments>
    <rprx:RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount
      contextRef="i68845df194e84a7d80a8bd8a4940e91d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzEyODY_217d5aae-37b6-4084-b54e-3967dfa36f65"
      unitRef="usd">1000000</rprx:RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount>
    <rprx:RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent
      contextRef="i68845df194e84a7d80a8bd8a4940e91d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzEzMDU_60b127e2-a9dc-4916-a6e7-7a6fc2ef93c3"
      unitRef="number">0.003125</rprx:RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent>
    <rprx:RelatedPartyTransactionAnnualIncreasePercentage
      contextRef="i97ca2cea9f6f43ddaa7f3e5b85bf3ea6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzE2MTU_b9ad86a9-d5c8-4e86-9cda-d556fb52e62f"
      unitRef="number">0.05</rprx:RelatedPartyTransactionAnnualIncreasePercentage>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="i97ca2cea9f6f43ddaa7f3e5b85bf3ea6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzEwOTk1MTE2NDE4MjA_354a756a-7c84-4482-8a9a-824b0d311cb5"
      unitRef="usd">145200000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="ie8e86ed407fe484e8200e769e2f1bb39_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzEwOTk1MTE2NDE4MzM_d17983e0-d7b4-4272-ba62-bf9615bd9f0d"
      unitRef="usd">112500000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="i645cb20517d04607a53311447c97b49a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzEwOTk1MTE2NDE4NDE_bdd4d930-a54c-45f3-a160-5d407d9c3061"
      unitRef="usd">60000000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzI5Njg2ODEzOTY1ODA3_9049bdcf-4018-4ccf-bc80-7312ebd250e0">The distribution payable to non-controlling interest as of December 31, 2021 and 2020 included the following (in thousands). &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due to Legacy Investors Partnerships&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due to RPSFT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total distribution payable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="i2e60ab1409db4a2697d00163b861a712_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90YWJsZTphOThlYWU5ZTI0NjE0MTY5OTEwMTJmOTlhZDJkNDdmOC90YWJsZXJhbmdlOmE5OGVhZTllMjQ2MTQxNjk5MTAxMmY5OWFkMmQ0N2Y4XzEtMS0xLTEtNDI4MDA_ccb70191-539c-416c-a25e-2a84bede4f85"
      unitRef="usd">92608000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="i70b38d22ad90490ba1b7d51417e278e8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90YWJsZTphOThlYWU5ZTI0NjE0MTY5OTEwMTJmOTlhZDJkNDdmOC90YWJsZXJhbmdlOmE5OGVhZTllMjQ2MTQxNjk5MTAxMmY5OWFkMmQ0N2Y4XzEtMi0xLTEtNDI4MDA_4f1f52a2-546f-44f4-8b9f-bf428a75201d"
      unitRef="usd">100047000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="ic7b7fdb0deff479196b3afda650a0570_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90YWJsZTphOThlYWU5ZTI0NjE0MTY5OTEwMTJmOTlhZDJkNDdmOC90YWJsZXJhbmdlOmE5OGVhZTllMjQ2MTQxNjk5MTAxMmY5OWFkMmQ0N2Y4XzItMS0xLTEtNDI4MDA_6dfc87bd-9a34-438f-b3fd-548f9a22e63d"
      unitRef="usd">15326000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="ie31b0e40de594cdd9c6ae104e8a737c1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90YWJsZTphOThlYWU5ZTI0NjE0MTY5OTEwMTJmOTlhZDJkNDdmOC90YWJsZXJhbmdlOmE5OGVhZTllMjQ2MTQxNjk5MTAxMmY5OWFkMmQ0N2Y4XzItMi0xLTEtNDI4MDA_2e165f79-2e65-4d88-bf9a-73a090e5dafb"
      unitRef="usd">26319000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="i355f63584077498c9358681b1f440182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90YWJsZTphOThlYWU5ZTI0NjE0MTY5OTEwMTJmOTlhZDJkNDdmOC90YWJsZXJhbmdlOmE5OGVhZTllMjQ2MTQxNjk5MTAxMmY5OWFkMmQ0N2Y4XzMtMS0xLTEtNDI4MDA_4a08c123-fe5a-4fb3-8186-fc284ee45b53"
      unitRef="usd">107934000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90YWJsZTphOThlYWU5ZTI0NjE0MTY5OTEwMTJmOTlhZDJkNDdmOC90YWJsZXJhbmdlOmE5OGVhZTllMjQ2MTQxNjk5MTAxMmY5OWFkMmQ0N2Y4XzMtMi0xLTEtNDI4MDA_70ab311f-66f9-45ab-b8d0-a162195388b2"
      unitRef="usd">126366000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="ibb1bbffa95a546f8bb9ed80b3df9b06b_D20171208-20171208"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzQ0NDI_a1725dd1-de53-4b80-95be-7efa574d9de3"
      unitRef="number">0.50</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="i61362e5f58b24b40a91040ec047f877f_D20171208-20171208"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzQ1Mjc_91079010-89f4-4eea-828a-11ad47bb15a6"
      unitRef="number">0.50</us-gaap:RelatedPartyTransactionRate>
    <rprx:RelatedPartyTransactionCumulativeFundingAmount
      contextRef="i892f2facb5f94c52a537787b30d9bedb_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzEwOTk1MTE2NDA0NTY_8073fa6b-5c02-4960-be02-552ae4eccff1"
      unitRef="usd">162400000</rprx:RelatedPartyTransactionCumulativeFundingAmount>
    <us-gaap:NotesReceivableNet
      contextRef="i67eff68d96604fa8be650fb4b9c29499_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzEwOTk1MTE2NDA0NzA_85a85013-75ba-44d4-bc28-22b5367063db"
      unitRef="usd">130900000</us-gaap:NotesReceivableNet>
    <us-gaap:NotesReceivableNet
      contextRef="i476f13cf218b4efabc6d088270acc46d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzEwOTk1MTE2Mzc4MDI_882f6a66-52ca-4a32-888a-a194d33ff924"
      unitRef="usd">150600000</us-gaap:NotesReceivableNet>
    <rprx:RelatedPartyTransactionInitialTerm
      contextRef="i5e9cfc8aaf7e4e8694cd83fe4460da68_D20210416-20210416"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzI5Njg2ODEzOTY1ODIz_ad4cc868-d4ba-419c-bac1-fbd8d0e8bc59">P7Y</rprx:RelatedPartyTransactionInitialTerm>
    <us-gaap:DueFromRelatedParties
      contextRef="ib2947dd542964da4bc1a05e210e2204b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzE0MjkzNjUxMTc4MDUw_a4067fb3-3952-454f-b77c-91d0dbd86598"
      unitRef="usd">0</us-gaap:DueFromRelatedParties>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i9edec4e140234b36b02f7525c49128f0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzE2NDkyNjc0NTQ5NDc_439b8d5f-98c2-4fa5-8f6c-69252f72b1a8"
      unitRef="usd">1000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <rprx:RelatedPartyTransactionNumberOfPartnershipInterestsAcquired
      contextRef="i577a0329d95541e3802de867916ac6d6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzY0MTM_7c40141c-971d-4cf8-823f-739f06107d6c"
      unitRef="shares">27210</rprx:RelatedPartyTransactionNumberOfPartnershipInterestsAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i8cc96b6d6e9e4707b52d5a0f86086779_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzE2NDkyNjc0NTU5NzE_432e8d93-1977-4b23-a2ec-284f6d8883d7"
      unitRef="usd">-4300000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="id61bed594e7b481cb6b9d98f501ad606_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzQ5NDc4MDIzNDE1ODc_8121da68-92fb-4b3c-9369-36d6422ff7c5"
      unitRef="usd">-1600000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="icb00ed73f9984375a78b3989a66be135_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjYvZnJhZzo3ZjNiY2FhMjZkOTg0ZjAwYWNkMDBlMzhhOTg4NzJiZC90ZXh0cmVnaW9uOjdmM2JjYWEyNmQ5ODRmMDBhY2QwMGUzOGE5ODg3MmJkXzQ5NDc4MDIzNDE1Nzg_e20a1b52-44f1-425a-bf74-fbb56ccf451e"
      unitRef="usd">-1900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzM3Mjc_bb6fda8a-bab0-4de0-8bb9-a3c064692197">Commitments and Contingencies&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of its business, we may enter into contracts or agreements that contain customary indemnifications relating to such things as confidentiality agreements and representations as to corporate existence and authority to enter into contracts. The maximum exposure under such agreements is indeterminable until a claim, if any, is made. However, no such claims have been made against us to date and we believe that the likelihood of such proceedings taking place in the future is remote.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys to support MorphoSys&#x2019; acquisition of Constellation, which closed on July 15, 2021. As part of the funding agreement, we agreed to make additional milestone payments of up to $150.0&#160;million and provide up to $350.0&#160;million of Development Funding Bonds, which MorphoSys may draw over a one-year period from the close of its acquisition of Constellation. MorphoSys is required to draw a minimum of $150.0&#160;million, for which we have recognized the Development Funding Bond Forward within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Available for sale debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; on the consolidated balance sheet as of December 31, 2021 (See Note 3&#x2013;Available for Sale Debt Securities for additional discussion). Once drawn, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years, with the first payment beginning two years after the funding. As of December 31, 2021, MorphoSys has not drawn any amount under the Development Funding Bonds.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On August 7, 2020, we entered into a funding agreement with Biohaven, including the Series B Biohaven Preferred Share Agreement, to fund the development of zavegepant and the commercialization of Nurtec ODT in exchange for royalties and success-based milestones. Pursuant to the Series B Biohaven Preferred Share Agreement, we agreed to provide further support for the ongoing launch of Nurtec ODT with the purchase of committed, non-contingent Commercial Launch Preferred Equity for a total of $200.0&#160;million payable on a quarterly basis between March 31, 2021 and December 31, 2024. In return, Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between March 31, 2025 and December 31, 2030. During the three months ended March 30, 2021, we began purchasing the Series B Biohaven Preferred Shares. We have a remaining commitment of $129.6&#160;million under the Commercial Launch Preferred Equity, for which we have recognized the Series B Forwards within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Available for sale debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; on the consolidated balance sheet as of December 31, 2021. See Note 3&#x2013;Available for Sale Debt Securities for additional discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, RPIFT agreed to pay $330.0&#160;million to purchase Eisai&#x2019;s royalties on future worldwide sales of Tazverik, a novel targeted therapy in late-stage clinical development that was approved by the FDA in January 2020 for epithelioid sarcoma, and with the potential to be approved in several cancer indications. Under the terms of our agreement with Eisai, we acquired Eisai&#x2019;s future worldwide royalties on net sales by Epizyme of Tazverik outside of Japan, for an upfront payment of $110.0&#160;million plus up to an additional $220.0&#160;million for the remainder of the royalty upon FDA approval of Tazverik for certain indications. The FDA approval of Tazverik in January 2020 triggered our obligation to fund the second $110.0&#160;million tranche in November 2020. On November 4, 2021, we funded the final $110.0&#160;million tranche. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We have commitments to advance funds to counterparties through our investment in the Avillion Entities and R&amp;amp;D arrangements. Please refer to Note 9&#x2013;Non-Consolidated Affiliates and Note 10&#x2013;Research &amp;amp; Development (&#x201c;R&amp;amp;D&#x201d;) Funding Expense, respectively, for details of these arrangements. We also have requirements to make Operating and Personnel Payments over the life of the management agreement as described in Note 16&#x2013;Related Party Transactions, which are variable and primarily based on cash receipts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to legal actions with respect to a variety of matters in the ordinary course of business. Some of these proceedings may be based on complex claims involving substantial uncertainties and unascertainable damages. Unless otherwise noted, it is not possible to determine the probability of loss or estimate damages, and therefore we have not established accruals for any of these proceedings in our consolidated balance sheets as of December 31, 2021 and 2020. When we determine that a loss is both probable and reasonably estimable, we record a liability, and, if the liability is material, we disclose the amount of the liability reserved. We do not believe the outcome of any existing legal proceedings to which we are a party, either individually or in the aggregate, will adversely affect our business, financial condition or results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <rprx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments
      contextRef="ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzEwOTk1MTE2MzIyNDk_b052fc2c-eabb-49e0-86c7-2a5de9b45af5"
      unitRef="usd">150000000</rprx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments>
    <rprx:CollaborativeArrangementRightsAndObligationsPaymentOfCapital
      contextRef="ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzEwOTk1MTE2MzIzNTQ_0132b80f-f7f5-41af-afdb-0c37a4e94ddb"
      unitRef="usd">350000000</rprx:CollaborativeArrangementRightsAndObligationsPaymentOfCapital>
    <rprx:CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm
      contextRef="ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzI5Njg2ODEzOTYwOTk3_57ddf6a6-b286-401f-9aba-ea8c38a0288a">P1Y</rprx:CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm>
    <rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund
      contextRef="ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzEwOTk1MTE2MzI3NzQ_1ad35bfd-d202-48ee-bc20-0a93c18bc695"
      unitRef="usd">150000000</rprx:CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund>
    <rprx:CollaborativeArrangementRightsAndObligationsPeriodOfReturn
      contextRef="ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzEwOTk1MTE2MzMyODA_c9eedcf2-2de5-438c-b09e-1e6d4ba0b6f3">P9Y</rprx:CollaborativeArrangementRightsAndObligationsPeriodOfReturn>
    <rprx:CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate
      contextRef="ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzEwOTk1MTE2MzMzNDM_1915f658-bf28-4176-87d2-002faa6a07ed">P2Y</rprx:CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate>
    <rprx:PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount
      contextRef="ib03c23cba7a244bb9c45ccd577d4c56b_D20200807-20200807"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzExNjU_7c76953f-efe1-4850-9b7f-fbf447afd948"
      unitRef="usd">200000000</rprx:PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount>
    <rprx:LongTermPurchaseCommitmentAmountOutstanding
      contextRef="i4719611fdef547db987f7d2d30dadbc7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzEwOTk1MTE2MzUwMTU_0666d905-8be3-4416-a66f-8e0d671d65c8"
      unitRef="usd">129600000</rprx:LongTermPurchaseCommitmentAmountOutstanding>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="id128cc5ba3f14e5e9d39b99e553584ce_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzE0NjE_ef1091f3-b433-4c90-ae2e-3a03bbccbb3b"
      unitRef="usd">330000000</us-gaap:LongTermPurchaseCommitmentAmount>
    <rprx:PurchaseCommitmentUpfrontPayment
      contextRef="i745d2f50fe8b4f46a787612b29f6bed4_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzE5MjI_3a482612-662f-4f59-865f-6017a60ee627"
      unitRef="usd">110000000</rprx:PurchaseCommitmentUpfrontPayment>
    <rprx:PurchaseCommitmentAdditionalPayment
      contextRef="i745d2f50fe8b4f46a787612b29f6bed4_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzE5NTA_4ee2fb7b-cc89-4ebc-945b-6beec4218c77"
      unitRef="usd">220000000</rprx:PurchaseCommitmentAdditionalPayment>
    <rprx:PurchaseCommitmentAdditionalPayment
      contextRef="id0a161191b444d5bac5c44aa63d77be4_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzIxMzA_966f5993-7c39-42de-9e1c-4b71021402ca"
      unitRef="usd">110000000</rprx:PurchaseCommitmentAdditionalPayment>
    <rprx:PurchaseCommitmentAdditionalPayment
      contextRef="i1895cd7ab821494986c2e4e15419aa87_D20211104-20211104"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNjkvZnJhZzplMTUxYTZmNTAxMzE0MDY3OWY4ODUwNmEzMjZjN2NhYy90ZXh0cmVnaW9uOmUxNTFhNmY1MDEzMTQwNjc5Zjg4NTA2YTMyNmM3Y2FjXzEwOTk1MTE2MzUzMTM_c10eac7b-51f8-405c-9ff4-24d37c6788f2"
      unitRef="usd">110000000</rprx:PurchaseCommitmentAdditionalPayment>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNzIvZnJhZzozYzFjYjRjMWU4NWI0YmU0YmUxMzk3YjIwZGJiNGVlZS90ZXh0cmVnaW9uOjNjMWNiNGMxZTg1YjRiZTRiZTEzOTdiMjBkYmI0ZWVlXzQ5Mw_fd9e9b18-af91-4c3d-a59c-00a896754984">Subsequent EventsIn January 2022, we acquired a royalty interest in aficamten from Cytokinetics, Incorporated (&#x201c;Cytokinetics&#x201d;) for $150.0&#160;million, comprised of an upfront payment of $50&#160;million and two additional $50&#160;million payments which are conditional upon the initiation of potential pivotal clinical trials for obstructive hypertrophic cardiomyopathy and nonobstructive hypertrophic cardiomyopathy, respectively. Additionally, we will provide Cytokinetics long-term capital of up to $300&#160;million (&#x201c;Cytokinetics Commercial Launch Funding&#x201d;) to support further development of aficamten and potential commercialization of omecamtiv mecarbil. The Cytokinetics Commercial Launch Funding is available in five tranches, including an initial tranche of $50&#160;million funded upon closing and four additional tranches in the aggregate amount of $250&#160;million upon the occurrence of certain regulatory and clinical development milestones.</us-gaap:SubsequentEventsTextBlock>
    <rprx:PaymentsToAcquireRoyaltyInterestsAggregateAmount
      contextRef="if022a6e3714949948eb2520d7c7ab729_D20220101-20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNzIvZnJhZzozYzFjYjRjMWU4NWI0YmU0YmUxMzk3YjIwZGJiNGVlZS90ZXh0cmVnaW9uOjNjMWNiNGMxZTg1YjRiZTRiZTEzOTdiMjBkYmI0ZWVlXzE0MjkzNjUxMTcyNTEy_c6f8c5eb-c67a-4358-ba84-5649416665f5"
      unitRef="usd">150000000</rprx:PaymentsToAcquireRoyaltyInterestsAggregateAmount>
    <rprx:PaymentsToAcquireRoyaltyInterestsUpfrontPayment
      contextRef="if022a6e3714949948eb2520d7c7ab729_D20220101-20220131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNzIvZnJhZzozYzFjYjRjMWU4NWI0YmU0YmUxMzk3YjIwZGJiNGVlZS90ZXh0cmVnaW9uOjNjMWNiNGMxZTg1YjRiZTRiZTEzOTdiMjBkYmI0ZWVlXzM4NDgyOTA3MDY2NzY_2a42658a-730a-40a0-bd37-60ffc132485f"
      unitRef="usd">50000000</rprx:PaymentsToAcquireRoyaltyInterestsUpfrontPayment>
    <rprx:PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments
      contextRef="if022a6e3714949948eb2520d7c7ab729_D20220101-20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNzIvZnJhZzozYzFjYjRjMWU4NWI0YmU0YmUxMzk3YjIwZGJiNGVlZS90ZXh0cmVnaW9uOjNjMWNiNGMxZTg1YjRiZTRiZTEzOTdiMjBkYmI0ZWVlXzM4NDgyOTA3MDY2ODQ_6998f0a0-1618-4ce5-9be5-3b3778fe23f4"
      unitRef="payment">2</rprx:PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments>
    <rprx:PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments
      contextRef="if022a6e3714949948eb2520d7c7ab729_D20220101-20220131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNzIvZnJhZzozYzFjYjRjMWU4NWI0YmU0YmUxMzk3YjIwZGJiNGVlZS90ZXh0cmVnaW9uOjNjMWNiNGMxZTg1YjRiZTRiZTEzOTdiMjBkYmI0ZWVlXzM4NDgyOTA3MDY2OTk_41b48c5b-53ff-4d09-b2b1-3ea3d96f5b8b"
      unitRef="usd">50000000</rprx:PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments>
    <rprx:LongTermFundingPartnershipAmount
      contextRef="if022a6e3714949948eb2520d7c7ab729_D20220101-20220131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNzIvZnJhZzozYzFjYjRjMWU4NWI0YmU0YmUxMzk3YjIwZGJiNGVlZS90ZXh0cmVnaW9uOjNjMWNiNGMxZTg1YjRiZTRiZTEzOTdiMjBkYmI0ZWVlXzE0MjkzNjUxMTY5NDQx_13581f6a-8932-40e7-8577-d1b6b342f466"
      unitRef="usd">300000000</rprx:LongTermFundingPartnershipAmount>
    <rprx:LongTermFundingPartnershipNumberOfTranches
      contextRef="if022a6e3714949948eb2520d7c7ab729_D20220101-20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNzIvZnJhZzozYzFjYjRjMWU4NWI0YmU0YmUxMzk3YjIwZGJiNGVlZS90ZXh0cmVnaW9uOjNjMWNiNGMxZTg1YjRiZTRiZTEzOTdiMjBkYmI0ZWVlXzE0MjkzNjUxMTY5NTEz_0bf9cc78-8c70-4858-a430-58ae015ac5ba"
      unitRef="tranche">5</rprx:LongTermFundingPartnershipNumberOfTranches>
    <rprx:LongTermFundingPartnershipInitialPayment
      contextRef="if022a6e3714949948eb2520d7c7ab729_D20220101-20220131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNzIvZnJhZzozYzFjYjRjMWU4NWI0YmU0YmUxMzk3YjIwZGJiNGVlZS90ZXh0cmVnaW9uOjNjMWNiNGMxZTg1YjRiZTRiZTEzOTdiMjBkYmI0ZWVlXzE0MjkzNjUxMTY5NDY5_9b372ac6-9ac1-412f-ab53-db99edd654fc"
      unitRef="usd">50000000</rprx:LongTermFundingPartnershipInitialPayment>
    <rprx:LongTermFundingPartnershipNumberOfAdditionalPayments
      contextRef="if022a6e3714949948eb2520d7c7ab729_D20220101-20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNzIvZnJhZzozYzFjYjRjMWU4NWI0YmU0YmUxMzk3YjIwZGJiNGVlZS90ZXh0cmVnaW9uOjNjMWNiNGMxZTg1YjRiZTRiZTEzOTdiMjBkYmI0ZWVlXzE0MjkzNjUxMTY5NTMw_75c4e0ad-1ca3-4e61-95af-589bae8f97f5"
      unitRef="tranche">4</rprx:LongTermFundingPartnershipNumberOfAdditionalPayments>
    <rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount
      contextRef="if022a6e3714949948eb2520d7c7ab729_D20220101-20220131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xNzIvZnJhZzozYzFjYjRjMWU4NWI0YmU0YmUxMzk3YjIwZGJiNGVlZS90ZXh0cmVnaW9uOjNjMWNiNGMxZTg1YjRiZTRiZTEzOTdiMjBkYmI0ZWVlXzE0MjkzNjUxMTY5NDU1_ff5ddd00-6daa-419a-a0eb-6307ac9e6733"
      unitRef="usd">250000000</rprx:LongTermFundingPartnershipAdditionalPaymentsAggregateAmount>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUyLTMtMS0xLTA_76e4811f-8f61-4261-8b05-1bb3b6605340"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUyLTMtMS0xLTA_76e4811f-8f61-4261-8b05-1bb3b6605340"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUyLTEtMS0xLTA_4ebc0264-fc9b-41e8-bd70-756d832684b4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUyLTEtMS0xLTA_4ebc0264-fc9b-41e8-bd70-756d832684b4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzU2LTEtMS0xLTM3MDIx_5072f657-16e7-4822-913b-4fa5624a9150"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzU2LTEtMS0xLTM3MDIx_5072f657-16e7-4822-913b-4fa5624a9150"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUzLTEtMS0xLTA_c5f85727-ab8f-46b3-91e4-92ac158a0433"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUzLTEtMS0xLTA_c5f85727-ab8f-46b3-91e4-92ac158a0433"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzU1LTMtMS0xLTM3MDAx_492268b9-a345-4c82-840d-920ff3e1f7c8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzU1LTMtMS0xLTM3MDAx_492268b9-a345-4c82-840d-920ff3e1f7c8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzU2LTMtMS0xLTM3MDAx_e03bcac5-4b4c-4b66-a2e9-e6f0e4129fe4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzU2LTMtMS0xLTM3MDAx_e03bcac5-4b4c-4b66-a2e9-e6f0e4129fe4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUzLTMtMS0xLTA_a435e31d-dffb-4b96-ba18-64e6deef6779"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUzLTMtMS0xLTA_a435e31d-dffb-4b96-ba18-64e6deef6779"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzU1LTEtMS0xLTM3MDIx_4990eee5-dee5-4619-8a5d-ff70d21298b6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzU1LTEtMS0xLTM3MDIx_4990eee5-dee5-4619-8a5d-ff70d21298b6"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90ZXh0cmVnaW9uOmE0MTg4YTgxMGFkNTQ0OGY4ZWFhM2I1MTIzNWFiZjQ0XzQwMw_44e224c8-6066-4813-9082-30da4843a311" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90ZXh0cmVnaW9uOmE0MTg4YTgxMGFkNTQ0OGY4ZWFhM2I1MTIzNWFiZjQ0XzQwMw_44e224c8-6066-4813-9082-30da4843a311" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents earnings per Class A ordinary share and weighted average Class A ordinary shares outstanding for the period from June 16, 2020 through December 31, 2020 following our initial public offering (&#x201c;IPO&#x201d;) in the year ended December 31, 2020. See Note 13&#x2013;Earnings per Share.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUyLTMtMS0xLTA_76e4811f-8f61-4261-8b05-1bb3b6605340"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90ZXh0cmVnaW9uOmE0MTg4YTgxMGFkNTQ0OGY4ZWFhM2I1MTIzNWFiZjQ0XzQwMw_44e224c8-6066-4813-9082-30da4843a311"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUyLTEtMS0xLTA_4ebc0264-fc9b-41e8-bd70-756d832684b4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90ZXh0cmVnaW9uOmE0MTg4YTgxMGFkNTQ0OGY4ZWFhM2I1MTIzNWFiZjQ0XzQwMw_44e224c8-6066-4813-9082-30da4843a311"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzU2LTEtMS0xLTM3MDIx_5072f657-16e7-4822-913b-4fa5624a9150"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90ZXh0cmVnaW9uOmE0MTg4YTgxMGFkNTQ0OGY4ZWFhM2I1MTIzNWFiZjQ0XzQwMw_44e224c8-6066-4813-9082-30da4843a311"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUzLTEtMS0xLTA_c5f85727-ab8f-46b3-91e4-92ac158a0433"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90ZXh0cmVnaW9uOmE0MTg4YTgxMGFkNTQ0OGY4ZWFhM2I1MTIzNWFiZjQ0XzQwMw_44e224c8-6066-4813-9082-30da4843a311"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzU1LTMtMS0xLTM3MDAx_492268b9-a345-4c82-840d-920ff3e1f7c8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90ZXh0cmVnaW9uOmE0MTg4YTgxMGFkNTQ0OGY4ZWFhM2I1MTIzNWFiZjQ0XzQwMw_44e224c8-6066-4813-9082-30da4843a311"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzU2LTMtMS0xLTM3MDAx_e03bcac5-4b4c-4b66-a2e9-e6f0e4129fe4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90ZXh0cmVnaW9uOmE0MTg4YTgxMGFkNTQ0OGY4ZWFhM2I1MTIzNWFiZjQ0XzQwMw_44e224c8-6066-4813-9082-30da4843a311"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzUzLTMtMS0xLTA_a435e31d-dffb-4b96-ba18-64e6deef6779"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90ZXh0cmVnaW9uOmE0MTg4YTgxMGFkNTQ0OGY4ZWFhM2I1MTIzNWFiZjQ0XzQwMw_44e224c8-6066-4813-9082-30da4843a311"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90YWJsZTpjZmMzMGRjYTM4ZTQ0OTliYjk0ZmU1YTEzZGM4Y2M3NS90YWJsZXJhbmdlOmNmYzMwZGNhMzhlNDQ5OWJiOTRmZTVhMTNkYzhjYzc1XzU1LTEtMS0xLTM3MDIx_4990eee5-dee5-4619-8a5d-ff70d21298b6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjE1ZmFmYzk5YWI1YzQxZGViMDhlZTgxNmNhNDcxNzJjL3NlYzoxNWZhZmM5OWFiNWM0MWRlYjA4ZWU4MTZjYTQ3MTcyY18xMDAvZnJhZzphNDE4OGE4MTBhZDU0NDhmOGVhYTNiNTEyMzVhYmY0NC90ZXh0cmVnaW9uOmE0MTg4YTgxMGFkNTQ0OGY4ZWFhM2I1MTIzNWFiZjQ0XzQwMw_44e224c8-6066-4813-9082-30da4843a311"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>86
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MB'7M&$[2="0YT@$\- R>/U6].(5I6G68]$ITH9'@+,9.X>$QA"U@'(V52G3
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M +_/E;(O-^VGR>VGZ,O_ %!+ P04    " !M2$]4YJ'KCZ,#  #F$   &
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MVYTCHOX"\"OAQZP0B,)!&3FWH5*/UX?J>B!969T:GYA49]#J,@62 -< ]?S
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M%D.-&0!MJY0&-':C2P[H$B^ZCQM1R^)/W9U4JRHJ"9-<S$ONF;C$'B_)LMA
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MV.B/:\YR7BL#N+\4D(W]%_6 PR\W;OX"4$L#!!0    ( &U(3U3^H ,SS@,
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M(*AR OM^*Z5YOG$!VK\DRQ]02P,$%     @ ;4A/5&U^@*O\"@  2S@  !@
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6S%6]MRVS@2_164=VHWJ8HBXL+;
MK..JR)9MQ?&E[&3W(34/M 1;W*%(#4G9R7[]-BA*%($F*,\DV1=;EX-&-]#H
M/MV@#I^S_/=B+F5)OBZ2M'AW,"_+Y:_#83&=RT54O,V6,H5O'K)\$97P-G\<
M%LM<1K-JT"(9,L?QAHLH3@^.#JO/;O*CPVQ5)G$J;W)2K!:+*/\VDDGV_.Z
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M"Q-LC4:UQ-;EAL,@$0J],D&0>NP^13!Z98) C&C9+V:"0#C0?Y=KLC[TR[I
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M& ?]?<>Y.BU,@*;)QW\ 4$L#!!0    ( &U(3U10:""\#@D  -PI   8
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MV*3W@G1%?0O+"#'4#S$#^1XT( M@#$:$J#N$-TB:A#1U_*%D$K6YFVT34Q(
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MZM8;_4GJ!1*)3]VBG*-"P>YFH?-D%])D@NM/'09I=8,K_78\+F>YN.:$IY>
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M:,JL#PX_=J&K@,/AE^^W#B2E:'?[O#G@&$7;!!BFA&_+;%TU>5-4>9V%#CX
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MB3%6;3?$>ZU-$.+Y;""TB(4/( NF%@.<T*;,01+ U2Y3Q/GTXCPBL5?OKA,
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MS&G0[A",GM215^Z %3^M1BDM5A[T=:E-3HS"8&DB;I_2,!L&TU/-]J<8ZZM
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M/(H!]-D?I1"'"^653)ODU9B*^+H6^*)1JUE7C^ N[;5=2P2(F$7-# E;5F!
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MH-<M_U22.GNB#CA5=PA+SEE!$WH_+L %#DAJAX?C:9]E()-(CBWSL2\$#7B
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M(%M49:"7(?5QB\QZ(I$-V.<U[H@A%IK,;I*WH#IA<]3"C:J*6B6W6ZV^@;Z
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M3^.3@M0O['1W^\8FG>]=U1"FZI(,62&>DR6WMBH<B$9<JVJU/J#3V!X>FL$
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ML;R9DOG%)W-SA/+Z*RQNCE"^F:"\(2C?#C']A+)AV9DOZF]L+N49NSD@F (
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M4%Z<TYO4@"D!.NC%2M\Y7Q*890M1,T=[L$P0()6VC.R8&_TAL(JKK,(JRQ5
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M<7KN3Z@FVCE=^,N9X!B/:0'>YQJFU3<DH#FR//\'4$L#!!0    ( &U(3U1
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M??W/@OYKH.$-]#[7-&&[!P88_KTL_@502P,$%     @ ;4A/5)5GHDO=#
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M#7B_T4C$X8843 ?IRW\!4$L#!!0    ( &U(3U0O2:*F:@0  &4,   9
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;+57;6_;-A#^*P<O&!) LR7ZI7;F
M&+"3=@O0HD'<;A^&?:"ELT64(EV2BIO]^ATI65:Z.&V&](M%GNZ>NWN.=Z*G
M.VT^V1S1P9="*GO1R9W;GO=Z-LVQX+:KMZCHS5J;@CO:FDW/;@WR+!@5LL?B
M>-0KN%"=V33(;LQLJDLGA<(; [8L"F[N%RCU[J*3=/:"6[')G1?T9M,MW^ 2
MW<?MC:%=KT')1('*"JW X/JB,T_.%P.O'Q3^$+BSK37X3%9:?_*;Z^RB$_N
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MT?#ER4$ 8.G&FR7_.&%FO#<57Q9 4,K2 KR?&V2G>$,'M+]6>?\_4$L#!!0
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MNY<__.W58O[R#5CU:ZN#9H:%X4A$A,D8CB+T5YK!<0'Z'5EGMF)^E,R;B-/
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ML1;V:#15',^+PF/4R?W0;A\'!'!2*7Z_-X?OGK_(C$0F7RJ:U-2>/VA6,OE
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M MSP# V;@#:/_B4&>DCRLJ>76[@D0/<M4NJWFV1@_"^P^ =02P,$%     @
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MP?.NXU?+(ET59=$5,A2^DA=M5M9MWQ $8&UX3#C[U'L\$V(#OH!_C^-$FSP
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M/6-F\GI@-&_J?K--[FMB+PUJ6+ W4"J+75&FC7RS0"3+@3\+GR5-C_DA<EA
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M%CKN8^8<:_JO8'=@;\%:0%( @KRN0.LGAG!;-Z!N,@OD8UFB9J""7&7FN5@
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M_@?9DQ@(T=R?.#4RE[ZB/8T^Q^Y&4==981Y*'P^$!7]DH+'KD1: ZP9>QWZ
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MI=1D#JP.5 +][(O+BRL0AW<^_>4.Z%34DA_@65;U+I*?I9,)0X)B!Z3DL[=
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M=Z1.WWPZ><]I='7+V-VFGAG0-:A4=J66&@)8E>WY^UZE0PB/,=K^(8TLRM!
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M@@?&0TJB15JU>0>P*MM_Y992<_6J:;8]T@3G'5BURV0M=ST7'ON]Y./V>J&
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M!9TU D,O>-L:]UREA4"#*/+KS0+TAP#Z[0B/L.,1&A[A 1Y/D%=973 BEF3
M[T?.))5IOMUGU^,4O^2,+$4!^<6K%='H'IMD_$^0?MFYD2K%K&_[CP6G"UYP
MS6&ISJDF&T;*)A0R L,EROAL9,0L@DQ,:RF1$V0#5[A$@P 9U4" 5QE/X2US
M2%H .[[D0(5C]J5"9L"208#KW&P94,Y;[2&C5"KY GDOQ#,C8]BL<U$KD%J=
M7Y ;A88#Q[-RP63G_ /?7?(3>V8%\>S3M\^ ?!$:E#\^>V/L=4'NJ,H)^[WF
M(*S) 0ACMH4TE-^@;"YKD(R<D6@^<_PH@+?OOYOYGO_#B[=^U@^=P/4/++.3
M=Z(LF33^6=,UZ-.N\ )G/D\.#9/$\9+X]?".20V.2(V'P$@96PO%=;<L=)UY
M%!X:)J$3@42OAI^-[DVH84 T\7,GY%I(X ,\%GHXTVY_ZQGX3C)@;H<'S>&[
MB1-&R<%Q&(*X0]WL^"V3!*!FZ$4'QY$;.?/$VQG?/%->&*M OR0*PN5-2\2Q
MX[IN^]B9G3OS6=@^FK#$_(,P;--Y&%MQ$#LSW[PU],Z(!P'E.2[$P2#T/,<+
M0G!S@BL;VOC1]^>.'P;D \2ZW@ZE]OW8268#PP:.ZP7$A\TS8..#!/%LOB-^
M^_T==O%FB9, Z?:Y,Q^B2^+N"4UZ0R5DXM@[WUT<-[3B_:1 2,/)/'ZA4E(P
M[]C?I7/H&3EA,'\U:IQ5B>I?.PYKK?DR\R%T/71=",'F&]^UYCNS),%',1H>
M?1G&D-UA:-3%#K"@A2FO]$"!Y%5:U%!=R1.3:._;WF+8$+ @WV/U$VOL\^0C
M5#4L\K<"D4"STL'B#V4<BC,6<:C,)_C5U&]&4E$I47!L$UDGJ\$M2+4PG[4@
MHI9$+ J^H@C:%'["^@K] T(2,M1\!/V09*?(+1<Y?685>0!(QR0VKJ><8N=&
MS<Z\R 7H5!2( NW60YHJ%$:MF<&*Q79R@F5=*[Z1=<>V_XS))L"(D?\(*+2!
MB2#OAY=DGY#L/9)]ZLGB!,TR8T2(S P03JT074],K#_V7D#N'];\SVW)" "?
M2E&+H=6@/X.41H+02G /NC]3--P+O(@NZ&P >_X+Q*5-A2-P*NK@5'04_/00
MRK']N@6R&>*5QPZMW"):<<C72BP4D\_&5)^J=:UQC0 L!$ (E=R'OXZ*@.>F
M"[6F*;L:P<$(B;.1 66F/RIB/E;&B7@(ZK%9X^6<5BO6^[Q< /EL"([&7?T
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MHC2O.:. T7$!S"\%5 <[0 ;=KS[7_P=02P,$%     @ ;4A/5)+T#ZO!!@
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M:CZAULPVY-:Q(QV)-P6F4<#K_#V$0N^5:8LA=5!6E97D"#GCI38H?O&ZM:B
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MN>H CZQP%O(GNOE$R@'U93R7AFG^'VS*ME8'N%G*:52"!8,HB(M?_%(FH@:
MS@$ *@&H+< N 79;@%,"G+: ?@GHMP4,2L"@+6!8 H:Y6$5V<VEFF./)F-$-
M8+*UB"8/<GUSM% DB.547' F[@8"QR<WSS@(\3(D0$QKL,#B8$:6'"R(F[&
M!R0%[\$C9@S+*0,N9H0+0/I.7/VZF(&+W]Z->USPD-%Z;MGG;=$G.M#G'UE\
M"2S4!<A"L $^U<-OLK6 #W.XU0"?&> )$_"^A,-1 _RC'CXC[B6PX4'R=^WA
M3>3O6\-WR?>$\I7\J)(?Y?'L@_&$UCCVP,<?6<!?:[)WP=VW]X\/X)\_!00\
M<!*E_VHZM*L.[;Q#YT"'\XRYOK .0%< ;\V]5,X]3_))*Q)-\A3QAWE\:;3/
MDZ'E.-"R1#J?ZT+L-]QI<;_? J(^1%NQMD;I5*-TM*/\3%GBT\5K"GX"89)B
MD+0LH!M12?&:"#/G7?!%'*>X\.1-P'TPQTR(P.EAD$:"?D6N?Q[-!U6' [WF
M^%52EY*[. DX#IL\8[ GAMVWBK]F,895]T.]&/@EB+((N#2* IXS$1E>92(#
M[E::\:$T%P2'^[-ECV Q1=NTW!K*5364*WTF"0NH)Q/)",]8W$13'V$$7@EF
MJ4;54<5E=!07D'(Q>X&'.6FBI0^&C+2@I58T2QMK9_W2Q:RMDO \-0.5,T/T
M:YUR5G:PXV^Z>0B5C4.]CR^$^F)O< OF8NM(&",>6/B8Z=.M[!,Z9TJW,D78
M_[7IGI8=U-.-+&W90^6@T&"A.UD6Z\H1TUPY)1R>*>_*T:#>D!ZS:$F8S'I:
MC"PIA?# 11"7%YLVF;,R\*">;V?4/Y!J96O0X&LL< E(!*>\[YR%W.I65YK)
MC/;$[UOPD/!(F1G2F]D3\4B4Y#N$1!+K2AZN6*'$<V(3#T,X,2$O+>MWW<Y1
M>2*";:F5SWY=$,2<"+TX8,W+P,P0$UZ9Z-5VMGK_G!6<9+[$.M7(11\ YFN2
MCHMR2V38]>Z7[RD&BI2!HC,9*%(&BO0&>G(A3\O ]4*V1R.TLZEJ: 4=:W"@
MP)2S(I.SGE#N4[2_6]65NS)@I-^KGE)34T-,<TTILT9ZLVZBQWU!SJ>A=[C2
MIH:PYDI3[HU,[KU7:8IT%Y2;UK_$U/\)R@<#W5.M\FG;.M.#M/)?N[7_MEH:
M#.',2X.MO-<V[%V/4&'W=5,K76JO&^PSZ:*\U]8__!^MBSY<"UV41]N&3>X1
MNIRR0-G*=NW!F711WFJW]M8VNDP-X>!5@R[E*ZH3D-N#4HYL&]X(M%+TRX8>
M]<1@*[^U1^?1T5%6Z_R_6V)#.'-].<J2';V''J/&*?7E* =VSO1BUU%6Z^@W
MN<?6ER&<IDIZM>\=\H/99\S609R"D*Q$*.MR*%R0%=^@BA-.D_P3R))R3J/\
MT"?8(TPV$/=7E/*W$_E5I?H2./D/4$L#!!0    ( &U(3U1Y<IFO> 0  $ 6
M   9    >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;+V86V_;-A3'OPHA]*$%
MVH@769?"-M#$"Q:@&X)ZR1Z&/= 6;0N51)>B[7:??I2LB)(IL<8TY,76Y9S#
M/P]Y?J0X/7'QM=@Q)L'W+,V+F;.3<O_1=8OUCF6TN.%[EJLW&RXR*M6MV+K%
M7C :5TY9ZF((?3>C2>[,I]6S1S&?\H-,DYP]"E <LHR*'[<LY:>9@YR7!U^2
M[4Z6#]SY=$^W;,GDT_Y1J#NWB1(G&<N+A.= L,W,^80^WI%)Z5!9/"?L5+2N
M0=F5%>=?RYN'>.; 4A%+V5J6(:CZ.[([EJ9E)*7C6QW4:=HL'=O7+]'OJ\ZK
MSJQHP>YX^F<2R]W,"1T0LPT]I/(+/_W*Z@Y5 M<\+:I?<*IMH0/6AT+RK'96
M"K(D/__3[W4B6@[(&W# M0.^UH'4#J3JZ%E9U:T%E70^%?P$1&FMHI4756XJ
M;]6;)"^'<2F%>ILH/SG_=*1)2E<I VI*@"55%PNVDF#)U@>1R(05X -8GL<8
M\ VXPO[M@DEE5+Q3GD_+!7C[YAUX Y(<_+'CAX+F<3%UI9)>"G#7M<S;LTP\
M('/!UC> H/< 0XQZW.^N=X===U<EK,D:;K*&JWAD,)[JLNH)^.7;(9$_6KU_
M#^Z?/_S^ /[ZK%S @V19\;>E0=(T2*H&O8$&[W@A^[)V]@HJK[)BCW,,O0F,
MINZQG1W3#'D3WPL:LXXHKQ'E644]Y0H<:?(/B\%6 :-W6,\1_%;+_B2,T(4^
MTRH,R(3TRYLT\B96>?<T$>"9I@?6)VQB-(D#Z$%XH:S'C!#8,NM(\QMIOE5:
MMXJ*LHKB<DH5K7FDK@3+>T?=-Y/J0T-ZCU44A5Z_\J!1'HQ6GO/<(CXP,PH]
M,_&F&?()1'Z__+"1'UKE7[#*4IE1$S%Z'10@J)$-_Q,,:K=.SH@'_? BM7UV
M%AR@UEJ"1@.A#M$9_\@C^%*C:>:'P1 2D 8WPB.@4#M?S+J),3E[[##J3.*N
M/(UY9.?\2##4T7]&ACZS830@O1X@^X(P'@[(7 FBH"?_IIE*OS=$!Z27#&1?
M,Y9,E%N86_"H=I-,R8S!<D>%E11(4Q_YK\0*C6MDY_4@*TR^JN7/0P,)U'Q%
M=L!>A8#0'#TURM% VYK$*!I3VY$YM=1N<*!DL:8QMM-X9,EB$\9#DC2'L9W#
MX^L0F_BU):NU;_X)?KDX47'Y!= -IF&)R>N4$]:$PW;"#943-H%TR2RK25>.
MQA6VX^J::L/F%A9A8B"USRST!T=<,P_;M[KVHL3F)K577(^919RF(QZ_F[55
MB0E10[G-I*M:,Q;;&?L_E'</@?O2'IK?C9:T:U!C.Z@7[,A2OL^4.G!_R.,D
MWX);K@JYQH/M@UESF<!7^D;7W"5V[@Y^I9LT'<@AT20E=I)>4_K$W*8.;U))
MZRS"ODFUES0Q-Y>61C5YR?B]I67&DZOI2S1]B9V^X^NP;B"PY\IM'>^59ZN_
M4;%5(PY2ME%N\"904<3YN/)\(_F^.O%;<2EY5EWN&(V9* W4^PWG\N6F/$1L
M#HWG_P)02P,$%     @ ;4A/5&Q?Q03,!0  #!L  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#4N>&ULQ5E+;]LX$/XKA+&'%$ACD;1D.T@"-''<IN@C2)KV
ML-@#*]&Q4$ET22INBOWQ.Y1DT;%HQFT7< \-17/>,]\,I9.ED-_4G'.-?N19
MH4Y[<ZT7Q_V^BN<\9^I(+'@!O\R$S)F&1WG?5PO)65(1Y5F?!$'4SUE:],Y.
MJKUK>78B2IVE!;^62)5YSN3C.<_$\K2'>ZN-F_1^KLU&_^QDP>[Y+==WBVL)
M3_V62Y+FO%"I*)#DL]/>*WS\FHX-077B<\J7:FV-C"E?A?AF'JZ2TUY@-.(9
MC[5AP>#/ [_@668X@1[?&Z:]5J8A7%^ON$\KX\&8KTSQ"Y%]21,]/^V->BCA
M,U9F^D8LW_#&H-#PBT6FJO_1LCX[!(EQJ;3(&V)XSM.B_LM^-(Y8(P ^;@+2
M$)!-@L$6 MH0T$V": O!H"$8["HA; C"70FBAB#:E6#8$ RK8-7>K4(S89J=
MG4BQ1-*<!FYF4<6WHH:(I(5)Q5LMX=<4Z/39A,OT@9ET0%>%TK*$--,*O40?
MF)3U_L&$:Y9FZ@7LWMU.T,%?+T[Z&F0;#OVXD7->RR%;Y&#T7A1ZKM!ED?#$
M03]YAIYX&/3!Z-9RLK+\G'@YOBVS(T3Q(2(!P0Z%+OSD'\0#D >&'(]=]OC)
M)SSV2K_<G3QPD$]W)G<J__HYUQ4KVS>5?Q(*VB8AK?C17TM"5B3H#4_NT^(>
MO3*0E>J4*S1)59P)54I8__T.6*$KS7/UCT>10:O(H%)D\*PBAZ@0!BM9AE@N
MRD*[O%0S&U;,#.8_G$5!\^^D_^#0(VSU"+UZW"[9 FDNH>!9A=@+]ECYQ)5H
M84<+' 5CNJY$G5+=@S0<#$:=@]/NP2WV1*T]T8Y^10!8&0/3P+&2QQRVG&A0
M\XO6=1U$4= UJGMP$)*0=(UR<(RV1VK86C;T6G97P "0I3]Y@NZA\:,#R$Q
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M93O0\X64YJ5A7T"K_T!&_P!02P,$%     @ ;4A/5$=3;P-!!0  K!@  !D
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MSNTZ4T:&ZUPSBDV37NBJ8%'&\AOPUR-G#.CFVV(1_^W &U9X0V<T)ICIPB(
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M]NKP#*0F%?]];(+\FJ]\]R;HUY6 W[3=L2J@E.H?K(V&;17@URSFNUGLM I
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M1J/6=#T.M>5MZ*F$J!GI4473*"3=DG+@X  -:SL(/[T(-6,^SGK$( RZC%Q
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M:;?6@9_,.K#+$AAN/WTV;%Q &@3A$!OK'?@,WH'[EA!C%H?=1R0'SDPF96S
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MP\$)8\)CSO@CC?L8.8O3..S7>-@E9'AN0N9Y3M?C!2Q02Y6!RN$J4QOW,))
M7;*>$2'I?":O40-IYSY]N1J8I=\I1LH.@[A?!A9\>]&"_U<(^ ?^RQ^4';VM
M[#7D8=_> <9?4*"6?/@CA?RC]L-UES\+O9:U@1)S @:70[K(]*%A.TRLVC0=
MR:VRU-\TPX*:7-3.@/9SI>S#Q#4Y7=L\^1=02P,$%     @ ;4A/5*'""9$K
M!   &0X  !D   !X;"]W;W)K<VAE971S+W-H965T-3,N>&ULQ5?+;MLX%/T5
MPNBB!9)(U%N%8R"Q$TR!%@B2Z70QF 4C75F:2J2'I./D[WLIR;(MRW* 671C
MB])]G</[(*<;(7^J'$"3UZKDZGJ2:[WZ;%DJR:%BZDJL@..73,B*:5S*I:56
M$EA:*U6EY=AV8%6LX)/9M'[W(&=3L=9EP>%!$K6N*B;?;J$4F^L)G6Q?/!;+
M7)L7UFRZ8DMX OU]]2!Q9756TJ("K@K!B83L>G)#/R^H;Q1JB;\*V*B]9V*@
M/ OQTRR^I-<3VT0$)23:F&#X]P)S*$MC">/XKS4ZZ7P:Q?WGK?7[&CR">68*
MYJ+\4:0ZOYY$$Y)"QM:E?A2;/Z %5 >8B%+5OV33RMH3DJR5%E6KC!%4!6_^
MV6M+Q)X"#4XH.*V"TU?P3BBXK8+[7@6O5?!J9AHH-0\+IMEL*L6&2".-ULQ#
M36:MC? +;O;]24O\6J">GLW7U;IDAGMR4V(2,)X 83PE.@?R(,5+4>\P)AB9
MYXPO09&"D[O7%>X;I&3.5$[N44^13(J*W!<<+12L)(_BC97ZC=PH!5J12_*$
M*9NN2R B(X->W^'CXP(T*TKU">U]?UJ0CQ\^D0]&^,]<K!6&K::61E8,-BMI
M&;AM&'!.,$ =\DUPG2MRQU-(#PU82&?'J;/E]-89M;B Y(JX]((XMD,' IJ_
M7]T>4%^\6YW&(VC<+D/<VIY[PEZ[I7Q)'B&!XH4]EW#1WS8)::')5Z$4^?LK
M&B!?-%3JGQ'W7N?>J]U[)]S?PK+@W+A_9J5Q.+3#C8FP-F$ZW<OLDCJ!&SG>
MU'K99WY , HBCT:'<HLA@W'D1''8"1Z@\3LT_BB:+SS![JPPP[6H2RS950([
MH#3950)L*R$QE9#MJBWKJDVVU<;J:ANBJ(DKV$<44R>D=H^A ;G \P/J]!@:
MD',=M'>"H* C*!@E"+/W-Q$4' 'RO"#V_1X_QV)^:,=^W*/G6(RZGF.[T3 ]
M84=/.$K/#UEHN!199KKH$#5#R,*C6!P:FLYT &Q *@YZ];,X%HI]ZI\ %76@
MHO.@R!94TTI*TTK&4,VCXWA]&GK#H<1=*/%H*/.UE, U68$L1$I6!P-P+S10
M%X2#'F([/MYY)Z9NC^UCJ4N*518%P_%3>S?/[5$$.,3.-,O6P&%S"V(O]OJY
MWDH&9_OJ8DBRUU@/\>R=3^CYY#"Y(0%S'6L<^\*)LA[*DM;Z0<;B6+5/A.7L
MPG+.)$I7>W=9AMWG@CPT.8,Y?).*E3G5XIA,_\4S')Z3]<@HI+M13'_++*:[
M84S__S2>T\'IZ82V?X+UW?2DX^/S;'(O6@/G?5M[9^8*Y+*^>RB2B#77S5&O
M>]O=;V[J4WWO_:VY]]1G\9V9YM+TC4ED2Y$2,C1I7X48FVSN(<U"BU5],G\6
M&L_Y]6..=S>01@"_9T+H[<(XZ&Z#LU]02P,$%     @ ;4A/5/1 &T:] @
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M =5D4'?KE+!']!>J%DQHPF%N>-YE;'RNRE.OG*!<%0?'3*(YAHKATOPI@+(
MLS^7$E\F]BRJ_SWZ?P!02P,$%     @ ;4A/5+N4X3DE P  P@@  !D   !X
M;"]W;W)K<VAE971S+W-H965T-34N>&ULO59;;]LV%/XK!T(+)$!C77R+"]M
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MM_23@=IMH.^Y4O8P<0;:WY;Y/U!+ P04    " !M2$]4"U8DW!0%  #J%P
M&0   'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6R]6-MNXS80_17"V ()L(E$
MZF(K< PX=BXN-FVPV6V!%GU@)-HB(HE>DHHW0#^^U,62K%L<-/9+(E%S9N9P
MACPTQQO&GX5/B 0_PR 2EP-?RO6%I@G7)R$6YVQ-(O5ER7B(I7KE*TVL.<%>
M"@H##>FZK8681H/).!U[X),QBV5 (_+ @8C#$//7*Q*PS>4 #K8#7^G*E\F
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M4Z^4>8?BJ* XZJ4X?:%!D!Q6%@OPKUK7W'T&4R'4X>P,//CJ\)%\F"D4=7$
MOG&*@Y[5[111G>-M*5 O-57O)?N[] D':DV&- W1I@NYB^HZ@0A9>FW1W;;9
MZ<JL9G?79N=4S7:Y5,X'\%U<Q&>P5M533^IHF\RKRX2:PQ,L -Y^.6T3DS?B
M6/JYKO_2-_VH3!F]H]>F?S4;39U=BI=WM!TLI0P>4<M@*6:P7\T^JEBW;\0Q
MS;>*58H8W$O%&K/S&:BCZ<X.F'TCB@<'MYS%ZX30=E"H2G\A*^R^YD.,"_"
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M4K(P??0)]@A/#-3W)6-R^Y($**[W)_\!4$L#!!0    ( &U(3U1M8A93W0,
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M#E#GYTQ-B,V.+E"O3$__!U!+ P04    " !M2$]4VI(HH.T&  #Q)   &0
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M:$<=$TPN(0[/(0JBL $^/AX>O(7[Y*^.):ICB1Q?O)./_-X(;51A,X ?'VD
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M=P(J.X">SR4M\*IC3Z+ZRV/T%U!+ P04    " !M2$]4^9-@K 0&  !M'
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M-I0UDN7?MO(30;?Z^\(C%8(F^G!#L.QU"B#OKR@5NQ.U0/F%<?H/4$L#!!0
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MM:*VR_;),++1,_'(F'9E@=O-Q!"%P$0Y8N],W.UI:'(9JA%X8_IRKIFX.]E
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MRK7!Z03Z\[NJ:I]?=!7L?H_B_/]02P,$%     @ ;4A/5&D8<A/3!0  JA<
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M+:'$S+>L<E7_12\M-AJ@Y5[IJF@'PPX*43;_V8_6$$<#8![_ -(.(/: N&<
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MHQ[8D,19E%&;G@>(DR2+>V0 DXX@"1*<-70@[>0M5<YD"?G<L%VCLBJ')Y+
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MR)/-JPS-!UWMZI_>%Y7655%?;L%H7!H ?+^N*OWVP2QP>*'D]G]02P,$%
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M>-CXA18E0[SCP'-M3@N$+W?V.[]X%\T9E<IGBL71T ^DE[DH#>Z,2H;&4N3
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M2]>!*TA\9ELDCW9<!5Q%GD*I*EX5U/T8O><Y7U9;30B )M1C$'A"S1Z^C%K
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M+-WG17%.+RC4;@#USY2RJXIS4+_)1G\!4$L#!!0    ( &U(3U0V-U-F)P(
M 'L%   9    >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;,6446^;,!#'OXK%
MTR9M)2%D22J"U&2=%JFMHE3K'J9I,G" 56,S^PC=MY]M",K6)-K;7L!GW^_O
M^QO.42O5LRX!D+Q47.BE5R+6U[ZOTQ(JJJ]D#<*LY%)5%$VH"E_7"FCFH(K[
MP6CTP:\H$UX<N;FMBB/9(&<"MHKHIJJH^K4"+MNE-_8.$SM6E&@G_#BJ:0&/
M@%_JK3*1/ZADK *AF11$0;[T;L;7Z]#FNX0G!JT^&A/K))'RV0:;;.F-;$'
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MQ+T'=]Y'\?H]%6_^3SCZ#5!+ P04    " !M2$]4EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( &U(3U3"L4WD>P4
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M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ ;4A/5,5K:ZDS!P  &QT  !@              ("!#0@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( &U(3U0;@.C2&@(  &@%   8
M              " @78/  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " !M2$]4K:// @H'  "6'@  &               @('&$0  >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ ;4A/5.:AZX^C P
MYA   !@              ("!!AD  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( &U(3U0+&Y!'&@@  ,4A   8              " @=\<
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !M2$]4_J #
M,\X#  ">#   &               @($O)0  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ ;4A/5&U^@*O\"@  2S@  !@
M ("!,RD  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( &U(
M3U2V:2.YI@(  / '   8              " @64T  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " !M2$]44&@@O X)  #<*0  &
M        @(%!-P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ ;4A/5&)$QF-=#   V24  !D              ("!A4   'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !M2$]4=).GEE0H  "CA0
M&0              @($930  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( &U(3U3%+I:EL@D   PB   9              " @:1U  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ ;4A/5+3Z?!T9
M"0  M!D  !D              ("!C7\  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " !M2$]4X^HL&$D1  "Q/0  &0
M@('=B   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( &U(
M3U04QV$G*0<  #\5   9              " @5V:  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ ;4A/5!@DB'>0!@  OA0  !D
M         ("!O:$  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " !M2$]40*/HAR,#  "R!P  &0              @(&$J   >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( &U(3U2.V_/(40@  & 6
M   9              " @=ZK  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ ;4A/5)U99 3 !   R0P  !D              ("!9K0
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !M2$]4E6>B
M2]T,   *)0  &0              @(%=N0  >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( &U(3U3/Y"T.20P  +LC   9
M  " @7'&  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
M;4A/5!  W4L'!P  OA8  !D              ("!\=(  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " !M2$]4AF>3CZD&  !4#P  &0
M            @($OV@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( &U(3U0O2:*F:@0  &4,   9              " @0_A  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ ;4A/5+(64X*G#
MN2(  !D              ("!L.4  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " !M2$]4 ,E2'=@)   V&   &0              @(&.
M\@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( &U(3U09
M;T:%F0,  !<(   9              " @9W\  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ ;4A/5/09&KOU,0  V*T  !D
M     ("!;0 ! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &U(3U0;+2!Q# 4  ($.   9              "
M@7]* 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ ;4A/
M5+*P%B'. @  J 8  !D              ("!PD\! 'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    " !M2$]4T?K/"?8#   H"@  &0
M        @(''4@$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( &U(3U1LNQ'_9P4  -X.   9              " @?16 0!X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ ;4A/5#B;&=K< P  PPH
M !D              ("!DEP! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    " !M2$]4?+3$,;P&  !G#P  &0              @(&E8 $
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( &U(3U3 NB54
M2 ,  ,4'   9              " @9AG 0!X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ ;4A/5,E(._>8 @  Q 4  !D
M ("!%VL! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " !M
M2$]4P8ON+P4&  !3(   &0              @('F;0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( &U(3U1-C9ME!@<  ,HB   9
M          " @2)T 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#
M%     @ ;4A/5,M)MT%(!0  %1P  !D              ("!7WL! 'AL+W=O
M<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " !M2$]4>7*9KW@$  !
M%@  &0              @('>@ $ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM
M;%!+ 0(4 Q0    ( &U(3U1L7\4$S 4   P;   9              " @8V%
M 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ ;4A/5"^_
M9'U6!   CA,  !D              ("!D(L! 'AL+W=O<FMS:&5E=',O<VAE
M970T-BYX;6Q02P$"% ,4    " !M2$]4AC"DYR(*  "+20  &0
M    @($=D $ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M &U(3U0N'-&[:00   \1   9              " @7:: 0!X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ ;4A/5$=3;P-!!0  K!@  !D
M             ("!%I\! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"
M% ,4    " !M2$]4\H/ZY: "  #Z!@  &0              @(&.I $ >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( &U(3U3 $#)ATP4
M &(@   9              " @66G 0!X;"]W;W)K<VAE971S+W-H965T-3$N
M>&UL4$L! A0#%     @ ;4A/5&AGLYTZ P  0@L  !D              ("!
M;ZT! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " !M2$]4
MH<()D2L$   9#@  &0              @('@L $ >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;%!+ 0(4 Q0    ( &U(3U3T0!M&O0(  (<(   9
M      " @4*U 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%
M  @ ;4A/5+N4X3DE P  P@@  !D              ("!-K@! 'AL+W=O<FMS
M:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " !M2$]4"U8DW!0%  #J%P
M&0              @(&2NP$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+
M 0(4 Q0    ( &U(3U1M8A93W0,  .,/   9              " @=W  0!X
M;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ ;4A/5'713>\K
M!0  I1X  !D              ("!\<0! 'AL+W=O<FMS:&5E=',O<VAE970U
M."YX;6Q02P$"% ,4    " !M2$]4VI(HH.T&  #Q)   &0
M@(%3R@$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( &U(
M3U0LD<M?V@(  (4(   9              " @7?1 0!X;"]W;W)K<VAE971S
M+W-H965T-C N>&UL4$L! A0#%     @ ;4A/5/F38*P$!@  ;1P  !D
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M=#8U+GAM;%!+ 0(4 Q0    ( &U(3U2*VS(8T 8  #,@   9
M  " @1;Z 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @
M;4A/5&=HM,P^!   V0\  !D              ("!'0$" 'AL+W=O<FMS:&5E
M=',O<VAE970V-RYX;6Q02P$"% ,4    " !M2$]415,]%/D"  "?"0  &0
M            @(&2!0( >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4
M Q0    ( &U(3U0V-U-F)P(  'L%   9              " @<(( @!X;"]W
M;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ ;4A/5"(FQGP\ P
M-!0   T              ( !( L" 'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" !M2$]4EXJ[',     3 @  "P              @ &'#@( 7W)E;',O+G)E
M;'-02P$"% ,4    " !M2$]4PK%-Y'L%  #Z+0  #P              @ %P
M#P( >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ ;4A/5)=W<N0L @  ]B@
M !H              ( !&!4" 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ ;4A/5-9((R[W 0  *R@  !,              ( !?!<"
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $T 30 2%0  I!D"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>455</ContextCount>
  <ElementCount>484</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>148</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1006008 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1007009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Purpose</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/OrganizationandPurpose</Role>
      <ShortName>Organization and Purpose</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Available for Sale Debt Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/AvailableforSaleDebtSecurities</Role>
      <ShortName>Available for Sale Debt Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Fair Value Measurements and Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments</Role>
      <ShortName>Fair Value Measurements and Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Financial Royalty Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FinancialRoyaltyAssetsNet</Role>
      <ShortName>Financial Royalty Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets</Role>
      <ShortName>Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2127108 - Disclosure - Intangible Royalty Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet</Role>
      <ShortName>Intangible Royalty Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2131109 - Disclosure - Non-Consolidated Affiliates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/NonConsolidatedAffiliates</Role>
      <ShortName>Non-Consolidated Affiliates</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2133110 - Disclosure - Research &amp; Development ("R&amp;D") Funding Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense</Role>
      <ShortName>Research &amp; Development ("R&amp;D") Funding Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2135111 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/Borrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2140112 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2144113 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2147114 - Disclosure - Indirect Cash Flow</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/IndirectCashFlow</Role>
      <ShortName>Indirect Cash Flow</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2150115 - Disclosure - Accumulated Other Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncome</Role>
      <ShortName>Accumulated Other Comprehensive Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2153116 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2156117 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2158118 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Available for Sale Debt Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables</Role>
      <ShortName>Available for Sale Debt Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/AvailableforSaleDebtSecurities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/DerivativeInstruments</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Fair Value Measurements and Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables</Role>
      <ShortName>Fair Value Measurements and Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2321304 - Disclosure - Financial Royalty Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FinancialRoyaltyAssetsNetTables</Role>
      <ShortName>Financial Royalty Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/FinancialRoyaltyAssetsNet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2324305 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables</Role>
      <ShortName>Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2328306 - Disclosure - Intangible Royalty Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables</Role>
      <ShortName>Intangible Royalty Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2336307 - Disclosure - Borrowings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/BorrowingsTables</Role>
      <ShortName>Borrowings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/Borrowings</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2341308 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/ShareholdersEquity</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2345309 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/EarningsPerShare</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2348310 - Disclosure - Indirect Cash Flow (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/IndirectCashFlowTables</Role>
      <ShortName>Indirect Cash Flow (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/IndirectCashFlow</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2351311 - Disclosure - Accumulated Other Comprehensive Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncome</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2354312 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/RelatedPartyTransactions</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization and Purpose (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/OrganizationandPurposeDetails</Role>
      <ShortName>Organization and Purpose (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/OrganizationandPurpose</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Available for Sale Debt Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails</Role>
      <ShortName>Available for Sale Debt Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails</Role>
      <ShortName>Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Derivative Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails</Role>
      <ShortName>Derivative Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Derivative Instruments - Summary of Derivatives and Reclassifications (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails</Role>
      <ShortName>Derivative Instruments - Summary of Derivatives and Reclassifications (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails</Role>
      <ShortName>Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Fair Value Measurements and Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements and Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails</Role>
      <ShortName>Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Financial Royalty Assets, Net - Summary of Financial Royalty Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails</Role>
      <ShortName>Financial Royalty Assets, Net - Summary of Financial Royalty Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails</Role>
      <ShortName>Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails</Role>
      <ShortName>Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails</Role>
      <ShortName>Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Intangible Royalty Assets, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails</Role>
      <ShortName>Intangible Royalty Assets, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2432416 - Disclosure - Non-Consolidated Affiliates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails</Role>
      <ShortName>Non-Consolidated Affiliates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/NonConsolidatedAffiliates</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Research &amp; Development ("R&amp;D") Funding Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails</Role>
      <ShortName>Research &amp; Development ("R&amp;D") Funding Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2437418 - Disclosure - Borrowings - Schedule of Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails</Role>
      <ShortName>Borrowings - Schedule of Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2438419 - Disclosure - Borrowings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/BorrowingsNarrativeDetails</Role>
      <ShortName>Borrowings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2439420 - Disclosure - Borrowings - Schedule of Repayments of Debt by Year (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails</Role>
      <ShortName>Borrowings - Schedule of Repayments of Debt by Year (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2442421 - Disclosure - Shareholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails</Role>
      <ShortName>Shareholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2443422 - Disclosure - Shareholders' Equity - Summary of Noncontrolling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails</Role>
      <ShortName>Shareholders' Equity - Summary of Noncontrolling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2446423 - Disclosure - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/EarningsPerShareTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2449424 - Disclosure - Indirect Cash Flow (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/IndirectCashFlowDetails</Role>
      <ShortName>Indirect Cash Flow (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/IndirectCashFlowTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2452425 - Disclosure - Accumulated Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2455426 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2457427 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2459428 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://royaltypharma.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://royaltypharma.com/role/SubsequentEvents</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="rprx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - rprx-20211231.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - rprx-20211231.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="rprx-20211231.htm">rprx-20211231.htm</File>
    <File>rprx-20211231.xsd</File>
    <File>rprx-20211231_cal.xml</File>
    <File>rprx-20211231_def.xml</File>
    <File>rprx-20211231_lab.xml</File>
    <File>rprx-20211231_pre.xml</File>
    <File>rprx-20211231ex231.htm</File>
    <File>rprx-20211231ex311.htm</File>
    <File>rprx-20211231ex312.htm</File>
    <File>rprx-20211231ex32.htm</File>
    <File>rprx-20211231ex42.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>rprx-20211231_g1.jpg</File>
    <File>rprx-20211231_g2.jpg</File>
    <File>rprx-20211231_g3.jpg</File>
    <File>rprx-20211231_g4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1067">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>92
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "rprx-20211231.htm": {
   "axisCustom": 1,
   "axisStandard": 42,
   "contextCount": 455,
   "dts": {
    "calculationLink": {
     "local": [
      "rprx-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "rprx-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "rprx-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rprx-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rprx-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rprx-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 714,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 1,
    "http://royaltypharma.com/20211231": 10,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 15
   },
   "keyCustom": 119,
   "keyStandard": 365,
   "memberCustom": 79,
   "memberStandard": 58,
   "nsprefix": "rprx",
   "nsuri": "http://royaltypharma.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://royaltypharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Purpose",
     "role": "http://royaltypharma.com/role/OrganizationandPurpose",
     "shortName": "Organization and Purpose",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Available for Sale Debt Securities",
     "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecurities",
     "shortName": "Available for Sale Debt Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - Derivative Instruments",
     "role": "http://royaltypharma.com/role/DerivativeInstruments",
     "shortName": "Derivative Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Fair Value Measurements and Financial Instruments",
     "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments",
     "shortName": "Fair Value Measurements and Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancingReceivablesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Financial Royalty Assets, Net",
     "role": "http://royaltypharma.com/role/FinancialRoyaltyAssetsNet",
     "shortName": "Financial Royalty Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancingReceivablesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CreditLossFinancialInstrumentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets",
     "role": "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets",
     "shortName": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CreditLossFinancialInstrumentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127108 - Disclosure - Intangible Royalty Assets, Net",
     "role": "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet",
     "shortName": "Intangible Royalty Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131109 - Disclosure - Non-Consolidated Affiliates",
     "role": "http://royaltypharma.com/role/NonConsolidatedAffiliates",
     "shortName": "Non-Consolidated Affiliates",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133110 - Disclosure - Research & Development (\"R&D\") Funding Expense",
     "role": "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense",
     "shortName": "Research & Development (\"R&D\") Funding Expense",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://royaltypharma.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135111 - Disclosure - Borrowings",
     "role": "http://royaltypharma.com/role/Borrowings",
     "shortName": "Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140112 - Disclosure - Shareholders' Equity",
     "role": "http://royaltypharma.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144113 - Disclosure - Earnings Per Share",
     "role": "http://royaltypharma.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147114 - Disclosure - Indirect Cash Flow",
     "role": "http://royaltypharma.com/role/IndirectCashFlow",
     "shortName": "Indirect Cash Flow",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150115 - Disclosure - Accumulated Other Comprehensive Income",
     "role": "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncome",
     "shortName": "Accumulated Other Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153116 - Disclosure - Related Party Transactions",
     "role": "http://royaltypharma.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2156117 - Disclosure - Commitments and Contingencies",
     "role": "http://royaltypharma.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2158118 - Disclosure - Subsequent Events",
     "role": "http://royaltypharma.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Available for Sale Debt Securities (Tables)",
     "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables",
     "shortName": "Available for Sale Debt Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i355f63584077498c9358681b1f440182_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Consolidated Balance Sheets",
     "role": "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i355f63584077498c9358681b1f440182_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NotesAndLoansReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Derivative Instruments (Tables)",
     "role": "http://royaltypharma.com/role/DerivativeInstrumentsTables",
     "shortName": "Derivative Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Fair Value Measurements and Financial Instruments (Tables)",
     "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables",
     "shortName": "Fair Value Measurements and Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321304 - Disclosure - Financial Royalty Assets, Net (Tables)",
     "role": "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetTables",
     "shortName": "Financial Royalty Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324305 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)",
     "role": "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables",
     "shortName": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328306 - Disclosure - Intangible Royalty Assets, Net (Tables)",
     "role": "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables",
     "shortName": "Intangible Royalty Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336307 - Disclosure - Borrowings (Tables)",
     "role": "http://royaltypharma.com/role/BorrowingsTables",
     "shortName": "Borrowings (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341308 - Disclosure - Shareholders' Equity (Tables)",
     "role": "http://royaltypharma.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345309 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://royaltypharma.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348310 - Disclosure - Indirect Cash Flow (Tables)",
     "role": "http://royaltypharma.com/role/IndirectCashFlowTables",
     "shortName": "Indirect Cash Flow (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2351311 - Disclosure - Accumulated Other Comprehensive Income (Tables)",
     "role": "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeTables",
     "shortName": "Accumulated Other Comprehensive Income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i355f63584077498c9358681b1f440182_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rprx:DeferredSharesParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i355f63584077498c9358681b1f440182_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rprx:DeferredSharesParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2354312 - Disclosure - Related Party Transactions (Tables)",
     "role": "http://royaltypharma.com/role/RelatedPartyTransactionsTables",
     "shortName": "Related Party Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization and Purpose (Details)",
     "role": "http://royaltypharma.com/role/OrganizationandPurposeDetails",
     "shortName": "Organization and Purpose (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "ibabbf759907e4aee8080ea0173539d93_D20200211-20200211",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "ifb99eff80794423ca92bd7db72623f54_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rprx:NumberOfNoncontrollingInterestsCreated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "partnership",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "ifb99eff80794423ca92bd7db72623f54_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rprx:NumberOfNoncontrollingInterestsCreated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "partnership",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Available for Sale Debt Securities - Narrative (Details)",
     "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
     "shortName": "Available for Sale Debt Securities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "ia849c0d494314af388e9fb0fc01f197d_D20190405-20190405",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i355f63584077498c9358681b1f440182_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details)",
     "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
     "shortName": "Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i355f63584077498c9358681b1f440182_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i58e8c79f7b7640d089df3eefd8c4584f_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Derivative Instruments - Narrative (Details)",
     "role": "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
     "shortName": "Derivative Instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i58e8c79f7b7640d089df3eefd8c4584f_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i00b63eb6a93e410fa76fd2e629ddcb94_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Derivative Instruments - Summary of Derivatives and Reclassifications (Details)",
     "role": "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails",
     "shortName": "Derivative Instruments - Summary of Derivatives and Reclassifications (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i00b63eb6a93e410fa76fd2e629ddcb94_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i355f63584077498c9358681b1f440182_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TradingSecuritiesDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details)",
     "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails",
     "shortName": "Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i6fb80ebaf7cf4a41b7bb7ee7eecd1a0c_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Fair Value Measurements and Financial Instruments - Narrative (Details)",
     "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
     "shortName": "Fair Value Measurements and Financial Instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i361e783ed15347028eee1b52d6e057f6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details)",
     "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails",
     "shortName": "Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "if100f3b0b4694f76acfbd85a49861791_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Consolidated Statements of Operations",
     "role": "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i81db589362444c02b90538016ac19ba1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "rprx:FinancingReceivablesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details)",
     "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails",
     "shortName": "Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i81db589362444c02b90538016ac19ba1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "rprx:FinancingReceivablesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i355f63584077498c9358681b1f440182_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesReceivableGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Financial Royalty Assets, Net - Summary of Financial Royalty Assets, Net (Details)",
     "role": "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails",
     "shortName": "Financial Royalty Assets, Net - Summary of Financial Royalty Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i355f63584077498c9358681b1f440182_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesReceivableGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i355f63584077498c9358681b1f440182_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Narrative (Details)",
     "role": "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails",
     "shortName": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details)",
     "role": "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails",
     "shortName": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "ifa26755fbc5e413fbf3122ec0db17370_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i355f63584077498c9358681b1f440182_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details)",
     "role": "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails",
     "shortName": "Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i355f63584077498c9358681b1f440182_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i874783a606094b5b9faa8d9db9749829_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Intangible Royalty Assets, Net - Narrative (Details)",
     "role": "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
     "shortName": "Intangible Royalty Assets, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i874783a606094b5b9faa8d9db9749829_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i355f63584077498c9358681b1f440182_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432416 - Disclosure - Non-Consolidated Affiliates (Details)",
     "role": "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails",
     "shortName": "Non-Consolidated Affiliates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "ie3c9990279364489bd57aa8cf39a801b_I20210731",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherCommitment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Research & Development (\"R&D\") Funding Expense (Details)",
     "role": "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails",
     "shortName": "Research & Development (\"R&D\") Funding Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "rprx:ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i355f63584077498c9358681b1f440182_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437418 - Disclosure - Borrowings - Schedule of Borrowings (Details)",
     "role": "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
     "shortName": "Borrowings - Schedule of Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i355f63584077498c9358681b1f440182_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i355f63584077498c9358681b1f440182_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438419 - Disclosure - Borrowings - Narrative (Details)",
     "role": "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
     "shortName": "Borrowings - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "ie681b3df9681426ba637a173be7ba1dc_I20210726",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Consolidated Statements of Comprehensive Income",
     "role": "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i355f63584077498c9358681b1f440182_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439420 - Disclosure - Borrowings - Schedule of Repayments of Debt by Year (Details)",
     "role": "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails",
     "shortName": "Borrowings - Schedule of Repayments of Debt by Year (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i2faebe6b2bb249f9bacffbdee1da7d22_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i355f63584077498c9358681b1f440182_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rprx:NumberOfClassesOfVotingStock",
      "reportCount": 1,
      "unitRef": "class",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442421 - Disclosure - Shareholders' Equity - Narrative (Details)",
     "role": "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails",
     "shortName": "Shareholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DividendsCommonStockCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "id30f26bcb6cd4b64982e6cd53528c44e_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443422 - Disclosure - Shareholders' Equity - Summary of Noncontrolling Interests (Details)",
     "role": "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
     "shortName": "Shareholders' Equity - Summary of Noncontrolling Interests (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "ie11ab38cff9248ce8459b4a78a07f67c_D20200618-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i355f63584077498c9358681b1f440182_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rprx:CommonStockExchangeRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446423 - Disclosure - Earnings Per Share (Details)",
     "role": "http://royaltypharma.com/role/EarningsPerShareDetails",
     "shortName": "Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i355f63584077498c9358681b1f440182_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rprx:CommonStockExchangeRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "ie1399e8120f4459da1c98eaec460657b_D20200618-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449424 - Disclosure - Indirect Cash Flow (Details)",
     "role": "http://royaltypharma.com/role/IndirectCashFlowDetails",
     "shortName": "Indirect Cash Flow (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "rprx:IncreaseDecreaseInFinancialRoyaltyAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452425 - Disclosure - Accumulated Other Comprehensive Income (Details)",
     "role": "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails",
     "shortName": "Accumulated Other Comprehensive Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i355f63584077498c9358681b1f440182_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DueToRelatedPartiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455426 - Disclosure - Related Party Transactions (Details)",
     "role": "http://royaltypharma.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i355f63584077498c9358681b1f440182_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DueToRelatedPartiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rprx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457427 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://royaltypharma.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "rprx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "if022a6e3714949948eb2520d7c7ab729_D20220101-20220131",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "rprx:PaymentsToAcquireRoyaltyInterestsAggregateAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459428 - Disclosure - Subsequent Events (Details)",
     "role": "http://royaltypharma.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "if022a6e3714949948eb2520d7c7ab729_D20220101-20220131",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "rprx:PaymentsToAcquireRoyaltyInterestsAggregateAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i7242e01e0d3e49c99430b9b17185b69d_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Consolidated Statements of Shareholders' Equity",
     "role": "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
     "shortName": "Consolidated Statements of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i7242e01e0d3e49c99430b9b17185b69d_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockDividendsPerShareCashPaid",
       "us-gaap:CommonStockDividendsPerShareCashPaid",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i08c8a6f2c3554638b8b9e8e94b41d3ab_D20211001-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006008 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)",
     "role": "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Shareholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007009 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rprx-20211231.htm",
      "contextRef": "i3422c7350bb14d2d869ff498fa12e855_D20200101-20200617",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - rprx-20211231.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - rprx-20211231.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 148,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r730",
      "r731",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r730",
      "r731",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r730",
      "r731",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r730",
      "r731",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r730",
      "r731",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://royaltypharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "rprx_A2020EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Equity Incentive Plan",
        "label": "2020 Equity Incentive Plan [Member]",
        "terseLabel": "2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "A2020EquityIncentivePlanMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_AZAssetPhaseIIAndPhaseIIIClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AZ Asset - Phase II and Phase III Clinical Trial",
        "label": "AZ Asset - Phase II and Phase III Clinical Trial [Member]",
        "terseLabel": "AZ Asset - Phase II and Phase III Clinical Trial"
       }
      }
     },
     "localname": "AZAssetPhaseIIAndPhaseIIIClinicalTrialMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_AccruedPurchaseObligationCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Purchase Obligation, Current",
        "label": "Accrued Purchase Obligation, Current",
        "terseLabel": "Accrued purchase obligation"
       }
      }
     },
     "localname": "AccruedPurchaseObligationCurrent",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_AccruedPurchaseObligationEquityInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Purchase Obligation, Equity Investment",
        "label": "Accrued Purchase Obligation, Equity Investment",
        "terseLabel": "Accrued purchase obligation - Tazverik"
       }
      }
     },
     "localname": "AccruedPurchaseObligationEquityInvestment",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_AccruedRoyaltyReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Royalty Receivable",
        "label": "Accrued Royalty Receivable",
        "terseLabel": "Accrued royalty receivable"
       }
      }
     },
     "localname": "AccruedRoyaltyReceivable",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition Of Limited Partnership Interests In Affiliate",
        "label": "Acquisition Of Limited Partnership Interests In Affiliate [Member]",
        "terseLabel": "Acquisition Of Limited Partnership Interests In Affiliate"
       }
      }
     },
     "localname": "AcquisitionOfLimitedPartnershipInterestsInAffiliateMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_AgreementWithMSCIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement with MSCI",
        "label": "Agreement with MSCI [Member]",
        "terseLabel": "Agreement with MSCI"
       }
      }
     },
     "localname": "AgreementWithMSCIMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_AssetsFairValueDisclosureCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets, Fair Value Disclosure, Current",
        "label": "Assets, Fair Value Disclosure, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureCurrent",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_AssetsFairValueDisclosureNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets, Fair Value Disclosure, Noncurrent",
        "label": "Assets, Fair Value Disclosure, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureNoncurrent",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_AssignmentAgreementBenefitOfPaymentStreamMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assignment Agreement - Benefit of Payment Stream",
        "label": "Assignment Agreement - Benefit of Payment Stream [Member]",
        "terseLabel": "Assignment Agreement - Benefit of Payment Stream"
       }
      }
     },
     "localname": "AssignmentAgreementBenefitOfPaymentStreamMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_AssignmentAgreementFundingObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assignment Agreement - Funding Obligations",
        "label": "Assignment Agreement - Funding Obligations [Member]",
        "terseLabel": "Assignment Agreement - Funding Obligations"
       }
      }
     },
     "localname": "AssignmentAgreementFundingObligationsMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://royaltypharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "rprx_AvillionEntitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Avillion Entities",
        "label": "Avillion Entities [Member]",
        "terseLabel": "Avillion Entities"
       }
      }
     },
     "localname": "AvillionEntitiesMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_AvillionIIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Avillion II",
        "label": "Avillion II [Member]",
        "terseLabel": "Avillion II"
       }
      }
     },
     "localname": "AvillionIIMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_AvillionIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Avillion I",
        "label": "Avillion I [Member]",
        "terseLabel": "Avillion I"
       }
      }
     },
     "localname": "AvillionIMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_BioCrystPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BioCryst Pharmaceuticals, Inc.",
        "label": "BioCryst Pharmaceuticals, Inc. [Member]",
        "terseLabel": "BioCryst Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "BioCrystPharmaceuticalsIncMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_BristolMyersSquibbMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol-Myers Squibb",
        "label": "Bristol-Myers Squibb [Member]",
        "terseLabel": "Bristol-Myers Squibb"
       }
      }
     },
     "localname": "BristolMyersSquibbMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_ClassBHoldersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class B Holders",
        "label": "Class B Holders [Member]",
        "terseLabel": "Class B Holders"
       }
      }
     },
     "localname": "ClassBHoldersMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_ClassRRedeemableStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class R Redeemable Stock",
        "label": "Class R Redeemable Stock [Member]",
        "terseLabel": "Class R Redeemable Stock"
       }
      }
     },
     "localname": "ClassRRedeemableStockMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_CollaborativeArrangementRightsAndObligationsExpectedReturn": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Expected Return",
        "label": "Collaborative Arrangement, Rights and Obligations, Expected Return",
        "terseLabel": "Expected return (as a percent)"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsExpectedReturn",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rprx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments",
        "label": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments",
        "terseLabel": "Maximum milestone payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund",
        "label": "Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund",
        "terseLabel": "Maximum commitment to fund collaborative arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Payment of Capital",
        "label": "Collaborative Arrangement, Rights and Obligations, Payment of Capital",
        "terseLabel": "Payment of capital"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsPaymentOfCapital",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Payment of Capital, Term",
        "label": "Collaborative Arrangement, Rights and Obligations, Payment of Capital, Term",
        "terseLabel": "Payment of capital term"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Period of Return",
        "label": "Collaborative Arrangement, Rights and Obligations, Period of Return",
        "terseLabel": "Period of return"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsPeriodOfReturn",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Period of Return, Start Date",
        "label": "Collaborative Arrangement, Rights and Obligations, Period of Return, Start Date",
        "terseLabel": "Period of return start date"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rprx_CommonStockExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Exchange Ratio",
        "label": "Common Stock, Exchange Ratio",
        "terseLabel": "Exchange ratio"
       }
      }
     },
     "localname": "CommonStockExchangeRatio",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "rprx_ContinuingInvestorsPartnershipMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Continuing Investors Partnership",
        "label": "Continuing Investors Partnership [Member]",
        "terseLabel": "Continuing Investors Partnerships"
       }
      }
     },
     "localname": "ContinuingInvestorsPartnershipMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_CysticFibrosisFranchiseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cystic Fibrosis Franchise",
        "label": "Cystic Fibrosis Franchise [Member]",
        "terseLabel": "Cystic fibrosis franchise"
       }
      }
     },
     "localname": "CysticFibrosisFranchiseMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_DPPIVPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DPP-IV Patents",
        "label": "DPP-IV Patents [Member]",
        "terseLabel": "DPP-IV patents"
       }
      }
     },
     "localname": "DPPIVPatentsMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio",
        "label": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio",
        "terseLabel": "Maximum consolidated leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition",
        "label": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition",
        "terseLabel": "Maximum consolidated leverage ratio following qualifying material acquisition"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio",
        "label": "Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio",
        "terseLabel": "Minimum consolidated coverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "rprx_DebtInstrumentIssuanceAsAPercentOfPar": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Issuance As A Percent Of Par",
        "label": "Debt Instrument, Issuance As A Percent Of Par",
        "terseLabel": "Debt issued as a percent of par value (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentIssuanceAsAPercentOfPar",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Change In Control Event, Period",
        "label": "Debt Securities, Available-For-Sale, Change In Control Event, Period",
        "terseLabel": "Change in control event, period"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleChangeInControlEventPeriod",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleFixedPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Fixed Payment",
        "label": "Debt Securities, Available-for-Sale, Fixed Payment",
        "terseLabel": "Preferred shares, fixed payment amount"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleFixedPayment",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Number Of Shares Purchased",
        "label": "Debt Securities, Available-For-Sale, Number Of Shares Purchased",
        "terseLabel": "Number of shares purchased (in shares)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleNumberOfSharesPurchased",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available For Sale, Policy",
        "label": "Debt Securities, Available For Sale, Policy [Policy Text Block]",
        "terseLabel": "Equity securities and Available for sale debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSalePolicyPolicyTextBlock",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rprx_DebtSecuritiesAvailableForSalePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Price Per Share",
        "label": "Debt Securities, Available-For-Sale, Price Per Share",
        "terseLabel": "Price per share (in USD per share)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSalePricePerShare",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Quarterly Payments",
        "label": "Debt Securities, Available-for-Sale, Quarterly Payments",
        "terseLabel": "Preferred shares, quarterly payments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleQuarterlyPayments",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Redemption Default, Interest Rate",
        "label": "Debt Securities, Available-For-Sale, Redemption Default, Interest Rate",
        "terseLabel": "Redemption default, interest rate"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Redemption, Default Period",
        "label": "Debt Securities, Available-For-Sale, Redemption, Default Period",
        "terseLabel": "Default period"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Redemption Default, Threshold Period",
        "label": "Debt Securities, Available-For-Sale, Redemption Default, Threshold Period",
        "terseLabel": "Redemption default, threshold period"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Redemption, Period",
        "label": "Debt Securities, Available-For-Sale, Redemption, Period [Axis]",
        "terseLabel": "Debt Securities, Available-For-Sale, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRedemptionPeriodAxis",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Redemption, Period",
        "label": "Debt Securities, Available-For-Sale, Redemption, Period [Domain]",
        "terseLabel": "Debt Securities, Available-For-Sale, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRedemptionPeriodDomain",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Redemption, Period One",
        "label": "Debt Securities, Available-For-Sale, Redemption, Period One [Member]",
        "terseLabel": "Redemption, Period One"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Redemption, Period Two",
        "label": "Debt Securities, Available-For-Sale, Redemption, Period Two [Member]",
        "terseLabel": "Redemption, Period Two"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Redemption Price, Percentage",
        "label": "Debt Securities, Available-For-Sale, Redemption Price, Percentage",
        "terseLabel": "Redemption price, percentage"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRedemptionPricePercentage",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Restriction Period",
        "label": "Debt Securities, Available-For-Sale, Restriction Period",
        "terseLabel": "Restrictions on selling common stock, period"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRestrictionPeriod",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital",
        "label": "Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital",
        "terseLabel": "Preferred shares, weighted average cost of capital"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rprx_DeferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Shares",
        "label": "Deferred Shares [Member]",
        "terseLabel": "Deferred Shares",
        "verboseLabel": "Deferred Shares"
       }
      }
     },
     "localname": "DeferredSharesMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_DeferredSharesParOrStatedValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Shares, Par or Stated Value Per Share",
        "label": "Deferred Shares, Par or Stated Value Per Share",
        "terseLabel": "Deferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "DeferredSharesParOrStatedValuePerShare",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "rprx_DeferredSharesSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Shares, Shares, Issued",
        "label": "Deferred Shares, Shares, Issued",
        "terseLabel": "Deferred stock, issued (in shares)"
       }
      }
     },
     "localname": "DeferredSharesSharesIssued",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "rprx_DeferredSharesSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Shares, Shares, Outstanding",
        "label": "Deferred Shares, Shares, Outstanding",
        "terseLabel": "Deferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "DeferredSharesSharesOutstanding",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "rprx_DeferredSharesValueIssued": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Shares, Value, Issued",
        "label": "Deferred Shares, Value, Issued",
        "terseLabel": "Deferred shares, $0.000001 par value, 361,170 and 316,407 issued and outstanding, respectively"
       }
      }
     },
     "localname": "DeferredSharesValueIssued",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_DevelopmentFundingBondForwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Funding Bond Forward",
        "label": "Development Funding Bond Forward [Member]",
        "terseLabel": "Development Funding Bond Forward"
       }
      }
     },
     "localname": "DevelopmentFundingBondForwardMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_EPAHoldingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EPA Holdings",
        "label": "EPA Holdings [Member]",
        "terseLabel": "EPA Holdings"
       }
      }
     },
     "localname": "EPAHoldingsMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_EpizymeCommonStockWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Epizyme Common Stock Warrant",
        "label": "Epizyme Common Stock Warrant [Member]",
        "terseLabel": "Epizyme Common Stock Warrant"
       }
      }
     },
     "localname": "EpizymeCommonStockWarrantMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_EpizymeIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Epizyme Inc.",
        "label": "Epizyme Inc. [Member]",
        "terseLabel": "Equity Investment In Epizyme Inc."
       }
      }
     },
     "localname": "EpizymeIncMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_EquityMethodInvestmentsUnfundedCommitments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments, Unfunded Commitments",
        "label": "Equity Method Investments, Unfunded Commitments",
        "terseLabel": "Equity method investment, unfunded commitments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsUnfundedCommitments",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_EvrysdiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evrysdi",
        "label": "Evrysdi [Member]",
        "terseLabel": "Evrysdi"
       }
      }
     },
     "localname": "EvrysdiMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_ExchangeOfferTransactionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange Offer Transaction",
        "label": "Exchange Offer Transaction [Member]",
        "terseLabel": "Exchange Offer Transaction"
       }
      }
     },
     "localname": "ExchangeOfferTransactionMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss), After Transfer To Level 3",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss), After Transfer To Level 3",
        "terseLabel": "Unrealized gains on available for sale debt securities"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions",
        "terseLabel": "Redemption"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FinancialRoyaltyAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Royalty Assets",
        "label": "Financial Royalty Assets [Member]",
        "terseLabel": "Income from financial royalty assets"
       }
      }
     },
     "localname": "FinancialRoyaltyAssetsMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows",
        "label": "Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows",
        "negatedLabel": "Cumulative allowance for changes in expected cash flows"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NotesReceivableNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)",
        "label": "Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)",
        "negatedLabel": "Cumulative allowance for credit losses"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Financial Royalty Asset, Writeoff",
        "label": "Financing Receivable, Allowance for Credit Loss, Financial Royalty Asset, Writeoff",
        "terseLabel": "Writeoff related to financial royalty asset"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense",
        "label": "Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense",
        "terseLabel": "Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets"
       }
      }
     },
     "localname": "FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense",
        "label": "Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense",
        "negatedTerseLabel": "Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets"
       }
      }
     },
     "localname": "FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents",
        "label": "Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents",
        "terseLabel": "Aggregate royalty amount when patents cease"
       }
      }
     },
     "localname": "FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NotesReceivableNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows",
        "label": "Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows",
        "totalLabel": "Net carrying value, before cumulative allowance for credit losses"
       }
      }
     },
     "localname": "FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FinancingReceivablesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivables, Fair Value Disclosure",
        "label": "Financing Receivables, Fair Value Disclosure",
        "terseLabel": "Financial royalty assets, net"
       }
      }
     },
     "localname": "FinancingReceivablesFairValueDisclosure",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_FormerOperatingAndPersonnelPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Operating and Personnel Payments",
        "label": "Former Operating and Personnel Payments [Member]",
        "terseLabel": "Former Operating and Personnel Payments"
       }
      }
     },
     "localname": "FormerOperatingAndPersonnelPaymentsMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_FundingAgreementWithBioCrystMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding Agreement With BioCryst",
        "label": "Funding Agreement With BioCryst [Member]",
        "terseLabel": "Funding Agreement With BioCryst"
       }
      }
     },
     "localname": "FundingAgreementWithBioCrystMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_FundingAgreementsWithPfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding Agreements With Pfizer",
        "label": "Funding Agreements With Pfizer [Member]",
        "terseLabel": "Funding Agreements With Pfizer"
       }
      }
     },
     "localname": "FundingAgreementsWithPfizerMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_FundingAgreementsWithSanofiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding Agreements With Sanofi",
        "label": "Funding Agreements With Sanofi [Member]",
        "terseLabel": "Funding Agreements With Sanofi"
       }
      }
     },
     "localname": "FundingAgreementsWithSanofiMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_GainLossOnDerivativeFinancialInstruments": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Derivative Financial Instruments",
        "label": "Gain (Loss) On Derivative Financial Instruments",
        "negatedTerseLabel": "Termination of derivative financial instruments"
       }
      }
     },
     "localname": "GainLossOnDerivativeFinancialInstruments",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_IPOContinuingInvestorsPartnershipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IPO - Continuing Investors Partnerships",
        "label": "IPO - Continuing Investors Partnerships [Member]",
        "terseLabel": "Public Stock Offering - Continuing Investors Partnerships Interests"
       }
      }
     },
     "localname": "IPOContinuingInvestorsPartnershipsMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_IPOSharesFromCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IPO - Shares From Company",
        "label": "IPO - Shares From Company [Member]",
        "terseLabel": "IPO - Shares From Company"
       }
      }
     },
     "localname": "IPOSharesFromCompanyMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_IPOSharesFromSellingShareholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IPO - Shares From Selling Shareholders",
        "label": "IPO - Shares From Selling Shareholders [Member]",
        "terseLabel": "IPO - Shares From Selling Shareholders"
       }
      }
     },
     "localname": "IPOSharesFromSellingShareholdersMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_ImbruvicaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Imbruvica",
        "label": "Imbruvica [Member]",
        "terseLabel": "Imbruvica"
       }
      }
     },
     "localname": "ImbruvicaMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_IncreaseDecreaseInAccruedRoyaltyReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accrued Royalty Receivable",
        "label": "Increase (Decrease) In Accrued Royalty Receivable",
        "negatedTerseLabel": "Accrued royalty receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedRoyaltyReceivable",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Cash Collections On Financing Receivables",
        "label": "Increase (Decrease) In Cash Collections On Financing Receivables",
        "terseLabel": "Cash collected on financial royalty assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashCollectionsOnFinancingReceivables",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_IncreaseDecreaseInDebtSecuritiesAvailableForSale": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Debt Securities, Available For Sale",
        "label": "Increase (Decrease) In Debt Securities, Available For Sale",
        "negatedTerseLabel": "Available for sale debt securities"
       }
      }
     },
     "localname": "IncreaseDecreaseInDebtSecuritiesAvailableForSale",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_IncreaseDecreaseInFinancialRoyaltyAssets": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Financial Royalty Assets",
        "label": "Increase (Decrease) In Financial Royalty Assets",
        "negatedTerseLabel": "Income from financial royalty assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInFinancialRoyaltyAssets",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Other Royalty Income Receivable",
        "label": "Increase (Decrease) In Other Royalty Income Receivable",
        "negatedTerseLabel": "Other royalty income receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherRoyaltyIncomeReceivable",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_IndividualLicenseesConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Individual Licensees Concentration Risk",
        "label": "Individual Licensees Concentration Risk [Member]",
        "terseLabel": "Individual Licensees Concentration List"
       }
      }
     },
     "localname": "IndividualLicenseesConcentrationRiskMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_IntangibleRoyaltyAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Royalty Assets",
        "label": "Intangible Royalty Assets [Member]",
        "terseLabel": "Revenue from intangible royalty assets"
       }
      }
     },
     "localname": "IntangibleRoyaltyAssetsMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss)",
        "label": "Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss)",
        "negatedTerseLabel": "Interest income accretion"
       }
      }
     },
     "localname": "InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_LegacyInvestorsPartnershipsAndRPSFTMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legacy Investors Partnerships and RPSFT",
        "label": "Legacy Investors Partnerships and RPSFT [Member]",
        "terseLabel": "Legacy Investors Partnerships and RPSFT"
       }
      }
     },
     "localname": "LegacyInvestorsPartnershipsAndRPSFTMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legacy Investors Partnerships and Royalty Pharma Select Finance Trust",
        "label": "Legacy Investors Partnerships and Royalty Pharma Select Finance Trust [Member]",
        "terseLabel": "RPSFT"
       }
      }
     },
     "localname": "LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_LegacyInvestorsPartnershipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legacy Investors Partnerships",
        "label": "Legacy Investors Partnerships [Member]",
        "terseLabel": "Legacy Investors Partnerships"
       }
      }
     },
     "localname": "LegacyInvestorsPartnershipsMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Partnership, Additional Payments, Aggregate Amount",
        "label": "Long Term Funding Partnership, Additional Payments, Aggregate Amount",
        "terseLabel": "Long term funding partnership, additional payments, aggregate amount"
       }
      }
     },
     "localname": "LongTermFundingPartnershipAdditionalPaymentsAggregateAmount",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_LongTermFundingPartnershipAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Partnership, Amount",
        "label": "Long Term Funding Partnership, Amount",
        "terseLabel": "Long term funding partnership, amount"
       }
      }
     },
     "localname": "LongTermFundingPartnershipAmount",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_LongTermFundingPartnershipInitialPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Partnership, Initial Payment",
        "label": "Long Term Funding Partnership, Initial Payment",
        "terseLabel": "Long term funding partnership, initial payment"
       }
      }
     },
     "localname": "LongTermFundingPartnershipInitialPayment",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_LongTermFundingPartnershipNumberOfAdditionalPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Partnership, Number of Additional Payments",
        "label": "Long Term Funding Partnership, Number of Additional Payments",
        "terseLabel": "Long term funding partnership, number of additional payments"
       }
      }
     },
     "localname": "LongTermFundingPartnershipNumberOfAdditionalPayments",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rprx_LongTermFundingPartnershipNumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Funding Partnership, Number of Tranches",
        "label": "Long Term Funding Partnership, Number of Tranches",
        "terseLabel": "Long term funding partnership, number of tranches"
       }
      }
     },
     "localname": "LongTermFundingPartnershipNumberOfTranches",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rprx_LongTermPurchaseCommitmentAmountOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Purchase Commitment, Amount Outstanding",
        "label": "Long Term Purchase Commitment, Amount Outstanding",
        "terseLabel": "Remaining commitment"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentAmountOutstanding",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Purchase Commitment, Funding Agreement With Biohaven Pharmaceuticals",
        "label": "Long Term Purchase Commitment, Funding Agreement With Biohaven Pharmaceuticals [Member]",
        "terseLabel": "Funding Agreement With Biohaven Pharmaceuticals"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Purchase Commitment, Purchase Of Eisai Royalties",
        "label": "Long Term Purchase Commitment, Purchase Of Eisai Royalties [Member]",
        "terseLabel": "Purchase Of Eisai Royalties"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_MerckAssetPhaseIIClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck Asset - Phase II Clinical Trial",
        "label": "Merck Asset - Phase II Clinical Trial [Member]",
        "terseLabel": "Merck Asset - Phase II Clinical Trial"
       }
      }
     },
     "localname": "MerckAssetPhaseIIClinicalTrialMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_MilestonePaymentAccruedButNotPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Accrued But Not Paid",
        "label": "Milestone Payment Accrued But Not Paid",
        "terseLabel": "Milestone payable - Erleada"
       }
      }
     },
     "localname": "MilestonePaymentAccruedButNotPaid",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_MorphoSysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MorphoSys",
        "label": "MorphoSys [Member]",
        "terseLabel": "MorphoSys"
       }
      }
     },
     "localname": "MorphoSysMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails",
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_NetIncomeLossAttributableToParentPriorToOffering": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/EarningsPerShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Income (Loss) Attributable to Parent, Prior To Offering",
        "label": "Net Income (Loss) Attributable to Parent, Prior To Offering",
        "terseLabel": "Less: net income attributable to Continuing Investors Partnerships prior to the IPO"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToParentPriorToOffering",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_NoncontrollingInterestIncreaseFromContributions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Increase from Contributions",
        "label": "Noncontrolling Interest, Increase from Contributions",
        "terseLabel": "Contributions"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromContributions",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_NoncontrollingInterestTransfersOfInterests": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Transfers Of Interests",
        "label": "Noncontrolling Interest, Transfers Of Interests",
        "terseLabel": "Transfer of interests"
       }
      }
     },
     "localname": "NoncontrollingInterestTransfersOfInterests",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_NumberOfClassesOfVotingStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Classes Of Voting Stock",
        "label": "Number Of Classes Of Voting Stock",
        "terseLabel": "Number of classes of voting shares"
       }
      }
     },
     "localname": "NumberOfClassesOfVotingStock",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rprx_NumberOfNoncontrollingInterests": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Noncontrolling Interests",
        "label": "Number of Noncontrolling Interests",
        "terseLabel": "Number of noncontrolling interests"
       }
      }
     },
     "localname": "NumberOfNoncontrollingInterests",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rprx_NumberOfNoncontrollingInterestsCreated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Noncontrolling Interests Created",
        "label": "Number Of Noncontrolling Interests Created",
        "terseLabel": "Number of noncontrolling interests created"
       }
      }
     },
     "localname": "NumberOfNoncontrollingInterestsCreated",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rprx_OldCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Old Credit Facility",
        "label": "Old Credit Facility [Member]",
        "terseLabel": "Old Credit Facility"
       }
      }
     },
     "localname": "OldCreditFacilityMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_OnePointSevenFivePercentSeniorNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Seven Five Percent Senior Notes Due 2027",
        "label": "One Point Seven Five Percent Senior Notes Due 2027 [Member]",
        "terseLabel": "One Point Seven Five Percent Senior Notes Due 2027"
       }
      }
     },
     "localname": "OnePointSevenFivePercentSeniorNotesDue2027Member",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Two Zero Percent Senior Notes Due 2025",
        "label": "One Point Two Zero Percent Senior Notes Due 2025 [Member]",
        "terseLabel": "One Point Two Zero Percent Senior Notes Due 2025"
       }
      }
     },
     "localname": "OnePointTwoZeroPercentSeniorNotesDue2025Member",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_OperatingAndPersonnelPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and Personnel Payments",
        "label": "Operating and Personnel Payments [Member]",
        "terseLabel": "Operating and Personnel Payments"
       }
      }
     },
     "localname": "OperatingAndPersonnelPaymentsMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_OptionIndexedToIssuersEquityTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Indexed to Issuer's Equity, Term",
        "label": "Option Indexed to Issuer's Equity, Term",
        "terseLabel": "Put option, term (in months)"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTerm",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rprx_OptionIndexedToIssuersEquityValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Indexed To Issuers Equity, Value",
        "label": "Option Indexed To Issuers Equity, Value",
        "terseLabel": "Put option to sell additional common stock"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityValue",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_OtherCommitmentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Commitments, Percentage",
        "label": "Other Commitments, Percentage",
        "terseLabel": "Other commitments, percentage of costs (as a percent)"
       }
      }
     },
     "localname": "OtherCommitmentsPercentage",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss) Reclassification Adjustment, Attributable From Noncontrolling Interest",
        "label": "Other Comprehensive Income (Loss) Reclassification Adjustment, Attributable From Noncontrolling Interest",
        "terseLabel": "Reclassification from non-controlling interest"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Reclassification Adjustment, Attributable to Noncontrolling Interest",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Reclassification to non-controlling interest"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_OtherFinancialRoyaltyAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Financial Royalty Asset",
        "label": "Other Financial Royalty Asset [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherFinancialRoyaltyAssetMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_OtherRoyaltyIncomeReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Royalty Income Receivable, Current",
        "label": "Other Royalty Income Receivable, Current",
        "terseLabel": "Other royalty income receivable"
       }
      }
     },
     "localname": "OtherRoyaltyIncomeReceivableCurrent",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_OvernightBankFundingRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Overnight Bank Funding Rate",
        "label": "Overnight Bank Funding Rate [Member]",
        "terseLabel": "Overnight Bank Funding Rate"
       }
      }
     },
     "localname": "OvernightBankFundingRateMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_PabloLegorretaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pablo Legorreta",
        "label": "Pablo Legorreta [Member]",
        "terseLabel": "Pablo Legorreta"
       }
      }
     },
     "localname": "PabloLegorretaMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_PaymentOfDividendsToShareholders": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Of Dividends To Shareholders",
        "label": "Payment Of Dividends To Shareholders",
        "negatedTerseLabel": "Dividends to shareholders"
       }
      }
     },
     "localname": "PaymentOfDividendsToShareholders",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsForCollateralPostedOnDerivativeInstruments": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Collateral Posted On Derivative Instruments",
        "label": "Payments For Collateral Posted On Derivative Instruments",
        "negatedTerseLabel": "Derivative collateral posted"
       }
      }
     },
     "localname": "PaymentsForCollateralPostedOnDerivativeInstruments",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsForDistributionsToShareholdersAndUnitholders": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Distributions To Shareholders and Unitholders",
        "label": "Payments For Distributions To Shareholders and Unitholders",
        "negatedLabel": "Distributions to shareholders/unitholders"
       }
      }
     },
     "localname": "PaymentsForDistributionsToShareholdersAndUnitholders",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsForMilestones": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Milestones",
        "label": "Payments For Milestones",
        "negatedTerseLabel": "Milestone payments"
       }
      }
     },
     "localname": "PaymentsForMilestones",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsForOngoingDevelopmentStageFunding": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Ongoing Development Stage Funding",
        "label": "Payments For Ongoing Development Stage Funding",
        "negatedTerseLabel": "Ongoing development-stage funding payments"
       }
      }
     },
     "localname": "PaymentsForOngoingDevelopmentStageFunding",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsForOperatingCostsAndProfessionalServices": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Operating Costs and Professional Services",
        "label": "Payments For Operating Costs and Professional Services",
        "negatedTerseLabel": "Payments for operating and professional costs"
       }
      }
     },
     "localname": "PaymentsForOperatingCostsAndProfessionalServices",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsForUpfrontDevelopmentStageFunding": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Upfront Development Stage Funding",
        "label": "Payments For Upfront Development Stage Funding",
        "negatedTerseLabel": "Upfront development-stage funding payments"
       }
      }
     },
     "localname": "PaymentsForUpfrontDevelopmentStageFunding",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Acquire Equity Investments, Upfront Payment",
        "label": "Payments to Acquire Equity Investments, Upfront Payment",
        "terseLabel": "Upfront payment for equity investment"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityInvestmentsUpfrontPayment",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsToAcquireEquitySecuritiesFNNI": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Equity Securities, FN-NI",
        "label": "Payments To Acquire Equity Securities, FN-NI",
        "negatedTerseLabel": "Purchases of equity securities"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesFNNI",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Royalty Interest, Additional Milestone Payments",
        "label": "Payments To Acquire Royalty Interest, Additional Milestone Payments",
        "terseLabel": "Payments to acquire royalty interests, additional milestone payments"
       }
      }
     },
     "localname": "PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsToAcquireRoyaltyInterestsAggregateAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Royalty Interests, Aggregate Amount",
        "label": "Payments To Acquire Royalty Interests, Aggregate Amount",
        "terseLabel": "Payments to acquire royalty interests"
       }
      }
     },
     "localname": "PaymentsToAcquireRoyaltyInterestsAggregateAmount",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Royalty Interests, Number Of Additional Payments",
        "label": "Payments To Acquire Royalty Interests, Number Of Additional Payments",
        "terseLabel": "Payments to acquire royalty interests, number of additional payments"
       }
      }
     },
     "localname": "PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rprx_PaymentsToAcquireRoyaltyInterestsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Royalty Interests, Upfront Payment",
        "label": "Payments To Acquire Royalty Interests, Upfront Payment",
        "terseLabel": "Payments to acquire royalty interests, upfront payment"
       }
      }
     },
     "localname": "PaymentsToAcquireRoyaltyInterestsUpfrontPayment",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsToAcquireWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Warrants",
        "label": "Payments To Acquire Warrants",
        "negatedTerseLabel": "Purchase of warrants"
       }
      }
     },
     "localname": "PaymentsToAcquireWarrants",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsToNoncontrollingInterestsOther": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Noncontrolling Interests, Other",
        "label": "Payments To Noncontrolling Interests, Other",
        "negatedTerseLabel": "Distributions to non-controlling interest- other"
       }
      }
     },
     "localname": "PaymentsToNoncontrollingInterestsOther",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PaymentsToTerminateDerivativeInstruments": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Terminate Derivative Instruments",
        "label": "Payments To Terminate Derivative Instruments",
        "negatedTerseLabel": "Termination payments on derivative instruments",
        "verboseLabel": "Swap termination payments"
       }
      }
     },
     "localname": "PaymentsToTerminateDerivativeInstruments",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PointSevenFivePercentSeniorNotesDue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Point Seven Five Percent Senior Notes Due 2023",
        "label": "Point Seven Five Percent Senior Notes Due 2023 [Member]",
        "terseLabel": "Point Seven Five Percent Senior Notes Due 2023"
       }
      }
     },
     "localname": "PointSevenFivePercentSeniorNotesDue2023Member",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Cash Collections From Other Royalties Received On Financing Receivables",
        "label": "Proceeds From Cash Collections From Other Royalties Received On Financing Receivables",
        "terseLabel": "Other royalty cash collections"
       }
      }
     },
     "localname": "ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Cash Collections From Royalties Received On Financing Receivables",
        "label": "Proceeds From Cash Collections From Royalties Received On Financing Receivables",
        "terseLabel": "Cash collections from financial royalty assets"
       }
      }
     },
     "localname": "ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Cash Collections From Royalties Received On Intangible Assets",
        "label": "Proceeds From Cash Collections From Royalties Received On Intangible Assets",
        "terseLabel": "Cash collections from intangible royalty assets"
       }
      }
     },
     "localname": "ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Collateral Received On Derivative Instruments",
        "label": "Proceeds From Collateral Received On Derivative Instruments",
        "terseLabel": "Derivative collateral received"
       }
      }
     },
     "localname": "ProceedsFromCollateralReceivedOnDerivativeInstruments",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Issuance Of Equity Securities, FN-NI",
        "label": "Proceeds From Issuance Of Equity Securities, FN-NI",
        "terseLabel": "Proceeds from equity securities"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfEquitySecuritiesFNNI",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_ProceedsFromNoncontrollingInterestsOther": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Noncontrolling Interests, Other",
        "label": "Proceeds From Noncontrolling Interests, Other",
        "terseLabel": "Contributions from non-controlling interest- other"
       }
      }
     },
     "localname": "ProceedsFromNoncontrollingInterestsOther",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Noncontrolling Interests, Research And Development",
        "label": "Proceeds From Noncontrolling Interests, Research And Development",
        "terseLabel": "Contributions from non-controlling interest- R&amp;D"
       }
      }
     },
     "localname": "ProceedsFromNoncontrollingInterestsResearchAndDevelopment",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PromactaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promacta",
        "label": "Promacta [Member]",
        "terseLabel": "Promacta"
       }
      }
     },
     "localname": "PromactaMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_PurchaseCommitmentAdditionalPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Commitment, Additional Payment",
        "label": "Purchase Commitment, Additional Payment",
        "terseLabel": "Purchase commitment, additional payments"
       }
      }
     },
     "localname": "PurchaseCommitmentAdditionalPayment",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Commitment, Committed Non-Contingent Commercial Launch Preferred Equity, Amount",
        "label": "Purchase Commitment, Committed Non-Contingent Commercial Launch Preferred Equity, Amount",
        "terseLabel": "Purchase commitment, purchase of committed, non-contingent Commercial Launch Preferred Equity payable"
       }
      }
     },
     "localname": "PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PurchaseCommitmentUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Commitment, Upfront Payment",
        "label": "Purchase Commitment, Upfront Payment",
        "terseLabel": "Purchase commitment, upfront payment"
       }
      }
     },
     "localname": "PurchaseCommitmentUpfrontPayment",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_PurchasingAndDonatingVentilatorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchasing And Donating Ventilators",
        "label": "Purchasing And Donating Ventilators [Member]",
        "terseLabel": "Purchasing And Donating Ventilators"
       }
      }
     },
     "localname": "PurchasingAndDonatingVentilatorsMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RPHoldingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RP Holdings",
        "label": "RP Holdings [Member]",
        "terseLabel": "RP Holdings"
       }
      }
     },
     "localname": "RPHoldingsMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RPI2019IntermediateFinanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RPI 2019 Intermediate Finance",
        "label": "RPI 2019 Intermediate Finance [Member]",
        "terseLabel": "RPI Intermediate FT"
       }
      }
     },
     "localname": "RPI2019IntermediateFinanceMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RPIFTSeniorSecuredCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RPIFT Senior Secured Credit Facilities",
        "label": "RPIFT Senior Secured Credit Facilities [Member]",
        "terseLabel": "RPIFT Senior Secured Credit Facilities"
       }
      }
     },
     "localname": "RPIFTSeniorSecuredCreditFacilitiesMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1",
        "label": "RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1 [Member]",
        "terseLabel": "RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1"
       }
      }
     },
     "localname": "RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1",
        "label": "RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1 [Member]",
        "terseLabel": "RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1"
       }
      }
     },
     "localname": "RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RedeemableStockRedemptionPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Stock, Redemption Price Per Share",
        "label": "Redeemable Stock, Redemption Price Per Share",
        "terseLabel": "Redeemable stock, redemption price (in euros per share)"
       }
      }
     },
     "localname": "RedeemableStockRedemptionPricePerShare",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "rprx_RelatedPartyTransactionAnnualIncreasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Annual Increase, Percentage",
        "label": "Related Party Transaction, Annual Increase, Percentage",
        "terseLabel": "Increase in quarterly installment payments (as a percent)"
       }
      }
     },
     "localname": "RelatedPartyTransactionAnnualIncreasePercentage",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rprx_RelatedPartyTransactionCumulativeFundingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Cumulative Funding Amount",
        "label": "Related Party Transaction, Cumulative Funding Amount",
        "terseLabel": "Cumulative funding amount"
       }
      }
     },
     "localname": "RelatedPartyTransactionCumulativeFundingAmount",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_RelatedPartyTransactionInitialTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Initial Term",
        "label": "Related Party Transaction, Initial Term",
        "terseLabel": "Initial term"
       }
      }
     },
     "localname": "RelatedPartyTransactionInitialTerm",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Number of Partnership Interests Acquired",
        "label": "Related Party Transaction, Number of Partnership Interests Acquired",
        "terseLabel": "Number of limited partnership interest acquired (in shares)"
       }
      }
     },
     "localname": "RelatedPartyTransactionNumberOfPartnershipInterestsAcquired",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Operating and Personal Payment Calculation, Amount",
        "label": "Related Party Transaction, Operating and Personal Payment Calculation, Amount",
        "terseLabel": "Amount calculated for operating and personal payment"
       }
      }
     },
     "localname": "RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Operating and Personal Payment Calculation, Percent",
        "label": "Related Party Transaction, Operating and Personal Payment Calculation, Percent",
        "terseLabel": "Percent for calculating operating and personal payment"
       }
      }
     },
     "localname": "RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rprx_RelatedPartyTransactionRateAdjustedCashReceipts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Rate, Adjusted Cash Receipts",
        "label": "Related Party Transaction, Rate, Adjusted Cash Receipts",
        "terseLabel": "Quarterly payments to affiliates, percent of adjusted cash receipts (as a percent)"
       }
      }
     },
     "localname": "RelatedPartyTransactionRateAdjustedCashReceipts",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rprx_RelatedPartyTransactionRateValueOfSecurityInvestments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Rate, Value Of Security Investments",
        "label": "Related Party Transaction, Rate, Value Of Security Investments",
        "terseLabel": "Quarterly payments to affiliates, percent of security investment (as a percent)"
       }
      }
     },
     "localname": "RelatedPartyTransactionRateValueOfSecurityInvestments",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments Of Long Term Debt, Contributions From Noncontrolling Interest, Noncash",
        "label": "Repayments Of Long Term Debt, Contributions From Noncontrolling Interest, Noncash",
        "terseLabel": "Repayments of long-term debt by contributions from non-controlling interest"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_RepaymentsOfLongTermDebtScheduledPayments": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments Of Long-term Debt, Scheduled Payments",
        "label": "Repayments Of Long-term Debt, Scheduled Payments",
        "negatedTerseLabel": "Scheduled repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebtScheduledPayments",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Expense, Upfront Payment and Premium Paid",
        "label": "Research and Development Expense, Upfront Payment and Premium Paid",
        "terseLabel": "Upfront payment and premium paid"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_ResearchAndDevelopmentRemainingFundingCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development, Remaining Funding Commitment",
        "label": "Research And Development, Remaining Funding Commitment",
        "terseLabel": "Remaining commitment for R&amp;D funding agreement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentRemainingFundingCommitment",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_RoyalPharmacySelectFinanceTrustMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royal Pharmacy Select Finance Trust",
        "label": "Royal Pharmacy Select Finance Trust [Member]",
        "terseLabel": "RPSFT"
       }
      }
     },
     "localname": "RoyalPharmacySelectFinanceTrustMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RoyaltyAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Assets, Policy",
        "label": "Royalty Assets, Policy [Policy Text Block]",
        "terseLabel": "Royalty assets"
       }
      }
     },
     "localname": "RoyaltyAssetsPolicyPolicyTextBlock",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Distribution Payable to Legacy Investors Partnerships",
        "label": "Royalty Distribution Payable to Legacy Investors Partnerships [Member]",
        "terseLabel": "Royalty Distribution Payable to Legacy Investors Partnerships"
       }
      }
     },
     "localname": "RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Distribution Payable to RP Select Finance Trust",
        "label": "Royalty Distribution Payable to RP Select Finance Trust [Member]",
        "terseLabel": "Royalty Distribution Payable to RP Select Finance Trust"
       }
      }
     },
     "localname": "RoyaltyDistributionPayableToRPSelectFinanceTrustMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RoyaltyIncomeOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Income, Other",
        "label": "Royalty Income, Other [Member]",
        "terseLabel": "Other royalty income"
       }
      }
     },
     "localname": "RoyaltyIncomeOtherMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RoyaltyPharmaCollectionTrustMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Pharma Collection Trust",
        "label": "Royalty Pharma Collection Trust [Member]",
        "terseLabel": "RPCT"
       }
      }
     },
     "localname": "RoyaltyPharmaCollectionTrustMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_RoyaltyPharmaInvestmentsOldRPIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Pharma Investments (Old RPI)",
        "label": "Royalty Pharma Investments (Old RPI) [Member]",
        "terseLabel": "Old RPI"
       }
      }
     },
     "localname": "RoyaltyPharmaInvestmentsOldRPIMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_SaleOfStockNumberOfSharesAvailableToConvert": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Number of Shares Available To Convert",
        "label": "Sale of Stock, Number of Shares Available To Convert",
        "verboseLabel": "Number of shares available to convert (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesAvailableToConvert",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rprx_SaleOfStockNumberOfSharesNotConverted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Number Of Shares Not Converted",
        "label": "Sale Of Stock, Number Of Shares Not Converted",
        "terseLabel": "Number of shares converted (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesNotConverted",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rprx_SeniorNotesDue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due 2031",
        "label": "Senior Notes Due 2031 [Member]",
        "terseLabel": "Senior Notes Due 2031"
       }
      }
     },
     "localname": "SeniorNotesDue2031Member",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_SeniorNotesDue2051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due 2051",
        "label": "Senior Notes Due 2051 [Member]",
        "terseLabel": "Senior Notes Due 2051"
       }
      }
     },
     "localname": "SeniorNotesDue2051Member",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_SeniorUnsecuredRevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Revolving Credit Facility",
        "label": "Senior Unsecured Revolving Credit Facility [Member]",
        "terseLabel": "Senior Unsecured Revolving Credit Facility"
       }
      }
     },
     "localname": "SeniorUnsecuredRevolvingCreditFacilityMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_SettlementsWithEquityMethodInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlements With Equity Method Investments",
        "label": "Settlements With Equity Method Investments",
        "terseLabel": "Settlement of Epizyme forward purchase contract"
       }
      }
     },
     "localname": "SettlementsWithEquityMethodInvestments",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_StockIssuedDuringPeriodSharesIssuedForRegistration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Issued For Registration",
        "label": "Stock Issued During Period, Shares, Issued For Registration",
        "terseLabel": "Initial share issuance upon registration of Royalty Pharma plc (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForRegistration",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Issued To Partnerships",
        "label": "Stock Issued During Period, Shares, Issued To Partnerships",
        "terseLabel": "Issuance of Class B shares to Continuing Investor Partnerships (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedToPartnerships",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "rprx_StockIssuedDuringPeriodValueIssuedForRegistration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Issued For Registration",
        "label": "Stock Issued During Period, Value, Issued For Registration",
        "terseLabel": "Initial share issuance upon registration of Royalty Pharma plc"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForRegistration",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_StockIssuedDuringPeriodValueIssuedToPartnerships": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Issued To Partnerships",
        "label": "Stock Issued During Period, Value, Issued To Partnerships",
        "terseLabel": "Issuance of Class B ordinary shares to Continuing Investors Partnerships"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedToPartnerships",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders' Equity, Shares, Effect Of Exchange And Reallocation",
        "label": "Stockholders' Equity, Shares, Effect Of Exchange And Reallocation",
        "terseLabel": "Effect of exchange by Continuing Investors of Class B shares for Class A shares and reallocation of historical equity (in shares)"
       }
      }
     },
     "localname": "StockholdersEquitySharesEffectOfExchangeAndReallocation",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "rprx_StockholdersEquityValueEffectOfExchangeAndReallocation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders' Equity, Value, Effect Of Exchange And Reallocation",
        "label": "Stockholders' Equity, Value, Effect Of Exchange And Reallocation",
        "terseLabel": "Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity"
       }
      }
     },
     "localname": "StockholdersEquityValueEffectOfExchangeAndReallocation",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rprx_TheNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Notes",
        "label": "The Notes [Member]",
        "terseLabel": "The Notes"
       }
      }
     },
     "localname": "TheNotesMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Five Five Percent Senior Notes Due 2050",
        "label": "Three Point Five Five Percent Senior Notes Due 2050 [Member]",
        "terseLabel": "Three Point Five Five Percent Senior Notes Due 2050"
       }
      }
     },
     "localname": "ThreePointFiveFivePercentSeniorNotesDue2050Member",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Three Five Percent Senior Notes Due 2051",
        "label": "Three Point Three Five Percent Senior Notes Due 2051 [Member]",
        "terseLabel": "Three Point Three Five Percent Senior Notes Due 2051"
       }
      }
     },
     "localname": "ThreePointThreeFivePercentSeniorNotesDue2051Member",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Three Zero Percent Senior Notes Due 2040",
        "label": "Three Point Three Zero Percent Senior Notes Due 2040 [Member]",
        "terseLabel": "Three Point Three Zero Percent Senior Notes Due 2040"
       }
      }
     },
     "localname": "ThreePointThreeZeroPercentSeniorNotesDue2040Member",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_TreasuryRateLockContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury Rate Lock Contracts",
        "label": "Treasury Rate Lock Contracts [Member]",
        "terseLabel": "Treasury Rate Lock Contracts"
       }
      }
     },
     "localname": "TreasuryRateLockContractsMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_TremfyaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tremfya",
        "label": "Tremfya [Member]",
        "terseLabel": "Tremfya"
       }
      }
     },
     "localname": "TremfyaMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_TwoPointOneFivePercentSeniorNotesDue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point One Five percent Senior Notes Due 2031",
        "label": "Two Point One Five percent Senior Notes Due 2031 [Member]",
        "terseLabel": "Two Point One Five percent Senior Notes Due 2031"
       }
      }
     },
     "localname": "TwoPointOneFivePercentSeniorNotesDue2031Member",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Two Zero Percent Senior Notes Due 2030",
        "label": "Two Point Two Zero Percent Senior Notes Due 2030 [Member]",
        "terseLabel": "Two Point Two Zero Percent Senior Notes Due 2030"
       }
      }
     },
     "localname": "TwoPointTwoZeroPercentSeniorNotesDue2030Member",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_TysabriMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tysabri",
        "label": "Tysabri [Member]",
        "terseLabel": "Tysabri"
       }
      }
     },
     "localname": "TysabriMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_UnitHoldersAndShareholdersContributionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unit Holders' and Shareholders' Contributions",
        "label": "Unit Holders' and Shareholders' Contributions [Member]",
        "terseLabel": "Unitholders\u2019/ Shareholders\u2019 Contributions"
       }
      }
     },
     "localname": "UnitHoldersAndShareholdersContributionsMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_VertexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vertex",
        "label": "Vertex [Member]",
        "terseLabel": "Vertex"
       }
      }
     },
     "localname": "VertexMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rprx_XtandiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xtandi",
        "label": "Xtandi [Member]",
        "terseLabel": "Xtandi"
       }
      }
     },
     "localname": "XtandiMember",
     "nsuri": "http://royaltypharma.com/20211231",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r421",
      "r575",
      "r576",
      "r579",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r55",
      "r57",
      "r138",
      "r139",
      "r351",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails",
      "http://royaltypharma.com/role/EarningsPerShareDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails",
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r146",
      "r155",
      "r162",
      "r273",
      "r441",
      "r442",
      "r443",
      "r459",
      "r460",
      "r515",
      "r518",
      "r520",
      "r521",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails",
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r146",
      "r155",
      "r162",
      "r273",
      "r441",
      "r442",
      "r443",
      "r459",
      "r460",
      "r515",
      "r518",
      "r520",
      "r521",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails",
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r146",
      "r155",
      "r162",
      "r273",
      "r441",
      "r442",
      "r443",
      "r459",
      "r460",
      "r515",
      "r518",
      "r520",
      "r521",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails",
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r228",
      "r410",
      "r412",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ManagementMember": {
     "auth_ref": [
      "r229",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management [Member]",
        "terseLabel": "The Manager"
       }
      }
     },
     "localname": "ManagementMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r350",
      "r393",
      "r424",
      "r426",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r618",
      "r691",
      "r694",
      "r722",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r228",
      "r410",
      "r412",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r226",
      "r410",
      "r411",
      "r623",
      "r690",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r226",
      "r410",
      "r411",
      "r623",
      "r690",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r350",
      "r393",
      "r413",
      "r424",
      "r426",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r618",
      "r691",
      "r694",
      "r722",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r350",
      "r393",
      "r413",
      "r424",
      "r426",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r618",
      "r691",
      "r694",
      "r722",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r56",
      "r57",
      "r138",
      "r139",
      "r351",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails",
      "http://royaltypharma.com/role/EarningsPerShareDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails",
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r3",
      "r143",
      "r144",
      "r145",
      "r147",
      "r148",
      "r152",
      "r153",
      "r154",
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r184",
      "r274",
      "r275",
      "r444",
      "r460",
      "r516",
      "r520",
      "r521",
      "r522",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r752",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r3",
      "r143",
      "r144",
      "r145",
      "r147",
      "r148",
      "r152",
      "r153",
      "r154",
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r184",
      "r274",
      "r275",
      "r444",
      "r460",
      "r516",
      "r520",
      "r521",
      "r522",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r752",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Reclassification, Adjustment [Member]",
        "terseLabel": "Revision of Prior Period, Reclassification, Adjustment"
       }
      }
     },
     "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r147",
      "r148",
      "r149",
      "r150",
      "r246",
      "r247",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r333",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r459",
      "r460",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r572",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting standards update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": {
     "auth_ref": [
      "r65",
      "r75",
      "r76",
      "r77",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]",
        "terseLabel": "Unrealized Losses on Interest Rate Swaps"
       }
      }
     },
     "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r59",
      "r60",
      "r61",
      "r65",
      "r75",
      "r76",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to noncontrolling interest.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Noncontrolling Interest [Member]",
        "terseLabel": "Unrealized gain/(loss) on available for sale debt securities, noncontrolling interest"
       }
      }
     },
     "localname": "AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r59",
      "r60",
      "r61",
      "r65",
      "r75",
      "r76",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member]",
        "terseLabel": "Unrealized gain/(loss) on available for sale debt securities, including noncontrolling interest"
       }
      }
     },
     "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r59",
      "r60",
      "r61",
      "r65",
      "r75",
      "r76",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized Gains on Available for Sale Debt Securities"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r30",
      "r63",
      "r64",
      "r65",
      "r675",
      "r702",
      "r706"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r75",
      "r76",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r62",
      "r65",
      "r75",
      "r76",
      "r77",
      "r143",
      "r144",
      "r145",
      "r477",
      "r697",
      "r698",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Total Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r28",
      "r444",
      "r584"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r441",
      "r442",
      "r443",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile consolidated net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r428",
      "r434",
      "r445"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock": {
     "auth_ref": [
      "r236",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on financing receivable.",
        "label": "Financing Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Schedule of Cumulative Allowance for Changes in Expected Cash Flows"
       }
      }
     },
     "localname": "AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r117",
      "r370",
      "r381",
      "r382",
      "r569"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r117",
      "r313",
      "r318"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r62",
      "r65",
      "r75",
      "r76",
      "r77",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income/(Loss)"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r117",
      "r322"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment charge"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r135",
      "r208",
      "r218",
      "r224",
      "r268",
      "r334",
      "r335",
      "r336",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r470",
      "r479",
      "r548",
      "r582",
      "r584",
      "r643",
      "r673"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r52",
      "r135",
      "r268",
      "r334",
      "r335",
      "r336",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r470",
      "r479",
      "r548",
      "r582",
      "r584"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r253",
      "r305"
     ],
     "calculation": {
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r249",
      "r254",
      "r305",
      "r648"
     ],
     "calculation": {
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r252",
      "r305"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": 3.0,
       "parentTag": "rprx_AssetsFairValueDisclosureCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Available for sale debt securities",
        "verboseLabel": "Available for sale debt securities, current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r252",
      "r305"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": 2.0,
       "parentTag": "rprx_AssetsFairValueDisclosureNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Available for sale debt securities",
        "verboseLabel": "Available for sale debt securities, noncurrent"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesMember": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Securities [Member]",
        "terseLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r430",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of preparation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r423",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r423",
      "r425",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Value, net"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r8",
      "r32",
      "r119"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "negatedTerseLabel": "Cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": 1.0,
       "parentTag": "rprx_AssetsFairValueDisclosureCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r17",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r113",
      "r119",
      "r125"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r113",
      "r557"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental Schedule of Non-cash Investing/Financing Activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "Indirect Cash Flow"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlow"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of Deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r133",
      "r135",
      "r166",
      "r170",
      "r175",
      "r178",
      "r180",
      "r188",
      "r189",
      "r190",
      "r268",
      "r334",
      "r339",
      "r340",
      "r341",
      "r345",
      "r346",
      "r391",
      "r392",
      "r395",
      "r396",
      "r548",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/Cover",
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/EarningsPerShareDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r408",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrant (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase additional shares (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r44",
      "r328",
      "r653",
      "r679"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r329",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common Class A"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/Cover",
      "http://royaltypharma.com/role/EarningsPerShareDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Common Class B [Member]",
        "terseLabel": "Common Class B"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/Cover",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Dividends paid (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r143",
      "r144",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars/pounds per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r25",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common shares outstanding",
        "verboseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r25",
      "r584"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r70",
      "r72",
      "r73",
      "r86",
      "r660",
      "r685"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to controlling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r70",
      "r72",
      "r85",
      "r468",
      "r485",
      "r659",
      "r684"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r84",
      "r96",
      "r658",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r197",
      "r198",
      "r228",
      "r546",
      "r547",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r197",
      "r198",
      "r228",
      "r546",
      "r547",
      "r708",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r197",
      "r198",
      "r228",
      "r546",
      "r547",
      "r708",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r193",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of credit risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r197",
      "r198",
      "r228",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Individual licensees exceeding 10% or more of revenue (as a percent)",
        "verboseLabel": "Concentration risk (as a percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r197",
      "r198",
      "r228",
      "r546",
      "r547",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r128",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r478",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Investments in non-consolidated affiliates"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r414",
      "r422",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses/(income), net"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Loss [Abstract]"
       }
      }
     },
     "localname": "CreditLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": {
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r281",
      "r282",
      "r289",
      "r291",
      "r293",
      "r294",
      "r295",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.",
        "label": "Credit Loss, Financial Instrument [Policy Text Block]",
        "terseLabel": "Allowance for current expected credit losses"
       }
      }
     },
     "localname": "CreditLossFinancialInstrumentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditLossFinancialInstrumentTextBlock": {
     "auth_ref": [
      "r282",
      "r292",
      "r293",
      "r297",
      "r298",
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.",
        "label": "Credit Loss, Financial Instrument [Text Block]",
        "terseLabel": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets"
       }
      }
     },
     "localname": "CreditLossFinancialInstrumentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r196",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r132",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r364",
      "r371",
      "r372",
      "r374",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/Borrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r19",
      "r21",
      "r22",
      "r134",
      "r141",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r379",
      "r380",
      "r381",
      "r382",
      "r570",
      "r644",
      "r645",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate (percentage)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r22",
      "r375",
      "r645",
      "r671"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "totalLabel": "Long-term debt, gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r347",
      "r379",
      "r380",
      "r568",
      "r570",
      "r571"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt issued, amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r41",
      "r378",
      "r568",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Weighted average effective interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r41",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument, stated rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r42",
      "r134",
      "r141",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r379",
      "r380",
      "r381",
      "r382",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Prior to the applicable par call date"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "terseLabel": "Upon occurrence of a change of control triggering event"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r42",
      "r134",
      "r141",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r373",
      "r379",
      "r380",
      "r381",
      "r382",
      "r399",
      "r402",
      "r403",
      "r404",
      "r567",
      "r568",
      "r570",
      "r571",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r360",
      "r376",
      "r379",
      "r380",
      "r569"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized debt discount and issuance costs",
        "terseLabel": "Unamortized discount and loan issuance costs on long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Summary of Available for Sale Debt Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Unrealized gains on available for sale debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average coupon rate (as a percent)"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r569"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r53",
      "r54",
      "r57",
      "r543"
     ],
     "calculation": {
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": 3.0,
       "parentTag": "rprx_AssetsFairValueDisclosureNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsNoncurrent": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Noncurrent",
        "terseLabel": "Derivative financial instruments"
       }
      }
     },
     "localname": "DerivativeAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r494"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Interest rate swaps"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r57",
      "r493",
      "r495",
      "r499",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r510",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivatives and hedging activities.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r498",
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Derivatives not designated as hedging instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r488",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r140",
      "r487",
      "r489",
      "r491",
      "r492",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsCash": {
     "auth_ref": [
      "r405",
      "r666"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.",
        "label": "Dividends, Cash",
        "negatedTerseLabel": "Dividends"
       }
      }
     },
     "localname": "DividendsCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedLabel": "Dividends declared and paid"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r137",
      "r337",
      "r339",
      "r340",
      "r344",
      "r345",
      "r346",
      "r576",
      "r651",
      "r680"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties",
        "terseLabel": "Amounts due from related parties"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r35",
      "r137",
      "r337",
      "r339",
      "r340",
      "r344",
      "r345",
      "r346",
      "r576"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Distribution payable to non-controlling interest"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesNoncurrent": {
     "auth_ref": [
      "r43",
      "r137",
      "r337",
      "r339",
      "r340",
      "r344",
      "r345",
      "r346",
      "r576"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.",
        "label": "Due to Related Parties, Noncurrent",
        "terseLabel": "Total distribution payable to non-controlling interest"
       }
      }
     },
     "localname": "DueToRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r87",
      "r152",
      "r153",
      "r155",
      "r156",
      "r157",
      "r163",
      "r166",
      "r178",
      "r179",
      "r180",
      "r184",
      "r185",
      "r521",
      "r522",
      "r661",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Earnings per Class A ordinary share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Earnings Per Share, Basic [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Earnings per Class A ordinary share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r87",
      "r152",
      "r153",
      "r155",
      "r156",
      "r157",
      "r166",
      "r178",
      "r179",
      "r180",
      "r184",
      "r185",
      "r521",
      "r522",
      "r661",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Earnings per Class A ordinary share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r181",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r435"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized share based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized share based compensation expense, period of recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r75",
      "r76",
      "r77",
      "r143",
      "r144",
      "r145",
      "r148",
      "r158",
      "r161",
      "r187",
      "r273",
      "r398",
      "r405",
      "r441",
      "r442",
      "r443",
      "r459",
      "r460",
      "r520",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r564",
      "r697",
      "r698",
      "r699",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "auth_ref": [
      "r82",
      "r112",
      "r117",
      "r681"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "terseLabel": "Distributions from non-consolidated affiliates"
       }
      }
     },
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://royaltypharma.com/role/IndirectCashFlowDetails",
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r6",
      "r135",
      "r268",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r6",
      "r135",
      "r268",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember": {
     "auth_ref": [
      "r6",
      "r135",
      "r268",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee or group of nonconsolidated investees. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee or Group of Investees"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r33",
      "r209",
      "r265"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Investments in non-consolidated affiliates"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Non-Consolidated Affiliates"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliates"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFVNINoncurrent": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": 1.0,
       "parentTag": "rprx_AssetsFairValueDisclosureNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.",
        "label": "Equity Securities, FV-NI, Noncurrent",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFVNINoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r540"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r264",
      "r687"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Losses/(gains) on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r18",
      "r20",
      "r260",
      "r672",
      "r715",
      "r716",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r362",
      "r379",
      "r380",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss": {
     "auth_ref": [
      "r533"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) recognized in income from asset (liability) measured at fair value on recurring basis using unobservable input (level 3) and still held.",
        "label": "Fair Value, Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Unrealized gain (loss) on equity securities still held"
       }
      }
     },
     "localname": "FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r524",
      "r525",
      "r526",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": {
     "auth_ref": [
      "r533"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3) and still held.",
        "label": "Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized gains included in earnings"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r529",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r529",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r524",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r362",
      "r379",
      "r380",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r525",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r362",
      "r379",
      "r380",
      "r524",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r524",
      "r525",
      "r527",
      "r528",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]",
        "terseLabel": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]"
       }
      }
     },
     "localname": "FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r362",
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about fair value of asset and liability not measured at fair value.",
        "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]",
        "terseLabel": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]"
       }
      }
     },
     "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about fair value of asset and liability not measured at fair value.",
        "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block]",
        "terseLabel": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements and Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r362",
      "r414",
      "r415",
      "r420",
      "r422",
      "r525",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r362",
      "r379",
      "r380",
      "r414",
      "r415",
      "r420",
      "r422",
      "r525",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r362",
      "r379",
      "r380",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r525",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss": {
     "auth_ref": [
      "r530"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "terseLabel": "Gains on equity securities"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": {
     "auth_ref": [
      "r531"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases",
        "terseLabel": "Purchases"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": {
     "auth_ref": [
      "r531"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements",
        "terseLabel": "Settlement of forwards"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "auth_ref": [
      "r532"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
        "terseLabel": "Transfer from level 2"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "auth_ref": [
      "r532"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "negatedLabel": "Transfer to Level 2"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "auth_ref": [
      "r529"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "periodEndLabel": "Balance at the end of the year",
        "periodStartLabel": "Balance at the beginning of the year"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r362",
      "r379",
      "r380",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r534",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r539",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FederalFundsPurchasedMember": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term borrowing where a bank borrows, at the federal funds rate, from another bank.",
        "label": "Federal Funds Purchased [Member]",
        "terseLabel": "Federal Funds Rate"
       }
      }
     },
     "localname": "FederalFundsPurchasedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLoansAndLeasesReceivablePolicy": {
     "auth_ref": [
      "r232",
      "r237",
      "r238",
      "r239",
      "r241",
      "r243",
      "r244",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for financing receivable.",
        "label": "Financing Receivable [Policy Text Block]",
        "terseLabel": "Financial royalty assets, net"
       }
      }
     },
     "localname": "FinanceLoansAndLeasesReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due the Company from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith. Such amount may include accrued interest receivable in accordance with the terms of the agreements. The agreements also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Financing Receivable [Member]",
        "terseLabel": "Current portion of Financial royalty assets"
       }
      }
     },
     "localname": "FinanceReceivablesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r256",
      "r257",
      "r261",
      "r262",
      "r263",
      "r282",
      "r288",
      "r289",
      "r290",
      "r297",
      "r309",
      "r310",
      "r311",
      "r312",
      "r373",
      "r397",
      "r510",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLosses": {
     "auth_ref": [
      "r233",
      "r279",
      "r284",
      "r287",
      "r649",
      "r743",
      "r745",
      "r746"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.",
        "label": "Financing Receivable, Allowance for Credit Loss",
        "negatedPeriodEndLabel": "Ending balance",
        "negatedPeriodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Financing Receivable, Allowance for Credit Loss [Line Items]",
        "terseLabel": "Financing Receivable, Allowance for Credit Loss [Line Items]"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLossesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails",
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs": {
     "auth_ref": [
      "r235",
      "r286",
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of writeoff of financing receivable, charged against allowance for credit loss.",
        "label": "Financing Receivable, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Write off of credit loss allowance"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLossesWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancingReceivableChangeInPresentValueExpenseReversal": {
     "auth_ref": [
      "r280",
      "r283",
      "r288"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on financing receivable, from change in present value of expected cash flows.",
        "label": "Financing Receivable, Change in Present Value, Expense (Reversal)",
        "negatedTerseLabel": "Write-off of cumulative allowance"
       }
      }
     },
     "localname": "FinancingReceivableChangeInPresentValueExpenseReversal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancingReceivablesTextBlock": {
     "auth_ref": [
      "r242",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financing receivable.",
        "label": "Financing Receivables [Text Block]",
        "terseLabel": "Financial Royalty Assets, Net"
       }
      }
     },
     "localname": "FinancingReceivablesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite lived intangible assets, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Projected amortization expense, 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r314",
      "r315",
      "r317",
      "r320",
      "r624",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r317",
      "r628"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r314",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r317",
      "r624"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Value",
        "verboseLabel": "Intangible royalty assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForwardContractsMember": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.",
        "label": "Forward Contracts [Member]",
        "terseLabel": "Forwards"
       }
      }
     },
     "localname": "ForwardContractsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing gain (loss) on derivative instruments.",
        "label": "Gain (Loss) on Derivative Instruments [Member]",
        "terseLabel": "Losses on derivative financial instruments"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "negatedLabel": "Losses on derivative financial instruments"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r117",
      "r383",
      "r384"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r491",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r81",
      "r208",
      "r217",
      "r220",
      "r223",
      "r225",
      "r641",
      "r656",
      "r664",
      "r688"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Consolidated net income before tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r82",
      "r117",
      "r206",
      "r265",
      "r655",
      "r681"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Equity in losses/(earnings) of non-consolidated affiliates",
        "verboseLabel": "Equity in income (loss) of non-consolidated affiliates"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/IndirectCashFlowDetails",
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r136",
      "r160",
      "r161",
      "r207",
      "r452",
      "r461",
      "r462",
      "r689"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r74",
      "r450",
      "r451",
      "r453",
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.",
        "label": "Increase (Decrease) in Interest Payable, Net",
        "terseLabel": "Interest payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Assets [Abstract]",
        "terseLabel": "Decrease/(increase) in operating assets:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Liabilities [Abstract]",
        "terseLabel": "(Decrease)/increase in operating liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedTerseLabel": "Other current assets and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedTerseLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r180"
     ],
     "calculation": {
      "http://royaltypharma.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Unvested RSUs (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Royalty Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r129",
      "r316",
      "r620",
      "r621",
      "r622",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible royalty assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r79",
      "r205",
      "r566",
      "r569",
      "r663"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestIncomeOperating": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.",
        "label": "Interest Income, Operating",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r110",
      "r114",
      "r121"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "negatedTerseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r15",
      "r16",
      "r39"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r92",
      "r94"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "negatedLabel": "Interest income",
        "verboseLabel": "Investment income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r260",
      "r642",
      "r665",
      "r718",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Available for Sale Debt Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38",
      "r135",
      "r219",
      "r268",
      "r334",
      "r335",
      "r336",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r471",
      "r479",
      "r480",
      "r548",
      "r582",
      "r583"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r31",
      "r135",
      "r268",
      "r548",
      "r584",
      "r647",
      "r678"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r40",
      "r135",
      "r268",
      "r334",
      "r335",
      "r336",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r471",
      "r479",
      "r480",
      "r548",
      "r582",
      "r583",
      "r584"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "London Interbank Offered Rate (LIBOR)"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r22",
      "r361",
      "r377",
      "r379",
      "r380",
      "r645",
      "r674"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total debt carrying value"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedNetLabel": "Less: Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Fair value of outstanding Notes"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r141",
      "r331",
      "r366"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r141",
      "r331",
      "r366"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r141",
      "r331",
      "r366"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r141",
      "r331",
      "r366"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r141",
      "r331",
      "r366"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r141",
      "r331",
      "r366"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "verboseLabel": "Total long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.",
        "label": "Long-term Purchase Commitment, Amount",
        "terseLabel": "Payment for purchase of royalties"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of items purchased under a long-term purchase commitment.",
        "label": "Category of Item Purchased [Axis]",
        "terseLabel": "Category of Item Purchased [Axis]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.",
        "label": "Long-term Purchase Commitment, Category of Item Purchased [Domain]",
        "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased [Domain]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Long-term Purchase Commitment [Line Items]",
        "terseLabel": "Long-term Purchase Commitment [Line Items]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.",
        "label": "Long-term Purchase Commitment [Table]",
        "terseLabel": "Long-term Purchase Commitment [Table]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r42",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r50",
      "r135",
      "r268",
      "r334",
      "r339",
      "r340",
      "r341",
      "r345",
      "r346",
      "r548",
      "r646",
      "r677"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Distributions"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Noncontrolling interest (percentage)"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership percentage (as a percent)"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInMinorityInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]"
       }
      }
     },
     "localname": "MovementInMinorityInterestRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by/(used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "verboseLabel": "Net cash flow from investing"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r113",
      "r115",
      "r118"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r6",
      "r68",
      "r71",
      "r77",
      "r83",
      "r118",
      "r135",
      "r147",
      "r152",
      "r153",
      "r155",
      "r156",
      "r160",
      "r161",
      "r176",
      "r208",
      "r217",
      "r220",
      "r223",
      "r225",
      "r268",
      "r334",
      "r335",
      "r336",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r522",
      "r548",
      "r657",
      "r682"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income attributable to controlling interest"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r68",
      "r71",
      "r77",
      "r160",
      "r161",
      "r474",
      "r484"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://royaltypharma.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Less: net income attributable to non-controlling interest",
        "verboseLabel": "Net income attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r152",
      "r153",
      "r155",
      "r156",
      "r163",
      "r164",
      "r177",
      "r180",
      "r208",
      "r217",
      "r220",
      "r223",
      "r225"
     ],
     "calculation": {
      "http://royaltypharma.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income attributable to Royalty Pharma plc - basic and diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r165",
      "r171",
      "r172",
      "r173",
      "r174",
      "r177",
      "r180"
     ],
     "calculation": {
      "http://royaltypharma.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income attributable to Royalty Pharma plc - basic and diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r155",
      "r162",
      "r184",
      "r246",
      "r247",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r333",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r457",
      "r458",
      "r459",
      "r460",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r572",
      "r625",
      "r626",
      "r627",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently adopted and issued accounting standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1": {
     "auth_ref": [
      "r122",
      "r123",
      "r124"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.",
        "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received",
        "terseLabel": "Receipt of contribution of investments in Legacy Investors Partnerships"
       }
      }
     },
     "localname": "NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r405",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-Controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedTotalLabel": "Total other expense/(income), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r26",
      "r230",
      "r231",
      "r650"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Financial royalty assets"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Financial royalty assets, net"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableGross": {
     "auth_ref": [
      "r240",
      "r279",
      "r289",
      "r296",
      "r299",
      "r300",
      "r742",
      "r743",
      "r744"
     ],
     "calculation": {
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of financing receivable.",
        "label": "Financing Receivable, before Allowance for Credit Loss",
        "terseLabel": "Gross Carrying Value"
       }
      }
     },
     "localname": "NotesReceivableGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableNet": {
     "auth_ref": [
      "r27",
      "r230",
      "r296"
     ],
     "calculation": {
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.",
        "label": "Financing Receivable, after Allowance for Credit Loss",
        "terseLabel": "Financial royalty asset, net",
        "totalLabel": "Net carrying value"
       }
      }
     },
     "localname": "NotesReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r208",
      "r217",
      "r220",
      "r223",
      "r225"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityStrikePrice1": {
     "auth_ref": [
      "r386",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.",
        "label": "Option Indexed to Issuer's Equity, Strike Price",
        "terseLabel": "Put option, selling price, maximum (in dollars per share)"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityStrikePrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "auth_ref": [
      "r387",
      "r507",
      "r508",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.",
        "label": "Option Indexed to Issuer's Equity, Type [Axis]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Axis]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.",
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r7",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Purpose"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurpose"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r51",
      "r584"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "terseLabel": "Other commitment"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r65",
      "r75",
      "r76",
      "r78",
      "r558",
      "r560",
      "r564"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Activity for the year"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r63",
      "r66",
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Amount of loss reclassified from AOCI into income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax": {
     "auth_ref": [
      "r58",
      "r496"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax",
        "terseLabel": "Reclassification of loss on interest rate swaps"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r69",
      "r72",
      "r75",
      "r76",
      "r78",
      "r84",
      "r398",
      "r558",
      "r563",
      "r564",
      "r658",
      "r683"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Total other comprehensive (loss)/income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Changes in other comprehensive income/(loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r69",
      "r72",
      "r468",
      "r469",
      "r476"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income attributable to non-controlling interest"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r63",
      "r66",
      "r67",
      "r259"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedLabel": "Reclassification of unrealized losses on available for sale debt securities",
        "negatedTerseLabel": "Reclassification of unrealized gains on available for sale debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r59",
      "r63",
      "r259"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax",
        "terseLabel": "Unrealized gains on available for sale debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r59",
      "r63"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gains on available for sale debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Cost and Expense, Operating",
        "terseLabel": "Other operating expenses"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other expense/(income)"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r39",
      "r584"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTerseLabel": "Other non-operating expense/(income), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchase of treasury interests"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Debt issuance costs and other"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r97",
      "r100",
      "r251"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of available for sale debt securities",
        "verboseLabel": "Purchase of available for sale debt securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedTerseLabel": "Investments in non-consolidated affiliates"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireFinanceReceivables": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the purchase of amounts due from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith.",
        "label": "Payments to Acquire Finance Receivables",
        "negatedLabel": "Acquisitions of financial royalty assets"
       }
      }
     },
     "localname": "PaymentsToAcquireFinanceReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r251"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable securities",
        "terseLabel": "Purchases of available for sale debt securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "Distributions to non-controlling interest"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r430",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Shares"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": {
     "auth_ref": [
      "r99",
      "r112"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.",
        "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital",
        "terseLabel": "Distributions from non-consolidated affiliates"
       }
      }
     },
     "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromInterestReceived": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest received on loans and other debt instruments during the current period.",
        "label": "Proceeds from Interest Received",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "ProceedsFromInterestReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from issuance of Class A ordinary shares upon IPO, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt, net of discount"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r97",
      "r98",
      "r251"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from available for sale debt securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r6",
      "r68",
      "r71",
      "r77",
      "r111",
      "r135",
      "r147",
      "r160",
      "r161",
      "r208",
      "r217",
      "r220",
      "r223",
      "r225",
      "r268",
      "r334",
      "r335",
      "r336",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r468",
      "r473",
      "r475",
      "r484",
      "r485",
      "r522",
      "r548",
      "r664"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Consolidated net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/EarningsPerShareDetails",
      "http://royaltypharma.com/role/IndirectCashFlowDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForLoanAndLeaseLosses": {
     "auth_ref": [
      "r116",
      "r234",
      "r662"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to estimated loss from loan and lease transactions.",
        "label": "Provision for Loan and Lease Losses",
        "terseLabel": "Provision for changes in expected cash flows from financial royalty assets"
       }
      }
     },
     "localname": "ProvisionForLoanAndLeaseLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForLoanLossesExpensed": {
     "auth_ref": [
      "r285",
      "r654"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of credit loss expense (reversal of expense) for financing receivable.",
        "label": "Financing Receivable, Credit Loss, Expense (Reversal)",
        "negatedTerseLabel": "Current period provision for credit losses, net"
       }
      }
     },
     "localname": "ProvisionForLoanLossesExpensed",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PutOptionMember": {
     "auth_ref": [
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A financial contract between two parties, the buyer and the seller (writer) of the option, where the buyer has the right but not the obligation to sell a commodity or financial instrument (the underlying instrument) to the seller (writer) at a certain time for a certain price (the strike price). The seller (writer) has the obligation to purchase the underlying asset at that strike price, if the buyer exercises the option.",
        "label": "Put Option [Member]",
        "terseLabel": "Put Option"
       }
      }
     },
     "localname": "PutOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r65",
      "r75",
      "r76",
      "r78",
      "r558",
      "r562",
      "r564"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Reclassification to net income"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r421",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r575",
      "r579"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Amount paid to CEO"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r421",
      "r575",
      "r576",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.",
        "label": "Related Party Transaction, Rate",
        "terseLabel": "Related party, rate (as a percent)"
       }
      }
     },
     "localname": "RelatedPartyTransactionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.",
        "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party",
        "terseLabel": "Operating and personnel payments incurred"
       }
      }
     },
     "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r421",
      "r575",
      "r579",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r573",
      "r574",
      "r576",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Repayments of long-term debt",
        "verboseLabel": "Repayments of outstanding debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r447",
      "r619",
      "r724"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development funding expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development funding expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "Research &amp; Development (\"R&amp;D\") Funding Expense"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r29",
      "r405",
      "r444",
      "r584",
      "r676",
      "r701",
      "r706"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r143",
      "r144",
      "r145",
      "r148",
      "r158",
      "r161",
      "r273",
      "r441",
      "r442",
      "r443",
      "r459",
      "r460",
      "r520",
      "r697",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r130",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue from intangible royalty assets and Accrued royalty receivable"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r80",
      "r135",
      "r203",
      "r204",
      "r216",
      "r221",
      "r222",
      "r226",
      "r227",
      "r228",
      "r268",
      "r334",
      "r335",
      "r336",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r548",
      "r664"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total income and other revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "verboseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.",
        "label": "Sale of Stock, Percentage of Ownership after Transaction",
        "terseLabel": "Ownership percentage following IPO"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.",
        "label": "Sale of Stock, Percentage of Ownership before Transaction",
        "terseLabel": "Exchange offering, ownership percentage"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfOwnershipBeforeTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "verboseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r197",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Summary of Financial Royalty Assets, Net"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r65",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Cash Flow, Supplemental Disclosures"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r42",
      "r141",
      "r379",
      "r381",
      "r399",
      "r402",
      "r403",
      "r404",
      "r567",
      "r568",
      "r571",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Borrowings"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r493",
      "r499",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Summary of Derivatives and Reclassifications"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r166",
      "r170",
      "r178",
      "r180",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r6",
      "r135",
      "r267",
      "r268",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Hierarchy"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable": {
     "auth_ref": [
      "r288",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about allowance for credit loss on financing receivable.",
        "label": "Financing Receivable, Allowance for Credit Loss [Table]",
        "terseLabel": "Financing Receivable, Allowance for Credit Loss [Table]"
       }
      }
     },
     "localname": "ScheduleOfFinancingReceivableAllowanceForCreditLossesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails",
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r314",
      "r316",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails",
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r314",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Royalty Interests"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Repayments of Debt by Year"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r577",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of Related Party Transactions"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r45",
      "r133",
      "r188",
      "r189",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.",
        "label": "Schedule of Stockholders Equity [Table Text Block]",
        "terseLabel": "Schedule of Balance Of Non-controlling Interests"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt and Equity Securities, FV-NI [Line Items]",
        "terseLabel": "Debt and Equity Securities, FV-NI [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]",
        "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Senior Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Debt Securities",
        "verboseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Shares"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Requisite service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r427",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r409",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Shareholders' Equity and Share-based Payments [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Shares, outstanding (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r127",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r133",
      "r135",
      "r166",
      "r170",
      "r175",
      "r178",
      "r180",
      "r188",
      "r189",
      "r190",
      "r268",
      "r334",
      "r339",
      "r340",
      "r341",
      "r345",
      "r346",
      "r391",
      "r392",
      "r395",
      "r396",
      "r398",
      "r548",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/Cover",
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/EarningsPerShareDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails",
      "http://royaltypharma.com/role/OrganizationandPurposeDetails",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r48",
      "r75",
      "r76",
      "r77",
      "r143",
      "r144",
      "r145",
      "r148",
      "r158",
      "r161",
      "r187",
      "r273",
      "r398",
      "r405",
      "r441",
      "r442",
      "r443",
      "r459",
      "r460",
      "r520",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r564",
      "r697",
      "r698",
      "r699",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails",
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r187",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r24",
      "r25",
      "r398",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of Class A ordinary shares sold in initial public offering, net of offering costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r24",
      "r25",
      "r398",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share based compensation and related issuance of Class A ordinary shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r24",
      "r25",
      "r398",
      "r405"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Class A ordinary shares sold in IPO, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r24",
      "r25",
      "r405",
      "r429",
      "r433"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation and related issuances of Class A ordinary shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased",
        "terseLabel": "Number of shares authorized under plan (in shares)"
       }
      }
     },
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r2",
      "r3",
      "r76",
      "r135",
      "r143",
      "r144",
      "r145",
      "r148",
      "r158",
      "r268",
      "r273",
      "r405",
      "r441",
      "r442",
      "r443",
      "r459",
      "r460",
      "r466",
      "r467",
      "r483",
      "r520",
      "r548",
      "r558",
      "r559",
      "r564",
      "r698",
      "r699",
      "r753"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "negatedLabel": "Cumulative adjustment to retained earnings",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total shareholders\u2019 equity",
        "verboseLabel": "Cumulative adjustment"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other exchanges"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOtherShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of increase (decrease) in shares of stock classified as other.",
        "label": "Stockholders' Equity, Other Shares",
        "terseLabel": "Other exchanges (in shares)"
       }
      }
     },
     "localname": "StockholdersEquityOtherShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r565",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r565",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r565",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r565",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r585",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/OrganizationandPurposeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradingSecuritiesDebt": {
     "auth_ref": [
      "r249",
      "r250"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": {
       "order": 2.0,
       "parentTag": "rprx_AssetsFairValueDisclosureCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Debt Securities, Trading",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "TradingSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails",
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r256",
      "r257",
      "r261",
      "r262",
      "r263",
      "r373",
      "r397",
      "r510",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r47",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock",
        "verboseLabel": "Treasury Interests"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r47",
      "r406",
      "r407"
     ],
     "calculation": {
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury interests"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r398",
      "r405",
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Purchase of treasury interests",
        "terseLabel": "Treasury interests"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://royaltypharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails",
      "http://royaltypharma.com/role/CommitmentsandContingenciesDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://royaltypharma.com/role/IndirectCashFlowDetails": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "negatedTerseLabel": "Losses on derivative financial instruments",
        "terseLabel": "Unrealized gain (loss) on derivatives"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/IndirectCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of open derivatives, commodity, or energy contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Derivatives and Commodity Contracts",
        "terseLabel": "Change in fair value of derivative contracts"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivativesAndCommodityContracts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Unsecured Debt"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails",
      "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r191",
      "r192",
      "r194",
      "r195",
      "r199",
      "r200",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails",
      "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Term of warrant (in years)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r165",
      "r180"
     ],
     "calculation": {
      "http://royaltypharma.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted average Class A ordinary shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r163",
      "r180"
     ],
     "calculation": {
      "http://royaltypharma.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted average Class A ordinary shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations",
      "http://royaltypharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Denominator"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted average Class A ordinary shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://royaltypharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3337-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "http://asc.fasb.org/topic&trid=2134446"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b,d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/subtopic&trid=2196772"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/subtopic&trid=2196816"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL6284393-111563"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124256539&loc=SL120269210-210444"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124256539&loc=SL120254536-210444"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124266218&loc=SL120267834-210445"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82919204-210446"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL120267845-210446"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919246-210447"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919260-210447"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919269-210447"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919272-210447"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL120267966-210447"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL120267969-210447"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919236-210447"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "79",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "80",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 6.M.Q4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122651532&loc=SL122037091-237805"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124268681&loc=SL120267897-210452"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13A",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=125515542&loc=SL120267917-210453"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=125515542&loc=SL120269220-210453"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL120267853-210455"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL120267859-210455"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL120267862-210455"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=117411753&loc=d3e23176-110880"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.23)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90193-114008"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90198-114008"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498357-110258"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.13(3)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.11)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column E)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column F)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "http://asc.fasb.org/subtopic&trid=2197926"
  },
  "r726": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r727": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r728": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r729": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r730": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r731": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r732": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r733": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r734": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r735": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r736": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r737": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r738": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r739": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r740": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r741": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r742": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1404"
  },
  "r743": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(1)"
  },
  "r744": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(2)"
  },
  "r745": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(3)"
  },
  "r746": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1405"
  },
  "r747": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r748": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>93
<FILENAME>0001802768-22-000011-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001802768-22-000011-xbrl.zip
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M.D(VBEQ2)":;"\<4K-T\]*\S#VT] SJ[MC%?0G<*8+).$KQGP1(2.^OSLKG
M1B"Y=O5VM=D9>G7;MFU@RDX5&>  L6+)R)AR*)DE:*P#(SJLYZ^$$=%J!)<#
M69\@(6'&S,% JLMZ\3 PHD_9&:OC!>:J/8L<9-/2TA."8%?9>>VI%E:]Y\5U
M9V>L#II4G=RKDI7S!HK.V+;F<L(@&CW&4GH/S3JS,U8'D\T534G6)0=@5$B:
MP19D[4$'K_KO:SN3G;'"H<6"5 %QB(J@%L1LBG<QH45;%/<?L[5D9ZS0*P'8
M&H)QX R(,TK RF0OH\HJJAND5KHS,W$E."J;7(I1I 60_!'\!#(F"DDY8^+F
M1*:]1LGY5M 7=2F<0;&/$(M/5H<2R04T&X/2]65GK#"4STDQFV)R9BC.I< :
MJL&"0?Y+^73+DN S.GO0-90*CV\]XI>T?W]Y/1=417LU'S^<O);!,IW-']-L
M,1%)L3<^_.Z*B^?4.$KS<1F3H$[[_''P=O]MWJ/)2WE'0H3=&4WFE)L5OOKM
M;V:DO[9^S<5#OVVB\$ATVY)(DZ-VX>?4.%B.!/[Y]!SR\.P$9^^</6]G^/1,
M<D*76Z6OECV>/$3+3NQ%]-&@2\F>)'5UD9"M5./.FU.F7>#"D^DQ[2^.'XNZ
M/: 35K8SSG?VRY/'#S>/D9?2R2Z1[#L,%FBA03">HDD06I\B71$<H_'6&_0]
MI\5=<?&\Q&-W=G3E"9BK J6D0%5[8X)!<?%,Q5@P#HLX>0*7N@O*WW(>$J)>
M NTI-\P>C"<TR?PUN-UDK@0@ZZQC7:V"K")R-DF%UHLN^^K,AG%E56;]'J?%
M0[GKLZ-VM1<I\?CA,B X8#'Z"WZP^Y0GX^GL*6=QL^6N_#=>/* \WA\OQCQO
M!E]NVFV]JNMZ-)V\;-_>KF_W^) O2^+3JVAO]H2>&KU%K+I00" .I"5J*>Q5
M<-J6D[:(W:3GU3#E3N>8\AWC5.Y JU]]Z2Z<6.V>L#-12C4X1!6X-6.)*BHF
MI8.85(G7; _"M6NGPQ?'A>CO2^0_WI#@[++;515JS"EFWTISQVB+4Q;$K"62
M,1$&YOP]B_H%*[H9MFS]](U5XCOVJ*RX8TPZ)67)0TS:0U&*/RBMTQYTE;Z?
M"=#/#GGX>&=C,I#^?GFA2X=^3_YX])JRBYJ ($".L4BD6FUR0#X&.)5T V6Z
M0IG+TNDB"[ZGS$&U-E<3;$(/7*I(J(BZ<HY:V??5;'MA058*T"I8N/1(0L&3
M#)@'L^E!6R2AR35(J>NW)V3!6!4+NQ D-*Q15QM V>J-2>6C,F\#D[Z/24]Y
MN>IY,2ED$UD%&LBU%HX.,U@MSDHL%E8+FG4$@!O+JEZBZ:)/WA>3O$O0-JY5
ML,9Q3%9AB.6L!X8_[X%A56?1_/)@;4E:X\G1,C?A*A=;UYT[_3&OOJ%'B%6K
ML!)9<T#Q,VVC7$V!8K#.>,K(AG(YGSTWV#4ZK67V_$J68E<P&6AP%8HV(7*M
M404$: 7\L<F/DH+QQE9W'M=<O6GY&YK^_6CXMCMPGG%P^)XF'Z4=+#&^<, W
M)Q]X#HPZ!$XZ0<9"WCN5L 9 5-GZ[N8L_?4P^[R1OK*1]KCE]:ZBR>E-RIF+
MF'R04+6PA!B:(^9*.I$&%WS"6+O=T?2)W.A3C-XW+WW"K\?MD)WZ6&[#[*1W
MZ1/.S57+=V7J90=3;+52!)^6D@^MW+?UM8BE,+EU8SCINZ#Q=+_K@-C?EUN"
MV=?N??T0WN_9SJPH.IVRB"L$5QPFQ45G T2(VL<>;6<6\Y_E$[,E:D_&\S_O
M'-_A2=X[H-D'&OIT&4&0YO'KEB:^,M/]B6OX> 'GKO!I>L"SCPY>A8O:HE?3
MV=DW7-R!\CO/!/8K#AG6LG_;)0DY78E>Y0)<'99B)'C@Y*JN@7R/6L,,'%X_
MAZ^K%\ZYT#^]TD^+_-,WOUG@<Z@UB;CWT1 X8 *#6=>DE,V,)9[Z;5!N=/:@
MJX/BA.ICVO]PB?KL@,>SL_VIU[R1_:D S//;W_3]*Y ),%+NZV3"I4._9T4@
M F95 ,%JH&IC9!0NU:QTU1A*C]@TP'IA[VU5EC7KJHR#+-9";$;F"H4QD3NM
M4Z545&%T]J"KL';=2-RY3C8U'Q9'*GR=#[MTZ/>DL)B$*L4*NG4Y\C[FB "$
M+BI,G'./V#3 >B%A.+<,=N6\Y@):I20F2.+$$)+\ST"?ZIT-1F+MP1K9$%Q.
MI(*P"8NC+,^#>""H.H'%4S;YMH9P^J!K;&HARMWI49MP;5/PQ]MTP!>"E*WI
M['!O^O1X90%9B[YVZNW9K.UJ^YBS;9<,I6D+P5[SA:,N;'U[-E[LM:GPX]WI
M7QU]]5SS(V6^CFN7#OT.KB%1$#^#"*U=82W1(2D#H(TV'DV'%SF^VF!=DU2]
MFBHB)6,KL^>\F */$C8$94W% "K5XFECX+ERLWXE\'A5M+<Z0!%)!Z2CCM:T
M%(^2,[O0@_I)7X3GP73VAF9E68)'+&5ORKO$;+(.)==6E,YQ2APRDW<LYBV4
MV&-D3LN-O>;]Z6%[]<'1I*VMWIE.RBE8/<$HUQQ8.X&% ;P5G8-&@6<BE4S@
M'C0=ZZ#O65W3EERIJ. MQY0@&IULP6"+*BZ(%#W;!=EK>*[5N*T.&0L^)E<2
M1;   4F\CU*EN PH1@]Z--5XS>'FJ>U,B^56K>7NK-NO:;S?5H>$#"VYL179
M/#AL(<')8O<EH_LM']R9?&D7UNJCXV^S-%\5QCUIX<_[A( M>CL^.#K8Q*E>
ME;,CHF+05TA&- .UYJ4281=TQNMA6'65I]<YK'??3#>1_!5-:!7>V;$$E\9$
M;:K*!C+GY6#HT<STX%-Z/..ZEOG[JA/YH)6S$HID'R*IR"TY(%M/JOB!_%T@
M_Y<M[T#^OS.)99SW/@:;3 $,H=5@4EX>5^>S*_5TN2&<+EZIT-V [Y[\ZM?+
M:?OW[&\95Q<H=U:@\XG<K4>"Z!7&?A_.[H>O7DF20U>RD@1:^:0-LM,)G'(Q
M<XAL?5!(!8SJ4=K?YZ$]WP%_FN+?T'WZAKZTHV$%X_5:\N NEVMURCMV:%7T
M$&N)I1KVABV5G+.%'J2;=QG4-269VZ(U0LF6':BB8ZO(P\0Z>%,=Q-/-'KI[
M6T3;I,!3^<9RU#:&GNS'V>+%WK2\WU/W\:O,'RP)WS\<OSL^$![DJ][UH?_V
MOK/+Q91*)<RMA)(CR,US-KE80B5EO*WN9!CJ\V$X0+>"D:F_863JU>RV%1&J
MP%E6*@= [5K/FJ!U  K1.F^Z.S+/LQ].-.XS:JD,BYW9D_'+O<7'^%UH:W1Z
M:%]&8DY>)QVB@P#1V/;'H:,4(;4!VEV$KGL #I1YGZRM=4D%14J!#DPZVX@N
M92RY6E4&X_WWN;.S#-D?3@J_Y;([?3B?'_%L?G(I'^^2>7RT./G )OJ.JF)R
MN@5<A5KR'CHFYT7HD5><<H=]Q\"NM=@EFTPM7E%$,."J:SF@6F'()83DR'5[
MSW<G"?-U,>9U9@*L<.NYU0!9)]]Z'@&Q31"#RI#$F6&U*6] CL8W1O]?_\4T
MGOU.^T=\Y_C\X;_EI] L[QT_:NE5'S#D[*"'D\.CQ7QYQ,KJ8E^XF*V3[8O+
MS*X9_\\13_+Q7US)A4/G3]HT^FP\>=F3')82O6N-NQ*CAN0#<C4>C(G%LD;3
M@ZZ@ W/[Q-S5I2T28<Q@39MV!5TTAJ128BXB[5*L?6IO_W6^\<I"NPYLM3%6
M!7*98V2(V9#R!@.SC3G6BF;C%DBN!\NUK(M4S88,5?$J&9A8PGEE ]M<*.J4
MZ\:MBUP+ENM9#E$J><O)$UJQL:I2\+6T52XLI740[Y&-_3>7E^+<[O%\_')R
M4B[I$HIG;W"Y/3\]]CWHUQL$795@D6AN>L#G.1>/IOD3]^$7&D\>3>?SG<FG
M+O8:EN>OW_L$;VO6&(WW&4+5$4PPRF=Y16)_WR?O,["\#RQ?BU\FZXK6EBDH
M XD\.E6-CE[I1+GZTB._/+"\!RQ?CV*I7%75):"+!-X6 MOVM9D"J1:1H(-B
MN0*>G9'\_MM#^?S*4J.[F):T'H6B04?#V5?0#% M2GSLJ1JOR4ODG >%,K"Z
M?XK$*:)"R6OT 4!;LKJU@R*+%J(.?9HI&%C=05:O1X&82 0<;9N*!O2 3D.F
M&)2/[&KU&Z1 MJ>3<D[L3C-I@W3UNBH7:PXVY!2]!9T=FE"HMF;A&)SBL$$*
M9&#UC9D3<6W=,'O#J0*8$+!0)$Z@""@9W:<]' .K.\CJ]2B09%U$[;P)5:BL
M=:K!U!@SD\)J;)]6;=8I:3=G1/52<6C-5$W;"FX3. @2*PK#7%1BG+,J?5J5
M&5C<!1:O16%$3)$LDK<&@3E1LFRK4LY6S3;V26$,+.X B]>5!^*(,F("L%"<
MC=ZG$"$[D<^V>.R1HE@+DZY!J:Z8U9N<;,A5VUPU!9.@>!L3!56X%L]9!3U,
M90QD[H^^T($+YE+0Z0()/().P6A#D;(IT"=],9"Y.V1>C\R(7D%"ZZV8Y[8=
M&!W8X$LP0N="I0PR8]/(?/7[_=:O-VJN+5]:1QLM@-8IU6J2#:!SS!QYT!L#
MJ_LG/((IOBA;K! -G"K$$0UF: UR,%D["(^!U?U3(*V]N[(Y$5D"[6HLVEIM
MA>K6DO=]6CJYPB*,72)Y+R4!V:RKM9"TUE!,JRF1@'R*-GD)Y5*/),% L^[Z
M:)U3K+FT?#24P"HE(51U#K+U66&O)@<&FG77:0;O2V7'X)B@!D/&LT.C?4I6
MF6)[4$.B2Z4<[M)\[_:DM+]:I9[7M-^(<_D"MJ83/MZBV9^\[#NU,HK?P#(2
M8G!+8M8N>K#@T#M=D3-CZ[&D7/?)VQ&^_.V!8P;R_NV2F\YY7S-8YR+DJ!&P
M)*JN6&^IJ![TI>P[>>U WK]+WM9ML.I*8FX3&  RF0*H&+(-A0P/Y!WX<FEC
M3<G964)5 ,!H%:-*[#$1<3#JI"ACMV/E06;VC+RKJ[-' )GDCTMBZ;SPRK5B
MYC5@5$$G[$&%R([P99"9UT_>&$UT56/K$@S)&BK1*D03E;+5IC20=Y"9G25O
M4L%A1!*I&2"B3SE3(@GUH\IMZGT@[\"7RUV=M6>0F$1'"\B9BJXJ6%:^<+;5
M=S\LZ9W,;/TK>-9J^#XF0>JF<7=U(5*D*/&0AI(KM^KCJ52#V(H@Z9 *FNYS
MMQMT&43F&B;BD;T$0A1C]5 "1>?9*=2IS<R;L"$3\1WF[HW3F*OC;I%@R!"I
M0N@EO%>40S4A5L>8^2Q &K@[T.6$+KDX7Q)J3)Q _D[HG%8UQI0C6Q6Z'Y(,
M$K-?W%U=>.2<Z$B7H;4, 8HU:F\154K).I,"=Y^[W:#+(#'7$-JS)0+EHK(,
M/AOB6%L>'& 3G @#=P>)V57NIJPRY)!]+KF50\$<.&')T9?H29>!NP-=+IHZ
M55R.2&C(030%2P"&E(P!'5P?DBOZ)S%YUGYSI@7/=^H]/IS.STYY<QB\NB#)
MV0P>,((I"82[I)U$2]J4MD\B4@_FX;M$FD%NKF$V/F-0T';TB/%5NE)R%KR)
M@3%$&WO06W$C&'SC1.?J& R8@("UKD&#J(GD$:-"YZUGL$X/#!Y(\Q%I5 @4
MM);()!% %,?M'2I#L;EQ3KK[D<H@/?O(X!7&VA$3!R]B,P0(D6,-R:!5T>7<
M:MYUG\%=(LT@/=>0;NQ]UMZD#*# 88S!A*1CC0Y*HF '!@_2L]L,5B5X;!N(
MO>@&U"KZZH))A3AH4U,<&#R0YF/20#7*LE9$!E*N%#DK5$XY0R:9T/UXY<%X
M0I,V__V^9L"',^2SP^E,^'*/T^)IPV>\&'.GDM57)GW[0N 5;N@MWH>"VF3K
M@%3&; ,2U]:CQ%<:"#P(SVX3F$5O5N:L$3(H[<1=!Q.3!P_"6X\#@0?=V6D"
M9V="9F=T:PE50Y7 WYB64Y]KK+X/D_8=(O -X8R*,9EHT%'VP-%1<J62IPA6
MN9AK]V.5#G%FD)W7'S=I+)B*U4X'!]5:RK4:("8,!:KJP731)A#XQLG.%<[8
MBZ..E:N1!Y 52-P?O/-%L?#:UQYD)6\"@6^<[%QAB04*/OA4O5<(7@(EPYH(
M$FO/P4(?BMMTA\ WA#.I4J4,%:HA8!&A51?2@:-PQDD(LQ&A2F=SV6^<W%SA
M=DDE,1++*8LSD$K"XDH$;,4W@Q,5.A!WD)F=)"[$U$K-D=$&091FI"0<=JVL
M-CHV/=CGVV?BWCAYN<+:B5&C2TF%HCT$XU)(WHIR*!+Y*V<'J3!PY7THHC"!
M<JU.809O8Y3P0WN;P1(0.;\1H4AGC=R-DY6KBX=*\AHK$@9P "$3)AM+:$F;
M-J+JP?;>/A/WQLG*U1$WH$\V1/)59U 9H@M8O;,2WI?DH ?YQGTF[HV3E:LC
MKJG6! [:8X[@3*O(7:*F6+7EHFP/:FMV@+@WA2L2/+>L=*.AK3$JU*BRU38&
MI4+U/>A5T2UY]T7B#JG%*XV*4D)3C5<2"T'),6G0E*J*V5>77 ^VHW>&,8/$
M7$.*DC%9B6]V&#UP"61((T#.04,VIRE* WT'H=E-^A;C,U+,)<8(/NAD<B /
MBEIYA5 &^@Z,^;!\#&5T6$5RL@9;,Y4BI$E@N3*QIAZ$)H/<[!M]5Q<M,4NT
MU%;$A<)0BL6$["-187'>$EOW@+Y=8<P@-]= 7Z<K> XFU0)"V&@A0RT2)ZF:
MF#=B*K[K]+UQ<G.%] V<M5-9>:%O!4:==<S&V"+_<2]:#7:%OC>$,463)K+6
M:0HB-UN"FQ.]:6JL,;&%'@0HG9*;/2'0ZN(5C23>TNK6 P",PY0, MF,04N0
M&_N0$SE(KK7.\($Q(48G?RI$U*@]&P_9A&H-YAM2\??&B9[5$<C7%!4GJB%7
M(- II!18I!!G\6XJ]XI -P2S7% $1^ 4C %NKL+FDBDA2)SE4P^JP@^R8ZVZ
ME8KR+64CLY)!;VO*N6J#R%!]!=V'0'V0'>N=J'2E>'$67D4H*2"$J"!X':*U
MY,W-(-"-DQVK(Q#Z:CV$Q*FM1]>$6MND@]7:I:1]'XIGW#C,5%+19U1R+PU$
MUE%7<-Z0JQ)X9-Z$Y=@'T]D;FI6[\K-GE!>=VF=_X_3."M.X:E$)DE?&$X16
MI0=5R@&5!E-R+[(0^\S<&R>T5KCW5,([E9UNQ2!%G >**A=C#=I I:A-* W9
M9>;>.(6WPN2M[!T'UY;46LO0@H78(UE0+B>GRL#<@2P7FB:!,U9A1K! "H@+
M(!>=4#$5ZD,XT &R#-+R^H.B'"@I3#6Y5*"0)1!1F;*)\GK6J0]3:7UF[HV3
MEBO<FF43,KL(69QR8["V"+$$MAY,3)M0/:_+S+UQTG*%RQ<A6:4D#*H1(.J0
M2JYDC+&(SF+NP_I7!YA[4\A"H>9L=56.(!<;K17C)LRI15MC^K"%KU,*[TO,
M?4:SF4!UTPB[NEBHVF2+"B$KK:'UCV6J@)HUITI:Q1X0=GT<&83D&KI_.&+.
MR5-A!>@\<JS6EIA(.8.F#RE$/23LC=./JR,L IOJ5)1(O4+P&%LUDUJ]KBE0
MSIO0[6/PPM^[\*)1,=N .BA@FY.)T#;-<TBH#/9A*]X@&[M/V!76!7>.0RX^
M)/:@4D[9IRI4U3F5J&@3JC)UT O?.-FXPG0BK;/QQ1GO \28D-!"#>*<57(F
M;L*:3P<)>^-DXPHGS%W1P?M<3 Z0=4'R[!,$$NT()6W"_M#!"W\G1UK96<B6
ME2D16MMUDSAY8Y6SV2/!'_>:2E7R[ZBK,<9\MKAU=WHD/VIV2+/%\38=\ E2
ML\/9VUM;T]GAWO3I\<JFI'>/#WFGWF[$>\D?4_+N='^?4FLA,W[-%X[:E4=S
MR@LYU[/Q8N]QN]3=Z5\=O7KZ"$5FBWNTX).X0[4_Y^<Y?^\<VO+^T$M<.WOG
M;W#->LTA6B[:60C*1&;6XCJ+9^5"[4/)[HXZM-OS.2_N[M/\@\;MK:/[XOBK
MNQAUQ2A5K52U227P* K+4ZX2$S@"C%Y+A-N(HG$@2C^)HG&%*0%:.[*>JQ!%
M:1=U\9$C&ENI:(,]\%X#8[KKL H80 C%$4?0+>(K5%TD96LIU?@EO=09O0;/
MU5]ZJ:^GEUH9O3!F S&P2\9#Y)"TPN*#L2EZ9:SMP;3^P*KKF-L/ ;Q+4(EM
M !=M+-9&,4**LTHIAUX)Y[_"YJG<#Y[??CSCRK,9EZ>+:?ZS3S-175'/WIB8
M+;#UZ &53:$8BSHP^4C^I,A3;]3SP)8KEM"$BK5'EO@[@[B>I+*$7-85I8EU
M2/V4T -MNJ2CD\4D4EI'9Q1PB92JR]:W\@O*9 []U-$#Q[HDIFW.0,H81:*1
MP+9:0Q:I@D>-K3!FK\3T0*VKKKL> V9GL&H%X% E;\F'1$45[6OL0T;^E]G2
MY]TD71'3UGE7-&L-SD..D5PJ1+6"TCKA2>FRWHOI&TN4%>KH$G0(!=O2EH*:
M?(O1404D:[4#6S=+1]\PQJQ?0E=@ XX3*9U Q59/PYH0DO5>#)33FR6A;S*]
MUJ*>B95!':H#$R Y$4<FHO@[[5Q!\7X;H9YO&*NN1#B3XE L@],$4+5/5 LH
MV\21EIC>;I:;N_V:QON4]KE.9W/:YZ]>.?CJBWBZD!';+GSY[3MU&=$-0=_Z
M':YX69^KZ'[+'G0MD51HI:<C%!TATD#T[A%M]:/NSC>-NEX2G5BG5@I&UV3
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M^/@R1$_X]73_]7CR\O)!US2K=L[2*[Z,COEW';_:O[\_]#O\>].D&7-,,4>
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MS*)4-=L$S!B#+UF8$VIK04K4:U+=/(6R?D*%R,R&:@Y%@V^!D K!*PFP2Y"
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MT#38PG<";"+NY4G<$7:[.UU!D73-7F;(LV5_.CHY$-!Y$B?Q81'!(*Y0>GU
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M.@NDQ,5K4/>:"++^'/1T1F[VR](G?OWM"ML+STTE3?6 Y!O82%<575E31,T
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M>[PG%3\L "NPDXB[X1)6 >8FT8"DJ!VPKX(8\+TW[ IG[.G9B"$00*TXR07
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M31B*+#=5L91F60S4(TOK""%@?X@[QZR/*]:IO@W2!-_H(XGPL[AK*_31HXX
M #8"V.$A;[EO]^? H#A[$.@5"0OD=K"BNX@C(A[E@+V;JY>PQZ,'*5BQU+B(
M:)H4&<<K &B.\H*=U#&!(?8%9B<(U67EY9\E(VC?B5WQ G@3C^6.E517#/A!
MAJ0\I"05, _'$W:I2R,'QE?ECJ!(BMQ=D*!\H)1^A);!E:J?P"- SKR 2U9E
M@AX9#S]9I.A1IA'$;E@ [E34E98I4WGR;N;62M-<1#O\G6I4QGFI4HFRM0"-
M:CZEAJ&?<5\'WP4NX?T(;.12@\](2&OB\@4G2 9] DS#I07S8:!\\0J7]]?A
MO/H:V8Y+4>"DR9"$>%CO-R?R5">"G(<X08@IV7 B)\>M;.N.\.7+CO &'RDY
M'/\N+9G;[R@NPL1%MIP5 ?-TE%H!XVH%DR?$_:<(4KHYLR<[LU'&U3 J)D88
MN+F[  \T0#,6-#W6U\I#L9T,\&Q%D)D].IL"T3#P J]6#U&(X04X.>T-V:EZ
MWI3AIKP,S^*[U3<H__PD#)(-/CPM#3<J-E=*PF%EG3I%!L-DH!LE'@TW<'\R
MN#-]N^2=@.9@$[L 9K] G9FRPC^NDW.Y-1PAS8J6-L>QJ.- &R5%IL1-O&A
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MU2G?PR&W'>=;P)7"/Y-^C%K1?T@T>%_]5:]A/W+2X@K@U!&VLYS"Z9:=UWU
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MMZP? KJSP/L P DF-K?*P>XDO3C!DV&'FG"7TNB"&0.%7W*V)D &O$H3C@D
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MB) N@WR(BTR*M*P!#2CP@/%R4"$DO1H, YK"$B)L/HJ 2D":_0,;S,L;UEQ
MBQYF:I$P' H.%6B6!Q$IP4H&@W (",9F'!1.&+CP5-T/KID9F0J0#RYT@,M
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M,_0Z"UDQ:#QU&9!&@$UL0(SVTN2:W2/A </B?B.N2 5QG%RQWD:,/Y:\SYF
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M&/&^>ZWUSZ:LS2CZ\.;SCZ_3 L4@ELA\(3@X"^N'*W#<W*,]D,9F8F 0]=H
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M[9THQ=32!7-=EM9O>[)\ESN@G<[)\@G!2C0=J&4J.A""XW#<0SS_X8+8QGR
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M8ZV!*]>G<=Y.%97F:VMQV8+^0#4'4]&!/TRJRA7O;^]5$D^-N*'8*+E7P,=
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MO[NA6YG1Y>EB>MHV6J.[1P%U94@_+Y+Z=KM3E0D>FRWT80ZB;,\J]^,[[;?
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M\.D0^$NK85O->K-!1/]G CR%AQZN/^+3&1)71&LV.K6NI=:#7^!RMW <V-(
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M@6OR5P3 MFX I$ 9T<2=1523WGMG-2Y^$?2"O\W0VE? !A"0")[/F9=PX>B
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M=A8.EC8O9O@$IOES]CTB@6?-J-H!M3T7FP8+<L.*@U!P!=%=0!0A4U-6V@'
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M9K <1B6_+/]<HS_EALV(OW7JM5:WL?+/]=KJOZU;ME&O=?J=O99=_[?61?O
MFWWT63;'!H##;[9;;QX26\\]1JX4P\\N=H^G$T<ZHP!;D,"BHVCU.,K^-J<5
MGLQG/N\J38].]S\D33XL29,M!F!M'']VI" A.3J/:D*.7I+CX="#&'<902B$
M=1S,WN*D-;*_+ 3:NJE\Y<3"-L/Y-I[V18&L_N2$6M&G /8KJZ+.G0#VRS8
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MW_2F?K1]40/<1T:C/#$#E3U(Y5FZ,R,E/V7Z0*<KUNZ^EL=!K*\\3:>>.XW
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MC4M[T3@J65J=G8<EZOA#L^V6$XL_?(I\9\)6X67%'[#:Y*!32G7XX4 EGCH
M<?J8U]S9?!SI3C+G:+R<6-#EB_,7;,7[>EEA%]L<C'34I=DXZC6O@XB.N1R
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M\=_P#_D+<;0K5'UO\$)*<K473%B0O+GBGQW\YLCJ 0/]OUL6N; ++*%RYTX
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ME8V"[B-3+VJ:%X?@_AVC.8VT.[ZL8F<<>0VV,L0.S>Q6KI 3X84S4&PR*)V
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M\"IBU(LN6@ERI,=;QD?>5LT4@F^;%4$<D.%?=.:&$Y%) 82>,)9K_XGT+BB
M&\)5R,Z()X_Q@@(_7^F4H[>B^%^[U(J)VA<X( #50=EP)>,<;=R_I-;)X$H(
M06<#>15U$RB-H.  87>8R*,;HSL&6$]BF2,#.T!#7[!SF7F!I!#W*O" UG>
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MX,)9&9/(N9=R"+9UA</FI4!2D0^"+,V;QP#1%O2U<JN#3(J8T!/H@N.+' !
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M^5_:"&HF&[T'&U:&VMI%/EH/KQ7C9A@@MUYM#++E''(DKBR,@_^5NWN=P^+
M+@Z1]LP+V80MP.SX\?K#*Z)UO'9&+W#]PORCXP*=&^]AE;DW]O!O&62"==DW
M\+. RQZVQ^Q>%M_35-I$*OT$B*XF4B0F($YODE8$A)$,_@VRE'T3[GF\.9O
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M>DC7 N6KL ZND3C@9/*=J]?QQ V2#4D$])9S/U'E>CXSQ:T1-14$/O9F>;O
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M!ZW>[D \.G'^SOCXA+5FUFK>0PZ6X73*$#"FD80S1JTZ.7CO',_GW4.Q#2N
M=0Z Q*< F  T;"9*8R.H#RJ7"U(JB.ZD4\?%WJ T5^&&N#G%,18S'.T1R);@
M?!<N',K!GN @CNG?\$S@4 ]:T3"UD7TA&6]/3AM>+'V/(D4<?-5MC)]OND+#
M:*[>H*&&Z#+>.KNLRWYE=Z%_AW3YCM/O1TZ_JPVP/Y6.V@5A:_5R"HONN&G.
MBI@;M^#]ZKG$C!,^MTV!1;!U-OKM)3(PWB#:[;<"9M?R2_K8>ON*SW<I?\M?
M%>??1,VIU]]!78BQT6^<CF-OXCG1RC1^O35^#/T)[WT,K,9;R++(+!XI+)Q\
MJ/0,210U>0 GN#G&U+MC5]2S/WV8(CB/J\:UV*\8OL$Q>U,C7=+<'0M4AYI0
M &_@7:U]$!31,B0-M4SAKYC%&R $Y$,@0J@L1&M%J0LW;PQ>O8;L_H8W"*$;
M9U(7C#2@MVA5(7\K1=TF*4?OV[S)B"WHO2"N(N>>]S[/] T<(8WK"]!:S'AY
M4Q6&C9^JT$!E\%DP?I%@L7%_+3'?Z9_<-!I0#A_9.$J1Z2TUWJ!B"BA-E/K&
M.\GC6!?@R2\1O-@1\R21A[&W_(Q&$W"++O+&:<)GN_QZ>P,V( :F ;(H_3Y^
MH9_@LC^QF>.N##YS,8QBX]:)$I"6\=Q;QBCL;^!A-#K!_L8I8V&:@,;@<TCI
MQH[DA^M&*1?\9-B;?'EXH1>0'L-A<OE?*@^ A'%\[RQ!$E=L<YN"<>@%AA\"
MXM8T%Q^,Z@1?49!=+P _KF,:O[2N6[2D,X&=>7$2D0R"W\%O3(*'CUHXXE/L
M5GP, 0XV(.,=<$^39_#?$GZ\P3[-O.-:%)]'DSOO9$D/2\(Q9[WGH;($7\#U
MEJ"HG 5>@O+I!O*0,1]R4,OFS\CF01^D*/_S_L:^[&5M%F_:,>>VA^3AB9O$
M9)[4.BBW>DI,X^6$)I$Q$G  6WN8)_A($0IR;)"*N\O>>DSRL'(ZS@BCW^+G
MGE]D=1HU9/ Z&XI)!\T&89^K4?$[DQ.\U8#Q[- >3B*_<R*/<7\&#4[NY;FP
MTS&H-U $86$>FQC$AE[@4I@&- [)]9TX]J8K_DWA3:O\+-)8#K/+YF. WH6'
M,1[UYKG1(&X>KO!:[$VW)^_*Q#I71\4,>>7]MX>)_5:QP]L"="S2?%_F7C2Y
MXM;.KY).CAF>IIB&9;TUKA4U>2(\@58MB%T,(=,%DD%6X))%Z.UA#!K-I7!Y
M15.B^'@HLG@< X0%"V+&:.W!VQACM!1TEI0+QA]SYP&<<;;"@4YHH-*\]I2/
MD(*7)"ON6B^</T(9#Z!19'R $\T1!AKW0CD:1@RGRN"K^'#+",)="%CSPO/R
MPN=5 '26>*[QVOAQ-8[ ZF@:2\1JB\_ '#@/5+B(?)KF'?.1TM&D>AU&8O <
M'Q?MD&_C+.GN@4E["(-KZ'("(%N5NULXH S\.,3IT'XZX?N$IY%A %+H<\)V
MY#T0S5(;LTQ!3,A9RR56P3?,6>"&IMXWAHPE;I#$M=02!VESQQ-^'+MS-DE]
M1OX8H$'Q;'FC- 0.'#3:ZL+YRG+CM]50T64Z!CDBAT.+:" -, UP>!M-K.,!
M0_C!G>/C/#8<YQJ5GI4HDTH3@:@"?0 ?5TZ$DXH<IY0+@&Z1''GF[O5:[;W*
MB3W>>=B/N!]O'UVDP!9*(F78ZB#8?OV[LUB^?6]\Y&QR)#E"$%)RY'<Q6'#N
M8<P'4S" V)"/<9I9, O12!/[!L6X6LHG@%!])P*^'WMA:<PBIVWBHW4!08,J
M,RM4BA?)_[&8^*@X@A3P!-;E;ACP)?Q>R!D:"HEWQ7=LTE(G$8P+ B9=@LX'
MZ2+AKB0$R$/8=D[-JRV3J!0V\[9=PEZ$C,05@3Y1K,H]NQC$F>!=RF.'(&I]
MO:.^_IE0?'W4; K!4L<#3"[.=61WL^!FEL,H$E=)+G8"ZGZ:L" +2X[3%<9>
M05UN$3"H:0,^3!<+_T)NR9.S&@97%--E,]#3X)ZR1 V(35!N)4H%9\XH*68_
MI.BY>#;GO9*$(>$"WL-7%!3"">:GJA0A/"2\[03\7O4>D.7- F\*WP9)WCOX
MG66&DWRO7/W!=?G(V*J%#3(TT$Q!0X.'S3'P54 <7O6"B4/7O_DX5TV79506
M6]WZ#DLC4L]V##"]QUL$O&JA4 ?>  -R&,X7!DI^_5L 5,+_/GC Z>AI*;\S
MGK8%F_8F_#H]-"0TA"'^#J-(X#F$$9 0AG1C!!]]_<(>]EHV3UP5>6#2$J=4
M 9XNT<C4I(U3"QN%'Y(SDQ#$IA :X&BQ66%N.1=X((F,/U.0>SAB6Z$3I4F&
M6@=O @%]2^:"W,'4%4H$C.@+WZ_IM^P2WC@)!B"3=%*0$9*TNT72QM':>=&1
MYD3'$F>3RY#LS>TGY(-_I@&_QR,T/HG1+ O ]Q"CK0VJ+&@*M36-Z *B!YU1
MJ[.&Z#QN'X2T-:H)T_JZX_(R<D:-S\C9MWNWHUWSB8Q8$;0PKJ,(W7ERI _/
MW\U*&#CJ%F\RP<_32)T@ ,'G4HRP$"857I",FBRSM![AD(71<AY^7I&RB-,E
M7E]D'XJ+DKPK1/?$(-?P8H2, YF>B-X3!8YX68;,<FT9USR-1KI5N2WPK6.V
M#MTTBG30W)Y$(F>GUY8U #PC445?%&E^'X+"DUO)%D#_"1,<#4QX!]B$@<@P
M70+@PTGF<]+N<7',;MIVW%9N=2\650U\__0BQ\"<HD6ZX#JUYLXI-!VQ)(T"
MGA;\#2RHA&?ZNXR2D\37O*K"IO0C'D#F64)9X(X^W/@F-.0HQR<,"O;<V(GA
M. 2F .\&$$H(4)G\,/6BK%3#& -5!;R X#[DSQHD+/FSZBZ@.H/4S,%P[L1D
M>LHTU)4\3Y;FM!EJ%VAD? J,ZW26 BX&N:*=0DH<PNPSK XO_=[XW@O1J@^,
MVXA-680/D6]JW*:1"\!GN6SDER*1_.$?K^68BU0[^7P67P@7"R]).(/(X$7'
M'(WLG.GYX/NX8X$&L$M,^J+7-D'5(A?C78]XE!8L9L3#VUGD>N#-_.2 ?)SG
M%OY %SAR_Z;(04^HA)^,\W:[U2[:;%M91XF29 ZP,1: R7DL;+F?'8"U(G]\
M(DQG\TU/E_FE2]*AUM)$#,"<0+!+CE\9W*H!XV,&$#%]2WB?/#6=<OJ)>(@T
M29C:HU:_B!$N),BS>1#5F_+9F^F57Z!HD[<X/'(J318G9W1F<@4Y/7?9#5PH
MPA5<TN"/U=T/QB[O>/(?" S@\P6_[4:RR=WD*,N$9_5F]@@&-E'U8Y!59,B1
ME\1?A:N(R^ % W]NDKLTEF[=]9V@5_A,5..A:L2T$24?LZ5)2/+SXC%!O'"]
MOD1Q332<V[6I[I1])@T6;@6!3)H#= $T:!E2>8D)R_C\FK_TN@QJ]*5(9HEE
MRD >3)SGXA1>48DC+^:I+Q/22 \<D&\U5_5IO.A:9;F[L<;E+)V0]D!<J&#<
MGQA"%@>MITKP6+]D!I%1(4Q P)#+XGB:^L !<P\P*"6I7*] 1A&;I4#48;02
M%ZNH!SF!"KF:W8$2^2(%$/7%#^1ST/[0QBN019:HD@4:8Z7IMH2<N)*C2(L#
M2@'5M)'3T L1B5)Z+L>K3H&0LYT2%.\QR80#:F)0%3-!,<GY+B&6C_T%J\[8
M$N]4;LF ZJ"DF$7.XL0)<M<[#ZS[@-7NT"BKEQ4,CDL3#[ZUX<)&'X9[.I34
MD"O9""85A>V9F2(JON^$:Q/ *:GN4?I07 !'C#M3R#A E?R:LFZ:;+U2#&JI
MD<7TJ(<'@-1WEC%[(_]X*WNJ>@$!AG[T=N%$X/W)?B"8H5!JX4&[X5]G<;%6
MF\?&1 LP\6;Q=8N^*C4DX=_U>RU[T-WX=;ME/?*[SO!QJV[;K-5K#2S[5#;;
M;?6Z_5K+BN9MI<BQQ;FYNB/9CGW;DG"YM[X\.Z:0O22K+4QAT4E<IYE[G3YM
M$3#PLMB-L*&]SZO;%]TJ$7<KI)H&# 'F1DK[2KCLGW&.>?;_@-)Z)C+8]JAN
M4/[X7IW-()]J00MVE+V/?K[/ [R&-=K;,)1D/TU>F])*;P\3$P[7=UA3L*;@
M39.;^@,33/HF4O"!^C3OT]Y_2.ET]MJ468\:V_\X-XVGC8*E8PY[IS\0KLGB
MH[L/F[466>H95T>VR\X;2U:O;W9V%A[-FPO<9.'1T[:'MCW.%$^/$A_:]MA%
M?/2U[:%MCW/$DM7M7H3M<=11H2JS0!LAN\*N][39G=H(.92.Q+E5IJW-D#V*
M$<J1?VD]RYS[1]Y\G-,(K>>]%SF+$5K/.S_Y&0%T&O>"FCLND#ML<]@;FKW.
MTVX5&SCEK=CSB3H+%YO+[*?;\+!6T0JH06P,C5T-,<^W_B!K4636:8UJ%3O(
MVE9*"58OD95D*N48"T<#K&25&<99-97O356/)$I(]E>J?7\A!;]>BY\'$:&[
M#Q2[#PS;15CH[@,/=A]8,AS-0"/C)L8MBV)L)U:1@;HKH3:U F-K2=!OJB#Z
M9R=P>+555HA+13'8I">K2WT(?%BV!H9\$AK]5N]O4C1<3W!0)#;BQR$0OV+Y
M^3*)J3R6:K[$^K1FNV7S'U(W56RYCV5P^::IO/+AA^OK6R'8\!74-FAJ,"=;
MKF5\SUP'^S'C P_NW(N-7(-752%7O7<S5R;/BY&H:RSOXRP$)G9@H:HW&C$
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M ]IB6%/ ';")$)VB=<?+8F$YF^IUK;?\GH=*7#_GA%.5VA,[*!1B5I<%?_8
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M5S)2)EM355J+%JQNE)O7640OGM-9P;$B^>_"R<VG5I;H!6LZ(]XIJNL+U:O
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M(-[F*+F]'C+'?@'-<7MUQPTEI VE:'I4+'"--P[U\/B7'\P\[-)G<:]AB!.
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M_X_1'X] S[CI?_'$Y(R;[W)RQL/UT\Z/GW03?PXDB:>[Y]L'NSB0)?IG_>C
MW6__]'8/O[*]G<V?'\EVS_U[^VSOFSW2F/+=G?6SK9U]LK=F\.Z/]S\V/[S_
ML?MC_RR,N^.?L_?MG^[>3J_7P=MI9^>S?V\';^ZLGV[Z]VRNK7_W]@9C&CE
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MMZ^!8U0DW@0GCKG8?I9*6*-<LB8K=,[DV7/WMC1R_01R72D7E2Y1C'-@I5*
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MRCTK7KFDW@=OVYF0V]!-_7CBO3!(6^&4M?R/1?.2UE"-76MTHHY&31+P8_E
MM@(,O*NB0$F.O.9G\RNF%ZR?FMZQ=3:\<=!W_<"@/'1JY-9<]O=J"**OVA_'
MHW%,8UCMVQUU.GT-I]U39\&Y&PZ:&_A.-W!GVJ.RL_X="X,Y5QH(^?_8^]*F
MMHYM[;^BHNZ'G"JUT\/JR3FE*HXA"6\%\("3XWQ)K9YL.2#Y2,+3KW][BUF
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M*QI+F R@3& N0F&0N6$^8JH/5))HM,4@<*TGNPI<5ZM%G5TD^2.&:P'"RTQ
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MNTI;XD;BQ@>!\#S<N+ CBL2-+>?&V11FU7W.Q2A9]JB;$:O(@JAF9%&YF?(
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M"!/"BQ@)>6_9TB94.!L&64_O#\>3@SR8_#P:'JSO/MOZ>3AZA?MYMYS%%"F
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M2#FKX*N?36<2A(JE!SDSB H.N[*$LKC^3826(./&YY*7+6KV^>A]B6=DY7'
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M" "24I^[000-4S/\RPP>,>*S9PX/;QOW_KFW]]8#45VEK0:>IZWP/&4#S]/
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M!(_7#2)J!RG@8(G>A!>?W=1\2VG8&P.0;CIU"BXMW_6'F3D277'XS.!7M1T
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MK>H[6,F79E'Q;T_. S+-Z9?' 8Z"E FLF0X20G'Z+D^TAKB2\S332<CY"J]
MD.#(Y%RR--:4)2(O8IYG:1S(#,+4/%WVDMZTL4[9SLIU?=WU0GS"X'-1HS/D
M-2CA+3=+@(FERGKN&J_*B6'!DINJ2./U6;*Q/V[(=4=XO0\XS0^N -^IGX^.
M$ B!E_4GAO5&>8[.3??B"-$]IDNM_47OK6?>;\A)A>/)O0QHBR"9F77!V-+
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M#%_J52?[>F:T&GH,8+@;@N'B 0PW@.$&,-R:/[L+AKL6W+8RD;-(9!9'.2O
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M]I;-BG!<]F\T):HMOT4>'5.R@:H;M;356=Q_EBRR[@VV9C4KL+I9!Z_Z+J5
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M5FJMIXS>;FM6"K&'#/5W;G?/'<NK,O?VX_7)Y1UXWP2\7R^8TRF/*8P<8>X
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M$?]*;>/ZEUE\>1\I\4" *GG%"4M6*16D]!@'(8/P:Z725V>OM9KG:H9[/H^
M'??CR([\\<4M]GG!%J1T6UP)2M^(LUOD]><0MN&B^O,'Y_*+HX -%2X2))S5
MB,,_D=%6(14YLY8+FZ)>YMIU\F?AK+^UU/\[@K57V9>QV)I+">(S-,G8 A2'
M6K\9CV,-.B=]Z_HGH(O#PJ;C/%EDZ58SAMCJG1_W_3%L37:C],=@0,.UHQA[
M)_&?>#*N[-NSZ23_VDYZI_8"#&6X*9@E8)2<5O38OC58J&EX N9I*T/B5KK
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M-C%(GYM*<=X2#P^?%Q0W%L7*2,> M&4BGF//M5 F2<%LLL$)?NL>-$4)/S*
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M86,25A9TOWQT_^C3)HM5_F@0OYR?M]JSX )%1$6*N  %[B*+2 HOL+0D"*7
M..>\Q<G5+K(%XB\%XC_ZQ,D"\4>#^.6</4D1*^PD"H9FB$> N- >!6N8UD&P
M($@3(?X*MJX#2$YM+_2KG\B_RJ[UZ^+]#FOI#=:84JXCT21Q(:D521OB8[IM
M3' -!OK5#MI?X[!34O$<%L,Y8C;W#L9#<CH8E)2TV6702 =F4=2"2ZJ4\):7
M>K^7#UJ= G;<24REY2HD*PUV7AE,. U>V@+:)P?M-+,N&>&6"(M4)!YQFC"
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M"0@UECT69C,UGCV*@?50"MF8I1"^RR,#?:,MTE11Q$72R!#)D%*2VV2ML-2
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M#>@?MP']\TK>W;5'_+O1!O[2'+XTAR_-X5]K5V6AE?&"FD0PY\)@)YF5RMF
M Y%)A^*D/NKQ8MN_?-G\^_WYYM\[>"<?#?;WQNG.P0[96H-[GG^A&W]_AK'O
MD,V/5XX7.]SX]4^R<[!!/A]\./B\]F%_Y_R7]N;!)[[YZU\'6]L[WSX??3Z
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M,G-VVW5'!WWOZ-'F35?V#*N_+H3-'O+,KV?BWHZ]M'KR6E4G#A:!NA<W3T7
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M"='A?. :D=YR113UNX2QI2?>Q/K=FA/Y^.6#<R#?F(K \XT1@H_;@-"SSVN
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MC<.B?AS46F'$P/!>[A/0JMS)+%&/%)R/ /&1ZML#4=O+DC"E\F,+%L^@6YW
MY?Z7!>W_'G]CGKXIZ/06!!!>' "[[>W!U';V5H_ M!N\Z_;6)[RVE?X8SM/M
MO 7S3+V%S__L8W_T5\?^;4ZVCM[#YW_[LGGPZ?3S 7QO^T^\L?9A?_/73WSG
M?.]T<WN=;<%K6W"-;/EO;7\A&]OK=.-\G6V<_[G+8I(:E@GY(#GBPN>NU2(A
M&07!&MO$<#Z@8)E=4YWI0*#@MV>)]-@4I(]5 9A<-95[V^N=9?(%V_$D9KNL
M#@'5/#M4\X!X%T'&XU!?7!^%7ZX EYFZN]4P'%_OC28_S\3P)_'<VBS(U_L#
MK-9V-AGKZXTR=9E4QKFZ*B?KJCI;5Z5>]ZAZ-PE:C4V5U3IH55\@/VH6&7BW
MW1D",XO,%8D9KL/*?USOWRMW%:>AIY4#S^UT-E?":H]KXAL.O3Q8ZT-[W(]O
MQC_\'-K]XT-[]J;=J9>L_M+/1[:WU^Z,'<:<H[GDX=7W&[[]\VD[#/:S?[J,
MA^&34?AR=.?1V\OU6Y<\UN%[5"]3+:Y]&R^3>[['-+_7-[\W6"*6.;W^[3+8
M^P]6+4O"GLM@\\S*6UWVAMKZ.Y2$/]%'B;CRV8;M/YX?QUVM+?LU,*F.'&@$
M1EI5WI)\(7KVI(OS+&9Q?1)D&6NZM9.15ST3(EO,Q-PZM];L*:OKW,%D&!DU
M?V6CYC:)K!N?_O5,X5QS[1;&V5UJ,,IT3Z9[$XSMB_):@;=0W84J[YXPOV&6
MFK:![.T9,*&O4ML!O-O9#P"AW&_W;P7MQVP*\NQD\-INCZJ:"44O<CH?L62J
M:6)Z^Y3^W9Z](2G[AY]CPW62AFI%A.4I*!ND<$0$KKRSU.HZ8(?+WK;KDO9=
MMK&V_NWSWY^_;)ZODL\'.=2V3N%>8O/OW_:W?MV$<7PBG]="^W/[4M+^P)]N
M;+\[_'P$8UG[ZVBS3OQ_AN?Z0G:.UOD.?7?T>?NO+YOTMZ-_SM<OM+K$Q#D<
M(F+U@06)!V0(44A8[(2T*K?-6EH1+:IX2\])V=]O9_7CEGH5:BO4UBQJ*XU
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MD U&V.T3PP&IEUIR^>52F3G:GC@H=!<9BA;S$ --5.%<F(QIM4[E*FGUWR
MU^H-;6=5PF\/\8S;[KN??O K5BUY?F.;NU=+OM^U61%]-7]1EM!7-!*OG;#!
M.L_!5#',<LZBLD8X Q_4-N5J:)^#69LR]R'V6A(4,&.(&ZR1"R& "B("LVB4
M#2(?TP&#TJP3?+.FRH.TB;V;</X^S^7]<.TCASAJL5V+[6\MRC*^A!^5V[4O
M825E_*4O(3!&8B(4"><<XL%SY 1QB!"IA5,,ZRC77AB.0<#?+)&X]%',WTG
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MV"\U=AR,.EE5]^-!1L.]/FCOT]-^[PL(NO525F:&&>4;8O^D_.CD)/9+=1\
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M#[:J&X?C780GC%MQ;Q0-VP6]FI]3' )N!/#6:>=G=#,&G")&BADI/=ZGHSX
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M6'H>?=;O1BAA152&$F>8L-?3JO_N]?N]LUPU\M;LZ.\B_[F)T[</\NJDA%)
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M&!N3"2S9M1?ROE*7'H;R:O?2JM);8^M8P'N![G;R^"_VJ0]"RL"0<A@CSI-
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MSF<D3 #R"!Z9:#$*WGIM*9&*B54L0%I[<5?94J@Y]KXY]M)6X)(Y$Y)&-+B
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M,1D!*71]^]1V"EON02:*BHS"*!8?XNDPYNH%16Z069[T6*ZLBU+.^(2-T1S
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ML /T"<CGCZ=CZNWY*AW8E]MCBZGR+^5HOP=BN-\^."C]847\$L=%24/OK'L
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M[ EHQ(1AWK3W;<M N]F&!1_;5"^F^WW.8P.$K18;IK9>VUI>72YN.2F#7N8
MFL5!VVYQ+N:\W">!9Y64-CFQGK/R^;^76?,"MO.G&^5.?_Y\F;NXC:ZFL!N-
M(N=6G!.Z>IW5R_DK__[^,EM0G+SHWINXTQFBI-0&D\23U3HHXAT.-ABFTZ#K
M0:[DJRB?9NI]?!-;NYO[%&?&5"*02D$A'H0!%YSDG5>J/895P27%&;V-Y^F^
M]7LF!1)DI$1SS84,SA+LO!,N*HVQ4]6Z/]VZ'ZWNZ^B\!&.)B'4$<6XDTM;
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MJ)17D7BA]S<>RE<#L-\\S1.VT^X48-\K::=S_GX:[72%\;/#^/6+ M\+G(>
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M9KL[;;.]$)\R!526 /5]T$XHZ\ 6WK:/6ZR70/S)YNQV\W2[E] ORX/KA6\
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M^)O>55C?]S$2!KJ/:#01<1D2,C"M* CIF.;*BZA'T]_$4),;ITLK(@>W4X=
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M+D6C]<NM]3,G!#-KF# 16:-!U[$ER. 0D/0T&JR%<=05,G\A[C/.L-'ZY^^
M_%BE;UR6>^C[S&6A2C/-E$"4.(*XH189YUP>:!H\9<IP*I]@9N>Y)35F]"FM
MPDR72\3L1&NR7K1&H +55**7RE3W*/[,),IR'K(N EK#?O-#$>T<5YT0+(A
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MB'?2LB=G(CX/HJ1O*O%N'(^KB&6.#VP<=<].#V/6CQ,[#*VCXZ$_R$Q))9
MF]7TCC[(D(?9KHS^Z8X/-O[GN#L^W8KC@T'8G(9PGONLJ8?"L:UY5Q=,=649
MI4@Q0A%GP2+M#4'84P<F'T],+<[5;?K+EE:?%SO<X7OTN?'5[JG4,U\M6*93
M!.-$.:(0%UPBS<%U8\:0%"+\PL=7KT5;W7^^5*/22ZO2"W-"%GE$XT:;;Z7-
M<ZZ&5B*X@!4*WA$$A[) 6F*/@N;>&4&CI689C^@7D'JLN9=F?L/ P3T5[[N%
M6AU[!O?:_5RG%HFZE%MLF+-^B#M1;\O;>E=VIIM2H=8,KQJ/8B%P]=>\1P&
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M(E1()A3E4?EE##8U\>-E]L#NJ,J-<W5/?9XY5Y9X[*+Q"&QH6LU"TH0S),$
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M?9A!#-\35+O#19>$7-W<BEQ]SN;\?6)SKIZS.7>SS9DK0<'*NVASONP%RP9
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M5$O"+1@FSHJ0 @;3A<E4$^U^(\8M+D+69O]+K$+757A[.]X2?^03Q9^/_SW
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MZY+-QBW6'G8(I2@LXLDQI(F6*'FJ>8Q<.,&R0ZG:AEW'+/D8.O0THFH-@#8
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M32IF4M-<F:Y9BIQ+'&P]LI1@3B2:_'";Z,-F=0L=N(-S!C-LFO\E' ]/!L,
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MF<++1.%$X9OH"]93,,MG*9@QQ.0'89)*O5HQID(?C&+E=>S#A1 J/\P-?.W
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MY=L9O!/B%@$$034-^?F2_DSK:;?:9JNS4Y,39F3%:JXNXQ\O#"L,,9Q'(7A
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MP=^-_ KH"@ X?;(8L!9@@ *)Z*Y#(+4(4%&[Z3![1J+SR(9P.LA'&OTY<EV
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MD[1ZQI"TO&<QR3Y^U&8\0PK+&S.D@0":)EW>'<_3Y[# MW$R_K3:CS.G@1,
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M?8756-O\BLO/,U*!7REH6#6=CKBD,# )"46NVI&EA5 L Z800V$L&.SC;M\
M:$CQ?C/]LM^V]RCMOD#'P!(J3 )2*194R!0V*N&!UH6T1,99[E/,MA'.\,I[
M]Y+__EO>HZYW9+5 7[O*4W"1'!Y%2^+D$V?ZSTB8R/'I$Y?>./VA29VR53HK
M'20DSFE?36#@2A8D./0U[>J-[;ZL <;<=Y7\+6,L[K+C[9@\FW[ZB/.C:F$O
MO%4Y>Y4+*HB9U_-DC1",Y!!K+BNX%(/JTZ>P&<^0(NQF#-A_YZ^PX*]/KV[/
M:_JYR=BC#TOZY\K<SLK;+SA???O>\X]N^-;F@Y"V0=]H(M+)U]=\\ND!PDCP
MX,E&U<2O)D_5,0F.@AX0Q#]G/2]2=?(*KH/9_[S^*TZ/B?JU_A==]L"5"Z B
MF?-8&PL")_Y:*;WI-.KF%,&0K,*^4K]^D'Z'76XXX6BQ&J'SR[<O.%T0BA*%
MYJSVUC-=*T-R!L]- -3)<)^RD9IW*@V\C&1'.]#WO*FUT/?:]H;I^.GL\L).
M\(RXX\;$B&"=H[6E7"!:#,!"*"(7'DKJXQ'>"&G_WI)3P;TDZ=X47V8>L]6>
MO+&LR<C3QD-P@N++R)0@Q\QEV6<:SE;PAJ0&VW#G>@-*:RDU;TXZ7:;U.7)>
M/$E2(8'0$CQ;]4II'J0TZ%(OJEP",B@]V8L5=]_Z9O+_CS">5F*^G;[ ^?@K
M+;%6CBR6\]5(V'H>\FZ.R_!MY+,G=J('KVOS!=<<7"">9HV1%RQ(R^Y"C&T1
M#NF0J@]ANLBJWPG6US?CWZ9S#)/QOS"?8A]EEI+E'&N-+FV <@8<XPD\J3[K
MDE.N4U9F.WQ#.M'JPZ(.<FIHC4[-X7J]]3@6 ^.%)82<C:V#%#Q0$"$A6*>X
M*MH4T>?H<P.8(1U7]3)*^TF@[?'$S6L,Y!^Q@A)LP421A;2D[(0!K@O93*M4
M9GW,T>VXAG1@U8<@#>72C"N7#U>O'L)N4&Y%L604\9A'0QJN#E6)S@9(RB@;
M1 ZA4SG%KDB'= #6AT]=9=<OH624\*QZYX(63\ZZ3! "16PVR.*C-1A-KU[3
MVQ)*NZ_LW7SV=5ROBJ =K_5RM6P.PV(5K=(Z@_;&N1"!Y4RZ'Y,!'[B$8K(V
MQ@7K2Y]UWHYK2#F#O;AQ]75H*(Z&'6X+I*^I V]?X%><S+Y4_^#TY<_<)FT]
M0L+:>;=JGN>L0$G*N2@,*[+/0=NML(9TWM:4(.V$T:Y$[:@V)_QKM15OR]62
M2K(.QJY <*<460=2W<XH#;0!W$47?+*=RM%NQ36D?$%3AC041[LT$T[)<YC4
MX4SY:#P=+Y;S5?KBW(.0W"N-X)F6H&+V$)1)P)+*46HCKDT=;I5=NAW8D-(!
M34G24B!M8[ZZS/-5GAU1C9BUCEP^!RD&BBQTR.!1)TC"<Y&9+$IV')9S ZHA
M)02:\J.9*)J1@SRC,EZN<U/18\FV@$B<GF^MJ@D)15Y0X$QF&87LTS]XCJ'M
MP=WZJI=CVMOSXHZ?L<SF)UV<'\,W7/SRC=Y1XM1X&N;?7Q$5%C?T_ZGL S-9
M@I.>PK&28PW'(A@E@Y#D0;+89WLZ+FI(#O\=F7C[J>#]4:!A]O8$Z(G"^)EL
M#&W4*"07'&8&#"4#Q46"B%:"B59' F0-ZS7I<".@09TM-B73?GO?K@(#EQ<J
M2E2)DJQ#! R*8A*-9"U\<L"3BX$KAR'V"1 OP6AH?GBJDSZ8 N[KS94N:[*K
M*&A5SAO)=;&="L=N,C_W7#-Q9VEO2'[<98_[\':K5GN'"EE)')S@ 52P"-%+
M#LA8PF*9E;Y/W+(SU$$IO7:4Z2NRQJ:QCZT/B?&LR-9S12XY;5^ 4$=[:*>C
MH/4D:QZXN]>R!A!MY-QF"R74VAJL1K:0:>3,&U4"\A+B?=8 WJ\N'PI/KW?T
MMY!GNT3%AL+9Z*3@WAKPO-#R?#'@./G=GN60@V1.V3ZWJOVP1OY^L]]#I=2^
M,KR?UI4-(YXN ]JOAV73UW=M9OGA>EIUM6PS'ZL(5[10==)1O69'>8J:75"@
M3<@N69N#[GBUT4ZSS]KNP'D]X2_?ZL IS/6#L^FZ#*B.A,(7N/[WLT+OWK/\
MW\>+LXN*Z]9YKQD/*D.(L=9], T>C01Z95QM87;<'7[K]E[6D$QS<P;?D/(=
M $%:'RAL7-)[3).P6(S+.*U%>@:YVJEG;Y^_.JE!>5LN#&XXW6B-+B9=ZR%K
MQ;ZJR15?+ZGADBDLCDGT?28E=%O2H +$>R7[X9C1G>CG]5/_.9O4.8+G->07
MBJ[FXP7]T0OZ<?KI';WILWRVFJ2$YMX+$$;3:RN+AN \@L@HDLHU#].G'Z37
MBH9T[']O+#\H+1H6X5U;R"F@.\W)]#P5GX(';FMWHO$&0JES+A,+3)GD4J>N
MYL8+:9C:%CY(+[D%G8H$);B"H%0-KKUATA>N11^S-LS4]GTR[I;D^"Y2.H@O
M=:87LG(UR+2 QM3B(IG!>5V+BT**HI!%+'VZ>UI-CSY<3>!PF-5<LH?0^*.4
MO,JY8O&U%)9S#4Y:!=86;A2W0G9J:KX%U- L'"MDFJ.*4%0=+54,)T5A288L
MV5*(,$SW*;WL:N$&:Q-VXN2&6Y+N3?8'-1([C3+WKC#%#2A+JD=)F<!I5X#G
M6KQFO8N=YG\W7LB@@NM>#+Y/X=]3-CXL/K^<S/YH.D?J_$O[9MXW8V^4;Z_?
M7O]?NXV_ADE]Y'N2Z7R<"$;]@V?3?/D7%SZY#C:O)A;/M. OW]+G,/V$[VDQ
MOY2":3E24FB-O(!SD8-R2=1K/1EDKW-"[E"43H;NH.ML4.!2(:R:C$C&/W__
M;5%G8)\=A3U+R_'7]6 XXYV0OK8)E"A ,17 "1L ;3:TO9J5T"<XWA[CH+R"
MX?)]0\E,#Q*TK,+:A&_=F7X97XY%%NLX.*S6R@<'WI&/8US)UNN @O4I?=D>
MXZ""S@=/TGU)T)ND+\?3,$V7\06,7 E=>S8UX5,6P6O"5[Q/)JGH>#@H23=@
M'%)2_.&3=%\2W(<FM=8(BSI YJQ.ZA,,HJD%5=)CO>X@)=[G_/ZNFO1.:>Z$
MF&^9P?9B7#%,\^+M_$7MB*L12BU0>H_+X_GT;3F]9]3J:(((9!:30.+,:@1!
M]B"*C874C<;2+4O>9@E#<ITZL71#_OP>Q-^N_2U\7P5N'V?/$J&?X^UW38S0
MDLM6)W#GX"2H'%F]"U>15?0^!!-\-'W2HSL"'51FY%!4["C+-O>E7T-X;6K8
MFS>O1BG($FJ#F>6LWEW"$S@C(TB7330%9<0KISTWW)V^U>-V=%(>-%,Z":%E
M,^Z9,EU7POR PC9+GSA#T%%6E)J#-]: YDD:'>M5;/U-YC9(A]3Q?P^6L;DP
M^QG 7\/\=UQED,_AC7*P5CCNZ!VH&8MZ#NH0!93:F)Z<2M+W.8#>"MZ.XP(>
MM KK)[=N6HPBRU_#LD+Z_K9LA"EH$[BIHQ!-S36LL@[)>@A)^1*]9#KU:?+8
M&>J@)A'>CQYK*\Y^BNRF@>#*1>16)P@ZT XDYL'90KJ6*293R*SH/JUJVR(<
MU.79]Z7.6DBO'[?6N2@\OP1W,7)1RZ2%!<U27;UQ$)@0D"Q#)UW*/!S(1%X'
MMPVCW&-GU)XR:QL!D@?XZY@@+&?3>IM+O1PW905>>D4*4Q3P0DC(.03&>.#"
M7+E'Y0<1WZ6OWT;Z_I%(O]$F=PKW_QGF\U"UF':<128U9.WJ3!)R]8.S#JSE
M&=$6RU3<2>#7'K%5*I(]1JGOM]N-)'_!9WJU6!Q7Q?.V;$PT..L-K53 ZGH@
M13X2.*DC6&X$"J'0;_ON;_W,K;CQ2/+4/<71^T1I4^U TL&*%"R0I\/KQ5^:
M]H ;X#PKKTTL6?1)0-^U@&2/-V=U9CF;3#"M#@SJK]ZOJK'H(6LSCOGM^;G@
M1<M>%+W;2A6@Q3 *?,G&.^,*6!D8T8A%CFKGM^KN>![ P="^9+OQA3N0%-LK
M[NV 7YL$FY,7EOQ*L*S.!@LR0PS10"PE!<5=C+9THMY=AO$>JDIFF+3;2WH'
MH=RJ_'?;%\9&Z[70M4&E3NYPMMX(6=-_CMX744?,RBW]RG:@AE0%,P 2=I-G
ME_SM:=7X*<X1:BX<>@J4951U\F&!*$DEUY%BW+IL4^XS+_@V5 _@=*D5Q9H+
MJ8,2(\*'99V#?<[NC5>KC;SWR'FL-1XY@_*D9YT-]0#,216C<4;<P4O;]O%#
MFC)]<,7414;-<V3G,-_-%LN;00K#N$U*@^&60&JF("J"R[(2R'APG&U)I)V?
MO>.)T+WD6=K2J*]X6J?>/N+\B$SK$C=#B\4+J8RNAU,UQ. $+>H 47!2DMP6
M5=).S/G1$Q_"Z4X7OC051>/[-;>M61QY9E5*6D,ISI!E58XPQD"0+;/9E\RN
MYA6:WK.Y+<X=#WP>,L<.(,CF9NWM]-.LSH YOVGHPS)\PI?'TUI./W*8)<,Z
MHISE.@9&T#O ZWBOJ*T3TJFT^W'0[8]\"$=$O8Q80V&T)\KIFD]O(:GC2G!1
M;S(+DP\X_SI.M L\!"8MK_=18:VW0 H0N207+9![%DN,+N:=^;+-DQ_$(5,W
MWC273?/KY]^%<1TN-:(':A?J)06\'H )ER%0) !2)!%<19:QB]6Z F37@Z<'
MS9<6PFBN4'[[0OM 9O$F94>J#6O"W2OM017!@.*[ (7[@L)(5NS.FN3V1VY%
MB?ON5.BE0AI*XSY:,+U HK"1=0M8'5<G(.9(+I5./C.)BK$^U>=W;<&\^WMS
MR7G\./OP.<SQ\VQ"]*R:_[?I>'GRTXBS@MK4P8)&K_(E 7PMY5:2=LDGG5D2
MN[Y"6S]]QW/&>WF9]F7232]3'Q%UJ"'\=3R=U>K9BPA'/B9R$\C-#/769668
MIWB$M(NSTNM0DN2V3Z?H[;@>0A]9*T)UD%3K9-;FD3Z+U9G2* 3-5W>]R,B0
MS(4CBV1KU9,L#EFVUEQMTOAA*NNVYSV$QK$NNJ:A&)KRXVTYRW9<5G^C(IDH
M5M:;)4G7*8<&8J!(I-!6B%@4EU?O"KZ=&3<^:<>#N$?#B39;W_XH[@:B;K[M
M>E1S]"RF""+: HI[TFR<S"0%*]E'Z\D=W9(F=X7P ([DVM+G(+(Z&*_6"A"Y
MM3;F>G,,)_<J6TD!C$2(*(4L*J82=S_5W=<2W7-3UJ%9L[LDVI#D/7XYL9)O
MR^O9]%,]\JG-K1_29\S'$\RG1G2D WI=B@:M6:H)^ Q.! UHZ+="2)7X=@=O
M6S_R(9R\->5)'V$TBXAN@C<JPB &7\ 6I 6K>@:8.0-MF%-"Y1@ZC;N^"=%#
MZ)]J'04UD4Z?FK2S"OY+N'14*197@"539ZPF!CZ4"*6N-4?+?>H40?\0VX['
M:X^!/HT%UCP-0QX[83A%MCK"&>G"&=H2P)E$YI*EFF]%"45FIHSECKF^+9P;
M0#V(([9>&9A]A=2<-2]G<]*+Q^2.AP71^?GLZ&@V_;"<I=]'Q<3"2B%(*=7"
M<8K]?:HW)P99BM>VWB/0E3PW8WL0QVZ].-1(9%TMV:LIK3=,WAW'R3B]+07K
MW4 CZ6TLNO8DU^&P*CD-KM[B7%2(0<MH5*<QK%M#W/7P[E'PJHO\^@Y:/QL\
M5-:#AU9!P%G?XX>ZP?/OLW+[QU[@DO[X3C/9FSZ_R?CV?CO2:-+[U5E1EY_\
M[*@._/]7O2]RL?PY+,;$:<F"E4:!-/5",\$,Q%3'KR2!M?M9"MYGALZN2/=5
MH#]X7DK'1Y43F/]C/ELLSN]DJY>QK>]$7MTG:&2($A.DF$.]QT-"\/4RCQBS
M\R(EP_N4Q#2!/ZASWJY4O:I^#R_]9I;_]O%O%^8G!6E#QJ1!IVHXZO!D5T(
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M"-D0+.W]$FEW ?6UIC_/YO/9'^1R7"@V.O_='M9RNR]N8@WOL(9&UNY27YE
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ML3AZ/X)%T6<LQE;PMN+68TLRMQ=<N_N7+HR\?%NNCC0<(6.Y8&V/DM:!$CR
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MY@J+(JB4B L6IQ_PP66%ZXXQM2;R&\\] XY[&G,+MQ5*RMY>AM$P_CR:^/D
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MI9&YR,-&L??^*I>=3WKR+->W9X,-RD7:NV4BPG3)@?0XX'*31W)(&&&STH:
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MWY,O5U]JB?AD67_IK]GKJVF^('Y&'GTA+TP64($.R!B2 I^XEX5)SM%U(L<
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M0^[ L$G?/Y[]7$VG,50U;L[;-MS-%6 'P+OMJ$$X=@SS:!3=[L^C Q0S;OG
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M7MJ9M1+M"78-_GCUY4N8?Y^5=;NFR?15F,^_T^F\^H!966='[:P4&Z?-\.$
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M!.50@]?U38\)8\E&"=,MT/G3QSYY=>TOI $ONE9(WM-20UINF!.1B<!LG:[
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MVR!/XEYU0)ITW\(.4M>XQ]X-T-K"[-I][P*W:8E=3\!'&F_?B@#=B3:8]DZ
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M+DKHV-GUP><\6?4.+<,V*3MY-EU9I)'PO2-.54>8\/WQYN6[#YO^H5H[EH4
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MGVCW3C$!)W/52V<B2WP2>AS-:3P^09ZCBPZ.X?<@MIT,?OMMM07?"6USUNC
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M^2M_7?G3^?8H91OBIECV )!CK,A!1!D,;UIKLHTFYU.IH?'Z,1RL8YX,)Q=
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MF:<^Q2.? #95KX+C;0OCY?]2&A/L']/;;^_(53N;+[Z]+U5VF[^1EJ$LR;C
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MH7>35M819Z+T;3O;@$5#,X9-CG?F2!M]_V+VA"@K<NQB:F'#36)LA0NQE:[
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M^&=&U>4ZX(AN%I"%\B]"%GN-5V+Y&^J+C+^=95ORD?1PU679PZA?@Q+I@*-
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M%3<U2O,G,+Z7&L:%U9M\^$D5 U2H[DK'.^=9-BRHH!/^K7)/85V*UN_.+EF
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M%WSH%F"]WHY6UKZ"BG'J3/@BQ/<C3\9$+X+@?HL/VE5E>F<* T3BKM>2KO2
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MJ'#1!LZ]8NN.47-V<$4Y,R7!8$T9T@,#EL-T-IVV5K@FU'/LL[/8*TJ]8Y/
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M5>T_V($_Z2L/WA@EH<NO:5=0'IN[-HC2:=?MCZ[]RW>$9H#SSQ>K-;XZ&RI
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MP@&L<KUEQYM;1.&%"EGZ7+ZA*%M/6IX6)YN?A_&#\&'Z'2JP0&7H%_I>!8L
M6:=7O=)T5Y2.K>C9[U_AO4*A.W_8:'_$<W*\$M$5G9]:MQR:I2N53\W7@.+
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MG/NU9TI_HD8\8NC8SWZTZF;>VQ@>)IQ6*C84)Y[H[4RY,24<U#3_[314-3G
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M^!(UJC7IP;!**1G71-W4Q&DF5JU(\/T;L/H@$L 5S0MV#]@WIPD_BQ/WU_<
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M6H'T9Y%8 U<,8TO]?".>)S%%T 9%*'#M  ;-;*F8QGC%1@<%YCFFHRKT7XJ
M,INE-EQ(Q2<[]OT$)R[,O+WMK"_!K<%H(BF0ZCO]W9;+(@P1N>/C%U65X?V\
MQ54$[L#M1K+P7<9IUW02PV3")!%R &9,EEF1:I=P0TBAZ7+SZT$>T.0[,,CW
MP]EY*C8IQZKV2C\3N9K,A<677,I@P)&R186O@Z7UW><L17I_6=OZK[NN- ?
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M1Z3BA9*C;R.NYVMY6);Z)*^^\%NH:Y'C2T>NZJ/0<3 2O?3B(^8J;^HW-]5
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M^,.QF!XI]V+6.I"^JK\ ;R8H4G9^9]E RS5C.*:]2NBI.2*:("Z;[<6NZI-
ME0Q#'11S>&>)!DDK4A3&+.M6T"WO !6\&!-OW'ATUQ@Y>[IPP 2*04IU\J(N
MHCJ&/(%@DX#<!ZD-X8 A41O\"Z7:";OF4=?9V5^DK6@C7LH0"%\:5^-O/.6W
M= XAS ^F,:NP\4U/;)S2;(6ZY'6HA';08W<V@)P(9'OR&L&%ITGPNHVZMX1K
MQ(OC)6XZ7YTYPH$OOG6HF!B%IT6=]"F__Y\N$]6,8)DD.L8QSJU\+OD7%!)6
M4FGZ*7;/7-M1"36#]]0S)'6LJ#M+2QQ5M5%G+]%A<RMSRZPWJE?85E!J10+#
M:OI@"KTY#O]QE5)515E@_T<0)V$/79'HARQ*,9QE-S2&UDN:VVL(\K+9I^GE
MYE!_?^0]/X\0'7L\C!)Q0(;JA%$(0RXO*MXN+OZ\"CH6\8U65IKU"NO%EW'@
MR2>6(<W=:@(@A=2<E:6-)(BDM&$LWJ+6KUK$S-J+MU@)ES/O /<WU<7GYOP7
M%@FL.D'=W]#:\4H)ATB*'01Q07<Z&'$K83\B^7X@(BYP4O8XT_2GK1(R#P%I
M7,A$^0?G%.SRUZ_?Z._@'YBTO3R,*#%3GH9<#_-*_G CRTK3ZO3)+X$?L^Q/
MS.ES[.,_JUGQW;IX65$E^E9?4ZVVN;8UT@,K7(AQ+V/ZV8,]D,[:'<#L4E;
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MU:U@(#7S.IPIY-G<]P,RN[G[R>T7<)4G5NMX]\GO &W#Z)<)*(I!71G-!-(
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M15*7*5T8B$CK^F.>5L;,X.1Y$<<8T7_/KN^EC3B_R121;4=IIZ%64G(NH:*
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MJ^K1>>T3JP_[E1R/[.%J)K0B%UG]O_2V]\]\^':< V%*50F:\MN43@7<[+F
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M'F*M@ILREB&//JNIJ7;"WJRA,;R7IZCNYQV 9@NPA--J_*M$(_25@I@%W?K
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M7_VE60M48HI4R\@H&E'+)F=;OA#(UK"U3>5J2F^!%$ZY@WIJ]*D;O%[;;$S
M7W7+5_4D].A2"'CBXX"F1=[2E-721F7NJNZ_?#@N)=*14[HNV^CYX_6MI- Y
M$59SI]W@5JO$?HXG0N5+(,@5'E V2B[T 2JO(DH-W 5&;O07-7/'!8,1E3Q:
MZB';3SQ'?UT8'+-D@RH]]1'+9Z10==\C9+Y5;FFS*.>G6]EIVVIW9RM%W+L4
M5=?.'A?117)W-%;W;>BVCN=EU.<);M-QKE*1=8W)'R:907[I72M(I(9^VNJ0
ME^[IA@C-*4Z5I[5K<0VI2;0@/J>?]/I5R,BN+L1_OLO)/4RG[N2T/'8W1\1)
MGWA![(OCN^.9DR($%XUK[*5&PZ[;]BS$1IM'OED_V<IDPQ,OR-OC:7DQ.97R
M+XC<9!NU&._;\MCW?.3U&ZJL(E2["<EY^28.:'M(]W8JM,%Y_P#E/9DRQ_..
MEG=3WCKYEK"8"<KTJ>BMI0\EO:6Q]E+"EK5!AVN0];(<$PDPPU8,+_9JW>L[
M2Y\ = _64(1BH?Y20Y4!R*IZ=*<*+Z0&F=?$E28GGR)7%U/3N57C1M&V\1=&
MV5;3P!K:.VC7",9@$5J4P_-*MS>?ZE"FS3SU[_#]E5*)RFH$?IVG.'Y?//C3
M9R#^/Y\IG9'ZN-NGF$G\%">]]4E7@K]T^K1IH'N^$I043PDCUSDM5"DN+%:;
M2B.T9UQ(WK!4W$4X,X;%9HO]+DN)F%_39=:I][(T](6\'J[]#R!S_)\*P0=F
M5>9T8WN.(I9"L*H>@!]"<?/NY13? Y>+PA\_W+@"^!40.V7.SBI/L3ER"/88
M+,.'[;KU\6M.-1+4UIAFO[++1P:-WI"<D,X+1H@@=.1ZDQE6;<HB9F<FU7NN
M]MM&K])G#GE2#">S#&)NI$4;ED<1I1;#, X:TG0<"7DW"^&(A83:&"[.KGF]
M5XXXXGJT8CHE^ZL^H@[K.@V*T6X5(4%+B)BOZPW?TG,,:QAP TR3FV^M: ;]
MTD2FNL4)>E+7;_PN@%T^7\L\/3;KZV*]@BQHXL,:R_N^*,AP3WR($MQ*Z%:G
ML\'OI\]JIOKY]TL9NX3!6O;%GVB1NHR T(UZ!7/\5&V7+;CLK5_<DY\ZTAXC
M \^_]R+CZ4X+A5B"N;6XZ>9KY;\>!1ZEM'49H5 <&N0NJU0>]:[ /ZFS<>K_
M:L.J\RPY=P527TY_QS"T]O-DWU&[(8CVB7 #R:'%='KE;Q^ K+8^8O0I'K\5
M*7*_C?(\;]B]!1:^C;F0Z\%ZLO[TZ^R*A*@$W5S+[BV>Y284[]J]P6[W'@!@
M&2RQ5%:(Y0V5C)1@W)&MB.FE*LB;EOQW7,_W;V*T-9975(ZZQ!I\]^MF^Z9G
M?F)F=QKX[$JB^J7<H00FC*%?$KP)O0?H7,_D,GY7*@( /C^"-5F[\L8+J%WN
M#1\(8]V<$8?20]$N_COM,/];PZ.Y2CF!)^7-7/!5*.@?+:)O[8G^O/6QZK/:
MEST="0'BDDQM3M^*XMH,ZV_-H2-;0<IWR\KSNQ.[' N=EMP&V7>X I,MDXJL
MI2SH(#T\9=Y6P]JF>*5@C143(^]P$<&8;]?3-IH5OYHF\]EWI^,6^U\Z1#X;
MJ!&V%W32OYW4U4[H86R^$&P-J8W;HZ XB=^</T[WXHF5;'O]A8IZ!?3: KK/
M0[QO9U1LH/,A)X:,ES64<\;/06\FLDI>8[W#]X4TUT"?]G1;R!3+[,_(V2MK
MO,3,_5W='K\+@C7@2^WYP0Q8Y\U-Q"(/F]&! OJZOB^)6G9 4ZD)>"AY2&9$
M//O4-MLGUYM_@LM&]FQM6WER!'84T55*1>W1GS_HR#_?4U3MG%LVT85 =O'*
MMCS78[,"<GD(>E?P6(\L+4:^2U^:VJ)X-Z,8W*3NX9OS4\[#'D]Z)@!I!IU,
M;EZ5YY@>'K9[L5]^]*O2IF:4%V@%N5+RPLU'KDRK=&K[_ZBRO=389PT;L@Y5
MO2QI+2:>0-$;8%]_)SI]6DJ,3T$RO' )QUW.+R<[57_ T>%:7G]6[L,7@RG:
M35,UBWW8E%*:'=X%3S$P)H#:V[[4[7;HD5#B*64L:AN.-ZO&]%C@J,GI*\LH
M&%^?Y;';KFU:]6A2CUQV_,-5&7OW[QF<8A*75AA<3L>><_M3S/H,\Q/:@S+T
M3"MIRJF< ,_W,9WW &]*Z$41D1,(S*G38N](LB8.N2(H<ME6'<<:[=?N>PAG
M-/ZA\D&MIKR39=+"A3<&BX="/K<F2A>WFH@PO< ,9)CE[J99Y\7"@[AF1<21
M*A27]Y+[O2X1)-5Y6S" 6^E 4V4?B+-)NV6*3BKUYR^76Z<]Z[<OJ+>3DLO1
MN:D?5W.-EG?O.*Q2 Z7I)KT7/PU^<65A^(ZSD9K.V:.]GC^XR94#,X#HD,I.
MRY?*]XQ>I(F+-[2,EMDV#;QKT+3UW[83YKG#@\KZ#\A,?!FS@9.;ZD37JKY:
MT_%II2<CMH[2[ZBQ7JMH.*G)M%K5HGY1<52ODWNWGC$"B!0&BWIV3<![X^2#
M%%HF))#B;$F YS\8%6T?]=)5F[U6BXV5WT&YUEZCGE033OBTB)N<;"R?Q,MD
MS[?<10SFV!?ZN0$S1-.4)L?[63YH7O3$RCD+JF^\280+/>K)=06]D^-<FI<1
MT%E:Z++EEO/#PG+W6WN#KAIN-K-4;P.2DL/2T1F0RW2S<*FC3M?Z@)F*+S9D
M(5G+J3N2O[R-TM>.42'6IF(-91C[>"Y;_B'\C+^C*#S6JJI-TS!VS3@0S8+:
MJ5I=BGJFR!W42;#CVN*\(GP0=EZKEWV3E742%0"2^JZG7U1]\&V/DN+;\B0*
MJ)_>XD4>@8B:FY@_%V86QC7PU'G887V9V7]V/OA?S;Y%H#ZE ZECL%L3:!J#
M"/J,[=IU#R @OT.WAA_@A2[J*7JYT PM0+G&>?Y6\HGTW8*1#FBQ'&5K&<;+
M-K#W?K;J\'9:";EE\S2KP6%-XO0]4LCCO.M&!34[J\9?F*I$&<4\'/DO6#7:
M(OF%DN,6,)=%& -L" U[!?CA?:'IR5:]'=:02$2!!*&EUN*A+N/7R5BIO[(J
MIKF%>7BB%"9M#PDBMS3IC-&0T3AN>$5[ @8=]693;$=E=MP][][7ON#\\=UG
M[3$%!V<OZFR29W0JDF1&>A*::5'B?%/\,WHU_=7K*=\<S*+@<>E"DD17/G7E
M6,4,J/)X]B3K!?29XFI?$K/U[(.W/_A)V>WFO]GMT;O@&[14@8"9\WI"PLS4
M8H[8:$FXF/GB6,'>4I?OA<#("%;#V55;EOS*.G?6U5B,OU,XI#X?<'&@OL0U
M3M!@/5K4C(NU%!B-S@I-F(;I#-25EHXV5?)%$+I]L7\"L(!!#EJQ]9;36=E"
M*FOA&'XF=KU%X+:17*>I\C6=NMS)A/ZA3JW=782YIK/W<[U[P(J"YMVS$D\X
MO7@L"9S?4O;L 3QJ.?\51;@O'KC5<T5\MCM^2?"9*?"TQ')^%.0+@;*5I4#Z
MW:,N2F3_A6LM_:D*/_H'3[TG!"QDJMQQBR1FRENT/G /]?[LBRVB>ER%*)62
MC)24(2PN[&3"QO=A^C8L ,K0,;@'V.T,%,2E]/+\]A0L1[T&K[S_? ^H$MX/
M+?&@&:P!0VZ!^PXR>KJAH?2%_XYSC3F[()+AC(2$L'->YIXL-D=+02RL"-E3
M%NMU-J9T80!<9&I?GV*4Y8(4R"B:;K:EY3  /$&4D>DS*$4D=@V'<NE);6B-
M.]=Q^0@(RBF?09E[BBDVIF#TT,0?J6E+VT6QLG^^3/QOSRHN@C4CHCPL"-2]
M@BEH6$:)59Z"!:HEN Z.:,M*/$023\Z[8<QXN/%0+5@/E9V)##!N0M2Q;'<9
M&Z[32B!>Y-X(DIO 8D(+KWPY/_K\?=O(9_ZM9M;0@P2!RL;QX])J?F+,V(KI
M@1'Q&(H7S< 7(R%".R*]7^8VC^PX1?27?O88> Y,-F&4[*930;1.)&YY C=>
ML#0MNSGP\[VB(C_Q=(5^R*J,9,P",WE'4)"D& C>#N.)G\AOYC6SA33I>#<$
MW%IJ\ZVJJ+,+?/T:%^F'B^. (ADU/?7-+++4YFEPUJ*I8YZ.$4R$>:!%2TK*
MW%G-,T5.BKQT=T5NY@?86E.;+G2/*V7<?/8'($'RS :_AP\62W/':^7(X/:M
M>)0-H):&UJ3?^S5+M%<^'B:>+50^TI]N1$:8P^7<NCL4I%[UPLLB[P'MVHME
MS:RM*S=7!Z9-\A.P8;X%CS?V8MN3]E9&,E=.&1:\R@O73DL+'QUC]?J:"H?%
MV@ .%V5%\9_T%Y);R@8,HE4[CD>R=LN6.;^/-1$4CZR95Q^_W'-87-#YNM'Y
M]$/A83K@%3_?X[AA2QNJ]D0DN,OK&%]>N%%[P2.%2L-FW>%5;[>@YXR5A%.3
MNA28VRYF]-?D5%,:RHQJ+0IC:3^=:;1:4"M#VGDW049#\O/@X\!K^V<[@C%Z
M+H0:*H4,$A(7W!%\W0IR!<H21$G_K:*>?[''>KR9NC'I>_82AGJ6;LDL:S1S
M-_+%D(1/AD'W /W:_<?ZWX<L[+%^S;9/Z7%"+A7SJSWF@H0LO&1MQPVF($Y0
MK/[M 6[GH=D-K2PM*GX0X-L>4[\(U= ]X-EER/<&^3.82"UZC&^CTV;&&PSW
M'7OIV_UQYH%VC':/+J5P9HMJ!4%L./?0#L7+%+4H]2DA+9NP14TN$7%\WQ'
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M.OBMME,3?#!*_KZGN0-:3N :( 3K].LTIU Z_V2)9@&SP7N$ N4I''2S?=6
M*L14;JIW"EIC_ZU)TBI"UE_7=:I[#4 Z'>L<UDI> U"_XZK67\8B5BLHSYV]
MW45FHF:N >^ PU%XW7\F#;$RGO,6U#SY?\NN4@1M\DO.<&8U%V@HUQ4MX)=
MX40;926(SL&&/C$/]>7OPB < 6L!SEB5%^ZG]"+?"&T+)?U[\1H0[P2MDHD3
MAH-5,3V3Z<HC]6BV:X!!LG-<?5+L:L>3PKT (_?"('EXZ(>6MCQ[<(>N6^AY
MWL2N18I[D6A8-!V=*D#G(]_4^O20X^0XLT@ONC0BS#L@-N(.;,WX:YQMG"J=
MOA5E=YX*W=:!-RTN3HOU_O/.*9=:JYK&I*W7WO-0XZN0ML N$*7S%;\?6)$Q
M2"OMMWZ6GET:4IM!5^56BFS4FV]A'DHCGJ.Q?Y(MB]?EV;2I_!C,QH6PVY:S
MFL0F3Q_,W3&_>EHENZH6+0A4C# %)]56FI9\ACGXOWO46R-6T\7OW\5ZZ2$3
MJO0@4ROU'::S)[/HU'3X<CJ&].X:=+_^T+X)T!<W^$0HELP]KZ]N'=]3I!9L
M1U&=[Q>C N_(L(9W3-8?\I/X7!3ZH(P45L$1)=C^WDNI'C#9#,Z"QAAH-LR"
MH/W<ATB2?FOUC362Q8Z+*'?Q?1L2-06/*<!0Y/FC\I@<X.Z6E@MB#CZ9 7V5
M<R1\?!Y#));9HR0P/R1*]=.JP"7_0J^KG,"WN[&>1=9)BGSZ.8L'VVX @(>F
M#N8:@&BGM,!*R)"U@.L*01:/ H%3E9I-K6_$7MOQR-WT1U@37L,C?J^K=>]4
MV:@77JA<?$A4)JMT?_)4O@N0X*Y+,'DCYXJ9MQ+E^-U%%)]O3-ZSX\9+5(SU
M[0U^T'5Z,N\\)'6>5N$3\=)K27@6Z;8C_L?YYX]5G'Q"?GF;U/H23V^ Q>4.
M]/25C"L!W/5M(<M?*&)ISLJO[\;&_?&F]GLH4I'Y&(2.XTC-DN5N6JF&6+9K
M%,<9-./WGQ WQ99@_M,^>4-6VS616*]#RF4AQ%4>&<@IGBB9AHDN1WTW3PC$
M6<;JG@G(NF)P^?B0 5WD%^ZEZE9HY@P,SR=>E=P_6,B]< I$K%#5B]QR.+>X
MJN.*&-1KUO"K>GAC3(K/FI,E(9E(FDEAJMNA@QIK%'W%M-#%WEM!E ]RB+G[
M8M1F_O.7D]2EK5@Z%KN0._N.I;WR-Q=>8^#=L)MF43@-8R!:8:J$5])<#>[B
MGO1$[4,N+]&X'.MZ#(A9:#%-1JO&EKQ)-=[YU="/])<7C6TODIO!()?"Z19'
MP(\?J_\95"6A#TDS4.3W7EYX_'GRWNO!1R2)-)>'0Y\5,JJUJHGP)\;XUM?D
MIPK]_9>$OT3VU29BH"_&_K0I($Q@2W]=7K?U(G4&Y=-(W_-CA>A=VD.:G=F,
MI=:,=XSL::N*]V 8UIMX9G2D86?0U9W40JS=!E[3AV,-XO;T>+DA 4.S#@D'
M\LKV![9B>#O73(*>1G5]2)P_JWB+PXKABW5 YSB[;V,J*NZ>MXJ$@)-C732Q
M]4E/#-AUG=K.]+-\5-BIG:AWV!YT3CUF,C,VZ;X&^'>&@7ENMO6OYH2U5!56
M^E7HV0(G:\_X. /R,I![A;L64GT\MIAN?*\'C$OZ(0[T!(+[!N\"=&*J/EF6
M'%FL@-+/;9HVSFI$8^8$\M0BH85)!C!VJ(?.F1"$K51\35/MPNXD<O(@!WYG
MV@]UHG^#9(=RVW):QF@$0EI%!F&<&5*40'I$_HY0'#(:BQF/96G^NI+%3J.K
M[RZQVO@FKI/:O@"ZKV#_3SOL0V)13;U'F9>5L@!9B+P DJ")*>AYL^+^M676
MG"TH2=&K_ZQZ+1%M&:X"?-QX7SU/PHF-?4J"-(''H#Z)PJU*5><J]JD$^N8T
M4\-]]Z#6RLK/BXM$A%?M]_>&#""K!L?APY4,:>A;BZ+(?S,C4Q+<G*)G%!CG
M%AT8##O8TR_DJ]ZJ<QG>FCH)#?_]6<QSY?-35,LC7:%B(;)-^K3(R!5+S3(0
MTM]KH217-1'9+%TF +' :+6OH8<A-L,WKP&#O8IR?KB?NWC4=X'EV$)NOWU_
MM 3N'F^Y<Q*?RUH\"L1![VW"/6]FDSQHY>$FC7@3OZU!TMU)Z@H43^F<8=^?
M/MNK(3MP_4!8O :T&I\+-Q=1DFI_Q8<\0-8US+9!G82*IT[0#R,>VM+Q)'A?
MR-L9-#2.&><(:,&-A3ITQ?MYB(EVI*_0[_WL'4@K2!.H7JL4MV0$A3\?]N@I
MLB4BXBE_RI[CJ2H5FI)6#5+D-+S\S3D6-%!5_75*XL(@QGC2&=$81]S[?GQ.
M/Z+I\S%Q[/KY'TM(E9_-'_7:&)W !?GGTRC#!+2D)Q/#$,MG=<!V.2R8M&\%
M:SE8Z50<)J4CW^IOJVCW7.%-X:B5.T[>L;$NL,C$3TR(1'W23,^G4RI)ZZ%]
M*L3W.R_Y@/S>(Z9N=3,X#L)1M,[M^<_O]=]_+&)\%?@;08?]8E?N3Z\:0LTZ
MR!2Q)@Z%%^-H0A==N,4712A(9-)U[9D*K5&!NGPTW$)U=CEVX:[^+Q*OG\C=
MS.,5^AT%WNDV#8KBM>BT=8VX^_LTIHL%W"UH #8QWA-9RM;S:Z?*L=Y\JY3A
M6\N4A=,?E3Y#0SMW++^]M\C]V86Y>M],Z(+:K<7&]6B[D2<DU?A/\P4SI0G=
MI@P$3GH*\LL?-(XS=P)/PMB?K5P#JE3<4_1[R H9G[6678E<D5@W+\$73UH+
MO=FC&X0LM]:TPXK&&Y4SGH6G]'U]^/H2-8=>8?V-X*W(=$DL<V)@4\VP P[E
M]#I][M0;!4N4O3'V6@AN:[P,_)[2O!PND[0\'S@8%C+.]%^:076B)S?;Q97P
MHMZBZFW*/D(3Y2&+!Y!\VQ\$<<N\ C\[=0RZ,[781.TN)_ECL4.<[4"5G*JS
M:EK*Y3:>^7E8<4=D*MYV]1*WJY%'K7[R5";&[Z>8U.0Q:/)28+H^[K[6:&7:
MC$9#_/*C&?O-A')Y]5,@&'JVJ"K6R'UQJ+5$T:07*_E/5'KX?V6:YM\ABRN:
M]MVF]PM+#=$?['$R;:&H;>AZ7;.Q]8VB6NZW(0X RJ:;K$95:DK:Y0@GU>0*
M!7U]FXW]!,/&R4I7+CZ'0%?9^ K:;[U@U;;U]>K8!NT[>#-MY]O8RD/AJI,S
MZ+=^FWQ!:6)O 4N3?+^ :T#O%4=MITSZR0O>WWRY5*\'1MP ?0J=Q:[@,1K-
M"K^)'DNV^D?%]@,J/"%'/ZD]_Q(S(Q?F5"8;CD+A=S!"I;<&);\![?O82P&4
M5'P]A.5Q5J53]Q7C?MS4D/--0.%^WX>WO _C2::_J_6N1"7BK8'36.4S33]G
M&D[BMW7$%&8'MD0/P4 X"A(Y?PT(]]*F]FM%P$_T+)>?G1@7U@\,OOH5=@0
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MOZ@_FUI:KN%2KN48W$4T-L"V0;ETMU%&,];'U""G/:[(?^Y6O0:+0W)R^!O
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M(2K J0C$F["B3>X)''M=3N-39H%Q:SQ?9=T-][*YAP=ZGI G H8+JT'\/>B
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M/I_Q5O'T4"5,3^[&BU,S6R(TCT[DUA1(\-9>[;J]BXY:F95CP^Z<KUN/8H<
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MU3"_!L01%'FBVUC+'-X\,2E1&J/?;7]IG5?.6!4"S5!1EQCF,TAE3BPG1TV
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M G)Q<[)SL[%SL/_S$"IJRCTTM RTM SLS(S,[/_+[;P3P'J1&DIG3TTE#+C
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M?S5UB1.L@!;%_1/:OR+[]P46]O\KLO\>V+_%A0(P45-1DD?-"H "R,9Y<1*
M_\1_(B^.Y' ."/L0T#$ JHT^H"X(\.\$L4.$G5&B)]'N?Y1KT_I??QS4R_KQ
M0PPU/3X15O6YRVX<\9:*J*@%=R"ZPGEGV[E(5#CE9 @?28<0BD:R!+RB;6>
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M*UMU QE\A:K]!B_X)=W$I:VJNWF!<GU'**IV6<J*TW$_XP[H=#TY!S"H2?T
MGW%-^^RU:2A:%M3+GV8J-4RUIA6GOWUQ;9!3+24*OOYSK08XT+%DAN^::W7
M2G4J-U?VY-9?/.L)KG"9E/F3%NE2CCVA"BL]/%Z:O;X8$1Z><X(/(R>W7U]"
M3&=Q'8ABC?4BX?K>6S:N"."\QT%>SNK&(,L(CY=DY+3NB=1!YM5X#KLW3ZB-
M\5[?<,CP#O=<?H)J#X09UY]&5 W(6]J<:5]"DPWO5\UXM _QURC0/<U3"AF6
M%:'RN_ @*/"BVV9E1$?M1 @\D**$5'!./>K(>VE/L%867ZI*B\:*K3TACW5_
M6GA)O(]YQB ZI#Y4.6\8?B9$Z-AP*?>%QD#8IL]XEY:[3>I4U<T5W;*'8OI/
M19_.W[*ST;TG.[HX$E((V^!+7@)M1'?#"!+:1;CH+@3[--P-W69S?+SCV#QO
M5ZUOY,LHQ1!.+21Q:'BXD?:J^*?A,-5?T'HEW<]SP&622#[!KF<>N?17,,5-
M(#V],NOX]%%>I,GJ9NVSRV5Z)Y79YP!WN26Y+EB#O5V/N*4U/<8PZD7^K/21
M*><;';=7QWG@D<Z E0,'?H%!8W4^-[)F8?G^:X>\77D-I4]5G[ZESBLEB6<Z
MKQJ9O_N:]N%";VB2H<4I;(.K!Y;D!VL0R\49HA-SHHL#7!>Z\"BEDD*WUVD6
MB4_B1[Y9<#>(O$VA[NW6H=(F75CRI913%1FDJR=!#-)&LW]"WY7H%5(B!?O)
M59"C8<-T^?L?5EVO?JW@-B*,Y%!#_M2QG@X1(H07+?-)^+88R)O+Z'L<BQE8
MH"3SF4.;I&-V^:B%G*@5=Z%U=+DX.7PJ0;,"KEA#L/1%,RC^UM=?\>R[G9,K
MDUYP5\LQ@[V^*<O\PXMA.MU3E!YWWRM07>7^ (:9'L\0O2[>G<RX0F@_V*BK
MX[IP.#UF=V-5QU^QM]VG^"8XYAQPS:,K+8=.E[X["]35)DX1J6$/]]JAL[[,
M%D=/)__4WS9H7"[05Q4-(@:(+GL4:.]C3.U$HA#L%RY@VG^2P]4"<?08?]*5
M0]5$Y2=<JY"ZAMG?8R"C>5%Y:@6'OI+T&'#$]_CQ (T/"U'.R-KD 77E,X89
M##14#AO_&"+;,9>7I9I\,":^WZZ#VOCFM()OW8*'1.KR#Q:P4=O-G0,<H*%(
M'C5:(C-A VWR(]1W'00*5"[2G0//'HA&^3<QF8VDHEQXQ:S<I;N\VLSUGQT
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M3%%,J\%GDAXVJ;9LU?6U39(/L5QV=5=3&!6+F*R]QO:*_=2+)3]$DX5*7)9
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MXI\^ >/KY2+_/LC%FKDET_WTA(;_#JS//P<($QGUKNK,M"ZEBL'^6)[H?GO
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M><,Q'1MME-O=;%I2-%JE5[$CZ>W%7)-W\VMVF:1[Q-=J?M8/_!L45@Y+1PR
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MV:;BCRDZ-;$^V 4+PXMBCSH9$UT]:0D;_:^]Y@[.)GQ2#>VN-5!?W*0JORS
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M TA#YGA%<!].2E(",? KOENC/(= !@33=Y?N>K'MQ!&N>A--7&/ .(KQ[*>
MYJ+@:_401S*@!4X&5 QLK$)!LRW;&P&\:A#4CX-@,L!H$F5"HI@;\5,<[M'6
M40F2"XZ!D0%H&?\?7%QIJ =JW -?(P-:.: CSW C9$ (E QXG$4Z5T\JK.Z
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M@8D?B#G$8#* 10\-+CM,IQA G.TVA B71/9.$W=BG08+%OWYC3<HP@@*^FW
MBNDRKA@O@Y.<7XZ4 ;,AU0(R?8;4SJ_."/>7J/9 C^ULNS2;Z+UK-&4+Y0R]
M@E"0"NPBG</2Q.Z".7#KYF.-%YW,.,5SH"UZ0M7C1>]?:2.<G8]?2?Z:/]6)
M$,DM"%(IBP1LZTUH[S_$V*-U9B?U3OL@\#=IGVR&3!=O)BNVNQ]_*_(LR42?
M4^NX5!HBB*H$B)+?X)Z%Q:J>P<!"]K98<2W(GS!KG:,8,Z1Y0S('L[1,LG2/
M;$.\EFB28/SW+F$'P83=#ZP_AH!>57TACT SH820<<KV4)2S$'^DPJ<$O3,Z
M7#<?^LS(E-^+.)O-6/V8B&*[]&P>R$MJAIYN<,9&D"Z:K5&< 312@CM@8X9M
ME*O958O*W-=(HOXY54/5G6T]8=G=$%:J63*@0G+#=79K M2BRH6IJBU<G^ (
M@ZA.HF6()YU\^C_KB7-.W!?T,**G"@5L"@:Y:03D$X3*L30M>"CUNME29<&$
MQK[S498>;R6A\:=5&=_XF6LM/!V%=;+&39T7&ATW\S*81#&Y&UL??;SG*Y!G
M]QC!9EAPU(^IR:5HR;W:!Z"'93/@SHB'D5<"[9[4A[U:6.S5\<OY1\JG8.V-
M+^C995T][Y/\]+FZBD4(Z2D5+YN5I8%>-1E@F?^]+8!OD8KD9=F@D25I^0B!
M>0M<O,[%:B(YOQ69QHCA"V:OG&=B63TR3A;O+-<N#'L0^BAZ3HK&L@"!*=%G
MFBB<76RF"KSH\\2>Y <6@2H;E^;HW\9&.?5;=+GT&636](!0]JT!X&.(>>&7
M,$I48%!<+)1?A,N.KE:/U@VK/OO@[9JG1LG Q"^:FNSH._+8\O9;LMS3=9A6
MW98BJLEE/_PW6225):]GXD#_+P8J\6>'6)X'12RDAVVSF?W3H]#^3 5'23FV
MF8@E1PYW,P8;T?>U1Y<6^D]$/G5O"*/-:0RJX07/#Y_9U!'I[@'MS.SDSCXG
M Z1Q)IR%N-;[8U3FA:L,&J3[B&T-,@ 238WKIX&M\?$/RKR/^J([S>,5*[<#
M7 WI!7$M;9'$'E<M%'^(:9\C[?;R@SMMR "1[;I+U)4-N-+"GM?.;,6O-O15
MT(>E KM%VC NI[':'2^G(KY"GA":A9HBLTO'M$J$:IP'.[>K#SY$R/)2-L7"
M%;%U* >-A._34[S-[;F2KS7(..3V$S* #;K!04-*;+4\!T7=&@FTZ9ZS7]1A
MO0?^F*:Y\#K+Z^FCHMP+;V8C-P@*V/IYX$M>[I^P?>$5G[\PCQE^8%DQE*/=
MYZ\I$+%E$^>JV1Q%#%JQ4[!"*,$=,]J6VK9_M$L_R&NN%VI!M#2R( .01IM\
M])2OPRQ+.@E@#&D"0L07G]K[B!B\?&N9A&<[Q*NY#S?-K;F>V![:%C=,60ML
M)8"(\,93N(/N2+VS/7-.B%77>6YKP %QC2.<J?#4 1%H,D10R[WX,=N1/>5+
M,+'[B^J<<$1C[,M(4J"3?_.,*E:R=?JNH^JYL4K>8SAKZ=4Q/>HKO*F/N<-*
M.V%2)7HTQ0KFPQ/7PD: C88FB_ 6).XR!=^>JI";D1K:4';-+6'[9,/NG7'Z
M6OS5SUCB@B"J.. #)FY_!J>-]2U&BU>2 3CURG=N)U/G 57?>E;B%SJF=KF#
M^:ZAK<2?G/!3K)GVY;U:R.FELA;IJ3Z :>5[,['3<_-W3%49UUUQ!U'$9D*!
M6>2?4_V?M?4:E!URO0:SU8:DPEDI:2X%MT%==UPXPQT"^TYUUFO<BG?SM&SW
M2..OQQ2I*F-><I5U0/3D)T&?NW_::#U+[5[Y? )^4;HF>K_'RTO/1FB8$H)>
MAU",;$SAUP,67SB:[A.N6A^G!X.V<,YOX6Y6.OF;ENAFU_E9:=[C?[;=KP1X
M^0JN2@?@ 6@*#(KV@APDP]/.X=PQZ6W)C9?&=M''9I9UZZJKG6\N/I)G.<<3
MGGE\2>,\CTB0KN)=FCXPYC;HK&.C*/%=I;B)V7#)7H#^>EMUG IZ%RTS6)U(
M([:A);SFA$C=?X\Y0%_&:G<H(MOB.)Q4V8GI!$DH7W+NZI%*Y?:D$\=I4W9S
M?*&ADL"U*8%GUR%M/&B/:5<"LV1'&N<PW#[ I%G8JDR/!>HT8]&539^HW5=>
M<5?R?6E"S2==^>?7E?F<V@.Y5["D/GBY/"4IDD2\ZK)&B1:&)=RHB!> 6^T(
M:&;X"R[T[+1SGWDGPF//K0M0P>\3:RIPWG@^G%GWG+[92CJ3EZ5+K_C-Y=8B
M_F"\G&W\S4D4B<YF^T UT/F[X)8,O!P4F8$SP=\+'*PSRAX]$FZ&,DY.K!V[
MIFFI=">]2_WA&:"8?]A[4Y/\&XAC7ZKW97%:^3[ _5L8T N"[R>$)Z1*.@!^
M9UB 121[C/G;9\V85\^R(T/T "5*QA+IL_#3!$-<$(1E3H?^3G\C$XZ/Z"+K
M[\PWJ.2D8VUVDT_I^NL\X\@I=#QX2WOQ(U @$E")Z6N;X/+IA-S!I9<\5F7!
MND9FL*=Q8#;KH8S%HZG9'">O)<D_N+/SF;D[^M4SBKL36U]9(WPF9E?@IZE1
M(+2.$TK3RGR+P\>C ]F<KWS1>/AZ"N"5:31O;]F)BS(+K'8=5(Y$&F+J4_!9
MG.LL4^NT9'O/5:SXI[#'C$=3<JOZ-[@6><L\UJYD+RP$7^=[_>= 4) 3"^C:
M906\,0XLG1>7;#WD.(CB@>]L ?N$%Q0#KY6(&N.J+WQ];"Q*BY8=ZR4#[F:]
M..JGR1:3^'I?\JN"F \UMLA9NX.++^&U:A9/&=.AO1-^],C&#<1BI53@$ZP_
MFBH_5FX1MUD.R5KY0C,KJOI<11$_O_C>E]W,IIROS_,\F.#E25@_N3/_J=Y-
M+WYT7WN5X7QZ3YE37.9S69BR>3%X0:_ LBY]COD5_-5\V;L)=;%OIE^TNK+_
M%%^4Y??WR8 $\  E0W&GI-J:):([G^!J<%?70UDBD(0X!]V-G(<K.J&EX >V
M:WV*U1ULXL4+^])BHT-:KE+$<7Z/(M67AH8F10_\A$.A#O!(U=.VBJ V(+-I
MYFX87M<D"AOS-I]0^%WY,B7/$L2-S8U&@]?\3"(R]0[M"U9+@S0^.D"J"%JP
MI)4BX; L@_D@*/]P=I7]"B*(#)@MG+"9L;"2Q$$]GT!CUV]^,?7<#;U;0P;
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MR2]YWNW_U95:M7_V9OAO2A71DAL&)="6&W@1@F*=>&UF65+/EX;4B$?4VS?
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MH+ZQO$ZBI=+HQW@Q:<@%*.2:55_DK'HMU'.FTR1L?JGM:)Q1+K^R[<>1V<[
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M.@T+3TNH_RTE$?S+G.=/30@GCV/ P__M^4:<)0:9"DKQ+:M*F^YB[_]P-YQ
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MQM\E]SWP\UCX]W!'\T==_?_23GX>5ZS5_5V$R$%X"M,O\OH+K[>,0#2R>US
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MD%:F:5.^-AS&]WL>M._RIS\M O[+'Q*2041!&)^@I4.)!<IYE7;UFK*78RB
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MI'BU^\P.5V%!/FKH_#<- ?.$'^YM::3,VIS)2KY#PT?6QI-&[C2!'U[?*Z$
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M[E=6(V8=EK.0MH[PA^G@L-A6AQ,?SKK+?L! -4&"VP+Z7$?G B,=F/L*7+_
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MI1OO%VEFST='Y*].+F?!N_F3XY>9TE6F3Y*PN\3EABEMPN.Y*J$MIWE_252
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M8V!K];;4WUZ<-;:A6:6KD^(40)C'A6*9*6W(Z]\*#UY8Q.]LJJ+9!KTCYRF
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M2K: G.0GZW"$@;;F* #M!;@"7.LD"[14YAWT!\G]=-&]B!.4! 7P-IO,27Y
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M=2N<ZW8+9,4RZ%F!)TAG'!@B<;0MR1I5.;]=Q%W,7 QPR>:1$Q;,IKFO,^D
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M09\6GL'.V>!XDD_R0@Z&"M?KI#>3!Q?0FPNOF!D_DVT=$OB7::>^NSV!"A%
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MV;ZN:TYWG^BL]S-PE1?&'F4L[,+G*&2?.I.5C4,BSU0P[NH%MMIE3:7<B8H
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M\-%/W%_5R#4<W!3F^&-<F4^9Q5W,%,"+;!4Z$=>^BO^,NQ>TVGO \^2.PDN
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M+8QWSH"$*N$30,P-D<RK)=]_FQ_6=G_$3!#TCGUBXZY-W^I[YF?T VHS(B0
M= "2<-#J*4<>:?XH\HX^*&UDQ9!3_"AL9 E((C#H-5L8RH\=6:]9#QW7>NR.
M[756^'Z!FCN]5K5:CH_*[2ID52H;,SUYO9FK3%W(&U$^''=VYDBPNQE9!(F
M.?()801$(2Z:ZD)S&T?'=WB[Z3X<E4>AR"<L?MYX8XCK*/2U/C,PG6CVX#"L
MJ@QV>6AXPGD'S"ZH\H.=[2) 4V$1?"+=1PX;0Q(&D[.&&Y=W1-&G1^ +SL2?
M*]TZ!^XY4)FAP:/9744OR ;L! )G^#A:"'-TAND,B)H&^"V.\OA,=/O0U&)
M#AV'@AZ=[M<Z7-U^&L5!#C1'SQ6P,KKE\2\>F(S,- $G$FUM)HT5R?7G4Z'M
M]5V2:*<AV/*.F.7ID>4%)[R&E<AD4@U[MGACGUBBI/5=\=KN#8<Q7]:/VKTU
MCDL6Y"-2U$Y1K*:'AGZ38SZ3J[H9F%W&R0-8[H%AX5YG6XW AQ%,;S+#Y,!Y
M;5+E3SCL84FJ*KL=CU_ ME?N%?#+;V<1')C3'Q1=KB]]_GM?8)HMPR+C\\\W
M;KVWEBG]Q\H#>S:8CS_*/^ST?N!@EW"CFYMWOFZB;U[3XN+KI(SE#7QAP;(=
M7&;BKHB$[@UKQXTQE-.A,'WEH_>\V?&?F:1EQ#BWAH97<T)1.LTSDT;G\BKO
M09:WH<8+,S= THA(L:*T#UR&-IP2KA)L,DEQTL&CU=*G_BVT]V8#NVO^5-V3
MW:^30 RJMG_]4GM/34[+%_T%--J-]1(6+'#*@:AU:F^D0N#"V=\6RA-:X#QH
MLZ5_J>%SP8CN5;\:^O!E!#/8U-R9XZ$Q\+SN)#!#Z;[1VMK W^I,5IK_\+'8
MM]T/B*&Z!'!&MK$>[5X!,:Q1JM$.O<]9 NM>Y[Y*\UM8#-#HY.I4B^#>_S]E
MJ7^G,I7U;>LXG;&1MI*+N%KG RC2 77GEY3.HV*R3_)OGHZE:]KKZ/'DHNCY
M,KXO[B#67N,GEE@IC5,TM76KA@4B^A(\4"8U:\-$K"2SU7-DD-K7>P%;Y@['
M^Z__;)4<O<E'9SV^\>04_BNS&,'PGFVC)5G'/Y\OH -1J";&S>VUZBD]%H/;
MI71T<ZSR:7(<$%\IJPB1@7BD+F<[?4L]^(7":RQ*_&5@;7XLN7\9&#W[^!4#
MBUIH!IPA_(PDE"3",^<W?@H:#?Z><ZW//JFN3NO-4L2G+<:0;]:$Y5@5:-)@
M3GJ&BW*YDQ4X[C%1Q<;'O!S98HVV$!]J7XM?9$R=J8[3>Y0=[@:PU7@\U<3J
M0]?N)JJO01J>XJ*_2-#X/N<ZXE0RH':Q9KW0&#G+OQ<=.>DHG3FIR!'-'[[]
MJ?;7\G*9S$,[^66D^JJ7L^&2V7"1T,X?9P\9<&QFQ"/=F=[A:PIR>U)2<DXY
M--D\NB@)74IU;>^X6BX#;HXLKDD5\P5T) OW7@!JHAPT%2 O"^C@NQ.PBTA)
M[:R.J>8JD.@ TP94^H\,?PL[=:LT_>EYYK#J%O7F5TG8!2@BLPPB*YJ]O-&Q
M&T#E5*$?I^N-XZYOJ!XNRJZN_9FXN:J8E&PON!V@)IN\"97 ^K<3[@TIA245
M]H#M&KUI$5+/_05Q,BK%1?+PT1P& ^LNW<=%/>94#/&AJY%E$@+G;F@3? KA
M'AU.ZA)0Z?/@S/33MOL3Y5OL=$MT'7RN4!=LTRBP_!*P\/"GA(5QY.>HCON?
MM-BGBIF">Y^:R=&D%I=S%VR@<BI-O0\?&^0R9Q,.BH8:^"'YZF-"%2D!>@2N
MI Q#4*[S8L)O!#SG$X:E.[CID.;K(II^DR#>H-%CMRA3FVV>[C[53DVUWG[?
MI?/=&DV$DK[KH170D8Y3 &WK3SJ2R_E[>9LFQWI14T-S ,<L.(E9*!X6#\BC
MO,DQ[EX7&QNZ$75<,,GGJ"QB&%=-^G,SI/:.=F0#?UE8#[7!/;'DSY7)BY/T
MW]]3A3Q0>;Z$D!3K'-#1C9;^/?((F5>MDYJQ5\N8;!3M5<C81E%D.KLS,L4Q
M,]T6WZ"M*]O^CF6":0E>M=@78?$(VS(5[7(BI%GK M<N;67,./)\-G[4*TE2
M7/06CLP?\#!@HA69F#"'=F*X?R_]V>[%-<A ,!E5'_%A;S^)E-K1E:H?3GNO
M-,X;]]B#YFAD-19!W8SUND=WIE)H#]CB-!BAN8>7 *-?N^7+]JE&W$JV3"P,
M%,FBF<C,QV/YG/;<QVE%M=CX]EFNJC R(]VP4SH[M27C H%?1GJ?5'8N =>E
M*56E;L#%^J(:!+$"J=XUWW/(<'7NV5U,HP_:2'1O(W&!X^P9-T(_J1;QPA]0
MD#&:?/:<4D)]D\:9[W*COT[@(Y<H(J'&.?(I^4YNLQ/")-W^?&XATC0/K^GM
MW!*MH>T T^/!&C%:0[B)S+)H[VQW%:9:VF+=356B?A:^R,R8W(5J.61IC.!1
M:<4%T=3(ZNJJ#T[L#5:K$+Q(/*;W"GEF;G/P84E\;693;:N33M8:D2 $K[,M
MP$^]TIAQ.=DMTI&ML#-XEI\ZSQM$8JG>GEEU)'KR^<1@-&+*U)L]W="M(8HG
M$SX<LA-3, >!Z8:^&G*Q*:L/BF<:8!)9IH0]43UEV(8M^$*JMDM5CFIU/#BZ
MI1I,Z0SG*0M^WJ4=B.F)G@D&?((P\*5_9XFV]_ND>9*E.I)*D\45O4N!W[+<
M:RB41WUWJGIP/$9_\/TMA\CR<M+=6];IOOD$;GS)8A^]<4",T>CWZ@IN@=N/
M7D0C4D)X9O!CG$H49,_U_C[V+5M8'8T)7#9/:Q:EM"#TT>+1WN.4,PJ]N':[
MYMCK^5E4_9@WR@%8+:QE&_@>9,9:$VR8?,33NQ)YA^G-*>;5S0#L;'4-SVD]
MJR/&EU;"G^_B++P<*<3]M,HEV)PU// 1)*9%7,1X_;2@)J NGG3&RJ!;$F 3
M]S3J*I8'\*5FEN=JT5AWZSY&RZE%Y=!":IGE"[%\;7ZC*7(?.K[EVKMQI\B*
M5V)-(U)Q]OLC/LCCLD'D A#.PKDGEYHXR7SN3:4ZA73.%MP)F/A4TOE&F^;W
M@+&L  F%W4:1Q:CA6>11A=25L[W0FM/&#RU><.T?;?;I5%54U\%$%E^7;]DZ
MFM)ULPHAL1PXKL3N):,HT:FS[BUSY=G9_;U0-UD_K]*Z;,_I%] Q"B5['#]?
M_8:*)2=!\0@'2[O8WA$(%(.T=.O5##OC&"'@G2#JZ4Z4*2D'T?>EE>5+ .Z#
MC1.04NQ"KRT6=.!$+/:QZ8X/^-ZS3OH.;YZ[KF[QJ0@*)B,Y)3/7GQ!YAR&U
MR2F!6C_2T=Q_+!:[+*Q1.T-.&J9@,KF3!MLS-N&<$5Q$H3TKZE P[=8EQOH^
MD L2TU1YT)PQEP/7.EM^-$KK+=G4+4T=O)%Z%ZEG5G^?D*\8.W0$2C@LK9IF
M&45)2#QMS)TUAKICOZ=P_DE,SGXP:*ZVVMN_,9IG"]L59U\^2UZJ<#99^QL9
M=AG$:WXZ[XNZ<:CW3&.>W:>>(XJ/'\W3T4IGB::7T@O1/%*[;6 OYJA6?A66
M/>G_<ULSK@""_S\5+E<WAC7N:]7Q70+>Y%M>W*L8-)K'QRQICQ#LUT4)MTZO
MSC);#7^\*.#3Z@>+D7WX?=/;K6>161&#G* E>U?4?^)V$_GNO9W<KV>29S-\
M^45Z;984F'.EI;Y;D$R-:BMD*_+=?N&(@G'# &5T%4L6P.9M30T*Q'?K'RTO
M MV-UF?^#DS<EP"AOZ6.%S]/_BP1S,\O <\RX7R'1&O_\C-JC= -R*#E]<WN
MW,F-2HFQ@4]6B8?JT/@0TE>(;\NLBR3?.OC2,LMRM<3>+(AY_HY*9?CL(P/[
MR$JS*\_AZ^Y4(QZ75/(-(3.E_Y7SQ4PM6"2!'3U+PH@03H[1Q*-R)_%V<\\:
M2X=P,[R3.F)UTI]=9C6NJT[^VG3KFH][HKK1[O;92+JY/UI,367&!"VD-<>N
M8I(5G^)7EHV%M0EX=$Q.2W_/\HK [ D,7BMA RR_8ZY>DX,P[?'Y=%@RGBLL
M1=-[7CPGDY/7%MCY5C4E4V0 3^28?V# P4,_R=?W X63!5;O"'F V8Y&Y';]
M _ITAX$.EP!:)[[OB>;24@4VQ@\6G#W8Y]^$\6L1D9//9"/X@/KXL;PMBR?%
M6,ZC^"PSR]??ISQ!/K<*;CWL9?5X(B<A3,011"&V5FXHW%W\">^84W-V++ (
MTO!]6H*/P$J?+=JV5_2B4(ZCQZY"B54/'!]5OXPOWO&^81,_)(O+8[F%S6X@
M'DG2JQAZ!T9GL;4*K'\^X;YQ+X-9X1>PC4(ARDA&R5.%3%VT/B2F>KQG) 59
M#M8;%-M%T#9PC0IXF6NW6K#6#@OHV3Q5N[OFM/SI]LF4Z8TX":*HL:=+0-:M
M=/D&C32[PVFZ_4<?]#G<B";T YEPDO1BO0,Z&B3/([4H*RKW#S'[3/GZR4[:
M'@.RC[%#;18T>QO][Z4#"[^_R6S.;;*]C8JK>_+[C&G4+@EK:CYP;L7Z$=-3
M.J-"5:6A<\O4)ISIQ8]L9YTQ ,(75R0-M]1MM=">0/O#9&*F1DK-IM[Y5: P
MCQ>[Y9R.=1!D_(P5.IR-$^J=/^^2_'K37M)A' ,@'_DZ/Q>=C [^/LP]Y!E-
M9S;7M:K]U+0&&_<\+RLO+RH50-( ZN,IN 24%:<6\2:759QC2BR-"SU/*D5E
M%0I8*4%&R?$F4Q/UPV%&8<-/HH3/VESL9%/3Z]4Z2&B02C1S=#]R:$JEIIQG
MTBC@LEYYD$;M ?Z*F]'?!@4:>L#%E.I[$L(<*\5Y,@$#[4(AT(#\<^"P3>U@
MSC,N;4%_WWBHGE"6$.X&ZY\Q&25KG)]%S\"*&1JE=0GX&C@(G3X>WA8#PAG2
MUL(L6T?%$Z598OB_.Q:6C\] 5SF8:F7*6$*C#@&> ,/9%.R4_F =YR7@UK#T
M@XB+3P.BVG=4Y,TD9CGKMI?CM%06X ?J?/1O7/=C^#-R=@]VMU9-T+J"&R?0
M6N;=T(:G6^EW]U8Z/I!5(G,=/1YPS>D&_<ZOW040 12V0F-33T?F[D/]Q^JL
M%GSZ*S2!ZND3"3!H\:_2?"&5&VI!L+O>'9)HL<SX)BM;O<D:4/)Q(]*M0,F
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MD55WDR@^]<4?\"XGT'72GQ/[=[8)G8C-L!+JMH%'Z@N=8P5Y5O:T/+EJW,Q
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MI9B,\C*%ID)YD2X"J6WC8H(/IE1JV,6WYOEUK)0-A^W#B@UM0S/<H]:61@$
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M7=CDPC)4".5:IXRS'4:S(NTG5;\3/(:AD.KR\"$UTV OQ#.[$$<'Y:J MM7
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MRETWE&4[^2D]P:;!P_C4?JI:-LY3CL[I@:-;SL_1/FGU/C-35C,S)C,S,PV
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M"S=I?%:Q^E#J'PO'.V[5<ZY!9GEECS[ DGZ#J\ /K0I;H?S+\H,)U'6[@(<
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MPM!IR)_KGY-1R3N[V%]'/N-R= +HU1B+GAG.J,ZVUN3= +;K!A>B*!HF5 "
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M>9OHF4(0_J<@@>:K#2<*:2-)E7D;]R1Z"347+3CO?/.$7[-XK/$L) "%0<5
MN<8ZL2\"-P%HIQKCA(J^_U>]0I?#T9F!?(^0/OH"69U*]0Z_""$%BY>/X<%'
MVY+XH;=0;J0P'(S[H 9^K28PG8O]2$'33%VG;(>QN-)U2"!U^'@LG:0C:(\<
M&#+?G[&K+_9XV);)R0.73'K8&3/#W0#T\3!6&Q<%X^[L1_XZ)H\*&J.B7B==
M[TDJSEU>Y>&OW=+(75S+K.K:#G<O+*)?W+[DZ&07B]N!V4#7>GLQ,^&@X,@3
M61+BWUX#+*Q!,>Y5G^G8P"0@M<6/^6SU:5 HWFM#+O3R!9,/"7+1Y<1(<Z#D
M?%T%8($[!5VV=5,S2#_.C)'.BQZXK,,B]$1<5S#=8:4SB^/O9R'I?A1!.UAV
M!W-H-BE:'Y43<=1AYL_9/R\@X^'.8[?=K$0[H1]L2%2^1XCOF%<T!CR*X-%Z
M^O<W9CR=?HP<O'<N%%+^(3S+%_FGAP;1DKUV+XL)3#YS9K<A=N18&M,[0:)_
M>,DK?O>VHW4[;_^\2CZ^0C[DKW@?&8;/%W _(X3N,]V>I&#!W"H6!-JER_5$
MVC9!K;0CS>3I ><2BSYO_O:7<]H7)F0&6+0NF'AT>5W3Z5("JU!:D/Q$[18T
M5FY9NJ5VRA.AL02C[X %VPEW79_9.?<P&M)@J_3X 'P3/A/"HW2  F[6DCZ=
M@MHS3R).0>N#DR&JT$,/X&,AZ3G ME3&NWG+TLJM83(CQ9]Y.D>(;B7A_@6G
M9W=V.@OA8^U0KF*D$@#1(TR%R]MHXSPF*FM^EMK8;/VL^BP='@>YY?!,>P0L
M_(GU4P]I!9C)GR5)D<-0SM+12#;HEL';Y-K#Y)'-Y-B:#1U+^D*&QXL!RXSL
M]G:](0^7&30#(=OG[6"P,V9K"K ATA *7,??8NT"4+\>"+HZ[TG;SXOZ/4OL
M3/6\WYF3Q4ZUC68XLVK96ULQ<DU3,$'[:20&,GW,_^;(S_)+QA=O_M87ZB.7
MJ*TK?ABJ\7G.=[Q4<#XG/;UX6 G$GF@L(MQ&#WZ*8\[&3DS'HRH[KU4UU]]'
MJ0FZR".2XI9<&__M%D\#,5X,$#\%W40"M:>@9Q:0?9/8@,4MN]SIS0P.<IW$
M =\=Z1++"SZ,[<\?2&1BXV)#93XZFM*6/]&^'@+1A#B3??"PM\W\F  B#),&
M#6]ZYNEH-K8?T#[\]IZ E8/N50:ME]2UZO!!VERS,TG3MA@M( P8GH)H\H@"
M.3BKHEA%(S01D>:^P5EL9&7NH./?<.N7+GVEUTI *LT5WGUI;C?&$R7$$W)\
M&05L(16O&%-UH@QEL9H.S9Q];N]2>G0--:67NF(G&#I;DYY.I0[.GVA%P(%\
MIE;I,*0TL7\2OW?"9I"T*N[D\=6UO.9&SQ:OEJ;H#Z&EJ=_YT<UL:VHWSX"R
M9D.-FV7@ZQKV6_J1Y3M+H1*'(WV1#(=/\HD<CGO625NY<IZ>R.=N4$!T*-2S
M^0YR(+.*J?7DIY'Y/JJ:G/+0/<+5M->"\W[Q!>12$O=<0>?CG=_R5/N03H,(
MRJUQB&,J2;N(Y$1TCO#U4+R?V5Z;DL;X>X9WU]B%OOA1KZ+D=V]VO^$/<U8^
MJ4(8$[)Q5R:S&B-)$1!?WN5QXS)RYQK( _P[+>57 HR"\U^6]'9]*;?N$(]=
M5?VJZ61*ZV EX;Y(IR:&> 6@",?T,-XS$W^=0(@0^?4>-1&:+ OJQK?'GC^.
MEVCCR>)A;;NO +9/JFCG%,]D46,Y(P$7X@F_<9Z5W]T$)"@#$QX(77PFGXU%
MR0>Y+O8_O0GW8S[N.7R\_]<[Z7J4[*Q_^Q7J];3_*W? +IR%/!0N/O*NM65*
MC(IN+ASZ.-D.QK]:&<R1*WW3U(X[@.?>\X(N3Y]PT?)2(\SA)^#>]P5-5T>B
M52M7BM&7\E887ES17^WU@]3;[H=OJD-/EJ3;X5)V<7@NPFI.@])3V<Q]5Z:K
M4[\,MI:789%G0KGU#E("#FE7#/3+QF\;V#0&<V&67QR_>U^=E]0J_X2AFUWG
MS=^09R_L,BYF,<T\\$TT^1@FSA!AG*!=(HD,)HD ]42N0T%R"$D:#^$%'AHP
M&US^.BP57[@1;^]O[RR>Z-F$D?*ZIWQY/KKW;FS.3!/UB8N;K80'O>6$&L<F
MD@_P"<8Y$X6G8CU+:9+](NX\2,)4V_=0U5ZO9'=5V#'O91ZGVC]0L#"ZN*#+
M;Q]+Y>1WAX[6R, .>JWU#-/HJBJ!8)Q!%';W]<I(,SL\TRJ8%6-)F;#PO?C%
MTI'-VN)M:&Y ;8JPB!\5$^V[8\6.7>S7V18TMPH7(;_MF!TI13P%13]WKY-T
M&E?K<'9W*Q+D^9:N>1-4+)M0R,?*O-^[0CW2Q$?,Q^VV>QC9*+8AE0E#T;>Y
MLQ59+=:P'3_G>I@=C:_IS+]],ICC)Y-,75?:BY8[!3GPZQF.HY?RH?P[JR.G
MH(IJT^&RH_5:MMBB6XT_: +>7C;\Y'#'^N,SO]_1!V<?<38"&K?CN=8@?)YH
MG(7%S :4_JOL@B68M;(CD-4BR>X*VO[\P[?FI4]VNFF=+?^U<?V;<O;QM=H1
M!TPS-Y'*\'RMSYA '[W;#2Z'4]?_N#KI8KF78WNU>-)+ T W>D1!:6O- I1A
M 66B66S5 +4E< ^5C77GO3I9M1TX9N@^?UOQID--8[I55J@G2"P#ML MH93%
M!/_:3$U^IZ:,> (,G)B1'#_;5(R42E852E8%;.=,B$1+2EUTKE>79-O:/@P=
MY*Y4>I/!]$B,+'UBAW!I(&>>@IPA//"QQYK!EJ/SDEO44K^LHG+-[5_>90X_
M2@C<Z@H$[2 <B>XMBY<=HR&<\"', G<2],"U>"/!DNOX$K_/\&1I_#(C;3O$
MD=([N3]OL.VMJXJ>WEE.&8SEX9A7>%__M(=;R(N^0%43$7,&[QC QS& H" =
M<W?]3->&=37+-3<V-$Y5@Q=M+^*_;$]>$T>T^M#+@/;J D&J:0:OU;@!'^+9
M7%]^G.KLFJ-%X6P>.UC;OG:MU-S 7<7X[?"S'SHBII" 2K U+^BP01S_TYE"
M9V*7#3"U05@]5>AV"9AVRZJ&AV[>;K/5RKJ"DG4#CBLT*X*W+BE[*;-2;:'=
MXV<?GQP:$%-"7\VBSVGC;< =DD)>4,N-78Y^ [;VBK 7DIE^-,2/V+_V=79>
MET#'T>5-%LL&3 "M=K!5^_'.9]S 37Y[]VW+/\KFU#)MA0'<4@9V&>XM:O1(
M+)10B7:!L2.N$IE"?,%4P'O=:J[)=12*L<_Z@:EB>PQW^TONU=BV(AV91B&6
ML![2?7)Q'H#&H>,%KA"D0X?>-MU>VK[^!V,Q)3+^@%5E@&:C;72Z?0&NP9=D
MJ?.'Z]?\QV[:L32##H/S[@MLC42M5#R9UI PD&KG4V+IYJ7G?.D)/6VJ^=<E
MEO0,67&8YN3^+JNK0L.W]RCW[ZXIAE$>NQ+?++)3F;2TC32H-QB1=LC>A1MC
M)+ZS06HB#A:5 &I374B!&-LZ&V.-AO&5'WLELUM]'SX*^ORTSJ;^M:;S3)UV
M#<9(F4)2 UPG["0UXL_(T%\C\F2+QYE9<#F#G^XI<@$5\=+;E[.65YQ=N9U7
M.[D3$YARA?YE"8.YF.ATEQ<9M/%A=ZIY!=T5VHX&[[0CM<@G@]I][_9L\I#/
MD*.\BV\/RH ;^5M;"!,<7$6FJ'.2+[MB7&T1)O:YY^)-Q8\LSR^;O+X7>D?B
MHNC&*>CM8LW58>1U^$G+PF5"E>T-(OAUE0CQ0OF%_,*:3_&>Y;GADNGW%#_A
M'.*5FZK_MC $M-".LIOU8J>V$U'+!M-EEL $85.S-O1X]%)3GS3SHUY)7H6;
M@M+)Q2)7M\5RLYX%.':.=2.[4%4<IZ 0M-UG6!2*+;?F[OGZ<6ETS75TTF_#
M\5+A":G:XN15=O/Y/*_"&C/&!(-D61#M++O9H"TUN4QDHLF;L(=IEB4$ JK-
MU]8]O@-.>'[C[06W-ZP!BGHK72L/[1V?L7?7>S16=MPC#!VV?UZFP>;]?J/"
MG;83[HA71C%U3Z:UU>1[QOM>D0[V=OR%W)@QS$VXE3C]]N]3F\$0\,/_W_<G
M^"0*:6!"<>6=(97*5\Y3%XK^*+MU"HHH "1/09JH%A1@;($B8@]X257-1-$(
M-?XSQ'S>9%P(Q!B/-BEFY67)S;L9=WF\X-7G9/672VC\,GU2[KDR3+M>%H&P
MR@;&]/3U,-C!S-+U0:_:-,=Q?^;RPU="X,'JHCW[0U'"U%L8^D79NXR[@'_.
M@!TA^5"YU?GP0W*7_G@I0_0S%D0^?=/#U@F^/FU!ESGV8UI,)G!3.TKM)N#<
MZ6_+ [ 4PR.AA(%^F:%<EX:ZA@NBSL;BD)F)RGJO@L3N?FKPQR=IH).,Z+\8
M(W*9E"\L&MN%05/#91#:>"B32X[E5(KQ1,27\PEBL8=/?2/L)4Y!38:A'%3=
M4K>\R**'FX!_$;*?*Y,O<M9N1.(3UMKUQ?<IUZ"/AAXA?LG/US0<&(NYEYQ!
M N7X^%CT91);:6D47EH L%>?M#")^/+=76%RBD9Q7LVJ[H7 G,^9_S\^,]R#
M9B$@!>\?"7'>]F\7N!33EK!1JU^XO@W[3D\8?BB9:F3_ZX']AW/%3RY8*U[6
MN1J<2!P[;!]'TE*&%R\W\\[#!19-?A"KM_/R,JHY:T9Z0,FXJWY)<[,L'YR[
MSVG44?6^#Z':G^#8,V@MFZ4[P:.V-9<SPWCC0[.&=U4DG55G-R:Q/8UQRWUI
M%]O>#C0Y^M.'S/2T&BD-N@NC/54U.OR0XE/-/*1;X\U"< B&MRI0=7LG);"-
MLF$<^\=B)I>5)T>]5T^N*Z'E];L$J@-'#H+H=BMQ%Z\03]Q;T@ZILN*C9Z2V
MG=J/-?0HE7:(6*68[SZ["?-K$^$D1OG]?O:)E-WX N*_-KK!MJZ0Y#99,VGY
M^<&WU87!7Z77XAXA>I.JO%.>!,IHB@X_H0D\>ONJC'X]:<-R,M\YUW7X%%3<
MB/YR-4IN8TL=_,4G WPVLX\ZDOUK \'Q*G+%6//.T7F#_$W.O:YS5$FCLDIT
MH(W'YQ%4!.?VR,/I,]X?!J^!<2=^A_.UR-@T1^)FRYNG$#YY32^;A#PD9C.,
M'NL\"TMH"LX[T44.4/C)6<W\ SESZY,RFS77G$=NWQ2DF_1G21@I\#V?K"#H
M?H/&X[F7#CO5%KO9$(0%[0X%M"GB\,\X]!L5&7!4DPWNY_DFC8)[A1OZW]0)
MY\W^+'VXIY@J-:41<3'S%M\?/D_G")2'C@KJ1&03PDN2Q,GYDJ/?UV1G;03&
MSU@PT/$^>U\L2ZO\\./?"UM+VV?B8H"#<!?5:G*^#)-)"]]["MPKF@8,+,9_
MC>[Z:D[8P[<=M>QK0,_-ZM0L=R$2+I>?*LO^ &L@_,B%$F>\']/2?&GD%0S0
M:_)>%@^/?S2FN515J^,3IC*V]=[-MW/\N5\-[940_P6N,PC?[<1NNF3P$W<C
M;I,=33ZM8VTK/7R\SI&7?^4DM^QV<53G +.8YFN3MVT$'TY5_30P&;76+C"?
M6="6.'P1*#%2Q/DN78#[\L>_8P1_HW%?&"#^.U;*-_B*R]W4405K<PG\*VT;
MM1$]H==F@6J*11Q&)JUB^5<#,[=BB6$MV-IM*N*!,0Z92?C=CI4X8H/GV%9/
M?1NW^YG,%V7J; *W9_EV$"#[7=%9V$<=; 7,XOW#FGDQKM(Q)(MLP%2\QK$V
M&&84,> D1O4L0LNFW<&97U8<>G]J?XC=Y3"M)K8 ZW9L@@VH.9J4*R8\BLP1
M+!3#S/&2=LC%*-=YC<,$<B1%" C3( AB26KOC:K'B@]F8W7U9ZO,#@=^_\S_
M0.,M(V!^W32XG^J18V0!Z1HY1UYZINL0#( +-CG?+UIO)EJN'3)K^6G_UK'>
M37L$EKI-IWO-XB='?0OMS/Z_)O)T*'==DNO)/3AZ"1U%$@1'(&"X$Y.?C';?
M^>^W;5Q/O"-^,X++N 8^R! \=%_&EN4$0O(#"HD:AR0@*F^CP2]<$AWQ JSE
MH:!J"R^I.OOE6WUYQD,G13D9$&Z2>=JP_EP(2.T4]+79G C>'J'1QC\NP1E<
MJ(U&<! V7E43+U23"R0= _0X$E]DR=S*[&N5L-5YW=5K):A*&P5Y$7L1\0 (
M6EJ\-.N*G<Q;EF2%L%C,N?.6'=K45R8DLG8N/(W0BYP5F?8KFU-RS&+*7BOU
MQQU%2Y,<<58>5L:$@]WP,J<TO.*H+^LW^ .?)C?KLK[DIV9_]:2N>#AQVX_\
MKU4ZTY##X'-5IR"L8(LL +$@@M^J0'*L=<K\FL%U$3Q2XR^O)^9&/_KFY??.
MX75ZG#B&0G>&FC)J["1ZX$LVL*DYJ6)6Z-:@W"/\L[DDP%VXWBEV>:XW>:V]
MX"6&08FZ[.'Q3C3H=_-5N +DK2WC!$))H;#091+[060AZ*>(2?2*UF*PX8R5
MYZ_>9&HOAH<?[UP;A=-B*@".)DZL:B&AR/44-*/]<.8MLN_77Z0II+$R>O%K
MB(HH#KH%6X*%JTD,D^YY!)1L'F7PE[_7)Y "?XW[:.=8Z0P.)N,$[^ON\?MW
MV[1]R0[!_\1&WP"5\N$76\ELRPHQ>=/NBG>_94I]+.@J<CV.B ^<K#5-,<SY
MVAV'WNJ[BCEW>>?CW(BZ !_AZ-!H%"&Z;-YDAH>P;=I")HMAI655J;[9--[3
MNE[?*W0$0^^,K(IE\7"_.LEV-^L\!55"(A$VRY)6'9;(\A) T69RZT)*B0W<
MSUSP;EX!]Z5;R3P7EM0,Q5XD7*8..1^XS4Z%1[.@':"@LR'G^H80^G,@S0A7
MUD^ZZ6$W+$6*8NXTC^UO;7\=4ZE F+%OW 5A$H&/9^SQ% 0$$04[,JX0(8='
M[YKD\*KT!K5CD@<>M)8R-KKLERKDA"H$RX.;N(QX&I+T@V4T_QW0OT1A )R7
M.N,#['%K4K9!?P<6<KZ[F1GX!Z.4N/><,^Y;S%)3BU+_8-]]MWCQ%3CN%,1X
M8$ -I,^C[-Q@GD?BSC>BM9CGM.\6O+AR;N3&G=\T2V&ARO\*MV\+'@H3I#(5
MWY2451NPP,,P BP-[@/4;0T_YXS6L8C<I-SGPLD>N:2OKD+TPUXZ.7BS+6?<
M8M2B0!4JIK99ANCT&5_">\=N3'!LI9RS)K&K[LW3I)&^<Z,/NX)D^B-I0%G!
MU)H@Q 'N%#1=BZ'P .02A-T/(OH=6R=O2[+RSZ'\ZLH'./6W6B\ $Y:NL"^+
M5WN47BR3E,BO29*$BB$\?TW8\A"?-CA>TG+62JXO7\=QSCJ5C4R_@M"7)78*
M>\JREXU5/:$=0M&?@IXS@4AR@#(>%EZ&*H67M6#W,UYA;=&2C0&LW@TZN:$7
MTV7$>7J<L,^-&A]O8]7HR0DJ@C@H%]RXW3*B$@_FAL*UAK8$KL2W<]U2L7RD
M[/>:%<,0-'V#&O%-ZZ^V$FBJ?D0=K&R#;#\^W[5]WI>8#!& #TYU5@:\3=(4
MR?!8"L^1N6BD4 FYWGF_\+G5+YKR%^_S3N0I711N<C*L21L2_B_-W4@2D9M2
MTS W6='I:-3A:,S?](+OMW?LK(ZGEKK@_-I_2P4,1@]1BNHL^12T)K9M-(I:
MGD<O4D)+_V,AB,;L/\K!P?YST4C^O[?XQ!,WR_!O,?E]J$*;V?5)YG<]O@%B
M&%8F4[^K3(/-+X'$?Z>F 24".:^V<F*GR1Z9'G"7A@_/N*O\\;[J<+7'X]B'
M@^/++ZT_^#N/?O@5FWORW6I-?$\.3TOBT.@,K-1E"FN2S 7<SGG5<FU-'0FT
M.SO8KQDV5^_5QD'<T#&9+(CV25)P<0],=+&Z,G,K0;$\CCD:Q6);HO*MJ5DA
M,:R,H_P$@H==@3NWBEFU(X5']L]3BYX8/XE>W/?C6&F^3JY7NP#W^")"/*C>
MZCL%2>S/*L<D(.,2/YR9JXB8NN+*_V6ZL;S'24GH>,Q].,) '_$21C@%R8F^
M#68Y+CE3!:U/U%A<BWOLO\&+S#R'.#[(:*&X/BE2E*W]<LZ^_!EA7.F$%E-B
MM#NV;9GKY4SY&[NYYQ:]$6<6855$ZCX<@]QW.J-953NG(!-"'MO92#(G4TS;
MFD,)9MM>% E &P?A1;_!UP2_M)K&#L!FWJ@]^'I+8^NWTM"]:-*KLF%86.8?
MUT5ZR.9O\U/0:%YIM)(3J\EZ*T9K_@#5NX@2S&B^GGOSH6%@V9[V:")E(H&(
M;G/F[]V DK]7G:D4-WU&XN^UNV_4FJW73D']=']KHH]YO"@VDH6SJV?W1%/[
M**@[07O"#UKE'UHFLZJ6]QRU_K/ [A04)U,:KP^4+_TT?PW#6PF+5D]NHLC<
MH+)W+J5BZ3)A*:TWI=-.08+PU>K)=;E=*Z7L\>=[+WY'_('LSCZL8!K0+>1Y
MF,X2M@L]CYTW<)0=@,DG//PI%!7]@Z3IUR#=N<N[%F2JZA=4D$*Q6*3RNKC?
M%ZJ]I!G 46?Z?3+V*=D$W;\=X<%%[%R(G!HW>[T&J99#%):ZR*"+CU_E,9$)
M,[248X[U!3Z@'@?F\-#3?ZYL%7$*2O%0#V#:IR'EDB^5?6EWY)Z3JORV/>^&
M9AK?+[2_83(J.[5S=^/F -]5FKB+W:KQPV/N7<KW_^=F[2WR-Y5[Y$B"<J>,
M=NZFY:^=_+SY]1J_NY??>Q?,Z:G4_*$Y?TWK1CVWU,D35JIG.K2K8$"(DE)*
M4@"T\>#S\-HV6S%",UKMIW?1_;2NR#(/CY5:=W?S5K:F^Y*S.;"$&OP%=<$[
M)S71H+]@"AT*MPWK1%4*+0@0%B.KT:R;9@UY11W.7UW]N<IJ%"2V*$8*+;1^
MG0;4MX<! ]SV;L<9XM(_ H(.;<X4X\K"I=IAAS#+L?SRY(5#/IUE,6)_=(=*
M>^?214$A-JC>&;)].-YMR7R;R8RV![\YBX1S K1$SL_+L6P=[^?=:A6/'<K7
MDY._Z:WN=:Q#KYMT8)G+&V6FYUX-59!, 4&\03BXUJP-'.,7*%6-SZ0V7Q=\
M,.XI'\0#*RW.M=*+,4E<"K?4X&'3^O710/L*HOYD,!I$.@61TRD"P"E(X\S7
MHQ%/@+ "A"J1,26,I.GNFS^[D2+3P?K 4L_55)OIJO#%6D?RM$^R[=W$Y4N$
M67QF&Y25,HGD,WBS($F4R%")WG*]F_'^N4/Y+?E:V8 (:U*__2>.*&HENUK0
MU*8J.]5?6"ZEOUD)J/Z7U3K:1.^!&W#7)@Z%D^XIE)$CB]?W7/_,(_9(4;^_
M1O:;";\V#NVK5>HN*T8[0-XM,B,"EM#T *H#<HFDNW1"YAUX<1!K95O+:5K)
M_76&SS+GN86 ELES!;&K\WOOJQ1'QY_0_E[<,C[# SQMZR)V;]DWH_'LQCKF
M(5&A4'@"_=;R:IJ;5=2.DQF;@) S:^<Y$1VAG9FJJ6EPE6AK">0P!%#$HZC<
MY(*3)&UG'12#_/D"1I)U'#NU[G='ZW1WTSBG[3^\08V'3G<])=9N%1$HJ' (
M.XD%?\\C9V%(*AX/9ESGLIR/G6@J=;@9H[.2)+<J]V,N++*53ANB8X.X3T06
MXM"<&\>TH:5)JA#=- _.67.(<\-$F:F"RS*S\RL95A8?D2GA^.[L>["'7T,@
M5RAR"%5@F[AXZ%@^CM DU'9R9<A'=L2J8O2?V\M8RAM)/)F9OK'(+M:> I.\
M)_'.\O'#H#(2N[T>T:R#20 Y5'O,A-GE63@+SP921448URSK^5.0<Y=\S8OR
M'J%+0AY7F?7J6:9C<TXPD*_[9Z:+?"T/99X[TV@DX^5)@G-,21-/H46LVJQU
M V&"I% B9C[;]G+W(MUGG!?_CWS0;QJV3 (8)_WN[)E!4*Q_"V]9&$*[2 ]O
M9175I%2XGO8J12$M2=Y,C.J+65^<NO"[#WX,CY>R?E"AM=?^I<-$HAC4KL/%
M*9?RB=*XPUK"8H=IALBX+TV*?E788_=ZZ0>C]Z?-LZ0E@LXWILA^O3$7(L>J
MGK,</[/;A69&/SL%A=%J$N*:%\0 _T)KE"MP!MN/ZBJ:$H4^=%MRK\8^FA8P
M90AZS;#$VMT+,7')8AI$8S74B5T=!K-\2YGM\9<0LL2($EP9$Q8[_S_8>\^P
M)KMT;3A6% 2D=X*"@E3ITA(;("HBJ*"T*(@TZ2 !0H(HO0D(* A1BH (D:Z4
MA%ZE]PZA-TDHX884WCSS?O/,?F?VS#.SCW?/L;_O^'ZL/Y#CSEHKUSJO\SS7
MNM=E\;ZDQUJUW7-3TT\V623Z4-,(X]/(F+?!&E#> JPRXB8UDR8*W-R=Z?Q!
M7R8Q]2:)2+#*"1G/U;SFEXB4E,K/9YZ!2CY>9W)RD0YM-1K8G: '_0A9C2)&
MI.Y2.*SQ//4IN".KR>#P"9?!SO:'Y=P87_.0P^?<!8";\P-7Q!['=EC#Q:=A
M#0818,+ME)B@J.DHQWKA"P1*AX>M2T&##/C^6P>.\2JW)L &)JG-N%'N$7>1
MTQF:]?8N0SWJVP$H>+JB&W$F<Q5<?-WR*#$["'_+7[?)="@X/_\Z[>;S1TX+
M9VP3\>;,/X_W)%FMUY6G NW3D$+5IHT0- >2!=!H0C$CSSKR-R@"Z"O)30]Z
MK8O>)*7-_"K;$WT!<G3W+J.\R[ 1H;W]/U]F93=#-3? -F(6S79>.AV P&PH
M+#35Y0]WO([?^8MO5_"[FY?SYQM+#A6UG(F:>]QXG_O,_<+9;A8]$M=>;$8'
M1IN>N2$#6#E]PBZ>$\I:<(:LZ5L,E[LOMMXG6C8Q%^$AVW>6CFVU1U_"LI7N
M'N79+5PN4U5U_]K%5>4DE5\EIQ1TG_UJ4T!QN:!DH-[T8<<M,NTD; ;-3H$,
MT"3ML9($[W"$/*34GYGZ.KGSI8_]T9XS;U4WGH:*N$R*MSV4;ZVY=(EZ(CT
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MD@GPP#,9L#5*+B?7FXTT^OC;LS.W2S,)W!!E=WZR\/U4"LO5>5.<-ITO=AZ
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M/^U:Y3?4.7D1B,6#A6Z;/>@7OG&HS51[\S+ZNB!27'P2FW+H#=XM[#[Z!\/
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MS_OK2KE,A5GER.TXU3*#RQJ':@096]+#]X_&&>N*T,E?S5]76OB_9XO]N;D
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M%L'RO16/NXBRPXS=:T:5'(VW[X)21"W993;M?#TSI2/&UME=GT&:F=*NONJ
MAX1IWOH"U)M7#7IU7)U],. BIC!N:7'C:9R.5BMT[E!X!Z:@;GZ;0-L:M#@
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M.^H[A93^HY 7;O5X1F%6G,$3=54ZZV$NKVA.)B8<]1@W)H*X5E0,N,SZ'8"
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M:D79QZ\/0!4A/T4_;9W>,048RS6]9F5NX<&1I1@.1_:]T;1\[W/S]2_&U^Z
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MX]_\Z9<-M-%6V3]:APX2F$O_A1V;O[2*C0#<ICN.$;5FUXO:+E*?<RP F Y
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M>)Q]0C*J-?MJ<RUB'-'!!KE+0D.\YC,>QJJ9,QNN35VI/)12A5IKE_74'O1
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M@?03HT>/L7?UY)N_1L.+WE.U=37"?)\"($@H$E\C&"F \4X@.>FGZ2^#"&)
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M"(((5XFTNB#QUN!!N4)Z;NGH3W?5\2RO,73RZC@4Z&7:9)O3%9V^2^R[G]'
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MF/$_/L'8+X=6-\9)?^X%T02(XI-+0X]7CGKP66XB7:=2<B(P.8:+ ":V'"6
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MB)P_MO1ZJ66VG@((H9HB2.WZ'UL@L! #_Q; *_T=P*/N<I-,MSG_JZNU;R@
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MU_GEI*1(8%0)XRYH/+\=C7T+4<.9MN@5*H)7[1JT/YY:^P'0^WZK/< JZ:3
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M)%:49*S?'.JUST.A@^$<B;!6)71'F3IC73J63T'_,6^TSAR7K>?(BA&*T+V
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MQ6U/&QY7,*"O_PPE181][:?^)^M#9_]+9>/6BF1OP!>\>>H=<)O4GP9PO9'
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M3(V3^<9%\*C0:_:&-/;]E*3'KRI&'SNT'0/0[*(K'AA15PH+5 W1D&/-ME1
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MO"%JG#4#3P1FMJ+?7YMSWGJB;7H,T#][#$!"ZQ&6B &9+<PCGC;,XI>ZH&/
M$M1Y?(4H];BY3!-A^/O6+<<__T>?K?\_6QS_G\%KT648IL34#8IH2 U3T>1B
M3[VE>WK<07K&5C*P/FF.M6>'GJ85T3D4@Z(E:^ 4NNLH;'@15*K?,[]V3_[
MC$)=Y<LQ6<53OT+.*@I$'4TAA([R4,Y\M(1$G-BH'%^*TO9[5]E,AV?VD^HW
MS7=&Y %.OYA[V#8?W$ P2NJ2I7#72PPS[9Y!14;L@!V&$0V';2C.)_:<^&NA
MZS/-81DB;^K-^<Q&&J2OMS)0__RJ^#:KB87V!ZJNN?Z/DOL_#X3K42KLL;X'
M(1'_N?)5;P'D26?R@3OX\9TK+[72,'E/^7+J)"!LF7H)!1PW&X5E/V0FC$.[
M8)7NN]M,RR-%&_A^UR75JT8>.UIFY7,/HEWBB[!>3 T%XX4@A+FO[R^?S.;,
MS";?%-\1B0LV;9],KHR?OF^D!    LP-0P(YLLDW<5EI&,3Y*>W\M1EO=?$
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MF[@\Y]J:*^IHT7?7JL__&)"5=L_OA]M:2?_-:E+O]C,AEV<"OE$ZL\65'RY
MPRQJDB<.16X?93;S+_J6C':_B2OHES/V(?>X9$<1AF2I"[;!(%KT#3O[V3^5
M<LG&<B&=YKYD>5+:LEX= R 4 %I2E$V;SG#&/#GUH*+LJFF9I*5X51@N-=3'
M@V>CI&"=O<Q3P0*:T(%:\%VC_<F%*$;RD,5&H;S6NQ$<#5_?U+K?[C8TBX&=
MHQ2@/J[M,S&M(]E&QPQ&);"5U?9Z'W]^. ;XSY8 O:S9?H:[9IEUVR=+^<*7
MCV ]OYHNG^2$0:W[_ZTP\H/_NN[R_W(*^Q]%JCWP$5$* XJC7$AJ7[@V1ID
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M_.2""+IN3T_>2VA4<_#A:NWA#]8$//<# Y"<BY#D)DTO'+;-@E_ +0$R4]W
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MG'P%OYOI]4ED-]A'=-4WG1)4Y&%Z*B)X*R8$J4.,_ZULB!5+/R1^G5Q?D*\
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M8*QR3$11OL76:UI#VE5XG[#\(.6M7V_2E6M(GDWB0IP3CQR:L0!VV^+$%A;
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M2\J/(>21'8JJFJY".>.:^L#NDVZE?F%?%JZKXNF;G@%U4N=-TQ!+'"RQ3^!
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MH<PWPFLQ_M+0J96B9E^K ]YVT>\+I93D:XMUV$*\U3;<=^XC)%E](*6Q[[N
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MG>IV+S4VUGC$=9<C8VK]&.J]4V--?(K6,6>&ITU6:K^ZL*>?E9YYP7[XJ=
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MUG_^VOB]N87?/_AS2#@"CD_^Y44'HJ?[7]?_D!<OC=>I?WW _"\ONE-1_WZ
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MZ#F]UIS6?L;K<N4O*Q#S#Q@3%82N1;YK&U:5C#;!##_I4=BZ'UF.YQLR7TG
MKNXQ^75(H%*PV>+E4_+3RL7I./<73]-2FIK>6=76>I&+H>A:!,ZR81ZZ1GE%
MO! W"6TQ0#TF>=<:,IQX)71CL-?%_9_)>53I+A<$-1T[Y\R4'T1*7]O:*1?A
M'H8!.FY! KZP=U$D_I"X4TD(C$J\V93X1^]_1)%8\_+?R+O[(6/PE>8U"<)<
M*8UA9,LHU)$*BG^!<!^]Z#)5M_LF'\:9A*T_RW>-"L);N9P6='^LKI<,(HL
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MPYL[;TWO@H#<5BJ(F87F5:EP:?3\'O2>A4%M5\2%%..94MROBGN84.*II;&
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M4Q;[*$R3DXIIB@/YLTA"M_;UZ8H9#NVHK*MWTER,P838]N5.F_/C@@3O?DM
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M;-Q9P&4>R1F=N[(*07F<F+7FC3U<-/9](' AX,4KR%67SHM:9C)DL#$(OH!
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MW(G_=C<3-SW\&FK2*Y8XE+G;RI[R[+1E2)2T9;"3?6A8V*5M:>_?)^?H^[O
M5! #@8SL4L.9VP+\]2O U."LV/"SNL/MNJAAB-YT1%J IF+D(ZQ*R73@7?^7
M96VQ/I)\Z?KO_ZE7G]]LL9P'HR&%:)0X (;A_*+35U:=35=X5> 69[J0 ['8
MW.FZ$2B36F 2W]5'GFD"#+8-YB4/=;B?()NA?1F/*6=0>.33>Q%Z2[%6DUB-
M3A0/D.+:,;VW:-FJ+NZO9C"=OLUQU]%!2CKLTSYD4^+UT9__"1Z&_L5?_,5?
M_,5?_/\6X,LQ]6*67/#8GIPLQ+,.@]>69T:<?&7GA?49EV/6Y@[VW.*@$O:,
M(SN_;]1$ 9?"6]M"7UAU_YEKGTKH[^L^KKXF1/'?WKPS]BMY!,^<&@YF<_$E
M=!QBGFS90[W;7@S!41=%Z0I*-MY\7D=Z&'??/=FVF*S79%=6=YYW?]85^?P"
M]WEPGS;/16=R$.?])#-MRU5SNY:.#OO[=5;ONSG(:<[&K5[*!1,& 9U3#XA"
M/O5ZAGC40!#O-F$V'O.ZPZ[H22MYMBJ47K"W;ZCF]?O@F#7ZT]Z:Q6L9[$#S
M(-^BX^\B[3R3)KJ>'_<PDO!NK2=A1WKKZ??M.2Y&KP:'-3PIU\V--,_I_;Q9
M37A=M-73\'D!Z_ [EW6R02RB4F3)[>B7^5Q>@=O(Z+UP#3OAIW U+]R&8?NC
M+L.WRXNEW?WF59:_NOS;E.A ?#KR6Q9W@+ UQ%,X;+4FB"O:8^QDEW4U-$*S
M)>*1#)OXB$SJANAG'1 ZK(C56^0?A5*.\-+K=799B>H![[%> 3,+L[/VLQ_?
M:=9<&N%ZC>%TJ?,*.,1N'DD4"H(7E2&S]R SX"+I PZ](?*KH9V(H6L7K>QK
MRT7OC6GE_SA7DNS!=J[DX7] H;ZM;M/M]&3E[&'G>EMKVY4#BS-H[JU8T"7Y
MY#X @8<,#^];,$ D9S2.I5,M1% MYYJO#*]G.A=_PAYNI\YQWANG,Q+GD+V>
M9),?J+8U2>IJZ"YLN!MNQ)I4=<5V30@CL7)(5JFT-+ZKG=JE4"1-ZXFO6=R?
MCU!_]#3[<Z)4:BK]7'JPXHT.7_MB6,'\J'E.R\Y4LW-E0/Y6FWJA[@OLN%!]
M?7V;Z]SS6\:"5?]O/PKX_QCF*Q*6Y8I6;=-XO)86Z4RJY,OE)NUO9]^+$&00
MJW@5X7?T?B&5ST@2_CG+2^&#Z"4I].TPEW%:X[VU#)DK;_^F;]#6_[RTQ*_M
MGUN[Y<RB27IO>AF*>@9X730/]"78IM^VN]F".[)" Y27\UIL9]9W<B:[%TPL
M]&7OO]C0J"WNO']?^7Y/DE]$B[WFFFKB249JA,Y/!-A?+"*YCW<GO-T.K-9D
MY@'(,_"H8?><)'EPZ:_0=>=;TA16MQSR/<_[C^3F[%^6L QD%M1HU#EY.6^=
MP^5DCFU71)G6;&Y-[9_>="]-M+)5U2;<^W,8N' BO^4WX:*_P@YW+W$;B4)S
M)VN_OSFJEOF'?(,N1LAL)$ IZMPX=+:-!%M[(/Y1UT:W(<D-(?N3MVN64(OA
MFC2_X)+CQJV9=GJR7%=3P7-3ES=A_\4;]%R$S%X@:2)ESF,C/K52!%.)/?W>
M3%-V?<J.6*#E4[O"'3W<UZ-T+;O?3:JEAR5YDCTF7H#S=:"$?3'ZQ):3>_7&
MH]KHDJ/>*';E]$K?BPH+RW+](2+R? .6*U:7UI#]^;]C*EQRY+&>?NG?HBS,
M")9WB8I+BT:JU1[=AY_V!"/KJET7EH>-C 6MK>=:#'B++;P=6ENT.>SHPG2'
M?UW8$@X1A<S,6Y7K7M@H,(NZ+RW29YVG9#L?F'PU/(<A\X.7>X[7)0:KF8I\
M&5K"@_X3[3!^N#>.^^FAZHYSV@WSSIGQ5[X5'Z>ZHK<[O=G_Z!/M);4O?/S9
MTEVO4.L[[/^Y/&H>%K4>E-BWJF:]7LHLOUX?86-GF:QO$8*A@K@1?8:>F,4E
M2T9VIWDI]2<&#N?UT9&GJ2#=<1QW"LEZ3:^@T.F@KZ[B]Z"-;P(^>>E&:.A.
MH:#ID![^AZ1ZD7]\@JZ(7IO5]<USGVO\:W+:K2;G>K J;S^@MT>X%4Y"Z[2=
M":U[B-RY'?_HTD%=<'QXC.8>SXJ2T,3S\F<RS?P/WW"901Z7X",J4U3_/ I"
M=WO,#F'+7>>T[2@^#L=C,V/:X4/1VX>UW?:8GW-)^HB@503?5DU(Q68U^/KD
MDV@;)+UZ.^4L-''J^% S1S-]>(3W1I>K+HQ#::&@];AR5'BW OLIIRRK$ZBM
MM^1.M"FW.+",<753;+DW^WY[REFY_KCA% G:C>LICEGEYHENVG"<WLOD\Z\J
MY3U;LL&66;50*H/<#YN<L-UK?:#X3Q9+J_*-Y:5=+UYGI0,%49<_M@RDX>]A
MKB\YF,!TANZXB4C[V':MQ8#WBZ$!G>\7[VT,K/K9O]V:N;\YK_)9IC;K=Y9B
M='-?AW::!CN2<_O]LE?WE]MK>]*17@8O)0TKHK7[PP!+PQ3C=CSG;@4^RV*&
M]*CL$A9I^#TLPVFZ)/LC1E)[&X[L^OGSU_9([/R?R%B8?Z?3#L*A[A#AC@@]
M:BN:HX(@&&/#MW[Y=S-!'3,1(LJ>WBPR'U[=,I<$?9;.WK1^+,)D_?P^K^OK
M.L5%(RZ?-O\M0789.Z$FS<+G>D8Z"8*@SM ;NAS9VS^FIVUT*K=_E.T$([C^
M6(3.SED#[:M+<HX1HS>8LB0,F,<#[I6J+:KLN*?371K6&;]4C^QU4YF"AV%2
M+/DW'7E_#.>F98SRIXMR?Y#*F&WUS\?-/03WBPVA5%Y5=6GI?DW1%\('!W@K
M]-F[I'(4EL6F>J;'(=@?#:X?%)MP[TWZQ4T2?H7%';4&F1_0,G7YEM_GBU-U
MSXK3T\QFCN[6C?@OYOA^RLMJMFR*FBF0E)W%DC0QVWL\2U1035-+EK?H=JO9
M\%JJO3SNH+]'M@=0%'R]?+;C_4R$LZ-*SU)7WM-?GF?7#$ ,=[CNKS$5XE(&
MBLY/2W7AH&D:L>TJ+?;^L6E.=[YJ(]46'\<HW:PR".6Z<7$<%E+EJWMOEB#L
M]+2U*X^S:594UL:7!1Q!I_^:ZW$N5R'DS&NUS<^&4Z\OB86\\))KWYU:UG_=
MYNPW-:TXYNCBE1B)TO :#9\R@SC'0/RW>Y)*7P(A#7#C!WP'MD!EY8(OWG&X
MD<W[*T*)5VETT9\W\]'4(L/*7&OLGB#\4N=,CYC?S=&0*(_12A<FJ3OI/^Y<
MV "EBX!"1B_: .VX$1/\(;)O%#:4RQ,=?[/MHI-OZ&B2[#]KOUDWV&XXG+JL
MH]. 025J2W+@7Y_D/6V5C;^*2EOOFI@/;?P1DIA"?)BZ'LL=T#$W$I;:QFK$
MJG+_1;7QD'5VJ^UH>+7QIK# ;F'.;)K;J.BMH9_?%P[]#8<NQKMMS0H[?="L
ML;IO$+7M7^$#U\7#(;HXK\2D4CJWU=,NUZ _7]?L=U XN#')$[.'W8K]^38G
MRVWP7,+[WVZ^9?IT9,O;S#)X1^V)AH0NZ;<PDOJWVOIZCOT;[]]].F6I_2HI
MU![XX)YA2Y\\FC[73P5)Z)\O\6^(4' RCLZS%Q)A=+/Y=.$3RQB]=SKE=7)>
MVK![\,3'3DN1JLJZ-5&-:2_%3I_"\G.57[-=)TJ*$^IL5P77#+\L.+845<%G
MDW9VB!=A5Z;#,Y+B^%*LIN':9^>7"C=]JSZ6==1XG6Z09J9[&O 0]%&$_DV#
M-I!$=(0S _9KHWJ8MA12$(-8SI\>EQ3A<8ETDR^!(HAJCF"F^][R[ ?V91&;
ML*M-77'TG-?K%;CS0^P*,E0-.AH4W^\4M)(.\<6O;H?,;$WVVUC.?QE3</F1
M]B<NDHA==P?&,7-/]:/NS';\RB^YEY!  /%%NX1[A7R2WB?4I2BZ>WD+OBQR
MO'JKFE7NP1@@,L(_741K/0D!@";Q"OP2D+V*XB&Y :7DUG*_],G?!!X_ZU$.
M;IE1Z<S3U0S.U[Z=6G=/B[5PTY,?"?TZ%M9_75!65GR,[<>"VWAGVL+TN,I7
M?'LZ3/A9I8)=:(O,E+\S[$;ZG)NAL8"=R<U;Q@*@_P*Z RH(*T$,0?5EI'ZC
MC,'8>L0KDTF^0GG%_KJ#Y82F_ =UN:^J_?U+%Z'Y5B99OO+\6-O4DF>B9>%+
M8I^AP\C%G#AZ2E^1++FM-6-^;TCX%F!MV#,=,<X00^#9LI,;+3?/R5E8^[PH
MWG?L4V1ESY$B%^)VG@IBO$5^&<<=-Q$'F>B"X1K6),;[&Q;T,-/+? 7]<1<G
M1>]D+9I-DRPD6E@17F=X_>S.;BWX/E'GD/FFR.3Z59Q^31[+B[](>$<%Q4?T
MJ,/]@#4,6=H<KWS4:WG:<:O))Q1*""Q53O83\GWK* KQ](]4GEP]G?VB\(*#
M^TOZ[?$T:$M&0AQ;W)@PK 727A&#5WGEJY)7)@X$+-[LZ?3!-#<Z5B@*!&D.
M?.N3>5Y]/CM,\*;I/A&Y.+Q:V3L^;SY$!;5:8AN)\B[P"^]QS7WYJHD:M#AV
M !X?P&*6SP64)F%SW)/-ZKT3E@1?I^WE*KQ10^'/KA&D\&T[[KBC?F2;#8HK
MD,2[2M8S;IY2[I$Q\R87(MY^]OJU.,S;H<?QT^I::M7*?E9%CR@P090 ,GJI
MH'?RP^,)5%"35E4-T(]N>$A1!LR'$"Q=!D%OS:M9:EL6ZZ WY\)'M>YZQQ;H
MY)_/%[B"_B?[2EE'*R@N'GZ.7'/8'43(["%G]FB3]*9(Y]<^D#B94_Y$:P3Q
M]M1X5OM:A :H<(1]#KBWK=DZGIMU)B-PL2#*/F"WD6@,M[^]8(F5I_FL$ <=
M1CQ>EFV<ZY+ $0F1,V?FX&8E2^6C!4O;NFFO<[7<[MVIRGS3DK]>$5KU4PUT
M_6G/])M3R>=HJ*K^3>@8\!6<SGI[[=-^N0+B>CD5Q +)I(*@VBA :)JNT=B3
M"NKC+D.,C^Y1&%O!N/A-\,%!+!7T*."RN( =E"1U8D(B+5-!:.=;?RW_6OZU
M_&OYU_*OY?^3EJ$G:1F/P@MO+!I/P\UDM//2A69G#NE_F3[(NS2,NCZ*1R:0
MO#UC&-R8OGGV/"V1BPG2S$LM]7X*XKX11NK$K5[DT))\\:L!<BW[YHU0BZ/4
MP).5@%;=\^Y^,Z\]RX*J0_T4]R)-(HQ#ECEQE<]4[_U"G/9=<2_T&CCO5:U?
MG"UA9L#E]P39O)Q4M>P" S(&%Y;6L\:&I/(J9).52(T/==%1>[\5\]]#)?0U
M=5_JZQ7D_"D@P*L0FE,Y*\8COQ8F3_HY$],<KW3;BB,4-E#E^6X=18]LL9H!
MBC<_Y,_V6[<5.=]E#SE]45'CZ@;=PTMNB0W%]9Z#*(Z@"&4&WS@!O/%8X:5P
M^X[<:R^.746XKHE+<+?=6S?#(./CV' YR'D-A\"S=VWYO\J?^24-O9@YO1_W
M2J>N2/I"KKO8K;(<F8;S;9U1+;=S%GU)-URJ%)V.)@7UU?O:VXG8>6.50A?D
M>@X).U?-46MJQU#5#[HOYH0F&>&$K_5T%;CB4,\.#:1M\G([$]8_-?%<T"X%
MOPS68;#K;GBBL21OV@:1PS,D!">=/I+;&<BZ3GL'G_WM;BY8."UBRTC0)$MM
MQL+LNKK]5)SC-;N92DG;R7\4)OJK0W(47H_NB6M,D:Q="_>6I,MKE4U651-H
M;9O@0K1LX)WVZ?KOOY8G+YYIN\FZH@)9_7/Z9*-2,QOCCV"$&T\%W9V4G5YO
M3E\UM];/;BH?8A(MO72<EW41:P<WP/E_[!%,*OFF5/G^0.U7A\O[C9,V:X=Q
M_K1A!5OU8Z-Y<T>+I4[Y%H\LRP+;KS\K-DT_3!8G;J3+FA?ZE);,=<;61+[O
MGFBM AKZ=36GYOT6#LM;)A8*\M)]9Z[W<;$_C_5.G:K5MWBS%0>V%'3<RM1Z
MC1-]NBCQ5II>-GW'4^32^#_VT%7P8S=ZO.UHZVRG;T@PH?:?V%VS3]"^!]>"
M0[8@[=\*,',)NTJ+-PH#)9=*OW_36"]V\0S4]5QHK3A(3*D9>U-5ONM<\*I3
MV6M"9K>V?IFR.W;GG4+JI9AVRNRL^4A-T(. @-8?W> 4?64EW*+1JCESUD_"
MXE">SS]IJ9C+^CC6VG&PWS*DC:B2AJ."#)/]"R;[+*YC/[8UW\IX]?!GTCB(
M:^G$5D(;#>V7.(O7Y-3N7Q5=NY1N^_RGY=L_D,/F_S;K9E[XW/WP0V#3HZ+*
MK-7;[/WDY,F8PNA6?<YDU(V3W*W;O^U3?U=J=%@XPZX2W#H.O\&87*/'-DS=
MU^I4QA9.+B7?'0K%?WW(84KW,S1LORCZ:#"L ;_7_WZRN_#H"<F$<SI4P-^S
MM-W#\..0SJ4M2.NW_R-IN-'#?M'A?CCN0Y&]A/AK@1^=;F-B]>3[%8.6O$\B
M9!6F&QZ\<$Z&/6FA9'H.Y _NIA2/U/CF"PZ5:\1&.CK?-I-SH$];NL 5\Z=V
MCPY^M1'?M^P$*0BI]-.%+[L2"F(RM)12:T)F3'\_0.E!_YM=;:<PE4_7IF'V
MZ>=GMQP&0EU8QPB70P6*/M35W/PJ"2ETLD5$M;R9;)X@3N2TOV@($ ]I_=-3
M=J5"?&O_"68OL Q9D1;@#QNC.(GG1>7F\HC7;+_%))ERRM0+&LK0?3Z4X:ZJ
MCQU<86]1E?##K0 %-U$?6AZ!Q$P[SM_;Y3)JJF<'5]4C; #Y&B!O8&M9#J]3
M<#D!/2+T2N3!/@_DEC3_8[J-2B"]Y* O[O34O?4>U(R*,A:=VC5E ;\E?5/=
M(2L8)#$:IF"I%^'C&3Q;5O;")C\P(/"'M7]>H,W2<EORMYE1KRW!<W9'"P&M
ME0H/5';VNA<6S0U&G&#Q<.62WU: M_FW.LS4+R[9%ILO.NX)GPQ"%7:1E=\W
MM2YLY@=4&P8%B:2+>(K8W+P JM?[>#+79YETET@1I((RI&?M+5X;Q<H55HM:
M:4M+!5K'9_[@T]$<BYM$\)(N$K4!)O SW8;$UC2G^<-S6-GD\9O?)X+L;V]$
MB7P).'G7\*9W/<)-JXB=VRBW/C/U7LGD_;<U"R/53M)#@]XB3M&B:_YVW;(Q
MEUP_^Y;>=R/,%[4:P\UK$;T6))8 CCAA %K_P^T2.Y^;/X9?GCS@$?=2]+!^
MF^ $'.*]US8&1/4OK0;%9_O<MZA+&8]Y.X(($S^//OLF,WB]<7,()*\/BBL5
M_MAED8>N3!Z\98,1C!K5@=T8R=\[_ T?XLZ(AJD-&[$^J=VZ$3B2R_^^>T4Y
M[W<;Y,V;AQ]K0(:GXQVHH/\F?$SU^4O??5E:E@P97+3_A/1PFH K8E!<YF&0
M1\4+\]T_'NU:M)S1'SK4H8+TLW_,P 0 <6-\P*^"MRO'F2Z;455A_F&!5SZQ
M44%T,N#G1Q)XVSVX <9 RT>Y52+2/$;%I;PES$]/S.[T\S?(ET2V_SYO1ZQ5
M>L?9#V.LW$:W_1U=]9:<B0M+$7-A/A[;"F-E=X]G\[J79YN/XYBXDR'*'V8J
M<+#^;JX',)=T(X%J7(?S@B16Z0G=H\R/V]NN0@T8"^[!A3M:11>_*06YWA0R
M.[O<V$X?.20MY8UB%N3!09[KNBPCT,Y6_VWVAMX:V9[.L4]_6SUT_UQH.:/
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M-FG]'6PA4->9'\KD73[21NPD-!GYRLEF5)CG0/D:-O^W7KO_%)],C_P+S+]
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MFSP 'UHUV"'P1#^)@OBJ/$KH@$\/Y"WP3L7EOFIV"($'_GT*Q<T&=L8 ()F
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MHZ!VH6XI*:9+:=:]\M'662O[^&%N4W4K3&U?X*.4J8T'69G<=_:YV%UKBCN
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M<_.SOFIJ7V]Y=%%&",KYKN1W%6<P@#D5RX8H/.-MN"F29P?*<[;B8A#R:87
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MFKI6:>DV3764\V3];;)J#I1O@[+X__3SQ?]K56+%"9MSKN4KA9"MO $'8N)
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M+N!OC+X#4"V->4)"_BYLSU6_P7^8&[C_64@-S7F9U9V:%T2KTK,@)S]E? >
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M!J[=E6BZ^@2NY1.@()%Z87Y/)J'AWE_CK-LQMC_&(0KVUA$J*(EPN%?Q#E4
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M7U9) 7H:8*Z,\8H()!QQ*4JK"[%(4T]5_B&P7S9A=F$+H\C7R%1DP5TV?J8
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M)U:(J]!FQ#(8%IKCQ=NTTN:+$=D'&%Z4ETSE@B <PSUK<+$LM*&_%O=,.IU
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M/*(YHRS'2,0126= [1W1?RF@W#-9TY I_;G$OO9,C:?E3#+G7 >KB?%V3\1
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M/5MUZH4B>4[.?V!32T90D4^D%6)FU&J??(%3]5$49_BAW!KZKO=]XKM]_<M
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M77ZL1O-&N,QQ>_<-I^M#*5ER\MAP,&'NO'SN3F-P= T?(HS[Y_N(8K[.0DJ
MI?L9#-K,CJE>A;;? 6AZ5J!(4A7C=$(XO@?5<P508H9WV#;?"[PI/_3Y=0%>
MKTQ-7@OB@,YJC4[$'N2CE#&'(/O\>,@1\65\K<&IN?5W5M(Y*):,GTN8F+\P
M[W'6^*M,]G+#SNM^55,FFIKI:]NR%O;-68,>Y1*5<]OM&4C<F0SNI33E'>#G
M),/%E%O;WWXR8'ZL@XV3!VPOR\)DN!*!7^R4</_;2.QAX3JTW1)C+F4,]L7N
ME8%@)MBD%;J_5(<>T"0I3N15G*S 8^^_E,/US^N[\7_G]UZ)6,)"K@6P1VN.
M11Z89VMY!U,12Z_EDXHY$,)*SXVM^4AX7,FB$F8F,9,8/*K,B2LX$&4C/NXX
MGN&@)BO<4B!TICZMJN:853QL9J/]=\.K"D>-$B/CAM/[,D^;G[CD1=L!28U:
M2MYLAD\=Y_%E+B>!KZ]5_<9O";"9Z/@G>!WZ,W^MGFB^@=BZW5.,8<8/^5HT
ML,]T_[2<5!,3&W5+L'/+BP46-]3'?%PW&ARXS15@MR65#(XG 8W@^Y_!E+#F
MU]0@2#<] 7HDRB/::'=&,VFUN:W.$D@V^FRI<BT@RJ)]6(,98RZ3ZJ+X%%/V
M:(-*%__1M1B77'(,_]9[EZCRI/WT&1!\BG;*Y4=I)T\PY=S<B7E.2VE;6?2E
M] ,P%T:Q?8BAPRAZ(R^YTJ: .6Y7LU?R=[F!H_,LE3N7$N,Y'B6CGH9_FR4D
MT,@SHF3MB*(UI["-OS:S(^*/JN8TH^#7"*I3\E/@N2?T#B#]Z@ZPG*WX#]G\
MEZJ_J%:9G4<QRH)=[O'C/85X91&Z=&6C [-EIDEOQT=]*N_5\BPV8$C"=GH:
MK"P,Y+:JV!'I$<$M-N7X*WCQ7"FZQ=)5F5F4JU2#]MY22SI*\4 $O;R:5RWO
MY'[EF$WBF*[1TKOOQ=85:O[[RM_T9"?-ODAQ8H5#X2$?ST-<R98,$KH2Q$!L
M&;D6VCGJWL==OG;M6_8+7RDUAL(2+QB_HK2^8T%T#YHY>+S?Y8\1J@87\R53
MZ"49/6+I_U6ZI59&GEQFR-NY4%ND.U# <>H1.*UYL!G[$X+B0R-N'OR\ [06
MW@&"$%T,I]2!MU>POZ;O  Z^Q$.2@DC%D++#=]]S6UD? (@L \K(#&\972\E
M+3X?NARU,K2A$1$UJN9//S-8-U0W!ZDZ";I$\4.[ F<#?S,&FG^,QZ@K=I,7
M:[5/:R>2.'@KOTP[LI^;M\G9]OJ(^0'6R;#M/R#XA[,PH']@+6X#WT.6=0?L
M(93->-E@LXG;OQ?G9<^;]CX=N-1Z=O%U1# A]&EB5P,S%SS;_@WR7^M-_( T
MXA790JSJ)E5P9>9TC:,;D7=(<MM)!_FEX9')@CO H]@0F6TA@ILSQ7]\T^1V
M>.(.L-7+<'W*]F^1LV+TO_<"VU_0_WP@"1A5A!\0J[&R!WT&"I@FJ8Q.GNZ/
MH%_5(IZ=B;D9^?#H0!]'58KUZ;TEF\ 9Y\YU.IP1ODTE2,XM5^0 [1++7CRH
M7_OQ(2\&Q*+IHTO.2E_,/2?3'&NO-GGN=5'FXTUZ!^BT0,5>/9&] _AJ_J/+
M^C+5-7> 2TSH[<WC$8P>#&6.C_4\ZI%^8<!851G4)QG"Z"P!D(AW!APJD4_H
ME8F3Y6GEJ/"IU9TJ<QL[57&HR0N?,__#(O)-0%N=%-^EAF;"''Y%/W/K8T[7
M52QBS?,&1D <8@.O'),G0/I=,T:9J%51EEH#)OI]!"O#:\CC%8]HKS7] ^,R
M RS/3*>%['@*J9E2\F&EP\@5PAK/[X'PSUWO"P:"5%!XW/A-K]%M;5A2XD?U
M ^%3_<P&K=VS1E.@<+EM:&R3ZG+*V[:13T[(R#7+.P Y3MD"?0= J9W"DSV)
M''/KJYA]?Z%D/^B@E>3O!XA7B@[?*X?^B\#TH$HT "_ KZM:TLUJHGKUII_6
MG>!MN'9_"[H#/*MG)GX-4\,:7DOCA+&J3DVOQW#76Y&65TF'](8$5'A51#$1
M!+(9DQ=M #\B._&HM+*C+E\>Y<W$ <X?HM:LS'$3"0=FT@PA]>=9_/GV1*:B
MJYRFZD]4=-;(4E[$7F27-]G/&*-H7UH6B_?;JAB7A[O#TZ2-L)&8R#7%;LX2
M\X@999:8I+Q=E[H4)\)/E%;WJ^J(B4(W.ESY$F($(J[:.J#DS<_7&!X;@++F
M=2.$6FH-J2D</[E*6TKOSC$$JZW!0J7I,3!_)QR0!^IT7\33FM)(5.>A 3#N
M&UYT*9G_@;G$G[#COR8SY]2-P?%@FU"_8Z(]7"UCT"_O &Q\@ '2V#9Z9T.7
M>LLL( $M1Z_S Y\#-XZ3LM >>;>I^''RA*J6UH>B33Q+<2_I)[BZ3W03$FV:
MFU1/S6?>[$"P[\!\=P#90IFC8IE_(TCQ4&UKK+<3W48NQ7@/!T&$P9A*8]QW
M63I9NIT_$/L_7=6O/LUN^T*$_?^-Y?Y#_*#]#W/,N25E((*,V@&O=\LA-K9W
M@),UX,T5V3_$>QK_?B3V'_UMN,G\X]DC43(7VYK_%M_CR_P78_*9/345'W:0
MNZ7Y_"'@9;RMI?SCL!R6\'T 53FPBZ'&J0-(BM6[[G'9K3N/V^DW.IP^)E=N
M'R8KAE Z\L$EOQ,#R3LBAUP7\#^/=T]'L;"\3$S3U\1FM23#!L92U6NI734S
MXIW:DK?L_PNTL<*]PB""I#FQTLN]TG25\B'6EO&/+$S1OPOP:>BN&+()6AP[
M'')-WU;/&\\K14GKO]4"CD8L$T9T63BC87(J[]/4N3TTBIPS..15>':2VOYS
MN"^!_EL[WJP'3->O#7"<G\%T*RWTTQ?=^A%\-*_I''3KM71\MRPN]#&2'^@E
MM\0&CFE;#08M&SXRI#OLQ^\N.Z6/"=N8M7 )L6KEC-%#_XOQ@"?^9&/:B.4'
M1T<X;LQ$IY?7R6^H;0UI;SB_Q#%9/-\&PY=]QF\2! 9[T%I]Q%X13GG%1VA,
M,.-+G5)_!RGPW#1DQW@J%(_6(@]L*?FNGX]LC4CH<2W?DYKM7F"6\'+Z+W.1
MG99Z"B<Y6S8%=?,!!_VBG&M9G#.&M?N($AA@_HBWTYA*LD7Q?816@#6#M]<=
M@$@5IX@-8XKK<FU],NH L8$BS;O^3 9SN*^M"ZVMT"JBDE*]C)3(<H7S!(MG
M-G;-?SO"A.()=2L&U1%ZGRW*]@_VOXV\SX@KS(U1EA&@QP%10RY0N$:0HT5*
MY^TK]%DZ=_^BU(]K08B$DC,&0*"=E$".F9M63D.\!.O^*/)U)6>?C.(Y4$]+
MJQ5LFEO2GU''S:QT?]SS 99/W;ZPS9LS=SJ14NQ=KO'J. +\3D9N15KXA#CG
M(X>%D]_>O]E\+/V>0/+8!\_,'M-T7IMUM<E[#TR0?@!/":-0,Z+LFZOW_>W/
MX$-G@&XS>]/Z]+;GBFXXX.JBU\+#HW@Y1ZPFYB#1Z/#VI=7&QA8K<Z'DA[/R
MBY61_;D52&#([O%@79ZOZS[%U3G+(IG8JA">_V'7$8/L-^DTC6['%T$?V;H>
MA9:5V,*-,B0D=H8DML=-ZJ8']R'(^MP$E:<IM_=3+MO:MV2L&4*^\G;<O#PR
MPNB'.;R<$7K?]OEXH0(>Y;9Q>/M">>!I!Z-'KT;Q/[% =V3_0.86_/$.T"87
M^V^Q]0[ VO]*C,)4 S\H.OM)(]S7V*G$2?]6,4\N6%*(19WP[7\+(,AWTLG^
M1)#_K3_\@T@"_L\@T-9_D9*^_O]=_\$#*S=.REB;:UL[)=ZU6+7I):N3BX\R
M?K\\&"Y.\:^FH0=-F ?+)E6CK=18QS.;^..] Q%.FJ]^ARPR6L.0E1>-,LBC
M%0B.98G*/,SL[ZJYTL^5ATD.*4]<'(G7HB DM!5'T5T)$2B_1R"&54C/4=25
M30\PW.Q9&N$3\3E*#:G4$+$EMG-$K?$1R1V@F9G(QDL=W^])*NKDR_U*$TZ5
MQ P7W424:/X:M2YSYMMK5Z.11H?SMJ'I8#M'$%N!;?_.>>37&T0+"!]'OB+S
MP#8+.%'K\Y$>:AU'DN'D+&VS,Y7.Y3OT!?*_=80V]VRY9.J@SQ-Z45K*GLJ&
MO/57;#UR')R6_SW[+U(,OIVGUHM;XPT]-V,</=3:/%)L9AEG5'W(;"*&H[*0
M>9>V*XU_.YYU'W,'""ZM630V^4,>D=.B,.[RX0F)XF^64:<?E%CI%%U&H>_$
M'3,4G@0QT__LENEL]EIMV[=8::,R'8!A*2ZN\30]ES[%2,Y+?-VGY(-ZK-VD
M88F6V4>J2L^]IS4HI\[CHNS&$S9<-\;YH^JT5%6EN)?.S:R^4J:)IH3]3&A4
M[MGQ\=!HV*%_@<U;X7V\/;&'7 [[PX07"<76$[:+)1)&'Q_;\\ZOM0OL/IU?
M HGH!"SF/KZ@M_RBZ791%S@RRC#<<,-P+HJM73TPY+[E!LLOYL]F5E ZKC?$
MR]\!/HC>(_B2 ?W$B>1IO8=C;D)_PE*8XQM&,@<QNW*]5L^%4":"YT^&W8;5
M78DYX]8D94?R=U=V$/CJA/*Z[/VY31+@ISN^5R7+2EM#?+QI:3KC1R5.IPKE
MT1C.=C_&B4]3I^9D1@O&[QIB#&97KI]&!>X"7Y3]0\/ZPXW_.E'@-9ATFL=#
M)D <,UFS\^ $C[*YD\ FPCQNEAB/E[6"CO,G5OO:#,N_U7$1B_%\R%7K*X2V
M@%=NHDG]*V6".U#^C.YBM/XSW];2W.U+Z7T4#%2F'8_A52D\N(26K+3Y_!G'
MF4;OB*B6K)>2\2=8TR8!Y'^1!\!(T:P'Z2@-"K!B;%=:6Y##:0O]T86>5W6%
M+866GS;/@RF]G5[/#,NX> E@Y!V@QJMS),BK<GM&S[YHEP4!M?I0:+0H49W0
M+KK=HD'5+@;3!_8N<$<,%%MD1T3D/7*M.ZS=L9Q:O#*T+ZNS'AM\Y9:[RU["
M:M'\GYMM\P[$'C(W.H\<OAI@KZ<"#2<\MX=<H',ARRS%H;W0?RV)Q*$;MW2Q
MMJNF_!>ZS1^=+"OP^5\;,_>/5?1_^[G&1!-6 NL%\RD^TG]*:RI6[+)I)Q"9
MH-<2WS+OPRM%P.5'_,I56[W_2LBM  N]5L+Q8VT+5!QKNYLFP?'32(="KL/9
M2R]/^1%713H!,SRTSTIY+*8?88 -QHCT/A,6>0;?=V#^5F[EJJJT3TE;K@3X
M2YQ!Y5#&IFW.7&FZILDI@N$9>$CK1$O6[0'4O?M7B2N,1]W2FE)" T O*R5U
M./-VK-1A?'A J3:$;9++1=ZQN%@*@ ?0[T=520[$\ E6TYYG? R)<,PDA/\/
M]MX[JLFHZQ.-@B(@8 &5&A40I$KO045 0(ATI$6D=^DMA"I(C70%(=)[D]X[
M"$COG81> @EBB"2$X;US[_W>;\TW:];,W#O?=^?ZQV^MK.SL\SPY9^]]?OL\
MS]F':S@I5[/8WE'+R$=F)?:>;T/TFOZM^.!Y4,N;7Y!NQ!Q""9,;]@4%"6+C
M\IPZ[J.37ER^Q+=/NQ%'>4DW:,T9$.U%X:YW#JBMZSF\/EN:$M7*9CCH0NV0
MO&N0&^)S0K8Q,D$VJC_Q3[FT6]L=$+,MXB:);3?CAOBGG#J]OOWX?;+!+S";
M!;FP59']EV71@T%[&V.ED<B?+RHF7$@L6NZ;J)8E8.=2R4:YG[-O<8IJ?"+F
M^WO/.0=T77ZA=1?B-I09Y7AYI/N.8;<:P\;W5Y%# P>,\_Y]"@<\A_],#S<(
M<D3[J-6-">A=_- WN< P=.N0G]N%6$G K;*/^(N+C^46R%E#>7S0/J?Z\H8C
M.MI2@O*RP'C]L-M.[.]C*&_W9].'@^RZ,GJ1JB5L\:&G>1F%)C+R4R+E%%%A
M/)$!MDY-PG7_=J:>XH@%(OD//ZYB8L(CJ^UC5%<K(L?G+>(B=/F>+7RBO20I
M619"D &? Q#W @Y'RV%AO#21ZF.I2>GIJ9[^Z;6^I;2?AV_C308"_N\F=?[)
MU;4%Q!#DAL/3=89E22P%"Z927!^%$<\I4>7G@'^)R3D\$P7ST0FU.',ML-5_
M7S@W_U?YE'X4;!I8_2B%(GP#KW]!73T*=]\J^G/6@N.H/:)]FX[;MW-.'K84
M0RYL!_?!KWS9H&M]=E[%1?"@;TF1S\^7ZL\6CAVCA$ -69OB\U&.TC+%G\NF
M91Y;FG1P^H_P KR7PEZQS8%J,,;6T3^%Q#!SM%=5;_>X_0*7/.XQ51<XTA@\
M;IE)@Q?JN88QI56E'Q XVY9]Y?<WD& JZ$.\FW/NLEWRFDY+SW 1\ON+4!<V
M_QO0UB^+?C/^_^TT\)18)]BY(4EE("M=_3B7X6B7N(S^[9L^:?O\ Z<&,_M(
M*R]1%/\8&PR4Z*[J83A5_$ZC,853O[<>Z-T5J((,VG6)Q *O7U#^0@*7G1>(
ML;D2;H+9^VDX1^PUB)#O80Z$9OEED_V0)&%/V_YEL/.,MQO%T$WSIK;B58H/
MT?&/W^KIL87>#.;=_#5,E_GYW;198 %FMG[E)$YMN4VES[;<Q%\O_!$[&5,5
MKGJ%@U#66EQX!"<*'L['6];CR^UV4Q4D+XB2#?L3/O.\V=D_:3X;'5L-:_!G
M"-PAYCK;S9K);,SO_=/NPJAT(=!+I-GDEY<;8,U <!GO0FQ<SF?8L'N3&Z-)
MGOP#3W2O4+1[.2?V9/\#IG>M$W0_H6.95<CN)*YZFM;J7<7+',E(L6$&@Y@6
MRDMP28#^$ KO%?N=YW9AXMJ2-7>=F-&RG;W1N)ZMFT/6L?[TF137AY_OQYP^
MF-J7^M3,#,Y4+HQ@NY"Z.;X6*:TBU>$$,S(#2A7FCM==LF:^0<-2]SU*$?_$
M^?[<7BW?WUD#QC9:#I<6[;G.&MA.]\Z\RM@41FZ0(_AUXD*U-%YN&Y')KE7A
MY;!1W?+DS<8K5V&RAD&.S*'?)_--+CR!XH/,CS](N32\KSLY;S_T1:^>>_'F
MK+X"C>E NA&A>;I*FZ3+Y<5H4[K$]0#Y2S5^(\G;M=-(7EY^[!S0A7@1\&^O
M*!@']+5%-=)U(,A[4+S^#\=/CW"641JU#E<28GZN!YT\/_7BD9F)QWOAJO!!
MW_!E R>HB]:V^=SYM5A'?9C4N@>^H"P$5#ZY_SB@57X+0TBLQ;+UBS $=P_]
M\FL>4JSO4+.6<D@XTY[=*_^,?/_;_^MR6W";VW;YO\V'BW]"[Q),H+>QIE5^
MN;M"-&R2$F*YR]FW0AN>"H,99Y?>YY??6T=GG@,<('-HEJ)!SW:6JR8<JX1?
M1LHQWJKNNKHQ^0,+JD=JCL>^)*92O0]\7>1K 3:MOR;^*Y-Z"3A,_G8K,]1D
MXD",[LJ/^"B5Y\8*8A4JM]GO)\G!)4%]XXT!_T(N6XB/1*CA77TWPU*_<E9G
M'2"RE5_Q/,_1^7;PY;^2#J@-:7<T>G143XJQ"E/J,V>EVDR%^;#<3JUCR$B1
M51,5KSV(S8R;H@^CR*2H+\W6^[J^QOAH^G1?R[;I8?F_'8C=_L7QLO_E8S'C
M?[A\Y/_K^=3?^__?X?Y#>E.'@U;AE'8@@<G]S"-1@G+ZS""9CV9GK'1"H-R0
MCU,507U[7K^=1A#UH37*S*48\K,VK"/AFL -$OZ3%'7U'>!AGN],Q!<LK6;"
M\.L>'4V7D((94X/J\LT%6\XFJ;UW!:\=U><'S@'LT_^UQT5?:^07K(VQM/&B
MX"M0[DA6N[7'+)FD\1NG.>^>O&FYM!I0\V;46P)7C]>V/ =0RS(*ZAU*,&6D
M<P1O?/(=I-SIE8(GL=RJ+T\H1)EJZT'G/*CJ4UWT"R6?S5,/J3Q:T:O^WM0:
MPP*6R.0B%#3D-JDY-Y_Z_=M]\:=5?KY\#0SG5($Q0A_4Q,MPAT!RF-Q3TA98
MU@M,(L&*0(F& G2S$>$=4:4UK8=T"],P45IR#O#"T5>&<7^&-U\VAHY+L/SN
M>Q:;> Y /;)(2C609MA;<5)57^*?;RG+GBDE84@S78-XE\26F\?Y_W8 6UNY
M+&_[65:_/+\+$IG!'*4Q\[/WGI61>H1H".E-X\W/*_!,G"3%0L _L9K]!+E!
M[_ KOTOH#YGG\G.R.9LM&L7. 5=,6&>AZGRZ(%]G$D7A?Y<!ZU<X_4?VCZ*-
MF+.,7$#C/TY@Y0C<FQ#])R[+X:)(M1\FIGBLV_Z-XG_@R+!+X4AX.!L-QJFN
M"!_2Y<OG62?]LY#SE](3QD2V$+RK"@=M3H)1HJ8!$C,+Y9>W5J(2:O)4'4#7
M+J5X+L L>F\&5^O&_8#:XQ6RH!88BU:62<\>KSL6$\Z>ZPN#L72-&=$R\/?7
MCNQ7YIBVP&=?MT;7*F(#&,YR/:[:?.1,=VVSUCL@MVR)^GJJ/T:O/[Q)9/VT
M95"(<A%M\Y%VS5MO K6AX',IBGE%TQOE@5WO'FV)%>N1FL<&B(QX:S-,&O(W
M/)3?4W0[PY&X*S]C+"Y1-Y$%Q^GHZRHR'*YBO*%ME&":Y[(5P9IJWU5_[.1?
M&P\.U?N(.0?,ZZ^2(V["./'ZW=*.A4++IORQM6.Q>@P_@Q7@N#N*_8<5^G6*
M]*]?5"C<>Z%(%9D-N#1*Y<&PM?&'C8+OIY#! ,]$MV1#P$+1O&]3W>9<$I^8
MM)BUELQ@P"=-18;]]$MO2'R8Z?0UX/45O+X^W*,VTPZCUG?_2:]R_:Y<>RD5
MKW1UX4PNCP?#&L>$R<18ILKC1QE]P<0'9]''<C(=C;EUW03OK<G?8MYFW@;
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MZ_C)Y$?*.J]:M=/]2^W#]FUC%W]78+19NI6A$B.0ZA!J:2J%OJ.4(*<F<MD
MH>4&$2[$IWW.'=(*8^0,\!1.<Z[2&N.<*O77D+'Z[>42GM?V!=E6#48_^T94
MQEB6_^,%U]LF(RZE+R-@-%7L10E!3I=V?\X.+T9?MS@HA._?2)BW<55&X8(A
M_/+(!S$37K+)1]=8E:G#UO!51*X966J"'/$1WJ,<C()<]S:Y=:#W4PO,KH8S
MBWUA%#&WDM&\)HEJ,MSJPG :_[JMS=S#DF37KR04+97XX%[3]D'ZYF]8J<>X
M>?+@30EM1ENY6ZHXE8 OV)C?;;WRP6S",R R/!MJ4Z'L592-&7A9_>9P/[O<
MC<2!*MHT,+N3\C?8 (3M&'C%VXJ S._A=Q3M=X_*NZ/N$W>4+(.2>Z_;(8\1
MM#NE5:=03#&"=\?OO!<CZJ')]<.$-ODLUK\Y?;.PJ@<RP0: %$0/%.\(_1Z3
MQ[I7RDBK9TT3=Q/FTMMZ=BY&4/ZCYGECZFYC&7BLQ*/NQT=2O:)%4MQ*B6<'
M1L5-A7OC.'!FHNN^WIVLPN?Z->-@)_V)0RGXO#PNOF74T1U.362:=G06X[=Q
M-FI23]B/B>VFG/*JLG#[ZBAK$0+&4Q.>[,&8L-I0+7Q+T:/<,JE?_$C;5\LO
MPDMBMP[K6:Y;"+Y6Z67$M.$DJ_!N6%,@HSJ*?M)]D'M>'429M2"LX:V%_V/
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M[HE]D1K*#K?@3TOU)YF.CHM136=_?/'T7>2?+P&VB'EME&[W?'XG(ORRG#A
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M+Z.\6MO]8VM'GLGB#@W:G7@MF1P;B[C.HN@JH7:RZ69S5!LZ?;7MJJD*\AQ
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M<"?=1R_ZUM>Z>-7#O'*O?%>=^SGKR247#2]^^W<_\>DO_N)_.R!!\K!Q!$6
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MFZ% 70LE9;GHBGTT%KNH^^^^ / 7?_$7?_$7?_$7_WW @!>,<$NU9\G6XZU
M/+ACFG0?.Q(!?8P"W_ .4)VL 5?,^4>]J(Y$X=[D4[*O^^"VX_J8FZH;_MQD
M>P$X:>2-Q0MBN7H@MT3EU)L],,-[G;[3$:5#>7:&%B?]'M=C(U@B7!REK_PJ
M78\U6&*,EU@O[HW.539_^E^\I?@7_VL!]3H'7(G$LQ)X8.,0\BT\!)M@E/(2
M'Y.#9^YA$\ KE^U(?_D^Y2 @NB>IAR[-U;K^<=#+*<'H4S_?*R_!'XRP[C)K
MU$A'0&@;*Q'HMDH7O4(KZGQ[>^9]/_T\K"8_9R?\>;3^>TYFV_O"G[HJKP:"
MWIT%M0K#5B ,,"9\>7NK!!;1=0Z@WVV[#N.T:Z5-05GVQKE<:8OA1YM5>7M<
M^U;KPJ+-.^+BZ%K0*U9?':>=S4.(W$'4-O^J=&8B\E=_Y)[-[F)*ZKH][ I;
M8*/0Z&UA5QP3A=#LB,]3A+M'&5%32^KQJO'R>D3>8]<,_!AYN2AH]%*07@'9
M")$YDS3U!)_!O/(10@\"&F__V$(S.<6LRFP+Y)J$TM0)[\;&I>-E._\ 8BD7
MY2[_9S^YG%></;]W,T=?2S63F7T@L?",)X5X_U292%P^!ZP:Z?V#)I\#KH'B
MS@'R$FWX.Y,!G70Y 2-#AZ0K-0Z:3^^= S A.\!?O_S. 4&.RG\U_VK^U?RK
M^5?SK^9?S;^:?S7_=]&<RLS;&;75RQI?6K>\KF'IVH=PT_MOG: <>S ^39HV
M8MZSV0RVF9?*3"+C^*A$52%[0YF<B5A]#@CV@<+&SP%F 7-<*+INQ%7BC;'?
M'\4.%^J,,;K$U[LAKY*'I\\!/2JY"VJ,:K8O!IT>J5?<9MI_7K3W%%AXK-^W
M4FU-I#\'] 5<7L'E5T^T6<OQZJ7A'#!W(E _4L$L_9?QD2.OZR:M+>\;2,QQ
M?K1%'X4(]V_2I0L-I0N2J$S6@)>@3C,P(&P*2.Y>?LW;<V;U3B;67FFF6I"A
MM5!R['CG6^SI,NYJS0>SQF=NUX/,XKU_\&4I+=0'^KLH0ELP@C@,?@$KB O"
M>'71W8/]@'%.- NNC5Q;W#T-B!%%WWUC#Z8S:8\;$#W3,FJ17KXV;Y/SZ'%6
MTM1ZQ!H5[ WS+M,_O9K9)J<-'H6QG ,ZW%MEH&!,79<)[3E ?RS DO^V44U=
M Z]-U3*KMM:MAO0'25D^MZZ-Y5[[^9S[?E DX(RJ",=4FU14TVGKF][27U-O
M(Q!ZF_>/<"!E# :F!PC6^?7C=WDRC"&@0^VW<R093JU9_E)IR47OSZ=TSAAF
MJT(-QP>17[)&@09'LFV51<O9/#X@*_PU+L^N$_LMQ%P5+NYB#%81B.]<:$9L
M$[*NG9^KVY0!DX].6.,FZN8KE(O'-UZ->%1*KKW[I(\FO3U5QC)AV/MYW\=L
M3YHC]'U@7J)^NK?$6ECE6ML\13>$JED**2>]UV7*C!G^XN>#(OC[Y @6+'])
M=S^NN^$@PY\=ALSY]>O[T<K-3QOA6:/_>;,B ^O24NF'DKJ9&:$N<J'J!'61
M#R]'KR>_\P9<BE<'R*HP?NIF<7I-+> #V*( !A%C^&%&L)]MM9MIV1<=J@\5
MPB;_PL6-$I57V^;/ 5T2TE9)2'O!FT;&$J%B-&PJ5J,,*&5!!^?JAEQ;=K-Z
MTQ_;X&LUN+)L@JEWZPIN'JN\;VV&@:LG^P-7-]K@HLXWU%"%[&J'$J_K*PGT
MHU'BXK-^KLMVS2N\= FRKRD:-2$/H(P7QIUM)U]-%R1OY0>_ F6M&9?5)*C@
M%72Q;.EFQ7LC8K$AMOF&77*=LCN76R9SRQS';G"\T>8+A?.:HZ#"%]J5T%?8
ME"[G#Y#;4&T"_W:J27YW^?S5-:1N3TU*M^V!U7@9>G/2<:NYRU:3LY/RN+\S
MJWX1SGQ7;XDIT+]2$>J/Y2)1U3EBDKO66K:ZX:'3AOSY'8*1;*R8&%PS5%%L
M.L.QQL]?&NGAUZLFYB?)OS:I,Y!IR?@1_N3J<O,A6I'P'C;=Z!P$H_9.6=T,
MPBS[RZ,HT Q9>"."ER)V?2:9B03G\2^CW#] 5;NP>#VB?/<E\N6[:]AO:5ZI
MWX N8YH&<L?)3_H+%WIH!E_DH;@?"3\$@2SU>7(360)[=.*&*523 ]E3C\:7
M#5;K&V/8K![2>P$:R#@ OB1Z_'JLP;3!5^&**V\TGE'4E_]$+)A#(+,SN$D\
M DL@45$2&/JQ 3AO?(QE3EX"%JP\JF_4A#=S=K1DN3V[-)<D8F10,S#H*U!:
M6:O2+[/.<WL92D,PA$KA'V/@JW7[503@BC*66QUCN*"-68F8I]$X&E:GZN15
M8_8KC$VW]9)1<6$O8'QZ=_!KTZ%.[&NZ\H+RCZ+.>!Y]M,J:H_8J// ?M7;)
MB4VCLI;8["ZVQTWP+L0MJ*Y'YB#R3%DA_EI^))ISXE7>,+A:651"J'=<A5$;
MY[&4M-JL>PZXHGM6#.*!RN(=*0)AE-ML5-C2-K2C(R9A[>Z'WP$,0P\7($:9
M+4<EY0^KW^)27N>\<KINE"RERN=D\.,;,#M1OR^ .6 UO^TVE%[6N1A*=Q;?
MK(#E64"F1#E"Y5%#P$Y?O2J_@ETO(WXVHJW5PJOX96V[.G-JV8KJ(?+!VAOL
M/L(DD0M_T&BSE2?;7:EN2>D:F>/J8JIIVY_+,;!O+!TNQ;+YB93N:-N"B]KB
M0]0](_>-,I^1!RJQL/SLNAP(FBTZU2O-M:^]N=OX*-_9QUX 6ISV)OGE"GE(
MF-:S#G)_16C-*F3!K1?"< ZP62$C#9T#F,\!5J67^SJ +*2[NQE<&(9#(L?*
MO)?$G>EW[8MSN[5@FT^=(U=SJ2_1SU FN?/-+8(NNBE8![9P#F"5MX3@N;;V
M0[*A+\]21?/P,FLK^PBR.>\]#6QABOY$C=_.1N2 7ZG$?A9'5?*:PX/QG763
MCJ7;#Z4!9_I9K;(5%PU]@S[%AD= 65&(4,3W@ BB&>:P)^ V)R:Z<3@DTU[;
M=&=ZT$ONT\S&0EZ:2'[$*B=N,266\I:6%T60Q#G ?&3!')=U,6+<WBFO&L^2
M9460%T.(YT)!(HBW4>4W\KMM!0ZF3]0L7EK7U(K?C%C]TD_>U+V#J._PDJ28
M3-2$T,+F3:6F81(!'6](9!<=+T>$7/1_9U4SAJUE;85QFZ_;"%^&&AN?'^C<
M#ABT-\CQK/?S_.E: ?^II],!(/@.GPYJAJ"E_=>U>U4NO[2XWL"JI*@&(0OH
M>&8VUO96?CX;9X3?(SSQ!FM@ZO$)V!EU/ 1[NPO&6AD[/M@M;57L[+)A;-QQ
M0\=G?Z/VS4,$\YCIBZ7*.7 %4>JLEB0!=?Z.@?<"@R!5BFV1H+O>Q2C6K; T
M_1KL\YZBV5FC19-YB8\<M?$/;E81U#,AG):VQ"]9:<QU3[\!7^EXI23[>GQM
M#,OT8+F#41H'RXY?>3FF].8+' "@Y#@N#Y&W+L<_5NXKIX4^P6=B;^.2,9!P
M,?[7I$E]!#6,=7N9#<NW6^=;;.=YJIX>?EC2'CSW4J3?_<TB' 2^SUKY]1R
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MAA=&>=\]<Y^-JN8TIQ.L8GVLQ.E&>YNX'O>1SH["&Q-/>[<"\WYI;E7F024
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M68,@;F_@4IAQ-#6_</09V_>A!A0^&ZG&*.L!DZ_O4-D9+Z&$ U"F,3^@^VL
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M,**:"N%/(N+$OGK)RTWJU^+ $NO:=SWYV^>/%]B$PRLT$DX^.<V^<>8T^]=
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M/SKQMERKY>J=7Z)(SPU(X]16X1IJ48IE8<?"-8XCW&?H+#[C'AT.1HV0QVN
MJ[8J-&-;%\KV>NNIG1#$-\O[HKLI?E^%)Z(S14!.G#1S0&\-E\D$F]8P)W 2
M>P<@=GC^DEMC#W/N<X]V44/#2M6YRF7G<5Y]46LBOV"^[BVYE4XNV>ZQT^QK
M]5. @F,G06!Q@6#9?P"* X-)X>Z^A++A[NQ'>DY,.7+QYD.G1ZV\+W>VU3V[
M&FW>2XW?:N7,QPGGQS7@#4H>G_]N21?26[L,>+#J=I Z,EV=]9-:VP1\/KR
MX5U<#"GO36/L404#0@_EVAV3\1OY0CXD-E[6N9$:%BR_$RP]H)T#\LIT$[OX
MT"MRDA^$B*+4,KGMB799?Z"MJC(ZC(K7=V<Q_AI\/_:]W_46X%/24'Q3-:[:
MNNT<3I@<F(F\P>BWP>X0=O6 [*P#$+X0VO)]A.7@,AI )R6/.C?3H(.38DZR
M6O+;&L%+W@_6":>6$@,3YU2+;"UNW?5;^=1DM?N@,"_P(L]AFG5MG*)K5.'A
M+&XS5:T^3_FCP'OZL)#;DJEJY.ZR[ =E67E?4">[$GLOIS8;!9K,>ES! :C%
M(3N[F.C837.!:T/=F)-H<L7/*]/(8T8UQ:)-XW)+[B:@S[QFPA-W*0\2#=@:
M!\H4PK%?H<U36[RL0MPC<VXYT * /TQA:9E?_;H'(+[7PF9D_K]YPX%B^?/C
M?FV1$Y$?#.?)C?V/52X,/)57B[F]G?,RZG9YA#R>QP5$ 0-*>EOC]<SWN+>U
M<4@>H-T%\]G0VKO"1"_MM[O+GMO*\J:&9.'AYEC#G=.'VRUWI'L\8T'HD(HT
MD,KW:/ 7--$631<9HS%Y!/1&C02W-)#")G@P<$F\;_?U2]^CM;H5!> 0YJ>3
M$^M7?Z"FJ4_98Q] S.PO@L\SER!O+8=1K"$708*1L]"F/R1A\*!&&O2H[%Q0
M.,/I.OG+Y[UWGE9SASEVKO:V_'KA>XDZOUM9E3;=\T!"7O0%A9UZ E@CHD7I
MDL!W,$GSSBL6D]K5_]1/6JTE@KD-_%V^4ZMSFCOCU$YV9[Z6RU+KO7A+8>E;
M@D;IUJ[>;$M_6% (?WF'Z9GRR$?GET6>LV=UL.PMFZG 2B:J/79KJ*.NT!]E
M+4>?U@(+]HP7VG;IR/,4G3]Q7MT)CG/:M:UBD6+4\3JS^?R71TIZ0-K-QG,^
MJNZ+];W -,O@/"AVI#R"P!(87S9J*S4HV5:,Y]TY F\;=2&';8;B_)W$VQ8J
M K7:[S'RMR\TO'=\8B>VB/3#^4C]4"KE^FKEQ0*LJ?R,/K&^#WT[P\)N2ZY-
M\G^XDIT6CT>Q1T?T3=WH9R&#)*,,@\\#RQR ?-TY\:*UB9"@!LGM7_B:IT0U
M19-ZNDYTNNVE6:?2"T7$XQ85%4OV"4$Y"JON+LHE+GSBMU3_Y1-K&$N[V%IV
M%NNMH%B<V><&E*^:[Y"X+G<H>=(LSZ5MCJ0>1$\)G^N+6TO>6/J(I57U?ZFG
M==%B5N1,Y3-$;WH_>PY2]F,GHK%1@^#F%+H(.W49""6C^R57V\/6P+&]>AT]
M0(%15MZ#X$#_"MO:5*_I[=HBT?A-E:6RK<JO<FT :3TDYSRZU>\_5X8;CA/!
M_=!4&746!G)3T!>!XHH-+"11FW%UAC;X!RF:O[YF[XIKWO'J=OTROUS7[N;#
M;4R9N@/5]T#U'S?D)8"_3*UAMN+(G,3WY G,J+2KXX/6&-_!J5>6A'=G_JX_
M]M?5'8\"V< 5.KMS3_6<>;?\\6:!#G7X'$D7YT\#8X4GE3%CJWK!DWJ>;\Z-
M^+%_A0FSBN$\TR 0*M@C2N&\RGC=$A@U;<RU3->F2%>/#A:42@3[P!=_JZF!
M[>5LW]V1M" I82O#L\Z^CV2[B?&% HK@$4B\C JCD&[9P)S;YVCEW"*1,?;D
M2U^&R5A7GP75;?QL^:_#&"R,ZFNU-QYR^;($UJ?/T2Q[ZX%2O)A9OM<-N>",
M<R!G_#_@L2-8&TVT-IJ&W<OYFR6HUR'U;,^^M&K_&N<'Y+\=5CCR$Y03XY?]
MR%@6X&3Y>(JQ$-V9DMBK0JF-W3:45(]P57,D>+I29UI-[I=YVC3%E2&$6J[<
MJCB]+7W?6)W5416F$MV)'$5RQR]B OAY1@2PR:Z>AO5DK+_48,YPU9)_M!-3
ML=S];?QGJ=#=V)QG^#<B,<^MKMW* FW:@I+9GL1SX=- '\F..:\!5/^^1P)1
MV@7+W!\;.*V^$[15A%7^:L;C+NLOKQEO$5F 0,%_-^C_YR0OQZ22GW1PE=GC
M%[NK9JJOON ?<[V?"LJN0ZLSBHP/(TP!/?P!2'01<1THK( /#B'5*9'5;S:+
M&"F)5;.>A6^.RQ^S#OG3KC"S.F_@:F9\6U'*N?]OT^C<1F984%Y#_?+)IW--
M%FXAM_4?ZS_WNL;Y#4P*H\D#"TSN899Z-D\?@'P@@LC/3/%Y[6<85G+CAK)F
M3C:'[C-#/5^E]-<[I9^JBIZ,[&(7PG,%BF0;7_#UWQ3=KUQCX7;!,*H5FM*K
M 1\<P4GM\=H=9X5%=5:(*EK/(UB':#/8+SY9'C<89O>H7+'3;K=5SJDV.R05
MSA5I,/Z[JKF? V?L9;LMJM?(>HWL<S3[T+!@?W!QQ+T<=7QWU;U*>3Q?V8V+
M8#U$#".9J4R_!UB3#0A;*'"+M(8]8+)V !( :@Y #C#0A*'^UZ[+3:,\)HRJ
MY&FOY2AA^:'0M!],#N8'I#9@2?-"^#%>ML+2'_HTU-+=LB]9]9R#$:S5?%@=
M;R)YM3TJ;GYPLG,U5Q.V/#JI&=?_1](L/.=P3J/WG:>W[W.5'_F?^Z[0Q9@@
M\)<\(IJ4N@;OD5HKP_+,@.,73 ?_=(T.MI*?^_QMM55R2;]Y"S_GZ."=A3?A
M[WFK?_YF>KBW^[A E7^NVY*Y]G]9H#JB;K'/]Y^PQ5T$GT4\8"0@-8"?U&J*
M+XF7[$E-F*:K^5+$"?(R1RB3.?5PS5:I!-&6A9DE#^=)=:+- PSQCM;9?.5/
M2=>%=:80AUAU[X-P!^36P(M+P]>9LZLRG^4894P^#[IA2\L!*"G84.UUOZ$+
MXM+&5^8<3&$Z?!SU1(5#T32G\Q(C3IOL6AZ=FB/2>,T]]G!>[(5MZT/IQ<6!
MYUW6MPFRF<B]W/,.TIV*L<8",RR?SBZ30K"1T_NXR>G4F;?3QF<09X!4(D88
MKC$JB-!7LBM=&-*;7=ET,6>6*-#+_.(M"F]:Y<G5Y@C'==Y']@$">+O4538R
MC_\!2-)8#3402*P?S^^:__U>.Z=VL?"6@YEC?KPU<CSD49HH7ZZF0<E*R6*V
MK]6;K!?3<9PO.&+%_N?4>\\L]1D003-'F$_W0 )I^O2(F1[A4$_BX;*AZ4 /
M(7>7);>9(NZ*_/?9NLIJ2^$Y'YO-" D71;ZY)SUTUW(M]I,Y7]MAYN\:='F;
M+2P#__ Y2STD#T!TH5748>3$ :BYO1^S&+AVI#9%![/8[-8\9ZC0 &\?1+_"
M;L:%+[TS)FFHO>AL"YJ2WIK9SKJY>-(-T?H!:&=RGZ(4C$":8:.XQ0/0-0:Z
MY8[&*#1=;/5"UX(2X+.KFV>(6BP-[C(K>G+I)FJK3M?K9:;[H$263.]:*5RM
MXIS;QYSRS>T^MJ67%=&/U.X$IA?FGO_D_34GUD&FJO0)&P5"*B;8Q4+:,20P
M^0_5.F&HJV%G")U8>J[M<^^I%3\74=+3MK)R]PTM5NZ]Y69WYKA7RQR^2,4T
M^,2N%8*\"/%]@EX*3QL;DW ^9F'"V<#S8^W^63EY+QD\_M.AZ?_>4?FV &;O
ME=M$M:Z4D03>T*]-;_?H5 *ZW\W(!Z"$T20%FWJ)-S7QKO6#,=297.TRG_:+
M&!\I(2U1#/Q;AS28*@-D_SNI 'N$@<% =/CTWCOVD5+VV9X+:[ 4R[[=]]B>
M-JTQ*C8/FFER:<4BMX4'.3EVZN_E_,'LRHV\Y277()KY@.7Z>:L__Y'U6FRL
ML3" 8BE4-D##0]A9C&,:3+L-?T!7($NM&0#C??EEY 9YFL/G=,M7Z"^MW)B6
M4.TQG7.2MCQ]<9X^\&I?J,;W&$ZB7KK.%%:8*#X,2\2TI/2W4;Y]'[:U<YOM
M/4R_"0B_@J3+OFN):GHK:V!K<>@7HP@KFOP[:+$B#='2=*<$X^Y;RNOG0ESW
MRM)VZ^X&B3S,?6BO^M9$V$X[[5':K96L0W%S>5^N<8Z P1!\$?@$4QM(H<9^
M-A2FF?N5\DU#_,N2VO8%LL-5=CAT7T97!US;$-YX.^X+5R=FO_=;-SEC>'3K
ME+'KT QG%@PKP.0.6\-AP_!Z]'-*(V49O?P+='6$0M7&PY 78>1UJ]]0O@#'
MT+_7 _5M1Y=P6^U"LD,.7++*<JLN#E&)C+P3.1.2$WQI/S9YFI['"USB/]-U
M7N'X":&C @]!9$P2KDD@PUB8N005@@08<:XI]#"E@>(JO]# 4L%N,B'Z_4Y+
MMW7PJ2(#%HFO?8!7\5&D[J];S:4Z1,E%-XA<XY2C743HS3.U$)R4]@$P/WP>
MQA]@?(:<55VYP91MB[51?&HT\?IQ-?:47+39I#QO3F['>[0H*U!NV5.*J1F4
MT8&2&]0ZH)_ #[L,6*X50X]OV!)@[!.UT #LN]?"YD&['W1( ]B!AG/6\O;*
MY[3*<4(<%OMWTT!_A:DQ+'V+9D[CFOX,-7@.X(Y"@C'-]$.]E*<[:<'&TFYP
M'4CK7JHZ6G)_S;;M\_![P8V=^[N=_"$SC[[!/\^5Z?:P4V4!J0A:!$*<4<?B
MQ-1>'?A=:'*O"J.>[K6JW#2S1RUS*+")<5>,AK\1^SYFA9;+>#5Y5\'37Y=3
MP0,R^\KKC^Y\G7Q7A]7G9Z?]3X"<G[--A5T$GT8XLMKE]H5^!WA!N^@.U*\=
MJAW<P8+[BWQRB-D\+O HG\I:#^<O'[QA4?YU,>45LI55O3=<-7_=R?@;IS>R
M08!\R:-^7V U""))YV74H/#E^KZ9;WZC09LR0N35SF#RZ)8RG].]!T(!+D^X
MD5=?P.6.7\MU':FN4G#K4/F=D6O)%ZP]<T966?7C/9"TM3;W7<T'1//%]D@Z
M)=N-Q4-CJZ+_>(A^DXS+9MD[5&J<9N$GSDO3!Z2ND9?ST\F[X<:RKMV\KF+/
M(=07- EGDMSM;I^_A7_[0?=U(>3+ FDN=H-?9]50_B2.M:$B.Y)M'2*$O%W.
MBN'K:2,&2Q]@7@4VG>W,67^%%/&95Q]S1WZV<COU\U-[_N]NJ4/X70=GH5H^
MMA^A99NGV;_:9;(>4(?QL^-&6%#LLI@7W%C,(=;SX T<=FL&>0IP,C\V2K#!
M"+SWF<Z?G/?WTAKE0X?*]P8E3BZ$W1ZJT4X#9V#(=E-+XM07C$R$.\V0.0UM
M%XM#$3%B$]46",MJA#H\O$%W9H!JT"<[FUSU^L\Y:\F_S:TC*R\<9&T[88UU
MY5S:';_/AX_#6[O?JVN(B8J'89>T-:T5.=:M%I<K\G)%NH^=7WXXM\?*:!?H
MNHPT.HJFCK $DHBP10&B8UP5$$B$I2E2+#KQ:#$@,GHI^)Q'AX-K]T^)X.T[
MX6GW4^7SLR2N=!==.,4W!H<] I.M-#B 7U16)H\O7HML\*1XCN $MY"R'G2?
MUADBS0&=%J209FM,E+*XG^X;]'@4)OHB<L@@+J<J\ADC_4I'9UMSXK+[LKS]
M&SW#+!&^YT?M.LL%GAJK(ONA+04D(YHD\!//28+0W#>PM1D(;UB-0L&C'CV\
MJ6?ECX;:U='H$,H&^H'<QQWMVY.D>[UW23<%#XO6>].$$$%D",GZ <T3H0K\
M(8S#CL.G^MH\I(&7=U[!9?VU,T,"E15S1Z^WQAOL%<U8'1GZ]*C4/_&Q5OWY
MG"L3>X-:K_)]0&RYUAO6(F_=S)K[SW3I)UM:O+_]\%@T:]Z*7_HW/580(L5X
MI4<0G^QT1WUD/5E_=(CZNE>=_&MU"<@ XJU\Y[85Q/X<T^DA10B67(:9K'<%
MC<QTXH10^#S]U5H\X]PHB@/B[T\_11FW!CKK$-;9Q/N M[KJCDXT#=JX>FNB
MIF5Y8]?YM6.Z^',OL_;4C*;SD7E;]?]GKU=Y[,?0JT:%J\?9/_TN%WC2J\SL
M+VO!C>QP(E11J= VF?0'Q)U#B#NSR),_]>L1>D];:(NO\;E<+3]5=.8J=75I
M\O<_[D[)67W\*_'%^(W$J%(IJS+XGUWYU+74]3KIZDCX,MN6U6&O:*^8P/=(
M?N1X5TIR[S'X%+Z,Q$:$\ ,'H$N4@D=TDSJ/#0I@LJ6V.NO4V]5=.@:O[ND4
MKJ/=L.Q6?GKBC6WT$1$VRM4XEM]YD9T&T8N<_;AFS@&[S*ZV@CK$::!G%0*8
M$E=</FX*^;4K1QCF4YWLM>L6VL:#0]6*T852AF;'WO=YKACS,<?;F:*,<H03
MS07A2E$O;H#3AI'B,W1MJ,7,ZLSHE1E5K\Y2 ^?KM[RC?#M[.O*M;R43OITV
MW]U=';[2T='>DO0FI-:JTJ0@UX+GE=&'C8O@<\@I#-DF.P%\^ #DC4K%-7'4
MHP/TOR<:RT^A%W5ZABP5,PDDDVTS2;5Z^O#MUJS-.V)AK=\B0;ZB)31]YC"J
MG7,0FE0 Y43J(7%MQ@8SX3#>J1?PHV%DW)833S9;>]I/9_A.\\MQ$?F*"JEP
MGX]-L+P[V9N?3"0X3^YIOU>*7U<HQ7KEZDHX61P6W#('(6+(LTSN)(HI830%
MXK7#/TRS_:$7BAR/W.WGRR03O6!"%OOR^V=7#D#"E]2.NRZ?^_J@_#U;GUN#
MS^8_84L59QZEK)9HD(PJVIJ)$"SL*K! J)\#'IQQ]7]8_21?0SKIH])UG^XV
M6*.91*X5^/M]@8O&L^V=;=W9DZT=UC?D89F#? GQ6D;\Y_7%-9.E8@^_>0#:
M8UKNE@OD,O50_6I;D #,4?K5!90?+%V]U!A()Y0(F,T:VN-7-%]7DC-[,Y'[
M-45!E?G^[E]M+UMTY5H^?M!AQBM9]PK,JOLR7%LV28EV'&'&*$0%P)9&31=:
M=TX U^WX7>'9YH!C4) V35GSN[M1?( <2:^)=-WKG+S]D:43ER5-E;X\N<;A
M&[^'.>97*C@;CA(-U"W*J@[T/N'4/B\9[3)HF%8N;N5QRT7G_.2LW!IMI#<T
MFRK#J#0TH$6SQ&F-S$G2P=<[4=#Q+5-\2LD194EZ48&>@9Y&0Y\^4!^UUO$U
MB77FA>[.'1-GNQ?VFU^$;==VARYD0' :@K#1@].I24!) S ^B@&'6^VA)8"_
M:FMO\ZXTMU]7#0ZO]U)O<Z2BV[PL_#VL+?Y6/5D[9LXJ\PU&9:\!\R-2F_$,
MA7\!:6NGJS:<&_(0*!XL\F;E%H1(*;A(U"=U]F87V+_#M7@OE\M=PBSTE!!_
M]KJ0\;N:"6U'BO:OL;I'U24KC2)'J_(^L4"^$=5OQ")@6!:J62.=97Q3P&D!
M4MX!B/?HPI ,?\&@2V0U*TES9@OT<+GHN3L2;"?>=\PY6IW*<4=T5)[!6R!&
M%+I@6Q!:*+!#O<,"F#XP%D5ES" \ZX!*PFHU?H47V@A J5S!#3NW=Q7G8*0;
MUR A[[YPS.2:G/"N^NOZ8'3^[?O<\GPEOM=LCC<>6S;H2N [LR?;"^4O6?%E
M<+T_;YA]CU7"[\J9?6#1O>QT7#-ZV#4;*S?X"S60 #QX!=S:$B9\W6#T:I!>
MJWWMP#'JD&,.X3^L;)MV9[P;G6#"%0>@_M/&RH OX4U"I3^FA9H01H1R,6?U
MVT?LCF[>0!@6J8AUS8%O^.^-%X>^U,X6T['^K&AM_Z3*JQ)?'X,^,M'ZZ3][
MOUGV_[/W^UR:]]D@?]\A)\/8ARBYO]<XWT,D(?@G@VNCB<8GX<U#.)F0<$B&
ML2X%EM)C6TVW(D\FRZ4/BN]SC61+-SR9^?#=Y.C/!-GQ4^=:O_5_O#Q=94TI
M8W(?@&BWD;,'H+<'H$?,0\A/T+:=E!V$*]'=]5(I5-"_C/=KNO4LJ>7=9>E+
MI_'_3-JWR/EB463'J8* UW['A*DL,3SZO"C1!2$8L'!M*K*QKJL(RRYRWSJN
M\ZG$\W\6W?Q?%CWW_[^M6":&9LK\B.(\  6@^;\ G&NXY(4A#]'6=S3WG20-
MMQ*(PY-3SL-?30^MRZM.GD*,>'%]L[%(0FDC? DP,>;H 8AL!TM%<C&>]YB\
M J((=B-VV'I3,F9 *M#V,@QX#-RXV3L;%"$1)*_6M3JS[C6'7;K#<ZHSRR][
MQZ%^3XFZ G#2S)'3!R ^M5Y).HA1I0U)X3;:QZ2^B4"#K-&9+N^/!D4JOO#]
M9GZ*Z.'\OC#[F^.]Y:,--'9Z&/"=IL>R$4Y2)<W%OU<G)GCO0P_X%7".4.4A
ME3U0X((@;LYL'^?_MECDU97%?73CD$B<)U=YYVV!"UWDK#CR&I/G\P.:"$*I
M#<6), 9>TC26 _:9*?B/_A_\Z_RQ0V(JT;"O2335F46/UN8)L45-6) I1Q+/
M5P!"M06L:2R [+]HZ$FII8H#@8$$ 0ZX 5ZF!JD.#QP<)LZT-B#&CZQF"U\Z
M.HC(G_:P4:W\4R^ZTK:M+E(6=0!*O@ ,1U!,1U"M\@<@:4.#8$JZ&Q *PZ.Y
M@'R!0^/_C[WWC&JJZ]J%HZATD=Z)"HA*B4I36E1$FHB-7J(B74!4)$A(I'=R
M P("0D1 1$JD*R410A$1$9 62@IB00([HF%C"B<^[_L\W_F^/]_/,\X8[X_%
M'T;VVGO-N:[KFGO/-:=>+BW3PC15KR+[I@:!$J$S=2P*3Z"Y[/$X,+;_7K$R
MZSP7RY?Y<4H+Q16<8&X[ZM B;J>[==2!&EH=E/ID=+5EJ"/AUH9\P7A06^:A
M0(U G)"2[?:EGB1G"/CC#>' )$$*TVV&N8Z?G3KWRHUW&'4*'*(IHO<B&_9#
M0YF&Q+10C?1+C:__$1_O:UW6EW%XF%H;<F_GGKV(R?N;<%H;1XI'ZBY5 2\"
MUKU0F>L3:#F4!).$+*=1DN -2J9KS6=",4VZ:WKO5YHLK[&JCJZD&64_:=&;
M2>6LU?ZG.KI "LAEFW,,N<\ZI>5)$AGW/8OPB90+]B7^)+R^[K,6)?7$E@XK
M]0]MZXJ:1Z5;R#*[%8VUT;ZH & J#4,MQ;VT9I0SE5E:$V$H98#4:V'RT0 :
M7^17$+%_-L!8/O?['XN.ZN\/<ED!XDM+ P4O$Z5F#+(?9"I#1\-FU:E?&<+,
MK]0YBCC<WY$,<P!]JBD+9PT1>RB@D9?O4H/B,7)O-L6M61PF-*Z3."&:,+UT
MPU&GD:_8T"A_L(U] KG!<N>^(@;IB@Z4[F'Z)U[]V"RN_08N>AUX:*%BLR'[
M*M6*0<L)F ]Q5[MT///EIG+X&\$2OL[I1JMR'Q&ISZ%_^ZG.T$<[Y6F(#(I
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MCS'N^CDC&NT///%YV+X8_;;?[^A>858$BLBV1 \2VT9Z*60C>"9<D!BZ!1$
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MFJFDQ]]*R1@UE&E%17K@-;8KZF1;<Y;;PF45V^J0,W.?&T2>;,M!;N_R9UT
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M7+O7D2&:O>T/M$^72KA[ZF^1UY3>BH!$G+DFT+A@_)=PL5-_\>.LI+$]J@<
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MG SMDN5\HE&O4[**Y2NGY](UGQ=84>&/Q7O"1;2VZ0M_$OC2 MO)J-U<9S_
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M;[@NT),D,>DQZ2PD:2OR2-\,\W6'L%7 RN:?2+B: 9[T0TX9 'O' +51R_,
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M8X*<4_K1FGA2*C*!XI"6C.XUHZBZ6BT^RX?I3OR*_ZNLWJWK5?G,J^X+2T7
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M8;U(>ANV,:$?F7=O[]Y]O $["C3@@Q^5L'^X.43[9KLB4*X(K+':ZMUCM2$
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M^>P)#%/$:$@P$<)/M+UZHXL[M\]HIQ6@.VJ!9:<7J)1B0/2:@;]O5 //G6X
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M= [1IUJ5L5GPF@6Q.?2Y;F5,#MVG6J&ISN!'>74,#^-=8#I\-G_5#!,>U;M
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M.BNA9\HZ W:BQK*=N.#'7N _R'T#:#'NA :WPY":]YTUP,AM2UJ=B:?M5FL
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M#+3CYA"VT%W=%\)XXLE:0MA"LML-PGH,R_*_73S$8WE+_[[.*]ZR,=\I7+#
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M8B$4'/F2Z*F .,,8QI[G<>[[&:%:YUEGQI\;GW?1Z(V,H!?2-$A_'\%AIG:
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MT^]1 F3- 7-J=1A,/ZG]80[+H25B,8)E#>(U?RQW7/!R9%6*?5U5*C@0!4&
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MG;#S@*W&^UT(K$>Q,TU[YVO.ZW=K:?86JUNBAJ:K14A#+\OD%R4*TTA^47
M<:3*JC+L$Q+%,:9:,;"7IYK;UZ,3#RRW$IL9I@.HZIFE;K :F>IWA+P!/6:_
M]8(Z//>YC(93DW1@NDD-TLMJ'YJC&G=8TD19/#WRZEDE?_Z*5UWRYP-_:3-V
MZCMQ+\F*YB]X^;'X3XZK#_(I6[ 0D\2+ AB1D$$4RS\R@0(8QYXOS=74H]@H
M/]Y*BKF1BWSH(D,VL0)?DVC&AG1L#I+R0Z5 4RCW!G0ZO-X )2Q0TCKDH6O
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MZ'1LWXQ)C.*HP% F!8>(EPB6>9+"G.6"<!*)7!HY_027=&KK[*$^C5?A8KF
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M1F7G&[W#]D:[QCNC2/_N[MPC]E.RO0'\HD9L5N941"7/%05G&42,Z*+?K%#
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M"\(S*&F)(8IP!@NF=VY9R6(L"TS-@JO<19C:<M&(J>_J&\=Z\-Q):N]M?\7
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M'7FN-F0^RXL()SR/H,CC#")!,21)5$"<QRG1E:*BI P25'@HR=1HI<N]M)2
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M2GTEJ\W;PXHLUH1I0VI7%'#!OZK9M5R0>1NT=T?F[&5>FUMMT/:,B;Q$1)$
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M1_$A;JTB7.2RB!F',F.Q(JT20TJ+ K("J2\S21-%8^9.4M>(,K6U0RD#^MJ
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MK1>0LSYPQLMH'F=<IK",=5 ,YQDL:1E!3&,N!,YISHQ\B%P%F-P2T//@:S4
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M3KCFQ@S%D%!<0$F9B2$FVH"R+V;Y8OBY$9X6$'02.KA-+V&S\#,'@3&V272
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M!JDRS7^CM(B31$8\=BJ[:#?MG,F]K7K3" X.)!_*V+WKX,K&H="=D&G]@1U
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M4D*$XQQ2;HH1LI12E0@9QX4+"WC*,3>JZ$0U9PY&V,-.$49>1];P71T[:ID
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MQ[+*X=9FVI*8NV5IK[,;5_H5EL1NTP@.\\@[QY%KW'0';B%OI 8'8H=,7G%
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M!+2JV!^OA.]A'P39L!WNAXDT*=F&@>^4>@.-ZFE[MM$V=^HX#O/ U(E33I3
M.93,E G%L8)8J@AFF)JZ,MKH5$YD>WW*N1'J84C2F_5F4[<E<+RTL@#:TJ8,
M"M_85N0!<OOK\9,0:V,^-ID7HQB1UGB%-1NO3SNMH6@-PPO3T/[)$/D8GW8Q
M(E%,\KPP]^-1$4-$$(5,IASF:5'D<<1H4EBU$;@RS]S8YN3M&!"(<PE8.Z()
M -<4E^6N2 W,V'B!PXAI&Y]>)Y3FBL+]"1PO/_[JW5K_FY8KX^LT1I84'U>U
M5W3D%#4^D?G40D0%)WD20<TQ!**4)9!FDFH"4B++6*8RM["<5]-D;L1FI*^
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M\H-: 5!K (P*79@6:)0 M19 JP&,'@XA=<Y+TT]BHP,^,IFY8WV=V0* [A#
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M54]2+!@MTKP@!9197D 4LQ12D6CW,,><%#2+,F25L79EGKF]MYVDH#)](6]
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M+A:,N0'[53K099?E6(%.FXF6Q,&KGVAI)G+[QUPBMZ.! +CVGAT,&7^ZPX4
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M;NJLIO7.H-P;](YAFL[K8F?'CXKVR!M.US'D2U.W]\!6US_<V_"L5N&P<D#
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M$JI*\;S@*N&)U:I^:O"IO>I;\1R2:R_QLDA+7H%"[ C&1C*?,MR72#CD$Z]
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MO/W:/"W6,X:0RO2^!TJ1Z^-:EIOX:YY E$M"4IRSHK#B]?6:?6J.9EOMMVX
M[30 R[Y/]J8^U9+PU\\:%H?!F!A']DC[Q92]\,=MR&_ 5@'0:1 3<*\:UO#
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M2.C\H5FMI;A?G/0[LY04E92)A+DDRG"4EK"2I8"T2CAC1"5<5@XDRYYB6+T
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M(8QA61 &$>,9I!AEL, B9U1P)'*K8\*)L:?F,[?B.9:MGH)MV*E="49D#^6
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M0:LU.%3;' ^WBH/?C.J@U]V1,BGJ=\8RG#F1;T+L8.@DO@17<JO&L4Y$WM7
M K\B)VL<Z(?Y6B/-Z7&D.+Y0>,OY\DF*OIW;KA!LQFB)2<HHQ&6ASQ85R[KK
M@!(CF>:%U*9('>X<.TYOY7'&OWC<B[M-#^ZN(#OLEAV,8''P"(SIZ]U%OEN
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M.H/?+[L 3%,'@:/O1!G'TU)S2UQRG#AE6:;.RNA/!\C]57L!0Y\-,$X2:A.
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M!P:T8Z<)O '<W I/;X,?SW(:HR?1VH01JBM,Y$BR<LYZ[[3C=3+D=Y+3PI7
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M/]PGTSA=3V(6-@M92NA4:>-74LE+)IWAAGL\JZF*==SHIVD;UYNNA*R!5=(
MR'Z;SA?+JXGWL%I/- <G>2FP8Q0W"=4,;2PP E'PF'(,2M5)Z;]/R;@N<R4
MG23N!N!R"_#=O7H9-+N$SS!?3;_!IN3WU\6JU+I<Y(_^.P84(#R+R)[.Z,JI
M(#"@T(GD)%2VVJKLZQBH PD=]_ZZUCE845D-8/'C$OSJ<OGC5N2@*!I=#IX(
M;7 W:>%)8.6&#"1CACK.8IW(_R$MX^9A5T+4B2(_'#1N YHY?"HH_ECQ]@CW
MP^RR-'-ZMUAV6EJOE]-PN2[Y"1\7Y<Y^,5\C,?B)GZZM=RH[)@$E*I4=DZ4J
M'J4B2; 4%;?<LSII2</0/VY>>"6,CJ#:!B[;G[KBF[A4YJ+Z3"SUG$AT4XD+
M)I+,@TDQNY1HG1*$IRAKYNGX61YQ3E?.8&![MIE$[SI-?(;U-/K9739.'%!T
M]Y,K3RO:P\9SCBZ2F8KD128^.(I C&@;$8,E(T%R*[SVM3M7/]_H(LV-"I$A
MK[XTN[,>HR/)RPYQH'GV],&PQJ%Y/9?118>@XHG118<(O8$PX/$!*P!"\B@B
MB4:75HDL($LH$\:H#&BO0=(ZY53G,;KH(#WW'EUTB- ;0,^.B0DB"#S->2*E
MJ)U(YH%XXR2)-''T/!,>RI5Z,9_-Z**#E/STZ*)#)-X"9A[.T\$=9,!D=.!"
MS&A^,6 )''F)B246F0RL4GW*&8PN.DB[3X\N.D34;8'E:IZ. 2>80G4:ZQ/N
MGF (AI.:(/%1>@U&^^I@:75TT4!@.4;48Z<2[!NX$Q,H'Z$$B 9/:&5+IQ_&
M"'.11<V4TO;>J\Q_@]%%QV!A4$DV8#YVU+Q;J;RA/).([EM)&BYS Z,D#$2(
M5JD,HD[V=N.CBP;Q9X\3<P- N95%]<XO+Y8=1ZF[HW\'RRZA9N(EZ.1P+PF9
MD24G K$N>#P_T19:$X4)-0<L[B6N$5?W2/T_GM(VB#+:PM<F.VN;F*511-:C
M.Y85QUV7E"*>T4AT4,"MDN!2I6AI-T&-F*3!<72TT%O$SL7E>K7V\_(F,PFN
M!)'6$IV"1!>-(R\A4>0E0RR!I)<U!WGNIFKLO+BZ*#I6_*.V)-V1(/JH;14&
MLLS:$ZIP:TBF2W=HX4F*O!316*TB[>4N]UMO[%RW0=!22[YCAU5W6;IG1F5,
M5@ QU)9+\ZP)&E"%T:'S&"!2&_4Q*=H''T<5L]AJ0>-H.;8(A]OVD$H#DO%(
M@-HRP8L'XG-I5!<U=2:98*@Z&A.'GC 5,\[J N-8B0Z&CIJ/V]?"6RWRQ5=8
M=I^^.O5A^Y%/'?Y1NP_Y SUH;Y(,KQ>\?JVD.;'HT&%-+FDB96FJSS(GU%O*
MK4V>FCI!PR,$#?QL[:5$)?M 7 1:)D=&X@$L88H*!E)[\'5RJ%MZMAY"]T^\
M5!\BYQ'/G=5R/7FW7*3+N$9W"I;?IA&Z9[24+:5>H@<%093VQYXX $&41F%X
MGAF7O>H*<8%;&,$_W<?'8Q0T<NERA#87 XJV#6ATJ6$;#E;;"_!(A0S*61+
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M0 ,;H)=-.81]3T'FF(D)GN')1$7IL9_1WF2(V8*&6DV?AF6DD58_K=P654)
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M-,KKGLV(GEBIR7R!FF@:1N:MX.C6#?0C>^0]:A3I_(P>P*VJJHG&>(O*K B
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M^W7IZ[-: V@X1H^+FD)M"B6O%K/B6J%";KM5T@-EH$LSFC(:1N!)&K)'V:5
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M;B(!E-,V$)<\BHS'2*S5@D1I?!8)E-I;@#=,/'N;HE;N6:J&K4>KH#DP[0K
M7^3UG>9U$Z J4"HSQCZ^E),PCQP*3UA*/K,(H%F=H_-02L>=\SOBG<E)*AO[
M2>)1T_WBFY_.RI7GQ\6KQ1RWP'J28LS1<O09N(SEV<T1JQ0EVE%E:!)*P;WV
MTH^\2ARPZ+@S?"N@JJK41S5Q^SG[?;'><@1IHIW(4KM,N'*62,T"\2IYHA07
MV3//->W7=Z[7<B,/YGUV$!TMZF8',GRX_/(%Y;?('Z:?YM,\C7Z^?A%CB9&G
M\T_O%K-I+/,=[[#1;S)#ST\>9D3#,6P,-*OAX3(W8YNH )HD)5$%0(>\%!HS
MQ(JCS*=D*-?W&P\/Y&$\3M/)7M8^^=X,*X&H(R^)>=24+GK1XT%-I2+)RPS&
M!$8KI2[VHV_<5ZB!$// FQI>-6=NMNJ;KU',V%CFS 6%4:'Q1,J 7SP%$AB+
M)")D8I(A:*//S)R]]*OIZB+?6^#'YNO-G@F>6QU%QIW2C?&59>J(X(1J//%Q
M\Z"W6"=4[$=?L^;L$,3<-V<55-/ 1?[?5NA9_K):3[_X-:PFU$2;T2"35*H[
MI<@1G=6,+B7#[R%&1WV=+767CG'?PBL!Z 11-P"4.R.2[H.>4T]Y8H88"QC9
M)-2O2Z6KC78Z6)^5$W4>$/=1->Z#=240#::&!B#U;CE=+#>#M]]#+*T>.Q>C
MTU#ZC\M-GX+7L(K+Z=?NNLTJ*TVR:%&!(G\8-1/K&) 8HJ4*LHNB3M+CH92.
M^WY="7I5U=4 ''%KE2O?9<?1^^GJCTTB<?EN(CV>Y%HE8IF-)3<.B-4^E<Y/
MT6J30M:QEH%[C*AQ7[;KV;=!E-  GC[ I[(CWL/7Q?)Q?S$&P]!(*Q*[#G!:
M*!*,R018YAAE4TFA3FIB+_+&?<BNA+'A%3/VV\ZV@\N+U0K6J]WL:*7!&ZI+
M0:I#J5%#7+2"9,.925QKGOMU?GQZK7$?IP<&30WY-F"<MOT&?UWX>>E6^2OX
M%:SP6(?IM_(HM>%N8JWS5D5.M"U3;*QQQ)7I?AQ2SEI)9V2=8Z\7>>.^0U<R
M3L,KI@&T;0[Q7Q>KU?4LW9LLR/L[*7/J0@R:>*I+3U2)!WZ*&G>2HS;S4NI7
MYT0\A,IQ7ZMK.5^UU-0 !-^B>N:?IKB%-E8<.9RNX=?I-TC;/>5<AB1D:2M3
M2A ]&N]@HRGUI3$H'Y(S=6;%/$G:R,_:E= VK$8:@-A[^ ;S2T!CO?B$K.RX
MH'&!!F]R(-I+W#,^*^*8!<(#6"58%,GOFP-Q2G;T$Z3U@]BYW=D/JY$&(/;&
M3Y=_][-+N#65_L9$;UW324Q!>R-*VUB'OJ@VC'@O)6'4T,Q4%DK5@5DO\OI!
M[=QN]X?73 -P>^57G]$)+?\I)=+?_.R&EYL])*EWUBF+SB@KQ4^AM&A@E'!C
M4Y*"99WJ7,OV(J\?W,[N'6!PS8Q]AU%J5[H.#EW3ANOTR#>+94E_VQUTL\1#
M-@R(H!FWDRKU4P(BX=9P3Y7B<+^EZR.7&D<LW@]7YW+)_RPJ:,"BO88E;I8U
M.ID/-@MEZ QPC&54+C%UR):4"A:B! \*LC$*ZB15/$Y3/XR=VQW_0#IH $UW
M7F/_[I?3LEVNZHA_Z6:%; ]^$X'GX!4QI<,"RHP19X0CMF2]"<\ *G4@Z$UB
M/ZR=VUU_'0TU +WWJ!\DH#@!KS'*F2V^%C_SE^]?8;ZZNB6DSFB:N296B))P
MSCPI+3X(ETQ22K7O.8WEB'#S2>+ZP>U<7@EJ::4!H+V=Q\47^.B_/\@VL5)3
MCX=^M*5!DLR2V*0H@6BX21C/^$HYU8]1U ]2Y_8@,(C\&\#1+WXY1]FLKBHZ
M[[-C7!1*EAIAB:87_Q^)!8X;!*6C5.+,V#KNUQ.$]4/5N5WU#ZF-!L#U._QY
M2U#+Q1R_C7#KYN4^?QYY@-)3E,J<B,0-0QR4BQ@(THHR^E'5>=D\E-)^J;#G
M=O=?55\-X/'Z-O W\*O+)=P\H#U@S&;KE8O$"%[*7Y(C7D2$C7<YQVR-@SH^
M6F\2^R'PW)X&ZFCHS N47L/:3V<5ZY.N%GC.\J2=3-6O3HJ"BIQI(!&H)5(E
M0X*QCC@=<M;>,0FIRL:N5YVTQVI?+%]]]O-/&%K?_HWI/$X1.]N&JI$"T*Q)
M+D4Q4J%S81EN7@5,8\PM<3O5$<A)9#=;RW0(O@XX?@=6Y(AG\:YQ\EP%RWG*
MQ/G(2^Q-T98G35(P+$=.C;7[,+B"^-=/BV\_XT=W\/M/6;XEFV\[S.U8=%P$
M/:.J%\/(?63(_')[Q'-V#$]_4$2%,E-16T:L=)DD1JUS*:JTMV*^'UYNKS@.
M6$Y6V6( ^8W] +EGGONVA7QIPF@RAA[244VD*7=XQE/<#4$#>,.HZC?@_,FE
MQH/!\>I;5)/EV,AXM2BV\1+-XRZ.KF:V:PY><4D4=Z6#IQ<$0U/</@G/9XPA
M!->R%SCZK#9.@>QP^!A<H@W$_ ]*EU[^N!YU"2Y9*90@/DI;BGTULN*@5(6G
MP(5V+H0JON\>HL8MLGY^OV1H/;4(N5NC,IF527-OB55>E1NS3'S*G&"@X*G'
M;:I$G23 /42-ZPH/IOBG '6D%EH U"7:XB^P?,#2UB0+ZGW20$EF&&HB]9$$
MQS0Q/&N+#F,*K$XCU"<(:PQ8QP+@/K &U$8+X'JX_U["/'[^XI=_=)M0,:<5
M\Y)DI221.921.UQAW"&D32Y: _*Y3LD[E(W;2J*IH_)XC36)P"MNMKM5>.6R
M1584+2VK2_Z9!XG\H L:@K9"N#K];YZBK#$#=Q(.G@39"4II &3;"LZ;FLVK
MD!>,ID*&0()GF4BP!GT,R4C*4@5(*4*H4V#V&$6M@>H4O>\NHSU-"0V Z0/J
MHS/UFQ%UKQ9?OB[FQ?)WVTYD%37ECOB,>T_*1/$[67I(11LBQN2,U?'Q]Y(U
M;O>;\4[+X735 /#N\;#=DLYER8$' HZF(AY5<LX4"=$('S0UHM(@A)WDC#R\
M;SAUWT_..EGV#0#H?7EVGT.ZRC2[BEE2L%H(M+^)EZ$@'K^SUA(JP'OD(+-J
M);"[Z!D70@,H^D$"\LE2;P [=Z>M7:7K;WF)63LJ:"3"4-Q9Z&$2SZ,A.2EK
M3<R652HWW$?5N)>IP^-H, V,B*;5<CUY=?GE<M;5&OV2,\3UIG_=17Z1%EV3
MNHVM%J69&#@\]$O/5BX,.IHEPY FX0(7BO>S2;C@+33AG^XCJ2]%X[9V>WX/
MJHJF&D?>=I,&%Y0R1A+CM2>214$P,$%G 3>8\.A .-?KSFL0[(WI5M7!P $
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M)BFM]+!G=\=(,2T5]P3H/)G+GA,VKSK5WBR^?IUMF((^+WZ[F.>S+&+@W'+
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M'=R+/D0?J!A:IZ*!Q(L!I9 2(98R)&6=T8F%D-LPWKT@MM"]H#"0+70?OW0
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M'B.!=HJ[&%V")!U6"EY;9S8)0)=K%V[-:W.;\'0D=W?K$Y&#_;T' _<^QN\
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MLW]>)@+\+ ;M8P@%G):I,M)JH$),0>9!:XK'B?DV7*Y#)1P&R!=T>=+4A1U
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MN-%JPTCB(P/O*W]T=%RRP&Q2C>=R',]UV?G^/6H-/Y8O>T+H(*X\BX[6L\K
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M^Y]-M3'DYF/.."N&TK4ZBZVF:X:V<=JN'6 2V@6KK?&Z[=H929.7L%[&P.B
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M(>A8\PY!-5>V$;S4RC#F<FR4QCTEV;,Y)CYFJQS5/5W";:O-U5+,@IOH)2U
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MI*;5RP&:?^#ZRX+@]1TOA['4>N/_7LSFZ_^F7UR0+M=MA<HEXYUA@+*>@)F
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MGRT$6J/91ZLQM=FU[PC2>4(X#NJ.,?[4M>S=6NWFM=59YDQFD2*$H@+5:ZJ
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M=&C9[JL@0@DH:@)XXG6FG@2'SD%0WO-L4[&E353Y&#7#GH2G:OA)P!PA[A%
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M0:F$*+B2M O-2)!9Z1W3*3X4-@_6VTM$Y[OYU6*2K%:<"0-(@J2 2COPW@K
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M4TN&; 2/)HN,C+;84R%GNZ+;0?K^'7-BG2K5,17=!F],MJE BDK4$B\)T8@
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MKA95"]OL^J!UUMD[B-7S)(80@C >;"PQ1Z6*LVWZFW2A;MB\R4'MW/%:&C4
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M@]$V=R:VKGY<7=:WH\W3U?P'??L[DC_["S=OJ?=YZ-;HN<MG^VGZ?# #/36
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M;=F![Y'(8\A$P-8\5T:PN1(+DL'?%BH60D*LL%"$03_8&G"+73U3MC-R@0D
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MP5>I8JI?J4WZ3I$XA4_];S)G+%2YO3$/VF7WN^MN%P>'7G?C&MZ[BEZA2Z[
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MSQ&5"259[,,OQR<_H%L:.]WRD2HX Y8G<W*;BEG,@@G 8+TCG5L" 452@6J
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M3_MK/X.L_O' 2_VN^;WI_-V>B;R]<.Z^$:FY/X&Q?XQS]CM02P,$%     @
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M!V?S"^SFJ\6;\44 P1R\'KRQ%_;$AL5L8JQ>J^,VOV=$IF3C!8RG\\M@-GT
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M>_"BJEQB-8XV5I<S&- /ESIXHG"UFC?EW)6UJIV:P,!PLS)3&Z6+E$E=@YV
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M8:Z"01EH4*,F*-;ZJZA[Z"Q-IVD)W+C<ASNO=)FRLTU/B4#^.W@)#1M@WHK
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M@11GL0.J9JU<BXK9T"P0\$+?<1 $>X2;M#%:LDV]#<BTM0SRQ7 NE_J#<==
MLS<M_./W\)-98&Q)]SD\H;#+[^PN]E+\'J2I-"JC-B,&([\8FBY I.7>%J:
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M+3(P,C$Q,C,Q+FAT;5!+ 0(4 Q0    ( &Y(3U0-K*!3?QL  *-- 0 1
M          "  0 1!0!R<')X+3(P,C$Q,C,Q+GAS9%!+ 0(4 Q0    ( &Y(
M3U2^Q+)!N"<  &>. 0 5              "  :XL!0!R<')X+3(P,C$Q,C,Q
M7V-A;"YX;6Q02P$"% ,4    " !N2$]4/JW!QX&Y  !Q/0@ %0
M    @ &95 4 <G!R>"TR,#(Q,3(S,5]D968N>&UL4$L! A0#%     @ ;DA/
M5(9BB9YU=0$ 8MD! !0              ( !30X& ')P<G@M,C R,3$R,S%?
M9S$N:G!G4$L! A0#%     @ ;DA/5!(=SH+R20$ ^\@! !0
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7;5!+!08     #P / .0#  #>=PX    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
